PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2555360-12	1989	Secondary amine mono-oxygenase is unique in its ability to function as cytochrome P-450 in activating molecular oxygen but to do so with a myoglobin-like active site.	Oxygen	21-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
2516815-0	1989	Metabolic activation of 7,12-dimethylbenz(a)anthracene: role of cytochrome P-450 isoenzymes in the formation of DNA and protein adducts in vitro.	7,12-dimethylbenz(a	24-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
2604729-1	1989	Effects of a cytochrome P-450 inhibitor on the formation and metabolism of oxygenated sterol products of lanosterol.	Sterols	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2604729-1	1989	Effects of a cytochrome P-450 inhibitor on the formation and metabolism of oxygenated sterol products of lanosterol.	Lanosterol	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2628054-0	1989	Species differences in specificity of hydrocarbon-inducible forms of cytochrome P-450.	Hydrocarbons	38-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2622477-3	1989	The present in vitro study was, therefore, designed to assess the influence of 5-fluorocytosine and 5-fluorouracil on the hepatic cytochrome P 450 concentration in human and rat liver microsomes.	Flucytosine	79-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
2622477-3	1989	The present in vitro study was, therefore, designed to assess the influence of 5-fluorocytosine and 5-fluorouracil on the hepatic cytochrome P 450 concentration in human and rat liver microsomes.	Fluorouracil	100-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
2597175-0	1989	Absence of an isotope effect in induction of cytochrome P-450 and xenobiotic metabolizing enzyme activities by stable isotope-labelled phenobarbital isotopomers.	Phenobarbital	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
2509067-0	1989	Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons.	Benzo(a)pyrene	75-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2509067-0	1989	Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons.	benzo(a)pyrene 7,8-dihydrodiol	91-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2509067-0	1989	Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons.	trans-1,2-dihydro-1,2-naphthalenediol	142-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2509067-0	1989	Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons.	Polycyclic Aromatic Hydrocarbons	169-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2605239-0	1989	Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation.	Chlorobenzenes	21-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
2605239-1	1989	Noncompetitive and competitive intermolecular deuterium isotope effects were measured for the cytochrome P-450 catalyzed hydroxylation of a series of selectively deuterated chlorobenzenes.	Deuterium	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
2605239-1	1989	Noncompetitive and competitive intermolecular deuterium isotope effects were measured for the cytochrome P-450 catalyzed hydroxylation of a series of selectively deuterated chlorobenzenes.	deuterated chlorobenzenes	162-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
2605239-5	1989	These results eliminate initial epoxide formation and initial electron abstraction (charge transfer) as viable mechanisms for the cytochrome P-450 catalyzed hydroxylation of chlorobenzene.	Epoxy Compounds	32-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
2605239-5	1989	These results eliminate initial epoxide formation and initial electron abstraction (charge transfer) as viable mechanisms for the cytochrome P-450 catalyzed hydroxylation of chlorobenzene.	chlorobenzene	174-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
2504483-4	1989	Thiotepa was shown to be metabolized under these conditions in a NADPH- and O2-dependent reaction that was catalyzed by one or more microsomal cytochrome P-450 enzymes that were present in the S-9 fraction.	Thiotepa	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
2688634-0	1989	Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.	Cyclosporine	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2515662-2	1989	The anaerobic NADPH-reduction of the isozymes cytochrome P-450 LM2 and LM4 was used as a functional tool to study the component interaction in reconstituted monooxygenase systems in dependence on different phospholipids.	NADP	14-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2515662-2	1989	The anaerobic NADPH-reduction of the isozymes cytochrome P-450 LM2 and LM4 was used as a functional tool to study the component interaction in reconstituted monooxygenase systems in dependence on different phospholipids.	Phospholipids	206-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2573205-4	1989	As a result, famotidine should be considered the H2-receptor antagonist of choice for critically ill patients who require gastric-acid suppression and at the same time are being treated with other drugs that depend on the cytochrome P-450 mixed-function oxidase system for their metabolism and/or on renal tubular mechanisms for their excretion.	Famotidine	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
2600595-0	1989	Demethylation of tertiary amines by a reconstituted cytochrome P-450 enzyme system: kinetics of oxygen consumption and hydrogen peroxide formation.	tertiary amines	17-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2600595-0	1989	Demethylation of tertiary amines by a reconstituted cytochrome P-450 enzyme system: kinetics of oxygen consumption and hydrogen peroxide formation.	Oxygen	96-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2600595-0	1989	Demethylation of tertiary amines by a reconstituted cytochrome P-450 enzyme system: kinetics of oxygen consumption and hydrogen peroxide formation.	Hydrogen Peroxide	119-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2600595-1	1989	Initial reaction rates of oxygen consumption and hydrogen peroxide formation in a cytochrome P-450 catalyzed reaction are practically independent of the nature of tertiary amines that were used as substrates.	Oxygen	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2600595-1	1989	Initial reaction rates of oxygen consumption and hydrogen peroxide formation in a cytochrome P-450 catalyzed reaction are practically independent of the nature of tertiary amines that were used as substrates.	Hydrogen Peroxide	49-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2600595-1	1989	Initial reaction rates of oxygen consumption and hydrogen peroxide formation in a cytochrome P-450 catalyzed reaction are practically independent of the nature of tertiary amines that were used as substrates.	Amines	172-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2600595-3	1989	Both hydrogen peroxide and water formation lower the efficiency of the monooxygenatic activity of cytochrome P-450.	Hydrogen Peroxide	5-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
2600595-3	1989	Both hydrogen peroxide and water formation lower the efficiency of the monooxygenatic activity of cytochrome P-450.	Water	27-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
2614264-0	1989	Mechanistic studies of lanosterol 14 alpha-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme.	Lanosterol	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
2614264-1	1989	Lanosterol 14 alpha-methyl demethylation is a cytochrome P-450-dependent process that proceeds through the oxidative sequence of alcohol, aldehyde followed by decarbonylation with formic acid release.	Lanosterol	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2614264-1	1989	Lanosterol 14 alpha-methyl demethylation is a cytochrome P-450-dependent process that proceeds through the oxidative sequence of alcohol, aldehyde followed by decarbonylation with formic acid release.	Alcohols	129-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2614264-1	1989	Lanosterol 14 alpha-methyl demethylation is a cytochrome P-450-dependent process that proceeds through the oxidative sequence of alcohol, aldehyde followed by decarbonylation with formic acid release.	Aldehydes	138-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2614264-1	1989	Lanosterol 14 alpha-methyl demethylation is a cytochrome P-450-dependent process that proceeds through the oxidative sequence of alcohol, aldehyde followed by decarbonylation with formic acid release.	formic acid	180-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2559440-0	1989	Oxidation of diethyldithiocarbamate to disulfiram by liver microsomal cytochrome P-450-containing monooxygenase system.	Ditiocarb	13-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
2559440-0	1989	Oxidation of diethyldithiocarbamate to disulfiram by liver microsomal cytochrome P-450-containing monooxygenase system.	Disulfiram	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
2559440-1	1989	We examined the involvement of cytochrome P-450 in the oxidation of diethyldithiocarbamate (DTC) to disulfiram (DS) by liver microsomes in the presence of NADPH.	Ditiocarb	68-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2559440-1	1989	We examined the involvement of cytochrome P-450 in the oxidation of diethyldithiocarbamate (DTC) to disulfiram (DS) by liver microsomes in the presence of NADPH.	Ditiocarb	92-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2559440-1	1989	We examined the involvement of cytochrome P-450 in the oxidation of diethyldithiocarbamate (DTC) to disulfiram (DS) by liver microsomes in the presence of NADPH.	Disulfiram	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2559440-1	1989	We examined the involvement of cytochrome P-450 in the oxidation of diethyldithiocarbamate (DTC) to disulfiram (DS) by liver microsomes in the presence of NADPH.	Disulfiram	112-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2559440-5	1989	With microsomes peroxidized by cumene hydroperoxide, the extent of NADPH-dependent DS production lowered in proportion to the decrease in cytochrome P-450.	cumene hydroperoxide	31-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-154
2559440-5	1989	With microsomes peroxidized by cumene hydroperoxide, the extent of NADPH-dependent DS production lowered in proportion to the decrease in cytochrome P-450.	NADP	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-154
2559440-6	1989	Inhibitors of cytochrome P-450 such as SKF-525A, metyrapone and n-octylamine dose-dependently inhibited the DS production.	Proadifen	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
2559440-6	1989	Inhibitors of cytochrome P-450 such as SKF-525A, metyrapone and n-octylamine dose-dependently inhibited the DS production.	Metyrapone	49-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
2559440-6	1989	Inhibitors of cytochrome P-450 such as SKF-525A, metyrapone and n-octylamine dose-dependently inhibited the DS production.	octylamine	64-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
2559440-8	1989	It is concluded that oxidation of DTC to DS by liver microsomes largely proceeds via the cytochrome P-450-containing monooxygenase system and partly by hydrogen peroxide generated during NADPH oxidation.	Ditiocarb	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
2559440-8	1989	It is concluded that oxidation of DTC to DS by liver microsomes largely proceeds via the cytochrome P-450-containing monooxygenase system and partly by hydrogen peroxide generated during NADPH oxidation.	Disulfiram	41-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
2618083-4	1989	Spectral interactions of N-containing heteroaromatic compounds with the cytochrome P-450 system are type I or type II depending on the state of induction, and are relatively weak.	Nitrogen	25-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2550511-2	1989	This compound is an imidazole derivative, and therefore, its possible effect on cytochrome P-450-dependent enzyme activities in the adrenal gland was evaluated.	imidazole	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
2504483-4	1989	Thiotepa was shown to be metabolized under these conditions in a NADPH- and O2-dependent reaction that was catalyzed by one or more microsomal cytochrome P-450 enzymes that were present in the S-9 fraction.	NADP	65-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
2504483-4	1989	Thiotepa was shown to be metabolized under these conditions in a NADPH- and O2-dependent reaction that was catalyzed by one or more microsomal cytochrome P-450 enzymes that were present in the S-9 fraction.	Oxygen	76-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
2504483-9	1989	These findings establish that the cytotoxic effects of thiotepa are oxygen dependent and may involve, at least in part, metabolic processes catalyzed by cytochrome P-450 enzymes.	Thiotepa	55-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-169
2504483-9	1989	These findings establish that the cytotoxic effects of thiotepa are oxygen dependent and may involve, at least in part, metabolic processes catalyzed by cytochrome P-450 enzymes.	Oxygen	68-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-169
2688863-8	1989	In contrast, N-demethylation of cocaine mediated by microsomal cytochrome P-450 produces norcocaine and this metabolite was shown to be pharmacologically active, the action being similar to cocaine.	Cocaine	32-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2775304-9	1989	The data in this paper are consistent with 4-hydroxylation of debrisoquine in both rat and human liver catalysed by a specific form of cytochrome P-450.	Debrisoquin	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
2590684-1	1989	Crosslinking of protein molecules with bifunctional reagents and subsequent electrophoresis of the modified proteins revealed the presence of cytochrome P-450 LM 2 oligomers in proteoliposome membranes obtained in different ways and differing in their phospholipid composition.	Phospholipids	252-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2688863-8	1989	In contrast, N-demethylation of cocaine mediated by microsomal cytochrome P-450 produces norcocaine and this metabolite was shown to be pharmacologically active, the action being similar to cocaine.	norcocaine	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2690426-1	1989	Cytochrome P-450 appears to catalyse most monooxygenation reactions by sequential one-electron steps rather than by a single, concerted transfer of the ferryl oxygen to the substrate.	Oxygen	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2572090-1	1989	Cimetidine, the first marketed histamine2-receptor antagonist, has been shown to decrease the clearance of warfarin consistently through inhibition of cytochrome P-450 metabolism.	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
2747769-2	1989	Since cimetidine inhibits the cytochrome P-450-dependent biotransformation of numerous drugs, we investigated the possibility that it might also inhibit the cytochrome P-450--dependent metabolism of estradiol.	Estradiol	199-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
2682943-3	1989	Rifampin and perhaps nafcillin induce cytochrome P-450-dependent isoenzyme metabolism of cyclosporine.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2682943-3	1989	Rifampin and perhaps nafcillin induce cytochrome P-450-dependent isoenzyme metabolism of cyclosporine.	Nafcillin	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2682943-3	1989	Rifampin and perhaps nafcillin induce cytochrome P-450-dependent isoenzyme metabolism of cyclosporine.	Cyclosporine	89-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2747769-2	1989	Since cimetidine inhibits the cytochrome P-450-dependent biotransformation of numerous drugs, we investigated the possibility that it might also inhibit the cytochrome P-450--dependent metabolism of estradiol.	Cimetidine	6-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2590249-0	1989	[A study of the interaction of substrates with cytochrome P-450 by a method of UV- and 1H-NMR spectroscopy].	Hydrogen	87-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2747769-2	1989	Since cimetidine inhibits the cytochrome P-450-dependent biotransformation of numerous drugs, we investigated the possibility that it might also inhibit the cytochrome P-450--dependent metabolism of estradiol.	Cimetidine	6-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
2590249-1	1989	Acceleration of substrate longitudinal relaxation (T1) was used to study cytochrome P-450-aminopyrine (1st type substrate) and P-450-4-methoxypyridine (2nd type substrate) complexes.	Aminopyrine	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
2803244-5	1989	The reasons for these differences have been investigated with particular reference to the mode of cytochrome P-450-catalysed decomposition of CHP, that is, via homolytic or heterolytic cleavage of the hydroperoxide dioxygen bond.	hydroperoxide dioxygen	201-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
2803244-9	1989	It is suggested that the inability of CHP to support ECOD activity in the olfactory epithelium and the extensive inactivation of cytochrome P-450 that it causes both stem from decomposition of the hydroperoxide occurring homolytically rather than heterolytically in this tissue.	Hydrogen Peroxide	197-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
2775621-5	1989	By contrast, ketoconazole had a much smaller effect on the 0-8 h urinary metabolic ratio of debrisoquine, indicating that ketoconazole has a selective inhibitory effect on different forms of cytochrome P-450.	Ketoconazole	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
2778096-4	1989	This is most likely due to the saturation within therapeutic dosage range of the subspecies of cytochrome P-450 responsible for hydroxylation of DMT.	desmethyltrimipramine	145-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2474030-0	1989	Cytochrome P-450-dependent omega-oxidation of leukotriene B4 in rodent and human epidermis.	Leukotriene B4	46-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2474030-9	1989	LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects.	Carbon Monoxide	68-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
2474030-9	1989	LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects.	Proadifen	87-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
2474030-9	1989	LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects.	Proadifen	143-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
2677363-4	1989	The basic mechanism of action of terconazole, inhibition of fungal cytochrome P-450, is similar to that of the imidazoles.	terconazole	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
2474030-9	1989	LTB4-omega-hydroxylase activity was inhibited (greater than 90%) by carbon monoxide or 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) (1 mM), whereas alpha-naphthoflavone produced only moderate (13%) or no effects.	alpha-naphthoflavone	169-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
2677363-5	1989	However, because of the additional nitrogen atom in the triazole ring and the lipophilic tail, terconazole establishes a firmer and longer-lasting link with the membrane-bound fungal cytochrome P-450.	Nitrogen	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
2677363-7	1989	Terconazole has far greater selectively for yeast cytochrome P-450 than for mammalian microsomal cytochrome P-450.	terconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
2677363-10	1989	The high affinity and selectivity of terconazole for fungal cytochrome P-450 and its potent in vitro and in vivo activity indicate that the drug may well become a significant agent for the treatment of fungal disease.	terconazole	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2677363-5	1989	However, because of the additional nitrogen atom in the triazole ring and the lipophilic tail, terconazole establishes a firmer and longer-lasting link with the membrane-bound fungal cytochrome P-450.	Triazoles	56-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
2677363-5	1989	However, because of the additional nitrogen atom in the triazole ring and the lipophilic tail, terconazole establishes a firmer and longer-lasting link with the membrane-bound fungal cytochrome P-450.	terconazole	95-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
2677363-7	1989	Terconazole has far greater selectively for yeast cytochrome P-450 than for mammalian microsomal cytochrome P-450.	terconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2669966-1	1989	The human liver cytochrome P-450 (P-450) proteins responsible for catalyzing the oxidation of mephenytoin, tolbutamide, and hexobarbital are encoded by a multigene family (CYP2C).	Mephenytoin	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2804165-0	1989	[Inactivation of cytochrome P-450 by hydrogen peroxide formed in the catalytic cycle during peroxy-complex degradation].	Hydrogen Peroxide	37-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
2804165-1	1989	It was shown that the crucial role in the inactivation of microsomal cytochrome P-450 in reactions of hydroxylation of type I (DMA, AP, BPh, p-NA) and type II (AN) substrates belongs to H2O2 directly formed in the enzyme active center during the decomposition of the peroxy complex.	N-myristoyl-alaninol	127-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2804165-1	1989	It was shown that the crucial role in the inactivation of microsomal cytochrome P-450 in reactions of hydroxylation of type I (DMA, AP, BPh, p-NA) and type II (AN) substrates belongs to H2O2 directly formed in the enzyme active center during the decomposition of the peroxy complex.	Hydrogen Peroxide	186-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2512389-1	1989	The involvement of cytochrome P-450 isozymes in the activation of benzo[a]pyrene (BP) by human placental and liver microsomes was studied in vitro using monoclonal antibodies (Mab) toward the major 3-methylcholanthrene (MC)-inducible and phenobarbital-inductible rat liver P-450 isozymes (Mab 1-7-1 and Mab 2-66-3, respectively).	Benzo(a)pyrene	66-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2512389-1	1989	The involvement of cytochrome P-450 isozymes in the activation of benzo[a]pyrene (BP) by human placental and liver microsomes was studied in vitro using monoclonal antibodies (Mab) toward the major 3-methylcholanthrene (MC)-inducible and phenobarbital-inductible rat liver P-450 isozymes (Mab 1-7-1 and Mab 2-66-3, respectively).	Benzo(a)pyrene	82-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2512389-1	1989	The involvement of cytochrome P-450 isozymes in the activation of benzo[a]pyrene (BP) by human placental and liver microsomes was studied in vitro using monoclonal antibodies (Mab) toward the major 3-methylcholanthrene (MC)-inducible and phenobarbital-inductible rat liver P-450 isozymes (Mab 1-7-1 and Mab 2-66-3, respectively).	Methylcholanthrene	198-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2761265-0	1989	Specificity of steroid binding to testicular microsomal cytochrome P-450.	Steroids	15-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
2761265-2	1989	On the basis of the concept that steroids accumulate in the lipid phase of endoplasmic reticulum membranes and approach the active sites of steroidogenic cytochromes P-450 from a hydrophobic environment, we describe a procedure that allows calculation of spectral dissociation constants Ks for steroid interaction with testicular microsomal cytochrome P-450 after correction for hydrophobic association of ligand with the membrane.	Steroids	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	341-357
2761265-2	1989	On the basis of the concept that steroids accumulate in the lipid phase of endoplasmic reticulum membranes and approach the active sites of steroidogenic cytochromes P-450 from a hydrophobic environment, we describe a procedure that allows calculation of spectral dissociation constants Ks for steroid interaction with testicular microsomal cytochrome P-450 after correction for hydrophobic association of ligand with the membrane.	Steroids	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	341-357
2508765-0	1989	[Study of the role of lysine residues of the cholesterol hydroxylating cytochrome P-450 by a method of chemical modification].	Lysine	22-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
2508765-0	1989	[Study of the role of lysine residues of the cholesterol hydroxylating cytochrome P-450 by a method of chemical modification].	Cholesterol	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
2765333-1	1989	Following anaesthesia with enflurane, some patients receiving isoniazid have increased serum concentrations of fluoride ion, presumably because of induction of an isozyme of cytochrome P450 which is responsible for enflurane biodegradation.	Enflurane	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
2765333-1	1989	Following anaesthesia with enflurane, some patients receiving isoniazid have increased serum concentrations of fluoride ion, presumably because of induction of an isozyme of cytochrome P450 which is responsible for enflurane biodegradation.	Isoniazid	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
2765333-1	1989	Following anaesthesia with enflurane, some patients receiving isoniazid have increased serum concentrations of fluoride ion, presumably because of induction of an isozyme of cytochrome P450 which is responsible for enflurane biodegradation.	Fluorides	111-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
2765333-1	1989	Following anaesthesia with enflurane, some patients receiving isoniazid have increased serum concentrations of fluoride ion, presumably because of induction of an isozyme of cytochrome P450 which is responsible for enflurane biodegradation.	Enflurane	215-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
2753040-0	1989	Rapid partial degradation of DDT by a cytochrome P-450 model system.	DDT	29-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2753040-1	1989	Heme compounds, in combination with a reducing agent and oxygen, can express various activities of cytochrome P-450 enzymes.	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2753040-1	1989	Heme compounds, in combination with a reducing agent and oxygen, can express various activities of cytochrome P-450 enzymes.	Oxygen	57-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2672473-0	1989	The control of cytochrome P-450 gene expression by dioxin.	Dioxins	51-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
2500151-1	1989	Cytochrome P-450, designated as P-450-MK2, was purified to an electrophoretic homogeneity from polychlorinated biphenyl (PCB)-treated female crab-eating monkeys.	Polychlorinated Biphenyls	95-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2500151-1	1989	Cytochrome P-450, designated as P-450-MK2, was purified to an electrophoretic homogeneity from polychlorinated biphenyl (PCB)-treated female crab-eating monkeys.	Polychlorinated Biphenyls	121-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2669966-1	1989	The human liver cytochrome P-450 (P-450) proteins responsible for catalyzing the oxidation of mephenytoin, tolbutamide, and hexobarbital are encoded by a multigene family (CYP2C).	Tolbutamide	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2669966-1	1989	The human liver cytochrome P-450 (P-450) proteins responsible for catalyzing the oxidation of mephenytoin, tolbutamide, and hexobarbital are encoded by a multigene family (CYP2C).	Hexobarbital	124-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2790077-0	1989	[Immunochemical study of cholesterol-hydroxylating cytochrome P-450.	Cholesterol	25-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2706014-4	1989	Bis(tri-n-butyltin)oxide (TBTO) produced dose- and time-dependent decreases in the content and functional activity of intestinal cytochrome P-450, together with an elevation (3-fold) in the activity of microsomal heme oxygenase.	bis(tri-n-butyltin)oxide	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
2519716-1	1989	In this perspective we have described a newly characterized pathway for the metabolism of the prosthetic heme of cytochrome P-450, which results in the formation of protein-bound adducts.	Heme	105-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
2519716-2	1989	This reaction occurs when the cytochrome P-450 metabolizes a variety of xenobiotics as well as endogenous compounds such as hydrogen peroxide and lipid hydroperoxides.	Hydrogen Peroxide	124-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2519716-2	1989	This reaction occurs when the cytochrome P-450 metabolizes a variety of xenobiotics as well as endogenous compounds such as hydrogen peroxide and lipid hydroperoxides.	Lipid Peroxides	146-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2707734-1	1989	Isaxonine and several other drugs transformed by cytochrome P-450 into reactive metabolites apparently lead to immunoallergic hepatitis in man.	isaxonine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
2707734-6	1989	At 60 min, the amount of isaxonine metabolite covalently bound per mg of protein was similar in plasma membranes (0.42 nmole metabolite.mg protein-1) and in microsomes (0.38); both values were decreased by about 70% in rats pretreated with piperonyl butoxide, an inhibitor of cytochrome P-450.	isaxonine	25-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	276-292
2634818-6	1989	This could result from an additional induction of cytochrome P-450 caused by alcohol and an accelerated oxidation of the drugs.	Alcohols	77-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2495281-6	1989	Cytochrome P-450 reduction was also examined in both phospholipid-containing and soluble systems where the LM2 and reductase were not present as a preformed complex.	Phospholipids	53-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2670357-8	1989	Specific forms of cytochrome P-450 have been shown to be involved in the initial step in the activation (N-hydroxylation) of aromatic amines and amides.	aromatic amines	125-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
2670357-8	1989	Specific forms of cytochrome P-450 have been shown to be involved in the initial step in the activation (N-hydroxylation) of aromatic amines and amides.	Amides	145-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
2670357-14	1989	Polymorphisms in both cytochrome P-450 and N-acetyltransferase expression may be critical determinants in the susceptibility of individuals to the toxicity and carcinogenicity of aromatic amines and amides.	aromatic amines	179-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-62
2670357-14	1989	Polymorphisms in both cytochrome P-450 and N-acetyltransferase expression may be critical determinants in the susceptibility of individuals to the toxicity and carcinogenicity of aromatic amines and amides.	Amides	199-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-62
2496984-0	1989	On the role of phospholipids in the reconstituted cytochrome P-450 system.	Phospholipids	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2496984-3	1989	The hypotheses proposed in the literature for the role of phospholipids in the reconstituted cytochrome P-450 system, mainly based on the comparison of systems without phospholipid and with Lau2GroPCho, were either validated or shown to be unlikely when tested by comparing reconstituted systems with different phosphatidylcholines.	Phospholipids	58-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2496984-3	1989	The hypotheses proposed in the literature for the role of phospholipids in the reconstituted cytochrome P-450 system, mainly based on the comparison of systems without phospholipid and with Lau2GroPCho, were either validated or shown to be unlikely when tested by comparing reconstituted systems with different phosphatidylcholines.	Phospholipids	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2496984-3	1989	The hypotheses proposed in the literature for the role of phospholipids in the reconstituted cytochrome P-450 system, mainly based on the comparison of systems without phospholipid and with Lau2GroPCho, were either validated or shown to be unlikely when tested by comparing reconstituted systems with different phosphatidylcholines.	lau2gropcho	190-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2496984-3	1989	The hypotheses proposed in the literature for the role of phospholipids in the reconstituted cytochrome P-450 system, mainly based on the comparison of systems without phospholipid and with Lau2GroPCho, were either validated or shown to be unlikely when tested by comparing reconstituted systems with different phosphatidylcholines.	Phosphatidylcholines	311-331	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2496984-4	1989	The higher activity in the Lau2GroPCho system as compared to the Ste2GroPCho system cannot be ascribed to (a) an increased affinity of cytochrome P-450 for the NADPH-cytochrome reductase in the Lau2GroPCho system, also not to (b) a Lau2GroPCho-dependent dissociation of protein multimers, nor to (c) a change in the spin state of the heme.	Heme	334-338	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
2496984-7	1989	From these observations it is concluded that the higher activity of the Lau2GroPCho system compared with the Ste2GroPCho system or with a system without additional phosphatidylcholine may at least in part be caused by a difference in the conformation of the cytochrome P-450 molecules in these systems.	Phosphatidylcholines	164-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-274
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	Phosphatidylcholines	43-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	Phosphatidylcholines	43-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	310-326
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	pentoxyresorufin	84-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	pentoxyresorufin	84-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	310-326
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	Phospholipids	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
2496984-8	1989	Furthermore, the different effects of both phosphatidylcholines on the Km and V for pentoxyresorufin not only suggest a role of phospholipids in the binding of the substrate to the active site of the cytochrome P-450 molecule, but also on the efficiency of electron transfer from NADPH-cytochrome reductase to cytochrome P-450.	Phospholipids	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	310-326
2758074-6	1989	The incorporation of cytochrome P-450 into liposomes caused the acceleration of PE and PG hydrolysis.	Phosphatidylglycerols	87-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
2702801-6	1989	This would imply that the cytochrome P-450 determined by the debrisoquin allele or some coinherited 4-hydroxylase(s) was induced to a greater extent in EMs than PMs.	Debrisoquin	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2706014-4	1989	Bis(tri-n-butyltin)oxide (TBTO) produced dose- and time-dependent decreases in the content and functional activity of intestinal cytochrome P-450, together with an elevation (3-fold) in the activity of microsomal heme oxygenase.	bis(tri-n-butyltin)oxide	26-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
2706014-5	1989	The effects of di-n-butyltin dichloride on heme oxygenase and cytochrome P-450 were pronounced in the small intestine and extended to the liver and kidneys within 21 hr after oral-exposure, whereas TBTO did not affect the liver until much later (6 days), when cytochrome P-450 content was reduced markedly (30%).	dibutyldichlorotin	15-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
2706014-5	1989	The effects of di-n-butyltin dichloride on heme oxygenase and cytochrome P-450 were pronounced in the small intestine and extended to the liver and kidneys within 21 hr after oral-exposure, whereas TBTO did not affect the liver until much later (6 days), when cytochrome P-450 content was reduced markedly (30%).	dibutyldichlorotin	15-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-276
2651504-4	1989	The dialkylnitrosamine carcinogens are activated by NADPH-dependent cytochrome P-450 enzymes in their target tissues.	dialkylnitrosamine	4-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2512166-4	1989	These findings suggest a certain inability of cytochrome P-450 mono-oxygenases to metabolise a specific group of PCBs.	Polychlorinated Biphenyls	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2649791-1	1989	A cDNA of a human liver cytochrome P-450, corresponding to P-450 human-2, was expressed in Saccharomyces cerevisiae cells by the use of a galactose-inducible expression vector containing the GAL7 promoter and terminator.	Galactose	138-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-72
2693891-0	1989	Induction of hepatic cytochrome P450 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin.	Polychlorinated Dibenzodioxins	56-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
2739204-5	1989	Isoprothiolane did not promote the activity of the demethylase and hydroxylase in liver microsomes but it promoted the formation of cytochrome P-450 and b5 whose contents in the animals treated with isoprothiolane of a dose of 50 or 100 mg/kg were about twice as high as those in the non-treated animals.	isoprothiolane	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
2739204-5	1989	Isoprothiolane did not promote the activity of the demethylase and hydroxylase in liver microsomes but it promoted the formation of cytochrome P-450 and b5 whose contents in the animals treated with isoprothiolane of a dose of 50 or 100 mg/kg were about twice as high as those in the non-treated animals.	isoprothiolane	199-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
2930594-2	1989	Under conditions enabling cytochrome P-450-dependent benzylic hydroxylation of BPBS and BDVS, both benzyl sulfides were mutagenic.	bpbs	79-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2930594-2	1989	Under conditions enabling cytochrome P-450-dependent benzylic hydroxylation of BPBS and BDVS, both benzyl sulfides were mutagenic.	bdvs	88-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2930594-2	1989	Under conditions enabling cytochrome P-450-dependent benzylic hydroxylation of BPBS and BDVS, both benzyl sulfides were mutagenic.	benzyl sulfide	99-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2930595-0	1989	Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450.	nilutamide	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2930595-12	1989	These results show that nilutamide inhibits hepatic cytochrome P-450 activity, and suggest that inhibition may actually occur after therapeutic doses of nilutamide in humans.	nilutamide	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2651504-4	1989	The dialkylnitrosamine carcinogens are activated by NADPH-dependent cytochrome P-450 enzymes in their target tissues.	NADP	52-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2917971-2	1989	Cytochrome P-450 is known to catalyze the following oxygen transfer reaction: RH + PhIO----ROH + PhI where RH represents a variety of hydroxylatable substrates and PhIO a variety of iodosobenzene derivatives that serve as oxygen donors, and neither molecular oxygen nor an external electron donor is required.	Oxygen	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2651504-7	1989	We have demonstrated that dietary zinc deficiency increased the cytochrome P-450-dependent microsomal metabolism of methylbenzylnitrosamine and dimethylnitrosamine, two members of this class of dialkylnitrosamine carcinogens, while the addition of zinc in vitro noncompetitively inhibits the microsomal metabolism of these carcinogens.	nitrosobenzylmethylamine	116-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
2917971-2	1989	Cytochrome P-450 is known to catalyze the following oxygen transfer reaction: RH + PhIO----ROH + PhI where RH represents a variety of hydroxylatable substrates and PhIO a variety of iodosobenzene derivatives that serve as oxygen donors, and neither molecular oxygen nor an external electron donor is required.	iodosobenzene	182-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2651504-7	1989	We have demonstrated that dietary zinc deficiency increased the cytochrome P-450-dependent microsomal metabolism of methylbenzylnitrosamine and dimethylnitrosamine, two members of this class of dialkylnitrosamine carcinogens, while the addition of zinc in vitro noncompetitively inhibits the microsomal metabolism of these carcinogens.	Dimethylnitrosamine	144-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
2917971-2	1989	Cytochrome P-450 is known to catalyze the following oxygen transfer reaction: RH + PhIO----ROH + PhI where RH represents a variety of hydroxylatable substrates and PhIO a variety of iodosobenzene derivatives that serve as oxygen donors, and neither molecular oxygen nor an external electron donor is required.	Oxygen	222-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2917971-2	1989	Cytochrome P-450 is known to catalyze the following oxygen transfer reaction: RH + PhIO----ROH + PhI where RH represents a variety of hydroxylatable substrates and PhIO a variety of iodosobenzene derivatives that serve as oxygen donors, and neither molecular oxygen nor an external electron donor is required.	Oxygen	222-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2651504-7	1989	We have demonstrated that dietary zinc deficiency increased the cytochrome P-450-dependent microsomal metabolism of methylbenzylnitrosamine and dimethylnitrosamine, two members of this class of dialkylnitrosamine carcinogens, while the addition of zinc in vitro noncompetitively inhibits the microsomal metabolism of these carcinogens.	dialkylnitrosamine	194-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
2565211-2	1989	Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.	Rifampin	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2752065-0	1989	[Interaction of cholesterol hydroxylating cytochrome P-450 with cytochrome b5].	Cholesterol	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
2565211-3	1989	A cytochrome P-450 involved in the metabolism of cyclosporin A (CsA) was isolated and purified to electrophoretic homogeneity from human liver microsomes of renal transplant donors.	Cyclosporine	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
2565211-3	1989	A cytochrome P-450 involved in the metabolism of cyclosporin A (CsA) was isolated and purified to electrophoretic homogeneity from human liver microsomes of renal transplant donors.	Cyclosporine	64-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
2650039-4	1989	Chloroform is discussed as an example of cytochrome P-450-mediated activation and dihaloethanes and hexachloro-1,3-butadiene as examples of glutathione conjugation followed by activation.	Chloroform	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
2744145-0	1989	[The immunotropic activity of GABA during cytochrome P-450 induction in the liver].	gamma-Aminobutyric Acid	30-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
2744145-2	1989	The use of GABA under induction of cytochrome P-450 of the liver by phenobarbital or rifampicin was not followed by immunodepression.	gamma-Aminobutyric Acid	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
2744145-2	1989	The use of GABA under induction of cytochrome P-450 of the liver by phenobarbital or rifampicin was not followed by immunodepression.	Phenobarbital	68-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
2744145-2	1989	The use of GABA under induction of cytochrome P-450 of the liver by phenobarbital or rifampicin was not followed by immunodepression.	Rifampin	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
2744145-3	1989	The obtained data indicate the dependence of GABA pharmacological activity from the function of cytochrome P-450-dependent monooxygenase system of the liver.	gamma-Aminobutyric Acid	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
2703963-1	1989	Acetaminophen (AA) is converted, presumably by cytochrome P-450, to an electrophile which is conjugated with glutathione (GS).	Acetaminophen	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	Methylcholanthrene	34-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	Polychlorinated Dibenzodioxins	59-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	Ethanol	179-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	Isoniazid	191-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	Pregnenolone	224-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-6	1989	Of the cytochrome P-450 inducers, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, increased the biliary excretion of AA-GS (2.9- and 3.2-fold, respectively) whereas ethanol and isoniazid did not affect it, and pregnenolone-16 alpha-carbonitrile tended to decrease it (43%).	16 alpha-carbonitrile	237-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	Methoxsalen	49-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	2-(4,6-dichloro-biphenyloxy) ethylamine	68-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	alpha-naphthoflavone	109-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	Proadifen	197-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	Piperonyl Butoxide	211-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2713464-0	1989	[Tetraphenylporphyrin-Sn4+ induction of cytochrome P-450].	tin tetraphenylporphyrin	1-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-57
2713464-5	1989	To clarity the mechanism of TPP-Sn4+ effect on cytochrome P-450, we studied its effect on the activity of heme oxygenase and LP rate.	tpp-sn4	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2644935-3	1989	CDDP induces a dramatic change in both the testosterone level and the microsomal cytochrome P-450 concentration.	cddp	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
2914926-0	1989	19F nuclear magnetic resonance as a probe of the spatial relationship between the heme iron of cytochrome P-450 and its substrate.	Heme	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2646846-1	1989	Hepatic cytochrome-P-450-linked microsomal metabolism is inhibited by cimetidine, and to a lesser extent by ranitidine.	Cimetidine	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2914926-0	1989	19F nuclear magnetic resonance as a probe of the spatial relationship between the heme iron of cytochrome P-450 and its substrate.	Iron	87-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2914926-1	1989	The distance between the heme iron of ferrous cytochrome P-450-CAM and a fluorine label attached to the 9-methyl carbon of its substrate, (1R)-(+)-camphor, has been determined using 19F NMR.	Heme	25-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2914926-1	1989	The distance between the heme iron of ferrous cytochrome P-450-CAM and a fluorine label attached to the 9-methyl carbon of its substrate, (1R)-(+)-camphor, has been determined using 19F NMR.	Iron	30-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2917006-6	1989	Both the increase and the decrease in cytochrome P-450 could be prevented by the administration of the protein synthesis inhibitor puromycin.	Puromycin	131-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2917006-7	1989	Various isozymes of cytochrome P-450 induced by phenobarbital, beta-napthaflavone and clofibrate were also depressed by this interferon.	Phenobarbital	48-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
2917006-7	1989	Various isozymes of cytochrome P-450 induced by phenobarbital, beta-napthaflavone and clofibrate were also depressed by this interferon.	beta-napthaflavone	63-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
2917006-7	1989	Various isozymes of cytochrome P-450 induced by phenobarbital, beta-napthaflavone and clofibrate were also depressed by this interferon.	Clofibrate	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
2923975-0	1989	[Protective action of fat- and water-soluble antioxidants on the cytochrome P-450 system during lipid peroxidation in liver microsomes].	Water	31-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
2923975-2	1989	It was shown that for optimal protection effect of cytochrome P-450 system the mixture of water and liposoluble antioxidants is required.	Water	90-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2912586-0	1989	Activation of the food-derived mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by rabbit and human liver microsomes and purified forms of cytochrome P-450.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	39-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-162
2914926-1	1989	The distance between the heme iron of ferrous cytochrome P-450-CAM and a fluorine label attached to the 9-methyl carbon of its substrate, (1R)-(+)-camphor, has been determined using 19F NMR.	Fluorine	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2914926-1	1989	The distance between the heme iron of ferrous cytochrome P-450-CAM and a fluorine label attached to the 9-methyl carbon of its substrate, (1R)-(+)-camphor, has been determined using 19F NMR.	Carbon	113-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2914926-1	1989	The distance between the heme iron of ferrous cytochrome P-450-CAM and a fluorine label attached to the 9-methyl carbon of its substrate, (1R)-(+)-camphor, has been determined using 19F NMR.	Camphor	138-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2663083-4	1989	Besides, some enzymes catalyzing the interconversions of active oxygen species (catalase superoxide dismutase, cytochrome P-450) are also inactivated in the course of catalysis under the oxidative action of active oxygen species.	Oxygen	64-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2663083-4	1989	Besides, some enzymes catalyzing the interconversions of active oxygen species (catalase superoxide dismutase, cytochrome P-450) are also inactivated in the course of catalysis under the oxidative action of active oxygen species.	Oxygen	214-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2646846-1	1989	Hepatic cytochrome-P-450-linked microsomal metabolism is inhibited by cimetidine, and to a lesser extent by ranitidine.	Ranitidine	108-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2546388-0	1989	Corneal arachidonate metabolism via cytochrome P450: characterization of two novel biologically active metabolites.	Arachidonic Acid	8-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
2784911-0	1989	Role of kidney microsomal cytochrome P-450 in cyclosporin induced nephropathy.	Cyclosporine	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2785364-0	1989	Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson"s disease.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	31-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
2565119-1	1989	The H2-receptor antagonist cimetidine has been reported to decrease the hepatic clearance of numerous drugs by inhibiting cytochrome P-450 metabolism, decreasing liver blood flow or both.	Cimetidine	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
2519233-0	1989	A theoretical study on the metabolic activation of paracetamol by cytochrome P-450: indications for a uniform oxidation mechanism.	Acetaminophen	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
2519233-1	1989	The cytochrome P-450 mediated activation of paracetamol (PAR) to the reactive electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI) has been studied by use of SV 6-31G ab initio energy calculations and spin distributions.	Acetaminophen	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2519233-1	1989	The cytochrome P-450 mediated activation of paracetamol (PAR) to the reactive electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI) has been studied by use of SV 6-31G ab initio energy calculations and spin distributions.	Acetaminophen	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2519233-1	1989	The cytochrome P-450 mediated activation of paracetamol (PAR) to the reactive electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI) has been studied by use of SV 6-31G ab initio energy calculations and spin distributions.	N-acetyl-4-benzoquinoneimine	105-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2519233-1	1989	The cytochrome P-450 mediated activation of paracetamol (PAR) to the reactive electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI) has been studied by use of SV 6-31G ab initio energy calculations and spin distributions.	N-acetyl-4-benzoquinoneimine	136-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2519233-2	1989	A simplified model for cytochrome P-450 has been used by substituting the proposed biologically active ferric-oxene state of cytochrome P-450 by a singlet oxygen atom.	ferric-oxene	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
2519233-2	1989	A simplified model for cytochrome P-450 has been used by substituting the proposed biologically active ferric-oxene state of cytochrome P-450 by a singlet oxygen atom.	ferric-oxene	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
2519233-2	1989	A simplified model for cytochrome P-450 has been used by substituting the proposed biologically active ferric-oxene state of cytochrome P-450 by a singlet oxygen atom.	Oxygen	155-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
2515836-6	1989	However, noxious effects may instead be induced for chemicals bioactivated by cytochrome P-450-dependent reactions, such as N-nitrosamines.	n-nitrosamines	124-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
2496778-0	1989	Cardiovascular and renal actions of cytochrome P-450 metabolites of arachidonic acid.	Arachidonic Acid	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
2496778-2	1989	Arachidonic acid (AA) can be oxidatively metabolized by cytochrome P-450 hemoproteins to an array of compounds identified as constituents of tissues and biological fluids.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
2785364-0	1989	Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson"s disease.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	36-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
2785364-2	1989	This study examines the interactions of MPTP with the cytochrome P-450 system--an enzyme system which is known to be involved in the detoxication of MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	40-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2785364-2	1989	This study examines the interactions of MPTP with the cytochrome P-450 system--an enzyme system which is known to be involved in the detoxication of MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	149-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2598298-2	1989	Both a reconstituted system of cytochrome P-450 (P-450) and cytochrome b5 (b5) with NADPH was capable of reducing Na2CrO4 (30 microM) provided anaerobic atmosphere.	NADP	84-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2598298-2	1989	Both a reconstituted system of cytochrome P-450 (P-450) and cytochrome b5 (b5) with NADPH was capable of reducing Na2CrO4 (30 microM) provided anaerobic atmosphere.	na2cro4	114-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2785364-6	1989	MPTP was found from in vitro studies to cause a mixed non-competitive inhibition of cytochrome P-450 dependent ethoxyresorufin O-dealkylase activity with an inhibition constant (Ki) of 0.06 mM.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
2642041-0	1989	Cytochrome P-450-catalyzed asymmetric epoxidation of simple prochiral and chiral aliphatic alkenes: species dependence and effect of enzyme induction on enantioselective oxirane formation.	Alkenes	91-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2785364-7	1989	Two binding sites of MPTP to hepatic cytochrome P-450 were found by spectral perturbation studies--the higher affinity site binding about a hundred times more avidly to MPTP than the other.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	21-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2642041-0	1989	Cytochrome P-450-catalyzed asymmetric epoxidation of simple prochiral and chiral aliphatic alkenes: species dependence and effect of enzyme induction on enantioselective oxirane formation.	Ethylene Oxide	170-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2785364-7	1989	Two binding sites of MPTP to hepatic cytochrome P-450 were found by spectral perturbation studies--the higher affinity site binding about a hundred times more avidly to MPTP than the other.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	169-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2785364-9	1989	Cytochrome P-450 levels were lowest 3 to 6 hours after treatment with MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	70-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2785364-10	1989	MPTP was also found to cause a dose-dependent decrease in the cytochrome P-450 enzyme activities bufuralol hydroxylase (buf) and aryl hydrocarbon hydroxylase (AHH) in the brain.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
2910635-0	1989	In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.	Propafenone	93-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
2910635-10	1989	Thus it can be concluded that 5-hydroxypropafenone is formed by the cytochrome P-450 isozyme involved in polymorphic bufuralol oxidation.	5-hydroxypropafenone	30-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2910635-10	1989	Thus it can be concluded that 5-hydroxypropafenone is formed by the cytochrome P-450 isozyme involved in polymorphic bufuralol oxidation.	bufuralol	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2910639-1	1989	The relative contributions of the debrisoquin and mephenytoin isozymes of hepatic cytochrome P-450 to the stereoselective metabolism of propranolol have been studied in a panel of volunteers of known oxidative phenotypes.	Debrisoquin	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2910639-1	1989	The relative contributions of the debrisoquin and mephenytoin isozymes of hepatic cytochrome P-450 to the stereoselective metabolism of propranolol have been studied in a panel of volunteers of known oxidative phenotypes.	Mephenytoin	50-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2910639-1	1989	The relative contributions of the debrisoquin and mephenytoin isozymes of hepatic cytochrome P-450 to the stereoselective metabolism of propranolol have been studied in a panel of volunteers of known oxidative phenotypes.	Propranolol	136-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2680407-0	1989	Induction of the alcohol-inducible form of cytochrome P-450 by nitrogen-containing heterocycles: effects on pyridine N-oxide production.	Nitrogen	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2680407-0	1989	Induction of the alcohol-inducible form of cytochrome P-450 by nitrogen-containing heterocycles: effects on pyridine N-oxide production.	pyridine N-oxide	108-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2680378-0	1989	Radical intermediates in the cytochrome P-450-catalyzed oxidation of aliphatic hydrocarbons.	radical	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
2680378-0	1989	Radical intermediates in the cytochrome P-450-catalyzed oxidation of aliphatic hydrocarbons.	Hydrocarbons	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
2680385-1	1989	A variety of organic compounds such as carbon tetrachloride, halothane, gentian violet, and benznidazole are reductively metabolized to free radicals by liver microsomal cytochrome P-450.	Carbon Tetrachloride	39-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
2698318-2	1989	Evidence is presented for the direct involvement of certain cytochrome P-450 isoenzymes in the major toxic effect of hexachlorobenzene, hepatic porphyria.	Hexachlorobenzene	117-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2680385-1	1989	A variety of organic compounds such as carbon tetrachloride, halothane, gentian violet, and benznidazole are reductively metabolized to free radicals by liver microsomal cytochrome P-450.	Halothane	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
2680385-1	1989	A variety of organic compounds such as carbon tetrachloride, halothane, gentian violet, and benznidazole are reductively metabolized to free radicals by liver microsomal cytochrome P-450.	Gentian Violet	72-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
2908851-0	1989	Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4"-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases.	4-biphenylamine	39-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
2908851-0	1989	Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4"-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases.	Methylenebis(chloroaniline)	59-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
2680385-1	1989	A variety of organic compounds such as carbon tetrachloride, halothane, gentian violet, and benznidazole are reductively metabolized to free radicals by liver microsomal cytochrome P-450.	benzonidazole	92-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
2806064-0	1989	[Rotational diffusion of cytochrome P-450 in a model membrane of various phospholipid composition].	Phospholipids	73-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
2680407-0	1989	Induction of the alcohol-inducible form of cytochrome P-450 by nitrogen-containing heterocycles: effects on pyridine N-oxide production.	Alcohols	17-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2908851-7	1989	MOCA ring-oxidation and methylene carbon oxidation showed varied cytochrome P-450 selectivity and accounted for 14 to 79% of total oxidation products.	Carbon	34-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
2908851-11	1989	Moreover, both the ABP N-oxidation and phenacetin O-deethylation activities of human liver microsomes showed a good correlation (R = 0.72) with the levels of cytochrome P-450 immunochemically related to rat P-450ISF-G.	Phenacetin	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-174
2500346-3	1989	Cytochrome P-450 activity was monitored by measuring urinary 6-beta-hydroxycortisol output and systemic antipyrine clearance.	6 beta-hydroxycortisol	61-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2500346-6	1989	The results are in keeping with the well known heterogeneity of the hepatic monooxygenase system, as phenytoin and carbamazepine induce different panels of cytochrome P-450 isoenzymes.	Phenytoin	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
2500346-6	1989	The results are in keeping with the well known heterogeneity of the hepatic monooxygenase system, as phenytoin and carbamazepine induce different panels of cytochrome P-450 isoenzymes.	Carbamazepine	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
2570698-1	1989	The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1).	Sparteine	4-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
2570698-1	1989	The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1).	Debrisoquin	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
2634093-4	1989	This prediction is achieved by comparing the molecular conformation of these drugs with lanosterol, the substrate of the fungal cytochrome P-450, and with phenobarbitone, an inducing agent of a family of mammalian cytochrome P-450, toward which the antifungal agents show highest inhibitory activity.	Phenobarbital	155-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
2643542-1	1989	Because steroids reach high concentrations within the adrenal cortex, effects of the direct interaction of steroids and cytochrome P450 enzymes are possible and may involve oxidative damage.	Steroids	8-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
2643542-3	1989	Release of oxidants during pseudosubstrate interaction with cytochrome P450s may be responsible for loss of enzymatic activity observed; enzyme activity can be protected by cytochrome P450 inhibitors, antioxidants, and lowered oxygen concentration.	Oxygen	227-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
2643542-5	1989	Cytochrome P450/pseudosubstrate effects could be involved in the aging and death of adrenocortical cells in vivo, and necrosis of the adrenal cortex due to excessive ACTH stimulation or due to the action of adrenolytic chemicals could result from damage by oxygen radicals originating from cytochrome P450s.	Reactive Oxygen Species	257-272	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
2634093-0	1989	Adverse reactions of imidazole antifungal agents: computer graphic studies of cytochrome P-450 interactions.	imidazole	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
2634093-3	1989	A computer graphic technique capable of predicting the interaction of these structurally-related imidazoles with fungal and mammalian cytochrome P-450 proteins is described.	Imidazoles	97-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
2634093-4	1989	This prediction is achieved by comparing the molecular conformation of these drugs with lanosterol, the substrate of the fungal cytochrome P-450, and with phenobarbitone, an inducing agent of a family of mammalian cytochrome P-450, toward which the antifungal agents show highest inhibitory activity.	Lanosterol	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
2634093-4	1989	This prediction is achieved by comparing the molecular conformation of these drugs with lanosterol, the substrate of the fungal cytochrome P-450, and with phenobarbitone, an inducing agent of a family of mammalian cytochrome P-450, toward which the antifungal agents show highest inhibitory activity.	Lanosterol	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
2615529-10	1989	The cytochrome P-450-dependent hydroxylation capacity was evaluated with debrisoquine but no correlation was found to the pharmacokinetics of 6-MP.	Debrisoquin	73-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2848247-3	1988	This gene is clearly a member of the cytochrome P-450 gene superfamily, because the sequence contains regions of marked homology to those of other members, notably a putative membrane-spanning region, I helix, Ozols, and heme-binding regions.	Heme	221-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2763709-1	1989	Oral therapy with nizoral and griseofulvin influences the system of cytochrome P = 450-dependent monoxygenases of the liver, this resulting in the depression of antipyrine microsomal oxidation.	Ketoconazole	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-86
2763709-1	1989	Oral therapy with nizoral and griseofulvin influences the system of cytochrome P = 450-dependent monoxygenases of the liver, this resulting in the depression of antipyrine microsomal oxidation.	Griseofulvin	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-86
3254979-2	1988	Even at a low dose (10 mg/kg), MCZ significantly increased cytochrome P-450 content and reduced nicotinamide adenine dinucleotide phosphate cytochrome c reductase activity.	Miconazole	31-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
3254979-5	1988	These results suggest that MCZ, but not KCZ, has inducing activity for hepatic cytochrome P-450-dependent oxidative metabolism of steroids and xenobiotics, in addition to its known inhibitory activity.	Miconazole	27-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3254979-5	1988	These results suggest that MCZ, but not KCZ, has inducing activity for hepatic cytochrome P-450-dependent oxidative metabolism of steroids and xenobiotics, in addition to its known inhibitory activity.	Steroids	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3072574-0	1988	Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3072574-0	1988	Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids.	Eicosanoids	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3198602-2	1988	Cytochrome P-450cam normally catalyzes the regiospecific hydroxylation of the monoterpene camphor.	Monoterpenes	78-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3198602-2	1988	Cytochrome P-450cam normally catalyzes the regiospecific hydroxylation of the monoterpene camphor.	Camphor	90-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3198602-10	1988	Camphane bound to cytochrome P-450cam exhibits a larger decrease in high spin fraction (45%) and a correspondingly larger KD (46 microM), suggesting that the carbonyl moiety of camphor plays an important steric role in addition to its interaction as a hydrogen bond acceptor.	camphane	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
3198602-10	1988	Camphane bound to cytochrome P-450cam exhibits a larger decrease in high spin fraction (45%) and a correspondingly larger KD (46 microM), suggesting that the carbonyl moiety of camphor plays an important steric role in addition to its interaction as a hydrogen bond acceptor.	Camphor	177-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
3198602-10	1988	Camphane bound to cytochrome P-450cam exhibits a larger decrease in high spin fraction (45%) and a correspondingly larger KD (46 microM), suggesting that the carbonyl moiety of camphor plays an important steric role in addition to its interaction as a hydrogen bond acceptor.	Hydrogen	252-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
2848247-5	1988	The expressed protein was similar in size to human placental aromatase system cytochrome P-450, as detected by immunoblot analysis, and catalyzed the aromatization of androstenedione, testosterone, and 16 alpha-hydroxyandrostenedione.	Androstenedione	167-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
2848247-5	1988	The expressed protein was similar in size to human placental aromatase system cytochrome P-450, as detected by immunoblot analysis, and catalyzed the aromatization of androstenedione, testosterone, and 16 alpha-hydroxyandrostenedione.	Testosterone	184-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
2848247-5	1988	The expressed protein was similar in size to human placental aromatase system cytochrome P-450, as detected by immunoblot analysis, and catalyzed the aromatization of androstenedione, testosterone, and 16 alpha-hydroxyandrostenedione.	alpha-hydroxyandrostenedione	205-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
3186722-4	1988	Using two assay systems with different selectivity for the two cytochrome P-450 isozymes catalyzing bufuralol metabolism in human liver, we show that anti-LKM1 exclusively recognizes cytochrome P-450db1.	bufuralol	100-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
3196735-2	1988	19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles.	19-hydroxyprostaglandin E1	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
3196735-2	1988	19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles.	19-hydroxyprostaglandin E2	20-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
3196735-2	1988	19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles.	Alprostadil	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
3196735-2	1988	19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles.	Dinoprostone	31-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
3196735-7	1988	20-Hydroxy-PGE1 and 20-hydroxy-PGE2 are formed from PGE1 and PGE2 by cytochrome P-450 in the vesicular glands and the ampullae of deferent ducts of the ram.	20-hydroxyprostaglandin E1	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3196735-7	1988	20-Hydroxy-PGE1 and 20-hydroxy-PGE2 are formed from PGE1 and PGE2 by cytochrome P-450 in the vesicular glands and the ampullae of deferent ducts of the ram.	20-hydroxyprostaglandin E2	20-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3196735-7	1988	20-Hydroxy-PGE1 and 20-hydroxy-PGE2 are formed from PGE1 and PGE2 by cytochrome P-450 in the vesicular glands and the ampullae of deferent ducts of the ram.	Alprostadil	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3196735-7	1988	20-Hydroxy-PGE1 and 20-hydroxy-PGE2 are formed from PGE1 and PGE2 by cytochrome P-450 in the vesicular glands and the ampullae of deferent ducts of the ram.	Dinoprostone	31-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3196735-9	1988	Polymorphism of cytochrome P-450 might contribute to variations in seminal prostaglandins in man and in sheep.	Prostaglandins	75-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3196361-9	1988	For a better understanding of the cytochrome P-450 mediated reactions, we studied the metabolism of midazolam in microsomal fractions prepared from twelve human livers.	Midazolam	100-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
3196361-11	1988	Furthermore, and since we demonstrated that midazolam was predominantly transformed by a single cytochrome P-450 enzyme, we could attribute the large inter-individual variations in midazolam metabolism to differences in human liver cytochrome P-450 content.	Midazolam	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3196361-11	1988	Furthermore, and since we demonstrated that midazolam was predominantly transformed by a single cytochrome P-450 enzyme, we could attribute the large inter-individual variations in midazolam metabolism to differences in human liver cytochrome P-450 content.	Midazolam	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-248
3196361-11	1988	Furthermore, and since we demonstrated that midazolam was predominantly transformed by a single cytochrome P-450 enzyme, we could attribute the large inter-individual variations in midazolam metabolism to differences in human liver cytochrome P-450 content.	Midazolam	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3196361-11	1988	Furthermore, and since we demonstrated that midazolam was predominantly transformed by a single cytochrome P-450 enzyme, we could attribute the large inter-individual variations in midazolam metabolism to differences in human liver cytochrome P-450 content.	Midazolam	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-248
3243660-6	1988	Since many drugs are metabolized by cytochrome P-450, similar to phenazone, it is likely that their elimination in patients with Hodgkin"s disease and in patients with non-Hodgkin"s lymphoma will be also changed.	Antipyrine	65-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
2848984-2	1988	The first compound was ketoconazole, a well-known inhibitor not only of fungal cytochrome P-450 but at higher concentrations also of mammalian cytochrome P-450 dependent enzymes.	Ketoconazole	23-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3149823-10	1988	Incubations of granulosa cells with DMBA in the absence or presence of gonadotropins, testosterone or anti--hCG were performed to investigate possible hormonal requirements for the cytochrome P-450 system(s) which metabolize DMBA.	9,10-Dimethyl-1,2-benzanthracene	36-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
3149823-10	1988	Incubations of granulosa cells with DMBA in the absence or presence of gonadotropins, testosterone or anti--hCG were performed to investigate possible hormonal requirements for the cytochrome P-450 system(s) which metabolize DMBA.	9,10-Dimethyl-1,2-benzanthracene	225-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
3191198-0	1988	[Mechanism of electron transport in the cholesterol-hydroxylating system of adrenal cortex mitochondria: a triple complex of adrenodoxin reductase, adrenodoxin and cytochrome P-450].	Cholesterol	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-181
3149823-14	1988	DMBA mono-oxygenase activity in cell cultures was inhibited about 95% by alpha-naphthoflavone (ANF), an inhibitor of certain cytochrome P-450-catalysed activities.	9,10-Dimethyl-1,2-benzanthracene	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
3149823-14	1988	DMBA mono-oxygenase activity in cell cultures was inhibited about 95% by alpha-naphthoflavone (ANF), an inhibitor of certain cytochrome P-450-catalysed activities.	alpha-naphthoflavone	73-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
3149823-14	1988	DMBA mono-oxygenase activity in cell cultures was inhibited about 95% by alpha-naphthoflavone (ANF), an inhibitor of certain cytochrome P-450-catalysed activities.	alpha-naphthoflavone	95-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
3196394-0	1988	Differentiation of cytochrome P-450 activities with scoparone as substrate.	scoparone	52-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3196394-2	1988	A direct and highly sensitive high performance liquid chromatography (HPLC) method for measuring cytochrome P-450 activities in biological probes, with the substrate scoparone, is described.	scoparone	166-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
3044903-0	1988	Disruption of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P-450.	Heme	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
3044903-2	1988	Porphyrinogenic chemicals deplete the regulatory free heme pool by interacting with cytochrome P-450 thereby inhibiting heme biosynthesis and/or causing heme breakdown.	Heme	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
3044903-2	1988	Porphyrinogenic chemicals deplete the regulatory free heme pool by interacting with cytochrome P-450 thereby inhibiting heme biosynthesis and/or causing heme breakdown.	Heme	120-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
3044903-2	1988	Porphyrinogenic chemicals deplete the regulatory free heme pool by interacting with cytochrome P-450 thereby inhibiting heme biosynthesis and/or causing heme breakdown.	Heme	120-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
3044903-5	1988	Heterocyclic compounds of this type cause mechanism-based inactivation of cytochrome P-450, leading to the formation of N-alkylporphyrins, with ferrochelatase-inhibitory activity resulting in lowering the free heme pool.	n-alkylporphyrins	120-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
3044903-5	1988	Heterocyclic compounds of this type cause mechanism-based inactivation of cytochrome P-450, leading to the formation of N-alkylporphyrins, with ferrochelatase-inhibitory activity resulting in lowering the free heme pool.	Heme	210-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
3044903-8	1988	In the process, the heme moiety of cytochrome P-450 is destroyed and the free heme pool is lowered.	Heme	20-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
3044903-8	1988	In the process, the heme moiety of cytochrome P-450 is destroyed and the free heme pool is lowered.	Heme	78-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
3140691-3	1988	The role of a specific cytochrome P-450 form, debrisoquine 4-hydroxylase, in the metabolism of alfentanil was investigated by competitive inhibition experiments over the concentration range 4-100 microM.	Alfentanil	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
3196692-1	1988	A cytochrome P-450 (P-450) multigene family codes for several related human liver enzymes, including the P-450 responsible for (S)-mephenytoin 4"-hydroxylation.	Mephenytoin	127-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
3419164-0	1988	The reoxidation of cytochrome P-450 by paraquat inhibits aldosterone biosynthesis from 18-hydroxycorticosterone.	Paraquat	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3419164-0	1988	The reoxidation of cytochrome P-450 by paraquat inhibits aldosterone biosynthesis from 18-hydroxycorticosterone.	Aldosterone	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3419164-0	1988	The reoxidation of cytochrome P-450 by paraquat inhibits aldosterone biosynthesis from 18-hydroxycorticosterone.	18-Hydroxycorticosterone	87-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3419164-1	1988	Paraquat is an artificial electron carrier that captures electrons from reduced cytochrome P-450 instead of the natural acceptors, thus decreasing the concentration of reduced mitochondrial cytochrome P-450.	Paraquat	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
3419164-1	1988	Paraquat is an artificial electron carrier that captures electrons from reduced cytochrome P-450 instead of the natural acceptors, thus decreasing the concentration of reduced mitochondrial cytochrome P-450.	Paraquat	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-206
3419164-5	1988	In our conditions, the inhibitory role of paraquat seems restricted to a capture of electrons from reduced cytochrome P-450.	Paraquat	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
3419164-6	1988	Under the same conditions metopirone and spironolactone, known to bind cytochrome P-450 11 beta at the steroid binding site, also inhibited the reaction.	Metyrapone	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3419164-6	1988	Under the same conditions metopirone and spironolactone, known to bind cytochrome P-450 11 beta at the steroid binding site, also inhibited the reaction.	Spironolactone	41-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3419164-6	1988	Under the same conditions metopirone and spironolactone, known to bind cytochrome P-450 11 beta at the steroid binding site, also inhibited the reaction.	Steroids	103-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	Aldosterone	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	Aldosterone	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	18-Hydroxycorticosterone	66-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	18-Hydroxycorticosterone	66-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	Steroids	110-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	Steroids	110-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
3419164-7	1988	Altogether these results show that for aldosterone synthesis from 18-hydroxycorticosterone to take place, the steroid binding site on cytochrome P-450 must be accessible to 18-hydroxycorticosterone and that the cytochrome P-450 must be the direct donor of reducing equivalents.	18-Hydroxycorticosterone	173-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3419164-8	1988	Hence, cytochrome P-450 appears as the final linking point between 18-hydroxycorticosterone and the reducing equivalents provided by NADPH.	18-Hydroxycorticosterone	67-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
3419164-8	1988	Hence, cytochrome P-450 appears as the final linking point between 18-hydroxycorticosterone and the reducing equivalents provided by NADPH.	NADP	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
3145044-0	1988	Modulation of hepatic cytochrome P-450 and DT-diaphorase by oral and sub-cutaneous administration of the pro-oxidant fungicide dichlone (2,3-dichloro-1,4-naphthoquinone).	dichlone	127-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3145044-0	1988	Modulation of hepatic cytochrome P-450 and DT-diaphorase by oral and sub-cutaneous administration of the pro-oxidant fungicide dichlone (2,3-dichloro-1,4-naphthoquinone).	dichlone	137-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3404442-7	1988	Imidazole was used because it is a potent inducer of cytochrome P-450 isozyme 3a which is also induced by ethanol.	imidazole	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3404442-7	1988	Imidazole was used because it is a potent inducer of cytochrome P-450 isozyme 3a which is also induced by ethanol.	Ethanol	106-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3404442-8	1988	The cytochrome P-450 in microsomes from a single human subject metabolized halothane at a rate comparable to that found in microsomes from phenobarbital- and imidazole-pretreated rabbits.	Halothane	75-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3404442-11	1988	Antibodies to cytochrome P-450 3a inhibited halothane metabolism by 90% in microsomes from imidazole-pretreated rabbits, suggesting that isozyme 3a catalyzes halothane metabolism in imidazole-pretreated rabbits.	Halothane	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3404442-11	1988	Antibodies to cytochrome P-450 3a inhibited halothane metabolism by 90% in microsomes from imidazole-pretreated rabbits, suggesting that isozyme 3a catalyzes halothane metabolism in imidazole-pretreated rabbits.	imidazole	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3404442-11	1988	Antibodies to cytochrome P-450 3a inhibited halothane metabolism by 90% in microsomes from imidazole-pretreated rabbits, suggesting that isozyme 3a catalyzes halothane metabolism in imidazole-pretreated rabbits.	Halothane	158-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3404442-11	1988	Antibodies to cytochrome P-450 3a inhibited halothane metabolism by 90% in microsomes from imidazole-pretreated rabbits, suggesting that isozyme 3a catalyzes halothane metabolism in imidazole-pretreated rabbits.	imidazole	182-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3372517-0	1988	Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines.	1,4-dihydropyridine	46-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3067018-3	1988	Metabolic pathways for various drugs have been correlated with debrisoquin metabolism, the observed polymorphism being attributed to variants of cytochrome P-450.	Debrisoquin	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
3263118-3	1988	The olfactory epithelium of male hamsters has been found to be extremely active in the cumene hydroperoxide-supported oxidation of tetramethylphenylenediamine, and this peroxidase activity has been shown to be cytochrome P-450-dependent.	cumene hydroperoxide	87-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	210-226
3263118-3	1988	The olfactory epithelium of male hamsters has been found to be extremely active in the cumene hydroperoxide-supported oxidation of tetramethylphenylenediamine, and this peroxidase activity has been shown to be cytochrome P-450-dependent.	Tetramethylphenylenediamine	131-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	210-226
3263118-14	1988	It is suggested that this behaviour is due to 4-ethyl DDC acting not only as a suicidal inhibitor but also as an inducer of certain forms of cytochrome P-450 in the liver; in the olfactory epithelium, however, inactivation, but not induction, occurs.	4-ethyl ddc	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-157
2839175-2	1988	Lipid peroxidation, monitored by the formation of thiobarbituric acid-reactive substance, was increased with increasing concentration of detergent-solubilized NADPH cytochrome P-450 reductase, cytochrome P-450 or Fe3+-ADP.	thiobarbituric acid	50-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
2839175-3	1988	Cytochrome P-450-dependent lipid peroxidation was parallel to O-2 generation monitored by chemiluminescence probe with 2-methyl-6-(p-methoxyphenol)-3,7-dihydroimidazo[1,2-a]pyrazin++ +-3-one.	2-methyl-6-(p-methoxyphenol)-3,7-dihydroimidazo[1,2-a]pyrazin++ +-3-one	119-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3203057-15	1988	Although the competitive inhibition between some sulphonamides and tolbutamide is consistent with metabolism by the same isozyme of cytochrome P-450 it does not prove it and further studies with purified enzymes will be necessary to confirm this.	Sulfonamides	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3203057-15	1988	Although the competitive inhibition between some sulphonamides and tolbutamide is consistent with metabolism by the same isozyme of cytochrome P-450 it does not prove it and further studies with purified enzymes will be necessary to confirm this.	Tolbutamide	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
2839175-1	1988	In order to evaluate the O-2 participation in NADPH-dependent microsomal lipid peroxidation, we used reconstructed system which contained detergent-solubilized NADPH-dependent cytochrome P-450 reductase, cytochrome P-450, phospholipid liposomes, NADPH and Fe3+-ADP.	NADP	160-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
3372517-1	1988	A variety of different 4-substituted 1,4-dihydropyridine Hantzsch esters are substrates for ring dehydrogenation by a cytochrome P-450 (P-450) enzyme (P-450 UT-A); the substitutent could be varied from a hydrogen to a naphthalenyl, but a pyrenyl derivative was not dehydrogenated.	4-substituted 1,4-dihydropyridine hantzsch esters	23-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
3372517-1	1988	A variety of different 4-substituted 1,4-dihydropyridine Hantzsch esters are substrates for ring dehydrogenation by a cytochrome P-450 (P-450) enzyme (P-450 UT-A); the substitutent could be varied from a hydrogen to a naphthalenyl, but a pyrenyl derivative was not dehydrogenated.	Hydrogen	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
3372517-1	1988	A variety of different 4-substituted 1,4-dihydropyridine Hantzsch esters are substrates for ring dehydrogenation by a cytochrome P-450 (P-450) enzyme (P-450 UT-A); the substitutent could be varied from a hydrogen to a naphthalenyl, but a pyrenyl derivative was not dehydrogenated.	naphthalenyl	218-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
3372517-1	1988	A variety of different 4-substituted 1,4-dihydropyridine Hantzsch esters are substrates for ring dehydrogenation by a cytochrome P-450 (P-450) enzyme (P-450 UT-A); the substitutent could be varied from a hydrogen to a naphthalenyl, but a pyrenyl derivative was not dehydrogenated.	pyrenyl	238-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
3378384-5	1988	The data suggest that this cytochrome P-450 is the major cyclosporine-metabolizing enzyme in human liver.	Cyclosporine	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
3378384-6	1988	The substrate specificity and the known inducers and inhibitors of this cytochrome P-450 explain several clinically observed drug interactions with cyclosporine.	Cyclosporine	148-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
3385648-3	1988	An improved method is described in which toxic APAP metabolites are generated by a purified and reconstituted cytochrome P-450 system, minimizing the amount of exogenous detoxification enzymes in the assay.	Acetaminophen	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
3135288-6	1988	Both cytochrome P-450 (P less than .01) and nicotinamide adenine dinucleotide phosphate (NADPH) cytochrome c reductase (P less than .06) were higher in ewes receiving PB than in controls.	Phenobarbital	167-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
3385648-8	1988	The data are consistent with the generation of cytochrome P-450-dependent reactive metabolites which subsequently can be detoxified by glutathione.	Glutathione	135-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
3382731-0	1988	[Effects of hydrogen peroxide on cytochrome P-450 inactivation].	Hydrogen Peroxide	12-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
3181604-2	1988	In man and animals, there is an associated rise in microsomal cytochrome P-450, including a specific form (P-450IIEI) with high affinity for ethanol and for the activation of some drugs (i.e. acetaminophen), carcinogens (i.e. N-nitrosodimethylamine) and hepatotoxic agents (i.e. CCl4), thereby contributing to the susceptibility of alcoholics to xenobiotics, including industrial solvents.	Ethanol	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3181604-2	1988	In man and animals, there is an associated rise in microsomal cytochrome P-450, including a specific form (P-450IIEI) with high affinity for ethanol and for the activation of some drugs (i.e. acetaminophen), carcinogens (i.e. N-nitrosodimethylamine) and hepatotoxic agents (i.e. CCl4), thereby contributing to the susceptibility of alcoholics to xenobiotics, including industrial solvents.	Acetaminophen	192-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3181604-2	1988	In man and animals, there is an associated rise in microsomal cytochrome P-450, including a specific form (P-450IIEI) with high affinity for ethanol and for the activation of some drugs (i.e. acetaminophen), carcinogens (i.e. N-nitrosodimethylamine) and hepatotoxic agents (i.e. CCl4), thereby contributing to the susceptibility of alcoholics to xenobiotics, including industrial solvents.	Dimethylnitrosamine	226-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3181604-3	1988	In addition, a benzoflavone-inducible liver cytochrome P-450 isoenzyme distinct but catalytically similar to cytochrome P-450IIE1 was purified which may play a significant role in drinkers who also are heavy smokers.	Benzoflavones	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
3382731-1	1988	Inactivation rate of purified oligomeric cytochrome P-450 LM2 has been investigated in glucose oxidase system and under the action of exogenous hydrogen peroxide (400 microM).	Hydrogen Peroxide	144-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3288213-2	1988	Anti-human NADPH-cytochrome P-450 reductase inhibited all theophylline metabolic pathways confirming the involvement of cytochrome P-450 isozymes in the metabolism of theophylline.	Theophylline	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
3382731-2	1988	It has been found that hydrogen peroxide has a distinct inactivating effect on cytochrome P-450.	Hydrogen Peroxide	23-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3288213-2	1988	Anti-human NADPH-cytochrome P-450 reductase inhibited all theophylline metabolic pathways confirming the involvement of cytochrome P-450 isozymes in the metabolism of theophylline.	Theophylline	167-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
3288213-12	1988	The results confirm that there are at least two distinct cytochrome P-450 isozymes involved in theophylline metabolism, one isozyme being involved with the demethylations and a different isozyme involved in the 8-hydroxylation pathway.	Theophylline	95-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3382731-4	1988	Benzphetamine, a substrate specific for this enzyme isoform, exerts a protective effect by decreasing the rate of cytochrome P-450 inactivation and SH-group oxidation.	Benzphetamine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
3045791-7	1988	Serum LDL-C levels are inversely proportional to hepatic cytochrome P-450 concentrations.	ldl-c	6-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3285175-8	1988	Additional experiments did not show any evidence for the involvement of a number of other human cytochrome P-450 enzymes in 17 alpha-ethynylestradiol 2-hydroxylation (i.e., P-450DB, P-450PA, P-450MP, P-450j).	Ethinyl Estradiol	124-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3367901-0	1988	Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.	Steroids	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3285175-0	1988	Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450.	Ethinyl Estradiol	13-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
3285175-7	1988	In addition, 17 alpha-ethynylestradiol appears to be a mechanism-based inhibitor in human liver microsomes, as shown by the loss of both spectrally detectable cytochrome P-450 and 17 alpha-ethynylestradiol 2-hydroxylase activity during incubation in the presence of NADPH.	Ethinyl Estradiol	13-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
2898328-1	1988	Halothane is reduced to 2-chloro-1,1,1-trifluoroethane (CTE) and 2-chloro-1,1-difluoroethene (CDE) by cytochrome P-450.	Halothane	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
3044468-15	1988	Subjects with a deficiency in a particular isoenzyme of cytochrome P-450 poorly metabolize perhexiline and are at higher risk of developing liver lesions.	Perhexiline	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	Histamine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	Cimetidine	43-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	Ranitidine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	Famotidine	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	mifentidine	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2899931-8	1988	The demonstration that cimetidine, ranitidine and histamine were all poor inhibitors of phenacetin oxidation further suggests the possible lack of identity between the human liver cytochrome P-450 isoenzymes responsible for catalyzing the oxidation of metoprolol and phenacetin.	Metoprolol	252-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
2899931-8	1988	The demonstration that cimetidine, ranitidine and histamine were all poor inhibitors of phenacetin oxidation further suggests the possible lack of identity between the human liver cytochrome P-450 isoenzymes responsible for catalyzing the oxidation of metoprolol and phenacetin.	Phenacetin	267-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
3355588-3	1988	Anti-human liver NADPH-cytochrome P-450 reductase IgG inhibited hydroxytolbutamide formation and this metabolite was not formed when NADPH-generating system was omitted from microsomal incubations.	hydroxymethyltolbutamide	64-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
3355588-3	1988	Anti-human liver NADPH-cytochrome P-450 reductase IgG inhibited hydroxytolbutamide formation and this metabolite was not formed when NADPH-generating system was omitted from microsomal incubations.	NADP	17-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
3355588-4	1988	Tolbutamide hydroxylation followed Michaelis-Menten kinetics, consistent with the involvement of a single form of cytochrome P-450 in this reaction.	Tolbutamide	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
2898328-1	1988	Halothane is reduced to 2-chloro-1,1,1-trifluoroethane (CTE) and 2-chloro-1,1-difluoroethene (CDE) by cytochrome P-450.	1,1,1-trifluoro-2-chloroethane	56-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
2898328-1	1988	Halothane is reduced to 2-chloro-1,1,1-trifluoroethane (CTE) and 2-chloro-1,1-difluoroethene (CDE) by cytochrome P-450.	2-chloro-1,1-difluoroethylene	65-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
3367901-0	1988	Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.	alpha-naphthoflavone	92-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3420813-1	1988	Content and catalytic activity of cytochrome P-450 were studied using amidopyrine as a substrate of the I type and aniline as a substrate of the II type.	Aminopyrine	70-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
3420813-1	1988	Content and catalytic activity of cytochrome P-450 were studied using amidopyrine as a substrate of the I type and aniline as a substrate of the II type.	aniline	115-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
3420813-2	1988	In hypoxia content of cytochrome P-450 and metabolism of amidopyrine were increased, while the enzyme content and the substrate metabolism were decreased in hyperoxia.	Aminopyrine	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3133648-6	1988	Lauric acid is a substrate known to be metabolized by a renal cytochrome P-450 to 11 and 12-hydroxylated products.	lauric acid	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3133648-8	1988	Based on these results we conclude that cytochrome P-450 plays at the most a limited role in human kidney metabolism of sulindac-sulphide.	sulindac sulfide	120-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3390478-1	1988	Studies were carried out of temperature quenching of self-fluorescence of cytochrome P-450 in solution and liposomes from natural phosphatidylcholine, dimiristoylphosphatidylcholine, dipalmitoylphosphatidylcholine.	dimiristoylphosphatidylcholine	151-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
3390478-1	1988	Studies were carried out of temperature quenching of self-fluorescence of cytochrome P-450 in solution and liposomes from natural phosphatidylcholine, dimiristoylphosphatidylcholine, dipalmitoylphosphatidylcholine.	1,2-Dipalmitoylphosphatidylcholine	183-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
3390478-2	1988	The fluorescence spectrum of cytochrome P-450 is a superposition of triptophane and tyrosine components.	triptophane	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
3390478-2	1988	The fluorescence spectrum of cytochrome P-450 is a superposition of triptophane and tyrosine components.	Tyrosine	84-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
2898328-1	1988	Halothane is reduced to 2-chloro-1,1,1-trifluoroethane (CTE) and 2-chloro-1,1-difluoroethene (CDE) by cytochrome P-450.	1,1,1-trifluoro-2-chloroethane	24-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
3356413-0	1988	Phenobarbital induction of cytochrome P-450 b,e genes is dependent on protein synthesis.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
3127205-2	1988	The reaction required molecular oxygen and NADPH, and was significantly inhibited by carbon monoxide, suggesting that a cytochrome P-450 is involved.	Oxygen	32-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3127205-2	1988	The reaction required molecular oxygen and NADPH, and was significantly inhibited by carbon monoxide, suggesting that a cytochrome P-450 is involved.	NADP	43-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3127205-2	1988	The reaction required molecular oxygen and NADPH, and was significantly inhibited by carbon monoxide, suggesting that a cytochrome P-450 is involved.	Carbon Monoxide	85-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3127205-3	1988	The neutrophil microsomal fraction showed a carbon monoxide difference spectrum with a peak at 450 nm in the presence of NADPH or dithionite, indicating the presence of a cytochrome P-450.	Carbon Monoxide	44-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-187
3127205-3	1988	The neutrophil microsomal fraction showed a carbon monoxide difference spectrum with a peak at 450 nm in the presence of NADPH or dithionite, indicating the presence of a cytochrome P-450.	NADP	121-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-187
3127205-3	1988	The neutrophil microsomal fraction showed a carbon monoxide difference spectrum with a peak at 450 nm in the presence of NADPH or dithionite, indicating the presence of a cytochrome P-450.	Dithionite	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-187
3127205-9	1988	These observations provide direct evidence that the oxygen-activating component of the LTB4 omega-hydroxylase system is a cytochrome P-450.	Oxygen	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-109
3127205-9	1988	These observations provide direct evidence that the oxygen-activating component of the LTB4 omega-hydroxylase system is a cytochrome P-450.	Oxygen	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
3356413-1	1988	Phenobarbital induces liver cytochrome P-450 b,e proteins mainly by increasing the rate of transcription of these genes.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3127205-14	1988	These characteristics indicate that the isoenzyme of cytochrome P-450 in human neutrophils, LTB4 omega-hydroxylase, is different from the ones reported to be involved in omega-hydroxylation reactions of prostaglandins and fatty acids.	Prostaglandins	203-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3127205-14	1988	These characteristics indicate that the isoenzyme of cytochrome P-450 in human neutrophils, LTB4 omega-hydroxylase, is different from the ones reported to be involved in omega-hydroxylation reactions of prostaglandins and fatty acids.	Prostaglandins	203-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-114
3356413-2	1988	The mechanism responsible for the phenobarbital increment in the rate of transcription of cytochrome P-450 b,e genes is unknown.	Phenobarbital	34-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
3127205-14	1988	These characteristics indicate that the isoenzyme of cytochrome P-450 in human neutrophils, LTB4 omega-hydroxylase, is different from the ones reported to be involved in omega-hydroxylation reactions of prostaglandins and fatty acids.	Fatty Acids	222-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3127205-14	1988	These characteristics indicate that the isoenzyme of cytochrome P-450 in human neutrophils, LTB4 omega-hydroxylase, is different from the ones reported to be involved in omega-hydroxylation reactions of prostaglandins and fatty acids.	Fatty Acids	222-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-114
3356413-3	1988	The objective of this study was to assess whether active protein synthesis was needed for phenobarbital to induce the liver cytochrome P-450 b,e genes.	Phenobarbital	90-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3356413-7	1988	While phenobarbital increased cytochrome P-450 b,e mRNAs about 12-fold at 3 hr, this induction was abolished by cycloheximide.	Phenobarbital	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
3356413-8	1988	To define whether the absence of protein synthesis in hepatocytes inhibited the phenobarbital induction of cytochrome P-450 at the transcriptional level, in vitro transcription rates using isolated nuclei were measured.	Phenobarbital	80-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
3356413-9	1988	After phenobarbital administration, there was about a 20-fold increment in transcriptional rate of cytochrome P-450 b,e genes.	Phenobarbital	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
3356413-11	1988	It is proposed that either preexisting regulatory proteins or transacting factors dependent on active protein synthesis participate in the regulation of liver cytochrome P-450 b,e gene transcription after phenobarbital.	Phenobarbital	205-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
3398207-0	1988	[Metabolism of lidocaine by cytochrome P-450].	Lidocaine	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-45
3341769-0	1988	The role of iron chelates on the selectivity of Fenton reagent in hydroxylation, N-demethylation, and sulfoxidation of cimetidine: a novel biomimetic model for the regioselectivity of cytochrome P-450.	Iron	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
3123495-1	1988	A novel human liver cytochrome P-450 isozyme (P-450-AA), which catalyzes arachidonic acid epoxidation, has been purified to electrophoretic homogeneity from human liver.	Arachidonic Acid	73-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
3123495-3	1988	Cytochrome P-450-AA appeared homogeneous as judged by the appearance of a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an estimated molecular weight of 53,100.	polyacrylamide	112-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3123495-4	1988	Although cytochrome P-450-AA had a relatively low specific content of 10.8 nmol/mg, it possessed a high activity of arachidonic acid epoxidation.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
3123495-6	1988	Moreover, the purified cytochrome P-450-AA catalyzed the de-ethylation of 7-ethoxyresorufin at the rate of 2970 pmol/nmol/min, whereas other cytochrome P-450-dependent reactions were carried out at 23-2,000-fold lower rates and ranged between 0.3-130 pmol/nmol/min.	ethoxyresorufin	74-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
3341769-0	1988	The role of iron chelates on the selectivity of Fenton reagent in hydroxylation, N-demethylation, and sulfoxidation of cimetidine: a novel biomimetic model for the regioselectivity of cytochrome P-450.	Cimetidine	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
3341769-4	1988	These results indicate that the oxidation of cimetidine with hydrogen peroxide activated by various chelated ferrous ions serves as a biomimetic model for the regioselectivity of multiple forms of cytochrome P-450 in the metabolism of cimetidine.	Cimetidine	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-213
3341769-4	1988	These results indicate that the oxidation of cimetidine with hydrogen peroxide activated by various chelated ferrous ions serves as a biomimetic model for the regioselectivity of multiple forms of cytochrome P-450 in the metabolism of cimetidine.	Hydrogen Peroxide	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-213
3341769-4	1988	These results indicate that the oxidation of cimetidine with hydrogen peroxide activated by various chelated ferrous ions serves as a biomimetic model for the regioselectivity of multiple forms of cytochrome P-450 in the metabolism of cimetidine.	Cimetidine	235-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-213
3370255-1	1988	The steady-state levels of aerobic and anaerobic reduction of cytochrome b5 by ascorbic acid and the initial rates of cytochrome b5 reduction in the presence of ascorbic acid and of anaerobic cytochrome P-450 reduction in the presence of NADH were used to calculate the rate constants for cytochrome b5 oxidation.	NAD	238-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-208
3337745-10	1988	These results suggest that the human cytochrome P-450 isozyme that is immunochemically similar and, thus, homologous to rat P-450d plays a major role in the metabolic activation of several procarcinogens examined, and that the activation of AFB1 is catalyzed by another and, possibly, not phenobarbital-inducible form(s) of human cytochrome P-450.	Phenobarbital	289-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
3337745-10	1988	These results suggest that the human cytochrome P-450 isozyme that is immunochemically similar and, thus, homologous to rat P-450d plays a major role in the metabolic activation of several procarcinogens examined, and that the activation of AFB1 is catalyzed by another and, possibly, not phenobarbital-inducible form(s) of human cytochrome P-450.	Phenobarbital	289-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-346
2827686-1	1988	The mechanism of action of azole antifungal agents is believed to involve inhibition of fungal cytochrome P-450, and, therefore, an investigation of the interaction of these drugs with mammalian cytochrome P-450 systems should provide some indication of their selectivity as antifungal agents.	Azoles	27-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-211
3337722-2	1988	These compounds inhibit oxidation and binding of the substrates of cytochrome P-450 (aminopyrine and aniline), inhibition being of a competitive character.	Aminopyrine	85-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3346844-2	1988	Ranitidine is thought to spare phase I hepatic metabolism mediated by cytochrome P-450, unlike its counterpart H2-receptor antagonist cimetidine.	Ranitidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
3337722-2	1988	These compounds inhibit oxidation and binding of the substrates of cytochrome P-450 (aminopyrine and aniline), inhibition being of a competitive character.	aniline	101-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3342091-0	1988	Species differences in adrenal spironolactone metabolism: relationship to cytochrome P-450 destruction.	Spironolactone	31-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
3350119-3	1988	Its mode of inhibitory action in ecdysone biosynthesis is probably inactivation of cytochrome P-450.	Ecdysone	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
2827463-3	1988	In the present paper we report the isolation and sequence of a cDNA clone for the human hepatic cytochrome P-450 responsible for mephenytoin (an anticonvulsant) oxidation.	Mephenytoin	129-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3250508-0	1988	Cytochrome P-450 model systems: alkene oxidation.	Alkenes	32-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2850750-7	1988	The choice of itraconazole--with its improved tissue affinity, its lower therapeutic dose requirements, and its increased selectivity for fungal cytochrome P-450--demonstrates very well that the use of animal and human pharmacology helps in the design of an antifungal drug with as much effect as possible on the fungus and as little effect as possible on the host.	Itraconazole	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
3276317-3	1988	It would appear that there is greater stereoselective control in the interaction of warfarin with cytochrome P-450 enzymes than that observed for interaction with the receptor, vitamin K1 epoxide reductase.	Warfarin	84-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
2854994-0	1988	Radical intermediates in the catalytic cycles of cytochrome P-450.	radical	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
2854994-1	1988	Schemes are presented summarizing current knowledge of the mechanism of action of cytochrome P-450 when it functions either as a monooxygenase with molecular oxygen as the oxygen donor or as a peroxygenase with peroxy compounds as the oxygen donor.	Oxygen	133-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
3342453-0	1988	Cytochrome P-450-mediated oxidation of substrates by electron-transfer; role of oxygen radicals and of 1- and 2-electron oxidation of paracetamol.	Acetaminophen	134-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2854994-1	1988	Schemes are presented summarizing current knowledge of the mechanism of action of cytochrome P-450 when it functions either as a monooxygenase with molecular oxygen as the oxygen donor or as a peroxygenase with peroxy compounds as the oxygen donor.	Oxygen	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2854994-1	1988	Schemes are presented summarizing current knowledge of the mechanism of action of cytochrome P-450 when it functions either as a monooxygenase with molecular oxygen as the oxygen donor or as a peroxygenase with peroxy compounds as the oxygen donor.	Oxygen	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
2854994-3	1988	In addition, cytochrome P-450 catalyzes reductive reactions, including a recently discovered reaction in which organic hydroperoxides are cleaved to yield hydrocarbons and aldehydes or ketones.	Hydrogen Peroxide	119-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2854994-3	1988	In addition, cytochrome P-450 catalyzes reductive reactions, including a recently discovered reaction in which organic hydroperoxides are cleaved to yield hydrocarbons and aldehydes or ketones.	Hydrocarbons	155-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2854994-3	1988	In addition, cytochrome P-450 catalyzes reductive reactions, including a recently discovered reaction in which organic hydroperoxides are cleaved to yield hydrocarbons and aldehydes or ketones.	Aldehydes	172-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2854994-3	1988	In addition, cytochrome P-450 catalyzes reductive reactions, including a recently discovered reaction in which organic hydroperoxides are cleaved to yield hydrocarbons and aldehydes or ketones.	Ketones	185-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2854994-5	1988	Evidence has been obtained that lipid hydroperoxides are physiological substrates for this reductive cleavage reaction catalyzed by cytochrome P-450.	Lipid Peroxides	32-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3132330-2	1988	The enzymatic oxidation of tetrachloro-1,4-hydroquinone (1,4-TCHQ), resulting in covalent binding to protein of tetrachloro-1,4-benzoquinone (1,4-TCBQ), was investigated, with special attention to the involvement of cytochrome P-450 and reactive oxygen species.	2,3,5,6-tetrachlorohydroquinone	27-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
3132330-2	1988	The enzymatic oxidation of tetrachloro-1,4-hydroquinone (1,4-TCHQ), resulting in covalent binding to protein of tetrachloro-1,4-benzoquinone (1,4-TCBQ), was investigated, with special attention to the involvement of cytochrome P-450 and reactive oxygen species.	2,3,5,6-tetrachlorohydroquinone	57-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
3132330-2	1988	The enzymatic oxidation of tetrachloro-1,4-hydroquinone (1,4-TCHQ), resulting in covalent binding to protein of tetrachloro-1,4-benzoquinone (1,4-TCBQ), was investigated, with special attention to the involvement of cytochrome P-450 and reactive oxygen species.	Chloranil	112-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
3132330-2	1988	The enzymatic oxidation of tetrachloro-1,4-hydroquinone (1,4-TCHQ), resulting in covalent binding to protein of tetrachloro-1,4-benzoquinone (1,4-TCBQ), was investigated, with special attention to the involvement of cytochrome P-450 and reactive oxygen species.	1,4-tcbq	142-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
3132330-2	1988	The enzymatic oxidation of tetrachloro-1,4-hydroquinone (1,4-TCHQ), resulting in covalent binding to protein of tetrachloro-1,4-benzoquinone (1,4-TCBQ), was investigated, with special attention to the involvement of cytochrome P-450 and reactive oxygen species.	Reactive Oxygen Species	237-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
3132330-7	1988	Inhibition of cytochrome P-450 by metyrapone, which is also known to block the P-450-mediated formation of reactive oxygen species, gave a 80% decrease in binding, while the addition of superoxide dismutase prevented 75% of the covalent binding, almost the same amount as found in anerobic incubations.	Metyrapone	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3132330-7	1988	Inhibition of cytochrome P-450 by metyrapone, which is also known to block the P-450-mediated formation of reactive oxygen species, gave a 80% decrease in binding, while the addition of superoxide dismutase prevented 75% of the covalent binding, almost the same amount as found in anerobic incubations.	Reactive Oxygen Species	107-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3132330-8	1988	A large part of the conversion of 1,4-TCHQ to 1,4-TCBQ is apparently not catalyzed by cytochrome P-450 itself, but is mediated by superoxide anion formed by this enzyme.	2,3,5,6-tetrachlorohydroquinone	34-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3132330-8	1988	A large part of the conversion of 1,4-TCHQ to 1,4-TCBQ is apparently not catalyzed by cytochrome P-450 itself, but is mediated by superoxide anion formed by this enzyme.	1,4-tcbq	46-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3132330-11	1988	1,4-TCHQ was shown to stimulate the oxidase activity of microsomal cytochrome P-450.	2,3,5,6-tetrachlorohydroquinone	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3288361-0	1988	Cytochrome P450 of fungi: primary target for azole antifungal agents.	Azoles	45-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
3288361-9	1988	Cytochrome P450, which mediates the 14 alpha-demethylation of lanosterol, is also present in mammalian cells.	Lanosterol	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
3288361-11	1988	If azole antifungal agents inhibit mammalian cytochrome P450 too, their systemic use may result in potentially significant adverse reactions.	Azoles	3-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
3276317-4	1988	Indeed, warfarin has been developed as a powerful stereochemical probe for in vitro studies of the terminal enzyme in the mixed-function oxidase system, cytochrome P-450.	Warfarin	8-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-169
3243187-3	1988	Our data show also that phenobarbital not only enhances both the direct and metabolism-mediated interaction of most tested PHH with microsomal cytochrome P-450, but also increases the affinity of hexachlorobutadiene, chloroform and carbon tetrachloride for the mitochondrial sites resulting in respiration inhibition.	Phenobarbital	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
3078287-2	1988	The role of the FMO relative to cytochrome P-450 in the oxidation of the sulfur atoms of organosulfur compounds is considered with particular reference to the hepatatoxicant thiobenzamide, the insecticide phorate and the drug, thioridazine.	Sulfur	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
2894945-1	1988	Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine.	Quinidine	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2894945-1	1988	Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine.	4-hydroxydebrisoquin	212-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2894945-1	1988	Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine.	Debrisoquin	221-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2894945-1	1988	Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine.	Sparteine	245-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2894945-8	1988	These observations indicate that none of the major oxidative reactions of QD are catalyzed by the sparteine/debrisoquine isozyme; QD may simply bind to this cytochrome P-450, without being oxidized by it.	Sparteine	98-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
3383988-11	1988	The two main inferences are first, that tolbutamide and antipyrine are metabolised by different forms of cytochrome P-450, and second that a battery of model substrates is needed to investigate the inhibitory effects of a drug in man.	Tolbutamide	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
3383988-11	1988	The two main inferences are first, that tolbutamide and antipyrine are metabolised by different forms of cytochrome P-450, and second that a battery of model substrates is needed to investigate the inhibitory effects of a drug in man.	Antipyrine	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
3128014-13	1988	These data suggest the possibility that propranolol oxidation may be mediated in part, by one or more human liver cytochrome P-450 species catalyzing phenacetin oxidation.	Propranolol	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
3406035-0	1988	Role of cytochrome P-450 in hydrocarbon formation from xenobiotic and lipid hydroperoxides.	Hydrocarbons	28-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
3406035-0	1988	Role of cytochrome P-450 in hydrocarbon formation from xenobiotic and lipid hydroperoxides.	Lipid Peroxides	70-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
3406035-1	1988	Cytochrome P-450 has recently been found to catalyze the reductive cleavage of both xenobiotic hydroperoxides and biologically occurring lipid hydroperoxides.	xenobiotic hydroperoxides	84-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3406035-1	1988	Cytochrome P-450 has recently been found to catalyze the reductive cleavage of both xenobiotic hydroperoxides and biologically occurring lipid hydroperoxides.	Lipid Peroxides	137-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3406036-0	1988	A unique deuterium/proton exchange during cytochrome P-450 mediated expoxidation of propene and butene.	Deuterium	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
3406036-0	1988	A unique deuterium/proton exchange during cytochrome P-450 mediated expoxidation of propene and butene.	propylene	84-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
3406036-0	1988	A unique deuterium/proton exchange during cytochrome P-450 mediated expoxidation of propene and butene.	butylene	96-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
3406036-1	1988	A cytochrome P-450 LM2 reconstituted system mediated expoxidations of small terminal alkenes to the corresponding alkyloxiranes.	Alkenes	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
3406036-1	1988	A cytochrome P-450 LM2 reconstituted system mediated expoxidations of small terminal alkenes to the corresponding alkyloxiranes.	alkyloxiranes	114-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
3129418-5	1988	The absolute spectrum of the aromatase exhibits a Soret peak at 423 nm in the absence of testosterone and addition of testosterone to the aromatase sample makes its absorption peak shift gradually from 423 to 393 nm (high spin type peak), which is a usual characteristic in the spectrum of cytochrome P-450.	Testosterone	118-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	290-306
3128014-13	1988	These data suggest the possibility that propranolol oxidation may be mediated in part, by one or more human liver cytochrome P-450 species catalyzing phenacetin oxidation.	Phenacetin	150-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
3689794-1	1987	Consideration of the computer-optimised dimensions of anthraflavic acid indicates that it is essentially a planar molecule with a large area/depth ratio, that would preferentially interact with the polycyclic aromatic hydrocarbon-induced family of cytochrome P-450 proteins (cytochromes P-448).	2,6-dihydroxyanthraquinone	54-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	248-264
3442670-4	1987	We have accumulated evidence that autoimmune antibodies observed in sera of patients with tienilic acid induced hepatitis (anti-liver kidney microsome 2 or anti-LKM2 antibodies) specifically recognize the cytochrome P-450 involved in the mephenytoin hydroxylation polymorphism.	Ticrynafen	90-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
3442670-4	1987	We have accumulated evidence that autoimmune antibodies observed in sera of patients with tienilic acid induced hepatitis (anti-liver kidney microsome 2 or anti-LKM2 antibodies) specifically recognize the cytochrome P-450 involved in the mephenytoin hydroxylation polymorphism.	Mephenytoin	238-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
3689794-1	1987	Consideration of the computer-optimised dimensions of anthraflavic acid indicates that it is essentially a planar molecule with a large area/depth ratio, that would preferentially interact with the polycyclic aromatic hydrocarbon-induced family of cytochrome P-450 proteins (cytochromes P-448).	Polycyclic Aromatic Hydrocarbons	198-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	248-264
3442670-6	1987	The cytochrome P-450 recognized by anti-LKM2 antibodies was immunopurified from microsomes derived from livers of extensive (EM) or poor metabolizers (PM) of (S)-mephenytoin.	Mephenytoin	158-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3435455-5	1987	At higher concentrations of alcohol (25-30 mM), rates of ethanol uptake were about 80 mumol/h per g, whereas rates of butanol uptake were only about 9 mumol/h per g. Because rates of butanol metabolism via cytochrome P-450 in deermice were more than an order of magnitude lower than rates of ethanol uptake in livers from ADH-negative deermice, it is concluded that ethanol uptake by perfused livers from ADH-negative deermice is catalysed predominantly via catalase-H2O2.	Ethanol	292-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
3442670-9	1987	These data strongly suggest that the mephenytoin hydroxylation deficiency is caused by a minor structural change leading to a functionally altered cytochrome P-450 isozyme.	Mephenytoin	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
3435455-3	1987	Thus butanol is oxidized by cytochrome P-450 in microsomal fractions, but not by cytosolic catalase, in tissues from ADH-negative deermice.	Butanols	5-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3689440-2	1987	The genetically controlled polymorphic oxidation of debrisoquine and sparteine is caused by the absence or functional deficiency of a cytochrome P-450 isozyme.	Debrisoquin	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3435455-5	1987	At higher concentrations of alcohol (25-30 mM), rates of ethanol uptake were about 80 mumol/h per g, whereas rates of butanol uptake were only about 9 mumol/h per g. Because rates of butanol metabolism via cytochrome P-450 in deermice were more than an order of magnitude lower than rates of ethanol uptake in livers from ADH-negative deermice, it is concluded that ethanol uptake by perfused livers from ADH-negative deermice is catalysed predominantly via catalase-H2O2.	Ethanol	292-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
3689440-2	1987	The genetically controlled polymorphic oxidation of debrisoquine and sparteine is caused by the absence or functional deficiency of a cytochrome P-450 isozyme.	Sparteine	69-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3435455-5	1987	At higher concentrations of alcohol (25-30 mM), rates of ethanol uptake were about 80 mumol/h per g, whereas rates of butanol uptake were only about 9 mumol/h per g. Because rates of butanol metabolism via cytochrome P-450 in deermice were more than an order of magnitude lower than rates of ethanol uptake in livers from ADH-negative deermice, it is concluded that ethanol uptake by perfused livers from ADH-negative deermice is catalysed predominantly via catalase-H2O2.	Alcohols	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
3689440-3	1987	In order to elucidate the mechanisms underlying the differences in cytochrome P-450 function we have studied the 1"-hydroxylation of the prototype drug bufuralol in human liver microsomes of individuals phenotyped in vivo as extensive metabolizers (EM, N = 10), poor metabolizers (PM, N = 5) and in subjects with an intermediate rate of metabolism (IM, N = 4).	bufuralol	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3689440-6	1987	Inhibition of bufuralol 1"-hydroxylation by quinidine was biphasic in EM microsomes, providing further support for the involvement of at least two cytochrome P-450 isozymes.	bufuralol	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
3689440-8	1987	Our data suggest that the debrisoquine/sparteine type of oxidation polymorphism is caused by an almost complete loss of a minor cytochrome P-450 isozyme which has a high affinity and stereoselectivity for (+)-bufuralol and a high sensitivity to inhibition by quinidine.	Debrisoquin	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
3689440-8	1987	Our data suggest that the debrisoquine/sparteine type of oxidation polymorphism is caused by an almost complete loss of a minor cytochrome P-450 isozyme which has a high affinity and stereoselectivity for (+)-bufuralol and a high sensitivity to inhibition by quinidine.	Sparteine	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
3689440-8	1987	Our data suggest that the debrisoquine/sparteine type of oxidation polymorphism is caused by an almost complete loss of a minor cytochrome P-450 isozyme which has a high affinity and stereoselectivity for (+)-bufuralol and a high sensitivity to inhibition by quinidine.	bufuralol	205-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
3435455-5	1987	At higher concentrations of alcohol (25-30 mM), rates of ethanol uptake were about 80 mumol/h per g, whereas rates of butanol uptake were only about 9 mumol/h per g. Because rates of butanol metabolism via cytochrome P-450 in deermice were more than an order of magnitude lower than rates of ethanol uptake in livers from ADH-negative deermice, it is concluded that ethanol uptake by perfused livers from ADH-negative deermice is catalysed predominantly via catalase-H2O2.	Butanols	183-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
3435455-5	1987	At higher concentrations of alcohol (25-30 mM), rates of ethanol uptake were about 80 mumol/h per g, whereas rates of butanol uptake were only about 9 mumol/h per g. Because rates of butanol metabolism via cytochrome P-450 in deermice were more than an order of magnitude lower than rates of ethanol uptake in livers from ADH-negative deermice, it is concluded that ethanol uptake by perfused livers from ADH-negative deermice is catalysed predominantly via catalase-H2O2.	Hydrogen Peroxide	467-471	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
3689440-8	1987	Our data suggest that the debrisoquine/sparteine type of oxidation polymorphism is caused by an almost complete loss of a minor cytochrome P-450 isozyme which has a high affinity and stereoselectivity for (+)-bufuralol and a high sensitivity to inhibition by quinidine.	Quinidine	259-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
2834196-8	1987	This increase in enzyme activity was associated with a parallel increase in placental microsomal protein immunochemically related to cytochrome P-450 form 6 [derived from 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced rabbit lung].	Polychlorinated Dibenzodioxins	171-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
3690940-10	1987	Other work has shown that inhibition of drug metabolism by methoxsalen is associated with both extensive covalent binding of metabolite(s) of methoxsalen to liver microsomal protein in vitro and in vivo and inactivation of cytochrome P-450.	Methoxsalen	59-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-239
2834196-8	1987	This increase in enzyme activity was associated with a parallel increase in placental microsomal protein immunochemically related to cytochrome P-450 form 6 [derived from 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced rabbit lung].	Polychlorinated Dibenzodioxins	208-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
2830916-2	1987	DCNQ was shown to be bound to microsomal cytochrome P-450 as a type I substrate; its N-demethylation was catalyzed by cytochrome P-450.	dcnq	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3435446-0	1987	Monoclonal antibodies against human cytochrome P-450 recognizing different pregnenolone 16 alpha-carbonitrile-inducible rat cytochromes P-450.	Pregnenolone	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
3435446-0	1987	Monoclonal antibodies against human cytochrome P-450 recognizing different pregnenolone 16 alpha-carbonitrile-inducible rat cytochromes P-450.	alpha-carbonitrile	91-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
2830916-2	1987	DCNQ was shown to be bound to microsomal cytochrome P-450 as a type I substrate; its N-demethylation was catalyzed by cytochrome P-450.	dcnq	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
2830916-3	1987	Cytochrome P-450 and NADPH-cytochrome P-450 reductase are capable of DCNQ reduction to semi- and hydroquinones.	dcnq	69-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2830916-3	1987	Cytochrome P-450 and NADPH-cytochrome P-450 reductase are capable of DCNQ reduction to semi- and hydroquinones.	Hydroquinones	97-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3445541-2	1987	Phenobarbital-induced cytochrome P-450 was especially sensitive to the influence of all the agents studied, while cytochrome P-450 from untreated animals was the least sensitive; the 3-methyl-cholanthrene-induced cytochrome P-448 exhibited the least sensitivity to guanidine.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
2825178-0	1987	12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea.	12(r)-hydroxyicosatetraenoic acid	0-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
2825178-0	1987	12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea.	Arachidonic Acid	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
3445541-2	1987	Phenobarbital-induced cytochrome P-450 was especially sensitive to the influence of all the agents studied, while cytochrome P-450 from untreated animals was the least sensitive; the 3-methyl-cholanthrene-induced cytochrome P-448 exhibited the least sensitivity to guanidine.	Methylcholanthrene	183-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3445541-2	1987	Phenobarbital-induced cytochrome P-450 was especially sensitive to the influence of all the agents studied, while cytochrome P-450 from untreated animals was the least sensitive; the 3-methyl-cholanthrene-induced cytochrome P-448 exhibited the least sensitivity to guanidine.	Guanidine	265-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3440754-1	1987	Immunocytochemical studies with a monoclonal antibody (MAb-HL3), which recognises a major isozyme of human hepatic cytochrome P-450, have demonstrated this cytochrome in both cryostat and formalin-fixed paraffin-embedded sections of normal human adult liver.	Formaldehyde	188-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
3689370-3	1987	In this study HHR were found to possess cytochrome P-450-dependent 7-ethoxyresorufin-O-deethylase (ERD) activity which measures cytochrome P-450 isoenzymes that are highly specific (in the order of greater than 95%) markers for the metabolic activation of many environmental carcinogenic substances such as the polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	311-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3689370-3	1987	In this study HHR were found to possess cytochrome P-450-dependent 7-ethoxyresorufin-O-deethylase (ERD) activity which measures cytochrome P-450 isoenzymes that are highly specific (in the order of greater than 95%) markers for the metabolic activation of many environmental carcinogenic substances such as the polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	311-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
3689370-3	1987	In this study HHR were found to possess cytochrome P-450-dependent 7-ethoxyresorufin-O-deethylase (ERD) activity which measures cytochrome P-450 isoenzymes that are highly specific (in the order of greater than 95%) markers for the metabolic activation of many environmental carcinogenic substances such as the polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	345-349	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3689370-3	1987	In this study HHR were found to possess cytochrome P-450-dependent 7-ethoxyresorufin-O-deethylase (ERD) activity which measures cytochrome P-450 isoenzymes that are highly specific (in the order of greater than 95%) markers for the metabolic activation of many environmental carcinogenic substances such as the polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	345-349	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
3675576-1	1987	Cytochrome P-450-ALC, an ethanol-oxidizing form of microsomal cytochrome P-450 (P-450), has been purified from human liver.	Ethanol	25-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3631597-2	1987	However, cimetidine is known to inhibit clearance of many drugs by reducing hepatic blood flow and by inhibiting cytochrome P-450 enzymes.	Cimetidine	9-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
3665337-6	1987	Based on formation clearance values estimated for 6-, 7-, and 8-hydroxywarfarin, rifampin appears to increase the clearance of the parent drug by induction of the cytochrome P-450 isozyme(s) responsible for aromatic hydroxylation.	Rifampin	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3654629-0	1987	P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate.	Dehydroepiandrosterone Sulfate	104-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3654629-11	1987	We conclude that P-450 HFLa is a form of cytochrome P-450 involved in the 16 alpha-hydroxylation of DHEA-sulfate.	Dehydroepiandrosterone Sulfate	100-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3440754-1	1987	Immunocytochemical studies with a monoclonal antibody (MAb-HL3), which recognises a major isozyme of human hepatic cytochrome P-450, have demonstrated this cytochrome in both cryostat and formalin-fixed paraffin-embedded sections of normal human adult liver.	Paraffin	203-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
3663218-2	1987	Oxidized and dithionite-reduced monomers of cytochrome P-450 were much less thermostable than its initial aggregates, while thermal stability of NADPH-specific flavoprotein did not depend on its aggregation state.	Dithionite	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
3663218-3	1987	Binding spectra of cytochrome P-450 monomers with benzphetamine were atypical and had an absorbance minimum at 422 nm only.	Benzphetamine	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3663218-5	1987	Investigation of the dependence of the initial rates of NADPH-dependent cytochrome P-450 reduction and benzphetamine oxidation on the stoichiometry of the flavoprotein and cytochrome P-450 at their constant total concentration showed that the molar ratio of 1:1 was required for maximal activity.	NADP	56-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
3663218-5	1987	Investigation of the dependence of the initial rates of NADPH-dependent cytochrome P-450 reduction and benzphetamine oxidation on the stoichiometry of the flavoprotein and cytochrome P-450 at their constant total concentration showed that the molar ratio of 1:1 was required for maximal activity.	NADP	56-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
3663218-5	1987	Investigation of the dependence of the initial rates of NADPH-dependent cytochrome P-450 reduction and benzphetamine oxidation on the stoichiometry of the flavoprotein and cytochrome P-450 at their constant total concentration showed that the molar ratio of 1:1 was required for maximal activity.	Benzphetamine	103-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
3663445-14	1987	Overall the in vitro studies are consistent with the in vivo results which suggest the involvement of two cytochrome P-450 isozymes in the metabolism of theophylline.	Theophylline	153-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
3040745-1	1987	LTB4 20-hydroxylase (P-450LTB) is the cytochrome P-450 in the microsomes of human polymorphonuclear leukocytes that catalyzes the omega-oxidation of leukotriene B4 (LTB4) to 20-OH LTB4.	Leukotriene B4	149-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3040745-1	1987	LTB4 20-hydroxylase (P-450LTB) is the cytochrome P-450 in the microsomes of human polymorphonuclear leukocytes that catalyzes the omega-oxidation of leukotriene B4 (LTB4) to 20-OH LTB4.	Leukotriene B4	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3040745-1	1987	LTB4 20-hydroxylase (P-450LTB) is the cytochrome P-450 in the microsomes of human polymorphonuclear leukocytes that catalyzes the omega-oxidation of leukotriene B4 (LTB4) to 20-OH LTB4.	20-oh ltb4	174-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3040745-7	1987	Thus, P-450LTB is a novel cytochrome P-450 of human polymorphonuclear leukocytes with substrate recognition determined by the triene bond configuration and the chirality of the hydroxyl groups.	TRIETHYLENETETRAMINE	126-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
3039885-0	1987	Cytochrome P-450-related arachidonic acid metabolites.	Arachidonic Acid	25-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3429444-0	1987	Purification of human liver cytochrome P-450 catalyzing testosterone 6 beta-hydroxylation.	Testosterone	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3429444-8	1987	These results indicate that P-450 human-1 is a major form of cytochrome P-450 responsible for microsomal testosterone 6 beta-hydroxylation.	Testosterone	105-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
3429444-9	1987	Thus, this paper is the first report on human cytochrome P-450 responsible for testosterone 6 beta-hydroxylation, which is the major hydroxylation pathway in human liver microsomes.	Testosterone	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
3039885-7	1987	Cytochrome P-450-dependent monooxygenases are also present in the lung where, in their suggested capacity as oxygen sensors, they generate metabolites of AA that modify pulmonary vasomotion.	Oxygen	31-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3608349-5	1987	The data indicate that a urinary metabolite ratio based on paraxanthine 7-demethylation/8-hydroxylation products reflects systemic caffeine clearance and likely monitors cytochrome P-450 activity inducible by polycyclic aromatic hydrocarbons.	Polycyclic Aromatic Hydrocarbons	209-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
3663765-1	1987	Using the previously obtained data on the substrate-type induction of monooxygenase by xenobiotics of phenobarbital type, the method of conversion of typical substrates for cytochrome P-450 into inducers of biosynthesis of this enzymatic system by blocking in the substrate molecule of the position subjected to oxidative conversion in the enzyme active center was tested.	Phenobarbital	102-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
3620298-7	1987	These studies suggest that tolbutamide is metabolised by an isozyme of cytochrome P-450 which appears to be distinct from those isozymes metabolising many other drugs.	Tolbutamide	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3608348-5	1987	Therefore rifampin preferentially affects norantipyrine or desmethyl- and 3-hydroxydiazepam metabolic formation, suggesting induction of different (iso)zymes of cytochrome P-450.	Rifampin	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3039980-1	1987	Several naphthoquinones, except 2-hydroxy-1,4-naphthoquinone, were found to inhibit microsomal cytochrome P-450-linked monooxygenase activities in rabbit liver and human placenta.	Naphthoquinones	8-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3608349-5	1987	The data indicate that a urinary metabolite ratio based on paraxanthine 7-demethylation/8-hydroxylation products reflects systemic caffeine clearance and likely monitors cytochrome P-450 activity inducible by polycyclic aromatic hydrocarbons.	1,7-dimethylxanthine	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-186
3039980-1	1987	Several naphthoquinones, except 2-hydroxy-1,4-naphthoquinone, were found to inhibit microsomal cytochrome P-450-linked monooxygenase activities in rabbit liver and human placenta.	lawsone	32-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3039980-0	1987	Inhibition of cytochrome P-450-linked monooxygenase systems by naphthoquinones.	Naphthoquinones	63-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
3039980-4	1987	Spectrophotometric studies revealed that naphthoquinones bind to the cytochrome P-450 component of the monooxygenase complex in both microsomal systems, suggesting that the inhibition is caused by direct interaction of these compounds with the heme.	Naphthoquinones	41-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3039980-4	1987	Spectrophotometric studies revealed that naphthoquinones bind to the cytochrome P-450 component of the monooxygenase complex in both microsomal systems, suggesting that the inhibition is caused by direct interaction of these compounds with the heme.	Heme	244-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3663627-1	1987	The ferric spin-state equilibrium and relaxation rate of cytochrome P-450 has been examined with temperature jump spectroscopy using a number of camphor analogues known to induce different mixed spin states in the substrate-bound complexes [Gould, P., Gelb, M., & Sligar, S. G. (1981) J. Biol.	Camphor	145-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3606650-0	1987	Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450.	amineptin	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Phenacetin	289-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Debrisoquin	326-338	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-263
3111319-6	1987	Arachidonic acid (the precursor of PGE2) may inactivates cytochrome P-450, completely reverses the contractile tension of the DA at both low (4 to 12 torr) and high (511 to 712 torr) oxygen tension and is equally effective in the presence and absence of indomethacin.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3111480-10	1987	It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.	Propranolol	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	426-442
3111319-6	1987	Arachidonic acid (the precursor of PGE2) may inactivates cytochrome P-450, completely reverses the contractile tension of the DA at both low (4 to 12 torr) and high (511 to 712 torr) oxygen tension and is equally effective in the presence and absence of indomethacin.	Dinoprostone	35-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3111319-6	1987	Arachidonic acid (the precursor of PGE2) may inactivates cytochrome P-450, completely reverses the contractile tension of the DA at both low (4 to 12 torr) and high (511 to 712 torr) oxygen tension and is equally effective in the presence and absence of indomethacin.	Oxygen	183-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3111319-6	1987	Arachidonic acid (the precursor of PGE2) may inactivates cytochrome P-450, completely reverses the contractile tension of the DA at both low (4 to 12 torr) and high (511 to 712 torr) oxygen tension and is equally effective in the presence and absence of indomethacin.	Indomethacin	254-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3111319-9	1987	Metyrapone and phenylimidazole, chemical inhibitors of cytochrome P-450, also relax the ductus.	Metyrapone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
3111319-9	1987	Metyrapone and phenylimidazole, chemical inhibitors of cytochrome P-450, also relax the ductus.	phenylimidazole	15-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
3594722-0	1987	Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A.	Proadifen	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3594722-1	1987	The crystal and molecular structure of the cytochrome P-450 inhibitor, SKF-525A [2-(diethylamino)ethyl 2,2-diphenylpentenoate; proadifen hydrochloride] is described.	Proadifen	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3594722-1	1987	The crystal and molecular structure of the cytochrome P-450 inhibitor, SKF-525A [2-(diethylamino)ethyl 2,2-diphenylpentenoate; proadifen hydrochloride] is described.	2-(diethylamino)ethyl 2,2-diphenylpentenoate	81-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3594722-1	1987	The crystal and molecular structure of the cytochrome P-450 inhibitor, SKF-525A [2-(diethylamino)ethyl 2,2-diphenylpentenoate; proadifen hydrochloride] is described.	Proadifen	127-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2891811-0	1987	A comparison of the inhibitory effects of roxatidine acetate hydrochloride and cimetidine on cytochrome P-450-mediated drug-metabolism in mouse hepatic microsomes and in man in vivo.	roxatidine acetate	42-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2891811-0	1987	A comparison of the inhibitory effects of roxatidine acetate hydrochloride and cimetidine on cytochrome P-450-mediated drug-metabolism in mouse hepatic microsomes and in man in vivo.	Cimetidine	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
3306269-5	1987	Theophylline is metabolised within the cytochrome P-450 system, with an average total body clearance of 50 to 60 ml/min.	Theophylline	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3114025-3	1987	The antiserum against the NADPH-cytochrome P-450 reductase component (antiserum denoted RE-DFBIV) gave a single major band at the Mr of the authentic enzyme by immunoblotting after electrophoretic separation of SDS-solubilized microsomes and inhibited both the reductase and aromatase activities in human placental and endometrial microsomes (Tseng, L. and Bellino, F.L.	Sodium Dodecyl Sulfate	211-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
3307484-2	1987	The ADH-independent pathway of ethanol metabolism by neural cells appeared to be dependent on one or more isoenzymes of cytochrome P-450.	Ethanol	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3036002-10	1987	In the absence of ferric-EDTA (and azide), microsomes catalyzed the oxidation of pyrazole to 4-hydroxypyrazole by a cytochrome P-450-dependent reaction which was independent of hydroxyl radicals.	pyrazole	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3036002-10	1987	In the absence of ferric-EDTA (and azide), microsomes catalyzed the oxidation of pyrazole to 4-hydroxypyrazole by a cytochrome P-450-dependent reaction which was independent of hydroxyl radicals.	4-hydroxypyrazole	93-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3675632-0	1987	[Chemical modification of cysteine residues of cholesterol-hydroxylating cytochrome P-450.	Cysteine	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
3675632-0	1987	[Chemical modification of cysteine residues of cholesterol-hydroxylating cytochrome P-450.	Cholesterol	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
3675633-0	1987	[Localization of tetranitromethane-modified tyrosine residues in the polypeptide chain of cholesterol-hydroxylating cytochrome P-450].	Tetranitromethane	17-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-133
3675633-0	1987	[Localization of tetranitromethane-modified tyrosine residues in the polypeptide chain of cholesterol-hydroxylating cytochrome P-450].	Tyrosine	44-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-133
3675633-0	1987	[Localization of tetranitromethane-modified tyrosine residues in the polypeptide chain of cholesterol-hydroxylating cytochrome P-450].	Cholesterol	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-133
3675633-3	1987	Tyr-93, -94 are supposedly involved in the active site formation of cytochrome P-450.	Tyrosine	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3109426-1	1987	SKF 525-A (proadifen), a well-known inhibitor of drug metabolism and cytochrome P-450 activity, stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro.	Proadifen	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3632717-1	1987	Immunoblot analysis of liver microsomes from nine patients demonstrated that each contained a cytochrome P-450 that reacted with an antibody directed against the ethanol-inducible rabbit liver cytochrome, P-450 3a.	Ethanol	162-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
3632717-6	1987	However, we conclude that there is a cytochrome P-450 present in human liver which is immunochemically and catalytically similar to the ethanol-inducible P-450 of rabbit liver.	Ethanol	136-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
3598900-0	1987	Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.	Tolbutamide	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3598900-1	1987	In vitro investigations suggest the same human liver cytochrome P-450 that catalyzes S-mephenytoin 4-hydroxylation, P-450MP, is responsible for methyl hydroxylation of the oral hypoglycemic agent tolbutamide.	Mephenytoin	85-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3598900-1	1987	In vitro investigations suggest the same human liver cytochrome P-450 that catalyzes S-mephenytoin 4-hydroxylation, P-450MP, is responsible for methyl hydroxylation of the oral hypoglycemic agent tolbutamide.	Tolbutamide	196-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3628967-2	1987	The incubation of liver microsomes with NADPH and CCl4 under anaerobic conditions (to avoid lipid peroxidation) results in an inhibition of cytochrome P-450 similar to that observed in the in vivo intoxication with a standard dose (0.25 ml/100 g body wt) of CCl4, when the level of covalent binding is 5-10 fold higher than that observed in the in vivo condition.	NADP	40-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3109426-1	1987	SKF 525-A (proadifen), a well-known inhibitor of drug metabolism and cytochrome P-450 activity, stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro.	Proadifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3579983-10	1987	Since the fast phase of enzymatic lipid peroxidation occurred during the fast phase of destruction of cytochrome P-450, it is postulated that iron made available from cytochrome P-450 is sufficient to promote optimal lipid peroxidation.	Iron	142-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
3579320-1	1987	The cytochrome P-450-dependent cholesterol side chain cleavage system of the brain has been studied using nonsynaptic mitochondria as the source of enzymatic activity.	Cholesterol	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3579983-10	1987	Since the fast phase of enzymatic lipid peroxidation occurred during the fast phase of destruction of cytochrome P-450, it is postulated that iron made available from cytochrome P-450 is sufficient to promote optimal lipid peroxidation.	Iron	142-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
3579983-0	1987	NADPH- and linoleic acid hydroperoxide-induced lipid peroxidation and destruction of cytochrome P-450 in hepatic microsomes.	NADP	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
3615351-0	1987	Spectral interaction between 4-methylphenol and beta-oestradiol on hepatic microsomal cytochrome P-450: difference between ethanol and phenobarbital pretreatment.	beta-oestradiol	48-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3579983-0	1987	NADPH- and linoleic acid hydroperoxide-induced lipid peroxidation and destruction of cytochrome P-450 in hepatic microsomes.	linoleic acid hydroperoxide	11-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
3036162-1	1987	Ketoconazole, an imidazole derivative, is a member of a class of metabolic inhibitors acting specifically at cytochrome-P450 mediated reactions.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
3615351-0	1987	Spectral interaction between 4-methylphenol and beta-oestradiol on hepatic microsomal cytochrome P-450: difference between ethanol and phenobarbital pretreatment.	4-cresol	29-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3036162-1	1987	Ketoconazole, an imidazole derivative, is a member of a class of metabolic inhibitors acting specifically at cytochrome-P450 mediated reactions.	imidazole	17-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
3566799-0	1987	Stabilization of the reduced halocarbon-cytochrome P-450 complex of halothane by N-alkanes.	Halothane	68-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3593412-2	1987	The nature of the cytochrome P-450-dependent enzyme reactions giving rise to four primary metabolites of caffeine was investigated using microsomes isolated from livers of human kidney donors.	Caffeine	105-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
3593412-8	1987	Taken together, the data support suggestions from in vivo studies that a PAH-inducible isozyme of cytochrome P-450 plays a significant role in the biotransformation of caffeine in man.	Polycyclic Aromatic Hydrocarbons	73-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
3593412-8	1987	Taken together, the data support suggestions from in vivo studies that a PAH-inducible isozyme of cytochrome P-450 plays a significant role in the biotransformation of caffeine in man.	Caffeine	168-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
3566799-0	1987	Stabilization of the reduced halocarbon-cytochrome P-450 complex of halothane by N-alkanes.	n-alkanes	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3566799-2	1987	Previous studies have shown that halothane forms such a complex with cytochrome P-450, and the result is a strong absorption at 470 nm.	Halothane	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3566799-4	1987	Data are presented which show that several organic solvents (C5-C7N-alkanes) will stabilize the complex formed between halothane and cytochrome P-450.	Halothane	119-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
3566799-7	1987	Stabilization of the halothane complex in a biological system may facilitate studies to identify precisely the halothane-cytochrome P-450 complex and to clarify the mechanisms of halothane reduction by cytochrome P-450.	Halothane	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
3566799-7	1987	Stabilization of the halothane complex in a biological system may facilitate studies to identify precisely the halothane-cytochrome P-450 complex and to clarify the mechanisms of halothane reduction by cytochrome P-450.	Halothane	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
3032300-1	1987	Hepatocyte membranes destruction in experimental toxic hepatitis caused by heliotrine administration was accompanied by a 10-fold increase in blood serum activity of aldolase fructose-I-monophosphate, a decrease in cytochrome P-450 content, an increase in the rate of cytochrome P-450 inactivation, as well as a decrease in microsomal glucose-6-phosphatase activity.	heliotrine	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-231
3032300-1	1987	Hepatocyte membranes destruction in experimental toxic hepatitis caused by heliotrine administration was accompanied by a 10-fold increase in blood serum activity of aldolase fructose-I-monophosphate, a decrease in cytochrome P-450 content, an increase in the rate of cytochrome P-450 inactivation, as well as a decrease in microsomal glucose-6-phosphatase activity.	heliotrine	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	268-284
3032300-3	1987	Phosphatidylcholine protective action is also manifested in an increase in the activity of glucose-6-phosphatase, a microsomal marker enzyme, up to its control level and in a 20% reduced rate of cytochrome P-450 inactivation.	Phosphatidylcholines	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-211
3566799-7	1987	Stabilization of the halothane complex in a biological system may facilitate studies to identify precisely the halothane-cytochrome P-450 complex and to clarify the mechanisms of halothane reduction by cytochrome P-450.	Halothane	111-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
3566799-7	1987	Stabilization of the halothane complex in a biological system may facilitate studies to identify precisely the halothane-cytochrome P-450 complex and to clarify the mechanisms of halothane reduction by cytochrome P-450.	Halothane	111-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
3470755-0	1987	Ferric chloride-catalyzed activation of hydrogen peroxide for the demethylation of N,N-dimethylaniline, the epoxidation of olefins, and the oxidative cleavage of vicinal diols in acetonitrile: a reaction mimic for cytochrome P-450.	vicinal diols	162-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
3472585-1	1987	In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out.	Debrisoquin	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3472585-1	1987	In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out.	Sparteine	100-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3472585-1	1987	In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out.	Sparteine	158-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3472585-4	1987	Thus it can be concluded that the gene controlling human cytochrome P-450 (debrisoquine/sparteine) is situated on the long arm of chromosome 22 in close vicinity to P1.	Debrisoquin	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3472585-4	1987	Thus it can be concluded that the gene controlling human cytochrome P-450 (debrisoquine/sparteine) is situated on the long arm of chromosome 22 in close vicinity to P1.	Sparteine	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3470755-0	1987	Ferric chloride-catalyzed activation of hydrogen peroxide for the demethylation of N,N-dimethylaniline, the epoxidation of olefins, and the oxidative cleavage of vicinal diols in acetonitrile: a reaction mimic for cytochrome P-450.	ferric chloride	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
3470755-0	1987	Ferric chloride-catalyzed activation of hydrogen peroxide for the demethylation of N,N-dimethylaniline, the epoxidation of olefins, and the oxidative cleavage of vicinal diols in acetonitrile: a reaction mimic for cytochrome P-450.	Hydrogen Peroxide	40-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
3671445-2	1987	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene (caffeine elimination) and phenobarbital inducible isoenzymes (metamizol elimination) of cytochrome P-450 are drawn.	Caffeine	117-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
3671445-2	1987	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene (caffeine elimination) and phenobarbital inducible isoenzymes (metamizol elimination) of cytochrome P-450 are drawn.	Phenobarbital	143-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
3671445-2	1987	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene (caffeine elimination) and phenobarbital inducible isoenzymes (metamizol elimination) of cytochrome P-450 are drawn.	Dipyrone	179-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
3829342-8	1987	We conclude that propafenone is metabolized via the same cytochrome P-450 responsible for debrisoquine"s 4-hydroxylation, and that its pharmacokinetics and concentration-response relationships and the incidence of central nervous system side effects are different in patients of different debrisoquine metabolic phenotype.	Propafenone	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3829342-8	1987	We conclude that propafenone is metabolized via the same cytochrome P-450 responsible for debrisoquine"s 4-hydroxylation, and that its pharmacokinetics and concentration-response relationships and the incidence of central nervous system side effects are different in patients of different debrisoquine metabolic phenotype.	Debrisoquin	90-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
3470755-0	1987	Ferric chloride-catalyzed activation of hydrogen peroxide for the demethylation of N,N-dimethylaniline, the epoxidation of olefins, and the oxidative cleavage of vicinal diols in acetonitrile: a reaction mimic for cytochrome P-450.	acetonitrile	179-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
3470755-5	1987	This is in contrast to the prevailing view that cytochrome P-450 acts as a redox catalyst to generate an Fe(V)-oxo species or an Fe(IV)-oxo cation radical as the reactive intermediate.	fe(iv)-oxo cation radical	129-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
3494453-0	1987	Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives.	Methoxsalen	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3104339-6	1987	Purified aromatase cytochrome P-450 displays catalytic characteristics similar to the enzyme in intact microsomes in the aromatization of androstenedione, 19-hydroxyandrostenedione and 19-oxoandrostenedione.	Androstenedione	138-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3104339-6	1987	Purified aromatase cytochrome P-450 displays catalytic characteristics similar to the enzyme in intact microsomes in the aromatization of androstenedione, 19-hydroxyandrostenedione and 19-oxoandrostenedione.	19-hydroxy-4-androstene-3,17-dione	155-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3104339-6	1987	Purified aromatase cytochrome P-450 displays catalytic characteristics similar to the enzyme in intact microsomes in the aromatization of androstenedione, 19-hydroxyandrostenedione and 19-oxoandrostenedione.	19-oxo-delta(4) androstene-3,17-dione	185-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3494453-0	1987	Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives.	Ficusin	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3494453-1	1987	The effects of psoralen derivatives on cytochrome P-450 have been studied in human liver microsomes.	Ficusin	15-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	Edetic Acid	88-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	NADP	97-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	Methoxsalen	137-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	Methoxsalen	150-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-9	1987	We conclude that methoxsalen is an extremely potent suicide inhibitor of cytochrome P-450 in human liver microsomes.	Methoxsalen	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
3494453-11	1987	In the latter derivative, a methyl group is attached on the furan ring and may hinder its metabolic activation and the inactivation of cytochrome P-450.	furan	60-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
3103627-2	1987	Many of these aldehydes have been reported to inhibit hepatic cytochrome P-450.	Aldehydes	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3103627-3	1987	Our laboratory has shown that trans,trans-muconaldehyde (a possible metabolite of benzene) as well as acrolein and crotonaldehyde, when added to hepatic microsomes, decreased cytochrome P-450 (measured spectrophotometrically).	Hexa-2,4-dienedial	30-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3030331-6	1987	Both the reduction of the quinone imines and the reduction of oxygen were found to be cytochrome P-450 dependent.	quinone imines	26-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3103627-3	1987	Our laboratory has shown that trans,trans-muconaldehyde (a possible metabolite of benzene) as well as acrolein and crotonaldehyde, when added to hepatic microsomes, decreased cytochrome P-450 (measured spectrophotometrically).	Benzene	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3030331-6	1987	Both the reduction of the quinone imines and the reduction of oxygen were found to be cytochrome P-450 dependent.	Oxygen	62-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
3030331-0	1987	Role of hepatic microsomal and purified cytochrome P-450 in one-electron reduction of two quinone imines and concomitant reduction of molecular oxygen.	quinone imines	90-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3030331-0	1987	Role of hepatic microsomal and purified cytochrome P-450 in one-electron reduction of two quinone imines and concomitant reduction of molecular oxygen.	Oxygen	144-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3103627-3	1987	Our laboratory has shown that trans,trans-muconaldehyde (a possible metabolite of benzene) as well as acrolein and crotonaldehyde, when added to hepatic microsomes, decreased cytochrome P-450 (measured spectrophotometrically).	Acrolein	102-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3030331-1	1987	The possible role of cytochrome P-450 in one-electron reduction of quinoid compounds as well as in the formation of reduced oxygen species was investigated in hepatic microsomal and reconstituted systems of purified cytochrome P-450 and purified NADPH-cytochrome P-450 reductase using electron spin resonance (ESR) methods.	quinoid	67-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
3030331-4	1987	Both NAPQI and 3,5-dimethyl-NAPQI underwent one-electron reduction in microsomal systems and in fully reconstituted systems of cytochrome P-450 and NADPH-cytochrome P-450 reductase under anaerobic and aerobic conditions.	N-acetyl-4-benzoquinoneimine	5-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
3030331-7	1987	Both activities of cytochrome P-450 may also be involved in the bioactivation of other compounds with quinoid structural elements, like many chemotherapeutic agents.	quinoid	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
3103627-3	1987	Our laboratory has shown that trans,trans-muconaldehyde (a possible metabolite of benzene) as well as acrolein and crotonaldehyde, when added to hepatic microsomes, decreased cytochrome P-450 (measured spectrophotometrically).	2-butenal	115-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3030331-4	1987	Both NAPQI and 3,5-dimethyl-NAPQI underwent one-electron reduction in microsomal systems and in fully reconstituted systems of cytochrome P-450 and NADPH-cytochrome P-450 reductase under anaerobic and aerobic conditions.	3,5-Dimethyl-napqi	15-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
3816008-6	1987	Erythromycin has known effects on hepatic enzyme function, with altered cytochrome P-450 function.	Erythromycin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
3032244-1	1987	A cDNA sequence related to the human cytochrome P-450 responsible for S-mephenytoin 4-hydroxylation (P-450MP) has been isolated from a human liver bacteriophage lambda gt11 library with antibodies specific for P-450MP.	Mephenytoin	70-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2882985-3	1987	It appears that the high affinity enzyme is a polycyclic aromatic hydrocarbon-inducible isozyme of cytochrome P-450, based on competitive inhibition by 7-ethoxyresorufin and benzo[a]pyrene, and based on a significant (p less than 0.001) correlation between 7-ethoxyresorufin-O-deethylation and methylxanthine demethylation rates.	Polycyclic Aromatic Hydrocarbons	46-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
3600619-0	1987	[Electron factors in the properties of cytochrome P-450 and mechanism of activation of molecular oxygen].	Oxygen	97-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3577206-1	1987	The cytochrome P-450 forms involved in debrisoquine 4-hydroxylation (P-450DB), phenacetin O-deethylation (P-450PA), S-mephenytoin 4-hydroxylation (P-450MP), and nifedipine 1,4-oxidation (P-450NF) have been purified to electrophoretic homogeneity from human liver microsomes.	Debrisoquin	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3577206-1	1987	The cytochrome P-450 forms involved in debrisoquine 4-hydroxylation (P-450DB), phenacetin O-deethylation (P-450PA), S-mephenytoin 4-hydroxylation (P-450MP), and nifedipine 1,4-oxidation (P-450NF) have been purified to electrophoretic homogeneity from human liver microsomes.	Nifedipine	161-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2882985-3	1987	It appears that the high affinity enzyme is a polycyclic aromatic hydrocarbon-inducible isozyme of cytochrome P-450, based on competitive inhibition by 7-ethoxyresorufin and benzo[a]pyrene, and based on a significant (p less than 0.001) correlation between 7-ethoxyresorufin-O-deethylation and methylxanthine demethylation rates.	ethoxyresorufin	152-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2882985-3	1987	It appears that the high affinity enzyme is a polycyclic aromatic hydrocarbon-inducible isozyme of cytochrome P-450, based on competitive inhibition by 7-ethoxyresorufin and benzo[a]pyrene, and based on a significant (p less than 0.001) correlation between 7-ethoxyresorufin-O-deethylation and methylxanthine demethylation rates.	Benzo(a)pyrene	174-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2882985-3	1987	It appears that the high affinity enzyme is a polycyclic aromatic hydrocarbon-inducible isozyme of cytochrome P-450, based on competitive inhibition by 7-ethoxyresorufin and benzo[a]pyrene, and based on a significant (p less than 0.001) correlation between 7-ethoxyresorufin-O-deethylation and methylxanthine demethylation rates.	7-ethoxyresorufin-o	257-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2882985-3	1987	It appears that the high affinity enzyme is a polycyclic aromatic hydrocarbon-inducible isozyme of cytochrome P-450, based on competitive inhibition by 7-ethoxyresorufin and benzo[a]pyrene, and based on a significant (p less than 0.001) correlation between 7-ethoxyresorufin-O-deethylation and methylxanthine demethylation rates.	methylxanthine	294-308	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
3806608-0	1987	Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1"(5")-iminium species.	Nicotine	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
3493777-0	1987	Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.	Steroids	75-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3493777-7	1987	We conclude that P-450 HFLa is a form of cytochrome P-450 which catalyzes testosterone 6 beta-hydroxylation and limited drug oxidations in human fetal and adult livers.	Testosterone	74-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3027095-1	1987	omega-Hydroxylation of leukotriene B4 (LTB4) has been reported in human and rodent polymorphonuclear leukocytes; preliminary information indicates that this metabolism is cytochrome P-450 dependent.	Leukotriene B4	23-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-187
3508090-4	1987	Production of the three isomers by microsomal protein occurs only in the presence of NADPH and shows that 2HAA proceeds through a cytochrome P-450 mediated pathway to a reactive intermediate similar to acetaminophen, possibly N-acetyl-o-quinoneimine.	2-hydroxyacetanilide	106-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
3111839-0	1987	Ketoconazole as a possible universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
3111839-1	1987	Modes of inhibition and binding of ketoconazole, an orally antimycotic agent, to NADPH-cytochrome P-450 dependent enzymes were investigated using subcellular fractions of human and rat testes, human adrenocortical adenoma tissue and rat adrenals and livers.	Ketoconazole	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
3111839-4	1987	Kinetic studies indicated that ketoconazole bound to cytochrome P-450 and not to other components of monooxygenase systems.	Ketoconazole	31-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3111839-5	1987	Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others.	Ketoconazole	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
3111839-5	1987	Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others.	Ketoconazole	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	250-266
3111839-5	1987	Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others.	Ketoconazole	194-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
3111839-5	1987	Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others.	Ketoconazole	194-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	250-266
3111839-5	1987	Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others.	Steroids	354-362	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
3032726-6	1987	The rates of cytochrome P-450-dependent FUra formation in the microsomal fraction of liver tissue from two patients (1.1 and 1.3 nmol/mg microsomal protein/30 min) were dramatically reduced to less than half of those of two control subjects (2.4 and 2.7).	Fluorouracil	40-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
3806608-0	1987	Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1"(5")-iminium species.	(s)-nicotine delta 1"(5")-iminium	90-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
3806608-1	1987	Mammals metabolize the tobacco alkaloid (S)-nicotine primarily to the lactam (S)-cotinine by a pathway involving an initial cytochrome P-450 catalyzed two-electron oxidation at the prochiral 5"-carbon atom.	Nicotine	40-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3806608-1	1987	Mammals metabolize the tobacco alkaloid (S)-nicotine primarily to the lactam (S)-cotinine by a pathway involving an initial cytochrome P-450 catalyzed two-electron oxidation at the prochiral 5"-carbon atom.	Lactams	70-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3806608-1	1987	Mammals metabolize the tobacco alkaloid (S)-nicotine primarily to the lactam (S)-cotinine by a pathway involving an initial cytochrome P-450 catalyzed two-electron oxidation at the prochiral 5"-carbon atom.	Cotinine	77-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3806608-1	1987	Mammals metabolize the tobacco alkaloid (S)-nicotine primarily to the lactam (S)-cotinine by a pathway involving an initial cytochrome P-450 catalyzed two-electron oxidation at the prochiral 5"-carbon atom.	Carbon	194-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3806608-8	1987	These findings suggest that the structure of the complex formed between (S)-nicotine and the active site of cytochrome P-450 is highly ordered and dictates the stereochemical course of the reaction pathway.	Nicotine	72-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
2821771-0	1987	Cytochrome P450-dependent arachidonate metabolism in corneal epithelium: formation of biologically active compounds.	Arachidonic Acid	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
3573427-0	1987	Action of carbon tetrachloride in the reconstituted monooxygenase system using partially purified cytochrome P-450 and P-448.	Carbon Tetrachloride	10-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-124
3621372-0	1987	Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P-450-mediated aniline hydroxylation.	Alcohols	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3304211-9	1987	Mechanistically best known is the program turned on by 3-methylcholanthrene-type inducers which includes enhanced synthesis of certain isoenzymes of cytochrome P-450, GT and probably GSH-transferase.	Methylcholanthrene	55-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
3621372-0	1987	Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P-450-mediated aniline hydroxylation.	aniline	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3621370-12	1987	Its likely environmental precursor, CF3Br, which is used as a fire extinguisher and a refrigerant, was found to be reduced by a ferrous porphyrin model for cytochrome P-450 only very slowly and thus is not expected to have a major toxic effect if inhaled.	bromotrifluoromethane	36-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3621372-6	1987	The mode of binding and effect on spin-state equilibria in cytochrome P-450 by alcohols has been elucidated by Testa, whereas an alternative hypothesis based on connectivity correlations has been reported by Sabljic and Sabljic (Mol.	Alcohols	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
3621370-12	1987	Its likely environmental precursor, CF3Br, which is used as a fire extinguisher and a refrigerant, was found to be reduced by a ferrous porphyrin model for cytochrome P-450 only very slowly and thus is not expected to have a major toxic effect if inhaled.	ferroporphyrin	128-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3691305-0	1987	[Triphenyldioxan--a new effective inducer of cytochrome P-450].	triphenyldioxan	1-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
3327676-14	1987	The first step in the metabolism involves oxidation to the corresponding pyridine derivative by the cytochrome P-450 system.	pyridine	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
3493905-5	1987	The result can be explained by the inability of the antibiotic to form inactive cytochrome P-450 metabolite complexes which can interfere with the metabolism of theophylline.	Theophylline	161-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
3609112-3	1987	After pretreatment with cimetidine, which inhibits the activity of cytochrome P-450, the peak plasma concentration and area under the plasma-time concentration curve for nifedipine were increased by a mean 84%.	Cimetidine	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3609112-3	1987	After pretreatment with cimetidine, which inhibits the activity of cytochrome P-450, the peak plasma concentration and area under the plasma-time concentration curve for nifedipine were increased by a mean 84%.	Nifedipine	170-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3111822-1	1987	The commercial mixture of polychlorinated biphenyls (Sovol) studied by biochemical and immunochemical methods was found to be an inducer of a wide range of cytochrome P-450 isoenzymes.	Polychlorinated Biphenyls	26-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3111822-1	1987	The commercial mixture of polychlorinated biphenyls (Sovol) studied by biochemical and immunochemical methods was found to be an inducer of a wide range of cytochrome P-450 isoenzymes.	Sovol	53-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3480222-9	1987	The results indicate that the theophylline-enoxacin interaction may be due to inhibition of the cytochrome P-450 isozymes responsible for theophylline metabolism.	Theophylline	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3480222-9	1987	The results indicate that the theophylline-enoxacin interaction may be due to inhibition of the cytochrome P-450 isozymes responsible for theophylline metabolism.	Enoxacin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3480222-9	1987	The results indicate that the theophylline-enoxacin interaction may be due to inhibition of the cytochrome P-450 isozymes responsible for theophylline metabolism.	Theophylline	138-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
3496215-1	1987	We estimate the "active" part of cytochrome P-450, which is involved in a special substrate transformation, by measuring the initial change of the production rate as a function of the relaxation transitions between two different steady states of the reaction cycle of cytochrome P-450 using the light-reversibility of the carbon monoxide inhibition.	Carbon Monoxide	322-337	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
3496215-1	1987	We estimate the "active" part of cytochrome P-450, which is involved in a special substrate transformation, by measuring the initial change of the production rate as a function of the relaxation transitions between two different steady states of the reaction cycle of cytochrome P-450 using the light-reversibility of the carbon monoxide inhibition.	Carbon Monoxide	322-337	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	268-284
3496215-4	1987	An application of our model to the O-deethylation of 7-ethoxycoumarin reveals that--in a time average--10%-15% of the spectroscopically detectable cytochrome P-450 is involved in that transformation.	7-ethoxycoumarin	53-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
3331377-3	1987	Representative examples of the above mechanisms are as following: (1) Ketoconazole possesses inhibitory effects in vitro on cytochrome P-450.	Ketoconazole	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3320551-2	1987	The pathway of biosynthesis of these steroids from cholesterol involves a sequence of transformations using cytochrome P-450 enzymes which varies within the adrenal cortex as a result of the differential localization of enzymes within the zones.	Steroids	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3027305-8	1987	Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions.	Etomidate	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3027305-8	1987	Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions.	Ketoconazole	11-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3027305-8	1987	Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions.	Miconazole	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2824357-1	1987	The metabolism of N-nitrosodiethylamine (NDEA) and its modulation by inhibitors of cytochrome P450 and prostaglandin H synthetase enzymes was investigated in seven well-differentiated early-passage human lung cancer cell lines.	Diethylnitrosamine	18-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
2824357-1	1987	The metabolism of N-nitrosodiethylamine (NDEA) and its modulation by inhibitors of cytochrome P450 and prostaglandin H synthetase enzymes was investigated in seven well-differentiated early-passage human lung cancer cell lines.	Diethylnitrosamine	41-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
3027305-8	1987	Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions.	Metyrapone	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3320551-2	1987	The pathway of biosynthesis of these steroids from cholesterol involves a sequence of transformations using cytochrome P-450 enzymes which varies within the adrenal cortex as a result of the differential localization of enzymes within the zones.	Cholesterol	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3320551-4	1987	These may include the following: (1) the normal morphological and functional zonation of the adrenal cortex may be regulated by gradients of steroids in the adrenal cortex; (2) destruction of cytochrome P-450 enzymes on interaction with certain steroids which act as pseudosubstrates may form part of the pathogenesis of some steroidogenic enzyme deficiencies.	Steroids	141-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-208
3320551-4	1987	These may include the following: (1) the normal morphological and functional zonation of the adrenal cortex may be regulated by gradients of steroids in the adrenal cortex; (2) destruction of cytochrome P-450 enzymes on interaction with certain steroids which act as pseudosubstrates may form part of the pathogenesis of some steroidogenic enzyme deficiencies.	Steroids	245-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-208
3320551-6	1987	Under some pathological conditions, individual cytochrome P-450 enzyme activities may become rate-limiting, with consequent overproduction of precursor steroids, leading to mineralocorticoid or androgen excess.	Steroids	152-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
3449750-2	1987	The first proposed step is enzymatic alpha-hydroxylation by the active oxygen species of cytochrome P-450, followed by nonenzymatic N-dealkylation and formation of diazohydroxides (RNNOH).	Oxygen	71-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
3449750-2	1987	The first proposed step is enzymatic alpha-hydroxylation by the active oxygen species of cytochrome P-450, followed by nonenzymatic N-dealkylation and formation of diazohydroxides (RNNOH).	pyrazine-2-diazohydroxide	164-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
3099185-0	1987	Aflatoxin B1 activation to a plasmid mutagen by a chemical model of cytochrome P-450.	Aflatoxin B1	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3099185-1	1987	Aflatoxin B1 (AFB1) was oxidised by a chemical model of cytochrome P-450 and the products obtained analysed by reversed-phase hplc.	Aflatoxin B1	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
3099185-1	1987	Aflatoxin B1 (AFB1) was oxidised by a chemical model of cytochrome P-450 and the products obtained analysed by reversed-phase hplc.	Aflatoxin B1	14-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
3449750-8	1987	This reaction appears to be a viable one to formation of an ultimate carcinogen by parent dialkylnitrosamines in the hydrophobic substrate binding site of cytochrome P-450.	dialkylnitrosamines	90-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
3628472-0	1987	Mechanisms of phenobarbital-type induction of cytochrome P-450 isozymes.	Phenobarbital	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
3540968-5	1987	It is also shown that anti-cytochrome P-450-8 antibodies as well as human serum containing anti-LKM2 antibodies specifically inhibit the hydroxylation of tienilic acid by human liver microsomes.	Ticrynafen	154-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
2895455-5	1987	The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring.	Theophylline	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2895455-5	1987	The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring.	Warfarin	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2895455-5	1987	The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring.	Cimetidine	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2895455-5	1987	The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring.	Ranitidine	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3540968-6	1987	These results indicate that anti-LKM2 antibodies appearing in patients with hepatitis and concomitant administration of tienilic acid are directed against a cytochrome P-450 isoenzyme that catalyzes the metabolic oxidation of this drug.	Ticrynafen	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Miconazole	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2892251-2	1987	It is well documented that cimetidine can inhibit the hepatic elimination of many drugs by binding to the cytochrome P-450 system.	Cimetidine	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
2892251-6	1987	Similarly, binding to cytochrome P-450 of human liver microsomes could be seen only with cimetidine and oxmetidine, whereas nizatidine did not affect the binding spectra.	Cimetidine	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
2892251-6	1987	Similarly, binding to cytochrome P-450 of human liver microsomes could be seen only with cimetidine and oxmetidine, whereas nizatidine did not affect the binding spectra.	oxmetidine	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
3810888-4	1987	A model is suggested which shows the phenobarbital participation in the formation of the specific configuration of the active site of cytochrome P-450 synthesized; the latter catalyzes the oxidation of a number of substrates by the way typical of inducer itself.	Phenobarbital	37-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3333881-8	1987	Apart from its clinical and rodenticidal uses, warfarin is an excellent substrate for probing the heterogeneity of cytochrome P.450, since its metabolic oxidation is mediated by this mixed function oxidase.	Warfarin	47-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Miconazole	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Ketoconazole	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Ketoconazole	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Itraconazole	118-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
3790167-9	1986	Under these conditions, the peroxidatic activity of catalase measured in vitro and the ethanol-dependent decrease in catalase-H2O2 in perfused livers also returned to near basal levels; however, the oxidation of ethanol by cytochrome P-450 was inhibited completely.	Ethanol	87-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-239
3782137-2	1986	The cDNAs encoding ethanol-inducible forms of rat and human cytochrome P-450s have been isolated, sequenced, and used to study the expression of this cytochrome P-450 during development and by various inducing agents.	Ethanol	19-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
3790167-9	1986	Under these conditions, the peroxidatic activity of catalase measured in vitro and the ethanol-dependent decrease in catalase-H2O2 in perfused livers also returned to near basal levels; however, the oxidation of ethanol by cytochrome P-450 was inhibited completely.	Ethanol	212-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-239
3025521-5	1986	Since ketoconazole is known to inhibit cytochrome P-450-dependent enzyme reactions, the results of the present study support the contention that cytochrome P-450 is involved in the aromatisation process.	Ketoconazole	6-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
3096378-0	1986	Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.	Mephenytoin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
3096378-0	1986	Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.	Mephenytoin	147-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
3096378-2	1986	By monitoring the activities of the two major oxidative pathways of mephenytoin metabolism in the column eluates, we have purified from human livers a cytochrome P-450 isozyme, P-450 meph, which exclusively and stereoselectively catalyzes the 4-hydroxylation of (S)-mephenytoin, the major pathway affected by the polymorphism, whereas P-450 meph was virtually devoid of catalytic activity for N-demethylation of mephenytoin, the pathway remaining unaffected by the genetic deficiency.	Mephenytoin	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
3096378-2	1986	By monitoring the activities of the two major oxidative pathways of mephenytoin metabolism in the column eluates, we have purified from human livers a cytochrome P-450 isozyme, P-450 meph, which exclusively and stereoselectively catalyzes the 4-hydroxylation of (S)-mephenytoin, the major pathway affected by the polymorphism, whereas P-450 meph was virtually devoid of catalytic activity for N-demethylation of mephenytoin, the pathway remaining unaffected by the genetic deficiency.	Mephenytoin	262-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
3096378-2	1986	By monitoring the activities of the two major oxidative pathways of mephenytoin metabolism in the column eluates, we have purified from human livers a cytochrome P-450 isozyme, P-450 meph, which exclusively and stereoselectively catalyzes the 4-hydroxylation of (S)-mephenytoin, the major pathway affected by the polymorphism, whereas P-450 meph was virtually devoid of catalytic activity for N-demethylation of mephenytoin, the pathway remaining unaffected by the genetic deficiency.	Mephenytoin	266-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
3025521-5	1986	Since ketoconazole is known to inhibit cytochrome P-450-dependent enzyme reactions, the results of the present study support the contention that cytochrome P-450 is involved in the aromatisation process.	Ketoconazole	6-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
22283296-0	1986	Oxygen activation by metalloporphyrins related to peroxidase and cytochrome P-450.	Oxygen	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
3021236-1	1986	A mitochondrial preparation from duck adrenal gland was used, under aerobic conditions, to show that the oxygen requirement for the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) is at the cytochrome P-450 level only.	Oxygen	105-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	242-258
3021236-1	1986	A mitochondrial preparation from duck adrenal gland was used, under aerobic conditions, to show that the oxygen requirement for the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) is at the cytochrome P-450 level only.	Aldosterone	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	242-258
3021236-1	1986	A mitochondrial preparation from duck adrenal gland was used, under aerobic conditions, to show that the oxygen requirement for the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) is at the cytochrome P-450 level only.	18-Hydroxycorticosterone	189-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	242-258
3021236-1	1986	A mitochondrial preparation from duck adrenal gland was used, under aerobic conditions, to show that the oxygen requirement for the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) is at the cytochrome P-450 level only.	Aldosterone	219-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	242-258
3021236-2	1986	Vitamin C and tetramethyl-p-phenylene-diamine (TMPD) were used to increase oxygen consumption at the cytochrome a3 level, thereby decreasing its availability to cytochrome P-450.	Ascorbic Acid	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3021236-2	1986	Vitamin C and tetramethyl-p-phenylene-diamine (TMPD) were used to increase oxygen consumption at the cytochrome a3 level, thereby decreasing its availability to cytochrome P-450.	tetramethyl-p-phenylenediamine	14-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3021236-2	1986	Vitamin C and tetramethyl-p-phenylene-diamine (TMPD) were used to increase oxygen consumption at the cytochrome a3 level, thereby decreasing its availability to cytochrome P-450.	tetramethyl-p-phenylenediamine	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3021236-2	1986	Vitamin C and tetramethyl-p-phenylene-diamine (TMPD) were used to increase oxygen consumption at the cytochrome a3 level, thereby decreasing its availability to cytochrome P-450.	Oxygen	75-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3021236-8	1986	According to polarographic and electron microscopy studies, the reversal of inhibition can only be explained by an increased availability of oxygen at the cytochrome P-450 level.	Oxygen	141-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
3021236-9	1986	Experiments performed under aerobic conditions, without a nitrogen atmosphere, show that oxygen is required in the transformation of 18-hydroxycorticosterone into aldosterone, at the cytochrome P-450 level.	Oxygen	89-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
3021236-9	1986	Experiments performed under aerobic conditions, without a nitrogen atmosphere, show that oxygen is required in the transformation of 18-hydroxycorticosterone into aldosterone, at the cytochrome P-450 level.	18-Hydroxycorticosterone	133-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
3021236-9	1986	Experiments performed under aerobic conditions, without a nitrogen atmosphere, show that oxygen is required in the transformation of 18-hydroxycorticosterone into aldosterone, at the cytochrome P-450 level.	Aldosterone	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
3787626-6	1986	Exposure to DSF alone decreased cytochrome P450 levels, but in combination with DCE, the decrement of cytochrome P450 was additive in a DCE concentration-dependent manner.	ethylene dichloride	80-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
3787626-6	1986	Exposure to DSF alone decreased cytochrome P450 levels, but in combination with DCE, the decrement of cytochrome P450 was additive in a DCE concentration-dependent manner.	ethylene dichloride	136-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
3787626-7	1986	However, depression of cytochrome P450 by DCE alone was not concentration dependent.	ethylene dichloride	42-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
3022748-0	1986	Differential effects of the cytochrome P-450/reductase ratio on the oxidation of ethanol and the hydroxyl radical scavenging agent 2-keto-4-thiomethylbutyric acid (KMBA).	Ethanol	81-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-54
3022748-0	1986	Differential effects of the cytochrome P-450/reductase ratio on the oxidation of ethanol and the hydroxyl radical scavenging agent 2-keto-4-thiomethylbutyric acid (KMBA).	Hydroxyl Radical	97-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-54
3022748-0	1986	Differential effects of the cytochrome P-450/reductase ratio on the oxidation of ethanol and the hydroxyl radical scavenging agent 2-keto-4-thiomethylbutyric acid (KMBA).	kmba	164-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-54
3022748-2	1986	The effect of various ratios of cytochrome P-450 (phenobarbital-inducible isozyme)/reductase on the oxidation of ethanol and KMBA was determined: There was essentially no increase in KMBA oxidation over the range of ratios from 0.5 to 5 as compared to the reductase-catalyzed rate.	Phenobarbital	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
3022748-2	1986	The effect of various ratios of cytochrome P-450 (phenobarbital-inducible isozyme)/reductase on the oxidation of ethanol and KMBA was determined: There was essentially no increase in KMBA oxidation over the range of ratios from 0.5 to 5 as compared to the reductase-catalyzed rate.	Ethanol	113-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
3464943-1	1986	Human liver cytochrome P-450NF is the form of cytochrome P-450 responsible for the oxidation of the calcium-channel blocker nifedipine, which has been reported to show polymorphism in clinical studies.	Nifedipine	124-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
22283296-0	1986	Oxygen activation by metalloporphyrins related to peroxidase and cytochrome P-450.	Metalloporphyrins	21-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
3757403-6	1986	These results are consistent with cimetidine inhibiting cytochrome P-450 enzymes in the liver and also competing with triamterene for renal tubular secretion.	Cimetidine	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
3096315-7	1986	The stereochemical and regiochemical differences between oxidation of BA-3,4-diol by peroxyl radicals and cytochrome P-450 are dramatic and suggest that BA-3,4-diol is uniquely suited as a probe to quantitate peroxyl radical-dependent epoxidation in vitro and in vivo.	ba-3,4-diol	153-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
3753522-0	1986	Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.	Debrisoquin	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
3745165-1	1986	Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.	bufuralol	164-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
3745165-2	1986	The debrisoquine/sparteine-type polymorphism of drug oxidation presumably is caused by the absence or deficiency of cytochrome P-450 (P-450) isozyme(s).	Debrisoquin	4-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3745165-2	1986	The debrisoquine/sparteine-type polymorphism of drug oxidation presumably is caused by the absence or deficiency of cytochrome P-450 (P-450) isozyme(s).	Sparteine	17-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3489441-4	1986	These results suggest that increased testicular heme oxygenase activity is associated with decreased microsomal heme and cytochrome P-450 content during human chorionic gonadotropin-induced desensitization.	Heme	48-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
3746811-6	1986	Oxidation of the 4-alkyl compounds led not only to the loss of P-450NF but also to decreases in catalytic activities of cytochrome P-450 isozymes catalyzing other reactions (phenacetin O-deethylation and hexobarbital 3"-hydroxylation).	4-alkyl	17-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3746811-6	1986	Oxidation of the 4-alkyl compounds led not only to the loss of P-450NF but also to decreases in catalytic activities of cytochrome P-450 isozymes catalyzing other reactions (phenacetin O-deethylation and hexobarbital 3"-hydroxylation).	Phenacetin	174-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3746811-6	1986	Oxidation of the 4-alkyl compounds led not only to the loss of P-450NF but also to decreases in catalytic activities of cytochrome P-450 isozymes catalyzing other reactions (phenacetin O-deethylation and hexobarbital 3"-hydroxylation).	Hexobarbital	204-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3748010-0	1986	Oxidation of quinidine by human liver cytochrome P-450.	Quinidine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3481957-1	1986	A phenobarbitone inducible cytochrome P-450 gene family (CYP1) has recently been localized to chromosome 19q13.1-qter.	Phenobarbital	2-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
2425812-2	1986	The genotoxic activities of cyclophosphamide and its direct acting metabolite, phosphoramide mustard, were studied in the hepatoma cells as cyclophosphamide is known to be metabolized by phenobarbital-inducible cytochrome P-450-associated metabolic activity.	Cyclophosphamide	28-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
2425812-2	1986	The genotoxic activities of cyclophosphamide and its direct acting metabolite, phosphoramide mustard, were studied in the hepatoma cells as cyclophosphamide is known to be metabolized by phenobarbital-inducible cytochrome P-450-associated metabolic activity.	Cyclophosphamide	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
2425812-5	1986	The cytochrome P-450-associated enzyme inhibitors, SKF-525A and metyrapone, were found to reduce the level of cyclophosphamide-induced sister chromatid exchanges in HepG2 and H4-II-E, suggesting that cyclophosphamide was activated by this pathway in both hepatoma lines.	Metyrapone	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2425812-5	1986	The cytochrome P-450-associated enzyme inhibitors, SKF-525A and metyrapone, were found to reduce the level of cyclophosphamide-induced sister chromatid exchanges in HepG2 and H4-II-E, suggesting that cyclophosphamide was activated by this pathway in both hepatoma lines.	Cyclophosphamide	110-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2425812-5	1986	The cytochrome P-450-associated enzyme inhibitors, SKF-525A and metyrapone, were found to reduce the level of cyclophosphamide-induced sister chromatid exchanges in HepG2 and H4-II-E, suggesting that cyclophosphamide was activated by this pathway in both hepatoma lines.	Cyclophosphamide	200-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2425812-6	1986	Direct evidence for the presence of mRNA transcript coding for a phenobarbital-inducible cytochrome P-450 was demonstrated in HepG2 cells by Northern blot analysis.	Phenobarbital	65-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
3729971-8	1986	These findings suggest that the inhibition of aminopyrine N-demethylase activity by primaquine is mediated via an interaction with the oxidised form of cytochrome P-450.	Primaquine	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
3729971-9	1986	In addition, the apparent change in inhibition kinetics suggests a concentration-dependent change in the capacity of primaquine to modulate substrate binding to cytochrome P-450 as well as the formation of a P-450-aminopyrine-primaquine ternary complex.	Primaquine	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3741500-2	1986	The metabolism of this drug to its principal metabolite, 4-hydroxydebrisoquine, is catalyzed by a discrete isozyme of cytochrome P-450.	4-hydroxydebrisoquin	57-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
2425856-0	1986	[Induction of the phenobarbital form of cytochrome P-450 by chemically unrelated compounds].	Phenobarbital	18-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Phenobarbital	21-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Phenobarbital	76-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Lead	91-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Hexachlorobenzene	95-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Hexachlorobenzene	114-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-1	1986	The induction of the phenobarbital form of cytochrome P-450 by xenobiotics (phenobarbital, PB, hexachlorobenzene, HCB; hexachlorocyclohexane.	Hexachlorocyclohexane	119-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2425856-4	1986	Using monospecific antibodies against the cytochrome P-450 form isolated from PB-induced microsomes (PB-cytochrome P-450), a double immunodiffusion test revealed immunological identity of cytochrome P-450 forms induced by phenobarbital and other xenobiotics.	Phenobarbital	222-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
2425856-4	1986	Using monospecific antibodies against the cytochrome P-450 form isolated from PB-induced microsomes (PB-cytochrome P-450), a double immunodiffusion test revealed immunological identity of cytochrome P-450 forms induced by phenobarbital and other xenobiotics.	Phenobarbital	222-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
2425856-4	1986	Using monospecific antibodies against the cytochrome P-450 form isolated from PB-induced microsomes (PB-cytochrome P-450), a double immunodiffusion test revealed immunological identity of cytochrome P-450 forms induced by phenobarbital and other xenobiotics.	Phenobarbital	222-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
2425856-6	1986	Antibodies against PB-cytochrome P-450 inhibited by 50-70% the benzphetamine-N-demethylase and aldrin-epoxidase activities, whereas the antibodies to methylcholanthrene-induced cytochrome P-450 were fairly ineffective.	Methylcholanthrene	150-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
2425856-6	1986	Antibodies against PB-cytochrome P-450 inhibited by 50-70% the benzphetamine-N-demethylase and aldrin-epoxidase activities, whereas the antibodies to methylcholanthrene-induced cytochrome P-450 were fairly ineffective.	Methylcholanthrene	150-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
3709029-10	1986	Moreover, this ratio may be used to detect drug interactions that involve the cytochrome P-450 isozyme(s) responsible for the polymorphic 4-hydroxylation of mephenytoin.	Mephenytoin	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
3742644-0	1986	The interaction of a homologous series of hydrocarbons with hepatic cytochrome P-450.	Hydrocarbons	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3742644-2	1986	The spectral interaction of a homologous series of alkyl-substituted benzenes and related compounds with purified mammalian cytochrome P-450 has been investigated.	alkyl-substituted benzenes	51-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3742644-3	1986	Each of the 10 hydrocarbons produced a Type I spectral change, indicative of a low to high spin transition of the haem iron of cytochrome P-450.	Hydrocarbons	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
3742644-3	1986	Each of the 10 hydrocarbons produced a Type I spectral change, indicative of a low to high spin transition of the haem iron of cytochrome P-450.	Iron	119-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
3742644-9	1986	Taken collectively, our data show the importance of the hydrophobic and charge transfer characteristics of hydrocarbon substrates in dictating the position of the cytochrome P-450 spin equilibrium, and as such, provides a rational molecular explanation based on sound chemical principles for the differential interaction of hydrocarbons with cytochrome P-450.	Hydrocarbons	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3742644-9	1986	Taken collectively, our data show the importance of the hydrophobic and charge transfer characteristics of hydrocarbon substrates in dictating the position of the cytochrome P-450 spin equilibrium, and as such, provides a rational molecular explanation based on sound chemical principles for the differential interaction of hydrocarbons with cytochrome P-450.	Hydrocarbons	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	342-358
3742644-9	1986	Taken collectively, our data show the importance of the hydrophobic and charge transfer characteristics of hydrocarbon substrates in dictating the position of the cytochrome P-450 spin equilibrium, and as such, provides a rational molecular explanation based on sound chemical principles for the differential interaction of hydrocarbons with cytochrome P-450.	Hydrocarbons	324-336	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3742644-9	1986	Taken collectively, our data show the importance of the hydrophobic and charge transfer characteristics of hydrocarbon substrates in dictating the position of the cytochrome P-450 spin equilibrium, and as such, provides a rational molecular explanation based on sound chemical principles for the differential interaction of hydrocarbons with cytochrome P-450.	Hydrocarbons	324-336	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	342-358
3018103-2	1986	The ability of different IFN species to induce xanthine oxidase correlated with their ability to depress liver cytochrome P-450-dependent drug metabolism, supporting the hypothesis that reactive oxygen metabolites generated by xanthine oxidase might be responsible for this impairment of liver function by IFN.	Oxygen	195-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3013312-0	1986	Direct formation of complexes between cytochrome P-450 and nitrosoarenes.	nitrosoarenes	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3013312-1	1986	The mechanism of the formation of the complexes between various nitrosobenzenes and cytochrome P-450 has been investigated.	nitrosobenzene	64-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
3013312-3	1986	Nitrosobenzene (NOB) itself reacts with cytochrome P-450 in the iron(III) state, in the absence of any exogenous reducing agent, to produce the iron(II)-NOB complex.	nitrosobenzene	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3013312-3	1986	Nitrosobenzene (NOB) itself reacts with cytochrome P-450 in the iron(III) state, in the absence of any exogenous reducing agent, to produce the iron(II)-NOB complex.	nitrosobenzene	16-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3013312-3	1986	Nitrosobenzene (NOB) itself reacts with cytochrome P-450 in the iron(III) state, in the absence of any exogenous reducing agent, to produce the iron(II)-NOB complex.	ferric sulfate	64-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3013312-3	1986	Nitrosobenzene (NOB) itself reacts with cytochrome P-450 in the iron(III) state, in the absence of any exogenous reducing agent, to produce the iron(II)-NOB complex.	iron(ii)-nob	144-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
3013312-5	1986	The reduction of the iron may occur via ligand-induced oxidation of the axially bound thiolate of cytochrome P-450.	Iron	21-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
3013312-5	1986	The reduction of the iron may occur via ligand-induced oxidation of the axially bound thiolate of cytochrome P-450.	thiolate	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
3011017-0	1986	Oxidation of 1,4-dihydropyridines by prostaglandin synthase and the peroxidic function of cytochrome P-450.	1,4-dihydropyridine	13-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
3011017-2	1986	Oxidation of 1,4-dihydropyridines by the hydroperoxidic function of cytochrome P-450 and prostaglandin synthase was investigated using felodipine as a model substance.	1,4-dihydropyridine	13-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-111
3011017-2	1986	Oxidation of 1,4-dihydropyridines by the hydroperoxidic function of cytochrome P-450 and prostaglandin synthase was investigated using felodipine as a model substance.	Felodipine	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-111
3960034-10	1986	These results of mutagenicity assay indicate that only the methyl derivatives of N-nitrosopropylamines, MHP and MOP are activated by the lung from 5 animal species and man, whereas the pancreas from all the tested animals did not activate the 7 N-nitrosopropylamines to mutagens, and that the phenobarbital-inducible major cytochrome P-450 in the lung of rodents is involved in the mutagenic activation of MHP.	n-nitrosopropylamines	81-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	323-339
2874666-0	1986	The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.	bufuralol	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
2874666-0	1986	The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.	Mephenytoin	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
2874666-1	1986	Using the stereospecific metabolism of (+)- and (-)-bufuralol and (+)- and (-)-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver.	Debrisoquin	162-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	328-344
2874666-1	1986	Using the stereospecific metabolism of (+)- and (-)-bufuralol and (+)- and (-)-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver.	Sparteine	175-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	328-344
2874666-4	1986	A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed.	bufuralol	93-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2874666-5	1986	Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50,000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1"-hydroxy-bufuralol.	bufuralol	160-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2874666-5	1986	Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50,000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1"-hydroxy-bufuralol.	Ro 03-7410	173-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2874666-13	1986	A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver.	Mephenytoin	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-18
3739365-5	1986	By monitoring the hydroxylation of DMI in various fractions during separation and purification of cytochrome P-450 from human liver microsomes we have purified a cytochrome P-450 which efficiently hydroxylates this drug.	Desipramine	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
3739365-5	1986	By monitoring the hydroxylation of DMI in various fractions during separation and purification of cytochrome P-450 from human liver microsomes we have purified a cytochrome P-450 which efficiently hydroxylates this drug.	Desipramine	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
3739365-8	1986	This is probably the major debrisoquine hydroxylating cytochrome P-450 in man.	Debrisoquin	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
3010988-0	1986	DNA strand scission by hemin-thiolate complexes as models of cytochrome P-450.	hemin-thiolate	23-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
3010988-1	1986	Hemin-thiolate complexes, as chemical models for cytochrome P-450 monooxygenases, have been shown to cause strand scission of DNA.	hemin-thiolate	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
3697359-2	1986	Cytochrome P-450 I-c and cytochrome P-450 II-d, both obtained from the hepatic microsome of polychlorinated biphenyl-treated rats, were used as P-450 type and P-448 type, respectively, and benzo[a]pyrene and 7-ethoxycoumarin were used as substrate.	Polychlorinated Biphenyls	92-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3697359-2	1986	Cytochrome P-450 I-c and cytochrome P-450 II-d, both obtained from the hepatic microsome of polychlorinated biphenyl-treated rats, were used as P-450 type and P-448 type, respectively, and benzo[a]pyrene and 7-ethoxycoumarin were used as substrate.	Polychlorinated Biphenyls	92-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
3697359-5	1986	Differences in the conformational change were observed between the two enzymes, and the conformational change of cytochrome P-450 II-d using benzo[a]pyrene as a substrate was different from that using 7-ethoxycoumarin.	Benzo(a)pyrene	141-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
3697359-5	1986	Differences in the conformational change were observed between the two enzymes, and the conformational change of cytochrome P-450 II-d using benzo[a]pyrene as a substrate was different from that using 7-ethoxycoumarin.	7-ethoxycoumarin	201-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
3697359-6	1986	The results suggest that the substrate-binding sites of the two enzymes differ in position toward the heme, and that there are at least two different substrate sites in cytochrome P-450 II-d, one for benzo[a]pyrene and another for 7-ethoxycoumarin.	Heme	102-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
3697359-6	1986	The results suggest that the substrate-binding sites of the two enzymes differ in position toward the heme, and that there are at least two different substrate sites in cytochrome P-450 II-d, one for benzo[a]pyrene and another for 7-ethoxycoumarin.	Benzo(a)pyrene	200-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
3697359-6	1986	The results suggest that the substrate-binding sites of the two enzymes differ in position toward the heme, and that there are at least two different substrate sites in cytochrome P-450 II-d, one for benzo[a]pyrene and another for 7-ethoxycoumarin.	7-ethoxycoumarin	231-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
3514607-0	1986	Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.	Nifedipine	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
3514607-5	1986	Nifedipine oxidation has been shown to be catalyzed by cytochrome P-450 (P-450) enzymes.	Nifedipine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
3964299-1	1986	Clofibrate, an antilipidemic drug that acts by a still obscure mechanism, is known to specifically increase up to 30-fold the activity of the hepatic cytochrome P-450 isozyme that omega-hydroxlates lauric acid.	Clofibrate	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
3964299-1	1986	Clofibrate, an antilipidemic drug that acts by a still obscure mechanism, is known to specifically increase up to 30-fold the activity of the hepatic cytochrome P-450 isozyme that omega-hydroxlates lauric acid.	lauric acid	198-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
3718550-0	1986	[Hydroxylation of steroids in a dienzyme system consisting of cytochrome P-450 and immobilized adrenodoxin].	Steroids	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3754494-0	1986	Metabolic nitrite formation from N-nitrosamines: are there other pathways than reductive denitrosation by cytochrome P-450?	Nitrites	10-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
3711591-1	1986	Effect of acute doses of technical grade of dichloro diphenyl trichloro ethane (DDT) and piperonyl butoxide (PB) on hepatic microsomal cytochrome P450 (<protein-id="4051">Cyt.	DDT	44-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
3711591-1	1986	Effect of acute doses of technical grade of dichloro diphenyl trichloro ethane (DDT) and piperonyl butoxide (PB) on hepatic microsomal cytochrome P450 (<protein-id="4051">Cyt.	DDT	80-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
3711591-1	1986	Effect of acute doses of technical grade of dichloro diphenyl trichloro ethane (DDT) and piperonyl butoxide (PB) on hepatic microsomal cytochrome P450 (<protein-id="4051">Cyt.	Piperonyl Butoxide	89-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
3711591-1	1986	Effect of acute doses of technical grade of dichloro diphenyl trichloro ethane (DDT) and piperonyl butoxide (PB) on hepatic microsomal cytochrome P450 (<protein-id="4051">Cyt.	Piperonyl Butoxide	109-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
3517618-0	1986	Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat.	isosafrole	73-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
3517618-0	1986	Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat.	isosafrole	73-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
3517618-6	1986	We conclude that, in man, there is a cytochrome P-450 family composed of two isozymes (HLc and HLd) that are immunochemically and structurally related to the 3-methylcholanthrene-inducible family observed in several other species.	Methylcholanthrene	158-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	Cysteine	15-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	Peptides	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	Peptides	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	Cysteine	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	thiolate	167-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3964273-2	1986	In addition, a cysteine containing peptide with a sequence homologous to those of peptides containing the cysteine residue which was suggested to provide the proximal thiolate ligand to the heme in other cytochrome p-450 isozymes, was identified.	Heme	190-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
3511825-4	1986	The possible causes for the injury from ostensibly nontoxic drug levels appear to be either the induction by chronic alcohol intake of the cytochrome P-450 system responsible for converting acetaminophen to a toxic metabolite, or the effect of alcoholism and the associated malnutrition in reducing the glutathione concentration, responsible normally for preventing hepatotoxicity by conjugation with the toxic metabolite.	Alcohols	117-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
3511825-4	1986	The possible causes for the injury from ostensibly nontoxic drug levels appear to be either the induction by chronic alcohol intake of the cytochrome P-450 system responsible for converting acetaminophen to a toxic metabolite, or the effect of alcoholism and the associated malnutrition in reducing the glutathione concentration, responsible normally for preventing hepatotoxicity by conjugation with the toxic metabolite.	Acetaminophen	190-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
3511825-4	1986	The possible causes for the injury from ostensibly nontoxic drug levels appear to be either the induction by chronic alcohol intake of the cytochrome P-450 system responsible for converting acetaminophen to a toxic metabolite, or the effect of alcoholism and the associated malnutrition in reducing the glutathione concentration, responsible normally for preventing hepatotoxicity by conjugation with the toxic metabolite.	Glutathione	303-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
3485990-0	1986	Inhibition of human liver cytochrome P-450 by omeprazole.	Omeprazole	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
3485990-1	1986	The effects of omeprazole on cytochrome P-450 mediated 7-ethoxycoumarin deethylation were studied in human liver microsomes.	Omeprazole	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
3485990-1	1986	The effects of omeprazole on cytochrome P-450 mediated 7-ethoxycoumarin deethylation were studied in human liver microsomes.	7-ethoxycoumarin	55-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
3485990-3	1986	The results are further evidence that the previously reported prolongation of the half-life of diazepam by omeprazole in vivo is due to inhibition of cytochrome P-450 monooxygenases.	Diazepam	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
3485990-3	1986	The results are further evidence that the previously reported prolongation of the half-life of diazepam by omeprazole in vivo is due to inhibition of cytochrome P-450 monooxygenases.	Omeprazole	107-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
3085302-0	1986	[Cytochrome P-450-dependent pathway of oxidation of arachidonic acid and its metabolites].	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	1-17
3085302-1	1986	The experimental data on the role of cytochrome P-450 in the metabolism of arachidonic acid and protanoids in different organs and tissues are analyzed.	Arachidonic Acid	75-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
3085302-1	1986	The experimental data on the role of cytochrome P-450 in the metabolism of arachidonic acid and protanoids in different organs and tissues are analyzed.	protanoids	96-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
3085302-3	1986	A conclusion is drawn that cytochrome P-450 takes an active part not only in oxidation of different xenobiotics and steroid hormones but also in the synthesis and decomposition of prostaglandins--the most important cell regulators.	Steroids	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
3085302-3	1986	A conclusion is drawn that cytochrome P-450 takes an active part not only in oxidation of different xenobiotics and steroid hormones but also in the synthesis and decomposition of prostaglandins--the most important cell regulators.	Prostaglandins	180-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
3004505-12	1986	The PAH produced a 2-fold increase in spectroscopically detectable cytochrome P-450 levels in NCI-H322.	Polycyclic Aromatic Hydrocarbons	4-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3004505-12	1986	The PAH produced a 2-fold increase in spectroscopically detectable cytochrome P-450 levels in NCI-H322.	4-Bromo-3-fluoroaniline	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3947400-0	1986	Induction of cytochrome P-450 by alcohols and 4-substituted pyrazoles.	Alcohols	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
3947400-0	1986	Induction of cytochrome P-450 by alcohols and 4-substituted pyrazoles.	4-substituted pyrazoles	46-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
3947400-2	1986	A comparison was made between 4-substituted pyrazoles and short-chain alcohols as inducers of cytochrome P-450.	4-substituted pyrazoles	30-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
3947400-2	1986	A comparison was made between 4-substituted pyrazoles and short-chain alcohols as inducers of cytochrome P-450.	Alcohols	70-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
3947400-3	1986	A quantitative structure-activity analysis of the data led to the following equations: (I) Pyrazoles: Log 1/C = 0.85 (+/- 0.21) Log P + 1.93 (+/- 0.38), r = 0.970 (II) Alcohols: Log 1/C = 0.78 (+/- 0.14) Log P + 1.46 (+/- 0.13), r = 0.988 where C is the concentration that caused a 50% increase in cytochrome P-450, is the partition coefficient between octanol and water, and r is the correlation coefficient.	Pyrazoles	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-314
3510912-4	1986	The liver contains the most important of these detoxification systems: the cytochrome P-450-dependent mixed function oxidase (MFO) and several conjugation enzymes, e.g., sulfotransferase, glucuronyl transferase, and glutathione transferase, which convert lipophilic compounds to more water-soluble products to enhance their excretion.	Water	284-289	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
3510912-8	1986	Diets restricted in calories, protein, or essential fatty acids, as well as those having low quality protein or high sugar content, can affect the component enzymes, cytochrome P-450 and the cytochrome P-450 reductase, and the MFO activity toward a variety of drugs.	Fatty Acids, Essential	42-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
3510912-8	1986	Diets restricted in calories, protein, or essential fatty acids, as well as those having low quality protein or high sugar content, can affect the component enzymes, cytochrome P-450 and the cytochrome P-450 reductase, and the MFO activity toward a variety of drugs.	Fatty Acids, Essential	42-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
3510912-8	1986	Diets restricted in calories, protein, or essential fatty acids, as well as those having low quality protein or high sugar content, can affect the component enzymes, cytochrome P-450 and the cytochrome P-450 reductase, and the MFO activity toward a variety of drugs.	Sugars	117-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
3510912-8	1986	Diets restricted in calories, protein, or essential fatty acids, as well as those having low quality protein or high sugar content, can affect the component enzymes, cytochrome P-450 and the cytochrome P-450 reductase, and the MFO activity toward a variety of drugs.	Sugars	117-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
3511095-2	1986	Such studies have revealed the important role that the central metal atom plays in determining the physiological and pharmacological properties of metal-porphyrin complexes; and they have demonstrated that the form in which animals and humans are exposed to trace metals, i.e., inorganic, organified, porphyrin-chelated, etc., can be of great importance in determining the biological responses that such elements elicit, especially with respect to actions on heme synthesis and degradation and cytochrome P-450 formation and function.	Metals	147-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	494-510
3511095-2	1986	Such studies have revealed the important role that the central metal atom plays in determining the physiological and pharmacological properties of metal-porphyrin complexes; and they have demonstrated that the form in which animals and humans are exposed to trace metals, i.e., inorganic, organified, porphyrin-chelated, etc., can be of great importance in determining the biological responses that such elements elicit, especially with respect to actions on heme synthesis and degradation and cytochrome P-450 formation and function.	Porphyrins	153-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	494-510
3082822-0	1986	A comparative study of the mutagenic activation of N-nitrosopropylamines by various animal species and man: evidence for a cytochrome P-450 dependent reaction.	n-nitrosopropylamines	51-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
3082822-8	1986	These results demonstrated that the phenobarbital-inducible major cytochrome P-450 in animal and human livers is involved in the mutagenic activation of the N-nitrosopropylamines.	Phenobarbital	36-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
3082822-8	1986	These results demonstrated that the phenobarbital-inducible major cytochrome P-450 in animal and human livers is involved in the mutagenic activation of the N-nitrosopropylamines.	n-nitrosopropylamines	157-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
3961272-2	1986	PEG-6000 and ammonium sulfate fractionation of human granulocyte post-mitochondrial supernatant (S1) fraction resulted in 3.9 and 2.25 fold purification of cytochrome P-450 respectively.	Polyethylene Glycol 6000	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3961272-2	1986	PEG-6000 and ammonium sulfate fractionation of human granulocyte post-mitochondrial supernatant (S1) fraction resulted in 3.9 and 2.25 fold purification of cytochrome P-450 respectively.	Ammonium Sulfate	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
3961272-3	1986	On the other hand, granulocyte S1 fractions subjected to noctylamino sepharose 4B and DEAE cellulose column chromatography separately revealed about 11 fold purification of cytochrome P-450.	noctylamino sepharose 4b	57-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
3961272-3	1986	On the other hand, granulocyte S1 fractions subjected to noctylamino sepharose 4B and DEAE cellulose column chromatography separately revealed about 11 fold purification of cytochrome P-450.	DEAE-Cellulose	86-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
3080992-1	1986	Water-soluble carbodiimide-catalyzed cross-linking of purified cytochrome P-450 LM2, cytochrome b5, and NADPH-cytochrome P-450 reductase was used to identify stable complexes formed between these proteins.	Water	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
3080992-1	1986	Water-soluble carbodiimide-catalyzed cross-linking of purified cytochrome P-450 LM2, cytochrome b5, and NADPH-cytochrome P-450 reductase was used to identify stable complexes formed between these proteins.	Carbodiimides	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
3955002-0	1986	Ligand and halide binding properties of chloroperoxidase: peroxidase-type active site heme environment with cytochrome P-450 type endogenous axial ligand and spectroscopic properties.	halide	11-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3955002-0	1986	Ligand and halide binding properties of chloroperoxidase: peroxidase-type active site heme environment with cytochrome P-450 type endogenous axial ligand and spectroscopic properties.	Heme	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3955002-4	1986	All of the ligands except for the halides, nitrate, and acetate form exclusively low-spin complexes in analogy to results obtained with the spectroscopically related protein, cytochrome P-450-CAM [Sono, M., &amp; Dawson, J.H.	Nitrates	43-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3955002-4	1986	All of the ligands except for the halides, nitrate, and acetate form exclusively low-spin complexes in analogy to results obtained with the spectroscopically related protein, cytochrome P-450-CAM [Sono, M., &amp; Dawson, J.H.	Acetates	56-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
3532707-4	1986	In our laboratory we have demonstrated that DBE is metabolized by both cytochrome P-450 and GSH S-transferases.	Ethylene Dibromide	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3532707-5	1986	Although the cytochrome P-450 metabolite is reactive and will covalently bind to protein and nucleic acid to some extent, and the GSH S-transferase system conjugates it and under conditions of low DBE exposure is able to detoxify it.	Ethylene Dibromide	197-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
3591537-7	1986	Zinc deficiency is known to increase the cytochrome P-450-dependent metabolism of methylbenzylnitrosamine (MBN), an esophageal carcinogen of this class.	nitrosobenzylmethylamine	82-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3591537-7	1986	Zinc deficiency is known to increase the cytochrome P-450-dependent metabolism of methylbenzylnitrosamine (MBN), an esophageal carcinogen of this class.	nitrosobenzylmethylamine	107-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3954830-3	1986	The data suggest that most of the ethanol metabolism by blood-monocyte-derived macrophages is mediated via the cytochrome-P-450-dependent microsomal ethanol-oxidising system.	Ethanol	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3954830-3	1986	The data suggest that most of the ethanol metabolism by blood-monocyte-derived macrophages is mediated via the cytochrome-P-450-dependent microsomal ethanol-oxidising system.	Ethanol	149-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3790107-0	1986	The molecular biology of the polycyclic aromatic hydrocarbon inducible cytochrome P-450; the past is prologue.	Polycyclic Aromatic Hydrocarbons	29-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
3940522-0	1986	Benznidazole: nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs.	benzonidazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
3955103-6	1986	The experimental results suggest that the activity and structure of cytochrome P-450 conformers is affected by the lipid microenvironment, type I substrates and Triton N-101.	Triton N 101	161-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3094971-6	1986	Aminoglutethimide, however, blocks other cytochrome P-450-mediated steroid hydroxylations, requires concomitant glucocorticoid administration, and is associated with initial side effects.	Aminoglutethimide	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3094971-6	1986	Aminoglutethimide, however, blocks other cytochrome P-450-mediated steroid hydroxylations, requires concomitant glucocorticoid administration, and is associated with initial side effects.	Steroids	67-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
3539534-10	1986	When drugs such as phenobarbital are administered to animals, there is a rapid induction in the liver of both cytochrome P-450 and ALV-synthase.	Phenobarbital	19-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-143
3539534-11	1986	It is proposed that the heme pool governing ALV-synthase levels is lowered by the increased heme demand due to cytochrome P-450 apoprotein formation.	Heme	24-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3539534-11	1986	It is proposed that the heme pool governing ALV-synthase levels is lowered by the increased heme demand due to cytochrome P-450 apoprotein formation.	Heme	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3539534-18	1986	Attacks of the disease are commonly precipitated by drugs which induce cytochrome P-450, and the uncontrolled accumulation of ALV-synthase which accompanies these attacks results from the combined action of the block in the heme pathway and the increased cytochrome P-450 levels.	Heme	224-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	255-271
2868861-2	1986	In agreement with earlier studies, cobalt chloride treatment produced a 1.5-fold increase in hepatic glutathione levels and a decrease in the cytochrome P-450-dependent oxidative metabolism of acetaminophen.	cobaltous chloride	35-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2868861-2	1986	In agreement with earlier studies, cobalt chloride treatment produced a 1.5-fold increase in hepatic glutathione levels and a decrease in the cytochrome P-450-dependent oxidative metabolism of acetaminophen.	Acetaminophen	193-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2868861-5	1986	Collectively, the data suggest that the protective effect of cobalt chloride treatment on acetaminophen hepatotoxicity results from a combination of the suppression of the toxic pathway of cytochrome P-450 oxidation, an increase in the protective capacity of glutathione, and an enhancement of the nontoxic pathway of glucuronidation.	cobaltous chloride	61-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-205
2868861-5	1986	Collectively, the data suggest that the protective effect of cobalt chloride treatment on acetaminophen hepatotoxicity results from a combination of the suppression of the toxic pathway of cytochrome P-450 oxidation, an increase in the protective capacity of glutathione, and an enhancement of the nontoxic pathway of glucuronidation.	Acetaminophen	90-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-205
3948674-0	1986	[The role of cytochrome P-450 in the activation of phosphatidyl choline hydrolysis by phospholipase A2].	Phosphatidylcholines	51-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
3549274-2	1986	The pathway of biosynthesis of these steroids from cholesterol involves a sequence of transformations using cytochrome P-450 enzymes.	Steroids	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3549274-2	1986	The pathway of biosynthesis of these steroids from cholesterol involves a sequence of transformations using cytochrome P-450 enzymes.	Cholesterol	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
3549274-3	1986	The hypothesis presented here is that damage to cytochrome P-450 enzymes on interaction with certain steroids, synthesized by the adrenal cortex itself, may be of pathological and perhaps physiological importance.	Steroids	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
3549274-4	1986	The interaction between cytochrome P-450 enzymes and these steroids, which act as pseudosubstrates, may form part of the pathogenesis of some steroidogenic enzyme deficiencies, with consequent overproduction of precursor steroids, leading to mineralocorticoid or androgen excess.	Steroids	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
3549274-4	1986	The interaction between cytochrome P-450 enzymes and these steroids, which act as pseudosubstrates, may form part of the pathogenesis of some steroidogenic enzyme deficiencies, with consequent overproduction of precursor steroids, leading to mineralocorticoid or androgen excess.	Steroids	221-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
3549274-7	1986	The high content of antioxidant compounds in the adrenal cortex, principally ascorbate, may serve to protect cytochrome P-450 enzymes from the damaging effects of oxygen radical species formed as a result of cytochrome P-450/pseudosubstrate interactions.	Ascorbic Acid	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
3549274-7	1986	The high content of antioxidant compounds in the adrenal cortex, principally ascorbate, may serve to protect cytochrome P-450 enzymes from the damaging effects of oxygen radical species formed as a result of cytochrome P-450/pseudosubstrate interactions.	Ascorbic Acid	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-224
3549274-7	1986	The high content of antioxidant compounds in the adrenal cortex, principally ascorbate, may serve to protect cytochrome P-450 enzymes from the damaging effects of oxygen radical species formed as a result of cytochrome P-450/pseudosubstrate interactions.	Oxygen	163-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
3549274-7	1986	The high content of antioxidant compounds in the adrenal cortex, principally ascorbate, may serve to protect cytochrome P-450 enzymes from the damaging effects of oxygen radical species formed as a result of cytochrome P-450/pseudosubstrate interactions.	Oxygen	163-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-224
3709653-3	1986	2-hydroxylation of DMI is probably mediated by debrisoquine hydroxylase, a cytochrome P-450 isozyme that is monogenically controlled.	Desipramine	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
3562262-1	1986	Thiolate-hemin complexes as chemical models for cytochrome P-450 have been shown to cause cleavage of DNA.	thiolate-hemin	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
3739442-0	1986	Effect of phenobarbital on the contents of microsomal cytochrome P-450 and levels of glutathione (GSH) in the liver of various animal species.	Phenobarbital	10-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2869518-0	1985	Cytochrome P450: substrate and prosthetic-group free radicals generated during the enzymatic cycle.	Free Radicals	48-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
4083898-1	1985	Aromatase cytochrome P-450 (P-450AROM) was partially purified from human placental microsomes by hydrophobic affinity chromatography using Phenyl-Sepharose and ion-exchange chromatography on DEAE-cellulose.	phenyl-sepharose	139-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
4083898-1	1985	Aromatase cytochrome P-450 (P-450AROM) was partially purified from human placental microsomes by hydrophobic affinity chromatography using Phenyl-Sepharose and ion-exchange chromatography on DEAE-cellulose.	DEAE-Cellulose	191-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
4083898-3	1985	When the cytochrome P-450-enriched fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and stained with Coomassie blue, there was an enrichment of two proteins having apparent molecular weights of 50,000 and 55,000.	Sodium Dodecyl Sulfate	63-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
4083898-3	1985	When the cytochrome P-450-enriched fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and stained with Coomassie blue, there was an enrichment of two proteins having apparent molecular weights of 50,000 and 55,000.	polyacrylamide gels	86-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
4083898-3	1985	When the cytochrome P-450-enriched fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and stained with Coomassie blue, there was an enrichment of two proteins having apparent molecular weights of 50,000 and 55,000.	Coomassie blue	138-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
4083898-10	1985	The finding that cytochrome P-450 and the 55-kDa protein were selectively retained by the affinity column and eluted with NaCl (2 M) and glycine (0.2 M, pH 3.0) and that this fraction contained aromatase activity upon reconstitution with purified NADPH-cytochrome P-450 reductase and phospholipid, is indicative that the 55-kDa protein is indeed cytochrome P-450AROM.	Sodium Chloride	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
4083898-10	1985	The finding that cytochrome P-450 and the 55-kDa protein were selectively retained by the affinity column and eluted with NaCl (2 M) and glycine (0.2 M, pH 3.0) and that this fraction contained aromatase activity upon reconstitution with purified NADPH-cytochrome P-450 reductase and phospholipid, is indicative that the 55-kDa protein is indeed cytochrome P-450AROM.	Glycine	137-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
3007100-0	1985	Model studies in cytochrome P-450-mediated toxicity of halogenated compounds: radical processes involving iron porphyrins.	iron porphyrins	106-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
3007100-1	1985	Haloalkane toxicity originates from attack on biological targets by reactive intermediates derived from haloalkane metabolism by a hemoprotein, cytochrome P-450.	haloalkane	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
3007100-3	1985	The reactions of iron porphyrin--a model for cytochrome P-450--with various carbon-centered and peroxyl radicals generated by pulse radiolysis are examined.	iron porphyrin	17-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
3007100-3	1985	The reactions of iron porphyrin--a model for cytochrome P-450--with various carbon-centered and peroxyl radicals generated by pulse radiolysis are examined.	Carbon	76-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
3007100-3	1985	The reactions of iron porphyrin--a model for cytochrome P-450--with various carbon-centered and peroxyl radicals generated by pulse radiolysis are examined.	perhydroxyl radical	96-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
3007100-6	1985	The importance of local oxygen concentration and structural arrangement of fatty acids around cytochrome P-450 is emphasized.	Fatty Acids	75-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
4061517-1	1985	Variations in cytochrome P-450 levels may influence the responsiveness of uterine and breast tissue as well as carcinomas to endocrine therapy and may be of particular importance with agents such as tamoxifen (Nolvadex) where hydroxylation is known to alter therapeutic activities.	Tamoxifen	199-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
4061517-1	1985	Variations in cytochrome P-450 levels may influence the responsiveness of uterine and breast tissue as well as carcinomas to endocrine therapy and may be of particular importance with agents such as tamoxifen (Nolvadex) where hydroxylation is known to alter therapeutic activities.	Tamoxifen	210-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
4061517-3	1985	Cyclohexane served as a substrate for several forms of cytochrome P-450.	Cyclohexane	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	Sodium Azide	23-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	N,N-dimethylaniline	166-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	N,N-dimethylaniline	183-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	Aminopyrine	189-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	Benzphetamine	207-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	Benzphetamine	222-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	4-nitroanisole	228-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	4-nitroanisole	244-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	aniline	272-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-1	1985	It has been shown that sodium azide, a catalase inhibitor, accelerates the inactivation of cytochrome P-450 in reactions of hydroxylation of type I substrates, e.g., dimethylaniline (DMA), aminopyrine (AP), benzphetamine (BPh), p-nitroanisole (p-Na) and type II substrates--aniline (AN).	an	283-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
4063403-4	1985	Studies on the mechanism of cytochrome P-450 inactivation demonstrated that hydrogen peroxide formed via the NADPH-dependent hydroxylase cycle exhibits an inactivating effect towards the enzyme.	Hydrogen Peroxide	76-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
4063403-5	1985	The value of inactivation constant for cytochrome P-450 in hydroxylation reactions proceeding in the presence of sodium azide coincides with that of enzyme inactivation in the NADPH-oxidase and glucose oxidase systems generating H2O2.	Sodium Azide	113-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
4063403-5	1985	The value of inactivation constant for cytochrome P-450 in hydroxylation reactions proceeding in the presence of sodium azide coincides with that of enzyme inactivation in the NADPH-oxidase and glucose oxidase systems generating H2O2.	Hydrogen Peroxide	229-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
4053486-5	1985	These results support our hypothesis that the mephenytoin polymorphism is caused by a partial or complete absence or inactivity of a cytochrome P-450 isozyme with high affinity for S-mephenytoin.	Mephenytoin	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
4053486-5	1985	These results support our hypothesis that the mephenytoin polymorphism is caused by a partial or complete absence or inactivity of a cytochrome P-450 isozyme with high affinity for S-mephenytoin.	Mephenytoin	181-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
4064917-10	1985	These results implicate cimetidine binding to the cytochrome P-450 system as the sole mechanism responsible for inhibition of the systemic clearance of co-administered drugs metabolized by the liver.	Cimetidine	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
3912769-0	1985	Cytochrome P-450 dependent pathways in corticosteroid hormones biosynthesis.	corticosteroid hormones	39-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
4095131-0	1985	[Elimination of caffeine and metamizol in in vivo characterization of cytochrome P-450 dependent biotransformation reactions in aged humans].	Caffeine	16-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
4095131-0	1985	[Elimination of caffeine and metamizol in in vivo characterization of cytochrome P-450 dependent biotransformation reactions in aged humans].	Dipyrone	29-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
4095131-2	1985	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene inducible (caffeine elimination) and of phenobarbital inducible (metamizol elimination) isoenzymes of cytochrome P-450 are drawn.	Methylcholanthrene	95-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	218-234
4095131-2	1985	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene inducible (caffeine elimination) and of phenobarbital inducible (metamizol elimination) isoenzymes of cytochrome P-450 are drawn.	Phenobarbital	156-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	218-234
4095131-2	1985	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene inducible (caffeine elimination) and of phenobarbital inducible (metamizol elimination) isoenzymes of cytochrome P-450 are drawn.	Dipyrone	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	218-234
4095132-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and metamizol (noramidopyrine methanesulfonate sodium) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Caffeine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
4095132-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and metamizol (noramidopyrine methanesulfonate sodium) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Methylcholanthrene	34-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
4095132-2	1985	That"s why the half life of caffeine and the elimination of the main metabolites of metamizol were used as parameters in vivo characterizing both groups of the cytochrome P-450-complex.	Caffeine	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4095132-2	1985	That"s why the half life of caffeine and the elimination of the main metabolites of metamizol were used as parameters in vivo characterizing both groups of the cytochrome P-450-complex.	Dipyrone	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
2997155-3	1985	To develop pharmacologically useful inhibitors of the LTB4 omega-hydroxylase in human PMN, we devised a general scheme for synthesizing terminal acetylenic fatty acids based on the "acetylenic zipper" reaction.	acetylenic fatty acids	145-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-76
2997155-4	1985	We found that the LTB4 omega-hydroxylase in intact PMN and in PMN sonicates is inactivated in a concentration-dependent fashion by terminal acetylenic analogues of lauric, palmitic, and stearic acids (i.e. 11-dodecynoic, 15-hexadecynoic, and 17-octadecynoic acids).	acetylenic	140-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-40
2997155-4	1985	We found that the LTB4 omega-hydroxylase in intact PMN and in PMN sonicates is inactivated in a concentration-dependent fashion by terminal acetylenic analogues of lauric, palmitic, and stearic acids (i.e. 11-dodecynoic, 15-hexadecynoic, and 17-octadecynoic acids).	Stearic Acids	186-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-40
2997155-4	1985	We found that the LTB4 omega-hydroxylase in intact PMN and in PMN sonicates is inactivated in a concentration-dependent fashion by terminal acetylenic analogues of lauric, palmitic, and stearic acids (i.e. 11-dodecynoic, 15-hexadecynoic, and 17-octadecynoic acids).	-dodecynoic	208-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-40
2997155-4	1985	We found that the LTB4 omega-hydroxylase in intact PMN and in PMN sonicates is inactivated in a concentration-dependent fashion by terminal acetylenic analogues of lauric, palmitic, and stearic acids (i.e. 11-dodecynoic, 15-hexadecynoic, and 17-octadecynoic acids).	17-octadecynoic acid	242-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-40
2997155-5	1985	Consistent with a suicidal process, inactivation of the LTB4 omega-hydroxylase requires molecular oxygen and NADPH, is time-dependent, and follows pseudo-first-order kinetics.	Oxygen	98-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-78
2997155-5	1985	Consistent with a suicidal process, inactivation of the LTB4 omega-hydroxylase requires molecular oxygen and NADPH, is time-dependent, and follows pseudo-first-order kinetics.	NADP	109-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-78
3000277-1	1985	We have recently isolated a cloned cDNA coding for a cytochrome P-450 of human liver microsomal membranes, which corresponds to a major phenobarbital-inducible cytochrome P-450 of rat liver.	Phenobarbital	136-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
3000277-1	1985	We have recently isolated a cloned cDNA coding for a cytochrome P-450 of human liver microsomal membranes, which corresponds to a major phenobarbital-inducible cytochrome P-450 of rat liver.	Phenobarbital	136-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4052098-3	1985	This epitope was also present on cytochrome P-450 PCN-E (pregnenolone-16 alpha-carbonitrile induced) from rat liver microsomes, but this isozyme differed from the human P-450(5) by its molecular weight.	pcn-e	50-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
4052098-3	1985	This epitope was also present on cytochrome P-450 PCN-E (pregnenolone-16 alpha-carbonitrile induced) from rat liver microsomes, but this isozyme differed from the human P-450(5) by its molecular weight.	Pregnenolone Carbonitrile	57-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
4074778-0	1985	[A shunted system of electron transport from NAD(P)H to cholesterol-hydroxylating cytochrome P-450 in adrenal cortex mitochondria].	nad(p)h	45-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
4074778-0	1985	[A shunted system of electron transport from NAD(P)H to cholesterol-hydroxylating cytochrome P-450 in adrenal cortex mitochondria].	Cholesterol	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
4074778-7	1985	Phenazine methosulfate can reduce microsomal cytochrome P-450 LM2 and b5, but not cytochrome P-450 LM4.	Methylphenazonium Methosulfate	0-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
3000715-0	1985	Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxin-inducible rabbit mRNAs encoding P-450 4 and P-450 6.	Dioxins	68-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
4052083-5	1985	Activities of 7-ethoxycoumarin O-deethylase and benzo(a)pyrene hydroxylase in livers but not in adrenals were inhibited by the anti-P-450 HFLa antibodies, probably suggesting that distinct forms of cytochrome P-450 are responsible for the oxidations in livers and adrenals.	7-ethoxycoumarin	14-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
3839750-0	1985	Identification and quantification of a messenger ribonucleic acid induced by polynuclear aromatic hydrocarbons--using a cloned human cytochrome P-450 gene.	Polycyclic Aromatic Hydrocarbons	77-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
3839750-1	1985	We have isolated four overlapping human genomic clones associated with the polynuclear aromatic hydrocarbon-induced form of cytochrome P-450.	Hydrocarbons, Aromatic	87-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
3935158-0	1985	Kinetics of cytochrome P-450 reduction: evidence for faster reduction of the high-spin ferric state.	Ferric enterobactin ion	87-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
3935158-10	1985	A mathematical expression of the fractional content of high-spin cytochrome P-450 was obtained by comparing the ratio of the initial rate of change in the fraction of total oxidized cytochrome remaining to the initial rate of change in the fraction of high-spin ferric P-450 remaining.	ferric p	262-270	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theophylline	45-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theobromine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theobromine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theophylline	176-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theobromine	262-273	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2865110-9	1985	When compared with previous data relating to theophylline, the results suggest that theobromine 3-demethylation is mediated by the same form(s) of cytochrome P-450 involved in theophylline demethylation, while a second form(s) of cytochrome P-450 is involved in theobromine 7-demethylation and theophylline 8-hydroxylation.	Theophylline	176-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2865110-10	1985	In addition, since AMMU formation was inhibited by cimetidine and induced by cigarette smoking and sulfinpyrazone, it would appear that the conversion of theobromine to AMMU is also mediated by cytochrome P-450.	ammu	19-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
2865110-10	1985	In addition, since AMMU formation was inhibited by cimetidine and induced by cigarette smoking and sulfinpyrazone, it would appear that the conversion of theobromine to AMMU is also mediated by cytochrome P-450.	Cimetidine	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
2865110-10	1985	In addition, since AMMU formation was inhibited by cimetidine and induced by cigarette smoking and sulfinpyrazone, it would appear that the conversion of theobromine to AMMU is also mediated by cytochrome P-450.	Sulfinpyrazone	99-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
2865110-10	1985	In addition, since AMMU formation was inhibited by cimetidine and induced by cigarette smoking and sulfinpyrazone, it would appear that the conversion of theobromine to AMMU is also mediated by cytochrome P-450.	Theobromine	154-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
2865110-10	1985	In addition, since AMMU formation was inhibited by cimetidine and induced by cigarette smoking and sulfinpyrazone, it would appear that the conversion of theobromine to AMMU is also mediated by cytochrome P-450.	ammu	169-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
4044832-6	1985	LTB4 omega-hydroxylase activity in isolated PMN membranes was linear with respect to duration of incubation and protein concentration, was maximal at pH 7.4, had a Km for LTB4 of 0.6 microM, and was dependent on oxygen and on reduced pyridine nucleotides (apparent Km for NADPH = 0.5 microM; apparent Km for NADH = 223 microM).	Oxygen	212-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
4044832-6	1985	LTB4 omega-hydroxylase activity in isolated PMN membranes was linear with respect to duration of incubation and protein concentration, was maximal at pH 7.4, had a Km for LTB4 of 0.6 microM, and was dependent on oxygen and on reduced pyridine nucleotides (apparent Km for NADPH = 0.5 microM; apparent Km for NADH = 223 microM).	pyridine nucleotides	234-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
4044832-6	1985	LTB4 omega-hydroxylase activity in isolated PMN membranes was linear with respect to duration of incubation and protein concentration, was maximal at pH 7.4, had a Km for LTB4 of 0.6 microM, and was dependent on oxygen and on reduced pyridine nucleotides (apparent Km for NADPH = 0.5 microM; apparent Km for NADH = 223 microM).	NAD	308-312	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
4044832-7	1985	The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase.	Carbon Monoxide	58-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-26
4044832-7	1985	The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase.	Carbon	48-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-26
4044832-7	1985	The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase.	Proadifen	94-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-26
4044832-7	1985	The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase.	Octoxynol	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-26
3898085-2	1985	We carried out immunoblot analyses of liver microsomes isolated from eight patients and found that each contained a cytochrome P-450, termed HLp, that reacted with antibodies directed against P-450p, a rat liver cytochrome that is inducible by the anti-glucocorticoid pregnenolone-16 alpha-carbonitrile, by glucocorticoids, by anti-seizure drugs, and by such macrolide antibiotics as triacetyloleandomycin.	macrolide antibiotics	359-380	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3898085-2	1985	We carried out immunoblot analyses of liver microsomes isolated from eight patients and found that each contained a cytochrome P-450, termed HLp, that reacted with antibodies directed against P-450p, a rat liver cytochrome that is inducible by the anti-glucocorticoid pregnenolone-16 alpha-carbonitrile, by glucocorticoids, by anti-seizure drugs, and by such macrolide antibiotics as triacetyloleandomycin.	Troleandomycin	384-405	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
3780149-9	1986	In patients who are receiving phenytoin, phenobarbital, or other drugs metabolized by the cytochrome P-450 system, serum concentrations of these drugs may increase as a result of influenza vaccination, and dosage adjustments may be necessary.	Phenytoin	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
3780149-9	1986	In patients who are receiving phenytoin, phenobarbital, or other drugs metabolized by the cytochrome P-450 system, serum concentrations of these drugs may increase as a result of influenza vaccination, and dosage adjustments may be necessary.	Phenobarbital	41-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
3898085-2	1985	We carried out immunoblot analyses of liver microsomes isolated from eight patients and found that each contained a cytochrome P-450, termed HLp, that reacted with antibodies directed against P-450p, a rat liver cytochrome that is inducible by the anti-glucocorticoid pregnenolone-16 alpha-carbonitrile, by glucocorticoids, by anti-seizure drugs, and by such macrolide antibiotics as triacetyloleandomycin.	Pregnenolone Carbonitrile	268-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
4026319-2	1985	The cytochrome P-450 preparation was electrophoretically homogeneous and had an apparent monomeric molecular weight of 51,000 as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	Sodium Dodecyl Sulfate	139-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
4026319-2	1985	The cytochrome P-450 preparation was electrophoretically homogeneous and had an apparent monomeric molecular weight of 51,000 as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	polyacrylamide	162-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3935180-1	1985	Emulgen 913, Triton N-101 and sodium cholate were compared for their reconstituting action on the dimethylaniline N-demethylation system containing cytochrome P-450 and NADPH-cytochrome P-450 reductase.	Triton N 101	13-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
4016117-3	1985	The compounds inhibit oxidation and binding of cytochrome P-450 substrates of type I (naphthalene, aminopyrine) and of type II (aniline).	naphthalene	86-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
4016117-3	1985	The compounds inhibit oxidation and binding of cytochrome P-450 substrates of type I (naphthalene, aminopyrine) and of type II (aniline).	Aminopyrine	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
4016117-3	1985	The compounds inhibit oxidation and binding of cytochrome P-450 substrates of type I (naphthalene, aminopyrine) and of type II (aniline).	aniline	128-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
4016117-8	1985	The data obtained make it possible to estimate the distance (r) between the membranes surface and Fe3+ in the active centre of the enzyme (r less than or equal to 20 A) under the assumption that all molecules of cytochrome P-450 are equally remote from the membrane surface.	ferric sulfate	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-228
4017418-6	1985	In view of the known inhibitory effects of cimetidine on cytochrome P-450-dependent enzymes, our data suggest that this enzyme system does not metabolize a significant fraction of ingested ethanol in subjects who have consumed moderate doses of alcohol for several weeks.	Cimetidine	43-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
2996790-2	1985	The toxicity of halogenated alkanes originates from their metabolism by cytochrome P-450 which leads to the formation of reactive intermediates.	Alkanes	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2996790-8	1985	The importance of local oxygen concentration and structural arrangement of fatty acids around cytochrome P-450 are emphasized.	Fatty Acids	75-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
3935180-1	1985	Emulgen 913, Triton N-101 and sodium cholate were compared for their reconstituting action on the dimethylaniline N-demethylation system containing cytochrome P-450 and NADPH-cytochrome P-450 reductase.	Sodium Cholate	30-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
3935180-1	1985	Emulgen 913, Triton N-101 and sodium cholate were compared for their reconstituting action on the dimethylaniline N-demethylation system containing cytochrome P-450 and NADPH-cytochrome P-450 reductase.	N,N-dimethylaniline	98-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
4005291-1	1985	Using a classical methodology of purification consisting of three chromatographic steps (Octyl-Sepharose, DEAE-cellulose, CM-cellulose) we have purified a new cytochrome P-450 from human liver microsomes.	octyl-sepharose CL-4B	89-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
4015695-1	1985	Diltiazem and verapamil were found to be inhibitors of the cytochrome P-450-dependent biotransformation of drugs.	Diltiazem	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
4015695-1	1985	Diltiazem and verapamil were found to be inhibitors of the cytochrome P-450-dependent biotransformation of drugs.	Verapamil	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
2409076-1	1985	Ferric bleomycin was tested for its ability to catalyze a set of six oxidative reactions characteristic of the heme-containing proteins, cytochrome P-450 and chloroperoxidase.	iron bleomycin	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-174
4005291-1	1985	Using a classical methodology of purification consisting of three chromatographic steps (Octyl-Sepharose, DEAE-cellulose, CM-cellulose) we have purified a new cytochrome P-450 from human liver microsomes.	DEAE-Cellulose	106-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
2409076-1	1985	Ferric bleomycin was tested for its ability to catalyze a set of six oxidative reactions characteristic of the heme-containing proteins, cytochrome P-450 and chloroperoxidase.	Heme	111-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-174
4005291-1	1985	Using a classical methodology of purification consisting of three chromatographic steps (Octyl-Sepharose, DEAE-cellulose, CM-cellulose) we have purified a new cytochrome P-450 from human liver microsomes.	7,8-diacetoxy-3-(4-nitrophenyl)coumarin	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
4015675-2	1985	The formation of 1,4-naphthoquinone, the major methanol-soluble product at early time points, showed an almost total dependence on cytochrome P-450, NADPH-cytochrome P-450 reductase and NADPH, and to a lesser extent on dilauroylphosphatidylcholine.	1,2-dilauroylphosphatidylcholine	219-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
4015675-0	1985	Cytochrome P-450 dependent metabolic activation of 1-naphthol to naphthoquinones and covalent binding species.	1-naphthol	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2990349-9	1985	Various substrate analogs of camphor induce varying degrees of low-spin to high-spin shift upon binding to ferric cytochrome P-450 (3).	Camphor	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
4015675-0	1985	Cytochrome P-450 dependent metabolic activation of 1-naphthol to naphthoquinones and covalent binding species.	Naphthoquinones	65-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
4015675-4	1985	1,4-Naphthoquinone formation was dependent on the concentration of both cytochrome P-450 (0.05-0.04 microM) and 1-naphthol (5-50 microM).	1,4-naphthoquinone	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
4015675-1	1985	1-Naphthol was metabolised by a fully reconstituted cytochrome P-450 system in the presence of NADPH to methanol-soluble and covalently bound products.	1-naphthol	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
4015675-1	1985	1-Naphthol was metabolised by a fully reconstituted cytochrome P-450 system in the presence of NADPH to methanol-soluble and covalently bound products.	Methanol	104-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
4015675-2	1985	The formation of 1,4-naphthoquinone, the major methanol-soluble product at early time points, showed an almost total dependence on cytochrome P-450, NADPH-cytochrome P-450 reductase and NADPH, and to a lesser extent on dilauroylphosphatidylcholine.	1,4-naphthoquinone	17-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
4015675-2	1985	The formation of 1,4-naphthoquinone, the major methanol-soluble product at early time points, showed an almost total dependence on cytochrome P-450, NADPH-cytochrome P-450 reductase and NADPH, and to a lesser extent on dilauroylphosphatidylcholine.	Methanol	47-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
4040350-5	1985	Conversely, the treatment of rats with human chorionic gonadotropin (hCG) fully reversed the effect of cis-platinum on heme and cytochrome P-450 concentrations.	Cisplatin	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
4015675-6	1985	In the absence of NADPH and NADPH-cytochrome P-450 reductase, 1-naphthol was metabolised, in a cumene hydroperoxide- and cytochrome P-450-dependent reaction, to 1,2- and 1,4-naphthoquinone and covalently bound products.	1-naphthol	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
4015675-6	1985	In the absence of NADPH and NADPH-cytochrome P-450 reductase, 1-naphthol was metabolised, in a cumene hydroperoxide- and cytochrome P-450-dependent reaction, to 1,2- and 1,4-naphthoquinone and covalently bound products.	cumene hydroperoxide	95-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
4015675-6	1985	In the absence of NADPH and NADPH-cytochrome P-450 reductase, 1-naphthol was metabolised, in a cumene hydroperoxide- and cytochrome P-450-dependent reaction, to 1,2- and 1,4-naphthoquinone and covalently bound products.	1,4-naphthoquinone	170-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
4015675-8	1985	These data show that cytochrome P-450 catalyses the activation of 1-naphthol to naphthoquinone metabolites and covalently bound species, the latter most likely being derived from naphthoquinones.	1-naphthol	66-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
4015675-8	1985	These data show that cytochrome P-450 catalyses the activation of 1-naphthol to naphthoquinone metabolites and covalently bound species, the latter most likely being derived from naphthoquinones.	Naphthoquinones	80-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
4027138-0	1985	Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?	Debrisoquin	127-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
4015675-8	1985	These data show that cytochrome P-450 catalyses the activation of 1-naphthol to naphthoquinone metabolites and covalently bound species, the latter most likely being derived from naphthoquinones.	Naphthoquinones	179-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
4018075-4	1985	The simple first-order kinetics of cytochrome P-450 reduction had been observed in the presence of non-ionic detergent Triton N-101.	Triton N 101	119-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
4028286-0	1985	Spin state control of cytochrome P-450 reduction and catalytic activity in a reconstituted P-450 LM2 system as induced by a series of benzphetamine analogues.	Benzphetamine	134-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
4028286-1	1985	Reconstituted liposomal cytochrome P-450 LM2 was reacted with a series of benzphetamine analogues as substrates.	Benzphetamine	74-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
4018075-5	1985	The apparent biphasity of cytochrome P-450 reduction by dithionite should be the result asymmetric distribution of hemoprotein in microsomal and proteoliposomal membranes as well as in cytochrome oligomers in solution.	Dithionite	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
3877043-2	1985	In rats and in humans, troleandomycin, erythromycin and erythromycin derivatives induce microsomal enzymes; the induced isozymes of cytochrome P-450 have a high activity for these macrolides but a poor activity with several other substrates.	Troleandomycin	23-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3877043-2	1985	In rats and in humans, troleandomycin, erythromycin and erythromycin derivatives induce microsomal enzymes; the induced isozymes of cytochrome P-450 have a high activity for these macrolides but a poor activity with several other substrates.	Erythromycin	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3877043-2	1985	In rats and in humans, troleandomycin, erythromycin and erythromycin derivatives induce microsomal enzymes; the induced isozymes of cytochrome P-450 have a high activity for these macrolides but a poor activity with several other substrates.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3877043-3	1985	These isozymes actively demethylate and oxidize these macrolides into nitrosoalkanes which form stable, inactive complexes with the iron of cytochrome P-450.	demethylate	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3877043-3	1985	These isozymes actively demethylate and oxidize these macrolides into nitrosoalkanes which form stable, inactive complexes with the iron of cytochrome P-450.	Macrolides	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3877043-3	1985	These isozymes actively demethylate and oxidize these macrolides into nitrosoalkanes which form stable, inactive complexes with the iron of cytochrome P-450.	nitrosoalkanes	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3877043-3	1985	These isozymes actively demethylate and oxidize these macrolides into nitrosoalkanes which form stable, inactive complexes with the iron of cytochrome P-450.	Iron	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3864428-4	1985	Along with previously published information the data from this subject suggest that tolbutamide hydroxylation, debrisoquine hydroxylation, theophylline N-demethylation, and theophylline 8-hydroxylation involve four distinct isozymes of cytochrome P-450.	Tolbutamide	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-252
2990535-8	1985	Fluorescence lifetime measurements of DPH indicate an average distance of greater than or equal to 60 A between the heme of cytochrome P-450 and DPH.	Diphenylhexatriene	38-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-148
2990535-8	1985	Fluorescence lifetime measurements of DPH indicate an average distance of greater than or equal to 60 A between the heme of cytochrome P-450 and DPH.	Heme	116-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-148
3875625-1	1985	High-performance liquid chromatographic techniques were developed for the simultaneous detection of metabolites in a cytochrome P-450 model system composed of NADH, haemoglobin and methylene blue.	NAD	159-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
3864428-4	1985	Along with previously published information the data from this subject suggest that tolbutamide hydroxylation, debrisoquine hydroxylation, theophylline N-demethylation, and theophylline 8-hydroxylation involve four distinct isozymes of cytochrome P-450.	Debrisoquin	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-252
3864428-4	1985	Along with previously published information the data from this subject suggest that tolbutamide hydroxylation, debrisoquine hydroxylation, theophylline N-demethylation, and theophylline 8-hydroxylation involve four distinct isozymes of cytochrome P-450.	Theophylline	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-252
3864428-4	1985	Along with previously published information the data from this subject suggest that tolbutamide hydroxylation, debrisoquine hydroxylation, theophylline N-demethylation, and theophylline 8-hydroxylation involve four distinct isozymes of cytochrome P-450.	Theophylline	173-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-252
4039724-0	1985	Inhibition of testicular cytochrome P-450-dependent steroid biosynthesis by cis-platinum.	Steroids	52-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
3873598-1	1985	Cytochrome P-450-dependent aryl hydrocarbon hydroxylase (AHH) and 7-ethoxycoumarin O-deethylase activities of a cloned line of human lymphoblastoid AHH-1 cells are inhibited by a monoclonal antibody (MAb 1-7-1) prepared to a 3-methylcholanthrene-induced rat liver cytochrome P-450.	Methylcholanthrene	225-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
3873598-2	1985	The monoclonal antibody inhibition determined that a single MAb 1-7-1-sensitive type of cytochrome P-450 is responsible for all of AHH expression in both the basal and benz[a]anthracene-induced cells.	anthracene	175-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
4039724-0	1985	Inhibition of testicular cytochrome P-450-dependent steroid biosynthesis by cis-platinum.	Cisplatin	76-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
4039724-5	1985	The effect of cis-platinum on the testicular cytochrome P-450 appeared unrelated to deficiencies in heme metabolic processes, in so far that neither was the activity of delta-aminolevulinate synthetase decreased, nor was that of heme oxygenase increased.	Cisplatin	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
4039724-10	1985	It is suggested that the mechanism of depletive action of cis-platinum on microsomal cytochrome P-450 involves an impairment of the effective assembly of heme and apoprotein moieties.	Cisplatin	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
4039724-10	1985	It is suggested that the mechanism of depletive action of cis-platinum on microsomal cytochrome P-450 involves an impairment of the effective assembly of heme and apoprotein moieties.	Heme	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
4025815-5	1985	The Km and Vmax rates obtained with a human liver microsomal preparation were 0.1 mM and 0.23 nmol 4-hydroxymephenytoin formed/min/nmol cytochrome P-450, respectively.	4-hydroxymephenytoin	99-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
2580351-5	1985	The amount of this cytochrome P-450 in human peripheral lymphocytes increased after treatment of the mitogenized lymphocytes with the cytochrome P-450 inducer benz[a]anthracene.	anthracene	166-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
4025815-7	1985	Activities varied from 5.6 to 156 pmol 4-hydroxymephenytoin formed/min/nmol cytochrome P-450 in 11 human liver microsomal preparations.	4-hydroxymephenytoin	39-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
3987629-8	1985	These results indicate that the antibodies inhibit side-chain cleavage by binding to a region close to the iron-sulfur protein-binding site, thereby preventing transfer of reducing electrons to the cytochrome P-450.	Iron	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
3987629-8	1985	These results indicate that the antibodies inhibit side-chain cleavage by binding to a region close to the iron-sulfur protein-binding site, thereby preventing transfer of reducing electrons to the cytochrome P-450.	Sulfur	112-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
3875933-0	1985	Characterization of pirenzepine interaction with cytochrome P-450.	Pirenzepine	20-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
3892954-2	1985	We than discuss some evidences for the possible involvement of cytochrome P-450 in the processing of antigens (parallelism between carcinogenesis and immunogenicity induced by aromatic hydrocarbons, high inducibility of cytochrome P-450 dependent enzyme activity in human monocytes, significance of compounds with quinone structure as allergens and carcinogenic agents.	Hydrocarbons, Aromatic	176-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
4053242-0	1985	Oxygen activation and olefin oxygenation by iron(III)porphyrin as a model of cytochrome P-450.	Oxygen	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
4053242-0	1985	Oxygen activation and olefin oxygenation by iron(III)porphyrin as a model of cytochrome P-450.	Alkenes	22-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
4053242-0	1985	Oxygen activation and olefin oxygenation by iron(III)porphyrin as a model of cytochrome P-450.	iron(iii)porphyrin	44-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
2580351-5	1985	The amount of this cytochrome P-450 in human peripheral lymphocytes increased after treatment of the mitogenized lymphocytes with the cytochrome P-450 inducer benz[a]anthracene.	anthracene	166-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
3892954-2	1985	We than discuss some evidences for the possible involvement of cytochrome P-450 in the processing of antigens (parallelism between carcinogenesis and immunogenicity induced by aromatic hydrocarbons, high inducibility of cytochrome P-450 dependent enzyme activity in human monocytes, significance of compounds with quinone structure as allergens and carcinogenic agents.	quinone	314-321	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
3892954-2	1985	We than discuss some evidences for the possible involvement of cytochrome P-450 in the processing of antigens (parallelism between carcinogenesis and immunogenicity induced by aromatic hydrocarbons, high inducibility of cytochrome P-450 dependent enzyme activity in human monocytes, significance of compounds with quinone structure as allergens and carcinogenic agents.	quinone	314-321	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	220-236
3920211-3	1985	Upon formation of the ternary complex between cytochromes P-450, b5, and benzphetamine the percentage of cytochrome P-450 in the high spin state was increased from 28 to 74 (RLM5) and from 9 to 85 (LM2).	Benzphetamine	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
4004771-1	1985	It is well established that liver microsomal cytochrome P-450 participates in steroid metabolism and probably also in the metabolism of anti-oestrogens such as tamoxifen (Nolvadex).	Steroids	78-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
4004771-1	1985	It is well established that liver microsomal cytochrome P-450 participates in steroid metabolism and probably also in the metabolism of anti-oestrogens such as tamoxifen (Nolvadex).	Tamoxifen	160-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
4004771-1	1985	It is well established that liver microsomal cytochrome P-450 participates in steroid metabolism and probably also in the metabolism of anti-oestrogens such as tamoxifen (Nolvadex).	Tamoxifen	171-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
4004771-3	1985	Therefore a simple sensitive spectrophotometric assay for determining levels of cytochrome P-450-dependent cyclohexane hydroxylation activity in breast and uterine microsomes (microsomal fractions) has been developed.	Cyclohexane	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
4004771-4	1985	Cyclohexane was chosen as a substrate because of the relatively high levels of cyclohexane hydroxylase activity in tumour microsomes and because cyclohexane serves as a substrate for several forms of cytochrome P-450.	Cyclohexane	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
2985426-3	1985	CO, which inhibits the cytochrome P-450-dependent oxygen radical formation, had no effect on the oxidation reaction, suggesting that the source of the reactive oxygen species is not the microsomal mixed-function oxidase.	Oxygen	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
3921030-7	1985	Spectrophotometric studies revealed that miconazole bound to the cytochrome P-450 component of the placental microsomal aromatase complex and had negligible effect on NADPH-cytochrome c (P-450) reductase activity.	Miconazole	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
3986002-0	1985	Altered induction response of hepatic cytochrome P-450 to phenobarbital, 3-methylcholanthrene, and beta-naphthoflavone in organotin-treated animals.	Phenobarbital	58-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3986002-0	1985	Altered induction response of hepatic cytochrome P-450 to phenobarbital, 3-methylcholanthrene, and beta-naphthoflavone in organotin-treated animals.	Methylcholanthrene	73-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3986002-0	1985	Altered induction response of hepatic cytochrome P-450 to phenobarbital, 3-methylcholanthrene, and beta-naphthoflavone in organotin-treated animals.	beta-Naphthoflavone	99-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
3986002-1	1985	The effects of tricyclohexyltin hydroxide on the induction of cytochrome P-450 in liver by phenobarbital, 3-methylcholanthrene and beta-naphthoflavone were studied.	cyhexatin	15-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3986002-1	1985	The effects of tricyclohexyltin hydroxide on the induction of cytochrome P-450 in liver by phenobarbital, 3-methylcholanthrene and beta-naphthoflavone were studied.	Phenobarbital	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3986002-1	1985	The effects of tricyclohexyltin hydroxide on the induction of cytochrome P-450 in liver by phenobarbital, 3-methylcholanthrene and beta-naphthoflavone were studied.	Methylcholanthrene	106-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3986002-1	1985	The effects of tricyclohexyltin hydroxide on the induction of cytochrome P-450 in liver by phenobarbital, 3-methylcholanthrene and beta-naphthoflavone were studied.	beta-Naphthoflavone	131-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3986002-2	1985	A single dose of the organotin (15 mg/kg body wt) prevented the full extent of phenobarbital induction of cytochrome P-450 from occurring; this was the case whether tricyclohexyltin was given 48 hr preceeding a single injection of phenobarbital, or administered simultaneously with the first of three daily doses of the drug.	Phenobarbital	79-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
3986002-6	1985	The electrophoretic profiles illustrate clearly that the apoprotein moieties of the various cytochrome P-450 subspecies are affected to a considerable extent by treatment with tricyclohexyltin hydroxide alone, and staining in these bands was noticeably reduced even when phenobarbital was administered together with the organotin.	cyhexatin	176-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
3986002-6	1985	The electrophoretic profiles illustrate clearly that the apoprotein moieties of the various cytochrome P-450 subspecies are affected to a considerable extent by treatment with tricyclohexyltin hydroxide alone, and staining in these bands was noticeably reduced even when phenobarbital was administered together with the organotin.	Phenobarbital	271-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
2983957-0	1985	Inhibition of cytochrome P-450-dependent mixed function oxidation by ethanol.	Ethanol	69-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
2983957-1	1985	The mechanism of inhibition of cytochrome P-450-dependent mixed function oxidation by ethanol was studied.	Ethanol	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2983957-2	1985	Ethanol competitively inhibited the binding of hexobarbital to liver microsomes, and increased the low spin signal of cytochrome P-450 in the electron spin resonance spectra.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
2983957-3	1985	Therefore, ethanol decreased the substrates bound to ferric cytochrome P-450 in the first step of mixed function oxidation.	Ethanol	11-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2983957-5	1985	The NADPH-dependent reduction of liver microsomal cytochrome P-450 was biphasic and composed of two first-order reactions.	NADP	4-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2983957-6	1985	Ethanol decreased the rate constants of the fast and slow phases of microsomal cytochrome P-450 reduction.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
2983957-7	1985	Thus, it is concluded that the inhibition of drug oxidation by ethanol may be due to the displacement of substrates from cytochrome P-450 and to the inhibition of reduction of cytochrome P-450 by NADPH-cytochrome P-450 reductase.	Ethanol	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
2983957-7	1985	Thus, it is concluded that the inhibition of drug oxidation by ethanol may be due to the displacement of substrates from cytochrome P-450 and to the inhibition of reduction of cytochrome P-450 by NADPH-cytochrome P-450 reductase.	Ethanol	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
3921030-8	1985	These results strongly support direct interaction of miconazole with microsomal cytochrome P-450 in human placental microsomes with high affinity resulting in the inhibition of aromatase activity.	Miconazole	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
3972828-0	1985	Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.	Heme	16-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3972828-0	1985	Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.	arylacetylenes	77-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
3972828-1	1985	Phenylacetylene and biphenylacetylene are oxidized by cytochrome P-450 to the corresponding arylacetic acids.	phenylacetylene	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
3972828-1	1985	Phenylacetylene and biphenylacetylene are oxidized by cytochrome P-450 to the corresponding arylacetic acids.	biphenylacetylene	20-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
3972828-1	1985	Phenylacetylene and biphenylacetylene are oxidized by cytochrome P-450 to the corresponding arylacetic acids.	arylacetic acids	92-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
3972828-4	1985	In contrast, the inactivation of cytochrome P-450 that occurs during the oxidation of phenylacetylene is insensitive to deuterium substitution.	phenylacetylene	86-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
2990136-6	1985	This blockade is due to the interaction of the imidazole structure with the cytochrome p-450.	imidazole	47-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
3974403-5	1985	Iproniazid must be directly metabolized by cytochrome P-450 to yield propane and propylene, presumably via an azo ester intermediate which could give rise to an isopropyl radical, the chemical species presumed to be responsible for the hepatoxicity apparent after administration of large doses of iproniazid in vivo.	Iproniazid	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3974403-5	1985	Iproniazid must be directly metabolized by cytochrome P-450 to yield propane and propylene, presumably via an azo ester intermediate which could give rise to an isopropyl radical, the chemical species presumed to be responsible for the hepatoxicity apparent after administration of large doses of iproniazid in vivo.	Propane	69-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3974403-5	1985	Iproniazid must be directly metabolized by cytochrome P-450 to yield propane and propylene, presumably via an azo ester intermediate which could give rise to an isopropyl radical, the chemical species presumed to be responsible for the hepatoxicity apparent after administration of large doses of iproniazid in vivo.	propylene	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3974403-5	1985	Iproniazid must be directly metabolized by cytochrome P-450 to yield propane and propylene, presumably via an azo ester intermediate which could give rise to an isopropyl radical, the chemical species presumed to be responsible for the hepatoxicity apparent after administration of large doses of iproniazid in vivo.	Isopropyl radical	161-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3974403-5	1985	Iproniazid must be directly metabolized by cytochrome P-450 to yield propane and propylene, presumably via an azo ester intermediate which could give rise to an isopropyl radical, the chemical species presumed to be responsible for the hepatoxicity apparent after administration of large doses of iproniazid in vivo.	Iproniazid	297-307	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2990136-7	1985	Ascorbinic acid is able to overcome this blockade, indicating that cytochrome p-450 is involved in the ascorbinic acid metabolism which is obligatory for the hydroxylation of cholesterol.	ascorbinic acid	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
2990136-7	1985	Ascorbinic acid is able to overcome this blockade, indicating that cytochrome p-450 is involved in the ascorbinic acid metabolism which is obligatory for the hydroxylation of cholesterol.	ascorbinic acid	103-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
2990136-7	1985	Ascorbinic acid is able to overcome this blockade, indicating that cytochrome p-450 is involved in the ascorbinic acid metabolism which is obligatory for the hydroxylation of cholesterol.	Cholesterol	175-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
3911848-0	1985	Biochemical properties of cytochrome P-450 in relation to steroid oxygenation.	Steroids	58-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
3920135-7	1985	Pretreatment of rats with CoCl2, which reduces cytochrome P-450 content, decreased the PBT by 40% and the ABT by 84%.	cobaltous chloride	26-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2579331-0	1985	Measurement of cytochrome P-450 dependent dealkylation of alkoxyphenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicumarol.	alkoxyphenoxazones	58-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
3978755-4	1985	The characteristics of the reactions leading to the covalent binding of the N-methyl group of the azo derivative to microsomal protein and its metabolism to form the hydrocarbon, methane, possessed a number of similarities in the apparent kinetic parameters (Km and Vmax), induction, and inhibition patterns indicating a common pathway of metabolism to form a reactive intermediate and the involvement of cytochrome P-450.	anthrone	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	405-421
3978755-4	1985	The characteristics of the reactions leading to the covalent binding of the N-methyl group of the azo derivative to microsomal protein and its metabolism to form the hydrocarbon, methane, possessed a number of similarities in the apparent kinetic parameters (Km and Vmax), induction, and inhibition patterns indicating a common pathway of metabolism to form a reactive intermediate and the involvement of cytochrome P-450.	Hydrocarbons	166-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	405-421
3978755-4	1985	The characteristics of the reactions leading to the covalent binding of the N-methyl group of the azo derivative to microsomal protein and its metabolism to form the hydrocarbon, methane, possessed a number of similarities in the apparent kinetic parameters (Km and Vmax), induction, and inhibition patterns indicating a common pathway of metabolism to form a reactive intermediate and the involvement of cytochrome P-450.	Methane	179-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	405-421
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	oxirene	52-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	aniline	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	aniline	124-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	4-aminophenol	133-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	acetanilide	151-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2983185-2	1985	Reaction thermodynamics have been calculated for an oxene model for cytochrome P-450 oxidations of four related arylamines: aniline, p-hydroxyaniline, acetanilide, and acetaminophen, by both radical and nonradical mechanisms, using a semiempirical molecular orbital method (modified neglect of differential overlap).	Acetaminophen	168-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3838470-10	1985	The scope of the biological activity of Zn-protoporphyrin to alter haem-dependent processes appeared limited in nature, insofar as the microsomal contents of cytochrome P-450 and b5, as well as the aniline hydroxylase, were similar to those of the control animals.	zn-protoporphyrin	40-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-181
3856261-1	1985	A previously reported cDNA clone [pP450(1)] coding for a phenobarbital-inducible cytochrome P-450 variant of rat liver microsomal membranes, designated P-450e(U.C.	Phenobarbital	57-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
3985310-6	1985	Cyclohexane was chosen as a substrate because of the relatively high levels of cyclohexane hydroxylase activity in tumor microsomes and because cyclohexane serves as a substrate for several forms of cytochrome P-450.	Cyclohexane	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-215
3938271-0	1985	Inhalation of butanols: changes in the cytochrome P-450 enzyme system.	Butanols	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
2983784-3	1985	The radicals were shown to change the optical spectra of Fe3+ located in the active site of the enzyme that are similar to those induced by cytochrome P-450 substrates.	ferric sulfate	57-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
3938271-1	1985	After inhalation of different butanol isomers for 3 days (2000 ppm) and 5 days (500 ppm), liver and kidney parameters of the microsomal cytochrome P-450 enzyme system were increased.	Butanols	30-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
3938271-2	1985	sec-Butanol caused the highest increase in cytochrome P-450 concentration with a 47% rise in the kidneys (500 ppm for 5 days) and 33% in the liver (2000 ppm for 3 days).	2-butanol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
3938271-7	1985	As a conclusion sec-butanol, probably through its metabolite methyl-ethyl-ketone, is the most potent inducer of microsomal cytochrome P-450 in liver and kidney while iso-butanol does not alter total cytochrome P-450.	2-butanol	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
3938271-7	1985	As a conclusion sec-butanol, probably through its metabolite methyl-ethyl-ketone, is the most potent inducer of microsomal cytochrome P-450 in liver and kidney while iso-butanol does not alter total cytochrome P-450.	2-butanol	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-215
3938271-7	1985	As a conclusion sec-butanol, probably through its metabolite methyl-ethyl-ketone, is the most potent inducer of microsomal cytochrome P-450 in liver and kidney while iso-butanol does not alter total cytochrome P-450.	methylethyl ketone	61-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
3004423-0	1985	Chemiluminescence of luminol caused by interaction of cytochrome P-450 and cytochrome C with cumene hydroperoxide: comparative studies.	Luminol	21-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2983784-5	1985	The alkylating radical substrate analogs covalently bound to microsomal cytochrome P-450 in the vicinity of the active center, resulting in the inhibition of oxidation of type I and II substrates (e. g., aniline and naphthalene).	aniline	204-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
3004423-0	1985	Chemiluminescence of luminol caused by interaction of cytochrome P-450 and cytochrome C with cumene hydroperoxide: comparative studies.	cumene hydroperoxide	93-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2983784-5	1985	The alkylating radical substrate analogs covalently bound to microsomal cytochrome P-450 in the vicinity of the active center, resulting in the inhibition of oxidation of type I and II substrates (e. g., aniline and naphthalene).	naphthalene	216-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2983784-6	1985	The value of the spectral binding constant (Ks) for naphthalene in the presence of the radical covalently bound to the cytochrome P-450 active center showed a tendency to increase.	naphthalene	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
2983784-7	1985	Using the ESR technique, the interaction between Fe3+ and the radical localized in the active site of cytochrome P-450 was demonstrated.	ferric sulfate	49-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
2983784-8	1985	The contribution of Fe3+ to the relaxation of the radicals covalently bound to cytochrome P-450 was evaluated from the values of the spin label ESR spectra saturation curves at 77K.	ferric sulfate	20-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3890847-5	1985	The formation of the cytochrome P-450-reductase-complex necessary for oxygen activation by transfer of electrons is dependent on the charge of the phospholipids.	Oxygen	70-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
2983785-0	1985	[Effect of phosphatidylglycerol on the incorporation process of cytochrome P-450 in liposomes from dimyristoylphosphatidylcholine].	Phosphatidylglycerols	11-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
3890847-5	1985	The formation of the cytochrome P-450-reductase-complex necessary for oxygen activation by transfer of electrons is dependent on the charge of the phospholipids.	Phospholipids	147-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
3966916-5	1985	The competitive inhibition of debrisoquine and bufuralol of each other"s metabolism, together with the similarity in the values for Km and Ki, support the conclusion that the same form of cytochrome P-450 catalyses these two reactions.	Debrisoquin	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
3966916-5	1985	The competitive inhibition of debrisoquine and bufuralol of each other"s metabolism, together with the similarity in the values for Km and Ki, support the conclusion that the same form of cytochrome P-450 catalyses these two reactions.	bufuralol	47-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
3978151-0	1985	[Effect of chemical modification of tyrosine residues of cholesterol-hydroxylating cytochrome P-450 on the interaction with high-spin effectors].	Tyrosine	36-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
3978151-0	1985	[Effect of chemical modification of tyrosine residues of cholesterol-hydroxylating cytochrome P-450 on the interaction with high-spin effectors].	Cholesterol	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
2983785-0	1985	[Effect of phosphatidylglycerol on the incorporation process of cytochrome P-450 in liposomes from dimyristoylphosphatidylcholine].	Dimyristoylphosphatidylcholine	99-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
2983785-1	1985	Using the electron paramagnetic resonance (EPR) method with spin-labeled fatty acids and gel-penetrating chromatography, the effect of phosphatidylglycerol on cytochrome P-450 incorporation into liposomes from dimyristoylphosphatidylcholine was investigated.	Phosphatidylglycerols	135-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
2983785-1	1985	Using the electron paramagnetic resonance (EPR) method with spin-labeled fatty acids and gel-penetrating chromatography, the effect of phosphatidylglycerol on cytochrome P-450 incorporation into liposomes from dimyristoylphosphatidylcholine was investigated.	Dimyristoylphosphatidylcholine	210-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
3914938-4	1985	Primary metabolism involves hydroxylation of the alicyclic rings at several carbon atoms by cytochrome P-450-mediated monooxygenase.	Carbon	76-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
3986004-0	1985	[Localization of the adrenodoxin-binding fragment of cholesterol hydroxylating cytochrome P-450 from adrenal cortex mitochondria].	Cholesterol	53-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
3914938-9	1985	Covalent modification of tissue macromolecules by reactive intermediates can be responsible for suicide inactivation of cytochrome P-450 and can possibly mediate some long-term toxic effects of PCP.	Phencyclidine	194-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
4064901-0	1985	[Primary structure of cholesterol-hydroxylating cytochrome P-450 from the mitochondria of the adrenal cortex in the bull].	Cholesterol	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
3987778-5	1985	There was a significant correlation (r (Pearson"s product moment correlation coefficient) = 0.91) between the hepatic phospholipid and cytochrome P-450 concentration.	Phospholipids	118-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
3881283-11	1985	Phenobarbital and other anticonvulsants are inducers of cytochrome P-450 and the mixed-function oxidase system.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
3000845-1	1985	Two isozymes of cytochrome P-450 were partially purified to specific contents of 7.0 and 0.5 nmol/mg of protein, respectively, from placenta of non-smoking women by chromatography on octyl Sepharose, hydroxylapatite, DEAE-cellulose and CM-cellulose.	octyl-sepharose CL-4B	183-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3000845-1	1985	Two isozymes of cytochrome P-450 were partially purified to specific contents of 7.0 and 0.5 nmol/mg of protein, respectively, from placenta of non-smoking women by chromatography on octyl Sepharose, hydroxylapatite, DEAE-cellulose and CM-cellulose.	Durapatite	200-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3000845-1	1985	Two isozymes of cytochrome P-450 were partially purified to specific contents of 7.0 and 0.5 nmol/mg of protein, respectively, from placenta of non-smoking women by chromatography on octyl Sepharose, hydroxylapatite, DEAE-cellulose and CM-cellulose.	DEAE-Cellulose	217-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3000845-1	1985	Two isozymes of cytochrome P-450 were partially purified to specific contents of 7.0 and 0.5 nmol/mg of protein, respectively, from placenta of non-smoking women by chromatography on octyl Sepharose, hydroxylapatite, DEAE-cellulose and CM-cellulose.	7,8-diacetoxy-3-(4-nitrophenyl)coumarin	236-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
3000845-2	1985	NADPH-cytochrome P-450 reductase was purified from phenobarbital-induced mouse liver and from human placenta and was combined with cytochrome P-450 and dilauroylphosphatidylcholine to reconstitute the cytochrome P-450 monooxygenase system.	Phenobarbital	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
3000845-2	1985	NADPH-cytochrome P-450 reductase was purified from phenobarbital-induced mouse liver and from human placenta and was combined with cytochrome P-450 and dilauroylphosphatidylcholine to reconstitute the cytochrome P-450 monooxygenase system.	1,2-dilauroylphosphatidylcholine	152-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
4029252-3	1985	In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined.	Antipyrine	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
4029252-3	1985	In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined.	6 beta-hydroxycortisol	212-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
4065184-2	1985	The subjects with a high liver cytochrome P-450, indicating hepatic microsomal enzyme induction, who showed an increase in liver size, had an elevated high-density lipoprotein concentration and high-density lipoprotein cholesterol/total cholesterol ratio, and a reduced low/high-density lipoprotein cholesterol ratio.	Cholesterol	219-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
4065184-2	1985	The subjects with a high liver cytochrome P-450, indicating hepatic microsomal enzyme induction, who showed an increase in liver size, had an elevated high-density lipoprotein concentration and high-density lipoprotein cholesterol/total cholesterol ratio, and a reduced low/high-density lipoprotein cholesterol ratio.	density lipoprotein cholesterol	199-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
3965304-0	1985	Catalytic activity of the membrane-bound methylcholanthrene-inducible cytochrome P-450.	Methylcholanthrene	41-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
3965304-1	1985	The benzopyrene hydroxylase activity of the methylcholanthrene-inducible form of cytochrome P-450 (P-448) has been studied in native and reconstituted liver microsomal membranes.	Methylcholanthrene	44-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
3987778-6	1985	The cytochrome P-450 concentration was inversely related (r = -0.74) to the triacylglycerol concentration.	Triglycerides	76-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
3987778-7	1985	The positive correlation between hepatic phospholipids and drug-metabolizing enzymes could be interpreted as indicating that in human liver phospholipid and cytochrome P-450 synthesis share common regulators, or that phospholipids are necessary for the maximum rate of cytochrome P-450 synthesis.	Phospholipids	41-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
3987778-7	1985	The positive correlation between hepatic phospholipids and drug-metabolizing enzymes could be interpreted as indicating that in human liver phospholipid and cytochrome P-450 synthesis share common regulators, or that phospholipids are necessary for the maximum rate of cytochrome P-450 synthesis.	Phospholipids	41-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	269-285
3987778-7	1985	The positive correlation between hepatic phospholipids and drug-metabolizing enzymes could be interpreted as indicating that in human liver phospholipid and cytochrome P-450 synthesis share common regulators, or that phospholipids are necessary for the maximum rate of cytochrome P-450 synthesis.	Phospholipids	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
3987778-7	1985	The positive correlation between hepatic phospholipids and drug-metabolizing enzymes could be interpreted as indicating that in human liver phospholipid and cytochrome P-450 synthesis share common regulators, or that phospholipids are necessary for the maximum rate of cytochrome P-450 synthesis.	Phospholipids	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	269-285
4093989-4	1985	Both primary and secondary oxidation of benzene and its metabolites are mediated via cytochrome P-450 in the liver, although the role of secondary metabolism in the bone marrow is not clear.	Benzene	40-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
4009422-0	1985	[Steroid 17 alpha-hydroxylase-C17,20 lyase (cytochrome P-450) from porcine adrenocortical microsomes: inhibition of lyase activity by progesterone and inhibition of hydroxylase activity by 17 alpha-hydroxyprogesterone].	17-alpha-Hydroxyprogesterone	189-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
2422643-1	1985	A new method for the removal of the stabilizing substrate, deoxycorticosterone, from adrenal cytochrome P-450(11) beta, has been developed.	Desoxycorticosterone	59-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2422643-3	1985	The substrate-free enzyme, obtained in this manner, has all the characteristic spectral properties of low-spin cytochrome P-450(11) beta and may be converted to the high-spin form by the addition of deoxycorticosterone.	Desoxycorticosterone	199-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2422643-5	1985	It does not require the addition of the cofactors for cytochrome P-450-dependant hydroxylation of deoxycorticosterone, small amounts of enzyme may be prepared in a short time and the enzyme preparation is not diluted to any great extent during the process.	Desoxycorticosterone	98-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2865858-3	1985	Since ethanol is metabolized via a cytochrome P-450 dependent biotransformation system (MEOS) in hepatic microsomes, the microsomal enzyme induction in the smooth endoplasmic reticulum has to be considered as an adaptive response.	Ethanol	6-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
3991787-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and noramidopyrine-methanesulfonate sodium (metamizol, Analgin) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Caffeine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
3991787-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and noramidopyrine-methanesulfonate sodium (metamizol, Analgin) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Methylcholanthrene	34-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
3983470-4	1985	Metyrapone inhibited the stimulation process, indicating that cytochrome P-450 function may be involved.	Metyrapone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3983470-5	1985	Increase of hydrogen peroxide formation occurred at the same (+)-cyanidanol-3 concentrations that were capable to inhibit lipid peroxidation, suggesting that the interference of (+)-cyanidanol-3 with the oxidase function of cytochrome P-450 does not compromise its antioxidative activity towards lipid peroxidation.	Hydrogen Peroxide	12-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	224-240
3983470-5	1985	Increase of hydrogen peroxide formation occurred at the same (+)-cyanidanol-3 concentrations that were capable to inhibit lipid peroxidation, suggesting that the interference of (+)-cyanidanol-3 with the oxidase function of cytochrome P-450 does not compromise its antioxidative activity towards lipid peroxidation.	Catechin	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	224-240
3983470-5	1985	Increase of hydrogen peroxide formation occurred at the same (+)-cyanidanol-3 concentrations that were capable to inhibit lipid peroxidation, suggesting that the interference of (+)-cyanidanol-3 with the oxidase function of cytochrome P-450 does not compromise its antioxidative activity towards lipid peroxidation.	Catechin	178-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	224-240
4009422-0	1985	[Steroid 17 alpha-hydroxylase-C17,20 lyase (cytochrome P-450) from porcine adrenocortical microsomes: inhibition of lyase activity by progesterone and inhibition of hydroxylase activity by 17 alpha-hydroxyprogesterone].	Progesterone	134-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
6498831-12	1984	N-OH-AAF:7-OH-AAF, and 7-OH-AAF:1-OH-AAF at the low concentration of AAF, and imply that similar forms of cytochrome P-450 produce these metabolites.	1-oh-aaf	32-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
6084519-5	1984	The present findings also-establish the most facile pathways for enzymatic activation of Fe(III)-bleomycin and Cu(II)-bleomycin, provide data concerning the nature of the activated metallobleomycins, and extend the analogy between the chemistry of cytochrome P-450 and bleomycin.	fe(iii)-bleomycin	89-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	248-278
6498831-12	1984	N-OH-AAF:7-OH-AAF, and 7-OH-AAF:1-OH-AAF at the low concentration of AAF, and imply that similar forms of cytochrome P-450 produce these metabolites.	2-Acetylaminofluorene	5-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
6594694-0	1984	Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.	Debrisoquin	80-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6096874-0	1984	Base (O.-2, e-, or OH-)-induced autoxygenation of organic substrates: a model chemical system for cytochrome P-450-catalyzed monoxygenation and dehydrogenation by dioxygen.	Oxygen	163-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6594694-7	1984	The level of translatable mRNA coding for the debrisoquine-hydroxylating cytochrome P-450 was an order of magnitude less in human liver than in rat liver.	Debrisoquin	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
6208195-0	1984	Cytochrome P-450-dependent oxidation of lanosterol in cholesterol biosynthesis.	Lanosterol	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6150639-7	1984	Marketed and investigational H2-antagonist drugs differ in their ability to inhibit drug metabolism due to the combined characteristics of cytochrome P-450 binding affinity and therapeutic dosage.	Hydrogen	29-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6208195-0	1984	Cytochrome P-450-dependent oxidation of lanosterol in cholesterol biosynthesis.	Cholesterol	54-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6208195-2	1984	Electron transfer to rat liver microsomal cytochrome P-450 of 14 alpha-methyl group demethylation of 24,25-dihydrolanosterol (C30-sterol) has been studied with a new radio-high-performance liquid chromatography assay.	lanostenol	101-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
6208195-2	1984	Electron transfer to rat liver microsomal cytochrome P-450 of 14 alpha-methyl group demethylation of 24,25-dihydrolanosterol (C30-sterol) has been studied with a new radio-high-performance liquid chromatography assay.	c30-sterol	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
6208195-3	1984	The monooxygenase is dependent upon NADPH plus oxygen, insensitive to CN-, and sensitive to CO. Microsomal oxidation is also sensitive to trypsin digestion, and reactivation is dependent upon the addition of purified, detergent-solubilized cytochrome P-450 reductase.	Oxygen	8-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-256
6208195-10	1984	Alternatively, administration of complete adjuvant in mineral oil drastically reduces amounts of total microsomal cytochrome P-450 while activity of 14 alpha-methyl sterol oxidase is not affected dramatically.	Mineral Oil	54-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
6508979-5	1984	Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
6508804-0	1984	Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1"-hydroxylation in poor metabolizers.	Debrisoquin	74-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
6508979-5	1984	Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine.	Antipyrine	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
6508804-0	1984	Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1"-hydroxylation in poor metabolizers.	Sparteine	87-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
6508804-0	1984	Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1"-hydroxylation in poor metabolizers.	bufuralol	187-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
6508804-4	1984	In a non-membraneous reconstituted system containing NADPH cytochrome P-450 reductase, a NADPH regenerating system and phospholipids, P-450[buf] exhibited an almost complete substrate stereoselectivity for (+)-isomer 1"-hydroxylation.	NADP	53-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
6508804-4	1984	In a non-membraneous reconstituted system containing NADPH cytochrome P-450 reductase, a NADPH regenerating system and phospholipids, P-450[buf] exhibited an almost complete substrate stereoselectivity for (+)-isomer 1"-hydroxylation.	Phospholipids	119-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
6508804-5	1984	It is concluded that the purified cytochrome P-450[buf] is the target of the debrisoquine-sparteine type oxidation polymorphism and that poor metabolizers have a quantitative or qualitative deficiency of this isozyme.	Debrisoquin	77-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6508979-5	1984	Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine.	Edaravone	127-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
6508804-5	1984	It is concluded that the purified cytochrome P-450[buf] is the target of the debrisoquine-sparteine type oxidation polymorphism and that poor metabolizers have a quantitative or qualitative deficiency of this isozyme.	Sparteine	90-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6508979-7	1984	This provides further evidence for the involvement of different iso-enzymes of the cytochrome P-450 system in antipyrine metabolism in man.	Antipyrine	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
6096071-3	1984	Like cimetidine, ranitidine binds to cytochrome P-450 in the liver where it appears to exert an inhibitory effect, but to a lesser extent than cimetidine.	Cimetidine	5-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
6525207-0	1984	[Molecular organization of cholesterol-hydroxylating cytochrome P-450 from adrenal cortex mitochondria.	Cholesterol	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
6096071-3	1984	Like cimetidine, ranitidine binds to cytochrome P-450 in the liver where it appears to exert an inhibitory effect, but to a lesser extent than cimetidine.	Ranitidine	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Ranitidine	29-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Warfarin	45-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Metoprolol	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Nifedipine	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Theophylline	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Fentanyl	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6093289-5	1984	The time frame during which enhanced sensitivity to parathion and pentobarbital was observed suggests that this sensitivity may have been caused by viral-induced interferon-mediated depression of cytochrome P-450.	Parathion	52-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-212
6093289-5	1984	The time frame during which enhanced sensitivity to parathion and pentobarbital was observed suggests that this sensitivity may have been caused by viral-induced interferon-mediated depression of cytochrome P-450.	Pentobarbital	66-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-212
6435621-2	1984	This MVP analog has been found to be a highly efficient and specific chemiluminescent probe for picomole quantities of singlet oxygen and singlet oxygen equivalents, and it produces significant chemiluminescence when reacted with cytochrome P-450 enzymes.	Singlet Oxygen	119-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
6091674-0	1984	Increased microsomal oxidation of ethanol by cytochrome P-450 and hydroxyl radical-dependent pathways after chronic ethanol consumption.	Ethanol	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6091674-0	1984	Increased microsomal oxidation of ethanol by cytochrome P-450 and hydroxyl radical-dependent pathways after chronic ethanol consumption.	Ethanol	116-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6435533-0	1984	The association of cytochrome P-450 and NADPH-cytochrome P-450 reductase in phospholipid membranes.	Phospholipids	76-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
6435533-1	1984	NADPH-cytochrome P-450 reductase and two purified isozymes of cytochrome P-450 have been incorporated into phospholipid vesicles by a cholate dialysis technique.	Phospholipids	107-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
6435621-2	1984	This MVP analog has been found to be a highly efficient and specific chemiluminescent probe for picomole quantities of singlet oxygen and singlet oxygen equivalents, and it produces significant chemiluminescence when reacted with cytochrome P-450 enzymes.	Singlet Oxygen	138-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
6091554-12	1984	This suggestion implies that the electron distribution of the iron at the catalytic sites of cytochrome P-450 and certain chlorin-containing enzymes is in some way similar, but distinct from that at the transport site of myoglobin.	Iron	62-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6477826-1	1984	Arylhydrocarbon-hydroxylase (AHH) is a cytochrome P-450-dependent polysubstrate mono-oxygenase which plays an important role in converting some compounds (e.g. benzo[a]pyrene) to highly reactive carcinogenic species.	Benzo(a)pyrene	160-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
6088105-9	1984	These results demonstrate that oxidation products of the peroxidation of lipids and fatty acids are able to react directly with benzo[a]pyrene to form products including benzo[a]pyrene quinones without the presence of enzymes such as the cytochrome P-450 mixed function oxidase system and prostaglandin synthetase.	Fatty Acids	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-254
6487483-6	1984	Previous studies have suggested that two forms of cytochrome P-450 are involved in theophylline metabolism, one mediating the N-demethylations and the other 8-oxidation.	Theophylline	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6508858-0	1984	[Localization of tetranitromethane-modified tyrosine residues in domains of cholesterol-hydroxylating cytochrome P-450].	Tetranitromethane	17-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-119
6508858-0	1984	[Localization of tetranitromethane-modified tyrosine residues in domains of cholesterol-hydroxylating cytochrome P-450].	Tyrosine	44-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-119
6508858-0	1984	[Localization of tetranitromethane-modified tyrosine residues in domains of cholesterol-hydroxylating cytochrome P-450].	Cholesterol	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-119
6508858-2	1984	With the aid of thiol-disulfide exchange chromatography and SDS polyacrylamide gel electrophoresis the F1 and F2 fragments of the modified cytochrome P-450 were isolated.	Sulfhydryl Compounds	16-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6508858-2	1984	With the aid of thiol-disulfide exchange chromatography and SDS polyacrylamide gel electrophoresis the F1 and F2 fragments of the modified cytochrome P-450 were isolated.	Disulfides	22-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6508858-2	1984	With the aid of thiol-disulfide exchange chromatography and SDS polyacrylamide gel electrophoresis the F1 and F2 fragments of the modified cytochrome P-450 were isolated.	Sodium Dodecyl Sulfate	60-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6508858-2	1984	With the aid of thiol-disulfide exchange chromatography and SDS polyacrylamide gel electrophoresis the F1 and F2 fragments of the modified cytochrome P-450 were isolated.	polyacrylamide	64-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6088105-9	1984	These results demonstrate that oxidation products of the peroxidation of lipids and fatty acids are able to react directly with benzo[a]pyrene to form products including benzo[a]pyrene quinones without the presence of enzymes such as the cytochrome P-450 mixed function oxidase system and prostaglandin synthetase.	Benzo(a)pyrene	128-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-254
6471064-0	1984	Oxidation of sparteines by cytochrome P-450: evidence against the formation of N-oxides.	Sparteine	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
6438379-0	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil.	Tegafur	49-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6438379-0	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil.	Fluorouracil	74-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Tegafur	49-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Tegafur	49-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Tegafur	90-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Tegafur	90-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Phenobarbital	157-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6438379-1	1984	Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)).	Methylcholanthrene	212-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6431911-0	1984	Studies on cytochrome P-450-dependent lipid hydroperoxide reduction.	Lipid Peroxides	38-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
6431911-1	1984	A reconstituted mixed-function oxidase system containing cytochrome P-450, cytochrome P-450 reductase, phosphatidylcholine, and NADPH catalyzed the reduction of 13-hydroperoxy-9,11-octadecadienoic acid to 13-hydroxy-9,11-octadecadienoic acid.	13-hydroperoxy-9,11-octadecadienoic acid	161-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6431911-1	1984	A reconstituted mixed-function oxidase system containing cytochrome P-450, cytochrome P-450 reductase, phosphatidylcholine, and NADPH catalyzed the reduction of 13-hydroperoxy-9,11-octadecadienoic acid to 13-hydroxy-9,11-octadecadienoic acid.	13-hydroperoxy-9,11-octadecadienoic acid	161-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
6431911-1	1984	A reconstituted mixed-function oxidase system containing cytochrome P-450, cytochrome P-450 reductase, phosphatidylcholine, and NADPH catalyzed the reduction of 13-hydroperoxy-9,11-octadecadienoic acid to 13-hydroxy-9,11-octadecadienoic acid.	13-hydroxy-9,11-octadecadienoic acid	205-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6431911-1	1984	A reconstituted mixed-function oxidase system containing cytochrome P-450, cytochrome P-450 reductase, phosphatidylcholine, and NADPH catalyzed the reduction of 13-hydroperoxy-9,11-octadecadienoic acid to 13-hydroxy-9,11-octadecadienoic acid.	13-hydroxy-9,11-octadecadienoic acid	205-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
6431911-4	1984	Incubation of cytochrome P-450 with only lipid hydroperoxide resulted in destruction of the hemoprotein.	Lipid Peroxides	41-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
6431911-5	1984	Addition of substrates such as aminopyrine decreased cytochrome P-450 destruction.	Aminopyrine	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
6548701-0	1984	Control of heme and cytochrome P-450 metabolism by inorganic metals, organometals and synthetic metalloporphyrins.	Metalloporphyrins	96-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
6747992-0	1984	The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system.	Warfarin	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
6747992-0	1984	The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system.	Octanols	114-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
6747992-0	1984	The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system.	Water	122-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	Warfarin	104-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	Warfarin	104-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	306-322
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	Warfarin	253-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	Warfarin	253-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	306-322
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	beta-Naphthoflavone	276-295	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
6747992-5	1984	On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed.	beta-Naphthoflavone	276-295	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	306-322
6548701-3	1984	The resulting increase in the rate of heme breakdown is reflected in a marked depression of cellular cytochrome P-450 content and impairment of the oxidative metabolism of natural and foreign chemicals dependent on this hemeprotein.	Heme	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
6548701-9	1984	These differences, among others which characterize metal actions in vivo and in vitro attest to the importance of pharmacokinetic, adaptive and other host factors in defining the responses of the heme-cytochrome P-450 systems to the impact of metals in the whole animal.	Metals	51-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-217
6744247-3	1984	Additional evidence is provided by the regiochemistry of cytochrome P-450 catalyzed oxidation of quinoline.	quinoline	97-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6484850-3	1984	Placentas from normal infants were found to have high levels of monooxygenase activities and low apparent Kms toward ethoxyresorufin (10(-7) M), reflecting induction of cytochrome P-450 enzymes usually associated with maternal cigarette smoking.	ethoxyresorufin	117-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
6429140-1	1984	Phospholipid has been reported to be necessary for optimal catalytic activity of a number of mammalian cytochrome P-450 (P-450) systems.	Phospholipids	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	Warfarin	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6148207-0	1984	Metabolism of alcohol and ketone by cytochrome P-450 oxygenase: fluoren-9-ol in equilibrium with fluoren-9-one.	Alcohols	14-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	Warfarin	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	259-275
6148207-0	1984	Metabolism of alcohol and ketone by cytochrome P-450 oxygenase: fluoren-9-ol in equilibrium with fluoren-9-one.	Ketones	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	Dehydrowarfarin	73-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6148207-0	1984	Metabolism of alcohol and ketone by cytochrome P-450 oxygenase: fluoren-9-ol in equilibrium with fluoren-9-one.	fluoren-9-ol	64-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	Dehydrowarfarin	73-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	259-275
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	4"-, 6-, 7-, 8-, and 10-hydroxywarfarin	93-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6148207-0	1984	Metabolism of alcohol and ketone by cytochrome P-450 oxygenase: fluoren-9-ol in equilibrium with fluoren-9-one.	9-fluorenone	97-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
6148215-2	1984	In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions.	4"-, 6-, 7-, 8-, and 10-hydroxywarfarin	93-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	259-275
6148215-0	1984	Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.	Warfarin	90-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
6148215-8	1984	Based on the known warfarin metabolite profiles of five purified cytochrome P-450 isozymes, the isozyme composition of the microsomes can be estimated.	Warfarin	19-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
6725517-1	1984	Dietary protein, when substituted for carbohydrate or fat, can increase cytochrome P-450-dependent drug oxidation rates in humans.	Carbohydrates	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6506763-0	1984	The measurement of FAD-containing mono-oxygenase activity in microsomes containing cytochrome P-450.	Flavin-Adenine Dinucleotide	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
6611155-1	1984	Deuterium labeling of 7-ethoxycoumarin on the carbon undergoing oxidation by cytochrome P-450 results in a redirection of metabolism from O-deethylation to ring hydroxylation at C6 (Harada, N. et al (1984) J Biol Chem 259, 3005-3010).	Deuterium	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
6611155-1	1984	Deuterium labeling of 7-ethoxycoumarin on the carbon undergoing oxidation by cytochrome P-450 results in a redirection of metabolism from O-deethylation to ring hydroxylation at C6 (Harada, N. et al (1984) J Biol Chem 259, 3005-3010).	7-ethoxycoumarin	22-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
6611155-1	1984	Deuterium labeling of 7-ethoxycoumarin on the carbon undergoing oxidation by cytochrome P-450 results in a redirection of metabolism from O-deethylation to ring hydroxylation at C6 (Harada, N. et al (1984) J Biol Chem 259, 3005-3010).	Carbon	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	Alcohols	88-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	Acetaldehyde	164-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	Ethanol	213-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	Hydrogen Peroxide	228-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	Oxygen	318-320	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6725272-2	1984	This laboratory has recently reported that, in a reconstituted enzyme system containing alcohol-induced isozyme 3a of liver microsomal cytochrome P-450, the sum of acetaldehyde generated by the monooxygenation of ethanol and of hydrogen peroxide produced by the NADPH oxidase activity is inadequate to account for the O2 and NADPH consumed.	NADP	262-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
6088030-1	1984	Using the all-valence electron, semiempirical molecular orbital method, MNDO, properties have been identified and calculated for eight chloroethanes which can serve as indicators of their extent of transformation to alcohols by cytochrome P450 and the subsequent formation of aldehydes by loss of HCl from these alcohols.	Ethyl Chloride	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
6542186-0	1984	Bioorganotin chemistry: a commentary on the reactions of organotin compounds with a cytochrome P-450 dependent monooxygenase enzyme system.	bioorganotin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6542186-1	1984	The biological oxidation of several tributyltin derivatives, by a cytochrome P-450 dependent monooxygenase enzyme system with reduced nicotinamideadeninedinucleotidephosphate as the essential cofactor, produced carbon-hydroxylated compounds identified as alpha-, beta-, gamma- and delta-hydroxybutyldibutyltin derivatives.	tributyltin	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
6542186-1	1984	The biological oxidation of several tributyltin derivatives, by a cytochrome P-450 dependent monooxygenase enzyme system with reduced nicotinamideadeninedinucleotidephosphate as the essential cofactor, produced carbon-hydroxylated compounds identified as alpha-, beta-, gamma- and delta-hydroxybutyldibutyltin derivatives.	NADP	134-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
6542186-1	1984	The biological oxidation of several tributyltin derivatives, by a cytochrome P-450 dependent monooxygenase enzyme system with reduced nicotinamideadeninedinucleotidephosphate as the essential cofactor, produced carbon-hydroxylated compounds identified as alpha-, beta-, gamma- and delta-hydroxybutyldibutyltin derivatives.	Carbon	211-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
6542186-1	1984	The biological oxidation of several tributyltin derivatives, by a cytochrome P-450 dependent monooxygenase enzyme system with reduced nicotinamideadeninedinucleotidephosphate as the essential cofactor, produced carbon-hydroxylated compounds identified as alpha-, beta-, gamma- and delta-hydroxybutyldibutyltin derivatives.	alpha-, beta-, gamma- and delta-hydroxybutyldibutyltin	255-309	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
6088030-1	1984	Using the all-valence electron, semiempirical molecular orbital method, MNDO, properties have been identified and calculated for eight chloroethanes which can serve as indicators of their extent of transformation to alcohols by cytochrome P450 and the subsequent formation of aldehydes by loss of HCl from these alcohols.	Alcohols	216-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
6088030-1	1984	Using the all-valence electron, semiempirical molecular orbital method, MNDO, properties have been identified and calculated for eight chloroethanes which can serve as indicators of their extent of transformation to alcohols by cytochrome P450 and the subsequent formation of aldehydes by loss of HCl from these alcohols.	Aldehydes	276-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
6088030-1	1984	Using the all-valence electron, semiempirical molecular orbital method, MNDO, properties have been identified and calculated for eight chloroethanes which can serve as indicators of their extent of transformation to alcohols by cytochrome P450 and the subsequent formation of aldehydes by loss of HCl from these alcohols.	Hydrochloric Acid	297-300	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
6088030-1	1984	Using the all-valence electron, semiempirical molecular orbital method, MNDO, properties have been identified and calculated for eight chloroethanes which can serve as indicators of their extent of transformation to alcohols by cytochrome P450 and the subsequent formation of aldehydes by loss of HCl from these alcohols.	Alcohols	312-320	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
6088030-5	1984	The molecular properties identified in this study as indicators of rank order or carcinogenic activity of the parent chloroethanes are consistent with the importance of cytochrome P450 in transforming halohydrocarbons to active carcinogens and of acylchlorides and chloroaldehydes as the active form.	Ethyl Chloride	117-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
6088030-5	1984	The molecular properties identified in this study as indicators of rank order or carcinogenic activity of the parent chloroethanes are consistent with the importance of cytochrome P450 in transforming halohydrocarbons to active carcinogens and of acylchlorides and chloroaldehydes as the active form.	Hydrocarbons, Halogenated	201-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
6088030-5	1984	The molecular properties identified in this study as indicators of rank order or carcinogenic activity of the parent chloroethanes are consistent with the importance of cytochrome P450 in transforming halohydrocarbons to active carcinogens and of acylchlorides and chloroaldehydes as the active form.	chloroacetaldehyde	265-280	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
6704207-1	1984	Cytochrome P-450 and NADPH cytochrome P-450 reductase were incorporated into large unilamellar lipid vesicles (200-300 nm in diameter) removing octylglucoside from mixed micelles by dialysis.	octyl-beta-D-glucoside	144-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-53
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	acetylenic	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6587349-0	1984	Epoxidation of olefins by cytochrome P-450 model compounds: mechanism of oxygen atom transfer.	Alkenes	15-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6587349-0	1984	Epoxidation of olefins by cytochrome P-450 model compounds: mechanism of oxygen atom transfer.	Oxygen	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6587349-5	1984	Some analogies to the biochemical epoxidation of olefins catalyzed by cytochrome P-450 are discussed.	Alkenes	49-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	lauric acid	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	11-dodecynoic acid	49-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	11-dodecynoic acid	69-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	lauric acid	187-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6088753-5	1984	The epoxide was found to resist the hydrolysis by epoxide hydrolase, and was further converted to several metabolites by monooxygenase system involving cytochrome P-450.	Epoxy Compounds	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
6200138-4	1984	Scavengers of hydrogen peroxide and hydroxyl radicals, including catalase and benzoate and inhibitors of microsomal cytochrome P-450-dependent monooxygenases such as 1-benzylimidazole, metyrapone and alpha-naphthoflavone, had no inhibitory effects on bleomycin-mediated DNA chain breakage.	1-benzylimidazole	166-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
6200138-4	1984	Scavengers of hydrogen peroxide and hydroxyl radicals, including catalase and benzoate and inhibitors of microsomal cytochrome P-450-dependent monooxygenases such as 1-benzylimidazole, metyrapone and alpha-naphthoflavone, had no inhibitory effects on bleomycin-mediated DNA chain breakage.	Metyrapone	185-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
6200138-4	1984	Scavengers of hydrogen peroxide and hydroxyl radicals, including catalase and benzoate and inhibitors of microsomal cytochrome P-450-dependent monooxygenases such as 1-benzylimidazole, metyrapone and alpha-naphthoflavone, had no inhibitory effects on bleomycin-mediated DNA chain breakage.	alpha-naphthoflavone	200-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
6200138-4	1984	Scavengers of hydrogen peroxide and hydroxyl radicals, including catalase and benzoate and inhibitors of microsomal cytochrome P-450-dependent monooxygenases such as 1-benzylimidazole, metyrapone and alpha-naphthoflavone, had no inhibitory effects on bleomycin-mediated DNA chain breakage.	Bleomycin	251-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
6088753-9	1984	These results indicate that 9 alpha, 10 alpha-EHHC formed from delta 9-THC is further metabolized not by epoxide hydrolase but by monooxygenase system involving cytochrome P-450, and that, on the contrary, 8 alpha, 9 alpha- and 8 beta, 9 beta-EHHCs derived from delta 8-THC may be metabolized by epoxide hydrolase rather than cytochrome P-450 in the human liver, forming 8 beta, 9 alpha-diOH-HHC.	-ehhc	45-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
6088753-9	1984	These results indicate that 9 alpha, 10 alpha-EHHC formed from delta 9-THC is further metabolized not by epoxide hydrolase but by monooxygenase system involving cytochrome P-450, and that, on the contrary, 8 alpha, 9 alpha- and 8 beta, 9 beta-EHHCs derived from delta 8-THC may be metabolized by epoxide hydrolase rather than cytochrome P-450 in the human liver, forming 8 beta, 9 alpha-diOH-HHC.	-ehhc	45-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	326-342
6088753-9	1984	These results indicate that 9 alpha, 10 alpha-EHHC formed from delta 9-THC is further metabolized not by epoxide hydrolase but by monooxygenase system involving cytochrome P-450, and that, on the contrary, 8 alpha, 9 alpha- and 8 beta, 9 beta-EHHCs derived from delta 8-THC may be metabolized by epoxide hydrolase rather than cytochrome P-450 in the human liver, forming 8 beta, 9 alpha-diOH-HHC.	6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
6088753-9	1984	These results indicate that 9 alpha, 10 alpha-EHHC formed from delta 9-THC is further metabolized not by epoxide hydrolase but by monooxygenase system involving cytochrome P-450, and that, on the contrary, 8 alpha, 9 alpha- and 8 beta, 9 beta-EHHCs derived from delta 8-THC may be metabolized by epoxide hydrolase rather than cytochrome P-450 in the human liver, forming 8 beta, 9 alpha-diOH-HHC.	6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	326-342
6422989-0	1984	Selective chemical modification of a functionally linked lysine in cytochrome P-450 LM2.	Lysine	57-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
6740183-5	1984	Cytochrome P-450 has a well known sine-qua-non activity in steroid hydroxylations within steroid tissues, and a decrease in the levels of this heme-enzyme might be expected to result in impaired steroidogenesis.	Steroids	59-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6740183-5	1984	Cytochrome P-450 has a well known sine-qua-non activity in steroid hydroxylations within steroid tissues, and a decrease in the levels of this heme-enzyme might be expected to result in impaired steroidogenesis.	Steroids	89-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6422989-1	1984	Fluorescein isothiocyanate (FITC) has been selectively bound to the epsilon-amino group of lysine-382 in cytochrome P-450 LM2 (RH, reduced-flavoprotein: oxygen oxidoreductase (RH-hydroxylating), EC 1.14.14.1) at pH 8.15.	Fluorescein-5-isothiocyanate	0-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
6422989-1	1984	Fluorescein isothiocyanate (FITC) has been selectively bound to the epsilon-amino group of lysine-382 in cytochrome P-450 LM2 (RH, reduced-flavoprotein: oxygen oxidoreductase (RH-hydroxylating), EC 1.14.14.1) at pH 8.15.	Fluorescein-5-isothiocyanate	28-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
6422989-2	1984	Benzphetamine N-demethylase activity of the reconstituted FITC-modified cytochrome P-450 LM2 was inhibited by 25%.	Fluorescein-5-isothiocyanate	58-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Cimetidine	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6696254-2	1984	In previous studies they have shown that the halothane-free radical produced by UV-irradiation is identical to that produced during reductive metabolism of halothane by hepatic cytochrome P-450.	Halothane	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
6696254-2	1984	In previous studies they have shown that the halothane-free radical produced by UV-irradiation is identical to that produced during reductive metabolism of halothane by hepatic cytochrome P-450.	Halothane	156-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
6370262-7	1984	When microsomal proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, ethanol-fed animals had a distinct band which reflected the increase in microsomal cytochrome P-450 content and seemed to reflect a unique form of cytochrome P-450 induced by ethanol.	Ethanol	108-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
6370262-7	1984	When microsomal proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, ethanol-fed animals had a distinct band which reflected the increase in microsomal cytochrome P-450 content and seemed to reflect a unique form of cytochrome P-450 induced by ethanol.	Ethanol	108-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	255-271
6370262-8	1984	Thus, despite the absence of the ADH pathway, a large amount of ethanol was metabolized by MEOS in ADH-negative deermice; this was associated with increased blood ethanol elimination rates, enhanced MEOS activity, and quantitative and qualitative changes of cytochrome P-450.	Ethanol	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-274
6697650-2	1984	We used human liver preparations to test whether mephenytoin competes with sparteine for binding to the genetically variable cytochrome P-450, which mediates metabolism of both sparteine and debrisoquine.	Mephenytoin	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6697650-2	1984	We used human liver preparations to test whether mephenytoin competes with sparteine for binding to the genetically variable cytochrome P-450, which mediates metabolism of both sparteine and debrisoquine.	Sparteine	75-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6697650-2	1984	We used human liver preparations to test whether mephenytoin competes with sparteine for binding to the genetically variable cytochrome P-450, which mediates metabolism of both sparteine and debrisoquine.	Sparteine	177-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6697650-2	1984	We used human liver preparations to test whether mephenytoin competes with sparteine for binding to the genetically variable cytochrome P-450, which mediates metabolism of both sparteine and debrisoquine.	Debrisoquin	191-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Ranitidine	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Theophylline	115-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Ranitidine	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Cimetidine	186-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6584903-6	1984	For example, phenanthrenequinone was converted to a nonmutagenic metabolite in a cytochrome P-450-dependent reaction, whereas danthron was converted to a highly mutagenic metabolite.	9,10-phenanthrenequinone	13-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6701906-4	1984	There was a concommitant time-dependent decline in cytochrome P-450 levels in the phenobarbital pretreated animals, but not controls.	Phenobarbital	82-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
6422948-7	1984	Cytochrome P-450 destruction in vivo was also greatest in the male rat given norethindrone, whereas no loss was detected in the hen.	Norethindrone	77-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6420437-1	1984	6 beta-Hydroxycortisol (6 beta OHF) is a highly polar metabolite of cortisol, probably formed in the endoplasmic reticulum of hepatocytes by cytochrome P-450-dependent microsomal monoxygenases.	beta-hydroxycortisol	2-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-157
6696448-1	1984	Complex formation between the phenobarbital-inducible form of rabbit liver microsomal cytochrome P-450 incorporated into phosphatidylcholine and detergent-solubilized cytochrome b5 is associated with a low-to-high spin transition of the former pigment.	Phenobarbital	30-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6696448-1	1984	Complex formation between the phenobarbital-inducible form of rabbit liver microsomal cytochrome P-450 incorporated into phosphatidylcholine and detergent-solubilized cytochrome b5 is associated with a low-to-high spin transition of the former pigment.	Phosphatidylcholines	121-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6696448-4	1984	Such a cytochrome b5-induced structural alteration of the reconstituted enzyme system is accompanied by an increase in affinity of 4-chloroaniline for cytochrome P-450, as measured in terms of cumene hydroperoxide-supported N-oxidation of the arylamine; the maximum velocity of the catalytic process remains unchanged.	4-chloroaniline	131-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
6696448-4	1984	Such a cytochrome b5-induced structural alteration of the reconstituted enzyme system is accompanied by an increase in affinity of 4-chloroaniline for cytochrome P-450, as measured in terms of cumene hydroperoxide-supported N-oxidation of the arylamine; the maximum velocity of the catalytic process remains unchanged.	cumene hydroperoxide	193-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
6696448-4	1984	Such a cytochrome b5-induced structural alteration of the reconstituted enzyme system is accompanied by an increase in affinity of 4-chloroaniline for cytochrome P-450, as measured in terms of cumene hydroperoxide-supported N-oxidation of the arylamine; the maximum velocity of the catalytic process remains unchanged.	aniline	243-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
6696448-6	1984	Stopped-flow spectrophotometric studies on the influence of cytochrome b5 on the kinetics of binding to cytochrome P-450 of 4-chloroaniline and/or cumene hydroperoxide show that the rates of formation and decay of the adducts change as the molar ratio of cytochrome b5 to cytochrome P-450 varies.	4-chloroaniline	124-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
6696448-6	1984	Stopped-flow spectrophotometric studies on the influence of cytochrome b5 on the kinetics of binding to cytochrome P-450 of 4-chloroaniline and/or cumene hydroperoxide show that the rates of formation and decay of the adducts change as the molar ratio of cytochrome b5 to cytochrome P-450 varies.	4-chloroaniline	124-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	272-288
6420437-1	1984	6 beta-Hydroxycortisol (6 beta OHF) is a highly polar metabolite of cortisol, probably formed in the endoplasmic reticulum of hepatocytes by cytochrome P-450-dependent microsomal monoxygenases.	beta ohf	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-157
6420437-1	1984	6 beta-Hydroxycortisol (6 beta OHF) is a highly polar metabolite of cortisol, probably formed in the endoplasmic reticulum of hepatocytes by cytochrome P-450-dependent microsomal monoxygenases.	Hydrocortisone	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-157
6433812-0	1984	Cytochrome P-450-dependent production of chemotactic arachidonate metabolites from human neutrophils.	Arachidonic Acid	53-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6708538-0	1984	Effect of human chorionic gonadotropin and estradiol in vivo on estradiol binder and cytochrome P-450 concentrations in rat testis.	Estradiol	43-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
6708538-5	1984	Both HCG- and estradiol-induced loss of cytochrome P-450 occur not only in Leydig cells but also in microsomes prepared from seminiferous tubules.	Estradiol	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
6595992-3	1984	The loss of cytochrome P-450 cannot be accounted for either by heme destruction or lipid peroxidation under anaerobic conditions.	Heme	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
6595995-2	1984	These findings exclude the possibility that the inhibitory effect of certain hydroxylation activities of the liver microsomes can be secondary to a direct effect of acrylonitrile on cytochrome P-450 but suggest the hypothesis that the inhibition is mediated by the cyanide released during acrylonitrile metabolism.	Acrylonitrile	165-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
6525185-0	1984	Effect of the gel-liquid crystalline phase transition on the reduction of cytochrome P-450 reconstituted into dimyristoyl-phosphatidylcholine liposomes.	Dimyristoylphosphatidylcholine	110-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
6691964-0	1984	Lateral diffusion of cytochrome P-450 in phospholipid bilayers.	Phospholipids	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
6146340-7	1984	It is concluded that cimetidine interactions do occur and can be predicted for substances metabolised by the cytochrome P-450 pathway.	Cimetidine	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
6331425-1	1984	The rotational motion of the spin labeled substrate analogue n- propylisocyanide bound to the active center of cytochrome P-450 was studied by saturation transfer EPR.	n- propylisocyanide	61-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
6091677-0	1984	[Selective chemical modification of cholesterol hydroxylating cytochrome P-450 from adrenal cortex mitochondria by tetranitromethane].	Cholesterol	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
6091677-0	1984	[Selective chemical modification of cholesterol hydroxylating cytochrome P-450 from adrenal cortex mitochondria by tetranitromethane].	Tetranitromethane	115-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
6091677-1	1984	Selective chemical modification of adrenocortical cytochrome P-450 responsible for the key stages in steroid biogenesis has been carried out.	Steroids	101-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6378529-3	1984	Recent studies with trace metals have revealed the potent ability of these elements to alter the synthesis and to enhance the degradation of heme moiety of cytochrome P-450.	Heme	141-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
6091677-3	1984	Analysis of the cytochrome P-450 nitration kinetics revealed several types of tyrosine residues differing in their accessifility for the reagent.	Tyrosine	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
6091677-6	1984	Cholesterol and adrenodoxin protected cytochrome P-450 against inactivation by tetranitromethane.	Cholesterol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
6091677-6	1984	Cholesterol and adrenodoxin protected cytochrome P-450 against inactivation by tetranitromethane.	Tetranitromethane	79-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
6091677-7	1984	The data obtained are discussed in terms of functional role of tyrosine residues in the cytochrome P-450 molecule.	Tyrosine	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
6525977-1	1984	The kinetics of cytochrome P-450 content in endoplasmic reticulum membranes at different stages of hepatocarcinogenesis was studied under the influence of unsaturated fatty acids by the EPR method.	Fatty Acids, Unsaturated	155-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
6525977-2	1984	At early stages of carcinogenesis the preparations containing oleic, linoleic and arachidonic acids prevent changes in the cytochrome P-450 content usually observed in case of nitrosodiethylamine introduction.	oleic	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
6525977-2	1984	At early stages of carcinogenesis the preparations containing oleic, linoleic and arachidonic acids prevent changes in the cytochrome P-450 content usually observed in case of nitrosodiethylamine introduction.	Linoleic Acid	69-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
6525977-2	1984	At early stages of carcinogenesis the preparations containing oleic, linoleic and arachidonic acids prevent changes in the cytochrome P-450 content usually observed in case of nitrosodiethylamine introduction.	Arachidonic Acids	82-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
6525977-2	1984	At early stages of carcinogenesis the preparations containing oleic, linoleic and arachidonic acids prevent changes in the cytochrome P-450 content usually observed in case of nitrosodiethylamine introduction.	Diethylnitrosamine	176-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
6525977-3	1984	The diet containing unsaturated fatty acids has a stabilizing effect revealed by the similar changes in the content of cytochrome P-450, phosphatidyl choline and fatty acids composition and also in the level of organization of the endoplasmic reticulum membrane lipid bilayer.	Fatty Acids, Unsaturated	20-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
6525977-3	1984	The diet containing unsaturated fatty acids has a stabilizing effect revealed by the similar changes in the content of cytochrome P-450, phosphatidyl choline and fatty acids composition and also in the level of organization of the endoplasmic reticulum membrane lipid bilayer.	Fatty Acids	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
6326394-0	1984	The influence of oxygen donor ligation on the spectroscopic properties of ferric cytochrome P-450: ester, ether and ketone co-ordination to the haem iron.	Oxygen	17-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6533032-0	1984	Metabolism of nitrosamines by cytochrome P-450 isozymes.	Nitrosamines	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
6326394-0	1984	The influence of oxygen donor ligation on the spectroscopic properties of ferric cytochrome P-450: ester, ether and ketone co-ordination to the haem iron.	Esters	99-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6426177-0	1984	Rate-limiting steps in cytochrome P-450-catalysed reactions: studies on isotope effects in the O-de-ethylation of 7-ethoxycoumarin.	7-ethoxycoumarin	114-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
6326394-0	1984	The influence of oxygen donor ligation on the spectroscopic properties of ferric cytochrome P-450: ester, ether and ketone co-ordination to the haem iron.	Ether	106-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6426177-1	1984	Primary deuterium isotope effects ranging from 2 to 6 were measured for the O-de-ethylation of 7-ethoxycoumarin catalysed by microsomal and purified cytochrome P-450 isozymes.	Deuterium	8-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6326394-0	1984	The influence of oxygen donor ligation on the spectroscopic properties of ferric cytochrome P-450: ester, ether and ketone co-ordination to the haem iron.	Ketones	116-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6426177-1	1984	Primary deuterium isotope effects ranging from 2 to 6 were measured for the O-de-ethylation of 7-ethoxycoumarin catalysed by microsomal and purified cytochrome P-450 isozymes.	7-ethoxycoumarin	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6326394-0	1984	The influence of oxygen donor ligation on the spectroscopic properties of ferric cytochrome P-450: ester, ether and ketone co-ordination to the haem iron.	Iron	149-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6326394-1	1984	Homogeneous low-spin complexes of cytochrome P-450-CAM with esters, ethers and ketones have been prepared and characterized by u.v.-visible absorption, circular dichroism (CD), magnetic circular dichroism (MCD) and electron paramagnetic resonance (EPR) spectroscopy.	Esters	60-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6326394-1	1984	Homogeneous low-spin complexes of cytochrome P-450-CAM with esters, ethers and ketones have been prepared and characterized by u.v.-visible absorption, circular dichroism (CD), magnetic circular dichroism (MCD) and electron paramagnetic resonance (EPR) spectroscopy.	Ethers	68-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6326394-1	1984	Homogeneous low-spin complexes of cytochrome P-450-CAM with esters, ethers and ketones have been prepared and characterized by u.v.-visible absorption, circular dichroism (CD), magnetic circular dichroism (MCD) and electron paramagnetic resonance (EPR) spectroscopy.	Ketones	79-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
6326394-8	1984	Anomalous spectral and substrate binding properties have been reported in the study of cytochrome P-450 under conditions employing solvents and non-phosphate buffers containing oxygen functionalities, and have been attributed to "solvent effects".	Phosphates	148-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
6326394-8	1984	Anomalous spectral and substrate binding properties have been reported in the study of cytochrome P-450 under conditions employing solvents and non-phosphate buffers containing oxygen functionalities, and have been attributed to "solvent effects".	Oxygen	177-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Alcohols	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Alcohols	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Amides	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Amides	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	carboxylate	80-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	carboxylate	80-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Oxygen	92-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Oxygen	92-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Oxygen	171-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Oxygen	171-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Iron	235-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
6326394-9	1984	The present work, in combination with our previous report of alcohol, amide and carboxylate oxygen donor complexes of cytochrome P-450, is evidence that a wide variety of oxygen-donor species are capable of direct ligation to the haem iron of cytochrome P-450.	Iron	235-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
6326394-10	1984	This leads us to suggest oxygen-donor ligation to cytochrome P-450 as the origin of spectral and substrate binding anomalies previously attributed to solvent effects.	Oxygen	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6372265-7	1984	The polymorphism in the 4-hydroxylation of debrisoquine observed in vivo has been shown to be due to a defect in a specific form of cytochrome P-450 which appears to be under monogenic regulation.	Debrisoquin	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
6661247-0	1983	Hepatic microsomal cytochrome p-450-dependent N-demethylation of methylguanidine.	Nitrogen	46-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
6372266-0	1984	Cytochrome P-450 spin state: inorganic biochemistry of haem iron ligation and functional significance.	Iron	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6661247-0	1983	Hepatic microsomal cytochrome p-450-dependent N-demethylation of methylguanidine.	Methylguanidine	65-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
6372267-1	1984	This review presents current ideas, models and experimental data relating to the precise chemistry that links the transition metal active centre of cytochrome P-450 systems, the unactivated alkane substrate and the triplet atmospheric dioxygen molecule.	Metals	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
6661247-1	1983	Cytochrome P-450-dependent N-demethylation of methylguanidine, a uremia toxin, was investigated.	Methylguanidine	46-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6372267-1	1984	This review presents current ideas, models and experimental data relating to the precise chemistry that links the transition metal active centre of cytochrome P-450 systems, the unactivated alkane substrate and the triplet atmospheric dioxygen molecule.	Alkanes	190-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6372267-1	1984	This review presents current ideas, models and experimental data relating to the precise chemistry that links the transition metal active centre of cytochrome P-450 systems, the unactivated alkane substrate and the triplet atmospheric dioxygen molecule.	Oxygen	235-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661254-1	1983	Bis(tri-n-butyltin)oxide, an agriculturally important biocidal agent, when added in vitro to liver microsomes containing the phenobarbital-induced form of cytochrome P-450, produced a typical type I binding spectrum (an absorption maximum at 390 nm; an absorption minimum at 420 nm).	bis(tri-n-butyltin)oxide	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Methylguanidine	116-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Methylguanidine	116-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Methylguanidine	116-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Carbon Monoxide	254-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Carbon Monoxide	254-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661254-1	1983	Bis(tri-n-butyltin)oxide, an agriculturally important biocidal agent, when added in vitro to liver microsomes containing the phenobarbital-induced form of cytochrome P-450, produced a typical type I binding spectrum (an absorption maximum at 390 nm; an absorption minimum at 420 nm).	Phenobarbital	125-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Carbon Monoxide	254-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Metyrapone	274-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
6661254-2	1983	Studies with microsomal preparations containing cytochrome P-448, induced by 3-methylcholanthrene or beta-naphthoflavone, revealed that this hemeprotein was more susceptible to direct degradation by bis(tri-n-butyltin)oxide than was the uninduced or phenobarbital-induced forms of cytochrome P-450.	bis(tri-n-butyltin)oxide	199-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	281-297
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Metyrapone	274-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661247-5	1983	The direct involvement of cytochrome P-450 in the N-demethylation is supported by the observations that addition of methylguanidine to purified cytochrome P-450 preparation caused a type I spectral change and that inhibitors of cytochrome P-450, such as carbon monoxide and metyrapone, markedly decreased the rate of demethylation.	Metyrapone	274-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
6661247-7	1983	In addition, guanidine formation was observed in the reconstituted system containing purified cytochrome P-450.	Guanidine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
6661254-4	1983	The formation of cytochrome P-420 was both time and temperature dependent, and it also occurred to a greater extent in microsomal preparations containing cytochrome P-448 than in microsomes containing the phenobarbital-induced form of cytochrome P-450.	Phenobarbital	205-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
6584878-0	1983	Nutrition-endocrine interactions: induction of reciprocal changes in the delta 4-5 alpha-reduction of testosterone and the cytochrome P-450-dependent oxidation of estradiol by dietary macronutrients in man.	Estradiol	163-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
6196179-5	1983	In correlation with the changes in these enzyme activities induced by hCG, the concentration of ovarian microsomal cytochrome P-450 decreased to barely detectable level after hCG treatment; this decrease was also prevented by pretreatment with cycloheximide.	Cycloheximide	244-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
6584878-6	1983	The mechanism by which reciprocal changes in the delta 4-5 alpha-reduction of testosterone and the cytochrome P-450-mediated oxidation of estradiol are produced by diets is not known.	Estradiol	138-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
6584878-4	1983	The delta 4-5 alpha-reduction of testosterone was considerably diminished, while the cytochrome P-450-dependent hydroxylation of estradiol at the C2 position was substantially enhanced during ingestion of the high-protein diet as compared with the high-carbohydrate diet.	Estradiol	129-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
6584878-7	1983	Similar changes in steroid delta 4-5 alpha-reduction and cytochrome P-450-dependent chemical oxidations have been observed in circumstances in which the mixed-function oxidase system in liver is induced by agents such as phenobarbital, hexachlorobenzene, dioxin, and polyhalogenated biphenyls.	Phenobarbital	221-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6584878-4	1983	The delta 4-5 alpha-reduction of testosterone was considerably diminished, while the cytochrome P-450-dependent hydroxylation of estradiol at the C2 position was substantially enhanced during ingestion of the high-protein diet as compared with the high-carbohydrate diet.	Carbohydrates	253-265	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
6584878-7	1983	Similar changes in steroid delta 4-5 alpha-reduction and cytochrome P-450-dependent chemical oxidations have been observed in circumstances in which the mixed-function oxidase system in liver is induced by agents such as phenobarbital, hexachlorobenzene, dioxin, and polyhalogenated biphenyls.	Hexachlorobenzene	236-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6639949-6	1983	Comparison to ferric myoglobin-thiolate complexes indicates that the negative sign observed for the cytochrome P-450 spectra is not a property of the thiolate fifth ligand, but rather arises from a different interaction of the cytochrome P-450 heme with its protein environment.	thiolate	31-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
6584878-7	1983	Similar changes in steroid delta 4-5 alpha-reduction and cytochrome P-450-dependent chemical oxidations have been observed in circumstances in which the mixed-function oxidase system in liver is induced by agents such as phenobarbital, hexachlorobenzene, dioxin, and polyhalogenated biphenyls.	Dioxins	255-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6584878-7	1983	Similar changes in steroid delta 4-5 alpha-reduction and cytochrome P-450-dependent chemical oxidations have been observed in circumstances in which the mixed-function oxidase system in liver is induced by agents such as phenobarbital, hexachlorobenzene, dioxin, and polyhalogenated biphenyls.	polyhalogenated biphenyls	267-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6639949-6	1983	Comparison to ferric myoglobin-thiolate complexes indicates that the negative sign observed for the cytochrome P-450 spectra is not a property of the thiolate fifth ligand, but rather arises from a different interaction of the cytochrome P-450 heme with its protein environment.	Heme	244-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
6639949-6	1983	Comparison to ferric myoglobin-thiolate complexes indicates that the negative sign observed for the cytochrome P-450 spectra is not a property of the thiolate fifth ligand, but rather arises from a different interaction of the cytochrome P-450 heme with its protein environment.	thiolate	31-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-243
6639949-6	1983	Comparison to ferric myoglobin-thiolate complexes indicates that the negative sign observed for the cytochrome P-450 spectra is not a property of the thiolate fifth ligand, but rather arises from a different interaction of the cytochrome P-450 heme with its protein environment.	Heme	244-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-243
6639949-6	1983	Comparison to ferric myoglobin-thiolate complexes indicates that the negative sign observed for the cytochrome P-450 spectra is not a property of the thiolate fifth ligand, but rather arises from a different interaction of the cytochrome P-450 heme with its protein environment.	thiolate	150-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
6661451-0	1983	[Comparative inhibitory analysis of aniline hydroxylation by cytochrome P-450 in NADPH-, hydroperoxide cumyl- and H2O2-dependent systems].	aniline	36-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6639949-8	1983	Hyperporphyrin (split Soret) cytochrome P-450 complexes with thiolates, phosphines and cyanide trans to cysteinate have complex CD spectra, reflecting the intrinsic non-degeneracy of the Soret pi pi transitions.	hyperporphyrin	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6639949-8	1983	Hyperporphyrin (split Soret) cytochrome P-450 complexes with thiolates, phosphines and cyanide trans to cysteinate have complex CD spectra, reflecting the intrinsic non-degeneracy of the Soret pi pi transitions.	thiolates	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6639949-8	1983	Hyperporphyrin (split Soret) cytochrome P-450 complexes with thiolates, phosphines and cyanide trans to cysteinate have complex CD spectra, reflecting the intrinsic non-degeneracy of the Soret pi pi transitions.	Phosphines	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6639949-8	1983	Hyperporphyrin (split Soret) cytochrome P-450 complexes with thiolates, phosphines and cyanide trans to cysteinate have complex CD spectra, reflecting the intrinsic non-degeneracy of the Soret pi pi transitions.	Cyanides	87-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6639949-8	1983	Hyperporphyrin (split Soret) cytochrome P-450 complexes with thiolates, phosphines and cyanide trans to cysteinate have complex CD spectra, reflecting the intrinsic non-degeneracy of the Soret pi pi transitions.	cysteinate	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6640098-2	1983	LPO activation in hepatocyte suspension by a catalytic system containing Fe2+--ADP plus NADP X H makes the destruction of cytochrome P-450 more rapid.	fe2+--adp	73-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
6640098-2	1983	LPO activation in hepatocyte suspension by a catalytic system containing Fe2+--ADP plus NADP X H makes the destruction of cytochrome P-450 more rapid.	nadp x h	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
6661451-0	1983	[Comparative inhibitory analysis of aniline hydroxylation by cytochrome P-450 in NADPH-, hydroperoxide cumyl- and H2O2-dependent systems].	NADP	81-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6640098-3	1983	Supplementation of the incubation medium with the antioxidant, 2-ethyl-6-methyl-3-hydroxypyridine (HP-6), inhibits LPO, on the one hand, and stabilizes cytochrome P-450, on the other one.	6-methyl-2-ethyl-3-hydroxypyridine	63-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
6661451-0	1983	[Comparative inhibitory analysis of aniline hydroxylation by cytochrome P-450 in NADPH-, hydroperoxide cumyl- and H2O2-dependent systems].	Hydrogen Peroxide	89-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6640098-3	1983	Supplementation of the incubation medium with the antioxidant, 2-ethyl-6-methyl-3-hydroxypyridine (HP-6), inhibits LPO, on the one hand, and stabilizes cytochrome P-450, on the other one.	hp-6	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
6661451-0	1983	[Comparative inhibitory analysis of aniline hydroxylation by cytochrome P-450 in NADPH-, hydroperoxide cumyl- and H2O2-dependent systems].	Hydrogen Peroxide	114-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6661451-1	1983	The p-hydroxylation of aniline in the presence of liver microsomes and isolated cytochrome P-450 in NADPH-, H2O2- and cumyl hydroperoxide (CHP)-dependent systems was investigated.	NADP	100-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6661451-1	1983	The p-hydroxylation of aniline in the presence of liver microsomes and isolated cytochrome P-450 in NADPH-, H2O2- and cumyl hydroperoxide (CHP)-dependent systems was investigated.	Hydrogen Peroxide	108-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6661451-1	1983	The p-hydroxylation of aniline in the presence of liver microsomes and isolated cytochrome P-450 in NADPH-, H2O2- and cumyl hydroperoxide (CHP)-dependent systems was investigated.	cumene hydroperoxide	118-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6661451-1	1983	The p-hydroxylation of aniline in the presence of liver microsomes and isolated cytochrome P-450 in NADPH-, H2O2- and cumyl hydroperoxide (CHP)-dependent systems was investigated.	cumene hydroperoxide	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6661451-4	1983	Since the kcat value for the H2O2-dependent system is much higher than that for the NADPH- or CHP-systems, it may be assumed that when H2O2 is used as a cosubstrate for this reaction, the true value of the degradation constant for the cytochrome P-450--O2(2-)--aniline peroxycomplex can be measured.	Hydrogen Peroxide	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
6661451-4	1983	Since the kcat value for the H2O2-dependent system is much higher than that for the NADPH- or CHP-systems, it may be assumed that when H2O2 is used as a cosubstrate for this reaction, the true value of the degradation constant for the cytochrome P-450--O2(2-)--aniline peroxycomplex can be measured.	NADP	84-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
6661451-4	1983	Since the kcat value for the H2O2-dependent system is much higher than that for the NADPH- or CHP-systems, it may be assumed that when H2O2 is used as a cosubstrate for this reaction, the true value of the degradation constant for the cytochrome P-450--O2(2-)--aniline peroxycomplex can be measured.	Hydrogen Peroxide	135-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
6661451-4	1983	Since the kcat value for the H2O2-dependent system is much higher than that for the NADPH- or CHP-systems, it may be assumed that when H2O2 is used as a cosubstrate for this reaction, the true value of the degradation constant for the cytochrome P-450--O2(2-)--aniline peroxycomplex can be measured.	o2(2-)--aniline	253-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
6684689-1	1983	Previous studies have shown that 6-thiopurine is metabolically activated by hepatic cytochrome P-450 to an intermediate capable of binding to proteins by a mixed disulfide linkage.	Mercaptopurine	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6357293-3	1983	The interaction of this protein and of the native protein with cholesterol-specific cytochrome P-450 and adrenodoxin reductase occurs in a similar way.	Cholesterol	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6684689-1	1983	Previous studies have shown that 6-thiopurine is metabolically activated by hepatic cytochrome P-450 to an intermediate capable of binding to proteins by a mixed disulfide linkage.	Disulfides	162-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6626210-1	1983	The filamentous fungus Aspergillus ochraceus TS produces an inducible microsomal cytochrome P-450 linked monooxygenase which is capable of hydroxylating benzo(a)pyrene in presence of O2 and NADPH.	Benzo(a)pyrene	153-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6888166-0	1983	Inhibition of lipid peroxide decomposition by compounds which bind with cytochrome p-450.	Lipid Peroxides	14-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6888166-2	1983	The results indicate that the in vitro interaction of hexobarbital and SKF-525 A (type I binding compounds) with microsomal cytochrome p-450 inhibits the peroxidase activity while the in vitro interaction of aniline (type II binding compound) only slightly affect the peroxidase activity.	Hexobarbital	54-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6888166-2	1983	The results indicate that the in vitro interaction of hexobarbital and SKF-525 A (type I binding compounds) with microsomal cytochrome p-450 inhibits the peroxidase activity while the in vitro interaction of aniline (type II binding compound) only slightly affect the peroxidase activity.	aniline	208-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6626210-1	1983	The filamentous fungus Aspergillus ochraceus TS produces an inducible microsomal cytochrome P-450 linked monooxygenase which is capable of hydroxylating benzo(a)pyrene in presence of O2 and NADPH.	Oxygen	183-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6626210-1	1983	The filamentous fungus Aspergillus ochraceus TS produces an inducible microsomal cytochrome P-450 linked monooxygenase which is capable of hydroxylating benzo(a)pyrene in presence of O2 and NADPH.	NADP	190-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
6626210-5	1983	These findings together with the results obtained with flavone on the metabolism of benzo(a)pyrene by various microsomal preparations suggest a parallel induction of multiple forms of cytochrome P-450 as observed in mammalian liver under identical condition.	flavone	55-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
6626210-5	1983	These findings together with the results obtained with flavone on the metabolism of benzo(a)pyrene by various microsomal preparations suggest a parallel induction of multiple forms of cytochrome P-450 as observed in mammalian liver under identical condition.	Benzo(a)pyrene	84-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
6409396-1	1983	There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes.	r,s-1-(tetrahydro-2-furanyl)-5-fluorouracil	20-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6409396-1	1983	There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes.	Fluorouracil	49-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6409396-1	1983	There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes.	Tegafur	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6409396-1	1983	There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes.	tetrahydrofuran	191-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
6871822-4	1983	Dimethylhydrazine metabolism in each segment is inhibited significantly by inhibitors of the cytochrome P-450-dependent mixed function oxidase system.	Dimethylhydrazines	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6411467-3	1983	The cytochrome P-450 content and response to induction by 3-methylcholanthrene and phenobarbitone; the distribution of lactate dehydrogenase, glucose-6-phosphatase, pyruvate kinase and tyrosine aminotransferase activities in the sub-populations is also reported.	Methylcholanthrene	58-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6411467-3	1983	The cytochrome P-450 content and response to induction by 3-methylcholanthrene and phenobarbitone; the distribution of lactate dehydrogenase, glucose-6-phosphatase, pyruvate kinase and tyrosine aminotransferase activities in the sub-populations is also reported.	Phenobarbital	83-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6411097-0	1983	Formation of electrophilic chlorine from carbon tetrachloride--involvement of cytochrome P-450.	Chlorine	27-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
6411097-0	1983	Formation of electrophilic chlorine from carbon tetrachloride--involvement of cytochrome P-450.	Carbon Tetrachloride	41-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
6136493-6	1983	Endotoxin administration was also shown to diminish, but not prevent, the induction of cytochrome P--450 and ethylmorphine N-demethylase activity produced by phenobarbital.	Phenobarbital	158-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-104
6412745-0	1983	Possible association of NADPH-cytochrome P-450 reductase and cytochrome P-450 in reconstituted phospholipid vesicles.	Phospholipids	95-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
6407834-0	1983	Reduction of cytochrome P-450 LM2 by NADPH in reconstituted phospholipid vesicles is dependent on membrane charge.	NADP	37-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
6407834-0	1983	Reduction of cytochrome P-450 LM2 by NADPH in reconstituted phospholipid vesicles is dependent on membrane charge.	Phospholipids	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
6407834-1	1983	The kinetics of the reduction of cytochrome P-450 LM2 mediated by NADPH-cytochrome P-450 reductase in reconstituted phospholipid vesicles was examined.	Phospholipids	116-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
6409115-5	1983	These data suggest that the discordant effects of phenobarbital on UDPGT and cytochrome P-450 previously reported in humans and rats may not be attributable solely to differences in the drug doses employed.	Phenobarbital	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
6407834-4	1983	In the presence of benzphetamine, the extent of cytochrome P-450 LM2 reduced 1 s after the addition of NADPH to the system was a linear function of the electrophoretic mobilities of the vesicles used.	Benzphetamine	19-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
6407834-4	1983	In the presence of benzphetamine, the extent of cytochrome P-450 LM2 reduced 1 s after the addition of NADPH to the system was a linear function of the electrophoretic mobilities of the vesicles used.	NADP	103-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
6872096-5	1983	BHA addition effectively discharged the activated oxygen complex of cytochrome P-450 (liver microsomes) as well as Comp.	bha	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
6305968-5	1983	Transfer of cholesterol to and from cytochrome P-450 occurred with similar first order rate constants and was also independent of the concentrations of cholesterol vesicles and P-450.	Cholesterol	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
6872096-5	1983	BHA addition effectively discharged the activated oxygen complex of cytochrome P-450 (liver microsomes) as well as Comp.	Oxygen	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
6354819-6	1983	NADPH is also the main donor for reducing equivalents in drug oxidations by the cytochrome P-450-dependent monooxygenase system which, with some notable exceptions, serves important purposes in detoxication.	NADP	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6309256-1	1983	The iodine-containing stable iminoxyl radicals with various distances between the N-O-group and the iodine atom are proposed to be used to study the structure of the active center of the microsomal cytochrome P-450.	Iodine	4-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
6859878-1	1983	Epoxyeicosatrienoic acids, formed during the cytochrome P-450-catalyzed oxidation of arachidonic acid, react with a liver cytosolic epoxide hydrolase to form vicinal diols of eicosatrienoic acid.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6309256-1	1983	The iodine-containing stable iminoxyl radicals with various distances between the N-O-group and the iodine atom are proposed to be used to study the structure of the active center of the microsomal cytochrome P-450.	iminoxyl	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
6859878-1	1983	Epoxyeicosatrienoic acids, formed during the cytochrome P-450-catalyzed oxidation of arachidonic acid, react with a liver cytosolic epoxide hydrolase to form vicinal diols of eicosatrienoic acid.	Arachidonic Acid	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6859878-1	1983	Epoxyeicosatrienoic acids, formed during the cytochrome P-450-catalyzed oxidation of arachidonic acid, react with a liver cytosolic epoxide hydrolase to form vicinal diols of eicosatrienoic acid.	vicinal diols	158-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6309256-1	1983	The iodine-containing stable iminoxyl radicals with various distances between the N-O-group and the iodine atom are proposed to be used to study the structure of the active center of the microsomal cytochrome P-450.	Iodine	100-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
6859878-1	1983	Epoxyeicosatrienoic acids, formed during the cytochrome P-450-catalyzed oxidation of arachidonic acid, react with a liver cytosolic epoxide hydrolase to form vicinal diols of eicosatrienoic acid.	Eicosatrienoic acid	5-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6309256-2	1983	The radicals used induce changes in the optical spectra of the Fe3+ ion located in the active center of the enzyme, as in the case of type 1 substrates and inhibit essentially the microsomal oxidation of cytochrome P-450 substrates of type 1 and 2.	ferric sulfate	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-220
6309256-4	1983	Cytochrome P-450 substrates (aminopyrine) protect the enzyme against the radical-induced inactivation.	Aminopyrine	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6309256-4	1983	Cytochrome P-450 substrates (aminopyrine) protect the enzyme against the radical-induced inactivation.	radical	73-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6309256-5	1983	The iodine-containing radicals are covalently bound to cytochrome P-450 in the vicinity of active center.	Iodine	4-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
6309256-7	1983	The EPR method was used to detect the coupling between Fe3+ and the radical located in the active center of cytochrome P-450.	ferric sulfate	55-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
6309256-8	1983	The saturation curves of radical SPR spectra at 77 degrees K were employed to determine the contribution of Fe3+ to the relaxation time, T1, of the radicals covalently bound to cytochrome P-450 and to estimate the distances between the Fe3+ ion and the N-O-group of these radicals in the enzyme active center.	ferric sulfate	108-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
6309256-8	1983	The saturation curves of radical SPR spectra at 77 degrees K were employed to determine the contribution of Fe3+ to the relaxation time, T1, of the radicals covalently bound to cytochrome P-450 and to estimate the distances between the Fe3+ ion and the N-O-group of these radicals in the enzyme active center.	ferric sulfate	236-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
6870907-0	1983	Correlations between spin equilibrium shift, reduction rate, and N-demethylation activity in liver microsomal cytochrome P-450 and a series of benzphetamine analogues as substrates.	Nitrogen	65-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Tolbutamide	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Phenytoin	176-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Sulfinpyrazone	20-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Warfarin	190-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Theophylline	252-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Antipyrine	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Warfarin	281-293	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6833253-0	1983	Stereochemistry of cytochrome P-450-catalyzed epoxidation and prosthetic heme alkylation.	Heme	73-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
6833253-1	1983	Oxidation of 1-octene by cytochrome P-450 results concurrently in formation of 1,2-oxidooctane and in N-alkylation by the catalytically activated olefin of the prosthetic heme group.	1-octene	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6833253-1	1983	Oxidation of 1-octene by cytochrome P-450 results concurrently in formation of 1,2-oxidooctane and in N-alkylation by the catalytically activated olefin of the prosthetic heme group.	1,2-oxidooctane	79-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6833253-1	1983	Oxidation of 1-octene by cytochrome P-450 results concurrently in formation of 1,2-oxidooctane and in N-alkylation by the catalytically activated olefin of the prosthetic heme group.	Alkenes	146-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6833253-1	1983	Oxidation of 1-octene by cytochrome P-450 results concurrently in formation of 1,2-oxidooctane and in N-alkylation by the catalytically activated olefin of the prosthetic heme group.	Heme	171-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6831832-4	1983	This suggests increasing theophylline metabolism with age due to developing hepatic cytochrome P-450 enzyme systems.	Theophylline	25-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6617864-0	1983	Effect of succinylacetone on heme and cytochrome P450 synthesis in hepatocyte culture.	succinylacetone	10-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
6833217-1	1983	We have employed small angle x-ray scattering to examine the solution conformation of cytochrome P-450cam in the presence and absence of its substrate, camphor.	Camphor	152-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6617864-1	1983	The effects of succinylacetone, a tyrosine metabolite, on the hepatic biosynthesis of heme and cytochrome P450 were studied in primary culture of chick embryo hepatocytes.	succinylacetone	15-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
6617864-2	1983	Succinylacetone potentiated the phenobarbital-mediated induction of delta-aminolevulinate synthase, strongly inhibited porphobilinogen synthase activity, reduced cellular heme concentration and impaired induction of cytochrome P450.	succinylacetone	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
6617864-2	1983	Succinylacetone potentiated the phenobarbital-mediated induction of delta-aminolevulinate synthase, strongly inhibited porphobilinogen synthase activity, reduced cellular heme concentration and impaired induction of cytochrome P450.	Phenobarbital	32-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
6617864-3	1983	Enhanced induction of delta-aminolevulinate synthase and decreased cytochrome P450 induction may be explained by the succinylacetone-mediated inhibition of porphobilinogen synthase and the subsequent depletion of intracellular heme, since these effects of succinylacetone were reversed by addition of heme.	succinylacetone	117-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
6617864-3	1983	Enhanced induction of delta-aminolevulinate synthase and decreased cytochrome P450 induction may be explained by the succinylacetone-mediated inhibition of porphobilinogen synthase and the subsequent depletion of intracellular heme, since these effects of succinylacetone were reversed by addition of heme.	Heme	227-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
6401621-1	1983	FSH, estradiol, or a combination of FSH and estradiol enhanced secretion of progesterone by primary cultures of immature porcine granulosa cells; they also increased the mitochondrial content of cytochrome P-450 and mitochondrial cholesterol side-chain cleavage activity.	Estradiol	5-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-211
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	Lidocaine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	Bupivacaine	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	Mepivacaine	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	Etidocaine	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	pyrrocaine	82-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838647-4	1983	In contrast, lidocaine and its derivatives (bupivacaine, mepivacaine, etidocaine, pyrrocaine and prilocaine) were found to induce delta-aminolevulinate synthetase and to cause accumulation of porphyrins and cytochrome P-450.	Prilocaine	97-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
6838653-1	1983	In rats, erythromycin has been shown to induce microsomal enzymes and to promote its own transformation into a metabolite which forms an inactive complex with reduced cytochrome P-450.	Erythromycin	9-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
6838653-3	1983	In the treated patients, NADPH-cytochrome c reductase activity was increased; the total cytochrome P-450 concn was also increased but part of the total cytochrome P-450 was complexed by an erythromycin metabolite.	Erythromycin	189-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
6838653-6	1983	We conclude that the administration of erythromycin propionate induces microsomal enzymes and results in the formation of an inactive cytochrome P-450-metabolite complex in humans.	erythromycin propionate	39-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
6401621-1	1983	FSH, estradiol, or a combination of FSH and estradiol enhanced secretion of progesterone by primary cultures of immature porcine granulosa cells; they also increased the mitochondrial content of cytochrome P-450 and mitochondrial cholesterol side-chain cleavage activity.	Estradiol	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-211
6185486-9	1983	The decay of activated bleomycin yields low spin ferric bleomycin, a complex with Mossbauer parameters nearly identical with those reported for ferric cytochrome P-450.	iron bleomycin	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
6826727-7	1983	In cultured hepatocytes, succinylacetone also inhibited ALA dehydratase activity, decreased the cellular content of heme and cytochrome P-450, and greatly potentiated the induction response of ALA synthase to drugs such as phenobarbital, chemicals such as allylisopropylacetamide and 3,5-dicarbethoxy-1,4-dihydrocollidine, and natural steroids such as etiocholanolone.	succinylacetone	25-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6220203-0	1983	Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.	Debrisoquin	88-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
6220203-1	1983	In the present study we have investigated the substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man by analyzing the kinetics of inhibition of this activity by potential alternative substrates for the enzyme.	Debrisoquin	134-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	iron bleomycin	9-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Heme	68-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Iron	9-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Sulfur	170-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Heme	189-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Iron	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6185486-10	1983	Although iron bleomycin does not have a polyaromatic structure like heme, many features of its electronic structure at the iron are very similar to those produced by the sulfur-coordinated heme iron of ferric cytochrome P-450, a protein that catalyzes a similar oxygen-dependent reaction.	Oxygen	262-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
6130930-4	1983	Cimetidine binds reversibly to the hepatic cytochrome P-450 and P-448 systems, resulting in decreased metabolism of drugs that undergo Phase I reactions (e.g., dealkylation and hydroxylation).	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-69
6624542-6	1983	HDL-C, A-I and the HDL-C/T-C ratio were directly proportional to liver phospholipids, protein and cytochrome P-450, inversely related to hepatic triglycerides.	Triglycerides	145-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6848512-0	1983	Chiral orientation of prosthetic heme in the cytochrome P-450 active site.	Heme	33-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6848512-3	1983	The orientation of the heme in cytochrome P-450, therefore, is unknown because a crystallographic structure is not available for any form of this enzyme.	Heme	23-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
6848512-4	1983	We report here that the absolute configurations of the N-ethylprotoporphyrin IX adducts formed from the prosthetic hemes of cytochrome P-450 and hemoglobin during catalytic turnover of appropriate substrates are identical.	N-ethylprotoporphyrin IX	55-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6848512-5	1983	The prosthetic heme in the inactivated cytochrome P-450 enzyme, therefore, has exactly the same orientation, relative to the fifth iron ligand, as the heme in hemoglobin.	Heme	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
6848512-5	1983	The prosthetic heme in the inactivated cytochrome P-450 enzyme, therefore, has exactly the same orientation, relative to the fifth iron ligand, as the heme in hemoglobin.	Iron	131-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
6848512-5	1983	The prosthetic heme in the inactivated cytochrome P-450 enzyme, therefore, has exactly the same orientation, relative to the fifth iron ligand, as the heme in hemoglobin.	Heme	151-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
6848512-6	1983	The approach described here can be used to determine the prosthetic heme orientation in other hemoproteins, including other cytochrome P-450 isozymes, for which x-ray structures are not available.	Heme	68-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6299293-0	1983	Mestranol-induced hypertension: characterization of cytochrome P-450 dependent catechol estrogen formation in brain microsomes.	Mestranol	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
6416251-2	1983	Model treatment of the NADPH-dependent first electron transfer reaction between cytochrome P-450 reductase and cytochrome P-450 LM2 in solution.	NADP	23-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
6416251-2	1983	Model treatment of the NADPH-dependent first electron transfer reaction between cytochrome P-450 reductase and cytochrome P-450 LM2 in solution.	NADP	23-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
6299293-0	1983	Mestranol-induced hypertension: characterization of cytochrome P-450 dependent catechol estrogen formation in brain microsomes.	catechol	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
6132787-1	1983	Metabolism of Aromatic hydrocarbons by the cytochrome P-450 system and epoxide hydrolase.	Hydrocarbons, Aromatic	14-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
6861274-0	1983	Kinetic evidence for the involvement of multiple forms of human liver cytochrome P-450 in the metabolism of acetylaminofluorene.	2-Acetylaminofluorene	108-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
6418502-10	1983	Another factor which may be involved is heme oxygenase activity, which is markedly induced in the liver after GSH depletion, after cobalt administration (which also depresses cytochrome P-450 activity), and during incubation of isolated hepatocytes.	Cobalt	131-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
6418502-1	1983	It is apparent that hepatic GSH may function in drug metabolism not only as a substrate for conjugation but also in regulation of cytochrome P-450 activity.	Glutathione	28-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
6418502-11	1983	This enzyme catalyzes the rate-limiting step in heme breakdown and may contribute to the loss of cytochrome P-450 activity associated with GSH depletion.	Heme	48-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
6418502-8	1983	Ongoing investigations include attempts to identify the cytochrome P-450 isozyme(s) which inhibit this response to GSH depletion.	Glutathione	115-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
6418502-9	1983	GSH-lipid peroxidation relationships have already been reported with isolated hepatocytes, and there may be a possible connection between this and the relative instability of cytochrome P-450 in cultured hepatocytes.	Glutathione	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-191
6418502-11	1983	This enzyme catalyzes the rate-limiting step in heme breakdown and may contribute to the loss of cytochrome P-450 activity associated with GSH depletion.	Glutathione	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
6678827-3	1983	Although the mechanism of this pharmacological effect remains unclarified, these results suggest that there is considerable potential for interactions to occur with other drugs metabolized by the same hepatic pathways (cytochrome P 450) in patients undergoing PUVA therapy.	puva	260-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-235
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Cimetidine	20-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6353196-1	1983	Liver endoplasmic reticulum contains as NADPH-dependent electron transport complex where the family of hemeproteins, termed cytochrome P-450, serve as catalysts for the oxidation of a variety of different organic chemicals.	NADP	40-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6341732-1	1983	The metabolism of tertiary amines is mediated primarily by cytochrome P-450 and MFAO, leading to alpha-C oxidation and N-oxidation, respectively.	Amines	27-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-84
6353196-2	1983	The content and inventory of the types of cytochrome P-450 is readily modified following in vivo treatment of animals with "inducing agents" such as barbiturates, steroids and polycyclic hydrocarbons.	Barbiturates	149-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
6341732-3	1983	The proposed oxidation of tertiary amines to iminium ions by cytochrome P-450 may explain the isolation of various intramolecular and cyanide-trapped metabolites.	Amines	35-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6353196-2	1983	The content and inventory of the types of cytochrome P-450 is readily modified following in vivo treatment of animals with "inducing agents" such as barbiturates, steroids and polycyclic hydrocarbons.	Steroids	163-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
6341732-3	1983	The proposed oxidation of tertiary amines to iminium ions by cytochrome P-450 may explain the isolation of various intramolecular and cyanide-trapped metabolites.	iminium	45-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6353196-2	1983	The content and inventory of the types of cytochrome P-450 is readily modified following in vivo treatment of animals with "inducing agents" such as barbiturates, steroids and polycyclic hydrocarbons.	Hydrocarbons, Cyclic	176-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
6341732-3	1983	The proposed oxidation of tertiary amines to iminium ions by cytochrome P-450 may explain the isolation of various intramolecular and cyanide-trapped metabolites.	Cyanides	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6356158-10	1983	Thus despite absence of ADH, ADH- deermice can consume large amounts of ethanol: this is associated with increased BEC, SER proliferation, enhanced MEOS activity and quantitative and qualitative changes of cytochrome P-450.	Ethanol	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-222
7160374-0	1982	Dynamics of the spin transition in camphor-bound ferric cytochrome P-450 versus temperature, pressure and viscosity.	Camphor	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
6186523-0	1982	Differential effect of phenobarbital and beta-naphthoflavone on the mRNAs coding for cytochrome P450 and NADPH cytochrome P450 reductase.	Phenobarbital	23-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
6186523-0	1982	Differential effect of phenobarbital and beta-naphthoflavone on the mRNAs coding for cytochrome P450 and NADPH cytochrome P450 reductase.	beta-Naphthoflavone	41-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
7160374-1	1982	The kinetics and equilibrium of the low-spin (LS) to high-spin (HS) transition in camphor-bound ferric cytochrome P-450 have been measured versus temperature, pressure and viscosity at selected pH and KCl concentration.	Potassium Chloride	201-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
7160374-1	1982	The kinetics and equilibrium of the low-spin (LS) to high-spin (HS) transition in camphor-bound ferric cytochrome P-450 have been measured versus temperature, pressure and viscosity at selected pH and KCl concentration.	Camphor	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
7161599-11	1982	Similarities between the hemin-mediated peroxide-supported reactions reported here, and the cytochrome P-450-mediated peroxide-supported reactions reinforce our earlier contentions that the alkaline hemin system appears to be a good model for the in vivo activation of oxygen by hemoproteins.	Peroxides	118-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
7161599-11	1982	Similarities between the hemin-mediated peroxide-supported reactions reported here, and the cytochrome P-450-mediated peroxide-supported reactions reinforce our earlier contentions that the alkaline hemin system appears to be a good model for the in vivo activation of oxygen by hemoproteins.	Oxygen	269-275	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
7181876-0	1982	Hematoporphyrin photosensitization of epidermal microsomes results in destruction of cytochrome P-450 and in decreased monooxygenase activities and heme content.	Hematoporphyrins	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7181912-0	1982	Occurrence of aromatic methyl migration (NIH-shift) during oxidation of p-methylanisole by hemin-thiolester complex as a cytochrome P-450 model.	methyl radical	23-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7181912-0	1982	Occurrence of aromatic methyl migration (NIH-shift) during oxidation of p-methylanisole by hemin-thiolester complex as a cytochrome P-450 model.	4-methyl anisole	72-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7181912-0	1982	Occurrence of aromatic methyl migration (NIH-shift) during oxidation of p-methylanisole by hemin-thiolester complex as a cytochrome P-450 model.	hemin-thiolester	91-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
6288676-2	1982	Cytochrome P-450 is destroyed during catalytic oxidation of several 4-substituted 3,5-bis(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine substrates.	4-substituted 3,5-bis(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine	68-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6288676-9	1982	Hydrogen peroxide formed in situ can support a part of the cytochrome P-450-catalyzed ethyl radical formation and DDEP-dependent self-inactivation.	Hydrogen Peroxide	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
6288676-9	1982	Hydrogen peroxide formed in situ can support a part of the cytochrome P-450-catalyzed ethyl radical formation and DDEP-dependent self-inactivation.	Ethyl radical	86-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
6288676-10	1982	The results provide persuasive evidence that oxidation of the nitrogen in DDEP by cytochrome P-450 proceeds in one-electron steps.	Nitrogen	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
6964386-1	1982	Bacterial cytochrome P-450 induced by camphor (P-450cam) is reconstituted with manganese-protoporphyrin IX, yielding an enzyme that displays unique spectral properties relative to previously characterized manganese-porphyrin systems.	Camphor	38-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
7107639-0	1982	Endogenous cysteine ligation in ferric and ferrous cytochrome P-450.	Cysteine	11-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
6964386-1	1982	Bacterial cytochrome P-450 induced by camphor (P-450cam) is reconstituted with manganese-protoporphyrin IX, yielding an enzyme that displays unique spectral properties relative to previously characterized manganese-porphyrin systems.	manganese protoporphyrin	79-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
6964386-1	1982	Bacterial cytochrome P-450 induced by camphor (P-450cam) is reconstituted with manganese-protoporphyrin IX, yielding an enzyme that displays unique spectral properties relative to previously characterized manganese-porphyrin systems.	manganese-porphyrin	205-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
7107639-2	1982	Extended x-ray absorption fine structure spectroscopy has been applied to the elucidation of the structure of the heme iron site of bacterial cytochrome P-450.	Heme	114-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
7107639-2	1982	Extended x-ray absorption fine structure spectroscopy has been applied to the elucidation of the structure of the heme iron site of bacterial cytochrome P-450.	Iron	119-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
6814537-0	1982	[Comparative study of the reaction kinetics of cytochrome P-450 reduction by NADPH-cytochrome P-450 reductase and dithionite].	Dithionite	114-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
6816226-0	1982	Participation of cytochrome P-450 in nicotine oxidation.	Nicotine	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
6286112-1	1982	Human colon tumor cells (cell line LS174T) retain a cytochrome P-450-containing drug metabolism system capable of hydroxylating polycyclic hydrocarbons and the anticancer drug cyclophosphamide.	Hydrocarbons, Cyclic	128-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
6814537-1	1982	The reactions of NADPH- or dithionite-dependent reduction of cytochrome P-450 were studied using a stopped flow technique.	NADP	17-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6286112-1	1982	Human colon tumor cells (cell line LS174T) retain a cytochrome P-450-containing drug metabolism system capable of hydroxylating polycyclic hydrocarbons and the anticancer drug cyclophosphamide.	Cyclophosphamide	176-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
6286112-4	1982	Cytochrome P-450 specific content is increased 2- to 3-fold by treatment with phenobarbital plus hydrocortisone and benz(a)anthracene, respectively.	Phenobarbital	78-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6286112-4	1982	Cytochrome P-450 specific content is increased 2- to 3-fold by treatment with phenobarbital plus hydrocortisone and benz(a)anthracene, respectively.	Hydrocortisone	97-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6814537-1	1982	The reactions of NADPH- or dithionite-dependent reduction of cytochrome P-450 were studied using a stopped flow technique.	Dithionite	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6286112-4	1982	Cytochrome P-450 specific content is increased 2- to 3-fold by treatment with phenobarbital plus hydrocortisone and benz(a)anthracene, respectively.	benz(a)anthracene	116-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6814537-4	1982	On the contrary, the breaks on the corresponding plots for the slow phase rate constants are observed at 22 and 33 degrees C for cytochrome P-450 reduction by dithionite and at 31 degrees C for NADPH-dependent reduction of cytochrome P-450.	Dithionite	159-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
6814537-4	1982	On the contrary, the breaks on the corresponding plots for the slow phase rate constants are observed at 22 and 33 degrees C for cytochrome P-450 reduction by dithionite and at 31 degrees C for NADPH-dependent reduction of cytochrome P-450.	NADP	194-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-239
6814537-5	1982	The coincidence of the values of the rate constants and activation energy (56 +/- 5 kJ/mol) for the fast phase of NADPH-dependent reduction of cytochrome P-450 with values of catalytic constants and activation energy for demethylation of tertiary amines suggests that the first electron transfer process from NADPH-cytochrome P-450 reductase to cytochrome P-450 may be the rate-limiting step.	NADP	114-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
6814537-5	1982	The coincidence of the values of the rate constants and activation energy (56 +/- 5 kJ/mol) for the fast phase of NADPH-dependent reduction of cytochrome P-450 with values of catalytic constants and activation energy for demethylation of tertiary amines suggests that the first electron transfer process from NADPH-cytochrome P-450 reductase to cytochrome P-450 may be the rate-limiting step.	NADP	114-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	315-331
6814537-5	1982	The coincidence of the values of the rate constants and activation energy (56 +/- 5 kJ/mol) for the fast phase of NADPH-dependent reduction of cytochrome P-450 with values of catalytic constants and activation energy for demethylation of tertiary amines suggests that the first electron transfer process from NADPH-cytochrome P-450 reductase to cytochrome P-450 may be the rate-limiting step.	Amines	247-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
7108267-9	1982	These studies indicate that orally administered 8-MOP induces hepatic drug-metabolizing enzymes and cytochrome P-450 to a lesser extent than do the barbituates and suggest that this drug could influence the rate of biotransformation of concomitantly administered drugs in patients undergoing PUVA therapy.	Methoxsalen	48-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
6292686-3	1982	The formation of this species is inhibited by carbon monoxide and metyrapone, suggesting the involvement of cytochrome P-450.	Carbon Monoxide	46-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
6292686-3	1982	The formation of this species is inhibited by carbon monoxide and metyrapone, suggesting the involvement of cytochrome P-450.	Metyrapone	66-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
7083192-3	1982	Aminoglutethimide binds competitively to cytochrome P-450 and inhibits a number of steroid hydroxylations but is more active as an aromatase inhibitor.	Aminoglutethimide	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
6897045-0	1982	Inactivation of cytochrome P-450 and production of N-alkylated porphyrins caused in isolated hepatocytes by substituted dihydropyridines.	Dihydropyridines	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
7138513-0	1982	Modification of the cysteine residues of cytochrome P-450cam with 2-bromoacetamido-4-nitrophenol.	Cysteine	20-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
7138513-0	1982	Modification of the cysteine residues of cytochrome P-450cam with 2-bromoacetamido-4-nitrophenol.	2-bromoacetamide-4-nitrophenol	66-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
7117257-0	1982	The D(V/K) isotope effect of the cytochrome P-450-mediated oxidation of ethanol and its biological applications.	Ethanol	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
7161848-6	1982	The relative importance of the FAD-containing monooxygenase vis-a-vis the cytochrome P-450-dependent monooxygenase system is discussed, based on in vitro studies on purified enzymes.	Flavin-Adenine Dinucleotide	31-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
7126232-0	1982	Suicidal inactivation of hepatic cytochrome P-450 in vitro by some aliphatic olefins.	aliphatic olefins	67-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
6285973-2	1982	The rate of transfer of spin-labeled phospholipid from donor vesicles of sonicated 1-acyl-2-(10-doxylstearoyl)-sn-glycero-3-phosphocholine to other vesicle was determined as a function of content of cytochrome P-450 and the phosphatidylcholine/phosphatidylethanolamine ratio in the acceptor vesicles.	Phospholipids	37-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-215
6285973-2	1982	The rate of transfer of spin-labeled phospholipid from donor vesicles of sonicated 1-acyl-2-(10-doxylstearoyl)-sn-glycero-3-phosphocholine to other vesicle was determined as a function of content of cytochrome P-450 and the phosphatidylcholine/phosphatidylethanolamine ratio in the acceptor vesicles.	1-acyl-2-(10-doxylstearoyl)-sn-glycero-3-phosphocholine	83-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-215
7126360-4	1982	Single and repeated doses of trans-1,2-DCE induced liver aminopyrine demethylase and cytochrome P-450 whereas the cis- isomer decreased them.	TRANS-1,2-DICHLOROETHYLENE	29-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7122438-6	1982	The approaches to the modelling of the cytochrome P-450 catalytic activity with the aid of ferroporphyrine are proposed.	ferroporphyrine	91-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
7122439-6	1982	In H2O2-dependent reactions the complex displayed V M and K M similar to those of liver microsomal cytochrome P-450.	Hydrogen Peroxide	3-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
6180744-0	1982	Sequential administrations of polyriboinosinic acid and polyribocytidylic acid induce interferon and depress the hepatic cytochrome P-450-dependent monooxygenase system.	Polyinosinic acid	30-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
6180744-0	1982	Sequential administrations of polyriboinosinic acid and polyribocytidylic acid induce interferon and depress the hepatic cytochrome P-450-dependent monooxygenase system.	Poly C	56-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7122439-7	1982	In NADPH-dependent reactions the specific activity of the complex was only 1-3% that of cytochrome P-450.	NADP	3-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
6810899-6	1982	A reconstituted enzyme system consisting of NADPH, NADPH-cytochrome P-450 reductase, phospholipid and cytochrome P-450 converted mitomycin C to a reactive metabolite(s) under hypoxic conditions.	Mitomycin	129-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
6810899-8	1982	These findings support the concept that the cytochrome P-450 system is capable of activating mitomycin C under hypoxic conditions to the alkylating metabolite(s) that is responsible for antineoplastic activity.	Mitomycin	93-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
7115427-0	1982	The 1,2-dichloroethylenes: their metabolism by hepatic cytochrome p-450 in vitro.	1,2-dichloroethylene	4-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
6980417-1	1982	Cytochrome P-450 (P-450)-dependent aryl hydrocarbon hydroxylase (AHHase) and 7-ethoxycoumarin deethylase (ECDEtase) in human tissues were differentially inhibited by monoclonal antibodies (MAbs) that were prepared to inhibit and completely inhibited the activity of 3-methylcholanthrene-induced rat liver P-450.	Methylcholanthrene	266-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7115427-1	1982	Cis- and trans-1,1-dichloroethylene bound to the active site of hepatic microsomal cytochrome P-450 with the production of a Type I difference spectrum and stimulated CO-inhibitable hepatic microsomal NADPH oxidation.	cis- and trans-1,1-dichloroethylene	0-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7115427-1	1982	Cis- and trans-1,1-dichloroethylene bound to the active site of hepatic microsomal cytochrome P-450 with the production of a Type I difference spectrum and stimulated CO-inhibitable hepatic microsomal NADPH oxidation.	NADP	201-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7115427-2	1982	Incubation of cis- and trans-1,2-dichloroethylene plus hepatic microsomes, NADPH-generating system-EDTA resulted in the production of measurable levels of 2,2-dichloroethanol and dichloroacetaldehyde but not of 2-chloroethanol, chloroacetaldehyde or chloroacetic acid and, also, resulted in decreased levels of hepatic microsomal cytochrome P-450 and heme.	cis- and trans-1,2-dichloroethylene	14-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-355
7115427-2	1982	Incubation of cis- and trans-1,2-dichloroethylene plus hepatic microsomes, NADPH-generating system-EDTA resulted in the production of measurable levels of 2,2-dichloroethanol and dichloroacetaldehyde but not of 2-chloroethanol, chloroacetaldehyde or chloroacetic acid and, also, resulted in decreased levels of hepatic microsomal cytochrome P-450 and heme.	NADP	75-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-355
7115427-2	1982	Incubation of cis- and trans-1,2-dichloroethylene plus hepatic microsomes, NADPH-generating system-EDTA resulted in the production of measurable levels of 2,2-dichloroethanol and dichloroacetaldehyde but not of 2-chloroethanol, chloroacetaldehyde or chloroacetic acid and, also, resulted in decreased levels of hepatic microsomal cytochrome P-450 and heme.	Edetic Acid	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-355
7115427-2	1982	Incubation of cis- and trans-1,2-dichloroethylene plus hepatic microsomes, NADPH-generating system-EDTA resulted in the production of measurable levels of 2,2-dichloroethanol and dichloroacetaldehyde but not of 2-chloroethanol, chloroacetaldehyde or chloroacetic acid and, also, resulted in decreased levels of hepatic microsomal cytochrome P-450 and heme.	2,2-dichloroethanol	155-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-355
7115427-2	1982	Incubation of cis- and trans-1,2-dichloroethylene plus hepatic microsomes, NADPH-generating system-EDTA resulted in the production of measurable levels of 2,2-dichloroethanol and dichloroacetaldehyde but not of 2-chloroethanol, chloroacetaldehyde or chloroacetic acid and, also, resulted in decreased levels of hepatic microsomal cytochrome P-450 and heme.	dichloroacetaldehyde	179-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	330-355
7115427-6	1982	The binding and metabolism of the 1,2-dichloroethylenes and the 1,2-dichloroethylene-mediated inactivation of cytochrome P-450 were enhanced per mg of microsomal protein, but generally not per nmole of cytochrome P-450 by prior induction with beta-naphthoflavone or phenobarbital.	1,2-dichloroethylene	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
7115427-6	1982	The binding and metabolism of the 1,2-dichloroethylenes and the 1,2-dichloroethylene-mediated inactivation of cytochrome P-450 were enhanced per mg of microsomal protein, but generally not per nmole of cytochrome P-450 by prior induction with beta-naphthoflavone or phenobarbital.	1,2-dichloroethylene	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
7115427-6	1982	The binding and metabolism of the 1,2-dichloroethylenes and the 1,2-dichloroethylene-mediated inactivation of cytochrome P-450 were enhanced per mg of microsomal protein, but generally not per nmole of cytochrome P-450 by prior induction with beta-naphthoflavone or phenobarbital.	1,2-dichloroethylene	34-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
7115427-6	1982	The binding and metabolism of the 1,2-dichloroethylenes and the 1,2-dichloroethylene-mediated inactivation of cytochrome P-450 were enhanced per mg of microsomal protein, but generally not per nmole of cytochrome P-450 by prior induction with beta-naphthoflavone or phenobarbital.	beta-Naphthoflavone	243-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
7115427-6	1982	The binding and metabolism of the 1,2-dichloroethylenes and the 1,2-dichloroethylene-mediated inactivation of cytochrome P-450 were enhanced per mg of microsomal protein, but generally not per nmole of cytochrome P-450 by prior induction with beta-naphthoflavone or phenobarbital.	Phenobarbital	266-279	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
7115427-7	1982	It is concluded that multiple forms of hepatic microsomal cytochrome P-450 bind and metabolize the 1,2-dichloroethylenes.	1,2-dichloroethylene	99-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
7115427-8	1982	The role of cytochrome P-450 in the metabolic activation of the dichloroethylenes is considered.	Dichloroethylenes	64-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
7106107-2	1982	A study using laser flash photolysis of the dynamics of the reduction of bacterial cytochrome P-450 in the presence of carbon monoxide.	Carbon Monoxide	119-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7106107-4	1982	The intramolecular photoreduction of the bacterial cytochrome P-450 demonstrated by the formation of the complex of reduced cytochrome m with camphor and CO has been studied by photolysis with a laser flash at 265 nm.	Camphor	142-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
6279597-0	1982	Low temperature EPR spectroscopic characterization of the interaction of cytochrome P-450cam with a spin label analog of metyrapone.	Metyrapone	121-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
6285925-0	1982	Aniline is hydroxylated by the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism.	aniline	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
6285925-0	1982	Aniline is hydroxylated by the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism.	Hydroxyl Radical	58-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
6284506-0	1982	The pressure dependence of the spin equilibrium in camphor-bound ferric cytochrome P-450.	Camphor	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6284506-1	1982	The spin equilibrium of camphor-bound ferric cytochrome P-450 has been measured between 1-1000 bar (10(5)-10(8) Pa).	Camphor	24-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
6284506-7	1982	The correlation can be approximated as delta V = 36 + 18 log K1, which implies that there is a pressure, 3000 bar, for camphor-bound ferric cytochrome P-450 at 4 degrees C, at which the changes in delta V are compensated by the other thermodynamic parameters leaving Ke independent of the solvent conditions.	Camphor	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
6284506-9	1982	Camphor-bound cytochrome P-450 appears to be a rather flexible protein, having a low denaturing pressure, a large volume change, and a high sensitivity to the protein environment.	Camphor	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
6802841-1	1982	A protein-protein association of cytochrome P-450 LM2 with NADPH-cytochrome P-450 reductase, with cytochrome b5, and with both proteins was demonstrated in reconstituted phospholipid vesicles by magnetic circular dichroism difference spectra.	Phospholipids	170-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
6802841-6	1982	Upon incorporation of cytochrome b5 into cytochrome P-450- and cytochrome P-450 reductase-containing vesicles, an increase of benzphetamine N-demethylation activity was observed.	Benzphetamine	126-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
6802841-6	1982	Upon incorporation of cytochrome b5 into cytochrome P-450- and cytochrome P-450 reductase-containing vesicles, an increase of benzphetamine N-demethylation activity was observed.	Benzphetamine	126-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
7093199-11	1982	With sulindac sulfide as substrate, though, both control and phenobarbital-induced microsomes catalyze sulfoxidation to yield the same (+)-sulfoxide enantiomer generated by the purified FAD-containing monoxygenase, suggesting a low degree of participation by the cytochrome P-450 isozymes in sulfoxidation of this compound.	sulindac sulfide	5-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-279
7093199-11	1982	With sulindac sulfide as substrate, though, both control and phenobarbital-induced microsomes catalyze sulfoxidation to yield the same (+)-sulfoxide enantiomer generated by the purified FAD-containing monoxygenase, suggesting a low degree of participation by the cytochrome P-450 isozymes in sulfoxidation of this compound.	Phenobarbital	61-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-279
7113709-8	1982	Strong correlations (r greater than 0.91) were seen only between aminopyrine or ethylmorphine demethylase activity and cytochrome P-450 content in samples obtained within 4 hours of death.	Aminopyrine	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
6980648-0	1982	Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans.	ammonium ferrous sulfate	42-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6980648-7	1982	We conclude that repeated administration of troleandomycin induces microsomal enzymes, produces an inactive cytochrome P-450 Fe(II)-metabolite complex, and decreases the clearance of antipyrine in humans.	Troleandomycin	44-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
6980648-0	1982	Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans.	Troleandomycin	92-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6980648-7	1982	We conclude that repeated administration of troleandomycin induces microsomal enzymes, produces an inactive cytochrome P-450 Fe(II)-metabolite complex, and decreases the clearance of antipyrine in humans.	ammonium ferrous sulfate	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
6980648-1	1982	In rats, it has been shown that troleandomycin induces its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450.	Troleandomycin	32-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-153
6980648-3	1982	In the treated patients, NADPH-cytochrome c reductase activity was increased by 48%; total cytochrome P-450 concentration was also increased, but 33% of total cytochrome P-450 was complexed by a troleandomycin metabolite.	Troleandomycin	195-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
6980648-4	1982	The cytochrome P-450 Fe(II)-metabolite complex exhibited properties identical to those of the inactive complex formed in rats: it exhibited a Soret peak at 456 nm, was unable to bind CO, and was destroyed by addition of 50 microM potassium ferricyanide.	ammonium ferrous sulfate	21-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6980648-4	1982	The cytochrome P-450 Fe(II)-metabolite complex exhibited properties identical to those of the inactive complex formed in rats: it exhibited a Soret peak at 456 nm, was unable to bind CO, and was destroyed by addition of 50 microM potassium ferricyanide.	potassium ferricyanide	230-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6802829-3	1982	A 200% stimulation of N-demethylation by cytochrome b5 was obtained at cytochrome P-450 reductase:cytochrome P-450 ratios similar to those in microsomes, compared to only a 20% stimulation at a ratio of 1:1.	Nitrogen	22-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
6802829-3	1982	A 200% stimulation of N-demethylation by cytochrome b5 was obtained at cytochrome P-450 reductase:cytochrome P-450 ratios similar to those in microsomes, compared to only a 20% stimulation at a ratio of 1:1.	Nitrogen	22-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6802829-7	1982	The function of cytochrome b5 was interpreted in terms of a model in which inhibition of cytochrome P-450-mediated reactions results from changes in phospholipid-protein interactions and activation occurs via facilitation of electron transfer between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane.	Phospholipids	149-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
6954546-3	1982	A single dose of cobalt-heme (125 mumol/kg of body weight) decreased within 48 hr hepatic cytochrome P-450 to approximately 20% of normal, at which level it remained for 10 days; normal levels were not achieved by 36 days.	cobaltiprotoporphyrin	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
7103956-0	1982	Limitations on the metyrapone assay for the major phenobarbital inducible form of cytochrome P-450.	Metyrapone	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
7103956-0	1982	Limitations on the metyrapone assay for the major phenobarbital inducible form of cytochrome P-450.	Phenobarbital	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
6285672-0	1982	Interindividual variation in benzo(a)pyrene metabolism and composition of isoenzymes of cytochrome P-450 as revealed by SDS-gel electrophoresis of human liver microsomal fractions.	Benzo(a)pyrene	29-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
6285672-0	1982	Interindividual variation in benzo(a)pyrene metabolism and composition of isoenzymes of cytochrome P-450 as revealed by SDS-gel electrophoresis of human liver microsomal fractions.	Sodium Dodecyl Sulfate	120-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
6285672-4	1982	One type of human liver microsomal fraction was selectively induced in specimens obtained from patients with known regular drug intake before death and correlated well in molecular weight to the phenobarbital-inducible form of cytochrome P-450 in the rabbit.	Phenobarbital	195-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-243
6954546-4	1982	Periodic administration (total, six injections) of a smaller dose of cobalt-heme (50 mumol/kg of body weight) maintained the cytochrome P-450 content at levels approximately 15% of normal for greater than 90 days with concurrent profound impairment of mono-oxygenase reactions catalyzed by this heme protein.	cobaltiprotoporphyrin	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6954546-4	1982	Periodic administration (total, six injections) of a smaller dose of cobalt-heme (50 mumol/kg of body weight) maintained the cytochrome P-450 content at levels approximately 15% of normal for greater than 90 days with concurrent profound impairment of mono-oxygenase reactions catalyzed by this heme protein.	Heme	76-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
6954546-5	1982	The ability of cobalt-heme to produce profound and prolonged depletion of cytochrome P-450 in vivo provides a valuable model for examining the role of cytochrome P-450-dependent metabolism in the biology of endogenous and exogenous chemicals.	cobaltiprotoporphyrin	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
6954546-5	1982	The ability of cobalt-heme to produce profound and prolonged depletion of cytochrome P-450 in vivo provides a valuable model for examining the role of cytochrome P-450-dependent metabolism in the biology of endogenous and exogenous chemicals.	cobaltiprotoporphyrin	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
7074090-0	1982	Kinetics of hepatic cytochrome P-450 reduction: correlation with spin state of the ferric heme.	ferric heme	83-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
6803794-0	1982	Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid.	Epoxy Compounds	6-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
7074051-0	1982	Oxidation of trichloroethylene by liver microsomal cytochrome P-450: evidence for chlorine migration in a transition state not involving trichloroethylene oxide.	Trichloroethylene	13-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
7074051-0	1982	Oxidation of trichloroethylene by liver microsomal cytochrome P-450: evidence for chlorine migration in a transition state not involving trichloroethylene oxide.	Chlorine	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	Trichloroethylene	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	Trichloroethylene	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	trichloroacetaldehyde	105-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	trichloroacetaldehyde	114-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	glyoxylic acid	145-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	formic acid	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	Carbon Monoxide	174-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-1	1982	Trichloroethylene (TCE) was metabolized by cytochrome P-450 containing mixed-function oxidase systems to chloral (2,2,2,-trichloroacetaldehyde), glyoxylic acid, formic acid, CO, and TCE oxide.	trichloroepoxyethane	182-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7074051-10	1982	The maximum levels of TCE oxide detected in systems using microsomal fractions and purified cytochrome P-450 were 5-28-fold lower than those predicted from the model.	trichloroepoxyethane	22-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
7074051-11	1982	The kinetic data and the discrepancies between the observed metabolites and TCE oxide breakdown products support the view that the epoxide is not an obligate intermediate in the formation of chloral, and an alternative model is presented in which chlorine migration occurs in an oxygenated TCE-cytochrome P-450 transition state.	Chlorine	247-255	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-310
6803794-0	1982	Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid.	Arachidonic Acid	69-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
6803786-0	1982	Mechanisms of hydroxylation by cytochrome P-450: exchange of iron-oxygen intermediates with water.	Iron	61-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
6803786-0	1982	Mechanisms of hydroxylation by cytochrome P-450: exchange of iron-oxygen intermediates with water.	Oxygen	66-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
6803786-0	1982	Mechanisms of hydroxylation by cytochrome P-450: exchange of iron-oxygen intermediates with water.	Water	92-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
7054190-0	1982	Effects of 3-methylcholanthrene, beta-naphthoflavone, and phenobarbital on the 3-methylcholanthrene-inducible isozyme of cytochrome P-450 within centrilobular, midzonal, and periportal hepatocytes.	Methylcholanthrene	11-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7054190-0	1982	Effects of 3-methylcholanthrene, beta-naphthoflavone, and phenobarbital on the 3-methylcholanthrene-inducible isozyme of cytochrome P-450 within centrilobular, midzonal, and periportal hepatocytes.	beta-Naphthoflavone	33-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7054190-0	1982	Effects of 3-methylcholanthrene, beta-naphthoflavone, and phenobarbital on the 3-methylcholanthrene-inducible isozyme of cytochrome P-450 within centrilobular, midzonal, and periportal hepatocytes.	Phenobarbital	58-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
7054190-0	1982	Effects of 3-methylcholanthrene, beta-naphthoflavone, and phenobarbital on the 3-methylcholanthrene-inducible isozyme of cytochrome P-450 within centrilobular, midzonal, and periportal hepatocytes.	Methylcholanthrene	79-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
6896277-4	1982	The decrease in cytochrome P-450 content normally associated with metal administration was, however, prevented, indicating that haem oxygenase induction by metals can proceed without the significant labilization of the haem moiety of cytochrome P-450.	Metals	66-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
7171721-1	1982	Absorption spectra of highly purified liver microsomal cytochrome P-450 in non-equilibrium states were obtained at 77 K by reduction with trapped electrons, formed by gamma-irradiation of the water-glycerol matrix.	Water	192-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
6801662-0	1982	Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids.	Arachidonic Acid	42-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6801662-0	1982	Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids.	hydroxyicosatetraenoic acids	62-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6801662-6	1982	THe isolation of these isomeric HETEs suggests that cytochrome P-450 may play a role in the oxidative metabolism of arachidonic acid to physiologically and pharmacologically important hydroxylated unsaturated fatty acids.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
6801662-6	1982	THe isolation of these isomeric HETEs suggests that cytochrome P-450 may play a role in the oxidative metabolism of arachidonic acid to physiologically and pharmacologically important hydroxylated unsaturated fatty acids.	Fatty Acids, Unsaturated	197-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
7171721-1	1982	Absorption spectra of highly purified liver microsomal cytochrome P-450 in non-equilibrium states were obtained at 77 K by reduction with trapped electrons, formed by gamma-irradiation of the water-glycerol matrix.	Glycerol	198-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
7171721-2	1982	In contrast to the equilibrium form of ferrous cytochrome P-450 with the heme iron in the high-spin state the non-equilibrium ferrous state has a low-spin heme iron.	Heme	73-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
7171721-2	1982	In contrast to the equilibrium form of ferrous cytochrome P-450 with the heme iron in the high-spin state the non-equilibrium ferrous state has a low-spin heme iron.	Iron	78-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
7171721-2	1982	In contrast to the equilibrium form of ferrous cytochrome P-450 with the heme iron in the high-spin state the non-equilibrium ferrous state has a low-spin heme iron.	Heme	155-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
7171721-2	1982	In contrast to the equilibrium form of ferrous cytochrome P-450 with the heme iron in the high-spin state the non-equilibrium ferrous state has a low-spin heme iron.	Iron	160-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
7173298-6	1982	Subjects with a normal liver undergoing treatment with enzyme-inducing drugs, such as phenytoin, phenobarbital and primidone, had higher HDL cholesterol, apoproteins A-I and A-II, HDL cholesterol/total cholesterol ratio, cytochrome P-450 and antipyrine clearance rate than subjects not receiving such therapy.	Phenytoin	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
7044288-2	1982	These toxic effects of thiono-sulfur-containing compounds appear to be at least partially the result of their metabolism to reactive intermediates by the cytochrome P-450-containing monooxygenase enzyme systems.	thiono-sulfur	23-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-170
7044288-3	1982	Covalent binding of (atomic) sulfur released in the cytochrome P-450 monooxygenase catalyzed metabolism of certain thiono-sulfur compounds appears to be responsible for the inhibition of monooxygenase activity and the loss of cytochrome P-450 seen on administration of these thiono-sulfur compounds in vivo or incubation with cytochrome P-450 monooxygenase enzymes in vitro.	Sulfur	29-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
7044288-3	1982	Covalent binding of (atomic) sulfur released in the cytochrome P-450 monooxygenase catalyzed metabolism of certain thiono-sulfur compounds appears to be responsible for the inhibition of monooxygenase activity and the loss of cytochrome P-450 seen on administration of these thiono-sulfur compounds in vivo or incubation with cytochrome P-450 monooxygenase enzymes in vitro.	thiono-sulfur	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
7044288-3	1982	Covalent binding of (atomic) sulfur released in the cytochrome P-450 monooxygenase catalyzed metabolism of certain thiono-sulfur compounds appears to be responsible for the inhibition of monooxygenase activity and the loss of cytochrome P-450 seen on administration of these thiono-sulfur compounds in vivo or incubation with cytochrome P-450 monooxygenase enzymes in vitro.	thiono-sulfur	275-288	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
7044288-5	1982	The rationale for implicating metabolites of thiono-sulfur compounds other than atomic sulfur in these effects derives from the experiments with thioacetamide and the fact that atomic sulfur is highly reactive and appears to bind predominantly or exclusively to cytochrome P-450.	thiono	45-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-278
7044288-5	1982	The rationale for implicating metabolites of thiono-sulfur compounds other than atomic sulfur in these effects derives from the experiments with thioacetamide and the fact that atomic sulfur is highly reactive and appears to bind predominantly or exclusively to cytochrome P-450.	Sulfur	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-278
7151648-3	1982	Fractions containing cytochrome P-450 from placentas from smokers will catalyze 7,8-benzoflavone-inhibitable activity in reconstituted systems.	alpha-naphthoflavone	80-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
7151648-4	1982	SDS polyacryl-amide gel electrophoresis reveals proteins (molecular weight 70,000-40,000) in cytochrome P-450-containing fractions, derived from women who smoke, which are not detected in material from nonsmokers.	Sodium Dodecyl Sulfate	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
7151648-4	1982	SDS polyacryl-amide gel electrophoresis reveals proteins (molecular weight 70,000-40,000) in cytochrome P-450-containing fractions, derived from women who smoke, which are not detected in material from nonsmokers.	polyacrylamide	4-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6118314-5	1982	High binding affinity of cimetidine for cytochrome P 450(Ks = 31 micro M) was seen, while no evidence for ranitidine binding to cytochrome P450- was observed.	Cimetidine	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
7173298-6	1982	Subjects with a normal liver undergoing treatment with enzyme-inducing drugs, such as phenytoin, phenobarbital and primidone, had higher HDL cholesterol, apoproteins A-I and A-II, HDL cholesterol/total cholesterol ratio, cytochrome P-450 and antipyrine clearance rate than subjects not receiving such therapy.	Phenobarbital	97-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
7173298-6	1982	Subjects with a normal liver undergoing treatment with enzyme-inducing drugs, such as phenytoin, phenobarbital and primidone, had higher HDL cholesterol, apoproteins A-I and A-II, HDL cholesterol/total cholesterol ratio, cytochrome P-450 and antipyrine clearance rate than subjects not receiving such therapy.	Primidone	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
7173298-8	1982	In the entire population, and also in subjects not taking inducing drugs, when considered separately, plasma HDL cholesterol, apoproteins A-I and A-II and the HDL cholesterol/total cholesterol ratio were significantly correlated with cytochrome P-450 concentration.	Cholesterol	113-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-250
7173298-8	1982	In the entire population, and also in subjects not taking inducing drugs, when considered separately, plasma HDL cholesterol, apoproteins A-I and A-II and the HDL cholesterol/total cholesterol ratio were significantly correlated with cytochrome P-450 concentration.	Cholesterol	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-250
7173298-8	1982	In the entire population, and also in subjects not taking inducing drugs, when considered separately, plasma HDL cholesterol, apoproteins A-I and A-II and the HDL cholesterol/total cholesterol ratio were significantly correlated with cytochrome P-450 concentration.	Cholesterol	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-250
6270145-6	1981	The phenobarbital-mediated induction of cytochrome P-450 hemoprotein(s) and its monooxygenase function were concomitantly diminished by glucose.	Phenobarbital	4-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
6300027-1	1982	Complementary (c)DNA clones of phenobarbital-inducible cytochrome P-450 which has a strong activity toward metabolic activation of aflatoxin B1 were identified by a hybridization-arrested translation assay and a positive hybridization-translation assay.	Phenobarbital	31-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
6300027-1	1982	Complementary (c)DNA clones of phenobarbital-inducible cytochrome P-450 which has a strong activity toward metabolic activation of aflatoxin B1 were identified by a hybridization-arrested translation assay and a positive hybridization-translation assay.	Aflatoxin B1	131-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
6300027-5	1982	Fourteen nucleotide substitutions occur in their 922 overlapping nucleotides and 7 of them result in 6 amino acid replacements, therefore indicating the presence of at least two similar but distinct mRNAs for phenobarbital-inducible cytochrome P-450.	Phenobarbital	209-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	233-249
6270145-6	1981	The phenobarbital-mediated induction of cytochrome P-450 hemoprotein(s) and its monooxygenase function were concomitantly diminished by glucose.	Glucose	136-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
6270145-8	1981	Glucagon and dibutyryl cAMP enhanced the induction of ALA synthase and cytochrome P-450 by phenobarbital and partially counteracted the glucose effect on both enzymes suggesting that the glucose effect may be mediated by changes in cAMP levels.	Glucagon	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
6270145-8	1981	Glucagon and dibutyryl cAMP enhanced the induction of ALA synthase and cytochrome P-450 by phenobarbital and partially counteracted the glucose effect on both enzymes suggesting that the glucose effect may be mediated by changes in cAMP levels.	Cyclic AMP	23-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
6270145-8	1981	Glucagon and dibutyryl cAMP enhanced the induction of ALA synthase and cytochrome P-450 by phenobarbital and partially counteracted the glucose effect on both enzymes suggesting that the glucose effect may be mediated by changes in cAMP levels.	Phenobarbital	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
6270145-8	1981	Glucagon and dibutyryl cAMP enhanced the induction of ALA synthase and cytochrome P-450 by phenobarbital and partially counteracted the glucose effect on both enzymes suggesting that the glucose effect may be mediated by changes in cAMP levels.	Glucose	187-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
6274987-0	1981	Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria.	C 27	28-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6274987-0	1981	Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria.	Steroids	32-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6274987-0	1981	Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria.	Cholecalciferol	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6274987-1	1981	The present study was undertaken to obtain information on the involvement of cytochrome P-450 in the 26-hydroxylation on bile acid intermediates and in the 25-hydroxylation of vitamin D3 in human liver mitochondria.	Bile Acids and Salts	121-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
6274987-7	1981	The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase.	Steroids	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6274987-7	1981	The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase.	Cholecalciferol	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6274987-7	1981	The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase.	NADP	135-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6274987-11	1981	It is concluded that human liver mitochondria contain cytochrome P-450 involved in the oxidation of the side chain of C27-steroids and vitamin D3.	C 27	118-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
6274987-11	1981	It is concluded that human liver mitochondria contain cytochrome P-450 involved in the oxidation of the side chain of C27-steroids and vitamin D3.	Steroids	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
6274987-11	1981	It is concluded that human liver mitochondria contain cytochrome P-450 involved in the oxidation of the side chain of C27-steroids and vitamin D3.	Cholecalciferol	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
6457649-0	1981	Comparison of the effects of inhibitors of cytochrome P-450-mediated reactions on human platelet aggregation and arachidonic acid metabolism.	Arachidonic Acid	113-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
6797104-1	1981	Phenobarbital stimulates the induction of liver microsomal drug-metabolizing enzyme, namely, cytochrome P-450, which enhances the rate of conversion of FT-207 to 5-FU, the active substance.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6797104-1	1981	Phenobarbital stimulates the induction of liver microsomal drug-metabolizing enzyme, namely, cytochrome P-450, which enhances the rate of conversion of FT-207 to 5-FU, the active substance.	Tegafur	152-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6797104-1	1981	Phenobarbital stimulates the induction of liver microsomal drug-metabolizing enzyme, namely, cytochrome P-450, which enhances the rate of conversion of FT-207 to 5-FU, the active substance.	Fluorouracil	162-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
6797104-2	1981	When FT-207 is administered in combination with phenobarbital to cancer patients, the fluctuation in level of the drug-metabolizing enzyme, cytochrome P-450, should be taken into consideration.	Phenobarbital	48-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
7295780-2	1981	MCD was applied to ferric and ferrous low-spin complexes of cytochrome P-450 cam to elucidate the electronic states and the nature of the axial ligands of the heme in cytochrome P-450cam.	Heme	159-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
7295780-6	1981	The ratio (4.2) for the alpha-picoline-bound form of cytochrome P-450cam, however, was the closest to that (2.7) for the camphor-free form of cytochrome P-450cam among those (4.2-9.0) for the external ligand-bound form of cytochrome P-450cam.	Picolines	24-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
7295780-6	1981	The ratio (4.2) for the alpha-picoline-bound form of cytochrome P-450cam, however, was the closest to that (2.7) for the camphor-free form of cytochrome P-450cam among those (4.2-9.0) for the external ligand-bound form of cytochrome P-450cam.	Camphor	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
7295780-7	1981	The ratio for the 2-methylimidazole-bound form of cytochrome P-450cam was the smallest among those of cytochrome P-450cam bound with imidizole derivatives.	2-methylimidazole	18-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6457649-1	1981	Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets.	Metyrapone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
7295780-7	1981	The ratio for the 2-methylimidazole-bound form of cytochrome P-450cam was the smallest among those of cytochrome P-450cam bound with imidizole derivatives.	imidizole	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6457649-1	1981	Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets.	Proadifen	15-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
6457649-1	1981	Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets.	amphenone B	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
6457649-1	1981	Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets.	Metyrapone	77-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
6457649-1	1981	Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets.	Arachidonic Acid	180-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
6457649-7	1981	These data provide further support for a role of cytochrome P-450 in thromboxane synthesis and platelet aggregation.	Thromboxanes	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
6797432-0	1981	Ethanol-mediated increase in cytochrome P-450 in cultured hepatocytes.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6272881-1	1981	The Cu-tyrosine complex, a low molecular weight analog of superoxide dismutase, exerts an inhibiting effect on cytochrome P-450.	copper(II)-tyrosine complex	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
7285242-4	1981	The binding of type I compounds, hexobarbital and androstanedione, with cytochrome P-450, as determined by the magnitude of the type I spectral change of microsomes, was markedly enhanced at alkaline pH compared to that at acid pH.	Hexobarbital	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6272881-3	1981	In case of p-hydroxylation of aniline the inhibiting effect of the Cu-tyrosine complex is much more pronounced than its inactivating effect on cytochrome P-450.	aniline	30-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
6272881-3	1981	In case of p-hydroxylation of aniline the inhibiting effect of the Cu-tyrosine complex is much more pronounced than its inactivating effect on cytochrome P-450.	copper(II)-tyrosine complex	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
6272881-6	1981	In a soluble system containing isolated cytochrome P-450 and cumole hydroperoxide only the aniline p-hydroxylation reaction was found sensitive to the effect of superoxide dismutase.	aniline	91-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
7285242-4	1981	The binding of type I compounds, hexobarbital and androstanedione, with cytochrome P-450, as determined by the magnitude of the type I spectral change of microsomes, was markedly enhanced at alkaline pH compared to that at acid pH.	Androstanedione	50-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
7285242-8	1981	On the contrary, the absorbance magnitude between peak and trough in the aniline- or alcohol-induced difference spectrum of microsomes was enhanced by decreasing the pH, indicating easy complex formation of type II and reverse type I compounds with cytochrome P-450 in the acid rather than the alkaline region.	aniline	73-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-265
7285242-8	1981	On the contrary, the absorbance magnitude between peak and trough in the aniline- or alcohol-induced difference spectrum of microsomes was enhanced by decreasing the pH, indicating easy complex formation of type II and reverse type I compounds with cytochrome P-450 in the acid rather than the alkaline region.	Alcohols	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-265
6796087-0	1981	1-Chloro-2,2,2-trifluoroethyl radical: Formation from halothane by human cytochrome P-450 in reconstituted vesicles and binding to phospholipids.	1-chloro-2,2,2-trifluoroethyl radical	0-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
7295776-2	1981	Reduced P-450SCC at pH 7.4 exhibited the V4 line at 1342 cm-1, which is an unusually low frequency compared with an ordinary protohemoprotein but is common to the family of cytochrome P-450, suggesting the coordination of a strong pi-donor such as thiolate anion at the fifth coordination position of the heme iron.	thiolate anion	248-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
7295776-2	1981	Reduced P-450SCC at pH 7.4 exhibited the V4 line at 1342 cm-1, which is an unusually low frequency compared with an ordinary protohemoprotein but is common to the family of cytochrome P-450, suggesting the coordination of a strong pi-donor such as thiolate anion at the fifth coordination position of the heme iron.	Heme	305-309	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
7295776-2	1981	Reduced P-450SCC at pH 7.4 exhibited the V4 line at 1342 cm-1, which is an unusually low frequency compared with an ordinary protohemoprotein but is common to the family of cytochrome P-450, suggesting the coordination of a strong pi-donor such as thiolate anion at the fifth coordination position of the heme iron.	Iron	310-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-189
7295776-6	1981	In the presence of 20alpha-hydroxycholesterol, oxidized P-450SCC gave the V10 line at 1637 cm-1, i.e., at a frequency similar to that of low-spin type cytochrome P-450.	20-hydroxycholesterol	19-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
6796087-0	1981	1-Chloro-2,2,2-trifluoroethyl radical: Formation from halothane by human cytochrome P-450 in reconstituted vesicles and binding to phospholipids.	Halothane	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
21043244-8	1981	Studies on the effects of the in vitro modifiers of monooxygenase activity alpha-naphthoflavone and metyrapone further supported the hypothesis that the two phases of O-deethylase activity represent two different forms or populations of cytochrome P-450.	alpha-naphthoflavone	75-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-253
21043244-8	1981	Studies on the effects of the in vitro modifiers of monooxygenase activity alpha-naphthoflavone and metyrapone further supported the hypothesis that the two phases of O-deethylase activity represent two different forms or populations of cytochrome P-450.	Metyrapone	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-253
6897891-2	1981	It follows that alterations in the activities of the enzymes of heme metabolism are often reflected in the heme dependent cellular functions, particularly those which depend on cytochrome P-450.	Heme	64-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
7285236-0	1981	Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation.	Ellipticines	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
7285236-2	1981	Some pharmacological properties of ellipticine (E) and its derivatives linked to their interaction with cytochrome P-450 have been investigated with human liver microsomes.	ellipticine	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
7285236-3	1981	9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM).	9-hydroxyellipticine	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
7285236-3	1981	9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM).	9-hydroxyellipticine	22-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
7297566-12	1981	The monooxygenase activities, the sensitivity to in vitro alpha-naphthoflavone and metyrapone, the results of steroid metabolism, and slab gel electrophoresis are strong indications for multiplicity of human liver cytochrome P-450.	alpha-naphthoflavone	58-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
7297566-12	1981	The monooxygenase activities, the sensitivity to in vitro alpha-naphthoflavone and metyrapone, the results of steroid metabolism, and slab gel electrophoresis are strong indications for multiplicity of human liver cytochrome P-450.	Metyrapone	83-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
7297566-12	1981	The monooxygenase activities, the sensitivity to in vitro alpha-naphthoflavone and metyrapone, the results of steroid metabolism, and slab gel electrophoresis are strong indications for multiplicity of human liver cytochrome P-450.	Steroids	110-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-230
6897891-2	1981	It follows that alterations in the activities of the enzymes of heme metabolism are often reflected in the heme dependent cellular functions, particularly those which depend on cytochrome P-450.	Heme	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
6897891-3	1981	Moreover, perturbations in cellular GSH levels may alter the biological inactivation of the intermediates of cytochrome P-450 activity normally inactivated by GSH-conjugation.	Glutathione	36-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
6897891-3	1981	Moreover, perturbations in cellular GSH levels may alter the biological inactivation of the intermediates of cytochrome P-450 activity normally inactivated by GSH-conjugation.	Glutathione	159-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
7196447-4	1981	The involvement of the cytochrome P-450 system in the activation of 6-thiopurine to the chemically reactive metabolite was supported by the effects of inhibitors of cytochrome P-450 mediated reactions and phenobarbital induction.	Mercaptopurine	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
7196447-4	1981	The involvement of the cytochrome P-450 system in the activation of 6-thiopurine to the chemically reactive metabolite was supported by the effects of inhibitors of cytochrome P-450 mediated reactions and phenobarbital induction.	Mercaptopurine	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
7196447-4	1981	The involvement of the cytochrome P-450 system in the activation of 6-thiopurine to the chemically reactive metabolite was supported by the effects of inhibitors of cytochrome P-450 mediated reactions and phenobarbital induction.	Phenobarbital	205-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
6946467-4	1981	These results suggest that each molecular form of cytochrome P-450 that converts antipyrine to a different metabolite exhibits genetically controlled interindividual variations in activity.	Antipyrine	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
6272772-0	1981	Glutathione-hemin complex as a cytochrome P-450 model characterization of the complex and its aromatic oxidation activities.	glutathione-hemin	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
7271831-0	1981	Cytochrome P-450-dependent metabolism of 1,1,2,2-tetrachloroethane to dichloroacetic acid in vitro.	1,1,2,2-tetrachloroethane	41-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
6114841-0	1981	Is a photo-oxidation product of histidine one of the triggers of induction of cytochrome P-450 drug-metabolizing enzyme systems?	Histidine	32-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
7288293-1	1981	Cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme for bile acid synthesis, was shown to be copurified with human liver microsomal cytochrome P-450.	Bile Acids and Salts	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-154
7288293-2	1981	When these cytochrome P-450 species were reconstituted in phospholipid-cholesterol vesicles together with NADPH-cytochrome P-450 reductase, high cholesterol 7 alpha-hydroxylase activity was obtained in the presence of NADPH.	Phospholipids	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
7288293-2	1981	When these cytochrome P-450 species were reconstituted in phospholipid-cholesterol vesicles together with NADPH-cytochrome P-450 reductase, high cholesterol 7 alpha-hydroxylase activity was obtained in the presence of NADPH.	NADP	106-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
7271831-0	1981	Cytochrome P-450-dependent metabolism of 1,1,2,2-tetrachloroethane to dichloroacetic acid in vitro.	Dichloroacetic Acid	70-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7250371-0	1981	Effects of dietary lipid and phenobarbitone on the distribution and concentration of cytochrome P-450 in the liver studied by quantitative cytochemistry.	Phenobarbital	29-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7262071-4	1981	This establishes a role for cytochrome b5 in donating electrons for the reduction of oxy-cytochrome P-450 to the active oxygen complex of cytochrome P-450 but also points to large variations in the importance of this role depending on the experimental conditions, the species of P-450 involved and the substrates employed.	Oxygen	120-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
7262071-4	1981	This establishes a role for cytochrome b5 in donating electrons for the reduction of oxy-cytochrome P-450 to the active oxygen complex of cytochrome P-450 but also points to large variations in the importance of this role depending on the experimental conditions, the species of P-450 involved and the substrates employed.	Oxygen	120-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-154
6264953-0	1981	Phospholipid interactions with cytochrome P-450 in reconstituted vesicles.	Phospholipids	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
7217086-0	1981	Destruction of cytochrome P-450 by ethylene.	ethylene	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
7217086-2	1981	The prosthetic heme of cytochrome P-450 is converted during the metabolism of ethylene into an abnormal hepatic porphyrin.	Heme	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
7217086-2	1981	The prosthetic heme of cytochrome P-450 is converted during the metabolism of ethylene into an abnormal hepatic porphyrin.	ethylene	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
7217086-6	1981	Strong support is provided by the structure of this porphyrin for our contention that the prosthetic heme of cytochrome P-450 is alkylated during attempted transfer of the catalytically-activated oxygen to the pi-bond of destructive unsaturated substrates.	Heme	101-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
7217086-6	1981	Strong support is provided by the structure of this porphyrin for our contention that the prosthetic heme of cytochrome P-450 is alkylated during attempted transfer of the catalytically-activated oxygen to the pi-bond of destructive unsaturated substrates.	Oxygen	196-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
7296714-0	1981	Oxidative dealkylation of tertiary amines by iron(III) porphyrin-iodosoxylene system as a model of cytochrome P-450.	Amines	35-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
6973977-0	1981	Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450.	Troleandomycin	18-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
7296714-0	1981	Oxidative dealkylation of tertiary amines by iron(III) porphyrin-iodosoxylene system as a model of cytochrome P-450.	iron(iii) porphyrin	45-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7296714-0	1981	Oxidative dealkylation of tertiary amines by iron(III) porphyrin-iodosoxylene system as a model of cytochrome P-450.	iodosoxylene	65-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7297957-1	1981	Hemoglobin and cytochrome P-450 have in common heme structure (i.e. protoporphyrin (IX), binding ability to molecular oxygen or carbon monoxide and enzyme-like activity (i.e. aniline hydroxylation; J.B.C.	Heme	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
7297957-1	1981	Hemoglobin and cytochrome P-450 have in common heme structure (i.e. protoporphyrin (IX), binding ability to molecular oxygen or carbon monoxide and enzyme-like activity (i.e. aniline hydroxylation; J.B.C.	protoporphyrin IX	68-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
7297957-1	1981	Hemoglobin and cytochrome P-450 have in common heme structure (i.e. protoporphyrin (IX), binding ability to molecular oxygen or carbon monoxide and enzyme-like activity (i.e. aniline hydroxylation; J.B.C.	Oxygen	118-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
7297957-1	1981	Hemoglobin and cytochrome P-450 have in common heme structure (i.e. protoporphyrin (IX), binding ability to molecular oxygen or carbon monoxide and enzyme-like activity (i.e. aniline hydroxylation; J.B.C.	Carbon Monoxide	128-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
7297957-1	1981	Hemoglobin and cytochrome P-450 have in common heme structure (i.e. protoporphyrin (IX), binding ability to molecular oxygen or carbon monoxide and enzyme-like activity (i.e. aniline hydroxylation; J.B.C.	aniline	175-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
6786868-2	1981	Many xenobiotics inhibit steroid hormone production as a result of interactions with cytochrome P-450-containing hydroxylases in adrenal mitochondria or microsomes.	Steroids	25-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7233442-0	1981	Depression of cytochrome P-450-dependent drug biotransformation by adriamycin.	Doxorubicin	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
6973978-0	1981	Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration.	Troleandomycin	39-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
6783456-0	1981	Electrophoretically homogeneous cytochrome P-450: influence of a series of unsaturated fatty acids on the reconstituted hydroxylase activity.	Fatty Acids, Unsaturated	75-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
6784732-0	1981	Effects of indole and tryptophan on cytochrome P-450, dimethylnitrosamine demethylase, and arylhydrocarbon hydroxylase activities.	indole	11-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-85
6784732-0	1981	Effects of indole and tryptophan on cytochrome P-450, dimethylnitrosamine demethylase, and arylhydrocarbon hydroxylase activities.	Tryptophan	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-85
7448777-5	1981	These results suggest that the inhibitory effects of quercetin, morin, and kaempferol on monooxygenase activity may be caused at least in part by an inhibition in the reduction of cytochrome P-450.	Quercetin	53-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
6894611-4	1981	Concomitant with heme oxygenase induction by antimony, microsomal heme and cytochrome P-450 contents decreased, the cyto-chrome P-450-dependent mixed function oxidase system was impaired, and delta-ami-nolevulinate synthase (ALAS), the rate-limiting enzyme of heme synthesis, underwent the sequential changes-initial inhibition followed by rebound induction-usually associated with the administration of transition elements such as cobalt.	Heme	17-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
7344478-0	1981	Regio- and stereoselectivity of hepatic cytochrome P-450 toward polycyclic aromatic hydrocarbon substrates.	Polycyclic Aromatic Hydrocarbons	64-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
7344478-1	1981	Although the cytochrome P-450 system shows broad substrate specificity toward the PAH, it also has regio- and stereoselectivity.	Polycyclic Aromatic Hydrocarbons	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
7344478-3	1981	Interestingly, the cytochrome P-450 system and epoxide hydrolase favor the formation of dihydrodiols with R,R configuration.	trans-1,2-dihydro-1,2-naphthalenediol	88-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
7344490-0	1981	The cytochrome P-450-mediated metabolism of biphenyl and the 4-halobiphenyls.	halobiphenyls	63-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
7344518-4	1981	Studies in vitro and in vivo indicate that cytochrome P-450 enzymes in the target tissues mediate the formation of highly reactive, electrophilic furan metabolites that bind covalently to tissue macromolecules.	furan	146-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
6124093-0	1981	Reaction schemes for the degradation of cytochrome P-450 by allyl-iso-propylacetamide and fluroxene.	Allylisopropylacetamide	60-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
6124093-0	1981	Reaction schemes for the degradation of cytochrome P-450 by allyl-iso-propylacetamide and fluroxene.	fluroxene	90-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
7285278-0	1981	Chloroethanes : their metabolism by hepatic cytochrome P-450 in vitro.	Ethyl Chloride	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
7285278-3	1981	Both NADPH oxidation and metabolite production are inhibited by CO, SKF 525A and/or metyrapone The induction of cytochrome P-450 with phenobarbital enhances the binding and metabolism of the chloroalkanes, while the induction of cytochrome P-448 with beta-naphthoflavone does not.	NADP	5-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7285278-3	1981	Both NADPH oxidation and metabolite production are inhibited by CO, SKF 525A and/or metyrapone The induction of cytochrome P-450 with phenobarbital enhances the binding and metabolism of the chloroalkanes, while the induction of cytochrome P-448 with beta-naphthoflavone does not.	Metyrapone	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7285278-3	1981	Both NADPH oxidation and metabolite production are inhibited by CO, SKF 525A and/or metyrapone The induction of cytochrome P-450 with phenobarbital enhances the binding and metabolism of the chloroalkanes, while the induction of cytochrome P-448 with beta-naphthoflavone does not.	Phenobarbital	134-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7285278-3	1981	Both NADPH oxidation and metabolite production are inhibited by CO, SKF 525A and/or metyrapone The induction of cytochrome P-450 with phenobarbital enhances the binding and metabolism of the chloroalkanes, while the induction of cytochrome P-448 with beta-naphthoflavone does not.	chloroalkanes	191-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7285278-3	1981	Both NADPH oxidation and metabolite production are inhibited by CO, SKF 525A and/or metyrapone The induction of cytochrome P-450 with phenobarbital enhances the binding and metabolism of the chloroalkanes, while the induction of cytochrome P-448 with beta-naphthoflavone does not.	beta-Naphthoflavone	251-270	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7285278-4	1981	1,1,1-trichloroethane is converted to 2,2,2-trichloroethanol by hepatic microsomal cytochrome P-450, while the major metabolites of 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane from this enzyme system are mono- and dichloroacetate, respectively.	1,1,1-trichloroethane	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7285278-4	1981	1,1,1-trichloroethane is converted to 2,2,2-trichloroethanol by hepatic microsomal cytochrome P-450, while the major metabolites of 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane from this enzyme system are mono- and dichloroacetate, respectively.	2,2,2-trichloroethanol	38-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7285278-4	1981	1,1,1-trichloroethane is converted to 2,2,2-trichloroethanol by hepatic microsomal cytochrome P-450, while the major metabolites of 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane from this enzyme system are mono- and dichloroacetate, respectively.	1,1,2-trichloroethane	132-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7448777-5	1981	These results suggest that the inhibitory effects of quercetin, morin, and kaempferol on monooxygenase activity may be caused at least in part by an inhibition in the reduction of cytochrome P-450.	kaempferol	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
7285278-4	1981	1,1,1-trichloroethane is converted to 2,2,2-trichloroethanol by hepatic microsomal cytochrome P-450, while the major metabolites of 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane from this enzyme system are mono- and dichloroacetate, respectively.	1,1,2,2-tetrachloroethane	158-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7285278-4	1981	1,1,1-trichloroethane is converted to 2,2,2-trichloroethanol by hepatic microsomal cytochrome P-450, while the major metabolites of 1,1,2-trichloroethane and 1,1,2,2-tetrachloroethane from this enzyme system are mono- and dichloroacetate, respectively.	mono- and dichloroacetate	212-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
7251630-6	1981	Dialkylnitrosamines are shown to be activated by oxidative dealkylation via cytochrome P-450 enzyme systems.	dialkylnitrosamines	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
7308271-5	1981	Alcohol excess was associated with decreased cytochrome P-450 content and AHH activity and this effect was independent of the histological status of the biopsy.	Alcohols	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
7341283-9	1981	It is concluded that this provides evidence for the involvement of at least two different forms of cytochrome P-450 in antipyrine metabolism in man.	Antipyrine	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7450397-1	1981	The aim of this study was to look for correlations between the metabolic clearance rate of antipyrine and (a) the concentration of cytochrome P-450, and (b) the NADPH cytochrome c reductase, aminopyrine demethylase, and aniline hydroxylase activities in the liver microsomes of 20 patients without liver diseases.	Antipyrine	91-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
7267701-6	1981	It is concluded that different species of the drug-oxidizing enzymes (cytochrome P-450 system) are involved in the metabolism of debrisoquine and antipyrine.	Debrisoquin	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
7267701-6	1981	It is concluded that different species of the drug-oxidizing enzymes (cytochrome P-450 system) are involved in the metabolism of debrisoquine and antipyrine.	Antipyrine	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
7256785-2	1981	The increase in 1,8-ANS binding is in accordance with the simultaneous increase of the ethoxycoumarin O-de-ethylase activity and cytochrome P-450 concentration.	1-anilino-8-naphthalenesulfonate	16-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
7256785-6	1981	The data suggest that chronic ethanol administration may effect the biotransformation enzyme activities by changing the structural properties of the membranes as well as increasing the cytochrome P-450 concentration.	Ethanol	30-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-201
6894538-3	1980	The decreases in cytochrome P-450 and haem contents and the sequential changes in delta-aminolaevulinate synthase (EC 2.3.1.37) activity that occur concomitant with haem oxygenase induction were largely eliminated with simultaneous or prior treatment with Mn2+ or Zn2+, but not when Mn2+ or Zn2+ was administered after Sn2+ or Ni2+.	Manganese(2+)	256-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
6111318-0	1980	Role of hepatic microsomal cytochrome P-450 in the toxicity of fluorinated ether anesthetics.	ether anesthetics	75-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
6894538-6	1980	The Zn2+ blockade of Cd2+ induction was examined in detail, and prior or simultaneous administration of Zn2+ was found to be effective in blocking the induction of haem oxygenase and the concomitant decreases in cytochrome P-450 and haem contents, ethylmorphine demethylase activity and the sequential changes in delta-aminolaevulinate synthase activity.	Zinc	104-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-228
7408405-7	1980	It is suggested that N-demethylation of theophylline to 3MX and 1MU is catalyzed by a different form of cytochrome P-450 than that involved in the 8-hydroxylation to DMU.	Theophylline	40-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
7408405-7	1980	It is suggested that N-demethylation of theophylline to 3MX and 1MU is catalyzed by a different form of cytochrome P-450 than that involved in the 8-hydroxylation to DMU.	1,3-dimethyluric acid	166-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
16661486-0	1980	Time Course of Induction of Cytochrome P-450, NADPH-Cytochrome c Reductase, and Cinnamic Acid Hydroxylase by Phenobarbital, Ethanol, Herbicides, and Manganese in Higher Plant Microsomes.	Phenobarbital	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
16661486-0	1980	Time Course of Induction of Cytochrome P-450, NADPH-Cytochrome c Reductase, and Cinnamic Acid Hydroxylase by Phenobarbital, Ethanol, Herbicides, and Manganese in Higher Plant Microsomes.	Ethanol	124-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
16661486-0	1980	Time Course of Induction of Cytochrome P-450, NADPH-Cytochrome c Reductase, and Cinnamic Acid Hydroxylase by Phenobarbital, Ethanol, Herbicides, and Manganese in Higher Plant Microsomes.	Manganese	149-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
16661486-2	1980	Although the microsomal hydroxylating complex is already induced by the slicing and aging process, 25 millimolar MnCl(2), 4 millimolar phenobarbital, and 300 millimolar ethanol caused a marked increase of hydroxylase activity and cytochrome P-450 content and shifted their time course.	manganese chloride	113-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
16661486-2	1980	Although the microsomal hydroxylating complex is already induced by the slicing and aging process, 25 millimolar MnCl(2), 4 millimolar phenobarbital, and 300 millimolar ethanol caused a marked increase of hydroxylase activity and cytochrome P-450 content and shifted their time course.	Phenobarbital	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
16661486-2	1980	Although the microsomal hydroxylating complex is already induced by the slicing and aging process, 25 millimolar MnCl(2), 4 millimolar phenobarbital, and 300 millimolar ethanol caused a marked increase of hydroxylase activity and cytochrome P-450 content and shifted their time course.	Ethanol	169-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-246
6779432-3	1980	In addition the in vitro inhibition of 7-ethoxycoumarin-deethylase by metyrapone (phenobarbital induced cytochrome P-450) or naphthoflavone (benzo[a]pyrene induced cytochrome P-448) was estimated.	Metyrapone	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
6773745-2	1980	This activity employs cytochrome P-450 as an oxygen donor.	Oxygen	45-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
7437045-0	1980	Iron-porphyrin catalysis of the oxidative dealkylation of para-nitro-anisole and 7-ethoxycoumarin by cumylhydroperoxide: a possible model for the corresponding cytochrome P 450-dependent reactions.	iron-porphyrin	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
6779432-3	1980	In addition the in vitro inhibition of 7-ethoxycoumarin-deethylase by metyrapone (phenobarbital induced cytochrome P-450) or naphthoflavone (benzo[a]pyrene induced cytochrome P-448) was estimated.	Phenobarbital	82-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
7437045-0	1980	Iron-porphyrin catalysis of the oxidative dealkylation of para-nitro-anisole and 7-ethoxycoumarin by cumylhydroperoxide: a possible model for the corresponding cytochrome P 450-dependent reactions.	4-nitroanisole	58-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
7437045-0	1980	Iron-porphyrin catalysis of the oxidative dealkylation of para-nitro-anisole and 7-ethoxycoumarin by cumylhydroperoxide: a possible model for the corresponding cytochrome P 450-dependent reactions.	7-ethoxycoumarin	81-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
7437045-0	1980	Iron-porphyrin catalysis of the oxidative dealkylation of para-nitro-anisole and 7-ethoxycoumarin by cumylhydroperoxide: a possible model for the corresponding cytochrome P 450-dependent reactions.	cumene hydroperoxide	101-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
7391085-0	1980	The kinetics of reduction of cytochrome P-450cam by the dithionite anion monomer.	dithionite anion	56-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
7236798-1	1980	This secondary structure of soluble cytochrome P-450 and the one incorporated into liposomes from egg lecithin and microsomal lipids has been studied.	Lecithins	102-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
7236798-3	1980	The binding of haemoprotein with the type II substrates--octylamine and diaminooctan, slightly increases alpha-helices in soluble cytochrome P-450.	octylamine	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
7236798-3	1980	The binding of haemoprotein with the type II substrates--octylamine and diaminooctan, slightly increases alpha-helices in soluble cytochrome P-450.	diaminooctan	72-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
7236798-5	1980	Cytochrome P-450 incorporated into the artificial membranes of phosphatidyl choline and microsomal phospholipid has almost identical secondary structure as does the soluble one.	Phosphatidylcholines	63-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7236798-5	1980	Cytochrome P-450 incorporated into the artificial membranes of phosphatidyl choline and microsomal phospholipid has almost identical secondary structure as does the soluble one.	Phospholipids	99-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7236798-6	1980	Data from circular dichroism suggest that the binding of the types I and II substrates to cytochrome P-450 incorporated into lecithin liposomes and microsomal lipid liposomes does not change the conformation of the polypeptide chain.	Lecithins	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
6105054-0	1980	Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.	Benzo(a)pyrene	66-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
7192358-6	1980	Addition of BHA to the medium inhibited growth of the culture on glucose and biosynthesis of cytochrome P-450 in these cells.	benzohydroxamic acid	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
7192358-8	1980	Apparently, hydroxamic acids can affect the operation of the microsomal monooxigenase system containing cytochrome P-450.	Hydroxamic Acids	12-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
6771263-2	1980	Two N,N-dimethylphentermine (N,N-dimethyl-2-amino-2-methyl-3-phenylpropane) substrates differing in deuterium substitution have been used to determine the intermolecular and intramolecular isotope effects associated with the cytochrome P-450-dependent N-demethylation of this substrate.	n,n-dimethyl-2-amino-2-methyl-3-phenylpropane	29-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-241
6105054-0	1980	Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.	7-ethoxycoumarin	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
6105054-4	1980	The correlation of cytochrome P-450 content with aryl hydrocarbon hydroxylase activity in human liver biopsy samples was relatively good (r = 0.75, p &lt; 0.001), but that with 7-ethoxycoumarin O-de-ethylase activity was much poorer (r = 0.42, p &lt; 0.001).	7-ethoxycoumarin	177-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
6105054-6	1980	This poor correlation was caused mainly by the nonequal effects of polycyclic aromatic hydrocarbons on cytochrome P-450 and aryl hydrocarbon hydroxylase.	Polycyclic Aromatic Hydrocarbons	67-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-152
7391974-0	1980	The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines.	1,1-disubstituted hydrazines	95-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
7379213-5	1980	The finding that singlet oxygen will oxidise a cell constituent into a powerful inducer is compatible with the hypothesis that excited states of oxygen and their oxidation products may play a central role in the induction of cytochrome P-450 and associated enzyme activities by many chemically unrelated inducers.	Singlet Oxygen	17-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-241
7379213-5	1980	The finding that singlet oxygen will oxidise a cell constituent into a powerful inducer is compatible with the hypothesis that excited states of oxygen and their oxidation products may play a central role in the induction of cytochrome P-450 and associated enzyme activities by many chemically unrelated inducers.	Oxygen	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-241
6772704-1	1980	The first step in ethanol metabolism is carried out by two enzyme systems: Alcohol dehydrogenase and cytochrome P-450.	Ethanol	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
7391953-0	1980	Ligand interaction of sustituted pyridines with cytochrome P-450.	Pyridines	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
7391953-1	1980	A series of pyridyl ketones and alkyl pyridines was evaluated as type II ligands for cytochrome P-450.	pyridyl ketones	12-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7391953-1	1980	A series of pyridyl ketones and alkyl pyridines was evaluated as type II ligands for cytochrome P-450.	alkyl pyridines	32-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7398652-0	1980	Visible and ultraviolet spectral transitions of camphor-bound cytochrome P-450.	Camphor	48-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
7398652-2	1980	A systematic analysis of the low-spin to high-spin transition in the ultraviolet and visible absorption spectrum of camphor-bound cytochrome P-450 is presented.	Camphor	116-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
7375915-2	1980	Antibody to the cytochrome P-450 induced by phenobarbital has relatively little or no effect on the aryl hydrocarbon hydroxylase activity of the same human cells.	Phenobarbital	44-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
7381464-5	1980	This apparent magnetic anisotropy of the mercaptide complex is in the same direction, although smaller, than that observed for bacterial cytochrome P-450.	mercaptide	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-153
7378257-2	1980	2 The apparent plasma clearance of propranolol was closely related both to the in vivo (antipyrine test) and in vitro (cytochrome P-450) indices of the activity of the hepatic mixed function oxidase system.	Propranolol	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
7371884-2	1980	Spectral studies indicated that the inhibition was a consequence of danazol"s interfering with the functioning of mitochondrial cytochrome P-450, an essential component of the enzyme system involved in progesterone biosynthesis.	Danazol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
7371884-2	1980	Spectral studies indicated that the inhibition was a consequence of danazol"s interfering with the functioning of mitochondrial cytochrome P-450, an essential component of the enzyme system involved in progesterone biosynthesis.	Progesterone	202-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
7387676-0	1980	Protection by N-acetylcysteine of cyclophosphamide metabolism - related in vivo depression of mixed function oxygenase activity and in vitro denaturation of cytochrome P-450.	Acetylcysteine	14-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
7387676-0	1980	Protection by N-acetylcysteine of cyclophosphamide metabolism - related in vivo depression of mixed function oxygenase activity and in vitro denaturation of cytochrome P-450.	Cyclophosphamide	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
7373548-0	1980	Inhibition of in vitro cytochrome P-450-catalyzed reactions by substituted pyridines.	Pyridines	75-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
7256184-4	1980	Serum triglyceride level was inversely related to the hepatic cytochrome P-450 content (r = 0.62, P less than 0.01).	Triglycerides	6-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
6767272-1	1980	Cytochrome P-450-dependent monooxygenase systems, which metabolize endogenous as well as foriegn compounds, are found in hepatic and several extrahepatic tissues of mammals, including humans.	foriegn compounds	89-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7373548-1	1980	A series of substituted pyridines was investigated as inhibitors of cytochrome P-450-catalyzed reactions.	Pyridines	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
6768169-0	1980	Induction of liver microsomal NADPH cytochrome C reductase and cytochrome P-450 by some new synthetic pyrethroids.	Pyrethrins	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
6929480-0	1980	Chemical mechanisms for cytochrome P-450 hydroxylation: evidence for acylation of heme-bound dioxygen.	Heme	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
6771479-0	1980	Induction of different species of cytochrome P-450 by coplanar and noncoplanar isomers of hexachlorobiphenyl.	2,2',3,4,5,6-Hexachlorobiphenyl	90-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
7388141-0	1980	[Induction of cytochrome P-450 and the immune response by free and covalently bound to albumin phenobarbital].	Phenobarbital	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	acyl peroxide	188-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	Oxygen	127-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
6929480-0	1980	Chemical mechanisms for cytochrome P-450 hydroxylation: evidence for acylation of heme-bound dioxygen.	Oxygen	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	Oxygen	127-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	dihydrolipoic acid	50-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	2,3-thioctic acid	70-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
6929480-1	1980	Using isotopic tracer methods, we have shown that dihydrolipoic acid (2,3-thioctic acid) acylates the distal oxygen of ferrous oxygenated Pseudomonas cytochrome P-450, forming a transient acyl peroxide intermediate that facilitates oxygen-oxygen bond cleavage.	Oxygen	109-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
7435083-0	1980	Characterization of the cytochrome P-450 species induced by trans-stilbene oxide.	stilbene oxide	60-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
6775511-0	1980	On the possible relationship of cytochrome P-450 to alcohol metabolism: fundamental aspects of the microsomal hydroxylation system, including properties and interactions of the components.	Alcohols	52-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
6775511-1	1980	Recent studies on the cytochrome P-450-containing enzyme system of liver microsomes have shown that the cytochrome is present as a number of distinct isozymes, one of which is induced in vivo by the administration of aromatic hydrocarbons, as well as several forms which are less well characterized and not known to be inducible.	Hydrocarbons, Aromatic	217-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
6775511-6	1980	The possible effect of ethanol on these interactions should be considered in evaluating the reported inhibition by high concentrations of ethanol of reactions catalyzed by liver microsomal cytochrome P-450.	Ethanol	23-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-205
6775511-6	1980	The possible effect of ethanol on these interactions should be considered in evaluating the reported inhibition by high concentrations of ethanol of reactions catalyzed by liver microsomal cytochrome P-450.	Ethanol	138-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-205
7370330-1	1980	Thermal inactivation of cytochrome P-450 in different states (microsomes, highly purified and immobilized), characterized by the loss of catalytic activity in cumene hydroperoxide--dependent aniline hydroxylation has been studied in the temperature range 40-58 degrees C. The process of thermoinactivation is characterized by the first order rate constants.	cumene hydroperoxide	159-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
6940467-4	1980	The loss of cytochrome P-450 elicited by IF-inducing agents is accompanied by a perturbation of heme metabolism associated with the dissociation of heme from cytochrome P-450.	Heme	96-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
7370330-1	1980	Thermal inactivation of cytochrome P-450 in different states (microsomes, highly purified and immobilized), characterized by the loss of catalytic activity in cumene hydroperoxide--dependent aniline hydroxylation has been studied in the temperature range 40-58 degrees C. The process of thermoinactivation is characterized by the first order rate constants.	aniline	191-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
7370330-2	1980	From the temperature dependence of these constants the energy of activation and the activation parameters of cytochrome P-450 thermoinactivation have been determined at 45 degrees C. In the presence of 20% glycerol the activation parameters of cytochrome P-450 thermoinactivation in microsomes in highly purified and immobilized states are very similar.	Glycerol	206-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
7370330-2	1980	From the temperature dependence of these constants the energy of activation and the activation parameters of cytochrome P-450 thermoinactivation have been determined at 45 degrees C. In the presence of 20% glycerol the activation parameters of cytochrome P-450 thermoinactivation in microsomes in highly purified and immobilized states are very similar.	Glycerol	206-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
7370331-0	1980	[Multiphasic character of the kinetics of cytochrome P-450 destruction in microsomal LM2- and LM4-forms in the reaction with cumene hydroperoxide].	cumene hydroperoxide	125-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
7370331-1	1980	Cytochrome P-450 destruction kinetics by cumene hydroperoxide has been studied in LM2 and LM4 microsomal and purified forms.	cumene hydroperoxide	41-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
7370331-2	1980	Three destruction phases of cytochrome P-450 were shown to be observed irrespective of the source and integration degree, cytochrome P-450 pseudomonomolecular consumption rate constants being dependent in a complex way upon the cumene hydroperoxide initial concentration.	cumene hydroperoxide	228-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
7370331-2	1980	Three destruction phases of cytochrome P-450 were shown to be observed irrespective of the source and integration degree, cytochrome P-450 pseudomonomolecular consumption rate constants being dependent in a complex way upon the cumene hydroperoxide initial concentration.	cumene hydroperoxide	228-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
7370331-3	1980	The radical character of cytochrome P-450 destruction was proved by experiments with 1-naphtol.	1-naphthol	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
6086112-0	1980	[Effect of phospholipids on the activity of highly-purified liver microsome cytochrome P-450 in a reaction of aniline and naphthalene hydroxylation by hydroperoxides].	Phospholipids	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
6933961-0	1980	Ligand binding of safrole to cytochrome P-450.	Safrole	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
6933961-1	1980	Safrole, a hepatocarcinogen, is converted by the microsomal mono-oxygenase system to a reactive intermediate which interacts with cytochrome P-450 to form a ligand complex.	Safrole	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
6086112-0	1980	[Effect of phospholipids on the activity of highly-purified liver microsome cytochrome P-450 in a reaction of aniline and naphthalene hydroxylation by hydroperoxides].	aniline	110-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
6086112-0	1980	[Effect of phospholipids on the activity of highly-purified liver microsome cytochrome P-450 in a reaction of aniline and naphthalene hydroxylation by hydroperoxides].	naphthalene	122-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
6086112-0	1980	[Effect of phospholipids on the activity of highly-purified liver microsome cytochrome P-450 in a reaction of aniline and naphthalene hydroxylation by hydroperoxides].	Hydrogen Peroxide	151-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
6086112-1	1980	The effect of different phospholipids on the functional activity of highly purified cytochrome P-450 used as a co-substrate of cumene hydroperoxide was examined.	Phospholipids	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
6086112-1	1980	The effect of different phospholipids on the functional activity of highly purified cytochrome P-450 used as a co-substrate of cumene hydroperoxide was examined.	cumene hydroperoxide	127-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
7423530-2	1980	In contrast, several other sulfur containing compounds, tetraethyl thiuramidisulfide, diethyldithiocarbamic acid, thiourea or 1-methyl-2-mercaptoimidazole, which are inhibitors of non-cytochrome P-450 dependent amine oxidase systems, significantly prevented thioacetamide induced liver necrosis at 24 h. Notwithstanding, diphenhydramine, nicotinamide, trimethylamine and imipramine, which are substrates of this amino oxidase system, do not protect.	Sulfur	27-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
6102422-0	1980	The role of cytochrome P-450-inducing agents in potentiaing the toxicity of fluroxene (2,2,2-trifluoroethyl vinyl ether).	fluroxene	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
6102422-0	1980	The role of cytochrome P-450-inducing agents in potentiaing the toxicity of fluroxene (2,2,2-trifluoroethyl vinyl ether).	fluroxene	87-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
7423530-2	1980	In contrast, several other sulfur containing compounds, tetraethyl thiuramidisulfide, diethyldithiocarbamic acid, thiourea or 1-methyl-2-mercaptoimidazole, which are inhibitors of non-cytochrome P-450 dependent amine oxidase systems, significantly prevented thioacetamide induced liver necrosis at 24 h. Notwithstanding, diphenhydramine, nicotinamide, trimethylamine and imipramine, which are substrates of this amino oxidase system, do not protect.	tetraethyl thiuramidisulfide	56-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
7423530-2	1980	In contrast, several other sulfur containing compounds, tetraethyl thiuramidisulfide, diethyldithiocarbamic acid, thiourea or 1-methyl-2-mercaptoimidazole, which are inhibitors of non-cytochrome P-450 dependent amine oxidase systems, significantly prevented thioacetamide induced liver necrosis at 24 h. Notwithstanding, diphenhydramine, nicotinamide, trimethylamine and imipramine, which are substrates of this amino oxidase system, do not protect.	Ditiocarb	86-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
7423530-2	1980	In contrast, several other sulfur containing compounds, tetraethyl thiuramidisulfide, diethyldithiocarbamic acid, thiourea or 1-methyl-2-mercaptoimidazole, which are inhibitors of non-cytochrome P-450 dependent amine oxidase systems, significantly prevented thioacetamide induced liver necrosis at 24 h. Notwithstanding, diphenhydramine, nicotinamide, trimethylamine and imipramine, which are substrates of this amino oxidase system, do not protect.	2-mercaptoimidazole	135-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
120229-0	1979	A model of the heme site of cytochrome P-450: characterization of a sulfhydryl- and imidazole-containing peptide-heme system in solution.	Heme	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
115873-1	1979	A re-examination of the effects of copper chelates on the function of cytochrome P-450.	Copper	35-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
115873-7	1979	In particular, it was found that the reported inhibition of cytochrome P-450-catalyzed hydroxylation reactions by copper-tyrosine is associated with an inhibition rather than a stimulation of the formation of hydrogen peroxide, the product of the dismutation of the superoxide radicals generated as a result of the decay of oxycytochrome P-450.	copper-tyrosine	114-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
115873-7	1979	In particular, it was found that the reported inhibition of cytochrome P-450-catalyzed hydroxylation reactions by copper-tyrosine is associated with an inhibition rather than a stimulation of the formation of hydrogen peroxide, the product of the dismutation of the superoxide radicals generated as a result of the decay of oxycytochrome P-450.	Hydrogen Peroxide	209-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
115873-7	1979	In particular, it was found that the reported inhibition of cytochrome P-450-catalyzed hydroxylation reactions by copper-tyrosine is associated with an inhibition rather than a stimulation of the formation of hydrogen peroxide, the product of the dismutation of the superoxide radicals generated as a result of the decay of oxycytochrome P-450.	Superoxides	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
120229-0	1979	A model of the heme site of cytochrome P-450: characterization of a sulfhydryl- and imidazole-containing peptide-heme system in solution.	sulfhydryl- and imidazole	68-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
120229-0	1979	A model of the heme site of cytochrome P-450: characterization of a sulfhydryl- and imidazole-containing peptide-heme system in solution.	Peptides	105-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
120229-0	1979	A model of the heme site of cytochrome P-450: characterization of a sulfhydryl- and imidazole-containing peptide-heme system in solution.	Heme	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
397836-2	1979	A special emphasis is laid upon the interaction of alcohols with terminal oxidase of the microsomal hydroxylating system, i.e. cytochrome P-450.	Alcohols	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
41598-3	1979	Differences in the Tyr2-Cu2+ complex effects on the cumule hydroperoxide-dependent xenobiotics hydroxylation and lipid peroxidation catalyzed by various forms of cytochrome P-450, e.	tyr2-cu2+	19-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-181
526052-0	1979	Dinitrochlorobenzene: influence on the cytochrome P-450 system and mutagenic effects.	Dinitrochlorobenzene	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
226536-0	1979	The effect of cytochrome P-450cam on the NMR relaxation rate of water protons.	Water	64-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
226536-1	1979	Cytochrome P-450cam in the native, substrate-free state (Fe3+, S = 1/2) substantially reduces the NMR relaxation times, T1 and T2, of water protons.	Water	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
40703-2	1979	With the exception of dioxolane, 4-methyldioxolane and 4-ethyldioxolane, these compounds interacted with ferric cytochrome P-450 to give complexes exhibiting type I optical difference spectra, and, after incubation with NADPH, spectra with peaks at about 430 nm.	NADP	220-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
115595-3	1979	p-Aminophenol administration lowered the microsomal cytochrome P-450 and b5 content and decreased the activity of NADPH cytochrome c reductase in kidney, but not in liver.	4-aminophenol	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-74
41598-3	1979	Differences in the Tyr2-Cu2+ complex effects on the cumule hydroperoxide-dependent xenobiotics hydroxylation and lipid peroxidation catalyzed by various forms of cytochrome P-450, e.	Hydrogen Peroxide	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-181
41598-5	1979	The data obtained suggest that the efficiency of the inhibitory effect of the Tyr2-Cu2+ complex depends on the type of cosubstrates (NADPH, cumole hydroperoxide) and substrates used as well as on the form of cytochrome P-450.	tyr2-cu2+	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-224
41598-5	1979	The data obtained suggest that the efficiency of the inhibitory effect of the Tyr2-Cu2+ complex depends on the type of cosubstrates (NADPH, cumole hydroperoxide) and substrates used as well as on the form of cytochrome P-450.	NADP	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-224
41598-5	1979	The data obtained suggest that the efficiency of the inhibitory effect of the Tyr2-Cu2+ complex depends on the type of cosubstrates (NADPH, cumole hydroperoxide) and substrates used as well as on the form of cytochrome P-450.	cumole hydroperoxide	140-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-224
116333-1	1979	Delta 9-THC and 11-OH-delta 9-THC appear to in vivo affect the metabolism of both Type I and Type II substrates involving cytochrome P-450 as well as to affect the metabolism of a substrate requiring cytochrome P-448.	Dronabinol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
43918-0	1979	The apparent loss of cytochrome P-450 associated with metabolic activation of carbon tetrachloride.	Carbon Tetrachloride	78-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
43918-3	1979	The addition of methylviologen also enhanced the carbon tetrachloride-induced loss of cytochrome P-450, while the apparent content of cytochrome b5 and the activity of NADPH-cytochrome c reductase remained unchanged.	Carbon Tetrachloride	49-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
43918-4	1979	Under a strong inhibition of lipid peroxidation by addition of EDTA, carbon tetrachloride induced a clear loss of cytochrome P-450 to the extent similar to that seen in the absence of EDTA.	Edetic Acid	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
43918-4	1979	Under a strong inhibition of lipid peroxidation by addition of EDTA, carbon tetrachloride induced a clear loss of cytochrome P-450 to the extent similar to that seen in the absence of EDTA.	Carbon Tetrachloride	69-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
43918-5	1979	These results indicate that cytochrome P-450 is directly degraded in association with the reductive metabolism of carbon tetrachloride by cytochrome P-450.	Carbon Tetrachloride	114-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
43918-5	1979	These results indicate that cytochrome P-450 is directly degraded in association with the reductive metabolism of carbon tetrachloride by cytochrome P-450.	Carbon Tetrachloride	114-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-154
519812-0	1979	A model system of cytochrome P-450: hydroxylation of aniline by iron- or hemin-thiol compound systems.	aniline	53-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
519812-0	1979	A model system of cytochrome P-450: hydroxylation of aniline by iron- or hemin-thiol compound systems.	Iron	64-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
519812-0	1979	A model system of cytochrome P-450: hydroxylation of aniline by iron- or hemin-thiol compound systems.	hemin-thiol	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
116333-1	1979	Delta 9-THC and 11-OH-delta 9-THC appear to in vivo affect the metabolism of both Type I and Type II substrates involving cytochrome P-450 as well as to affect the metabolism of a substrate requiring cytochrome P-448.	11-oh-delta 9-thc	16-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
507813-0	1979	Induction by manganese, ethanol, phenobarbital, and herbicides of microsomal cytochrome P-450 in higher plant tissues.	Manganese	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
507813-0	1979	Induction by manganese, ethanol, phenobarbital, and herbicides of microsomal cytochrome P-450 in higher plant tissues.	Ethanol	24-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
507813-0	1979	Induction by manganese, ethanol, phenobarbital, and herbicides of microsomal cytochrome P-450 in higher plant tissues.	Phenobarbital	33-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
383076-0	1979	The role of cytochrome P-450 forms in 2-aminoanthracene and benz[alpha]pyrene mutagenesis.	2-anthramine	38-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
455885-3	1979	Plasma antipyrine clearance and cytochrome P-450 content in biopsies were related to propranolol elimination from plasma, the best fit being obtained with the clearance values.	Propranolol	85-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
383076-0	1979	The role of cytochrome P-450 forms in 2-aminoanthracene and benz[alpha]pyrene mutagenesis.	benz[alpha]pyrene	60-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
109441-1	1979	The interaction between cytochrome P-450 and NADPH-cytochrome c reductase during catalysis has been investigated with a reconstituted monooxygenase system composed of the two purified enzyme components and synthetic phospholipid.	Phospholipids	216-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
109441-4	1979	In agreement with this equation, the observed Vmax for benzphetamine N-demethylation was found to be directly proportional to the calculated concentration of the cytochrome P-450 .	Benzphetamine	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
109441-4	1979	In agreement with this equation, the observed Vmax for benzphetamine N-demethylation was found to be directly proportional to the calculated concentration of the cytochrome P-450 .	Nitrogen	69-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
456582-0	1979	Subzero temperature studies of microsomal cytochrome P-450: O-dealkylation of 7-ethoxycoumarin coupled to single turnover.	7-ethoxycoumarin	78-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
447633-0	1979	The metabolism of benzo(alpha)pyrene by cytochrome P-450 in transformable and nontransformable C3H mouse fibroblasts.	Benzo[alpha]pyrene	18-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
762169-0	1979	Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone.	Spironolactone	73-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
221013-3	1979	The results show that the heme plane of cytochrome P-450 lies in the same plane as the membrane surface, whereas the cytochrome b5 heme plane has a random orientation.	Heme	26-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
483858-9	1979	Any treatment of microsomes which resulted in a reduction of cytochrome P-450 also produced a concomitant fall in N-oxidation of the pyridines.	Pyridines	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
428008-6	1979	Metyrapone and SKF 525-A inhibit covalent binding of the hormone to cytoplasmic macromolecules, which suggests participation of the cytochrome P-450 system in covalent binding of the hormone.	Metyrapone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
223025-1	1979	Cytochrome P450 in the mitochondria of the adrenal cortex functions in the monooxygenation reactions for the biosynthesis of various steroid hormones, such as cholesterol side chain cleavage, hydroxylation at 11 beta-position and that at 18-position of the steroid structure.	Steroids	133-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
223025-1	1979	Cytochrome P450 in the mitochondria of the adrenal cortex functions in the monooxygenation reactions for the biosynthesis of various steroid hormones, such as cholesterol side chain cleavage, hydroxylation at 11 beta-position and that at 18-position of the steroid structure.	Cholesterol	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
223025-1	1979	Cytochrome P450 in the mitochondria of the adrenal cortex functions in the monooxygenation reactions for the biosynthesis of various steroid hormones, such as cholesterol side chain cleavage, hydroxylation at 11 beta-position and that at 18-position of the steroid structure.	Steroids	257-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
223025-7	1979	These effects are important from the point of view that the primary role of the heme of cytochrome P450 is the activation of molecular oxygen.	Heme	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
223025-7	1979	These effects are important from the point of view that the primary role of the heme of cytochrome P450 is the activation of molecular oxygen.	Oxygen	135-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
112378-0	1979	Inhibition of hepatic microsomal cytochrome P-450-dependent monooxygenase reactions by fatty acyl CoA.	fatty	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
112378-0	1979	Inhibition of hepatic microsomal cytochrome P-450-dependent monooxygenase reactions by fatty acyl CoA.	Coenzyme A	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
428008-6	1979	Metyrapone and SKF 525-A inhibit covalent binding of the hormone to cytoplasmic macromolecules, which suggests participation of the cytochrome P-450 system in covalent binding of the hormone.	Proadifen	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
35794-0	1979	Iopronic acid interaction with hepatic microsomal cytochrome P-450: relationship between chemical structure and binding.	iopronic acid	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
284396-0	1979	Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme.	ethynyl sterols	68-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
284396-0	1979	Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme.	Heme	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
284396-1	1979	The hepatic pigment accumulated as a consequence of the self-catalyzed destruction of cytochrome P-450 by norethisterone (17-hydroxy-19-nor-17 alpha-pregn-4-en-20-yn-3-one), after acidic methylation and purification, consists of two virtually identical, probably isomeric, porphyrins.	Norethindrone	106-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
284396-1	1979	The hepatic pigment accumulated as a consequence of the self-catalyzed destruction of cytochrome P-450 by norethisterone (17-hydroxy-19-nor-17 alpha-pregn-4-en-20-yn-3-one), after acidic methylation and purification, consists of two virtually identical, probably isomeric, porphyrins.	Norethindrone	122-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
284396-1	1979	The hepatic pigment accumulated as a consequence of the self-catalyzed destruction of cytochrome P-450 by norethisterone (17-hydroxy-19-nor-17 alpha-pregn-4-en-20-yn-3-one), after acidic methylation and purification, consists of two virtually identical, probably isomeric, porphyrins.	Porphyrins	273-283	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
284396-4	1979	Cytochrome P-450 is therefore destroyed by self-catalyzed addition of norethisterone to its heme prosthetic group.	Norethindrone	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
284396-4	1979	Cytochrome P-450 is therefore destroyed by self-catalyzed addition of norethisterone to its heme prosthetic group.	Heme	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
284396-5	1979	Cytochrome P-450 is also destroyed by norgestrel (13-ethyl-17-hydroxyl-18, 19-dinor-17 alpha-pregn-4-en-20-yn-3-one) and by 1-ethynylcyclohexanol but not by 17-hydroxy-19-nor-17alpha-pregn-4,20-dien-3-one.	Norgestrel	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
284396-5	1979	Cytochrome P-450 is also destroyed by norgestrel (13-ethyl-17-hydroxyl-18, 19-dinor-17 alpha-pregn-4-en-20-yn-3-one) and by 1-ethynylcyclohexanol but not by 17-hydroxy-19-nor-17alpha-pregn-4,20-dien-3-one.	13-ethyl-17-hydroxyl-18, 19-dinor-17 alpha-pregn-4-en-20-yn-3-one	50-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
284396-5	1979	Cytochrome P-450 is also destroyed by norgestrel (13-ethyl-17-hydroxyl-18, 19-dinor-17 alpha-pregn-4-en-20-yn-3-one) and by 1-ethynylcyclohexanol but not by 17-hydroxy-19-nor-17alpha-pregn-4,20-dien-3-one.	1-Ethynyl-1-cyclohexanol	124-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
284396-5	1979	Cytochrome P-450 is also destroyed by norgestrel (13-ethyl-17-hydroxyl-18, 19-dinor-17 alpha-pregn-4-en-20-yn-3-one) and by 1-ethynylcyclohexanol but not by 17-hydroxy-19-nor-17alpha-pregn-4,20-dien-3-one.	17-hydroxy-19-nor-17alpha-pregn-4,20-dien-3-one	157-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
42248-0	1979	NADPH reduction of cytochrome P-450 at different integrational levels of the enzyme system.	NADP	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
42248-2	1979	The aerobic NADPH reduction of microsomes, solubilized and reconstituted systems follows a biphasic kinetics, the two phases are attributed to associated state (cluster) and random cytochrome P-450 reduction.	NADP	12-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
42252-0	1979	Electrochemical investigations on the oxygen activation by cytochrome P-450.	Oxygen	38-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
42252-7	1979	In contrast the cytochrome P-450 catalyzed NADPH-dependent reaction with the same substrate gives corticosterone, O2- represents only an intermediate in the activation of oxygen and is not the "activated oxygen" species.	NADP	43-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
42252-7	1979	In contrast the cytochrome P-450 catalyzed NADPH-dependent reaction with the same substrate gives corticosterone, O2- represents only an intermediate in the activation of oxygen and is not the "activated oxygen" species.	Corticosterone	98-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
42252-7	1979	In contrast the cytochrome P-450 catalyzed NADPH-dependent reaction with the same substrate gives corticosterone, O2- represents only an intermediate in the activation of oxygen and is not the "activated oxygen" species.	Oxygen	114-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
42252-7	1979	In contrast the cytochrome P-450 catalyzed NADPH-dependent reaction with the same substrate gives corticosterone, O2- represents only an intermediate in the activation of oxygen and is not the "activated oxygen" species.	Oxygen	171-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
42252-9	1979	The interaction of adsorbed cytochrome P-450 on the electrode surface with the reduced oxygen species in the absence of NADPH was studied.	Oxygen	87-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
42252-12	1979	In a model of electro-enzyme-reactor several substrates were hydroxylated by microsomal cytochrome P-450 with cathodically reduced oxygen which substitutes NADPH.	Oxygen	131-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
42252-12	1979	In a model of electro-enzyme-reactor several substrates were hydroxylated by microsomal cytochrome P-450 with cathodically reduced oxygen which substitutes NADPH.	NADP	156-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
117659-1	1979	Cytochrome P-450 and NADPH-cytochrome P-450 reductase were covalently attached to Sepharose 4B in different ways in order to find out factors which are important for the organization of the individual components to a catalytically active system.	Sepharose	82-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
229672-3	1979	The present study of the kinetics of reduction of cytochrome P-450cam by reduced putidaredoxin has shown that the reaction obeys first order kinetics with a rate constant of 33 s-1 at 25 degrees C with respect to: 1) the appearance of the carbon monoxide complex of Fe(II) cytochrome P-450cam; 2) the disappearance of the 645 nm absorbance band of high-spin Fe(III) cytochrome P-450cam; and 3) the disappearance of the g = 1.94 EPR signal of reduced putidaredoxin.	Carbon Monoxide	239-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
229673-1	1979	Spin state transitions of membrane-bound cytochrome P-450 were investigated by difference spectrophotometry using the "D"-charge transfer absorbance band at 645 nm as a measure of the amount of hemin iron present in the 5-coordinated state.	Iron	200-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
229673-2	1979	The magnitude of the "D"-absorbance band in the absence of exogenous substrates, e.g., the concentration of native high spin cytochrome P-450, was evaluated from the difference in absorbance at 645 nm between ferric cytochrome P-450 and the carbon monoxide derivative of the pigment in its ferrous state.	Carbon Monoxide	241-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
229673-3	1979	The contribution of the native high spin species to the total cytochrome P-450 content of microsomes was calculated to be between 40% and 65% after induction with phenobarbital and polycyclic hydrocarbons, respectively.	Phenobarbital	163-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
517003-4	1979	Liposome-bound cytochrome P-450 has a higher dimethylaniline, aniline and p-nitroanisole hydroxylase activity than its soluble form.	N,N-dimethylaniline	45-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
229673-3	1979	The contribution of the native high spin species to the total cytochrome P-450 content of microsomes was calculated to be between 40% and 65% after induction with phenobarbital and polycyclic hydrocarbons, respectively.	Hydrocarbons, Cyclic	181-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
229673-5	1979	Further, the steady state concentrations of high spin cytochrome P-450, observed in the presence of reduced pyridine nucleotides, suggest that the rate limiting step for microsomal mixed function oxidation reactions is variable and dependent on the substrate under investigation.	pyridine nucleotides	108-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
229680-1	1979	Studies on model complexes have supported the presence of a mercaptide as the fifth ligand of cytochrome P-450 monooxygenases.	mercaptide	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
229680-2	1979	When alcohol or thiol ligands are added to the sixth coordination position of a five-coordinated 4-nitrobenzene thiolate complex of FeIII protoporphyrin IX dimethyl ester chloride low spin complexes with optical and EPR-spectra very similar to cytochrome P-450 are obtained.	Alcohols	5-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
229680-2	1979	When alcohol or thiol ligands are added to the sixth coordination position of a five-coordinated 4-nitrobenzene thiolate complex of FeIII protoporphyrin IX dimethyl ester chloride low spin complexes with optical and EPR-spectra very similar to cytochrome P-450 are obtained.	Sulfhydryl Compounds	16-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
229680-2	1979	When alcohol or thiol ligands are added to the sixth coordination position of a five-coordinated 4-nitrobenzene thiolate complex of FeIII protoporphyrin IX dimethyl ester chloride low spin complexes with optical and EPR-spectra very similar to cytochrome P-450 are obtained.	4-nitrobenzene thiolate	97-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
229680-2	1979	When alcohol or thiol ligands are added to the sixth coordination position of a five-coordinated 4-nitrobenzene thiolate complex of FeIII protoporphyrin IX dimethyl ester chloride low spin complexes with optical and EPR-spectra very similar to cytochrome P-450 are obtained.	ferric sulfate	132-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
229680-2	1979	When alcohol or thiol ligands are added to the sixth coordination position of a five-coordinated 4-nitrobenzene thiolate complex of FeIII protoporphyrin IX dimethyl ester chloride low spin complexes with optical and EPR-spectra very similar to cytochrome P-450 are obtained.	protoporphyrin ix dimethyl ester chloride	138-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
229682-7	1979	Measurements of the reduction of succinylated cytochrome c using purified cytochrome P-450 and the flavoprotein, NADPH-cytochrome P-450 reductase, directly demonstrate the formation of superoxide anions.	Superoxides	185-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-145
517003-4	1979	Liposome-bound cytochrome P-450 has a higher dimethylaniline, aniline and p-nitroanisole hydroxylase activity than its soluble form.	aniline	53-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
517003-5	1979	Only the aniline hydroxylase activity of microsomal, proteoliposomal and soluble cytochrome P-450 was inhibited by tyrosine .	Tyrosine	115-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
517003-7	1979	The inhibitory action of the Tyr2-Cu2+ complex on the other hydroxylase activities depended on the cytochrome P-450 forms and the type of cosubstrates and substrates used.	tyr2-cu2+	29-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
517006-0	1979	Mercaptide chelated protoheme: a model compound for cytochrome P-450.	mercaptide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	mercaptide	2-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	Heme	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	di-3-amino-propyl-disulfide	113-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	Heme	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	Disulfides	131-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517006-1	1979	A mercaptide chelated heme having the spectral characteristics of cytochrome P-450 has been prepared by coupling di-3-amino-propyl-disulfide to protoheme, followed by reduction and disulfide cleavage with sodium dithionithe.	sodium dithionithe	205-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
517008-0	1979	Quantum chemical interpretation of the spectral properties of the CO and O2 complexes of hemoglobin and cytochrome P-450.	Carbon Monoxide	66-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
517008-0	1979	Quantum chemical interpretation of the spectral properties of the CO and O2 complexes of hemoglobin and cytochrome P-450.	Oxygen	73-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
517008-1	1979	The electronic transitions of CO and O2 complexes of hemoglobin and cytochrome P-450 were calculated using a PPP method extended for metal complexes.	Carbon Monoxide	30-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
517008-1	1979	The electronic transitions of CO and O2 complexes of hemoglobin and cytochrome P-450 were calculated using a PPP method extended for metal complexes.	Oxygen	37-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
517008-1	1979	The electronic transitions of CO and O2 complexes of hemoglobin and cytochrome P-450 were calculated using a PPP method extended for metal complexes.	Metals	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
517008-2	1979	The calculations show that the unusual spectral properties of cytochrome P-450 are very sensitive to the iron-sulfur bond distance.	Iron	105-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
517008-2	1979	The calculations show that the unusual spectral properties of cytochrome P-450 are very sensitive to the iron-sulfur bond distance.	Sulfur	110-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
517008-3	1979	It is suggested from these calculations that for the conversion of cytochrome P-450 to cytochrome P-420 an increase of the iron-sulfur bond distance of only about 0.2 A is sufficient.	Iron	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
517008-3	1979	It is suggested from these calculations that for the conversion of cytochrome P-450 to cytochrome P-420 an increase of the iron-sulfur bond distance of only about 0.2 A is sufficient.	Sulfur	128-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
517008-4	1979	The anomalous Soret band of the CO complex as well as the normal Soret band of the O2 complex of cytochrome P-450 are explicable assuming a mercaptide sulfur as fifth ligand.	mercaptide sulfur	140-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
517010-3	1979	The two maxima of the nonequilibrium form of cytochrome P-450 without substrate in the visible absorption spectrum (alpha-band, beta-band) and the ratio of their intensities indicate the low-spin character of the heme iron.	Heme	213-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
517010-3	1979	The two maxima of the nonequilibrium form of cytochrome P-450 without substrate in the visible absorption spectrum (alpha-band, beta-band) and the ratio of their intensities indicate the low-spin character of the heme iron.	Iron	218-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
517010-4	1979	These spectral properties give evidence for a reduced cytochrome P-450 with two heme-linked axial ligands.	Heme	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
31893-0	1979	Cumene hydroperoxide-supported microsomal hydroxylations of warfarin--a probe of cytochrome P-450 multiplicity and specificity.	cumene hydroperoxide	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
31893-0	1979	Cumene hydroperoxide-supported microsomal hydroxylations of warfarin--a probe of cytochrome P-450 multiplicity and specificity.	Warfarin	60-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
119555-0	1979	[Cytochrome P-450 and transformation from 18-hydroxycorticosterone to aldosterone].	Aldosterone	70-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	1-17
552352-8	1979	Ethanol inhibition of drug metabolism in vitro appears to result from a modification of the lipophilic milieu that surrounds the cytochrome P-450 in the microsomal membrane.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
441518-4	1979	However, single doses of 400 mg/kg and accumulative doses of 500 mg/kg do cause a decrease in cytochrome P450 content as part of the dantrolene induced inhibition of the hepatic MFO system.	Dantrolene	133-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
118858-7	1979	The interface between plants and insects is enormous, and therefore it appears probable that cytochrome P-450 will one day be shown to be important in the conversion/utilization of other plant secondary substances, e.g., synthesis of cholesterol from phytosterols, and sex pheromones from olefins, terpenes, and alkaloids.	Cholesterol	234-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
118858-7	1979	The interface between plants and insects is enormous, and therefore it appears probable that cytochrome P-450 will one day be shown to be important in the conversion/utilization of other plant secondary substances, e.g., synthesis of cholesterol from phytosterols, and sex pheromones from olefins, terpenes, and alkaloids.	Phytosterols	251-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
118858-7	1979	The interface between plants and insects is enormous, and therefore it appears probable that cytochrome P-450 will one day be shown to be important in the conversion/utilization of other plant secondary substances, e.g., synthesis of cholesterol from phytosterols, and sex pheromones from olefins, terpenes, and alkaloids.	Alkenes	289-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
118858-7	1979	The interface between plants and insects is enormous, and therefore it appears probable that cytochrome P-450 will one day be shown to be important in the conversion/utilization of other plant secondary substances, e.g., synthesis of cholesterol from phytosterols, and sex pheromones from olefins, terpenes, and alkaloids.	Terpenes	298-306	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
118858-7	1979	The interface between plants and insects is enormous, and therefore it appears probable that cytochrome P-450 will one day be shown to be important in the conversion/utilization of other plant secondary substances, e.g., synthesis of cholesterol from phytosterols, and sex pheromones from olefins, terpenes, and alkaloids.	Alkaloids	312-321	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
441518-4	1979	However, single doses of 400 mg/kg and accumulative doses of 500 mg/kg do cause a decrease in cytochrome P450 content as part of the dantrolene induced inhibition of the hepatic MFO system.	mfo	178-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
32885-0	1978	The degradation of different forms of cytochrome P-450 in vivo by fluroxene and allyl-iso-propylacetamide.	fluroxene	66-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
217389-0	1978	Trophoblast estrogen synthetase stimulation by dibutyryl cyclic AMP and theophylline: increase in cytochrome P-450 content.	Bucladesine	47-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
32885-0	1978	The degradation of different forms of cytochrome P-450 in vivo by fluroxene and allyl-iso-propylacetamide.	Allylisopropylacetamide	80-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
711851-5	1978	AHH, a cytochrome P-450 dependent carcinogen-metabolizing enzyme appears to play an important role in the activation of polycyclic hydrocarbons into reactive moieties that can bind to DNA and that may directly induce cancer.	Hydrocarbons, Cyclic	120-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
719999-4	1978	Hexachlorobenzene administration for 45 days resulted in the development of porphyria in rats, which biochemically closely resembles symptomatic porphyria in humans, with elevation of urinary uroporphyrin excretion, hepatic uroporphyrin content, and hepatic cytochrome P-450 content, in addition to appearance of porphyrins of the isocoproporphyrin (P1) series in the faeces.	Hexachlorobenzene	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-274
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Aminopyrine	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Aminopyrine	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Benzo(a)pyrene	88-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Benzo(a)pyrene	88-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Hexachlorobenzene	210-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Hexachlorobenzene	210-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Hexachlorobenzene	303-320	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Hexachlorobenzene	303-320	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Phenobarbital	430-443	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Phenobarbital	430-443	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Methylcholanthrene	447-467	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
719999-8	1978	Study in vitro of the kinetics of two reactions, namely aminopyrine N-demethylation and 3,4-benzpyrene hydroxylation, catalysed by the hepatic microsomal cytochrom P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450-dependent enzyme system, suggested that hexachlorobenzene induced a form of cytochrome P-450 with different catalytic properties from those of forms induced by either phenobarbital or 3-methylcholanthrene.	Methylcholanthrene	447-467	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	339-355
722999-0	1978	Glutathione depletion by aniline analogs in vitro associated with liver microsomal cytochrome P-450.	Glutathione	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
722999-0	1978	Glutathione depletion by aniline analogs in vitro associated with liver microsomal cytochrome P-450.	aniline	25-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
722999-1	1978	Enzymic depletion of glutathione (GSH) in vitro by aniline analogs was mostly dependent on the cytochrome P-450 level in liver microsomes.	Glutathione	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
722999-1	1978	Enzymic depletion of glutathione (GSH) in vitro by aniline analogs was mostly dependent on the cytochrome P-450 level in liver microsomes.	Glutathione	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
722999-1	1978	Enzymic depletion of glutathione (GSH) in vitro by aniline analogs was mostly dependent on the cytochrome P-450 level in liver microsomes.	aniline	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
17539139-7	1978	Studies of mixed function oxidases and cytochrome P-450 system in male gonads demonstrated that the presence of AHH, EH, and GSH-ST implicate activation and detoxification of polycyclic hydrocarbons.	Glutathione	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
28473-0	1978	Reduction of tertiary amine N-oxides by cytochrome P-450.	tertiary amine	13-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
28473-0	1978	Reduction of tertiary amine N-oxides by cytochrome P-450.	n-oxides	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
28181-0	1978	Complexes of trivalent oxygenated phosphorus compounds with cytochrome P-450 and cytochrome P-420: the origin of double Soret spectra.	Phosphorus	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
17539139-7	1978	Studies of mixed function oxidases and cytochrome P-450 system in male gonads demonstrated that the presence of AHH, EH, and GSH-ST implicate activation and detoxification of polycyclic hydrocarbons.	Hydrocarbons, Cyclic	175-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
206545-0	1978	Studies of the oxygen binding site of cytochrome P-450.	Oxygen	15-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
208787-0	1978	A model of cytochrome P-450; optical and EPR properties of a thiol-containing peptide-hemin system and its activity of aniline hydroxylation.	Sulfhydryl Compounds	61-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
208787-0	1978	A model of cytochrome P-450; optical and EPR properties of a thiol-containing peptide-hemin system and its activity of aniline hydroxylation.	Peptides	78-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
208787-0	1978	A model of cytochrome P-450; optical and EPR properties of a thiol-containing peptide-hemin system and its activity of aniline hydroxylation.	Hemin	86-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
208787-0	1978	A model of cytochrome P-450; optical and EPR properties of a thiol-containing peptide-hemin system and its activity of aniline hydroxylation.	aniline	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
647071-0	1978	[Kinetic and spectral parameters of the amines oxidative N-dealkylation with participation of the liver microsomal cytochrome P-450.	Amines	40-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
96251-1	1978	Treatment of animals with cobaltous chloride caused decreases in hepatic, pulmonary and renal cytochrome P-450, and alterations in levels of other components of microsomal mixed-function oxidases, which can alter the rate of biotransformation of certain drug substrates.	cobaltous chloride	26-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
647071-2	1978	Kinetics of demethylation of a number of amines involving hepatic microsomal cytochrome P-450 and organic hydroperoxides (tret-butyl- and cumylhydroperoxide) have been investigated.	Amines	41-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
647071-3	1978	Decomposition rate constants for the substrate-cytochrome P-450-ROOH complexes have been determined in a generalized form.	Lipid Peroxides	64-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
23870-0	1978	[Kinetics of N-dealkylation of amines with participation of microsomal cytochrome P-450].	Nitrogen	13-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
647840-0	1978	The affinity of cytochrome P-450 for ethyl isocyanide: an explanation of double soret spectra.	ethyl isocyanide	37-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
23870-0	1978	[Kinetics of N-dealkylation of amines with participation of microsomal cytochrome P-450].	Amines	31-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
23870-1	1978	Within the temperature range of 20-37 degrees C the kinetics of the demethylation reactions of a variety of amines with participation of hepatic microsomal cytochrome P-450, NADPH and O2 has been studied.	Amines	108-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
23870-6	1978	The nature of the limiting step of the enzymatic amine demethylation involving cytochrome P-450 of hepatic microsomes is discussed.	Amines	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
318378-0	1978	Induction of multiple cytochrome P-450 species in housefly microsomes--SDS-gel electrophoresis studies.	Sodium Dodecyl Sulfate	71-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
318378-2	1978	Microsomal fractions isolated from various housefly strains have been characterized with respect to multiple forms of cytochrome P-450 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	Sodium Dodecyl Sulfate	138-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
318378-2	1978	Microsomal fractions isolated from various housefly strains have been characterized with respect to multiple forms of cytochrome P-450 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	polyacrylamide	161-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
318378-10	1978	Induction with alpha-pinene and phenobarbital was expressed by a shift of the maximum absorbance at 452 nm in the CO-difference spectrum to lower wavelengths in the NAIDM strain; whereas, beta-naphthoflavone, although increasing the amount of cytochrome P-450, did not change the wavelength of maximum absorbance.	alpha-pinene	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
318378-10	1978	Induction with alpha-pinene and phenobarbital was expressed by a shift of the maximum absorbance at 452 nm in the CO-difference spectrum to lower wavelengths in the NAIDM strain; whereas, beta-naphthoflavone, although increasing the amount of cytochrome P-450, did not change the wavelength of maximum absorbance.	Phenobarbital	32-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
318378-10	1978	Induction with alpha-pinene and phenobarbital was expressed by a shift of the maximum absorbance at 452 nm in the CO-difference spectrum to lower wavelengths in the NAIDM strain; whereas, beta-naphthoflavone, although increasing the amount of cytochrome P-450, did not change the wavelength of maximum absorbance.	naidm	165-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-259
212769-0	1978	Spectral evidence for weak ligand in sixth position of hepatic microsomal cytochrome P-450 low spin ferric iron in vivo.	ferric sulfate	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
25763-3	1977	The fluroxene molecule (2,2,2-trifluroethyl vinyl ether) is composed of two moieties; both are toxic as a result of their metabolism: the vinyl moiety destroys heme of cytochrome P-450 while being metabolized to the final product, CO2.	fluroxene	4-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
25763-3	1977	The fluroxene molecule (2,2,2-trifluroethyl vinyl ether) is composed of two moieties; both are toxic as a result of their metabolism: the vinyl moiety destroys heme of cytochrome P-450 while being metabolized to the final product, CO2.	2,2,2-trifluroethyl vinyl ether	24-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
25763-3	1977	The fluroxene molecule (2,2,2-trifluroethyl vinyl ether) is composed of two moieties; both are toxic as a result of their metabolism: the vinyl moiety destroys heme of cytochrome P-450 while being metabolized to the final product, CO2.	Heme	160-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
25763-7	1977	Fluroxene metabolism and toxicity are modified by drugs metabolized by or affecting the activity of the microsomal cytochrome P-450-system or enzymes involved in ethanol metabolism.	fluroxene	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
25763-7	1977	Fluroxene metabolism and toxicity are modified by drugs metabolized by or affecting the activity of the microsomal cytochrome P-450-system or enzymes involved in ethanol metabolism.	Ethanol	162-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
925482-5	1977	This was confirmed by studies of the effect of ethinyl estradiol on the level of microsomal cytochrome P-450 over a 10-day period.	Ethinyl Estradiol	47-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
925482-2	1977	After 5 days of ethinyl estradiol, 5 mg/kg/day, there was a significant decrease in the activity of ethylmorphine-N-demethylase and in cytochrome P-450, cytochrome b2, and NADPH cytochrome c reductase.	Ethinyl Estradiol	16-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
334441-0	1977	Regulation of cytochrome P-450-dependent microsomal drug-metabolizing enzymes by nickel, cobalt, and iron.	Nickel	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
925482-4	1977	After 5 days of ethinyl estradiol administration, the rate of degradation of cytochrome P-450 apoprotein was reduced (half-life of 50 hr compared to 24 hr in control), and their relative rate of synthesis was likewise reduced, indicating that a new steady state of protein turnover associated with reduced synthesis rate had been reached.	Ethinyl Estradiol	16-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
611643-0	1977	The additive effects of progestins on testosterone-stimulated hepatic ethylmorphine metabolism and cytochrome P-450 content.	Testosterone	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
202259-0	1977	Relationship between the reduction of oxygen, artificial acceptors and cytochrome P-450 by NADPH--cytochrome c reductase.	Oxygen	38-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
202259-5	1977	In contrast with the process of electron transfer to cytochrome c, the rate of reduction of cytochrome P-450 and the rate of oxidation of adrenaline in liver microsomal fraction are correlated.	Epinephrine	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
588632-0	1977	[O-demethylation kinetics of anisole and p-chloroanisole by cumene hydroperoxide and cytochrome P-450 of liver microsomes].	4-chloroanisole	41-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
334441-0	1977	Regulation of cytochrome P-450-dependent microsomal drug-metabolizing enzymes by nickel, cobalt, and iron.	Cobalt	89-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
334441-0	1977	Regulation of cytochrome P-450-dependent microsomal drug-metabolizing enzymes by nickel, cobalt, and iron.	Iron	101-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
913025-5	1977	It is suggested that phenylbutazone and oxyphenbutazone act by inducing form of cytochrome P-450 with low activity for tolbutamide hydroxylation, whereas sulfaphenazole acts by direct inhibition of the microsomal mixed function oxidase system.	Phenylbutazone	21-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
909072-0	1977	The in vitro metabolism of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) by hepatic microsomal cytochrome P-450.	Halothane	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
913025-5	1977	It is suggested that phenylbutazone and oxyphenbutazone act by inducing form of cytochrome P-450 with low activity for tolbutamide hydroxylation, whereas sulfaphenazole acts by direct inhibition of the microsomal mixed function oxidase system.	Oxyphenbutazone	40-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
913025-5	1977	It is suggested that phenylbutazone and oxyphenbutazone act by inducing form of cytochrome P-450 with low activity for tolbutamide hydroxylation, whereas sulfaphenazole acts by direct inhibition of the microsomal mixed function oxidase system.	Tolbutamide	119-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
909072-0	1977	The in vitro metabolism of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) by hepatic microsomal cytochrome P-450.	Halothane	38-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
909072-5	1977	Phenobarbital pretreatment of the animals resulted ina significant increase in both the formation of TFAA and the cytochrome P-450 content of microsomes.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
409715-1	1977	Qualitative and quantitative changes of cytochrome P-450 after chronic ethanol consumption.	Ethanol	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
923570-0	1977	The low-spin/high-spin transition equilibrium of camphor-bound cytochrome P-450.	Camphor	49-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
923570-2	1977	The spin state of camphor-bound cytochrome P-450 is shown to depend largely on medium and temperature in aqueous as well as in mixed organic buffer.	Camphor	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
897674-1	1977	Stannous fluoride, the widely used anticaries toothpaste additive, and other tin and germanium dihalides form complexes with hemoproteins such as hepatic cytochrome P-450, hemoglobin, and peroxidase.	Tin Fluorides	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-198
897674-1	1977	Stannous fluoride, the widely used anticaries toothpaste additive, and other tin and germanium dihalides form complexes with hemoproteins such as hepatic cytochrome P-450, hemoglobin, and peroxidase.	Tin	77-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-198
897674-1	1977	Stannous fluoride, the widely used anticaries toothpaste additive, and other tin and germanium dihalides form complexes with hemoproteins such as hepatic cytochrome P-450, hemoglobin, and peroxidase.	germanium dihalides	85-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-198
909072-6	1977	A good correlation was found between formation of TFAA and microsomal cytochrome P-450 levels.	Trifluoroacetic Acid	50-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
199115-1	1977	Electron spin resonance spectroscopy as a probe of the hemin iron of cytochrome P-450: the influence of buffer composition, alcohols, and nitrogenous ligands.	Iron	61-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
408351-0	1977	Heterogeneity of cytochrome P-450s induced by polychlorinated biphenyls.	Polychlorinated Biphenyls	46-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
303176-7	1977	Ca2+ stimulated the reduction of cytochrome P-450 by NADPH and this was inhibited by ADP.	Calcium	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
589727-0	1977	Aromatic methyl group migration and hydroxylation of p-toluidine by iron-thiol and hemin-thiol systems as a model of cytochrome P-450.	4-toluidine	53-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
589727-0	1977	Aromatic methyl group migration and hydroxylation of p-toluidine by iron-thiol and hemin-thiol systems as a model of cytochrome P-450.	hemin-thiol	83-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
303176-7	1977	Ca2+ stimulated the reduction of cytochrome P-450 by NADPH and this was inhibited by ADP.	NADP	53-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
303176-7	1977	Ca2+ stimulated the reduction of cytochrome P-450 by NADPH and this was inhibited by ADP.	Adenosine Diphosphate	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	50-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	50-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Adenosine Diphosphate	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Adenosine Diphosphate	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	237-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	237-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	237-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Calcium	237-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Adenosine Diphosphate	307-310	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
303176-13	1977	These data have been interpreted to indicate that Ca2+ and ADP influence the relationship between adrenodoxin and cytochrome P-450 so that a complex of increased activity in the reduction of cytochrome P-450 is formed in the presence of Ca2+ and a less active complex is formed in the presence of Ca2+ plus ADP.	Adenosine Diphosphate	307-310	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-207
19254-0	1977	Ionization dependence of camphor binding and spin conversion of the complex between cytochrome P-450 and camphor.	Camphor	25-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
873899-1	1977	Two forms of highly purified liver microsomal cytochrome P-450, P-450LM2, and P-450LM4, have been titrated with standardized solutions of sodium dithionite under anaerobic conditions.	Dithionite	138-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
19254-0	1977	Ionization dependence of camphor binding and spin conversion of the complex between cytochrome P-450 and camphor.	Camphor	105-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
873899-3	1977	The present results are in disagreement with earlier dithionite titrations and reoxidation experiments which indicate that liver microsomal cytochrome P-450 is a 2-electron acceptor, but are in accord with previous potentimetric titrations and product yield data which indicate that this hemeprotein is a 1-electron acceptor.	Dithionite	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
872430-3	1977	The cytochrome P-450 content was also measured by recording the difference absorption spectra of carbon monoxide-complexed P-450.	Carbon Monoxide	97-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
198028-0	1977	[Interrelationship between the generation of oxygen anion-radicals and the reduction of artificial acceptors and cytochrome P-450 by NADPH-cytochrome c reductase].	oxygen anion-radicals	45-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
198028-4	1977	In contrast to the process of electron transfer on cytochrome c, there is a direct correlation between the rate of cytochrome P-450 reduction and the rate of adrenaline oxidation in liver microsomes.	Epinephrine	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
198028-6	1977	On the basis of the data obtained it is suggested that the reactions of NADPH-cytochrome c reductase interaction with oxygen and artificial "anaerobic" acceptors are connected with different redox-states of flavoprotein or with different flavine coenzymes, and that the electron transport on cytochrome P-450 and directly on oxygen takes place in interrelated redox-states of flavoprotein.	Oxygen	118-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-308
198028-6	1977	On the basis of the data obtained it is suggested that the reactions of NADPH-cytochrome c reductase interaction with oxygen and artificial "anaerobic" acceptors are connected with different redox-states of flavoprotein or with different flavine coenzymes, and that the electron transport on cytochrome P-450 and directly on oxygen takes place in interrelated redox-states of flavoprotein.	3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE	238-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-308
198028-6	1977	On the basis of the data obtained it is suggested that the reactions of NADPH-cytochrome c reductase interaction with oxygen and artificial "anaerobic" acceptors are connected with different redox-states of flavoprotein or with different flavine coenzymes, and that the electron transport on cytochrome P-450 and directly on oxygen takes place in interrelated redox-states of flavoprotein.	Oxygen	325-331	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-308
891529-0	1977	Nitrosoalkanes as Fe(II) ligands in the 455-nm-absorbing cytochrome P-450 complexes formed from nitroalkanes in reducing conditions.	nitrosoalkanes	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
891529-0	1977	Nitrosoalkanes as Fe(II) ligands in the 455-nm-absorbing cytochrome P-450 complexes formed from nitroalkanes in reducing conditions.	ammonium ferrous sulfate	18-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
891529-0	1977	Nitrosoalkanes as Fe(II) ligands in the 455-nm-absorbing cytochrome P-450 complexes formed from nitroalkanes in reducing conditions.	nitroalkanes	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
193841-0	1977	Imidazole, the ligand trans to mercaptide in ferric cytochrome P-450.	imidazole	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
193841-0	1977	Imidazole, the ligand trans to mercaptide in ferric cytochrome P-450.	mercaptide	31-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
592792-0	1977	Ligand binding to human placental cytochrome P-450: interaction of steroids and heme-binding ligands.	Steroids	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
888486-3	1977	The endplasmic reticulum of the hepatocytes is hypertropic but is hypoactive with respect to drug metabolism, a condition which is partly due to interference to substances retained in cholestatic livers (bile salts) with drug biotransformation and to cytochrome P-450 diminution in the microsomal membranes.	Bile Acids and Salts	204-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	251-267
880239-1	1977	By using 3-amino-1,2,4-triazole, an inhibitor of haem synthesis, and 2-allyl-2-isopropylacetamide, a drug that degrades the haem moiety of cytochrome P-450, the involvement of haem in cytochrome P-450 synthesis and assembly was investigated.	Amitrole	9-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
880239-1	1977	By using 3-amino-1,2,4-triazole, an inhibitor of haem synthesis, and 2-allyl-2-isopropylacetamide, a drug that degrades the haem moiety of cytochrome P-450, the involvement of haem in cytochrome P-450 synthesis and assembly was investigated.	Allylisopropylacetamide	69-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
880239-1	1977	By using 3-amino-1,2,4-triazole, an inhibitor of haem synthesis, and 2-allyl-2-isopropylacetamide, a drug that degrades the haem moiety of cytochrome P-450, the involvement of haem in cytochrome P-450 synthesis and assembly was investigated.	Allylisopropylacetamide	69-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-200
880239-2	1977	Phenobarbital was used to stimulate apo-(cytochrome P-450) synthesis.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
880239-7	1977	In animals receiving successive injections of phenobarbital plus 3-amino-1,2,4-triazole, compared with those receiving phenobarbital only, the holo-(cytochrome P-450) content measured spectrally shows a greater decrease than could be accounted for by the decrease in the content of the total apoprotein.	Phenobarbital	46-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
880239-7	1977	In animals receiving successive injections of phenobarbital plus 3-amino-1,2,4-triazole, compared with those receiving phenobarbital only, the holo-(cytochrome P-450) content measured spectrally shows a greater decrease than could be accounted for by the decrease in the content of the total apoprotein.	Amitrole	65-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
880239-7	1977	In animals receiving successive injections of phenobarbital plus 3-amino-1,2,4-triazole, compared with those receiving phenobarbital only, the holo-(cytochrome P-450) content measured spectrally shows a greater decrease than could be accounted for by the decrease in the content of the total apoprotein.	Phenobarbital	119-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
880239-9	1977	This particular effect could be due to a direct interaction of 3-amino-1,2,4-triazole or its metabolites with cytochrome P-450 rather than a consequence of haem deficiency.	Amitrole	63-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
880239-10	1977	Apo-(cytochrome P-450) is capable of binding to the endoplasmic reticulum in a form and at a site, which can be reconstituted with haemin to yield the functional protein.	Hemin	131-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
17803-0	1977	Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: role of cytochrome P-450.	Carbon Tetrachloride	17-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
853192-0	1977	The electronic structure of chromyl chloride: a functional model for cytochrome P-450.	CHROMYL CHLORIDE	28-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
884775-5	1977	Thus, in addition to its interaction with cytochrome P-450, n-octylamine causes a reduction of cytochrome b5 which subsequently becomes reoxidized.	octylamine	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
17803-0	1977	Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: role of cytochrome P-450.	Bromotrichloromethane	54-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
191295-5	1977	Based on recent evidence, we conclude that it is unnecessary to postulate that ethanol is oxidized directly via cytochrome P-450.	Ethanol	79-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
406056-0	1977	Separation of pure polychlorinated biphenyl isomers into two types of inducers on the basis of induction of cytochrome P-450 or P-448.	Polychlorinated Biphenyls	19-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
849980-7	1977	Evidence for the presence of cytochrome P-450 in the villus fraction was obtained by measuring the carbon monoxide-dithionite difference spectrum.	Carbon Monoxide	99-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
849980-7	1977	Evidence for the presence of cytochrome P-450 in the villus fraction was obtained by measuring the carbon monoxide-dithionite difference spectrum.	Dithionite	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
881409-3	1977	On the other hand, the amount of cytochrome P-450 was depressed strongly by both cobalt treatments.	Cobalt	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
852592-0	1977	Sub-zero temperature studies of microsomal cytochrome P-450: interaction of Fe2+ with oxygen.	ammonium ferrous sulfate	76-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
881409-5	1977	The incorporations of [3H]leucine as well as 5-amino[3H]levulinate into cytochrome b5 in cobalt-treated animals were almost the same as those in the controls 5 h after injections of the radioisotopes, whereas the radioactivity of heme labelled with 5-amino[3H]levulinate in microsomal residues after trypsin digestion, which would consist mainly of cytochrome P-450, was higher in the controls than in cobalt-treated animals after 5 h.	Cobalt	89-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	349-365
852592-0	1977	Sub-zero temperature studies of microsomal cytochrome P-450: interaction of Fe2+ with oxygen.	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
337820-0	1977	Chronic ethanol administration induces a form of cytochrome P-450 with specific spectral and catalytic properties.	Ethanol	8-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
853543-3	1977	The arylating metabolite is formed by a cytochrome P-450 dependent N-hydroxylation process.	Nitrogen	67-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
19937-4	1977	Of interest are recent studies demonstrating the ability of hydrogen peroxide to initiate a cytochrome P-450 dependent peroxidatic reaction competent for supporting substrate hydroxylation.	Hydrogen Peroxide	60-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
19937-5	1977	The fact that the function of cytochrome P-450 is sensitive to changes in oxygen tension establishes its role as an "oxygen sensor" for cellular metabolism.	Oxygen	74-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
19937-5	1977	The fact that the function of cytochrome P-450 is sensitive to changes in oxygen tension establishes its role as an "oxygen sensor" for cellular metabolism.	Oxygen	117-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
598281-0	1977	[Isolation in pure form of 20alpha, (22R)-cholesterol-hydroxylating cytochrome P-450 and some of its characteristics].	(22r)-cholesterol	36-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
140033-4	1977	Rifampicin seems to be a potent inducer of drug metabolism in humans and it causes a proliferation of the smooth endoplasmatic reticulum and an increase of cytochrome P450 content in the liver.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
838934-0	1977	[Effect of catatoxic steroids on the conformation of cytochrome P-450].	Steroids	21-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
598675-0	1977	Methods for polyacrylamide gel electrophoresis of mammilian liver cytochrome P-450 in the presence of sodium dodecyl sulfact: a critique.	polyacrylamide	12-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
598675-0	1977	Methods for polyacrylamide gel electrophoresis of mammilian liver cytochrome P-450 in the presence of sodium dodecyl sulfact: a critique.	sodium dodecyl sulfact	102-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Mephenytoin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Phenytoin	13-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	pheneturide	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Phenobarbital	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Hexobarbital	127-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Ethosuximide	222-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Hexobarbital	280-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
13927-2	1976	The addition of vinyl chloride to microsomes causes a Type 1 spectra shift, similar to that seen for phenobarbital [11[ which indicates the direct involvement of a cytochrome P-450 species; this difference spectrum is characteristic of substrate binding to this type of enzyme.	Vinyl Chloride	16-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
1001810-7	1976	Both androstenedione and 16alpha-hydroxytestosterone cause type I spectral perturbations associated with binding to cytochrome P-450 when added to placental microsomes; however, the deltaA390-420 is twice as great in response to saturating amounts of androstenedione than in response to 16alpha-hydroxytestosterone.	Hydroxytestosterones	33-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
1001810-7	1976	Both androstenedione and 16alpha-hydroxytestosterone cause type I spectral perturbations associated with binding to cytochrome P-450 when added to placental microsomes; however, the deltaA390-420 is twice as great in response to saturating amounts of androstenedione than in response to 16alpha-hydroxytestosterone.	Androstenedione	5-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
1001810-7	1976	Both androstenedione and 16alpha-hydroxytestosterone cause type I spectral perturbations associated with binding to cytochrome P-450 when added to placental microsomes; however, the deltaA390-420 is twice as great in response to saturating amounts of androstenedione than in response to 16alpha-hydroxytestosterone.	16-hydroxytestosterone	25-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
999697-0	1976	Platelet cytochrome P450: a possible role in arachidonate-induced aggregation.	Arachidonic Acid	45-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
13927-2	1976	The addition of vinyl chloride to microsomes causes a Type 1 spectra shift, similar to that seen for phenobarbital [11[ which indicates the direct involvement of a cytochrome P-450 species; this difference spectrum is characteristic of substrate binding to this type of enzyme.	Phenobarbital	101-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
184090-0	1976	Purification and characterization of adrenal cortex mitochondrial cytochrome P-450 specific for cholesterol side chain cleavage activity.	Cholesterol	96-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
824157-2	1976	Cytochrome P-450 serves as the binding site for oxygen and substrate while the reductase acts as an electron carrier shuttling electrons from NADPH to cytochrome P-450.	Oxygen	48-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
824157-2	1976	Cytochrome P-450 serves as the binding site for oxygen and substrate while the reductase acts as an electron carrier shuttling electrons from NADPH to cytochrome P-450.	Oxygen	48-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
824157-2	1976	Cytochrome P-450 serves as the binding site for oxygen and substrate while the reductase acts as an electron carrier shuttling electrons from NADPH to cytochrome P-450.	NADP	142-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
824157-2	1976	Cytochrome P-450 serves as the binding site for oxygen and substrate while the reductase acts as an electron carrier shuttling electrons from NADPH to cytochrome P-450.	NADP	142-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
824157-3	1976	The phospholipid facilitates the transfer of electrons from NADPH-cytochrome c reductase to cytochrome P-450 but itself is not an electron carrier.	Phospholipids	4-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
187927-0	1976	Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis.	Methyldopa	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
187927-0	1976	Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis.	Catechols	40-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
187927-0	1976	Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis.	Superoxides	80-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
187927-0	1976	Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis.	Methyldopa	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
12746-0	1976	Mechanism of inhibition by carbonyl cyanide m-chlorophenylhydrazone and sodium deoxycholate of cytochrome P-450-catalysed hepatic microsomal drug metabolism.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	27-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
12746-0	1976	Mechanism of inhibition by carbonyl cyanide m-chlorophenylhydrazone and sodium deoxycholate of cytochrome P-450-catalysed hepatic microsomal drug metabolism.	Deoxycholic Acid	72-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
12746-5	1976	In the presence of 0.03-0.09% sodium deoxycholate the rate-limiting factor in p-hydroxylation of aniline is the content of cytochrome P-450.	Deoxycholic Acid	30-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
184090-1	1976	Cytochrome P-450 was purified from bovine adrenal cortex mitochondria by affinity chromatography using an octylamine-substituted Sepharose column.	octylamine	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12746-5	1976	In the presence of 0.03-0.09% sodium deoxycholate the rate-limiting factor in p-hydroxylation of aniline is the content of cytochrome P-450.	aniline	97-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
184090-1	1976	Cytochrome P-450 was purified from bovine adrenal cortex mitochondria by affinity chromatography using an octylamine-substituted Sepharose column.	Sepharose	129-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
184090-3	1976	The specific concentration of cytochrome P-450 in the preparation was about 5 nmol of heme per mg of protein.	Heme	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
12746-10	1976	In the mechanism of action of carbonyl cyanide m-chlorophenylhydrazone the key step may be the electrostatic interaction of its protonated form and one of the forms of activated oxygen at the catalytic centre of cytochrome P-450.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	30-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-228
12746-10	1976	In the mechanism of action of carbonyl cyanide m-chlorophenylhydrazone the key step may be the electrostatic interaction of its protonated form and one of the forms of activated oxygen at the catalytic centre of cytochrome P-450.	Oxygen	178-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-228
12746-11	1976	5. at least two different phospholipid-dependent hydrophobic zones are assumed to exist in the microsomal membrane, both coupled with cytochrome P-450.	Phospholipids	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
12746-12	1976	One of them reveals selective sensitivity to the protonation action of carbonyl cyanide m-chlorophenylhydrazone and contains the "binding protein" for type I substrates and NADPH-cytochrome P-450 reductase; the other contains the cytochrome P-450 haem group and binding sites for type II substrates.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	71-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
184090-5	1976	Polyacrylamide gel electrophoresis of the purified cytochrome P-450 preparation treated with sodium dodecyl sulfate and mercaptoethanol showed a single major band with a molecular weight of about 60,000.	polyacrylamide	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
184090-5	1976	Polyacrylamide gel electrophoresis of the purified cytochrome P-450 preparation treated with sodium dodecyl sulfate and mercaptoethanol showed a single major band with a molecular weight of about 60,000.	Sodium Dodecyl Sulfate	93-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
184090-5	1976	Polyacrylamide gel electrophoresis of the purified cytochrome P-450 preparation treated with sodium dodecyl sulfate and mercaptoethanol showed a single major band with a molecular weight of about 60,000.	Mercaptoethanol	120-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
184090-10	1976	After reconstitution with adrenodoxin and its reductase, this cytochrome P-450 was highly active for cholesterol desmolase with an NADPH-generating system as electron donor but was not active for steroid 11beta-hydroxylase.	NADP	131-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
1068446-0	1976	Carbon monoxide binding to pentacoordinate mercaptide-heme complexes: kinetic study on models for cytochrome P-450.	Carbon Monoxide	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
10855-0	1976	A highly sensitive radiometric assay for zoxazolamine hydroxylation by liver microsomal cytochrome P-450 and P-448: properties of the membrane-bound and purified reconstituted system.	Zoxazolamine	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-114
1068446-0	1976	Carbon monoxide binding to pentacoordinate mercaptide-heme complexes: kinetic study on models for cytochrome P-450.	mercaptide-heme	43-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
985554-0	1976	Polarity in aromatic hydroxylation by hemin-thiol model systems for cytochrome P-450.	hemin-thiol	38-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
10902-0	1976	Stimulatory effect of FMN and methyl viologen on cytochrome P-450 dependent reduction of tertiary amine N-oxide.	tertiary amine n-oxide	89-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
955110-0	1976	Ligand partitioning into membranes: its significance in determining Km and Ks values for cytochrome P-450 and other membrane bound receptors and enzymes.	Potassium	75-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
954149-0	1976	A new class of inhibitory cytochrome P-450 complexes formed during metabolism: a comparison with amphetamine and SKF 525-A type complexes.	Amphetamine	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
948753-0	1976	Cytochrome P-450 induction by phenobarbital and 3-methylcholanthrene in primary cultures of hepatocytes.	Phenobarbital	30-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
948753-0	1976	Cytochrome P-450 induction by phenobarbital and 3-methylcholanthrene in primary cultures of hepatocytes.	Methylcholanthrene	48-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
948753-1	1976	The characteristic hepatocellular changes resulting from phenobarbital administration in vivo, namely an increase in the levels of cytochrome P-450 and proliferation of membranes of the smooth endoplasmic reticulum, have been demonstrated in primary cultures of nonreplicating hepatocytes on floating collagen membranes.	Phenobarbital	57-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
954149-0	1976	A new class of inhibitory cytochrome P-450 complexes formed during metabolism: a comparison with amphetamine and SKF 525-A type complexes.	Proadifen	113-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
954149-1	1976	During the metabolism of p-chloroaniline, sulfanilamide, 2-methylindoline, and dapsone, complexes with cytochrome P-450 are formed which absorb maximally at 448, 450, 451, and 452 nm, respectively.	4-chloroaniline	25-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
954149-1	1976	During the metabolism of p-chloroaniline, sulfanilamide, 2-methylindoline, and dapsone, complexes with cytochrome P-450 are formed which absorb maximally at 448, 450, 451, and 452 nm, respectively.	Sulfanilamide	42-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
182488-0	1976	Binding of a metyrapone spin label to microsomal cytochrome P-450.	Metyrapone	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
954149-1	1976	During the metabolism of p-chloroaniline, sulfanilamide, 2-methylindoline, and dapsone, complexes with cytochrome P-450 are formed which absorb maximally at 448, 450, 451, and 452 nm, respectively.	2-Methylindoline	57-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
954149-1	1976	During the metabolism of p-chloroaniline, sulfanilamide, 2-methylindoline, and dapsone, complexes with cytochrome P-450 are formed which absorb maximally at 448, 450, 451, and 452 nm, respectively.	Dapsone	79-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
954149-3	1976	Similarly, the formation is mainly a property of phenobarbital-induced cytochrome P-450 and is inhibited by comparable concentrations of metyrapone and 2-O-iodophenoxymethylimidazole.	Phenobarbital	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
954149-3	1976	Similarly, the formation is mainly a property of phenobarbital-induced cytochrome P-450 and is inhibited by comparable concentrations of metyrapone and 2-O-iodophenoxymethylimidazole.	Metyrapone	137-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
182488-1	1976	Probing of the active site of microsomal cytochrome P-450 was carried out with a spin label derived from 2-methyl-1,2-bis(3-pyridyl)-1-propanone (metyrapone).	Metyrapone	105-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
182488-1	1976	Probing of the active site of microsomal cytochrome P-450 was carried out with a spin label derived from 2-methyl-1,2-bis(3-pyridyl)-1-propanone (metyrapone).	Metyrapone	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
182488-2	1976	Its optical binding spectra to cytochrome P-450 resemble the spectra with metyrapone.	Metyrapone	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
182488-4	1976	Since the apparent optical and EPR binding constants agree very well (Ks approximately 2-10(-5) M), and metyrapone is found to displace the spin label, we conclude, that the spin label binds to the active site of cytochrome P-450.	Potassium	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	213-229
182488-4	1976	Since the apparent optical and EPR binding constants agree very well (Ks approximately 2-10(-5) M), and metyrapone is found to displace the spin label, we conclude, that the spin label binds to the active site of cytochrome P-450.	Metyrapone	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	213-229
182488-6	1976	The EPR signal accounts for only 60% of the bound spin label due to its dipolar interaction with the low-spin ferric heme of cytochrome P-450.	ferric heme	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
182488-8	1976	This supports the model that one of the pyridine nitrogens of metyrapone is coordinated to the iron of cytochrome P-450.	pyridine	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
182488-8	1976	This supports the model that one of the pyridine nitrogens of metyrapone is coordinated to the iron of cytochrome P-450.	Nitrogen	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
182488-8	1976	This supports the model that one of the pyridine nitrogens of metyrapone is coordinated to the iron of cytochrome P-450.	Metyrapone	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
182488-8	1976	This supports the model that one of the pyridine nitrogens of metyrapone is coordinated to the iron of cytochrome P-450.	Iron	95-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
939705-1	1976	The cytochrome P-450 is known to be a key enzymic component in steroid hydroxylation.	Steroids	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
177476-1	1976	Models for the oxidized reaction states of cytochrome P-450 enzymes and the molecular structure of iron(III) protoporphyrin IX dimethyl ester p-nitrobenzenethiolate.	iron(iii) protoporphyrin ix dimethyl ester p-nitrobenzenethiolate	99-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
956135-1	1976	The slow reduction of microsomal cytochrome P-450 by dithionite consists of an initial fast and then a slow phase.	Dithionite	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
956135-2	1976	During reduction of aniline and azide complexes with cytochrome P-450, an intermediate spectrum developed in the fast phase and changed to that of the reduced form in the slow phase.	aniline	20-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
956135-2	1976	During reduction of aniline and azide complexes with cytochrome P-450, an intermediate spectrum developed in the fast phase and changed to that of the reduced form in the slow phase.	Azides	32-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
956135-6	1976	The electron spin resonance spectrum of cytochrome P450 was greatly reduced in the initial phase of reduction with dithionite.	Dithionite	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
956135-7	1976	These results indicate that reduction of the aniline and azide complexes of cytochrome P-450 involves two steps: first reduction of cytochrome P-450 and then some changes in reduced state.	aniline	45-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
956135-7	1976	These results indicate that reduction of the aniline and azide complexes of cytochrome P-450 involves two steps: first reduction of cytochrome P-450 and then some changes in reduced state.	aniline	45-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
956135-7	1976	These results indicate that reduction of the aniline and azide complexes of cytochrome P-450 involves two steps: first reduction of cytochrome P-450 and then some changes in reduced state.	Azides	57-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
956135-7	1976	These results indicate that reduction of the aniline and azide complexes of cytochrome P-450 involves two steps: first reduction of cytochrome P-450 and then some changes in reduced state.	Azides	57-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
956135-8	1976	The aniline and cyanide difference spectra of reduced cytochrome P-450 showed peaks at 423 nm and 429 nm, respectively, while that of azide had a peak at 445 nm and a trough at 404 nm.	aniline	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
956135-8	1976	The aniline and cyanide difference spectra of reduced cytochrome P-450 showed peaks at 423 nm and 429 nm, respectively, while that of azide had a peak at 445 nm and a trough at 404 nm.	Cyanides	16-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
1275497-0	1976	Spironolactone and cytochrome P-450: impairment of steroid 21-hydroxylation in the adrenal cortex.	Steroids	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
1257757-1	1976	Tin greatly enhances heme breakdown in kidney, thus impairing heme-dependent cellular functions, such as cytochrome P-450 mediated drug biotransformation.	Tin	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
7270-0	1976	The role of cytochrome P-450 in the toxicity of fluroxene (2,2,2-trifluoroethyl vinyl ether) anaesthesia in vivo.	fluroxene	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1257757-1	1976	Tin greatly enhances heme breakdown in kidney, thus impairing heme-dependent cellular functions, such as cytochrome P-450 mediated drug biotransformation.	Heme	62-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
7270-0	1976	The role of cytochrome P-450 in the toxicity of fluroxene (2,2,2-trifluoroethyl vinyl ether) anaesthesia in vivo.	fluroxene	59-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1278381-0	1976	A model compound for nitrosyl cytochrome P-450; further evidence for mercaptide sulfur ligation to heme.	mercaptide sulfur	69-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1262443-5	1976	These data demonstrate that metyrapone inhibits both mitochondrial reactions involved in cortisol synthesis--initial cholesterol cleavage and final 11beta-hydroxylation; these effects probably result from interference by this agent with the interaction between substrate and related cytochrome P - 450.	Metyrapone	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	283-301
1278381-0	1976	A model compound for nitrosyl cytochrome P-450; further evidence for mercaptide sulfur ligation to heme.	Heme	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
983604-0	1976	An infrared study of the carbon monoxide complexes of cytochrome P-450 and cytochrome P-420.	Carbon Monoxide	25-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-91
173534-9	1975	A second effect of aniline, a type II ligand of cytochrome P-450, was to remove the g = 6 signal, suggesting that it also interacts with cytochrome P-420.	aniline	19-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
998274-0	1976	On the formation of cytochrome P-450 product complexes during the metabolism of phenylalkylamines.	phenylalkylamines	80-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
1008481-2	1976	In this study the ability of liver homogenates to metabolise aminopyrine and benzpyrene was correlated with hepatic cytochrome P-450 levels and with liver ultrastructure.	Aminopyrine	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
1008481-2	1976	In this study the ability of liver homogenates to metabolise aminopyrine and benzpyrene was correlated with hepatic cytochrome P-450 levels and with liver ultrastructure.	Benzopyrenes	77-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
1044321-0	1976	Proceedings: The role of cytochrome P-450 in carbon tetrachloride-induced hepatic injury.	Carbon Tetrachloride	45-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
183224-3	1976	Both acetaminophen and furosemide decreased the concentrations of cytochrome P-450 and cytochrome b5 in microsomes, and the activity of microsomal ethylmorphine N-demethylase and aniline hydroxylase.	Acetaminophen	5-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-100
183224-3	1976	Both acetaminophen and furosemide decreased the concentrations of cytochrome P-450 and cytochrome b5 in microsomes, and the activity of microsomal ethylmorphine N-demethylase and aniline hydroxylase.	Furosemide	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-100
1176584-4	1975	These findings are consistent with a previously-reported spironolactone-induced destruction of the microsomal enzyme cytochrome P-450, an enzyme necessary for 17-hydroxylase and desmolase activity.	Spironolactone	57-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
1209686-2	1975	A possible explanation was found when it was shown that androst-4-en-3,17-dione and testosterone could displace bound carbon monoxide from human placental microsomal cytochrome P-450.	Androstenedione	56-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
1209686-2	1975	A possible explanation was found when it was shown that androst-4-en-3,17-dione and testosterone could displace bound carbon monoxide from human placental microsomal cytochrome P-450.	Testosterone	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
1209686-2	1975	A possible explanation was found when it was shown that androst-4-en-3,17-dione and testosterone could displace bound carbon monoxide from human placental microsomal cytochrome P-450.	Carbon Monoxide	118-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
6092-4	1975	VMAX for the hydroxylation of DMA calculated as per 1 nmol of the cytochrome P--450 was higher in the cells than in the microsomes.	N,N-dimethylaniline	30-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-83
1216968-0	1975	Proceedings: The effects of adducts and the nature of activated oxygen for cytochrome P-450 catalyzed hydroxylation reactions.	Oxygen	64-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
1052431-0	1975	Effect of cobalt on microsomal cytochrome P-450: differences between liver and intestinal mucosa.	Cobalt	10-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1160997-0	1975	Early role during chemical evolution for cytochrome P450 in oxygen detoxification.	Oxygen	60-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
1201750-3	1975	On the basis of binding studies with ethyl isocyanide, degradation of cytochrome P-450 to P-420, redox potential, aniline binding, and relative rates of reduction by NADPH and NADH, it is suggested that the cytochrome P-450 system is analogous to that mammalian microsomes.	ethyl isocyanide	37-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
166885-0	1975	Nitric oxide complexes of cytochrome P-450.	Nitric Oxide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
240656-0	1975	Interaction of aromatic nitro compounds with reduced hepatic microsomal cytochrome P-450.	aromatic nitro compounds	15-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
240656-5	1975	There is apparent mutual inhibition of binding of carbon monoxide, metyrapone, and nitro compounds with reduced cytochrome P-450, since addition of metyrapone or carbon monoxide to reference and sample cuvettes does not alter qualitative aspects of the nitro binding spectra, but only its magnitude.	Carbon Monoxide	50-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
240656-5	1975	There is apparent mutual inhibition of binding of carbon monoxide, metyrapone, and nitro compounds with reduced cytochrome P-450, since addition of metyrapone or carbon monoxide to reference and sample cuvettes does not alter qualitative aspects of the nitro binding spectra, but only its magnitude.	Metyrapone	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
1201750-3	1975	On the basis of binding studies with ethyl isocyanide, degradation of cytochrome P-450 to P-420, redox potential, aniline binding, and relative rates of reduction by NADPH and NADH, it is suggested that the cytochrome P-450 system is analogous to that mammalian microsomes.	aniline	114-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
240656-5	1975	There is apparent mutual inhibition of binding of carbon monoxide, metyrapone, and nitro compounds with reduced cytochrome P-450, since addition of metyrapone or carbon monoxide to reference and sample cuvettes does not alter qualitative aspects of the nitro binding spectra, but only its magnitude.	nitro	83-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
240656-6	1975	From the relative KS values, it is concluded that metyrapone and carbon monoxide interact with reduced cytochrome P-450 more tenaciously than nitro compounds.	Potassium	18-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
1201750-3	1975	On the basis of binding studies with ethyl isocyanide, degradation of cytochrome P-450 to P-420, redox potential, aniline binding, and relative rates of reduction by NADPH and NADH, it is suggested that the cytochrome P-450 system is analogous to that mammalian microsomes.	NADP	166-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
240656-6	1975	From the relative KS values, it is concluded that metyrapone and carbon monoxide interact with reduced cytochrome P-450 more tenaciously than nitro compounds.	Metyrapone	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
1201750-3	1975	On the basis of binding studies with ethyl isocyanide, degradation of cytochrome P-450 to P-420, redox potential, aniline binding, and relative rates of reduction by NADPH and NADH, it is suggested that the cytochrome P-450 system is analogous to that mammalian microsomes.	NADP	166-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
240656-6	1975	From the relative KS values, it is concluded that metyrapone and carbon monoxide interact with reduced cytochrome P-450 more tenaciously than nitro compounds.	Carbon Monoxide	65-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
1201750-3	1975	On the basis of binding studies with ethyl isocyanide, degradation of cytochrome P-450 to P-420, redox potential, aniline binding, and relative rates of reduction by NADPH and NADH, it is suggested that the cytochrome P-450 system is analogous to that mammalian microsomes.	NAD	176-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-223
1233229-5	1975	The acceleration of oestrogen hydroxylation by rifampicin was paralleled by an increase in microsomal cytochrome P-450, and also by microsomal reduction of rifampicin-quinone, a reactive metabolite of rifampicin.	Rifampin	47-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
1902-2	1975	In oxidation of NADP.H2 there were at least three point of molecular O2 reduction: NADP.H2-specific flavoprotein, Fe2+ participating in reactions of peroxidation of unsaturated fatty acids and cytochrome P-450.	NADP	16-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-209
1142995-0	1975	Interactions of steroids with human placental cytochrome P-450 in the presence of carbon monoxide.	Steroids	16-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
1142995-0	1975	Interactions of steroids with human placental cytochrome P-450 in the presence of carbon monoxide.	Carbon Monoxide	82-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
806264-0	1975	Metobolism of chlorobenzene with hepatic microsomes and solubilized cytochrome P-450 systems.	chlorobenzene	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
1902-2	1975	In oxidation of NADP.H2 there were at least three point of molecular O2 reduction: NADP.H2-specific flavoprotein, Fe2+ participating in reactions of peroxidation of unsaturated fatty acids and cytochrome P-450.	Hydrogen	21-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-209
1902-2	1975	In oxidation of NADP.H2 there were at least three point of molecular O2 reduction: NADP.H2-specific flavoprotein, Fe2+ participating in reactions of peroxidation of unsaturated fatty acids and cytochrome P-450.	Oxygen	69-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-209
1902-2	1975	In oxidation of NADP.H2 there were at least three point of molecular O2 reduction: NADP.H2-specific flavoprotein, Fe2+ participating in reactions of peroxidation of unsaturated fatty acids and cytochrome P-450.	NADP	83-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-209
1902-3	1975	Efficiency of cytochrome P-450 inhibitors could not be evaluated by polarography as in the pathway several sites of molecular O2 activation were observed.	Oxygen	126-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
1131251-0	1975	Purification of cytochrome P-450 from bovin adrenocortical mitochondria by an "aniline-sepharose" and the properties.	aniline	79-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
1131251-0	1975	Purification of cytochrome P-450 from bovin adrenocortical mitochondria by an "aniline-sepharose" and the properties.	Sepharose	87-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
1186237-0	1975	The role of cholesterol and cytochrome P-450 in the cholesterol side chain cleavage reaction in adrenal cortex and corpora lutea.	Cholesterol	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
1133375-1	1975	Possible relationship to cytochrome P-450 enzymes and the structure of (p-nitrobenzenethiolato)iron(III) protoporphyrin IX dimethyl ester.	(p-nitrobenzenethiolato)iron(iii) protoporphyrin ix dimethyl ester	71-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
234439-5	1975	Cytochrome P-450 is recovered in a floating pellet after the addition of 25% ammonium sulfate followed by centrifugation, whereas cytochrome P-450I remains in the 25% ammonium sulfate supernatant fluid.	Ammonium Sulfate	77-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
234439-6	1975	Cytochrome P-450 is purified further by Sephadez G-200 and DEAE-Sephadex A-50 column chromatography, which also allows the isolation of cytochrome b5 and NADPH-dependent cytochrome P-450 reductase in good yields and with little cross-contamination.	sephadez g-200	40-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
234439-6	1975	Cytochrome P-450 is purified further by Sephadez G-200 and DEAE-Sephadex A-50 column chromatography, which also allows the isolation of cytochrome b5 and NADPH-dependent cytochrome P-450 reductase in good yields and with little cross-contamination.	2-diethylaminoethanol	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
234439-16	1975	The cytochrome P-450 aggregate is dissociated by 6 M urea, but cytochrome P-450I remains as such.	Urea	53-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
4374132-0	1974	Reduced nicotinamide adenine dinucleotide-cytochrome b5 reductase and cytochrome b5 as electron carriers in NADH-supported cytochrome P-450 -dependent enzyme activities in liver microsomes.	NAD	108-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
805803-0	1975	Involvement of cytochrome P-450 in the intracellular formation of lipid peroxides.	Lipid Peroxides	66-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
1120111-4	1975	(1) The hydrophilic sulfate group directs the steroid molecule so that it only interacts with the active site of cytochrome P-450 with its non-sulfurylated, hydrophobic end.	Sulfates	20-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
1120111-4	1975	(1) The hydrophilic sulfate group directs the steroid molecule so that it only interacts with the active site of cytochrome P-450 with its non-sulfurylated, hydrophobic end.	Steroids	46-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
1120111-5	1975	(2) The sulfate group interacts with the enzyme surface resulting in exposure of a slightly different part of the hydrophobic end of the substrate to the active site of cytochrome P-450 than when the same end of the free steroid is exposed to the active site of the enzyme.	Sulfates	8-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
1120111-5	1975	(2) The sulfate group interacts with the enzyme surface resulting in exposure of a slightly different part of the hydrophobic end of the substrate to the active site of cytochrome P-450 than when the same end of the free steroid is exposed to the active site of the enzyme.	Steroids	221-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
1139001-1	1975	The absence of correlation between the effect of aniline and aminoantipyrine derivatives on cytochrome P-450 reduction rate and its oxidation rate draw to the conclusion that the reductase reaction is not a limiting step of hydroxylation for all substrates.	Ampyrone	61-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
1116950-5	1975	Subtraction of the nitrogen values from the carbon monoxide values, after allowing for an absorption shift, gives the absolute spectrum of cytochrome P450.	Nitrogen	19-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
1116950-5	1975	Subtraction of the nitrogen values from the carbon monoxide values, after allowing for an absorption shift, gives the absolute spectrum of cytochrome P450.	Carbon Monoxide	44-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
1116950-8	1975	The content of cytochrome P450 in animals fed with phenobarbitone was 2.4 times greater than in control animals.	Phenobarbital	51-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
4550000-0	1974	Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex.	Steroids	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
4371680-0	1974	Spectral and catalytic properties of cytochrome P-450 from a diazinon-resistant housefly strain.	Diazinon	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
4531003-5	1974	We have also shown that the molar magnetic ellipticity for reduced + CO treated cytochrome P-450 of Pseudomonas grown on camphor is of similar value to that of reduced + CO treated microsomal P-450 and P-448.	Camphor	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
4432244-0	1974	Increased antitumor activity of cyclophosphamide (Endoxan) following pretreatment with inducer of drug-metabolizing enzymes (cytochrome P-450).	Cyclophosphamide	32-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
4432244-0	1974	Increased antitumor activity of cyclophosphamide (Endoxan) following pretreatment with inducer of drug-metabolizing enzymes (cytochrome P-450).	Cyclophosphamide	50-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
4153511-0	1974	The formation of complexes absorbing at 455 nm from cytochrome P-450 and metabloites of compounds related to SKF 525-A.	Proadifen	109-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
4831127-0	1974	Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism.	Testosterone	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
4153124-0	1974	The influence of cytochrome P-450 induction on the metabolic formation of 455-NM complexes from amphetamines.	Amphetamines	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
4364009-0	1974	Phospholipids of adrenal cortex mitochondria and the steroid hydroxylases: the lipid-environment of cytochrome P-450.	Phospholipids	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
4151581-0	1974	Redox properties of the reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 and reduced nicotinamide adenine dinucleotide-cytochrome b5 reductases.	NAD	32-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
4136627-0	1974	Detection of cytochrome P-450 in subcellular fractions of Endomycopsislipolytica grown on n-hexadecane.	n-hexadecane	90-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
4204348-0	1974	Differences in inducibility of cutaneous and hepatic drug metabolizing enzymes and cytochrome P-450 by polychlorinated biphenyls and 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT).	Polychlorinated Biphenyls	103-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
4522784-1	1974	Induction of hepatic microsomal cytochrome P-450 and ethylmorphine N-demethylase activity by phenobarbital requires de novo synthesis of mRNA.	Phenobarbital	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-80
4828525-0	1974	The effect of phenobarbital, 3-methylcholanthrene, 3,4-benzpyrene, and pregnenolone-16 alpha-carbonitrile on microsomal heme oxygenase and splenic cytochrome P-450.	Pregnenolone Carbonitrile	71-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
4204348-0	1974	Differences in inducibility of cutaneous and hepatic drug metabolizing enzymes and cytochrome P-450 by polychlorinated biphenyls and 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT).	DDT	133-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
4204348-0	1974	Differences in inducibility of cutaneous and hepatic drug metabolizing enzymes and cytochrome P-450 by polychlorinated biphenyls and 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT).	DDT	180-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Carbon Monoxide	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
4149283-0	1973	The role of cytochrome P-450 in cholesterol biosynthesis.	Cholesterol	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Carbon Monoxide	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Glycerol	180-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Glycerol	180-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Water	189-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
4721048-1	1973	Rebinding of carbon monoxide to myoglobin and to cytochrome P-450 after removal by a light flash occurs down to 50 degrees K for myoglobin and 25 degrees K for cytochrome P-450 in glycerol-water solution.	Water	189-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4733995-0	1973	Role of cytochrome P-450 in carbon tetrachloride activation and CCl 4-induced necrosis.	Carbon Tetrachloride	28-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
4741599-0	1973	Some spectral properties of cytochrome P-450 from microsomes isolated from control, phenobarbital- and naphthalene-treated houseflies.	Phenobarbital	84-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
4741599-0	1973	Some spectral properties of cytochrome P-450 from microsomes isolated from control, phenobarbital- and naphthalene-treated houseflies.	naphthalene	103-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
4122821-0	1973	The role of cytochrome P-450 in N-hydroxylation of 2-acetylaminofluorene.	Nitrogen	32-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
4122821-0	1973	The role of cytochrome P-450 in N-hydroxylation of 2-acetylaminofluorene.	2-Acetylaminofluorene	51-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
4146295-0	1973	Iron-dependent loss of liver cytochrome P-450 haem in vivo and in vitro.	Iron	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
4149394-0	1973	Breakdown of cytochrome P-450 heme by secobarbital and other allyl-containing barbiturates.	Heme	30-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
4155922-0	1973	The role of cytochrome P-450 and P-448 in drug and steroid hydroxylations.	Steroids	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-38
4375425-0	1973	Testicular cytochrome P-450 and iron-sulfur protein as related to steroid metabolism.	Steroids	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
4149394-0	1973	Breakdown of cytochrome P-450 heme by secobarbital and other allyl-containing barbiturates.	Barbiturates	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
4149397-0	1973	The role of cytochrome P-450 in the N-oxidation of individual amines.	Amines	62-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
4650623-0	1972	A reconstituted microsomal enzyme system that converts naphthalene to trans-1,2-dihydroxy-1,2-dihydronaphthalene via naphthalene-1,2-oxide: presence of epoxide hydrase in cytochrome P-450 and P-448 fractions.	naphthalene	55-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-197
4267597-0	1973	Active centers of microsomal cytochrome P-450 determined with metyrapone by mutural depletion system kinetics.	Metyrapone	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
4650623-0	1972	A reconstituted microsomal enzyme system that converts naphthalene to trans-1,2-dihydroxy-1,2-dihydronaphthalene via naphthalene-1,2-oxide: presence of epoxide hydrase in cytochrome P-450 and P-448 fractions.	1,2-dihydroxy-1,2-dihydronaphthalene	70-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-197
4650623-0	1972	A reconstituted microsomal enzyme system that converts naphthalene to trans-1,2-dihydroxy-1,2-dihydronaphthalene via naphthalene-1,2-oxide: presence of epoxide hydrase in cytochrome P-450 and P-448 fractions.	naphthalene 1,2-oxide	117-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-197
11946722-0	1972	On the participation of cytochrome P-450 in the formation of 16, 17-dihydroxylated C(19) steroids from 16-dehydro-C(19) steroids.	16, 17-dihydroxylated c	61-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
11946722-0	1972	On the participation of cytochrome P-450 in the formation of 16, 17-dihydroxylated C(19) steroids from 16-dehydro-C(19) steroids.	Steroids	89-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
11946722-0	1972	On the participation of cytochrome P-450 in the formation of 16, 17-dihydroxylated C(19) steroids from 16-dehydro-C(19) steroids.	16-dehydro-c	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
11946722-0	1972	On the participation of cytochrome P-450 in the formation of 16, 17-dihydroxylated C(19) steroids from 16-dehydro-C(19) steroids.	Steroids	120-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
4401153-2	1972	Role of the cytochrome P-450 and P-448 fractions in drug and steroid hydroxylations.	Steroids	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-38
5051307-0	1972	Decrease in hepatic cytochrome P-450 and catalase following allylisopropyl acetamide: the effect of concomitant hemin administration.	Allylisopropylacetamide	60-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-49
5076665-0	1972	Is the liver cytochrome P-450-linked biotransformation system lecithin-dependent?	Lecithins	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
5013819-0	1972	Spectral studies of the binding of O,O-diethyl p-nitrophenylphosphorothionate (parathion) to cytochrome P-450.	o,o-diethyl p-nitrophenylphosphorothionate	35-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
5008942-0	1972	Decreased levels of cytochrome P-450 and catalase in hepatic porphyria caused by substituted acetamides and barbiturates.	Acetamides	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-49
5013819-0	1972	Spectral studies of the binding of O,O-diethyl p-nitrophenylphosphorothionate (parathion) to cytochrome P-450.	Parathion	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
5008942-0	1972	Decreased levels of cytochrome P-450 and catalase in hepatic porphyria caused by substituted acetamides and barbiturates.	Barbiturates	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-49
4399944-0	1971	Conversion of agroclavine by mammalian cytochrome P-450.	agroclavine	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
4335684-0	1971	Cytochrome P-450 from the adrenal cortex: interaction of steroids and the hydroxylation reaction.	Steroids	57-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
5144763-0	1971	The binding of metyrapone to cytochrome P-450 and its inhibitory action on liver microsomal mixed-function oxidase reactions.	Metyrapone	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
5144765-0	1971	Model systems for mono-oxygenases, with results with iron(II)-sulphur complexes as models for cytochrome P-450.	ammonium ferrous sulfate	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
5116661-0	1971	Formation rates of the two ethyl isocyanide compounds of liver cytochrome P-450 at low temperatures.	ethyl isocyanide	27-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
5098347-0	1971	[Binding of carbon tetrachloride to reduced microsomal cytochrome P-450 and to heme].	Carbon Tetrachloride	12-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
4400522-0	1972	Incorporation of radioactive- -aminolevulinic acid into microsomal cytochrome P 450 : selective breakdown of the hemoprotein by allylisopropylacetamide and carbon tetrachloride.	radioactive- -aminolevulinic acid	17-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
4400522-0	1972	Incorporation of radioactive- -aminolevulinic acid into microsomal cytochrome P 450 : selective breakdown of the hemoprotein by allylisopropylacetamide and carbon tetrachloride.	Allylisopropylacetamide	128-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
4400522-0	1972	Incorporation of radioactive- -aminolevulinic acid into microsomal cytochrome P 450 : selective breakdown of the hemoprotein by allylisopropylacetamide and carbon tetrachloride.	Carbon Tetrachloride	156-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
4404917-0	1972	[Formation of chloroform from carbon tetrachloride in liver microsomes, lipid peroxidation and destruction of cytochrome P-450].	Chloroform	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-127
4570969-0	1972	The binding of metyrapone to cytochrome P-450 and its inhibitory action on microsomal hepatic mixed function oxidation reactions.	Metyrapone	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
5118111-0	1971	Species differences in the effect of morphine administration or adrenalectomy on the substrate interactions with cytochrome P-450 and drug oxidations by liver microsomes.	Morphine	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
4397379-0	1971	Effect of temperature on the relationship between hepatic microsomal cytochrome P-450 reduction and ethylmorphine demethylation.	Ethylmorphine	100-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
4099847-0	1971	Properties of cytochrome P-450 as affected by environmental factors: qualitative changes due to administration of polycyclic hydrocarbons.	Hydrocarbons, Cyclic	114-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
5289597-0	1970	Some chemical properties of cytochrome P-450 and its carbon monoxide compound (P-450.CO).	Carbon Monoxide	53-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
5497445-0	1970	Incorporation of radioactive iron into cytochrome b5 and cytochrome P-450 of liver microsomes.	Iron	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
5535939-0	1970	Effect of adrenalectomy on the substrate interaction with cytochrome P-450 in the hydroxylation of steroid hormones by liver microsomes.	Steroids	99-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
11947411-0	1970	Rapid loss of cytochrome P-450 and haem caused in the liver microsomes by the porphyrogenic agent 2-allyl-2-isopropylacetamide.	Allylisopropylacetamide	98-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
4391249-0	1969	Cytochrome P-450 in steroid biogenesis.	Steroids	20-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
5360680-0	1969	Cytochrome P-450 in the omega-oxidation of fatty acids.	Fatty Acids	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
4390185-0	1969	The role of heme synthesis during the induction of hepatic microsomal cytochrome P-450 and drug metabolism produced by benzpyrene.	Heme	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
5433592-0	1970	In vivo interaction of metyrapone with adrenal cortical mitochondrial cytochrome P-450.	Metyrapone	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
4390187-0	1969	Hydroxylation of benzphetamine and other drugs by a solubilized form of cytochrome P-450 from liver microsomes: lipid requirement for drug demethylation.	Benzphetamine	17-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
4185033-0	1969	The role of cytochrome P-450 in the mechanism of inhibition of steroid 11 beta-hydroxylation by dicumarol.	Steroids	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
5796288-0	1969	A model for the interaction of cytochrome P-450 with carbon monoxide.	Carbon Monoxide	53-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
4185033-0	1969	The role of cytochrome P-450 in the mechanism of inhibition of steroid 11 beta-hydroxylation by dicumarol.	Dicumarol	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
5805284-0	1969	The interaction of metopirone with adrenal mitochondrial cytochrome P-450.	Metyrapone	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
5725573-0	1968	Mechanism of p-nitrobenzoate reduction in liver: the possible role oc cytochrome P-450 in liver microsomes.	p-nitrobenzoate	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
4385526-0	1968	The electron spin resonance and absorption spectra of microsomal cytochrome P-450 and its isocyanide complexes.	Cyanides	90-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
33932713-0	2021	Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.	chloromethylindoline	49-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
5688265-0	1968	Effect of partial hepatectomy of the responsiveness of microsomal enzymes and cytochrome P-450 to phenobarbital or 3-methylcholanthrene.	Phenobarbital	98-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
5688265-0	1968	Effect of partial hepatectomy of the responsiveness of microsomal enzymes and cytochrome P-450 to phenobarbital or 3-methylcholanthrene.	Methylcholanthrene	115-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
33932713-3	2021	In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill.	morin	62-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
33932713-3	2021	In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill.	morin	62-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
33932713-0	2021	Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.	chloromethylindoline	49-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
33932713-3	2021	In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill.	seco-oh-chloromethylindoline	32-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
33932713-3	2021	In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill.	seco-oh-chloromethylindoline	32-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
28520368-5	2012	Clozapine is metabolized in the liver by the cytochrome P450 (CYP) system of enzymes.	Clozapine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
33652071-0	2021	Identification of human cytochrome P450 isozymes involved in the oxidative metabolism of carfentanil.	carfentanil	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
33652071-2	2021	In the present study, the human cytochrome P450 (CYP) isozymes catalyzing the oxidative metabolism of carfentanil were investigated.	carfentanil	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
33652071-2	2021	In the present study, the human cytochrome P450 (CYP) isozymes catalyzing the oxidative metabolism of carfentanil were investigated.	carfentanil	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
28520368-6	2012	CYP1A2 is the main CYP isoform in clozapine metabolism and CYP1A2 activity is an important determinant of clozapine dose (4).	Clozapine	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
28520368-6	2012	CYP1A2 is the main CYP isoform in clozapine metabolism and CYP1A2 activity is an important determinant of clozapine dose (4).	Clozapine	106-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
28520368-5	2012	Clozapine is metabolized in the liver by the cytochrome P450 (CYP) system of enzymes.	Clozapine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
28520368-7	2012	Other CYP enzymes involved in clozapine metabolism include CYP2D6 and CYP3A4.	Clozapine	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
34048999-1	2021	Gilteritinib is primarily metabolized via cytochrome P450 (CYP).	gilteritinib	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
34048999-1	2021	Gilteritinib is primarily metabolized via cytochrome P450 (CYP).	gilteritinib	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
33982687-1	2021	Cytochrome-P450-reductase transfers electrons to cytochrome-P450 through its flavin mononucleotide binding domain (FBD).	Flavin Mononucleotide	77-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
33610566-2	2021	However, its glucuronidation, glucuronides excretion, and drug-drug interaction (DDI) involving in human cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT) enzymes, and efflux transporters (BCRP and MRPs) remains unclear so far.	Glucuronides	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
33934248-0	2021	Transcriptomic analysis of saffron at different flowering stages using RNA sequencing uncovers cytochrome P450 genes involved in crocin biosynthesis.	crocin	129-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
33934248-2	2021	This study aimed to screen differentially expressed genes (DEGs) in saffron at different flowering stages and identify cytochrome P450 (CYP) genes involved in crocin biosynthesis.	crocin	159-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
33934248-2	2021	This study aimed to screen differentially expressed genes (DEGs) in saffron at different flowering stages and identify cytochrome P450 (CYP) genes involved in crocin biosynthesis.	crocin	159-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-139
6541651-2	1984	In spite of numerous spectroscopic similarities between chloroperoxidase and cytochrome P-450 (P-450) which suggest endogenous cysteinate axial ligation in chloroperoxidase as has been established for P-450, assignment of the endogenous axial ligand of chloroperoxidase has remained controversial since no available free sulfhydryl groups have been detected in chemical studies of chloroperoxidase.	cysteinate	127-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
33610566-0	2021	Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters.	isobavachalcone	69-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
33610566-2	2021	However, its glucuronidation, glucuronides excretion, and drug-drug interaction (DDI) involving in human cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT) enzymes, and efflux transporters (BCRP and MRPs) remains unclear so far.	Glucuronides	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
33748959-2	2021	Their narrow therapeutic index and metabolism through cytochrome p450 (CYP) enzymes can result in a drug interaction when used concomitantly with rifamycins.	rifamycin S	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
33748959-2	2021	Their narrow therapeutic index and metabolism through cytochrome p450 (CYP) enzymes can result in a drug interaction when used concomitantly with rifamycins.	rifamycin S	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
33748959-4	2021	OBJECTIVE: To examine literature which evaluates the concomitant use of opioids and rifamycins with clinically-relevant CYP-inducing properties METHODS: A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was performed.	rifamycin S	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
33987428-12	2021	Circumstantial evidence suggests that reactive oxygen species (ROS) generated by cytochrome P450 could be responsible for the initial steps of injury, but details are unknown.	Reactive Oxygen Species	38-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
33890704-1	2021	We investigated the effect of deglucuronidation on the plasma concentration of the constituents of the Basel phenotyping cocktail and on the interpretation of the phenotyping results under basal conditions and after cytochrome P450 (CYP) induction with metamizole.	Dipyrone	253-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
33719395-2	2021	Several of these PAs are genotoxic and carcinogenic, primarily in the liver, upon cytochrome P450 (CYP)-catalyzed activation into reactive (pyrrolic and pyrrole-like) metabolites.	Pyrroles	153-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
33719395-2	2021	Several of these PAs are genotoxic and carcinogenic, primarily in the liver, upon cytochrome P450 (CYP)-catalyzed activation into reactive (pyrrolic and pyrrole-like) metabolites.	Pyrroles	153-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
33728909-2	2021	We aimed to investigate the inhibitory effect of binimetinib on cytochrome P450 using human liver microsomes.	binimetinib	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
33592181-1	2021	Human cytochrome P450 enzymes (CYPs or P450s) are known to be reduced by their electron transfer partners in the absence of substrate and in turn to reduce other acceptor molecules such as molecular oxygen, thereby creating superoxide anions (O2- ).	Oxygen	199-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
33592181-1	2021	Human cytochrome P450 enzymes (CYPs or P450s) are known to be reduced by their electron transfer partners in the absence of substrate and in turn to reduce other acceptor molecules such as molecular oxygen, thereby creating superoxide anions (O2- ).	Superoxides	224-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
33592181-1	2021	Human cytochrome P450 enzymes (CYPs or P450s) are known to be reduced by their electron transfer partners in the absence of substrate and in turn to reduce other acceptor molecules such as molecular oxygen, thereby creating superoxide anions (O2- ).	Oxygen	243-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
33935788-14	2021	The correlation analysis between CYP protein abundance and CYP enzyme activity showed that CYP3A22 protein abundance correlated clearly with the metabolism of midazolam at PND 7.	Midazolam	159-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
33935788-14	2021	The correlation analysis between CYP protein abundance and CYP enzyme activity showed that CYP3A22 protein abundance correlated clearly with the metabolism of midazolam at PND 7.	Midazolam	159-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
33936006-1	2021	Cytochrome P450 enzymes, or P450s, are haem monooxygenases renowned for their ability to insert one atom from molecular oxygen into an exceptionally broad range of substrates while reducing the other atom to water.	Oxygen	48-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33936006-1	2021	Cytochrome P450 enzymes, or P450s, are haem monooxygenases renowned for their ability to insert one atom from molecular oxygen into an exceptionally broad range of substrates while reducing the other atom to water.	Water	208-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33987428-12	2021	Circumstantial evidence suggests that reactive oxygen species (ROS) generated by cytochrome P450 could be responsible for the initial steps of injury, but details are unknown.	Reactive Oxygen Species	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
33538960-9	2021	This complicates the drug-disease interaction profile of the patients as both the investigational drugs (e.g., remdesivir, dexamethasone) and the agents for comorbidities can be affected by compromised CYP-mediated hepatic metabolism.	Dexamethasone	123-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
33400885-1	2021	INTRODUCTION: Cytochrome P450 (CYP) metabolizes vital endogenous (steroids, vitamins) and exogenous (drugs, toxins) substrates.	Steroids	66-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
33400885-1	2021	INTRODUCTION: Cytochrome P450 (CYP) metabolizes vital endogenous (steroids, vitamins) and exogenous (drugs, toxins) substrates.	Steroids	66-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
33400885-6	2021	An opposite role of the hypothalamic paraventricular and arcuate nuclei and 5-HT receptors present therein in the regulation of CYP is described.	Serotonin	76-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
33189850-1	2021	Cytochrome P450 (P450) 11B1 and 11B2 both catalyze the 11beta-hydroxylation of 11-deoxycorticosterone and the subsequent 18-hydroxylation of the product.	Desoxycorticosterone	79-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-27
33570057-5	2021	Rhamnetin treatment decreased expression of the drug resistance-related downstream genes of PXR (cyp3a4 [cytochrome P-450] or mdr-1 [multi-drug resistance 1]), which mediate the metabolism or elimination of sorafenib in HCC cells.	rhamnetin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
33570057-5	2021	Rhamnetin treatment decreased expression of the drug resistance-related downstream genes of PXR (cyp3a4 [cytochrome P-450] or mdr-1 [multi-drug resistance 1]), which mediate the metabolism or elimination of sorafenib in HCC cells.	Sorafenib	207-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
33545101-2	2021	We demonstrate the nascent approach of site-specific 2D IR spectroscopy to investigate the archetypical cytochrome P450, P450cam, to better delineate the mechanism of the lower regioselectivity of hydroxylation of the substrate norcamphor in comparison to the native substrate camphor.	norcamphor	228-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
33545101-2	2021	We demonstrate the nascent approach of site-specific 2D IR spectroscopy to investigate the archetypical cytochrome P450, P450cam, to better delineate the mechanism of the lower regioselectivity of hydroxylation of the substrate norcamphor in comparison to the native substrate camphor.	Camphor	231-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
33212179-6	2021	The highest activity was exhibited by methyl ophiopogonanone B and ginsenoside F2, indicating that they are CYP inducers.	methylophiopogonanone B	38-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
33212179-6	2021	The highest activity was exhibited by methyl ophiopogonanone B and ginsenoside F2, indicating that they are CYP inducers.	ginsenoside F2	67-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
33538960-9	2021	This complicates the drug-disease interaction profile of the patients as both the investigational drugs (e.g., remdesivir, dexamethasone) and the agents for comorbidities can be affected by compromised CYP-mediated hepatic metabolism.	remdesivir	111-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
33125290-0	2021	Human Mass Balance, Metabolism, and Cytochrome P450 Phenotyping of Lusutrombopag.	lusutrombopag	67-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
32918831-0	2021	Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.	pexidartinib	54-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
33747646-2	2021	Hypercalcemia is a rare yet important side-effect of ATRA, especially when it is used concomitantly with a medication that impedes its metabolism by inhibiting cytochrome P-450 in the liver and thus increasing the duration of exposure to ATRA.	Tretinoin	53-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Famotidine	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Famotidine	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	fostemsavir	136-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Temsavir	156-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Temsavir	156-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	fostemsavir	287-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Rifampin	334-342	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Carbamazepine	344-357	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Phenytoin	359-368	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Mitotane	370-378	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	enzalutamide	380-392	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33078993-0	2021	Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of Nafithromycin, a next generation lactone ketolide antibiotic.	nafithromycin	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
33078993-0	2021	Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of Nafithromycin, a next generation lactone ketolide antibiotic.	nafithromycin	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
33078993-4	2021	To facilitate comparative assessment of drug-drug interaction potential, CYP inhibitory activities of nafithromycin was evaluated in comparison with clarithromycin, telithromycin, cethromycin and solithromycin.	nafithromycin	102-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
33747646-4	2021	These medications inhibit two vital enzymes of cytochrome P-450, CYP2C9 and CYP3A4, potentiating the effects of ATRA on calcium metabolism.	Tretinoin	112-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
33747646-4	2021	These medications inhibit two vital enzymes of cytochrome P-450, CYP2C9 and CYP3A4, potentiating the effects of ATRA on calcium metabolism.	Calcium	120-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
32725383-4	2021	RESULTS: Seventy-two metabolic drug interaction studies were identified where volume of distribution at steady-state (Vss) values were available for the CYP index substrates caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), theophylline (CYP1A2), and tolbutamide (CYP2C9).	Caffeine	174-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-156
32888176-0	2021	Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4.	Methotrimeprazine	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
32869328-4	2021	A clinical study in healthy subjects (n = 27) evaluated the inhibition of CYP3A4, CYP2C8, and CYP2C9 in vivo by administering single doses of probe CYP substrates (midazolam, pioglitazone, and tolbutamide) alone and in combination with relacorilant (350 mg).	Pioglitazone	175-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
32869328-4	2021	A clinical study in healthy subjects (n = 27) evaluated the inhibition of CYP3A4, CYP2C8, and CYP2C9 in vivo by administering single doses of probe CYP substrates (midazolam, pioglitazone, and tolbutamide) alone and in combination with relacorilant (350 mg).	Tolbutamide	193-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
33717590-14	2021	GSEA results showed that high expressed DYNLRB2 and SPTBN1 were enriched in Drug metabolism cytochrome P450, Cardiac muscle contraction, Retinol metabolism.	gsea	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
33717590-14	2021	GSEA results showed that high expressed DYNLRB2 and SPTBN1 were enriched in Drug metabolism cytochrome P450, Cardiac muscle contraction, Retinol metabolism.	Vitamin A	137-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
33215946-9	2021	EXPERT OPINION: Overall, the CYP enzymes, depending upon the isoform, play a contributory or protective role in hyperoxic lung injury, and are, therefore, ideal candidates for developing drugs that can treat oxygen-mediated lung injury.	Oxygen	208-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
32888176-0	2021	Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4.	Clozapine	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
32888176-1	2021	BACKGROUND: Cytochrome P450 (CYP) enzymes are involved in the metabolism of many important endogenous substrates (steroids, melatonin), drugs and toxic xenobiotics.	Steroids	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
32888176-1	2021	BACKGROUND: Cytochrome P450 (CYP) enzymes are involved in the metabolism of many important endogenous substrates (steroids, melatonin), drugs and toxic xenobiotics.	Melatonin	124-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
33572963-0	2021	Pharmacokinetic Estimation Models-based Approach to Predict Clinical Implications for CYP Induction by Calcitriol in Human Cryopreserved Hepatocytes and HepaRG Cells.	Calcitriol	103-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	quinoneimines	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	quinoneimines	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	Mefenamic Acid	68-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	Mefenamic Acid	68-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	Glutathione	150-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
33259822-2	2021	Quinoneimines formed by cytochrome P450 (CYP)-mediated oxidation of MFA are considered to be causal metabolites of the toxicity and are detoxified by glutathione conjugation.	Glutathione	150-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
33146575-5	2021	The formation of 3-OH-NAB was observed after the incubation of NAB with various cytochrome P450 (CYP) isoforms.	3-oh-nab	17-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
33146575-5	2021	The formation of 3-OH-NAB was observed after the incubation of NAB with various cytochrome P450 (CYP) isoforms.	3-oh-nab	17-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
33146575-5	2021	The formation of 3-OH-NAB was observed after the incubation of NAB with various cytochrome P450 (CYP) isoforms.	Nabumetone	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
33146575-5	2021	The formation of 3-OH-NAB was observed after the incubation of NAB with various cytochrome P450 (CYP) isoforms.	Nabumetone	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
33146575-10	2021	Further in vitro inhibition experiments showed that multiple non-CYP enzymes are involved in the formation of 6-MNA from 3-OH-NAB.	6-methoxy-2-naphthylacetic acid	110-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
33146575-10	2021	Further in vitro inhibition experiments showed that multiple non-CYP enzymes are involved in the formation of 6-MNA from 3-OH-NAB.	3-oh-nab	121-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
33572963-2	2021	The purpose of this study was to predict the clinical significance of cytochrome P450 (CYP) induction by calcitriol using in vitro human cryopreserved hepatocytes, HepaRG experimental systems, and various pharmacokinetic estimation models.	Calcitriol	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
33572963-2	2021	The purpose of this study was to predict the clinical significance of cytochrome P450 (CYP) induction by calcitriol using in vitro human cryopreserved hepatocytes, HepaRG experimental systems, and various pharmacokinetic estimation models.	Calcitriol	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
33572963-7	2021	Therefore, we conclude that CYP induction by calcitriol treatment would not be clinically significant under typical clinical conditions.	Calcitriol	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32827665-0	2020	Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: A review of recent studies.	Linoleic Acid	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33461459-2	2021	BACKGROUND: Current pharmacokinetic investigations consider reactive oxygen species formed in microsomal reactions as toxic waste products, whereas our works (Manoj et al., 2016) showed that DROS are the reaction mainstay in cytochrome P450 mediated metabolism and that they play significant roles in explaining several unexplained physiologies (Parashar et al., 2018).	Oxygen	69-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-240
33096358-0	2021	Curcumin ameliorates mercuric chloride-induced liver injury via modulating cytochrome P450 signaling and Nrf2/HO-1 pathway.	Curcumin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
33096358-0	2021	Curcumin ameliorates mercuric chloride-induced liver injury via modulating cytochrome P450 signaling and Nrf2/HO-1 pathway.	Mercuric Chloride	21-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
33096358-5	2021	Additionally, we also found that curcumin could suppress inflammatory damage, unbalance of trace elements (including sodium, magnesium, kalium, calcium overload), oxidative burst induced by HgCl2, which could be associated with cytochrome P450 (CYP450) signaling.	Curcumin	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
33096358-5	2021	Additionally, we also found that curcumin could suppress inflammatory damage, unbalance of trace elements (including sodium, magnesium, kalium, calcium overload), oxidative burst induced by HgCl2, which could be associated with cytochrome P450 (CYP450) signaling.	Mercuric Chloride	190-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
33411110-1	2022	PURPOSE: Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP).	Rivaroxaban	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
33411110-1	2022	PURPOSE: Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP).	Rivaroxaban	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
33411110-4	2022	Furthermore, the catalytic efficiency of CYP isoforms was compared via metabolic kinetic studies of rivaroxaban with recombinant CYP isoenzymes, as well as via CYP-specific inhibitory studies.	Rivaroxaban	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
33411110-6	2022	RESULTS: Multiple CYP isoforms were involved in the hydroxylation of rivaroxaban, with decreasing catalytic rates as follows: CYP2J2 > 3A4 > 2D6 > 4F3 > 1A1 > 3A5 > 3A7 > 2A6 > 2E1 > 2C9 > 2C19.	Rivaroxaban	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
32979584-0	2021	Interspecies differences in cytochrome P450-mediated metabolism of neonicotinoids among cats, dogs, rats, and humans.	Neonicotinoids	67-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
32979584-3	2021	Cytochrome P450 (CYP) is among the most significant xenobiotic metabolizing enzymes that oxidizes several chemicals, including neonicotinoids.	Neonicotinoids	127-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32979584-3	2021	Cytochrome P450 (CYP) is among the most significant xenobiotic metabolizing enzymes that oxidizes several chemicals, including neonicotinoids.	Neonicotinoids	127-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
32979584-4	2021	However, CYP activities and metabolite compositions of neonicotinoid metabolites are unknown in most domesticated pet species.	Neonicotinoids	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
32979584-9	2021	CYP activities in metabolism of acetamiprid to dm-acetamiprid and N-acetyl-acetamiprid were determined to be significantly higher in humans compared to other species.	acetamiprid	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32979584-9	2021	CYP activities in metabolism of acetamiprid to dm-acetamiprid and N-acetyl-acetamiprid were determined to be significantly higher in humans compared to other species.	dm-acetamiprid	47-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32979584-9	2021	CYP activities in metabolism of acetamiprid to dm-acetamiprid and N-acetyl-acetamiprid were determined to be significantly higher in humans compared to other species.	n-acetyl-acetamiprid	66-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32979584-10	2021	However, further studies should be targeted at identifying the differences in hepatic metabolism of neonicotinoids in these species using recombinant CYP enzymes.	Neonicotinoids	100-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
32696500-1	2021	The glycopeptide antibiotics (GPAs) are a fascinating example of complex natural product biosynthesis, with the non-ribosomal synthesis of the peptide core coupled to a cytochrome P450-mediated cyclisation cascade that crosslinks aromatic side chains within this peptide.	glycopeptide antibiotics	4-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
32696500-1	2021	The glycopeptide antibiotics (GPAs) are a fascinating example of complex natural product biosynthesis, with the non-ribosomal synthesis of the peptide core coupled to a cytochrome P450-mediated cyclisation cascade that crosslinks aromatic side chains within this peptide.	gpas	30-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
33310663-1	2021	Cytochrome P450 4F (CYP4F) enzymes are responsible for the metabolism of eicosanoids, which play important roles in inflammation.	Eicosanoids	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-18
33310663-1	2021	Cytochrome P450 4F (CYP4F) enzymes are responsible for the metabolism of eicosanoids, which play important roles in inflammation.	Eicosanoids	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-25
33388475-0	2021	Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease.	epoxyeicosanoid	34-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
33388475-2	2021	Preclinical studies indicate that epoxyeicosanoids, a class of bioactive lipid mediators that are generated by cytochrome P450 (CYP) epoxygenases and inactivated by the soluble epoxide hydrolase (sEH), play a protective role in NAFLD.	epoxyeicosanoids	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-126
33388475-2	2021	Preclinical studies indicate that epoxyeicosanoids, a class of bioactive lipid mediators that are generated by cytochrome P450 (CYP) epoxygenases and inactivated by the soluble epoxide hydrolase (sEH), play a protective role in NAFLD.	epoxyeicosanoids	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
33252269-3	2020	The aim of this study was to investigate the relationship between polymorphisms of the drug-metabolizing enzyme gene, cytochrome P450 (CYP450), and the drug transporter gene, ATP-binding cassette subfamily B member 1 (ABCB1), as well as their DNA methylation status with the pathogenesis of steroid-induced ONFH.	Steroids	291-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	Coronaric acid	39-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	12,13-epoxyoctadecenoic acid	81-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	Leukotoxin diol	125-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	Leukotoxin diol	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	(+/-)12,13-Dihome	180-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32827665-2	2020	Cytochrome P450-derived LA metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME), 12,13-epoxyoctadecenoic acid (12,13-EpOME), 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) and 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) have been studied for their association with various disease states and biological functions.	(+/-)12,13-Dihome	218-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32223485-0	2020	In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes.	cepharanthine	31-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
32673137-0	2020	In vitro inhibitory effect of lysionotin on the activity of cytochrome P450 enzymes.	nevadensin	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
32673137-2	2020	A study of lysionotin on the activity of human liver cytochrome P450 (CYP) enzymes can provide guidance on the clinical application of lysionotin.	nevadensin	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
32673137-2	2020	A study of lysionotin on the activity of human liver cytochrome P450 (CYP) enzymes can provide guidance on the clinical application of lysionotin.	nevadensin	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
32673137-2	2020	A study of lysionotin on the activity of human liver cytochrome P450 (CYP) enzymes can provide guidance on the clinical application of lysionotin.	nevadensin	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
32673137-2	2020	A study of lysionotin on the activity of human liver cytochrome P450 (CYP) enzymes can provide guidance on the clinical application of lysionotin.	nevadensin	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
32279279-0	2020	The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro.	iloperidone	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
32279279-0	2020	The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro.	Lurasidone Hydrochloride	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
32223485-3	2020	In addition, the enzyme kinetic parameters were calculated.Results: The results showed that the activity of CYP3A4, CYP2E1 and CYP2C9 was inhibited by CEP, with IC50 values of 16.29, 25.62 and 24.57 muM, respectively, but other CYP isoforms were not affected.	cepharanthine	151-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	iloperidone	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	iloperidone	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
32791187-6	2020	OBJECTIVE: To test the hypothesis that hyperoxia induces greater lung injury and inflammation in Nrf2-/- mice compared to wild type (WT) that differs between sexes, and that this phenotype will be rescued by the administration of the cytochrome P450 (CYP) 1A inducer beta-naphthoflavone (BNF).	beta-Naphthoflavone	267-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-258
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	iloperidone	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-230
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	Lurasidone Hydrochloride	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	Lurasidone Hydrochloride	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
32279279-2	2020	BACKGROUND: The present study aimed at examining the inhibitory effect of two atypical neuroleptics iloperidone and lurasidone on the main human cytochrome P450 (CYP) enzymes in pooled human liver microsomes and cDNA-expressed CYP enzymes (supersomes).	Lurasidone Hydrochloride	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-230
32279279-3	2020	METHODS: The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4"-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1"-hydroxylation/CYP2D6 and testosterone 6beta-hydroxylation/CYP3A4, respectively, using HPLC.	Caffeine	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32279279-3	2020	METHODS: The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4"-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1"-hydroxylation/CYP2D6 and testosterone 6beta-hydroxylation/CYP3A4, respectively, using HPLC.	Diclofenac	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32279279-3	2020	METHODS: The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4"-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1"-hydroxylation/CYP2D6 and testosterone 6beta-hydroxylation/CYP3A4, respectively, using HPLC.	Perazine	166-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32279279-3	2020	METHODS: The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4"-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1"-hydroxylation/CYP2D6 and testosterone 6beta-hydroxylation/CYP3A4, respectively, using HPLC.	bufuralol	200-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32279279-3	2020	METHODS: The activity of these enzymes was determined by the following CYP-specific reactions: caffeine 3-N-demethylation/CYP1A2, diclofenac 4"-hydroxylation/CYP2C9, perazine N-demethylation/CYP2C19, bufuralol 1"-hydroxylation/CYP2D6 and testosterone 6beta-hydroxylation/CYP3A4, respectively, using HPLC.	Testosterone	238-250	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32672501-2	2020	Pyrethroid metabolism was also studied with some human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Pyrethrins	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
32672501-2	2020	Pyrethroid metabolism was also studied with some human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Pyrethrins	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
32672501-10	2020	All pyrethroids were metabolised by some of the human expressed CYP enzymes studied and apart from BIF were also metabolised by CES enzymes.	Pyrethrins	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
32672501-0	2020	Metabolism of bifenthrin, beta-cyfluthrin, lambda-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes.	bifenthrin	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-147
32672501-0	2020	Metabolism of bifenthrin, beta-cyfluthrin, lambda-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes.	cyfluthrin	26-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-147
32672501-0	2020	Metabolism of bifenthrin, beta-cyfluthrin, lambda-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes.	cyhalothrin	43-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-147
32672501-0	2020	Metabolism of bifenthrin, beta-cyfluthrin, lambda-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes.	cyphenothrin	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-147
32672501-0	2020	Metabolism of bifenthrin, beta-cyfluthrin, lambda-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes.	fenvalerate	80-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-147
32761661-0	2020	How do metal ions modulate the rate-determining electron transfer step in Cytochrome P450 reactions?	Metals	7-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
32761661-3	2020	To understand the effect of external perturbations on the CYP450 first reduction step, we performed a computational study with model complexes in the presence of metal and organic ions, solvent molecules and an electric field effect.	Metals	162-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-64
32761661-6	2020	Calculations on a large crystal structure with alkali metal ions bound implicated inhibition patterns of the ions; therefore, we predict that active forms of the natural CYP450 isozymes will not have more than one alkali metal ions bound in the second-coordination sphere.	Metals	54-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-176
32761661-6	2020	Calculations on a large crystal structure with alkali metal ions bound implicated inhibition patterns of the ions; therefore, we predict that active forms of the natural CYP450 isozymes will not have more than one alkali metal ions bound in the second-coordination sphere.	Metals	221-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-176
33175492-2	2020	By the use of a combinatorial and modular approach for gene expression, including a cytochrome P450 and the corresponding reductase, engineered Synechoccous elongatus PCC 7942 as a model cyanobacterium enabled the biosynthesis of ent-kaurenoic acid at 2.9 +- 0.01 mg L-1 from CO2.	kaurenoic acid	230-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
33175492-2	2020	By the use of a combinatorial and modular approach for gene expression, including a cytochrome P450 and the corresponding reductase, engineered Synechoccous elongatus PCC 7942 as a model cyanobacterium enabled the biosynthesis of ent-kaurenoic acid at 2.9 +- 0.01 mg L-1 from CO2.	Carbon Dioxide	276-279	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
32791187-6	2020	OBJECTIVE: To test the hypothesis that hyperoxia induces greater lung injury and inflammation in Nrf2-/- mice compared to wild type (WT) that differs between sexes, and that this phenotype will be rescued by the administration of the cytochrome P450 (CYP) 1A inducer beta-naphthoflavone (BNF).	beta-Naphthoflavone	288-291	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-258
33201326-3	2022	Among cytochrome P-450 (CYP) isoforms in humans, CYP3A4 is the major isoform involved in metabolic decyclopropylmethylation of nalfurafine hydrochloride.	decyclopropylmethylation	99-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
33201326-3	2022	Among cytochrome P-450 (CYP) isoforms in humans, CYP3A4 is the major isoform involved in metabolic decyclopropylmethylation of nalfurafine hydrochloride.	decyclopropylmethylation	99-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
33201326-3	2022	Among cytochrome P-450 (CYP) isoforms in humans, CYP3A4 is the major isoform involved in metabolic decyclopropylmethylation of nalfurafine hydrochloride.	TRK 820	127-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
33201326-3	2022	Among cytochrome P-450 (CYP) isoforms in humans, CYP3A4 is the major isoform involved in metabolic decyclopropylmethylation of nalfurafine hydrochloride.	TRK 820	127-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
32763298-5	2020	Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ.	Hydroxychloroquine	71-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33207662-0	2020	Cytochrome P450 Metabolism of Polyunsaturated Fatty Acids and Neurodegeneration.	Fatty Acids, Unsaturated	30-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33207662-4	2020	Recent research demonstrated that the oxidized metabolites, particularly the cytochrome P450 (CYP) metabolites, of PUFAs are beneficial to several neurodegenerative diseases, including Alzheimer"s disease and Parkinson"s disease; however, their mechanism(s) remains unclear.	Fatty Acids, Unsaturated	115-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
33207662-4	2020	Recent research demonstrated that the oxidized metabolites, particularly the cytochrome P450 (CYP) metabolites, of PUFAs are beneficial to several neurodegenerative diseases, including Alzheimer"s disease and Parkinson"s disease; however, their mechanism(s) remains unclear.	Fatty Acids, Unsaturated	115-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
33207662-8	2020	We will also discuss the potential mechanism(s) of CYP PUFA metabolites in neurodegeneration, which will ultimately improve our understanding of how PUFAs affect neurodegeneration and may identify potential drug targets for neurodegenerative diseases.	Fatty Acids, Unsaturated	55-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
32763298-5	2020	Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ.	Chloroquine	72-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32889110-7	2020	Dip-based CMCs not only alter Dip-mediated inhibition or activation of CYP enzymes but also change the degree to which rCYPs are involved in Dip metabolism.	dipfluzine	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32889110-7	2020	Dip-based CMCs not only alter Dip-mediated inhibition or activation of CYP enzymes but also change the degree to which rCYPs are involved in Dip metabolism.	dipfluzine	30-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32889110-7	2020	Dip-based CMCs not only alter Dip-mediated inhibition or activation of CYP enzymes but also change the degree to which rCYPs are involved in Dip metabolism.	dipfluzine	30-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
32889110-10	2020	The effects of the alterations of Dip CMCs on the interaction between Dip and CYP enzymes are not attributed to a simple superposition of Dip and the respective precursor and may be due to the presence of interaction forces between Dip and precursor molecules.	dipfluzine	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
32889110-10	2020	The effects of the alterations of Dip CMCs on the interaction between Dip and CYP enzymes are not attributed to a simple superposition of Dip and the respective precursor and may be due to the presence of interaction forces between Dip and precursor molecules.	dipfluzine	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
32889110-10	2020	The effects of the alterations of Dip CMCs on the interaction between Dip and CYP enzymes are not attributed to a simple superposition of Dip and the respective precursor and may be due to the presence of interaction forces between Dip and precursor molecules.	dipfluzine	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
32889110-11	2020	These results are the first to provide preliminary experimental evidence that CMCs change the interaction between API and CYP enzymes.	CMCS	78-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
32941854-0	2020	Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes.	asenapine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
33879433-0	2020	Hepato-protective role of itraconazole mediated cytochrome p450 pathway inhibition in liver fibrosis.	Itraconazole	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
33879433-6	2020	Based upon this fact, present study is aimed to evaluate the repurposing of Itraconazole in the prevention of hepatic fibrosis via inhibition of cytochrome P450 pathway.	Itraconazole	76-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32941854-0	2020	Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes.	iloperidone	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	asenapine	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	asenapine	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	Lurasidone Hydrochloride	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	Lurasidone Hydrochloride	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	iloperidone	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
32941854-4	2020	The present study aimed at examining the effects of the three atypical neuroleptics asenapine, lurasidone and iloperidone on cytochrome P450 (CYP) expression in the human liver.	iloperidone	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
32941854-7	2020	CYP activities were measured in the incubation medium using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A1/2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19) and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32941854-7	2020	CYP activities were measured in the incubation medium using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A1/2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19) and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
32941854-7	2020	CYP activities were measured in the incubation medium using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A1/2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19) and testosterone 6beta-hydroxylation (CYP3A4).	Diclofenac	127-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32941854-7	2020	CYP activities were measured in the incubation medium using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A1/2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19) and testosterone 6beta-hydroxylation (CYP3A4).	Perazine	165-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
32941854-7	2020	CYP activities were measured in the incubation medium using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A1/2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19) and testosterone 6beta-hydroxylation (CYP3A4).	Testosterone	204-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
33023027-0	2020	Cytochrome P450 Can Epoxidize an Oxepin to a Reactive 2,3-Epoxyoxepin Intermediate: Potential Insights into Metabolic Ring-Opening of Benzene.	Oxepins	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33050335-3	2020	The results indicated that lipoxygenase and cytochrome P450-derived eicosanoids were elevated (5-HETE, 12-HETE, 20-HETE, and 20-COOH-AA), and there appeared to be no differences in levels measured in eyes with tractional retinal detachments versus those without.	Eicosanoids	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
33050335-3	2020	The results indicated that lipoxygenase and cytochrome P450-derived eicosanoids were elevated (5-HETE, 12-HETE, 20-HETE, and 20-COOH-AA), and there appeared to be no differences in levels measured in eyes with tractional retinal detachments versus those without.	5-hydroxy-6,8,11,14-eicosatetraenoic acid	95-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
33050335-3	2020	The results indicated that lipoxygenase and cytochrome P450-derived eicosanoids were elevated (5-HETE, 12-HETE, 20-HETE, and 20-COOH-AA), and there appeared to be no differences in levels measured in eyes with tractional retinal detachments versus those without.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	103-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
33095237-1	2020	Arachidonic acid can be metabolized in blood vessels by three primary enzymatic pathways; cyclooxygenase (COX), lipoxygenase (LO), and cytochrome P450 (CYP).	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
33095237-1	2020	Arachidonic acid can be metabolized in blood vessels by three primary enzymatic pathways; cyclooxygenase (COX), lipoxygenase (LO), and cytochrome P450 (CYP).	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
33095237-7	2020	CYP enzymes produce two types of eicosanoid products: EDHF vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-HETE.	Eicosanoids	33-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
33095237-7	2020	CYP enzymes produce two types of eicosanoid products: EDHF vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-HETE.	eets	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
33095237-7	2020	CYP enzymes produce two types of eicosanoid products: EDHF vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-HETE.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	128-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
33093609-5	2020	Pathway enrichment analysis revealed that drug metabolism-cytochrome P450, biopterin metabolism, vitamin B9 (folate) metabolism, selenoamino acid metabolism, and methionine and cysteine metabolism showed significant enrichment in vitiligo patients compared with the status in healthy controls.	Folic Acid	109-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
33060725-1	2020	Cytochrome P450 (CYP) is involved in the metabolism of nevirapine (NVP); especially, CYP2B6 has been known to be one of the main enzymes involved in NVP metabolism.	Nevirapine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33060725-1	2020	Cytochrome P450 (CYP) is involved in the metabolism of nevirapine (NVP); especially, CYP2B6 has been known to be one of the main enzymes involved in NVP metabolism.	Nevirapine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
33023027-0	2020	Cytochrome P450 Can Epoxidize an Oxepin to a Reactive 2,3-Epoxyoxepin Intermediate: Potential Insights into Metabolic Ring-Opening of Benzene.	oxepin epoxide	54-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33023027-0	2020	Cytochrome P450 Can Epoxidize an Oxepin to a Reactive 2,3-Epoxyoxepin Intermediate: Potential Insights into Metabolic Ring-Opening of Benzene.	Benzene	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
33023027-2	2020	The present study demonstrates that separate incubations of 4,5-benzoxepin with three cytochrome P450 isoforms (2E1, 1A2, and 3A4) as well as pooled human liver microsomes (pHLM) also produce 1H-2-benzopyran-1-carboxaldehyde as the major product, likely via the 2,3-epoxyoxepin.	4,5-benzoxepin	60-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
33023027-2	2020	The present study demonstrates that separate incubations of 4,5-benzoxepin with three cytochrome P450 isoforms (2E1, 1A2, and 3A4) as well as pooled human liver microsomes (pHLM) also produce 1H-2-benzopyran-1-carboxaldehyde as the major product, likely via the 2,3-epoxyoxepin.	1H-isochromene-1-carbaldehyde	192-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
33023027-2	2020	The present study demonstrates that separate incubations of 4,5-benzoxepin with three cytochrome P450 isoforms (2E1, 1A2, and 3A4) as well as pooled human liver microsomes (pHLM) also produce 1H-2-benzopyran-1-carboxaldehyde as the major product, likely via the 2,3-epoxyoxepin.	oxepin epoxide	262-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
31658882-1	2020	As an important member of cytochrome P450 (CYP) enzymes, human CYP1A2 is associated with the metabolism of caffeine and melatonin and the activation of precarcinogens.	Caffeine	107-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
31658882-1	2020	As an important member of cytochrome P450 (CYP) enzymes, human CYP1A2 is associated with the metabolism of caffeine and melatonin and the activation of precarcinogens.	Caffeine	107-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
31658882-1	2020	As an important member of cytochrome P450 (CYP) enzymes, human CYP1A2 is associated with the metabolism of caffeine and melatonin and the activation of precarcinogens.	Melatonin	120-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
31658882-1	2020	As an important member of cytochrome P450 (CYP) enzymes, human CYP1A2 is associated with the metabolism of caffeine and melatonin and the activation of precarcinogens.	Melatonin	120-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
32797061-10	2020	Eicosanoids were grouped by biosynthetic pathway, defined by (1) the fatty acid precursor, including linoleic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), and (2) the enzyme group, including cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 (CYP).	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	285-300
32681429-0	2020	Altered expression of cytochrome P450 enzymes involved in metabolism of androgens and vitamin D in the prostate as a risk factor for prostate cancer.	Vitamin D	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-169
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	20-carbon polyunsaturated fatty acids	40-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	20-carbon polyunsaturated fatty acids	40-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-169
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	Fatty Acids, Unsaturated	79-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32808658-2	2020	Eicosanoids are oxidised derivatives of 20-carbon polyunsaturated fatty acids (PUFAs) formed by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (cytP450) pathways.	Fatty Acids, Unsaturated	79-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-169
32249465-2	2020	It is a pro-drug that is extensively metabolized to carebastine, its active carboxylic acid metabolite, by the hepatic microsomal isoenzyme cytochrome P450 (CYP).	carebastine	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
32249465-2	2020	It is a pro-drug that is extensively metabolized to carebastine, its active carboxylic acid metabolite, by the hepatic microsomal isoenzyme cytochrome P450 (CYP).	carebastine	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
32249465-2	2020	It is a pro-drug that is extensively metabolized to carebastine, its active carboxylic acid metabolite, by the hepatic microsomal isoenzyme cytochrome P450 (CYP).	Carboxylic Acids	76-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
32249465-2	2020	It is a pro-drug that is extensively metabolized to carebastine, its active carboxylic acid metabolite, by the hepatic microsomal isoenzyme cytochrome P450 (CYP).	Carboxylic Acids	76-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
32797061-17	2020	Eicosanoids derived from AA via the CYP and LOX biosynthetic pathways were positively associated with SGA.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
33015460-2	2020	TCDD is considered a carcinogen and has proinflammatory influence on animals and humans, promoting free radicals" formation, and binding with the aryl hydrocarbon receptor (AhR) leads to expression of cytochrome p-450 genes that in turn predisposes to mutations.	Polychlorinated Dibenzodioxins	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-217
33005200-3	2020	Recombinant CYP450 supersomes and liver microsomes were used to study the metabolic profiles of kurarinone and its inhibitory actions against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes.	kurarinone	96-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
32338045-1	2020	BACKGROUND: The benefit of cytochrome P450 (CYP450) enzyme system metabolized medications, especially clopidogrel, was reported more pronounced in smoking than nonsmoking patients, but limited evidence was available from Asian patients.	Clopidogrel	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
32907722-5	2020	Bioavailability of hydrocarbons was evident particularly for high molecular weight PAHs, which also caused significant variations of cellular biomarkers, such as cytochrome P450 metabolization in fish, lysosomal membrane destabilization in mussels, genotoxic effects both in fish and molluscs.	Hydrocarbons	19-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-245
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-250
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-295
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	Heme	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-245
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	Heme	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-250
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	Heme	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-295
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-245
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-250
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-295
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	134-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-245
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	134-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	247-250
32515070-3	2020	By re-visiting and engineering the well-known Fe-N-C electrocatalyst that has a heme-like Fe-N x active sites, herein, we report that Fe-N-C could not only catalyze drug metabolization but also had inhibition behaviors similar to cytochrome P450 (CYP), endowing it a potential replacement of CYP for preliminary evaluation of massive potential chemicals, drug dosing guide and outcome prediction.	fe-n-c	134-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-295
32700706-3	2020	The Sn(iv)-metalated COF material Sn-CPF-3 exhibits high photocatalytic efficiency and selectivity in aerobic oxidation of sulfides to produce highly value-added sulfoxides with up to 23 334 turnovers and 648 h-1 turnover frequency under visible light irradiation.	Sulfides	123-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-42
32700706-3	2020	The Sn(iv)-metalated COF material Sn-CPF-3 exhibits high photocatalytic efficiency and selectivity in aerobic oxidation of sulfides to produce highly value-added sulfoxides with up to 23 334 turnovers and 648 h-1 turnover frequency under visible light irradiation.	Sulfoxides	162-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-42
32797061-10	2020	Eicosanoids were grouped by biosynthetic pathway, defined by (1) the fatty acid precursor, including linoleic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), and (2) the enzyme group, including cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 (CYP).	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	302-305
32874920-7	2020	Primary cultured rat and human hepatocytes were considered to be useful for the evaluation of effects of the benzimidazole compounds on their inducibility and inhibitory activities of cytochrome P450 forms.	benzimidazole	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199
32216303-8	2020	Two examples are chosen to demonstrate the synergy advantage in elucidation of metabolic mechanism of triphenyl phosphate and atrazine catalyzed by CYP, respectively, which shows the interplay between experiments and computations allows gaining greater insight than the isolated methods.	triphenyl phosphate	102-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	acacetin	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	acacetin	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	Catechin	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	Catechin	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	eriodictyol	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	eriodictyol	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	capillin	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	capillin	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-7	2021	This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors - Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB.	luteolin-7-glucoside	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
32746771-7	2021	This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors - Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB.	linarin	49-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
32778735-5	2020	The results showed DPTM exhibited a moderate inhibitory potential against CYP3A/4 (IC50 values of 10 +- 2 and 8 +- 2 muM, respectively) and weak against the other CYP enzymes based on their IC50 values.	dptm	19-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
32778735-6	2020	Compared to the control, CYP isoforms and their transcriptional regulators mRNA expressions significantly increased when the Hep G2 cells were treated with DPTM for a certain period of time.	dptm	156-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
32385545-1	2020	PURPOSE: Cytochrome P450 (CYP) is involved in the metabolism of valproic acid (VPA).	Valproic Acid	64-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
32385545-1	2020	PURPOSE: Cytochrome P450 (CYP) is involved in the metabolism of valproic acid (VPA).	Valproic Acid	64-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32385545-1	2020	PURPOSE: Cytochrome P450 (CYP) is involved in the metabolism of valproic acid (VPA).	Valproic Acid	79-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
32385545-1	2020	PURPOSE: Cytochrome P450 (CYP) is involved in the metabolism of valproic acid (VPA).	Valproic Acid	79-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32519194-8	2020	The most frequently prescribed CYP inhibitors were melperone (n = 2504, 28.1%) and duloxetine (n = 1324, 14.9%).	Duloxetine Hydrochloride	83-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
32519194-10	2020	Carbamazepine was the most frequently prescribed CYP inducer (n = 733, 88.8%).	Carbamazepine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
32519194-14	2020	Physicians should be aware of the CYP inhibitory and inducing potential of psychotropic and internistic drugs (especially, melperone).	metylperon	123-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
32216303-8	2020	Two examples are chosen to demonstrate the synergy advantage in elucidation of metabolic mechanism of triphenyl phosphate and atrazine catalyzed by CYP, respectively, which shows the interplay between experiments and computations allows gaining greater insight than the isolated methods.	Atrazine	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
32537715-0	2020	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.	Fedratinib	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
32655683-0	2020	Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug-drug interactions.	Alkaloids	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
32655683-0	2020	Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug-drug interactions.	Saponins	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
32655683-0	2020	Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug-drug interactions.	kang-ai	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
32537715-2	2020	In vitro studies indicated that fedratinib was an inhibitor of several cytochrome P450 (CYP) enzymes.	Fedratinib	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
32537715-9	2020	These results serve as the basis for dose modifications of these CYP substrate drugs when co-administered with fedratinib.	Fedratinib	111-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
32537715-2	2020	In vitro studies indicated that fedratinib was an inhibitor of several cytochrome P450 (CYP) enzymes.	Fedratinib	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
32537715-3	2020	The primary objective of this study was to evaluate the effects of repeated doses of fedratinib on the activity of CYP2D6, CYP2C19, and CYP3A4 in patients with solid tumors using a CYP probe cocktail.	Fedratinib	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
32325076-1	2020	OBJECTIVE: To explore the pharmacokinetic interaction between isotretinoin, a cytochrome P-450 (CYP) inducer and potent teratogen, and the etonogestrel contraceptive implant.	Isotretinoin	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
32415468-0	2020	Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.	Imatinib Mesylate	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
32415468-3	2020	OBJECTIVE: To investigate whether polymorphisms in genes encoding cytochrome P450 (CYP) enzymes and ABCB1 transporter affect imatinib pharmacokinetic parameters.	Imatinib Mesylate	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
32325076-1	2020	OBJECTIVE: To explore the pharmacokinetic interaction between isotretinoin, a cytochrome P-450 (CYP) inducer and potent teratogen, and the etonogestrel contraceptive implant.	Isotretinoin	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
32065749-1	2020	Cytochrome P450-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHNVP) has been implicated in NVP toxicities.	Nevirapine	58-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31855101-0	2020	A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.	nabumetone	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
31855101-0	2020	A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.	6-methoxy-2-naphthylacetic acid	91-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
31855101-0	2020	A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.	6-methoxy-2-naphthylacetic acid	124-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
31855101-10	2020	Further in vitro inhibition studies demonstrated that multiple non-cytochrome P450 enzymes are involved in the formation of 6-MNA.	6-methoxy-2-naphthylacetic acid	124-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
32875445-4	2020	Cytochrome P450 metabolism of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).	long-chain fatty acids	43-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32875445-4	2020	Cytochrome P450 metabolism of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).	Epoxy Compounds	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32875445-4	2020	Cytochrome P450 metabolism of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).	epoxy-fatty acids	97-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32875445-4	2020	Cytochrome P450 metabolism of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).	epfa	116-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32065749-1	2020	Cytochrome P450-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHNVP) has been implicated in NVP toxicities.	Nevirapine	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32065749-1	2020	Cytochrome P450-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHNVP) has been implicated in NVP toxicities.	12-Hydroxynevirapine	78-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32065749-1	2020	Cytochrome P450-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHNVP) has been implicated in NVP toxicities.	12-ohnvp	94-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32083470-0	2020	Biotransformation Mechanism of Pesticides by Cytochrome P450: A DFT Study on Dieldrin.	Dieldrin	77-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
32306288-4	2020	Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance.	Chloroquine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
32112562-3	2020	Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI.	Warfarin	201-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
32112562-3	2020	Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI.	Amiodarone	210-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
32327267-6	2020	The risk of drug interaction with dotinurad was expected to be low, because it weakly inhibits metabolic enzymes such as cytochrome P450 (CYP).	Dotinurad	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
32327267-6	2020	The risk of drug interaction with dotinurad was expected to be low, because it weakly inhibits metabolic enzymes such as cytochrome P450 (CYP).	Dotinurad	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Perazine	151-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	bufuralol	187-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-0	2020	In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.	asenapine	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
32219694-2	2020	The present study aimed at examining the inhibitory effect of the novel antipsychotic drug asenapine on the main CYP enzymes in human liver.	asenapine	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	bufuralol	187-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	76-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Testosterone	228-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	76-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Nitrogen	86-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Testosterone	228-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Nitrogen	86-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
32219694-5	2020	The rates of the CYP-specific reactions were assessed in the absence and presence of asenapine using HPLC.	asenapine	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Diclofenac	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
32219694-4	2020	Activities of CYP enzymes were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6), and testosterone 6beta-hydroxylation (CYP3A4).	Diclofenac	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
32486438-3	2020	In order to study a possible role for CYP induction in neurorepair, we designed an in vitro model where undifferentiated neuroblastoma SH-SY5Y cells were treated with the CYP inducers beta-naphthoflavone (betaNF) and ethanol (EtOH) before and during exposure to the parkinsonian neurotoxin, MPP+.	beta-Naphthoflavone	184-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
32483226-0	2020	Green analytical method for the simultaneous analysis of cytochrome P450 probe substrates by poly(N-isopropylacrylamide)-based temperature-responsive chromatography.	poly-N-isopropylacrylamide	93-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
32483226-6	2020	This study sought to develop the simultaneous analysis of multiple CYP substrates by using poly(N-isopropylacrylamide) (PNIPAAm)-based temperature-responsive chromatography with only aqueous solvents and isocratic methods.	poly-N-isopropylacrylamide	91-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
32483226-6	2020	This study sought to develop the simultaneous analysis of multiple CYP substrates by using poly(N-isopropylacrylamide) (PNIPAAm)-based temperature-responsive chromatography with only aqueous solvents and isocratic methods.	poly-N-isopropylacrylamide	120-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	Phosphorus	165-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	nipaam-co-n-butyl methacrylate	167-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	bma	199-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	p(nipaam-co-n-acryloyl l-tryptophan methyl ester	210-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	l-trp-ome	260-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-7	2020	Good separation of multiple CYP substrates was achieved without using organic solvents and any gradient methods by temperature-responsive chromatography utilizing a P(NIPAAm-co-n-butyl methacrylate (BMA))- and P(NIPAAm-co-N-acryloyl L-tryptophan methyl ester (L-Trp-OMe))-grafted silica column.	Silicon Dioxide	280-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
32483226-8	2020	Overall, PNIPAAm-based temperature-responsive chromatography represents a remarkably simple, versatile, and environmentally friendly bioanalytical method for CYP substrates and their metabolites.	poly-N-isopropylacrylamide	9-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
32486438-6	2020	These treatments also protected complex I activity against the inhibitory effects caused by MPP+, suggesting a possible neuroprotective role for CYP inducers.	mangion-purified polysaccharide (Candida albicans)	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
32201191-0	2020	Identification and in silico prediction of metabolites of tebufenozide derivatives by major human cytochrome P450 isoforms.	tebufenozide	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
31919943-1	2020	The regio- (and stereo-) selectivity and specific activity of Cytochrome P450s are determined by the accessibility of potential sites-of-metabolism (SOMs) of the bound substrate relative to the heme, and the activation barrier of the regioselective oxidation reaction.	Heme	194-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
32201191-5	2020	In our previous study, we identified the metabolites of tebufenozide, an insect growth regulator, formed by two human CYP isoforms: CYP3A4 and CYP2C19.	tebufenozide	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
32201191-6	2020	The accessibility of each site of tebufenozide to the reaction center of CYP enzymes and the susceptibility of each hydrogen atom for metabolism by CYP enzymes were evaluated by a docking simulation and hydrogen atom abstraction energy estimation at the density functional theory level, respectively.	tebufenozide	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
32201191-6	2020	The accessibility of each site of tebufenozide to the reaction center of CYP enzymes and the susceptibility of each hydrogen atom for metabolism by CYP enzymes were evaluated by a docking simulation and hydrogen atom abstraction energy estimation at the density functional theory level, respectively.	Hydrogen	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
32201191-6	2020	The accessibility of each site of tebufenozide to the reaction center of CYP enzymes and the susceptibility of each hydrogen atom for metabolism by CYP enzymes were evaluated by a docking simulation and hydrogen atom abstraction energy estimation at the density functional theory level, respectively.	Hydrogen	203-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
32201191-6	2020	The accessibility of each site of tebufenozide to the reaction center of CYP enzymes and the susceptibility of each hydrogen atom for metabolism by CYP enzymes were evaluated by a docking simulation and hydrogen atom abstraction energy estimation at the density functional theory level, respectively.	Hydrogen	203-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
32198084-1	2020	Cytochrome P450 (P450) 2E1 is the major P450 enzyme involved in ethanol metabolism.	Ethanol	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
32364297-2	2020	To investigate herb-drug interaction potential associated with deoxyshikonin, we examined the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes using cocktail substrate-incubated human liver microsomes.	deoxyshikonin	116-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32406758-3	2020	CYP2C9 is one of the most abundant CYP enzymes and responsible for the metabolism of over 15% clinical drugs, including oral sulfonylurea hypoglycemics, nonsteroidal anti-inflammatory agents, selective cyclooxygenase-2 inhibitors, antiepileptics, angiotensin II receptor inhibitors and anticoagulants.	Sulfonylurea Compounds	125-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
31938857-2	2020	Phenytoin is a commonly used drug, and its metabolism is mediated by a specific cytochrome-P450 isoform, CYP2C9, which is encoded by a polymorphic gene.	Phenytoin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
32027168-1	2020	BACKGROUND AND OBJECTIVES: Clopidogrel is widely used after the percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and requires activation by cytochrome P450 (CYP), primarily CYP2C19.	clopidogrel	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-194
32027168-1	2020	BACKGROUND AND OBJECTIVES: Clopidogrel is widely used after the percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and requires activation by cytochrome P450 (CYP), primarily CYP2C19.	clopidogrel	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-199
32041058-6	2020	Interestingly, ~50% of esterase/lipase/cytochrome P450 genes enriched by DEHP under aerobic conditions were from Nocardioides, a bacterial genus that has not been previously directly linked to phthalate ester degradation.	phthalic acid	193-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
32364297-2	2020	To investigate herb-drug interaction potential associated with deoxyshikonin, we examined the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes using cocktail substrate-incubated human liver microsomes.	deoxyshikonin	116-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
32196986-9	2020	Ataluren showed no or little potential to inhibit or induce most of the CYP enzymes.	ataluren	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
32333310-1	2020	Cytochrome p450-mediated metabolism of GRS (indolinone antiaggregant) and its effects on activities of cytochrome p450 isoenzymes were studied.	Oxindoles	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32333310-1	2020	Cytochrome p450-mediated metabolism of GRS (indolinone antiaggregant) and its effects on activities of cytochrome p450 isoenzymes were studied.	Oxindoles	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
31628422-2	2020	Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition.	efavirenz	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31628422-2	2020	Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition.	efavirenz	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
32155912-0	2020	Testing the Pharmacokinetic Interactions of 24 Colonic Flavonoid Metabolites with Human Serum Albumin and Cytochrome P450 Enzymes.	Flavonoids	55-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
31733338-0	2020	Cytochrome P450-Derived Eicosanoids and Inflammation in Liver Diseases.	Eicosanoids	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31733338-5	2020	Members of omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid and arachidonic acid, respectively, can be metabolized by CYP isoforms leading to the production of biologically active lipid mediators called eicosanoids.	Fatty Acids, Unsaturated	30-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
31733338-5	2020	Members of omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid and arachidonic acid, respectively, can be metabolized by CYP isoforms leading to the production of biologically active lipid mediators called eicosanoids.	Eicosapentaenoic Acid	82-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
31733338-5	2020	Members of omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid and arachidonic acid, respectively, can be metabolized by CYP isoforms leading to the production of biologically active lipid mediators called eicosanoids.	Arachidonic Acids	108-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
31733338-5	2020	Members of omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid and arachidonic acid, respectively, can be metabolized by CYP isoforms leading to the production of biologically active lipid mediators called eicosanoids.	Eicosanoids	247-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
31733338-6	2020	CYP-derived eicosanoids have been shown to play significant roles in the pathophysiology and protection of multiple inflammatory liver diseases.	Eicosanoids	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
31733338-7	2020	In this review, we elucidate the intricate role of CYP-derived eicosanoids in inflammation in liver diseases paving the way for better therapeutic approaches.	Eicosanoids	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
31698143-0	2020	Prostaglandins and Other Lipid Mediators Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.	Prostaglandins	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
31698143-0	2020	Prostaglandins and Other Lipid Mediators Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.	Fatty Acids	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Arachidonic Acids	36-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Arachidonic Acids	36-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Arachidonic Acids	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Arachidonic Acids	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Fatty Acids	68-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Fatty Acids	68-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Fatty Acids	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	Fatty Acids	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	5,6-epoxy-8,11,14-eicosatrienoic acid	102-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	5,6-epoxy-8,11,14-eicosatrienoic acid	102-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	5,6-epoxy-8,11,14-eicosatrienoic acid	129-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31698143-1	2020	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders.	5,6-epoxy-8,11,14-eicosatrienoic acid	129-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
32155912-5	2020	Therefore, in this in vitro study, we investigated the interactions of 24 microbial flavonoid metabolites with human serum albumin and cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes.	Flavonoids	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
32131538-0	2020	Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5"-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes.	Maytansine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	3,4-epoxy-1-butene	62-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
32129155-0	2020	Samarium enriches antitumor activity of ZnO nanoparticles via downregulation of CXCR4 receptor and cytochrome P450.	Samarium	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
32129155-0	2020	Samarium enriches antitumor activity of ZnO nanoparticles via downregulation of CXCR4 receptor and cytochrome P450.	Zinc Oxide	40-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
32129155-2	2020	Zinc oxide nanoparticles play an effective role in tumor treatment but with some cautions, such as overexpression of cytochrome P450, hepatic overload, and the mammalian target of rapamycin pathway resistance.	Zinc Oxide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
32129155-8	2020	Moreover, samarium:zinc oxide nanoparticles exhibited minimum toxicity which was indicated by suppressed activities of cytochrome P450 and hepatic enzymes, including alanine transaminase and aspartate transaminase.	Samarium	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
32129155-8	2020	Moreover, samarium:zinc oxide nanoparticles exhibited minimum toxicity which was indicated by suppressed activities of cytochrome P450 and hepatic enzymes, including alanine transaminase and aspartate transaminase.	Zinc Oxide	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	3,4-epoxy-1-butene	82-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	diepoxybutane	87-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	diepoxybutane	110-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	3,4-epoxybutane-1,2-diol	119-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
31702786-3	2020	BD undergoes cytochrome P450-mediated metabolic activation to 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-dihydroxy-3,4-epoxybutane (EBD), which form covalent adducts with DNA.	3,4-epoxybutane-1,2-diol	150-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
31744669-0	2020	Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.	Caffeine	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
31744669-0	2020	Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.	Tolbutamide	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
31744669-0	2020	Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.	Dextromethorphan	105-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
31744669-0	2020	Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.	Alprazolam	127-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
31679131-6	2020	Etravirine exhibits the potential for bi-directional drug-drug interactions with other antiretrovirals and concomitant medications through its interactions with cytochrome P450 (CYP) isozymes: CYP3A4, CYP2C9, and CYP2C19.	etravirine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-176
31092058-5	2020	All three were found to have elevated neuronal and glial auto-antibodies, biomarkers of central nervous system injury, and all three had genetic polymorphisms of paraoxonase (PON-1) and two of cytochrome P450, leading to a reduced ability to metabolize organophosphate compound (OPs).Discussion: A similar constellation of symptoms has been described in other studies of aircrew, although objective evidence of exposure is lacking in most of these studies.	Organophosphates	253-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-208
31679131-6	2020	Etravirine exhibits the potential for bi-directional drug-drug interactions with other antiretrovirals and concomitant medications through its interactions with cytochrome P450 (CYP) isozymes: CYP3A4, CYP2C9, and CYP2C19.	etravirine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-181
31902468-7	2020	In this review, we present important, recent developments in the computational prediction of the inhibition of four clinically crucial CYP isoforms (CYP1A2, 2C9, 2D6, and 3A4) and three nuclear receptors (aryl hydrocarbon receptor, constitutive androstane receptor, and pregnane X receptor) involved in the induction of CYP1A2, 2B6, and 3A4, respectively.	Hydrocarbons	205-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
31727673-8	2020	Subsequently, oxycodone was metabolized to other metabolites including noroxycodone, noroxymorphone and oxymorphone via cytochrome P-450.	Oxycodone	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
31902468-7	2020	In this review, we present important, recent developments in the computational prediction of the inhibition of four clinically crucial CYP isoforms (CYP1A2, 2C9, 2D6, and 3A4) and three nuclear receptors (aryl hydrocarbon receptor, constitutive androstane receptor, and pregnane X receptor) involved in the induction of CYP1A2, 2B6, and 3A4, respectively.	androstane	245-255	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
31727673-8	2020	Subsequently, oxycodone was metabolized to other metabolites including noroxycodone, noroxymorphone and oxymorphone via cytochrome P-450.	noroxymorphone	85-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
31902468-7	2020	In this review, we present important, recent developments in the computational prediction of the inhibition of four clinically crucial CYP isoforms (CYP1A2, 2C9, 2D6, and 3A4) and three nuclear receptors (aryl hydrocarbon receptor, constitutive androstane receptor, and pregnane X receptor) involved in the induction of CYP1A2, 2B6, and 3A4, respectively.	Pregnanes	270-278	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
31629065-7	2020	The cytotoxicity of ADQ was increased in CYP2C8 and 3A4 overexpressing HepG2 cells compared to HepG2/CYP vector cells, confirming that NADQ was more toxic than ADQ.	Amodiaquine	20-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
31837525-0	2020	Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems.	vandetanib	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31494843-14	2020	The in vitro CYP inhibition study only found very weak action for CYP3A4 (midazolam 1"-hydroxylation) and CYP3A4 (midazolam 6beta-hydroxylation) with IC50 of 56.8 microM and 41.1 microM, respectively.	Midazolam	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
31494843-14	2020	The in vitro CYP inhibition study only found very weak action for CYP3A4 (midazolam 1"-hydroxylation) and CYP3A4 (midazolam 6beta-hydroxylation) with IC50 of 56.8 microM and 41.1 microM, respectively.	Midazolam	114-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
31842058-3	2020	Recent research has shown that Cytochrome P450 (CYP) enzymes affect venlafaxine efficacy by mediating its metabolism.	venlafaxine	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
31842058-3	2020	Recent research has shown that Cytochrome P450 (CYP) enzymes affect venlafaxine efficacy by mediating its metabolism.	venlafaxine	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
31842058-4	2020	The present study investigates genetic polymorphisms of cytochrome P450 family 2 subfamily C member 19 (CYP2C19) are associated with remission after venlafaxine treatment for MDD.	venlafaxine	149-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
31859010-4	2020	Further investigation indicated that compound 16h potently suppressed the migration of A549 cells, had moderate stability in rat liver microsomes and showed moderate inhibitory activity against various subtypes of human cytochrome P450.	N-[(1R,3R)-3-hydroxy-1-(hydroxymethyl)-3-phenylpropyl]hexadecanamide	46-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	220-235
31979355-4	2020	Tofogliflozin is metabolized and inactivated by five different enzymes CYP2C18, CYP3A4, CYP3A5, CYP4A11, and CYP4F3.	6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-115
31020909-0	2020	In vitro inhibitory effects of phellodendrine on human liver cytochrome P450 enzymes.	phellodendrine	31-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
31020909-3	2020	However, whether phellodendrine affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.2.	phellodendrine	17-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
31020909-3	2020	However, whether phellodendrine affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.2.	phellodendrine	17-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
31020909-4	2020	In this study, the inhibitory effects of phellodendrine on eight human liver CYP isoforms (i.e. 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8) were investigated in vitro using human liver microsomes (HLMs).3.	phellodendrine	41-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
31020909-5	2020	The results showed that phellodendrine inhibited the activity of CYP1A2, 3A4 and 2C9, with IC50 values of 20.56, 14.98 and 16.30 muM, respectively, but that other CYP isoforms were not affected.	phellodendrine	24-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
31020909-8	2020	The in vitro studies of phellodendrine with CYP isoforms indicate that phellodendrine could inhibit the activities of CYP1A2, 3A4 and 2C9.	phellodendrine	24-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
31020909-8	2020	The in vitro studies of phellodendrine with CYP isoforms indicate that phellodendrine could inhibit the activities of CYP1A2, 3A4 and 2C9.	phellodendrine	71-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
31815452-4	2020	(Driscoll, et al 2018) Here cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) reaction phenotyping experiments using recombinant enzymes were performed on bromfenac and BI to identify the CYP and UGT enzymes responsible for bromfenac"s metabolism and bioactivation.	bromfenac	165-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
31773494-0	2020	Correction to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.	Cyclophosphamide	122-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
31648049-11	2020	CYP2C9 and CYP2C19 were the two CYP isozymes that produced 3"-hydroxylnalbuphine and 4"-hydroxylnalbuphine.	AN 3	59-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
31648049-11	2020	CYP2C9 and CYP2C19 were the two CYP isozymes that produced 3"-hydroxylnalbuphine and 4"-hydroxylnalbuphine.	BE 4-4-4-4	85-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
31555969-0	2020	Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.	Cyclophosphamide	107-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
32094037-2	2020	CASE SUMMARY: Polycyclic aromatic hydrocarbons present in cigarette smoke are well-known inducers of cytochrome P450 (CYP) enzymes.	Polycyclic Aromatic Hydrocarbons	14-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
32094037-2	2020	CASE SUMMARY: Polycyclic aromatic hydrocarbons present in cigarette smoke are well-known inducers of cytochrome P450 (CYP) enzymes.	Polycyclic Aromatic Hydrocarbons	14-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
33327871-9	2020	Based on GO and KEGG analyses, we found that miR-205-5p was correlated with the progression of HNSCC through association with signaling pathways, including the drug metabolism-cytochrome P450 pathway.	mir-205-5p	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
31378969-1	2020	The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach.	upadacitinib	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-147
31378969-1	2020	The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach.	upadacitinib	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-152
31956764-1	2020	Cytochrome P450 (CYP450) enzymes belong to a superfamily of heme-containing proteins that are involved in the metabolism of structurally diverse endogenous and exogenous compounds.	Heme	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31956764-1	2020	Cytochrome P450 (CYP450) enzymes belong to a superfamily of heme-containing proteins that are involved in the metabolism of structurally diverse endogenous and exogenous compounds.	Heme	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
31730751-3	2019	In this work, we report on the metabolism of BACs in human liver microsomes (HLM) and by recombinant human hepatic cytochrome P450 (CYP) enzymes.	Benzalkonium Compounds	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
31730751-3	2019	In this work, we report on the metabolism of BACs in human liver microsomes (HLM) and by recombinant human hepatic cytochrome P450 (CYP) enzymes.	Benzalkonium Compounds	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
31730751-12	2019	Furthermore, we demonstrate that CYP-mediated oxidation of C10-BAC mitigates the potent inhibition of cholesterol biosynthesis exhibited by this short-chain BAC.	Cholesterol	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
31730751-13	2019	Furthermore, we demonstrate that CYP-mediated oxidation of C10-BAC mitigates the potent inhibition of cholesterol biosynthesis exhibited by this short-chain BAC.	Cholesterol	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	Dimethyl Fumarate	45-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	Dimethyl Fumarate	45-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
31832203-4	2019	In vitro inhibition experiments using CYP-selective substrates with human liver microsomes showed 50% inhibitory concentrations (IC50) of >666 micromol/L for DMF and >750 micromol/L for MMF.	Dimethyl Fumarate	158-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	citraconic acid	73-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
31832203-4	2019	In vitro inhibition experiments using CYP-selective substrates with human liver microsomes showed 50% inhibitory concentrations (IC50) of >666 micromol/L for DMF and >750 micromol/L for MMF.	mmf	186-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	citraconic acid	73-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	mmf	93-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
31832203-2	2019	The present investigation determined whether DMF and its main metabolite monomethylfumarate (MMF) interact with hepatic cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) transporter, and was performed as part of DMF"s regulatory commitments.	mmf	93-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
31686406-1	2019	INTRODUCTION: Factor Xa-inhibiting direct oral anticoagulants (FXa-DOACs) undergo hepatic metabolism via cytochrome P-450 (CYP450).	doacs	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
31605674-9	2019	Cytochrome P450 isozyme models accurately predicted the likelihood for terbinafine N-demethylation, but overestimated the likelihood for a minor N-denaphthylation pathway.	terbinafine	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31605674-9	2019	Cytochrome P450 isozyme models accurately predicted the likelihood for terbinafine N-demethylation, but overestimated the likelihood for a minor N-denaphthylation pathway.	Nitrogen	83-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31605674-9	2019	Cytochrome P450 isozyme models accurately predicted the likelihood for terbinafine N-demethylation, but overestimated the likelihood for a minor N-denaphthylation pathway.	Nitrogen	145-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31686406-1	2019	INTRODUCTION: Factor Xa-inhibiting direct oral anticoagulants (FXa-DOACs) undergo hepatic metabolism via cytochrome P-450 (CYP450).	doacs	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-129
31571146-7	2019	The enzymatic activity of nine CYP isoforms was not inhibited or slightly inhibited in vitro with darolutamide, and a rank order and mechanistic static assessment indicated that risk of clinically relevant DDIs via CYP inhibition is very low.	darolutamide	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
31571146-13	2019	CONCLUSIONS: Darolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note.	darolutamide	13-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
31571146-3	2019	METHODS: In vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters.	darolutamide	72-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
31571146-3	2019	METHODS: In vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters.	darolutamide	72-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
31172535-0	2019	Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.	3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione	149-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
31172535-0	2019	Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.	3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione	160-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
31456483-0	2019	In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes.	lespenefril	31-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
31456483-4	2019	Materials and methods: In vitro, HLMs were used to investigate the inhibitory effects of KF (100 muM) on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8), and corresponding probe substrates were used.	kf	89-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
31456483-3	2019	Objective: This study investigates the effects of KF on eight major CYP isoforms in human liver microsomes (HLMs).	kf	50-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
31663733-1	2019	Sterol 14alpha-demethylases (CYP51) are the cytochrome P450 enzymes required for biosynthesis of sterols in eukaryotes, the major targets for antifungal agents and prospective targets for treatment of protozoan infections.	Sterols	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
30865484-8	2019	Using human recombinant CYP450 enzymes and chemical inhibitor method, the metabolism of safrole RMs was predominantly carried out through the CYP1A2 with minor contributions by CYP2E1.	Safrole	88-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-30
31663733-1	2019	Sterol 14alpha-demethylases (CYP51) are the cytochrome P450 enzymes required for biosynthesis of sterols in eukaryotes, the major targets for antifungal agents and prospective targets for treatment of protozoan infections.	Sterols	97-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
31273423-0	2019	Cytochrome P450 and Glutathione-S-Transferase Activity are Altered Following Environmentally Relevant Atrazine Exposures in Crayfish (Faxoniusvirilis).	Atrazine	102-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-45
31763971-0	2021	Carbon-Carbon Bond Cleavage Catalyzed by Human Cytochrome P450 Enzymes: a-Ketol as the Key Intermediate Metabolite in Sequential Metabolism of Olanexidine.	Carbon	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
31763971-0	2021	Carbon-Carbon Bond Cleavage Catalyzed by Human Cytochrome P450 Enzymes: a-Ketol as the Key Intermediate Metabolite in Sequential Metabolism of Olanexidine.	olanexidine	143-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
31763971-5	2021	METHODS: A pair of regioisomers of alpha-ketol-containing C8 side chain olanexidine analogs (3,2-ketol olanexidine and 2,3-ketol olanexidine) were synthesized, followed by incubation in human liver microsomes, recombinant human cytochrome P450 enzymes or human hepatocytes, and subsequent metabolite identification using LC/UV/MS.	fatty acid ketols	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
31763971-7	2021	Among 19 cytochrome P450 enzymes tested, CYP2D6, CYP3A4 and CYP3A5 were identified to catalyze carbon-carbon bond cleavage.	Carbon	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
30557096-2	2019	Catalpol possesses numerous pharmacological activities, and however, little data available for the effects of catalpol on the activity of human liver cytochrome P450 (CYP) enzymes.	catalpol	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-165
30557096-2	2019	Catalpol possesses numerous pharmacological activities, and however, little data available for the effects of catalpol on the activity of human liver cytochrome P450 (CYP) enzymes.	catalpol	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
30557096-7	2019	The results indicated that catalpol could inhibit the activity of CYP3A4, CYP2E1 and CYP2C9, with IC50 values of 14.27, 22.4 and 14.69 muM, respectively, but those other CYP isoforms were not affected.	catalpol	27-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
31418753-4	2019	The smoker"s paradox may be due to enhanced platelet response to clopidogrel therapy in active smokers as compared with nonsmokers caused by hepatic cytochrome P450 activation resulting in an increased generation of clopidogrel active metabolite.	Clopidogrel	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
31418753-4	2019	The smoker"s paradox may be due to enhanced platelet response to clopidogrel therapy in active smokers as compared with nonsmokers caused by hepatic cytochrome P450 activation resulting in an increased generation of clopidogrel active metabolite.	Clopidogrel	216-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
31515991-0	2019	In Vitro Metabolism of Auriculasin and Its Inhibitory Effects on Human Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes.	auriculasin	23-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
31515991-6	2019	In addition, CYP2D6, CYP2C9, CYP2C19, and CYP2C8 were the major CYP isoforms involved in the metabolism of auriculasin.	auriculasin	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
31077555-1	2019	AIM: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI).	Eicosanoids	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
31077555-1	2019	AIM: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI).	Eicosanoids	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
31077555-5	2019	Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI.	Eicosanoids	16-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
31077555-12	2019	CONCLUSIONS: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention.	Eicosanoids	61-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
31077555-13	2019	Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.	Eicosanoids	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
31745121-11	2019	Among the enzymatic pathways that differentiate eicosanoid metabolites, we observed the highest prediction of overall preterm birth by lipoxygenase metabolites using random forest (AUC = 0.83 [0.69, 0.96]), followed by cytochrome p450 metabolites using adaptive elastic-net (AUC = 0.74 [0.52, 0.96]).	Eicosanoids	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-234
31782268-1	2019	Fatty acid (FA)-derived lipid products generated by cytochrome P450 (CYP), lipoxygenase (LOX), and cyclo-oxygenase (COX) influence cardiovascular function.	Fatty Acids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
31782268-1	2019	Fatty acid (FA)-derived lipid products generated by cytochrome P450 (CYP), lipoxygenase (LOX), and cyclo-oxygenase (COX) influence cardiovascular function.	Fatty Acids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
31782268-8	2019	We used tandem mass spectrometry (LC-MS/MS) to measure epoxides derived from CYP monooxygenase, as well as metabolites derived from LOX, COX, and CYP hydroxylase pathways.	Epoxy Compounds	55-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
31273423-3	2019	We examined sublethal effects of atrazine on the expression and activity of the detoxification enzymes cytochrome P450 (CYP450) and glutathione-S-transferase (GST) in crayfish.	Atrazine	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
31273423-3	2019	We examined sublethal effects of atrazine on the expression and activity of the detoxification enzymes cytochrome P450 (CYP450) and glutathione-S-transferase (GST) in crayfish.	Atrazine	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-126
31273423-6	2019	Atrazine exposure caused differential expression and activity of CYP450 and GST.	Atrazine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-71
31375472-10	2019	Here, we report the application of MMHH in a high-throughput assay in a 384-well plate format for the evaluation of cytochrome P450 (P450) inhibition.	mmhh	35-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
31430908-0	2019	In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.	AKB48	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
31359235-5	2019	As the model drug, we chose diclofenac because of its known high CV toxicity, as markers of CV risks, we assessed concentrations of cytochrome P450-mediated metabolites of arachidonic acid (ArA), and we used adjuvant arthritis as an experimental model of arthritis.	Arachidonic Acid	172-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-147
31469704-0	2019	Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.	Nimodipine	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
31469704-4	2019	METHODS AND RESULTS: This article reviews the CYP450 enzyme system including a review of the pharmacotherapy and pharmacogenomics of nimodipine for patients with aSAH illustrated with case study of a patient with abnormal drug metabolism.	Nimodipine	133-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
29676195-0	2019	In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes.	sophocarpine	31-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
29676195-3	2019	However, whether sophocarpine affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	sophocarpine	17-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
29676195-3	2019	However, whether sophocarpine affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	sophocarpine	17-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
29676195-5	2019	In this study, the inhibitory effects of sophocarpine on the eight human liver CYP isoforms (CYP1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8) were investigated in vitro using human liver microsomes (HLMs).	sophocarpine	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
29676195-7	2019	The results indicate that sophocarpine could inhibit the activity of CYP3A4 and 2C9, with the IC50 values of 12.22 and 15.96 muM, respectively, but that other CYP isoforms were not affected.	sophocarpine	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
29676195-11	2019	The in vitro studies of sophocarpine with CYP isoforms suggested that sophocarpine has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4 and 2C9.	sophocarpine	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
31254976-1	2019	The spatial distributions of cytochrome P450 (CYP450) and glutathione (GSH) in liver lobules determine the heterogeneous hepatotoxicity of acetaminophen (APAP).	Acetaminophen	139-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
31254976-1	2019	The spatial distributions of cytochrome P450 (CYP450) and glutathione (GSH) in liver lobules determine the heterogeneous hepatotoxicity of acetaminophen (APAP).	Acetaminophen	139-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
31254976-1	2019	The spatial distributions of cytochrome P450 (CYP450) and glutathione (GSH) in liver lobules determine the heterogeneous hepatotoxicity of acetaminophen (APAP).	Acetaminophen	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
31254976-1	2019	The spatial distributions of cytochrome P450 (CYP450) and glutathione (GSH) in liver lobules determine the heterogeneous hepatotoxicity of acetaminophen (APAP).	Acetaminophen	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
31254976-5	2019	We found that the spatial distribution of GSH, glutathione S-transferases (GSTs), and CYP450 all contributes to the high acetaminophen protein adduct formation at zone 3 of the lobules.	Acetaminophen	121-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-92
31254976-6	2019	The reversed spatial gradients of CYP450 and GSH cause quick depletion of GSH, which is further accelerated by the distribution of GST.	Glutathione	74-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-40
31656654-3	2019	The cytochrome P450 (CYP) enzyme inducer, rifampicin, and the CYP inhibitor, clarithromycin, have clinical activity against MAC and key drugs in the treatment of MAC infection.	Rifampin	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
31005596-3	2019	Tramadol labeling indicates cytochrome P450 (CYP) isozyme 2D6 ultrarapid metabolizer can produce dangerous (+)-M1 levels, and CYP2D6 poor metabolizers insufficient (+)-M1 for analgesia.	Tramadol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
31005596-3	2019	Tramadol labeling indicates cytochrome P450 (CYP) isozyme 2D6 ultrarapid metabolizer can produce dangerous (+)-M1 levels, and CYP2D6 poor metabolizers insufficient (+)-M1 for analgesia.	Tramadol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
31005596-7	2019	In trial B, CYP inhibition significantly depressed tramadol steady-state (+)-M1, reduced its adverse events, and led to insignificant analgesia comparable with placebo.	Tramadol	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
31656654-3	2019	The cytochrome P450 (CYP) enzyme inducer, rifampicin, and the CYP inhibitor, clarithromycin, have clinical activity against MAC and key drugs in the treatment of MAC infection.	Clarithromycin	77-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
30272491-0	2019	Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes.	coumarin	19-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
30272491-4	2019	Molecular modeling indicated that 3-phenylcoumarin offers an excellent scaffold for the development of selective substrate compounds for various human CYP forms, as they could be metabolized to fluorescent 7-hydroxycoumarin derivatives.	3-Phenylcoumarin	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
30272491-4	2019	Molecular modeling indicated that 3-phenylcoumarin offers an excellent scaffold for the development of selective substrate compounds for various human CYP forms, as they could be metabolized to fluorescent 7-hydroxycoumarin derivatives.	7-hydroxycoumarin	206-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
30272491-5	2019	Oxidation of profluorescent coumarin derivatives to fluorescent metabolites by 13 important human liver xenobiotic-metabolizing CYP forms was determined by enzyme kinetic assays.	coumarin	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
31296661-1	2019	Human cytochrome P450 (P450) 11B2 catalyzes the formation of aldosterone, the major endogenous human mineralocorticoid.	Aldosterone	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
30973652-1	2019	Different views appear in the literature on the extent of specific cytochrome P450 (CYP) involvement in methadone metabolism.	Methadone	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
31103741-5	2019	Our study aimed to analyze whether the PA representative lasiocarpine is toxified by human cytochrome P450 (CYP) enzymes.	Pyrrolizidine Alkaloids	39-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
31103741-5	2019	Our study aimed to analyze whether the PA representative lasiocarpine is toxified by human cytochrome P450 (CYP) enzymes.	Pyrrolizidine Alkaloids	39-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
31103741-5	2019	Our study aimed to analyze whether the PA representative lasiocarpine is toxified by human cytochrome P450 (CYP) enzymes.	lasiocarpine	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
31103741-5	2019	Our study aimed to analyze whether the PA representative lasiocarpine is toxified by human cytochrome P450 (CYP) enzymes.	lasiocarpine	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
31428108-6	2019	The enzymes that form the flavonoid scaffold structures probably first appeared by recruitment of enzymes from primary metabolic pathways, and later, enzymes that belong to superfamilies such as 2-oxoglutarate-dependent dioxygenase, cytochrome P450, and short-chain dehydrogenase/reductase modified and varied the structures.	Flavonoids	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	233-289
30973652-1	2019	Different views appear in the literature on the extent of specific cytochrome P450 (CYP) involvement in methadone metabolism.	Methadone	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
31212689-0	2019	In Vitro Human Metabolism and Inhibition Potency of Verbascoside for CYP Enzymes.	acteoside	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
31333461-4	2019	Cytochrome P450 enzymes metabolize endogenous substrates (polyunsaturated fatty acids) to bioactive fatty acid epoxides that demonstrate biological activity with generally protective/anti-inflammatory and insulin-sensitizing effects.	Fatty Acids, Unsaturated	58-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31333461-4	2019	Cytochrome P450 enzymes metabolize endogenous substrates (polyunsaturated fatty acids) to bioactive fatty acid epoxides that demonstrate biological activity with generally protective/anti-inflammatory and insulin-sensitizing effects.	fatty acid epoxides	100-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31111189-5	2019	Incubation of 21 recombinant human CYP enzymes with 0.5 microM IMQ and subsequent LC-MS analyses, in fact, identified CYP1A1 and CYP1A2 as being predominantly responsible for IMQ metabolism.	Imiquimod	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
31029719-0	2019	Oxidative stress and cell death induction by amitraz and its metabolite BTS-27271 mediated through cytochrome P450 and NRF2 pathway alteration in primary hippocampal cell.	Pyruvic Acid	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
31029719-3	2019	Amitraz was shown to induce different cytochrome P450 (CYP) isoenzymes involved with ROS and apoptotic cell death induction.	amitraz	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
30964977-0	2019	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes.	5-hydroxyflavone	22-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
30964977-0	2019	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes.	chrysin	44-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
30964977-0	2019	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes.	mono-, di-, and tri-hydroxyflavones	68-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
30964977-2	2019	In order to better understand the metabolism of these flavonoids in humans, we examined the oxidation of flavone, 5-hydroxyflavone (5OHF), and 57diOHF to various products by human cytochrome P450 (P450 or CYP) and liver microsomal enzymes.	Flavonoids	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
30964977-2	2019	In order to better understand the metabolism of these flavonoids in humans, we examined the oxidation of flavone, 5-hydroxyflavone (5OHF), and 57diOHF to various products by human cytochrome P450 (P450 or CYP) and liver microsomal enzymes.	flavone	105-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
30964977-2	2019	In order to better understand the metabolism of these flavonoids in humans, we examined the oxidation of flavone, 5-hydroxyflavone (5OHF), and 57diOHF to various products by human cytochrome P450 (P450 or CYP) and liver microsomal enzymes.	5-hydroxyflavone	114-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
30964977-2	2019	In order to better understand the metabolism of these flavonoids in humans, we examined the oxidation of flavone, 5-hydroxyflavone (5OHF), and 57diOHF to various products by human cytochrome P450 (P450 or CYP) and liver microsomal enzymes.	5ohf	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
30964977-2	2019	In order to better understand the metabolism of these flavonoids in humans, we examined the oxidation of flavone, 5-hydroxyflavone (5OHF), and 57diOHF to various products by human cytochrome P450 (P450 or CYP) and liver microsomal enzymes.	57diohf	143-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
31111189-3	2019	Treatment of human keratinocytes with 2.5 microM benzo[a]pyrene (BaP), a tobacco smoke constituent and aryl hydrocarbon receptor (AHR) agonist, for 24 h induced cytochrome P450 (CYP) 1A enzyme activity.	Benzo(a)pyrene	49-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-176
31111189-3	2019	Treatment of human keratinocytes with 2.5 microM benzo[a]pyrene (BaP), a tobacco smoke constituent and aryl hydrocarbon receptor (AHR) agonist, for 24 h induced cytochrome P450 (CYP) 1A enzyme activity.	Benzo(a)pyrene	49-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-181
31111189-3	2019	Treatment of human keratinocytes with 2.5 microM benzo[a]pyrene (BaP), a tobacco smoke constituent and aryl hydrocarbon receptor (AHR) agonist, for 24 h induced cytochrome P450 (CYP) 1A enzyme activity.	Benzo(a)pyrene	65-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-176
31111189-3	2019	Treatment of human keratinocytes with 2.5 microM benzo[a]pyrene (BaP), a tobacco smoke constituent and aryl hydrocarbon receptor (AHR) agonist, for 24 h induced cytochrome P450 (CYP) 1A enzyme activity.	Benzo(a)pyrene	65-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-181
31068367-0	2019	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.	alectinib	16-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
31029719-3	2019	Amitraz was shown to induce different cytochrome P450 (CYP) isoenzymes involved with ROS and apoptotic cell death induction.	amitraz	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
31029719-3	2019	Amitraz was shown to induce different cytochrome P450 (CYP) isoenzymes involved with ROS and apoptotic cell death induction.	Reactive Oxygen Species	85-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
31029719-3	2019	Amitraz was shown to induce different cytochrome P450 (CYP) isoenzymes involved with ROS and apoptotic cell death induction.	Reactive Oxygen Species	85-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
30964977-0	2019	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes.	flavone	13-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
31058221-3	2019	With oxidase catalysis as a model reaction, experimental studies and theoretical calculations revealed that single-atom nanozymes with carbon nanoframe-confined FeN5 active centers (FeN5 SA/CNF) catalytically behaved like the axial ligand-coordinated heme of cytochrome P450.	Carbon	135-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	259-274
30981875-0	2019	Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.	N-Demethyllysergic acid diethylamide	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30981875-0	2019	Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.	2-oxo-3-hydroxylysergic acid diethylamide	75-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	N-Demethyllysergic acid diethylamide	117-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	N-Demethyllysergic acid diethylamide	117-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	N-Demethyllysergic acid diethylamide	150-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	N-Demethyllysergic acid diethylamide	150-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	2-oxo-3-hydroxylysergic acid diethylamide	163-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	2-oxo-3-hydroxylysergic acid diethylamide	163-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	o-h-lsd	184-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
30981875-3	2019	The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics.	o-h-lsd	184-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30845890-2	2019	Amiodarone may also alter the pharmacokinetics of medications metabolized via cytochrome P450.	Amiodarone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
31091646-8	2019	SRIs are metabolized in the liver by several cytochrome P450 (CYP) enzymes.	sris	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
31091646-8	2019	SRIs are metabolized in the liver by several cytochrome P450 (CYP) enzymes.	sris	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
30918015-7	2019	Deactivation caused by DCA-induced cytochrome P450-cytochrome P420 conversion, as shown by the spectral titrations of isolated CYP3A proteins, was observed when DCA levels were near or higher than the critical micelle concentration (about 1500 muM).	Deoxycholic Acid	23-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-66
30918015-7	2019	Deactivation caused by DCA-induced cytochrome P450-cytochrome P420 conversion, as shown by the spectral titrations of isolated CYP3A proteins, was observed when DCA levels were near or higher than the critical micelle concentration (about 1500 muM).	Deoxycholic Acid	161-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-66
31151284-9	2019	AIs and N/DSs sharing the cytochrome P450 pathway are at risk of negative interactions.	Nitrogen	8-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Caffeine	23-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Dextromethorphan	33-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Midazolam	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Omeprazole	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Losartan	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
30888624-3	2019	The primary metabolic pathways for olanzapine are direct glucuronidation via uridine 5"-diphospho-glucuronosyltransferase (UGT)1A4 and cytochrome P450 (CYP)-mediated oxidation, mainly by CYP1A2.	Olanzapine	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
31006007-10	2019	Cytochrome-P450-derived anti-inflammatory and cardioprotective epoxy-PUFAs increased linearly with n-3 PUFA dose and showed low interindividual variance (r2 > 0.95).	epoxy-pufas	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30888624-3	2019	The primary metabolic pathways for olanzapine are direct glucuronidation via uridine 5"-diphospho-glucuronosyltransferase (UGT)1A4 and cytochrome P450 (CYP)-mediated oxidation, mainly by CYP1A2.	Olanzapine	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Ritonavir	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Ritonavir	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-201
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Cobicistat	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Cobicistat	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-201
30733060-0	2019	Cytochrome P450 enzymes: A driving force of plant diterpene diversity.	Diterpenes	50-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30733060-1	2019	In plant terpene biosynthesis, oxidation of the hydrocarbon backbone produced by terpene synthases is typically carried out by cytochrome P450 oxygenases (CYPs).	Hydrocarbons	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
31278717-1	2019	Ketoconazole is a first orally available anti-fungal drug which has been reported as a potent inhibitor of human cytochrome P-450.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
30733060-1	2019	In plant terpene biosynthesis, oxidation of the hydrocarbon backbone produced by terpene synthases is typically carried out by cytochrome P450 oxygenases (CYPs).	Terpenes	9-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
30914192-0	2019	Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.	ellipticine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
30861250-3	2019	CYP2J2 is a membrane-bound cytochrome P450 in the heart involved in the metabolism of fatty acids and xenobiotics.	Fatty Acids	86-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
30914192-6	2019	The interaction of ApoElli with microsomal membrane particles containing cytochrome P450 (CYP) biotransformation enzymes accelerated the release of ellipticine from this nanocarrier making it possible to be transferred into this membrane system even at pH 7.4 and facilitating CYP-mediated metabolism.	ellipticine	148-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
30914192-6	2019	The interaction of ApoElli with microsomal membrane particles containing cytochrome P450 (CYP) biotransformation enzymes accelerated the release of ellipticine from this nanocarrier making it possible to be transferred into this membrane system even at pH 7.4 and facilitating CYP-mediated metabolism.	ellipticine	148-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
30914192-6	2019	The interaction of ApoElli with microsomal membrane particles containing cytochrome P450 (CYP) biotransformation enzymes accelerated the release of ellipticine from this nanocarrier making it possible to be transferred into this membrane system even at pH 7.4 and facilitating CYP-mediated metabolism.	ellipticine	148-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-280
30821969-5	2019	As an illustrative example with reliable data from previous GCMC simulations, absolute binding affinity of camphor to cytochrome P450 was calculated.	Camphor	107-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
29779438-0	2019	Metabolism of deltamethrin and cis- and trans-permethrin by human expressed cytochrome P450 and carboxylesterase enzymes.	decamethrin	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-112
29779438-0	2019	Metabolism of deltamethrin and cis- and trans-permethrin by human expressed cytochrome P450 and carboxylesterase enzymes.	cis- and trans-permethrin	31-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-112
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Pyrethrins	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	decamethrin	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	decamethrin	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Permethrin	79-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Permethrin	97-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
29779438-1	2019	The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.	Permethrin	97-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
29779438-3	2019	Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5.	Pyrethrins	77-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
29779438-6	2019	Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol.	Pyrethrins	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
29779438-8	2019	Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.	Pyrethrins	41-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
29790809-5	2019	Cytochrome p450 (CYP) 2D6 was found to be the dominant CYP enzyme involved in the biotransformation of leelamine to its hydroxylated metabolite, whereas CYP2C19, CYP1A1, and CYP3A4 contributed to some extent.	dehydroabietylamine	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29790809-5	2019	Cytochrome p450 (CYP) 2D6 was found to be the dominant CYP enzyme involved in the biotransformation of leelamine to its hydroxylated metabolite, whereas CYP2C19, CYP1A1, and CYP3A4 contributed to some extent.	dehydroabietylamine	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
29790809-5	2019	Cytochrome p450 (CYP) 2D6 was found to be the dominant CYP enzyme involved in the biotransformation of leelamine to its hydroxylated metabolite, whereas CYP2C19, CYP1A1, and CYP3A4 contributed to some extent.	dehydroabietylamine	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
30701961-1	2019	Human cytochrome P450 (P450) family 4 enzymes are involved in the metabolism of fatty acids and the bioactivation of carcinogenic arylamines and toxic natural products, e.g., 4-ipomeanol.	Fatty Acids	80-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-37
30936195-5	2019	Although variants were reported for all drugs, the highest level of evidence was found in cytochrome P450 (CYP450) genotype variation related to clopidogrel response.	Clopidogrel	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
30936195-5	2019	Although variants were reported for all drugs, the highest level of evidence was found in cytochrome P450 (CYP450) genotype variation related to clopidogrel response.	Clopidogrel	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-113
30998396-1	2019	Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention.	Clopidogrel	215-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-62
30998396-1	2019	Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention.	Clopidogrel	254-265	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-62
30701961-1	2019	Human cytochrome P450 (P450) family 4 enzymes are involved in the metabolism of fatty acids and the bioactivation of carcinogenic arylamines and toxic natural products, e.g., 4-ipomeanol.	arylamines	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-37
30701961-1	2019	Human cytochrome P450 (P450) family 4 enzymes are involved in the metabolism of fatty acids and the bioactivation of carcinogenic arylamines and toxic natural products, e.g., 4-ipomeanol.	4-ipomeanol	175-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-37
29987837-9	2019	Cytochrome P450-mediated biotransformation of cladribine is of minor importance.	Cladribine	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30428505-2	2019	Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression.	ONX 0912	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
30428505-2	2019	Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression.	ONX 0912	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Warfarin	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Warfarin	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Warfarin	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Phenobarbital	122-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Phenobarbital	122-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
30689138-4	2019	Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible.	Phenobarbital	122-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
30976185-3	2019	The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10).	pterostilbene	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
30467864-0	2019	Effect of an anxiolytic botanical containing Souroubea sympetala and Platanus occidentalis on in-vitro diazepam human cytochrome P450-mediated metabolism.	Diazepam	103-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
30976185-3	2019	The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10).	pterostilbene	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
30976185-3	2019	The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10).	Amodiaquine	160-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
30976185-3	2019	The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10).	Amodiaquine	160-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
30389730-0	2019	Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions.	Oligonucleotides	61-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
30860683-13	2019	CONCLUSION: The results found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib cause a decrease in oxidative activation of DNA-damaging drug ellipticine by several CYP enzymes in vitro which might lead to a decrease in its pharmacological efficiency.	ellipticine	154-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
30247644-10	2019	This was supported by significantly increased transcriptional levels of 5-lipoxygenase and CYP4F3 in whole blood cells from AG patients compared with those of controls, and the uric acid-caused dose-relevant and time-dependent activation of 5-lipoxygenase and CYP4F3 at the transcriptional and molecular levels in vitro.	Uric Acid	177-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-97
30247644-10	2019	This was supported by significantly increased transcriptional levels of 5-lipoxygenase and CYP4F3 in whole blood cells from AG patients compared with those of controls, and the uric acid-caused dose-relevant and time-dependent activation of 5-lipoxygenase and CYP4F3 at the transcriptional and molecular levels in vitro.	Uric Acid	177-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-266
30633519-2	2019	CYP450 is a nanomachine that uses dioxygen and two reducing and two proton equivalents to oxidize a plethora of molecules (so-called substrates) as a means of supplying bio-organisms with essential molecules (e.g., brain neurotransmitters, sex hormones, etc.)	nanomachine	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30633519-2	2019	CYP450 is a nanomachine that uses dioxygen and two reducing and two proton equivalents to oxidize a plethora of molecules (so-called substrates) as a means of supplying bio-organisms with essential molecules (e.g., brain neurotransmitters, sex hormones, etc.)	Oxygen	34-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30633519-7	2019	CYP450 is a heme enzyme that contains a ferric ion (FeIII) coordinated by a porphyrin ligand, a water molecule, and a cysteinate ligand that is provided by a strategic residue of the encapsulating protein.	Heme	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30633519-7	2019	CYP450 is a heme enzyme that contains a ferric ion (FeIII) coordinated by a porphyrin ligand, a water molecule, and a cysteinate ligand that is provided by a strategic residue of the encapsulating protein.	Porphyrins	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30633519-7	2019	CYP450 is a heme enzyme that contains a ferric ion (FeIII) coordinated by a porphyrin ligand, a water molecule, and a cysteinate ligand that is provided by a strategic residue of the encapsulating protein.	Water	96-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30633519-7	2019	CYP450 is a heme enzyme that contains a ferric ion (FeIII) coordinated by a porphyrin ligand, a water molecule, and a cysteinate ligand that is provided by a strategic residue of the encapsulating protein.	cysteinate	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30399481-1	2019	Cytochrome P450 (CYP) is a class of heme-containing enzymes which mainly catalyze a monooxygenation reaction of various chemicals, and hence CYP plays a key role in the drug metabolism.	Heme	36-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
30399481-1	2019	Cytochrome P450 (CYP) is a class of heme-containing enzymes which mainly catalyze a monooxygenation reaction of various chemicals, and hence CYP plays a key role in the drug metabolism.	Heme	36-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
30399481-1	2019	Cytochrome P450 (CYP) is a class of heme-containing enzymes which mainly catalyze a monooxygenation reaction of various chemicals, and hence CYP plays a key role in the drug metabolism.	Heme	36-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
30399481-2	2019	Although CYP2C19 isoform is a minor hepatic CYP, it metabolizes clinically important drugs such as omeprazole and S-mephenytoin.	Omeprazole	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
30399481-2	2019	Although CYP2C19 isoform is a minor hepatic CYP, it metabolizes clinically important drugs such as omeprazole and S-mephenytoin.	Mephenytoin	114-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
30860683-7	2019	METHODS: Ellipticine oxidation catalyzed by hepatic microsomes, recombinant CYP enzymes and peroxidases (horseradish peroxidase, lactoperoxidase and myeloperoxidase) and the effect of TKIs (vandetanib, lenvatinib and cabozantinib) on this oxidation were analyzed by HPLC used for separation of ellipticine metabolites and quantification of their amounts formed during oxidation.	ellipticine	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
30860683-8	2019	RESULTS: The CYP enzymatic system oxidizes ellipticine up to five metabolites (9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N2- oxide), while peroxidases form predominantly ellipticine dimer.	ellipticine	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
30860683-8	2019	RESULTS: The CYP enzymatic system oxidizes ellipticine up to five metabolites (9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N2- oxide), while peroxidases form predominantly ellipticine dimer.	9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine	79-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
30860683-8	2019	RESULTS: The CYP enzymatic system oxidizes ellipticine up to five metabolites (9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N2- oxide), while peroxidases form predominantly ellipticine dimer.	ellipticine n2- oxide	143-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
30860683-8	2019	RESULTS: The CYP enzymatic system oxidizes ellipticine up to five metabolites (9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N2- oxide), while peroxidases form predominantly ellipticine dimer.	ellipticine	126-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	50-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	50-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
30860683-10	2019	Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 &gt; 2D1 &gt; 2C9 &gt; 3A1 &gt; 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency.	ellipticine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
30860683-13	2019	CONCLUSION: The results found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib cause a decrease in oxidative activation of DNA-damaging drug ellipticine by several CYP enzymes in vitro which might lead to a decrease in its pharmacological efficiency.	vandetanib	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
30860683-13	2019	CONCLUSION: The results found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib cause a decrease in oxidative activation of DNA-damaging drug ellipticine by several CYP enzymes in vitro which might lead to a decrease in its pharmacological efficiency.	lenvatinib	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
30860683-13	2019	CONCLUSION: The results found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib cause a decrease in oxidative activation of DNA-damaging drug ellipticine by several CYP enzymes in vitro which might lead to a decrease in its pharmacological efficiency.	cabozantinib	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
31576541-6	2019	We also review the updated roles of the ethanol-inducible cytochrome P450-2E1 (CYP2E1) and other cytochrome P450 isozymes in the metabolism of various potentially toxic substrates, and consequent toxicities, including carcinogenesis in different tissues.	Ethanol	40-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
30828066-0	2019	Prediction of Human Hepatic Clearance for Cytochrome P450 Substrates via a New Culture Method Using the Collagen Vitrigel Membrane Chamber and Fresh Hepatocytes Isolated from Liver Humanized Mice.	vitrigel	113-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
30499388-0	2019	Biology of Heme: Drug Interactions and Adverse Drug Reactions with CYP450.	Heme	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-73
30389730-3	2019	Other oligonucleotides have been previously shown to have in vitro test-system-dependent outcomes when potent cytochrome P450 inhibition in human liver microsomes (HLM) is observed, but such inhibition is not observed in cryopreserved human hepatocytes (CHH).	Oligonucleotides	6-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
30371861-0	2019	Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study.	Fentanyl	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
30371861-6	2019	Functional CYP polymorphisms can significantly alter opiate levels resulting in inadequate analgesia or life-threatening toxicity.	Opiate Alkaloids	53-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-14
30151903-1	2019	Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1.	Acetaminophen	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
30151903-1	2019	Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1.	Acetaminophen	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
30151903-1	2019	Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1.	Acetaminophen	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
30151903-1	2019	Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1.	Acetaminophen	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
30151903-2	2019	We previously demonstrated CYP inhibition following administration of a liquid APAP formulation containing propylene glycol, a CYP2E1 inhibitor, and other excipients.	Acetaminophen	79-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
30151903-2	2019	We previously demonstrated CYP inhibition following administration of a liquid APAP formulation containing propylene glycol, a CYP2E1 inhibitor, and other excipients.	Propylene Glycol	107-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
30151903-3	2019	This study was undertaken to determine if propylene glycol specifically inhibits production of CYP-derived metabolites and if propylene glycol reduces the rise in alanine aminotransferase (ALT) seen following prolonged APAP dosing.	Propylene Glycol	42-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
30151903-8	2019	For all subjects, the mean percentage of CYP-derived metabolites produced was 5.8% (APAP) versus 4.3% (APAP + propylene glycol); P = .018.	Acetaminophen	84-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30151903-8	2019	For all subjects, the mean percentage of CYP-derived metabolites produced was 5.8% (APAP) versus 4.3% (APAP + propylene glycol); P = .018.	Acetaminophen	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30151903-8	2019	For all subjects, the mean percentage of CYP-derived metabolites produced was 5.8% (APAP) versus 4.3% (APAP + propylene glycol); P = .018.	Propylene Glycol	110-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30151903-9	2019	This effect was solely attributable to the responders: the mean percentage of CYP metabolites of responders was 7.7% (APAP) versus 4.6% (APAP + propylene glycol), P = .050, whereas there was no difference for the nonresponders.	Acetaminophen	118-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
30544127-0	2019	In vitro Inhibitory Effects of Isofraxidin on Human Liver Cytochrome P450 Enzymes.	isofraxidin	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
30544127-2	2019	However, whether isofraxidin affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	isofraxidin	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
30544127-7	2019	The in vitro studies of isofraxidin with CYP isoforms indicate that isofraxidin has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by -CYP1A2, 3A4, and 2E1.	isofraxidin	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30544127-2	2019	However, whether isofraxidin affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	isofraxidin	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
30544127-7	2019	The in vitro studies of isofraxidin with CYP isoforms indicate that isofraxidin has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by -CYP1A2, 3A4, and 2E1.	isofraxidin	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
31587003-8	2019	CONCLUSION: The in vitro studies of cynaroside with CYP isoforms indicate that cynaroside has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by CYP1A2, 3A4, and 2C9.	luteolin-7-glucoside	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
31587003-2	2019	However, whether cynaroside affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	luteolin-7-glucoside	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
31587003-2	2019	However, whether cynaroside affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	luteolin-7-glucoside	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
30544127-3	2019	In this study, the inhibitory effects of isofraxidin on the 8 human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8) were investigated in vitro using human liver microsomes.	isofraxidin	41-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
31587003-3	2019	The purpose of this study was to investigate the effects of cynaroside on 8 major CYP isoforms in human liver microsomes (HLMs).	luteolin-7-glucoside	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
31587003-8	2019	CONCLUSION: The in vitro studies of cynaroside with CYP isoforms indicate that cynaroside has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by CYP1A2, 3A4, and 2C9.	luteolin-7-glucoside	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
30544127-4	2019	The results showed that isofraxidin inhibited the activity of CYP1A2, 3A4, and 2E1, with IC50 values of 23.01, 15.49, and 15.98 micromol/L, respectively, but that other CYP isoforms were not affected.	isofraxidin	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
31587003-4	2019	METHODS: In this study, the inhibitory effects of cynaroside on the 8 human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8) were investigated in vitro using HLMs.	luteolin-7-glucoside	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
31587003-5	2019	RESULTS: The results showed that cynaroside inhibited the activity of CYP1A2, 3A4, and 2C9, with IC50 values of 21.74, 15.88, and 16.58 mumol/L, respectively, but that other CYP isoforms were not affected.	luteolin-7-glucoside	33-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
30576387-5	2018	Activation of the AHR leads to upregulation of cytochrome P450 (CYP) metabolizing enzymes which are important for the biotransformation of toxicants to less toxic, or in the case of PAHs, more toxic intermediates.	Polycyclic Aromatic Hydrocarbons	182-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
30560267-0	2018	Role of cytochrome P450 epoxygenase-dependent arachidonic acid metabolites in kidney physiology and diseases.	Arachidonic Acid	46-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
30560267-3	2018	Pharmacological and biochemical tools have been used to conduct detailed studies on the metabolization of arachidonic acid by cytochrome P450 (CYP450) in renal microvasculature.	Arachidonic Acid	106-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
30560267-3	2018	Pharmacological and biochemical tools have been used to conduct detailed studies on the metabolization of arachidonic acid by cytochrome P450 (CYP450) in renal microvasculature.	Arachidonic Acid	106-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-149
30560267-4	2018	CYP450 epoxygenase metabolites epoxyeicosatrienoic acids (EETs) are mainly produced in renal microvessels.	epoxyeicosatrienoic acids	31-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30560267-4	2018	CYP450 epoxygenase metabolites epoxyeicosatrienoic acids (EETs) are mainly produced in renal microvessels.	eets	58-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
30583596-5	2018	In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters (Glycoprotein p, breast cancer resistance proteins, and multidrug resistance proteins) and metabolizing enzymes (Cytochrome P450 and UDP-glucuronosyltransferases).	Cannabinoids	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-295
30576387-5	2018	Activation of the AHR leads to upregulation of cytochrome P450 (CYP) metabolizing enzymes which are important for the biotransformation of toxicants to less toxic, or in the case of PAHs, more toxic intermediates.	Polycyclic Aromatic Hydrocarbons	182-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
30576387-11	2018	SRM1649b PAH mixtures enhanced Th17 differentiation in an AHR-dependent but CYP-independent manner and increased the percent of IFNgamma positive DCs.	Polycyclic Aromatic Hydrocarbons	9-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
30422622-2	2018	Herein, a novel light-driven enzymatic bionanoreactor is designed with the gold nanoparticle (NP)-modified carbon nanocage (Au@CNC) as a nanoreactor and meso-tetrakis(4-carboxyphenyl)porphyrin (TCPP) as a photosensitizer for cytochrome P450-mediated drug metabolism.	meso	153-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-240
30587978-10	2018	Conclusion: Our findings revealed that DN, GO and GN might interfere with xenobiotic and drug metabolism in the liver by interactions with CYP isoenzymes responsible for the process.	dn	39-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
30587978-10	2018	Conclusion: Our findings revealed that DN, GO and GN might interfere with xenobiotic and drug metabolism in the liver by interactions with CYP isoenzymes responsible for the process.	graphene oxide	43-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
30205091-2	2018	Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
30587978-10	2018	Conclusion: Our findings revealed that DN, GO and GN might interfere with xenobiotic and drug metabolism in the liver by interactions with CYP isoenzymes responsible for the process.	gossypolone	50-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
30422622-0	2018	Enhanced Metabolic Activity of Cytochrome P450 via Carbon Nanocage-Based Photochemical Bionanoreactor.	Carbon	51-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
30422622-2	2018	Herein, a novel light-driven enzymatic bionanoreactor is designed with the gold nanoparticle (NP)-modified carbon nanocage (Au@CNC) as a nanoreactor and meso-tetrakis(4-carboxyphenyl)porphyrin (TCPP) as a photosensitizer for cytochrome P450-mediated drug metabolism.	Gold	124-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-240
29858835-4	2018	Most drug interaction reports with CAM focus on cytochrome P450 (CYP) modulation.	cafestol palmitate	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
29858835-4	2018	Most drug interaction reports with CAM focus on cytochrome P450 (CYP) modulation.	cafestol palmitate	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
30205091-2	2018	Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
30205091-2	2018	Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8.	Nitrogen	20-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
30205091-2	2018	Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8.	Nitrogen	20-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
30205091-5	2018	In general, CYP inhibitors altered methadone exposure with no adverse effects.	Methadone	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
30205091-6	2018	CYP inducers generally decreased methadone exposure with some reports of withdrawal symptoms in the subjects.	Methadone	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30205091-8	2018	For certain antiviral medicines which are dual inhibitor(s) and inducer(s) for CYP enzymes, their effect on methadone pharmacokinetics can change with time since the effect of induction is usually delayed compared to the effect of inhibition.	Methadone	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
29935100-1	2018	BACKGROUND &amp; AIMS: Fatty liver disease is an important complication associated with liver transplantation, and the cytochrome P-450 system of the donor liver may be involved in its pathogenesis.	Adenosine Monophosphate	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
31070542-9	2018	DISCUSSION AND CONCLUSIONS: The in vitro studies of bergenin with CYP isoforms indicate that bergenin has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, 2E1 and 2C9.	bergenin	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Fatty Acids	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Fatty Acids	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Eicosanoids	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Eicosanoids	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Vitamin D	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
30280198-1	2018	Cytochrome P450 family 4 (CYP4) enzymes are known as microsomal omega (omega)-hydroxylases that metabolize fatty acids, eicosanoids, vitamin D and carcinogens.	Vitamin D	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
29964123-4	2018	Small molecule compounds targeting enzymes and CYP epoxy-fatty acid metabolites have evolved rapidly over the last two decades.	Fatty Acids	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
30048707-1	2018	20-HETE, the omega-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-120
30607725-0	2018	A New Method for Quantitative Determination of Steroid Metabolites of Cytochrome P450-Dependent Reactions Using Fluorescent Spectroscopy.	Steroids	47-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
30048707-1	2018	20-HETE, the omega-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation.	Arachidonic Acid	44-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-120
28385095-0	2018	In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes.	pristimerin	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	ecbs	158-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	epoxyeicosatrienoic acids	76-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	epoxyeicosatrienoic acids	76-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	eets	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	eets	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	113-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	113-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	146-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
30400671-2	2018	Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	146-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
30400671-3	2018	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids may compete with AA for CYP450-dependent bioactive lipid mediator formation.	Eicosapentaenoic Acid	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
30400671-3	2018	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids may compete with AA for CYP450-dependent bioactive lipid mediator formation.	Eicosapentaenoic Acid	23-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
30400671-3	2018	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids may compete with AA for CYP450-dependent bioactive lipid mediator formation.	Docosahexaenoic Acids	32-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
30400671-3	2018	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids may compete with AA for CYP450-dependent bioactive lipid mediator formation.	Docosahexaenoic Acids	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
30400671-3	2018	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids may compete with AA for CYP450-dependent bioactive lipid mediator formation.	omega-3 polyunsaturated fatty acids	59-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
30400671-5	2018	Fatty acid profile moderately correlated with the corresponding CYP450-derived metabolites but their levels did not differ between children with normal BP (NBP) and high BP (HBP), except for higher EPA-derived epoxyeicosatetraenoic acids (EEQs) and their diols in HBP group, in which also the estimated CYP450-epoxygenase activity was higher.	Fatty Acids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-70
30259074-3	2018	Therefore, this study was designed to develop CYP4F selective inhibitors using a novel inhibitory assay of 20-HETE formation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	107-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-51
30122094-0	2018	In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes.	friedelin	31-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
30122094-2	2018	However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	friedelin	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
30122094-2	2018	However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	friedelin	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
30122094-3	2018	OBJECTIVE: This study investigates the inhibitory effects of Friedelin on the major human liver CYP isoforms (CYP3A4, 1A2, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8).	friedelin	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
30122094-4	2018	MATERIALS AND METHODS: First, the inhibitory effects of Friedelin (100 muM) on the eight human liver CYP isoforms were investigated in vitro using human liver microsomes (HLMs), and then enzyme inhibition, kinetic studies, and time-dependent inhibition studies were conducted to investigate the IC50, Ki and Kinact/KI values of Friedelin.	friedelin	56-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
30122094-5	2018	RESULTS: The results indicate that Friedelin inhibited the activity of CYP3A4 and 2E1, with the IC50 values of 10.79 and 22.54 muM, respectively, but other CYP isoforms were not affected.	friedelin	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
30122094-8	2018	DISCUSSION AND CONCLUSION: The in vitro studies of Friedelin with CYP isoforms suggested that Friedelin has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4 and 2E1.	friedelin	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30122094-8	2018	DISCUSSION AND CONCLUSION: The in vitro studies of Friedelin with CYP isoforms suggested that Friedelin has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4 and 2E1.	friedelin	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	ecbs	158-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	ecbs	158-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	Epoxy Compounds	176-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	Epoxy Compounds	176-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	Epoxy Compounds	176-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
30285425-8	2018	As a result, the role of O-AEA as an endogenous eCB inhibitor of CYP2J2 may provide a new mode of regulation to control the activity of cardiovascular CYP2J2 in vivo and suggests a potential cross-talk between the cardiovascular endocannabinoids and the cytochrome P450 system.	virodhamine	25-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-269
29752906-5	2018	Various risk factors such as medical comorbidities, use or abuse of supratherapeutic doses of tramadol, and concomitant administration of proconvulsant serotonergic cytochrome P-450 inhibitors will help clinicians identify individuals at an elevated risk for serotonin toxicity and seizures.	Serotonin	259-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
30501426-2	2018	Different CYP isoenzymes mediate metabolism of many endogenous substrates such as monoaminergic neurotransmitters, neurosteroids, cholesterol, vitamins and arachidonic acid.	Cholesterol	130-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
30501426-2	2018	Different CYP isoenzymes mediate metabolism of many endogenous substrates such as monoaminergic neurotransmitters, neurosteroids, cholesterol, vitamins and arachidonic acid.	Arachidonic Acid	156-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
30264400-11	2018	CYP function was determined by measuring resorufin formation and oxcarbazepine (OXC) metabolism.	resorufin	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30501426-5	2018	The article focuses on the role of cerebral CYP isoforms in the metabolism of neurotransmitters, neurosteroids, and cholesterol, and their possible involvement in animal behavior, as well as in stress, depression, schizophrenia, cognitive processes, learning, and memory.	Cholesterol	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
30501426-6	2018	CYP-mediated alternative pathways of dopamine and serotonin synthesis may have a significant role in the local production of these neurotransmitters in the brain regions where the disturbances of these neurotransmitter systems are observed in depression and schizophrenia.	Dopamine	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30501426-6	2018	CYP-mediated alternative pathways of dopamine and serotonin synthesis may have a significant role in the local production of these neurotransmitters in the brain regions where the disturbances of these neurotransmitter systems are observed in depression and schizophrenia.	Serotonin	50-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30264400-11	2018	CYP function was determined by measuring resorufin formation and oxcarbazepine (OXC) metabolism.	Oxcarbazepine	65-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30051214-0	2018	Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.	Tramadol	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
30264400-11	2018	CYP function was determined by measuring resorufin formation and oxcarbazepine (OXC) metabolism.	Oxcarbazepine	80-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30051214-2	2018	This study aimed to evaluate the impacts of cytochrome P450 (CYP) genotype and serum inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.	Tramadol	138-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
30264400-14	2018	GR EPI-EC silencing or inhibition led to (1) increased Pphenytoin BBB permeability as compared to control; (2) decreased CYP function, indirectly evaluated by resorufin formation; (3) improved OXC bioavailability with increased abluminal (brain-side) OXC levels as compared to control.	epi-ec	3-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
30051214-2	2018	This study aimed to evaluate the impacts of cytochrome P450 (CYP) genotype and serum inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.	Tramadol	138-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
30373287-0	2018	beta-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP+ Toxicity in Human Neuroblastoma SH-SY5Y Cells.	beta-naphtoflavone	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
30253245-4	2018	The effects of 2-HOBA on the mRNA expression of select cytochrome P450 (CYP) enzymes were also assessed in cryopreserved human hepatocytes.	2-(aminomethyl)phenol	15-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
30373287-0	2018	beta-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP+ Toxicity in Human Neuroblastoma SH-SY5Y Cells.	Ethanol	23-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
30373287-4	2018	We have studied the inducibility of CYP isozymes in human neuroblastoma SH-SY5Y cells, treated with beta-naphtoflavone (beta-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot (WB), and metabolic activity assays.	beta-naphtoflavone	100-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
30373287-4	2018	We have studied the inducibility of CYP isozymes in human neuroblastoma SH-SY5Y cells, treated with beta-naphtoflavone (beta-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot (WB), and metabolic activity assays.	beta-Naphthoflavone	120-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
30373287-4	2018	We have studied the inducibility of CYP isozymes in human neuroblastoma SH-SY5Y cells, treated with beta-naphtoflavone (beta-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot (WB), and metabolic activity assays.	Ethanol	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
30373287-4	2018	We have studied the inducibility of CYP isozymes in human neuroblastoma SH-SY5Y cells, treated with beta-naphtoflavone (beta-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot (WB), and metabolic activity assays.	Ethanol	141-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
30109772-1	2018	An organic semiconducting polymer nanobiocatalyst (SPNB) composed of a semiconducting polymer core conjugated with microsomal cytochrome P450 (CYP) has been developed for photoactivation of intracellular redox.	Polymers	26-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
30322383-2	2018	In addition to nuclear receptors, there are other intracellular RA binding proteins such as cellular retinoic acid binding proteins (CRABP1 and CRABP2) and cytochrome P450 (CYP) enzymes, whose contributions to the RA signaling pathway have not been fully understood.	Tretinoin	64-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
30322383-2	2018	In addition to nuclear receptors, there are other intracellular RA binding proteins such as cellular retinoic acid binding proteins (CRABP1 and CRABP2) and cytochrome P450 (CYP) enzymes, whose contributions to the RA signaling pathway have not been fully understood.	Tretinoin	64-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
30322383-2	2018	In addition to nuclear receptors, there are other intracellular RA binding proteins such as cellular retinoic acid binding proteins (CRABP1 and CRABP2) and cytochrome P450 (CYP) enzymes, whose contributions to the RA signaling pathway have not been fully understood.	Tretinoin	134-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
30109772-1	2018	An organic semiconducting polymer nanobiocatalyst (SPNB) composed of a semiconducting polymer core conjugated with microsomal cytochrome P450 (CYP) has been developed for photoactivation of intracellular redox.	Polymers	26-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-146
30109772-2	2018	The core serves as the light-harvesting unit to initiate photoinduced electron transfer (PET) and facilitate the regeneration of dihydronicotinamide adenine dinucleotide phosphate (NADPH), while CYP is the catalytic center for intracellular redox.	NADP	181-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
30073515-1	2018	We report the development and characterization of digital microfluidic (DMF) immobilized enzyme reactors (IMERs) for studying cytochrome P450 (CYP)-mediated drug metabolism on droplet scale.	Dimethylformamide	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
30073515-1	2018	We report the development and characterization of digital microfluidic (DMF) immobilized enzyme reactors (IMERs) for studying cytochrome P450 (CYP)-mediated drug metabolism on droplet scale.	Dimethylformamide	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-146
30073515-3	2018	The DMF devices also incorporate inexpensive, inkjet-printed microheaters for on-demand regio-specific heating of the IMERs to physiological temperature, which is crucial for maintaining the activity of the temperature-sensitive CYP reaction.	Dimethylformamide	4-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	229-232
29858511-3	2018	Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors.	Warfarin	169-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
29858511-3	2018	Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors.	Warfarin	169-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
29858511-3	2018	Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors.	Clopidogrel	179-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
29858511-3	2018	Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors.	Clopidogrel	179-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
30262788-5	2018	In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like beta-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson"s disease with levodopa, and others.	2-fluoropyrimidine	238-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
29762875-2	2018	In vitro data showed that pomalidomide is a substrate of multiple cytochrome P450 (CYP) isozymes and that its oxidative metabolism is mediated primarily by CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6.	pomalidomide	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
29762875-2	2018	In vitro data showed that pomalidomide is a substrate of multiple cytochrome P450 (CYP) isozymes and that its oxidative metabolism is mediated primarily by CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6.	pomalidomide	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
30262788-5	2018	In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like beta-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson"s disease with levodopa, and others.	Levodopa	347-355	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
30066055-1	2018	While cytochrome P450 (CYP)-mediated biosynthesis of arachidonic acid (AA) epoxides promotes tumor growth by driving angiogenesis, cancer cell intrinsic functions of CYPs are less understood.	arachidonic acid (aa) epoxides	53-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
29858741-3	2018	Eicosanoids, which are metabolites of polyunsaturated fatty acids produced by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, are important lipid-signaling molecules involved in the regulation of inflammation and tumorigenesis.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
29858741-3	2018	Eicosanoids, which are metabolites of polyunsaturated fatty acids produced by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, are important lipid-signaling molecules involved in the regulation of inflammation and tumorigenesis.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
29858741-3	2018	Eicosanoids, which are metabolites of polyunsaturated fatty acids produced by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, are important lipid-signaling molecules involved in the regulation of inflammation and tumorigenesis.	Fatty Acids, Unsaturated	38-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
29858741-3	2018	Eicosanoids, which are metabolites of polyunsaturated fatty acids produced by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, are important lipid-signaling molecules involved in the regulation of inflammation and tumorigenesis.	Fatty Acids, Unsaturated	38-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
30066055-1	2018	While cytochrome P450 (CYP)-mediated biosynthesis of arachidonic acid (AA) epoxides promotes tumor growth by driving angiogenesis, cancer cell intrinsic functions of CYPs are less understood.	arachidonic acid (aa) epoxides	53-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
30066055-2	2018	CYP-derived AA epoxides, called epoxyeicosatrienoic acids (EETs), also promote the growth of tumor epithelia.	epoxyeicosatrienoic acids	32-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30066055-2	2018	CYP-derived AA epoxides, called epoxyeicosatrienoic acids (EETs), also promote the growth of tumor epithelia.	eets	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29226313-0	2018	Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.	alectinib	70-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
29226313-2	2018	Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro.	alectinib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
29226313-6	2018	This work supports that alectinib can be prescribed without dose adjustment for CYP-mediated DDI liabilities.	alectinib	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
30066055-4	2018	Recently, the diabetes drug metformin was found to inhibit CYP AA epoxygenase activity, allowing the design of more potent biguanides to target tumor growth.	Metformin	28-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
29226313-2	2018	Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro.	alectinib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
30066055-4	2018	Recently, the diabetes drug metformin was found to inhibit CYP AA epoxygenase activity, allowing the design of more potent biguanides to target tumor growth.	Biguanides	123-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
30278485-1	2018	BACKGROUND: Human cytochrome P450 (CYP) is an enzyme responsible for the metabolic activation of many carcinogens, including nitrosamines.	Nitrosamines	125-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
29496531-7	2018	The results suggested that multiple dose administration of Danshen capsules could induce cytochrome P450 (CYP) isoenzymes, thereby increasing the clearance of clopidogrel.	Clopidogrel	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
29496531-7	2018	The results suggested that multiple dose administration of Danshen capsules could induce cytochrome P450 (CYP) isoenzymes, thereby increasing the clearance of clopidogrel.	Clopidogrel	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
30170758-2	2018	The primary enzyme involved in the metabolism of ertugliflozin is uridine diphosphate-glucuronosyltransferase (UGT) 1A9, with minor contributions from UGT2B7 and cytochrome P450 (CYP) isoenzymes 3A4, 3A5, and 2C8.	ertugliflozin	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
30170758-2	2018	The primary enzyme involved in the metabolism of ertugliflozin is uridine diphosphate-glucuronosyltransferase (UGT) 1A9, with minor contributions from UGT2B7 and cytochrome P450 (CYP) isoenzymes 3A4, 3A5, and 2C8.	ertugliflozin	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
30429697-3	2018	Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes.	Triazoles	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
30429697-3	2018	Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes.	Triazoles	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
30278485-1	2018	BACKGROUND: Human cytochrome P450 (CYP) is an enzyme responsible for the metabolic activation of many carcinogens, including nitrosamines.	Nitrosamines	125-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	Acetaminophen	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
30200214-5	2018	In this study, we elucidated the structure of generated metabolites using a high-resolution quadrupole-orbitrap mass spectrometer (HR-MS/MS) and characterized the major human cytochrome P450 (CYP) and uridine 5"-diphospho-glucuronosyltransferase (UGT) isozymes involved in osthenol metabolism in human liver microsomes (HLMs).	osthenol	273-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
30200214-5	2018	In this study, we elucidated the structure of generated metabolites using a high-resolution quadrupole-orbitrap mass spectrometer (HR-MS/MS) and characterized the major human cytochrome P450 (CYP) and uridine 5"-diphospho-glucuronosyltransferase (UGT) isozymes involved in osthenol metabolism in human liver microsomes (HLMs).	osthenol	273-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-195
30052045-0	2018	Proximal Pocket Controls Alkene Oxidation Selectivity of Cytochrome P450 and Chloroperoxidase toward Small, Nonpolar Substrates.	Alkenes	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-93
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	Acetaminophen	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-196
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	N-(4-hydroxyphenyl)arachidonylamide	80-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	N-(4-hydroxyphenyl)arachidonylamide	80-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-196
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	N-acetyl-4-benzoquinoneimine	134-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
30121710-3	2018	Paracetamol is known to be metabolized into N-(4-hydroxyphenyl)-arachidonamide (AM404) via fatty acid amide hydrolase (FAAH) and into N-acetyl-p-benzoquinone imine (NAPQI) via cytochrome P450 (CYP) enzymes.	N-acetyl-4-benzoquinoneimine	134-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-196
30121710-5	2018	In addition, paracetamol has the potential to interact with other drugs that are also involved with CYP family enzymes (inducer/inhibitor/substrate), an example being illicit drugs.	Acetaminophen	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
30072626-0	2018	Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation.	loxoprofen	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
30072626-4	2018	In the present study, we investigated metabolic enzymes, such as cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), which are involved in the metabolism of loxoprofen.	loxoprofen	166-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
30072626-4	2018	In the present study, we investigated metabolic enzymes, such as cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), which are involved in the metabolism of loxoprofen.	loxoprofen	166-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
30072626-6	2018	Based on the results for the formation of metabolites when incubated in dexamethasone-induced microsomes, incubation with ketoconazole, and human recombinant cDNA-expressed cytochrome P450s, we identified CYP3A4 and CYP3A5 as the major CYP isoforms involved in the hydroxylation of loxoprofen (M3 and M4).	Dexamethasone	72-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
30072626-6	2018	Based on the results for the formation of metabolites when incubated in dexamethasone-induced microsomes, incubation with ketoconazole, and human recombinant cDNA-expressed cytochrome P450s, we identified CYP3A4 and CYP3A5 as the major CYP isoforms involved in the hydroxylation of loxoprofen (M3 and M4).	Ketoconazole	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	eets	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	Eicosanoids	181-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	Arachidonic Acid	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	Arachidonic Acid	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
30072626-6	2018	Based on the results for the formation of metabolites when incubated in dexamethasone-induced microsomes, incubation with ketoconazole, and human recombinant cDNA-expressed cytochrome P450s, we identified CYP3A4 and CYP3A5 as the major CYP isoforms involved in the hydroxylation of loxoprofen (M3 and M4).	loxoprofen	282-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	epoxyeicosatrienoic acids	127-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	Eicosanoids	181-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29908721-11	2018	As the placenta is absolutely crucial for prenatal development, arachidonic acid is essential part of human nutrient and CYP epoxygenases expression can be affected by xenobiotics, further investigation of the exact role of CYP epoxygenases, sEH, and their metabolites in normal pregnancy and under pathological conditions is needed.	Arachidonic Acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	epoxyeicosatrienoic acids	127-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29027195-3	2018	Here we show that TSPYLs, especially TSPYL 1, 2, and 4, can regulate the expression of many CYP genes, including CYP17A1, a key enzyme in androgen biosynthesis, and CYP3A4, an enzyme that catalyzes the metabolism of abiraterone, a CYP17 inhibitor.	abiraterone	216-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
29908721-1	2018	CYP2C and CYP2 J enzymes, commonly named as cytochrome P450 (CYP) epoxygenases, convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs), biologically active eicosanoids with many functions in organism.	eets	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
29916051-4	2018	This review collects available information of which-taken with great caution because of the still very limited data-the most salient points are: in the skin of all animal species and skin-derived in vitro systems considered in this review cytochrome P450 (CYP)-dependent monooxygenase activities (largely responsible for initiating xenobiotica metabolism in the organ which provides most of the xenobiotica metabolism of the mammalian organism, the liver) are very low to undetectable.	xenobiotica	332-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	239-254
29916051-4	2018	This review collects available information of which-taken with great caution because of the still very limited data-the most salient points are: in the skin of all animal species and skin-derived in vitro systems considered in this review cytochrome P450 (CYP)-dependent monooxygenase activities (largely responsible for initiating xenobiotica metabolism in the organ which provides most of the xenobiotica metabolism of the mammalian organism, the liver) are very low to undetectable.	xenobiotica	332-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	256-259
29916051-6	2018	Moreover, conjugating enzyme activities such as glutathione transferases and glucuronosyltransferases are much higher than the oxidative CYP activities.	Glutathione	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
29722926-4	2018	Akin to cytochrome-b5 (cyt-b5 ), Arg 125 on the C-helix of CYP450s is found to be important for effective electron transfer, thus supporting the competitive behavior of redox partners for CYP450s.	Arginine	33-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-65
30039377-6	2018	This review describes the metabolic pathways of 13 prevalent synthetic cannabinoids and various drug-metabolizing enzymes responsible for their metabolism, including cytochrome P450 (CYP), UDP-glucuronosyltransferases (UGTs), and carboxylesterases.	Cannabinoids	71-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-181
30039377-6	2018	This review describes the metabolic pathways of 13 prevalent synthetic cannabinoids and various drug-metabolizing enzymes responsible for their metabolism, including cytochrome P450 (CYP), UDP-glucuronosyltransferases (UGTs), and carboxylesterases.	Cannabinoids	71-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-186
30039377-7	2018	The inhibitory effects of synthetic cannabinoids on CYP and UGT activities are also reviewed to predict the potential of synthetic cannabinoids for drug-drug interactions.	Cannabinoids	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
30039377-8	2018	The drug-metabolizing enzymes responsible for metabolism of synthetic cannabinoids should be characterized and the effects of synthetic cannabinoids on CYP and UGT activities should be determined to predict the pharmacokinetics of synthetic cannabinoids and synthetic cannabinoid-induced drug-drug interactions in the clinic.	Cannabinoids	136-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
30039377-8	2018	The drug-metabolizing enzymes responsible for metabolism of synthetic cannabinoids should be characterized and the effects of synthetic cannabinoids on CYP and UGT activities should be determined to predict the pharmacokinetics of synthetic cannabinoids and synthetic cannabinoid-induced drug-drug interactions in the clinic.	Cannabinoids	136-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
29921510-0	2018	The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells.	Benzo(a)pyrene	45-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
29751197-0	2018	Investigating Cytochrome P450 specificity during glycopeptide antibiotic biosynthesis through a homologue hybridization approach.	Glycopeptides	49-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
29746911-3	2018	Previous studies suggested that 4-MAA demethylation can be performed by hepatic cytochrome P450 (CYP) 3A4, but the possible contribution of other CYPs remains unclear.	4-maa	32-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
29746911-3	2018	Previous studies suggested that 4-MAA demethylation can be performed by hepatic cytochrome P450 (CYP) 3A4, but the possible contribution of other CYPs remains unclear.	4-maa	32-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29746911-5	2018	Based on CYP induction (HepaRG cells) and CYP inhibition (HLM) we could identify CYP2B6, 2C8, 2C9 and 3A4 as major contributors to 4-MAA demethylation.	4-maa	131-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
29746911-5	2018	Based on CYP induction (HepaRG cells) and CYP inhibition (HLM) we could identify CYP2B6, 2C8, 2C9 and 3A4 as major contributors to 4-MAA demethylation.	4-maa	131-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
29458047-0	2018	Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.	Methadone	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	158-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
29888644-0	2018	Regulation of cytochrome P450 gene expression by ketamine: a review.	Ketamine	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
29735753-0	2018	Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.	siponimod	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-152
29888644-2	2018	Ketamine undergoes extensive oxidative metabolism by cytochrome P450 (CYP) enzymes.	Ketamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
29888644-2	2018	Ketamine undergoes extensive oxidative metabolism by cytochrome P450 (CYP) enzymes.	Ketamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
29888644-3	2018	Considerable efforts have been expended to elucidate the ketamine-induced regulation of CYP gene expression.	Ketamine	57-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
29888644-5	2018	Understanding how ketamine regulates CYP gene expression is clinically meaningful.	Ketamine	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
29888644-6	2018	Areas covered: In this article, the authors provide a brief review of clinical applications of ketamine and its metabolism by CYP enzymes.	Ketamine	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
29888644-7	2018	We discuss the effects of ketamine on the regulation of CYP gene expression, exploring aspects of cytoskeletal remodeling, mitochondrial functions, and calcium homeostasis.	Ketamine	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
29888644-8	2018	Expert opinion: Ketamine may inhibit CYP gene expression through inhibiting calcium signaling, decreasing ATP levels, producing excessive reactive oxygen species, and subsequently perturbing cytoskeletal dynamics.	Ketamine	16-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
29888644-8	2018	Expert opinion: Ketamine may inhibit CYP gene expression through inhibiting calcium signaling, decreasing ATP levels, producing excessive reactive oxygen species, and subsequently perturbing cytoskeletal dynamics.	Calcium	76-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
29719203-0	2018	The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer.	Vitamin D	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
29719203-1	2018	The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health.	Cholecalciferol	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
29888644-8	2018	Expert opinion: Ketamine may inhibit CYP gene expression through inhibiting calcium signaling, decreasing ATP levels, producing excessive reactive oxygen species, and subsequently perturbing cytoskeletal dynamics.	Adenosine Triphosphate	106-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
29719203-1	2018	The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health.	Cholecalciferol	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
29888644-8	2018	Expert opinion: Ketamine may inhibit CYP gene expression through inhibiting calcium signaling, decreasing ATP levels, producing excessive reactive oxygen species, and subsequently perturbing cytoskeletal dynamics.	Reactive Oxygen Species	138-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Rifampin	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
29989011-0	2018	Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes.	thymoquinone	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	thymoquinone	46-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	Phenacetin	97-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	Tolbutamide	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	Dextromethorphan	144-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	Testosterone	177-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	NADP	234-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	thymoquinone	270-272	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Caffeine	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Warfarin	111-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Omeprazole	121-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Metoprolol	133-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Midazolam	148-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
28686070-2	2018	The pharmacokinetics were investigated for human cytochrome P450 probes after single intravenous and oral administrations of 0.20 and 1.0 mg/kg, respectively, of caffeine, warfarin, omeprazole, metoprolol and midazolam to aged (10-14 years old, n = 4) or rifampicin-treated/young (3 years old, n = 3) male common marmosets all genotyped as heterozygous for a cytochrome P450 2C19 variant.	Caffeine	162-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
29759551-10	2018	Additionally, glucocorticoids, asparaginase, anthracycline, vincristine and cytarabine that trans-repress gene expression, deprives cells of asparagine, triggers cell cycle arrest, influences cytochrome-P450 polymorphism and inhibits DNA polymerase, respectively, have been used in chemotherapy in ALL patients.	Anthracyclines	45-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-207
29914111-6	2018	For example, cytochrome P450 enzymes that metabolize statins may affect n-3 long chain polyunsaturated fatty acid metabolism and vice versa.	n-3 long chain polyunsaturated fatty acid	72-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
29196978-1	2018	Several studies have demonstrated the role of cytochrome P450 (CYP) and its associated arachidonic acid (AA) metabolites in the anthracyclines-induced cardiac toxicity.	Arachidonic Acid	87-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
29196978-1	2018	Several studies have demonstrated the role of cytochrome P450 (CYP) and its associated arachidonic acid (AA) metabolites in the anthracyclines-induced cardiac toxicity.	Arachidonic Acid	87-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
29196978-1	2018	Several studies have demonstrated the role of cytochrome P450 (CYP) and its associated arachidonic acid (AA) metabolites in the anthracyclines-induced cardiac toxicity.	Anthracyclines	128-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
29196978-1	2018	Several studies have demonstrated the role of cytochrome P450 (CYP) and its associated arachidonic acid (AA) metabolites in the anthracyclines-induced cardiac toxicity.	Anthracyclines	128-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
29196978-2	2018	However, the ability of daunorubicin (DNR) to induce cardiotoxicity through the modulation of CYP and its associated AA metabolites has not been investigated yet.	Daunorubicin	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
29621538-0	2018	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.	Ketamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
29621538-0	2018	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.	Ketamine	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
29759551-10	2018	Additionally, glucocorticoids, asparaginase, anthracycline, vincristine and cytarabine that trans-repress gene expression, deprives cells of asparagine, triggers cell cycle arrest, influences cytochrome-P450 polymorphism and inhibits DNA polymerase, respectively, have been used in chemotherapy in ALL patients.	Vincristine	60-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-207
29759551-10	2018	Additionally, glucocorticoids, asparaginase, anthracycline, vincristine and cytarabine that trans-repress gene expression, deprives cells of asparagine, triggers cell cycle arrest, influences cytochrome-P450 polymorphism and inhibits DNA polymerase, respectively, have been used in chemotherapy in ALL patients.	Cytarabine	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-207
29759551-10	2018	Additionally, glucocorticoids, asparaginase, anthracycline, vincristine and cytarabine that trans-repress gene expression, deprives cells of asparagine, triggers cell cycle arrest, influences cytochrome-P450 polymorphism and inhibits DNA polymerase, respectively, have been used in chemotherapy in ALL patients.	Asparagine	141-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-207
29650790-0	2018	Effect of Endocannabinoid Oleamide on Rat and Human Liver Cytochrome P450 Enzymes in In Vitro and In Vivo Models.	endocannabinoid oleamide	10-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
29576510-0	2018	Probing cytochrome P450 bioactivation and fluorescent properties with morpholinyl-tethered anthraquinones.	morpholinyl-tethered anthraquinones	70-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
28639016-8	2018	On the other hand, it was inferred that CB156 is difficult to be metabolized by these four CYP isozymes.	cb156	40-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
29264831-0	2018	CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris ), is Associated with Microtubule Disruption.	monomethyl auristatin E	40-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29526504-0	2018	Efficient hydroxylation of cycloalkanes by co-addition of decoy molecules to variants of the cytochrome P450 CYP102A1.	Cycloparaffins	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
29526504-1	2018	The wild-type cytochrome P450 (CYP) monooxygenase enzyme CYP102A1 (P450Bm3) has low activity for cycloalkane oxidation.	Cycloparaffins	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
29526504-1	2018	The wild-type cytochrome P450 (CYP) monooxygenase enzyme CYP102A1 (P450Bm3) has low activity for cycloalkane oxidation.	Cycloparaffins	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
28730856-0	2018	In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.	Budesonide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
28730856-4	2018	This study aimed to evaluate the potential of budesonide to act as a perpetrator or a victim of transporter- or CYP-mediated drug-drug interactions (DDIs).	Budesonide	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-115
29517843-0	2018	Diverging Mechanisms: Cytochrome-P450-Catalyzed Demethylation and gamma-Lactone Formation in Bacterial Gibberellin Biosynthesis.	4-hexanolide	66-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
29517843-0	2018	Diverging Mechanisms: Cytochrome-P450-Catalyzed Demethylation and gamma-Lactone Formation in Bacterial Gibberellin Biosynthesis.	Gibberellins	103-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
29274758-2	2018	The DOACs are P-glycoprotein (P-gp) and cytochrome p-450 (CYP3A4) substrates.	doacs	4-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
29530595-1	2018	Cytochrome P450 (CYP) monoxygenses utilize heme cofactors to catalyze oxidation reactions.	Heme	43-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29530595-1	2018	Cytochrome P450 (CYP) monoxygenses utilize heme cofactors to catalyze oxidation reactions.	Heme	43-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
29530595-9	2018	These results suggest that water-bridged complexes are under-represented in CYP structural databases and can have energies similar to other ligation modes.	Water	27-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
29449127-1	2018	BACKGROUND AND GOAL: Cytochrome P450 (CYP) enzymes are responsible for the conversion of clopidogrel into its active metabolite and the metabolism of proton pump inhibitors (PPIs), which may also inhibit CYP enzymes.	Clopidogrel	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
29449127-1	2018	BACKGROUND AND GOAL: Cytochrome P450 (CYP) enzymes are responsible for the conversion of clopidogrel into its active metabolite and the metabolism of proton pump inhibitors (PPIs), which may also inhibit CYP enzymes.	Clopidogrel	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
29449127-1	2018	BACKGROUND AND GOAL: Cytochrome P450 (CYP) enzymes are responsible for the conversion of clopidogrel into its active metabolite and the metabolism of proton pump inhibitors (PPIs), which may also inhibit CYP enzymes.	Clopidogrel	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207
28657402-0	2018	In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.	olaparib	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
28657402-2	2018	In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes.	olaparib	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
28657402-2	2018	In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes.	olaparib	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
28657402-9	2018	Assessment of the CYP induction potential of olaparib (0.061-44 muM) showed minor concentration-related increases in CYP1A2 and more marked increases in CYP2B6 and CYP3A4 mRNA, compared with positive control activity; however, no significant change in CYP3A4/5 enzyme activity was observed.	olaparib	45-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29719052-0	2018	Effect of single-walled carbon nanotubes on cytochrome P450 activity in human liver microsomes in vitro.	Carbon	24-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
29576510-1	2018	Structural features from the anticancer prodrug nemorubicin (MMDX) and the DNA-binding molecule DRAQ5  were used to prepare anthraquinone-based compounds, which were assessed for their potential to interrogate cytochrome P450 (CYP) functional activity and localisation.	Anthraquinones	124-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-230
29436156-0	2018	Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.	Tamoxifen	50-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29436156-3	2018	We tested for associations between CYP diplotypes and plasma concentrations of tamoxifen and metabolites.	Tamoxifen	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
29588191-1	2018	Few studies exist on cytochrome P450 (CYP450) metabolites of arachidonic acid (AA) pertaining to the pathophysiological events in pregnancy.	Arachidonic Acid	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
29069987-1	2018	Cytochrome P450 enzymes are required for the synthesis of cholesterol and steroid hormones.	Cholesterol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29069987-1	2018	Cytochrome P450 enzymes are required for the synthesis of cholesterol and steroid hormones.	Steroids	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29596975-0	2018	Role of cytochrome P450 enzymes in fimasartan metabolism in vitro.	fimasartan	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
29596975-2	2018	The purpose of this study was to characterize enzymes involved in NADPH-dependent FMS metabolism using recombinant enzymes such as cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO), as well as selective chemical inhibitors.	NADP	66-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
29596975-2	2018	The purpose of this study was to characterize enzymes involved in NADPH-dependent FMS metabolism using recombinant enzymes such as cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO), as well as selective chemical inhibitors.	NADP	66-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
29588191-1	2018	Few studies exist on cytochrome P450 (CYP450) metabolites of arachidonic acid (AA) pertaining to the pathophysiological events in pregnancy.	Arachidonic Acid	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-44
29698447-3	2018	It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes.	Arachidonic Acid	26-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
29698447-7	2018	Individual CYP450- and LOX- but not COX-derived metabolites were higher with celecoxib than placebo (P&lt;0.05) and differences were greater among non-aspirin users.	Celecoxib	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-17
29698447-3	2018	It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes.	Arachidonic Acid	26-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-172
29698447-9	2018	20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women.	Celecoxib	80-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
29659506-0	2018	In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.	Cannabinoids	41-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
29698447-9	2018	20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women.	Aspirin	97-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
29659506-0	2018	In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.	(4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
30181852-0	2018	Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.	meglitinide	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
30181852-3	2018	Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions.	meglitinide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
30181852-3	2018	Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions.	meglitinide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
30181852-4	2018	This article focuses on the drug interactions of meglitinides involving CYP enzymes and OATP1B1 transporter.	meglitinide	49-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
29670361-9	2018	Besides, the Kyoto Encyclopedia of Genes and Genomes pathways including chemical carcinogenesis, drug metabolism-cytochrome P450, tryptophan metabolism, and retinol metabolism were involved.	Tryptophan	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
29670361-9	2018	Besides, the Kyoto Encyclopedia of Genes and Genomes pathways including chemical carcinogenesis, drug metabolism-cytochrome P450, tryptophan metabolism, and retinol metabolism were involved.	Vitamin A	157-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-119
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-119
29105855-1	2018	AIM: The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin.	Dicloxacillin	85-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
28436281-2	2018	Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction.	Terfenadine	81-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-41
28436281-2	2018	Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction.	Terfenadine	147-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-41
28436281-2	2018	Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction.	Ketoconazole	159-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-41
29277574-0	2018	Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.	n-2-methoxybenzyl (nbome)	45-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
29277574-3	2018	Therefore, the aims of the present study were to determine the Km and Vmax values for CYP isoforms using the substrate depletion approach for the six N-2-methoxybenzyl (NBOMe)-derived NPS 25B-NBOMe, 25C-NBOMe, 25I-NBOMe, 3,4-DMA-NBOMe, 4-EA-NBOMe, and 4-MMA-NBOMe.	2-methoxybenzyl	152-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
29636974-4	2018	However, it is important to be aware that plasma levels of DOACs are affected by drugs that alter the cell efflux transporter P-glycoprotein and/or cytochrome P450.	doacs	59-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
29105855-1	2018	AIM: The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin.	Dicloxacillin	85-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
29105855-8	2018	Investigations in primary hepatocytes showed a statistically significant dose-dependent increase in CYP expression and activity by dicloxacillin, caused by activation of the pregnane X receptor.	Dicloxacillin	131-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
29255971-0	2018	Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.	daclatasvir	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
29255971-0	2018	Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.	asunaprevir	55-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
29255971-0	2018	Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.	8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
29080699-2	2018	This review covers recent findings indicating that a variety of these beneficial effects are mediated by "omega-3 epoxyeicosanoids", a class of novel n-3 LC-PUFA-derived lipid mediators, which are generated via the cytochrome P450 (CYP) epoxygenase pathway.	omega-3 epoxyeicosanoids	106-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
29316516-4	2018	We also characterized fetal cytochrome P450 (CYP) mRNA expression and its associations with PBDE exposures.	Halogenated Diphenyl Ethers	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
29316516-4	2018	We also characterized fetal cytochrome P450 (CYP) mRNA expression and its associations with PBDE exposures.	Halogenated Diphenyl Ethers	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
29316516-14	2018	CONCLUSION: Our findings suggest that under normal conditions of mid-gestation, the human fetus is directly exposed to concentrations of PBDEs that may be higher than previously estimated based on maternal serum and that these exposures are associated with the expression of mRNAs coding for CYP enzymes.	Halogenated Diphenyl Ethers	137-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	292-295
29080699-2	2018	This review covers recent findings indicating that a variety of these beneficial effects are mediated by "omega-3 epoxyeicosanoids", a class of novel n-3 LC-PUFA-derived lipid mediators, which are generated via the cytochrome P450 (CYP) epoxygenase pathway.	omega-3 epoxyeicosanoids	106-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-235
29080699-3	2018	CYP enzymes, previously identified as arachidonic acid (20:4n-6; AA) epoxygenases, accept eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA), the major fish oil n-3 LC-PUFAs, as efficient alternative substrates.	Arachidonic Acid	38-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29080699-3	2018	CYP enzymes, previously identified as arachidonic acid (20:4n-6; AA) epoxygenases, accept eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA), the major fish oil n-3 LC-PUFAs, as efficient alternative substrates.	Eicosapentaenoic Acid	90-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29080699-3	2018	CYP enzymes, previously identified as arachidonic acid (20:4n-6; AA) epoxygenases, accept eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA), the major fish oil n-3 LC-PUFAs, as efficient alternative substrates.	Docosahexaenoic Acids	131-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29080699-3	2018	CYP enzymes, previously identified as arachidonic acid (20:4n-6; AA) epoxygenases, accept eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA), the major fish oil n-3 LC-PUFAs, as efficient alternative substrates.	dehydroacetic acid	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29080699-3	2018	CYP enzymes, previously identified as arachidonic acid (20:4n-6; AA) epoxygenases, accept eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA), the major fish oil n-3 LC-PUFAs, as efficient alternative substrates.	Fatty Acids, Unsaturated	194-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	dehydroacetic acid	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	Eicosanoids	101-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	dehydroacetic acid	141-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	17,18-epoxy-5,8,11,14-eicosatetraenoic acid	225-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	17(18)-EpETE	259-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	19,20-epoxydocosapentaenoic acid	274-306	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29080699-4	2018	In humans and rodents, dietary EPA/DHA supplementation causes a profound shift of the endogenous CYP-eicosanoid profile from AA- to EPA- and DHA-derived metabolites, increasing, in particular, the plasma and tissue levels of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP).	19(20)-EpDPE	308-317	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29479969-0	2018	Detection of Cytochrome P450 Polymorphisms in BreastCancer Patients May Impact on Tamoxifen Therapy Background: Breast cancer is the most common cancer among women worldwide.	Tamoxifen	82-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
29479969-2	2018	TAM is metabolized by cytochrome P450 (CYP450) enzymes,including CYP2D6, CYP3A5 and CYP2C19, whose genetic variations may have clinicopathological importance.However, reports on the association of various P450 polymorphisms with certain cancers are contradictory.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
29479969-2	2018	TAM is metabolized by cytochrome P450 (CYP450) enzymes,including CYP2D6, CYP3A5 and CYP2C19, whose genetic variations may have clinicopathological importance.However, reports on the association of various P450 polymorphisms with certain cancers are contradictory.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
28668640-1	2018	The cytochrome P450 monooxygenases (P450s) are thiolate heme proteins that can, often under physiological conditions, catalyze many distinct oxidative transformations on a wide variety of molecules, including relatively simple alkanes or fatty acids, as well as more complex compounds such as steroids and exogenous pollutants.	thiolate	47-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Carbon	80-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Carbon	80-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Hydrogen	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Hydrogen	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Oxygen	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29266939-1	2018	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of chemically inert carbon-hydrogen bonds in diverse endogenous and exogenous organic compounds by atmospheric oxygen.	Oxygen	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
29527583-1	2018	The cytochrome P450 (CYP) enzymes are a diverse group of heme monooxygenases that, through the course of their reaction cycle, contribute to cellular reactive oxygen species (ROS).	Reactive Oxygen Species	150-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
29527583-1	2018	The cytochrome P450 (CYP) enzymes are a diverse group of heme monooxygenases that, through the course of their reaction cycle, contribute to cellular reactive oxygen species (ROS).	Reactive Oxygen Species	150-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
29527583-1	2018	The cytochrome P450 (CYP) enzymes are a diverse group of heme monooxygenases that, through the course of their reaction cycle, contribute to cellular reactive oxygen species (ROS).	Reactive Oxygen Species	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
29527583-1	2018	The cytochrome P450 (CYP) enzymes are a diverse group of heme monooxygenases that, through the course of their reaction cycle, contribute to cellular reactive oxygen species (ROS).	Reactive Oxygen Species	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
29527583-3	2018	However, during the course of the CYP catalytic cycle, ROS can be generated through uncoupling of the enzymatic cycle.	Reactive Oxygen Species	55-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
28473297-0	2018	NADH reduction of nitroaromatics as a probe for residual ferric form high-spin in a cytochrome P450.	NAD	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
28473297-0	2018	NADH reduction of nitroaromatics as a probe for residual ferric form high-spin in a cytochrome P450.	nitroaromatics	18-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
28668640-1	2018	The cytochrome P450 monooxygenases (P450s) are thiolate heme proteins that can, often under physiological conditions, catalyze many distinct oxidative transformations on a wide variety of molecules, including relatively simple alkanes or fatty acids, as well as more complex compounds such as steroids and exogenous pollutants.	Alkanes	227-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
28473297-0	2018	NADH reduction of nitroaromatics as a probe for residual ferric form high-spin in a cytochrome P450.	Ferric enterobactin ion	57-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
28668640-1	2018	The cytochrome P450 monooxygenases (P450s) are thiolate heme proteins that can, often under physiological conditions, catalyze many distinct oxidative transformations on a wide variety of molecules, including relatively simple alkanes or fatty acids, as well as more complex compounds such as steroids and exogenous pollutants.	Fatty Acids	238-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
28473297-1	2018	The existence of a substrate-sensitive equilibrium between high spin (S=5/2) and low spin (S=1/2) ferric iron is a well-established phenomenon in the cytochrome P450 (CYP) superfamily, although its origins are still a subject of discussion.	ferric sulfate	98-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-165
28473297-1	2018	The existence of a substrate-sensitive equilibrium between high spin (S=5/2) and low spin (S=1/2) ferric iron is a well-established phenomenon in the cytochrome P450 (CYP) superfamily, although its origins are still a subject of discussion.	ferric sulfate	98-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
28668640-1	2018	The cytochrome P450 monooxygenases (P450s) are thiolate heme proteins that can, often under physiological conditions, catalyze many distinct oxidative transformations on a wide variety of molecules, including relatively simple alkanes or fatty acids, as well as more complex compounds such as steroids and exogenous pollutants.	Steroids	293-301	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
28473297-7	2018	These results suggest that reduction of nitroaromatics may provide a useful probe of residual high spin states in the CYP superfamily.	nitroaromatics	40-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
28865153-1	2018	AIMS: This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein.	ARQ 197	98-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
29984664-0	2018	Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line.	Genistein	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
27637911-2	2018	The aim of this study was to investigate the association between cytochrome P450 ( CYP) genetic variants and clinical adverse outcomes of concomitant use of PPIs and clopidogrel by patients.	Clopidogrel	166-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
27637911-2	2018	The aim of this study was to investigate the association between cytochrome P450 ( CYP) genetic variants and clinical adverse outcomes of concomitant use of PPIs and clopidogrel by patients.	Clopidogrel	166-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
28118749-0	2018	Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants.	Warfarin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
28118749-1	2018	Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR).	Warfarin	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
28118749-1	2018	Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR).	Warfarin	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
28118749-1	2018	Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR).	Warfarin	156-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
28118749-1	2018	Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR).	Warfarin	156-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
27875967-1	2018	Cytochrome P450 enzymes are a structurally conserved but functionally diverse group of heme-containing mixed function oxidases found across both prokaryotic and eukaryotic forms of the microbial world.	Heme	87-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Omeprazole	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Omeprazole	158-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Phenobarbital	175-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Phenobarbital	190-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	210-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	222-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29984664-2	2018	Of particular interest regarding cancer preventive properties of flavonoids is their interaction with cytochrome P450 enzymes (CYPs).	Flavonoids	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
29984664-4	2018	OBJECTIVE: The aim of this study was to investigate the effects of genistein on cytochrome P450 (CYP) gene expression levels in human hepatocellular carcinoma (HepG2/C3A) and colon adenocarcinoma (HT29) cells.	Genistein	67-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
29984664-4	2018	OBJECTIVE: The aim of this study was to investigate the effects of genistein on cytochrome P450 (CYP) gene expression levels in human hepatocellular carcinoma (HepG2/C3A) and colon adenocarcinoma (HT29) cells.	Genistein	67-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
29491651-0	2018	Studying the Inhibitory Effect of Quercetin and Thymoquinone on Human Cytochrome P450 Enzyme Activities.	Quercetin	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
29555536-8	2018	The results demonstrate that the xenobiotic metabolism conferred by transfection of CYP-encoding mRNAs shifts the dose-response relationship for some of the tested chemicals such as aflatoxin B1 (bioactivation) and fenazaquin (detoxification).	Aflatoxin B1	182-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
29555536-8	2018	The results demonstrate that the xenobiotic metabolism conferred by transfection of CYP-encoding mRNAs shifts the dose-response relationship for some of the tested chemicals such as aflatoxin B1 (bioactivation) and fenazaquin (detoxification).	fenazaquin	215-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
29393278-0	2018	Effect of Oridonin on Cytochrome P450 Expression and Activities in HepaRG Cell.	oridonin	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
29618712-3	2018	In this study, however, after 3-4 weeks of culture according to the manufacturer"s instructions, human cytochrome P450 (P450) 2C9- and 2C19-dependent diclofenac 4"-hydroxylation and omeprazole 5-hydroxylation activities of the iPS-derived hepatocytes had significantly increased above the activities at 1 week and had reached levels similar to those in HepaRG cells, a human hepatocyte-like cell line.	diclofenac 4"	150-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-129
29618712-3	2018	In this study, however, after 3-4 weeks of culture according to the manufacturer"s instructions, human cytochrome P450 (P450) 2C9- and 2C19-dependent diclofenac 4"-hydroxylation and omeprazole 5-hydroxylation activities of the iPS-derived hepatocytes had significantly increased above the activities at 1 week and had reached levels similar to those in HepaRG cells, a human hepatocyte-like cell line.	IPS	227-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-129
29491651-0	2018	Studying the Inhibitory Effect of Quercetin and Thymoquinone on Human Cytochrome P450 Enzyme Activities.	thymoquinone	48-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
29503429-4	2018	Our previous studies revealed that sesamin was sequentially metabolized by cytochrome P450 (CYP) and UDP-glucuronosyltransferase or sulfotransferase.	sesamin	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
29503429-4	2018	Our previous studies revealed that sesamin was sequentially metabolized by cytochrome P450 (CYP) and UDP-glucuronosyltransferase or sulfotransferase.	sesamin	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
29024391-1	2017	A cytochrome P450 was engineered to selectively incorporate Ir(Me)-deuteroporphyrin IX (Ir(Me)-DPIX), in lieu of heme, in bacterial cells.	deuteroporphyrin-IX	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-17
29024391-1	2017	A cytochrome P450 was engineered to selectively incorporate Ir(Me)-deuteroporphyrin IX (Ir(Me)-DPIX), in lieu of heme, in bacterial cells.	dpix	95-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-17
29024391-1	2017	A cytochrome P450 was engineered to selectively incorporate Ir(Me)-deuteroporphyrin IX (Ir(Me)-DPIX), in lieu of heme, in bacterial cells.	Heme	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-17
29075787-9	2017	We suggest that intracellularly generated salicylic acid metabolites through CYP450 enzymes within the colonic epithelial cells, or the salicylic acid metabolites generated by gut microflora may significantly contribute to the preferential chemopreventive effect of aspirin against CRC through inhibition of CDKs.	Salicylic Acid	42-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
29131622-1	2017	Cytochrome P450 enzymes were recently engineered to catalyze the C-H amination reaction of aryl sulfonyl azides with excellent regio- and stereoselectivity (Arnold and co-workers J.	aryl sulfonyl azides	91-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28702763-6	2017	Azoles are substrates and inhibitors of cytochrome P450 (CYP) isoenzymes and are therefore involved in numerous drug-drug interactions.	Azoles	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
28702763-6	2017	Azoles are substrates and inhibitors of cytochrome P450 (CYP) isoenzymes and are therefore involved in numerous drug-drug interactions.	Azoles	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
29075787-3	2017	Our goal here was to investigate the ability of salicylic acid metabolites, known to be generated through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent kinase (CDK) inhibitors to gain new insights into aspirin"s chemopreventive actions.	Salicylic Acid	48-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
29075787-3	2017	Our goal here was to investigate the ability of salicylic acid metabolites, known to be generated through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent kinase (CDK) inhibitors to gain new insights into aspirin"s chemopreventive actions.	Salicylic Acid	48-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-129
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Flavonoids	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
29075787-3	2017	Our goal here was to investigate the ability of salicylic acid metabolites, known to be generated through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent kinase (CDK) inhibitors to gain new insights into aspirin"s chemopreventive actions.	Aspirin	230-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
29075787-3	2017	Our goal here was to investigate the ability of salicylic acid metabolites, known to be generated through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent kinase (CDK) inhibitors to gain new insights into aspirin"s chemopreventive actions.	Aspirin	230-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-129
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Luteolin	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Quercetin	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
28872689-7	2017	KEY FINDINGS: Luteolin and quercetin inhibited human CYP isoforms to varying degrees, with greatest potency towards CYP1A2 and CYP2C8.	Quercetin	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
28872689-11	2017	CONCLUSIONS: Inhibition of human CYP activity by luteolin and quercetin occurred with IC50 values exceeding customary in-vivo human exposure with tolerable supplemental doses of these compounds.	Quercetin	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
27841077-3	2017	The purpose of this study was to evaluate in vitro the potential to inhibit and induce cytochrome P450 (CYP) isoforms for alectinib and its major metabolite M4.	alectinib	122-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
28614988-3	2017	However, whether DHM affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	dihydromyricetin	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
28614988-3	2017	However, whether DHM affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.	dihydromyricetin	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
28614988-4	2017	MATERIALS AND METHODS: The inhibitory effects of DHM on eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8) were investigated in vitro using human liver microsomes (HLMs).	dihydromyricetin	49-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
28614988-5	2017	RESULTS: The results showed that DHM could inhibit the activity of CYP3A4, CYP2E1 and CYP2D6, with IC50 values of 14.75, 25.74 and 22.69 muM, respectively, but that other CYP isoforms were not affected.	dihydromyricetin	33-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
28614988-8	2017	DISCUSSION AND CONCLUSION: The in vitro studies of DHM with CYP isoforms indicate that DHM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, CYP2E1 and CYP2D6.	dihydromyricetin	51-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
28614988-8	2017	DISCUSSION AND CONCLUSION: The in vitro studies of DHM with CYP isoforms indicate that DHM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, CYP2E1 and CYP2D6.	dihydromyricetin	87-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
28614988-0	2017	In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.	dihydromyricetin	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
29143058-1	2017	Heme"s spin-multiplicity is key in determining the enzymatic function of cytochrome P450 (cytP450).	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
29143058-1	2017	Heme"s spin-multiplicity is key in determining the enzymatic function of cytochrome P450 (cytP450).	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-97
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	Nevirapine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	Nevirapine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	2-Hydroxy Nevirapine	127-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	2-Hydroxy Nevirapine	127-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
27841077-3	2017	The purpose of this study was to evaluate in vitro the potential to inhibit and induce cytochrome P450 (CYP) isoforms for alectinib and its major metabolite M4.	alectinib	122-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
27841077-8	2017	Out of the seven CYP isoforms in HLM, alectinib and M4 showed time-dependent inhibition (TDI) of only CYP3A4, which suggests low TDI potential due to low inactivation efficiency.	alectinib	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	8-Hydroxynevirapine	169-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	8-Hydroxynevirapine	169-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
27841077-12	2017	In summary, the risk of alectinib causing drug-drug interactions with coadministered drugs is expected to be low due to the weak potential of CYP inhibition and induction estimated in the preclinical studies.	alectinib	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	12-Hydroxynevirapine	194-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
28947469-1	2017	Nevirapine is metabolized by several hepatic cytochrome P450 (CYP) isoforms to generate four primary hydroxylated metabolites: 2-hydroxynevirapine, 3-hydroxynevirapine, 8-hydroxynevirapine, and 12-hydroxynevirapine.	12-Hydroxynevirapine	194-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
29170672-0	2017	Triterpene Structural Diversification by Plant Cytochrome P450 Enzymes.	Triterpenes	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
28431455-6	2017	In addition, the specific cytochrome P450 (CYP) enzymes involved in the metabolism of cnidilin were identified using chemical inhibition and CYP recombinant enzymes.	cnidilin	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
28431455-6	2017	In addition, the specific cytochrome P450 (CYP) enzymes involved in the metabolism of cnidilin were identified using chemical inhibition and CYP recombinant enzymes.	cnidilin	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
28431455-6	2017	In addition, the specific cytochrome P450 (CYP) enzymes involved in the metabolism of cnidilin were identified using chemical inhibition and CYP recombinant enzymes.	cnidilin	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
29022838-4	2017	Areas covered: This manuscript reviews the pharmacogenomics (i.e. the influence of genetics on drug disposition) of triazole antifungal agents related to their CYP-mediated metabolism and summarizes their implications on triazole efficacy, safety, and tolerability.	Triazoles	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
28856745-5	2017	RESULTS: A total of 10 publications were identified in which a CYP450 enzyme inducer was utilized intentionally to enhance CNI clearance in the setting of supratherapeutic concentrations; 7 case reports describe the use of phenytoin and 3 case reports describe the use of phenobarbital.	Phenytoin	223-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-69
28856745-5	2017	RESULTS: A total of 10 publications were identified in which a CYP450 enzyme inducer was utilized intentionally to enhance CNI clearance in the setting of supratherapeutic concentrations; 7 case reports describe the use of phenytoin and 3 case reports describe the use of phenobarbital.	Phenobarbital	272-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-69
29022838-4	2017	Areas covered: This manuscript reviews the pharmacogenomics (i.e. the influence of genetics on drug disposition) of triazole antifungal agents related to their CYP-mediated metabolism and summarizes their implications on triazole efficacy, safety, and tolerability.	Triazoles	221-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
29053951-0	2017	Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
28527918-0	2017	Cytochrome P450 eicosanoids in cerebrovascular function and disease.	Eicosanoids	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28527918-1	2017	Cytochrome P450 eicosanoids play important roles in brain function and disease through their complementary actions on cell-cell communications within the neurovascular unit (NVU) and mechanisms of brain injury.	Eicosanoids	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28527918-2	2017	Epoxy- and hydroxyeicosanoids, respectively formed by cytochrome P450 epoxygenases and omega-hydroxylases, play opposing roles in cerebrovascular function and in pathological processes underlying neural injury, including ischemia, neuroinflammation and oxidative injury.	epoxy- and hydroxyeicosanoids	0-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
28756170-0	2017	Confirmation of metabolites of the neuroleptic drug prothipendyl using human liver microsomes, specific CYP enzymes and authentic forensic samples-Benefit for routine drug testing.	prothipendyl	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
28756170-1	2017	Metabolism of the tricyclic azaphenothiazine neuroleptic drug prothipendyl was investigated with in vitro studies using human liver microsomes but also specific isoforms of cytochrome P450 (CYP) enzymes.	azaphenothiazine	28-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-188
28756170-1	2017	Metabolism of the tricyclic azaphenothiazine neuroleptic drug prothipendyl was investigated with in vitro studies using human liver microsomes but also specific isoforms of cytochrome P450 (CYP) enzymes.	azaphenothiazine	28-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-193
28756170-1	2017	Metabolism of the tricyclic azaphenothiazine neuroleptic drug prothipendyl was investigated with in vitro studies using human liver microsomes but also specific isoforms of cytochrome P450 (CYP) enzymes.	prothipendyl	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-188
28756170-1	2017	Metabolism of the tricyclic azaphenothiazine neuroleptic drug prothipendyl was investigated with in vitro studies using human liver microsomes but also specific isoforms of cytochrome P450 (CYP) enzymes.	prothipendyl	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-193
28756170-5	2017	N-demethyl-prothipendyl was predominantly formed by isoforms CYP2C19 and CYP1A2, while particularly the CYP isoenzyme 3A4 was responsible for the formation of prothipendyl sulfoxide.	n-demethyl-prothipendyl	0-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
29065189-6	2017	Furthermore, preincubation of TC-HepG2 cells with CYP inhibitors known as time-dependent inhibitors (TDI) prior to the addition of CYP-specific substrates determined that CYP inhibition was enhanced in the TDI group than in the non-TDI group.	Toluene 2,4-Diisocyanate	101-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
29065189-6	2017	Furthermore, preincubation of TC-HepG2 cells with CYP inhibitors known as time-dependent inhibitors (TDI) prior to the addition of CYP-specific substrates determined that CYP inhibition was enhanced in the TDI group than in the non-TDI group.	Toluene 2,4-Diisocyanate	206-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
29065189-6	2017	Furthermore, preincubation of TC-HepG2 cells with CYP inhibitors known as time-dependent inhibitors (TDI) prior to the addition of CYP-specific substrates determined that CYP inhibition was enhanced in the TDI group than in the non-TDI group.	Toluene 2,4-Diisocyanate	206-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
29065189-6	2017	Furthermore, preincubation of TC-HepG2 cells with CYP inhibitors known as time-dependent inhibitors (TDI) prior to the addition of CYP-specific substrates determined that CYP inhibition was enhanced in the TDI group than in the non-TDI group.	Toluene 2,4-Diisocyanate	206-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
28919040-0	2017	Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
28919040-0	2017	Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.	Biguanides	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
29053951-0	2017	Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.	Biguanides	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
28960974-5	2017	We pinpointed numerous reactive cysteines as the targets of RMs of diclofenac, including the active (heme-binding) sites on several key CYP450 isoforms (1A2, 2E1 and 3A4 for human, 2C39 and 3A11 for mouse).	Diclofenac	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
28960974-5	2017	We pinpointed numerous reactive cysteines as the targets of RMs of diclofenac, including the active (heme-binding) sites on several key CYP450 isoforms (1A2, 2E1 and 3A4 for human, 2C39 and 3A11 for mouse).	Heme	101-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
28701518-0	2017	Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.	Arachidonic Acid	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
28677033-1	2017	Due to intestinal cytochrome P450 (CYP450)-mediated metabolism and P-glycoprotein (P-gp) efflux, poor oral bioavailability hinders ginsenoside-Rh1 (Rh1) and ginsenoside-Rh2 (Rh2) from clinical application.	ginsenoside Rh1	131-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
28677033-1	2017	Due to intestinal cytochrome P450 (CYP450)-mediated metabolism and P-glycoprotein (P-gp) efflux, poor oral bioavailability hinders ginsenoside-Rh1 (Rh1) and ginsenoside-Rh2 (Rh2) from clinical application.	ginsenoside Rh1	131-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-41
28677033-1	2017	Due to intestinal cytochrome P450 (CYP450)-mediated metabolism and P-glycoprotein (P-gp) efflux, poor oral bioavailability hinders ginsenoside-Rh1 (Rh1) and ginsenoside-Rh2 (Rh2) from clinical application.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
28677033-1	2017	Due to intestinal cytochrome P450 (CYP450)-mediated metabolism and P-glycoprotein (P-gp) efflux, poor oral bioavailability hinders ginsenoside-Rh1 (Rh1) and ginsenoside-Rh2 (Rh2) from clinical application.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-41
28677033-7	2017	We confirmed that SME containing CYP450 and P-gp inhibitory excipient could distinctively improve the oral availabilities of Rh1 compared to free drug or SME containing P-gp inhibitory excipient.	8-O-acetyl shanzhiside methyl ester	18-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-39
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	1-aminobenzotriazole	27-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	1-aminobenzotriazole	27-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	1-aminobenzotriazole	27-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	1-aminobenzotriazole	27-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	Ketoconazole	120-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	Ketoconazole	120-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
28185143-1	2017	BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics.	Ketoconazole	120-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
28767146-0	2017	A Randomized Trial of Effects of Alcohol on Cytochrome P450 Eicosanoids, Mediators of Inflammation Resolution, and Blood Pressure in Men.	Alcohols	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
28767146-0	2017	A Randomized Trial of Effects of Alcohol on Cytochrome P450 Eicosanoids, Mediators of Inflammation Resolution, and Blood Pressure in Men.	Eicosanoids	60-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	Alcohols	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	Alcohols	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-238
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	107-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	107-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-238
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-238
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	Eicosanoids	189-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	Eicosanoids	189-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-238
28767146-2	2017	We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid.	Arachidonic Acid	253-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
28767146-10	2017	These paradoxical findings require further studies to determine whether alcohol stimulates different CYP450 enzymes and whether the findings can be replicated in females.	Alcohols	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
28701518-1	2017	Thirty-five years ago, a third pathway for the metabolism of arachidonic acid by cytochrome P450 enzymes emerged.	Arachidonic Acid	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
28701518-4	2017	Studies in animal models suggest that changes in the production of cytochrome P450 eicosanoids alter BP.	Eicosanoids	83-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
28701518-4	2017	Studies in animal models suggest that changes in the production of cytochrome P450 eicosanoids alter BP.	Benzo(a)pyrene	101-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
28701518-8	2017	Our review summarizes the emerging evidence that cytochrome P450 eicosanoids have a role in the pathogenesis of hypertension, polycystic kidney disease, AKI, and CKD.	Eicosanoids	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
29183231-1	2017	The cytochrome P450 (CYP) enzyme superfamily is involved in phase I metabolism which chemically modifies a variety of substrates via oxidative reactions to make them more water-soluble and easier to eliminate.	Water	171-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
29183231-1	2017	The cytochrome P450 (CYP) enzyme superfamily is involved in phase I metabolism which chemically modifies a variety of substrates via oxidative reactions to make them more water-soluble and easier to eliminate.	Water	171-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
28886714-9	2017	Observed changes in oxylipin levels can be connected to activation of cytochrome P450 (CYP) and 5-lipoxygenase (5-LOX) metabolic pathways in malaria infected individuals compared to controls, and related to increased levels of all linoleic acid oxylipins in severe patients compared to uncomplicated ones.	linoleic acid oxylipins	231-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
27819189-0	2017	Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes.	curculigoside	22-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
27819189-2	2017	Curculigoside possesses numerous pharmacological activities, and however, little data available for the effects of curculigoside on the activity of human liver cytochrome P450 (CYP) enzymes.	curculigoside	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
27819189-4	2017	This study investigates the inhibitory effects of curculigoside on the main human liver CYP isoforms.	curculigoside	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
27819189-5	2017	In this study, the inhibitory effects of curculigoside on the eight human liver CYP isoforms 1A2, 2A6, 2E1, 2D6, 2C9, 2C19, 2C8, and 3A4 were investigated in human liver microsomes.	curculigoside	41-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27819189-7	2017	The results indicated that curculigoside could inhibit the activity of CYP1A2, CYP2C8, and CYP3A4, with IC50 values of 15.26, 11.93, and 9.47 muM, respectively, but that other CYP isoforms were not affected.	curculigoside	27-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
27819189-11	2017	The in vitro studies of curculigoside with CYP isoforms suggest that curculigoside has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by CYP1A2, CYP2C8, and CYP3A4.	curculigoside	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
27819189-11	2017	The in vitro studies of curculigoside with CYP isoforms suggest that curculigoside has the potential to cause pharmacokinetic drug interactions with other coadministered drugs metabolized by CYP1A2, CYP2C8, and CYP3A4.	curculigoside	69-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
28951593-1	2017	MicroRNAs (miRNAs) that regulate the cytochrome P-450 isoforms involved in acetaminophen (APAP) toxicity were examined in HepaRG cells treated with APAP (20 mM).	Acetaminophen	75-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
28951593-1	2017	MicroRNAs (miRNAs) that regulate the cytochrome P-450 isoforms involved in acetaminophen (APAP) toxicity were examined in HepaRG cells treated with APAP (20 mM).	Acetaminophen	90-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
28951593-1	2017	MicroRNAs (miRNAs) that regulate the cytochrome P-450 isoforms involved in acetaminophen (APAP) toxicity were examined in HepaRG cells treated with APAP (20 mM).	Acetaminophen	148-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
28732807-7	2017	Moreover, the metabolism of alpha- and beta-asarone occurs mainly through cytochrome-P450 pathways.	alpha- and beta-asarone	28-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
28370390-8	2017	Voriconazole-N-oxide inhibition of cytochrome P450 (CYP) isoforms 2C19 and 3A4 were assessed with the P450-Glo luminescence assay.	Voriconazole N-Oxide	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
28370390-8	2017	Voriconazole-N-oxide inhibition of cytochrome P450 (CYP) isoforms 2C19 and 3A4 were assessed with the P450-Glo luminescence assay.	Voriconazole N-Oxide	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
28370390-11	2017	Concentration giving 50% CYP inhibition of voriconazole N-oxide was 146 +- 23 mumol l-1 for CYP3A4, and 40.2 +- 4.2 mumol l-1 for CYP2C19.	Voriconazole N-Oxide	43-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
28991531-0	2017	Identification of human cytochrome P450 and UGT enzymes involved in the metabolism of ferulic acid, a major bioactive component in traditional Chinese medicines.	ferulic acid	86-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-47
28628909-0	2017	Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of alpha-tocopherol (vitamin E).	alpha-Tocopherol	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
28628909-0	2017	Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of alpha-tocopherol (vitamin E).	Vitamin E	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
28731962-1	2017	Cytochrome P450 oxidoreductase (POR) has played a potential role in the metabolism of drugs and steroids by supplying electrons to microsomal cytochrome P450 (CYP) enzymes.	Steroids	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
28731962-1	2017	Cytochrome P450 oxidoreductase (POR) has played a potential role in the metabolism of drugs and steroids by supplying electrons to microsomal cytochrome P450 (CYP) enzymes.	Steroids	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
28741929-1	2017	Cytochrome P450 CYP101A1 (P450cam) hydroxylates camphor by receiving two distinct electrons from its unique reductase, putidaredoxin (Pdx).	Camphor	48-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28701464-1	2017	Recently, zebrafish and human cytochrome P450 (P450) 27C1 enzymes have been shown to be retinoid 3,4-desaturases.	Retinoids	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-57
28495902-1	2017	A beta-blocker, metoprolol, is one of the in vivo probes for human cytochrome P450 (P450) 2D6.	Metoprolol	16-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-93
27935260-7	2017	Studies using incubations with nicotinamide adenine dinucleotide phosphate-fortified pHLM with or without uridine 5"-diphosphoglucuronic acid and incubations with CYP-enzymes identified the main metabolic pathway of flubromazolam as hydroxylation on the alpha- and/or 4-position mediated by CYP3A4 and CYP3A5, with subsequent glucuronidation of the hydroxylated metabolites as well as of the parent drug.	flubromazolam	216-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-166
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Atomoxetine Hydrochloride	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Atomoxetine Hydrochloride	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-98
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Fluoxetine	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Fluoxetine	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-98
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Fluoxetine	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
29349890-2	2017	Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.	Fluoxetine	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-98
27896399-0	2017	Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.	Triclosan	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28726718-0	2017	Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.	Sulfur	41-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
28726718-7	2017	To illustrate effects of CYP inhibition by trapping agents on reactive intermediate trapping, an example drug (ticlopidine) and trapping agent (NEM) were chosen for further studies.	Ticlopidine	111-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
28726718-8	2017	For the same amount of ticlopidine (1 muM), increasing concentrations of the trapping agent NEM (0.007-40 mM) resulted in a bell-shaped response curve of NEM-trapped ticlopidine S-oxide (TSO-NEM), due to CYP inhibition by NEM.	Ticlopidine S-oxide	166-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207
28726718-8	2017	For the same amount of ticlopidine (1 muM), increasing concentrations of the trapping agent NEM (0.007-40 mM) resulted in a bell-shaped response curve of NEM-trapped ticlopidine S-oxide (TSO-NEM), due to CYP inhibition by NEM.	tso-nem	187-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207
28104494-5	2017	We review the synthesis and roles of especially PGRMC1- and cyP450-bound heme, the sources and transport of cholesterol, the involvement of PGRMC1 in cholesterol regulation, and the production of the first progestogen pregnenolone from cholesterol.	Heme	73-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-66
28747995-1	2017	BACKGROUND: The objective of this study was to examine the inhibitory potential of darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride on the seven major human cytochrome P450 enzymes (CYP) by using a standardized and validated seven-in-one cytochrome P450 cocktail inhibition assay.	trospium chloride	164-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-222
28747995-1	2017	BACKGROUND: The objective of this study was to examine the inhibitory potential of darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride on the seven major human cytochrome P450 enzymes (CYP) by using a standardized and validated seven-in-one cytochrome P450 cocktail inhibition assay.	trospium chloride	164-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	288-303
28366651-0	2017	The impact of porous silicon nanoparticles on human cytochrome P450 metabolism in human liver microsomes in vitro.	Silicon	21-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
28366651-2	2017	This study focuses on the hitherto unaddressed impact of porous silicon (PSi) nanoparticles on human cytochrome P450 (CYP) metabolism, which is the major detoxification route of most pharmaceuticals and other xenobiotics.	Silicon	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
28366651-2	2017	This study focuses on the hitherto unaddressed impact of porous silicon (PSi) nanoparticles on human cytochrome P450 (CYP) metabolism, which is the major detoxification route of most pharmaceuticals and other xenobiotics.	Silicon	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
27896399-8	2017	Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity.	Triclosan	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
27896399-8	2017	Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity.	Triclosan	203-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
27896399-8	2017	Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity.	Triclosan	203-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
27896399-10	2017	Conjugation of triclosan, catalyzed by human glucuronosyltransferases (UGTs) and sulfotransferases (SULTs), also occurred in HepG2/CYP-overexpressing cells and primary human hepatocytes, with a greater extent of conjugation being associated with higher cell viability.	Triclosan	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
27896399-12	2017	Among the 18 CYP-overexpressing cell lines, an inverse correlation was observed between cell viability and the level of triclosan in the culture medium.	Triclosan	120-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
27896399-13	2017	In conclusion, human CYP isoforms that metabolize triclosan were identified, and the metabolism of triclosan by CYPs, UGTs, and SULTs decreased its cytotoxicity in hepatic cells.	Triclosan	50-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
27896399-13	2017	In conclusion, human CYP isoforms that metabolize triclosan were identified, and the metabolism of triclosan by CYPs, UGTs, and SULTs decreased its cytotoxicity in hepatic cells.	Triclosan	99-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
27896399-2	2017	The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity.	Triclosan	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
27896399-2	2017	The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity.	Triclosan	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
27896399-2	2017	The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity.	Triclosan	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
27896399-4	2017	The extent of triclosan metabolism by each CYP was assessed by reversed-phase high-performance liquid chromatography with online radiochemical detection.	Triclosan	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
28959657-0	2017	CYP polymorphisms and pathological conditions related to chronic exposure to organochlorine pesticides.	Hydrocarbons, Chlorinated	77-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
28369648-3	2017	Cytochrome P450 enzymes are expressed at a relatively high level in astrocytes and may play a critical role in the biotransformation of endogenous or exogenous compounds, including chlorpyrifos, an organophosphate insecticide that affects the central nervous system.	Chlorpyrifos	181-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28369648-3	2017	Cytochrome P450 enzymes are expressed at a relatively high level in astrocytes and may play a critical role in the biotransformation of endogenous or exogenous compounds, including chlorpyrifos, an organophosphate insecticide that affects the central nervous system.	Organophosphates	198-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27412850-0	2017	In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.	Diterpenes, Clerodane	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
27412850-0	2017	In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.	Diterpenes	55-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
27412850-0	2017	In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.	polyandric acid A	67-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	Diterpenes	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	Diterpenes	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	52-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	52-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	71-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	71-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	Alcohols	178-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	Alcohols	178-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	209-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	polyandric acid A	209-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	paah	228-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	344-359
27412850-2	2017	The metabolism of the anti-inflammatory diterpenoid polyandric acid A (PAA), a constituent of the Australian Aboriginal medicinal plant Dodonaea polyandra, and its de-esterified alcohol metabolite, hydrolysed polyandric acid A (PAAH) was studied in vitro using human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzymes.	paah	228-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	361-364
27412850-7	2017	Reaction phenotyping utilising selective enzyme inhibitors and recombinant human UGT and CYP enzymes revealed UGT2B7 and UGT1A1, and CYP2C9 and CYP3A4 as the major enzymes involved in the metabolism of PAAH.	paah	202-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
28959657-1	2017	The association between genetic variations in the cytochrome P450 (CYP) family genes and pathological conditions related to long-term exposure to organochlorine compounds (OCs) deserves further elucidation.	Hydrocarbons, Chlorinated	146-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
28959657-1	2017	The association between genetic variations in the cytochrome P450 (CYP) family genes and pathological conditions related to long-term exposure to organochlorine compounds (OCs) deserves further elucidation.	Hydrocarbons, Chlorinated	146-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
28524079-8	2017	CYP450 activity was induced/inhibited in spheroids as expected, separate from any toxic response.	spheroids	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
28300390-0	2017	Recruitment and Regulation of the Non-ribosomal Peptide Synthetase Modifying Cytochrome P450 Involved in Nikkomycin Biosynthesis.	nikkomycin	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
28300390-2	2017	The cytochrome P450 (NikQ) hydroxylates the amino acid while it is appended via a phosphopantetheine linker to the non-ribosomal peptide synthetase (NRPS) NikP1.	4'-phosphopantetheine	82-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
28173639-0	2017	Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.	Bosentan	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
28173639-0	2017	Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.	Rifampin	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Bosentan	30-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-149
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Bosentan	30-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-157
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-149
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-157
28173639-7	2017	These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.	Rifampin	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-102
28173639-7	2017	These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.	Bosentan	36-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-102
28403941-14	2017	Since 5-HETE is a 5LOX product, 11-HETE is marker of lipid peroxidation, and vicinal diols are formed through soluble epoxide hydrolase (sEH) metabolism of CYP epoxygenated PUFAs, therefore, these results indicate that obesity is likely associated with altered metabolism with distinct oxygenating pathways.	vicinal diols	77-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
28468305-2	2017	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 (CYP) enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency.	dimethyllirioresinol	29-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
28468305-2	2017	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 (CYP) enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency.	Epimagnolin A	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
28468305-2	2017	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 (CYP) enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency.	Epimagnolin A	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
28468305-2	2017	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 (CYP) enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency.	fargesin	76-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
28468305-0	2017	Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.	dimethyllirioresinol	22-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
28468305-0	2017	Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.	Epimagnolin A	44-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
28468305-0	2017	Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.	fargesin	69-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
28468305-0	2017	Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.	magnolin	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
28376352-2	2017	This study aims to identify the metabolic profile of five flavonoids (loureirin A, loureirin B, loureirin C, 7,4"-dihydroxyflavone and 5,7,4"-trihydroxyflavanone) from DB in HLMs as well as the CYP enzymes that are involved in the metabolism of them.	Flavonoids	58-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-197
27226420-9	2017	Both cytochrome p450 (CYP) 3A4 and non-CYP mechanisms govern the clearance of panobinostat.	Panobinostat	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-20
28301931-0	2017	Tunneling Effect That Changes the Reaction Pathway from Epoxidation to Hydroxylation in the Oxidation of Cyclohexene by a Compound I Model of Cytochrome P450.	cyclohexene	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
27868228-9	2017	IMPLICATIONS FOR THERAPY: Amiodarone inhibits cytochrome P450 (CYP) isoforms 2C8 and 3A4 as well as P-glycoprotein (P-gp) for which taxanes are substrates.	Amiodarone	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
27868228-9	2017	IMPLICATIONS FOR THERAPY: Amiodarone inhibits cytochrome P450 (CYP) isoforms 2C8 and 3A4 as well as P-glycoprotein (P-gp) for which taxanes are substrates.	Amiodarone	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
27868228-9	2017	IMPLICATIONS FOR THERAPY: Amiodarone inhibits cytochrome P450 (CYP) isoforms 2C8 and 3A4 as well as P-glycoprotein (P-gp) for which taxanes are substrates.	Taxoids	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
27868228-9	2017	IMPLICATIONS FOR THERAPY: Amiodarone inhibits cytochrome P450 (CYP) isoforms 2C8 and 3A4 as well as P-glycoprotein (P-gp) for which taxanes are substrates.	Taxoids	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
28340451-3	2017	Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications.	abiraterone	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
28340451-3	2017	Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications.	abiraterone	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
28340451-3	2017	Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications.	enzalutamide	255-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
28340451-3	2017	Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications.	enzalutamide	255-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
28274629-0	2017	Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.	6-paradol	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
28274629-0	2017	Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.	unsaturated ketone	25-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
28274629-3	2017	In this study, the inhibitory effects of 6-paradol on the activities of cytochrome P450 (CYP) enzymes were investigated with human liver microsomes and recombinant CYP isozymes.	6-paradol	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
28274629-3	2017	In this study, the inhibitory effects of 6-paradol on the activities of cytochrome P450 (CYP) enzymes were investigated with human liver microsomes and recombinant CYP isozymes.	6-paradol	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
28274629-3	2017	In this study, the inhibitory effects of 6-paradol on the activities of cytochrome P450 (CYP) enzymes were investigated with human liver microsomes and recombinant CYP isozymes.	6-paradol	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
28274629-4	2017	6-Paradol showed concentration-dependent inhibitory effects on CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 isozymes, with IC50 values ranging from 3.8 to 21.4microM in recombinant CYP isozymes.	6-paradol	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
27449533-2	2017	CyP4F22, a protein of the cytochrome-P450 family 4, encodes an epidermal omega-hydroxylase decisive in the formation of acylceramides, which is hypothesized to be crucial for skin-barrier function.	acylceramides	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-50
27347703-11	2017	These results demonstrate that luseogliflozin is metabolized through multiple pathways, including CYP-mediated oxidation and glucuronidation, in human.	1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol	31-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
27226420-9	2017	Both cytochrome p450 (CYP) 3A4 and non-CYP mechanisms govern the clearance of panobinostat.	Panobinostat	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
27226420-9	2017	Both cytochrome p450 (CYP) 3A4 and non-CYP mechanisms govern the clearance of panobinostat.	Panobinostat	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
28377720-1	2017	Cytochrome P450 enzymes are often responsible for the toxic and carcinogenic effects of toxicants, such as aflatoxin B1 (AFB1).	Aflatoxin B1	107-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28215634-8	2017	We have confirmed that the hepatocyte-like cells prepared by our methods were able to increase gene expression of cytochrome P450 enzymes upon encountering rifampicin, phenobarbital, or omeprazole.	Rifampin	156-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
28215634-8	2017	We have confirmed that the hepatocyte-like cells prepared by our methods were able to increase gene expression of cytochrome P450 enzymes upon encountering rifampicin, phenobarbital, or omeprazole.	Phenobarbital	168-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
28215634-8	2017	We have confirmed that the hepatocyte-like cells prepared by our methods were able to increase gene expression of cytochrome P450 enzymes upon encountering rifampicin, phenobarbital, or omeprazole.	Omeprazole	186-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
28377720-1	2017	Cytochrome P450 enzymes are often responsible for the toxic and carcinogenic effects of toxicants, such as aflatoxin B1 (AFB1).	Aflatoxin B1	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28331291-5	2017	The effect of genetic polymorphisms of cytochrome-P450 (CYP) enzymes on the pharmacokinetics of DA-8031 was evaluated.	DA 8031	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
28331291-5	2017	The effect of genetic polymorphisms of cytochrome-P450 (CYP) enzymes on the pharmacokinetics of DA-8031 was evaluated.	DA 8031	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
28287454-0	2017	AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5"-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.	1-(5-fluoropentyl)-3-(1-naphthoyl)indole	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
27718269-0	2017	Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.	Amodiaquine	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
28287454-2	2017	However, there are no reports of the inhibitory effect of AM-2201 on human cytochrome P450 (CYP) or uridine 5"-diphospho-glucuronosyltransferase (UGT) enzymes.	1-(5-fluoropentyl)-3-(1-naphthoyl)indole	58-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
27718269-0	2017	Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.	desethylamodiaquine	105-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
27718269-1	2017	AIMS: Oxidative bioactivation of amodiaquine (AQ) by cytochrome P450s to a reactive quinoneimine is considered as an important mechanism underlying its idiosyncratic hepatotoxicity.	Amodiaquine	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
27718269-1	2017	AIMS: Oxidative bioactivation of amodiaquine (AQ) by cytochrome P450s to a reactive quinoneimine is considered as an important mechanism underlying its idiosyncratic hepatotoxicity.	Amodiaquine	46-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
27718269-1	2017	AIMS: Oxidative bioactivation of amodiaquine (AQ) by cytochrome P450s to a reactive quinoneimine is considered as an important mechanism underlying its idiosyncratic hepatotoxicity.	quinoneimine	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
27924364-0	2017	Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.	1-(5-fluoropentyl)-1h-indol-3-yl)	31-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
28253085-3	2017	To the best of our knowledge, no study to date has evaluated the effects of water pipe smoking on cytochrome P450 (CYP450) activities and drug interaction potential in humans, whereas only limited information is available on the impact of secondhand smoke on drug metabolism.	Water	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
28253085-11	2017	Further studies in larger prospective samples are recommended to evaluate water pipe and secondhand tobacco smoke effects on CYP450 function, particularly at higher smoke exposure conditions.	Water	74-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-131
28140586-3	2017	These also are often found near cytochrome P450 (CYP) mono-oxygenases that presumably further decorate the ensuing diterpene, suggesting that these fungi might produce more elaborate diterpenoids.	Diterpenes	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
28140586-3	2017	These also are often found near cytochrome P450 (CYP) mono-oxygenases that presumably further decorate the ensuing diterpene, suggesting that these fungi might produce more elaborate diterpenoids.	Diterpenes	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
28140586-3	2017	These also are often found near cytochrome P450 (CYP) mono-oxygenases that presumably further decorate the ensuing diterpene, suggesting that these fungi might produce more elaborate diterpenoids.	Diterpenes	183-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
28140586-3	2017	These also are often found near cytochrome P450 (CYP) mono-oxygenases that presumably further decorate the ensuing diterpene, suggesting that these fungi might produce more elaborate diterpenoids.	Diterpenes	183-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
27966929-2	2017	Experimental studies indicate that cytochrome P450 (CYP) enzymes catalyze the bioactivation of estrogens to catechols, which can exert their harmful effects via various routes.	Catechols	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
27966929-2	2017	Experimental studies indicate that cytochrome P450 (CYP) enzymes catalyze the bioactivation of estrogens to catechols, which can exert their harmful effects via various routes.	Catechols	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	Estrone	117-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	Estrone	178-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	Equilin	187-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	Equilenin	200-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	7-methoxy-6-(2'-methoxy-3'-hydroxy-3'-methyl butyl)	343-350	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
27966929-6	2017	We studied the structure of human estrogen metabolizing enzymes (CYP1A1, CYP1A2, CYP1B1, and CYP3A4) in complex with estrone using docking and investigated the susceptibility of estrone, equilin, and equilenin (which only differ in the unsaturation of ring B) to undergo 2- and 4-hydroxylation using several models of CYP enzymes (Compound I, methoxy, and phenoxy radical).	phenoxy radical	356-371	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
28080030-1	2017	Cytochrome P450 enzymes have been engineered to catalyze abiological C-H bond amination reactions, but the yields of these reactions have been limited by low chemoselectivity for the amination of C-H bonds over competing reduction of the azide substrate to a sulfonamide.	Azides	238-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28080030-1	2017	Cytochrome P450 enzymes have been engineered to catalyze abiological C-H bond amination reactions, but the yields of these reactions have been limited by low chemoselectivity for the amination of C-H bonds over competing reduction of the azide substrate to a sulfonamide.	Sulfonamides	259-270	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27457692-5	2017	AIM OF THE STUDY: Aim of the Study was to investigate herb-drug interaction (HDI) of Ridayarishta formulation through human hepatic cytochrome P450 (CYP450) enzyme inhibition assay.	ridayarishta	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-147
27457692-5	2017	AIM OF THE STUDY: Aim of the Study was to investigate herb-drug interaction (HDI) of Ridayarishta formulation through human hepatic cytochrome P450 (CYP450) enzyme inhibition assay.	ridayarishta	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-155
27457692-14	2017	It may be concluded that consumption of Ridayarishta along with selective cardio protective, antihypertensive and anti-diabetic conventional medicine is safe with negligible or without any significant CYP450 (CYP1A2, 2C19, 2D6 and 3A4) inhibition mediated HDI.	ridayarishta	40-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-207
28344492-3	2017	Cytochrome P450 (CYP) enzymes, an essential source of variability in drug-response, play role in not only phase I-dependent metabolism of xenobiotics but also metabolism of endogenous compounds such as steroids, vitamins and fatty acids.	Steroids	202-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28344492-3	2017	Cytochrome P450 (CYP) enzymes, an essential source of variability in drug-response, play role in not only phase I-dependent metabolism of xenobiotics but also metabolism of endogenous compounds such as steroids, vitamins and fatty acids.	Steroids	202-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
28344492-3	2017	Cytochrome P450 (CYP) enzymes, an essential source of variability in drug-response, play role in not only phase I-dependent metabolism of xenobiotics but also metabolism of endogenous compounds such as steroids, vitamins and fatty acids.	Fatty Acids	225-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28344492-3	2017	Cytochrome P450 (CYP) enzymes, an essential source of variability in drug-response, play role in not only phase I-dependent metabolism of xenobiotics but also metabolism of endogenous compounds such as steroids, vitamins and fatty acids.	Fatty Acids	225-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
27924364-0	2017	Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.	4-methyl-1-naphthalenyl)-methanone	65-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
26874845-0	2017	Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein.	triptolide	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
26874845-2	2017	However, it remains unclear how triptolide influences the activity of human liver cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp).	triptolide	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
26874845-2	2017	However, it remains unclear how triptolide influences the activity of human liver cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp).	triptolide	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
26874845-3	2017	METHODS: In this study, the inhibitory effects of triptolide on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8) were investigated in vitro using human liver microsomes (HLMs), and the effects of triptolide on the activity of P-gp were investigated using a rhodamine-123 uptake assay.	triptolide	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
26874845-4	2017	RESULTS: The results showed that triptolide inhibited the activity of CYP1A2 and CYP3A4, with 50 % inhibitory concentration (IC50) values of 14.18 and 8.36 muM, respectively, but that other CYP isoforms were not affected.	triptolide	33-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
26874845-8	2017	CONCLUSIONS: The in vitro studies of triptolide with CYP isoforms and P-gp indicate that triptolide has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2 and CYP3A4.	triptolide	37-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
26874845-8	2017	CONCLUSIONS: The in vitro studies of triptolide with CYP isoforms and P-gp indicate that triptolide has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2 and CYP3A4.	triptolide	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	edhfs	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	edhfs	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	Arachidonic Acid	133-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	Arachidonic Acid	133-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	epoxyeicosatrienoic acids	166-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	epoxyeicosatrienoic acids	166-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	eets	193-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
28007573-1	2017	OBJECTIVE: Prominent among the endothelium-derived hyperpolarizing factors (EDHFs) are the Cytochrome P450 (CYP) epoxygenase-derived arachidonic acid metabolites-the epoxyeicosatrienoic acids (EETs), that are known as vasodilators in the microcirculation.	eets	193-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
27861439-3	2017	The opioid analgesic potency of a given dose of tramadol is influenced by an individual"s CYP genetics, with poor metabolizers experiencing little conversion to the active M1 opioid metabolite and individuals with a high metabolic profile, or ultra-metabolizers, experiencing the greatest opioid analgesic effects.	Tramadol	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
27712037-4	2017	The pharmacokinetics of CYP selective substrates: caffeine, losartan, and omeprazole changed significantly in a diabetic NASH mouse model, indicating attenuation of the activity of Cyp1a2 and Cyp2c29, respectively.	Caffeine	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
27712037-4	2017	The pharmacokinetics of CYP selective substrates: caffeine, losartan, and omeprazole changed significantly in a diabetic NASH mouse model, indicating attenuation of the activity of Cyp1a2 and Cyp2c29, respectively.	Losartan	60-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
27712037-4	2017	The pharmacokinetics of CYP selective substrates: caffeine, losartan, and omeprazole changed significantly in a diabetic NASH mouse model, indicating attenuation of the activity of Cyp1a2 and Cyp2c29, respectively.	Omeprazole	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
28197402-0	2017	Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference.	cyclopropylamine	49-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
28197402-1	2017	N-benzyl-N-cyclopropylamine (BCA) has been attracting great interests for decades for its partial suicide inactivation role to cytochrome P450 (P450) via a ring-opening mechanism besides acting as a role of normal substrates.	N-Benzylcyclopropylamine	0-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
28197402-1	2017	N-benzyl-N-cyclopropylamine (BCA) has been attracting great interests for decades for its partial suicide inactivation role to cytochrome P450 (P450) via a ring-opening mechanism besides acting as a role of normal substrates.	alpha-bromocinnamaldehyde	29-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
27861439-4	2017	The importance of the CYP metabolism has led to the adoption of computer clinical decision support with pharmacogenomics tools guiding tramadol treatment in major medical centers.	Tramadol	135-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
27861439-7	2017	This review provides updated important information on the pharmacology, pharmacokinetics, CYP genetic polymorphisms, drug interactions, toxicity, withdrawal, and illicit use of tramadol.	Tramadol	177-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	isavuconazole	27-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27482943-0	2017	The Pharmacogenomic Association of Fcgamma Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.	Cyclophosphamide	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Bupropion	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	repaglinide	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Caffeine	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Dextromethorphan	135-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Methadone	157-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27863990-0	2017	Cytochrome P450 enzymes but not NADPH oxidases are the source of the NADPH-dependent lucigenin chemiluminescence in membrane assays.	10,10'-dimethyl-9,9'-biacridinium	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27816611-3	2017	In the same years the cytochrome P-450 dependent metabolism of vitamin E was characterized and a first series of studies on short-chain carboxyethyl metabolites in the 1990s paved the way to the hypothesis of a biological role for this metabolism alternative to vitamin E catabolism.	Vitamin E	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
27816611-4	2017	In the last decade other physiological metabolites of vitamin E have been identified, such as alpha-tocopheryl phosphate and the long-chain metabolites formed by the omega-hydroxylase activity of cytochrome P-450.	Vitamin E	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-212
27863990-7	2017	Using a combination of native protein electrophoresis, NADPH-stimulated assays and mass spectrometry, mitochondrial proteins and cytochrome P450 were identified as possible source of the assay signal.	NADP	55-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
29104319-1	2017	Abstract: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4.	ellipticine	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
29104319-1	2017	Abstract: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4.	ellipticine	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
29104318-7	2017	We found that in contrast to AAI, AAII is oxidized only by several CYP enzymatic systems and their efficiency is much lower for oxidation of AAII than AAI.	aaii	34-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
28102631-0	2017	Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.	Propranolol	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
29104318-7	2017	We found that in contrast to AAI, AAII is oxidized only by several CYP enzymatic systems and their efficiency is much lower for oxidation of AAII than AAI.	aai	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	125-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	125-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	158-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	158-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	Cadmium	247-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
28132967-9	2017	Blood pressure control is mediated at least in part by cytochrome P450 (CYP) enzymes such as CYP4A11 and CYP4F2 that produce 20-hydroxyeicosatetraenoic acid (20-HETE), involved in salt balance in the kidney, and all are known to be altered during Cd exposure.	Cadmium	247-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
27452206-3	2016	Dimerization is required for association with cytochrome P450 (cyP450) enzymes, which mediates chemoresistance to doxorubicin and may be responsible for PGRMC1"s anti-apoptotic activity.	Doxorubicin	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
27727524-1	2016	Cytochrome P450 enzymes are heme-containing mono-oxygenases that mainly react through oxygen-atom transfer.	Oxygen	49-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
28006925-1	2016	This review summarizes the importance of bile acids (BA) as important regulators of various homeostatic mechanisms with detailed focus on cytochrome P450 (CYP) enzymes.	Bile Acids and Salts	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
28006925-1	2016	This review summarizes the importance of bile acids (BA) as important regulators of various homeostatic mechanisms with detailed focus on cytochrome P450 (CYP) enzymes.	Bile Acids and Salts	53-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
27452206-3	2016	Dimerization is required for association with cytochrome P450 (cyP450) enzymes, which mediates chemoresistance to doxorubicin and may be responsible for PGRMC1"s anti-apoptotic activity.	Doxorubicin	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-69
27836712-0	2016	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol.	Carvedilol	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
27317413-2	2016	The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes.	daas	16-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
27317413-2	2016	The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes.	daas	16-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-120
27718490-3	2016	METHODS: To overcome this drawback, the cross-reactivities exhibited by six chemical inhibitors (furafylline, montelukast, sulfaphenazole, ticlopidine, quinidine and ketoconazole) were quantified using specific CYP enzyme marker reactions.	Ketoconazole	166-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
27836712-1	2016	To evaluate the relative contribution of cytochrome P450 (CYP) isoforms responsible for carvedilol (CAR) oxidation, enantioselective metabolism of CAR was investigated in human liver microsomes (HLMs) and recombinant human CYPs by using the substrate depletion assay.	Carvedilol	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
27836712-1	2016	To evaluate the relative contribution of cytochrome P450 (CYP) isoforms responsible for carvedilol (CAR) oxidation, enantioselective metabolism of CAR was investigated in human liver microsomes (HLMs) and recombinant human CYPs by using the substrate depletion assay.	Carvedilol	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
27507240-9	2016	Pre-treatment with the cytochrome-P450 inhibitor malathion supports a non-target site metabolism-based mechanism of herbicide resistance.	Malathion	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	hydroxytamoxifen	40-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	4-hydroxy-N-desmethyltamoxifen	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	4-hydroxy-N-desmethyltamoxifen	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
27198207-2	2016	CYP phenotypes have been correlated to tamoxifen outcomes, but few have considered drug interactions or combinations of genes.	Tamoxifen	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
27198207-11	2016	With 3 impaired CYP phenotypes, endoxifen concentrations were lower than if only CYP2D6 was impaired (P = .05).	4-hydroxy-N-desmethyltamoxifen	32-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
27779894-0	2016	Influence of Sulforaphane Metabolites on Activities of Human Drug-Metabolizing Cytochrome P450 and Determination of Sulforaphane in Human Liver Cells.	sulforaphane	13-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
27289043-1	2016	The importance of Cytochrome P450-catalyzed modifications of natural products produced by non-ribosomal peptide synthetase machineries is most apparent during glycopeptide antibiotic biosynthesis: specifically, the formation of essential amino acid side chains crosslinks in the peptide backbone of these clinically relevant antibiotics.	Amino Acids, Essential	228-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
27805325-0	2016	Corrigendum: Mutating a Highly Conserved Residue in Diverse Cytochrome P450s Facilitates Diastereoselective Olefin Cyclopropanation.	Alkenes	108-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
29908557-0	2016	[The in vitro inhibition and induction of cytochrome P450 activities by bentysrepinine: a novel candidate of anti-hepatitis B virus drug].	N-(N-benzoyl-O-(2-dimethylaminoethyl)tyrosyl)phenylalaninol	72-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	46-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	Arachidonic Acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
27591243-1	2016	Epoxyeicosatrienoic acids (EETs) are metabolic products of free arachidonic acid, which are produced through cytochrome P-450 (CYP) epoxygenases.	Arachidonic Acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	dihydroxyeicosatrienoic acids	261-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	dihetes	292-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	180-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	180-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	20-Hete	213-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	epoxyeicosatrienoic acids	223-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
27087514-1	2016	AIM: To better understand the relationship between the interactions among rs17110453, rs751141, and rs9333025 variants and plasma levels of cytochrome P450 (CYP) metabolites, i.e.,20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs) in ischemia stroke (IS).	eets	250-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
26975734-0	2016	The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.	edhf	14-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	46-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	75-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	75-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26931777-11	2016	Based upon in vitro studies, the potential for LCZ696 to inhibit or induce cytochrome P450 (CYP) enzymes and cause CYP-mediated drug interactions clinically was found to be low.	sacubitril and valsartan sodium hydrate drug combination	47-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	eets	102-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26931777-11	2016	Based upon in vitro studies, the potential for LCZ696 to inhibit or induce cytochrome P450 (CYP) enzymes and cause CYP-mediated drug interactions clinically was found to be low.	sacubitril and valsartan sodium hydrate drug combination	47-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
26931777-11	2016	Based upon in vitro studies, the potential for LCZ696 to inhibit or induce cytochrome P450 (CYP) enzymes and cause CYP-mediated drug interactions clinically was found to be low.	sacubitril and valsartan sodium hydrate drug combination	47-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
26975734-1	2016	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs).	eets	102-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	Arachidonic Acid	15-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	omega-3 polyunsaturated fatty acids	74-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	Fatty Acids, Unsaturated	111-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	Eicosapentaenoic Acid	119-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	Docosahexaenoic Acids	145-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-3	2016	In addition to arachidonic acid, the CYP epoxygenases also metabolize the Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators.	lipid epoxide	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
26975734-6	2016	It seems that the overall consequences of CYP epoxygenase activation largely depend on enzyme substrate preference and the endogenous Omega-3/Omega-6 PUFA ratio.	omega-3	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
26975734-6	2016	It seems that the overall consequences of CYP epoxygenase activation largely depend on enzyme substrate preference and the endogenous Omega-3/Omega-6 PUFA ratio.	omega-6	142-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
27769286-6	2016	AGEs are associated with hyperandrogenism in PCOS possibly by altering the activity of various enzymes such as cholesterol side-chain cleavage enzyme cytochrome P450, steroidogenic acute regulatory protein, 17alpha-hydroxylase, and 3beta-hydroxysteroid dehydrogenase.	Cholesterol	111-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-197
26961113-0	2016	Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.	Clopidogrel	53-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
27474842-2	2016	Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite.	Losartan	38-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26750984-4	2016	Although there have been studies on the biological effects of glycyrol, the inhibitory effects of glycyrol on cytochrome P450 (CYP) activities have not been investigated.	glycyrol	98-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
26750984-4	2016	Although there have been studies on the biological effects of glycyrol, the inhibitory effects of glycyrol on cytochrome P450 (CYP) activities have not been investigated.	glycyrol	98-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
26750984-6	2016	We investigated the inhibitory effects of glycyrol on the activities of CYP isoforms using a cocktail of probe substrates in pooled human liver microsome (HLM) and human recombinant cDNA-expressed CYPs.	glycyrol	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
27009433-10	2016	In conclusion, Geneva cocktail combined with an innovative DBS sampling device can be used routinely as a test for simultaneous CYP phenotyping.	dbs	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
27474842-2	2016	Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite.	losartan carboxylic acid	50-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27458223-2	2016	Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes.	OPC-67683	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-256
27458223-2	2016	Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes.	OPC-67683	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
27458223-2	2016	Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes.	Rifampin	211-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-256
27318274-0	2016	Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.	flavokawain A	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
27318274-3	2016	AIM OF THE STUDY: The current study was purposed to investigate the interaction between Flavokawain A and Cytochrome P450, including the inhibitory effects of Flavokawain A on predominant CYP450 isotypes and further clarified the inhibitory mechanism of FKA on CYP450 enzymes.	flavokawain A	88-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
27318274-3	2016	AIM OF THE STUDY: The current study was purposed to investigate the interaction between Flavokawain A and Cytochrome P450, including the inhibitory effects of Flavokawain A on predominant CYP450 isotypes and further clarified the inhibitory mechanism of FKA on CYP450 enzymes.	BENZYL-CARBAMIC ACID [8-DEETHYL-ASCOMYCIN-8-YL]ETHYL ESTER	254-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Midazolam	107-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Nifedipine	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Testosterone	130-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Triazolam	147-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
27474842-2	2016	Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite.	losartan carboxylic acid	50-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
27474842-6	2016	Differences in tolerated losartan daily doses with respect to CYP metabolic classes were assessed through the Kruskal-Wallis test.	Losartan	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
27474842-2	2016	Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite.	Losartan	38-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
27101231-1	2016	Objectives: To determine relations between drug concentrations and the cytochrome P450-CYP2D6 genotype or phenotype among elderly patients treated with nortriptyline or venlafaxine.	Nortriptyline	152-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-93
27171763-8	2016	Our results suggest that caution may be warranted when CYP-related co-medications are administered during sildenafil treatment for PH.	Sildenafil Citrate	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
27795624-2	2016	Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP).	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
27795624-2	2016	Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP).	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
27795624-3	2016	There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrates: amlodipine and metoprolol.	Rifampin	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
27795624-3	2016	There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrates: amlodipine and metoprolol.	Amlodipine	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
27795624-3	2016	There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrates: amlodipine and metoprolol.	Metoprolol	133-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
27101231-1	2016	Objectives: To determine relations between drug concentrations and the cytochrome P450-CYP2D6 genotype or phenotype among elderly patients treated with nortriptyline or venlafaxine.	Venlafaxine Hydrochloride	169-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-93
27251443-1	2016	Cytochrome P450 (CYP) enzymes play important roles in the metabolism of exogenous compounds such as polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	100-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27387538-5	2016	Of the CYP enzymes tested, CYP2B6-catalyzed bupropion 6-hydroxylation was inhibited by S002-333 (IC50 ~ 9.25 +- 2.46 muM) in a stereoselective manner with (S)-isomer showing potent inhibition (IC50 ~ 5.28 +- 1.25 muM) in contrast to (R)-isomer which showed negligible inhibition on CYP2B6 activity (IC50 &gt; 50 muM).	Bupropion	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27251443-1	2016	Cytochrome P450 (CYP) enzymes play important roles in the metabolism of exogenous compounds such as polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	100-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
27251443-1	2016	Cytochrome P450 (CYP) enzymes play important roles in the metabolism of exogenous compounds such as polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	134-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27251443-1	2016	Cytochrome P450 (CYP) enzymes play important roles in the metabolism of exogenous compounds such as polycyclic aromatic hydrocarbons (PAHs).	Polycyclic Aromatic Hydrocarbons	134-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26360322-0	2016	Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.	(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	66-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27516570-13	2016	Apart from hydrolytic degradation, endocannabinoids may also be oxidized by cyclooxygenase-2, lipoxygenases, and cytochrome P450.	Endocannabinoids	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
26360322-4	2016	This study extends previous studies by identifying the specific CYP enzymes involved in the metabolism of UR-144 and XLR-11 utilizing a panel of nine recombinant enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 3A4, and 2E1).	Urea	106-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
26360322-6	2016	Incubations of UR-144 and XLR-11 with recombinant CYP enzymes revealed that UR-144 and XLR-11 are extensively metabolized by CYP3A4 at the tetramethylcyclopropyl (TMCP) moiety, but also CYP1A2 and CYP2C19 showed activity.	Urea	15-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
26360322-6	2016	Incubations of UR-144 and XLR-11 with recombinant CYP enzymes revealed that UR-144 and XLR-11 are extensively metabolized by CYP3A4 at the tetramethylcyclopropyl (TMCP) moiety, but also CYP1A2 and CYP2C19 showed activity.	Urea	76-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27179126-9	2016	Dasabuvir was cleared mainly through cytochrome P450-mediated oxidation metabolism to M1.	dasabuvir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
27179126-12	2016	Cytochrome P450 profiling indicated that dasabuvir was mainly metabolized by CYP2C8, followed by CYP3A4.	dasabuvir	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26360322-6	2016	Incubations of UR-144 and XLR-11 with recombinant CYP enzymes revealed that UR-144 and XLR-11 are extensively metabolized by CYP3A4 at the tetramethylcyclopropyl (TMCP) moiety, but also CYP1A2 and CYP2C19 showed activity.	tmcp	163-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
26360322-7	2016	Inhibition of CYP3A4 in HLM attenuated the metabolism of UR-144 and XLR-11, while inhibition of the other CYP enzymes in HLM had only minor effects.	Urea	57-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
26360322-8	2016	Thus, CYP3A4 is the major contributor to the CYP mediated metabolism of UR-144 and XLR-11 with minor contributions from CYP1A2.	Urea	72-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Benzodiazepines	96-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27286171-1	2016	Polyunsaturated fatty acids (PUFAs) undergo cytochrome P450 (CYP)-dependent oxidation to epoxides that modulate important physiological functions, including vasoactivity, inflammation, nociception, proliferation and viability.	Fatty Acids, Unsaturated	0-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
27286171-1	2016	Polyunsaturated fatty acids (PUFAs) undergo cytochrome P450 (CYP)-dependent oxidation to epoxides that modulate important physiological functions, including vasoactivity, inflammation, nociception, proliferation and viability.	Fatty Acids, Unsaturated	0-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
27286171-1	2016	Polyunsaturated fatty acids (PUFAs) undergo cytochrome P450 (CYP)-dependent oxidation to epoxides that modulate important physiological functions, including vasoactivity, inflammation, nociception, proliferation and viability.	Epoxy Compounds	89-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
27286171-1	2016	Polyunsaturated fatty acids (PUFAs) undergo cytochrome P450 (CYP)-dependent oxidation to epoxides that modulate important physiological functions, including vasoactivity, inflammation, nociception, proliferation and viability.	Epoxy Compounds	89-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Benzodiazepines	96-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Benzodiazepines	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Benzodiazepines	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Carbamazepine	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Carbamazepine	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Carbamazepine	135-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Carbamazepine	135-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenytoin	141-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenytoin	141-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenytoin	152-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenytoin	152-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenobarbital	157-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenobarbital	157-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenobarbital	172-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Phenobarbital	172-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Valproic Acid	181-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Valproic Acid	181-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Valproic Acid	196-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27490534-3	2016	Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA).	Valproic Acid	196-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27490534-4	2016	The induction of CYP450 isoenzymes may cause vitamin D deficiency, hypocalcemia, increased fracture risks, and altered bone turnover, leading to impaired bone mineral density (BMD).	Vitamin D	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
27267697-1	2016	Cytochrome P450 (P450) enzymes are important in the metabolism of drugs, steroids, fat-soluble vitamins, carcinogens, pesticides, and many other types of chemicals.	Steroids	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27467145-1	2016	Although Plasmodium vivax relapses are classically associated with hypnozoite activation, it has been proposed that a proportion of these cases are due to primaquine (PQ) treatment failure caused by polymorphisms in cytochrome P-450 2D6 (CYP2D6).	Primaquine	155-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
27467145-1	2016	Although Plasmodium vivax relapses are classically associated with hypnozoite activation, it has been proposed that a proportion of these cases are due to primaquine (PQ) treatment failure caused by polymorphisms in cytochrome P-450 2D6 (CYP2D6).	Primaquine	167-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Cobicistat	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
27347790-0	2016	Effect of Cholesterol on the Interaction of Cytochrome P450 Substrate Drug Chlorzoxazone with the Phosphatidylcholine Bilayer.	Cholesterol	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
27347790-0	2016	Effect of Cholesterol on the Interaction of Cytochrome P450 Substrate Drug Chlorzoxazone with the Phosphatidylcholine Bilayer.	Chlorzoxazone	75-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
27347790-0	2016	Effect of Cholesterol on the Interaction of Cytochrome P450 Substrate Drug Chlorzoxazone with the Phosphatidylcholine Bilayer.	Phosphatidylcholines	98-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Cholesterol	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Chlorzoxazone	100-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Chlorzoxazone	115-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Phosphatidylcholines	154-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Phosphatidylcholines	175-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-6	2016	In this study, the cholesterol concentration dependence of the interaction of a CYP substrate drug, chlorzoxazone (CZX), with model membranes composed of phosphatidylcholine (PC) and cholesterol was examined via differential scanning calorimetry (DSC), UV-visible spectroscopy, and X-ray diffraction.	Cholesterol	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
27347790-11	2016	The low cholesterol contents (12-20 mol %) of ER membranes might be the most suitable for the CYP drug metabolism process in ER membranes.	Cholesterol	8-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
27185541-1	2016	The purpose of this work was to investigate the in vitro metabolism of nitracaine, a new psychoactive substance, using human liver microsome incubations, to evaluate the cytochrome P450 (CYP) enzyme isoforms responsible for the phase-I metabolism and to compare the information from the in vitro experiments with data resulting from an authentic user"s urine sample.	Nitracaine	71-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-185
27185541-1	2016	The purpose of this work was to investigate the in vitro metabolism of nitracaine, a new psychoactive substance, using human liver microsome incubations, to evaluate the cytochrome P450 (CYP) enzyme isoforms responsible for the phase-I metabolism and to compare the information from the in vitro experiments with data resulting from an authentic user"s urine sample.	Nitracaine	71-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	187-190
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Cobicistat	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Ritonavir	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Ritonavir	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
26945713-4	2016	Since cobicistat is a more selective CYP inhibitor than ritonavir and is devoid of enzyme-inducing properties, differences are expected in their interaction profiles with some co-medications.	Cobicistat	6-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
27212636-4	2016	The total cytochrome P450 activity was determined by measuring the transformation of 7-ethoxycoumarin.	7-ethoxycoumarin	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	epoxyeicosatrienoic acids	12-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	epoxyeicosatrienoic acids	12-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	eets	39-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	eets	39-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	Arachidonic Acid	104-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
27115337-1	2016	BACKGROUND: Epoxyeicosatrienoic acids (EETs) derived from cytochrome P450 (CYP)-dependent metabolism of arachidonic acid are increased in the plasma of women with preeclampsia as compared with normal pregnancy and are significantly higher in fetal than in maternal plasma and erythrocytes.	Arachidonic Acid	104-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
27113703-2	2016	To investigate the role of drug metabolism in this liver toxicity, amiodarone and its major metabolite desethylamiodarone were incubated with HepG2 cells overexpressing a series of cytochrome P450 (CYP) isoforms.	desethylamiodarone	103-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-201
26965288-8	2016	Leukotoxin levels correlated with goblet cell abundance (r=0.72; p=0.028).These findings suggest a mechanism by which goblet cell-associated cytochrome-P450 and sEH activity produce elevated leukotoxin-diol levels, which play a putative role in the clinical manifestations of COPD in a female-dominated disease sub-phenotype.	diol	202-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
27060436-2	2016	Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI).	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27060436-2	2016	Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI).	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27029743-4	2016	Cytochrome P450s were the main enzymes involved in the metabolism of daclatasvir.	daclatasvir	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26921441-1	2016	20-Hydroxyeicosatetraeonic acid (20-HETE) produced by cytochrome P-450 monooxygenases in NADPH-dependent manner is proinflammatory, and it contributes to the pathogenesis of systemic and pulmonary hypertension.	20-Hete	0-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	epoxyeicosatrienoic acids	72-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	eets	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	dihydroxyeicosatetraenoic acid	106-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	hydroxyeicosatetraeonic acid	141-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27100515-1	2016	Cytochrome P450s enzymes catalyze the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid and hydroxyeicosatetraeonic acid (HETEs).	Hydroxyeicosatetraenoic Acids	171-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	alpha-naphthoflavone	56-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Tranylcypromine	78-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Ticlopidine	95-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Fluconazole	108-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Quinidine	121-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Ketoconazole	132-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	1-abt	149-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
26921441-1	2016	20-Hydroxyeicosatetraeonic acid (20-HETE) produced by cytochrome P-450 monooxygenases in NADPH-dependent manner is proinflammatory, and it contributes to the pathogenesis of systemic and pulmonary hypertension.	20-Hete	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
26921441-1	2016	20-Hydroxyeicosatetraeonic acid (20-HETE) produced by cytochrome P-450 monooxygenases in NADPH-dependent manner is proinflammatory, and it contributes to the pathogenesis of systemic and pulmonary hypertension.	NADP	89-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
26921388-1	2016	Replacement of hydrogen with fluorine is a useful drug design strategy when decreases in cytochrome P450 (P450) metabolic lability are needed.	Hydrogen	15-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27265124-0	2016	Maintenance of High Cytochrome P450 Expression in HepaRG Cell Spheroids in DMSO-Free Medium.	Dimethyl Sulfoxide	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26921388-1	2016	Replacement of hydrogen with fluorine is a useful drug design strategy when decreases in cytochrome P450 (P450) metabolic lability are needed.	Fluorine	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	epoxyecosatrienoic acids	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	epoxyecosatrienoic acids	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	eets	26-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	eets	26-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	diols	225-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
27079253-3	2016	Epoxyecosatrienoic acids (EETs), the products of arachidonic acid metabolism mediated by cytochrome P450 (CYP) 2J, 2C and other isoforms, are regulated by soluble epoxide hydrolase (sEH)-catalyzed conversion into less active diols.	diols	225-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
26714750-7	2016	The activation of cytochrome P450 (CYP) enzymes in HepG2 cells grown on CBD-CAS-coated honeycomb collagen sponge was measured at the mRNA level and was found to increase between two and six times compared to cells grown without the CBD-CAS coating, showing that this culture system induced CYP gene expression and thus may be useful in drug metabolism assays.	cbd-cas	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
26969934-2	2016	It is bioactivated by cytochrome P450 (CYP) enzymes to reactive metabolites, which may further react with glutathione to form S-linked and N-linked conjugates.	Glutathione	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
26969934-2	2016	It is bioactivated by cytochrome P450 (CYP) enzymes to reactive metabolites, which may further react with glutathione to form S-linked and N-linked conjugates.	Glutathione	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
26969934-6	2016	Menthofuran was also incubated with recombinant human CYP enzymes and GSH to elucidate the CYPs responsible for the formation of the reactive metabolites.	menthofuran	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
26969934-9	2016	CYP1A2, 2B6 and 3A4 were observed to produce more GSH conjugates than other CYP isoforms.	Glutathione	50-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
27128896-0	2016	Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5"-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.	aschantin	22-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	4-hydroxy-N-desmethyltamoxifen	72-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	4-hydroxy-N-desmethyltamoxifen	72-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
26690878-0	2016	Mutating a Highly Conserved Residue in Diverse Cytochrome P450s Facilitates Diastereoselective Olefin Cyclopropanation.	Alkenes	95-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
26714750-7	2016	The activation of cytochrome P450 (CYP) enzymes in HepG2 cells grown on CBD-CAS-coated honeycomb collagen sponge was measured at the mRNA level and was found to increase between two and six times compared to cells grown without the CBD-CAS coating, showing that this culture system induced CYP gene expression and thus may be useful in drug metabolism assays.	cbd-cas	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
26714750-7	2016	The activation of cytochrome P450 (CYP) enzymes in HepG2 cells grown on CBD-CAS-coated honeycomb collagen sponge was measured at the mRNA level and was found to increase between two and six times compared to cells grown without the CBD-CAS coating, showing that this culture system induced CYP gene expression and thus may be useful in drug metabolism assays.	cbd-cas	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	290-293
26714750-7	2016	The activation of cytochrome P450 (CYP) enzymes in HepG2 cells grown on CBD-CAS-coated honeycomb collagen sponge was measured at the mRNA level and was found to increase between two and six times compared to cells grown without the CBD-CAS coating, showing that this culture system induced CYP gene expression and thus may be useful in drug metabolism assays.	cbd-cas	232-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
26714750-7	2016	The activation of cytochrome P450 (CYP) enzymes in HepG2 cells grown on CBD-CAS-coated honeycomb collagen sponge was measured at the mRNA level and was found to increase between two and six times compared to cells grown without the CBD-CAS coating, showing that this culture system induced CYP gene expression and thus may be useful in drug metabolism assays.	cbd-cas	232-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
26753974-3	2016	Metabolic efficiency of the mutant library towards a selection of CYP model substrates, being amitriptyline (AMI), buspirone (BUS), coumarine (COU), dextromethorphan (DEX), diclofenac (DIC) and norethisterone (NET), was investigated.	Amitriptyline	94-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
26633836-4	2016	However, VKAs can interfere with clopidogrel metabolism via the cytochrome P450 (CYP) system which in turn may result in an increase in platelet reactivity.	Clopidogrel	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26633836-4	2016	However, VKAs can interfere with clopidogrel metabolism via the cytochrome P450 (CYP) system which in turn may result in an increase in platelet reactivity.	Clopidogrel	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
26316040-11	2016	CYP polymorphisms may explain why there is wide variation in blood HCQ concentrations.	Hydroxychloroquine	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26658226-0	2016	Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes.	turinabol	19-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
26658226-0	2016	Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes.	Steroids	38-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
26658226-1	2016	The human mitochondrial cytochrome P450 enzymes CYP11A1, CYP11B1, and CYP11B2 are involved in the biosynthesis of steroid hormones.	Steroids	114-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
26727525-0	2016	Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity.	Ethanol	19-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
26727525-0	2016	Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity.	Darunavir	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
26727525-4	2016	METHODS: This study examined the chronic effects of EtOH and ART (darunavir/ritonavir), alone and in combination, on expression/levels of cytochrome P450 enzymes (CYPs), antioxidant enzymes (AOEs), reactive oxygen species (ROS), and cytotoxicity in U937 cells.	Ethanol	52-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
26727525-4	2016	METHODS: This study examined the chronic effects of EtOH and ART (darunavir/ritonavir), alone and in combination, on expression/levels of cytochrome P450 enzymes (CYPs), antioxidant enzymes (AOEs), reactive oxygen species (ROS), and cytotoxicity in U937 cells.	art	61-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
26727525-4	2016	METHODS: This study examined the chronic effects of EtOH and ART (darunavir/ritonavir), alone and in combination, on expression/levels of cytochrome P450 enzymes (CYPs), antioxidant enzymes (AOEs), reactive oxygen species (ROS), and cytotoxicity in U937 cells.	Darunavir	66-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
26727525-4	2016	METHODS: This study examined the chronic effects of EtOH and ART (darunavir/ritonavir), alone and in combination, on expression/levels of cytochrome P450 enzymes (CYPs), antioxidant enzymes (AOEs), reactive oxygen species (ROS), and cytotoxicity in U937 cells.	Ritonavir	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-153
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	142-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	142-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
25398514-2	2016	We have investigated the role of TP53 in cytochrome P450 (CYP)-mediated metabolic activation of three polycyclic aromatic hydrocarbons (PAHs) in a panel of isogenic colorectal HCT116 cells with differing TP53 status.	Polycyclic Aromatic Hydrocarbons	102-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
25398514-2	2016	We have investigated the role of TP53 in cytochrome P450 (CYP)-mediated metabolic activation of three polycyclic aromatic hydrocarbons (PAHs) in a panel of isogenic colorectal HCT116 cells with differing TP53 status.	Polycyclic Aromatic Hydrocarbons	102-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
25398514-2	2016	We have investigated the role of TP53 in cytochrome P450 (CYP)-mediated metabolic activation of three polycyclic aromatic hydrocarbons (PAHs) in a panel of isogenic colorectal HCT116 cells with differing TP53 status.	Polycyclic Aromatic Hydrocarbons	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
25398514-2	2016	We have investigated the role of TP53 in cytochrome P450 (CYP)-mediated metabolic activation of three polycyclic aromatic hydrocarbons (PAHs) in a panel of isogenic colorectal HCT116 cells with differing TP53 status.	Polycyclic Aromatic Hydrocarbons	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
26446141-1	2016	BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6.	Tamoxifen	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
26446141-1	2016	BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6.	Tamoxifen	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
26446141-1	2016	BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6.	4-hydroxy-N-desmethyltamoxifen	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
26446141-1	2016	BACKGROUND AND OBJECTIVE: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6.	4-hydroxy-N-desmethyltamoxifen	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
26820384-0	2016	Structure of OxyA tei: completing our picture of the glycopeptide antibiotic producing Cytochrome P450 cascade.	Glycopeptides	53-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
26820384-1	2016	Cyclization of glycopeptide antibiotic precursors occurs in either three or four steps catalyzed by Cytochrome P450 enzymes.	Glycopeptides	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	n-desethyl hcq	187-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-12	2016	The role of an individual"s CYP polymorphisms should be considered when prescribing oral HCQ.	Hydroxychloroquine	89-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	n-desethyl hcq	187-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	dhcq	203-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	dhcq	203-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	epoxyeicosatrienoic acids	55-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	epoxyeicosatrienoic acids	55-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	eets	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	eets	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	Arachidonic Acid	141-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	Arachidonic Acid	141-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	dihydroxyeicosatrienoic acids	173-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
27144772-1	2016	Soluble epoxide hydrolase (sEH) converts highly active epoxyeicosatrienoic acids (EETs) generated by cytochrome P450 (CYP) epoxygenases from arachidonic acid to less active dihydroxyeicosatrienoic acids.	dihydroxyeicosatrienoic acids	173-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
27280598-4	2016	OBJECTIVE: To investigate the effects of sodium fusidate on recombinant cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) in-vitro.	Fusidic Acid	41-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
27245908-1	2016	Cytochrome P450 enzymes are a large family of heme-containing proteins that have important functions in the biotransformation of xenobiotics, including pharmacologic and environmental agents, as well as of endogenously produced chemicals with broad structural and functional diversity.	Heme	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27642356-0	2016	Traditional Preparations and Methanol Extracts of Medicinal Plants from Papua New Guinea Exhibit Similar Cytochrome P450 Inhibition.	Methanol	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
27451096-1	2016	Endothelial and vascular smooth cells generate cytochrome P450 (CYP) arachidonic acid metabolites that can impact endothelial cell function and vascular homeostasis.	Arachidonic Acid	69-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
27451096-1	2016	Endothelial and vascular smooth cells generate cytochrome P450 (CYP) arachidonic acid metabolites that can impact endothelial cell function and vascular homeostasis.	Arachidonic Acid	69-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	Eicosanoids	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	Eicosanoids	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	Eicosanoids	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	epoxyeicosatrienoic acids	59-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	epoxyeicosatrienoic acids	59-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	epoxyeicosatrienoic acids	59-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	eets	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	eets	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	eets	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	Hydroxyeicosatetraenoic Acids	125-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
27451096-3	2016	The CYP pathway produces two types of eicosanoid products: epoxyeicosatrienoic acids (EETs), formed by CYP epoxygenases, and hydroxyeicosatetraenoic acids (HETEs), formed by CYP hydroxylases.	Hydroxyeicosatetraenoic Acids	156-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
27451096-4	2016	Advances in CYP enzymes, EETs, and 20-HETE by pharmacological and genetic means have led to a more complete understanding of how these eicosanoids impact on endothelial cell function.	Eicosanoids	135-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
28057170-1	2016	Purpose - The CEIBA cocktail consisting of caffeine (CAF), omeprazole (OZ), dextromethorphan (DM) and losartan (LOS) was previously proposed for the clinical phenotyping of five major human cytochrome P450 (CYP) isoenzymes.	ceiba cocktail	14-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
28057170-1	2016	Purpose - The CEIBA cocktail consisting of caffeine (CAF), omeprazole (OZ), dextromethorphan (DM) and losartan (LOS) was previously proposed for the clinical phenotyping of five major human cytochrome P450 (CYP) isoenzymes.	ceiba cocktail	14-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
26831703-0	2016	Facile Synthetic Access to Glycopeptide Antibiotic Precursor Peptides for the Investigation of Cytochrome P450 Action in Glycopeptide Antibiotic Biosynthesis.	Glycopeptides	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	Hydrocarbons, Cyclic	4-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26747234-0	2016	Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.	Eicosanoids	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26747234-1	2016	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
26747234-1	2016	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
26747234-1	2016	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke.	Eicosanoids	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
26747234-1	2016	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke.	Eicosanoids	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
26153439-11	2016	It was demonstrated that EWD or MXCT pretreatment obviously induced CYP1A2, therefore, in patients taking EWD or MXCT, possible CYP-induced drug interaction should be noted to decrease the risk of therapeutic failure or adverse effects resulting from the use of additional therapeutic agents.	mxct	32-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
26153439-11	2016	It was demonstrated that EWD or MXCT pretreatment obviously induced CYP1A2, therefore, in patients taking EWD or MXCT, possible CYP-induced drug interaction should be noted to decrease the risk of therapeutic failure or adverse effects resulting from the use of additional therapeutic agents.	mxct	113-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
27239927-3	2016	They initially received dual antiplatelet therapy: clopidogrel 75 mg + acetylsalicylic acid (ASA) 300 mg. Genetic testing was performed in all the patients to reveal the carriage of allelic variants of the genes of cytochrome P-450 isoenzymes and the efficiency of antiplatelet therapy was evaluated.	Clopidogrel	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-231
27239927-3	2016	They initially received dual antiplatelet therapy: clopidogrel 75 mg + acetylsalicylic acid (ASA) 300 mg. Genetic testing was performed in all the patients to reveal the carriage of allelic variants of the genes of cytochrome P-450 isoenzymes and the efficiency of antiplatelet therapy was evaluated.	Aspirin	71-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-231
27239927-3	2016	They initially received dual antiplatelet therapy: clopidogrel 75 mg + acetylsalicylic acid (ASA) 300 mg. Genetic testing was performed in all the patients to reveal the carriage of allelic variants of the genes of cytochrome P-450 isoenzymes and the efficiency of antiplatelet therapy was evaluated.	Aspirin	93-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-231
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	Polycyclic Aromatic Hydrocarbons	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	pyrene	36-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	1-hydroxypyrene	44-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	1-nitropyrene	61-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26247835-2	2016	The polycyclic hydrocarbons (PAHs), pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme.	1-Acetylpyrene	79-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-177
26756638-3	2015	Two lesser-known enzymatic pathways of arachidonic acid metabolism are the lipoxygenase (LO) and cytochrome P450 (CYP) pathways.	Arachidonic Acid	39-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
25659768-6	2015	After 14 days, Amiodarone major oxidative metabolite (mono-N-desethylamiodarone) was detected at limited levels, indicating the presence of active drug metabolism enzymes (i.e. cytochrome P450) in both models.	mono-N-desethylamiodarone	54-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-192
26756638-3	2015	Two lesser-known enzymatic pathways of arachidonic acid metabolism are the lipoxygenase (LO) and cytochrome P450 (CYP) pathways.	Arachidonic Acid	39-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
26756638-6	2015	Proximal and distal tubular sodium transport and fluid and electrolyte homeostasis are also significantly influenced by renal CYP and LO levels.	Sodium	28-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aristolochic acid I	80-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26627649-0	2015	Small-angle scattering determination of the shape and localization of human cytochrome P450 embedded in a phospholipid nanodisc environment.	Phospholipids	106-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
27747722-10	2015	CONCLUSION: The close relationship between diclofenac and pantoprazole, and the cytochrome P450 and P-glycoprotein systems offers a strong indication that a drug interaction may be occurring.	Diclofenac	43-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
26481538-0	2015	Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.	phenothiazine	52-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26481538-0	2015	Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.	Methotrimeprazine	78-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26481538-2	2015	The present study was aimed at examining the inhibitory effect of the phenothiazine neuroleptic levomepromazine on main CYP isoenzymes in human liver.	phenothiazine	70-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
26481538-2	2015	The present study was aimed at examining the inhibitory effect of the phenothiazine neuroleptic levomepromazine on main CYP isoenzymes in human liver.	Methotrimeprazine	96-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Caffeine	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Diclofenac	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Diclofenac	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Perazine	150-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	bufuralol	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26481538-4	2015	CYP isoenzyme activities were determined using the CYP-specific reactions: caffeine 3-N-demethylation (CYP1A2), diclofenac 4"-hydroxylation (CYP2C9), perazine N-demethylation (CYP2C19), bufuralol 1"-hydroxylation (CYP2D6) and testosterone 6beta-hydroxylation (CYP3A4).	Testosterone	226-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26481538-5	2015	The rates of the CYP-specific reactions were assessed in the absence and presence of levomepromazine (1-50 muM).	Methotrimeprazine	85-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aristolochic acid I	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aristolochic acid I	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	8-hydroxyaristolochic acid i	71-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	8-hydroxyaristolochic acid i	71-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
26396054-2	2015	The objective of the current study was to evaluate the acute and short-term effects of walnut intake on changes in microvascular function and the relationship of these effects to plasma epoxides, the cytochrome-P450-derived metabolites of fatty acids.	Epoxy Compounds	186-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-215
27182450-0	2015	CYP-epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells against LPS-induced cytotoxicity Through SIRT1.	Docosahexaenoic Acids	31-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	Docosahexaenoic Acids	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	Docosahexaenoic Acids	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	epoxydocosapentaenoic acids	87-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	epoxydocosapentaenoic acids	87-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	edps	116-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	edps	116-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	Docosahexaenoic Acids	189-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27182450-5	2015	Emerging evidence indicates that cytochrome P450 (CYP) epoxygenase metabolites of DHA, epoxydocosapentaenoic acids (EDPs), produce more potent biological activity compared to its precursor DHA.	Docosahexaenoic Acids	189-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27182450-8	2015	Our results illustrate the CYP epoxygenase metabolite of DHA, 19,20-EDP, confers extensive protection to HL-1 cardiac cells against LPS-induced cytotoxicity via activation of SIRT1.	Docosahexaenoic Acids	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
27182450-8	2015	Our results illustrate the CYP epoxygenase metabolite of DHA, 19,20-EDP, confers extensive protection to HL-1 cardiac cells against LPS-induced cytotoxicity via activation of SIRT1.	19(20)-EpDPE	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aristolochic acid I	80-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aaia	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26593908-2	2015	AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa).	aaia	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
26593908-9	2015	We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation.	aristolochic acid I	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
26593908-10	2015	Our results indicate that utilization of experimental and theoretical methods is an appropriate study design to examine the CYP-catalyzed reaction mechanisms of AAI oxidation and contributions of human hepatic CYPs to this metabolism.	aristolochic acid I	161-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
26276083-0	2015	Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps.	lephetamine	18-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
26443405-9	2015	CYP2D6 and CYP3A4 played an important role in the isomerization and glycination of limonoids in HLMs, whereas other CYP isoforms were considerably less active.	Limonins	83-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26452461-7	2015	Cytochrome P450 activity was delivered into Human cervix carcinoma cells via transfecting P22-CYP nanoparticles with lipofectamine.	Lipofectamine	117-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26318115-2	2015	Paraoxonase-1 (PON1), butyrylcholinesterase (BChE) and Cytochrome-P450 constitute major classes of XME involved in the detoxification of pesticide chemicals, in particular organophosphates.	XME	99-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
26318115-2	2015	Paraoxonase-1 (PON1), butyrylcholinesterase (BChE) and Cytochrome-P450 constitute major classes of XME involved in the detoxification of pesticide chemicals, in particular organophosphates.	Organophosphates	172-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
25940755-3	2015	CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9).	Midazolam	55-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25940755-3	2015	CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9).	Omeprazole	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25940755-3	2015	CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9).	5-hydroxyomeprazol	85-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25940755-3	2015	CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9).	Losartan	134-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25940755-3	2015	CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9).	losartan carboxylic acid	143-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26220948-0	2015	Human Liver Cytochrome P450 Enzymes and Microsomal Thiol Methyltransferase Are Involved in the Stereoselective Formation and Methylation of the Pharmacologically Active Metabolite of Clopidogrel.	Clopidogrel	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
26350273-2	2015	Hydrocodone undergoes cytochrome P-450 (CYP)-mediated metabolism involving the CYP3A4 and CYP2D6 isozymes.	Hydrocodone	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
26350273-2	2015	Hydrocodone undergoes cytochrome P-450 (CYP)-mediated metabolism involving the CYP3A4 and CYP2D6 isozymes.	Hydrocodone	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
26214067-0	2015	Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation.	Arachidonic Acid	30-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Toremifene	102-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Toremifene	102-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Toremifene	102-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	271-274
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Toremifene	102-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	271-274
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	n-desmethyl	109-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	n-desmethyl	109-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	ndm	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	ndm	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Estetrol	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Estetrol	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Estetrol	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Estetrol	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26423799-3	2015	In this study, we examined the role of individual cytochrome P450 (CYP) isoforms in the metabolism of TOR to N-desmethyl (NDM), 4-hydroxy (4OH) and 4OH-NDM metabolites in comparison with TAM using human liver microsomes (HLMs) with selective chemical inhibitors for each CYP isoform and recombinant CYP proteins.	Tamoxifen	187-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
26214067-1	2015	BACKGROUND: Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft.	Arachidonic Acid	12-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
26214067-1	2015	BACKGROUND: Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft.	Arachidonic Acid	12-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
26214067-1	2015	BACKGROUND: Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft.	epoxyeicosatrienoic acids	116-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
26214067-1	2015	BACKGROUND: Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft.	epoxyeicosatrienoic acids	116-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
26100226-0	2015	Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.	licochalcone A	47-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26106235-0	2015	Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450.	Benzbromarone	31-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
26135009-3	2015	In this study we assessed the perpetrator potential of desloratadine based on in vitro studies of its inhibitory effects on cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes (HLM).	desloratadine	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
26336590-0	2015	Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay.	Mesalamine	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26336590-0	2015	Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay.	mosapride	78-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
25920956-5	2015	Patients were genotyped for polymorphic variants and cytochrome P450 (CYP)-eicosanoid CSF levels were measured over 14 days.	Eicosanoids	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
26163112-0	2015	Role of cytochrome P450 and UDP-glucuronosyltransferases in metabolic pathway of homoegonol in human liver microsomes.	homoegonol	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Irinotecan	272-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Irinotecan	272-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Fluorouracil	284-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Fluorouracil	284-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Leucovorin	304-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	Leucovorin	304-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	FOLFIRI regimen	316-323	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
25934339-1	2015	The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).	FOLFIRI regimen	316-323	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
25934339-2	2015	All SNPs in CYP450, whose minor allele frequency were more than 10 %, were genotyped in 82 patients with mCRC who received first-line FOLFIRI regimen.	FOLFIRI regimen	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-18
26157146-8	2015	Previous studies showed that human cytochrome P450 (P450) 2D6 can catalyze thebaine O(3)-demethylation.	Thebaine	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-61
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
26489070-5	2015	On the other hand, dosage adjustments may be required when vortioxetine is coadministered with strong CYP2D6 inhibitors or broad-spectrum CYP inducers.	Vortioxetine	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	4'-hydroxytamoxifen	173-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	4'-hydroxytamoxifen	173-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	4-hydroxy-N-desmethyltamoxifen	197-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
25940823-3	2015	Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen.	4-hydroxy-N-desmethyltamoxifen	197-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
26015560-7	2015	In an in vitro cytochrome P450 (CYP) panel, cabozantinib and EXEL-1644 both inhibited most potently CYP2C8 (Kiapp = 4.6 and 1.1 microM, respectively).	cabozantinib	44-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
26015560-7	2015	In an in vitro cytochrome P450 (CYP) panel, cabozantinib and EXEL-1644 both inhibited most potently CYP2C8 (Kiapp = 4.6 and 1.1 microM, respectively).	cabozantinib	44-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
26015560-7	2015	In an in vitro cytochrome P450 (CYP) panel, cabozantinib and EXEL-1644 both inhibited most potently CYP2C8 (Kiapp = 4.6 and 1.1 microM, respectively).	UNII-NI7FZ38DO2	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
26015560-7	2015	In an in vitro cytochrome P450 (CYP) panel, cabozantinib and EXEL-1644 both inhibited most potently CYP2C8 (Kiapp = 4.6 and 1.1 microM, respectively).	UNII-NI7FZ38DO2	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
26163112-4	2015	We characterized the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes responsible for homoegonol metabolism using human liver microsomes, and cDNA-expressed CYP and UGT enzymes.	homoegonol	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26163112-4	2015	We characterized the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes responsible for homoegonol metabolism using human liver microsomes, and cDNA-expressed CYP and UGT enzymes.	homoegonol	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
26622646-10	2015	Additional large-scale studies are required in order to evaluate the role of CYP enzymes in bortezomib treatments for patients with multiple myeloma.	Bortezomib	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
26104032-2	2015	Pharmacokinetic studies show that pitavastatin is carried into the liver by a range of transporters and is minimally metabolized by cytochrome P450 in healthy volunteers, indicating a reduced potential for drug-drug interactions (DDIs).	pitavastatin	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-147
25808545-6	2015	Differentiated cells produce albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes, while demonstrating an 8-fold induction of CYP450 activity in response to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR agonist rifampicin.	Omeprazole	226-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-161
26181717-0	2015	The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation.	5-amino levulinic acid	14-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
26181717-4	2015	We hypothesized that the addition of 5-aminolevulinic acid (ALA), a precursor in the porphyrin biosynthetic pathway, enhances the synthesis of heme, leading to the up-regulation of CYP activity.	5-amino levulinic acid	37-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
26181717-4	2015	We hypothesized that the addition of 5-aminolevulinic acid (ALA), a precursor in the porphyrin biosynthetic pathway, enhances the synthesis of heme, leading to the up-regulation of CYP activity.	5-amino levulinic acid	60-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
26181717-4	2015	We hypothesized that the addition of 5-aminolevulinic acid (ALA), a precursor in the porphyrin biosynthetic pathway, enhances the synthesis of heme, leading to the up-regulation of CYP activity.	Porphyrins	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
26181717-4	2015	We hypothesized that the addition of 5-aminolevulinic acid (ALA), a precursor in the porphyrin biosynthetic pathway, enhances the synthesis of heme, leading to the up-regulation of CYP activity.	Heme	143-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
26181717-7	2015	We show here that ALA increased CYP2A6-dependent tegafur activation, suggesting that ALA elevated CYP activity and potentiated the activation of the prodrug.	5-amino levulinic acid	18-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
26181717-7	2015	We show here that ALA increased CYP2A6-dependent tegafur activation, suggesting that ALA elevated CYP activity and potentiated the activation of the prodrug.	5-amino levulinic acid	85-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
25808545-6	2015	Differentiated cells produce albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes, while demonstrating an 8-fold induction of CYP450 activity in response to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR agonist rifampicin.	Rifampin	288-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-161
26056268-3	2015	Here we identified the cytochrome P450 gene CYP4F22 (cytochrome P450, family 4, subfamily F, polypeptide 22) as the long-sought fatty acid omega-hydroxylase gene required for acylceramide production.	acylceramide	175-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-78
25986600-2	2015	Their antihypertensive action may be due to the reduction of the omega-6/omega-3 ratio and the resulting competitive effect of omega-3 as compared to arachidonic acid (an omega-6 PUFA) as a substrate of cytochrome P450 (CYP450) enzymes involved in the production of vasoactive mediators.	omega-3	127-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	203-218
25986600-2	2015	Their antihypertensive action may be due to the reduction of the omega-6/omega-3 ratio and the resulting competitive effect of omega-3 as compared to arachidonic acid (an omega-6 PUFA) as a substrate of cytochrome P450 (CYP450) enzymes involved in the production of vasoactive mediators.	omega-3	127-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	220-226
25834924-5	2015	Mechanisms through which omega-3 FA act are manifolds and still a matter of investigation: beside their interaction with ion channel and their influence on plasma membrane fluidity, probably the main effect is acting as competitor for cytochrome P-450 (CYP) with respect to omega-6 FA.	omega-6 fa	274-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
25834924-5	2015	Mechanisms through which omega-3 FA act are manifolds and still a matter of investigation: beside their interaction with ion channel and their influence on plasma membrane fluidity, probably the main effect is acting as competitor for cytochrome P-450 (CYP) with respect to omega-6 FA.	omega-6 fa	274-284	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-256
25862215-0	2015	Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.	Lisdexamfetamine Dimesylate	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
26042637-1	2015	The remarkable aliphatic C-H hydroxylations catalyzed by the heme-containing enzyme, cytochrome P450, have attracted sustained attention for more than four decades.	Heme	61-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
26047326-0	2015	All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.	Tretinoin	10-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
26082767-3	2015	We have recently shown the possible role of cytochrome P450 (CYP) in smoking/nicotine-mediated viral replication.	Nicotine	77-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
26082767-3	2015	We have recently shown the possible role of cytochrome P450 (CYP) in smoking/nicotine-mediated viral replication.	Nicotine	77-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
26082767-4	2015	In this review, we focus on the potential role of CYP pathway in polycyclic aromatic hydrocarbons (PAH), important constituents of cigarette smoke, mediated HIV pathogenesis.	Polycyclic Aromatic Hydrocarbons	65-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
26082767-4	2015	In this review, we focus on the potential role of CYP pathway in polycyclic aromatic hydrocarbons (PAH), important constituents of cigarette smoke, mediated HIV pathogenesis.	Polycyclic Aromatic Hydrocarbons	99-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
26082767-5	2015	More specifically, we will discuss the role of CYP1A1 and CYP1B1, which are the major PAH-activating CYP enzymes.	Polycyclic Aromatic Hydrocarbons	86-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
25862215-1	2015	INTRODUCTION: This open-label, randomized, two-period drug interaction study assessed lisdexamfetamine dimesylate (LDX) effects on cytochrome P450 (CYP) enzyme (CYP1A2, CYP2D6, CYP2C19, and CYP3A) activity.	Lisdexamfetamine Dimesylate	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
25862215-1	2015	INTRODUCTION: This open-label, randomized, two-period drug interaction study assessed lisdexamfetamine dimesylate (LDX) effects on cytochrome P450 (CYP) enzyme (CYP1A2, CYP2D6, CYP2C19, and CYP3A) activity.	Lisdexamfetamine Dimesylate	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
25808509-0	2015	Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy.	Ropivacaine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-21
25850753-1	2015	Tacrolimus is prescribed to prevent allograft rejection in pediatric liver transplant recipients; however, its metabolism through the cytochrome P-450 enzyme system presents a multitude of challenges in regard to drug interactions.	Tacrolimus	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
25897563-7	2015	According to the results obtained in the heterogeneous process, Cu4CuP3S mimicked the activity of cytochrome P-450 and catecholase.	cu4cup3s	64-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-130
25603423-3	2015	In addition, many tumors over-express cyclooxygenase, lipoxygenase or cytochrome P450 enzymes that mediate the biotransformation of omega-6 polyunsaturated fatty acids (PUFAs) to potent eicosanoid regulators of tumor cell proliferation and cell death.	omega-6 polyunsaturated fatty acids	132-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
25603423-3	2015	In addition, many tumors over-express cyclooxygenase, lipoxygenase or cytochrome P450 enzymes that mediate the biotransformation of omega-6 polyunsaturated fatty acids (PUFAs) to potent eicosanoid regulators of tumor cell proliferation and cell death.	Fatty Acids, Unsaturated	169-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
25603423-3	2015	In addition, many tumors over-express cyclooxygenase, lipoxygenase or cytochrome P450 enzymes that mediate the biotransformation of omega-6 polyunsaturated fatty acids (PUFAs) to potent eicosanoid regulators of tumor cell proliferation and cell death.	Eicosanoids	186-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
25808509-1	2015	BACKGROUND: Ropivacaine is frequently used for local anesthesia in the clinic and is metabolized by cytochrome P450 (CYP450) in the liver.	Ropivacaine	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
25808509-1	2015	BACKGROUND: Ropivacaine is frequently used for local anesthesia in the clinic and is metabolized by cytochrome P450 (CYP450) in the liver.	Ropivacaine	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
25808509-3	2015	In this study, we selected six CYP450 polymorphisms from the dbSNP and HapMap databases, using a combination of functional analysis and Tag SNP strategies and examined these polymorphisms for association with the efficacy of epidural ropivacaine in patients during mastectomy.	Ropivacaine	234-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-37
25677220-1	2015	Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) enzymes for its cytotoxicity.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Thromboxane A2	148-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Thromboxane A2	148-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Thromboxane A2	164-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Thromboxane A2	164-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Prostaglandin H2	199-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Prostaglandin H2	199-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Prostaglandin H2	217-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
25900452-1	2015	Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the isomerization of prostaglandin H2 (PGH2).	Prostaglandin H2	217-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25677220-1	2015	Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) enzymes for its cytotoxicity.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
25677220-1	2015	Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) enzymes for its cytotoxicity.	Cyclophosphamide	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
25677220-1	2015	Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) enzymes for its cytotoxicity.	Cyclophosphamide	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
25585969-6	2015	RESULTS: Pharmacogenetic testing revealed a relation between this adverse event and an allelic variant of cytochrome P450, CYP2C9, subsequently leading to discontinuation of the drug along with counseling to caution the patient to avoid the use of celecoxib and other drugs metabolized by the same enzyme.	Celecoxib	248-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
25515945-1	2015	Voriconazole is frequently utilized for the prevention and treatment of invasive fungal infections (IFIs), and is extensively metabolized by the cytochrome P450 (CYP) system.	Voriconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
25470432-0	2015	Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes.	Metronidazole	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
25470432-12	2015	We also found that MTZ use may alter the disposition of drugs metabolized by the CYP isozymes investigated.	Metronidazole	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
25793416-1	2015	Cytochrome P450 enzymes are renowned for their ability to insert oxygen into an enormous variety of compounds with a high degree of chemo- and regio-selectivity under mild conditions.	Oxygen	65-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
25515945-1	2015	Voriconazole is frequently utilized for the prevention and treatment of invasive fungal infections (IFIs), and is extensively metabolized by the cytochrome P450 (CYP) system.	Voriconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
25162212-1	2015	BACKGROUND: Tacrolimus (TAC) is a known substrate for cytochrome P450 (CYP) enzyme.	Tacrolimus	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
25162212-1	2015	BACKGROUND: Tacrolimus (TAC) is a known substrate for cytochrome P450 (CYP) enzyme.	Tacrolimus	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
25658971-2	2015	This study presents density functional theory calculations of the CYP-mediated metabolism of acetaminophen and a series of related compounds that can form reactive metabolites by hydrogen abstraction.	Acetaminophen	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
25658971-2	2015	This study presents density functional theory calculations of the CYP-mediated metabolism of acetaminophen and a series of related compounds that can form reactive metabolites by hydrogen abstraction.	Hydrogen	179-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
29560240-1	2015	Cytochrome P450 enzymes are heme based monoxygenases that catalyse a range of oxygen atom transfer reactions with various substrates, including aliphatic and aromatic hydroxylation as well as epoxidation reactions.	Oxygen	42-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
25642975-0	2015	Oxidation of Acenaphthene and Acenaphthylene by Human  Cytochrome P450 Enzymes.	acenaphthene	13-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
25642975-0	2015	Oxidation of Acenaphthene and Acenaphthylene by Human  Cytochrome P450 Enzymes.	acenaphthylene	30-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
25253429-0	2015	MDR1 and cytochrome P450 gene-expression profiles as markers of chemosensitivity in human chronic myelogenous leukemia cells treated with cisplatin and Ru(III) metallocomplexes.	Cisplatin	138-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
25253429-0	2015	MDR1 and cytochrome P450 gene-expression profiles as markers of chemosensitivity in human chronic myelogenous leukemia cells treated with cisplatin and Ru(III) metallocomplexes.	ru(iii)	152-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
25388680-2	2015	We investigated the relationship between polymorphic genes involved in EET biosynthesis/metabolism, cytochrome P450 (CYP) eicosanoid levels, and outcomes in 363 patients with aneurysmal subarachnoid hemorrhage (aSAH).	Eicosanoids	122-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-120
26002730-2	2015	CYP enzymes catalyze monooxygenation reactions by inserting one oxygen atom from O2 into an enormous number and variety of substrates.	Oxygen	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25533794-7	2015	Among CYP isoforms, CYP2E1 activity was selectively inhibited by MDGA through a competitive inhibitory mode, with an inhibitory constant (Ki) value of 13.1 microM.	dihydroguaiaretic acid	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
25636872-0	2015	Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship.	maslinic acid	58-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
25448283-0	2015	Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.	Cyclophosphamide	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
25448283-0	2015	Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.	Ifosfamide	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	18-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	18-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Ifosfamide	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Ifosfamide	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Ifosfamide	39-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
25448283-1	2015	Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes.	Ifosfamide	39-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
25448283-3	2015	Gene-directed enzyme prodrug therapies (GDEPT) have been suggested to facilitate local CPA and IFA bioactivation by expressing CYP enzymes within the tumor cells, thereby increasing efficacy.	Cyclophosphamide	87-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
25448283-4	2015	We screened bacterial CYP BM3 mutants, previously engineered to metabolize drug-like compounds, for their ability to catalyze 4-hydroxylation of CPA and IFA.	Cyclophosphamide	145-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25448283-4	2015	We screened bacterial CYP BM3 mutants, previously engineered to metabolize drug-like compounds, for their ability to catalyze 4-hydroxylation of CPA and IFA.	Ifosfamide	153-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
25448283-5	2015	Two CYP BM3 mutants showed very rapid initial bioactivation of CPA and IFA, followed by a slower phase of product formation.	Cyclophosphamide	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
25448283-7	2015	Using purified CYP BM3 as an extracellular bioactivation tool, cytotoxicity of CPA and IFA metabolism was confirmed in U2OS cells.	Cyclophosphamide	79-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
25448283-9	2015	To our knowledge, the observed rate of CPA and IFA 4-hydroxylation by these CYP BM3 mutants is the fastest reported to date, and might be of potential interest for CPA and IFA GDEPT.	Cyclophosphamide	39-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
25448283-9	2015	To our knowledge, the observed rate of CPA and IFA 4-hydroxylation by these CYP BM3 mutants is the fastest reported to date, and might be of potential interest for CPA and IFA GDEPT.	Cyclophosphamide	164-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
26002730-2	2015	CYP enzymes catalyze monooxygenation reactions by inserting one oxygen atom from O2 into an enormous number and variety of substrates.	Oxygen	81-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-3	2015	The catalytic versatility of CYP stems from its ability to functionalize unactivated carbon-hydrogen (C-H) bonds of substrates through monooxygenation.	hydrogen carbon	85-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
26002730-5	2015	CYP-mediated hydroxylations occur via a consensus H atom abstraction/oxygen rebound mechanism involving an initial abstraction by CpdI of a H atom from the substrate, generating a highly-reactive protonated Compound II (CpdII) intermediate (FeIV-OH) and a carbon-centered alkyl radical that rebounds onto the ferryl hydroxyl moiety to yield the hydroxylated substrate.	Oxygen	69-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-5	2015	CYP-mediated hydroxylations occur via a consensus H atom abstraction/oxygen rebound mechanism involving an initial abstraction by CpdI of a H atom from the substrate, generating a highly-reactive protonated Compound II (CpdII) intermediate (FeIV-OH) and a carbon-centered alkyl radical that rebounds onto the ferryl hydroxyl moiety to yield the hydroxylated substrate.	feiv-oh	241-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26233909-4	2015	CYP4F3A in myeloid tissue catalyzes the omega-hydroxylation of leukotriene B4 to 20-hydroxy leukotriene B4, an inactivation process that is critical for the regulation of the inflammatory response.	Leukotrienes	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
26233909-4	2015	CYP4F3A in myeloid tissue catalyzes the omega-hydroxylation of leukotriene B4 to 20-hydroxy leukotriene B4, an inactivation process that is critical for the regulation of the inflammatory response.	5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid	81-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
26233910-2	2015	Some cytochrome P450 (CYP) enzymes play key roles in bile acid synthesis.	Bile Acids and Salts	53-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-20
26233903-0	2015	Involvement of Cytochrome P450 in Reactive Oxygen Species Formation and Cancer.	Reactive Oxygen Species	34-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
26233903-1	2015	This review examines the involvement of cytochrome P450 (CYP) enzymes in the formation of reactive oxygen species in biological systems and discusses the possible involvement of reactive oxygen species and CYP enzymes in cancer.	Reactive Oxygen Species	90-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
26233903-1	2015	This review examines the involvement of cytochrome P450 (CYP) enzymes in the formation of reactive oxygen species in biological systems and discusses the possible involvement of reactive oxygen species and CYP enzymes in cancer.	Reactive Oxygen Species	90-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
26233910-2	2015	Some cytochrome P450 (CYP) enzymes play key roles in bile acid synthesis.	Bile Acids and Salts	53-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
26002730-5	2015	CYP-mediated hydroxylations occur via a consensus H atom abstraction/oxygen rebound mechanism involving an initial abstraction by CpdI of a H atom from the substrate, generating a highly-reactive protonated Compound II (CpdII) intermediate (FeIV-OH) and a carbon-centered alkyl radical that rebounds onto the ferryl hydroxyl moiety to yield the hydroxylated substrate.	Carbon	256-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26233903-1	2015	This review examines the involvement of cytochrome P450 (CYP) enzymes in the formation of reactive oxygen species in biological systems and discusses the possible involvement of reactive oxygen species and CYP enzymes in cancer.	Reactive Oxygen Species	178-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
26233903-3	2015	Two endogenous sources of reactive oxygen species are the mammalian CYP-dependent microsomal electron transport system and the mitochondrial electron transport chain.	Reactive Oxygen Species	26-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
26233903-4	2015	CYP enzymes catalyze the oxygenation of an organic substrate and the simultaneous reduction of molecular oxygen.	Oxygen	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26233905-3	2015	In polychemotherapy, prodrugs (like ifosfamide), which have to be activated by cytochrome P450 enzymes (CYPs), play an important role.	Ifosfamide	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
26002730-5	2015	CYP-mediated hydroxylations occur via a consensus H atom abstraction/oxygen rebound mechanism involving an initial abstraction by CpdI of a H atom from the substrate, generating a highly-reactive protonated Compound II (CpdII) intermediate (FeIV-OH) and a carbon-centered alkyl radical that rebounds onto the ferryl hydroxyl moiety to yield the hydroxylated substrate.	centered alkyl radical	263-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	Hydrogen Peroxide	20-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	peracids	36-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	perborate	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	sodium percarbonate	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	metaperiodate	71-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	chlorite	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	iodosobenzene	92-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26394652-0	2015	Cytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica.	decursin	59-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	n-oxides	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	Oxygen	132-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	Pyranocoumarins	65-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26002730-6	2015	CYP enzymes utilize hydroperoxides, peracids, perborate, percarbonate, periodate, chlorite, iodosobenzene and N-oxides as surrogate oxygen atom donors to oxygenate substrates via the shunt pathway in the absence of NAD(P)H/O2 and reduction-oxidation (redox) auxiliary proteins.	Oxygen	223-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	Pyranocoumarins	65-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	Pyranocoumarins	65-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
26002734-1	2015	Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations.	Alkenes	261-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26002734-1	2015	Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations.	Alkenes	261-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	110-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	110-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	110-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
26002734-1	2015	Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations.	arene	272-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	decursin	89-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
26002734-1	2015	Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations.	arene	272-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
26002735-0	2015	Cytochrome p450 enzymes in the bioactivation of polyunsaturated Fatty acids and their role in cardiovascular disease.	Fatty Acids, Unsaturated	48-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	doh	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26002735-1	2015	Various members of the cytochrome P450 (CYP) superfamily have the capacity of metabolizing omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs).	omega-6	91-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	doh	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	doh	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
26002735-1	2015	Various members of the cytochrome P450 (CYP) superfamily have the capacity of metabolizing omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs).	omega-6	91-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	doh	239-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
26002735-1	2015	Various members of the cytochrome P450 (CYP) superfamily have the capacity of metabolizing omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs).	omega-3 polyunsaturated fatty acids	103-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
26394652-1	2015	We have shown that the in vitro hepatic microsomal metabolism of pyranocoumarin compound decursinol angelate (DA) to decursinol (DOH) exclusively requires cytochrome P450 (CYP) enzymes, whereas the conversion of its isomer decursin (D) to DOH can be mediated by CYP and esterase(s).	doh	239-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
26002735-1	2015	Various members of the cytochrome P450 (CYP) superfamily have the capacity of metabolizing omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs).	omega-3 polyunsaturated fatty acids	103-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
26002735-3	2015	The individual CYP enzymes differ in their substrate specificities as well as regio- and stereoselectivities and thus produce distinct sets of epoxy and/or hydroxy metabolites, collectively termed CYP eicosanoids.	Eicosanoids	201-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
26002735-3	2015	The individual CYP enzymes differ in their substrate specificities as well as regio- and stereoselectivities and thus produce distinct sets of epoxy and/or hydroxy metabolites, collectively termed CYP eicosanoids.	Eicosanoids	201-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	Testosterone	189-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
26002735-4	2015	Nutrition has a major impact on the endogenous CYP-eicosanoid profile.	Eicosanoids	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	Testosterone	189-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
26002735-6	2015	In general, CYP eicosanoids are formed as second messengers of numerous hormones, growth factors and cytokines regulating cardiovascular and renal function, and a variety of other physiological processes.	Eicosanoids	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	6 beta-hydroxytestosterone	205-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	6 beta-hydroxytestosterone	205-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	Ketoconazole	270-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
25864949-7	2015	The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.	Ketoconazole	270-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
26002735-7	2015	Imbalances in the formation of individual CYP eicosanoids are linked to the development of hypertension, myocardial infarction, maladaptive cardiac hypertrophy, acute kidney injury, stroke and inflammatory disorders.	Eicosanoids	46-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
25336106-6	2015	Among the cells tested, HepG2 cells were highly responsive to CYP inducers, such as 3-methylcholanthrene for CYP1A2 and phenobarbital for CYP2B6 and CYP3A4.	Methylcholanthrene	84-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
25336106-6	2015	Among the cells tested, HepG2 cells were highly responsive to CYP inducers, such as 3-methylcholanthrene for CYP1A2 and phenobarbital for CYP2B6 and CYP3A4.	Phenobarbital	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
26357656-2	2015	In order to investigate the effects of MGCD0103 on the metabolic capacity of cytochrome P450 (CYP) enzymes, a cocktail method was employed to evaluate the activities of human CYP2B1, CYP1A2, CYP2C11, CYP2D6, CYP3A4, and CYP2C9.	mocetinostat	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
26357656-2	2015	In order to investigate the effects of MGCD0103 on the metabolic capacity of cytochrome P450 (CYP) enzymes, a cocktail method was employed to evaluate the activities of human CYP2B1, CYP1A2, CYP2C11, CYP2D6, CYP3A4, and CYP2C9.	mocetinostat	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
25417047-1	2015	PURPOSE: Imatinib is a substrate of drug transporters and metabolizing enzymes, including members of the cytochrome P450 (CYP) system.	Imatinib Mesylate	9-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
25417047-1	2015	PURPOSE: Imatinib is a substrate of drug transporters and metabolizing enzymes, including members of the cytochrome P450 (CYP) system.	Imatinib Mesylate	9-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
26467069-3	2015	In particular, flavonoids could interfere with statins" bioavailability through different mechanisms, such as competition with cytochrome P450 (CYP) enzymes, esterases, uridine diphosphate glucuronosyltransferases and transporters (P-glycoprotein, multi-drug resistance-associated proteins, organic anion transporting polypeptides, breast cancer-resistance protein and monocarboxylate transporters).	Flavonoids	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
26467069-3	2015	In particular, flavonoids could interfere with statins" bioavailability through different mechanisms, such as competition with cytochrome P450 (CYP) enzymes, esterases, uridine diphosphate glucuronosyltransferases and transporters (P-glycoprotein, multi-drug resistance-associated proteins, organic anion transporting polypeptides, breast cancer-resistance protein and monocarboxylate transporters).	Flavonoids	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
26526837-0	2015	Cytochrome P450-Mediated Estrogen Metabolites and Autoimmunity: Relationship and Link to Free Radicals.	Free Radicals	89-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
25200585-10	2015	Clozapine and risperidone concentration-to-dose ratios are provided as two examples of this approach of how to integrate CYP genotyping and TDM in psychiatry.	Clozapine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
26526837-4	2015	Here we report that cytochrome P450-mediated estrogen metabolites produce high ROS concentrations that can result in DNA damage.	ros	79-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
26639695-3	2015	The non-responsiveness to clopidogrel in cardiac patients of different populations is due to genetic variations in the cytochrome P450 (CYP) gene [2].	Clopidogrel	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
26639695-3	2015	The non-responsiveness to clopidogrel in cardiac patients of different populations is due to genetic variations in the cytochrome P450 (CYP) gene [2].	Clopidogrel	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-139
26639695-6	2015	Such mutations in this variant allele are responsible for the inability of the CYP enzyme to convert clopidogrel into its active metabolite, which may result in the increased risk of death, heart attack or stroke among patients who have undergone percutaneous coronary intervention (PCI) [5].	Clopidogrel	101-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
25427230-0	2015	Cytochrome P450 eicosanoids in hypertension and renal disease.	Eicosanoids	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
25200585-10	2015	Clozapine and risperidone concentration-to-dose ratios are provided as two examples of this approach of how to integrate CYP genotyping and TDM in psychiatry.	Risperidone	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
25285405-2	2015	Palmatine (10 muM) was metabolized using suspensions of human hepatocytes and human recombinant cytochrome P450 (CYP) enzymes.	palmatine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
25285405-2	2015	Palmatine (10 muM) was metabolized using suspensions of human hepatocytes and human recombinant cytochrome P450 (CYP) enzymes.	palmatine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
25285405-3	2015	Our analyses using electrospray ionization-quadrupole time-of-flight mass spectrometry revealed that palmatine was relatively resistant to the metabolic activity of human hepatocytes and recombinant CYP enzymes.	palmatine	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-202
25666703-8	2015	Dual antiplatelet therapy with ASA and clopidogrel increases the risk of gastrointestinal bleeding in patients with acute coronary syndrome in whom concomitant treatment with a proton-pump inhibitor (PPI) was less effective owing to the interaction of clopidogrel and PPI with the same hepatic cytochrome P-450.	Aspirin	31-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-310
25454080-8	2015	Lastly, different CYP families were induced in RL-14 cells using 2,3,7,8-tetrachlorodibenzo-p-dioxin and fenofibrate at mRNA and protein levels.	Polychlorinated Dibenzodioxins	65-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
25454080-8	2015	Lastly, different CYP families were induced in RL-14 cells using 2,3,7,8-tetrachlorodibenzo-p-dioxin and fenofibrate at mRNA and protein levels.	Fenofibrate	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
25666703-8	2015	Dual antiplatelet therapy with ASA and clopidogrel increases the risk of gastrointestinal bleeding in patients with acute coronary syndrome in whom concomitant treatment with a proton-pump inhibitor (PPI) was less effective owing to the interaction of clopidogrel and PPI with the same hepatic cytochrome P-450.	Clopidogrel	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-310
25518709-5	2014	METHODS: Stable isotope 13C-labelled primaquine and its two enantiomers were incubated with recombinant cytochrome-P450 supersomes containing CYP2D6 under optimized conditions.	13c	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
26514046-6	2015	Some antidepressants, such as paroxetine and fluvoxamine, are strong inhibitors of the CYP system.	Paroxetine	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
26514046-6	2015	Some antidepressants, such as paroxetine and fluvoxamine, are strong inhibitors of the CYP system.	Fluvoxamine	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
25579709-7	2015	All our subjects received rifabutin instead of rifampin in the anti-TB treatment regime as rifabutin is a less-potent inducer of cytochrome P-450.	Rifabutin	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
25518709-5	2014	METHODS: Stable isotope 13C-labelled primaquine and its two enantiomers were incubated with recombinant cytochrome-P450 supersomes containing CYP2D6 under optimized conditions.	Primaquine	37-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
26579418-1	2014	Cytochrome P450 (CYP) enzymes metabolize numerous endogenous substrates, such as retinoids, androgens, estrogens and vitamin D, that can modulate important cellular processes, including proliferation, differentiation and apoptosis.	Retinoids	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26579418-1	2014	Cytochrome P450 (CYP) enzymes metabolize numerous endogenous substrates, such as retinoids, androgens, estrogens and vitamin D, that can modulate important cellular processes, including proliferation, differentiation and apoptosis.	Retinoids	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26579418-1	2014	Cytochrome P450 (CYP) enzymes metabolize numerous endogenous substrates, such as retinoids, androgens, estrogens and vitamin D, that can modulate important cellular processes, including proliferation, differentiation and apoptosis.	Vitamin D	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
26579418-1	2014	Cytochrome P450 (CYP) enzymes metabolize numerous endogenous substrates, such as retinoids, androgens, estrogens and vitamin D, that can modulate important cellular processes, including proliferation, differentiation and apoptosis.	Vitamin D	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
25047139-1	2014	WHAT IS KNOWN AND OBJECTIVE: Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4.	navitoclax	29-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
25047139-1	2014	WHAT IS KNOWN AND OBJECTIVE: Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4.	navitoclax	29-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
25520592-2	2014	Herein we report a systematic investigation of the impacts of gold nanoparticles (AuNPs) on five major CYP isozymes under in vitro incubations of human liver microsomes (HLMs) with tannic acid (TA)-stabilized AuNPs in the size range of 5 to 100 nm.	Tannins	181-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
25148377-2	2014	This suggestion was predicated on observations of highly attenuated morphine antinociception in rodents after intracerebroventricular injection of fluconazole or carrying a neuron-specific deletion of the cytochrome P450 reductase.	Morphine	68-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-220
25148377-2	2014	This suggestion was predicated on observations of highly attenuated morphine antinociception in rodents after intracerebroventricular injection of fluconazole or carrying a neuron-specific deletion of the cytochrome P450 reductase.	Fluconazole	147-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-220
25148377-4	2014	Although CYP inhibitors such as fluconazole are unlikely to attenuate remifentanil analgesia in humans, extrapolation of the findings to other opioids is premature because differences among opioid effects, such as ligand-selective biased signaling at opioid receptors, leave the possibility that CYP-dependent opioid signaling in the brain might be limited to morphine and may not extend to remifentanil.	Fluconazole	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	Arachidonic Acid	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
25426071-1	2014	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome P450 (CYP) epoxygenases have many biological functions.	Arachidonic Acid	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
24882266-1	2014	Beyond their contribution to the metabolism of xenobiotics, cytochrome P450 (CYP) epoxygenases are actively involved in the metabolism of endogenous substances, like arachidonic acid (AA).	Arachidonic Acid	166-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
24803100-1	2014	AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin.	Clopidogrel	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-224
24803100-1	2014	AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin.	Clopidogrel	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-229
24803100-1	2014	AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin.	Simvastatin	260-271	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-224
24803100-1	2014	AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin.	Simvastatin	260-271	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-229
24803100-10	2014	CONCLUSIONS: Our data indicate that treatment with CYP 3A4-metabolized simvastatin does not jeopardize clopidogrel-mediated inhibition of platelet aggregation.	Simvastatin	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
25363545-0	2014	Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.	artemisinin	121-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24944083-0	2014	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro.	naftopidil	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
24882266-1	2014	Beyond their contribution to the metabolism of xenobiotics, cytochrome P450 (CYP) epoxygenases are actively involved in the metabolism of endogenous substances, like arachidonic acid (AA).	Arachidonic Acid	166-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
24882266-2	2014	The main human CYP epoxygenases, i.e. CYP2C8, CYP2C9, CYP2C19 and CYP2J2, convert AA to four regioisomer epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	105-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
24882266-2	2014	The main human CYP epoxygenases, i.e. CYP2C8, CYP2C9, CYP2C19 and CYP2J2, convert AA to four regioisomer epoxyeicosatrienoic acids (EETs).	eets	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
24681287-0	2014	Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes.	17 alpha-Hydroxyprogesterone Caproate	10-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
25285807-4	2014	The oxidation reactions mediated by CYP450 are known to occur by either a single electron transfer (SET) or a hydrogen atom transfer (HAT) mechanism.	Hydrogen	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-42
25238648-0	2014	Effect of axial ligand, spin state, and hydrogen bonding on the inner-sphere reorganization energies of functional models of cytochrome P450.	Hydrogen	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	Hydrogen	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-126
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	Hydrogen	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-134
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	thiolate	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-126
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	thiolate	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-134
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	thiolate	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-126
25238648-8	2014	The results suggest that while the hydrogen bonding to the thiolate in the 5C HS thiolate bound active site of cytochrome P450 (cyp450) shifts the potential up, resulting in a negative DeltaG, it also increases lambda resulting in an overall low barrier for the electron transfer process.	thiolate	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-134
24681287-1	2014	OBJECTIVE: The aim of this study was to examine the effects of 17-alpha-hydroxyprogesterone caproate (17OHP-C) on the activity and expression of several common hepatic cytochrome P450 (CYP) enzymes.	17 alpha-Hydroxyprogesterone Caproate	63-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
24681287-1	2014	OBJECTIVE: The aim of this study was to examine the effects of 17-alpha-hydroxyprogesterone caproate (17OHP-C) on the activity and expression of several common hepatic cytochrome P450 (CYP) enzymes.	17 alpha-Hydroxyprogesterone Caproate	63-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-188
24681287-1	2014	OBJECTIVE: The aim of this study was to examine the effects of 17-alpha-hydroxyprogesterone caproate (17OHP-C) on the activity and expression of several common hepatic cytochrome P450 (CYP) enzymes.	17 alpha-Hydroxyprogesterone Caproate	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
24681287-1	2014	OBJECTIVE: The aim of this study was to examine the effects of 17-alpha-hydroxyprogesterone caproate (17OHP-C) on the activity and expression of several common hepatic cytochrome P450 (CYP) enzymes.	17 alpha-Hydroxyprogesterone Caproate	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-188
25047407-2	2014	This open-label, single-centre, 2-period study evaluated the effect of armodafinil, a moderate inducer of cytochrome-P450 (CYP) isoenzyme CYP3A4, on the pharmacokinetics and safety of ziprasidone, an atypical antipsychotic used to treat bipolar I disorder and metabolized in part by CYP3A4.	Modafinil	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
25047407-2	2014	This open-label, single-centre, 2-period study evaluated the effect of armodafinil, a moderate inducer of cytochrome-P450 (CYP) isoenzyme CYP3A4, on the pharmacokinetics and safety of ziprasidone, an atypical antipsychotic used to treat bipolar I disorder and metabolized in part by CYP3A4.	Modafinil	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
24535830-2	2014	In vitro assays based on the use of human liver microsomes and recombinant cytochrome P450 isoforms were developed and applied to characterize the phase I metabolic profile of the prohibited agent stanozolol, both in the absence and in the presence of substances (ketoconazole, itraconazole, miconazole, cimetidine, ranitidine, and nefazodone) not included in the World Anti-Doping Agency (WADA) list of prohibited substances and methods and frequently administered to athletes.	Stanozolol	197-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
24987833-4	2014	Components of cancer inflammation include chemokines, prostaglandins, and cytokines, and these have been shown to downregulate cytochrome P450 (CYP) enzyme activity.	Prostaglandins	54-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
24987833-4	2014	Components of cancer inflammation include chemokines, prostaglandins, and cytokines, and these have been shown to downregulate cytochrome P450 (CYP) enzyme activity.	Prostaglandins	54-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
25048408-0	2014	Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.	Clobazam	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
25048408-1	2014	PURPOSE: The aim of this study was to evaluate the effect of cytochrome P450 (CYP) inducers/inhibitors on the pharmacokinetics of clobazam (CLB) in patients receiving antiepileptic polypharmacy.	Clobazam	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
25048408-1	2014	PURPOSE: The aim of this study was to evaluate the effect of cytochrome P450 (CYP) inducers/inhibitors on the pharmacokinetics of clobazam (CLB) in patients receiving antiepileptic polypharmacy.	Clobazam	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
25048408-1	2014	PURPOSE: The aim of this study was to evaluate the effect of cytochrome P450 (CYP) inducers/inhibitors on the pharmacokinetics of clobazam (CLB) in patients receiving antiepileptic polypharmacy.	Clobazam	140-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
25048408-1	2014	PURPOSE: The aim of this study was to evaluate the effect of cytochrome P450 (CYP) inducers/inhibitors on the pharmacokinetics of clobazam (CLB) in patients receiving antiepileptic polypharmacy.	Clobazam	140-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
24128439-2	2014	We examined whether DNA methylation levels of Cytochrome P450 (CYP) enzymes (CYP2R1, CYP24A1, CYP27A1, and CYP27B1) are potential biomarkers predicting vitamin D response variation.	Vitamin D	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
24128439-2	2014	We examined whether DNA methylation levels of Cytochrome P450 (CYP) enzymes (CYP2R1, CYP24A1, CYP27A1, and CYP27B1) are potential biomarkers predicting vitamin D response variation.	Vitamin D	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
25151892-0	2014	Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease.	Eicosanoids	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
25068656-3	2014	Mice, unlike humans, have the ability to detoxify hydrophobic bile salts by cytochrome P450-mediated (re)hydroxylation and thus have a less toxic bile salt pool.	Bile Acids and Salts	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
25068656-3	2014	Mice, unlike humans, have the ability to detoxify hydrophobic bile salts by cytochrome P450-mediated (re)hydroxylation and thus have a less toxic bile salt pool.	Bile Acids and Salts	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
25484616-3	2014	Experimental animal and human data indicate that TCE metabolism occurs through two major pathways: cytochrome P450 (CYP)-dependent oxidation and glutathione (GSH) conjugation catalyzed by GSH S-transferases (GSTs).	Trichloroethylene	49-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
25484616-3	2014	Experimental animal and human data indicate that TCE metabolism occurs through two major pathways: cytochrome P450 (CYP)-dependent oxidation and glutathione (GSH) conjugation catalyzed by GSH S-transferases (GSTs).	Trichloroethylene	49-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	103-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	103-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	136-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	136-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	epoxyeicosatrienoic acids	149-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	epoxyeicosatrienoic acids	149-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	eets	176-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
25151892-1	2014	Previous studies have indicated that cytochrome P450 (CYP) metabolites of arachidonic acid (AA), i.e., 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), play an important role in the regulation of renal tubular and vascular function.	eets	176-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
25061110-9	2014	Because CYP3A4/5/7 represent up to 40% of total cytochrome P450 in the liver, these data indicate that these enzymes are the major source of H2O2 in human liver microsomes.	Hydrogen Peroxide	141-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
25061110-0	2014	Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions.	Hydrogen Peroxide	59-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
25408661-3	2014	Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide.	Ifosfamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
25061110-3	2014	In the presence of redox active transition metals, H2O2 can form highly toxic hydroxyl radicals and, depending on the "oxidase" activity of individual cytochrome P450 isoenzymes, this can compromise cellular functioning and contribute to tissue injury.	Hydrogen Peroxide	51-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
25061110-6	2014	Significantly greater activity was detected in preparations containing individual cytochrome P450s coexpressed with CPR (from 6.0 nmol H2O2/min/nmol P450 to 0.2 nmol/min/nmol P450); CYP1A1 was the most active, followed by CYP2D6, CYP3A4, CYP2E1, CYP4A11, CYP1A2, and CYP2C subfamily enzymes.	Hydrogen Peroxide	135-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
25061110-7	2014	H2O2 generating activity of the cytochrome P450s was independent of the ratio of CYP/CPR.	Hydrogen Peroxide	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
24929095-3	2014	In addition, normal CYP activity may produce reactive oxygen species (ROS) that contribute to cell damage through oxidative mechanisms.	Reactive Oxygen Species	45-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
24929095-3	2014	In addition, normal CYP activity may produce reactive oxygen species (ROS) that contribute to cell damage through oxidative mechanisms.	Reactive Oxygen Species	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
24929095-4	2014	CYP2E1 is a CYP isoform that can generate ROS leading to cytotoxicity in multiple tissue types.	Reactive Oxygen Species	42-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
25408661-3	2014	Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide.	Ifosfamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
25408661-3	2014	Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide.	4-hydroxyifosfamide	112-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
25408661-3	2014	Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide.	4-hydroxyifosfamide	112-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
24949552-10	2014	In this study, GSTM1 which is known to be highly polymorphic within the human population, but so far could not be linked to toxicity in acetaminophen-poisoned patients, is suggested to cause interindividual variability in acetaminophen-metabolism, dependent on the individual"s gene expression-responses of CYP-enzymes.	Acetaminophen	222-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	307-310
25408844-2	2014	Among substrates for CYP450 is the tryptophan metabolite skatole (3-methylindole), one of the major contributors to the off-odour associated with boar-tainted meat.	Tryptophan	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-27
25408844-2	2014	Among substrates for CYP450 is the tryptophan metabolite skatole (3-methylindole), one of the major contributors to the off-odour associated with boar-tainted meat.	Skatole	57-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-27
25408844-2	2014	Among substrates for CYP450 is the tryptophan metabolite skatole (3-methylindole), one of the major contributors to the off-odour associated with boar-tainted meat.	Skatole	66-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-27
24926821-3	2014	The level of the active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25D), is controlled in part by VDR-dependent induction of cytochrome P450, family 24, subfamily 1, polypeptide1 (CYP24A1), which metabolizes 1,25D to an inactive form.	Vitamin D	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-179
24973543-2	2014	Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance.	Ritonavir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
24973543-2	2014	Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance.	Ritonavir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-112
24548191-1	2014	AIMS: To examine whether initiation of fibrates or statins in sulfonylurea users is associated with hypoglycaemia, and examine in vitro inhibition of cytochrome P450 (CYP) enzymes by statins, fenofibrate and glipizide.	Fenofibrate	192-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
24548191-1	2014	AIMS: To examine whether initiation of fibrates or statins in sulfonylurea users is associated with hypoglycaemia, and examine in vitro inhibition of cytochrome P450 (CYP) enzymes by statins, fenofibrate and glipizide.	Glipizide	208-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
24548191-3	2014	We also characterized the in vitro inhibition of CYP enzymes by statins, fenofibrate and glipizide using fluorometric CYP450 inhibition assays, and estimated area under the concentration-time curve ratios (AUCRs) for the drug pairs.	Fenofibrate	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
24548191-3	2014	We also characterized the in vitro inhibition of CYP enzymes by statins, fenofibrate and glipizide using fluorometric CYP450 inhibition assays, and estimated area under the concentration-time curve ratios (AUCRs) for the drug pairs.	Glipizide	89-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
24548191-7	2014	The predicted CYP-based AUCRs for fenofibrate-glyburide and gemfibrozil-glyburide interactions were only 1.09 and 1.04, suggesting that CYP inhibition is unlikely to explain such an interaction.	fenofibrate-glyburide	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
24548191-7	2014	The predicted CYP-based AUCRs for fenofibrate-glyburide and gemfibrozil-glyburide interactions were only 1.09 and 1.04, suggesting that CYP inhibition is unlikely to explain such an interaction.	gemfibrozil-glyburide	60-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
24926821-3	2014	The level of the active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25D), is controlled in part by VDR-dependent induction of cytochrome P450, family 24, subfamily 1, polypeptide1 (CYP24A1), which metabolizes 1,25D to an inactive form.	Calcitriol	49-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-179
25114852-1	2014	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	Tamoxifen	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
24590553-3	2014	The present study demonstrates that such control is possible by using wild type or mutant forms of the monooxygenase cytochrome P450 BM3 as catalysts in the oxidative hydroxylation of methylcyclohexane and seven other monosubstituted cyclohexane derivatives.	methylcyclohexane	184-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
24590553-3	2014	The present study demonstrates that such control is possible by using wild type or mutant forms of the monooxygenase cytochrome P450 BM3 as catalysts in the oxidative hydroxylation of methylcyclohexane and seven other monosubstituted cyclohexane derivatives.	cyclohexane derivatives	234-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
24722393-8	2014	Minimally invasive one- and three-point (at 2, 3, and 6 h) DBS-sampling methods were found to reliably reflect CYP and P-gp activities at each session.	dbs	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
24981927-4	2014	Cytochrome P450 (CYP) enzymes activate the xenobiotic making it more reactive, while the Glutathione S-transferases (GST) enzymes conjugate the reduced glutathione with electrophilic compounds, facilitating the toxic products excretion.	Glutathione	152-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24981927-4	2014	Cytochrome P450 (CYP) enzymes activate the xenobiotic making it more reactive, while the Glutathione S-transferases (GST) enzymes conjugate the reduced glutathione with electrophilic compounds, facilitating the toxic products excretion.	Glutathione	152-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
25123135-0	2014	Mammalian cytochrome P450-dependent metabolism of polychlorinated dibenzo-p-dioxins and coplanar polychlorinated biphenyls.	Polychlorinated Dibenzodioxins	50-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
25123135-0	2014	Mammalian cytochrome P450-dependent metabolism of polychlorinated dibenzo-p-dioxins and coplanar polychlorinated biphenyls.	Polychlorinated Biphenyls	97-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
25123135-3	2014	A number of human CYP isoforms belonging to the CYP1 and CYP2 families showed remarkable activities toward low-chlorinated PCDDs.	Polychlorinated Dibenzodioxins	123-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
25114852-1	2014	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	Tamoxifen	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
25114852-1	2014	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	4-hydroxy-N-desmethyltamoxifen	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
25114852-1	2014	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	4-hydroxy-N-desmethyltamoxifen	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
24889073-0	2014	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy.	9-aminocamptothecin	72-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24194261-3	2014	Here, to investigate the inhibitory effects of PL on the activities of CYP isoforms, CYP inhibition assays were conducted using a cocktail of probe substrates in pooled human liver microsome (HLMs) and human recombinant cDNA-expressed CYP.	piperlonguminine	47-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
25056785-2	2014	The aim of the present work was to evaluate the impact of arecoline on human hepatic cytochrome P450 (CYP) enzymes in vitro and rat hepatic CYP enzymes, as well as the hepatic oxidative stress and liver injury of rats in vivo.	Arecoline	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
24816159-7	2014	The specific cytochrome P450 (CYP) enzymes responsible for m-nisoldipine metabolites were identified using chemical inhibition and cDNA expressed CYP enzymes.	m-Nisoldipine	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
24816159-7	2014	The specific cytochrome P450 (CYP) enzymes responsible for m-nisoldipine metabolites were identified using chemical inhibition and cDNA expressed CYP enzymes.	m-Nisoldipine	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
24816159-7	2014	The specific cytochrome P450 (CYP) enzymes responsible for m-nisoldipine metabolites were identified using chemical inhibition and cDNA expressed CYP enzymes.	m-Nisoldipine	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
25056785-2	2014	The aim of the present work was to evaluate the impact of arecoline on human hepatic cytochrome P450 (CYP) enzymes in vitro and rat hepatic CYP enzymes, as well as the hepatic oxidative stress and liver injury of rats in vivo.	Arecoline	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
24839071-1	2014	The purpose of this study is to characterize the involvement of hepato-biliary transport and cytochrome-P450 (CYP)-mediated metabolism in the disposition of glyburide and predict its pharmacokinetic variability due to drug interactions and genetic variations.	Glyburide	157-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-108
24575896-0	2014	Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes.	Carboxylic Acids	102-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
24575896-0	2014	Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes.	acylglucuronides	145-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	1-aminobenzotriazole	48-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	1-aminobenzotriazole	48-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	1-aminobenzotriazole	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
24710199-2	2014	The tutorial instructs the reader how to construct the VB diagrams and how to estimate HAT barriers from raw data, starting with the simplest reaction H + H2 and going all the way to HAT in the enzyme cytochrome P450.	Hydrogen	155-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	1-aminobenzotriazole	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	isoborneol	79-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
24575896-2	2014	In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes.	isoborneol	79-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
24575896-3	2014	We found that 3 mM ABT and 300 muM borneol were the most suitable experimental levels to specifically inhibit CYP and <protein-id="55757">UGT.	1-aminobenzotriazole	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
24575896-3	2014	We found that 3 mM ABT and 300 muM borneol were the most suitable experimental levels to specifically inhibit CYP and <protein-id="55757">UGT.	isoborneol	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
25024195-1	2014	Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis.	epoxyeicosatrienoic acids	65-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-148
25024195-1	2014	Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis.	eets	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-148
25024195-1	2014	Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis.	Eicosanoids	177-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-148
24956138-3	2014	In this work, the ionization potentials (IPs) of the S-NPC1161 (NPC1161a) hydroxylated derivatives, which are possible metabolites derived from action of endogenous cytochrome P450 (CYP450) enzymes, were calculated at the B3LYP-SCRF(PCM)/6-311++G**//B3LYP/6-31G** level in water.	IPS	41-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
24956138-3	2014	In this work, the ionization potentials (IPs) of the S-NPC1161 (NPC1161a) hydroxylated derivatives, which are possible metabolites derived from action of endogenous cytochrome P450 (CYP450) enzymes, were calculated at the B3LYP-SCRF(PCM)/6-311++G**//B3LYP/6-31G** level in water.	IPS	41-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-188
24956138-3	2014	In this work, the ionization potentials (IPs) of the S-NPC1161 (NPC1161a) hydroxylated derivatives, which are possible metabolites derived from action of endogenous cytochrome P450 (CYP450) enzymes, were calculated at the B3LYP-SCRF(PCM)/6-311++G**//B3LYP/6-31G** level in water.	Water	273-278	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
24956138-3	2014	In this work, the ionization potentials (IPs) of the S-NPC1161 (NPC1161a) hydroxylated derivatives, which are possible metabolites derived from action of endogenous cytochrome P450 (CYP450) enzymes, were calculated at the B3LYP-SCRF(PCM)/6-311++G**//B3LYP/6-31G** level in water.	Water	273-278	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-188
24956138-8	2014	Molecular orbital analysis implies that the N1" position should be the most reactive center when NPC1161 approaches the heme in CYP450.	Heme	120-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-134
24839071-1	2014	The purpose of this study is to characterize the involvement of hepato-biliary transport and cytochrome-P450 (CYP)-mediated metabolism in the disposition of glyburide and predict its pharmacokinetic variability due to drug interactions and genetic variations.	Glyburide	157-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
24400699-0	2014	Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.	artemisinin	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
24752505-0	2014	Contribution of carboxylesterase and cytochrome P450 to the bioactivation and detoxification of isocarbophos and its enantiomers in human liver microsomes.	isocarbophos	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
24405273-5	2014	We evaluated rose bengal as an in vitro inhibitor of cytochrome P450 (CYP) or UDP-glucuronosyltransferase (UGT) enzymes in both human liver microsomes (HLM) and cryopreserved human hepatocytes (CHHs) under both yellow light and dark conditions.	Rose Bengal	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
24405273-5	2014	We evaluated rose bengal as an in vitro inhibitor of cytochrome P450 (CYP) or UDP-glucuronosyltransferase (UGT) enzymes in both human liver microsomes (HLM) and cryopreserved human hepatocytes (CHHs) under both yellow light and dark conditions.	Rose Bengal	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
24762860-8	2014	CONCLUSIONS: Both loss-of-function and gain-of-function CYP polymorphisms affecting clopidogrel metabolism are associated with increased mortality among clopidogrel-treated patients after acute myocardial infarction; the specific polymorphism and the putative mechanism vary according to race.	Clopidogrel	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
24762860-1	2014	BACKGROUND: Clopidogrel is recommended after acute myocardial infarction but has variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism.	Clopidogrel	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-159
24875119-3	2014	Together with the recent determination of an iron(IV)hydroxide pK(a) ~ 12 in the thiolate-ligated heme enzyme cytochrome P450, this result provides insight into Nature"s ability to tune catalytic function through its choice of axial ligand.	Iron	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
24875119-3	2014	Together with the recent determination of an iron(IV)hydroxide pK(a) ~ 12 in the thiolate-ligated heme enzyme cytochrome P450, this result provides insight into Nature"s ability to tune catalytic function through its choice of axial ligand.	hydroxide ion	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
24875119-3	2014	Together with the recent determination of an iron(IV)hydroxide pK(a) ~ 12 in the thiolate-ligated heme enzyme cytochrome P450, this result provides insight into Nature"s ability to tune catalytic function through its choice of axial ligand.	thiolate	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
24762860-1	2014	BACKGROUND: Clopidogrel is recommended after acute myocardial infarction but has variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism.	Clopidogrel	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
24762860-8	2014	CONCLUSIONS: Both loss-of-function and gain-of-function CYP polymorphisms affecting clopidogrel metabolism are associated with increased mortality among clopidogrel-treated patients after acute myocardial infarction; the specific polymorphism and the putative mechanism vary according to race.	Clopidogrel	153-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
24634501-0	2014	Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway.	Fatty Acids, Omega-3	8-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
23797843-3	2014	In the present study, the metabolism of PQ was evaluated by incubating the drug with pooled human hepatocytes cultured in vitro as well as with recombinant cytochrome P450 (CYP) iso- enzymes, monoamine oxidases (MAO), and flavin-containing monooxygenases (FMO).	Primaquine	40-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
23797843-3	2014	In the present study, the metabolism of PQ was evaluated by incubating the drug with pooled human hepatocytes cultured in vitro as well as with recombinant cytochrome P450 (CYP) iso- enzymes, monoamine oxidases (MAO), and flavin-containing monooxygenases (FMO).	Primaquine	40-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
24634501-0	2014	Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway.	Eicosanoids	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
24634501-1	2014	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA) contribute to the regulation of cardiovascular function.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24634501-1	2014	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA) contribute to the regulation of cardiovascular function.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	dehydroacetic acid	32-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	dehydroacetic acid	32-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	Eicosanoids	150-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	Eicosanoids	150-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	Fatty Acids, Omega-3	205-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
24634501-2	2014	CYP enzymes also accept EPA and DHA to yield more potent vasodilatory and potentially anti-arrhythmic metabolites, suggesting that the endogenous CYP-eicosanoid profile can be favorably shifted by dietary omega-3 fatty acids.	Fatty Acids, Omega-3	205-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
24634501-5	2014	The metabolite/precursor fatty acid ratios indicated that CYP epoxygenases metabolized EPA with an 8.6-fold higher efficiency and DHA with a 2.2-fold higher efficiency than AA.	Fatty Acids	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
24634501-5	2014	The metabolite/precursor fatty acid ratios indicated that CYP epoxygenases metabolized EPA with an 8.6-fold higher efficiency and DHA with a 2.2-fold higher efficiency than AA.	dehydroacetic acid	130-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
24634501-7	2014	We propose that CYP-dependent epoxy-metabolites of EPA and DHA may function as mediators of the vasodilatory and cardioprotective effects of omega-3 fatty acids and could serve as biomarkers in clinical studies investigating the cardiovascular effects of EPA/DHA supplementation.	dehydroacetic acid	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
24634501-7	2014	We propose that CYP-dependent epoxy-metabolites of EPA and DHA may function as mediators of the vasodilatory and cardioprotective effects of omega-3 fatty acids and could serve as biomarkers in clinical studies investigating the cardiovascular effects of EPA/DHA supplementation.	Fatty Acids, Omega-3	141-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
24634501-7	2014	We propose that CYP-dependent epoxy-metabolites of EPA and DHA may function as mediators of the vasodilatory and cardioprotective effects of omega-3 fatty acids and could serve as biomarkers in clinical studies investigating the cardiovascular effects of EPA/DHA supplementation.	dehydroacetic acid	259-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
24797816-1	2014	BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation.	Sorafenib	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
24797816-1	2014	BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation.	Sorafenib	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
24802986-5	2014	Results demonstrated that scutellarin showed negligible inhibitory effects on the six major CYP isoenzymes in human/rat liver microsomes with almost all of the IC50 values exceeding 100 muM, whereas it showed values of 63.8 muM for CYP2C19 in human liver microsomes, and 63.1 and 85.6 muM for CYP2C7 and CYP2C79 in rat liver microsomes, respectively.	scutellarin	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
24790817-15	2014	Amiodarone was the CYP inhibitor most frequently coprescribed.	Amiodarone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
24304147-0	2014	Metabolism and clinical pharmacokinetics of 2-methyl-n-(2"-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1"-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.	2-methyl-n-(2"-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1"-biphenyl]-4-yl)propran-1-amine	44-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	27-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-173
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	27-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-178
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-173
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-178
24760842-0	2014	Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3alpha,5alpha-THP and reduces long-term operant ethanol self-administration.	5alpha-thp	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
24760842-0	2014	Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3alpha,5alpha-THP and reduces long-term operant ethanol self-administration.	Ethanol	167-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
24760842-4	2014	Cytochrome P450 side chain cleavage (P450scc) converts cholesterol to pregnenolone, the rate-limiting enzymatic reaction in neurosteroidogenesis.	Cholesterol	55-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24760842-4	2014	Cytochrome P450 side chain cleavage (P450scc) converts cholesterol to pregnenolone, the rate-limiting enzymatic reaction in neurosteroidogenesis.	Pregnenolone	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24372170-2	2014	However, while in eukaryotes, the cytochrome P450 (CYP)-mediated activation of benzo[a]pyrene (B[a]P) has become a model for metabolism-mediated carcinogenesis, the oxidative degradation of B[a]P by microorganisms is less well studied.	Benzo(a)pyrene	79-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
24372170-2	2014	However, while in eukaryotes, the cytochrome P450 (CYP)-mediated activation of benzo[a]pyrene (B[a]P) has become a model for metabolism-mediated carcinogenesis, the oxidative degradation of B[a]P by microorganisms is less well studied.	Benzo(a)pyrene	79-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
24567279-1	2014	BACKGROUND: The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.	Lacosamide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
24567279-1	2014	BACKGROUND: The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.	Lacosamide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
24464803-9	2014	Cytochrome P450 (P450) profiling indicated that tofacitinib was mainly metabolized by CYP3A4, with a smaller contribution from CYP2C19.	tofacitinib	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24165884-0	2014	The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.	etravirine	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
24165884-1	2014	The effect of etravirine on cytochrome P450 (CYP) enzymes and P-glycoprotein were evaluated in two randomized, crossover trials in healthy subjects.	etravirine	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
24165884-1	2014	The effect of etravirine on cytochrome P450 (CYP) enzymes and P-glycoprotein were evaluated in two randomized, crossover trials in healthy subjects.	etravirine	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
24380714-0	2014	In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2,3,5-trimethoxy-xanthone purified from Halenia elliptica D. Don.	1-hydroxyl-2,3,5-trimethoxy-xanthone	86-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
24642534-4	2014	NADPH-cytochrome P450 oxidoreductase (POR) is a membrane-bound enzyme required for electron transfer to cytochrome P450 (CYP), vital in the processes of the metabolism of drugs and steroid production in humans.	Steroids	181-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
24642534-4	2014	NADPH-cytochrome P450 oxidoreductase (POR) is a membrane-bound enzyme required for electron transfer to cytochrome P450 (CYP), vital in the processes of the metabolism of drugs and steroid production in humans.	Steroids	181-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
24642534-4	2014	NADPH-cytochrome P450 oxidoreductase (POR) is a membrane-bound enzyme required for electron transfer to cytochrome P450 (CYP), vital in the processes of the metabolism of drugs and steroid production in humans.	Steroids	181-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
24342125-2	2014	Inhibition of major human cytochrome P450 enzymes by a standardized hop extract and isolated hop prenylated phenols was evaluated using a fast and efficient assay based on ultrahigh pressure liquid chromatography-tandem mass spectrometry.	Phenols	108-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
24618756-2	2014	These flavoproteins function as obligatory intermediates that accept 2 electrons from NAD(P)H with subsequent 1-electron transfers to a variety of cytochrome P450 (CYP) heme proteins within the mitochondria matrix (type I) and the (microsomal) endoplasmic reticulum (type II).	nad(p)h	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
24618756-2	2014	These flavoproteins function as obligatory intermediates that accept 2 electrons from NAD(P)H with subsequent 1-electron transfers to a variety of cytochrome P450 (CYP) heme proteins within the mitochondria matrix (type I) and the (microsomal) endoplasmic reticulum (type II).	nad(p)h	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
24618756-2	2014	These flavoproteins function as obligatory intermediates that accept 2 electrons from NAD(P)H with subsequent 1-electron transfers to a variety of cytochrome P450 (CYP) heme proteins within the mitochondria matrix (type I) and the (microsomal) endoplasmic reticulum (type II).	Heme	169-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
24618756-2	2014	These flavoproteins function as obligatory intermediates that accept 2 electrons from NAD(P)H with subsequent 1-electron transfers to a variety of cytochrome P450 (CYP) heme proteins within the mitochondria matrix (type I) and the (microsomal) endoplasmic reticulum (type II).	Heme	169-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
24618756-5	2014	In the microsomal type II system, a diflavin (FAD/FMN)-dependent cytochrome P450 oxidoreductase [NAD(P)H-cytochrome P450 reductase (CPR)] donates electrons to a multitude of heme oxygenases.	diflavin	36-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
24618756-5	2014	In the microsomal type II system, a diflavin (FAD/FMN)-dependent cytochrome P450 oxidoreductase [NAD(P)H-cytochrome P450 reductase (CPR)] donates electrons to a multitude of heme oxygenases.	Flavin Mononucleotide	50-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
24618756-6	2014	Both flavoenzyme complexes exhibit a commonality of function with all CYP enzymes and are crucial for maintaining a balance of cholesterol and vitamin D metabolites.	Cholesterol	127-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
24618756-6	2014	Both flavoenzyme complexes exhibit a commonality of function with all CYP enzymes and are crucial for maintaining a balance of cholesterol and vitamin D metabolites.	Vitamin D	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
24218006-11	2014	The use of DBS or saliva samples seems feasible for phenotyping of the selected CYP isoforms.	dbs	11-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	Fluoxetine	81-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	Fluoxetine	81-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	norfluoxetine	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	norfluoxetine	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	norfluoxetine	135-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
24464553-2	2014	Although FLX is used as racemate in the clinic, the clinical pharmacokinetics of FLX and its N-demethylation metabolite norfluoxetine (NFLX) show obvious cytochrome P450 (CYP) polymorphism dependency and exhibit marked stereoselectivity.	norfluoxetine	135-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
24387291-2	2014	The importance of CYP enzymes in cardiovascular physiology derives from their ability to metabolize arachidonic acid to epoxyeicosatrienoic and hydroxyeicosatetraenoic acids, which are involved in the maintenance of cardiovascular health, including the regulation of vascular tone, cardiac ion channels and heart contractility.	Arachidonic Acid	100-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
24387291-2	2014	The importance of CYP enzymes in cardiovascular physiology derives from their ability to metabolize arachidonic acid to epoxyeicosatrienoic and hydroxyeicosatetraenoic acids, which are involved in the maintenance of cardiovascular health, including the regulation of vascular tone, cardiac ion channels and heart contractility.	epoxyeicosatrienoic and hydroxyeicosatetraenoic acids	120-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
23775837-0	2014	Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.	Isoniazid	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
24753822-4	2014	Dixon plots of CYP inhibition indicated that thelephoric acid was a competitive inhibitor of CYP1A2 and CYP3A4.	thelephoric acid	45-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
24316028-1	2014	Efavirenz (EFV) exhibits interindividual pharmacokinetic variability caused by differences in cytochrome P450 (CYP) expression.	efavirenz	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
24316028-1	2014	Efavirenz (EFV) exhibits interindividual pharmacokinetic variability caused by differences in cytochrome P450 (CYP) expression.	efavirenz	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
24753822-0	2014	A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity.	thelephoric acid	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
24753822-0	2014	A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity.	Proadifen	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
24753822-6	2014	Our findings indicate that thelephoric acid may be a novel, non-specific CYP inhibitor, suggesting that it could replace SKF-525A in inhibitory studies designed to investigate the effects of CYP enzymes on the metabolism of given compounds.	thelephoric acid	27-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
24753822-6	2014	Our findings indicate that thelephoric acid may be a novel, non-specific CYP inhibitor, suggesting that it could replace SKF-525A in inhibitory studies designed to investigate the effects of CYP enzymes on the metabolism of given compounds.	thelephoric acid	27-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-194
24160757-4	2014	CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism.	Dronabinol	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-7
24753822-2	2014	In the present study, the inhibitory effects of polyozellin and thelephoric acid on 9 cytochrome P450 (CYP) family members (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were examined in pooled human liver microsomes (HLMs) using a cocktail probe assay.	polyozellin	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
24753822-2	2014	In the present study, the inhibitory effects of polyozellin and thelephoric acid on 9 cytochrome P450 (CYP) family members (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were examined in pooled human liver microsomes (HLMs) using a cocktail probe assay.	polyozellin	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
24753822-2	2014	In the present study, the inhibitory effects of polyozellin and thelephoric acid on 9 cytochrome P450 (CYP) family members (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were examined in pooled human liver microsomes (HLMs) using a cocktail probe assay.	thelephoric acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
24753822-2	2014	In the present study, the inhibitory effects of polyozellin and thelephoric acid on 9 cytochrome P450 (CYP) family members (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were examined in pooled human liver microsomes (HLMs) using a cocktail probe assay.	thelephoric acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
24753822-3	2014	Polyozellin exhibited weak inhibitory effects on the activities of all 9 CYPs examined, whereas thelephoric acid exhibited dose- and time-dependent inhibition of all 9 CYP isoforms (IC50 values, 3.2-33.7 muM).	polyozellin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
24040964-0	2014	Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	102-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
24040964-1	2014	In addition to their role as xenobiotic metabolizing enzymes, cytochrome P450 (CYP) epoxygenases actively contribute to the metabolism of endogenous substances such as arachidonic acid.	Arachidonic Acid	168-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
24040964-1	2014	In addition to their role as xenobiotic metabolizing enzymes, cytochrome P450 (CYP) epoxygenases actively contribute to the metabolism of endogenous substances such as arachidonic acid.	Arachidonic Acid	168-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
24160757-4	2014	CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism.	Dronabinol	190-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-7
24160757-4	2014	CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism.	Cannabinoids	213-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-7
25658126-12	2014	Oxidative bio-activation of this azo dye catalyzed by CYPs and peroxidases leads to generation of proximate genotoxic metabolites (the CYP-catalyzed formation of the benzenediazonium cation and the peroxidase-mediated generation of one-electron oxidation products), which covalently modify DNA both in vitro and in vivo.	Azo Compounds	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
24168324-0	2014	Cytochrome P450 isoforms are differently up-regulated in aflatoxin B1-exposed human lymphocytes and monocytes.	Aflatoxin B1	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24634794-3	2014	Here, we report that cytochrome P450 enzymes can serve as efficient catalysts for mediating intramolecular benzylic C-H amination reactions in a variety of arylsulfonyl azide compouds.	arylsulfonyl azide	156-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
26161443-2	2014	Enantiomeric separation and quantification of warfarin enantiomers and clinically important major hydroxylation metabolites are essential for drug interaction studies and phenotypic characterization of CYP2C9 and CYP3A4, the major cytochrome P450 (CYP) enzymes involved in warfarin metabolism.	Warfarin	46-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	231-246
26161443-2	2014	Enantiomeric separation and quantification of warfarin enantiomers and clinically important major hydroxylation metabolites are essential for drug interaction studies and phenotypic characterization of CYP2C9 and CYP3A4, the major cytochrome P450 (CYP) enzymes involved in warfarin metabolism.	Warfarin	46-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
24602259-5	2014	However, a detailed literature review of statin metabolism and of SSRI effects on CYP enzymes suggests that escitalopram, citalopram, and paroxetine are almost certain to be safe with all statins, and rosuvastatin, pitavastatin, and pravastatin are almost certain to be safe with all SSRIs.	Paroxetine	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
24265353-3	2014	Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
24265353-3	2014	Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-51
24265353-3	2014	Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen.	4-hydroxy-N-desmethyltamoxifen	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
24265353-3	2014	Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes to the more active metabolite endoxifen.	4-hydroxy-N-desmethyltamoxifen	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-51
24265353-4	2014	Several genetic variants in the CYP450 enzymes reduce tamoxifen metabolism, leading to reduced endoxifen levels.	Tamoxifen	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-38
24265353-4	2014	Several genetic variants in the CYP450 enzymes reduce tamoxifen metabolism, leading to reduced endoxifen levels.	4-hydroxy-N-desmethyltamoxifen	95-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-38
24265353-8	2014	Genotyping of 33 single nucleotide polymorphisms in CYP450 genes involved in tamoxifen metabolism was carried out using Sequenom MassARRAY.	Tamoxifen	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-58
25061471-10	2014	Fustin showed moderate inhibitory effects on the CYP2C19 (IC50, 64.3 mug/mL) and weak inhibition of the other CYP isoforms similar to aRVS.	fustin	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-188
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-193
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	320-323
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	pitavastatin	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-188
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	pitavastatin	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-193
24156555-5	2014	EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes.	pitavastatin	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	320-323
23474437-0	2014	Cytochrome P450-mediated metabolic alterations in preeclampsia evaluated by quantitative steroid signatures.	Steroids	89-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24500235-1	2014	Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
24500235-1	2014	Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
23474437-2	2014	The association between various cytochrome P450 (CYP)-mediated steroid metabolic markers and preeclampsia risk was therefore investigated.	Steroids	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
23474437-2	2014	The association between various cytochrome P450 (CYP)-mediated steroid metabolic markers and preeclampsia risk was therefore investigated.	Steroids	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
23474437-3	2014	The serum levels of 54 CYP-mediated regioselective hydroxysteroids and their substrates were quantitatively evaluated from both pregnant women with preeclampsia (n=30; age, 30.8+-4.5 years) and normotensive controls (n=30; age, 31.0+-3.5 years), who were similar with respect to maternal age, gestational age, and body mass index.	Hydroxysteroids	51-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
23474437-8	2014	Our metabolic profiling suggests the CYP-mediated alterations in steroid metabolism and hydroxylation in pregnancy-induced hypertension.	Steroids	65-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	cedrene	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	thujopsene	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
25343291-11	2014	These results indicate that S-sibutramine was more rapidly metabolized by CYP isoforms than R-sibutramine, and that enantioselective metabolism needs to be considered in drug interactions involving sibutramine and co-administered drugs.	sibutramine	28-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
25343291-11	2014	These results indicate that S-sibutramine was more rapidly metabolized by CYP isoforms than R-sibutramine, and that enantioselective metabolism needs to be considered in drug interactions involving sibutramine and co-administered drugs.	sibutramine	30-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
25343291-0	2014	Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms.	Nitrogen	17-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
25343291-0	2014	Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms.	sibutramine	54-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	thujopsene	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
25343291-1	2014	The enantioselective metabolism of sibutramine was examined using human liver microsomes (HLM) and recombinant cytochrome P-450 (CYP) isoforms.	sibutramine	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
25343291-1	2014	The enantioselective metabolism of sibutramine was examined using human liver microsomes (HLM) and recombinant cytochrome P-450 (CYP) isoforms.	sibutramine	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-132
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	cedrol	67-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	cedrol	238-244	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	cedrol	67-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	cedrene	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
25343299-3	2014	The aim of this study was to investigate the inhibitory effects of cedrol, beta-cedrene, and thujopsene on the activities of eight major human cytochrome P-450 (CYP) enzymes using human liver microsomes to assess potential beta-cedrene-, cedrol-, and thujopsene-drug interactions.	thujopsene	251-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
24233717-0	2013	Iron(IV)hydroxide pK(a) and the role of thiolate ligation in C-H bond activation by cytochrome P450.	thiolate	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
24184833-6	2013	Chemical inhibitors of cytochrome P450 (CYP450) and individual human recombinant CYP450 enzyme were used to identify the CYP450 isozymes involved in the formation of each metabolite of alisol A.	alisol A	185-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
24184833-6	2013	Chemical inhibitors of cytochrome P450 (CYP450) and individual human recombinant CYP450 enzyme were used to identify the CYP450 isozymes involved in the formation of each metabolite of alisol A.	alisol A	185-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-46
24184833-6	2013	Chemical inhibitors of cytochrome P450 (CYP450) and individual human recombinant CYP450 enzyme were used to identify the CYP450 isozymes involved in the formation of each metabolite of alisol A.	alisol A	185-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-87
24184833-6	2013	Chemical inhibitors of cytochrome P450 (CYP450) and individual human recombinant CYP450 enzyme were used to identify the CYP450 isozymes involved in the formation of each metabolite of alisol A.	alisol A	185-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-87
24060875-1	2013	Rifampin is a potent inducer of cytochrome P450 (CYP) enzymes and transporters.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
24060875-1	2013	Rifampin is a potent inducer of cytochrome P450 (CYP) enzymes and transporters.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
23974699-0	2013	Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.	Rifampin	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Clopidogrel	30-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Clopidogrel	30-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Rifampin	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Rifampin	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
24378836-3	2013	There are growing evidences that clopidogrel response variability is associated with cytochrome P450 (CYP) enzyme genetic polymorphisms, primarily CYP2C19 which is responsible for the conversion of clopidogrel into its active metabolite.	Clopidogrel	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
24378836-3	2013	There are growing evidences that clopidogrel response variability is associated with cytochrome P450 (CYP) enzyme genetic polymorphisms, primarily CYP2C19 which is responsible for the conversion of clopidogrel into its active metabolite.	Clopidogrel	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
24378836-3	2013	There are growing evidences that clopidogrel response variability is associated with cytochrome P450 (CYP) enzyme genetic polymorphisms, primarily CYP2C19 which is responsible for the conversion of clopidogrel into its active metabolite.	Clopidogrel	198-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
24378836-3	2013	There are growing evidences that clopidogrel response variability is associated with cytochrome P450 (CYP) enzyme genetic polymorphisms, primarily CYP2C19 which is responsible for the conversion of clopidogrel into its active metabolite.	Clopidogrel	198-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
24378837-2	2013	However, clopidogrel is associated with great variability in antiplatelet response, mostly caused by variable efficacy of cytochrome P450 (CYP) isoforms, which convert clopidogrel to its active metabolite in a two-step process.	Clopidogrel	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
24378837-2	2013	However, clopidogrel is associated with great variability in antiplatelet response, mostly caused by variable efficacy of cytochrome P450 (CYP) isoforms, which convert clopidogrel to its active metabolite in a two-step process.	Clopidogrel	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
24378837-2	2013	However, clopidogrel is associated with great variability in antiplatelet response, mostly caused by variable efficacy of cytochrome P450 (CYP) isoforms, which convert clopidogrel to its active metabolite in a two-step process.	Clopidogrel	168-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
24378837-2	2013	However, clopidogrel is associated with great variability in antiplatelet response, mostly caused by variable efficacy of cytochrome P450 (CYP) isoforms, which convert clopidogrel to its active metabolite in a two-step process.	Clopidogrel	168-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
25278738-5	2013	Genes encoding the liver cytochrome P-450 (CYP) enzymes that are involved with the metabolism of methadone (CYP2B6, 3A4 and 2C19) were selected and genotyped in this cohort.	Methadone	97-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
25278738-5	2013	Genes encoding the liver cytochrome P-450 (CYP) enzymes that are involved with the metabolism of methadone (CYP2B6, 3A4 and 2C19) were selected and genotyped in this cohort.	Methadone	97-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
23988488-0	2013	Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse.	glaucine	91-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
24523110-4	2014	The great diversity of reactions catalyzed by CYP enzymes appears to be based on two unique properties of these heme proteins, the ability of their iron to exist under multiple oxidation states with different reactivities and a flexible active site that can accommodate a wide variety of substrates.	Heme	112-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
24523110-4	2014	The great diversity of reactions catalyzed by CYP enzymes appears to be based on two unique properties of these heme proteins, the ability of their iron to exist under multiple oxidation states with different reactivities and a flexible active site that can accommodate a wide variety of substrates.	Iron	148-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
24312617-4	2013	We investigated four CYP subfamilies (CYP1A, CYP2D, CYP2C, and CYP3A) that are involved in 90% of all metabolic drug transformations and identified four amino acid interaction networks associated with specific CYP functionalities, i.e., membrane binding, heme binding, catalytic activity, and dimerization.	Heme	255-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
24312617-4	2013	We investigated four CYP subfamilies (CYP1A, CYP2D, CYP2C, and CYP3A) that are involved in 90% of all metabolic drug transformations and identified four amino acid interaction networks associated with specific CYP functionalities, i.e., membrane binding, heme binding, catalytic activity, and dimerization.	Heme	255-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
24233717-1	2013	Cytochrome P450 enzymes activate oxygen at heme iron centers to oxidize relatively inert substrate carbon-hydrogen bonds.	Oxygen	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24233717-1	2013	Cytochrome P450 enzymes activate oxygen at heme iron centers to oxidize relatively inert substrate carbon-hydrogen bonds.	Heme	43-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24233717-1	2013	Cytochrome P450 enzymes activate oxygen at heme iron centers to oxidize relatively inert substrate carbon-hydrogen bonds.	Iron	48-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24233717-1	2013	Cytochrome P450 enzymes activate oxygen at heme iron centers to oxidize relatively inert substrate carbon-hydrogen bonds.	Carbon	99-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24233717-1	2013	Cytochrome P450 enzymes activate oxygen at heme iron centers to oxidize relatively inert substrate carbon-hydrogen bonds.	Hydrogen	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24117377-0	2013	Cytochrome P450 modified polycrystalline indium tin oxide film as a drug metabolizing electrochemical biosensor with a simple configuration.	polycrystalline indium tin oxide	25-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24207099-1	2013	INTRODUCTION: The cytochrome P450 (CYP) enzymes are a class of heme-containing enzymes involved in phase I metabolism of a large number of xenobiotics.	Heme	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
24207099-1	2013	INTRODUCTION: The cytochrome P450 (CYP) enzymes are a class of heme-containing enzymes involved in phase I metabolism of a large number of xenobiotics.	Heme	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
24117377-2	2013	We have successfully detected the direct electron transfer (DET) from a human CYP layer or a CYP microsome adsorbed on a bare indium tin oxide (ITO) film electrode without any modification layers and applied it to drug metabolism evaluation.	indium tin oxide	126-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
24117377-2	2013	We have successfully detected the direct electron transfer (DET) from a human CYP layer or a CYP microsome adsorbed on a bare indium tin oxide (ITO) film electrode without any modification layers and applied it to drug metabolism evaluation.	indium tin oxide	144-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
24117377-4	2013	CYP on polycrystalline ITO film enhanced the electron transfer rate of oxygen reduction about fifteen times more than with amorphous film.	polycrystalline ito	7-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
24117377-4	2013	CYP on polycrystalline ITO film enhanced the electron transfer rate of oxygen reduction about fifteen times more than with amorphous film.	Oxygen	71-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
24117377-5	2013	The polycrystalline ITO film was a suitable electrode for the adsorption of CYP proteins while maintaining efficient DET and enzymatic activity, probably because of its larger surface area and negatively charged surface.	polycrystalline ito	4-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
24117377-6	2013	The oxygen reduction current at the polycrystalline ITO film electrodes had increased 3- to 4-fold, specifically coupled with the oxidation of drugs (testosterone and quinidine) by the monooxygenase activity of CYP.	Oxygen	4-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
24117377-6	2013	The oxygen reduction current at the polycrystalline ITO film electrodes had increased 3- to 4-fold, specifically coupled with the oxidation of drugs (testosterone and quinidine) by the monooxygenase activity of CYP.	polycrystalline	36-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
24117377-6	2013	The oxygen reduction current at the polycrystalline ITO film electrodes had increased 3- to 4-fold, specifically coupled with the oxidation of drugs (testosterone and quinidine) by the monooxygenase activity of CYP.	Testosterone	150-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
24117377-6	2013	The oxygen reduction current at the polycrystalline ITO film electrodes had increased 3- to 4-fold, specifically coupled with the oxidation of drugs (testosterone and quinidine) by the monooxygenase activity of CYP.	Quinidine	167-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
24117377-7	2013	In contrast, the oxygen reduction current completely disappeared in the presence of the CYP inhibitor (ketoconazole).	Oxygen	17-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
24117377-7	2013	In contrast, the oxygen reduction current completely disappeared in the presence of the CYP inhibitor (ketoconazole).	Ketoconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
24117377-9	2013	These results indicate that the CYP modified polycrystalline ITO electrode offers the potential for electrochemically evaluating CYP activity for drug metabolism with a simple configuration.	polycrystalline	45-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
24117377-9	2013	These results indicate that the CYP modified polycrystalline ITO electrode offers the potential for electrochemically evaluating CYP activity for drug metabolism with a simple configuration.	polycrystalline	45-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-132
24113184-3	2013	In the present study, we demonstrate that gp120 and methamphetamine (MA) causes apoptotic cell death by inducing oxidative stress through the cytochrome P450 (CYP) and NADPH oxidase (NOX) pathways.	Methamphetamine	52-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
24096258-0	2013	Acute effects of red wine on cytochrome P450 eicosanoids and blood pressure in men.	Eicosanoids	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	Eicosanoids	25-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	Eicosanoids	25-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	Arachidonic Acid	50-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	Arachidonic Acid	50-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	epoxyeicosatrienoic acids	87-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	epoxyeicosatrienoic acids	87-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	eets	114-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	eets	114-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	20-hydroxyeicosatrieneoic acid	144-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	20-hydroxyeicosatrieneoic acid	144-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	20-Hete	175-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24096258-2	2013	Cytochrome P450 (CYP450) eicosanoids derived from arachidonic acid include vasodilator epoxyeicosatrienoic acids (EETs) and the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE).	20-Hete	175-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
24113184-11	2013	Furthermore, we showed that DAS, DPI, and DFO completely abolished apoptosis and cell death, suggesting the involvement of CYP and NOX pathways in ROS-mediated apoptotic cell death.	Deferoxamine	42-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
24113184-11	2013	Furthermore, we showed that DAS, DPI, and DFO completely abolished apoptosis and cell death, suggesting the involvement of CYP and NOX pathways in ROS-mediated apoptotic cell death.	Reactive Oxygen Species	147-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
24113184-3	2013	In the present study, we demonstrate that gp120 and methamphetamine (MA) causes apoptotic cell death by inducing oxidative stress through the cytochrome P450 (CYP) and NADPH oxidase (NOX) pathways.	Methamphetamine	52-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
23987522-2	2013	Cytochrome-P450-mediated metabolism of each leads to the generation of pharmacologically active (omega)- and (omega-1)-monohydroxyl metabolites that retain high affinity for cannabinoid type-1 receptors, exhibit Delta(9)-THC-like effects in rodents, and are conjugated with glucuronic acid prior to excretion in human urine.	(omega-1)-monohydroxyl	109-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23987522-2	2013	Cytochrome-P450-mediated metabolism of each leads to the generation of pharmacologically active (omega)- and (omega-1)-monohydroxyl metabolites that retain high affinity for cannabinoid type-1 receptors, exhibit Delta(9)-THC-like effects in rodents, and are conjugated with glucuronic acid prior to excretion in human urine.	Dronabinol	212-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23987522-2	2013	Cytochrome-P450-mediated metabolism of each leads to the generation of pharmacologically active (omega)- and (omega-1)-monohydroxyl metabolites that retain high affinity for cannabinoid type-1 receptors, exhibit Delta(9)-THC-like effects in rodents, and are conjugated with glucuronic acid prior to excretion in human urine.	Glucuronic Acid	274-289	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23770984-2	2013	This study was designed to explore the potential effects of pungent ginger components, 6-, 8-, and 10-gingerol, on human cytochrome P450 (CYP450) enzymes that are responsible for the metabolism of many prescription drugs.	6-, 8-, and 10-gingerol	87-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
25505563-0	2013	Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.	Tegafur	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
25505563-0	2013	Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.	Fluorouracil	77-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Tegafur	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Tegafur	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Tegafur	9-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Tegafur	9-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	29-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	29-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	45-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	111-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
25505563-1	2013	Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes.	Fluorouracil	111-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
23852652-0	2013	Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.	Ospemifene	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	216-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23852652-4	2013	RESULTS: Although several CYP inhibitors decreased the in vitro formation of ospemifene metabolites, none of them completely blocked metabolism.	Ospemifene	77-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
23852652-7	2013	CONCLUSIONS: The clinical pharmacokinetic findings and in vitro data suggest that CYP3A4 is important for ospemifene metabolism, but other CYP isoforms and metabolic pathways also contribute.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
23770984-2	2013	This study was designed to explore the potential effects of pungent ginger components, 6-, 8-, and 10-gingerol, on human cytochrome P450 (CYP450) enzymes that are responsible for the metabolism of many prescription drugs.	6-, 8-, and 10-gingerol	87-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-144
23770984-9	2013	CONCLUSION: 6-, 8-, and 10-gingerol suppress human cytochrome P450 activity, while 8- and 10-gingerol inhibit CYP3A4 expression.	6-, 8-, and 10-gingerol	12-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
23903277-6	2013	Lipophilic statins, such as atorvastatin, are predominantly metabolized by CYP3A4 and may interfere with CYP activation of clopidogrel, contrary to what happens with hydrophilic statins, such as rosuvastin or pravastatin.	Clopidogrel	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
23877932-0	2013	Effects of beta-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism.	beta-lapachone	11-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
23877932-1	2013	PURPOSE: This study aimed to assess the potential inhibitory effects of beta-lapachone, a new anticancer candidate, on the activities of the cytochrome P450 (CYP450) enzymes in vitro.	beta-lapachone	72-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
23877932-1	2013	PURPOSE: This study aimed to assess the potential inhibitory effects of beta-lapachone, a new anticancer candidate, on the activities of the cytochrome P450 (CYP450) enzymes in vitro.	beta-lapachone	72-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-164
23877932-6	2013	CONCLUSIONS: These results suggest that pharmacological drug-drug interactions might occur between beta-lapachone and drugs co-administered with it, which are extensively metabolized by CYP450 enzymes, and thus, careful observation is required in clinical pharmacokinetic studies.	beta-lapachone	99-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-192
23835282-0	2013	Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.	hyperoside	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
23835282-2	2013	In the present study, we investigated potential herb-drug inhibitory effects of hyperoside on nine cytochrome P450 (CYP) isoforms in pooled human liver microsomes (HLMs) and human recombinant cDNA expressed CYP using a cocktail probe assay.	hyperoside	80-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
23835282-2	2013	In the present study, we investigated potential herb-drug inhibitory effects of hyperoside on nine cytochrome P450 (CYP) isoforms in pooled human liver microsomes (HLMs) and human recombinant cDNA expressed CYP using a cocktail probe assay.	hyperoside	80-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
23903277-2	2013	Clopidogrel is a pro-drug which requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits platelet aggregation.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
23903277-2	2013	Clopidogrel is a pro-drug which requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits platelet aggregation.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
23903277-5	2013	Also drug-drug interactions that influence the function of CYP isoenzymes may affect the response to clopidogrel.	Clopidogrel	101-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
23903277-6	2013	Lipophilic statins, such as atorvastatin, are predominantly metabolized by CYP3A4 and may interfere with CYP activation of clopidogrel, contrary to what happens with hydrophilic statins, such as rosuvastin or pravastatin.	Atorvastatin	28-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
23903277-6	2013	Lipophilic statins, such as atorvastatin, are predominantly metabolized by CYP3A4 and may interfere with CYP activation of clopidogrel, contrary to what happens with hydrophilic statins, such as rosuvastin or pravastatin.	Pravastatin	209-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
27536445-2	2013	This study investigated the human metabolites of 4-AP and the cytochrome P450 (CYP450) pathways responsible for 4-AP metabolism.	4-Aminopyridine	112-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
25580095-0	2013	DESIGN, SYNTHESIS, AND EVALUATION OF CARBAZOLE ANALOGS AS POTENTIAL CYTOCHROME P450 INHIBITORS.	carbazole	37-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
23850985-0	2013	Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.	Sesquiterpenes	16-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
23850985-0	2013	Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.	zederone	31-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
23850985-0	2013	Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.	germacrone	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
23850985-1	2013	Misclassification of Curcuma species (family Zingiberaceae) may lead to unwanted human exposure to Curcuma elata sesquiterpenes zederone and germacrone which have caused hepatotoxicity and changes in CYP expression in laboratory animals.	Sesquiterpenes	113-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-203
23850985-1	2013	Misclassification of Curcuma species (family Zingiberaceae) may lead to unwanted human exposure to Curcuma elata sesquiterpenes zederone and germacrone which have caused hepatotoxicity and changes in CYP expression in laboratory animals.	germacrone	141-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-203
23850985-6	2013	CYP inhibition studies with pooled human liver microsomes (HLMs) indicated that zederone and germacrone moderately inhibited CYP2B6 and CYP3A4 activities in vitro, with IC50 values below 10 muM.	zederone	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
23850985-6	2013	CYP inhibition studies with pooled human liver microsomes (HLMs) indicated that zederone and germacrone moderately inhibited CYP2B6 and CYP3A4 activities in vitro, with IC50 values below 10 muM.	germacrone	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
23561191-0	2013	Hepatic biotransformation of alkylresorcinols is mediated via cytochrome P450 and beta-oxidation: a proof of concept study.	alkylresorcinols	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
27536445-2	2013	This study investigated the human metabolites of 4-AP and the cytochrome P450 (CYP450) pathways responsible for 4-AP metabolism.	4-Aminopyridine	112-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-85
23554079-0	2013	Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line.	bixin	10-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
23554079-0	2013	Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line.	norbixin	20-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
23554079-3	2013	In this study, the ability of bixin and norbixin to induce the cytochrome P450 (CYP) enzymes was assessed in HepG2 human hepatoma cell line.	bixin	30-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
23554079-3	2013	In this study, the ability of bixin and norbixin to induce the cytochrome P450 (CYP) enzymes was assessed in HepG2 human hepatoma cell line.	bixin	30-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
23554079-3	2013	In this study, the ability of bixin and norbixin to induce the cytochrome P450 (CYP) enzymes was assessed in HepG2 human hepatoma cell line.	norbixin	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
23554079-3	2013	In this study, the ability of bixin and norbixin to induce the cytochrome P450 (CYP) enzymes was assessed in HepG2 human hepatoma cell line.	norbixin	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	telaprevir	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	telaprevir	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	telaprevir	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	telaprevir	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	Morphine	112-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	Morphine	112-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	Methadone	125-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
23879227-1	2013	Telaprevir (TVR) effects on P-glycloprotein and cytochrome P450 (CYP) may significantly elevate serum levels of morphine and methadone.	Methadone	125-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
23545481-3	2013	Ranks of CLint for CYP-mediated oxidation/dealkylation of MEHP were human liver&gt;rat liver&gt;human intestine&gt;rat intestine.	mono-(2-ethylhexyl)phthalate	58-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
23545481-7	2013	These species/organ differences in major metabolic pathway and CYP isoforms should be considered for appraisal of the potential adverse health effects of DEHP.	Diethylhexyl Phthalate	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	epoxyeicosatrienoic acids	53-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23851904-0	2013	GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicin.	Steroids	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
23851904-0	2013	GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicin.	Rifampin	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
23851904-2	2013	METHODS: Urinary steroid profiling based on gas chromatography-mass spectrometry (GC-MS) was used for simultaneous quantification of CYP-mediated regioselective hydroxysteroids and their substrates, including 26 androgens, 9 estrogens, 5 progestins, and 7 corticoids.	Steroids	17-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
23851904-3	2013	The quantitative data were visualized using a hierarchically clustered heat map to allow identification of CYP-mediated steroid signatures.	Steroids	120-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
23851904-4	2013	Twelve healthy subjects were orally administered 600 mg of rifampicin a day for 7 days, and their CYP enzyme activity was evaluated.	Rifampin	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
23851904-8	2013	CONCLUSIONS: This CYP-mediated steroid signature profile allows simultaneous assessment of CYP1A, CYP1B, CYP2C, CYP3A, CYP11B, CYP17A, CYP19A, and CYP21A in urine samples.	Steroids	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
23880855-0	2013	Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.	Ospemifene	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
23880855-1	2013	The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism.	Ospemifene	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
23880855-1	2013	The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism.	Ospemifene	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
23880855-2	2013	Ospemifene underwent testing for possible effects on CYP enzyme activity in human liver microsomes and in isolated human hepatocytes.	Ospemifene	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
23880855-3	2013	Based on the results obtained in vitro, three Phase 1 crossover pharmacokinetic studies were conducted in healthy postmenopausal women to assess the in vivo effects of ospemifene on CYP-mediated drug metabolism.	Ospemifene	168-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-185
23880855-8	2013	Therefore, the risk that ospemifene will affect the pharmacokinetics of drugs that are substrates for CYP enzymes is low.	Ospemifene	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
23479398-3	2013	Efavirenz and protease inhibitor boosted with ritonavir are major components of the antiretroviral therapy and are inducers and/or inhibitors of several cytochrome P450 (CYP) isoforms.	Ritonavir	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
23479398-3	2013	Efavirenz and protease inhibitor boosted with ritonavir are major components of the antiretroviral therapy and are inducers and/or inhibitors of several cytochrome P450 (CYP) isoforms.	Ritonavir	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
23983642-5	2013	Cytochrome p450 (CYP) families are implicated in the metabolic activation of BQ- and areca nut-specific nitrosamines.	Nitrosamines	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23983642-5	2013	Cytochrome p450 (CYP) families are implicated in the metabolic activation of BQ- and areca nut-specific nitrosamines.	Nitrosamines	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
23643326-2	2013	Since ATRA is metabolized by cytochrome P450 (CYP) enzymes, we sought to identify drug interactions that might be associated with a higher risk for the development of DS in addition to other predictive factors related to the incidence of DS.	Tretinoin	6-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
23643326-2	2013	Since ATRA is metabolized by cytochrome P450 (CYP) enzymes, we sought to identify drug interactions that might be associated with a higher risk for the development of DS in addition to other predictive factors related to the incidence of DS.	Tretinoin	6-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	epoxyeicosatrienoic acids	53-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	eets	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	eets	80-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	-hydroxy-5,8	92-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	-hydroxy-5,8	92-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
24216999-2	2013	Cytochrome P450 (CYP) activity and synthesis of both epoxyeicosatrienoic acids (EETs) and 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE), together with vascular endothelial growth factor (VEGF) and heme oxygenase system (HO) have emerged as important modulators of tumor growth and metastasis.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
23632015-1	2013	Cytochrome P450 enzymes have major roles in the metabolism of steroids, drugs, carcinogens, eicosanoids, and numerous other chemicals.	Steroids	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23632015-1	2013	Cytochrome P450 enzymes have major roles in the metabolism of steroids, drugs, carcinogens, eicosanoids, and numerous other chemicals.	Eicosanoids	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23632016-1	2013	Cytochrome P450 enzymes primarily catalyze mixed-function oxidation reactions, plus some reductions and rearrangements of oxygenated species, e.g. prostaglandins.	Prostaglandins	147-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23619744-8	2013	Surprisingly, the CYP metabolites of AA, epoxyeicosatrienoic acids (EETs), were much less potent activators of TRPV4, and CYP inhibitors did not affect EET production in HCAECs.	epoxyeicosatrienoic acids	41-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
23256458-0	2013	The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro.	Acrylamide	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
23600686-0	2013	Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy.	Arachidonic Acid	33-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
23600686-3	2013	The alteration in CYP and sEH expression results in derailed CYP-mediated arachidonic acid (AA) metabolism.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
23600686-3	2013	The alteration in CYP and sEH expression results in derailed CYP-mediated arachidonic acid (AA) metabolism.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
26583848-0	2013	The Fe(III)(H2O2) Complex as a Highly Efficient Oxidant in Sulfoxidation Reactions: Revival of an Underrated Oxidant in Cytochrome P450.	ferric sulfate	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
26583848-0	2013	The Fe(III)(H2O2) Complex as a Highly Efficient Oxidant in Sulfoxidation Reactions: Revival of an Underrated Oxidant in Cytochrome P450.	Hydrogen Peroxide	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
23149816-2	2013	Clopidogrel is a prodrug which requires a two-step hepatic biotransformation thanks to the cytochrome P450 (CYP450) enzyme system.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
23149816-2	2013	Clopidogrel is a prodrug which requires a two-step hepatic biotransformation thanks to the cytochrome P450 (CYP450) enzyme system.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-114
23149816-3	2013	Genetic polymorphism of CYP450 system (e.g., CYP2C19*2) responsible for altered clopidogrel metabolism is a major cause of high on-treatment platelet reactivity (HTPR), which translates into thrombotic events in stented patients.	Clopidogrel	80-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-30
23379642-3	2013	ROS is produced by a number of pathways, including the mitochondrial electron transport chain, cytochrome P450, xanthine oxidase and uncoupled nitric oxide synthase.	Reactive Oxygen Species	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Clotrimazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Clotrimazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Clotrimazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Azoles	7-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Azoles	7-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
23340899-1	2013	Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP.	Azoles	7-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-170
23619744-8	2013	Surprisingly, the CYP metabolites of AA, epoxyeicosatrienoic acids (EETs), were much less potent activators of TRPV4, and CYP inhibitors did not affect EET production in HCAECs.	eets	68-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	Polycyclic Aromatic Hydrocarbons	69-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	Polycyclic Aromatic Hydrocarbons	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	acenaphthene	154-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	acenaphthylene	168-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	benzo(c)phenanthrene	184-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	fluoranthene	206-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	fluoranthene-2,3-diol	220-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
23432465-1	2013	Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene.	1-nitropyrene	247-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-33
22999230-3	2013	Concentrations of doxepin metabolites and isomers, pharmacokinetic modelling and genotyping of the doxepin-metabolizing cytochrome P450 (CYP) enzymes led to the following conclusion: the lethal doxepin concentration of 2100 ng/mL was more likely to have been reached due to drug interactions and genetic peculiarities leading to a reduction of the metabolic capacity and not by an acute (suicidal) overdose.	Doxepin	99-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
22999230-3	2013	Concentrations of doxepin metabolites and isomers, pharmacokinetic modelling and genotyping of the doxepin-metabolizing cytochrome P450 (CYP) enzymes led to the following conclusion: the lethal doxepin concentration of 2100 ng/mL was more likely to have been reached due to drug interactions and genetic peculiarities leading to a reduction of the metabolic capacity and not by an acute (suicidal) overdose.	Doxepin	99-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
22999230-3	2013	Concentrations of doxepin metabolites and isomers, pharmacokinetic modelling and genotyping of the doxepin-metabolizing cytochrome P450 (CYP) enzymes led to the following conclusion: the lethal doxepin concentration of 2100 ng/mL was more likely to have been reached due to drug interactions and genetic peculiarities leading to a reduction of the metabolic capacity and not by an acute (suicidal) overdose.	Doxepin	99-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
22999230-3	2013	Concentrations of doxepin metabolites and isomers, pharmacokinetic modelling and genotyping of the doxepin-metabolizing cytochrome P450 (CYP) enzymes led to the following conclusion: the lethal doxepin concentration of 2100 ng/mL was more likely to have been reached due to drug interactions and genetic peculiarities leading to a reduction of the metabolic capacity and not by an acute (suicidal) overdose.	Doxepin	99-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
23299247-2	2013	This study characterized the phase I and phase II metabolites, metabolic kinetics, and cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes responsible for the metabolism of jatrorrhizine in human liver microsomes (HLMs).	jatrorrhizine	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
23466098-0	2013	Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.	Eicosanoids	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23466098-1	2013	OBJECTIVE: Accumulating preclinical and epidemiologic evidence has emerged to suggest that modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable vascular protective therapeutic strategy for the secondary prevention of coronary artery disease (CAD).	Eicosanoids	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
23466098-1	2013	OBJECTIVE: Accumulating preclinical and epidemiologic evidence has emerged to suggest that modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable vascular protective therapeutic strategy for the secondary prevention of coronary artery disease (CAD).	Eicosanoids	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
23466098-2	2013	The functional relationship between CYP-derived eicosanoid metabolite levels and vascular dysfunction in humans with established CAD, however, has not been evaluated.	Eicosanoids	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
23466098-5	2013	Relationships between biomarkers of CYP-mediated eicosanoid metabolism and vascular function phenotypes were evaluated by Pearson"s correlation.	Eicosanoids	49-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
23466098-6	2013	RESULTS: A significant inverse association was observed between 20-HETE levels (a biomarker of CYP omega-hydroxylase metabolism) and brachial artery flow-mediated dilation (r = -0.255, p = 0.010).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Brz2001	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Brz2001	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-147
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Brassinosteroids	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Brassinosteroids	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-147
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Triazoles	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
23299247-2	2013	This study characterized the phase I and phase II metabolites, metabolic kinetics, and cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes responsible for the metabolism of jatrorrhizine in human liver microsomes (HLMs).	jatrorrhizine	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Triazoles	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-147
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Heme	174-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-147
23319543-0	2013	Estradiol-17beta and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites selectively stimulate production of prostacyclin in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta.	Epoprostenol	131-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-74
23514038-3	2013	Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron.	Iron	183-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-147
23480885-1	2013	Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele.	Clopidogrel	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
23480885-1	2013	Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele.	Clopidogrel	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
23682310-0	2013	How Do Perfluorinated Alkanoic Acids Elicit Cytochrome P450 to Catalyze Methane Hydroxylation?	alkanoic acids	22-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
23682310-0	2013	How Do Perfluorinated Alkanoic Acids Elicit Cytochrome P450 to Catalyze Methane Hydroxylation?	Methane	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
23336137-5	2013	RESULTS: The cytochrome P-450 catalyzed hydroxylation rate decreased as the number of chlorine substitutions increased.	Chlorine	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
23599745-6	2013	AFB1 is metabolized by cytochrome-P450 enzymes to the reactive intermediate AFB1-8, 9 epoxide (AFBO) which binds to liver cell DNA, resulting in DNA adducts.	Aflatoxin B1	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
23599745-6	2013	AFB1 is metabolized by cytochrome-P450 enzymes to the reactive intermediate AFB1-8, 9 epoxide (AFBO) which binds to liver cell DNA, resulting in DNA adducts.	afb1-8, 9 epoxide	76-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
23599745-6	2013	AFB1 is metabolized by cytochrome-P450 enzymes to the reactive intermediate AFB1-8, 9 epoxide (AFBO) which binds to liver cell DNA, resulting in DNA adducts.	afbo	95-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
23117072-1	2013	BACKGROUND: This study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate (IM) and clinical response in chronic myeloid leukemia (CML).	Imatinib Mesylate	156-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
23117072-1	2013	BACKGROUND: This study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate (IM) and clinical response in chronic myeloid leukemia (CML).	Imatinib Mesylate	156-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
23406885-5	2013	FINDINGS: We conducted CYP phenotyping in recombinantly expressed systems, and in human liver microsomes, to evaluate CYP isozyme contributions to the metabolism of PiB (carrier) and profiled microsomal and hepatocyte incubations for metabolites.	4-iodobenzenesulfonamide	165-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
22937971-0	2013	Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.	cyclic phosphates	43-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
22937971-0	2013	Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.	Mesalamine	64-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	cyclic phosphates	11-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	cyclic phosphates	11-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-143
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	Mesalamine	60-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	Mesalamine	60-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-143
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	Mesalamine	83-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
22937971-1	2013	Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs.	Mesalamine	83-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-143
22765278-3	2013	METHODS: Fourteen healthy, male volunteers aged 18 to 45 years were recruited into an open label, two period, single centre study in which CYP enzyme activity was measured by administration of the selectively metabolized probe drugs theophylline (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6) and dapsone (CYP3A4) on day 1 of the study.	Theophylline	233-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
22765278-3	2013	METHODS: Fourteen healthy, male volunteers aged 18 to 45 years were recruited into an open label, two period, single centre study in which CYP enzyme activity was measured by administration of the selectively metabolized probe drugs theophylline (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6) and dapsone (CYP3A4) on day 1 of the study.	Tolbutamide	256-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
22765278-3	2013	METHODS: Fourteen healthy, male volunteers aged 18 to 45 years were recruited into an open label, two period, single centre study in which CYP enzyme activity was measured by administration of the selectively metabolized probe drugs theophylline (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6) and dapsone (CYP3A4) on day 1 of the study.	Mephenytoin	278-289	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
22765278-3	2013	METHODS: Fourteen healthy, male volunteers aged 18 to 45 years were recruited into an open label, two period, single centre study in which CYP enzyme activity was measured by administration of the selectively metabolized probe drugs theophylline (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6) and dapsone (CYP3A4) on day 1 of the study.	Debrisoquin	301-313	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
22765278-3	2013	METHODS: Fourteen healthy, male volunteers aged 18 to 45 years were recruited into an open label, two period, single centre study in which CYP enzyme activity was measured by administration of the selectively metabolized probe drugs theophylline (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6) and dapsone (CYP3A4) on day 1 of the study.	Dapsone	327-334	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
23224081-5	2013	Mass spectrometric analysis identified CYP2S1 as a novel macrophage CYP and CYP2S1-containing microsomes generated epoxides of arachidonic, linoleic and eicosapentaenoic acid.	Epoxy Compounds	115-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
22809523-3	2013	CYP reactions in vivo require the cofactor NADPH as the source of electrons and an additional enzyme, cytochrome P450 reductase (CPR), as the electron transfer partner; consequently, any laboratory or industrial use of CYPs is limited by the need to supply NADPH and CPR.	NADP	43-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22809523-3	2013	CYP reactions in vivo require the cofactor NADPH as the source of electrons and an additional enzyme, cytochrome P450 reductase (CPR), as the electron transfer partner; consequently, any laboratory or industrial use of CYPs is limited by the need to supply NADPH and CPR.	NADP	257-262	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
23215036-1	2013	The explosive Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is known to be degraded aerobically by various isolates of the Rhodococcus species, with denitration being the key step, mediated by Cytochrome P450.	cyclonite	14-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-208
23215036-1	2013	The explosive Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is known to be degraded aerobically by various isolates of the Rhodococcus species, with denitration being the key step, mediated by Cytochrome P450.	cyclonite	55-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-208
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Midazolam	214-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Midazolam	214-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
24362992-1	2013	Lanosterol 14a-demethylase CYP51 is the most conserved cytochrome P450 (CYP) and is a part of hepatic cholesterol synthesis.	Lanosterol	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
24362992-1	2013	Lanosterol 14a-demethylase CYP51 is the most conserved cytochrome P450 (CYP) and is a part of hepatic cholesterol synthesis.	Lanosterol	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
24362992-1	2013	Lanosterol 14a-demethylase CYP51 is the most conserved cytochrome P450 (CYP) and is a part of hepatic cholesterol synthesis.	Cholesterol	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
24362992-1	2013	Lanosterol 14a-demethylase CYP51 is the most conserved cytochrome P450 (CYP) and is a part of hepatic cholesterol synthesis.	Cholesterol	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
23224081-1	2013	Cytochrome P450 (CYP) epoxygenases metabolize endogenous polyunsaturated fatty acids to their corresponding epoxides, generating bioactive lipid mediators.	Fatty Acids, Unsaturated	57-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23224081-1	2013	Cytochrome P450 (CYP) epoxygenases metabolize endogenous polyunsaturated fatty acids to their corresponding epoxides, generating bioactive lipid mediators.	Fatty Acids, Unsaturated	57-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
23224081-1	2013	Cytochrome P450 (CYP) epoxygenases metabolize endogenous polyunsaturated fatty acids to their corresponding epoxides, generating bioactive lipid mediators.	Epoxy Compounds	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23224081-1	2013	Cytochrome P450 (CYP) epoxygenases metabolize endogenous polyunsaturated fatty acids to their corresponding epoxides, generating bioactive lipid mediators.	Epoxy Compounds	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
23224081-5	2013	Mass spectrometric analysis identified CYP2S1 as a novel macrophage CYP and CYP2S1-containing microsomes generated epoxides of arachidonic, linoleic and eicosapentaenoic acid.	arachidonic	127-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
23224081-5	2013	Mass spectrometric analysis identified CYP2S1 as a novel macrophage CYP and CYP2S1-containing microsomes generated epoxides of arachidonic, linoleic and eicosapentaenoic acid.	Linoleic Acid	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
23224081-5	2013	Mass spectrometric analysis identified CYP2S1 as a novel macrophage CYP and CYP2S1-containing microsomes generated epoxides of arachidonic, linoleic and eicosapentaenoic acid.	Eicosapentaenoic Acid	153-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
23587001-1	2013	The mammalian cytochrome P450 (CYP) enzymes play important roles in drug metabolism, steroid biosynthesis, and xenobiotic degradation.	Steroids	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
23587001-1	2013	The mammalian cytochrome P450 (CYP) enzymes play important roles in drug metabolism, steroid biosynthesis, and xenobiotic degradation.	Steroids	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
23586999-0	2013	Amphipol trapping of a functional CYP system.	amphipol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
23419353-0	2013	In vitro inhibition and induction of human liver cytochrome P450 enzymes by gentiopicroside: potent effect on CYP2A6.	gentiopicroside	76-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
23001793-0	2013	Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes.	tetrahydropalmatine	36-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
23688132-5	2013	These inhibitors generally target the cytochrome P450 (CYP) enzymes because RA clearance is predominantly mediated by P450s.	Tretinoin	76-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
23688132-5	2013	These inhibitors generally target the cytochrome P450 (CYP) enzymes because RA clearance is predominantly mediated by P450s.	Tretinoin	76-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
23688133-0	2013	CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid omega-hydroxylase activities.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	125-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-175
23165864-8	2013	Genetic factors including single nucleotide polymorphisms (SNPs) that change cytochrome P450 (CYP) activity and epigenetic regulation that modifies CYP expression levels may contribute to the changes in pharmacokinetics and adverse drug reactions (ADRs) of thalidomide.	Thalidomide	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
23165864-8	2013	Genetic factors including single nucleotide polymorphisms (SNPs) that change cytochrome P450 (CYP) activity and epigenetic regulation that modifies CYP expression levels may contribute to the changes in pharmacokinetics and adverse drug reactions (ADRs) of thalidomide.	Thalidomide	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
23419353-2	2013	However, the inhibitory and inducible effects of GE on the activity of cytochrome P450 (CYP450) are unclear.	gentiopicroside	49-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
23419353-2	2013	However, the inhibitory and inducible effects of GE on the activity of cytochrome P450 (CYP450) are unclear.	gentiopicroside	49-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-94
23903227-0	2013	Enhancement of quinone hepatotoxicity by cytochrome P450 inhibition.	quinone	15-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
23293967-4	2013	We investigated the levels of 8- hydroxydeoxyguanosine (8-OHdG), one of the most sensitive biomarkers for measuring OS and the association between polymorphisms in Cytochrome P450 (CYP) and Glutathione S-Transferase (GST) genes that are known to play a significant role in the activation and detoxification of xenobiotics.	8-ohdg	56-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
22426195-2	2013	A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier.	Docetaxel	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
22426195-2	2013	A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier.	Ketoconazole	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
23483888-5	2013	Our data in centenarians support promotion of cellular detoxification mechanisms through specific modulation of the arachidonic acid metabolic cascade as we underpinned increased concentration of 8,9-EpETrE, suggesting enhanced cytochrome P450 (CYP) enzyme activity.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
23483888-5	2013	Our data in centenarians support promotion of cellular detoxification mechanisms through specific modulation of the arachidonic acid metabolic cascade as we underpinned increased concentration of 8,9-EpETrE, suggesting enhanced cytochrome P450 (CYP) enzyme activity.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-248
23481074-0	2013	Cytochrome P450 (CYP2C9*2,*3) &amp; vitamin-K epoxide reductase complex (VKORC1 -1639G&lt;A) gene polymorphisms &amp; their effect on acenocoumarol dose in patients with mechanical heart valve replacement.	Acenocoumarol	134-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23481074-1	2013	BACKGROUND &amp; OBJECTIVES: Studies have demonstrated the effect of CYP2C9 (cytochrome P450) and VKORC1 (vitamin K epoxide reductase complex) gene polymorphisms on the dose of acenocoumarol.	Adenosine Monophosphate	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
23481074-1	2013	BACKGROUND &amp; OBJECTIVES: Studies have demonstrated the effect of CYP2C9 (cytochrome P450) and VKORC1 (vitamin K epoxide reductase complex) gene polymorphisms on the dose of acenocoumarol.	Acenocoumarol	177-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
23947696-1	2013	Iron(III)-porphyrin complexes are generally regarded as green catalysts, since they mimic the catalytic center of cytochrome-P450 and widely used as green catalysts for degrading halogenated phenols in wastewater, such as landfill leachates.	iron(iii)-porphyrin	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
23947696-1	2013	Iron(III)-porphyrin complexes are generally regarded as green catalysts, since they mimic the catalytic center of cytochrome-P450 and widely used as green catalysts for degrading halogenated phenols in wastewater, such as landfill leachates.	Phenols	191-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
23903227-4	2013	A drug metabolizing enzyme, cytochrome P450 is closely involved in the hepatotoxicity of therapeutic agents in general, but quinone hepatotoxicity has been considered not to contribute to cytochrome P450 because the structure of quinone is not modified by cytochrome P450 and thus quinone compounds are thought to be metabolized mainly via a conjugation process.	quinone	229-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
23903227-4	2013	A drug metabolizing enzyme, cytochrome P450 is closely involved in the hepatotoxicity of therapeutic agents in general, but quinone hepatotoxicity has been considered not to contribute to cytochrome P450 because the structure of quinone is not modified by cytochrome P450 and thus quinone compounds are thought to be metabolized mainly via a conjugation process.	quinone	229-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
23903227-5	2013	However, we have recently shown that quinone hepatotoxicity is enhanced under conditions of cytochrome P450 inhibition, indicating clearly the involvement of cytochrome P450 in quinone hepatotoxicity.	quinone	37-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
23903227-5	2013	However, we have recently shown that quinone hepatotoxicity is enhanced under conditions of cytochrome P450 inhibition, indicating clearly the involvement of cytochrome P450 in quinone hepatotoxicity.	quinone	37-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-173
23903227-5	2013	However, we have recently shown that quinone hepatotoxicity is enhanced under conditions of cytochrome P450 inhibition, indicating clearly the involvement of cytochrome P450 in quinone hepatotoxicity.	quinone	177-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
23903227-5	2013	However, we have recently shown that quinone hepatotoxicity is enhanced under conditions of cytochrome P450 inhibition, indicating clearly the involvement of cytochrome P450 in quinone hepatotoxicity.	quinone	177-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-173
23903227-6	2013	Here, we revisit the generally accepted mechanisms of quinone hepatotoxicity and propose the importance of cytochrome P450 systems in quinone-induced hepatotoxicity on the basis of our recent work.	quinone	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
23186213-1	2012	Cytochrome P450 (P450) 2E1 is the major enzyme that oxidizes N-nitrosodimethylamine [N,N-dimethylnitrosamine (DMN)], a carcinogen and also a representative of some nitrosamines formed endogenously.	Dimethylnitrosamine	61-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
23186213-1	2012	Cytochrome P450 (P450) 2E1 is the major enzyme that oxidizes N-nitrosodimethylamine [N,N-dimethylnitrosamine (DMN)], a carcinogen and also a representative of some nitrosamines formed endogenously.	Dimethylnitrosamine	85-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
23186213-1	2012	Cytochrome P450 (P450) 2E1 is the major enzyme that oxidizes N-nitrosodimethylamine [N,N-dimethylnitrosamine (DMN)], a carcinogen and also a representative of some nitrosamines formed endogenously.	Dimethylnitrosamine	110-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
23186213-1	2012	Cytochrome P450 (P450) 2E1 is the major enzyme that oxidizes N-nitrosodimethylamine [N,N-dimethylnitrosamine (DMN)], a carcinogen and also a representative of some nitrosamines formed endogenously.	Nitrosamines	164-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
22834478-6	2012	Whereas positive controls (100 microM omeprazole and 10 microM rifampin) caused the anticipated CYP induction, the highest concentration of mirabegron (10 microM; 37 times plasma C(max)) had minimal effect on CYP1A2 and CYP3A4/5 activity, and CYP1A2 and CYP3A4 mRNA levels in freshly isolated human hepatocytes, suggesting that mirabegron is not an inducer of these enzymes.	Rifampin	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
23174983-2	2012	The catalytic properties of cytochrome P-450 and soluble methane monooxygenase enzymes are associated with oxo species on mononuclear iron haem and diiron non-haem platforms, respectively.	Iron	134-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
23174983-2	2012	The catalytic properties of cytochrome P-450 and soluble methane monooxygenase enzymes are associated with oxo species on mononuclear iron haem and diiron non-haem platforms, respectively.	diiron	148-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
23174983-2	2012	The catalytic properties of cytochrome P-450 and soluble methane monooxygenase enzymes are associated with oxo species on mononuclear iron haem and diiron non-haem platforms, respectively.	Heme	139-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
23585710-2	2012	Herein we validate the use of our non-heme iron complex, Fe(PDP), as an oxidative tailoring enzyme mimic to test the proposal that this class of natural products derives from cafestol via cytochrome P-450-mediated furan oxidation.	Iron	43-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
23585710-2	2012	Herein we validate the use of our non-heme iron complex, Fe(PDP), as an oxidative tailoring enzyme mimic to test the proposal that this class of natural products derives from cafestol via cytochrome P-450-mediated furan oxidation.	Iron	57-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
23585710-2	2012	Herein we validate the use of our non-heme iron complex, Fe(PDP), as an oxidative tailoring enzyme mimic to test the proposal that this class of natural products derives from cafestol via cytochrome P-450-mediated furan oxidation.	cafestol	175-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
23585710-2	2012	Herein we validate the use of our non-heme iron complex, Fe(PDP), as an oxidative tailoring enzyme mimic to test the proposal that this class of natural products derives from cafestol via cytochrome P-450-mediated furan oxidation.	furan	214-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
22851614-4	2012	Cytochrome P450 (P450) phenotyping studies revealed that the formation of M1 and M2 were NADPH-dependent and primarily catalyzed by CYP3A4 among the studied P450 isoforms.	NADP	89-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22676424-3	2012	We examined the effect rifampicin, a well-known inducer of many cytochrome P450 (CYP) enzymes and transporters, on the pharmacokinetics of intravenous and oral S-ketamine in healthy volunteers.	Rifampin	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
22676424-3	2012	We examined the effect rifampicin, a well-known inducer of many cytochrome P450 (CYP) enzymes and transporters, on the pharmacokinetics of intravenous and oral S-ketamine in healthy volunteers.	Rifampin	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
22738989-3	2012	In the present study, the oxidative metabolism of BDE-99 was assessed using pooled and single-donor human liver microsomes, a panel of human recombinant cytochrome P450 (CYP) enzymes, and CYP-specific antibodies.	2,2',4,4',5-brominated diphenyl ether	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
23092891-1	2012	Cytochrome P450 enzymes catalyze the biosynthesis of steroid hormones and metabolize drugs.	Steroids	53-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Hydrogen Peroxide	62-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Platinum	85-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Reactive Oxygen Species	114-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Platinum	164-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Oxygen	123-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22927483-3	2012	Sorafenib metabolism was evaluated in vitro at 10 mumol/L using a panel of purified human cytochrome P450 (CYP) enzymes.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
22927483-3	2012	Sorafenib metabolism was evaluated in vitro at 10 mumol/L using a panel of purified human cytochrome P450 (CYP) enzymes.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
22828666-7	2012	At a low dose, 5 mug/ml (15 muM), carnosic acid activated the expression of 3 genes, induced through the presence of antioxidant response elements, including genes involved in glutathione biosynthesis (CYP4F3, GCLC) and transport (SLC7A11).	salvin	34-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-208
22828666-7	2012	At a low dose, 5 mug/ml (15 muM), carnosic acid activated the expression of 3 genes, induced through the presence of antioxidant response elements, including genes involved in glutathione biosynthesis (CYP4F3, GCLC) and transport (SLC7A11).	Glutathione	176-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-208
22738989-3	2012	In the present study, the oxidative metabolism of BDE-99 was assessed using pooled and single-donor human liver microsomes, a panel of human recombinant cytochrome P450 (CYP) enzymes, and CYP-specific antibodies.	2,2',4,4',5-brominated diphenyl ether	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
22738989-3	2012	In the present study, the oxidative metabolism of BDE-99 was assessed using pooled and single-donor human liver microsomes, a panel of human recombinant cytochrome P450 (CYP) enzymes, and CYP-specific antibodies.	2,2',4,4',5-brominated diphenyl ether	50-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
22621785-3	2012	Epoxyeicosatrienoic acids (EETs), products of cytochrome P-450 epoxidation of arachidonic acid, have vasculoprotective and anti-inflammatory effects including inhibition of platelet activation, cell migration, and adhesion.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
22639088-0	2012	Defluorination of 4-fluorophenol by cytochrome P450(BM3)-F87G: activation by long chain fatty aldehydes.	4-fluorophenol	18-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-55
22639088-0	2012	Defluorination of 4-fluorophenol by cytochrome P450(BM3)-F87G: activation by long chain fatty aldehydes.	long chain fatty aldehydes	77-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-55
22639088-1	2012	Cytochrome P450(BM3)-F87G catalyzed the oxidative defluorination of 4-fluorophenol, followed by reduction of the resulting benzoquinone to hydroquinone via the NADPH P450-reductase activity of the enzyme.	4-fluorophenol	68-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
22639088-1	2012	Cytochrome P450(BM3)-F87G catalyzed the oxidative defluorination of 4-fluorophenol, followed by reduction of the resulting benzoquinone to hydroquinone via the NADPH P450-reductase activity of the enzyme.	quinone	123-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
22639088-1	2012	Cytochrome P450(BM3)-F87G catalyzed the oxidative defluorination of 4-fluorophenol, followed by reduction of the resulting benzoquinone to hydroquinone via the NADPH P450-reductase activity of the enzyme.	hydroquinone	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
22411763-1	2012	Previously, our laboratory reported that cyclic peptide prodrugs of the opioid peptide H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE) are metabolized by cytochrome P450 (CYP450) enzymes, which limits their systemic exposure after oral dosing to animals.	DADLE	87-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
22411763-1	2012	Previously, our laboratory reported that cyclic peptide prodrugs of the opioid peptide H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE) are metabolized by cytochrome P450 (CYP450) enzymes, which limits their systemic exposure after oral dosing to animals.	DADLE	87-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-166
22411763-1	2012	Previously, our laboratory reported that cyclic peptide prodrugs of the opioid peptide H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE) are metabolized by cytochrome P450 (CYP450) enzymes, which limits their systemic exposure after oral dosing to animals.	DADLE	117-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
22411763-1	2012	Previously, our laboratory reported that cyclic peptide prodrugs of the opioid peptide H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE) are metabolized by cytochrome P450 (CYP450) enzymes, which limits their systemic exposure after oral dosing to animals.	DADLE	117-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-166
22634049-4	2012	By both a pharmacological and a siRNA approaches, we demonstrated that recruitment of the Pregnane X Receptor (PXR) was required to mediate CYP4F3 induction by lovastatin.	Lovastatin	160-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-146
22634049-5	2012	Furthermore, the CYP4F3 gene promoter was transcriptionally activated by PXR, and responded to lovastatin.	Lovastatin	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
22634049-6	2012	Finally, the expression of fatty acid-responsive genes was increased in response to the statin or 20-HETE in a CYP4F3-dependent way.	Fatty Acids	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-117
22634049-7	2012	We propose that metabolites produced by CYP4F3 could modulate lipid metabolism in response to lovastatin.	Lovastatin	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-46
22808947-1	2012	Although pharmaceutical excipients are supposed to be pharmacologically inactive, solubilizing agents like Cremophor EL have been shown to interact with cytochrome P450 (CYP)-dependent drug metabolism as well as efflux transporters such as P-glycoprotein (ABCB1) and multidrug resistance associated protein 2 (ABCC2).	cremophor EL	107-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
22808947-1	2012	Although pharmaceutical excipients are supposed to be pharmacologically inactive, solubilizing agents like Cremophor EL have been shown to interact with cytochrome P450 (CYP)-dependent drug metabolism as well as efflux transporters such as P-glycoprotein (ABCB1) and multidrug resistance associated protein 2 (ABCC2).	cremophor EL	107-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
22773874-2	2012	We demonstrated that, like testosterone, dihydrotestosterone can be oxidized by human cytochrome P450 (P450) 19A1, the steroid aromatase.	Testosterone	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-113
22773874-2	2012	We demonstrated that, like testosterone, dihydrotestosterone can be oxidized by human cytochrome P450 (P450) 19A1, the steroid aromatase.	Dihydrotestosterone	41-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-113
22610824-0	2012	Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate.	reactive	141-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
22610824-0	2012	Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate.	nitroso intermediate	150-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
22610824-7	2012	The study was performed using Cpd I [iron (IV-oxo] heme porphine with SH(-) as the axial ligand) to represent the catalytic domain of CYP, simulating the biotransformation process.	iron (iv-oxo] heme porphine	37-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
22621785-3	2012	Epoxyeicosatrienoic acids (EETs), products of cytochrome P-450 epoxidation of arachidonic acid, have vasculoprotective and anti-inflammatory effects including inhibition of platelet activation, cell migration, and adhesion.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
22621785-3	2012	Epoxyeicosatrienoic acids (EETs), products of cytochrome P-450 epoxidation of arachidonic acid, have vasculoprotective and anti-inflammatory effects including inhibition of platelet activation, cell migration, and adhesion.	Arachidonic Acid	78-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
22173545-0	2012	Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?	Arachidonic Acid	104-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
22101002-1	2012	The thick ascending limb of Henle"s loop (TAL) is capable of metabolizing arachidonic acid (AA) by cytochrome P450 (CYP450) and cyclooxygenase (COX) pathways and has been identified as a nephron segment that contributes to salt-sensitive hypertension.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
22686547-14	2012	Saxagliptin and, to a lesser extent, sitagliptin are largely metabolized by hepatic cytochrome P450 (CYP) 3A4 and 3A5 isoforms.	saxagliptin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
22686547-14	2012	Saxagliptin and, to a lesser extent, sitagliptin are largely metabolized by hepatic cytochrome P450 (CYP) 3A4 and 3A5 isoforms.	saxagliptin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
22686547-14	2012	Saxagliptin and, to a lesser extent, sitagliptin are largely metabolized by hepatic cytochrome P450 (CYP) 3A4 and 3A5 isoforms.	Sitagliptin Phosphate	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
22686547-14	2012	Saxagliptin and, to a lesser extent, sitagliptin are largely metabolized by hepatic cytochrome P450 (CYP) 3A4 and 3A5 isoforms.	Sitagliptin Phosphate	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
22788578-7	2012	In this review, the known in vitro and in vivo effects of resveratrol on various cytochrome P450 (CYP) isoenzymes are summarized.	Resveratrol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
22788578-7	2012	In this review, the known in vitro and in vivo effects of resveratrol on various cytochrome P450 (CYP) isoenzymes are summarized.	Resveratrol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
22101002-1	2012	The thick ascending limb of Henle"s loop (TAL) is capable of metabolizing arachidonic acid (AA) by cytochrome P450 (CYP450) and cyclooxygenase (COX) pathways and has been identified as a nephron segment that contributes to salt-sensitive hypertension.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-122
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	Arachidonic Acid	45-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	Arachidonic Acid	45-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	107-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	107-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	Sodium	206-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22173545-2	2012	Cytochrome P450 (CYP)-derived metabolites of arachidonic acid such as epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE), active on vascular tone, endothelial function and renal sodium reapportion, have been identified as candidate mediators in the development of hypertension in several animal models, with remarkable sex-specific effect.	Sodium	206-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	n-oxide	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	n-oxide	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
22513143-4	2012	In the present study CYP-mediated pathways of sorafenib oxidation in human liver were evaluated.	Sorafenib	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
22513143-7	2012	In human hepatic microsomes metabolite formation was correlated with CYP3A4-mediated midazolam 1"-hydroxylation, but not with other CYP-specific substrate oxidations.	Midazolam	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
22541353-4	2012	High CYP expression and activities could be further enhanced by culturing the induced HDFs either as spheroids or into several kinds of scaffolds, particularly the tri-copolymer scaffold composed of gelatin, chondroitin and hyaluronan.	tri-copolymer	164-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-8
22541353-4	2012	High CYP expression and activities could be further enhanced by culturing the induced HDFs either as spheroids or into several kinds of scaffolds, particularly the tri-copolymer scaffold composed of gelatin, chondroitin and hyaluronan.	Chondroitin	208-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-8
22541353-4	2012	High CYP expression and activities could be further enhanced by culturing the induced HDFs either as spheroids or into several kinds of scaffolds, particularly the tri-copolymer scaffold composed of gelatin, chondroitin and hyaluronan.	Hyaluronic Acid	224-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-8
22513183-2	2012	This review focuses on the therapeutic promise of dihydroquercetin in major disease states such as cancer, cardiovascular disease and liver disease by reviewing the proposed mechanism(s) of action, including the activation of the antioxidant response element (ARE) and detoxifying phase II enzymes, inhibition of cytochrome P(450) and fatty acid synthase in carcinogenesis.	taxifolin	50-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	313-330
22233204-12	2012	RESULTS: In vitro studies demonstrated low potential for CYP inhibition (IC(50) estimates tofacitinib &gt; 30 microm), CYP3A4 mRNA induction (observed at tofacitinib concentrations &gt;= 25 microm) and no effect on enzymatic activity of CYP substrates.	tofacitinib	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
22568693-6	2012	Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired.	Clopidogrel	248-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	380-395
22568693-6	2012	Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired.	Clopidogrel	248-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	318-321
22568693-6	2012	Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired.	Clopidogrel	473-484	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	380-395
22568693-6	2012	Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired.	Clopidogrel	473-484	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	318-321
22568693-9	2012	Neither appears to be affected by the same genetic polymorphisms as clopidogrel; prasugrel requires only a single CYP-mediated step to produce its active metabolite and ticagrelor is not a pro-drug.	Prasugrel Hydrochloride	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
22692316-0	2012	[Metabolic detoxification of bakuchiol is mediated by cytochrome P450 enzymes in human liver microsomes].	bakuchiol	29-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
22692316-1	2012	OBJECTIVE: To analyze cytochrome P450 (CYP) phenotyping for bakuchiol metabolism and study the mechanism of detoxification of bakuchiol by  human liver microsomes (HLM) in vitro.	bakuchiol	60-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
22692316-1	2012	OBJECTIVE: To analyze cytochrome P450 (CYP) phenotyping for bakuchiol metabolism and study the mechanism of detoxification of bakuchiol by  human liver microsomes (HLM) in vitro.	bakuchiol	60-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
22692316-2	2012	METHODS: The CYP phenotyping for bakuchiol metabolism was determined using HLM combined with CYP  specific inhibitors and recombinant human CYP isoforms.	bakuchiol	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
22692316-2	2012	METHODS: The CYP phenotyping for bakuchiol metabolism was determined using HLM combined with CYP  specific inhibitors and recombinant human CYP isoforms.	bakuchiol	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
22692316-2	2012	METHODS: The CYP phenotyping for bakuchiol metabolism was determined using HLM combined with CYP  specific inhibitors and recombinant human CYP isoforms.	bakuchiol	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
22692316-3	2012	The relative activities of CYP isoforms were determined by analyzing the formation of the  substrate metabolites using HPLC-MS/MS, in presence or absence of 1-aminobenzotriazole (ABT) which was CYP enzymes" broad spectrum inhibitor.	1-aminobenzotriazole	157-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
22692316-3	2012	The relative activities of CYP isoforms were determined by analyzing the formation of the  substrate metabolites using HPLC-MS/MS, in presence or absence of 1-aminobenzotriazole (ABT) which was CYP enzymes" broad spectrum inhibitor.	1-aminobenzotriazole	157-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-197
22692316-3	2012	The relative activities of CYP isoforms were determined by analyzing the formation of the  substrate metabolites using HPLC-MS/MS, in presence or absence of 1-aminobenzotriazole (ABT) which was CYP enzymes" broad spectrum inhibitor.	1-aminobenzotriazole	179-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
22692316-3	2012	The relative activities of CYP isoforms were determined by analyzing the formation of the  substrate metabolites using HPLC-MS/MS, in presence or absence of 1-aminobenzotriazole (ABT) which was CYP enzymes" broad spectrum inhibitor.	1-aminobenzotriazole	179-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-197
22692316-5	2012	The effects of CYP enzymes on the nephrotoxicity of bakuchiol were investigated using human kidney-2(HK-2) by MTT assay, in presence or  absence of ABT.	bakuchiol	52-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
22692316-10	2012	CONCLUSION: The mechanism of metabolic detoxification of bakuchiol by HLM is  associated with bakuchiol metabolism by CYP enzymes to form non toxic or lower toxic metabolites.	bakuchiol	57-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
22692316-10	2012	CONCLUSION: The mechanism of metabolic detoxification of bakuchiol by HLM is  associated with bakuchiol metabolism by CYP enzymes to form non toxic or lower toxic metabolites.	bakuchiol	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
22233204-2	2012	Non-renal elimination accounts for 70% of the total clearance of tofacitinib and the metabolism is primarily mediated by cytochrome P450 (CYP) 3A4.	tofacitinib	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
22233204-2	2012	Non-renal elimination accounts for 70% of the total clearance of tofacitinib and the metabolism is primarily mediated by cytochrome P450 (CYP) 3A4.	tofacitinib	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
22617226-0	2012	Effects of CYP induction by rifampicin on tamoxifen exposure.	Rifampin	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-14
22617226-0	2012	Effects of CYP induction by rifampicin on tamoxifen exposure.	Tamoxifen	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-14
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Tamoxifen	100-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Tamoxifen	100-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Tamoxifen	250-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
22617226-5	2012	Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers.	Tamoxifen	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
22568886-4	2012	Several applications in drug discovery studies are discussed and the use of HepaRG, as a human relevant predictive in vitro CYP induction model, is described.	heparg	76-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
22426923-3	2012	PATIENTS AND METHODS: 79 SNPs in CYP450, whose minor allele frequency were &gt;= 10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine.	Docetaxel	142-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-39
22426923-3	2012	PATIENTS AND METHODS: 79 SNPs in CYP450, whose minor allele frequency were &gt;= 10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine.	Capecitabine	157-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-39
22503544-0	2012	Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.	Eicosanoids	38-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
22503544-1	2012	OBJECTIVE: Preclinical and genetic epidemiologic studies suggest that modulating cytochrome P450 (CYP)-mediated arachidonic acid metabolism may have therapeutic utility in the management of coronary artery disease (CAD).	Arachidonic Acid	112-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
22503544-1	2012	OBJECTIVE: Preclinical and genetic epidemiologic studies suggest that modulating cytochrome P450 (CYP)-mediated arachidonic acid metabolism may have therapeutic utility in the management of coronary artery disease (CAD).	Arachidonic Acid	112-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
22503544-2	2012	However, predictors of inter-individual variation in CYP-derived eicosanoid metabolites in CAD patients have not been evaluated to date.	Eicosanoids	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
22503544-9	2012	CONCLUSIONS: Collectively, these findings suggest that CYP-mediated eicosanoid metabolism is dysregulated in certain subsets of CAD patients, and demonstrate that biomarkers of CYP epoxygenase and sEH, but not CYP omega-hydroxylase, metabolism are altered in stable CAD patients relative to healthy individuals.	Eicosanoids	68-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	6-oh-3mi	233-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
22554311-10	2012	DISCUSSION/CONCLUSION: The results suggest that fomepizole induces its own metabolism via cytochrome P-450, leading to enhanced fomepizole elimination and 4-CP excretion.	Fomepizole	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
22554311-10	2012	DISCUSSION/CONCLUSION: The results suggest that fomepizole induces its own metabolism via cytochrome P-450, leading to enhanced fomepizole elimination and 4-CP excretion.	Fomepizole	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
22554311-10	2012	DISCUSSION/CONCLUSION: The results suggest that fomepizole induces its own metabolism via cytochrome P-450, leading to enhanced fomepizole elimination and 4-CP excretion.	4-carboxypyrazole	155-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	epoxyeicosatrienoic acid	30-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	epoxyeicosatrienoic acid	30-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	EET	56-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	EET	56-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	Arachidonic Acid	84-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
22493087-2	2012	Recent evidence suggests that epoxyeicosatrienoic acid (EET), which is derived from arachidonic acid by cytochrome p450 (CYP) epoxygenase, has an essential role in PAH.	Arachidonic Acid	84-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Terfenadine	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Terfenadine	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Astemizole	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Astemizole	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
22616812-3	2012	The aim of this article was to review the preclinical testing of a new antihistamine (i.e., bilastine) in terms of its biotransformation in various animal species, including humans, and to evaluate its potential for possible drug-drug interactions involving the CYP system.	bilastine	92-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
22627182-1	2012	OBJECTIVES: Pitavastatin, a statin recently approved in the United States, has a potential benefit of reduced risk of cytochrome P450 (CYP)-mediated drug-drug interaction due to minimal metabolism by the CYP system.	pitavastatin	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
22627182-1	2012	OBJECTIVES: Pitavastatin, a statin recently approved in the United States, has a potential benefit of reduced risk of cytochrome P450 (CYP)-mediated drug-drug interaction due to minimal metabolism by the CYP system.	pitavastatin	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
22627182-1	2012	OBJECTIVES: Pitavastatin, a statin recently approved in the United States, has a potential benefit of reduced risk of cytochrome P450 (CYP)-mediated drug-drug interaction due to minimal metabolism by the CYP system.	pitavastatin	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207
22558931-0	2012	The roles of different porcine cytochrome P450 enzymes and cytochrome b5A in skatole metabolism.	Skatole	77-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	Skatole	19-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	Skatole	19-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-148
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	3-methyl-1H-indol-6-ol	207-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	3-methyl-1H-indol-6-ol	207-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-148
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	6-oh-3mi	233-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-148
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	3-methyl-1H-indol-6-ol	243-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	3-methyl-1H-indol-6-ol	243-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-148
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	Skatole	252-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
22558931-2	2012	The key enzymes in skatole metabolism are thought to be cytochrome P450 2E1 (CYP2E1) and cytochrome 2A (CYP2A); however, the cytochrome P450 (CYP450) isoform responsible for the production of the metabolite 6-hydroxy-3-methylindole (6-OH-3MI, 6-hydroxyskatole), which is thought to be involved in the clearance of skatole, has not been established conclusively.	Skatole	252-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-148
22558931-3	2012	The aim of this study was to characterize the role of porcine CYP450s in skatole metabolism by expressing them individually in the human embryonic kidney HEK293-FT cell line.	Skatole	73-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-68
22558931-9	2012	Further information regarding the abundance of different CYP450 isoforms is required to fully understand their contribution to skatole metabolism in vivo in the pig.	Skatole	127-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
22051186-4	2012	We have determined how a related set of three human CYP enzymes bind and interact with a common inhibitor, the muscarinic receptor agonist drug pilocarpine.	Pilocarpine	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
28509155-1	2012	It is well known that miconazole inhibits cytochrome P450 (CYP).	Miconazole	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
28509155-1	2012	It is well known that miconazole inhibits cytochrome P450 (CYP).	Miconazole	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
22471442-0	2012	Computational toxicological investigation on the mechanism and pathways of xenobiotics metabolized by cytochrome P450: a case of BDE-47.	2,2',4,4'-tetrabromodiphenyl ether	129-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Losartan	84-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21751216-6	2012	Moreover, cells exposed to the combination of OSM, DEX, and HGF gradually featured highly differentiated hepatic functions, including ALB secretion, glycogen storage, urea production, and cytochrome P450 (CYP) activity.	Dexamethasone	51-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-203
21751216-6	2012	Moreover, cells exposed to the combination of OSM, DEX, and HGF gradually featured highly differentiated hepatic functions, including ALB secretion, glycogen storage, urea production, and cytochrome P450 (CYP) activity.	Dexamethasone	51-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Caffeine	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22330698-7	2012	In multivariate regression models a significant positive correlation between serum vitamin D levels and the expression of vitamin D-regulated targets, cytochrome P450, family 24, subfamily a (cyp24a) expression by PBMCs (P = .0084, pediatric asthma group only) and serum LL-37 levels (P = .0006 in the pediatric group but P = .0067 in the adult asthma group), was found.	Vitamin D	83-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-177
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Omeprazole	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Dextromethorphan	125-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Midazolam	154-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22266842-0	2012	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.	lorcaserin	114-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
22706230-3	2012	Apart from the omega-hydroxylation of leukotriene B4 and prostaglandins, CYP4F3 is the main catalyst in the oxidation of fatty acid epoxides.	Leukotriene B4	38-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-79
22706230-3	2012	Apart from the omega-hydroxylation of leukotriene B4 and prostaglandins, CYP4F3 is the main catalyst in the oxidation of fatty acid epoxides.	fatty acid epoxides	121-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-79
22252457-0	2012	Comment on "binding free energies of inhibitors to iron porphyrin complex as a model for cytochrome P450".	iron porphyrin	51-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
22317799-4	2012	Ideally, such an assay would use a single PCR reaction and, without further processing, a single microchip electrophoresis (ME) run to determine the 3 single-nucleotide polymorphisms (SNPs) affecting warfarin sensitivity [i.e., CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) *2, CYP2C9 *3, and the VKORC1 (vitamin K epoxide reductase complex 1) A/B haplotype].	Warfarin	200-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-261
22510212-0	2012	Role of perferryl-oxo oxidant in alkane hydroxylation catalyzed by cytochrome P450: a hybrid density functional study.	Alkanes	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
22113809-0	2012	Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.	iron porphyrin	39-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
22266842-0	2012	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.	Serotonin	150-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
22422635-0	2012	Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.	Clobazam	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
22589111-3	2012	Kinetics of clopidogrel metabolism is driven by enzymatic activity of the Cytochrome P450 system.	Clopidogrel	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
22366455-5	2012	Absence of cytochrome P450, family 26, subfamily b, polypeptide 1 (Cyp26b1), a retinoic-acid-degrading enzyme, results in aberrant epidermal differentiation and filaggrin expression, defective cornified envelopes and skin barrier formation, in conjunction with peridermal retention.	Tretinoin	79-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-50
22422635-1	2012	STUDY OBJECTIVE: To investigate potential drug-drug interactions between clobazam and cytochrome P450 (CYP) isoenzyme substrates, inhibitors, and inducers.	Clobazam	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
22422635-1	2012	STUDY OBJECTIVE: To investigate potential drug-drug interactions between clobazam and cytochrome P450 (CYP) isoenzyme substrates, inhibitors, and inducers.	Clobazam	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
22330256-2	2012	Recent investigations at our lab have shown that the metabolites generated through cytochrome P(450)-dependent metabolic reactions are responsible for hemotoxic effects of primaquine, which could be monitored with accumulation of methemoglobin and increased oxidative stress.	Primaquine	172-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-100
21415279-0	2012	Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.	Aminopyrine	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
21415279-1	2012	Aminopyrine is metabolized by cytochrome P450 (CYP) in the liver.	Aminopyrine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
21415279-1	2012	Aminopyrine is metabolized by cytochrome P450 (CYP) in the liver.	Aminopyrine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
21415279-6	2012	Omeprazole and lansoprazole at the standard doses inhibit CYP activity but rabeprazole does not, whereas high-dose omeprazole seems to induce CYPs.	Omeprazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
21415279-6	2012	Omeprazole and lansoprazole at the standard doses inhibit CYP activity but rabeprazole does not, whereas high-dose omeprazole seems to induce CYPs.	Lansoprazole	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
22022918-3	2012	In the present study, several in vitro approaches were used to identify the cytochrome P450 (CYP) enzymes responsible for ilaprazole sulfone formation.	ilaprazole sulfone	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
22022918-3	2012	In the present study, several in vitro approaches were used to identify the cytochrome P450 (CYP) enzymes responsible for ilaprazole sulfone formation.	ilaprazole sulfone	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
20740300-1	2012	OBJECTIVE: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation.	Axitinib	11-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
22155354-4	2012	The AhR has particular importance in the lung and is most commonly associated with the up-regulation of cytochrome P-450 (CYP)-mediated metabolism of benzo[a]pyrene (B[a]P) to reactive intermediates.	Benzo(a)pyrene	150-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
22155354-4	2012	The AhR has particular importance in the lung and is most commonly associated with the up-regulation of cytochrome P-450 (CYP)-mediated metabolism of benzo[a]pyrene (B[a]P) to reactive intermediates.	Benzo(a)pyrene	150-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
26596595-0	2012	Development of Accurate DFT Methods for Computing Redox Potentials of Transition Metal Complexes: Results for Model Complexes and Application to Cytochrome P450.	Metals	81-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
26596595-8	2012	Application of the LOC scheme to the rate-determining hydrogen atom transfer step in substrate hydroxylation by cytochrome P450 shows that this approach is able to correct the B3LYP barriers in comparison to recent kinetics experiments.	Hydrogen	54-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
22050110-1	2012	The steroid and xenobiotic receptor (SXR) regulates cytochrome P450 (CYP) enzymes, which are key inactivators of testosterone in the liver and prostate.	Testosterone	113-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
22050110-1	2012	The steroid and xenobiotic receptor (SXR) regulates cytochrome P450 (CYP) enzymes, which are key inactivators of testosterone in the liver and prostate.	Testosterone	113-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
20740300-1	2012	OBJECTIVE: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation.	Axitinib	11-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	138-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
20740300-1	2012	OBJECTIVE: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation.	Axitinib	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	138-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	rifapentine	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
20740300-1	2012	OBJECTIVE: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation.	Axitinib	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	rifapentine	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
20740300-2	2012	Co-administration with CYP inhibitors may increase systemic exposure to axitinib and alter its safety profile.	Axitinib	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifabutin	166-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
21899994-5	2012	DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCepsilon.	Reactive Oxygen Species	72-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifabutin	166-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
22197672-4	2012	First is accessibility of each substrate atom to the oxygenated Fe atom of heme in a CYP protein, and the other is the oxidative reactivity of each substrate atom.	Iron	64-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
22197672-4	2012	First is accessibility of each substrate atom to the oxygenated Fe atom of heme in a CYP protein, and the other is the oxidative reactivity of each substrate atom.	Heme	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
21899994-5	2012	DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCepsilon.	Reactive Oxygen Species	72-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
21899994-5	2012	DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCepsilon.	Reactive Oxygen Species	97-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
21899994-5	2012	DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCepsilon.	Reactive Oxygen Species	97-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
21899994-8	2012	In conclusion, DG treatment activated both ERK/Nrf2 and PKCepsilon pathways, presumably by ROS arising from CYP-catalyzed processes, with resultant inhibition of hypoxia/reoxygenation-induced apoptosis immediately after DG treatment or even after an extended time interval following DG treatment.	Reactive Oxygen Species	91-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
22687469-1	2012	Mammalian cytochrome P450 (CYP) comprise a large group of enzymes that play many important roles in the biosynthesis of steroid hormones and vitamins.	Steroids	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	0-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	0-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	33-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	Arachidonic Acid	94-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
23013331-6	2012	20-Hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor omega-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by CYP4A and CYP4F isoforms.	Arachidonic Acid	94-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
22087535-1	2012	Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability.	Heme	33-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
22087535-1	2012	Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability.	Heme	33-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
22087535-1	2012	Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability.	Iron	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
22087535-1	2012	Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability.	Iron	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
22687469-1	2012	Mammalian cytochrome P450 (CYP) comprise a large group of enzymes that play many important roles in the biosynthesis of steroid hormones and vitamins.	Steroids	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
22687469-4	2012	In recent years, however, significant progress has been made in the X-ray crystallographic analysis of mammalian CYP enzymes involved in the steroid hormone and vitamin D(3) metabolism.	Steroids	141-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
22687469-4	2012	In recent years, however, significant progress has been made in the X-ray crystallographic analysis of mammalian CYP enzymes involved in the steroid hormone and vitamin D(3) metabolism.	Vitamin D	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	tanespimycin	61-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	tanespimycin	61-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	17-Amino-17-demethoxygeldanamycin	100-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	17-Amino-17-demethoxygeldanamycin	100-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	17-AG	135-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
21594721-1	2012	PURPOSE: To assess the inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin (17-AG) on cytochrome P450 (CYP) enzymes.	17-AG	135-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
21594721-2	2012	METHODS: The inhibitory effect of tanespimycin and 17-AG on various CYP enzymes was determined in human liver microsomes.	tanespimycin	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
21594721-2	2012	METHODS: The inhibitory effect of tanespimycin and 17-AG on various CYP enzymes was determined in human liver microsomes.	17-AG	51-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
21626050-0	2012	Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.	Docetaxel	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
23018445-3	2012	In this study, the metabolic activities of three major hepatic CYP isoforms (2C19, 2D6, and 3A4) were investigated on structurally different central nervous system (CNS) acting drugs, amitriptyline, fluphenazine, and dothiepin.	Amitriptyline	184-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23018445-3	2012	In this study, the metabolic activities of three major hepatic CYP isoforms (2C19, 2D6, and 3A4) were investigated on structurally different central nervous system (CNS) acting drugs, amitriptyline, fluphenazine, and dothiepin.	Fluphenazine	199-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23018445-3	2012	In this study, the metabolic activities of three major hepatic CYP isoforms (2C19, 2D6, and 3A4) were investigated on structurally different central nervous system (CNS) acting drugs, amitriptyline, fluphenazine, and dothiepin.	Dothiepin	217-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
22975950-0	2012	Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation.	epoxyeicosanoids	36-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
22701192-7	2012	Concomitant administration of medications such as triazole antifungals which influence the cytochrome P-450 system can exacerbate this potential complication of ATRA.	Triazoles	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
22701192-7	2012	Concomitant administration of medications such as triazole antifungals which influence the cytochrome P-450 system can exacerbate this potential complication of ATRA.	Tretinoin	161-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
22856659-5	2012	Cytochrome P450 (CYP450)-mediated cocaine metabolism yields the reactive pro-oxidant compound norcocaine (NCOC) and further oxidative metabolites.	Cocaine	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22856659-5	2012	Cytochrome P450 (CYP450)-mediated cocaine metabolism yields the reactive pro-oxidant compound norcocaine (NCOC) and further oxidative metabolites.	Cocaine	34-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
22856659-5	2012	Cytochrome P450 (CYP450)-mediated cocaine metabolism yields the reactive pro-oxidant compound norcocaine (NCOC) and further oxidative metabolites.	norcocaine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
22856659-5	2012	Cytochrome P450 (CYP450)-mediated cocaine metabolism yields the reactive pro-oxidant compound norcocaine (NCOC) and further oxidative metabolites.	norcocaine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-23
22975950-0	2012	Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation.	Ristocetin	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
21989950-4	2012	A series of in vitro studies were conducted to identify the human esterases involved in the prodrug hydrolysis and to identify the primary human cytochrome P450 and sulfotransferase (SULT) enzymes involved in the metabolism of brivanib.	brivanib	227-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-181
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	Arachidonic Acid	92-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
22975950-1	2012	Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall.	Arachidonic Acid	92-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
22123124-1	2012	Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to several oxygenase enzymes including cytochrome P450 (CYP).	NADP	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	hydroxytamoxifen	110-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
22975950-11	2012	These results indicate a highly specific role of CYP-eicosanoids in preventing thromboembolic events and suggest that the formation of 17,18-EEQ and 19,20-EDP may contribute to the anti-thrombotic effects of omega-3 fatty acids.	Eicosanoids	53-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	hydroxytamoxifen	110-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	4-hydroxy-N-desmethyltamoxifen	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	4-hydroxy-N-desmethyltamoxifen	133-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
22123124-1	2012	Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to several oxygenase enzymes including cytochrome P450 (CYP).	NADP	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
22041137-4	2012	The genetic polymorphisms in the other drug-metabolizing enzymes, including other CYP isoforms, sulfotransferases and UDP-glucuronosyltransferases might contribute to individual differences in the tamoxifen metabolism and clinical outcome of tamoxifen therapy although their contributions would be small.	Tamoxifen	197-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
22975950-11	2012	These results indicate a highly specific role of CYP-eicosanoids in preventing thromboembolic events and suggest that the formation of 17,18-EEQ and 19,20-EDP may contribute to the anti-thrombotic effects of omega-3 fatty acids.	Fatty Acids, Omega-3	208-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
22041137-4	2012	The genetic polymorphisms in the other drug-metabolizing enzymes, including other CYP isoforms, sulfotransferases and UDP-glucuronosyltransferases might contribute to individual differences in the tamoxifen metabolism and clinical outcome of tamoxifen therapy although their contributions would be small.	Tamoxifen	242-251	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	Sodium Dodecyl Sulfate	128-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
22100140-1	2012	Because of the increasing number of immunocompromised patients and due to problems with antifungal treatment, especially with the most widely used antifungals, azoles, there is an urgent need for new, potent and safe antifungals with fewer cytochrome P450 (CYP)-mediated interactions with other drugs.	Azoles	160-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-255
22100140-1	2012	Because of the increasing number of immunocompromised patients and due to problems with antifungal treatment, especially with the most widely used antifungals, azoles, there is an urgent need for new, potent and safe antifungals with fewer cytochrome P450 (CYP)-mediated interactions with other drugs.	Azoles	160-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	257-260
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	Arachidonic Acid	136-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	Arachidonic Acid	136-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	dihydroxyeicosatrienoic acids	256-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	dihydroxyeicosatrienoic acids	256-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	dhets	287-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
22848834-1	2012	Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs).	dhets	287-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	Arachidonic Acid	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
22182836-1	2012	Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases.	Arachidonic Acid	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	Sodium Dodecyl Sulfate	128-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	polyacrylamide	151-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	polyacrylamide	151-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	Sodium Dodecyl Sulfate	187-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
22903709-1	2012	In this chapter we explore the inducible cytochrome P450 (CYP) forms as an example of membrane proteins analysis that relies on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation with subsequent mass spectrometric (MS) identification.	Sodium Dodecyl Sulfate	187-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
22778656-3	2012	A model used to effectively describe the cytochrome P450 deposition onto carbon nanotubes was confirmed by Monte Carlo simulations.	Carbon	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
25298920-2	2012	In the last decade there has been an increase in realization of the power of CYP biocatalysts for detoxification of soil and water contaminants using transgenic plants.	Water	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Fatty Acids	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Fatty Acids	52-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Eicosanoids	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Eicosanoids	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Vitamin D	82-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-24
22079551-1	2012	Cytochrome P450 family 4 (CYP4) proteins metabolize fatty acids, eicosanoids, and vitamin D and are important for chemical defense.	Vitamin D	82-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-30
22778656-0	2012	Electrochemical detection of anti-breast-cancer agents in human serum by cytochrome P450-coated carbon nanotubes.	Carbon	96-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
21880455-0	2011	Rapid simultaneous analysis of cyclooxygenase, lipoxygenase and cytochrome P-450 metabolites of arachidonic and linoleic acids using high performance liquid chromatography/mass spectrometry in tandem mode.	arachidonic and linoleic acids	96-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
22778656-2	2012	Multi-walled carbon nanotubes were functionalized with three different cytochrome P450 isoforms (CYP1A2, CYP2B6, and CYP3A4).	Carbon	13-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
21946300-0	2011	Human cytochrome-P450 enzymes metabolize N-(2-methoxyphenyl)hydroxylamine, a metabolite of the carcinogens o-anisidine and o-nitroanisole, thereby dictating its genotoxicity.	N-(2-methoxyphenyl)hydroxylamine	41-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
21946300-0	2011	Human cytochrome-P450 enzymes metabolize N-(2-methoxyphenyl)hydroxylamine, a metabolite of the carcinogens o-anisidine and o-nitroanisole, thereby dictating its genotoxicity.	2-anisidine	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
21946300-0	2011	Human cytochrome-P450 enzymes metabolize N-(2-methoxyphenyl)hydroxylamine, a metabolite of the carcinogens o-anisidine and o-nitroanisole, thereby dictating its genotoxicity.	2-nitroanisole	123-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
21880455-1	2011	Eicosanoids are oxidized arachidonate-derived lipid products generated by cyclooxygenase, lipoxygenase and cytochrome P-450 pathways.	Eicosanoids	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
21880455-1	2011	Eicosanoids are oxidized arachidonate-derived lipid products generated by cyclooxygenase, lipoxygenase and cytochrome P-450 pathways.	Arachidonic Acid	25-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
21411308-1	2011	Protein engineering of cytochrome P450 monooxygenases (P450s) has been very successful in generating valuable non-natural activities and properties, allowing these powerful catalysts to be used for the synthesis of drug metabolites and in biosynthetic pathways for the production of precursors of artemisinin and paclitaxel.	artemisinin	297-308	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
21689071-0	2011	Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21689071-1	2011	CYP450AAM [arachidonic acid metabolites of the CYP450 (cytochrome P450) enzyme system] have a range of biological functions.	Arachidonic Acid	11-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
21689071-1	2011	CYP450AAM [arachidonic acid metabolites of the CYP450 (cytochrome P450) enzyme system] have a range of biological functions.	Arachidonic Acid	11-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
22048864-2	2011	Changes in dietary fatty acids, specifically the polyunsaturated fatty acids of the omega-3 and omega-6 families and some derived eicosanoids from lipoxygenases, cyclooxygenases, and cytochrome P-450, seem to control the activity of transcription factor families involved in cancer cell proliferation or cell death.	Fatty Acids	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
22048864-2	2011	Changes in dietary fatty acids, specifically the polyunsaturated fatty acids of the omega-3 and omega-6 families and some derived eicosanoids from lipoxygenases, cyclooxygenases, and cytochrome P-450, seem to control the activity of transcription factor families involved in cancer cell proliferation or cell death.	Fatty Acids, Unsaturated	49-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
22048864-2	2011	Changes in dietary fatty acids, specifically the polyunsaturated fatty acids of the omega-3 and omega-6 families and some derived eicosanoids from lipoxygenases, cyclooxygenases, and cytochrome P-450, seem to control the activity of transcription factor families involved in cancer cell proliferation or cell death.	Eicosanoids	130-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
21411308-1	2011	Protein engineering of cytochrome P450 monooxygenases (P450s) has been very successful in generating valuable non-natural activities and properties, allowing these powerful catalysts to be used for the synthesis of drug metabolites and in biosynthetic pathways for the production of precursors of artemisinin and paclitaxel.	Paclitaxel	313-323	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
21995615-0	2011	Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.	Triazoles	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
22089302-11	2011	Results suggest the CYP metabolites (i.e., DHETs) are released during short-term high-intensity and long-term moderate-intensity exercise.	dhets	43-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
21964476-4	2011	DCPT toxicity is dependent upon the presence of an intact TZD ring and cytochrome P450 (CYP)-mediated biotransformation.	3-(3,5-dichlorophenyl)-2,4-thiazolidinedione	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
21964476-4	2011	DCPT toxicity is dependent upon the presence of an intact TZD ring and cytochrome P450 (CYP)-mediated biotransformation.	3-(3,5-dichlorophenyl)-2,4-thiazolidinedione	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
21901220-0	2011	Oxidation of 10-undecenoic acid by cytochrome P450(BM-3) and its Compound I transient.	undecylenic acid	13-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-55
21901220-1	2011	Oxidations of 10-undecenoic acid by cytochrome P450(BM-3) and its Compound I transient were studied.	undecylenic acid	14-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-56
21350850-1	2011	BACKGROUND: In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.	Sorafenib	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
21350850-1	2011	BACKGROUND: In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.	Sorafenib	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
21995615-2	2011	As substrates and inhibitors of cytochrome P450 (CYP), the triazoles can interact with many drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment.	Triazoles	59-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
21995615-2	2011	As substrates and inhibitors of cytochrome P450 (CYP), the triazoles can interact with many drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment.	Triazoles	59-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
21995615-4	2011	AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions.	Triazoles	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
21995615-4	2011	AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions.	Triazoles	159-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
21995615-4	2011	AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions.	Triazoles	159-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
21995615-5	2011	A search of English language, original research and scholarly reviews describing interactions between triazole antifungal agents and human CYP published from 1980 to present was undertaken using PubMed.	Triazoles	102-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
21995615-6	2011	EXPERT OPINION: Triazoles interact with many drugs and the primary mechanism for these interactions is hepatic CYP.	Triazoles	16-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
21995615-8	2011	However, advances in genotyping, improved analytical technology and bioanalytical methods, which enable accurate molecular identification and stereochemical analysis, have substantially added to the understanding of the role hepatic CYP plays in triazole-drug interactions in humans.	Triazoles	246-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	233-236
21996372-2	2011	TRPV4 is also thermosensitive and responds to moderate heat (from 24 to 27  C) as well as to phorbol esters (4alpha-PDD) and several endogenous substances including arachidonic acid (AA), the endocannabinoids anandamide and 2-AG, and cytochrome P-450 metabolites of AA, such as epoxyeicosatrienoic acids.	Phorbol Esters	93-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-250
26598170-0	2011	Do Two Different Reaction Mechanisms Contribute to the Hydroxylation of Primary Amines by Cytochrome P450?	Amines	80-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
21864702-3	2011	A well-studied group of autacoid mediators that are the products of arachidonic acid metabolism include: the prostaglandins, leukotrienes, lipoxins and cytochrome P450 (CYP) derived bioactive products.	Arachidonic Acid	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
21864702-3	2011	A well-studied group of autacoid mediators that are the products of arachidonic acid metabolism include: the prostaglandins, leukotrienes, lipoxins and cytochrome P450 (CYP) derived bioactive products.	Arachidonic Acid	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
27147854-0	2011	Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?	Acetaminophen	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-20
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	Acetaminophen	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	Acetaminophen	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	N-acetyl-4-benzoquinoneimine	219-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	N-acetyl-4-benzoquinoneimine	219-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	N-acetyl-4-benzoquinoneimine	249-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
27147854-3	2011	These include the dose of paracetamol ingested, time to presentation, decreased liver glutathione, and induction of cytochrome P450 (CYP) isoenzymes responsible for the metabolism of paracetamol to its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI).	N-acetyl-4-benzoquinoneimine	249-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
27147854-4	2011	In this paper, we review the currently published literature to determine whether induction of relevant CYP isoenzymes is a risk factor for hepatotoxicity in patients with acute paracetamol overdose.	Acetaminophen	177-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
26598170-1	2011	Three possible mechanisms have been suggested for the hydroxylation of primary and secondary amines by the cytochrome P450 enzyme family.	Amines	93-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
27147854-5	2011	Animal and human in vitro studies have shown that the CYP isoenzyme responsible for the majority of human biotransformation of paracetamol to NAPQI is CYP2E1 at both therapeutic and toxic doses of paracetamol.	Acetaminophen	127-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
21970838-1	2011	AIM: To investigate the metabolism of 3-cyanomethyl-4-methyl-DCK (CMDCK), a novel anti-HIV agent, by human liver microsomes (HLMs) and recombinant cytochrome P450 enzymes (CYPs).	3-cyanomethyl	38-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
27147854-5	2011	Animal and human in vitro studies have shown that the CYP isoenzyme responsible for the majority of human biotransformation of paracetamol to NAPQI is CYP2E1 at both therapeutic and toxic doses of paracetamol.	N-acetyl-4-benzoquinoneimine	142-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
27147854-5	2011	Animal and human in vitro studies have shown that the CYP isoenzyme responsible for the majority of human biotransformation of paracetamol to NAPQI is CYP2E1 at both therapeutic and toxic doses of paracetamol.	Acetaminophen	197-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
21854846-0	2011	Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.	Nortriptyline	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	228-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	8-hydroxyloxapine	142-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	7-hydroxyloxapine	161-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21826677-0	2011	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.	Loxapine	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	7-hydroxyloxapine	161-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Loxapine	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	n-desmethylloxapine	180-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Loxapine	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	n-desmethylloxapine	180-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	8-hydroxyloxapine	142-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21352268-2	2011	The main enzyme responsible for activating clopidogrel is the cytochrome P450 (CYP) isoenzyme CYP2C19, which is polymorphic.	Clopidogrel	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
21352268-2	2011	The main enzyme responsible for activating clopidogrel is the cytochrome P450 (CYP) isoenzyme CYP2C19, which is polymorphic.	Clopidogrel	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
21352268-5	2011	In particular, omeprazole has been shown to inhibit the CYP-mediated metabolism of clopidogrel, and some studies have shown that the combination was associated with a higher incidence of cardiovascular adverse reactions than clopidogrel given alone.	Omeprazole	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Amoxapine	201-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21352268-5	2011	In particular, omeprazole has been shown to inhibit the CYP-mediated metabolism of clopidogrel, and some studies have shown that the combination was associated with a higher incidence of cardiovascular adverse reactions than clopidogrel given alone.	Clopidogrel	83-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Amoxapine	201-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Loxapine N-oxide	216-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
21826677-1	2011	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide.	Loxapine N-oxide	216-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21685474-2	2011	Previous studies showed that the presence of one or two minor alleles of the cytochrome P450, subfamily 2C polypeptide 8 gene (CYP2C8) polymorphism rs1934951 was an independent prognostic marker associated with development of osteonecrosis of the jaw in multiple myeloma patients treated with bisphosphonates.	Diphosphonates	293-308	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-120
21826477-2	2011	The available thienopyridines are prodrugs and must be converted into active forms by the cytochrome P450 (CYP) enzyme system.	Thienopyridines	14-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
21826477-2	2011	The available thienopyridines are prodrugs and must be converted into active forms by the cytochrome P450 (CYP) enzyme system.	Thienopyridines	14-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
21826477-7	2011	Conversely, agents that induce CYP activity increase clopidogrel responsiveness.	Clopidogrel	53-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Macrolides	280-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Macrolides	280-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Fluoroquinolones	296-312	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Fluoroquinolones	296-312	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Azoles	362-367	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Azoles	362-367	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
21564387-1	2011	BACKGROUND: Phenobarbital induces specific hepatic cytochrome P-450 enzyme pathways causing increased clearance of hepatically metabolized drugs.	Phenobarbital	12-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Codeine	93-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
22145115-0	2011	Study on cytochrome p-450 dependent retinoic Acid metabolism and its inhibitors as potential agents for cancer therapy.	Tretinoin	36-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
22145115-13	2011	1-Substituted imidazoles bind to cytochrome P-450 with a very high affinity but substitution in the other position of the imidazole decreases the binding affinity.	1-substituted imidazoles	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
22145115-13	2011	1-Substituted imidazoles bind to cytochrome P-450 with a very high affinity but substitution in the other position of the imidazole decreases the binding affinity.	imidazole	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	Toremifene	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-185
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	N-desmethyltoremifene	114-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	N-desmethyltoremifene	114-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-185
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	N-desmethyltoremifene	137-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	N-desmethyltoremifene	137-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-185
21726172-6	2011	CYP inhibition by NDMT was similar in magnitude to toremifene.	N-desmethyltoremifene	18-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21496210-2	2011	In this study, the interaction of degarelix with human cytochrome P450 (CYP450) enzymes was investigated in vitro.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
21496210-2	2011	In this study, the interaction of degarelix with human cytochrome P450 (CYP450) enzymes was investigated in vitro.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	34-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-78
21496210-6	2011	Induction of CYP450 enzyme activity by degarelix was investigated using primary human hepatocytes.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-19
21496210-10	2011	Degarelix appears to be a poor substrate of the CYP450 enzyme system, and the in vitro results indicate that the interaction between CYP450 and degarelix is low.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-54
21496210-10	2011	Degarelix appears to be a poor substrate of the CYP450 enzyme system, and the in vitro results indicate that the interaction between CYP450 and degarelix is low.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-54
21496210-10	2011	Degarelix appears to be a poor substrate of the CYP450 enzyme system, and the in vitro results indicate that the interaction between CYP450 and degarelix is low.	acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide	144-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-139
21726172-0	2011	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.	Toremifene	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
21726172-0	2011	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.	N-desmethyltoremifene	45-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
21726172-2	2011	Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes.	Toremifene	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
21870861-0	2011	A mechanistic hypothesis for the cytochrome P450-catalyzed cis-trans isomerization of 4-hydroxytamoxifen: an unusual redox reaction.	hydroxytamoxifen	86-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-151
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-156
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	4-hydroxy-N-desmethyltamoxifen	87-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-151
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	4-hydroxy-N-desmethyltamoxifen	87-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-156
21798277-1	2011	The environmental pollutant 7H-dibenzo[c,g]carbazole (DBC) and its derivative, 5,9-dimethylDBC (DiMeDBC), produced significant and dose-dependent levels of micronuclei followed by a substantial increase in the frequency of apoptotic cells in the V79MZh3A4 cell line stably expressing the human cytochrome P450 (hCYP) 3A4.	7H-dibenzo(c,g)carbazole	28-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-320
21798277-1	2011	The environmental pollutant 7H-dibenzo[c,g]carbazole (DBC) and its derivative, 5,9-dimethylDBC (DiMeDBC), produced significant and dose-dependent levels of micronuclei followed by a substantial increase in the frequency of apoptotic cells in the V79MZh3A4 cell line stably expressing the human cytochrome P450 (hCYP) 3A4.	7H-dibenzo(c,g)carbazole	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-320
21798277-1	2011	The environmental pollutant 7H-dibenzo[c,g]carbazole (DBC) and its derivative, 5,9-dimethylDBC (DiMeDBC), produced significant and dose-dependent levels of micronuclei followed by a substantial increase in the frequency of apoptotic cells in the V79MZh3A4 cell line stably expressing the human cytochrome P450 (hCYP) 3A4.	5,9-dimethyldbc	79-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-320
21798277-1	2011	The environmental pollutant 7H-dibenzo[c,g]carbazole (DBC) and its derivative, 5,9-dimethylDBC (DiMeDBC), produced significant and dose-dependent levels of micronuclei followed by a substantial increase in the frequency of apoptotic cells in the V79MZh3A4 cell line stably expressing the human cytochrome P450 (hCYP) 3A4.	dimedbc	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-320
21763268-0	2011	C-26 vs. C-27 hydroxylation of insect steroid hormones: regioselectivity of a microsomal cytochrome P450 from a hormone-resistant cell line.	Carbon	0-1	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
21763268-0	2011	C-26 vs. C-27 hydroxylation of insect steroid hormones: regioselectivity of a microsomal cytochrome P450 from a hormone-resistant cell line.	Steroids	38-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
21763268-3	2011	26-Hydroxylation of the insect steroid hormone 20-hydroxyecdysone by a microsomal cytochrome P450 was previously found to be responsible for hormonal resistance in a Chironomus cell line mainly producing the (25S)-epimer of 20,26-dihydroxyecdysone.	Steroids	31-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
21763268-3	2011	26-Hydroxylation of the insect steroid hormone 20-hydroxyecdysone by a microsomal cytochrome P450 was previously found to be responsible for hormonal resistance in a Chironomus cell line mainly producing the (25S)-epimer of 20,26-dihydroxyecdysone.	Ecdysterone	47-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
21763268-3	2011	26-Hydroxylation of the insect steroid hormone 20-hydroxyecdysone by a microsomal cytochrome P450 was previously found to be responsible for hormonal resistance in a Chironomus cell line mainly producing the (25S)-epimer of 20,26-dihydroxyecdysone.	20,26-dihydroxyecdysone	224-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
21750172-1	2011	BACKGROUND: Tamoxifen is oxidized by cytochrome-P450 enzymes (e.g., CYP2D6) to two active metabolites, which are eliminated via glucuronidation by UDP-glucuronosyl transferases (UGT).	Tamoxifen	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Codeine	93-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Oxycodone	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Oxycodone	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Hydrocodone	113-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Hydrocodone	113-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Fentanyl	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Fentanyl	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Tramadol	136-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Tramadol	136-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Methadone	150-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
21999760-5	2011	Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects.	Methadone	150-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
21999760-6	2011	Conversely, opioids that are not metabolized by that system (morphine, oxymorphone, and hydromorphone) tend to be involved in fewer CYP450-associated pharmacokinetic DDIs.	Morphine	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-138
21999760-6	2011	Conversely, opioids that are not metabolized by that system (morphine, oxymorphone, and hydromorphone) tend to be involved in fewer CYP450-associated pharmacokinetic DDIs.	Oxymorphone	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-138
21999760-6	2011	Conversely, opioids that are not metabolized by that system (morphine, oxymorphone, and hydromorphone) tend to be involved in fewer CYP450-associated pharmacokinetic DDIs.	Hydromorphone	88-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-138
21876481-0	2011	Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay.	Alkaloids	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
21740382-1	2011	The original map of mammalian cytochrome P450 (CYP450) residues involved in substrate recognition was prepared for the CYP2 family by Gotoh in 1992 by manual alignment of mammalian CYP450 residues with substrate recognition site (SRS) residues manually delimited from a bacterial cytochrome P450-substrate complex.	gotoh	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
21740382-1	2011	The original map of mammalian cytochrome P450 (CYP450) residues involved in substrate recognition was prepared for the CYP2 family by Gotoh in 1992 by manual alignment of mammalian CYP450 residues with substrate recognition site (SRS) residues manually delimited from a bacterial cytochrome P450-substrate complex.	gotoh	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-53
21740382-1	2011	The original map of mammalian cytochrome P450 (CYP450) residues involved in substrate recognition was prepared for the CYP2 family by Gotoh in 1992 by manual alignment of mammalian CYP450 residues with substrate recognition site (SRS) residues manually delimited from a bacterial cytochrome P450-substrate complex.	gotoh	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-187
21740382-1	2011	The original map of mammalian cytochrome P450 (CYP450) residues involved in substrate recognition was prepared for the CYP2 family by Gotoh in 1992 by manual alignment of mammalian CYP450 residues with substrate recognition site (SRS) residues manually delimited from a bacterial cytochrome P450-substrate complex.	gotoh	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-295
21861666-1	2011	AIMS: To investigate associations between novel human cytochrome P450 (CYP450) combinatory (multigene) and substrate-specific drug metabolism indices, and elements of metabolic syndrome, such as low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), triglycerides and BMI, using physiogenomic analysis.	Triglycerides	284-297	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
21861666-1	2011	AIMS: To investigate associations between novel human cytochrome P450 (CYP450) combinatory (multigene) and substrate-specific drug metabolism indices, and elements of metabolic syndrome, such as low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), triglycerides and BMI, using physiogenomic analysis.	Triglycerides	284-297	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-77
21682551-6	2011	Pitavastatin has a distinctive metabolic profile that means it is marginally metabolised by CYP enzymes, and is therefore expected to have a low risk of DDIs and related ADRs.	pitavastatin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
21704641-0	2011	Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.	Cannabidiol	72-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
21694616-3	2011	In our previous study, we found that the cytochrome P-450 (CYP) isozyme 2B6 preferentially metabolizes the S-methadone enantiomer.	Methadone	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
21694616-3	2011	In our previous study, we found that the cytochrome P-450 (CYP) isozyme 2B6 preferentially metabolizes the S-methadone enantiomer.	Methadone	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
21704641-3	2011	In this study, we examined in vitro metabolism of CBD with human liver microsomes (HLMs) to clarify cytochrome P450 (CYP) isoforms involved in the CBD oxidations.	Cannabidiol	50-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
21704641-3	2011	In this study, we examined in vitro metabolism of CBD with human liver microsomes (HLMs) to clarify cytochrome P450 (CYP) isoforms involved in the CBD oxidations.	Cannabidiol	50-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-120
21704641-7	2011	Seven of 14 recombinant human CYP enzymes examined (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) were capable of metabolizing CBD.	Cannabidiol	142-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
21704641-8	2011	The correlations between CYP isoform-specific activities and CBD oxidative activities in 16 individual HLMs indicated that 6beta-OH- and 4""-OH-CBDs were mainly formed by CYP3A4, which was supported by inhibition studies using ketoconazole and an anti-CYP3A4 antibody.	6beta-oh- and 4""-oh-cbds	123-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
21704641-8	2011	The correlations between CYP isoform-specific activities and CBD oxidative activities in 16 individual HLMs indicated that 6beta-OH- and 4""-OH-CBDs were mainly formed by CYP3A4, which was supported by inhibition studies using ketoconazole and an anti-CYP3A4 antibody.	Ketoconazole	227-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
21466844-0	2011	Assessment of a novel beta2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities.	trantinterol	50-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
21757024-1	2011	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
21757024-1	2011	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
21757024-1	2011	Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes.	Eicosanoids	121-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
21757024-6	2011	A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves beta-cell function and reduces beta-cell apoptosis in diabetes.	epoxyeicosatrienoic acids	69-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
21757024-6	2011	A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves beta-cell function and reduces beta-cell apoptosis in diabetes.	Eicosanoids	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
21466844-1	2011	The effect of a novel beta(2)-adrenoceptor agonist, trantinterol on the activities of cytochrome P450 (CYP450) was investigated with human liver microsomes and human cryohepatocytes in order to assess the potential for drug-drug interactions.	trantinterol	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
21466844-1	2011	The effect of a novel beta(2)-adrenoceptor agonist, trantinterol on the activities of cytochrome P450 (CYP450) was investigated with human liver microsomes and human cryohepatocytes in order to assess the potential for drug-drug interactions.	trantinterol	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-109
21466844-2	2011	The ability of trantinterol to inhibit CYP450 activities was evaluated in vitro in human liver microsomes.	trantinterol	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
21508826-2	2011	It is metabolized in the liver to norketamine via cytochrome P450 (CYP) enzymes.	norketamine	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
21477627-1	2011	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids.	Arachidonic Acid	46-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21477627-1	2011	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids.	Arachidonic Acid	46-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
21477627-1	2011	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids.	Eicosanoids	86-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21477627-1	2011	Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids.	Eicosanoids	86-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
21476972-3	2011	However, some CYP enzymes are highly expressed in the heart and catalyze arachidonic acid oxidation to a variety of eicosanoids, which attenuates ischemia-reperfusion injury of the heart.	Arachidonic Acid	73-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
21476972-3	2011	However, some CYP enzymes are highly expressed in the heart and catalyze arachidonic acid oxidation to a variety of eicosanoids, which attenuates ischemia-reperfusion injury of the heart.	Eicosanoids	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
21476972-5	2011	CYP enzymes also represent a significant source of reactive oxygen species (ROS) that may target cellular homeostatic mechanisms and mitochondria.	Reactive Oxygen Species	51-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21476972-5	2011	CYP enzymes also represent a significant source of reactive oxygen species (ROS) that may target cellular homeostatic mechanisms and mitochondria.	Reactive Oxygen Species	76-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21476972-6	2011	CYP isoforms expressed in the heart are critical for generation of epoxyeicosatrienoic acids (EETs) and ROS.	epoxyeicosatrienoic acids	67-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21476972-6	2011	CYP isoforms expressed in the heart are critical for generation of epoxyeicosatrienoic acids (EETs) and ROS.	eets	94-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21476972-6	2011	CYP isoforms expressed in the heart are critical for generation of epoxyeicosatrienoic acids (EETs) and ROS.	Reactive Oxygen Species	104-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21148022-0	2011	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia.	Quetiapine Fumarate	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21148022-0	2011	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia.	norquetiapine	68-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21148022-4	2011	This study aimed to identify the possible associations of CYP and ABCB1 genetic polymorphisms with quetiapine and norquetiapine plasma and cerebrospinal fluid (CSF) concentrations and with response to treatment.	Quetiapine Fumarate	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
21148022-4	2011	This study aimed to identify the possible associations of CYP and ABCB1 genetic polymorphisms with quetiapine and norquetiapine plasma and cerebrospinal fluid (CSF) concentrations and with response to treatment.	norquetiapine	114-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
21199317-4	2011	We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids.	Dichlorodiphenyl Dichloroethylene	128-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-181
21508826-4	2011	The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers.	Ketamine	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
21508826-4	2011	The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers.	norketamine	154-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
21508826-2	2011	It is metabolized in the liver to norketamine via cytochrome P450 (CYP) enzymes.	norketamine	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
21508826-3	2011	There are few human data on the involvement of CYP enzymes on the elimination of norketamine and its possible contribution to analgesic effect.	norketamine	81-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
21508826-4	2011	The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers.	Rifampin	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
21463219-7	2011	EXPERT OPINION: This article aims to provide an overview of the multiple gains in incorporating cyclodextrins in poly(anhydride) nanoparticles, including improvement of their bioadhesive capability, the loading of lipophilic drugs and the effect on efflux membrane proteins and cytochrome P450.	Cyclodextrins	96-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	278-293
21799712-7	2011	The detection of four cytochrome P-450 enzyme activities was demonstrated following induction by 3-methylcholantlene, with a sensitivity significantly higher than that in conventional monolayer culture.	3-methylcholantlene	97-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
21294626-3	2011	In this study, we characterized the human liver cytochrome P450 (CYP) enzymes responsible for the biotransformation of three major metabolites--M1, M2, and M4--of magnolin.	magnolin	163-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
21539368-0	2011	The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation?	Dopamine	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
21539368-1	2011	Dopamine can be generated from tyramine via arene hydroxylation catalyzed by a cytochrome P450 enzyme (CYP2D6).	Dopamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21539368-1	2011	Dopamine can be generated from tyramine via arene hydroxylation catalyzed by a cytochrome P450 enzyme (CYP2D6).	Tyramine	31-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21539368-1	2011	Dopamine can be generated from tyramine via arene hydroxylation catalyzed by a cytochrome P450 enzyme (CYP2D6).	arene	44-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21543025-4	2011	Cyclophosphamide is metabolized and activated by the cytochrome P450 (CYP) system and in particular CYP enzymes 2B6 and 2C19.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21543025-4	2011	Cyclophosphamide is metabolized and activated by the cytochrome P450 (CYP) system and in particular CYP enzymes 2B6 and 2C19.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
21543025-4	2011	Cyclophosphamide is metabolized and activated by the cytochrome P450 (CYP) system and in particular CYP enzymes 2B6 and 2C19.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	Nitrogen	41-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	Nitrogen	41-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	iminium	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	iminium	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	Amines	112-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
21504003-6	2011	The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions.	Amines	112-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
21112752-0	2011	In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression.	prenyloxycinnamic acids	28-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
21309752-0	2011	Eicosanoid formation by a cytochrome P450 isoform expressed in the pharynx of Caenorhabditis elegans.	Eicosanoids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
21309752-1	2011	Caenorhabditis elegans harbours several CYP (cytochrome P450) genes that are homologous with mammalian CYP isoforms important to the production of physiologically active AA (arachidonic acid) metabolites.	Arachidonic Acid	174-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
21309752-1	2011	Caenorhabditis elegans harbours several CYP (cytochrome P450) genes that are homologous with mammalian CYP isoforms important to the production of physiologically active AA (arachidonic acid) metabolites.	Arachidonic Acid	174-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
21309752-1	2011	Caenorhabditis elegans harbours several CYP (cytochrome P450) genes that are homologous with mammalian CYP isoforms important to the production of physiologically active AA (arachidonic acid) metabolites.	Arachidonic Acid	174-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
21309752-2	2011	We tested the hypothesis that mammals and C. elegans may share similar basic mechanisms of CYP-dependent eicosanoid formation and action.	Eicosanoids	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
21309752-4	2011	Co-expression of CYP33E2 with the human NADPH-CYP reductase in insect cells resulted in the reconstitution of an active microsomal mono-oxygenase system that metabolized EPA (eicosapentaenoic acid) and, with lower activity, also AA to specific sets of regioisomeric epoxy- and hydroxy-derivatives.	Eicosapentaenoic Acid	170-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
21309752-4	2011	Co-expression of CYP33E2 with the human NADPH-CYP reductase in insect cells resulted in the reconstitution of an active microsomal mono-oxygenase system that metabolized EPA (eicosapentaenoic acid) and, with lower activity, also AA to specific sets of regioisomeric epoxy- and hydroxy-derivatives.	Eicosapentaenoic Acid	175-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
21309752-8	2011	These results demonstrate that EPA and AA are efficient CYP33E2 substrates and suggest that CYP-eicosanoids, influencing in mammals the contractility of cardiomyocytes and vascular smooth muscle cells, may function in C. elegans as regulators of the pharyngeal pumping activity.	Eicosapentaenoic Acid	31-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
21309752-8	2011	These results demonstrate that EPA and AA are efficient CYP33E2 substrates and suggest that CYP-eicosanoids, influencing in mammals the contractility of cardiomyocytes and vascular smooth muscle cells, may function in C. elegans as regulators of the pharyngeal pumping activity.	Eicosanoids	96-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
21193036-1	2011	Cytochrome P450 enzymes play an important role in steroid hormone biosynthesis of the human adrenal gland, e.g., the production of cortisol and aldosterone.	Steroids	50-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21193036-1	2011	Cytochrome P450 enzymes play an important role in steroid hormone biosynthesis of the human adrenal gland, e.g., the production of cortisol and aldosterone.	Hydrocortisone	131-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21193036-1	2011	Cytochrome P450 enzymes play an important role in steroid hormone biosynthesis of the human adrenal gland, e.g., the production of cortisol and aldosterone.	Aldosterone	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20807350-3	2011	Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s).	Dichlorodiphenyl Dichloroethylene	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	255-261
20807350-3	2011	Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s).	Dichlorodiphenyl Dichloroethylene	107-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-306
21210720-11	2011	Drug-induced cytochrome P450 gene expression was increased with rifampicin induction.	Rifampin	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
21294626-3	2011	In this study, we characterized the human liver cytochrome P450 (CYP) enzymes responsible for the biotransformation of three major metabolites--M1, M2, and M4--of magnolin.	magnolin	163-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
21294626-4	2011	CYP2C8, CYP2C9, CYP2C19, and CYP3A4 were identified as the major enzymes responsible for the formation of the two O-desmethyl magnolins (M1 and M2), on the basis of a combination of correlation analysis and experiments, including immunoinhibition of magnolin in human liver microsomes and metabolism of magnolin by human cDNA-expressed CYP enzymes.	magnolin	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21294626-4	2011	CYP2C8, CYP2C9, CYP2C19, and CYP3A4 were identified as the major enzymes responsible for the formation of the two O-desmethyl magnolins (M1 and M2), on the basis of a combination of correlation analysis and experiments, including immunoinhibition of magnolin in human liver microsomes and metabolism of magnolin by human cDNA-expressed CYP enzymes.	magnolin	250-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21444768-0	2011	Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.	Dextromethorphan	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
21363914-4	2011	Here, we use a new mathematical model to compare the effects of conventional cyclophosphamide therapy with those induced when macrophages are used to deliver hypoxia-inducible cytochrome P450 to locally activate cyclophosphamide.	Cyclophosphamide	77-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
21363914-4	2011	Here, we use a new mathematical model to compare the effects of conventional cyclophosphamide therapy with those induced when macrophages are used to deliver hypoxia-inducible cytochrome P450 to locally activate cyclophosphamide.	Cyclophosphamide	212-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
20851588-12	2011	The results provide initial structure-activity information about the interaction of isoquinoline alkaloids with major human xenobiotic-metabolizing CYP enzymes, and illustrate potential novel structures as CYP form-selective inhibitors.	isoquinoline alkaloids	84-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
20851588-12	2011	The results provide initial structure-activity information about the interaction of isoquinoline alkaloids with major human xenobiotic-metabolizing CYP enzymes, and illustrate potential novel structures as CYP form-selective inhibitors.	isoquinoline alkaloids	84-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
21348461-3	2011	Here we show that the selective cytotoxic action of austocystin D arises from its selective activation by cytochrome P450 (CYP) enzymes in specific cancer cell lines, leading to induction of DNA damage in cells and in vitro.	austocystin D	52-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
21348461-3	2011	Here we show that the selective cytotoxic action of austocystin D arises from its selective activation by cytochrome P450 (CYP) enzymes in specific cancer cell lines, leading to induction of DNA damage in cells and in vitro.	austocystin D	52-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
21348461-5	2011	Furthermore, the pattern of cytotoxicity of austocystin D was distinct from doxorubicin and etoposide and unlike aflatoxin B(1), a compound that resembles austocystin D and is also activated by CYP enzymes to induce DNA damage.	austocystin D	44-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-197
20851588-0	2011	Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.	isoquinoline alkaloids	71-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
20851588-3	2011	The purpose of this study was to determine in vitro CYP inhibition potencies of a set of isoquinoline alkaloids to gain insight into interactions of novel chemical structures with CYP enzymes.	isoquinoline alkaloids	89-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
20851588-3	2011	The purpose of this study was to determine in vitro CYP inhibition potencies of a set of isoquinoline alkaloids to gain insight into interactions of novel chemical structures with CYP enzymes.	isoquinoline alkaloids	89-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
21392639-2	2011	Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y12 adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
21276781-11	2011	These findings suggest that co-administration of OS products, especially those with high eupatorin content, with conventional drugs may have the potential to cause drug-herb interactions involving inhibition of major CYP enzymes.	eupatorin	89-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	n-oxide	54-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	n-oxide	54-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	Cimetidine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	Cimetidine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	Cimetidine	148-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
20484614-8	2011	The increase in tPDE4i of roflumilast and roflumilast N-oxide following coadministration with cimetidine was mainly due to the inhibitory effect of cimetidine on cytochrome P450 (CYP) isoenzymes CYP1A2, CYP3A, and CYP2C19.	Cimetidine	148-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
21392639-3	2011	Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness.	Omeprazole	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
21392639-2	2011	Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y12 adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
21392639-3	2011	Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness.	Clopidogrel	136-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
21392639-3	2011	Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness.	Clopidogrel	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
21392639-3	2011	Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness.	Atorvastatin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
21392639-4	2011	Conversely, other agents increase clopidogrel responsiveness by inducing CYP activity.	Clopidogrel	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	49-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-0	2011	Cytochrome P450 eicosanoids and cerebral vascular function.	Eicosanoids	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	Eicosanoids	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	Eicosanoids	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	16-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	16-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21393488-10	2011	Caution should be exercised when coadministering any statin with drugs that metabolize through cytochrome P-450 IIIA-4 in particular fibrates, cyclosporine, and azole antifungals.	Cyclosporine	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
20951188-1	2011	Cytochrome P450 (CYP) enzyme inhibitory properties of six chromenylated amide compounds (CAs) from Amyris plumieri are described.	Amides	72-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20951188-1	2011	Cytochrome P450 (CYP) enzyme inhibitory properties of six chromenylated amide compounds (CAs) from Amyris plumieri are described.	Amides	72-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20951188-1	2011	Cytochrome P450 (CYP) enzyme inhibitory properties of six chromenylated amide compounds (CAs) from Amyris plumieri are described.	cas	89-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20951188-1	2011	Cytochrome P450 (CYP) enzyme inhibitory properties of six chromenylated amide compounds (CAs) from Amyris plumieri are described.	cas	89-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	49-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	epoxyeicosatrienoic acids	62-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	epoxyeicosatrienoic acids	62-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	eets	89-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	eets	89-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	Arachidonic Acid	139-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21356152-1	2011	The eicosanoids 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs), which are generated from the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes, possess a wide array of biological actions, including the regulation of blood flow to organs.	Arachidonic Acid	139-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-179
21356152-3	2011	Investigations are beginning to unravel the molecular and cellular mechanisms by which these CYP eicosanoids regulate cerebral vascular function and the changes that occur in pathological states.	Eicosanoids	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
21356152-7	2011	Thus, the CYP eicosanoids are key regulators of cerebral vascular function and novel therapeutic targets for cardiovascular diseases and neurological disorders.	Eicosanoids	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
20723094-2	2011	BACKGROUND: Tramadol (M) is metabolized by O-demethylation (cytochrome P450 [CYP] 2D6) to the pharmacodynamic active metabolite O-demethyl tramadol (M1).	Tramadol	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-85
20845077-2	2011	Cytochrome P450 (CYP) polymorphisms have been proposed as possible mechanisms for nonresponsiveness to clopidogrel.	Clopidogrel	103-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20845077-2	2011	Cytochrome P450 (CYP) polymorphisms have been proposed as possible mechanisms for nonresponsiveness to clopidogrel.	Clopidogrel	103-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20723094-2	2011	BACKGROUND: Tramadol (M) is metabolized by O-demethylation (cytochrome P450 [CYP] 2D6) to the pharmacodynamic active metabolite O-demethyl tramadol (M1).	O-demethyltramadol	128-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-85
21401511-5	2011	These two dopaminergic pathways stimulate the secretion of pituitary hormones, which directly (GH) or indirectly (ACTH, TSH) activate hepatic nuclear/ cytosolic receptors controlling CYP genes.	Thyrotropin	120-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-186
21147774-1	2011	Cytochrome P450 (P450) 7A1 is well known as the cholesterol 7alpha-hydroxylase, the first enzyme involved in bile acid synthesis from cholesterol.	Bile Acids and Salts	109-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
21147774-1	2011	Cytochrome P450 (P450) 7A1 is well known as the cholesterol 7alpha-hydroxylase, the first enzyme involved in bile acid synthesis from cholesterol.	Cholesterol	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
26596155-1	2011	The mixed density functional theory (DFT) and valence bond study described herein focuses on the activation of 17 benzene derivatives by the active species of Cytochrome P450, so-called Compound I (Cpd I), as well as by the methoxy radical, as a potentially simple model of Cpd I (Jones, J. P.; Mysinger, M.; Korzekwa, K. R. Drug Metab.	Benzene	114-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-174
21401511-6	2011	Recent preliminary studies with selective noradrenaline or serotonin neurotoxins suggest also involvement of the brain noradrenergic and serotonergic systems in the regulation of liver CYP.	Norepinephrine	42-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-188
21401511-7	2011	Moreover, the influence of the peripheral nervous system involving several neurotransmitters (acetylcholine, noradrenaline, adrenaline, dopamine, serotonin) on liver function may also be important for the physiological regulation of hepatic CYP activity.	Acetylcholine	94-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
20860521-0	2011	Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.	Heme	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21401511-7	2011	Moreover, the influence of the peripheral nervous system involving several neurotransmitters (acetylcholine, noradrenaline, adrenaline, dopamine, serotonin) on liver function may also be important for the physiological regulation of hepatic CYP activity.	Norepinephrine	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
21401511-7	2011	Moreover, the influence of the peripheral nervous system involving several neurotransmitters (acetylcholine, noradrenaline, adrenaline, dopamine, serotonin) on liver function may also be important for the physiological regulation of hepatic CYP activity.	Epinephrine	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
21401511-7	2011	Moreover, the influence of the peripheral nervous system involving several neurotransmitters (acetylcholine, noradrenaline, adrenaline, dopamine, serotonin) on liver function may also be important for the physiological regulation of hepatic CYP activity.	Dopamine	136-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
21401511-7	2011	Moreover, the influence of the peripheral nervous system involving several neurotransmitters (acetylcholine, noradrenaline, adrenaline, dopamine, serotonin) on liver function may also be important for the physiological regulation of hepatic CYP activity.	Serotonin	146-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
21087116-1	2011	This study aims to characterize the metabolism of alpha-thujone in human liver preparations in vitro and to identify the role of cytochrome P450 (CYP) and possibly other enzymes catalyzing alpha-thujone biotransformations.	beta-thujone	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
21068193-0	2011	Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.	OSI 930	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-42
21068193-0	2011	Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.	Thiophenes	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-42
21068193-2	2011	Results showed that OSI-930 inactivated purified, recombinant cytochrome P450 (P450) 3A4 in the reconstituted system in a mechanism-based manner.	OSI 930	20-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-88
20641061-0	2011	Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions.	corynoline	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
20641061-0	2011	Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions.	corynoline	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
20641061-5	2011	Among seven major CYP isoforms tested, corynoline showed strong inhibitory effects on the activities of CYP3A4 and CYP2C9, with an IC(50) of 3.3 +- 0.9 microm and 31.5 +- 0.5 microm, respectively.	corynoline	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
21087116-1	2011	This study aims to characterize the metabolism of alpha-thujone in human liver preparations in vitro and to identify the role of cytochrome P450 (CYP) and possibly other enzymes catalyzing alpha-thujone biotransformations.	beta-thujone	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
21087116-6	2011	Screening of alpha-thujone metabolism with CYP recombinant enzymes indicated that CYP2A6 was principally responsible for the major 7- and 4-hydroxylation reactions, although CYP3A4 and CYP2B6 participated to a lesser extent and CYP3A4 and CYP2B6 catalyzed minor 2-hydroxylation.	beta-thujone	13-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
21251580-2	2011	BACKGROUND: CCBs inhibit a variety of cytochrome P-450 enzymes, some of which contribute to clopidogrel metabolic activation.	Clopidogrel	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
21168332-0	2011	(13)C-labeled indolequinone-DTPA-Gd conjugate for NMR probing cytochrome:P450 reductase-mediated one-electron reduction.	Indolequinones	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
21168546-2	2011	The enzyme cytochrome P450 was covalently attached to screen-printed carbon electrodes.	Carbon	69-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
20825389-1	2011	In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone.	Methadone	23-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21039635-3	2011	This study is designed to assess the effect of alcohol on the ABCC1 and CYP enzymes involved in the metabolism of NNRTIs and PIs (CYP2B6, CYP2D6, and CYP3A4) and oxidative stress (CYP1A1, CYP2A6, and CYP2E1) in U937 macrophages.	Alcohols	47-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
21226615-2	2011	The conversion of tamoxifen to active metabolites involves several cytochrome P450 (CYP) enzymes.	Tamoxifen	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
21226615-2	2011	The conversion of tamoxifen to active metabolites involves several cytochrome P450 (CYP) enzymes.	Tamoxifen	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
22126492-2	2011	Many CYP enzymes function in the liver, but presence of CYP2E1 in the brain is demonstrating its role in both nicotine and ethanol metabolism.	Ethanol	123-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-8
21168332-0	2011	(13)C-labeled indolequinone-DTPA-Gd conjugate for NMR probing cytochrome:P450 reductase-mediated one-electron reduction.	Pentetic Acid	28-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
21168332-0	2011	(13)C-labeled indolequinone-DTPA-Gd conjugate for NMR probing cytochrome:P450 reductase-mediated one-electron reduction.	Gadolinium	33-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
21168332-1	2011	We designed and synthesized a new class of (13)C-labeled NMR probe, (13)C-IQ-Gd, to monitor one-electron reductions by cytochrome:P450 (CYP450) reductase under hypoxic conditions.	Carbon	47-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
21168332-1	2011	We designed and synthesized a new class of (13)C-labeled NMR probe, (13)C-IQ-Gd, to monitor one-electron reductions by cytochrome:P450 (CYP450) reductase under hypoxic conditions.	Carbon	47-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
21168332-3	2011	The (13)C NMR signal of (13)C-IQ-Gd was suppressed because of the intramolecular paramagnetic effect of Gd(3+), whereas enzymatic reduction mediated by CYP450 reductase under hypoxic conditions yielded an intensed (13)C NMR signal due to enzymatic activation of the IQ unit followed by release of the DTPA-Gd unit from (13)C-IQ-Gd.	Pentetic Acid	301-305	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-158
21039635-11	2011	CONCLUSIONS: Our study showed that alcohol causes increases in the genetic and functional expressions of ABCC1 and CYP enzymes in U937 macrophages.	Alcohols	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
20825389-1	2011	In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone.	Methadone	23-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
20825389-1	2011	In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone.	Methadone	23-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
20825389-1	2011	In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone.	Methadone	211-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
20825389-3	2011	CYP supersome activity for methadone use and EDDP formation ranked CYP2B6 &gt; 3A4 &gt; 2C19 &gt; 2D6 &gt; 2C18, 3A7 &gt; 2C8, 2C9, 3A5.	Methadone	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
21532165-0	2011	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.	6-methoxy-2-napthylacetic acid	88-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
20576524-3	2011	The CYP-mediated ellipticine metabolites 9-hydroxy- and 7-hydroxyellipticine and the product of ellipticine oxidation by peroxidases, the ellipticine dimer, are the detoxication metabolites of this compound.	ellipticine	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20869469-0	2011	Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids.	Fatty Acids, Unsaturated	56-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	epoxyeicosatrienoic acids	78-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	epoxyeicosatrienoic acids	78-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	108-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20869469-1	2011	Cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA), such as epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, serve as second messengers of various hormones and growth factors and play pivotal roles in the regulation of vascular, renal and cardiac function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	108-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Fatty Acids, Unsaturated	118-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Fatty Acids, Unsaturated	147-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Linoleic Acid	164-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	eicosapentaenoic	174-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Eicosapentaenoic Acid	192-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Docosahexaenoic Acids	201-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-2	2011	As discussed in the present review, virtually all of the major AA metabolizing CYP isoforms accept a variety of other polyunsaturated fatty acids (PUFA), including linoleic, eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), as efficient alternative substrates.	Docosahexaenoic Acids	224-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
20869469-7	2011	Taken together, these findings indicate that CYP-dependent signaling pathways are highly susceptible to changes in the relative bioavailability of the different PUFAs and may provide novel insight into the complex mechanisms that link essential dietary fatty acids to the development of cardiovascular disease.	essential dietary fatty acids	235-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
20576524-0	2011	Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.	Alkaloids	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-31
20576524-0	2011	Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.	ellipticine	74-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-31
20576524-1	2011	An antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation in target tissues.	Alkaloids	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
20576524-1	2011	An antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation in target tissues.	Alkaloids	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
20576524-1	2011	An antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation in target tissues.	ellipticine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
20576524-1	2011	An antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation in target tissues.	ellipticine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
20576524-3	2011	The CYP-mediated ellipticine metabolites 9-hydroxy- and 7-hydroxyellipticine and the product of ellipticine oxidation by peroxidases, the ellipticine dimer, are the detoxication metabolites of this compound.	ellipticine	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20576524-3	2011	The CYP-mediated ellipticine metabolites 9-hydroxy- and 7-hydroxyellipticine and the product of ellipticine oxidation by peroxidases, the ellipticine dimer, are the detoxication metabolites of this compound.	9-hydroxy- and 7-hydroxyellipticine	41-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20576524-3	2011	The CYP-mediated ellipticine metabolites 9-hydroxy- and 7-hydroxyellipticine and the product of ellipticine oxidation by peroxidases, the ellipticine dimer, are the detoxication metabolites of this compound.	ellipticine	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20576524-8	2011	It also suggests ellipticine reactive metabolites 13-hydroxyellipticine and 12-hydroxyellipticine to be good candidates for targeting to tumors absent from the CYP and peroxidase activation enzymes.	ellipticine	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
20576524-8	2011	It also suggests ellipticine reactive metabolites 13-hydroxyellipticine and 12-hydroxyellipticine to be good candidates for targeting to tumors absent from the CYP and peroxidase activation enzymes.	13-hydroxyellipticine	50-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
20576524-8	2011	It also suggests ellipticine reactive metabolites 13-hydroxyellipticine and 12-hydroxyellipticine to be good candidates for targeting to tumors absent from the CYP and peroxidase activation enzymes.	12-hydroxyellipticine	76-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
21532165-0	2011	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.	Nabumetone	156-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
21198441-2	2011	The specific CYP substrates used in this cocktail assay included phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4/5).	Phenacetin	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
21198441-2	2011	The specific CYP substrates used in this cocktail assay included phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4/5).	Mephenytoin	150-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
21084761-1	2011	Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to all microsomal cytochrome P450 (CYP) enzymes and is necessary for microsomal CYP activities.	NADP	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
21084761-1	2011	Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to all microsomal cytochrome P450 (CYP) enzymes and is necessary for microsomal CYP activities.	NADP	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
21084761-1	2011	Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to all microsomal cytochrome P450 (CYP) enzymes and is necessary for microsomal CYP activities.	NADP	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
21198441-2	2011	The specific CYP substrates used in this cocktail assay included phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4/5).	Dextromethorphan	175-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
21198441-2	2011	The specific CYP substrates used in this cocktail assay included phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4/5).	Midazolam	206-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
21771377-3	2011	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel"s active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	Omeprazole	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
21205193-0	2011	Cytochrome P450 metabolizing fatty acids in living organisms.	Fatty Acids	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21047828-1	2011	BACKGROUND: rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450.	Rifampin	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
21047828-1	2011	BACKGROUND: rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450.	Nevirapine	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
20980920-1	2011	Clopidogrel is metabolically activated by cytochrome P450 (CYP) isoenzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
20980920-1	2011	Clopidogrel is metabolically activated by cytochrome P450 (CYP) isoenzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
21142269-0	2011	Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.	Oxycodone	99-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
21142269-1	2011	BACKGROUND AND OBJECTIVE: Oxycodone is a mu-opioid receptor agonist that is mainly metabolized by hepatic cytochrome P450 (CYP) enzymes.	Oxycodone	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
21142269-1	2011	BACKGROUND AND OBJECTIVE: Oxycodone is a mu-opioid receptor agonist that is mainly metabolized by hepatic cytochrome P450 (CYP) enzymes.	Oxycodone	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
21142269-2	2011	Because CYP enzymes can be inhibited by other drugs, the pharmacokinetics of oxycodone are prone to drug interactions.	Oxycodone	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
21574905-9	2011	CONCLUSION: Since concurrent exposure to DDEs with the potential to cause PK DDIs may be relatively common, policy decisions-makers should consider the use of long-acting opioids that are not metabolized through the CYP450 pathway.	Dichlorodiphenyl Dichloroethylene	41-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-222
21771377-3	2011	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel"s active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	Omeprazole	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
21771377-3	2011	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel"s active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	Clopidogrel	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-243
21771377-3	2011	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel"s active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	Clopidogrel	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
21558760-1	2011	This review focuses on the development of ruthenium and flavin catalysts for environmentally benign oxidation reactions based on mimicking the functions of cytochrome P-450 and flavoenzymes, and low valent transition-metal catalysts that replace conventional acids and bases.	Ruthenium	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
21558760-1	2011	This review focuses on the development of ruthenium and flavin catalysts for environmentally benign oxidation reactions based on mimicking the functions of cytochrome P-450 and flavoenzymes, and low valent transition-metal catalysts that replace conventional acids and bases.	4,6-dinitro-o-cresol	56-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
21228620-1	2011	Talarozole is a new highly potent and selective azole derivative which inhibits cytochrome-P450-dependent all-trans-retinoic acid catabolism.	R 115866	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
21546883-2	2011	The thienopyridine clopidogrel is a prodrug that requires bioactivation by the cytochrome P450 (CYP) system in order to exert its antiplatelet effect.	thienopyridine	4-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21546883-2	2011	The thienopyridine clopidogrel is a prodrug that requires bioactivation by the cytochrome P450 (CYP) system in order to exert its antiplatelet effect.	thienopyridine	4-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
21546883-2	2011	The thienopyridine clopidogrel is a prodrug that requires bioactivation by the cytochrome P450 (CYP) system in order to exert its antiplatelet effect.	Clopidogrel	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21546883-2	2011	The thienopyridine clopidogrel is a prodrug that requires bioactivation by the cytochrome P450 (CYP) system in order to exert its antiplatelet effect.	Clopidogrel	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
21228620-1	2011	Talarozole is a new highly potent and selective azole derivative which inhibits cytochrome-P450-dependent all-trans-retinoic acid catabolism.	Azoles	48-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
21228620-1	2011	Talarozole is a new highly potent and selective azole derivative which inhibits cytochrome-P450-dependent all-trans-retinoic acid catabolism.	Tretinoin	110-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
21098752-13	2010	Cytochrome P450 enzyme induction by phenobarbital could be responsible for the production of reactive metabolites of lamotrigine that might be causative for the observed hematologic effects.	Phenobarbital	36-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21462897-0	2011	In vitro metabolism of glycyrrhetic acid by human cytochrome P450.	Glycyrrhetinic Acid	23-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
20609441-0	2010	Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro.	Ketamine	133-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
20609441-0	2010	Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro.	norketamine	146-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
20609441-3	2010	Enantioselective capillary electrophoresis with multiple isomer sulfated beta-cyclodextrin as chiral selector was used to identify cytochrome P450 enzymes involved in hepatic ketamine and norketamine biotransformation in vitro.	betadex	73-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
20609441-3	2010	Enantioselective capillary electrophoresis with multiple isomer sulfated beta-cyclodextrin as chiral selector was used to identify cytochrome P450 enzymes involved in hepatic ketamine and norketamine biotransformation in vitro.	Ketamine	175-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
20609441-3	2010	Enantioselective capillary electrophoresis with multiple isomer sulfated beta-cyclodextrin as chiral selector was used to identify cytochrome P450 enzymes involved in hepatic ketamine and norketamine biotransformation in vitro.	norketamine	188-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
20609441-4	2010	The N-demethylation of ketamine to norketamine and subsequently the biotransformation of norketamine to other metabolites were studied via analysis of alkaline extracts of in vitro incubations of racemic ketamine and racemic norketamine with nine recombinantly expressed human cytochrome P450 enzymes and human liver microsomes.	Ketamine	23-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-292
21098752-13	2010	Cytochrome P450 enzyme induction by phenobarbital could be responsible for the production of reactive metabolites of lamotrigine that might be causative for the observed hematologic effects.	Lamotrigine	117-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20941528-0	2010	Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.	Eicosanoids	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
21191764-3	2010	This study characterized the human liver cytochrome P450 (CYP) and UDPglucuronosyltransferase (UGT) enzymes responsible for the metabolism of jaceosidin.	jaceosidin	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
21191764-3	2010	This study characterized the human liver cytochrome P450 (CYP) and UDPglucuronosyltransferase (UGT) enzymes responsible for the metabolism of jaceosidin.	jaceosidin	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
21191764-4	2010	CYP1A2 was identified as the major enzyme responsible for the formation of 6-O-desmethyljaceosidin and hydroxyjaceosidin from jaceosidin on the basis of a combination of correlation analysis and experiments including immuno-inhibition, chemical inhibition in human liver microsomes, and metabolism by human cDNA-expressed CYP enzymes.	6-o-desmethyljaceosidin	75-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
20941528-4	2010	However, arachidonic acid is also substrate for a third enzymatic pathway, the cytochrome P450 (CYP) system.	Arachidonic Acid	9-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
21191764-4	2010	CYP1A2 was identified as the major enzyme responsible for the formation of 6-O-desmethyljaceosidin and hydroxyjaceosidin from jaceosidin on the basis of a combination of correlation analysis and experiments including immuno-inhibition, chemical inhibition in human liver microsomes, and metabolism by human cDNA-expressed CYP enzymes.	hydroxyjaceosidin	103-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
20941528-4	2010	However, arachidonic acid is also substrate for a third enzymatic pathway, the cytochrome P450 (CYP) system.	Arachidonic Acid	9-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
21191764-4	2010	CYP1A2 was identified as the major enzyme responsible for the formation of 6-O-desmethyljaceosidin and hydroxyjaceosidin from jaceosidin on the basis of a combination of correlation analysis and experiments including immuno-inhibition, chemical inhibition in human liver microsomes, and metabolism by human cDNA-expressed CYP enzymes.	jaceosidin	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
20844025-2	2010	This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis.	Steroids	154-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
24688155-1	2010	BACKGROUND: Fluoxetine is an inhibitor of the main metabolizing enzymes (cytochrome P450 [CYP] 2C19 and CYP3A4) of omeprazole and thus might influence that drug"s pharmacokinetics.	Fluoxetine	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-99
24688155-1	2010	BACKGROUND: Fluoxetine is an inhibitor of the main metabolizing enzymes (cytochrome P450 [CYP] 2C19 and CYP3A4) of omeprazole and thus might influence that drug"s pharmacokinetics.	Omeprazole	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-99
20851877-0	2010	Metabolism of sesamin by cytochrome P450 in human liver microsomes.	sesamin	14-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
20851877-1	2010	Metabolism of sesamin by cytochrome P450 (P450) was examined using yeast expression system and human liver microsomes.	sesamin	14-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
20844025-2	2010	This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis.	Steroids	154-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
21067460-6	2010	Desvenlafaxine has clinically insignificant effects on the activity of CYP and P-gp.	Desvenlafaxine Succinate	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
20863199-0	2010	Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin.	Capsaicin	70-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
21062303-6	2010	Other prototypical inhibitors used for characterization of human CYP activities such as furafylline (CYP1A), tranylcypromine (CYP2B) and sulfaphenazole (CYP2C) did not show significant effects in cat and dog liver microsomes.	furafylline	88-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
20412007-5	2010	Monooxygenases such as Cytochrome-P450 enzymes do not show any change between the culture systems after 1 day, but exhibit significant up-regulation in CS cultures after 3 days in comparison to hepatocyte monolayers.	Cesium	152-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
20863199-2	2010	To investigate potential food-drug or drug-drug interactions, capsaicin was evaluated in vitro against seven human drug-metabolizing cytochrome P450 (CYP) enzymes.	Capsaicin	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
20881954-1	2010	Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro.	pazopanib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
21226440-11	2010	All patients were prescribed "azole" antifungal agents and five patients were also on high-dose steroids, both agents known to induce cytochrome P-450 enzymes and hence potentiating dapsone toxicity.	Steroids	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
20945912-1	2010	Menthofuran is a monoterpene present in mint plants that is oxidized by mammalian cytochrome P450 (CYP) to hepatotoxic metabolites.	menthofuran	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
20945912-1	2010	Menthofuran is a monoterpene present in mint plants that is oxidized by mammalian cytochrome P450 (CYP) to hepatotoxic metabolites.	menthofuran	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
20945912-1	2010	Menthofuran is a monoterpene present in mint plants that is oxidized by mammalian cytochrome P450 (CYP) to hepatotoxic metabolites.	Monoterpenes	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
20945912-1	2010	Menthofuran is a monoterpene present in mint plants that is oxidized by mammalian cytochrome P450 (CYP) to hepatotoxic metabolites.	Monoterpenes	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
20881954-1	2010	Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro.	pazopanib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-178
20881954-2	2010	This study in patients with advanced cancer evaluated the effect of pazopanib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of pazopanib.	pazopanib	68-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-87
20881954-2	2010	This study in patients with advanced cancer evaluated the effect of pazopanib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of pazopanib.	pazopanib	190-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-87
20378604-1	2010	Lipoxygenase, cyclo-oxygenase and cytochrome P450 (CYP) products of arachidonic acid (AA) are implicated in pulmonary vasoregulation.	Arachidonic Acid	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
20378604-1	2010	Lipoxygenase, cyclo-oxygenase and cytochrome P450 (CYP) products of arachidonic acid (AA) are implicated in pulmonary vasoregulation.	Arachidonic Acid	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
20378604-2	2010	The CYP-mediated epoxyeicosatrienoates (EETs) have been described previously as the predominant eicosanoids in human lungs upon stimulation with the Ca(2+) ionophore A23187.	epoxyeicosatrienoates	17-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20378604-2	2010	The CYP-mediated epoxyeicosatrienoates (EETs) have been described previously as the predominant eicosanoids in human lungs upon stimulation with the Ca(2+) ionophore A23187.	eets	40-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20378604-2	2010	The CYP-mediated epoxyeicosatrienoates (EETs) have been described previously as the predominant eicosanoids in human lungs upon stimulation with the Ca(2+) ionophore A23187.	Eicosanoids	96-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
20378604-2	2010	The CYP-mediated epoxyeicosatrienoates (EETs) have been described previously as the predominant eicosanoids in human lungs upon stimulation with the Ca(2+) ionophore A23187.	Calcimycin	166-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
21031626-0	2010	Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside.	tiliroside	80-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21071321-8	2010	RESULTS: The development of pseudotumor cerebri after initiation of voriconazole may have been secondary to the inhibition of the cytochrome P450 (CYP) enzymes.	Voriconazole	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
21071321-8	2010	RESULTS: The development of pseudotumor cerebri after initiation of voriconazole may have been secondary to the inhibition of the cytochrome P450 (CYP) enzymes.	Voriconazole	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
21031626-3	2010	The inhibition of seven CYP isoforms (CYP3A4, CYP1A2, CYP2A6, CYP2D6, CYP2C9, CYP2C8 and CYP2E1) by tiliroside was investigated using in vitro human liver microsomal incubation assays.	tiliroside	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
21031626-4	2010	The results showed that tiliroside strongly inhibited the activity of CYP3A4 (IC(50) = 9.0 +- 1.7 mum), CYP2C8 (IC(50) = 12.1 +- 0.9 mum) and CYP2C9 (IC(50) = 10.2 +- 0.9 mum) with other CYP isoforms negligibly influenced.	tiliroside	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
21031626-5	2010	Further kinetic analysis showed that inhibition of these three CYP isoforms by tiliroside is best fit to a competitive way.	tiliroside	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
21031626-7	2010	The relatively low K(i) values suggested that tiliroside might induce drug-drug interactions with many clinically used drugs which are mainly metabolized by these three CYP isoforms.	tiliroside	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
20937004-0	2010	In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.	3-((methylsulfonyl)amino)-2-phenyl-N-(1-phenylpropyl)quinolin-4-carboxamide	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-136
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	5-sulfoxidation	94-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	5-sulfoxidation	94-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	mono-n-octyl phthalate	111-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	mono-n-octyl phthalate	111-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	aliphatic-	162-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	aliphatic-	162-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	phenothiazine	177-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	phenothiazine	177-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	Chlorpromazine	203-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
20615392-1	2010	The aim of the present study was to identify cytochrome P450 (CYP) isoenzymes involved in the 5-sulfoxidation, mono-N-demethylation and di-N-demethylation of the aliphatic-type phenothiazine neuroleptic chlorpromazine in human liver.	Chlorpromazine	203-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
20615392-3	2010	The obtained results indicate that CYP1A2 is the only CYP isoform that catalyzes the mono-N-demethylation and di-N-demethylation of chlorpromazine (100%) and is the main isoform responsible for chlorpromazine 5-sulfoxidation (64%) at a therapeutic concentration of the drug (10 microM).	mono-n-octyl phthalate	85-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
20615392-3	2010	The obtained results indicate that CYP1A2 is the only CYP isoform that catalyzes the mono-N-demethylation and di-N-demethylation of chlorpromazine (100%) and is the main isoform responsible for chlorpromazine 5-sulfoxidation (64%) at a therapeutic concentration of the drug (10 microM).	Chlorpromazine	132-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
20615392-3	2010	The obtained results indicate that CYP1A2 is the only CYP isoform that catalyzes the mono-N-demethylation and di-N-demethylation of chlorpromazine (100%) and is the main isoform responsible for chlorpromazine 5-sulfoxidation (64%) at a therapeutic concentration of the drug (10 microM).	chlorpromazine 5-sulfoxidation	194-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
20967245-0	2010	Cytochrome P450 reductase: a harbinger of diffusible reduced oxygen species.	Oxygen	61-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20967245-1	2010	The bi-enzymatic system of cytochrome P450 (CYP, a hemoprotein) and cytochrome P450 reductase (CPR, a diflavoenzyme) mediate the redox metabolism of diverse indigenous and xenobiotic molecules in various cellular and organ systems, using oxygen and NADPH.	Oxygen	238-244	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
20967245-1	2010	The bi-enzymatic system of cytochrome P450 (CYP, a hemoprotein) and cytochrome P450 reductase (CPR, a diflavoenzyme) mediate the redox metabolism of diverse indigenous and xenobiotic molecules in various cellular and organ systems, using oxygen and NADPH.	Oxygen	238-244	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
20967245-1	2010	The bi-enzymatic system of cytochrome P450 (CYP, a hemoprotein) and cytochrome P450 reductase (CPR, a diflavoenzyme) mediate the redox metabolism of diverse indigenous and xenobiotic molecules in various cellular and organ systems, using oxygen and NADPH.	NADP	249-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
20967245-1	2010	The bi-enzymatic system of cytochrome P450 (CYP, a hemoprotein) and cytochrome P450 reductase (CPR, a diflavoenzyme) mediate the redox metabolism of diverse indigenous and xenobiotic molecules in various cellular and organ systems, using oxygen and NADPH.	NADP	249-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
20967245-7	2010	We also quantitatively demonstrate that the rate of oxygen activation and peroxide depletion by CPR accounts for the major reactivity in the CYP+CPR mixture.	Oxygen	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
20967245-7	2010	We also quantitatively demonstrate that the rate of oxygen activation and peroxide depletion by CPR accounts for the major reactivity in the CYP+CPR mixture.	Peroxides	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
20599500-5	2010	Difference between the groups was explained by peculiarities of reductase activity and cytochrome P450 enzyme activities with 7-ethoxyresorufin, 7-methoxyresorufin, 7-methoxycoumarin, 7-benzyloxyresorufin and 7-benzyloxyquinoline.	ethoxyresorufin	126-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20967245-11	2010	Some of the activities that were primarily attributed to the heme-center of CYP are now established to be a facet of the flavins of CPR.	Heme	61-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
20967245-11	2010	Some of the activities that were primarily attributed to the heme-center of CYP are now established to be a facet of the flavins of CPR.	Flavins	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
21603375-11	2010	One of the newer opiates, oxymorphone, has recently been studied as it is metabolized in a non-cytochrome P-450 pathway and therefore bypasses many of the drug-drug interactions common to the elderly.	Opiate Alkaloids	17-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
20599500-5	2010	Difference between the groups was explained by peculiarities of reductase activity and cytochrome P450 enzyme activities with 7-ethoxyresorufin, 7-methoxyresorufin, 7-methoxycoumarin, 7-benzyloxyresorufin and 7-benzyloxyquinoline.	7-methoxyresorufin	145-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20599500-5	2010	Difference between the groups was explained by peculiarities of reductase activity and cytochrome P450 enzyme activities with 7-ethoxyresorufin, 7-methoxyresorufin, 7-methoxycoumarin, 7-benzyloxyresorufin and 7-benzyloxyquinoline.	herniarin	165-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20599500-5	2010	Difference between the groups was explained by peculiarities of reductase activity and cytochrome P450 enzyme activities with 7-ethoxyresorufin, 7-methoxyresorufin, 7-methoxycoumarin, 7-benzyloxyresorufin and 7-benzyloxyquinoline.	benzyloxyresorufin	184-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20599500-5	2010	Difference between the groups was explained by peculiarities of reductase activity and cytochrome P450 enzyme activities with 7-ethoxyresorufin, 7-methoxyresorufin, 7-methoxycoumarin, 7-benzyloxyresorufin and 7-benzyloxyquinoline.	7-benzyloxyquinoline	209-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20634336-6	2010	Incubations with recombinant flavin-containing monooxygenase (FMO) and UDP-glucuronosyltransferase (UGT) enzymes and inhibition studies using the nonselective cytochrome P450 (P450) chemical inhibitor 1-aminobenzotriazole in human hepatocytes indicated that FMO1 and FMO3 contributed to cediranib N-oxidation, whereas UGT1A4 had a major role in cediranib N(+)-glucuronidation.	1H-1,2,3-benzotriazol-4-amine	203-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-202
21603375-11	2010	One of the newer opiates, oxymorphone, has recently been studied as it is metabolized in a non-cytochrome P-450 pathway and therefore bypasses many of the drug-drug interactions common to the elderly.	Oxymorphone	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
20877451-5	2010	Cytochrome P450 (CYP) enzymes, CYP2D6 in particular, play a major role in the metabolism of tamoxifen to active metabolites.	Tamoxifen	92-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	Benzo(a)pyrene	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	Benzo(a)pyrene	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	37-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	37-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
20399842-2	2010	BP is converted in liver and lung to benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) by the enzymes of the cytochrome P450 (CYP) superfamily, namely CYP1A1/1A2, and CYP1B1.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
20877451-5	2010	Cytochrome P450 (CYP) enzymes, CYP2D6 in particular, play a major role in the metabolism of tamoxifen to active metabolites.	Tamoxifen	92-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
20652238-1	2010	The angular dioxygenase, cytochrome P450, lignin peroxidase, and dehalogenase are known as dioxin-metabolizing enzymes.	Dioxins	91-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-59
20735423-1	2010	BACKGROUND AND PURPOSE: The conversion of clopidogrel to its active metabolite, R-130964, is a two-step cytochrome P450 (CYP)-dependent process.	Clopidogrel	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
20735423-1	2010	BACKGROUND AND PURPOSE: The conversion of clopidogrel to its active metabolite, R-130964, is a two-step cytochrome P450 (CYP)-dependent process.	Clopidogrel	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
20735423-2	2010	The current investigations were performed to characterize in vitro the effects of different CYP inhibitors on the biotransformation and on the antiplatelet effect of clopidogrel.	Clopidogrel	166-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
24278521-0	2010	Bioactivation of Aromatic Amines by Human CYP2W1, An Orphan Cytochrome P450 Enzyme.	aromatic amines	17-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
20629947-0	2010	Measurement and diagnostic use of hepatic cytochrome P450 metabolism of oleic acid in liver disease.	Oleic Acid	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
20629947-2	2010	As of today, the contribution of individual cytochrome P450 (CYP) mono-oxygenases to the epoxidation of this fatty acid is unknown.	Fatty Acids	109-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
20629947-2	2010	As of today, the contribution of individual cytochrome P450 (CYP) mono-oxygenases to the epoxidation of this fatty acid is unknown.	Fatty Acids	109-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
20629947-5	2010	Fifteen CYP mono-oxygenases were investigated in vitro as a potential source of cis-EODA.	9,10-epoxystearic acid	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
20629947-7	2010	Production of cis-EODA was catalysed by CYP in the following order: 2C8, 2C9, 2C19, 3A4, 1A2 and CYP3A7.	9,10-epoxystearic acid	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
20699675-5	2010	Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin.	pitavastatin	8-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
20699675-5	2010	Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin.	pitavastatin	195-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
19904716-2	2010	This method was established by the characteristics of recombinant cytochrome P-450 (CYP) isozymes, where CYP2C19 prefers to metabolize R-methadone and CYP2B6 prefers to metabolize S-methadone.	Methadone	135-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
20493836-1	2010	Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid (AA) catalyzed by cytochrome P450 (CYP), have many essential biologic roles in the cardiovascular system including inhibition of apoptosis in cardiomyocytes.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
20532872-7	2010	Polymorphism in the metabolic enzyme cytochrome P-450 is associated with risk of myocardial infarction in caffeine users.	Caffeine	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	232-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
19804952-6	2010	The main metabolite M2 (m/z 320) resulted from ring-cleavage of SA followed by demethylation, whereas M4 (m/z 348) is oxidized by CYP in the presence of NADPH.	NADP	153-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
20610983-6	2010	Although new triazole antifungals are well tolerated, they still cause significant inhibition of CYP enzymes.	Triazoles	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
20610983-8	2010	Azole antimycotics are amongst the strongest inhibitors of CYP-mediated drug metabolism.	Azoles	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
20658791-7	2010	Duloxetine and escitalopram are extensively metabolized via cytochrome P450 (CYP) enzymes and the decreased hepatic metabolism present in many older adults should be taken into account when prescribing these medications.	Duloxetine Hydrochloride	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
20658791-7	2010	Duloxetine and escitalopram are extensively metabolized via cytochrome P450 (CYP) enzymes and the decreased hepatic metabolism present in many older adults should be taken into account when prescribing these medications.	Duloxetine Hydrochloride	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
20658791-7	2010	Duloxetine and escitalopram are extensively metabolized via cytochrome P450 (CYP) enzymes and the decreased hepatic metabolism present in many older adults should be taken into account when prescribing these medications.	Citalopram	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
20658791-7	2010	Duloxetine and escitalopram are extensively metabolized via cytochrome P450 (CYP) enzymes and the decreased hepatic metabolism present in many older adults should be taken into account when prescribing these medications.	Citalopram	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
19904716-2	2010	This method was established by the characteristics of recombinant cytochrome P-450 (CYP) isozymes, where CYP2C19 prefers to metabolize R-methadone and CYP2B6 prefers to metabolize S-methadone.	Methadone	135-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
19904716-2	2010	This method was established by the characteristics of recombinant cytochrome P-450 (CYP) isozymes, where CYP2C19 prefers to metabolize R-methadone and CYP2B6 prefers to metabolize S-methadone.	Methadone	180-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
19904716-2	2010	This method was established by the characteristics of recombinant cytochrome P-450 (CYP) isozymes, where CYP2C19 prefers to metabolize R-methadone and CYP2B6 prefers to metabolize S-methadone.	Methadone	180-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
20052538-2	2010	Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen.	Tamoxifen	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
20382753-0	2010	Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.	Erlotinib Hydrochloride	89-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20382753-5	2010	Cytochrome P450 (P450)-dependent adducts are proposed to be formed via reactive epoxide and electrophilic quinone-imine intermediates.	reactive epoxide	71-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20382753-5	2010	Cytochrome P450 (P450)-dependent adducts are proposed to be formed via reactive epoxide and electrophilic quinone-imine intermediates.	quinone-imine	106-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
20052538-2	2010	Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen.	Tamoxifen	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
20052538-2	2010	Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen.	4-hydroxy-N-desmethyltamoxifen	154-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
20052538-2	2010	Orally administered tamoxifen, is extensively metabolized by cytochrome P450 (CYP) enzymes, namely CYP3A4 and CYP2D6, into active metabolites, especially endoxifen.	4-hydroxy-N-desmethyltamoxifen	154-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
20570348-2	2010	The heterocyclic amine, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-borne carcinogen being metabolically activated by cytochrome P450 (CYP) enzymes, especially by CYP1A1/2.	heterocyclic amine	4-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
20570348-2	2010	The heterocyclic amine, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-borne carcinogen being metabolically activated by cytochrome P450 (CYP) enzymes, especially by CYP1A1/2.	heterocyclic amine	4-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
20570348-2	2010	The heterocyclic amine, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-borne carcinogen being metabolically activated by cytochrome P450 (CYP) enzymes, especially by CYP1A1/2.	2-amino-3-methylimidazo(4,5-f)quinoline	24-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
20570348-2	2010	The heterocyclic amine, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-borne carcinogen being metabolically activated by cytochrome P450 (CYP) enzymes, especially by CYP1A1/2.	2-amino-3-methylimidazo(4,5-f)quinoline	24-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
20408551-4	2010	Unwanted side effects are preventable without remarkable loss of activity when the responsible constituent(s) are carefully removed during the extraction process, as demonstrated for hyperforin (3), which is responsible for the induction of cytochrome P450 (CYP)-metabolizing enzymes (CYP3A4, in particular).	hyperforin	183-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-256
20606811-2	2010	The cytochrome P(450) isoform (CYP2E1) specifically involved in ethanol oxidation is discussed.	Ethanol	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-21
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Carbon	17-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	-hydroxyethyl	35-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Oxygen	54-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	centered (hydroxyl)	61-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Ethanol	115-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	hydroxyethyl radicals	156-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Oxygen	244-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	(p(450)-fe(3+)o	328-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Heme	384-388	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20606811-6	2010	The formation of carbon-centered (1-hydroxyethyl) and oxygen-centered (hydroxyl) radicals during the metabolism of ethanol is considered: the generation of hydroxyethyl radicals, which occurs likely during the process of univalent reduction of dioxygen, is highlighted and is carried out by ferric cytochrome P(450) oxy-complex (P(450)-Fe(3+)O(2) (.-)) formed during the reduction of heme-oxygen.	Oxygen	246-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	298-315
20408551-4	2010	Unwanted side effects are preventable without remarkable loss of activity when the responsible constituent(s) are carefully removed during the extraction process, as demonstrated for hyperforin (3), which is responsible for the induction of cytochrome P450 (CYP)-metabolizing enzymes (CYP3A4, in particular).	hyperforin	183-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-261
19513837-8	2010	This leak may pose a clinical danger by increasing drug uptake into the bloodstream, a phenomenon which would act synergistically with the effect of omeprazole on inhibiting liver cytochrome P450s that remove drugs from the bloodstream, thereby elevating drug blood levels.	Omeprazole	149-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
20437462-0	2010	Contributions of human cytochrome P450 enzymes to glyburide metabolism.	Glyburide	50-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
20437462-3	2010	Therefore, there has been a continued interest in identifying human cytochrome P450 (CYP) isoforms that play a major role in the metabolism of GLB.	Glyburide	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
20437462-3	2010	Therefore, there has been a continued interest in identifying human cytochrome P450 (CYP) isoforms that play a major role in the metabolism of GLB.	Glyburide	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20437462-5	2010	The present study systematically investigated the contributions of various human CYP isoforms (CYP3A4, CYP3A5, CYP2C8, CYP2C9 and CYP2C19) to in vitro metabolism of GLB.	Glyburide	165-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
20437462-6	2010	GLB depletion and metabolite formation in human liver microsomes were most significantly inhibited by the CYP3A inhibitor ketoconazole compared with the inhibitors of other CYP isoforms.	Glyburide	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
20437462-6	2010	GLB depletion and metabolite formation in human liver microsomes were most significantly inhibited by the CYP3A inhibitor ketoconazole compared with the inhibitors of other CYP isoforms.	Ketoconazole	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
20437462-7	2010	Furthermore, multiple correlation analysis between GLB depletion and individual CYP activities was performed, demonstrating a significant correlation between GLB depletion and the CYP3A probe activity in 16 individual human liver microsomal preparations, but not between GLB depletion and the CYP2C19, CYP2C8 or CYP2C9 probe activity.	Glyburide	158-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
20437462-7	2010	Furthermore, multiple correlation analysis between GLB depletion and individual CYP activities was performed, demonstrating a significant correlation between GLB depletion and the CYP3A probe activity in 16 individual human liver microsomal preparations, but not between GLB depletion and the CYP2C19, CYP2C8 or CYP2C9 probe activity.	Glyburide	158-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
20437462-8	2010	By using recombinant supersomes overexpressing individual human CYP isoforms, it was found that GLB could be depleted by all the enzymes tested; however, the intrinsic clearance (V(max)/K(m)) of CYP3A4 for GLB depletion was 4-17 times greater than that of other CYP isoforms.	Glyburide	96-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
20437462-8	2010	By using recombinant supersomes overexpressing individual human CYP isoforms, it was found that GLB could be depleted by all the enzymes tested; however, the intrinsic clearance (V(max)/K(m)) of CYP3A4 for GLB depletion was 4-17 times greater than that of other CYP isoforms.	Glyburide	96-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
20437462-8	2010	By using recombinant supersomes overexpressing individual human CYP isoforms, it was found that GLB could be depleted by all the enzymes tested; however, the intrinsic clearance (V(max)/K(m)) of CYP3A4 for GLB depletion was 4-17 times greater than that of other CYP isoforms.	Glyburide	206-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
20437462-8	2010	By using recombinant supersomes overexpressing individual human CYP isoforms, it was found that GLB could be depleted by all the enzymes tested; however, the intrinsic clearance (V(max)/K(m)) of CYP3A4 for GLB depletion was 4-17 times greater than that of other CYP isoforms.	Glyburide	206-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
20124396-7	2010	Lersivirine was extensively metabolized, primarily by UDP glucuronosyltransferase- and cytochrome P450-dependent pathways, with 22 metabolites being identified in this study.	UK 453,061	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
20609060-4	2010	KEY FINDINGS: The results showed that nateglinide inhibited CYP2C9 and CYP2C19 with an IC50(app) (apparent value of the 50% inhibitory concentration) of 125 micromol/l and 946 micromol/l, respectively, while M1 did not inhibit any of the CYP isoforms.	Nateglinide	38-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
20609060-0	2010	Inhibition of human liver microsomal CYP by nateglinide.	Nateglinide	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
20609060-8	2010	The results revealed that the inhibition of CYP by nateglinide was not influenced by pre-incubation, and that the possibility of MBI is very low.	Nateglinide	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
20609060-1	2010	OBJECTIVES: Nateglinide is metabolized by CYP2C9 and CYP3A4, therefore drug-drug interactions through cytochrome P450 (CYP) inhibition may occur.	Nateglinide	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
20609060-9	2010	CONCLUSIONS: The possibility of drug-drug interactions involving nateglinide that might be attributable to CYP inhibition is low.	Nateglinide	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
20609060-1	2010	OBJECTIVES: Nateglinide is metabolized by CYP2C9 and CYP3A4, therefore drug-drug interactions through cytochrome P450 (CYP) inhibition may occur.	Nateglinide	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
20218941-6	2010	In addition to CYP gene expression, nuclear receptor proteins regulate the expression of complex gene networks, and therefore mediate the metabolism and modify the effects of steroid hormones, fat-soluble vitamins, and free fatty acids on the metabolic, reproductive, and developmental processes of mammals.	Steroids	175-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
20609060-2	2010	In this study, we examined the inhibitory effects of nateglinide and its major metabolite N-[trans-4-(1-hydroxy-1-methylethyl)-cyclohexanecarbonyl]-D-phenylalanine (M1) on various CYP isoforms in human liver microsomes.	n-[trans-4-(1-hydroxy-1-methylethyl)-cyclohexanecarbonyl]-d-phenylalanine	90-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
20218941-6	2010	In addition to CYP gene expression, nuclear receptor proteins regulate the expression of complex gene networks, and therefore mediate the metabolism and modify the effects of steroid hormones, fat-soluble vitamins, and free fatty acids on the metabolic, reproductive, and developmental processes of mammals.	Fatty Acids, Nonesterified	219-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
19998329-0	2010	Cytochrome P450-dependent toxicity of dapsone in human erythrocytes.	Dapsone	38-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19998329-2	2010	An in vitro microsomal/cytochrome P(450) (CYP)-linked assay, which allows reactive metabolites generated in situ to react with the co-incubated human erythrocytes, was employed to profile CYP isoforms responsible for hemotoxicity of dapsone.	Dapsone	233-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-40
20207119-1	2010	Polyunsaturated fatty acids of nutritional value may affect cell functions after their release from cell lipid storage sites, especially phospholipids, and specific oxygenation by cyclooxygenases, lipoxygenases and cytochrome P(450).	Fatty Acids, Unsaturated	0-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-232
19562511-1	2010	Acenocoumarol is mainly catabolized by CYP2C9 isoform of cytochrome P450 (CYP) liver complex and exerts its anticoagulant effect through the inhibition of Vitamin K Epoxide Reductase (VKOR).	Acenocoumarol	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
19562511-1	2010	Acenocoumarol is mainly catabolized by CYP2C9 isoform of cytochrome P450 (CYP) liver complex and exerts its anticoagulant effect through the inhibition of Vitamin K Epoxide Reductase (VKOR).	Acenocoumarol	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
20051482-1	2010	Cytochrome P450 (P450)1A1 plays a critical role in the metabolic activation and detoxification of polycyclic aromatic hydrocarbons (PAHs), many of which are potent human carcinogens.	Polycyclic Aromatic Hydrocarbons	98-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
20051482-1	2010	Cytochrome P450 (P450)1A1 plays a critical role in the metabolic activation and detoxification of polycyclic aromatic hydrocarbons (PAHs), many of which are potent human carcinogens.	Polycyclic Aromatic Hydrocarbons	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
20350136-1	2010	AIMS: The antidepressant escitalopram (S-CIT) is metabolized by the cytochrome-P450 (CYP) enzymes CYP 2D6, 2C19 and 3A4.	Citalopram	25-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
20350136-1	2010	AIMS: The antidepressant escitalopram (S-CIT) is metabolized by the cytochrome-P450 (CYP) enzymes CYP 2D6, 2C19 and 3A4.	Citalopram	25-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20350136-1	2010	AIMS: The antidepressant escitalopram (S-CIT) is metabolized by the cytochrome-P450 (CYP) enzymes CYP 2D6, 2C19 and 3A4.	Sulfur	3-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
20350136-1	2010	AIMS: The antidepressant escitalopram (S-CIT) is metabolized by the cytochrome-P450 (CYP) enzymes CYP 2D6, 2C19 and 3A4.	Sulfur	3-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20218935-0	2010	Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail.	n-in-one	134-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Nitrosamines	37-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20153303-7	2010	As a basis for additionally coordinating and focusing research on critical data gaps in a risk assessment context, five key events in the mode of action for benzene-induced leukemia are proposed: (1) benzene metabolism via Cytochrome P450, (2) the interaction of benzene metabolites with target cells in the bone marrow, (3) formation of initiated, mutated target cells, (4) selective proliferation of the mutated cells and (5) production of leukemia.	Benzene	157-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
20153303-7	2010	As a basis for additionally coordinating and focusing research on critical data gaps in a risk assessment context, five key events in the mode of action for benzene-induced leukemia are proposed: (1) benzene metabolism via Cytochrome P450, (2) the interaction of benzene metabolites with target cells in the bone marrow, (3) formation of initiated, mutated target cells, (4) selective proliferation of the mutated cells and (5) production of leukemia.	Benzene	200-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
20153303-7	2010	As a basis for additionally coordinating and focusing research on critical data gaps in a risk assessment context, five key events in the mode of action for benzene-induced leukemia are proposed: (1) benzene metabolism via Cytochrome P450, (2) the interaction of benzene metabolites with target cells in the bone marrow, (3) formation of initiated, mutated target cells, (4) selective proliferation of the mutated cells and (5) production of leukemia.	Benzene	200-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
20036648-5	2010	CYP4F3A, which encodes the leukotriene B(4) (LTB(4)) omega-hydroxylase, is important for inactivation of LTB(4) in neutrophils.	Leukotriene B4	27-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-70
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Dimethylnitrosamine	61-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Dimethylnitrosamine	86-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Diethylnitrosamine	95-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Diethylnitrosamine	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	alkyl diazohydroxides	128-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Aldehydes	193-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Dimethylnitrosamine	214-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20061389-1	2010	Cytochrome P450 (P450) 2A6 activates nitrosamines, including N,N-dimethylnitrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and CH(3)CHO from DEN).	Diethylnitrosamine	236-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
20393001-5	2010	An ex vivo model of cryopreserved human hepatocytes was used to evaluate the CYP450 metabolism induction potential of curcumin for CYP P450 3A4, 2C8/2C9, and 2D6.	Curcumin	118-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-83
20393001-7	2010	At a curcumin concentration of 58.3 microM, 10.5% and 22.5% inhibition of CYP450 2C9 and CYP450 2C8 activity, respectively, was observed.	Curcumin	5-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-80
20393001-7	2010	At a curcumin concentration of 58.3 microM, 10.5% and 22.5% inhibition of CYP450 2C9 and CYP450 2C8 activity, respectively, was observed.	Curcumin	5-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
20393001-10	2010	CONCLUSION: There is low potential for CYP450 mediated drug interactions at physiologic serum concentrations of liposomal curcumin.	Curcumin	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
20393001-11	2010	Based on preliminary data, liposomal curcumin will not interact with other chemotherapy agents that are metabolized and/or eliminated via the primary drug metabolizing CYP450 pathways.	Curcumin	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-174
20002521-3	2010	Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.	(R)-(-)-1-Aminoindan	94-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
20002521-3	2010	Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
20002521-3	2010	Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.	Amphetamine	118-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
20180610-2	2010	However, clopidogrel is a prodrug that needs to be metabolized to the active thiol metabolite by the cytochrome P450 (CYP) system.	Clopidogrel	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
20180610-2	2010	However, clopidogrel is a prodrug that needs to be metabolized to the active thiol metabolite by the cytochrome P450 (CYP) system.	Clopidogrel	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
20180610-2	2010	However, clopidogrel is a prodrug that needs to be metabolized to the active thiol metabolite by the cytochrome P450 (CYP) system.	Sulfhydryl Compounds	77-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
20180610-2	2010	However, clopidogrel is a prodrug that needs to be metabolized to the active thiol metabolite by the cytochrome P450 (CYP) system.	Sulfhydryl Compounds	77-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	Arachidonic Acid	90-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19931366-5	2010	The aromatic hydroxylation of alpha-ZAL is almost exclusively mediated by the human cytochrome P450 (hCYP) 1A2 isoform.	Zeranol	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-110
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	Arachidonic Acid	90-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	epoxyeicosatrienoic acids	110-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	epoxyeicosatrienoic acids	110-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	eets	137-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	eets	137-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	dihydroxyeicosatrienoic acids	176-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	dihydroxyeicosatrienoic acids	176-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	dhets	207-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19891972-1	2010	The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH).	dhets	207-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
19904241-2	2010	Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
19919843-0	2010	Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.	Clopidogrel	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
19919843-2	2010	Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 (CYP) enzyme system.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
19919843-2	2010	Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 (CYP) enzyme system.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
19919843-2	2010	Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 (CYP) enzyme system.	thienopyridine	15-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
19919843-2	2010	Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 (CYP) enzyme system.	thienopyridine	15-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
19919843-4	2010	Recent data demonstrated patients carrying a genetic variant of CYP enzymes (e.g. CYP2C19) would have a higher rate of ischemic events than non-carriers due to an attenuation of the pharmacokinetic and pharmacodynamic responses to clopidogrel.	Clopidogrel	231-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
19919843-6	2010	PPIs are extensively metabolized by the cytochrome P450 system and have been associated with decreased antiplatelet activity of clopidogrel.	Clopidogrel	128-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
19904241-2	2010	Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
19904241-12	2010	As the presence of PPIs and clopidogrel in plasma is short lived, separation by 12-20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential, though unproven, clinical interaction.	Clopidogrel	28-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
20001672-2	2010	The present study aimed to profile the phase I metabolites of schizandrin and identify the cytochrome P450 (CYP) isoforms involved.	schizandrin	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
20923245-2	2010	Ambrisentan is primarily metabolized by glucuronidation and undergoes cytochrome P450 (CYP)-mediated oxidation to a lesser extent.	ambrisentan	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
20923245-2	2010	Ambrisentan is primarily metabolized by glucuronidation and undergoes cytochrome P450 (CYP)-mediated oxidation to a lesser extent.	ambrisentan	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
20425602-2	2010	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	Tamoxifen	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
20425602-2	2010	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	Tamoxifen	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
20425602-2	2010	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	4-hydroxy-N-desmethyltamoxifen	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
20425602-2	2010	Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform.	4-hydroxy-N-desmethyltamoxifen	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
20002088-4	2009	* This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.	Caffeine	134-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	Arachidonic Acid	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	Arachidonic Acid	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	epoxyeicosatrienoic	121-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	epoxyeicosatrienoic	121-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	145-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
19615687-1	2009	BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	145-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
19615687-2	2009	CYP enzymes have been linked to hypertension and generation of reactive oxygen species.	Reactive Oxygen Species	63-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
19932643-1	2009	A rapid simultaneous determination method for in vitro Cytochrome P450 (CYP) activity assay of 1,2,3,4-tetrahydroacridin-9-amine (tacrine) metabolites using ultra high performance liquid chromatography (UHPLC) coupled with computer-assisted in-source collision induced dissociation (CID) monitoring was investigated.	Tacrine	95-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
19932643-1	2009	A rapid simultaneous determination method for in vitro Cytochrome P450 (CYP) activity assay of 1,2,3,4-tetrahydroacridin-9-amine (tacrine) metabolites using ultra high performance liquid chromatography (UHPLC) coupled with computer-assisted in-source collision induced dissociation (CID) monitoring was investigated.	Tacrine	95-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
19932643-1	2009	A rapid simultaneous determination method for in vitro Cytochrome P450 (CYP) activity assay of 1,2,3,4-tetrahydroacridin-9-amine (tacrine) metabolites using ultra high performance liquid chromatography (UHPLC) coupled with computer-assisted in-source collision induced dissociation (CID) monitoring was investigated.	Tacrine	130-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
19932643-1	2009	A rapid simultaneous determination method for in vitro Cytochrome P450 (CYP) activity assay of 1,2,3,4-tetrahydroacridin-9-amine (tacrine) metabolites using ultra high performance liquid chromatography (UHPLC) coupled with computer-assisted in-source collision induced dissociation (CID) monitoring was investigated.	Tacrine	130-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
20002088-4	2009	* This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.	Warfarin	153-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20002088-4	2009	* This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.	Omeprazole	173-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20002088-4	2009	* This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.	Metoprolol	194-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20002088-4	2009	* This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.	Midazolam	218-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Ticlopidine	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
19616568-10	2009	This was further confirmed by significant inhibition of primaquine hemotoxicity by the selective CYP inhibitors, namely thiotepa (CYP2B6), fluoxetine (CYP2D6) and troleandomycin (CYP3A4).	Fluoxetine	139-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
19616568-10	2009	This was further confirmed by significant inhibition of primaquine hemotoxicity by the selective CYP inhibitors, namely thiotepa (CYP2B6), fluoxetine (CYP2D6) and troleandomycin (CYP3A4).	Troleandomycin	163-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
19616568-13	2009	The results provide significant insights regarding CYP isoforms contributing to hemotoxicity and may be useful in controlling toxicity of primaquine to increase its therapeutic utility.	Primaquine	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
19523520-5	2009	Using the plant cytochrome P450 CYP79A1 and CYP71E1 as model systems, we demonstrate that a full-length CYP79A1 strepII tagged at the N-terminal expresses well and is able to translocate over the lipid bilayer to produce a functionally active protein that is amenable to affinity purification.	Lipid Bilayers	196-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
19616568-0	2009	Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.	Primaquine	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-17
19616568-9	2009	Multiple CYP isoforms (CYP2E1, CYP2B6, CYP1A2, CYP2D6 and CYP3A4) variably contributed to the hemotoxicity of primaquine.	Primaquine	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
19616568-10	2009	This was further confirmed by significant inhibition of primaquine hemotoxicity by the selective CYP inhibitors, namely thiotepa (CYP2B6), fluoxetine (CYP2D6) and troleandomycin (CYP3A4).	Primaquine	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
19616568-10	2009	This was further confirmed by significant inhibition of primaquine hemotoxicity by the selective CYP inhibitors, namely thiotepa (CYP2B6), fluoxetine (CYP2D6) and troleandomycin (CYP3A4).	Thiotepa	120-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Ditiocarb	74-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Caffeine	215-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Nitrogen	252-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	Tamoxifen	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
19534515-0	2009	Quantum mechanics/molecular mechanics studies on the sulfoxidation of dimethyl sulfide by compound I and compound 0 of cytochrome P450: which is the better oxidant?	dimethyl sulfide	70-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
19788974-7	2009	RESULTS: Data demonstrate the presence, in some tested tissues, of cytochrome P-450 epoxygenase and soluble epoxide hydrolase, which respectively produce and degrade epoxyeicosatrienoic acid regioisomers.	epoxyeicosatrienoic acid	166-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
19422358-4	2009	Probe drugs used to measure CYP activities were caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1) and midazolam (CYP3A4).	Caffeine	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
19198839-0	2009	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4"-methanol-bisbenzonitrile in vitro.	Letrozole	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
19198839-0	2009	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4"-methanol-bisbenzonitrile in vitro.	4,4'-methanol-bisbenzonitrile	126-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
19198839-1	2009	PURPOSE: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4"-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.	Letrozole	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
19198839-1	2009	PURPOSE: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4"-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.	Letrozole	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
19198839-1	2009	PURPOSE: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4"-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.	4,4'-methanol-bisbenzonitrile	89-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-162
19198839-1	2009	PURPOSE: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4"-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.	4,4'-methanol-bisbenzonitrile	89-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
19198839-2	2009	METHODS: Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor.	Letrozole	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	Tamoxifen	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	4-hydroxy-N-desmethyltamoxifen	145-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	4-hydroxy-N-desmethyltamoxifen	145-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
19708688-0	2009	Kinetics and activation parameters for oxidations of styrene by Compounds I from the cytochrome P450(BM-3) (CYP102A1) heme domain and from CYP119.	Styrene	53-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-105
19536146-3	2009	Here, we used normal human epidermal keratinocytes (NHEKs) to determine the effects of attainable levels of ozone exposure on the family of cytochrome P450 (CYP) isoforms, which plays a determinant role in the biotransformation of many environmental pollutants.	Ozone	108-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
19536146-3	2009	Here, we used normal human epidermal keratinocytes (NHEKs) to determine the effects of attainable levels of ozone exposure on the family of cytochrome P450 (CYP) isoforms, which plays a determinant role in the biotransformation of many environmental pollutants.	Ozone	108-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
19708688-0	2009	Kinetics and activation parameters for oxidations of styrene by Compounds I from the cytochrome P450(BM-3) (CYP102A1) heme domain and from CYP119.	Heme	118-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-105
19708688-4	2009	We report here application of the photo-oxidation method for production of Compound I from the heme domain of CYP102A1 (cytochrome P450(BM-3)), and product and kinetic studies of reactions of styrene with this Compound I transient and also Compound I from CYP119.	Heme	95-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-140
19708688-4	2009	We report here application of the photo-oxidation method for production of Compound I from the heme domain of CYP102A1 (cytochrome P450(BM-3)), and product and kinetic studies of reactions of styrene with this Compound I transient and also Compound I from CYP119.	Styrene	192-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-140
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	Arachidonic Acid	81-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	Arachidonic Acid	81-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	epoxyeicosatrienenoic acids	120-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	epoxyeicosatrienenoic acids	120-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	eets	149-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	eets	149-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	hydroxyeicosatetrenoic acids	159-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	hydroxyeicosatetrenoic acids	159-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	hetes	189-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
19549792-1	2009	Cytochrome P-450 (CYP450) enzymes of the CYP2 and -4 family in humans metabolize arachidonic acid to generate bioactive epoxyeicosatrienenoic acids (EETs) and hydroxyeicosatetrenoic acids (HETEs).	hetes	189-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
19593168-0	2009	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.	Clozapine	70-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
21217854-9	2009	Metabolic activation of Sudan I by both types of enzymes leads to formation of reactive species (the benzenediazonium ion by CYP and Sudan I radicals by peroxidase) that bind to DNA and RNA, generating covalent adducts in vitro and in vivo.	1-phenylazo-2-naphthol	24-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
21217854-9	2009	Metabolic activation of Sudan I by both types of enzymes leads to formation of reactive species (the benzenediazonium ion by CYP and Sudan I radicals by peroxidase) that bind to DNA and RNA, generating covalent adducts in vitro and in vivo.	reactive species	79-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
21217854-9	2009	Metabolic activation of Sudan I by both types of enzymes leads to formation of reactive species (the benzenediazonium ion by CYP and Sudan I radicals by peroxidase) that bind to DNA and RNA, generating covalent adducts in vitro and in vivo.	benzenediazonium	101-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
19480554-0	2009	Cytochrome P450-catalysed arene-epoxidation of the bioactive tea tree oil ingredient p-cymene: indication for the formation of a reactive allergenic intermediate?	arene	26-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19480554-0	2009	Cytochrome P450-catalysed arene-epoxidation of the bioactive tea tree oil ingredient p-cymene: indication for the formation of a reactive allergenic intermediate?	4-cymene	85-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	tree oil	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	tree oil	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-210
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	4-cymene	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	4-cymene	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-210
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	4-cymene	81-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
19480554-2	2009	The cytochrome P450-mediated metabolism of the tea tree oil ingredient p-cymene (p-isopropyltoluene) was studied by the application of in vitro enzymatic assays using different recombinant human cytochrome P450 enzymes.	4-cymene	81-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-210
19480554-7	2009	The enzymatic products of p-cymene resulted from catalysed enzymatic arene-epoxidation and hydroxylation reactions by the studied cytochrome P450 enzymes.	4-cymene	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
19480554-7	2009	The enzymatic products of p-cymene resulted from catalysed enzymatic arene-epoxidation and hydroxylation reactions by the studied cytochrome P450 enzymes.	arene	69-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
19480554-13	2009	The results also indicate that skin sensitization and irritation reactions not only can be explained by the frequently in literature reported auto-oxidation of tea tree resulting in bioactive oxidized products, but also now by the formation of epoxide intermediates resulting from catalysed arene-epoxidation reactions by selected human cytochrome P450 enzymes which are also located in different organs in humans.	Epoxy Compounds	244-251	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	337-352
19480554-13	2009	The results also indicate that skin sensitization and irritation reactions not only can be explained by the frequently in literature reported auto-oxidation of tea tree resulting in bioactive oxidized products, but also now by the formation of epoxide intermediates resulting from catalysed arene-epoxidation reactions by selected human cytochrome P450 enzymes which are also located in different organs in humans.	arene	291-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	337-352
19541489-2	2009	Highly oxidized lignans produced during the cytochrome P-450 metabolism in the cells show biological activities significantly different from those of their parent natural compounds.	Lignans	16-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
19576320-0	2009	Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.	Clopidogrel	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
19576320-1	2009	Clopidogrel is a prodrug that has to be converted to an active metabolite by hepatic cytochrome P450 (CYP) isoenzymes to inhibit platelet aggregation.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
19576320-1	2009	Clopidogrel is a prodrug that has to be converted to an active metabolite by hepatic cytochrome P450 (CYP) isoenzymes to inhibit platelet aggregation.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
19576320-3	2009	In this study, we sought to determine the relation of genetic polymorphisms of CYP genes to clopidogrel resistance in Koreans.	Clopidogrel	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
19324859-0	2009	Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.	Polychlorinated Dibenzodioxins	126-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
19372226-4	2009	Cytochrome P450 (P450) 3A4 is the major isozyme involved in the oxidative biotransformation of motesanib, but the CYP2D6 and CYP1A isozymes also make minor contributions.	motesanib diphosphate	95-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
19324859-0	2009	Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.	Polychlorinated Dibenzodioxins	126-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
19324859-1	2009	PURPOSE: Cytochrome P450 (CYP) enzymes metabolize endogenous compounds such as steroid hormones, fatty acids, and xenobiotics, including drugs and carcinogens.	Steroids	79-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
19324859-1	2009	PURPOSE: Cytochrome P450 (CYP) enzymes metabolize endogenous compounds such as steroid hormones, fatty acids, and xenobiotics, including drugs and carcinogens.	Steroids	79-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
19324859-1	2009	PURPOSE: Cytochrome P450 (CYP) enzymes metabolize endogenous compounds such as steroid hormones, fatty acids, and xenobiotics, including drugs and carcinogens.	Fatty Acids	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
19324859-1	2009	PURPOSE: Cytochrome P450 (CYP) enzymes metabolize endogenous compounds such as steroid hormones, fatty acids, and xenobiotics, including drugs and carcinogens.	Fatty Acids	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
19489632-6	2009	CYP3A4, CYP3A5, CYP3A7, and CYP19 (aromatase) inhibition to the log concentration of beta-acid content was significant with r(2) &gt; 0.37, suggesting that these components can account for some of the variation in inhibition of CYP metabolism.	6-Hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylic acid	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
19496669-1	2009	OBJECTIVE: To investigate cytochrome P450 (CYP) enzymes involved in metabolism of racemic and S-ketamine in various species and to evaluate metabolic interactions of other analgesics with ketamine.	Ketamine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
19496669-1	2009	OBJECTIVE: To investigate cytochrome P450 (CYP) enzymes involved in metabolism of racemic and S-ketamine in various species and to evaluate metabolic interactions of other analgesics with ketamine.	Ketamine	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
19496669-1	2009	OBJECTIVE: To investigate cytochrome P450 (CYP) enzymes involved in metabolism of racemic and S-ketamine in various species and to evaluate metabolic interactions of other analgesics with ketamine.	Ketamine	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
19496669-1	2009	OBJECTIVE: To investigate cytochrome P450 (CYP) enzymes involved in metabolism of racemic and S-ketamine in various species and to evaluate metabolic interactions of other analgesics with ketamine.	Ketamine	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
19496669-10	2009	CONCLUSIONS AND CLINICAL RELEVANCE: Enzymes of the CYP 3A4 family and orthologs of CYP 2C9 were involved in ketamine metabolism in horses, dogs, and humans.	Ketamine	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
19480547-3	2009	Using this system, we confirmed that multiple CYP inactivation caused by mechanism-based inhibitors such as isoniazid and amiodarone could be detected simultaneously.	Isoniazid	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
19473111-0	2009	Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications.	Steroids	55-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
19473111-2	2009	Human cytochrome P450 (CYP) enzymes present in probably every tissue are found responsible for biosynthesis and catabolism of steroids, which could result in either active or inactive metabolites.	Steroids	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
19473111-2	2009	Human cytochrome P450 (CYP) enzymes present in probably every tissue are found responsible for biosynthesis and catabolism of steroids, which could result in either active or inactive metabolites.	Steroids	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
19473111-3	2009	In addition, exposure to endogenous and exogenous steroids that causes modulation of CYP activities may substantially affect the pharmacokinetic behavior of a given drug.	Steroids	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
19473111-4	2009	OBJECTIVE: This article summarizes our current understanding of the ability of steroids to act as substrates, inhibitors or heteroactivators for human CYP enzymes, with a specific focus on their functional consequences.	Steroids	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
19473111-5	2009	METHODS: In the current review, we compare the mechanisms and regulation of CYP-mediated biotransformation of steroids, and in particular examine the diverse tissue distributions and biological roles of individual CYPs.	Steroids	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
19480547-3	2009	Using this system, we confirmed that multiple CYP inactivation caused by mechanism-based inhibitors such as isoniazid and amiodarone could be detected simultaneously.	Amiodarone	122-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Polycyclic Aromatic Hydrocarbons	0-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
19414633-0	2009	Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.	Prasugrel Hydrochloride	58-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19414633-1	2009	BACKGROUND: Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes.	Clopidogrel	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
19414633-1	2009	BACKGROUND: Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes.	Clopidogrel	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
19414633-1	2009	BACKGROUND: Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes.	Prasugrel Hydrochloride	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
19414633-1	2009	BACKGROUND: Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes.	Prasugrel Hydrochloride	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
19414633-3	2009	The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown.	Prasugrel Hydrochloride	82-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Polycyclic Aromatic Hydrocarbons	0-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Polycyclic Aromatic Hydrocarbons	34-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Polycyclic Aromatic Hydrocarbons	34-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Glutathione	175-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Glutathione	175-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Glutathione	188-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
19330882-1	2009	Polycyclic aromatic hydrocarbons (PAHs) are activated by cytochrome P450 (CYP) isozymes, and a subset of the reactive metabolites generated is detoxified via conjugation with glutathione (GSH) by specific glutathione S-transferases (GSTs).	Glutathione	188-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
19426684-4	2009	These effects were associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by the cytochrome P450- and peroxidase-mediated ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine.	ellipticine	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-158
19420747-4	2009	Here, we examined the induction of CYP gene expression by an inducer by examining the effect of phenobarbital treatment on CYP gene expression in the co-culture system.	Phenobarbital	96-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
19420747-4	2009	Here, we examined the induction of CYP gene expression by an inducer by examining the effect of phenobarbital treatment on CYP gene expression in the co-culture system.	Phenobarbital	96-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
19426684-4	2009	These effects were associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by the cytochrome P450- and peroxidase-mediated ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine.	ellipticine	168-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-158
19426684-4	2009	These effects were associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by the cytochrome P450- and peroxidase-mediated ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine.	13-hydroxy- and 12-hydroxyellipticine	193-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-158
19030860-0	2009	Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.	Lenalidomide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
19030860-1	2009	PURPOSE: To assess the potential for drug-drug interactions between lenalidomide and substrates and inhibitors of cytochrome P450 (CYP) isozymes.	Lenalidomide	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
19030860-3	2009	The inhibitory and inductive effects of lenalidomide on the CYP activities were evaluated in human liver microsomes and cultured human hepatocytes, respectively.	Lenalidomide	40-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
19470220-3	2009	For studies on the quantitative involvement of human cytochrome P450 (CYP) isoenzymes in the initial hydroxylation, a reference standard of HO-MPHP was needed.	ho-mphp	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
19519346-1	2009	Drug interactions occur frequently with triazole antifungal agents because of their properties as inhibitors of 1 or more phase 1 (cytochrome P450) biotransformation enzymes and, possibly, as inhibitors or substrates of a phase 2 biotransformation enzyme or transporter protein.	Triazoles	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
19470220-3	2009	For studies on the quantitative involvement of human cytochrome P450 (CYP) isoenzymes in the initial hydroxylation, a reference standard of HO-MPHP was needed.	ho-mphp	140-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
19470220-5	2009	MPHP.HNO(3) (250 micromol) was incubated with 1 L culture of the fission yeast (Schizosaccharomyces pombe) strain CAD64 heterologously co-expressing human CYP reductase and CYP2D6.	Nitric Acid	5-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
19144770-1	2009	Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6.	Phencyclidine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-82
19245299-0	2009	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.	dalcetrapib	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
19245299-1	2009	OBJECTIVE: The primary objective of this study was to investigate the drug-drug interaction potential of dalcetrapib on drugs metabolized via major cytochrome P450 (CYP) isoforms using both in vitro and clinical approaches.	dalcetrapib	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
19245299-1	2009	OBJECTIVE: The primary objective of this study was to investigate the drug-drug interaction potential of dalcetrapib on drugs metabolized via major cytochrome P450 (CYP) isoforms using both in vitro and clinical approaches.	dalcetrapib	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
19245299-6	2009	RESULTS: In vitro, dalcetrapib was inhibitory to all CYP enzymes tested.	dalcetrapib	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
19245299-11	2009	CONCLUSIONS: Although in vitro studies indicated that dalcetrapib inhibits CYP activity, two clinical studies showed no clinically relevant effect on any of the major CYP isoforms at a 900 mg dose, which is higher than the 600 mg dose being explored in phase III studies.	dalcetrapib	54-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
19601875-0	2009	Inhibitory properties of trapping agents: glutathione, potassium cyanide, and methoxylamine, against major human cytochrome p450 isoforms.	Glutathione	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
19601875-0	2009	Inhibitory properties of trapping agents: glutathione, potassium cyanide, and methoxylamine, against major human cytochrome p450 isoforms.	methoxyamine	78-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
19144770-1	2009	Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6.	Phencyclidine	15-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-82
19241405-2	2009	Cytochrome P450 enzymes can also be used in artificial systems in which organic peroxides act as cosubstrates.	Peroxides	80-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19350451-0	2009	Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel.	7-epipaclitaxel	81-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	7-epipaclitaxel	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	7-epipaclitaxel	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	posaconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
19414330-0	2009	Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket.	Heme	83-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	posaconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	Triazoles	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	Triazoles	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	Sirolimus	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
19337788-1	2009	The presence of cytochrome P450 (CYP) variant alleles may reduce the activation of the prodrug clopidogrel to its active state.	Clopidogrel	95-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
19074527-1	2009	Cytochrome P450 (P450) 2B6 metabolizes a number of clinically relevant drugs and is one of the most highly polymorphic human P450 enzymes, with the Lys(262)--&gt;Arg substitution being especially common in several genetic variants.	Lysine	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
19074527-1	2009	Cytochrome P450 (P450) 2B6 metabolizes a number of clinically relevant drugs and is one of the most highly polymorphic human P450 enzymes, with the Lys(262)--&gt;Arg substitution being especially common in several genetic variants.	Arginine	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Flavonoids	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Flavones	134-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Flavones	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	6-hydroxyflavone	153-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	7-hydroxyflavone	171-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	chrysin	189-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	baicalein	198-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Apigenin	209-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Luteolin	219-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	scutellarein	229-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	wogonin	247-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Flavonols	260-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	fisetin	281-288	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	kaempferol	290-300	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Quercetin	313-322	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
19337788-1	2009	The presence of cytochrome P450 (CYP) variant alleles may reduce the activation of the prodrug clopidogrel to its active state.	Clopidogrel	95-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
19022226-0	2009	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.	N-(1-phenylcyclohexyl)-2-ethoxyethanamine	104-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
19029318-0	2009	Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.	Voriconazole	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
19029318-0	2009	Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.	Voriconazole	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
19029318-2	2009	To identify the mechanisms of these interactions, we tested the inhibitory potency of voriconazole with eight human cytochrome P450 (CYP) enzymes.	Voriconazole	86-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
19029318-2	2009	To identify the mechanisms of these interactions, we tested the inhibitory potency of voriconazole with eight human cytochrome P450 (CYP) enzymes.	Voriconazole	86-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
19022226-0	2009	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.	N-(1-phenylcyclohexyl)-2-ethoxyethanamine	104-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
19022226-0	2009	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.	N-(1-phenylcyclohexyl)-2-methoxyethanamine	151-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
19022226-0	2009	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.	N-(1-phenylcyclohexyl)-2-methoxyethanamine	151-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	Eicosapentaenoic Acid	54-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
19182369-1	2009	Our earlier investigations demonstrated the remarkable activation of cytochrome P-450 reductase and nitric oxide synthase by 7,8-diacetoxy-4-methylcoumarin, a model polyphenolic acetate by way of acetylation, catalyzed by the Calreticulin.	7,8-diacetoxy-4-methylcoumarin	125-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
19182369-1	2009	Our earlier investigations demonstrated the remarkable activation of cytochrome P-450 reductase and nitric oxide synthase by 7,8-diacetoxy-4-methylcoumarin, a model polyphenolic acetate by way of acetylation, catalyzed by the Calreticulin.	polyphenolic acetate	165-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
19004845-4	2009	Published data and data obtained from the drug"s manufacturer implies that the dose escalation after 48 hours is to compensate for fomepizole-induced increased body clearance resulting from autoinduction of the cytochrome P450 (CYP) drug metabolizing enzyme CYP2E1.	Fomepizole	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-226
19004845-4	2009	Published data and data obtained from the drug"s manufacturer implies that the dose escalation after 48 hours is to compensate for fomepizole-induced increased body clearance resulting from autoinduction of the cytochrome P450 (CYP) drug metabolizing enzyme CYP2E1.	Fomepizole	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-231
19029204-0	2009	Induction of CYP4F3 by benzene metabolites in human white blood cells in vivo in human promyelocytic leukemic cell lines and ex vivo in human blood neutrophils.	Benzene	23-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-19
19029204-9	2009	Induction of CYP4F3 by phenol was also observed in differentiated HL-60 cells, in the proerythroid cell line K562, and ex vivo in human neutrophils.	Phenol	23-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-19
19029204-11	2009	The findings demonstrated, for the first time, that benzene and metabolites induce CYP4F3 in human blood cells both in vivo and in vitro.	Benzene	52-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
19029204-12	2009	Induction of CYP4F3 may play a role in the development of benzene hematotoxicity and serve as a biomarker of benzene exposure.	Benzene	58-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-19
19029204-12	2009	Induction of CYP4F3 may play a role in the development of benzene hematotoxicity and serve as a biomarker of benzene exposure.	Benzene	109-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-19
19106084-1	2009	BACKGROUND: Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect.	Clopidogrel	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-93
19106084-1	2009	BACKGROUND: Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect.	Clopidogrel	12-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
19106084-3	2009	METHODS: We tested the association between functional genetic variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects.	Clopidogrel	173-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	Eicosapentaenoic Acid	77-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	omega-3-polyunsaturated fatty acid	86-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	pufa	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	17(18)-epoxyeicosatetraenoic acid	160-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
18978038-1	2009	Human cytochrome P-450 epoxygenase enzymes metabolize eicosapentaenoic acid (EPA), an omega-3-polyunsaturated fatty acid (PUFA), and leads to the production of 17(18)-epoxyeicosatetraenoic acid, or 17(18)-EpETE.	17,18-epoxy-5,8,11,14-eicosatetraenoic acid	198-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Ciprofloxacin	75-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
19133059-1	2009	AIMS: To investigate the influence of different cytochrome P450 (CYP) activities and other potential covariates on the disposition of methadone in patients on methadone maintenance therapy (MMT).	Methadone	134-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
19133059-1	2009	AIMS: To investigate the influence of different cytochrome P450 (CYP) activities and other potential covariates on the disposition of methadone in patients on methadone maintenance therapy (MMT).	Methadone	134-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
19133059-1	2009	AIMS: To investigate the influence of different cytochrome P450 (CYP) activities and other potential covariates on the disposition of methadone in patients on methadone maintenance therapy (MMT).	mmt	190-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Retinoids	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Retinoids	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Tretinoin	130-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Tretinoin	130-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Tretinoin	140-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	Tretinoin	140-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	R 115866	227-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
19016711-1	2009	BACKGROUND: An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).	R 115866	227-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Ciprofloxacin	75-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Clozapine	109-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Clozapine	109-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Clozapine	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
19067475-10	2009	We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations.	Clozapine	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
19127490-3	2009	Unlike various other antidepressants including venlafaxine, desvenlafaxine is not metabolized by cytochrome p450 (CYP) enzyme pathways and is associated with minimal inhibition of CYP enzymes.	Desvenlafaxine Succinate	60-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
18838506-1	2009	In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates.	Ticrynafen	139-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-135
18838506-1	2009	In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates.	Flurbiprofen	178-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-135
18838506-1	2009	In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates.	Diclofenac	196-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-135
18838506-1	2009	In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates.	Warfarin	212-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-135
19252340-0	2009	Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.	hydrocotarnine	10-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
19252340-2	2009	In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated.	hydrocotarnine	30-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
19566113-12	2009	Cinacalcet is extensively metabolized by multiple hepatic cytochrome P450 (CYP) enzymes (primarily 3A4, 2D6 and 1A2) with &lt;1% of the parent drug excreted in the urine.	Cinacalcet	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
19252340-2	2009	In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated.	hydrocotarnine	30-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
19566113-12	2009	Cinacalcet is extensively metabolized by multiple hepatic cytochrome P450 (CYP) enzymes (primarily 3A4, 2D6 and 1A2) with &lt;1% of the parent drug excreted in the urine.	Cinacalcet	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
19385713-1	2009	BACKGROUND AND OBJECTIVE: Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19.	Bortezomib	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199
19385713-1	2009	BACKGROUND AND OBJECTIVE: Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19.	Bortezomib	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-204
19385713-4	2009	The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated.	Bortezomib	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
19252340-6	2009	Furthermore, mice were intraperitoneally injected with hydrocotarnine for 14 days and the mRNA levels of major CYP isozymes and P-gp in the liver and small intestine were determined by real-time RT-PCR.	hydrocotarnine	55-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
20408500-3	2009	Induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 by CGS (0.01, 0.3 and 3 mM) was evaluated in cryopreserved human hepatocytes, by determining CYP mRNA expression using quantitative RT-PCR.	cysteinylglycine	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
19209593-0	2009	Chiral polychlorinated biphenyls are biotransformed enantioselectively by mammalian cytochrome P-450 isozymes to form hydroxylated metabolites.	Polychlorinated Biphenyls	7-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	Glucosamine	92-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	Glucosamine	92-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	cysteinylglycine	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
20408500-1	2009	The induction and inhibition of human hepatic cytochrome P450 (CYP) isoforms by crystalline glucosamine sulfate (CGS) was investigated in vitro.	cysteinylglycine	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
18848727-0	2009	Quantum chemical studies for oxidation of morpholine by Cytochrome P450.	morpholine	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
18815777-0	2009	Cytochrome P450 and gene activation--cholesterol elimination and regression of atherosclerosis: author reply to the commentary.	Cholesterol	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
18984015-1	2009	Cytochrome P450 (P450) 2A6 is able to catalyze indole hydroxylation to form the blue dye indigo.	indole	47-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
18984015-1	2009	Cytochrome P450 (P450) 2A6 is able to catalyze indole hydroxylation to form the blue dye indigo.	Indigo Carmine	89-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
18848727-1	2009	Since morpholine oxidation has recently been shown to involve Cytochrome P450, the study on its mechanism at molecular level using quantum chemical calculations for the model of cytochrome active site is reported here.	morpholine	6-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
18992797-1	2008	The environmental carcinogen 5-methylchrysene (5MC) can be activated to mutagenic metabolites by several isozymes of cytochrome P-450 (CYP).	5-methylchrysene	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
18779756-1	2009	OBJECTIVE: The genetic variations of the genes encoding cytochrome P-450 enzymes are considered to play an important role in the metabolism of estradiol.	Estradiol	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
20027147-1	2009	OBJECTIVES: The aim of this study was to assess the effect of various flavonoids on the NADPH:cytochrome P450 oxidoreductase (CYPOR) activity in respect of the reduction of different electron acceptors as well as to study an impact of flavonoids on monooxygenation of a model substrate of cytochrome P450 (CYP).	Flavonoids	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
20027147-1	2009	OBJECTIVES: The aim of this study was to assess the effect of various flavonoids on the NADPH:cytochrome P450 oxidoreductase (CYPOR) activity in respect of the reduction of different electron acceptors as well as to study an impact of flavonoids on monooxygenation of a model substrate of cytochrome P450 (CYP).	Flavonoids	235-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
20027147-1	2009	OBJECTIVES: The aim of this study was to assess the effect of various flavonoids on the NADPH:cytochrome P450 oxidoreductase (CYPOR) activity in respect of the reduction of different electron acceptors as well as to study an impact of flavonoids on monooxygenation of a model substrate of cytochrome P450 (CYP).	Flavonoids	235-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
20027147-5	2009	RESULTS: The stimulation of CYPOR activity via ANF was found to be associated with following electron acceptors: cytochrome c, potassium ferricyanide, cytochrome b5, but not with CYP.	potassium ferricyanide	127-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
19629022-6	2009	CONCLUSIONS: Considering in vitro and available clinical data, desvenlafaxine and venlafaxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6.	Desvenlafaxine Succinate	63-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	257-260
19629022-6	2009	CONCLUSIONS: Considering in vitro and available clinical data, desvenlafaxine and venlafaxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6.	Venlafaxine Hydrochloride	66-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	257-260
19495700-3	2009	This chapter describes methods for the measurement of the expression and catalytic activity of three key cytochrome P450 (CYP) enzymes involved in the production of progesterone and estrogens, aromatase (CYP19), steroid 17-hydroxylase/17,20-lyase (CYP17), and cholesterol side-chain cleavage (CYP11A).	Progesterone	165-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
19495700-3	2009	This chapter describes methods for the measurement of the expression and catalytic activity of three key cytochrome P450 (CYP) enzymes involved in the production of progesterone and estrogens, aromatase (CYP19), steroid 17-hydroxylase/17,20-lyase (CYP17), and cholesterol side-chain cleavage (CYP11A).	Progesterone	165-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
19495700-3	2009	This chapter describes methods for the measurement of the expression and catalytic activity of three key cytochrome P450 (CYP) enzymes involved in the production of progesterone and estrogens, aromatase (CYP19), steroid 17-hydroxylase/17,20-lyase (CYP17), and cholesterol side-chain cleavage (CYP11A).	Cholesterol	260-271	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
19495700-3	2009	This chapter describes methods for the measurement of the expression and catalytic activity of three key cytochrome P450 (CYP) enzymes involved in the production of progesterone and estrogens, aromatase (CYP19), steroid 17-hydroxylase/17,20-lyase (CYP17), and cholesterol side-chain cleavage (CYP11A).	Cholesterol	260-271	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
20027147-0	2009	Modulation of cytochrome P450 enzyme system by selected flavonoids.	Flavonoids	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
20027147-1	2009	OBJECTIVES: The aim of this study was to assess the effect of various flavonoids on the NADPH:cytochrome P450 oxidoreductase (CYPOR) activity in respect of the reduction of different electron acceptors as well as to study an impact of flavonoids on monooxygenation of a model substrate of cytochrome P450 (CYP).	Flavonoids	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
19814645-8	2009	CYP testing revealed the patient to be homozygous for inactivating polymorphism CYP2C19*2, which is responsible for the metabolism of lansoprazole.	Lansoprazole	134-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
19219743-0	2009	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone.	eperisone	87-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
19219743-2	2009	The objective of this study was to characterize the metabolic pathway involved in the biotransformation of eperisone mediated by human cytochrome P450 (CYP) enzymes.	eperisone	107-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
19219743-2	2009	The objective of this study was to characterize the metabolic pathway involved in the biotransformation of eperisone mediated by human cytochrome P450 (CYP) enzymes.	eperisone	107-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
19219744-0	2009	Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes.	Acetaminophen	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	113-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	113-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	144-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	144-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	310-315	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	N-acetyl-4-benzoquinoneimine	310-315	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	Glutathione	352-363	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
19219744-3	2009	The key mechanism in the hepatotoxicity is cytochrome P450 (CYP)-catalysed formation of the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) that is capable of binding to cellular macromolecules and in that way an LC/MS liquid chromatography/mass spectrometry (LC/MS) method was developed to measure NAPQI formation by trapping it to reduced glutathione.	Glutathione	352-363	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
19219744-4	2009	This method was used to determine the bioactivation of acetaminophen at two concentrations: 50 microM therapeutic and 1 mM toxic by using nine human recombinant CYP enzymes: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4; and with different microsomes from experimental animals.	Acetaminophen	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
19219744-9	2009	This study suggests that CYP3A4 is the major CYP enzyme form catalysing acetaminophen oxidation to NAPQI in human liver.	Acetaminophen	72-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
19219744-9	2009	This study suggests that CYP3A4 is the major CYP enzyme form catalysing acetaminophen oxidation to NAPQI in human liver.	N-acetyl-4-benzoquinoneimine	99-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
19105833-1	2008	BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids.	Arachidonic Acid	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
19105833-1	2008	BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids.	Arachidonic Acid	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
19105833-1	2008	BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids.	Eicosanoids	151-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
19105833-1	2008	BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids.	Eicosanoids	151-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
19105833-4	2008	This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease.	Eicosanoids	70-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
18938231-0	2008	2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.	2,5-dimethoxyamphetamine	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
18938231-0	2008	2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.	2,5-dimethoxyamphetamine	0-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
18992797-1	2008	The environmental carcinogen 5-methylchrysene (5MC) can be activated to mutagenic metabolites by several isozymes of cytochrome P-450 (CYP).	5-methylchrysene	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
18992797-1	2008	The environmental carcinogen 5-methylchrysene (5MC) can be activated to mutagenic metabolites by several isozymes of cytochrome P-450 (CYP).	5-methylchrysene	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
18992797-1	2008	The environmental carcinogen 5-methylchrysene (5MC) can be activated to mutagenic metabolites by several isozymes of cytochrome P-450 (CYP).	5-methylchrysene	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
18992797-4	2008	The parent compound 5MC was only 2-fold more cytotoxic in the CYP-expressing cell lines than in the V79MZ parental cell line, while 5MC-1,2-dihydrodiol was more than 30-fold more cytotoxic in CYP-transfected cells compared to V79MZ cells.	5-methylchrysene	20-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
18992797-4	2008	The parent compound 5MC was only 2-fold more cytotoxic in the CYP-expressing cell lines than in the V79MZ parental cell line, while 5MC-1,2-dihydrodiol was more than 30-fold more cytotoxic in CYP-transfected cells compared to V79MZ cells.	1,2-dihydro-1,2-dihydroxy-5-methylchrysene	132-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-195
18992797-5	2008	Cells co-expressing either hCYP1B1 or hCYP1A1 together with hGSTP1 were 2-fold less sensitive to 5MC or 5MC-1,2-diol cytotoxicity than their CYP-only parent lines.	5-methylchrysene	97-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
18992797-5	2008	Cells co-expressing either hCYP1B1 or hCYP1A1 together with hGSTP1 were 2-fold less sensitive to 5MC or 5MC-1,2-diol cytotoxicity than their CYP-only parent lines.	5mc-1,2-diol	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
18992797-10	2008	These studies show that the relative efficacy of protection by hGSTP1 against mutagenicity of 5MC or 5MC-1,2-diol is in part determined by the specific CYP pathway that catalyzes activation to the toxic or mutagenic metabolites.	5-methylchrysene	94-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
18992797-10	2008	These studies show that the relative efficacy of protection by hGSTP1 against mutagenicity of 5MC or 5MC-1,2-diol is in part determined by the specific CYP pathway that catalyzes activation to the toxic or mutagenic metabolites.	5mc-1,2-diol	101-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
19051152-3	2008	The high-profile withdrawal of drugs such as mibefradil from the market because of unfavorable drug-drug interaction profiles has focused efforts on screening for cytochrome P450 (CYP)-mediated drug interactions early in the discovery paradigm and on predicting the impact of inhibition on the in vivo situation.	Mibefradil	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
19051152-3	2008	The high-profile withdrawal of drugs such as mibefradil from the market because of unfavorable drug-drug interaction profiles has focused efforts on screening for cytochrome P450 (CYP)-mediated drug interactions early in the discovery paradigm and on predicting the impact of inhibition on the in vivo situation.	Mibefradil	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
18779363-3	2008	Here, we report the ability of 12(R)-hydroxy-5(Z),8(Z),10(E), 14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid metabolite produced by either a lipoxygenase or cytochrome P-450 pathway, to act as a potent indirect modulator of the AHR pathway.	12(r)-hydroxy-5	31-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
18955142-0	2008	Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes.	isoflavonoids	48-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
18955142-2	2008	In this study we investigated whether past oral contraceptive (OC) administration or current dietary isoflavonoids (IF) affected expression and/or activity of steroid hormone-metabolizing cytochrome P450 (CYP) enzymes using complementary primate and cell culture models.	isoflavonoids	101-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
18955142-2	2008	In this study we investigated whether past oral contraceptive (OC) administration or current dietary isoflavonoids (IF) affected expression and/or activity of steroid hormone-metabolizing cytochrome P450 (CYP) enzymes using complementary primate and cell culture models.	Steroids	159-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-203
18955142-2	2008	In this study we investigated whether past oral contraceptive (OC) administration or current dietary isoflavonoids (IF) affected expression and/or activity of steroid hormone-metabolizing cytochrome P450 (CYP) enzymes using complementary primate and cell culture models.	Steroids	159-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
18955142-6	2008	For in vitro studies, we measured effects of the isoflavonoids genistein, daidzein and equol on CYP activity using intact V79 cells stably transfected to express CYP1A1, CYP1B1, or CYP3A4.	isoflavonoids	49-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
18955142-6	2008	For in vitro studies, we measured effects of the isoflavonoids genistein, daidzein and equol on CYP activity using intact V79 cells stably transfected to express CYP1A1, CYP1B1, or CYP3A4.	Genistein	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
18955142-6	2008	For in vitro studies, we measured effects of the isoflavonoids genistein, daidzein and equol on CYP activity using intact V79 cells stably transfected to express CYP1A1, CYP1B1, or CYP3A4.	daidzein	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
18779363-3	2008	Here, we report the ability of 12(R)-hydroxy-5(Z),8(Z),10(E), 14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid metabolite produced by either a lipoxygenase or cytochrome P-450 pathway, to act as a potent indirect modulator of the AHR pathway.	Arachidonic Acids	66-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
18779363-3	2008	Here, we report the ability of 12(R)-hydroxy-5(Z),8(Z),10(E), 14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid metabolite produced by either a lipoxygenase or cytochrome P-450 pathway, to act as a potent indirect modulator of the AHR pathway.	Arachidonic Acid	107-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
18595692-1	2008	A derivative of rhodamine 110 has been designed and assessed as a probe for cytochrome P450 activity.	rhodamine 110	16-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
18595692-4	2008	In cellulo, the probe revealed the induction of cytochrome P450 activity by the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, and its repression by the chemoprotectant resveratrol.	Polychlorinated Dibenzodioxins	91-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
18595692-4	2008	In cellulo, the probe revealed the induction of cytochrome P450 activity by the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, and its repression by the chemoprotectant resveratrol.	Resveratrol	170-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
18640101-6	2008	Honokiol efficiently scavenged superoxide radicals in xanthine oxidase and cytochrome P-450 cell-free systems with the rate constant 3.2x10(5)M(-1)s(-1), which is similar to reactivity of ascorbic acid but 20-times higher than reactivity of vitamin E analog trolox.	honokiol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
18787075-1	2008	Cytochrome P-450 (CYP) epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acid (EET) regioisomers, which activate several signaling pathways to promote endothelial cell proliferation, migration, and angiogenesis.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
18787075-1	2008	Cytochrome P-450 (CYP) epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acid (EET) regioisomers, which activate several signaling pathways to promote endothelial cell proliferation, migration, and angiogenesis.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
18787075-1	2008	Cytochrome P-450 (CYP) epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acid (EET) regioisomers, which activate several signaling pathways to promote endothelial cell proliferation, migration, and angiogenesis.	epoxyeicosatrienoic acid	67-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
18787075-1	2008	Cytochrome P-450 (CYP) epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acid (EET) regioisomers, which activate several signaling pathways to promote endothelial cell proliferation, migration, and angiogenesis.	epoxyeicosatrienoic acid	67-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
18585438-1	2008	Methoxychlor undergoes metabolism by cytochrome P450 (CYP) enzymes forming a chiral mono-phenolic derivative (Mono-OH-M) as main metabolite.	Methoxychlor	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
18585438-1	2008	Methoxychlor undergoes metabolism by cytochrome P450 (CYP) enzymes forming a chiral mono-phenolic derivative (Mono-OH-M) as main metabolite.	Methoxychlor	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
18634893-3	2008	METHODS: The assay consisted of human liver microsomes and a cocktail of probe substrates metabolized by the five major CYP isoforms (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4).	Tacrine	134-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
18634893-3	2008	METHODS: The assay consisted of human liver microsomes and a cocktail of probe substrates metabolized by the five major CYP isoforms (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4).	Diclofenac	154-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
18634893-3	2008	METHODS: The assay consisted of human liver microsomes and a cocktail of probe substrates metabolized by the five major CYP isoforms (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4).	Dextromethorphan	206-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
18634893-3	2008	METHODS: The assay consisted of human liver microsomes and a cocktail of probe substrates metabolized by the five major CYP isoforms (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4).	Midazolam	238-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
18566475-1	2008	The regulation of the human liver-specific cytochrome P450 4F3B (CYP4F3B) isoform, a splice variant of the CYP4F3 gene with strong substrate specificity for long chain fatty acids, is yet an unsolved question.	long chain fatty acids	157-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-71
18566475-5	2008	SiRNA-mediated-silencing of CYP4F3 suppresses both 20-HETE synthesis and PGA1 induced 20-HETE production.	20-Hete	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-34
18566475-5	2008	SiRNA-mediated-silencing of CYP4F3 suppresses both 20-HETE synthesis and PGA1 induced 20-HETE production.	prostaglandin A1	73-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-34
18566475-5	2008	SiRNA-mediated-silencing of CYP4F3 suppresses both 20-HETE synthesis and PGA1 induced 20-HETE production.	20-Hete	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-34
18606824-0	2008	Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors.	Arachidonic Acid	51-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
18606824-2	2008	The released arachidonic acid can be metabolized by three enzymatic pathways: the cyclooxygenase pathway forming prostaglandins and thromboxanes, the lipoxygenase pathway generating leukotrienes and lipoxins, and the cytochrome P450 (cP450) pathway producing epoxyeicosatrienoic acids and hydroxyeicosatetraenoic acids.	Arachidonic Acid	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-232
18606824-2	2008	The released arachidonic acid can be metabolized by three enzymatic pathways: the cyclooxygenase pathway forming prostaglandins and thromboxanes, the lipoxygenase pathway generating leukotrienes and lipoxins, and the cytochrome P450 (cP450) pathway producing epoxyeicosatrienoic acids and hydroxyeicosatetraenoic acids.	Arachidonic Acid	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-239
18585438-1	2008	Methoxychlor undergoes metabolism by cytochrome P450 (CYP) enzymes forming a chiral mono-phenolic derivative (Mono-OH-M) as main metabolite.	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	110-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
18585438-1	2008	Methoxychlor undergoes metabolism by cytochrome P450 (CYP) enzymes forming a chiral mono-phenolic derivative (Mono-OH-M) as main metabolite.	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	110-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
18640101-6	2008	Honokiol efficiently scavenged superoxide radicals in xanthine oxidase and cytochrome P-450 cell-free systems with the rate constant 3.2x10(5)M(-1)s(-1), which is similar to reactivity of ascorbic acid but 20-times higher than reactivity of vitamin E analog trolox.	Superoxides	31-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
18657024-3	2008	She was treated with rifabutin-the rifamycin with the least cytochrome P450 (CYP) enzyme induction-and therapeutic drug monitoring was performed so that target serum concentrations of all antimicrobial agents could be achieved.	rifamycin SV	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
18633604-0	2008	Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis.	Cholesterol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
18687246-3	2008	Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
18687246-3	2008	Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2.	Clopidogrel	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Carbamazepine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Carbamazepine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Phenytoin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Phenytoin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Phenobarbital	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Phenobarbital	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Primidone	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
18803983-9	2008	Carbamazepine, phenytoin, phenobarbital, and primidone were found to have prominent cytochrome P450 (CYP) enzyme-induction effects, while valproic acid had an inhibitory effect.	Primidone	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
19356091-1	2008	Troglitazone (TGZ) induced hepatotoxicity has been linked to cytochrome P450 (CYP)-catalyzed reactive metabolite formation.	Troglitazone	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
19356091-1	2008	Troglitazone (TGZ) induced hepatotoxicity has been linked to cytochrome P450 (CYP)-catalyzed reactive metabolite formation.	Troglitazone	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
19356091-1	2008	Troglitazone (TGZ) induced hepatotoxicity has been linked to cytochrome P450 (CYP)-catalyzed reactive metabolite formation.	Troglitazone	14-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
19356091-1	2008	Troglitazone (TGZ) induced hepatotoxicity has been linked to cytochrome P450 (CYP)-catalyzed reactive metabolite formation.	Troglitazone	14-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
18606824-7	2008	This is the first evidence of a cytochrome P450-dependent arachidonate metabolite that can activate G-protein-coupled cell membrane receptors and suggests a functional link between the cytochrome P450 enzyme system and the endocannabinoid system.	Arachidonic Acid	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
18606824-7	2008	This is the first evidence of a cytochrome P450-dependent arachidonate metabolite that can activate G-protein-coupled cell membrane receptors and suggests a functional link between the cytochrome P450 enzyme system and the endocannabinoid system.	Arachidonic Acid	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-200
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	alternariol	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	alternariol	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	alternariol monomethyl ether	40-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	alternariol monomethyl ether	40-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	altenuene	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	altenuene	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	Isoaltenuene	94-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
23604745-1	2008	TheAlternaria toxins alternariol (AOH), alternariol-9-methyl ether (AME), altenuene (ALT) and isoaltenuene (iALT) undergo extensive oxidative metabolism, but the cytochrome P450 (CYP) isoforms responsible for the reported hydroxylation reactions are yet unknown.	Isoaltenuene	94-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
23604745-2	2008	In the present study, the activities of twelve human CYP isoforms for the hydroxylation of AOH, AME, ALT and iALT at different positions have been determined.	alternariol	91-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
19040121-1	2008	Cytochrome P450 (CYP) is a heme-containing enzyme superfamily metabolizing a wide variety of xenobiotics, including drugs and carcinogens.	Heme	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19040121-1	2008	Cytochrome P450 (CYP) is a heme-containing enzyme superfamily metabolizing a wide variety of xenobiotics, including drugs and carcinogens.	Heme	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
18648675-0	2008	Ruthenium catalyzed biomimetic oxidation in organic synthesis inspired by cytochrome P-450.	Ruthenium	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
18648675-1	2008	Simulation of the function of cytochrome P-450 with low valent ruthenium complex catalysts leads to the discovery of biomimetic, catalytic oxidation of various substrates selectively under mild conditions.	Ruthenium	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
18249473-5	2008	Apart from insights in important molecular properties for CYP inhibition, the present results may also guide further design of curcumin analogues with less susceptibility to drug-drug interactions.	Curcumin	127-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
18657024-3	2008	She was treated with rifabutin-the rifamycin with the least cytochrome P450 (CYP) enzyme induction-and therapeutic drug monitoring was performed so that target serum concentrations of all antimicrobial agents could be achieved.	rifamycin SV	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
18346045-0	2008	Inhibitory effects on cytochrome p450 enzymes of pentamidine and its amidoxime pro-drug.	Pentamidine	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
18346045-0	2008	Inhibitory effects on cytochrome p450 enzymes of pentamidine and its amidoxime pro-drug.	amidoxime	69-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
18399696-0	2008	SNP detection for cytochrome P450 alleles by target-assembled tandem oligonucleotide systems based on exciplexes.	Oligonucleotides	69-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
19138946-3	2008	Genotoxicity may be caused by cytochrome P450 (CYP)-mediated oxidation of catechol estrogens to quinones that react with DNA to form depurinating estrogen-DNA adducts.	catechol	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
19138946-3	2008	Genotoxicity may be caused by cytochrome P450 (CYP)-mediated oxidation of catechol estrogens to quinones that react with DNA to form depurinating estrogen-DNA adducts.	catechol	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
19138946-3	2008	Genotoxicity may be caused by cytochrome P450 (CYP)-mediated oxidation of catechol estrogens to quinones that react with DNA to form depurinating estrogen-DNA adducts.	Quinones	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
19138946-3	2008	Genotoxicity may be caused by cytochrome P450 (CYP)-mediated oxidation of catechol estrogens to quinones that react with DNA to form depurinating estrogen-DNA adducts.	Quinones	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
19138946-6	2008	Resveratrol has anticancer effects in diverse in vitro and in vivo systems and is an AhR antagonist that decreases CYP expression but induces NQO1 expression.	Resveratrol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
18433732-5	2008	The omega-hydroxylation and inactivation of pro-inflammatory eicosanoids by members of the CYP4F subfamily and the association of the CYP4F2 and CYP4F3 genes with inflammatory celiac disease indicate an important role in the resolution of inflammation.	Eicosanoids	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-151
19468476-11	2008	Rifampicin has to be avoided in allograft recipients as it activates cytochrome-P450 enzymes and thereby decreases the therapeutic levels of cyclosporine and prednisolone.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
18388875-1	2008	The cytochrome P450 (CYP) gene superfamily comprises a large group of hemoproteins with diverse functions in steroid, lipid, and xenobiotic metabolism.	Steroids	109-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
18388875-1	2008	The cytochrome P450 (CYP) gene superfamily comprises a large group of hemoproteins with diverse functions in steroid, lipid, and xenobiotic metabolism.	Steroids	109-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
18520135-12	2008	Bound sulfur also affected redox regulation by modifying active thiol residues in some liver cytosol enzymes and effectively inhibited cytochrome P-450-dependent lipid peroxidation induced by CCl(4) and t-BuOOH.	Sulfur	6-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
18493655-4	2008	In support of this idea, we found that adding FKBP blocks binding of FK506 to the common cytochrome P(450) enzyme CYP3A4 in vitro.	Tacrolimus	69-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-106
18496131-1	2008	PURPOSE: The anticancer agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), glutathione S-transferase (GST) and aldehyde dehydrogenase (ALDH) enzymes.	Cyclophosphamide	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
18496131-1	2008	PURPOSE: The anticancer agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), glutathione S-transferase (GST) and aldehyde dehydrogenase (ALDH) enzymes.	Cyclophosphamide	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
18520135-12	2008	Bound sulfur also affected redox regulation by modifying active thiol residues in some liver cytosol enzymes and effectively inhibited cytochrome P-450-dependent lipid peroxidation induced by CCl(4) and t-BuOOH.	Cefaclor	192-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
18570159-0	2008	Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes.	Thiabendazole	65-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Cholesterol	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18570159-2	2008	The objective of this study was to investigate the effects of four food chemicals, namely butylated hydroxytoluene (BHT), curcumin (CC), propyl gallate (PG) and thiabendazole (TB), on cytochrome P450 (CYP) forms in cultured human hepatocytes.	Butylated Hydroxytoluene	90-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199
18570159-2	2008	The objective of this study was to investigate the effects of four food chemicals, namely butylated hydroxytoluene (BHT), curcumin (CC), propyl gallate (PG) and thiabendazole (TB), on cytochrome P450 (CYP) forms in cultured human hepatocytes.	Thiabendazole	161-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199
18570159-11	2008	In summary, the results demonstrate that TB is a mixed inducer of CYP forms in human hepatocytes inducing CYP1A, CYP2B and CYP3A forms, whereas BHT is an inducer of CYP2B and CYP3A forms.	Thiabendazole	41-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
18482659-2	2008	BACKGROUND: The cytochrome P450 (CYP)-dependent conversion of clopidogrel to its active metabolite may contribute to the variability in antiplatelet effect of clopidogrel.	Clopidogrel	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
18482659-2	2008	BACKGROUND: The cytochrome P450 (CYP)-dependent conversion of clopidogrel to its active metabolite may contribute to the variability in antiplatelet effect of clopidogrel.	Clopidogrel	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
18482659-2	2008	BACKGROUND: The cytochrome P450 (CYP)-dependent conversion of clopidogrel to its active metabolite may contribute to the variability in antiplatelet effect of clopidogrel.	Clopidogrel	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
18482659-2	2008	BACKGROUND: The cytochrome P450 (CYP)-dependent conversion of clopidogrel to its active metabolite may contribute to the variability in antiplatelet effect of clopidogrel.	Clopidogrel	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Cholesterol	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Bile Acids and Salts	138-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Oxysterols	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Oxysterols	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Fatty Acids	190-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Fatty Acids	190-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Prostaglandins	203-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Prostaglandins I	219-232	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Leukotrienes	234-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Leukotrienes	234-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Steroids	248-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Steroids	248-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Ketones	266-272	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	Ketones	266-272	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	vitamines a	281-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18646550-5	2008	CYP isoenzymes participate in metabolic pathways important for proper physiological functioning of the human organism, i.e.: cholesterol, bile acid and oxysterol biosynthesis; metabolism of fatty acids, prostaglandins, prostacyclins, leukotrienes, steroid hormones, ketone bodies, vitamines A and D. CYP isoenzymes participate in the metabolism of over 80% of drugs and other xenobiotic substances which can be present in the human organism.	vitamines a	281-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
18402469-0	2008	Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels.	benzo(a)pyrene 7,8-dihydrodiol	15-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-117
18473751-2	2008	The formation of hydroxyderivatives of tacrine is well-established step in the metabolization of this drug in liver by microsomal cytochrome P450 enzymes family.	Tacrine	39-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
18451235-2	2008	EXPERIMENTAL DESIGN: Human microsomes were used to determine the cytochrome P450 enzyme(s) involved in the metabolism of ixabepilone.	ixabepilone	121-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
18421623-7	2008	The UGT 1 and 2 families were involved in the glucuronidation, and several CYPs participated in the metabolism of febuxostat, suggesting that there is little possibility that the blood concentration of febuxostat varies widely even if febuxostat is concomitantly administered with drugs that inhibit CYP or UGT enzyme.	Febuxostat	114-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
18356043-0	2008	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.	Lynestrenol	98-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
18356043-0	2008	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.	Norethindrone	114-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Lynestrenol	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Lynestrenol	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Norethindrone	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Norethindrone	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Norethindrone	153-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
18356043-1	2008	This study examined the cytochrome P450 (CYP) enzyme selectivity of in vitro bioactivation of lynestrenol to norethindrone and the further metabolism of norethindrone.	Norethindrone	153-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
18004755-1	2008	Cytochrome P450 (P450) 2J2 catalyzes epoxidation of arachidonic acid to eicosatrienoic acids, which are related to a variety of diseases such as coronary artery disease, hypertension, and carcinogenesis.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
18004755-1	2008	Cytochrome P450 (P450) 2J2 catalyzes epoxidation of arachidonic acid to eicosatrienoic acids, which are related to a variety of diseases such as coronary artery disease, hypertension, and carcinogenesis.	formic acid	72-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
18421623-0	2008	In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.	Febuxostat	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
18421623-8	2008	Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP.	Febuxostat	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
18421623-8	2008	Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP.	Febuxostat	80-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
18421623-8	2008	Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP.	Febuxostat	80-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
17868191-1	2008	The arachidonic acid metabolizing CYP enzymes with prominent roles in vascular regulation are epoxygenases of the two gene family which generate epoxyeicosatrienoic acids.	Arachidonic Acid	4-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
17868191-1	2008	The arachidonic acid metabolizing CYP enzymes with prominent roles in vascular regulation are epoxygenases of the two gene family which generate epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	145-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
18311908-1	2008	Type II cytochrome P450 (CYP) ligands cause inhibition by direct coordination to the heme iron atom.	Heme	85-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
26620942-0	2008	Transition-State Docking of Flunitrazepam and Progesterone in Cytochrome P450.	Flunitrazepam	28-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
26620942-0	2008	Transition-State Docking of Flunitrazepam and Progesterone in Cytochrome P450.	Progesterone	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
18311908-1	2008	Type II cytochrome P450 (CYP) ligands cause inhibition by direct coordination to the heme iron atom.	Heme	85-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
18311908-1	2008	Type II cytochrome P450 (CYP) ligands cause inhibition by direct coordination to the heme iron atom.	Iron	90-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
18311908-1	2008	Type II cytochrome P450 (CYP) ligands cause inhibition by direct coordination to the heme iron atom.	Iron	90-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
18311908-3	2008	The approach to design compounds with diminished CYP inhibition is different depending on whether the compound binds (type II ligand) or not (type I ligand) to the iron atom of the heme group.	Iron	164-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
18311908-3	2008	The approach to design compounds with diminished CYP inhibition is different depending on whether the compound binds (type II ligand) or not (type I ligand) to the iron atom of the heme group.	Heme	181-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
18311908-4	2008	In this study, the structural characteristics of nitrogen-containing compounds, which bind to the iron atom in two CYP isoforms (CYP2C9 and CYP3A4), were investigated.	Nitrogen	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
18311908-4	2008	In this study, the structural characteristics of nitrogen-containing compounds, which bind to the iron atom in two CYP isoforms (CYP2C9 and CYP3A4), were investigated.	Iron	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
17996418-4	2008	Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
17996418-4	2008	Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
17996418-4	2008	Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases.	Eicosanoids	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
17996418-4	2008	Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases.	Eicosanoids	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
18048487-0	2008	Physical incorporation of NADPH-cytochrome P450 reductase and cytochrome P450 into phospholipid vesicles using glycocholate and Bio-Beads.	Phospholipids	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
18048487-0	2008	Physical incorporation of NADPH-cytochrome P450 reductase and cytochrome P450 into phospholipid vesicles using glycocholate and Bio-Beads.	Glycocholic Acid	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
18187347-8	2008	Cytochrome P450 enzyme inducing AEDs are most commonly associated with a negative impact on bone, but studies also suggest an effect of valproate.	Valproic Acid	136-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
18065749-6	2008	CYP4F11 was the lone CYP4F/A enzyme that effectively oxidized 3-hydroxypalmitate.	3-hydroxypalmitate	62-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-5
18065749-0	2008	Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11.	3-hydroxy fatty acids	19-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-59
18065749-4	2008	Polyspecific CYP4F antibodies markedly inhibited microsomal omega-hydroxylation of 3-hydroxystearate (68%) and 3-hydroxypalmitate (99%), whereas CYP4A11 and CYP2E1 antibodies had little effect.	3-hydroxystearate	83-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-18
18065749-4	2008	Polyspecific CYP4F antibodies markedly inhibited microsomal omega-hydroxylation of 3-hydroxystearate (68%) and 3-hydroxypalmitate (99%), whereas CYP4A11 and CYP2E1 antibodies had little effect.	3-hydroxypalmitate	111-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-18
18338302-3	2008	The pathophysiology of renal toxicity in acetaminophen poisoning has been attributed to cytochrome P-450 mixed function oxidase isoenzymes present in the kidney, although other mechanisms have been elucidated, including the role of prostaglandin synthetase and N-deacetylase enzymes.	Acetaminophen	41-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
17967930-12	2008	Cytochrome P450 inducers enhanced the conversion of benzo[a]pyrene to these metabolites without altering mRNA levels of major phenol-conjugating SULT forms (SULT1A1, SULT1A3, and SULT1B1).	Benzo(a)pyrene	52-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
18274957-3	2008	After 60-min incubation in human liver microsomes with beta-nicotinamide adenine dinucleotide phosphate (NADPH) or uridine diphosphate glucuronic acid (UDPGA), the residual KBH-A40 was 90.6% +/- 5.1% and 28.9% +/- 2.0% (t(1/2) = 26 min), respectively, suggesting that KBH-A40 is likely predominantly metabolized by glucuronidation, rather than by cytochrome P450 (CYP)-mediated oxidation.	NADP	55-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	347-362
18274957-3	2008	After 60-min incubation in human liver microsomes with beta-nicotinamide adenine dinucleotide phosphate (NADPH) or uridine diphosphate glucuronic acid (UDPGA), the residual KBH-A40 was 90.6% +/- 5.1% and 28.9% +/- 2.0% (t(1/2) = 26 min), respectively, suggesting that KBH-A40 is likely predominantly metabolized by glucuronidation, rather than by cytochrome P450 (CYP)-mediated oxidation.	NADP	55-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	364-367
17980859-4	2008	Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.	5-methoxy-N,N-diisopropyltryptamine	24-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
18076219-0	2008	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.	Modafinil	23-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
18063021-2	2008	Disposition of carboplatin is determined by renal clearance, while the taxanes are metabolized by cytochrome P450 (CYP450) enzymes.	Taxoids	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
18063021-2	2008	Disposition of carboplatin is determined by renal clearance, while the taxanes are metabolized by cytochrome P450 (CYP450) enzymes.	Taxoids	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-121
18063021-3	2008	Although the majority of taxane metabolism occurs in the liver, recent data have shown that some solid tumors express CYP450 enzymes in the tumors themselves.	taxane	25-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-124
18076219-2	2008	The objective of this article is to summarize the results of three clinical drug-interaction studies assessing the potential for drug interactions of armodafinil with agents metabolized by cytochrome P450 (CYP) enzymes 1A2, 3A4 and 2C19.	Modafinil	150-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
18076219-2	2008	The objective of this article is to summarize the results of three clinical drug-interaction studies assessing the potential for drug interactions of armodafinil with agents metabolized by cytochrome P450 (CYP) enzymes 1A2, 3A4 and 2C19.	Modafinil	150-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
18855665-1	2008	Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions.	Heme	51-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19026034-4	2008	Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees.	Triazoles	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
19026034-4	2008	Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees.	Triazoles	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
18781947-5	2008	Lasting recent years it has become clear that human skin cells express various CYP enzymes, including CYP26AI which is responsible for the metabolism of retinoic acid in skin cells.	Tretinoin	153-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
18479171-22	2008	Therefore, clinically significant drug interactions between abacavir and drugs metabolized by CYP enzymes are unlikely.	abacavir	60-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
18855665-1	2008	Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions.	Heme	51-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
19326769-3	2008	The present study was designed to examine chlorpyrifos and DEET mediated induction of CYP isoforms and also to characterize their potential cytotoxic effects on primary human hepatocytes.	Chlorpyrifos	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
19326769-5	2008	Chlorpyrifos and DEET also mediated the expression of CYP isoforms, particularly CYP3A4, CYP2B6 and CYP1A1, as shown by CYP3A4-specific protein expression, testosterone metabolism and CYP1Al-specific activity assays.	Chlorpyrifos	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
19326769-5	2008	Chlorpyrifos and DEET also mediated the expression of CYP isoforms, particularly CYP3A4, CYP2B6 and CYP1A1, as shown by CYP3A4-specific protein expression, testosterone metabolism and CYP1Al-specific activity assays.	Testosterone	156-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
19326769-7	2008	Therefore, DEET and chlorpyrifos mediated induction of CYP mRNA and functional CYP isoforms together with their cytotoxic potential in human hepatocytes suggests that exposure to chlorpyrifos and/or DEET should be considered in human health impact analysis.	Chlorpyrifos	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
19326769-7	2008	Therefore, DEET and chlorpyrifos mediated induction of CYP mRNA and functional CYP isoforms together with their cytotoxic potential in human hepatocytes suggests that exposure to chlorpyrifos and/or DEET should be considered in human health impact analysis.	Chlorpyrifos	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
19326769-7	2008	Therefore, DEET and chlorpyrifos mediated induction of CYP mRNA and functional CYP isoforms together with their cytotoxic potential in human hepatocytes suggests that exposure to chlorpyrifos and/or DEET should be considered in human health impact analysis.	Chlorpyrifos	179-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
19326769-7	2008	Therefore, DEET and chlorpyrifos mediated induction of CYP mRNA and functional CYP isoforms together with their cytotoxic potential in human hepatocytes suggests that exposure to chlorpyrifos and/or DEET should be considered in human health impact analysis.	Chlorpyrifos	179-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
18098061-2	2008	CYP3A4 was identified as the major enzyme and CYP2C8 as a minor enzyme responsible for mirodenafil N-dealkylation based on correlation analysis, inhibition studies, and cDNA-expressed CYP enzyme activities.	mirodenafil	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	Prasugrel Hydrochloride	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	Prasugrel Hydrochloride	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	thienopyridine	13-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	thienopyridine	13-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	Adenosine Diphosphate	201-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
18094219-1	2008	Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)-dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate-induced platelet aggregation.	Adenosine Diphosphate	201-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
18685268-5	2008	There are several microbial mechanisms responsible for biodegradation of dioxins, including oxidative degradation by dioxygenase-containing aerobic bacteria, bacterial and fungal cytochrome P-450, fungal lignolytic enzymes, reductive dechlorination by anaerobic bacteria, and direct ether ring cleavage by fungi containing etherase-like enzymes.	Dioxins	73-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
18589587-4	2008	A population with slow acetylation has a higher risk of toxicity, as that potent inhibition of cytochrome P450 (CYP450) isoforms by isoniazid (CYP2C19 y CYP3A) are dependent of INH plasmatic concentration.	Isoniazid	132-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
18589587-4	2008	A population with slow acetylation has a higher risk of toxicity, as that potent inhibition of cytochrome P450 (CYP450) isoforms by isoniazid (CYP2C19 y CYP3A) are dependent of INH plasmatic concentration.	Isoniazid	132-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-118
18098061-0	2008	Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil.	Nitrogen	58-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
18098061-0	2008	Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil.	mirodenafil	101-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	133-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	133-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
18176065-1	2008	We propose an improved method to measure urinary D-glucaric acid (GA), which might be of value as an indirect index of the activity of cytochrome P450 (CYP).	Glucaric Acid	49-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	133-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	286-289
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	N-dehydroxyethylmirodenafil	188-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	N-dehydroxyethylmirodenafil	188-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	N-dehydroxyethylmirodenafil	188-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	286-289
18176065-1	2008	We propose an improved method to measure urinary D-glucaric acid (GA), which might be of value as an indirect index of the activity of cytochrome P450 (CYP).	Glucaric Acid	49-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	205-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
18176065-1	2008	We propose an improved method to measure urinary D-glucaric acid (GA), which might be of value as an indirect index of the activity of cytochrome P450 (CYP).	Glucaric Acid	66-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	205-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
18098061-1	2008	The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral erectogenic, mirodenafil, to a major circulating active metabolite, N-dehydroxyethyl-mirodenafil, and to investigate the inhibitory potential of mirodenafil on seven CYP enzymes in human liver microsomes.	mirodenafil	205-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	286-289
18176065-1	2008	We propose an improved method to measure urinary D-glucaric acid (GA), which might be of value as an indirect index of the activity of cytochrome P450 (CYP).	Glucaric Acid	66-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-155
17872452-2	2007	Here we address the mechanisms by which cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) contribute to this effect in native and cultured endothelial cells.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
17872452-2	2007	Here we address the mechanisms by which cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) contribute to this effect in native and cultured endothelial cells.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
17872452-2	2007	Here we address the mechanisms by which cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) contribute to this effect in native and cultured endothelial cells.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
17872452-2	2007	Here we address the mechanisms by which cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) contribute to this effect in native and cultured endothelial cells.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
17872452-3	2007	METHODS AND RESULTS: In native CYP2C-expressing endothelial cells, bradykinin elicited a Ca(2+) influx that was potentiated by the soluble epoxide hydrolase inhibitor, 1-adamantyl-3-cyclohexylurea (ACU), and attenuated by CYP inhibition.	CHEMBL242255	168-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
17900275-3	2007	OBJECTIVE: To determine the relationship between genetic variation in cytochrome P450 (CYP) isoenzymes and the pharmacokinetic/pharmacodynamic response to prasugrel and clopidogrel.	Prasugrel Hydrochloride	155-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
18220565-4	2007	Their formation is the result of hydrolysis (INA, HZ), cytochrome P450 (CYP)-dependent oxidation (HZ, NH(3), oxidizing free radicals), and N-acetyltransferase (NAT) activity (AcINH, AcHZ, DiAcHZ).	Free Radicals	119-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
18034666-1	2007	The nonsteroidal anti-inflammatory drug diclofenac is extensively metabolized by cytochrome P450 (CYP) enzymes, mainly by CYP2C9.	Diclofenac	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
18034666-1	2007	The nonsteroidal anti-inflammatory drug diclofenac is extensively metabolized by cytochrome P450 (CYP) enzymes, mainly by CYP2C9.	Diclofenac	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
18034666-2	2007	Our objective was to study the effect of voriconazole, a potent inhibitor of several CYP enzymes, on the pharmacokinetics of diclofenac.	Voriconazole	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
18034666-2	2007	Our objective was to study the effect of voriconazole, a potent inhibitor of several CYP enzymes, on the pharmacokinetics of diclofenac.	Diclofenac	125-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
18034666-10	2007	In conclusion, voriconazole increased exposure to diclofenac, probably mainly by inhibition of its cytochrome P450 (CYP)-mediated metabolism.	Voriconazole	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
18034666-10	2007	In conclusion, voriconazole increased exposure to diclofenac, probably mainly by inhibition of its cytochrome P450 (CYP)-mediated metabolism.	Voriconazole	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
18034666-10	2007	In conclusion, voriconazole increased exposure to diclofenac, probably mainly by inhibition of its cytochrome P450 (CYP)-mediated metabolism.	Diclofenac	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
18034666-10	2007	In conclusion, voriconazole increased exposure to diclofenac, probably mainly by inhibition of its cytochrome P450 (CYP)-mediated metabolism.	Diclofenac	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
18220565-4	2007	Their formation is the result of hydrolysis (INA, HZ), cytochrome P450 (CYP)-dependent oxidation (HZ, NH(3), oxidizing free radicals), and N-acetyltransferase (NAT) activity (AcINH, AcHZ, DiAcHZ).	Ammonia	102-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
18220565-4	2007	Their formation is the result of hydrolysis (INA, HZ), cytochrome P450 (CYP)-dependent oxidation (HZ, NH(3), oxidizing free radicals), and N-acetyltransferase (NAT) activity (AcINH, AcHZ, DiAcHZ).	Ammonia	102-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
17900275-3	2007	OBJECTIVE: To determine the relationship between genetic variation in cytochrome P450 (CYP) isoenzymes and the pharmacokinetic/pharmacodynamic response to prasugrel and clopidogrel.	Prasugrel Hydrochloride	155-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
17900275-3	2007	OBJECTIVE: To determine the relationship between genetic variation in cytochrome P450 (CYP) isoenzymes and the pharmacokinetic/pharmacodynamic response to prasugrel and clopidogrel.	Clopidogrel	169-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
17900275-3	2007	OBJECTIVE: To determine the relationship between genetic variation in cytochrome P450 (CYP) isoenzymes and the pharmacokinetic/pharmacodynamic response to prasugrel and clopidogrel.	Clopidogrel	169-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
18001838-4	2007	We present a review of the major polymorphic CYP alleles and conclude that this variability is of greatest importance for treatment with several antidepressants, antipsychotics, antiulcer drugs, anti-HIV drugs, anticoagulants, antidiabetics and the anticancer drug tamoxifen.	Tamoxifen	265-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
18066112-10	2007	Our data indicate that both the aqueous and methanol extracts of all 5 uva-ursi products showed high cytochrome P450 isozyme inhibition, with the exception of the methanol extracts against cytochromes P3A4 and P19, which had low to moderate activity.	Methanol	44-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
18033636-0	2007	Metabolism of CJ-036878, N-(3-phenethoxybenzyl)-4-hydroxybenzamide, in liver microsomes and recombinant cytochrome P450 enzymes: metabolite identification by LC-UV/MS(n) and (1)H-NMR.	N-(3-phenethoxybenzyl)-4-hydroxybenzamide	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
18033636-2	2007	The present study investigated the phase I metabolism of CJ-036878 (N-(3-phenethoxybenzyl)-4-hydroxybenzamide), a potent antagonist of the N-methyl-D-asparatate (NMDA) receptor, using liver microsomes and representative recombinant cytochrome P450 enzymes.	N-(3-phenethoxybenzyl)-4-hydroxybenzamide	57-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-247
17709371-3	2007	In the present study, the resistance of methoxylated flavones toward oxidative metabolism was investigated with human liver microsomes and recombinant cytochrome P450 (P450) isoforms.	Flavones	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-182
17850846-3	2007	Of the stress-related genes, the expressions of the aryl hydrocarbon receptor (AhR), cytochrome P450 (CYP) and p53 genes were most significantly induced by exposure to PCDDs/DFs.	Polychlorinated Dibenzodioxins	168-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
17850846-3	2007	Of the stress-related genes, the expressions of the aryl hydrocarbon receptor (AhR), cytochrome P450 (CYP) and p53 genes were most significantly induced by exposure to PCDDs/DFs.	Polychlorinated Dibenzodioxins	168-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
17850846-3	2007	Of the stress-related genes, the expressions of the aryl hydrocarbon receptor (AhR), cytochrome P450 (CYP) and p53 genes were most significantly induced by exposure to PCDDs/DFs.	aspartyl-phenylalanine	174-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
17850846-3	2007	Of the stress-related genes, the expressions of the aryl hydrocarbon receptor (AhR), cytochrome P450 (CYP) and p53 genes were most significantly induced by exposure to PCDDs/DFs.	aspartyl-phenylalanine	174-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
17850846-6	2007	Statistical tests revealed significant correlations between the PCDDs/DFs concentration and the AhR and CYP gene expression/cell viability/DNA damage.	Polychlorinated Dibenzodioxins	64-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
17850846-6	2007	Statistical tests revealed significant correlations between the PCDDs/DFs concentration and the AhR and CYP gene expression/cell viability/DNA damage.	aspartyl-phenylalanine	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
17709372-0	2007	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.	o-demethylate	39-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-30
17709372-0	2007	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.	pafuramidine	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-30
17709372-1	2007	CYP4F enzymes, including CYP4F2 and CYP4F3B, were recently shown to be the major enzymes catalyzing the initial oxidative O-demethylation of the antiparasitic prodrug pafuramidine (DB289) by human liver microsomes.	pafuramidine	167-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-5
21783812-10	2007	This suggests that NMPA formation is partially dependent on cytochrome-P450 reductase.	N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide	19-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
17709372-1	2007	CYP4F enzymes, including CYP4F2 and CYP4F3B, were recently shown to be the major enzymes catalyzing the initial oxidative O-demethylation of the antiparasitic prodrug pafuramidine (DB289) by human liver microsomes.	pafuramidine	181-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-5
17709372-11	2007	We conclude that enteric CYP4F enzymes could play a role in the first-pass biotransformation of DB289 and other xenobiotics.	pafuramidine	96-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-30
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	6beta-hydroxy	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17693640-3	2007	Approximately 500 pmol of norbenzphetamine and 58 pmol of cyclohexanol were formed per nmol of cyt P450.	norbenzphetamine	26-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-103
17693640-3	2007	Approximately 500 pmol of norbenzphetamine and 58 pmol of cyclohexanol were formed per nmol of cyt P450.	Cyclohexanols	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-103
17693640-5	2007	Four hundred picomoles of norbenzphetamine and 21 pmol of cyclohexanol were formed per nmol of cyt P450.	norbenzphetamine	26-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-103
17693640-5	2007	Four hundred picomoles of norbenzphetamine and 21 pmol of cyclohexanol were formed per nmol of cyt P450.	Cyclohexanols	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-103
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	7beta-ohgz	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	7beta-ohgz	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	6beta-hydroxy	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	meoh-gz	169-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	6beta-ohgz	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	meoh-gz	169-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	gliclizide	193-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	6beta-ohgz	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	gliclizide	193-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	7beta-hydroxy	123-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	gz	118-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	gz	118-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17517049-1	2007	AIMS: To identify the human cytochrome P450 (CYP) enzymes responsible for the formation of the 6beta-hydroxy (6beta-OHGz), 7beta-hydroxy (7beta-OHGz) and hydroxymethyl (MeOH-Gz) metabolites of gliclizide (Gz).	7beta-hydroxy	123-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
17576805-0	2007	Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.	diuron n	20-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
17763085-2	2007	NDMA is acutely toxic to humans at high doses, is genotoxic after cytochrome P-450 metabolism, and is carcinogenic in several animal species.	Dimethylnitrosamine	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
17823102-3	2007	PAHs are potent inducers of the hepatic cytochrome P-450 (CYP) isoenzymes 1A1, 1A2, and, possibly, 2E1.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
17823102-3	2007	PAHs are potent inducers of the hepatic cytochrome P-450 (CYP) isoenzymes 1A1, 1A2, and, possibly, 2E1.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
17676386-7	2007	Oral griseofulvin induced an increase in mitochondrial cytochrome P-450 levels, while chronic Isoflurane produced a reduction on its levels, without alterations on microsomal cytochrome P-450.	Griseofulvin	5-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
17676386-8	2007	Allylisopropylacetamide diminished both mitochondrial and microsomal cytochrome P-450 brain levels; a similar pattern was detected in liver.	Allylisopropylacetamide	0-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
17676386-9	2007	Mitochondria cytochrome P-450 liver levels were only diminished after chronic Isoflurane administration.	Isoflurane	78-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
17676386-10	2007	In kidney only mitochondrial cytochrome P-450 levels were modified by veronal; while in microsomes, only acute anaesthesia with Enflurane diminished cytochrome P-450 content.	Enflurane	128-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
17676386-12	2007	Acute delta-aminolevulinic acid administration reduced brain and liver cytochrome P-450 levels in both fractions; chronic delta-aminolevulinic acid administration diminished only liver mitochondrial cytochrome P-450.	Aminolevulinic Acid	6-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
17676386-12	2007	Acute delta-aminolevulinic acid administration reduced brain and liver cytochrome P-450 levels in both fractions; chronic delta-aminolevulinic acid administration diminished only liver mitochondrial cytochrome P-450.	Aminolevulinic Acid	122-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-215
17676386-13	2007	(5) Brain NADPH cytochrome P-450 reductase activity in animals receiving allylisopropylacetamide, dietary griseofulvin and delta-aminolevulinic acid showed a similar profile as that for total cytochrome P-450 levels.	Allylisopropylacetamide	73-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
17676386-13	2007	(5) Brain NADPH cytochrome P-450 reductase activity in animals receiving allylisopropylacetamide, dietary griseofulvin and delta-aminolevulinic acid showed a similar profile as that for total cytochrome P-450 levels.	Griseofulvin	106-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
17676386-13	2007	(5) Brain NADPH cytochrome P-450 reductase activity in animals receiving allylisopropylacetamide, dietary griseofulvin and delta-aminolevulinic acid showed a similar profile as that for total cytochrome P-450 levels.	Aminolevulinic Acid	123-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
17434921-2	2007	Tamoxifen is metabolized by various cytochrome P450 (CYP) enzymes, but predominantly by CYP3A4.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
17434921-2	2007	Tamoxifen is metabolized by various cytochrome P450 (CYP) enzymes, but predominantly by CYP3A4.	Tamoxifen	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
17635335-0	2007	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.	Benzodiazepines	86-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
17764757-1	2007	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are lipid signalling molecules that elicit vasodilatation and modulate various intracellular signalling cascades.	epoxyeicosatrienoic acids	30-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17764757-1	2007	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are lipid signalling molecules that elicit vasodilatation and modulate various intracellular signalling cascades.	epoxyeicosatrienoic acids	30-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17764757-1	2007	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are lipid signalling molecules that elicit vasodilatation and modulate various intracellular signalling cascades.	eets	57-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17764757-1	2007	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are lipid signalling molecules that elicit vasodilatation and modulate various intracellular signalling cascades.	eets	57-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
26627620-1	2007	We have developed force-field parameters for the hydrogen-abstraction transition state of aliphatic hydroxylation by cytochrome P450 using the Q2MM approach.	Hydrogen	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
17708140-5	2007	Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes.	Warfarin	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
19356040-0	2007	cAMP-mediated regulation of CYP enzymes and its application in chemotherapy.	Cyclic AMP	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
17635335-7	2007	Further studies on the effects of genetic polymorphisms of CYP enzymes on the pharmacokinetics and pharmacodynamics of BZPs are necessary to guide treatment individualization and optimization.	Benzodiazepines	119-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
17505056-1	2007	P450 oxidoreductase (POR) has a pivotal role in facilitating electron transfer from nicotinamide adenine dinucleotide phosphate to microsomal cytochrome P450 (CYP) enzymes, including the steroidogenic enzymes CYP17A1 and CYP21A2.	NADP	84-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
17654255-0	2007	Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	123-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	251-254
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4- or 5-o-desmethyl-hm-30181	120-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4- or 5-o-desmethyl-hm-30181	120-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	6- or 7-o-desmethyl-hm-30181	158-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
17505056-1	2007	P450 oxidoreductase (POR) has a pivotal role in facilitating electron transfer from nicotinamide adenine dinucleotide phosphate to microsomal cytochrome P450 (CYP) enzymes, including the steroidogenic enzymes CYP17A1 and CYP21A2.	NADP	84-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	6- or 7-o-desmethyl-hm-30181	158-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	CHEBI:166892	69-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
17654255-2	2007	This study was performed to characterize human cytochrome P-450 (CYP) enzymes involved in the metabolism of HM-30181 to 4- or 5-O-desmethyl-HM-30181 (M2) and 6- or 7-O-desmethyl-HM-30181 (M3) and to investigate the inhibitory potential of HM-30181 on CYP enzymes in human liver microsomes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	251-254
17654255-3	2007	CYP3A4 was identified as the major isozyme responsible for the O-demethylation of HM-30181 to M2 and M3 based on the correlation analysis, chemical inhibition and immuno-inhibition study and metabolism in cDNA-expressed human CYP isozymes.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	CHEBI:166892	69-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-195
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	rooperol	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	rooperol	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-195
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	Sterols	101-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
17336049-4	2007	The potential of extracts of AP, AP formulations as well as HYP, its aglycone rooperol (ROP) and the sterols to inhibit in vitro metabolism of drug marker substrates by human cytochrome P450 (CYP) enzymes such as CYP3A4, 3A5 and CYP19 were investigated.	Sterols	101-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	192-195
17701830-3	2007	The specific CYPs responsible for O-demethylation of eupatilin to the major metabolite, 4-O-desmethyleupatilin were identified using a combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by human cDNA-expressed CYP enzymes.	4-o-desmethyleupatilin	88-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
17413125-5	2007	One important xenobiotic substrate for CYP enzymes in cigarette smoke is polycyclic aromatic hydrocarbon, which in its native form is relatively harmless in small doses but upon bioactivation by CYP enzymes, can become very toxic substances for the lungs.	Polycyclic Aromatic Hydrocarbons	73-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
17413125-5	2007	One important xenobiotic substrate for CYP enzymes in cigarette smoke is polycyclic aromatic hydrocarbon, which in its native form is relatively harmless in small doses but upon bioactivation by CYP enzymes, can become very toxic substances for the lungs.	Polycyclic Aromatic Hydrocarbons	73-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	Arachidonic Acid	43-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	Arachidonic Acid	43-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	epoxyeicosatrienoic acids	82-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	epoxyeicosatrienoic acids	82-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	EET	109-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17638876-1	2007	Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EET), which exert diverse biological activities in a variety of systems.	EET	109-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17573638-1	2007	trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions.	trans-bromuconazole	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
17573638-1	2007	trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions.	trans-bromuconazole	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
17573638-1	2007	trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions.	Triazoles	70-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
17573638-1	2007	trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions.	Triazoles	70-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-145
17398093-0	2007	Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.	3-(1H-1,3-benzimidazol-2-yl)-2(1H)-pyridinone	37-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
17570247-0	2007	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA.	catechol	47-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17570247-0	2007	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA.	Quinones	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17497828-3	2007	The potential for inhibition of the CYP isoforms was measured by monitoring the level of the metabolites 6beta-hydroxytestosterone (3A4), dextrorphan (2D6), 4"-hydroxydiclofenac (2C9), and acetaminophen (1A2) formed in the presence of drug candidates using an eight-point titration.	6 beta-hydroxytestosterone	105-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
17452028-2	2007	Consequently dextromethorphan, flurbiprofen, midazolam and other compounds are commonly used as probe substrates to evaluate cytochrome P450 function in humans.	Dextromethorphan	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
17452028-2	2007	Consequently dextromethorphan, flurbiprofen, midazolam and other compounds are commonly used as probe substrates to evaluate cytochrome P450 function in humans.	Flurbiprofen	31-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
17452028-2	2007	Consequently dextromethorphan, flurbiprofen, midazolam and other compounds are commonly used as probe substrates to evaluate cytochrome P450 function in humans.	Midazolam	45-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
17497828-3	2007	The potential for inhibition of the CYP isoforms was measured by monitoring the level of the metabolites 6beta-hydroxytestosterone (3A4), dextrorphan (2D6), 4"-hydroxydiclofenac (2C9), and acetaminophen (1A2) formed in the presence of drug candidates using an eight-point titration.	Dextrorphan	138-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
17497828-3	2007	The potential for inhibition of the CYP isoforms was measured by monitoring the level of the metabolites 6beta-hydroxytestosterone (3A4), dextrorphan (2D6), 4"-hydroxydiclofenac (2C9), and acetaminophen (1A2) formed in the presence of drug candidates using an eight-point titration.	4'-hydroxydiclofenac	157-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
17497828-3	2007	The potential for inhibition of the CYP isoforms was measured by monitoring the level of the metabolites 6beta-hydroxytestosterone (3A4), dextrorphan (2D6), 4"-hydroxydiclofenac (2C9), and acetaminophen (1A2) formed in the presence of drug candidates using an eight-point titration.	Acetaminophen	189-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
17398093-0	2007	Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.	imidazole	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
17521300-0	2007	Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.	artemisinin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
17521300-1	2007	The aim of this study was to investigate which principal human cytochrome P450 (CYP450) enzymes are affected by artemisinin and to what degree the artemisinin derivatives differ with respect to their respective induction and inhibition capacity.	artemisinin	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
17521300-10	2007	These results show that intake of artemisinin antimalarials affect the activities of several principal human drug metabolizing CYP450 enzymes.	artemisinin	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-133
17521300-1	2007	The aim of this study was to investigate which principal human cytochrome P450 (CYP450) enzymes are affected by artemisinin and to what degree the artemisinin derivatives differ with respect to their respective induction and inhibition capacity.	artemisinin	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-86
17504220-0	2007	CYP-mediated clozapine interactions: how predictable are they?	Clozapine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
17449539-0	2007	Interaction between cytochrome P450 gene polymorphisms and serum organochlorine TEQ levels in the risk of endometriosis.	organochlorine teq	65-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
17504219-1	2007	Cytochrome P450 (CYP, P450) is the collective term for a superfamily of heme-containing membrane proteins responsible for the metabolism of approximately 70 - 80 % of clinically used drugs.	Heme	72-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17187958-0	2007	Cytochrome P450 destruction by benzene metabolites 1,4-benzoquinone and 1,4-hydroquinone and the formation of hydroxyl radicals in minipig liver microsomes.	Benzene	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17187958-0	2007	Cytochrome P450 destruction by benzene metabolites 1,4-benzoquinone and 1,4-hydroquinone and the formation of hydroxyl radicals in minipig liver microsomes.	quinone	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17187958-0	2007	Cytochrome P450 destruction by benzene metabolites 1,4-benzoquinone and 1,4-hydroquinone and the formation of hydroxyl radicals in minipig liver microsomes.	1,4-hydroquinone	72-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17187958-0	2007	Cytochrome P450 destruction by benzene metabolites 1,4-benzoquinone and 1,4-hydroquinone and the formation of hydroxyl radicals in minipig liver microsomes.	Hydroxyl Radical	110-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17187958-2	2007	Since minipigs have been proposed as a suitable model species in toxicological and pharmacological research, the aim of this study was to explore mechanisms by which catechol, 1,4-hydroquinone and 1,4-benzoquinone destroy cytochrome P450 (P450) and induce oxidative stress in minipig liver microsomes.	catechol	166-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
17187958-2	2007	Since minipigs have been proposed as a suitable model species in toxicological and pharmacological research, the aim of this study was to explore mechanisms by which catechol, 1,4-hydroquinone and 1,4-benzoquinone destroy cytochrome P450 (P450) and induce oxidative stress in minipig liver microsomes.	1,4-hydroquinone	176-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
17187958-2	2007	Since minipigs have been proposed as a suitable model species in toxicological and pharmacological research, the aim of this study was to explore mechanisms by which catechol, 1,4-hydroquinone and 1,4-benzoquinone destroy cytochrome P450 (P450) and induce oxidative stress in minipig liver microsomes.	quinone	197-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
17504219-1	2007	Cytochrome P450 (CYP, P450) is the collective term for a superfamily of heme-containing membrane proteins responsible for the metabolism of approximately 70 - 80 % of clinically used drugs.	Heme	72-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17504220-4	2007	The majority of the interactions with clozapine are reported to be mediated by cytochrome P450 (CYP) enzymes.	Clozapine	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
17504220-4	2007	The majority of the interactions with clozapine are reported to be mediated by cytochrome P450 (CYP) enzymes.	Clozapine	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
17489643-5	2007	Of the drugs indicated for OAB, tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450, but trospium is not.	Tolterodine Tartrate	32-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
17489643-5	2007	Of the drugs indicated for OAB, tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450, but trospium is not.	darifenacin	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
17489643-5	2007	Of the drugs indicated for OAB, tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450, but trospium is not.	Solifenacin Succinate	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
17489643-5	2007	Of the drugs indicated for OAB, tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450, but trospium is not.	oxybutynin	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
17372695-0	2007	Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.	cyclic phosphate	6-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
17293117-0	2007	Cytochrome P-450 model reactions: efficient and highly selective oxidation of alcohols with tetrabutylammonium peroxymonosulfate catalyzed by Mn-porphyrins.	Alcohols	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
17293117-0	2007	Cytochrome P-450 model reactions: efficient and highly selective oxidation of alcohols with tetrabutylammonium peroxymonosulfate catalyzed by Mn-porphyrins.	SCHEMBL1259012	92-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
17293117-0	2007	Cytochrome P-450 model reactions: efficient and highly selective oxidation of alcohols with tetrabutylammonium peroxymonosulfate catalyzed by Mn-porphyrins.	mn-porphyrins	142-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
17220239-11	2007	CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8.	Sitagliptin Phosphate	97-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
17381666-0	2007	Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
17381666-1	2007	BACKGROUND: Although cytochrome P450 (CYP) 2D6 is often thought to be the only CYP responsible for the metabolism of risperidone, many reports suggest that CYP3A may be involved too.	Risperidone	117-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
17381666-1	2007	BACKGROUND: Although cytochrome P450 (CYP) 2D6 is often thought to be the only CYP responsible for the metabolism of risperidone, many reports suggest that CYP3A may be involved too.	Risperidone	117-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
17381666-1	2007	BACKGROUND: Although cytochrome P450 (CYP) 2D6 is often thought to be the only CYP responsible for the metabolism of risperidone, many reports suggest that CYP3A may be involved too.	Risperidone	117-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
17407229-0	2007	Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.	Cyclophosphamide	73-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17372695-0	2007	Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.	Alcohols	90-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
17372695-1	2007	PURPOSE: A cyclic phosphate prodrug of a descriptive molecule containing an alcohol functionality was designed, synthesized and characterized in vitro as a cytochrome P450 (CYP) -selective prodrug.	cyclic phosphate	11-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
17372695-1	2007	PURPOSE: A cyclic phosphate prodrug of a descriptive molecule containing an alcohol functionality was designed, synthesized and characterized in vitro as a cytochrome P450 (CYP) -selective prodrug.	cyclic phosphate	11-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
17372695-1	2007	PURPOSE: A cyclic phosphate prodrug of a descriptive molecule containing an alcohol functionality was designed, synthesized and characterized in vitro as a cytochrome P450 (CYP) -selective prodrug.	Alcohols	76-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
17372695-1	2007	PURPOSE: A cyclic phosphate prodrug of a descriptive molecule containing an alcohol functionality was designed, synthesized and characterized in vitro as a cytochrome P450 (CYP) -selective prodrug.	Alcohols	76-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
17372695-2	2007	MATERIALS AND METHODS: To achieve efficient CYP-oxidation and prodrug bioconversion, 1,3-cyclic propyl ester of phosphate was designed to have a C4-aryl substituent and synthesized using phosphorus(III) chemistry.	1,3-cyclic propyl ester	85-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
17372695-2	2007	MATERIALS AND METHODS: To achieve efficient CYP-oxidation and prodrug bioconversion, 1,3-cyclic propyl ester of phosphate was designed to have a C4-aryl substituent and synthesized using phosphorus(III) chemistry.	Phosphates	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
17372695-3	2007	The two-step bioconversion of the cyclic phosphate prodrug was evaluated in vitro using human liver microsomes and recombinant CYP enzymes.	cyclic phosphate	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
17372695-4	2007	RESULTS: This cyclic phosphate prodrug underwent initial CYP-catalyzed oxidation and was mainly catalyzed by the CYP3A4 form.	cyclic phosphate	14-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
17372695-8	2007	CONCLUSIONS: Since CYP enzymes reside predominantly in the liver and secondarily in the small intestine, the results indicate that cyclic phosphate prodrugs represent a very feasible liver- or intestinal-targeted drug delivery strategy for drug molecules containing an alcohol functionality.	cyclic phosphate	131-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
17372695-8	2007	CONCLUSIONS: Since CYP enzymes reside predominantly in the liver and secondarily in the small intestine, the results indicate that cyclic phosphate prodrugs represent a very feasible liver- or intestinal-targeted drug delivery strategy for drug molecules containing an alcohol functionality.	Alcohols	269-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
17303175-0	2007	Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.	Dronabinol	54-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17292855-0	2007	Evaluation of cytochrome P450(BSbeta) reactivity against polycyclic aromatic hydrocarbons and drugs.	Polycyclic Aromatic Hydrocarbons	57-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-37
17292855-1	2007	The oxidation of 10 polycyclic aromatic hydrocarbons (PAH) by cytochrome P450(BSbeta) using three different electron acceptors is reported.	Polycyclic Aromatic Hydrocarbons	20-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-85
17292855-1	2007	The oxidation of 10 polycyclic aromatic hydrocarbons (PAH) by cytochrome P450(BSbeta) using three different electron acceptors is reported.	Polycyclic Aromatic Hydrocarbons	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-85
17303175-0	2007	Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.	Cannabinol	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17160483-0	2007	Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes.	n-methyl, n-propargylphenylethylamine	14-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-123
17322161-4	2007	Cranberry juice is a flavonoid, which has been shown to induce, inhibit, or act as a substrate for the biosynthesis of several cytochrome P-450 (CYP) isoenzymes.	Flavonoids	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
17322161-4	2007	Cranberry juice is a flavonoid, which has been shown to induce, inhibit, or act as a substrate for the biosynthesis of several cytochrome P-450 (CYP) isoenzymes.	Flavonoids	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
17160483-0	2007	Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes.	n-methyl, n-propargylphenylethylamine	14-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	n-methyl,n-propargyl-2-phenylethylamine	189-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	MPPE	230-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	N-methylphenethylamine	239-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	N-methylphenethylamine	265-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	n-propargylphenylethylamine	282-309	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17160483-2	2007	We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA).	n-propargylpea	311-325	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
17329906-0	2007	Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates.	Nitric Oxide	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17346171-1	2007	This article aims to give an overview on the characterization, properties and regulation of enzymes, particularly the cytochrome (CYP) P450 enzymes, in the formation of bile acids from cholesterol.	Bile Acids and Salts	169-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
17346171-1	2007	This article aims to give an overview on the characterization, properties and regulation of enzymes, particularly the cytochrome (CYP) P450 enzymes, in the formation of bile acids from cholesterol.	Cholesterol	185-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
17237483-1	2007	Pro-carcinogens, such as benzo[a]pyrene (B[a]P), that are exogenous ligands of the aromatic hydrocarbon receptor may influence the susceptibility of target-cell populations through the up-regulation of cytochrome P450 (CYP) mixed function oxidases.	Benzo(a)pyrene	25-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-217
17237483-1	2007	Pro-carcinogens, such as benzo[a]pyrene (B[a]P), that are exogenous ligands of the aromatic hydrocarbon receptor may influence the susceptibility of target-cell populations through the up-regulation of cytochrome P450 (CYP) mixed function oxidases.	Benzo(a)pyrene	25-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-222
17237483-1	2007	Pro-carcinogens, such as benzo[a]pyrene (B[a]P), that are exogenous ligands of the aromatic hydrocarbon receptor may influence the susceptibility of target-cell populations through the up-regulation of cytochrome P450 (CYP) mixed function oxidases.	Benzo(a)pyrene	41-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-217
17237483-1	2007	Pro-carcinogens, such as benzo[a]pyrene (B[a]P), that are exogenous ligands of the aromatic hydrocarbon receptor may influence the susceptibility of target-cell populations through the up-regulation of cytochrome P450 (CYP) mixed function oxidases.	Benzo(a)pyrene	41-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-222
17329906-0	2007	Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates.	Aspirin	67-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17329906-0	2007	Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates.	Nitrates	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17329906-2	2007	We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN).	Nitrates	113-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17329906-2	2007	We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN).	Nitroglycerin	130-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17329906-2	2007	We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN).	Nitroglycerin	145-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17329906-2	2007	We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN).	Isosorbide Dinitrate	154-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17329906-2	2007	We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN).	Isosorbide Dinitrate	176-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17222962-1	2007	Cytochrome P450 side-chain cleavage (CYP11A1) catalyzes the conversion of cholesterol to pregnenolone, the first step in steroidogenesis.	Cholesterol	74-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17253801-0	2007	Regioselective oxyfunctionalization of unactivated carbons in steroids by a model of cytochrome P-450: osmiumporphyrin complex/tert-butyl hydroperoxide system.	Carbon	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
17253801-0	2007	Regioselective oxyfunctionalization of unactivated carbons in steroids by a model of cytochrome P-450: osmiumporphyrin complex/tert-butyl hydroperoxide system.	Steroids	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
17253801-0	2007	Regioselective oxyfunctionalization of unactivated carbons in steroids by a model of cytochrome P-450: osmiumporphyrin complex/tert-butyl hydroperoxide system.	osmiumporphyrin complex	103-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
17253801-0	2007	Regioselective oxyfunctionalization of unactivated carbons in steroids by a model of cytochrome P-450: osmiumporphyrin complex/tert-butyl hydroperoxide system.	tert-Butylhydroperoxide	127-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
17222962-1	2007	Cytochrome P450 side-chain cleavage (CYP11A1) catalyzes the conversion of cholesterol to pregnenolone, the first step in steroidogenesis.	Pregnenolone	89-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17484517-0	2007	Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes.	imidafenacin	44-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
17286541-5	2007	Amodiaquine is almost entirely metabolized by the polymorphic cytochrome P450 (CYP) isoform 2C8 to the pharmacologically active desethylamodiaquine.	Amodiaquine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
17286541-5	2007	Amodiaquine is almost entirely metabolized by the polymorphic cytochrome P450 (CYP) isoform 2C8 to the pharmacologically active desethylamodiaquine.	Amodiaquine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
17286541-5	2007	Amodiaquine is almost entirely metabolized by the polymorphic cytochrome P450 (CYP) isoform 2C8 to the pharmacologically active desethylamodiaquine.	desethylamodiaquine	128-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
17286541-5	2007	Amodiaquine is almost entirely metabolized by the polymorphic cytochrome P450 (CYP) isoform 2C8 to the pharmacologically active desethylamodiaquine.	desethylamodiaquine	128-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
17484517-0	2007	Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes.	imidafenacin	155-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-200
17484519-0	2007	Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine.	Fluvoxamine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	offluvoxamine	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	offluvoxamine	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	offluvoxamine	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-203
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	fluvoxamino alcohol	126-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	fluvoxamino alcohol	126-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
17484519-2	2007	The present study was carried out to identify the cytochrome P450 (CYP) enzyme(s) involved in the metabolism offluvoxamine to fluvoxamino alcohol using human liver microsomes and cDNA-expressed human CYP enzymes.	fluvoxamino alcohol	126-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-203
17484519-4	2007	The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol.	fluvoxamino alcohol	17-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
17484519-4	2007	The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol.	Fluvoxamine	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
17484519-4	2007	The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol.	Quinidine	118-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
17484519-5	2007	In addition, only CYP2D6 of several cDNA-expressed human CYP enzymes examined showed substantial activity for the formation of fluvoxamino alcohol.	fluvoxamino alcohol	127-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
17067556-0	2007	Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).	phenethylamine	98-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
17201456-5	2007	Because they are metabolised via cytochrome P450 (CYP), glitazones are exposed to numerous pharmacokinetic interactions.	Thiazolidinediones	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Cyclophosphamide	163-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Cyclophosphamide	163-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Bupropion	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	Bupropion	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	efavirenz	247-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	efavirenz	247-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
17375980-14	2007	Escitalopram is metabolised by the cytochrome P450 (CYP) isoenzymes CYP2C19, CYP2D6 and CYP3A4.	Citalopram	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
17375980-14	2007	Escitalopram is metabolised by the cytochrome P450 (CYP) isoenzymes CYP2C19, CYP2D6 and CYP3A4.	Citalopram	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
17375983-7	2007	The body surface area, peak concentrations of etoposide, urinary recovery of dechloroethylcyclophosphamide (formed by cytochrome P450 [CYP] 3A4) relative to the cyclophosphamide dose and number of cycles had a significant effect on toxicity.	dechloroethylcyclophosphamide	77-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-143
17375983-7	2007	The body surface area, peak concentrations of etoposide, urinary recovery of dechloroethylcyclophosphamide (formed by cytochrome P450 [CYP] 3A4) relative to the cyclophosphamide dose and number of cycles had a significant effect on toxicity.	Cyclophosphamide	90-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-143
17201456-5	2007	Because they are metabolised via cytochrome P450 (CYP), glitazones are exposed to numerous pharmacokinetic interactions.	Thiazolidinediones	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
17201456-11	2007	Although some food components have also been shown to potentially interfere with drugs metabolised with the CYP system, no published study deals specifically with these possible CYP-mediated food-drug interactions with glitazones.	Thiazolidinediones	219-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-181
19356015-2	2007	The CYP form with the lowest in vitro K(i) is evaluated first clinically, employing a suitable probe drug like midazolam (CYP3A4), theophylline (CYP1A2), (S)-warfarin (CYP2C9) and desipramine (CYP2D6), and the NCE is classified as a "none", "weak", "moderate", or "strong" inhibitor.	Midazolam	111-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
18690854-16	2007	These interactions are caused by the metabolism of triazoles in the liver where the cytochrome P450 (CYP) system is involved at a different extend as well as by their mechanisms of action.	Triazoles	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
18690854-16	2007	These interactions are caused by the metabolism of triazoles in the liver where the cytochrome P450 (CYP) system is involved at a different extend as well as by their mechanisms of action.	Triazoles	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
18447001-0	2007	The effect of chlorpyrifos-oxon and other xenobiotics on the human cytochrome P450-dependent metabolism of naphthalene and deet.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	14-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
18447001-0	2007	The effect of chlorpyrifos-oxon and other xenobiotics on the human cytochrome P450-dependent metabolism of naphthalene and deet.	naphthalene	107-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	neozone	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	neozone	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	4'-hydroxy-n-phenyl-2-naphthylamine	156-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	4'-hydroxy-n-phenyl-2-naphthylamine	156-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	quinone imine	234-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	quinone imine	234-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	2-Naphthylamine	176-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
17674211-5	2007	To explain the metabolic dephenylation process, it has been suggested that PBNA is metabolized by cytochrome P-450 (CYP) enzymes to the phenolic derivative 4"-hydroxy-N-phenyl-2-naphthylamine, followed by its further oxidation to the quinone imine, which subsequently hydrolyses to form the dephenylation product 2-naphthylamine.	2-Naphthylamine	176-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
17786620-1	2007	Ronald Estabrook made his initial impact studying cytochrome P450 by demonstrating the oxidative metabolism function of this unique class of enzymes, which had an unusual spectral peak at 450 nm when reduced and in the presence of carbon monoxide.	Carbon Monoxide	231-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
17786620-2	2007	Utilizing a photochemical action spectrum, he demonstrated that a cytochrome P450 was responsible for steroid 21 hydroxylation catalyzed by microsomes prepared from adrenal cortex tissue.	Steroids	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
19356015-2	2007	The CYP form with the lowest in vitro K(i) is evaluated first clinically, employing a suitable probe drug like midazolam (CYP3A4), theophylline (CYP1A2), (S)-warfarin (CYP2C9) and desipramine (CYP2D6), and the NCE is classified as a "none", "weak", "moderate", or "strong" inhibitor.	Theophylline	131-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
19356015-2	2007	The CYP form with the lowest in vitro K(i) is evaluated first clinically, employing a suitable probe drug like midazolam (CYP3A4), theophylline (CYP1A2), (S)-warfarin (CYP2C9) and desipramine (CYP2D6), and the NCE is classified as a "none", "weak", "moderate", or "strong" inhibitor.	Warfarin	156-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
19356015-2	2007	The CYP form with the lowest in vitro K(i) is evaluated first clinically, employing a suitable probe drug like midazolam (CYP3A4), theophylline (CYP1A2), (S)-warfarin (CYP2C9) and desipramine (CYP2D6), and the NCE is classified as a "none", "weak", "moderate", or "strong" inhibitor.	Desipramine	180-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
17936932-6	2007	A number of pesticides, including chlorpyrifos, fipronil and permethrin, and the repellent, DEET, have been shown to be inducers of CYP isoforms in human hepatocytes, with fipronil being the most potent.	Chlorpyrifos	34-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
17427179-0	2007	Inhibition of fipronil and nonane metabolism in human liver microsomes and human cytochrome P450 isoforms by chlorpyrifos.	fipronil	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
17936932-6	2007	A number of pesticides, including chlorpyrifos, fipronil and permethrin, and the repellent, DEET, have been shown to be inducers of CYP isoforms in human hepatocytes, with fipronil being the most potent.	fipronil	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
17427179-0	2007	Inhibition of fipronil and nonane metabolism in human liver microsomes and human cytochrome P450 isoforms by chlorpyrifos.	nonane	27-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
17936932-3	2007	OPs are potent irreversible inhibitors of testosterone metabolism by cytochrome P450 (CYP) 3A4 and of estradiol metabolism by CYP3A4 and CYP1A2.	Testosterone	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
17936932-6	2007	A number of pesticides, including chlorpyrifos, fipronil and permethrin, and the repellent, DEET, have been shown to be inducers of CYP isoforms in human hepatocytes, with fipronil being the most potent.	Permethrin	61-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
17936932-3	2007	OPs are potent irreversible inhibitors of testosterone metabolism by cytochrome P450 (CYP) 3A4 and of estradiol metabolism by CYP3A4 and CYP1A2.	Testosterone	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
17936932-4	2007	All of these CYP inhibitions are believed to be due to the release of reactive sulfur during CYP-catalyzed oxidative desulfuration.	Sulfur	79-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
17427179-0	2007	Inhibition of fipronil and nonane metabolism in human liver microsomes and human cytochrome P450 isoforms by chlorpyrifos.	Chlorpyrifos	109-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	Chlorpyrifos	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	Chlorpyrifos	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
17936932-6	2007	A number of pesticides, including chlorpyrifos, fipronil and permethrin, and the repellent, DEET, have been shown to be inducers of CYP isoforms in human hepatocytes, with fipronil being the most potent.	fipronil	172-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	Chlorpyrifos	53-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
17936932-4	2007	All of these CYP inhibitions are believed to be due to the release of reactive sulfur during CYP-catalyzed oxidative desulfuration.	Sulfur	79-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
17011724-0	2007	Significant transcriptional down-regulation of the human MDR1 gene by beta-naphthoflavone: a proposed hypothesis linking potent CYP gene induction to MDR1 inhibition.	beta-Naphthoflavone	70-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
17507873-1	2007	Isoflavonoids exert a regulatory function on the expression of cytochrome P450 enzymes and also up-regulate the vitamin D(3) receptor (VDR) on cancer cells, which increase their sensitivity to 1,25-dihydroxyvitamin D(3) , the hormonally active form of vitamin D(3) .	isoflavonoids	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	Chlorpyrifos	53-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	fipronil	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	fipronil	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	nonane	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
17427179-1	2007	Previous studies have established that chlorpyrifos (CPS), fipronil, and nonane can all be metabolized by human liver microsomes (HLM) and a number of cytochrome P450 (CYP) isoforms.	nonane	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
17427179-3	2007	In this study the effect of either coincubation or preincubation of CPS with HLM or CYP isoforms with either fipronil or nonane as substrate was investigated.	fipronil	109-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
17427179-3	2007	In this study the effect of either coincubation or preincubation of CPS with HLM or CYP isoforms with either fipronil or nonane as substrate was investigated.	nonane	121-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
17164129-0	2007	Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids.	Arachidonic Acid	104-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
17164129-0	2007	Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids.	Eicosanoids	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Fatty Acids, Essential	28-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Fatty Acids, Essential	28-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Eicosanoids	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
17164129-1	2007	Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis.	Eicosanoids	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	109-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	142-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	142-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	194-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	194-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	eets	221-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
17164129-4	2007	A number of these enzymes, including members of the CYP 4 family, predominantly catalyze conversion of AA to 20-hydroxyeicosatetraenoic acid (20-HETE) while the CYP epoxygenases generate mainly epoxyeicosatrienoic acids (EETs).	eets	221-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
17164129-5	2007	This review will focus on the emerging roles of inhibitors of eicosanoid production with emphasis on the CYP pathways, in the regulation of angiogenesis and tumor growth.	Eicosanoids	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
17164132-5	2007	Current research suggests important differences with respect to the cardiovascular actions of specific CYP mediated arachidonic acid metabolites.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
17164132-6	2007	For example, CYP mediated hydroxylation of AA produces 20-hydroxyeicosatetraenoic acid (20-HETE) which has detrimental effects in the heart during ischemia, pro-inflammatory effects during reperfusion and potent vasoconstrictor effects in the coronary circulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	55-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
17164132-6	2007	For example, CYP mediated hydroxylation of AA produces 20-hydroxyeicosatetraenoic acid (20-HETE) which has detrimental effects in the heart during ischemia, pro-inflammatory effects during reperfusion and potent vasoconstrictor effects in the coronary circulation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	88-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
18192961-8	2007	Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme.	Loperamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
18192961-8	2007	Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme.	Loperamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
17164132-7	2007	Conversely, epoxidation of AA by CYP enzymes generates 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) that have been shown to reduce ischemia-reperfusion injury, have potent anti-inflammatory effects within the vasculature, and are potent vasodilators in the coronary circulation.	5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids	55-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
17164132-7	2007	Conversely, epoxidation of AA by CYP enzymes generates 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) that have been shown to reduce ischemia-reperfusion injury, have potent anti-inflammatory effects within the vasculature, and are potent vasodilators in the coronary circulation.	14,15-epoxy-5,8,11-eicosatrienoic acid	111-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17164133-1	2007	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17202847-5	2006	Furthermore, SOCE is regulated by cytochrome P-450, as demonstrated by the fact that the products of cytochrome P-450 activity (14,15 EET) stimulated SOCE while econazole, an inhibitor of cytochrome P450, suppressed BK-stimulated Ca2+ entry.	Econazole	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
17520800-3	2007	This review focuses on the flavonoid effects on cytochrome P450 (CYP) enzyme CYP1, 2E1, 3A4 and 19.	Flavonoids	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
17520800-3	2007	This review focuses on the flavonoid effects on cytochrome P450 (CYP) enzyme CYP1, 2E1, 3A4 and 19.	Flavonoids	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
17520800-4	2007	Flavonoids alter CYPs by various mechanisms, including the stimulation of gene expression via specific receptors and/or CYP protein, or mRNA stabilization and so on.	Flavonoids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
17202847-5	2006	Furthermore, SOCE is regulated by cytochrome P-450, as demonstrated by the fact that the products of cytochrome P-450 activity (14,15 EET) stimulated SOCE while econazole, an inhibitor of cytochrome P450, suppressed BK-stimulated Ca2+ entry.	Econazole	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
17177535-0	2006	Metalloporphyrins as biomimetic models for cytochrome p-450 in the oxidation of atrazine.	Metalloporphyrins	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
17177535-0	2006	Metalloporphyrins as biomimetic models for cytochrome p-450 in the oxidation of atrazine.	Atrazine	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
17177535-1	2006	The aim of this work was to evaluate whether metalloporphyrin models could mimic the action of cytochrome P-450 in the oxidation of atrazine, a herbicide.	Metalloporphyrins	45-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
17177535-1	2006	The aim of this work was to evaluate whether metalloporphyrin models could mimic the action of cytochrome P-450 in the oxidation of atrazine, a herbicide.	Atrazine	132-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
17177535-4	2006	Yields as high as 32% were obtained for the Mn(TFPP)Cl/PhIO system, which shows that these catalysts can mimic both the in vivo and the in vitro action of cytochrome P-450, with formation of the metabolites DEA and DIA.	dea	207-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
17177535-4	2006	Yields as high as 32% were obtained for the Mn(TFPP)Cl/PhIO system, which shows that these catalysts can mimic both the in vivo and the in vitro action of cytochrome P-450, with formation of the metabolites DEA and DIA.	4-(4-dihexadecylaminostyryl)-N-methylpyridium	215-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
17084997-0	2006	Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
17178892-6	2006	When MCF-7 cells were treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increased dose dependently the formation of (-)-anti-BPDE-dG and decreased the cytochrome P450 (CYP)-dependent formation of (+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-BP the adduct.	benzo(a)pyrene 7,8-dihydrodiol	51-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
17178892-6	2006	When MCF-7 cells were treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increased dose dependently the formation of (-)-anti-BPDE-dG and decreased the cytochrome P450 (CYP)-dependent formation of (+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-BP the adduct.	benzo(a)pyrene 7,8-dihydrodiol	51-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
17178892-6	2006	When MCF-7 cells were treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increased dose dependently the formation of (-)-anti-BPDE-dG and decreased the cytochrome P450 (CYP)-dependent formation of (+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-BP the adduct.	(-)-anti-bpde-dg	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
17178892-6	2006	When MCF-7 cells were treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increased dose dependently the formation of (-)-anti-BPDE-dG and decreased the cytochrome P450 (CYP)-dependent formation of (+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-BP the adduct.	(+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-bp	208-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
17178892-6	2006	When MCF-7 cells were treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increased dose dependently the formation of (-)-anti-BPDE-dG and decreased the cytochrome P450 (CYP)-dependent formation of (+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-BP the adduct.	(+)-r-7,t-8-dihydroxy-c-9,10-oxy-7,8,9,10-tetrahydro-bp	208-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
17084997-0	2006	Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.	Acetaldehyde	23-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
17178266-1	2006	OBJECTIVES: Rosiglitazone is metabolically inactivated predominantly via the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	12-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
16978758-0	2006	In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms.	tributyltin	23-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16978758-0	2006	In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms.	triphenyltin	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	tributyltin	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	tributyltin	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	tributyltin	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	triphenyltin	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	triphenyltin	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
16978758-2	2006	We used human hepatic cytochrome P-450 (CYP) systems to confirm the specific CYP(s) involved in the in vitro metabolism of tributyltin and triphenyltin.	triphenyltin	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
17109460-1	2006	The ongoing interest in very efficient systems for the imitation of cytochrome P-450-dependent monooxygenase reactions, consisting of metalloporphyrin and oxygen donor, prompted us to develop a method to compare the catalytic activity of soluble metalloporphyrins with those which have been immobilised on different silica surfaces.	Metalloporphyrins	134-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
17109460-1	2006	The ongoing interest in very efficient systems for the imitation of cytochrome P-450-dependent monooxygenase reactions, consisting of metalloporphyrin and oxygen donor, prompted us to develop a method to compare the catalytic activity of soluble metalloporphyrins with those which have been immobilised on different silica surfaces.	Oxygen	99-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
17109460-1	2006	The ongoing interest in very efficient systems for the imitation of cytochrome P-450-dependent monooxygenase reactions, consisting of metalloporphyrin and oxygen donor, prompted us to develop a method to compare the catalytic activity of soluble metalloporphyrins with those which have been immobilised on different silica surfaces.	Metalloporphyrins	246-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
17109460-1	2006	The ongoing interest in very efficient systems for the imitation of cytochrome P-450-dependent monooxygenase reactions, consisting of metalloporphyrin and oxygen donor, prompted us to develop a method to compare the catalytic activity of soluble metalloporphyrins with those which have been immobilised on different silica surfaces.	Silicon Dioxide	316-322	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
17296539-7	2006	Rasagiline is almost completely eliminated by oxidative metabolism (catalyzed by cytochrome P-450 [CYP] isozyme 1A2) followed by renal excretion of conjugated parent compound and metabolites.	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-115
17178266-1	2006	OBJECTIVES: Rosiglitazone is metabolically inactivated predominantly via the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	12-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
17178267-0	2006	ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.	Methadone	65-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
17178267-1	2006	BACKGROUND AND OBJECTIVE: The in vivo implication of various cytochrome P450 (CYP) isoforms and of P-glycoprotein on methadone kinetics is unclear.	Methadone	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
17178267-12	2006	CONCLUSION: In vivo, CYP3A4 and CYP2B6 are the major CYP isoforms involved in methadone metabolism, with CYP2D6 contributing to a minor extent.	Methadone	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
16997912-0	2006	CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].	pafuramidine	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-5
16997912-0	2006	CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].	pafuramidine	132-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-5
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	138-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	138-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	183-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	183-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	206-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	206-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	183-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17080490-1	2006	The use of CE for rapid assessment of metabolic stability of drugs with cytochrome P450 (CYP) enzymes, based on relative rates of reduced nicotinamide adenine dinucleotide phosphate (NADPH) consumption and nicotinamide adenine dinucleotide phosphate (NADP) production, was investigated.	NADP	183-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
17190370-1	2006	OBJECTIVE: Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP).	Lansoprazole	11-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
17190370-1	2006	OBJECTIVE: Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP).	Lansoprazole	11-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
17190370-1	2006	OBJECTIVE: Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP).	Tacrolimus	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
17190370-1	2006	OBJECTIVE: Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP).	Tacrolimus	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
16835590-8	2006	CYP4F3 and CYP4F2 catalyse the inactivation of leukotriene B4 (LTB4), a potent mediator of inflammation responsible for recruitment and activation of neutrophils.	Leukotriene B4	47-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
16980726-0	2006	Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth.	Hydroxyeicosatetraenoic Acids	0-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	Hydroxyeicosatetraenoic Acids	50-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	Hydroxyeicosatetraenoic Acids	50-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-140
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	Hydroxyeicosatetraenoic Acids	81-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	Hydroxyeicosatetraenoic Acids	81-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-140
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
16980726-4	2006	Our results show that 3T6 fibroblasts synthesized hydroxyeicosatetraenoic acids (HETEs) such as 12-HETE through the cytochrome P-450 (CYP450) pathway.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-140
16980726-6	2006	In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS.	Proadifen	56-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-36
16980726-6	2006	In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS.	17-octadecynoic acid	66-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-36
16980726-6	2006	In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS.	1-aminobenzotriazole	88-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-36
16980726-6	2006	In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS.	6-(2-propargyloxyphenyl)hexanoic acid	114-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-36
17159771-2	2006	Recently, we found that after cytochrome P450 (CYP)-mediated oxidation ellipticine forms covalent DNA adducts.	ellipticine	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
17159771-2	2006	Recently, we found that after cytochrome P450 (CYP)-mediated oxidation ellipticine forms covalent DNA adducts.	ellipticine	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
17159771-3	2006	Ellipticine oxidation by isolated CYP and its binding to DNA is the target of this study.	ellipticine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	NADP	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	NADP	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	ellipticine	78-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	ellipticine	78-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine	117-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine	117-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	ellipticine n(2)-oxide	180-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
17159771-6	2006	RESULTS: Purified CYP enzymes reconstituted with NADPH:CYP reductase oxidized ellipticine to up to five metabolites, 7-hydroxy-, 9-hydroxy-, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N(2)-oxide.	ellipticine n(2)-oxide	180-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
17159771-10	2006	CONCLUSIONS: The results showed that the system of purified CYPs reconstituted with NADPH: CYP reductase proved for ellipticine oxidation provide a true reflection of the situation in the microsomal membrane.	NADP	84-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
17159771-10	2006	CONCLUSIONS: The results showed that the system of purified CYPs reconstituted with NADPH: CYP reductase proved for ellipticine oxidation provide a true reflection of the situation in the microsomal membrane.	ellipticine	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
17164372-0	2006	Effects of repeated green tea catechin administration on human cytochrome P450 activity.	Catechin	30-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
17164372-2	2006	We conducted this clinical study to determine the effect of repeated green tea catechin administration on human cytochrome P450 (CYP) enzyme activities.	Catechin	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
17164372-2	2006	We conducted this clinical study to determine the effect of repeated green tea catechin administration on human cytochrome P450 (CYP) enzyme activities.	Catechin	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-132
16926051-0	2006	Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism.	Eicosanoids	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-18
16926051-1	2006	The cytochrome P450 4F (CYP4F) subfamily has over the last few years come to be recognized for its dual role in modulating the concentrations of eicosanoids during inflammation as well as in the metabolism of clinically significant drugs.	Eicosanoids	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-22
16926051-1	2006	The cytochrome P450 4F (CYP4F) subfamily has over the last few years come to be recognized for its dual role in modulating the concentrations of eicosanoids during inflammation as well as in the metabolism of clinically significant drugs.	Eicosanoids	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-29
16926051-2	2006	The first CYP4F was identified because it catalyzed the hydroxylation of leukotriene B(4) (LTB(4)) and since then many additional members of this subfamily have been documented for their distinct catalytic roles and functional significance.	Leukotriene B4	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-15
16926051-5	2006	From this standpoint variations in relative CYP4F levels in humans may have direct influence on the metabolic outcome through their ability to generate and/or degrade bioactive eicosanoids or therapeutic agents.	Eicosanoids	177-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-49
16926051-6	2006	This review covers the enzymatic characteristics and regulatory properties of human and rodent CYP4F isoforms and their physiological relevance to major pathways in eicosanoid and drug metabolism.	Eicosanoids	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-100
16945988-1	2006	The present study investigated the role of specific human cytochrome P450 (CYP) enzymes in the in vitro metabolism of valproic acid (VPA) by a complementary approach that used individual cDNA-expressed CYP enzymes, chemical inhibitors of specific CYP enzymes, CYP-specific inhibitory monoclonal antibodies (MAbs), individual human hepatic microsomes, and correlational analysis.	Valproic Acid	118-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
16945988-1	2006	The present study investigated the role of specific human cytochrome P450 (CYP) enzymes in the in vitro metabolism of valproic acid (VPA) by a complementary approach that used individual cDNA-expressed CYP enzymes, chemical inhibitors of specific CYP enzymes, CYP-specific inhibitory monoclonal antibodies (MAbs), individual human hepatic microsomes, and correlational analysis.	Valproic Acid	118-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
16945988-1	2006	The present study investigated the role of specific human cytochrome P450 (CYP) enzymes in the in vitro metabolism of valproic acid (VPA) by a complementary approach that used individual cDNA-expressed CYP enzymes, chemical inhibitors of specific CYP enzymes, CYP-specific inhibitory monoclonal antibodies (MAbs), individual human hepatic microsomes, and correlational analysis.	Valproic Acid	133-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
16945988-1	2006	The present study investigated the role of specific human cytochrome P450 (CYP) enzymes in the in vitro metabolism of valproic acid (VPA) by a complementary approach that used individual cDNA-expressed CYP enzymes, chemical inhibitors of specific CYP enzymes, CYP-specific inhibitory monoclonal antibodies (MAbs), individual human hepatic microsomes, and correlational analysis.	Valproic Acid	133-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
16835590-8	2006	CYP4F3 and CYP4F2 catalyse the inactivation of leukotriene B4 (LTB4), a potent mediator of inflammation responsible for recruitment and activation of neutrophils.	Leukotriene B4	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
16940989-1	2006	BACKGROUND AND PURPOSE: The types of hepatic microsomal cytochrome P450 (CYP) isozymes responsible for the metabolism of metformin in humans and rats have not been published to date.	Metformin	121-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
16778795-2	2006	Metabolic transformation of all-trans RA to 4-hydroxylated RA appears to be primarily catalyzed by the cytochrome P450 (CYP) 26AI.	Tretinoin	38-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
16778795-2	2006	Metabolic transformation of all-trans RA to 4-hydroxylated RA appears to be primarily catalyzed by the cytochrome P450 (CYP) 26AI.	Tretinoin	38-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
16778795-2	2006	Metabolic transformation of all-trans RA to 4-hydroxylated RA appears to be primarily catalyzed by the cytochrome P450 (CYP) 26AI.	Tretinoin	59-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
16778795-2	2006	Metabolic transformation of all-trans RA to 4-hydroxylated RA appears to be primarily catalyzed by the cytochrome P450 (CYP) 26AI.	Tretinoin	59-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
16965820-0	2006	New approach to the activation of anti-cancer pro-drugs by metalloporphyrin-based cytochrome P450 mimics in all-aqueous biologically relevant system.	Metalloporphyrins	59-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
16824612-4	2006	Furthermore, mounting evidence points to the role of endogenous CYP metabolites, such as epoxyeicosatrienoic acids (EETs), hydroxyeicosatetraenoic acids (HETEs), prostacyclin (PGI(2)), aldosterone, and sex hormones, in the maintenance of cardiovascular health.	Aldosterone	185-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
16943206-0	2006	Cytochrome P450 active site plasticity: attenuation of imidazole binding in cytochrome P450(cam) by an L244A mutation.	imidazole	55-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16943206-0	2006	Cytochrome P450 active site plasticity: attenuation of imidazole binding in cytochrome P450(cam) by an L244A mutation.	imidazole	55-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
16857327-0	2006	Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028.	Krypton	107-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
16857327-2	2006	This study was performed to characterize the cytochrome P450 (CYP) enzymes that are involved in the metabolism of KR-33028.	Krypton	114-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
16857327-2	2006	This study was performed to characterize the cytochrome P450 (CYP) enzymes that are involved in the metabolism of KR-33028.	Krypton	114-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
16857327-4	2006	Among the nine c-DNA expressed CYP isoforms tested, KR-33028 was 5-hydroxylated by CYP3A4 and 7-hydroxylated by CYP1A2, CYP3A4, and CYP2C19.	Krypton	52-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
16857327-7	2006	Correlation analysis between the known CYP enzyme activities and the rates of the formation of 5-hydroxy- and 7-hydroxy-KR-33028 in the 16 human liver microsomes has showed significant correlations with CYP3A4-mediated midazolam 1"-hydroxylation and CYP1A2-mediated phenacetin O-deethylation, respectively.	5-hydroxy- and 7-hydroxy-kr	95-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
16857327-7	2006	Correlation analysis between the known CYP enzyme activities and the rates of the formation of 5-hydroxy- and 7-hydroxy-KR-33028 in the 16 human liver microsomes has showed significant correlations with CYP3A4-mediated midazolam 1"-hydroxylation and CYP1A2-mediated phenacetin O-deethylation, respectively.	Midazolam	219-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
16857327-7	2006	Correlation analysis between the known CYP enzyme activities and the rates of the formation of 5-hydroxy- and 7-hydroxy-KR-33028 in the 16 human liver microsomes has showed significant correlations with CYP3A4-mediated midazolam 1"-hydroxylation and CYP1A2-mediated phenacetin O-deethylation, respectively.	Phenacetin	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
16857327-9	2006	The kinetics of the major biotransformation of KR-33028 were studied: CYP3A4 mediated the formation of 5-hydroxy-KR-33028 from KR-33028 with Cl(int)=0.22microl/min/pmol CYP.	5-hydroxy-kr	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
16857327-9	2006	The kinetics of the major biotransformation of KR-33028 were studied: CYP3A4 mediated the formation of 5-hydroxy-KR-33028 from KR-33028 with Cl(int)=0.22microl/min/pmol CYP.	Krypton	47-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
16857327-10	2006	The intrinsic clearance for 7-hydroxy-KR-33028 formation by CYP1A2, CYP2C19, and CYP3A4 were 0.26, 0.19, and 0.03microl/min/pmol CYP, respectively.	7-hydroxy-kr	28-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	255-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	255-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	255-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
16772608-2	2006	To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d.	Clopidogrel	255-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
16940989-1	2006	BACKGROUND AND PURPOSE: The types of hepatic microsomal cytochrome P450 (CYP) isozymes responsible for the metabolism of metformin in humans and rats have not been published to date.	Metformin	121-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
16927149-0	2006	Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.	Rabeprazole	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
17018623-8	2006	Inhibition of SULTs and cytochrome P450 (CYP) enzymes by natural flavonoids blocked the antiproliferative activity of AF and the formation of AF-DNA adducts.	Flavonoids	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
17018623-8	2006	Inhibition of SULTs and cytochrome P450 (CYP) enzymes by natural flavonoids blocked the antiproliferative activity of AF and the formation of AF-DNA adducts.	Flavonoids	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
17018623-10	2006	Metabolism studies showed that AF can be oxidized by CYP at two amino groups to form N-hydroxyl metabolites that are substrates for bioactivation by SULTs.	n-hydroxyl	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	138-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	138-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	N-desmethylvenlafaxine	211-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	N-desmethylvenlafaxine	211-233	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	N-desmethylvenlafaxine	235-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	N-desmethylvenlafaxine	235-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	N-acetylserotonin	84-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
17197724-1	2006	Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of DNA adducts mediated by cytochrome P450 (CYP).	ellipticine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-186
17197724-1	2006	Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of DNA adducts mediated by cytochrome P450 (CYP).	ellipticine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
17225875-5	2006	CYP enzymes, including CYP2D6, participate in the metabolism of some porphyrinogenic drugs, leading to the deregulation of heme biosynthesis.	Heme	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
16914311-6	2006	These versions suggest that some cytochrome P-450"s catalyze the introduction of both oxygen atoms of dioxygen into an appropriate sterol precursor.	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
16914311-6	2006	These versions suggest that some cytochrome P-450"s catalyze the introduction of both oxygen atoms of dioxygen into an appropriate sterol precursor.	Oxygen	102-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
16914311-6	2006	These versions suggest that some cytochrome P-450"s catalyze the introduction of both oxygen atoms of dioxygen into an appropriate sterol precursor.	Sterols	131-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	Melatonin	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	Melatonin	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	6-sulfatoxymelatonin	31-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	N-acetylserotonin	84-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	6-sulfatoxymelatonin	31-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	amt6s	54-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	amt6s	54-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	N-acetylserotonin	65-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
17003850-1	2006	The metabolism of melatonin to 6-sulphatoxymelatonin (aMT6S) and N-acetylserotonin (NAS) is catalyzed by cytochrome-P450 (CYP) isozymes CYP1A2 and CYP2C19 respectively.	N-acetylserotonin	65-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
16380164-1	2006	Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
16380164-3	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the nitric oxide and prostacyclin (PGI2)-independent vasodilatation of several vascular beds and EETs have been identified as endothelium-derived hyperpolarizing factors (EDHFs).	Nitric Oxide	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16380164-3	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the nitric oxide and prostacyclin (PGI2)-independent vasodilatation of several vascular beds and EETs have been identified as endothelium-derived hyperpolarizing factors (EDHFs).	Epoprostenol	101-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16380164-3	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the nitric oxide and prostacyclin (PGI2)-independent vasodilatation of several vascular beds and EETs have been identified as endothelium-derived hyperpolarizing factors (EDHFs).	Epoprostenol	115-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16380164-3	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the nitric oxide and prostacyclin (PGI2)-independent vasodilatation of several vascular beds and EETs have been identified as endothelium-derived hyperpolarizing factors (EDHFs).	Biotin	242-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16380164-3	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the nitric oxide and prostacyclin (PGI2)-independent vasodilatation of several vascular beds and EETs have been identified as endothelium-derived hyperpolarizing factors (EDHFs).	edhfs	251-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16925400-3	2006	Upon binding of a substrate molecule (e.g., camphor), the absorption band of cytochrome P450 shifts to shorter wavelength.	Camphor	44-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
16925400-4	2006	The event of camphor binding to a nanoparticle surface modified with cytochrome P450 protein receptors is monitored using UV-vis spectroscopy.	Camphor	13-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
16802166-0	2006	Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.	Buprenorphine	64-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
16867264-0	2006	Influences of 3-methylcholanthrene, phenobarbital and dexamethasone on xenobiotic metabolizing-related cytochrome P450 enzymes and steroidogenesis in human fetal adrenal cortical cells.	Methylcholanthrene	14-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
16867264-0	2006	Influences of 3-methylcholanthrene, phenobarbital and dexamethasone on xenobiotic metabolizing-related cytochrome P450 enzymes and steroidogenesis in human fetal adrenal cortical cells.	Phenobarbital	36-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
16867264-0	2006	Influences of 3-methylcholanthrene, phenobarbital and dexamethasone on xenobiotic metabolizing-related cytochrome P450 enzymes and steroidogenesis in human fetal adrenal cortical cells.	Dexamethasone	54-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
16867264-11	2006	CONCLUSION: 3-Methylcholanthrene, phenobarbital or dexamethasone could interfere with the synthesis of cortisol, aldosterone and progesterone in primary human fetal adrenal cortical cells, which likely act through xenobiotic metabolizing-related cytochrome P450 isoform activation.	Methylcholanthrene	12-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-261
16867264-11	2006	CONCLUSION: 3-Methylcholanthrene, phenobarbital or dexamethasone could interfere with the synthesis of cortisol, aldosterone and progesterone in primary human fetal adrenal cortical cells, which likely act through xenobiotic metabolizing-related cytochrome P450 isoform activation.	Phenobarbital	34-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-261
16867264-11	2006	CONCLUSION: 3-Methylcholanthrene, phenobarbital or dexamethasone could interfere with the synthesis of cortisol, aldosterone and progesterone in primary human fetal adrenal cortical cells, which likely act through xenobiotic metabolizing-related cytochrome P450 isoform activation.	Dexamethasone	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-261
16867264-11	2006	CONCLUSION: 3-Methylcholanthrene, phenobarbital or dexamethasone could interfere with the synthesis of cortisol, aldosterone and progesterone in primary human fetal adrenal cortical cells, which likely act through xenobiotic metabolizing-related cytochrome P450 isoform activation.	Hydrocortisone	103-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-261
16867264-11	2006	CONCLUSION: 3-Methylcholanthrene, phenobarbital or dexamethasone could interfere with the synthesis of cortisol, aldosterone and progesterone in primary human fetal adrenal cortical cells, which likely act through xenobiotic metabolizing-related cytochrome P450 isoform activation.	Progesterone	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-261
16890580-1	2006	OBJECTIVE: Our objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate-binding cassette transporters (ABCB1 and ABCG2) and enzymes (cytochrome P450 [CYP] 2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) of putative relevance for imatinib.	Imatinib Mesylate	66-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-246
16802166-1	2006	OBJECTIVE: The aim of the present study was to estimate the drug interaction potential of psychtropic medication on buprenorphine (BUP) N-dealkylation using cDNA-expressed cytochrome P450 (CYP) enzymes.	Buprenorphine	116-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
16802166-1	2006	OBJECTIVE: The aim of the present study was to estimate the drug interaction potential of psychtropic medication on buprenorphine (BUP) N-dealkylation using cDNA-expressed cytochrome P450 (CYP) enzymes.	Buprenorphine	116-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-192
16820944-15	2006	Inhibition of proinflammatory cytokines by curcumin may provide a novel approach to modulate the hepatic CYP function in sepsis.	Curcumin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
16937919-17	2006	Bz also inhibits the metabolism of several xenobiotics biotransformed by the cytochrome P450 system and its reactive metabolites react with fetal components in vivo.	benzonidazole	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
16494911-7	2006	The present data indicating alterations in the expression of xenobiotic metabolizing CYPs during development following prenatal exposure to deltamethrin may be of significance as these CYP enzymes are not only involved in the neurobehavioral toxicity of deltamethrin but have a role in regulating the levels of ligands that modulate growth, differentiation, and neuroendocrine functions.	decamethrin	140-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
16494911-7	2006	The present data indicating alterations in the expression of xenobiotic metabolizing CYPs during development following prenatal exposure to deltamethrin may be of significance as these CYP enzymes are not only involved in the neurobehavioral toxicity of deltamethrin but have a role in regulating the levels of ligands that modulate growth, differentiation, and neuroendocrine functions.	decamethrin	254-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
16639745-1	2006	To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin.	Warfarin	170-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
16764555-2	2006	Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids.	Arachidonic Acid	142-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-61
16764555-2	2006	Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids.	Arachidonic Acid	142-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
16764555-2	2006	Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids.	Eicosanoids	184-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-61
16764555-2	2006	Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids.	Eicosanoids	184-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
16782090-0	2006	Identification of the cytochrome P450 enzymes responsible for the omega-hydroxylation of phytanic acid.	Phytanic Acid	89-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
16782090-3	2006	With the use of specific inhibitors we now show that members of the cytochrome P450 (CYP450) family 4 class are responsible for phytanic acid omega-hydroxylation.	Phytanic Acid	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
16782090-3	2006	With the use of specific inhibitors we now show that members of the cytochrome P450 (CYP450) family 4 class are responsible for phytanic acid omega-hydroxylation.	Phytanic Acid	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-91
16782090-4	2006	Incubations with microsomes containing human recombinant CYP450s (Supersomes) revealed that multiple CYP450 enzymes of the family 4 class are able to omega-hydroxylate phytanic acid with the following order of efficiency: CYP4F3A&gt;CYP4F3B&gt;CYP4F2&gt;CYP4A11.	Phytanic Acid	168-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
16782090-4	2006	Incubations with microsomes containing human recombinant CYP450s (Supersomes) revealed that multiple CYP450 enzymes of the family 4 class are able to omega-hydroxylate phytanic acid with the following order of efficiency: CYP4F3A&gt;CYP4F3B&gt;CYP4F2&gt;CYP4A11.	Phytanic Acid	168-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
16886668-1	2006	Like most pharmaceutical agents, vitamin D analogs are subject to hepatic metabolism by a variety of cytochrome P450 (CYP)-based systems.	Vitamin D	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
16886668-1	2006	Like most pharmaceutical agents, vitamin D analogs are subject to hepatic metabolism by a variety of cytochrome P450 (CYP)-based systems.	Vitamin D	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
16639745-1	2006	To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin.	Warfarin	170-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
16639745-1	2006	To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin.	Warfarin	274-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
16639745-1	2006	To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin.	Warfarin	274-282	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Oxygen	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
16864505-0	2006	Metabolism of cytostatically active 6-aminobenzo[c]phenanthridines by human and porcine hepatic microsomes and recombinant cytochrome P450 enzymes.	6-aminobenzo[c]phenanthridines	36-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
16713055-6	2006	These observations suggest that NOS2 can behave similarly to cytochrome P-450 in the catalysis of acetaldehyde formation from ethanol via the generation of alpha-hydroxyethyl radical when L-arginine is present.	Acetaldehyde	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16713055-6	2006	These observations suggest that NOS2 can behave similarly to cytochrome P-450 in the catalysis of acetaldehyde formation from ethanol via the generation of alpha-hydroxyethyl radical when L-arginine is present.	Ethanol	126-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16713055-6	2006	These observations suggest that NOS2 can behave similarly to cytochrome P-450 in the catalysis of acetaldehyde formation from ethanol via the generation of alpha-hydroxyethyl radical when L-arginine is present.	alpha-hydroxyethyl radical	156-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16713055-6	2006	These observations suggest that NOS2 can behave similarly to cytochrome P-450 in the catalysis of acetaldehyde formation from ethanol via the generation of alpha-hydroxyethyl radical when L-arginine is present.	Arginine	188-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Oxygen	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Oxygen	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-261
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Arachidonic Acid	152-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Arachidonic Acid	152-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Arachidonic Acid	152-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-261
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Cimetidine	244-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Cimetidine	244-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
16641218-1	2006	Animal studies have shown that induction of cytochrome P450 (CYP) in the lung by oxygen exposure may result in the release of free radical oxidants and arachidonic acid metabolites, which can cause lung injury that is reduced by treatment with cimetidine, a CYP inhibitor.	Cimetidine	244-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-261
16510126-0	2006	Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.	5-methoxy-N,N-diisopropyltryptamine	24-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
16607661-2	2006	We describe the use of the dynamic light-scattering technique (DLS) to determine the stoichiometry of the protein cytochrome P450(BSbeta) attached to CdS and CdSe quantum dots (QDs).	Cadmium	150-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-137
16607661-2	2006	We describe the use of the dynamic light-scattering technique (DLS) to determine the stoichiometry of the protein cytochrome P450(BSbeta) attached to CdS and CdSe quantum dots (QDs).	cdse	158-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-137
16467135-1	2006	The objective of this study was to evaluate the duration of oral pleconaril (a picornavirus inhibitor) effect on intestinal and hepatic cytochrome P450 (P450) 3A activity as assessed by oral midazolam.	pleconaril	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-161
16365879-7	2006	Furthermore, the UVB-dependent induction of 24-hydroxylase was blocked by the cytochrome-P450 inhibitor ketoconazole.	Ketoconazole	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
16527260-0	2006	Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	75-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16527260-0	2006	Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	124-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
16318905-0	2006	Characterization of human liver cytochrome P450 enzymes involved in the metabolism of rutaecarpine.	rutecarpine	86-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
16318905-3	2006	The specific cytochrome P450 (CYP) isozymes responsible for rutaecarpine metabolites were identified using the combination of chemical inhibition, immuno-inhibition and metabolism by cDNA expressed CYP enzymes.	rutecarpine	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
16318905-3	2006	The specific cytochrome P450 (CYP) isozymes responsible for rutaecarpine metabolites were identified using the combination of chemical inhibition, immuno-inhibition and metabolism by cDNA expressed CYP enzymes.	rutecarpine	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
16318905-3	2006	The specific cytochrome P450 (CYP) isozymes responsible for rutaecarpine metabolites were identified using the combination of chemical inhibition, immuno-inhibition and metabolism by cDNA expressed CYP enzymes.	rutecarpine	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-201
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	232-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	232-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
16750462-7	2006	In vitro studies have indicated that the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; therefore, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone.	Eszopiclone	232-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
16525816-0	2006	Investigation of sarizotan"s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.	sarizotan	17-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
16609933-0	2006	Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4.	Propafenone	78-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	Epoxy Compounds	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	Epoxy Compounds	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
16490839-1	2006	Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases.	Arachidonic Acid	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
16490839-2	2006	The activation of CYP epoxygenases in endothelial cells is an important step in the NO and prostacyclin-independent vasodilatation of several vascular beds, and EETs have been identified as an endothelium-derived hyperpolarizing factor.	Epoprostenol	91-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
16443667-0	2006	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).	lonafarnib	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
16525816-2	2006	We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate the risk of CYP-related drug-drug interactions.	sarizotan	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
16525816-2	2006	We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate the risk of CYP-related drug-drug interactions.	sarizotan	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-112
16497287-3	2006	We showed that beta-carotene at 20 microM significantly enhanced NNK-induced DNA strand breaks and 7-mGua levels by 90% (p &lt; 0.05) and 70% (p &lt; 0.05), respectively, and that the effect of beta-carotene was associated with an increased metabolism of NNK by CYP because the concomitant addition of 1-aminobenzotriazole, a CYP inhibitor, with beta-carotene to cells strongly inhibited NNK-induced DNA strand breaks.	beta Carotene	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
16483564-0	2006	Vitamins C and E protect hepatic cytochrome P450 dysfunction induced by polymicrobial sepsis.	Carbon	9-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
16497287-3	2006	We showed that beta-carotene at 20 microM significantly enhanced NNK-induced DNA strand breaks and 7-mGua levels by 90% (p &lt; 0.05) and 70% (p &lt; 0.05), respectively, and that the effect of beta-carotene was associated with an increased metabolism of NNK by CYP because the concomitant addition of 1-aminobenzotriazole, a CYP inhibitor, with beta-carotene to cells strongly inhibited NNK-induced DNA strand breaks.	beta Carotene	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	326-329
16251477-1	2006	Arachidonic acid (AA) is a substrate for a variety of proinflammatory mediators, which are generated by cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P-450 (CYP450) enzymes.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-170
16251477-1	2006	Arachidonic acid (AA) is a substrate for a variety of proinflammatory mediators, which are generated by cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P-450 (CYP450) enzymes.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-178
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	5,6-epoxy-8,11,14-eicosatrienoic acid	162-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	5,6-epoxy-8,11,14-eicosatrienoic acid	192-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	205-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	238-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	5-(s)-hydroperoxyeicosatetrenoic acid	277-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16251477-3	2006	We previously found that mechanical strain generated by subjecting lymphocytes to hypotonic challenge triggered AA production and that two CYP450 products of AA, 5,6-epoxyeicosatrienoic acid (5,6-EET) and 20-hydroxyeicosatetraenoic acid (20-HETE), as well as a product of LOX, 5-(S)-hydroperoxyeicosatetrenoic acid (5-HPETE), induced Ca(2+) entry into primary B cells.	arachidonic acid 5-hydroperoxide	316-323	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-145
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Carbamazepine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Carbamazepine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Primidone	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Phenytoin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Phenytoin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Phenobarbital	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Phenobarbital	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16487217-4	2006	Carbamazepine, phenytoin, phenobarbital and primidone induce many cytochrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce drastically the serum concentration of associated drugs which are substrates of the same enzymes.	Primidone	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
16436457-4	2006	FLJ39501 encodes a protein which was found to be a cytochrome P450, family 4, subfamily F, polypeptide 2 homolog of the leukotriene B4-omega-hydroxylase (CYP4F2) and could catalyze the 20-hydroxylation of trioxilin A3 from the 12(R)-lipoxygenase pathway.	flj39501	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-152
16537715-4	2006	Therefore, we assessed the human cytochrome P450-dependent oxidation of estrone using substrate concentrations that more closely approximate the maximum expected concentrations in breast tissue.	Estrone	72-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
16537715-5	2006	The in vitro metabolism of estrone by recombinant human cytochrome P450 enzymes and human liver microsomes was studied.	Estrone	27-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
16436457-4	2006	FLJ39501 encodes a protein which was found to be a cytochrome P450, family 4, subfamily F, polypeptide 2 homolog of the leukotriene B4-omega-hydroxylase (CYP4F2) and could catalyze the 20-hydroxylation of trioxilin A3 from the 12(R)-lipoxygenase pathway.	8,11,12-trihydroxy-5,9,14-eicosatrienoic acid	205-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-152
16470567-10	2006	Imatinib metabolites were produced in microsomal incubations containing CYP isozymes.	Imatinib Mesylate	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
16484569-1	2006	Eight water-soluble components of aged garlic extract were evaluated to assess their potential to inhibit the activity of human cytochrome-P450 (CYP) enzymes.	Water	6-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-143
16484569-1	2006	Eight water-soluble components of aged garlic extract were evaluated to assess their potential to inhibit the activity of human cytochrome-P450 (CYP) enzymes.	Water	6-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
16157466-1	2006	The oxidative metabolism of coumarin via several human cytochrome P450 (CYP) enzymes from families CYP1, CYP2 and CYP3 is rationalized in terms of molecular modelling studies carried out on the key interactions with various amino acid residues in the relevant active sites.	coumarin	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
16289744-5	2006	This review focuses on the flavonoid effects on cytochrome P450 (CYP) enzymes involved in the activation of procarcinogens and phase II enzymes, largely responsible for the detoxification of carcinogens.	Flavonoids	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
16289744-5	2006	This review focuses on the flavonoid effects on cytochrome P450 (CYP) enzymes involved in the activation of procarcinogens and phase II enzymes, largely responsible for the detoxification of carcinogens.	Flavonoids	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
16157466-1	2006	The oxidative metabolism of coumarin via several human cytochrome P450 (CYP) enzymes from families CYP1, CYP2 and CYP3 is rationalized in terms of molecular modelling studies carried out on the key interactions with various amino acid residues in the relevant active sites.	coumarin	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
16289744-6	2006	A number of naturally occurring flavonoids have been shown to modulate the CYP450 system, including the induction of specific CYP isozymes, and the activation or inhibition of these enzymes.	Flavonoids	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
16719544-2	2006	In an attempt to explain this variability, three pharmacokinetic studies were carried out in healthy volunteers to investigate the relationship between exposure to gefitinib and cytochrome P450 (CYP) 3A phenotype (study 1), CYP3A5 genotype (study 2) and CYP2D6 genotype (study 3).	Gefitinib	164-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-193
16401082-0	2006	Radical intermediates in the catalytic oxidation of hydrocarbons by bacterial and human cytochrome P450 enzymes.	radical	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
16401082-0	2006	Radical intermediates in the catalytic oxidation of hydrocarbons by bacterial and human cytochrome P450 enzymes.	Hydrocarbons	52-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
16280384-0	2006	Aflatoxin B1 alters the expression of p53 in cytochrome P450-expressing human lung cells.	Aflatoxin B1	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
16719544-0	2006	Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.	Gefitinib	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
16719544-2	2006	In an attempt to explain this variability, three pharmacokinetic studies were carried out in healthy volunteers to investigate the relationship between exposure to gefitinib and cytochrome P450 (CYP) 3A phenotype (study 1), CYP3A5 genotype (study 2) and CYP2D6 genotype (study 3).	Gefitinib	164-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
16802848-10	2006	Clearance is hepatic via N-oxidation by the hepatic cytochrome P450 (CYP) isoenzymes, CYP2C19, CYP2C9 and CYP3A4.	Nitrogen	25-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
16802848-10	2006	Clearance is hepatic via N-oxidation by the hepatic cytochrome P450 (CYP) isoenzymes, CYP2C19, CYP2C9 and CYP3A4.	Nitrogen	25-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
16536934-1	2006	OBJECTIVES: To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex.	Chloroquine	170-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
17181373-5	2006	For example, protease inhibitors often must be avoided if the potent CYP inducer rifampicin is co-administered.	Rifampin	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
16379042-0	2006	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.	Trabectedin	87-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
16379042-0	2006	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.	trabectidin	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
16379042-2	2006	To assess the biotransformation and CYP reaction phenotype and their potential implications for human pharmacology and toxicology, the in vitro metabolism of ET-743 was characterized using incubations with human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes.CYP supersomes and liver microsomes showed that ET-743 was metabolized mainly by CYP3A4, but also by CYP2C9, 2C19, 2D6, and 2E1.	Trabectedin	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
16379042-2	2006	To assess the biotransformation and CYP reaction phenotype and their potential implications for human pharmacology and toxicology, the in vitro metabolism of ET-743 was characterized using incubations with human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes.CYP supersomes and liver microsomes showed that ET-743 was metabolized mainly by CYP3A4, but also by CYP2C9, 2C19, 2D6, and 2E1.	Trabectedin	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-247
16379042-2	2006	To assess the biotransformation and CYP reaction phenotype and their potential implications for human pharmacology and toxicology, the in vitro metabolism of ET-743 was characterized using incubations with human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes.CYP supersomes and liver microsomes showed that ET-743 was metabolized mainly by CYP3A4, but also by CYP2C9, 2C19, 2D6, and 2E1.	Trabectedin	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-252
16379042-2	2006	To assess the biotransformation and CYP reaction phenotype and their potential implications for human pharmacology and toxicology, the in vitro metabolism of ET-743 was characterized using incubations with human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes.CYP supersomes and liver microsomes showed that ET-743 was metabolized mainly by CYP3A4, but also by CYP2C9, 2C19, 2D6, and 2E1.	Trabectedin	158-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-252
16379042-7	2006	ET-743 was more extensively metabolized when CYP activity was combined with phase II enzymes UGT and glutathione-S-transferase (GST), indicating that CYP, UGT, and GST simultaneously metabolize ET-743 in the S9 fraction.	Trabectedin	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
16379042-7	2006	ET-743 was more extensively metabolized when CYP activity was combined with phase II enzymes UGT and glutathione-S-transferase (GST), indicating that CYP, UGT, and GST simultaneously metabolize ET-743 in the S9 fraction.	Trabectedin	0-6	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
16379042-7	2006	ET-743 was more extensively metabolized when CYP activity was combined with phase II enzymes UGT and glutathione-S-transferase (GST), indicating that CYP, UGT, and GST simultaneously metabolize ET-743 in the S9 fraction.	Trabectedin	194-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
16379042-7	2006	ET-743 was more extensively metabolized when CYP activity was combined with phase II enzymes UGT and glutathione-S-transferase (GST), indicating that CYP, UGT, and GST simultaneously metabolize ET-743 in the S9 fraction.	Trabectedin	194-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
16719370-4	2006	CYP are b-type cytochromes, containing protoporphyrin IX as the prosthetic group.	protoporphyrin IX	39-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
16719370-6	2006	In its oxidized, or ferric state, CYP exists as an equilibrium mixture of high- and low-spin configurations, each with distinctive UV/Vis absorption peaks.	Ferric enterobactin ion	20-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
16497109-2	2006	Systemic blood pressure, after inhibitory intervention in arachidonic acid metabolism cytochrome P-450 inhibition by miconazole 0.5 mg/100 g b.w.	Arachidonic Acid	58-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
16497109-2	2006	Systemic blood pressure, after inhibitory intervention in arachidonic acid metabolism cytochrome P-450 inhibition by miconazole 0.5 mg/100 g b.w.	Miconazole	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
16944963-5	2006	Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance.	Simvastatin	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
16944963-5	2006	Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance.	Simvastatin	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	199-202
16338087-2	2006	The first step in steroidogenesis involves the delivery of free cholesterol to the inner mitochondrial membrane where it can be converted into pregnenolone by the enzyme cytochrome P450side chain cleavage.	Cholesterol	64-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-185
16338087-2	2006	The first step in steroidogenesis involves the delivery of free cholesterol to the inner mitochondrial membrane where it can be converted into pregnenolone by the enzyme cytochrome P450side chain cleavage.	Pregnenolone	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-185
16541400-0	2006	Bilirubin degradation by uncoupled cytochrome P450.	Bilirubin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
16541400-3	2006	Degradation of bilirubin takes place (a) on interaction with oxidative free radicals and (b) when cytochrome P450 (CYP) enzymes are uncoupled by polyhalogenated substrate analogues.	Bilirubin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
16541400-3	2006	Degradation of bilirubin takes place (a) on interaction with oxidative free radicals and (b) when cytochrome P450 (CYP) enzymes are uncoupled by polyhalogenated substrate analogues.	Bilirubin	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
16541400-10	2006	Fe-EDTA/H2O2 and uncoupled CYP(Fe=O) may both initiate the reaction, the latter in an attempt to reduce the ferryl oxygen to water.	Oxygen	115-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
16541400-10	2006	Fe-EDTA/H2O2 and uncoupled CYP(Fe=O) may both initiate the reaction, the latter in an attempt to reduce the ferryl oxygen to water.	Water	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
16536934-1	2006	OBJECTIVES: To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex.	Amodiaquine	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
16536934-1	2006	OBJECTIVES: To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex.	Proguanil	212-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
16143297-0	2005	Steroid hydroxylations: a paradigm for cytochrome P450 catalyzed mammalian monooxygenation reactions.	Steroids	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
16183271-0	2005	A thiolate ligand on a cytochrome P-450 mimic permits the use of simple environmentally benign oxidants for biomimetic steroid hydroxylation in water.	thiolate	2-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
16183271-0	2005	A thiolate ligand on a cytochrome P-450 mimic permits the use of simple environmentally benign oxidants for biomimetic steroid hydroxylation in water.	Steroids	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
16183271-0	2005	A thiolate ligand on a cytochrome P-450 mimic permits the use of simple environmentally benign oxidants for biomimetic steroid hydroxylation in water.	Water	144-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
16137656-0	2005	First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives.	Thiophenes	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
16137656-5	2005	These results provide the first evidence that cytochrome P450 may catalyze the oxidation of thiophene compounds with the simultaneous formation of two reactive intermediates, a thiophene-S-oxide and a thiophene epoxide.	Thiophenes	92-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
16375696-1	2005	Cytochrome P450 (CYP) is a group of enzymes that metabolize drugs to a more water-soluble form, rendering them available for renal excretion.	Water	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16137656-5	2005	These results provide the first evidence that cytochrome P450 may catalyze the oxidation of thiophene compounds with the simultaneous formation of two reactive intermediates, a thiophene-S-oxide and a thiophene epoxide.	thiophene-s-oxide	177-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
16137656-5	2005	These results provide the first evidence that cytochrome P450 may catalyze the oxidation of thiophene compounds with the simultaneous formation of two reactive intermediates, a thiophene-S-oxide and a thiophene epoxide.	thiophene epoxide	201-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
16207711-1	2005	Cytochrome P450 (P450) 2A6 is an important human enzyme involved in the metabolism of many xenobiotic chemicals including coumarin, indole, nicotine, and carcinogenic nitrosamines.	coumarin	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
16207711-1	2005	Cytochrome P450 (P450) 2A6 is an important human enzyme involved in the metabolism of many xenobiotic chemicals including coumarin, indole, nicotine, and carcinogenic nitrosamines.	indole	132-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
16207711-1	2005	Cytochrome P450 (P450) 2A6 is an important human enzyme involved in the metabolism of many xenobiotic chemicals including coumarin, indole, nicotine, and carcinogenic nitrosamines.	Nicotine	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
16207711-1	2005	Cytochrome P450 (P450) 2A6 is an important human enzyme involved in the metabolism of many xenobiotic chemicals including coumarin, indole, nicotine, and carcinogenic nitrosamines.	Nitrosamines	167-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
16126163-5	2005	Oxy-I resembles the ferrous oxygen complex known for cytochrome P450, whereas oxy-II appears to be locked in the superoxide form.	oxy-i	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-84
16126163-5	2005	Oxy-I resembles the ferrous oxygen complex known for cytochrome P450, whereas oxy-II appears to be locked in the superoxide form.	ferrous oxygen	20-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-84
16126163-5	2005	Oxy-I resembles the ferrous oxygen complex known for cytochrome P450, whereas oxy-II appears to be locked in the superoxide form.	Superoxides	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-84
16322314-5	2005	Studies with cDNA-expressed human cytochrome P450 enzymes revealed that BPU was metabolized predominantly by CYP3A4 and CYP1A1 but was also a substrate for CYP2C8, CYP2D6, CYP3A5, and CYP3A7.	bpu	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
16322314-12	2005	Thus, we conclude that (a) CYP3A4 and CYP1A1 are the predominant cytochrome P450 enzymes that catalyze BPU metabolism, (b) BPU is metabolized to two cytotoxic and four noncytotoxic metabolites, and (c) ritonavir inhibits BPU metabolism to improve the systemic exposure to BPU without altering cumulative exposure to BPU and the cytotoxic metabolites.	bpu	103-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16322314-12	2005	Thus, we conclude that (a) CYP3A4 and CYP1A1 are the predominant cytochrome P450 enzymes that catalyze BPU metabolism, (b) BPU is metabolized to two cytotoxic and four noncytotoxic metabolites, and (c) ritonavir inhibits BPU metabolism to improve the systemic exposure to BPU without altering cumulative exposure to BPU and the cytotoxic metabolites.	Ritonavir	202-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16322314-12	2005	Thus, we conclude that (a) CYP3A4 and CYP1A1 are the predominant cytochrome P450 enzymes that catalyze BPU metabolism, (b) BPU is metabolized to two cytotoxic and four noncytotoxic metabolites, and (c) ritonavir inhibits BPU metabolism to improve the systemic exposure to BPU without altering cumulative exposure to BPU and the cytotoxic metabolites.	bpu	123-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16322314-12	2005	Thus, we conclude that (a) CYP3A4 and CYP1A1 are the predominant cytochrome P450 enzymes that catalyze BPU metabolism, (b) BPU is metabolized to two cytotoxic and four noncytotoxic metabolites, and (c) ritonavir inhibits BPU metabolism to improve the systemic exposure to BPU without altering cumulative exposure to BPU and the cytotoxic metabolites.	bpu	123-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16322314-12	2005	Thus, we conclude that (a) CYP3A4 and CYP1A1 are the predominant cytochrome P450 enzymes that catalyze BPU metabolism, (b) BPU is metabolized to two cytotoxic and four noncytotoxic metabolites, and (c) ritonavir inhibits BPU metabolism to improve the systemic exposure to BPU without altering cumulative exposure to BPU and the cytotoxic metabolites.	bpu	123-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16375696-1	2005	Cytochrome P450 (CYP) is a group of enzymes that metabolize drugs to a more water-soluble form, rendering them available for renal excretion.	Water	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
16202979-2	2005	It has been reported that the metabolic activation of PAHs by cytochrome P450 (CYP) is an important step for PAH-induced atherosclerosis.	Polycyclic Aromatic Hydrocarbons	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
16291720-1	2005	Recent studies suggest that cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) elicit cell proliferation and promote angiogenesis.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
16291720-1	2005	Recent studies suggest that cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) elicit cell proliferation and promote angiogenesis.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
16291720-1	2005	Recent studies suggest that cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) elicit cell proliferation and promote angiogenesis.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
16291720-1	2005	Recent studies suggest that cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) elicit cell proliferation and promote angiogenesis.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
16291720-4	2005	In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE).	Oligonucleotides	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
16291720-4	2005	In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE).	Oligonucleotides	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
16291720-4	2005	In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE).	N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide	189-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
16291720-4	2005	In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE).	14,15-episulfide eicosatrienoic acid	220-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
16291720-4	2005	In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE).	14,15-episulfide eicosatrienoic acid	220-253	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-82
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Ergosterol	33-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Ergosterol	33-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-82
16202979-2	2005	It has been reported that the metabolic activation of PAHs by cytochrome P450 (CYP) is an important step for PAH-induced atherosclerosis.	Polycyclic Aromatic Hydrocarbons	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
16202979-2	2005	It has been reported that the metabolic activation of PAHs by cytochrome P450 (CYP) is an important step for PAH-induced atherosclerosis.	Polycyclic Aromatic Hydrocarbons	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
16202979-2	2005	It has been reported that the metabolic activation of PAHs by cytochrome P450 (CYP) is an important step for PAH-induced atherosclerosis.	Polycyclic Aromatic Hydrocarbons	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
16243813-0	2005	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.	Midazolam	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
16236141-3	2005	In vitro and in vivo data suggest that the metabolism of fluoxetine to norfluoxetine is stereoselective and mediated, at least in part, by the polymorphic cytochrome P450 (CYP) isoenzymes CYP2D6, CYP2C9 and CYP2C19.	Fluoxetine	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
16236141-3	2005	In vitro and in vivo data suggest that the metabolism of fluoxetine to norfluoxetine is stereoselective and mediated, at least in part, by the polymorphic cytochrome P450 (CYP) isoenzymes CYP2D6, CYP2C9 and CYP2C19.	Fluoxetine	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
16236141-3	2005	In vitro and in vivo data suggest that the metabolism of fluoxetine to norfluoxetine is stereoselective and mediated, at least in part, by the polymorphic cytochrome P450 (CYP) isoenzymes CYP2D6, CYP2C9 and CYP2C19.	norfluoxetine	71-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
16236141-3	2005	In vitro and in vivo data suggest that the metabolism of fluoxetine to norfluoxetine is stereoselective and mediated, at least in part, by the polymorphic cytochrome P450 (CYP) isoenzymes CYP2D6, CYP2C9 and CYP2C19.	norfluoxetine	71-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-175
16300378-0	2005	Bioactivation of dibrominated biphenyls by cytochrome P450 activity to metabolites with estrogenic activity and estrogen sulfotransferase inhibition capacity.	diphenyl	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
16243813-1	2005	PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe.	Midazolam	169-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
16243813-1	2005	PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe.	Midazolam	169-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
16162970-3	2005	In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and 2E1, and the phase II enzymes uridine diphosphoglucuronosyl transferase and glutathione-S-transferase.	Trabectedin	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16162970-3	2005	In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and 2E1, and the phase II enzymes uridine diphosphoglucuronosyl transferase and glutathione-S-transferase.	Trabectedin	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
16162970-5	2005	Therefore, the effect of CYP and phase II activity on the cytotoxicity of ET-743 was investigated in vitro in a human cell line model system.	Trabectedin	74-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
16162970-6	2005	The effect of different CYP and phase II inhibitors and CYP inducers on ET-743 cytotoxicity was studied after 48 and 120 h of treatment in Hep G2 cells using different assays.	Trabectedin	72-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
16162970-6	2005	The effect of different CYP and phase II inhibitors and CYP inducers on ET-743 cytotoxicity was studied after 48 and 120 h of treatment in Hep G2 cells using different assays.	Trabectedin	72-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-70
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Trabectedin	29-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-164
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-70
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Metyrapone	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	12-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-164
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	phenanthrene	154-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-164
16276979-4	2005	Cimetidine (CMT) inhibits the breakdown of drugs metabolized by CYP450 and reduces the clearance of coadministered drug resulted from both the CMT binding to CYP450 and the decreased hepatic blood flow due to CMT.	Cimetidine	143-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-164
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Piperonyl Butoxide	193-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Proadifen	218-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Ritonavir	245-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16162970-8	2005	Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19).	Warfarin	266-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
16162970-10	2005	CYP metabolites of ET-743 were less toxic compared with ET-743.	Trabectedin	19-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
16162970-11	2005	These findings indicate that combination therapy of ET-743 with CYP inhibitors, e.g. other anti-cancer drugs, could lead to changes in the hepatotoxicity of ET-743 and are therefore of clinical importance.	Trabectedin	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
16162970-11	2005	These findings indicate that combination therapy of ET-743 with CYP inhibitors, e.g. other anti-cancer drugs, could lead to changes in the hepatotoxicity of ET-743 and are therefore of clinical importance.	Trabectedin	157-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
15916533-0	2005	Cytochrome P450/NADPH-dependent biosynthesis of 5,6-trans-epoxyeicosatrienoic acid from 5,6-trans-arachidonic acid.	5,6-trans-epoxyeicosatrienoic acid	48-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-21
16408808-2	2005	METHODS: Imrecoxib was incubated with heterologous expression human cytochrome P450 (rCYPs) in vitro, and metabolites and remained parent drug were detected with liquid chromatography-multistage mass spectrometry.	Imrecoxib	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
15993870-4	2005	Several lines of data support the possibility that certain CYP metabolites resulting from the hydroxylation of AA such as 20-hydroxyeicosatetraenoic acid (20-HETE) are potent vasoconstrictors and may produce detrimental effects in the heart during ischemia and pro-inflammatory effects during reperfusion.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	122-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
15993870-4	2005	Several lines of data support the possibility that certain CYP metabolites resulting from the hydroxylation of AA such as 20-hydroxyeicosatetraenoic acid (20-HETE) are potent vasoconstrictors and may produce detrimental effects in the heart during ischemia and pro-inflammatory effects during reperfusion.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	155-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
16298597-1	2005	Cytochrome-P450 enzymes metabolize cyclosporine both in the liver and in the intestinal wall.	Cyclosporine	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
16051450-0	2005	Two novel transposable elements in a cytochrome P450 gene govern anthocyanin biosynthesis of commercial petunias.	Anthocyanins	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
15916533-0	2005	Cytochrome P450/NADPH-dependent biosynthesis of 5,6-trans-epoxyeicosatrienoic acid from 5,6-trans-arachidonic acid.	5(E)-Arachidonic acid	88-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-21
16111645-8	2005	Depending on the examined system, this parallelism may be distorted due to the cytochrome P-450 and COMT-catalyzed transformation of polyphenols.	Polyphenols	133-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
15993852-0	2005	Role of Ca2+-independent phospholipase A2 and cytochrome P-450 in store-operated calcium entry in 3T6 fibroblasts.	Calcium	81-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
15993852-3	2005	Thapsigargin-induced elevation of [Ca2+]i was inhibited by cytochrome P-450 inhibitors and by cytochrome P-450 epoxygenase inhibitor and was reverted by 11,12 EET addition.	Thapsigargin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
15993852-3	2005	Thapsigargin-induced elevation of [Ca2+]i was inhibited by cytochrome P-450 inhibitors and by cytochrome P-450 epoxygenase inhibitor and was reverted by 11,12 EET addition.	Thapsigargin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
15993852-7	2005	Thus, AA released by Ca2+-independent phospholipase A2 and AA metabolism through cytochrome P-450 pathway may be crucial molecular determinant in thapsigargin activation of SOC channels and store-operated Ca2+ entry pathway in 3T6 fibroblasts.	Thapsigargin	146-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
15993852-8	2005	Moreover, EETs, the main cytochrome P-450 epoxygenase metabolites of AA, are involved in thapsigargin-stimulated Ca2+ influx.	Thapsigargin	89-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
16011979-1	2005	The antiplatelet potency of clopidogrel may be attenuated by short-term co-administration of lipophilic statins metabolized through the cytochrome P-450, isoform 3A4.	Clopidogrel	28-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
15896668-6	2005	Results showed that treatment with CP-55,940 decreased CYP concentrations by 80% and increased HO activity by 158%.	cp-55	35-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
16022919-1	2005	To clarify the role of cytochrome P450 in docetaxel and cisplatin combination chemotherapy, cytochrome P450 activity was measured by simple antipyrine test, and its correlation with the drugs" pharmacodynamics was assessed.	Docetaxel	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
16022919-1	2005	To clarify the role of cytochrome P450 in docetaxel and cisplatin combination chemotherapy, cytochrome P450 activity was measured by simple antipyrine test, and its correlation with the drugs" pharmacodynamics was assessed.	Cisplatin	56-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
16022919-9	2005	We concluded that antipyrine test and cytochrome P450 play an important role in predicting toxicities of docetaxel and cisplatin combination chemotherapy.	Docetaxel	105-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
16022919-9	2005	We concluded that antipyrine test and cytochrome P450 play an important role in predicting toxicities of docetaxel and cisplatin combination chemotherapy.	Cisplatin	119-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
16087391-0	2005	Nitrogen-substitution effects on the mutagenicity and cytochrome P450 isoform-selectivity of chrysene analogs.	Nitrogen	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16087391-0	2005	Nitrogen-substitution effects on the mutagenicity and cytochrome P450 isoform-selectivity of chrysene analogs.	chrysene	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
16087391-8	2005	However, in Ames tests using microsomes from insect cells expressing various human CYP isoforms, the mutagenicity of 1,10-DAC was induced only by recombinant human CYP1A2, whereas both recombinant human CYP2A6 and 1A2 contributed to the mutagenicity of 4,10-DAC.	1,10-diazachrysene	117-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16087391-8	2005	However, in Ames tests using microsomes from insect cells expressing various human CYP isoforms, the mutagenicity of 1,10-DAC was induced only by recombinant human CYP1A2, whereas both recombinant human CYP2A6 and 1A2 contributed to the mutagenicity of 4,10-DAC.	4,10-dac	253-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
16087391-10	2005	In conclusion, our results suggested that the difference in the nitrogen-substituted position in the chrysene molecule might affect the mutagenic activity through influencing the ratio of participation of the metabolic activation enzyme isoforms of CYP.	Nitrogen	64-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-252
16087391-10	2005	In conclusion, our results suggested that the difference in the nitrogen-substituted position in the chrysene molecule might affect the mutagenic activity through influencing the ratio of participation of the metabolic activation enzyme isoforms of CYP.	chrysene	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	249-252
16922637-4	2005	These interactions may occur not only in the liver, but also in the brain, and may change the activity of CYP towards the metabolism of drugs, sex steroids, neurosteroids and amine neurotransmitters.	Steroids	147-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
16922637-4	2005	These interactions may occur not only in the liver, but also in the brain, and may change the activity of CYP towards the metabolism of drugs, sex steroids, neurosteroids and amine neurotransmitters.	Amines	175-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
16278191-1	2005	The role of the major drug-metabolizing cytochrome P450 (CYP) enzymes as well as P-glycoprotein (PGP) was investigated in the disposition of ketobemidone in vitro.	ketobemidone	141-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
16278191-1	2005	The role of the major drug-metabolizing cytochrome P450 (CYP) enzymes as well as P-glycoprotein (PGP) was investigated in the disposition of ketobemidone in vitro.	ketobemidone	141-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
27722966-13	2005	In contrast, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver via the CYP system and thus, may be subject to drug-drug metabolic interactions.	meglitinide	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
15963101-1	2005	AIMS: The genetically polymorphic cytochrome P450 (CYP) enzyme CYP2C9 metabolizes most sulphonylurea oral hypoglycaemic agents.	Sulfonylurea Compounds	87-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
15963101-1	2005	AIMS: The genetically polymorphic cytochrome P450 (CYP) enzyme CYP2C9 metabolizes most sulphonylurea oral hypoglycaemic agents.	Sulfonylurea Compounds	87-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-255
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-255
16178456-1	2005	Interests on the effects of cytochrome P450 (CYP450) monooxygenases and epoxyeicosatrienoic acids (EETs) on myocardial ischemic-reperfusion injury has been increased in recent years.	eets	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-51
16178456-2	2005	The CYP450/EET system may influence the degree of myocardial ischemic-reperfusion injury through "poly-targets", such us oxygen free radical, calcium overload, leukocytes adherence, nitric oxide, ATP-sensitive K+ channels, and mitogen activated protein kinase.	oxygen free radical	121-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-10
16178456-2	2005	The CYP450/EET system may influence the degree of myocardial ischemic-reperfusion injury through "poly-targets", such us oxygen free radical, calcium overload, leukocytes adherence, nitric oxide, ATP-sensitive K+ channels, and mitogen activated protein kinase.	Calcium	142-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-10
27722966-13	2005	In contrast, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver via the CYP system and thus, may be subject to drug-drug metabolic interactions.	Thiazolidinediones	57-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
16002382-2	2005	Organophosphorus insecticides (OPs) target the developing nervous system, and until recently, the most common residential insecticides were chlorpyrifos and diazinon, two OPs metabolized in the body through the cytochrome P450/paraoxonase 1 (PON1) pathway.	organophosphorus	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-240
27722966-19	2005	The effects of inducers or inhibitors of CYP isoenzymes on the metabolism and pharmacokinetics of the glucose-lowering agents of each pharmacological class has been tested.	Glucose	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
16002382-2	2005	Organophosphorus insecticides (OPs) target the developing nervous system, and until recently, the most common residential insecticides were chlorpyrifos and diazinon, two OPs metabolized in the body through the cytochrome P450/paraoxonase 1 (PON1) pathway.	Chlorpyrifos	140-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-240
27722966-20	2005	Significantly increased (with CYP inhibitors) or decreased (with CYP inducers) plasma levels of sulphonylureas, meglitinide derivatives and thiazolidinediones have been reported in healthy volunteers, and these pharmacokinetic changes may lead to enhanced or reduced glucose-lowering action, and thus hypoglycaemia or worsening of metabolic control, respectively.	meglitinide	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
16002382-2	2005	Organophosphorus insecticides (OPs) target the developing nervous system, and until recently, the most common residential insecticides were chlorpyrifos and diazinon, two OPs metabolized in the body through the cytochrome P450/paraoxonase 1 (PON1) pathway.	Diazinon	157-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-240
27722966-20	2005	Significantly increased (with CYP inhibitors) or decreased (with CYP inducers) plasma levels of sulphonylureas, meglitinide derivatives and thiazolidinediones have been reported in healthy volunteers, and these pharmacokinetic changes may lead to enhanced or reduced glucose-lowering action, and thus hypoglycaemia or worsening of metabolic control, respectively.	Thiazolidinediones	140-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
16025433-2	2005	Chloroform targets the liver in humans, where cytochrome P-450-dependent biotransformation to phosgene results in mitochondrial damage and cell death.	Chloroform	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
15931672-0	2005	Arachidonic acid induces neuronal death through lipoxygenase and cytochrome P450 rather than cyclooxygenase.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
15931672-4	2005	Exposure of cultured cortical neurons to AA (50 microM) yielded significantly apoptotic neuronal death, which was attenuated greatly by LOX inhibitors (nordihydroguaiaretic acid, AA861, and baicalein), or CYP450 inhibitors (SKF525A and metyrapone), rather than COX inhibitors (indomethacin and NS398).	baicalein	190-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-211
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	NADP	91-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	NADP	91-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15854816-1	2005	Cytochrome P450 (CYP) is a large family of enzymes containing heme as the active site.	Heme	62-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15854816-1	2005	Cytochrome P450 (CYP) is a large family of enzymes containing heme as the active site.	Heme	62-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	Bupropion	140-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	Cyclophosphamide	151-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	Propofol	169-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	efavirenz	183-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	Oxygen	42-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	Oxygen	42-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	Water	137-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15922018-2	2005	FMO, like cytochrome P450 (CYP), is a monooxygenase, utilizing the reducing equivalents of NADPH to reduce 1 atom of molecular oxygen to water, while the other atom is used to oxidize the substrate.	Water	137-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15840428-0	2005	Lack of evidence for metabolism of p-phenylenediamine by human hepatic cytochrome P450 enzymes.	4-phenylenediamine	35-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
15840428-1	2005	p-Phenylenediamine (PPD) is a widely used ingredient in permanent hair dyes; however, little has been published on its metabolism, especially with respect to hepatic cytochrome P450 (CYP)-mediated oxidation.	4-phenylenediamine	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-181
15840428-1	2005	p-Phenylenediamine (PPD) is a widely used ingredient in permanent hair dyes; however, little has been published on its metabolism, especially with respect to hepatic cytochrome P450 (CYP)-mediated oxidation.	4-phenylenediamine	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-186
15840428-1	2005	p-Phenylenediamine (PPD) is a widely used ingredient in permanent hair dyes; however, little has been published on its metabolism, especially with respect to hepatic cytochrome P450 (CYP)-mediated oxidation.	4-phenylenediamine	20-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-181
15840428-1	2005	p-Phenylenediamine (PPD) is a widely used ingredient in permanent hair dyes; however, little has been published on its metabolism, especially with respect to hepatic cytochrome P450 (CYP)-mediated oxidation.	4-phenylenediamine	20-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-186
15840428-6	2005	In contrast, 2-aminofluorene underwent CYP-mediated metabolism to &gt; or = 4 different hydroxylated metabolites.	2-aminofluorene	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
15772082-1	2005	Testosterone 6beta-hydroxylation is a prototypic reaction of cytochrome P450 (P450) 3A4, the major human P450.	testosterone 6beta	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-87
16192110-0	2005	Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.	Valsartan	75-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
16192110-3	2005	The current in vitro studies were conducted to identify the cytochrome P450 (CYP) enzymes involved in the formation of 4-OH valsartan.	4-oh valsartan	119-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
16192110-3	2005	The current in vitro studies were conducted to identify the cytochrome P450 (CYP) enzymes involved in the formation of 4-OH valsartan.	4-oh valsartan	119-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80
16192110-9	2005	For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan.	furafylline	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
16192110-9	2005	For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan.	Troleandomycin	113-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
16192110-9	2005	For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan.	Diclofenac	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
16192110-9	2005	For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan.	4-oh valsartan	173-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
16192110-11	2005	Although CYP2C9 is involved in valsartan metabolism, CYP-mediated drug-drug interaction between valsartan and other co-administered drugs would be negligible.	Valsartan	31-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
15836631-2	2005	CYP1A1, a cytochrome P-450 enzyme, bioactivates polycyclic aromatic hydrocarbons to reactive metabolite(s) that bind to DNA and initiate carcinogenesis.	Polycyclic Aromatic Hydrocarbons	48-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
15986265-5	2005	Before subjecting patients on methadone to other drugs, the QT-interval should be determined and it should be ascertained whether the new agent has the property to prolong the QT-interval or is metabolised by the cytochrome-P450 system.	Methadone	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	213-228
15842554-1	2005	AIMS: We evaluated the involvement of cytochrome P450 (CYP) isoforms 2C9 and 2C19 in chlorpropamide 2-hydroxylation in vitro and in chlorpropamide disposition in vivo.	Chlorpropamide	85-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
15842554-1	2005	AIMS: We evaluated the involvement of cytochrome P450 (CYP) isoforms 2C9 and 2C19 in chlorpropamide 2-hydroxylation in vitro and in chlorpropamide disposition in vivo.	Chlorpropamide	85-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
15842554-2	2005	METHODS: To identify CYP isoforms(s) that catalyse 2-hydroxylation of chlorpropamide, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms.	Chlorpropamide	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15842554-2	2005	METHODS: To identify CYP isoforms(s) that catalyse 2-hydroxylation of chlorpropamide, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms.	Chlorpropamide	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
15842554-5	2005	In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).	CHEBI:143296	69-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
15778010-0	2005	Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.	Safrole	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
15863898-0	2005	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.	Nicardipine	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
15863898-0	2005	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.	Nicardipine	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
15863898-1	2005	To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated.	Nicardipine	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
15863898-1	2005	To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated.	Nicardipine	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
15863898-1	2005	To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated.	Nicardipine	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
15863898-1	2005	To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated.	Nicardipine	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
15863898-1	2005	To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated.	Nicardipine	123-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
15863898-2	2005	Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine.	Nicardipine	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
15863898-4	2005	CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes.	Nicardipine	83-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
15769614-1	2005	In breast cancer, cytochrome P450 (CYP) metabolizes both endogenous substrates (i.e. estradiol) and exogenous substrates (i.e. anticancer drugs), which is associated not only with tumor development and progression but also with efficacy of cancer treatment.	Estradiol	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
15769614-1	2005	In breast cancer, cytochrome P450 (CYP) metabolizes both endogenous substrates (i.e. estradiol) and exogenous substrates (i.e. anticancer drugs), which is associated not only with tumor development and progression but also with efficacy of cancer treatment.	Estradiol	85-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
16012077-0	2005	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam.	4-Hydroxy Estazolam	77-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
15843388-0	2005	Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines.	aromatic amines	193-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
16012077-0	2005	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam.	Estazolam	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
16012077-1	2005	To predict drug interactions with estazolam, the biotransformation of estazolam to its major hydoxylated metabolite, 4-hydroxyestazolam was studied in vitro using pooled human liver microsomes and individual expressed human cytochrome P450 (CYP) enzymes.	Estazolam	70-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-244
16012077-5	2005	When estazolam was incubated with expressed human CYP enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), it was metabolized only by CYP3A4.	Estazolam	5-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
16833677-5	2005	This thiolate complex is used as a mimic for the cytochrome P450s active site to model the first step of the catalytic cycle of this enzyme.	thiolate	5-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
16833677-8	2005	These calculations are in line with the experimentally observed change in the spin state from low to high spin upon this removal of the axial hydroxo ligand by binding of the substrate in the heme pocket of cytochrome P450.	Heme	192-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-222
15876406-0	2005	New assumptions about oxidative processes involved in steroid hormone biosynthesis: is the role of cytochrome P-450-activated dioxygen limited to hydroxylation reactions or are dioxygen insertion reactions also possible?	Steroids	54-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
15576430-8	2005	Our results suggest that the cerebral endothelial barrier dysfunction seen in response to glutamate is Ca(2+) dependent and may require several intracellular signaling events mediated by oxidants derived from reduced nicotinamide adenine dinucleotide oxidase, cytochrome P-450, and the mitochondria.	Glutamic Acid	90-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-276
15665333-1	2005	Human cytochrome P450 (P450) 2A6 catalyzes 7-hydroxylation of coumarin, and the reaction rate is enhanced by cytochrome b5 (b5).	coumarin	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-32
15876406-0	2005	New assumptions about oxidative processes involved in steroid hormone biosynthesis: is the role of cytochrome P-450-activated dioxygen limited to hydroxylation reactions or are dioxygen insertion reactions also possible?	Oxygen	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
15784278-0	2005	NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms.	Estradiol	30-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15772515-8	2005	These findings suggest that nicorandil causes vasodilation in forearm circulation in humans, at least in part through a pathway that is dependent on K-ATP channels and cytochrome P-450, but not on endogenous NO and prostaglandins.	Nicorandil	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
15784278-3	2005	Precise knowledge of the CYP-mediated formation of these metabolites, particularly those with unique biological activities (e.g., 4-hydroxy-E(2), 16alpha-hydroxy-E(1), 15alpha-hydroxy-E(2), 16-epiestriol, and 2-methoxyestradiol) in human liver and extrahepatic target tissues and cells, would add significantly to our understanding of the diverse biological functions that are associated with endogenous estrogens.	4-hydroxy-e(2)	130-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
15784278-3	2005	Precise knowledge of the CYP-mediated formation of these metabolites, particularly those with unique biological activities (e.g., 4-hydroxy-E(2), 16alpha-hydroxy-E(1), 15alpha-hydroxy-E(2), 16-epiestriol, and 2-methoxyestradiol) in human liver and extrahepatic target tissues and cells, would add significantly to our understanding of the diverse biological functions that are associated with endogenous estrogens.	16alpha-hydroxy-e(	146-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
15784278-3	2005	Precise knowledge of the CYP-mediated formation of these metabolites, particularly those with unique biological activities (e.g., 4-hydroxy-E(2), 16alpha-hydroxy-E(1), 15alpha-hydroxy-E(2), 16-epiestriol, and 2-methoxyestradiol) in human liver and extrahepatic target tissues and cells, would add significantly to our understanding of the diverse biological functions that are associated with endogenous estrogens.	15alpha-hydroxy-e(	168-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
15784278-3	2005	Precise knowledge of the CYP-mediated formation of these metabolites, particularly those with unique biological activities (e.g., 4-hydroxy-E(2), 16alpha-hydroxy-E(1), 15alpha-hydroxy-E(2), 16-epiestriol, and 2-methoxyestradiol) in human liver and extrahepatic target tissues and cells, would add significantly to our understanding of the diverse biological functions that are associated with endogenous estrogens.	), 16-epiestriol	187-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
15784278-3	2005	Precise knowledge of the CYP-mediated formation of these metabolites, particularly those with unique biological activities (e.g., 4-hydroxy-E(2), 16alpha-hydroxy-E(1), 15alpha-hydroxy-E(2), 16-epiestriol, and 2-methoxyestradiol) in human liver and extrahepatic target tissues and cells, would add significantly to our understanding of the diverse biological functions that are associated with endogenous estrogens.	2-Methoxyestradiol	209-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
15784278-4	2005	In this article, we review recent results on the NADPH-dependent metabolism of endogenous estrogens to polar (hydroxylated and keto) metabolites as well as to nonpolar metabolites by human tissues and recombinant human CYP isoforms.	NADP	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-222
15784278-5	2005	The available data show that a large number of polar and nonpolar metabolites of E(2) and E(1) are formed by human tissues, and a variety of human CYP isoforms are involved in the NADPH-dependent formation of polar as well as nonpolar estrogen metabolites.	NADP	180-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
15713371-0	2005	Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.	Vorinostat	11-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
15750390-2	2005	This research examined the impact of single nucleotide polymorphisms (SNP) of MDR1 and CYP genes on nelfinavir and efavirenz pharmacokinetics and the response to highly active antiretroviral therapy (HAART) in HIV-1 infected children.	Nelfinavir	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
15713371-0	2005	Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.	trichostatin A	47-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
15713371-3	2005	Results from our study indicated a significant increase in CYP activity in comparison to vehicle control in cells treated with SAHA or TSA as measured by ethoxyresorufin-O-deethylase assay.	trichostatin A	135-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
15608133-0	2005	Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8.	Glucuronides	38-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15713371-8	2005	These results suggest that while CYP enzyme activity and gene expression were affected by the HDAC inhibitors SAHA and TSA, they had no apparent influence on B[a]P DNA binding.	trichostatin A	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
15608133-2	2005	Cytochrome P450-mediated oxidation of steroid sulfate has been described, suggesting that oxidation of polar metabolites such as glucuronide derivatives of endogenous compounds can occur.	steroid sulfate	38-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15608133-2	2005	Cytochrome P450-mediated oxidation of steroid sulfate has been described, suggesting that oxidation of polar metabolites such as glucuronide derivatives of endogenous compounds can occur.	Glucuronides	129-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15608133-7	2005	This is the first demonstration of cytochrome P450-mediated oxidation of a steroid glucuro-conjugate.	Steroids	75-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
15616733-0	2005	Biomimetic alcohol oxidations by an iron(III) porphyrin complex: relevance to cytochrome P-450 catalytic oxidation and involvement of the two-state radical rebound mechanism.	Alcohols	11-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
16019948-0	2005	Identification of cytochrome P450 enzymes involved in the metabolism of 3",4"-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.	3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone	72-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
16019948-0	2005	Identification of cytochrome P450 enzymes involved in the metabolism of 3",4"-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.	3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3",4"-methylenedioxy-a-pyrrolidinopropiophenone	18-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-292
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3",4"-methylenedioxy-a-pyrrolidinopropiophenone	18-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-297
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-292
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-297
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3",4"-dihydroxy-pyrrolidinopropiophenone	137-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-292
16019948-1	2005	The metabolism of 3",4"-methylenedioxy-a-pyrrolidinopropiophenone (MDPPP), a novel designer drug, to its demethylenated major metabolite 3",4"-dihydroxy-pyrrolidinopropiophenone (di-HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	3",4"-dihydroxy-pyrrolidinopropiophenone	137-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	294-297
15767245-6	2005	We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system.	Warfarin	55-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
15767245-6	2005	We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system.	Warfarin	55-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
15767245-6	2005	We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system.	Warfarin	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
15767245-6	2005	We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system.	Warfarin	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
15767245-7	2005	Concurrent administration of aspirin and other drugs that are metabolized through or are inhibitors of the CYP system may have enhanced the interaction that occurred in this patient.	Aspirin	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
15746054-2	2005	Cytochrome P450 enzymes are primarily expressed in the liver and convert the prodrug cyclophosphamide to an active phosphoramide mustard and acrolein.	Cyclophosphamide	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15746054-2	2005	Cytochrome P450 enzymes are primarily expressed in the liver and convert the prodrug cyclophosphamide to an active phosphoramide mustard and acrolein.	phosphoramide	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15746054-2	2005	Cytochrome P450 enzymes are primarily expressed in the liver and convert the prodrug cyclophosphamide to an active phosphoramide mustard and acrolein.	Acrolein	141-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15596250-1	2005	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is highly toxic in experimental animals, and is known to induce cytochrome P450 (CYP) gene expression.	Polychlorinated Dibenzodioxins	0-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
15596250-1	2005	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is highly toxic in experimental animals, and is known to induce cytochrome P450 (CYP) gene expression.	Polychlorinated Dibenzodioxins	0-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
15596250-1	2005	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is highly toxic in experimental animals, and is known to induce cytochrome P450 (CYP) gene expression.	Polychlorinated Dibenzodioxins	37-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
15596250-1	2005	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is highly toxic in experimental animals, and is known to induce cytochrome P450 (CYP) gene expression.	Polychlorinated Dibenzodioxins	37-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
15596250-7	2005	However, when lymphocytes were treated in vitro with 10 nM TCDD, CYP1B1 and CYP1A1 mRNA expression was strongly induced and modified by CYP variant alleles.	Polychlorinated Dibenzodioxins	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
15596250-11	2005	Genetic variation in cytochrome P450 induction may identify subjects with variable responsiveness to TCDD and potentially increased risk of disease.	Polychlorinated Dibenzodioxins	101-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
15616733-0	2005	Biomimetic alcohol oxidations by an iron(III) porphyrin complex: relevance to cytochrome P-450 catalytic oxidation and involvement of the two-state radical rebound mechanism.	iron(iii) porphyrin	36-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
15616733-1	2005	The systematic oxidation reactions of a wide range of alcohols have been carried out by using an iron porphyrin complex in order to understand their relation to cytochrome P-450 enzymes and to have a practical application to organic synthesis.	Alcohols	54-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
15616733-1	2005	The systematic oxidation reactions of a wide range of alcohols have been carried out by using an iron porphyrin complex in order to understand their relation to cytochrome P-450 enzymes and to have a practical application to organic synthesis.	iron porphyrin	97-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
15596297-2	2005	TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
15581596-2	2005	Following intracellular metabolism by cytochrome P450 (CYP) enzymes, drug metabolites are excreted into bile or urine via ATP-dependent multidrug resistance proteins (MDR1 and MRPs).	Adenosine Triphosphate	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
15581596-2	2005	Following intracellular metabolism by cytochrome P450 (CYP) enzymes, drug metabolites are excreted into bile or urine via ATP-dependent multidrug resistance proteins (MDR1 and MRPs).	Adenosine Triphosphate	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	Krypton	42-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	Krypton	42-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	374-377
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	pyrrole-kr	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	o-demethylpyrrole-kr	106-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	n-dehydroxyethyl-kr	134-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
15585365-4	2005	The specific CYP isozymes responsible for KR-60436 oxidation to four major metabolites, pyrrole-KR-60436, O-demethylpyrrole-KR-60436, N-dehydroxyethyl-KR-60436 and an active metabolite, O-demethyl-KR-60436 were identified using the combination of correlation analysis, immuno-inhibition, chemical inhibition in human liver microsomes and metabolism by expressed recombinant CYP enzymes.	o-demethyl-kr	186-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
15596297-2	2005	TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5.	Tamoxifen	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
16175235-2	2005	Ifosfamide must be activated by cytochrome P450 (P450) enzymes in the liver, initially to a short lived intermediate and then to toxic metabolites that are subsequently distributed by the circulatory system.	Ifosfamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
15630035-0	2005	Cytochrome P-450 under pressure: more evidence for a link between 20-hydroxyeicosatetraenoic acid and hypertension.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	66-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	dolasetron	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15635191-1	2005	The effects of sulpiride, an antipsychotic drug, on cytochrome P450 (CYP) activities in human liver microsomes were investigated.	Sulpiride	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
15635191-1	2005	The effects of sulpiride, an antipsychotic drug, on cytochrome P450 (CYP) activities in human liver microsomes were investigated.	Sulpiride	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	2,4-thiazolidinedione	23-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	2,4-thiazolidinedione	23-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
15635179-0	2005	Soybean oil fat emulsion prevents cytochrome P450 mRNA down-regulation induced by fat-free overdose total parenteral nutrition in infant rats.	Oils	8-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
15665498-0	2005	Interaction of modified cyclodextrins with cytochrome P-450.	Cyclodextrins	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
15665498-1	2005	The effects of modified cyclodextrins (CDs) hydroxypropyl-beta-CD and methyl-beta-CD were studied in vitro on cDNA-expressed human cytochrome P-450 (CYP) activities (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).	Cyclodextrins	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
15665498-1	2005	The effects of modified cyclodextrins (CDs) hydroxypropyl-beta-CD and methyl-beta-CD were studied in vitro on cDNA-expressed human cytochrome P-450 (CYP) activities (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).	Cyclodextrins	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-152
15665498-1	2005	The effects of modified cyclodextrins (CDs) hydroxypropyl-beta-CD and methyl-beta-CD were studied in vitro on cDNA-expressed human cytochrome P-450 (CYP) activities (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).	Cyclodextrins	39-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
15665498-1	2005	The effects of modified cyclodextrins (CDs) hydroxypropyl-beta-CD and methyl-beta-CD were studied in vitro on cDNA-expressed human cytochrome P-450 (CYP) activities (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).	methyl-beta-cyclodextrin	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
16176119-2	2005	Preclinical studies were conducted to determine the cytochrome P450 (CYP) isoenzymes involved in the metabolism of gefitinib and to evaluate the potential of gefitinib to cause drug interactions through inhibition of CYP isoenzymes.	Gefitinib	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
16176119-2	2005	Preclinical studies were conducted to determine the cytochrome P450 (CYP) isoenzymes involved in the metabolism of gefitinib and to evaluate the potential of gefitinib to cause drug interactions through inhibition of CYP isoenzymes.	Gefitinib	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
16176119-2	2005	Preclinical studies were conducted to determine the cytochrome P450 (CYP) isoenzymes involved in the metabolism of gefitinib and to evaluate the potential of gefitinib to cause drug interactions through inhibition of CYP isoenzymes.	Gefitinib	158-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
16176119-4	2005	METHODS: In preclinical studies radiolabelled gefitinib was incubated with: (i) hepatic microsomal protein in the presence of selective CYP inhibitors; and (ii) expressed CYP enzymes.	Gefitinib	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-139
16176119-4	2005	METHODS: In preclinical studies radiolabelled gefitinib was incubated with: (i) hepatic microsomal protein in the presence of selective CYP inhibitors; and (ii) expressed CYP enzymes.	Gefitinib	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
16176119-5	2005	Human hepatic microsomal protein was incubated with selective CYP substrates in the presence of gefitinib.	Gefitinib	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	dolasetron	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Granisetron	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Granisetron	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Ondansetron	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Ondansetron	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-260
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Tropisetron	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Tropisetron	63-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
15963007-13	2005	In contrast, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver via the CYP system and thus, may be subject to drug-drug metabolic interactions.	meglitinide	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
15963007-13	2005	In contrast, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver via the CYP system and thus, may be subject to drug-drug metabolic interactions.	Thiazolidinediones	57-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
15963007-20	2005	The effects of inducers or inhibitors of CYP isoenzymes on the metabolism and pharmacokinetics of the glucose-lowering agents of each pharmacological class has been tested.	Glucose	102-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
15963007-21	2005	Significantly increased (with CYP inhibitors) or decreased (with CYP inducers) plasma levels of sulphonylureas, meglitinide derivatives and thiazolidinediones have been reported in healthy volunteers, and these pharmacokinetic changes may lead to enhanced or reduced glucose-lowering action, and thus hypoglycaemia or worsening of metabolic control, respectively.	meglitinide	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
16393888-6	2005	Both CPA and IFO are prodrugs that require activation by hepatic cytochrome P450 (CYP)-catalyzed 4-hydroxylation, yielding cytotoxic nitrogen mustards capable of reacting with DNA molecules to form crosslinks and lead to cell apoptosis and/or necrosis.	Cyclophosphamide	5-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
15963007-21	2005	Significantly increased (with CYP inhibitors) or decreased (with CYP inducers) plasma levels of sulphonylureas, meglitinide derivatives and thiazolidinediones have been reported in healthy volunteers, and these pharmacokinetic changes may lead to enhanced or reduced glucose-lowering action, and thus hypoglycaemia or worsening of metabolic control, respectively.	Thiazolidinediones	140-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
16393888-6	2005	Both CPA and IFO are prodrugs that require activation by hepatic cytochrome P450 (CYP)-catalyzed 4-hydroxylation, yielding cytotoxic nitrogen mustards capable of reacting with DNA molecules to form crosslinks and lead to cell apoptosis and/or necrosis.	Cyclophosphamide	5-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
15895287-1	2005	The cytochrome P450 (CYP) is a monooxidase, which regulates metabolism of drugs and fatty acids in the liver and kidney.	Fatty Acids	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
16393888-6	2005	Both CPA and IFO are prodrugs that require activation by hepatic cytochrome P450 (CYP)-catalyzed 4-hydroxylation, yielding cytotoxic nitrogen mustards capable of reacting with DNA molecules to form crosslinks and lead to cell apoptosis and/or necrosis.	Nitrogen	133-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
16393888-6	2005	Both CPA and IFO are prodrugs that require activation by hepatic cytochrome P450 (CYP)-catalyzed 4-hydroxylation, yielding cytotoxic nitrogen mustards capable of reacting with DNA molecules to form crosslinks and lead to cell apoptosis and/or necrosis.	Nitrogen	133-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
16393888-11	2005	The alternative CYP-catalyzed inactivation pathway by N-dechloroethylation generates the neurotoxic and nephrotoxic byproduct chloroacetaldehyde (CAA).	Nitrogen	54-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
16393888-11	2005	The alternative CYP-catalyzed inactivation pathway by N-dechloroethylation generates the neurotoxic and nephrotoxic byproduct chloroacetaldehyde (CAA).	chloroacetaldehyde	126-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
16393888-11	2005	The alternative CYP-catalyzed inactivation pathway by N-dechloroethylation generates the neurotoxic and nephrotoxic byproduct chloroacetaldehyde (CAA).	chloroacetaldehyde	146-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
21783461-0	2005	Formation of estrogenic metabolites of benzo[a]pyrene and chrysene by cytochrome P450 activity and their combined and supra-maximal estrogenic activity.	Benzo(a)pyrene	39-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
21783461-0	2005	Formation of estrogenic metabolites of benzo[a]pyrene and chrysene by cytochrome P450 activity and their combined and supra-maximal estrogenic activity.	chrysene	58-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
21783461-8	2005	BaP itself exhibited estrogenicity in the ER-CALUX assay due to bio-activation into estrogenic metabolites, probably via aryl hydrocarbon receptor (AhR) induced CYP activity.	Benzo(a)pyrene	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	oxybutynin	149-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	oxybutynin	149-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	Tolterodine Tartrate	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	Tolterodine Tartrate	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	darifenacin	174-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	darifenacin	174-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	Solifenacin Succinate	190-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
16363885-13	2005	Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions.	Solifenacin Succinate	190-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
16329398-0	2005	[Ratio of low- and high-spin cytochrome P-450 in liver microsomes of N-nitrosodiethylamine-induced hepatomas].	Diethylnitrosamine	69-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
15895287-1	2005	The cytochrome P450 (CYP) is a monooxidase, which regulates metabolism of drugs and fatty acids in the liver and kidney.	Fatty Acids	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
16116487-1	2005	Cyclophosphamide (CP), a widely used cytostatic, is metabolized by polymorphic drug metabolizing enzymes particularly cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
16265100-4	2005	An increase in oxidative stress, due to the generation of reactive oxygen species as a result of mitochondrial abnormalities and induction of the cytochrome P-450 system could be one mechanism by which the nonalcoholic fatty liver develops into nonalcoholic steatohepatitis.	Reactive Oxygen Species	58-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-162
16116487-1	2005	Cyclophosphamide (CP), a widely used cytostatic, is metabolized by polymorphic drug metabolizing enzymes particularly cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
15635280-7	2005	In the present review, cytochrome P450 monooxygenases involved in the biosyntheses of three structurally and biosynthetically interesting compounds, secologanin, cornoside, and shikonin, a described together with the results of previous and recent biosynthetic studies.	shikonin	177-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
20021073-5	2005	Recent studies have demonstrated that an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) arachidonic acid metabolizing enzymes in the kidney may contribute to the renal damage associated with obesity.	Arachidonic Acid	113-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
20021073-5	2005	Recent studies have demonstrated that an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) arachidonic acid metabolizing enzymes in the kidney may contribute to the renal damage associated with obesity.	Arachidonic Acid	113-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-111
15560889-6	2004	The affinity of carbofuran for CYP enzymes involved in the oxidation to 3-hydroxycarbofuran is significantly less in HLM (Km=1.950 mM) than in RLM (Km=0.210 mM), or MLM (Km=0.550 mM).	Carbofuran	16-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
15593150-0	2004	An oxidative phenol coupling reaction catalyzed by oxyB, a cytochrome P450 from the vancomycin-producing microorganism.	Vancomycin	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
15635280-7	2005	In the present review, cytochrome P450 monooxygenases involved in the biosyntheses of three structurally and biosynthetically interesting compounds, secologanin, cornoside, and shikonin, a described together with the results of previous and recent biosynthetic studies.	secologanin	149-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15635280-7	2005	In the present review, cytochrome P450 monooxygenases involved in the biosyntheses of three structurally and biosynthetically interesting compounds, secologanin, cornoside, and shikonin, a described together with the results of previous and recent biosynthetic studies.	cornoside	162-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15560889-5	2004	Carbofuran is metabolized by cytochrome P450 (CYP) leading to the production of one major ring oxidation metabolite, 3-hydroxycarbofuran, and two minor metabolites.	Carbofuran	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
15560889-5	2004	Carbofuran is metabolized by cytochrome P450 (CYP) leading to the production of one major ring oxidation metabolite, 3-hydroxycarbofuran, and two minor metabolites.	Carbofuran	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
15560889-6	2004	The affinity of carbofuran for CYP enzymes involved in the oxidation to 3-hydroxycarbofuran is significantly less in HLM (Km=1.950 mM) than in RLM (Km=0.210 mM), or MLM (Km=0.550 mM).	3-hydroxycarbofuran	72-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
15560889-5	2004	Carbofuran is metabolized by cytochrome P450 (CYP) leading to the production of one major ring oxidation metabolite, 3-hydroxycarbofuran, and two minor metabolites.	3-hydroxycarbofuran	117-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
15560889-5	2004	Carbofuran is metabolized by cytochrome P450 (CYP) leading to the production of one major ring oxidation metabolite, 3-hydroxycarbofuran, and two minor metabolites.	3-hydroxycarbofuran	117-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
15560889-8	2004	A screen of 15 major human CYP isoforms for metabolic ability with respect to carbofuran metabolism demonstrated that CYP3A4 is the major isoform responsible for carbofuran oxidation in humans.	Carbofuran	78-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15560889-8	2004	A screen of 15 major human CYP isoforms for metabolic ability with respect to carbofuran metabolism demonstrated that CYP3A4 is the major isoform responsible for carbofuran oxidation in humans.	Carbofuran	162-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15560889-11	2004	Normalization of HLM data with the average levels of each CYP in native HLM, indicates that carbofuran metabolism is primarily mediated by CYP3A4 (percent total normalized rate (% TNR)=77.5), although CYP1A2 and 2C19 play ancillary roles (% TNR=9.0 and 6.0, respectively).	Carbofuran	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
15560889-15	2004	The variation in carbofuran metabolism among 17 single-donor HLM samples is over 5-fold and the best correlation between CYP isoform activity and carbofuran metabolism was observed with CYP3A4 (r2=0.96).	Carbofuran	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
15560889-15	2004	The variation in carbofuran metabolism among 17 single-donor HLM samples is over 5-fold and the best correlation between CYP isoform activity and carbofuran metabolism was observed with CYP3A4 (r2=0.96).	Carbofuran	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	NADP	200-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15519301-1	2004	Alkylresorufins are model substrates for cytochrome P450 (P450) 1A2.	alkylresorufins	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-67
15585441-12	2004	As with other protease inhibitors, atazanavir is also a substrate and moderate inhibitor of the cytochrome P450 (CYP) system, in particular CYP3A4 and CYP2C9.	Atazanavir Sulfate	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	Steroids	118-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	Steroids	118-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	Oxygen	188-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	Oxygen	188-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15644946-1	2004	The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner.	NADP	200-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15513903-3	2004	Microsomal cytochrome P-450s induced production of reactive radical species, leading to differential modification of the proteins.	reactive radical species	51-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
15513903-6	2004	Cytochrome P-450 inhibitors or antioxidants inhibited the production of reactive radical species and protein modification.	reactive radical species	72-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
15585441-12	2004	As with other protease inhibitors, atazanavir is also a substrate and moderate inhibitor of the cytochrome P450 (CYP) system, in particular CYP3A4 and CYP2C9.	Atazanavir Sulfate	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
15535984-1	2004	Two in vitro studies assessed the potential of daptomycin (Cubicin), a newly marketed antibiotic, to affect the cytochrome P450 (CYP450) isoforms in primary cultured human hepatocytes.	Daptomycin	47-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
15535984-1	2004	Two in vitro studies assessed the potential of daptomycin (Cubicin), a newly marketed antibiotic, to affect the cytochrome P450 (CYP450) isoforms in primary cultured human hepatocytes.	Daptomycin	47-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-135
15451555-0	2004	Non-specific inhibition of human cytochrome P450-catalyzed reactions by hemin.	Hemin	72-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
15548707-2	2004	We found that ellipticine also forms the cytochrome P450 (CYP)-mediated covalent DNA adducts.	ellipticine	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
15548707-2	2004	We found that ellipticine also forms the cytochrome P450 (CYP)-mediated covalent DNA adducts.	ellipticine	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
15451555-2	2004	Inhibitory effects of hemin on the cytochrome P450 (CYP)-catalyzed reactions of human liver microsomes and reconstituted systems containing purified CYP and NADPH-cytochrome P450 reductase (NPR) were seen.	Hemin	22-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
15451555-2	2004	Inhibitory effects of hemin on the cytochrome P450 (CYP)-catalyzed reactions of human liver microsomes and reconstituted systems containing purified CYP and NADPH-cytochrome P450 reductase (NPR) were seen.	Hemin	22-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
15560776-2	2004	Cytochrome P450 enzymes promote a number of oxidative biotransformations including the hydroxylation of unactivated hydrocarbons.	Hydrocarbons	116-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15451555-3	2004	Hemin non-specifically inhibited all of the microsomal CYP activities examined.	Hemin	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
15451555-6	2004	Spectrally detectable CYP was destroyed in human liver microsomes and in a reconstituted system in the presence of hemin and an NADPH-generating system.	Hemin	115-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
15451555-6	2004	Spectrally detectable CYP was destroyed in human liver microsomes and in a reconstituted system in the presence of hemin and an NADPH-generating system.	NADP	128-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
15451555-7	2004	We propose that the antimutagenic effect of hemin might be due to inhibition of CYP and NPR enzymes involved in the bioactivation of mutagens.	Hemin	44-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
15543094-7	2004	These proinflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting metabolism of several endogenous lipophilic substances, such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances.	Steroids	271-279	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
15543094-7	2004	These proinflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting metabolism of several endogenous lipophilic substances, such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances.	Prostaglandins	305-319	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
15543094-7	2004	These proinflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting metabolism of several endogenous lipophilic substances, such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances.	Leukotrienes	321-333	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
15543094-7	2004	These proinflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting metabolism of several endogenous lipophilic substances, such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances.	Thromboxanes	335-347	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
15372129-0	2004	Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.	Cimetidine	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
15372129-0	2004	Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.	hypericin	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	Nitrogen	88-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
15528841-2	2004	However, the information regarding human CYP inhibition by antituberculosis drugs is limited to isoniazid.	Isoniazid	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
15528841-3	2004	In the current study, we examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid.	Pyrazinamide	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
15528841-3	2004	In the current study, we examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid.	Ethionamide	77-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
15528841-3	2004	In the current study, we examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid.	Isoniazid	130-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
15528841-9	2004	In contrast, isoniazid might contribute to the severe drug interactions by a different inhibitory mechanism depending on each of the CYP isozymes, in addition to the reported observations.	Isoniazid	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
15662082-1	2004	Although there are no literature data, which would clearly describe the role of catecholaminergic systems (including dopaminergic system) in the expression of the liver cytochrome P-450, there are well documented reports on physiological regulation of cytochrome P-450 by endogenous hormones (glucocorticoids, sex hormones, thyroid hormones, growth hormone, insulin) and by the immune system (cytokines), and all these factors remain under central nervous system control.	Growth Hormone	342-356	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
15662082-1	2004	Although there are no literature data, which would clearly describe the role of catecholaminergic systems (including dopaminergic system) in the expression of the liver cytochrome P-450, there are well documented reports on physiological regulation of cytochrome P-450 by endogenous hormones (glucocorticoids, sex hormones, thyroid hormones, growth hormone, insulin) and by the immune system (cytokines), and all these factors remain under central nervous system control.	Growth Hormone	342-356	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	252-268
15662082-3	2004	The mechanism underlying dopamine-induced regulation of the liver cytochrome P-450 expression seems not to be direct, but rather mediated by pituitary hormones and cytokines.	Dopamine	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
15696928-1	2004	AIM: To identify the cytochrome P450 (CYP) isoform (s) involved in daidzein mono-hydroxylated metabolites using human liver microsomes.	daidzein	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
15696928-1	2004	AIM: To identify the cytochrome P450 (CYP) isoform (s) involved in daidzein mono-hydroxylated metabolites using human liver microsomes.	daidzein	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
15696928-3	2004	Nine selective inhibitors or substrate probes specific for different CYP isoforms were applied for screening the isoform(s) responsible for mono-hydroxylated metabolism of daidzein.	daidzein	172-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	Nitrogen	88-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	Nitrogen	88-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	273-276
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	udenafil	130-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	udenafil	130-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	udenafil	130-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	273-276
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	DA-8164	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	DA-8164	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	DA-8164	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	273-276
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	udenafil	262-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
15801542-1	2004	The purpose of this paper was to characterize cytochrome P450 (CYP) enzymes involved in N-dealkylation of a new oral erectogenic, DA-8159 to DA-8164, a major circulating active metabolite, in human liver microsomes and to investigate the inhibitory potential of DA-8159 on CYP enzymes.	udenafil	262-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
15801542-2	2004	CYP3A4 was identified as the major enzyme responsible for DA-8159 N-dealkylation to DA-8164 based on correlation analysis and specific CYP inhibitor and antibody-mediated inhibition study in human liver microsomes, and DA-8159 metabolism in cDNA expressed CYP enzymes.	udenafil	58-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
15801542-2	2004	CYP3A4 was identified as the major enzyme responsible for DA-8159 N-dealkylation to DA-8164 based on correlation analysis and specific CYP inhibitor and antibody-mediated inhibition study in human liver microsomes, and DA-8159 metabolism in cDNA expressed CYP enzymes.	udenafil	58-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
15801542-2	2004	CYP3A4 was identified as the major enzyme responsible for DA-8159 N-dealkylation to DA-8164 based on correlation analysis and specific CYP inhibitor and antibody-mediated inhibition study in human liver microsomes, and DA-8159 metabolism in cDNA expressed CYP enzymes.	DA-8164	84-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
15801542-2	2004	CYP3A4 was identified as the major enzyme responsible for DA-8159 N-dealkylation to DA-8164 based on correlation analysis and specific CYP inhibitor and antibody-mediated inhibition study in human liver microsomes, and DA-8159 metabolism in cDNA expressed CYP enzymes.	udenafil	219-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
15801544-1	2004	The study was carried out to identify and characterize kinetically the cytochrome P450 (CYP) enzymes responsible for the major metabolite formation of quazepam.	quazepam	151-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
15801544-1	2004	The study was carried out to identify and characterize kinetically the cytochrome P450 (CYP) enzymes responsible for the major metabolite formation of quazepam.	quazepam	151-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
15382119-2	2004	At the hepatic level, the orphan nuclear constitutive androstane receptor (CAR) (NR1I3) controls phase I (cytochrome P450 [CYP] 2B and CYP3A), phase II (UGT1A1), and transporter (SLC21A6, MRP2) genes involved in drug metabolism and bilirubin clearance in response to xenobiotics such as phenobarbital or endobiotics such as bilirubin.	Bilirubin	324-333	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-130
15554232-2	2004	Upon application of this method to patients receiving different kinds of drug therapy, Herbert Remmer was the first to describe that total human hepatic cytochrome P450 was markedly elevated by the new anti-tuberculosis drug rifampicin.	Rifampin	225-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
15382119-2	2004	At the hepatic level, the orphan nuclear constitutive androstane receptor (CAR) (NR1I3) controls phase I (cytochrome P450 [CYP] 2B and CYP3A), phase II (UGT1A1), and transporter (SLC21A6, MRP2) genes involved in drug metabolism and bilirubin clearance in response to xenobiotics such as phenobarbital or endobiotics such as bilirubin.	Bilirubin	232-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-130
15356430-8	2004	Because several inflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting the metabolism of several endogenous lipophilic substances such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances, their irregularities in the body may eventually lead to the flare of latent diseases in some predisposed subjects.	Steroids	281-289	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
15382119-2	2004	At the hepatic level, the orphan nuclear constitutive androstane receptor (CAR) (NR1I3) controls phase I (cytochrome P450 [CYP] 2B and CYP3A), phase II (UGT1A1), and transporter (SLC21A6, MRP2) genes involved in drug metabolism and bilirubin clearance in response to xenobiotics such as phenobarbital or endobiotics such as bilirubin.	Phenobarbital	287-300	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-130
15764407-0	2004	Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP).	Chlorpyrifos	21-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
15764407-0	2004	Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP).	Diazinon	38-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	organophosphorothioate	60-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	organophosphorothioate	60-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	Chlorpyrifos	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	Chlorpyrifos	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	Diazinon	113-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15764407-1	2004	The cytochrome P450 (CYP)-mediated biotransformation of the organophosphorothioate insecticides chlorpyrifos and diazinon was investigated.	Diazinon	113-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15764407-9	2004	However, the role of individual CYP enzymes in these two biotransformation pathways varied according to the structure of the organophosphorothioate, which was reflected in different activation/detoxification ratios for chlorpyrifos and diazinon.	organophosphorothioate	125-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
15764407-9	2004	However, the role of individual CYP enzymes in these two biotransformation pathways varied according to the structure of the organophosphorothioate, which was reflected in different activation/detoxification ratios for chlorpyrifos and diazinon.	Chlorpyrifos	219-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
15764407-9	2004	However, the role of individual CYP enzymes in these two biotransformation pathways varied according to the structure of the organophosphorothioate, which was reflected in different activation/detoxification ratios for chlorpyrifos and diazinon.	Diazinon	236-244	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
15764407-10	2004	Variability in activity of individual CYP enzymes may influence interindividual sensitivity to the toxic effects of chlorpyrifos and diazinon.	Chlorpyrifos	116-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
15258138-0	2004	Radical rebound mechanism in cytochrome P-450-catalyzed hydroxylation of the multifaceted radical clocks alpha- and beta-thujone.	alpha- and beta-thujone	105-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
15764407-10	2004	Variability in activity of individual CYP enzymes may influence interindividual sensitivity to the toxic effects of chlorpyrifos and diazinon.	Diazinon	133-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
15356430-8	2004	Because several inflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting the metabolism of several endogenous lipophilic substances such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances, their irregularities in the body may eventually lead to the flare of latent diseases in some predisposed subjects.	Prostaglandins	315-329	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
15356430-8	2004	Because several inflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting the metabolism of several endogenous lipophilic substances such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances, their irregularities in the body may eventually lead to the flare of latent diseases in some predisposed subjects.	Leukotrienes	331-343	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
15356430-8	2004	Because several inflammatory cytokines down-regulate gene expression of major cytochrome P-450 and/or other enzymes with the specific effects on mRNA levels, protein expression, and enzyme activity, thus affecting the metabolism of several endogenous lipophilic substances such as steroids, lipid-soluble vitamins, prostaglandins, leukotrienes, thromboxanes, and exogenous substances, their irregularities in the body may eventually lead to the flare of latent diseases in some predisposed subjects.	Thromboxanes	345-357	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
15503650-4	2004	Cytochrome P450 metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) or epoxyeicosatrienoic acids (EETs) provides a mechanism for the constriction and relaxation of cerebral arteries, respectively.	Arachidonic Acid	30-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15314576-1	2004	The porphyrin complexes of manganese catalysts are biomimetic catalysts whose structural analogy with the active site of cytochrome P-450 enzymes can be used to obtain synthetic models of therapeutic agent metabolites.	Porphyrins	4-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
15314576-1	2004	The porphyrin complexes of manganese catalysts are biomimetic catalysts whose structural analogy with the active site of cytochrome P-450 enzymes can be used to obtain synthetic models of therapeutic agent metabolites.	Manganese	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
15503650-4	2004	Cytochrome P450 metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) or epoxyeicosatrienoic acids (EETs) provides a mechanism for the constriction and relaxation of cerebral arteries, respectively.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	50-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15503650-4	2004	Cytochrome P450 metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) or epoxyeicosatrienoic acids (EETs) provides a mechanism for the constriction and relaxation of cerebral arteries, respectively.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	83-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15503650-4	2004	Cytochrome P450 metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) or epoxyeicosatrienoic acids (EETs) provides a mechanism for the constriction and relaxation of cerebral arteries, respectively.	epoxyeicosatrienoic acids	95-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15503650-4	2004	Cytochrome P450 metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) or epoxyeicosatrienoic acids (EETs) provides a mechanism for the constriction and relaxation of cerebral arteries, respectively.	eets	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15669763-0	2004	Biomimetic oxidation of unactivated carbons in steroids by a model of cytochrome P-450, oxorutheniumporphyrinate complex.	Carbon	36-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
15669763-0	2004	Biomimetic oxidation of unactivated carbons in steroids by a model of cytochrome P-450, oxorutheniumporphyrinate complex.	Steroids	47-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
15669763-0	2004	Biomimetic oxidation of unactivated carbons in steroids by a model of cytochrome P-450, oxorutheniumporphyrinate complex.	oxorutheniumporphyrinate	88-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	Carbon	36-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	Steroids	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	oxorutheniumporphyrinate	126-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	2,6-dichloropyridine N-oxide	190-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	Oxygen	225-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	(5,10,15,20-tetramesitylporphyrinate) ruthenium(ii) carbonyl complex	242-310	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15669763-1	2004	Biomimetic oxidation of unactivated carbons for structurally different steroids was studied with a model of cytochrome P-450, oxorutheniumporphyrinate complex, which is generated in situ by 2,6-dichloropyridine N-oxide as an oxygen donor and (5,10,15,20-tetramesitylporphyrinate) ruthenium(II) carbonyl complex and HBr as catalysts.	Hydrobromic Acid	315-318	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
15247556-0	2004	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.	Lopinavir	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
15315710-0	2004	Inducible cytochrome P450 activities in renal glomerular mesangial cells: biochemical basis for antagonistic interactions among nephrocarcinogenic polycyclic aromatic hydrocarbons.	Polycyclic Aromatic Hydrocarbons	147-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15159443-0	2004	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.	Tamoxifen	28-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
15276085-1	2004	This study was aimed at identifying the isoform(s) of human liver cytochrome P450 (CYP) involved in the hepatic biotransformation of trans-resveratrol (trans-3,5,4"-trihydroxystilbene).	Resveratrol	133-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
15276085-1	2004	This study was aimed at identifying the isoform(s) of human liver cytochrome P450 (CYP) involved in the hepatic biotransformation of trans-resveratrol (trans-3,5,4"-trihydroxystilbene).	Resveratrol	133-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
15276085-1	2004	This study was aimed at identifying the isoform(s) of human liver cytochrome P450 (CYP) involved in the hepatic biotransformation of trans-resveratrol (trans-3,5,4"-trihydroxystilbene).	trans-3,5,4"-trihydroxystilbene	152-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
15276085-1	2004	This study was aimed at identifying the isoform(s) of human liver cytochrome P450 (CYP) involved in the hepatic biotransformation of trans-resveratrol (trans-3,5,4"-trihydroxystilbene).	trans-3,5,4"-trihydroxystilbene	152-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
15247556-0	2004	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.	Ritonavir	30-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
15247556-0	2004	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.	Phenytoin	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
15247556-1	2004	Lopinavir/ritonavir (LPV/RTV) is a CYP3A4 inhibitor and substrate; it also may induce cytochrome P-450 (CYP) isozymes.	Lopinavir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
15247556-1	2004	Lopinavir/ritonavir (LPV/RTV) is a CYP3A4 inhibitor and substrate; it also may induce cytochrome P-450 (CYP) isozymes.	Lopinavir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
15247556-1	2004	Lopinavir/ritonavir (LPV/RTV) is a CYP3A4 inhibitor and substrate; it also may induce cytochrome P-450 (CYP) isozymes.	Ritonavir	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
15247556-1	2004	Lopinavir/ritonavir (LPV/RTV) is a CYP3A4 inhibitor and substrate; it also may induce cytochrome P-450 (CYP) isozymes.	Ritonavir	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
15122071-2	2004	To assess the biotransformation and the potential implications for human pharmacology and toxicology, the in vitro metabolism of thiocoraline was characterized using human plasma, human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes and human cell lines.	thiocoraline	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-221
15289791-0	2004	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.	Yohimbine	64-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
15122071-2	2004	To assess the biotransformation and the potential implications for human pharmacology and toxicology, the in vitro metabolism of thiocoraline was characterized using human plasma, human liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes and human cell lines.	thiocoraline	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-226
15122071-4	2004	Using CYP supersomes it was shown that thiocoraline is mainly metabolized by CYP3A4, with CYP1A1, CYP2C8 and CYP2C9 playing a minor role in the biotransformation (&lt;3%).	thiocoraline	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
15122071-10	2004	These results provide evidence that human CYP3A4 plays a major role in the metabolism of thiocoraline in vitro and that the metabolites formed by CYP are conjugated by the phase II enzymes UGT, ST and GST.	thiocoraline	89-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
15145985-0	2004	Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides.	fatty acid epoxides	57-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-12
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	Estradiol	25-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-99
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	Estradiol	25-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	catecholestradiols	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-99
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	catecholestradiols	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	methoxyestradiols	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-99
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	methoxyestradiols	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	Estradiol	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-99
15292328-1	2004	Sequential conversion of estradiol to catecholestradiols and methoxyestradiols by cytochrome-P(450) (CYP450) and catechol-O-methyltransferase (COMT), respectively, contributes to the antimitogenic effects of estradiol on vascular smooth muscle cell (SMC) growth via estrogen receptor-independent mechanisms.	Estradiol	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-107
15145985-8	2004	Moreover, vicinal diol from both C18-epoxides and EETs were omega-hydroxylated by liver microsomes and by CYP4F2 and CYP4F3.	vicinal diol	10-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
15145985-8	2004	Moreover, vicinal diol from both C18-epoxides and EETs were omega-hydroxylated by liver microsomes and by CYP4F2 and CYP4F3.	c18-epoxides	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
15145985-8	2004	Moreover, vicinal diol from both C18-epoxides and EETs were omega-hydroxylated by liver microsomes and by CYP4F2 and CYP4F3.	eets	50-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-123
15285849-7	2004	However, flavonol aglycones, the biflavonol amentoflavone and several other non-glycosidic constituents are significant in-vitro inhibitors of CYP.	3-hydroxyflavone	9-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-146
15285849-7	2004	However, flavonol aglycones, the biflavonol amentoflavone and several other non-glycosidic constituents are significant in-vitro inhibitors of CYP.	aglycones	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-146
15285849-7	2004	However, flavonol aglycones, the biflavonol amentoflavone and several other non-glycosidic constituents are significant in-vitro inhibitors of CYP.	biflavonol amentoflavone	33-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-146
15672756-2	2004	It has previously been reported that N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100) was predominantly metabolized by cytochrome P450 (CYP) 2D6 in human liver microsomes (HLM).	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	37-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
15262846-1	2004	BACKGROUND: 20-hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 (omega-hydroxylase) metabolite of arachidonic acid with vasoconstrictor activity that may be involved in the pathogenesis of hypertension.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	12-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-93
15262846-1	2004	BACKGROUND: 20-hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 (omega-hydroxylase) metabolite of arachidonic acid with vasoconstrictor activity that may be involved in the pathogenesis of hypertension.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	45-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-93
15262846-1	2004	BACKGROUND: 20-hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 (omega-hydroxylase) metabolite of arachidonic acid with vasoconstrictor activity that may be involved in the pathogenesis of hypertension.	Arachidonic Acid	109-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-93
15238214-4	2004	The HL60 cells, which were differentiated into PMN-like shapes by treatment with all-trans-retinoic acid (RA), also expressed CYP4F3, CYP4F3B and CYP4F12.	Tretinoin	81-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-132
15238214-4	2004	The HL60 cells, which were differentiated into PMN-like shapes by treatment with all-trans-retinoic acid (RA), also expressed CYP4F3, CYP4F3B and CYP4F12.	Tretinoin	106-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-132
15238214-5	2004	CYP4F3 was expressed in one third of the peripheral monocytes, which omega-hydroxylated leukotriene B(4) (LTB(4)) at a rate 11 times lower than that of PMN.	Leukotriene B4	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
15238214-5	2004	CYP4F3 was expressed in one third of the peripheral monocytes, which omega-hydroxylated leukotriene B(4) (LTB(4)) at a rate 11 times lower than that of PMN.	Leukotriene B4	106-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
15238214-6	2004	The cells that were differentiated into a form similar to monocytes/macrophages in shape by treatment with 12-myristate 13-acetate expressed mRNA for CYP4F3 and CYP4F3B.	12-myristate 13-acetate	107-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-156
15248218-0	2004	Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.	Cyclophosphamide	91-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15248218-3	2004	Cyclophosphamide is a prodrug that requires activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
15248218-3	2004	Cyclophosphamide is a prodrug that requires activation by cytochrome P450 (CYP) enzymes.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
15248218-10	2004	CONCLUSION: Determination of selected cytochrome P450 enzyme genotypes may be valuable for predicting the risk of premature ovarian failure in lupus nephritis patients treated with cyclophosphamide.	Cyclophosphamide	181-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
15197521-1	2004	OBJECTIVE: This study aimed to investigate the importance of cytochrome P(450) enzymes for the reported interaction between tramadol and warfarin.	Tramadol	124-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-78
15197521-1	2004	OBJECTIVE: This study aimed to investigate the importance of cytochrome P(450) enzymes for the reported interaction between tramadol and warfarin.	Warfarin	137-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-78
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	desglymidodrine	80-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	desglymidodrine	80-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	Deanol	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	Deanol	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	Midodrine	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15537169-1	2004	The human cytochrome P450 (CYP) isoforms catalyzing the oxidation metabolism of desglymidodrine (DMAE), an active metabolite of midodrine, were studied.	Midodrine	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15537169-4	2004	Quinidine (a selective inhibitor of CYP2D6) inhibited the O-demethylation of DMAE in pooled human microsomes by 86%, while selective inhibitors for other forms of CYP did not show any appreciable effect.	Quinidine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
15537169-4	2004	Quinidine (a selective inhibitor of CYP2D6) inhibited the O-demethylation of DMAE in pooled human microsomes by 86%, while selective inhibitors for other forms of CYP did not show any appreciable effect.	Deanol	77-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
15672756-2	2004	It has previously been reported that N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100) was predominantly metabolized by cytochrome P450 (CYP) 2D6 in human liver microsomes (HLM).	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	37-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
15672756-3	2004	In the present study, the contribution of CYP forms involved in the formation of the major metabolites of NE-100 in human liver lacking CYP2D6 activity (PM-HLM) has been predicted by use of in vitro kinetic data on recombinant CYPs microsomes (rCYPs).	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	106-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
15081936-3	2004	Cytochrome P450 dependent epoxidation and non-enzymic lipid peroxidation of oleic acid (cis-9-octadecenoic acid) result in the formation of cis-9,10-epoxyoctadecanoic acid (cis-EODA).	9,10-epoxystearic acid	140-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
14751845-2	2004	We also explored the contribution of cytochrome P-450 (CYP450) product of arachidonic acid (AA) metabolism, hydrogen peroxide (H(2)O(2)), and gap junctions that have been suggested to be involved in EDHF-mediated responses.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
14751845-2	2004	We also explored the contribution of cytochrome P-450 (CYP450) product of arachidonic acid (AA) metabolism, hydrogen peroxide (H(2)O(2)), and gap junctions that have been suggested to be involved in EDHF-mediated responses.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-61
20945304-0	2004	Human cytochrome P450: metabolism of testosterone by CYP3A4 and inhibition by ketoconazole.	Testosterone	37-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
20945304-0	2004	Human cytochrome P450: metabolism of testosterone by CYP3A4 and inhibition by ketoconazole.	Ketoconazole	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
15204103-0	2004	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.	Cytarabine	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15204103-0	2004	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.	Idarubicin	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15204103-0	2004	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.	Itraconazole	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15204103-0	2004	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.	Caspofungin	115-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Cytarabine	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Cytarabine	115-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Idarubicin	129-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Idarubicin	129-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Itraconazole	145-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Itraconazole	145-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Caspofungin	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Caspofungin	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Cytarabine	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Cytarabine	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Cytarabine	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Idarubicin	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Idarubicin	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Idarubicin	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Caspofungin	119-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Caspofungin	119-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Caspofungin	119-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-5	2004	RESULTS: Idarubicin is a substrate for CYP450 2D6 and 2C9.	Idarubicin	9-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
15204103-6	2004	Cytarabine is a substrate of CYP450 3A4.	Cytarabine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-35
15204103-7	2004	Idarubicin inhibits CYP450 2D6, and cytarabine, itraconazole, and caspofungin inhibit CYP450 3A4.	Idarubicin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-26
15204103-7	2004	Idarubicin inhibits CYP450 2D6, and cytarabine, itraconazole, and caspofungin inhibit CYP450 3A4.	Cytarabine	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-92
15204103-7	2004	Idarubicin inhibits CYP450 2D6, and cytarabine, itraconazole, and caspofungin inhibit CYP450 3A4.	Caspofungin	66-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-92
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	4r-oh-ota	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	4r-oh-ota	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	4s-oh-ota	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	4s-oh-ota	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	ota-quinones	169-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
15046773-2	2004	OTA is metabolised by cytochrome P450 (CYP450) enzymes resulting in hydroxylated metabolites, 4R-OH-OTA and 4S-OH-OTA, and possibly in other minor metabolites including OTA-quinones.	ota-quinones	169-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-45
15180494-0	2004	Role of cytochrome P450 metabolites of arachidonic acid in hypertension.	Arachidonic Acid	39-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
15180494-1	2004	Considerable evidence has accumulated over the last decade implicating a role of cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA) in the pathogenesis of hypertension.	Arachidonic Acid	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
15180494-1	2004	Considerable evidence has accumulated over the last decade implicating a role of cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA) in the pathogenesis of hypertension.	Arachidonic Acid	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
15311563-4	2004	Posaconazole is a CYP3A4 inhibitor, but it does not inhibit the activity of other CYP enzymes.	posaconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
15081936-3	2004	Cytochrome P450 dependent epoxidation and non-enzymic lipid peroxidation of oleic acid (cis-9-octadecenoic acid) result in the formation of cis-9,10-epoxyoctadecanoic acid (cis-EODA).	9,10-epoxystearic acid	173-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15081398-0	2004	Cytochrome P450-dependent toxicity of environmental polycyclic aromatic hydrocarbons towards human macrophages.	Polycyclic Aromatic Hydrocarbons	52-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15128933-1	2004	The synthesis of bioactive vitamin D requires hydroxylation at the 1 alpha and 25 positions by cytochrome P450 enzymes in the kidney and liver, respectively.	Vitamin D	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
15081421-5	2004	Especially, the heme-thiolate containing proteins cytochrome P450(BM-3) (wild type and F87Y variant) and prostacyclin synthase were nitrated with high efficacy.	heme-thiolate	16-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-70
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	59-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15156965-6	2004	Gefitinib is metabolized by the cytochrome P-450 isoenzyme system and may be affected by other drugs that influence this enzyme activity.	Gefitinib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
14764421-5	2004	Under steady-state conditions, most of the de novo synthesis of cholesterol in the brain appears to be balanced by excretion of the cytochrome P-450-generated oxysterol 24S-hydroxycholesterol.	Oxysterols	159-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
14764421-5	2004	Under steady-state conditions, most of the de novo synthesis of cholesterol in the brain appears to be balanced by excretion of the cytochrome P-450-generated oxysterol 24S-hydroxycholesterol.	24-hydroxycholesterol	169-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	59-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	331-340	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15237850-1	2004	The cytochrome P450 (P450) field came out of interest in the metabolism of drugs, carcinogens, and steroids, which remain major focal points.	Steroids	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	80-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15237852-7	2004	Furthermore, the results provide proof of principle for NMR as a method for studying CYP allosterism, and demonstrate that the model ligand 9-aminophenanthrene binds in two discrete events to individual subsites within the active site of CYP(eryF).	9-aminophenanthrene	140-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	331-340	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15237852-7	2004	Furthermore, the results provide proof of principle for NMR as a method for studying CYP allosterism, and demonstrate that the model ligand 9-aminophenanthrene binds in two discrete events to individual subsites within the active site of CYP(eryF).	9-aminophenanthrene	140-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-241
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	80-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15237857-1	2004	Cytochrome P450 (CYP) enzymes in the brain may have a role in the activation or inactivation of centrally acting drugs, in the metabolism of endogenous compounds, and in the generation of damaging toxic metabolites and/or oxygen stress.	Oxygen	222-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15237857-1	2004	Cytochrome P450 (CYP) enzymes in the brain may have a role in the activation or inactivation of centrally acting drugs, in the metabolism of endogenous compounds, and in the generation of damaging toxic metabolites and/or oxygen stress.	Oxygen	222-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	4-hydroxy-N-desmethyltamoxifen	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	206-209
15111773-4	2004	A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy- N -desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome p450 (CYP) 206 ge notype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production.	Tamoxifen	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-204
15078344-1	2004	It has been shown that large doses of acetaminophen can result in increased degradation of the hepatic cytochrome P450 (CYP) enzymes in vivo; however, the proteolytic pathways have not been identified.	Acetaminophen	38-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
15043991-0	2004	Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.	Oleanolic Acid	44-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
15043991-0	2004	Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.	ursolic acid	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
15056479-0	2004	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.	Piperazine	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
15056479-0	2004	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.	phenothiazine	38-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
15056479-0	2004	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.	Perazine	24-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
15056479-1	2004	Identification of cytochrome P-450 isoenzymes (CYPs) involved in perazine 5-sulphoxidation and N-demethylation was carried out using human liver microsomes and cDNA-expressed human CYPs (Supersomes).	Perazine	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
15056479-1	2004	Identification of cytochrome P-450 isoenzymes (CYPs) involved in perazine 5-sulphoxidation and N-demethylation was carried out using human liver microsomes and cDNA-expressed human CYPs (Supersomes).	Nitrogen	95-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
15370958-0	2004	Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.	Glyburide	106-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
15370958-0	2004	Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.	Lansoprazole	124-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
15370958-2	2004	The identification and relative contributions of human cytochrome P450 (CYP) enzymes involved in the metabolism of glibenclamide and lansoprazole in human liver microsomes were investigated using an approach based on the in vitro disappearance rate of unchanged drug.	Glyburide	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
15370958-2	2004	The identification and relative contributions of human cytochrome P450 (CYP) enzymes involved in the metabolism of glibenclamide and lansoprazole in human liver microsomes were investigated using an approach based on the in vitro disappearance rate of unchanged drug.	Glyburide	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
15370958-2	2004	The identification and relative contributions of human cytochrome P450 (CYP) enzymes involved in the metabolism of glibenclamide and lansoprazole in human liver microsomes were investigated using an approach based on the in vitro disappearance rate of unchanged drug.	Lansoprazole	133-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
15370958-2	2004	The identification and relative contributions of human cytochrome P450 (CYP) enzymes involved in the metabolism of glibenclamide and lansoprazole in human liver microsomes were investigated using an approach based on the in vitro disappearance rate of unchanged drug.	Lansoprazole	133-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Glucuronides	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Glucuronides	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Sulfates	84-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Sulfates	84-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Steroids	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
15135080-5	2004	Hydroxylation by cytochrome P450 (CYP) enzymes and conjugation with glucuronide and sulfate are among the major hepatic pathways of steroid inactivation.	Steroids	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
15135080-7	2004	The barbiturate phenobarbital and the environmental toxicant 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) are among the well characterized inducers for the CYP 2B and 3A enzymes and selected conjugation enzymes.	barbituric acid	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
15135080-7	2004	The barbiturate phenobarbital and the environmental toxicant 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) are among the well characterized inducers for the CYP 2B and 3A enzymes and selected conjugation enzymes.	Phenobarbital	16-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
15135080-7	2004	The barbiturate phenobarbital and the environmental toxicant 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) are among the well characterized inducers for the CYP 2B and 3A enzymes and selected conjugation enzymes.	Dichlorodiphenyl Dichloroethylene	61-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
15135080-7	2004	The barbiturate phenobarbital and the environmental toxicant 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) are among the well characterized inducers for the CYP 2B and 3A enzymes and selected conjugation enzymes.	Dichlorodiphenyl Dichloroethylene	107-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
15078344-1	2004	It has been shown that large doses of acetaminophen can result in increased degradation of the hepatic cytochrome P450 (CYP) enzymes in vivo; however, the proteolytic pathways have not been identified.	Acetaminophen	38-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
15051744-12	2004	Since this isozyme had the lowest in vitro IC(50) values for the cytochrome P450s most commonly involved with the metabolism of drugs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), azimilide-related drug interactions mediated via these isozymes are not anticipated.	azimilide	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
15089095-1	2004	Cytochrome p450 (p450) 1A2 and NADPH-P450 reductase (NPR) catalyzed the oxidation of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), with consumption of NADPH.	2-amino-3-methylimidazo(4,5-f)quinoline	85-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
15066665-0	2004	Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.	posaconazole	10-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
15066665-2	2004	In this randomised, open-label, two-way crossover study, the potential for drug interactions with posaconazole via the cytochrome P450 (CYP450) enzyme pathway was evaluated.	posaconazole	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
15066665-2	2004	In this randomised, open-label, two-way crossover study, the potential for drug interactions with posaconazole via the cytochrome P450 (CYP450) enzyme pathway was evaluated.	posaconazole	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15066665-9	2004	Drug interactions mediated by various CYP450 are common with the currently available triazole antifungals, however these results suggest that posaconazole may have an improved and more narrow drug interaction profile (CYP3A4 only) compared with other triazoles.	posaconazole	142-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-44
15268978-0	2004	Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone.	Hydromorphone	79-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
15102545-1	2004	The human cytochrome P450 (CYP) complement of heme-thiolate enzymes is reviewed.	Heme	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
15102545-1	2004	The human cytochrome P450 (CYP) complement of heme-thiolate enzymes is reviewed.	Heme	46-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
15041065-8	2004	This mini-review gives a summary and commentary on early studies on effects of lead on haem metabolism that provide us the clue to why investigations of the impacts of other toxic heavy metals and metalloids such as cadmium and arsenic on different human cytochrome P450 forms have become of great interest at the current time.	Cadmium	216-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	255-270
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Nitrogen	104-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Nitrogen	104-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Hydromorphone	123-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Hydromorphone	123-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Hydromorphone	245-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
15268978-2	2004	The aim was to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other hydromorphone metabolites.	Hydromorphone	245-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
15104117-0	2004	Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP).	ethylbenzene	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
14993813-0	2004	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.	nilvadipine	10-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
14993813-1	2004	The effects of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	nilvadipine	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
14993813-1	2004	The effects of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	nilvadipine	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
14504090-6	2004	These data suggest that azole antifungals, through differential inhibition of hepatic cytochrome P-450 isoenzymes, affect CY metabolism and conditioning-related toxicities.	Azoles	24-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
14998432-1	2004	AIMS: To identify the cytochrome p450 (CYP) enzyme(s) that catalyze the metabolism of tizanidine in vitro.	tizanidine	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
14998432-1	2004	AIMS: To identify the cytochrome p450 (CYP) enzyme(s) that catalyze the metabolism of tizanidine in vitro.	tizanidine	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
14998432-2	2004	METHODS: The effect of CYP isoform inhibitors on the elimination of tizanidine was studied using pooled human liver microsomes.	tizanidine	68-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
14660610-0	2004	CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids.	Fatty Acids	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-95
15202615-1	2004	PURPOSE OF REVIEW: Cytochrome P-450 metabolites of arachidonic acid have been reported to play an important role in the control of renal function and vascular tone, and in the long-term control of arterial pressure.	Arachidonic Acid	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
15202615-4	2004	RECENT FINDINGS: Studies have demonstrated that the expression of cytochrome P-450 enzymes and the synthesis of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in the kidney and peripheral vasculature are altered in many genetic and experimental models of hypertension.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	112-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
15202615-4	2004	RECENT FINDINGS: Studies have demonstrated that the expression of cytochrome P-450 enzymes and the synthesis of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in the kidney and peripheral vasculature are altered in many genetic and experimental models of hypertension.	epoxyeicosatrienoic acids	148-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
15202615-7	2004	SUMMARY: This review summarizes recent findings that address the issue of whether cytochrome P-450 metabolites of arachidonic acid play an important role in the regulation of renal tubular and peripheral vascular function and contribute to the pathogenesis of hypertension.	Arachidonic Acid	114-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
15038401-3	2004	Potent inductors of CYP isoenzymes are carbamazepine, phenobarbital, phenytoin, and primidone, thereby decreasing not only their own plasma levels and efficacy but also that of other antiepileptics and other drugs.	Carbamazepine	39-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
15038401-3	2004	Potent inductors of CYP isoenzymes are carbamazepine, phenobarbital, phenytoin, and primidone, thereby decreasing not only their own plasma levels and efficacy but also that of other antiepileptics and other drugs.	Phenobarbital	54-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
15038401-3	2004	Potent inductors of CYP isoenzymes are carbamazepine, phenobarbital, phenytoin, and primidone, thereby decreasing not only their own plasma levels and efficacy but also that of other antiepileptics and other drugs.	Phenytoin	69-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
15038401-3	2004	Potent inductors of CYP isoenzymes are carbamazepine, phenobarbital, phenytoin, and primidone, thereby decreasing not only their own plasma levels and efficacy but also that of other antiepileptics and other drugs.	Primidone	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-23
15038401-4	2004	Felbamate, oxcarbazepine, and topiramate are weak inductors of the CYP isoenzyme 3A4, whereas they inhibit CYP2C19.	Felbamate	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
15038401-4	2004	Felbamate, oxcarbazepine, and topiramate are weak inductors of the CYP isoenzyme 3A4, whereas they inhibit CYP2C19.	Oxcarbazepine	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
15038401-4	2004	Felbamate, oxcarbazepine, and topiramate are weak inductors of the CYP isoenzyme 3A4, whereas they inhibit CYP2C19.	Topiramate	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
15038401-5	2004	Valproic acid is a potent inhibitor of several CYP isoenzymes and glucuronyltransferases, resulting in an increase in plasma concentrations and toxicity of antiepileptics and other drugs.	Valproic Acid	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
15013014-0	2004	Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.	trans epoxides	45-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-21
15013014-0	2004	Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.	trans-arachidonic acids	65-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-21
15013014-2	2004	We found that hepatic microsomes oxidized trans-AA via cytochrome P450/NADPH system to epoxides, which were hydrolyzed by epoxide hydrolase to diols (DiHETEs).	Epoxy Compounds	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-76
15013014-2	2004	We found that hepatic microsomes oxidized trans-AA via cytochrome P450/NADPH system to epoxides, which were hydrolyzed by epoxide hydrolase to diols (DiHETEs).	diols	143-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-76
15013014-2	2004	We found that hepatic microsomes oxidized trans-AA via cytochrome P450/NADPH system to epoxides, which were hydrolyzed by epoxide hydrolase to diols (DiHETEs).	dihetes	150-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-76
14729370-2	2004	To investigate the cytochrome P450 (CYP) isoform involved in the activation of 10-azaBaP to the genotoxic form, the mutagenicity of 10-azaBaP using nine individual donors" and pooled human liver microsome preparations was compared with each CYP activity.	10-azabenzo(a)pyrene	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14729370-2	2004	To investigate the cytochrome P450 (CYP) isoform involved in the activation of 10-azaBaP to the genotoxic form, the mutagenicity of 10-azaBaP using nine individual donors" and pooled human liver microsome preparations was compared with each CYP activity.	10-azabenzo(a)pyrene	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14729370-2	2004	To investigate the cytochrome P450 (CYP) isoform involved in the activation of 10-azaBaP to the genotoxic form, the mutagenicity of 10-azaBaP using nine individual donors" and pooled human liver microsome preparations was compared with each CYP activity.	10-azabenzo(a)pyrene	132-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14729370-7	2004	With regard to the proposal that BaP may be activated by human CYP1A1, our results suggest that the nitrogen-substitution at position-10 of BaP may cause the CYP enzyme-specificity in metabolic activation to change from CYP1A1 to CYP1A2.	Benzo(a)pyrene	33-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
14729370-7	2004	With regard to the proposal that BaP may be activated by human CYP1A1, our results suggest that the nitrogen-substitution at position-10 of BaP may cause the CYP enzyme-specificity in metabolic activation to change from CYP1A1 to CYP1A2.	Nitrogen	100-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
14729370-7	2004	With regard to the proposal that BaP may be activated by human CYP1A1, our results suggest that the nitrogen-substitution at position-10 of BaP may cause the CYP enzyme-specificity in metabolic activation to change from CYP1A1 to CYP1A2.	Benzo(a)pyrene	140-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
14744142-1	2004	Cytochrome P450 (P450) 1A2 is the major enzyme involved in the metabolism of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline (MeIQ) and other heterocyclic arylamines and their bioactivation to mutagens.	3H-Imidazo(4,5-f)quinolin-2-amine, 3,5-dimethyl-	77-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
14744142-1	2004	Cytochrome P450 (P450) 1A2 is the major enzyme involved in the metabolism of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline (MeIQ) and other heterocyclic arylamines and their bioactivation to mutagens.	2-amino-3,4-dimethylimidazo(4,5-f)quinoline	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
14744142-1	2004	Cytochrome P450 (P450) 1A2 is the major enzyme involved in the metabolism of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline (MeIQ) and other heterocyclic arylamines and their bioactivation to mutagens.	aniline	151-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
15022728-2	2004	This study was performed to identify the metabolic pathway of KR-31543 in human liver microsomes and to characterize cytochrome P450 (CYP) enzymes that are involved in the metabolism of KR-31543.	Krypton	62-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
15022728-2	2004	This study was performed to identify the metabolic pathway of KR-31543 in human liver microsomes and to characterize cytochrome P450 (CYP) enzymes that are involved in the metabolism of KR-31543.	Krypton	62-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	Rifampin	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	Rifampin	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	simvastatin acid	162-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	simvastatin acid	162-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14985146-0	2004	In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.	1-(4-methoxyphenyl)piperazine	44-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
15049511-0	2004	Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.	Tranylcypromine	54-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
15049511-2	2004	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	Tranylcypromine	26-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
15049511-2	2004	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	Tranylcypromine	26-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
15049511-6	2004	A range of substrate concentrations was coincubated with a range of tranylcypromine concentrations in the presence of each of the CYP enzymes at 37 degrees C for a predetermined period of time.	Tranylcypromine	68-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
14730412-1	2004	BACKGROUND: In vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P(450) (CYP) 2D6 enzyme and co-administration of deramciclane and the CYP2D6 probe drug desipramine is possible in clinical practice.	Desipramine	213-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-131
14730412-1	2004	BACKGROUND: In vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P(450) (CYP) 2D6 enzyme and co-administration of deramciclane and the CYP2D6 probe drug desipramine is possible in clinical practice.	Desipramine	213-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
14610241-1	2004	In the studies reported here, the ability of atomoxetine hydrochloride (Strattera) to inhibit or induce the metabolic capabilities of selected human isoforms of cytochrome P450 was evaluated.	Atomoxetine Hydrochloride	45-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-176
14630070-5	2004	Testosterone was used as a marker substrate for cytochrome P450 mediated drug metabolism (phase I).	Testosterone	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
14985146-0	2004	In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.	1-(4-methoxyphenyl)piperazine	75-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
14698415-1	2004	Heterocyclic amines (HCAs) produced by cooking meat products at high temperatures are promutagens that are activated by cytochrome P450 (CYP) lA2.	heterocyclic amines	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
14698415-1	2004	Heterocyclic amines (HCAs) produced by cooking meat products at high temperatures are promutagens that are activated by cytochrome P450 (CYP) lA2.	heterocyclic amines	0-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
14698415-1	2004	Heterocyclic amines (HCAs) produced by cooking meat products at high temperatures are promutagens that are activated by cytochrome P450 (CYP) lA2.	hcas	21-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
14698415-1	2004	Heterocyclic amines (HCAs) produced by cooking meat products at high temperatures are promutagens that are activated by cytochrome P450 (CYP) lA2.	hcas	21-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
14709907-0	2004	Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.	Cefixime	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
15344842-2	2004	Almost the entire radioactivity was from the unchanged substance or lactone form in human hepatocytes, and the cytochrome P450 (CYP)-mediated metabolism of pitavastatin was negligible.	pitavastatin	156-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-126
15344842-2	2004	Almost the entire radioactivity was from the unchanged substance or lactone form in human hepatocytes, and the cytochrome P450 (CYP)-mediated metabolism of pitavastatin was negligible.	pitavastatin	156-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
15285699-6	2004	Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes.	Pravastatin	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
15285699-6	2004	Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes.	Pravastatin	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
15285699-6	2004	Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes.	Rosuvastatin Calcium	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
15285699-6	2004	Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes.	Rosuvastatin Calcium	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
14709907-0	2004	Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.	Cefdinir	23-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
14709907-0	2004	Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.	Cephalosporins	38-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cephalosporins	33-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cephalosporins	33-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cefixime	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cefixime	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cefdinir	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14709907-1	2004	The effects of two kinds of oral cephalosporins, cefixime and cefdinir, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.	Cefdinir	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14729637-1	2004	Cytochrome P450 (CYP) gene transfer sensitizes tumor xenografts to anticancer prodrugs such as cyclophosphamide (CPA) without a detectable increase in host toxicity.	Cyclophosphamide	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
14729637-1	2004	Cytochrome P450 (CYP) gene transfer sensitizes tumor xenografts to anticancer prodrugs such as cyclophosphamide (CPA) without a detectable increase in host toxicity.	Cyclophosphamide	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
14729637-1	2004	Cytochrome P450 (CYP) gene transfer sensitizes tumor xenografts to anticancer prodrugs such as cyclophosphamide (CPA) without a detectable increase in host toxicity.	Cyclophosphamide	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
14729637-1	2004	Cytochrome P450 (CYP) gene transfer sensitizes tumor xenografts to anticancer prodrugs such as cyclophosphamide (CPA) without a detectable increase in host toxicity.	Cyclophosphamide	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
14628297-1	2004	Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
31394618-0	2004	Altered Levels of Cytochrome P450 Genes in Hepatitis B or C Virus-infected Liver Identified by Oligonucleotide Microarray.	Oligonucleotides	95-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
14628297-1	2004	Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
14628297-4	2004	The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively.	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine	127-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
14628297-1	2004	Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP.	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
14628297-4	2004	The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively.	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	178-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
14628297-1	2004	Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP.	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
14628297-4	2004	The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively.	Methadone	197-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
14628297-4	2004	The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively.	Methadone	272-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
14628297-3	2004	The cytochrome P450 (CYP) isoform involved in methadone"s metabolism is thought to be CYP3A4, but human drug-drug interaction studies are not consistent with this.	Methadone	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
14628297-3	2004	The cytochrome P450 (CYP) isoform involved in methadone"s metabolism is thought to be CYP3A4, but human drug-drug interaction studies are not consistent with this.	Methadone	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
14628297-8	2004	Michaelis-Menten kinetic data demonstrated that CYP2B6 had the highest V(max) (44 ng/min/10pmol) and the lowest K(m) (12.6 microg/ml) for EDDP formation of all the CYP isoforms.	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	138-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
14715049-15	2004	The main CYP isoforms involved are CYP3A4 for lidocaine and bupivacaine and CYP1A2 for ropivacaine.	Ropivacaine	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
15509184-15	2004	Although bicalutamide is a CYP inducer in laboratory animals, dosages &lt; or = 150 mg/day have shown no evidence of enzyme induction in humans.	bicalutamide	9-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
14715049-15	2004	The main CYP isoforms involved are CYP3A4 for lidocaine and bupivacaine and CYP1A2 for ropivacaine.	Lidocaine	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
14715049-15	2004	The main CYP isoforms involved are CYP3A4 for lidocaine and bupivacaine and CYP1A2 for ropivacaine.	Bupivacaine	60-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
15244495-7	2004	Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations, diurnal rhythm, food administration, corticosteroid dosage, diarrhoea and cytochrome P450 (CYP) isoenzyme and P-glycoprotein expression.	Tacrolimus	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	341-356
15244495-7	2004	Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations, diurnal rhythm, food administration, corticosteroid dosage, diarrhoea and cytochrome P450 (CYP) isoenzyme and P-glycoprotein expression.	Tacrolimus	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	358-361
15509184-11	2004	Bicalutamide appears to be cleared almost exclusively by metabolism; this is largely mediated by cytochrome P450 (CYP) for (R)-bicalutamide, but glucuronidation is the predominant metabolic route for (S)-bicalutamide.	bicalutamide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
15509184-11	2004	Bicalutamide appears to be cleared almost exclusively by metabolism; this is largely mediated by cytochrome P450 (CYP) for (R)-bicalutamide, but glucuronidation is the predominant metabolic route for (S)-bicalutamide.	bicalutamide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
15509184-11	2004	Bicalutamide appears to be cleared almost exclusively by metabolism; this is largely mediated by cytochrome P450 (CYP) for (R)-bicalutamide, but glucuronidation is the predominant metabolic route for (S)-bicalutamide.	(R)-Bicalutamide	123-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
15611610-4	2004	Biochemical studies indicated that the Erg11p from the TIMM3209 strain showed reduced susceptibility both to fluconazole and itraconazole of cell-free ergosterol biosynthesis, and cytochrome P-450 also showed reduced affinity to fluconazole in the carbon monoxidecytochrome P-450 complex formation assay.	Fluconazole	229-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
15509184-11	2004	Bicalutamide appears to be cleared almost exclusively by metabolism; this is largely mediated by cytochrome P450 (CYP) for (R)-bicalutamide, but glucuronidation is the predominant metabolic route for (S)-bicalutamide.	(R)-Bicalutamide	123-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
15760805-4	2004	The pharmacokinetics of oral oxycodone differs from oral morphine in that it has a higher bioavailability, a slightly longer half-life, and is hepatically metabolized by cytochrome P450 rather than undergoing glucuronidation.	Oxycodone	29-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-185
15611610-6	2004	We found that the cytochrome P-450 from the TIMM3209 strain decayed during incubation at 37 C without fluconazole although it is unknown whether or not the phenomenon is linked to the resistant phenotype.	Fluconazole	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
14966856-4	2004	When ethoxidine was incubated with BNF-treated rat liver microsomes or with cells expressing different recombinant human cytochrome P450, the same four ethoxidine metabolites (m(1)-m(4)) were detected and were formed exclusively by CYP1A1.	ethoxidine	5-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
15379059-1	2004	Cytochrome P450 (CYP) enzymes participate in the metabolism of a variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2.	NADP	141-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15379059-1	2004	Cytochrome P450 (CYP) enzymes participate in the metabolism of a variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2.	NADP	141-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
15379059-1	2004	Cytochrome P450 (CYP) enzymes participate in the metabolism of a variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2.	Oxygen	151-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
15379059-1	2004	Cytochrome P450 (CYP) enzymes participate in the metabolism of a variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2.	Oxygen	151-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
14966856-4	2004	When ethoxidine was incubated with BNF-treated rat liver microsomes or with cells expressing different recombinant human cytochrome P450, the same four ethoxidine metabolites (m(1)-m(4)) were detected and were formed exclusively by CYP1A1.	ethoxidine	152-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Fluconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
12966104-4	2003	These are reminiscent of the mechanism of cytochrome P-450, where a heme iron stabilizes the activated O2 species.	Heme	68-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
12966104-4	2003	These are reminiscent of the mechanism of cytochrome P-450, where a heme iron stabilizes the activated O2 species.	Iron	73-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
12966104-4	2003	These are reminiscent of the mechanism of cytochrome P-450, where a heme iron stabilizes the activated O2 species.	Oxygen	103-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
12966104-9	2003	In the context of the open and fully solvent-accessible active site for the homologous peptidylglycine-alpha-hydroxylating monooxygenase and by analogy to cytochrome P-450, the accumulation of a reduced and activated oxygen species in DbetaM before C-H cleavage would be expected to give some uncoupling of oxygen and substrate consumption.	Oxygen	127-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
12966104-9	2003	In the context of the open and fully solvent-accessible active site for the homologous peptidylglycine-alpha-hydroxylating monooxygenase and by analogy to cytochrome P-450, the accumulation of a reduced and activated oxygen species in DbetaM before C-H cleavage would be expected to give some uncoupling of oxygen and substrate consumption.	Oxygen	217-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Fluconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Fluconazole	13-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Fluconazole	13-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Phenytoin	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Phenytoin	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Phenytoin	128-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
14580893-1	2003	Fluconazole (FCZ) is a potent inhibitor of the cytochrome P450 (CYP)-mediated metabolism of the anti-epileptic agent phenytoin (PHT), a well-known human and animal teratogen.	Phenytoin	128-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
14580893-2	2003	It has been postulated that phenytoin must be bioactivated via the CYP system to initiate teratogenesis.	Phenytoin	28-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
14684755-2	2003	In the liver, fatty acids can be metabolized by cytochrome P450 (CYP) enzymes, but little is known about the role of these enzymes in the vascular endothelium.	Fatty Acids	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
14689466-5	2003	The chemical inhibition and correlation data indicated that the following substrates can be used as specific functional probes for individual cytochrome P450 present in human liver microsomes: coumarin for CYP2A6 (r=0.82), AMMC for CYP2D6 (r=0.83) and DBF for CYP3A4 (r=0.92).	coumarin	193-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
14689466-5	2003	The chemical inhibition and correlation data indicated that the following substrates can be used as specific functional probes for individual cytochrome P450 present in human liver microsomes: coumarin for CYP2A6 (r=0.82), AMMC for CYP2D6 (r=0.83) and DBF for CYP3A4 (r=0.92).	ammc	223-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
14689466-5	2003	The chemical inhibition and correlation data indicated that the following substrates can be used as specific functional probes for individual cytochrome P450 present in human liver microsomes: coumarin for CYP2A6 (r=0.82), AMMC for CYP2D6 (r=0.83) and DBF for CYP3A4 (r=0.92).	dibenzylfluorescein	252-255	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
14652237-1	2003	BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes.	Tamoxifen	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
14652237-1	2003	BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes.	Tamoxifen	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
14652237-1	2003	BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes.	4'-hydroxytamoxifen	87-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
14652237-1	2003	BACKGROUND: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes.	4'-hydroxytamoxifen	87-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-159
14652237-6	2003	To determine which CYP isoforms were involved in the metabolism of tamoxifen to specific metabolites, we used CYP isoform-specific inhibitors.	Tamoxifen	67-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
14652237-6	2003	To determine which CYP isoforms were involved in the metabolism of tamoxifen to specific metabolites, we used CYP isoform-specific inhibitors.	Tamoxifen	67-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
14684755-2	2003	In the liver, fatty acids can be metabolized by cytochrome P450 (CYP) enzymes, but little is known about the role of these enzymes in the vascular endothelium.	Fatty Acids	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
14684755-4	2003	We investigated the role of CYP-mediated mechanisms of linoleic acid metabolism in endothelial cell activation by examining the effects of linoleic acid or its oxidized metabolites such as LTX and leukotoxin diol (LTD).	Linoleic Acid	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
14668935-4	2003	In humans, however, azole antifungals also interfere with several hepatic and intestinal cytochrome P-450 isoenzymes responsible for the metabolism of numerous drugs.	Azoles	20-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
14570773-5	2003	In contrast to microsomes, the oxidation of rofecoxib to 5-hydroxyrofecoxib by S9 fractions followed two pathways, one NADPH-dependent and one NAD+-dependent (non-cytochrome P450), with the latter accounting for about 40% of total activity.	rofecoxib	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
14570773-5	2003	In contrast to microsomes, the oxidation of rofecoxib to 5-hydroxyrofecoxib by S9 fractions followed two pathways, one NADPH-dependent and one NAD+-dependent (non-cytochrome P450), with the latter accounting for about 40% of total activity.	5-hydroxyrofecoxib	57-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-178
12970580-6	2003	Co-treatment of PC3/AR cells with SKF-525A, a nonselective inhibitor of cytochrome P450 (CYP) enzymes, enhanced the antiandrogenic effect, indicating that the antiandrogenic effect is caused by intact species of DEPE constituents.	Proadifen	34-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
12970580-6	2003	Co-treatment of PC3/AR cells with SKF-525A, a nonselective inhibitor of cytochrome P450 (CYP) enzymes, enhanced the antiandrogenic effect, indicating that the antiandrogenic effect is caused by intact species of DEPE constituents.	Proadifen	34-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
14742142-0	2003	Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543.	cp-195	126-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
14742142-2	2003	The major human cytochrome P450 (CYP) form(s) responsible for the metabolism of CP-195,543, a potent leukotriene B4 antagonist, were investigated.	cp-195	80-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
14742142-2	2003	The major human cytochrome P450 (CYP) form(s) responsible for the metabolism of CP-195,543, a potent leukotriene B4 antagonist, were investigated.	cp-195	80-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
14742142-2	2003	The major human cytochrome P450 (CYP) form(s) responsible for the metabolism of CP-195,543, a potent leukotriene B4 antagonist, were investigated.	Leukotriene B4	101-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
14742142-2	2003	The major human cytochrome P450 (CYP) form(s) responsible for the metabolism of CP-195,543, a potent leukotriene B4 antagonist, were investigated.	Leukotriene B4	101-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
14742144-2	2003	Studies using human liver microsomes and recombinant human cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) were performed to identify the enzymes responsible for the metabolism of S-methyl-esonarimod (M2), an active metabolite of esonarimod (KE-298, a novel antirheumatic drug).	esonarimod	205-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
14742144-2	2003	Studies using human liver microsomes and recombinant human cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) were performed to identify the enzymes responsible for the metabolism of S-methyl-esonarimod (M2), an active metabolite of esonarimod (KE-298, a novel antirheumatic drug).	esonarimod	205-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
14742144-2	2003	Studies using human liver microsomes and recombinant human cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) were performed to identify the enzymes responsible for the metabolism of S-methyl-esonarimod (M2), an active metabolite of esonarimod (KE-298, a novel antirheumatic drug).	esonarimod	246-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
14742144-2	2003	Studies using human liver microsomes and recombinant human cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) were performed to identify the enzymes responsible for the metabolism of S-methyl-esonarimod (M2), an active metabolite of esonarimod (KE-298, a novel antirheumatic drug).	esonarimod	258-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
14678248-0	2003	Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.	Tamoxifen	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
14678248-0	2003	Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.	z-4-hydroxy-tamoxifen	37-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
14678248-8	2003	Cytochrome P450 (CYP) isoform-specific chemical and monoclonal antibody inhibition studies have demonstrated that CYP2B6, CYP2C9, CYP2D6 and CYP3A4 all mediate the formation of Z-4-OH-tam.	z-4-oh-tam	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
14678248-8	2003	Cytochrome P450 (CYP) isoform-specific chemical and monoclonal antibody inhibition studies have demonstrated that CYP2B6, CYP2C9, CYP2D6 and CYP3A4 all mediate the formation of Z-4-OH-tam.	z-4-oh-tam	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
14678248-10	2003	Significant associations between the percentage inhibition of Z-4-OH-tam by CYP isoform-specific inhibitors and the rate of metabolism of CYP isoform-specific index reactions and between individual expression of CYP2B6, CYP2C9 and CYP2D6 and Z-4-OH-tam formation rates indicate predominant roles for these isoforms in this pathway.	z-4-oh-tam	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
14678248-10	2003	Significant associations between the percentage inhibition of Z-4-OH-tam by CYP isoform-specific inhibitors and the rate of metabolism of CYP isoform-specific index reactions and between individual expression of CYP2B6, CYP2C9 and CYP2D6 and Z-4-OH-tam formation rates indicate predominant roles for these isoforms in this pathway.	z-4-oh-tam	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
14678248-10	2003	Significant associations between the percentage inhibition of Z-4-OH-tam by CYP isoform-specific inhibitors and the rate of metabolism of CYP isoform-specific index reactions and between individual expression of CYP2B6, CYP2C9 and CYP2D6 and Z-4-OH-tam formation rates indicate predominant roles for these isoforms in this pathway.	z-4-oh-tam	242-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
14678248-10	2003	Significant associations between the percentage inhibition of Z-4-OH-tam by CYP isoform-specific inhibitors and the rate of metabolism of CYP isoform-specific index reactions and between individual expression of CYP2B6, CYP2C9 and CYP2D6 and Z-4-OH-tam formation rates indicate predominant roles for these isoforms in this pathway.	z-4-oh-tam	242-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
14517708-1	2003	RATIONALE AND OBJECTIVE: Bromazepam, an anti-anxiety agent, has been reported to be metabolized by cytochrome P(450) (CYP).	Bromazepam	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-116
14517708-1	2003	RATIONALE AND OBJECTIVE: Bromazepam, an anti-anxiety agent, has been reported to be metabolized by cytochrome P(450) (CYP).	Bromazepam	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
14550947-0	2003	DNA adduct formation by the environmental contaminant 3-nitrobenzanthrone in V79 cells expressing human cytochrome P450 enzymes.	3-nitrobenzanthrone	54-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
12892558-3	2003	In particular, there has been considerable support for a role for the cytochrome P450 metabolites, the epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	103-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
12892558-3	2003	In particular, there has been considerable support for a role for the cytochrome P450 metabolites, the epoxyeicosatrienoic acids (EETs).	eets	130-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
14522569-1	2003	AIMS: Clopidogrel is a pro-drug which is converted to an active, unstable drug by cytochrome P450 (CYP).	Clopidogrel	6-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
14522569-1	2003	AIMS: Clopidogrel is a pro-drug which is converted to an active, unstable drug by cytochrome P450 (CYP).	Clopidogrel	6-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-102
14522569-3	2003	It has been recently suggested that the most abundant human CYP isoform, 3A4, activates clopidogrel.	Clopidogrel	88-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
12904931-0	2003	Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.	Fluorouracil	21-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-62
22900324-0	2003	Cytochrome P450-mediated oxidative damage of nuclear membrane proteins and its prevention by vitamin C.	Ascorbic Acid	93-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12943422-0	2003	Products of cytochrome P450(BioI) (CYP107H1)-catalyzed oxidation of fatty acids.	Fatty Acids	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-33
12943422-1	2003	[reaction: see text] Oxidation of tetradecanoic and hexadecanoic acids by cytochrome P450(BioI) (CYP107H1) produces mainly the 11-, 12-, and 13-hydroxy C(14) fatty acids and the 11- to 15-hydroxy C(16) fatty acids, respectively.	tetradecanoic	34-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-95
12943422-1	2003	[reaction: see text] Oxidation of tetradecanoic and hexadecanoic acids by cytochrome P450(BioI) (CYP107H1) produces mainly the 11-, 12-, and 13-hydroxy C(14) fatty acids and the 11- to 15-hydroxy C(16) fatty acids, respectively.	Palmitic Acid	52-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-95
12943422-1	2003	[reaction: see text] Oxidation of tetradecanoic and hexadecanoic acids by cytochrome P450(BioI) (CYP107H1) produces mainly the 11-, 12-, and 13-hydroxy C(14) fatty acids and the 11- to 15-hydroxy C(16) fatty acids, respectively.	Fatty Acids	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-95
12943422-1	2003	[reaction: see text] Oxidation of tetradecanoic and hexadecanoic acids by cytochrome P450(BioI) (CYP107H1) produces mainly the 11-, 12-, and 13-hydroxy C(14) fatty acids and the 11- to 15-hydroxy C(16) fatty acids, respectively.	Fatty Acids	202-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-95
12919179-1	2003	AIMS: To identify the principal human cytochrome P450 (CYP) enzyme(s) responsible for the human in vitro biotransformation of repaglinide.	repaglinide	126-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
12919179-1	2003	AIMS: To identify the principal human cytochrome P450 (CYP) enzyme(s) responsible for the human in vitro biotransformation of repaglinide.	repaglinide	126-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12919179-3	2003	METHODS: [14C]-Repaglinide was incubated with recombinant CYP and with human liver microsomes (HLM) from individual donors in the presence of inhibitory antibodies specific for individual CYP enzymes.	repaglinide	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
12919179-3	2003	METHODS: [14C]-Repaglinide was incubated with recombinant CYP and with human liver microsomes (HLM) from individual donors in the presence of inhibitory antibodies specific for individual CYP enzymes.	repaglinide	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
12919179-18	2003	This dual CYP biotransformation may have consequences for the clinical pharmacokinetics and drug-drug interactions involving repaglinide if one CYP pathway has sufficient capacity to compensate if the other is inhibited.	repaglinide	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
12919179-18	2003	This dual CYP biotransformation may have consequences for the clinical pharmacokinetics and drug-drug interactions involving repaglinide if one CYP pathway has sufficient capacity to compensate if the other is inhibited.	repaglinide	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
14604738-9	2003	Because ezetimibe is eliminated primarily by glucuronidation and not by cytochrome P450 (CYP) oxidation, it is subject to minimal drug interactions involving the CYP enzyme system.	Ezetimibe	8-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12920490-9	2003	We identified hepatic CYP enzymes responsible for metabolism of some compounds (praziquantel-1A2, 2C19, 3A4; primaquine-1A2, 3A4; chloroquine-2C8, 2D6, 3A4; artesunate-2A6; pyrantel-2D6).	pyrantel-2d6	173-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
14626496-0	2003	Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.	Arachidonic Acid	34-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
14626496-1	2003	Arachidonic acid (AA) can undergo monooxygenation or epoxidation by enzymes in the cytochrome P450 (CYP) family in the brain, kidney, lung, vasculature, and the liver.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
14626496-1	2003	Arachidonic acid (AA) can undergo monooxygenation or epoxidation by enzymes in the cytochrome P450 (CYP) family in the brain, kidney, lung, vasculature, and the liver.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
14626496-2	2003	CYP-AA metabolites, 19- and 20-hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and diHETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	62-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
14626496-2	2003	CYP-AA metabolites, 19- and 20-hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and diHETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli.	epoxyeicosatrienoic acids	70-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
14626496-2	2003	CYP-AA metabolites, 19- and 20-hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and diHETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli.	eets	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
14626496-2	2003	CYP-AA metabolites, 19- and 20-hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and diHETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli.	dihetes	107-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
14626496-11	2003	Compared with other organs, the liver has the highest total CYP content and contains the highest levels of individual CYP enzymes involved in the metabolism of fatty acids.	Fatty Acids	160-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
14626496-12	2003	In humans, 50-75% of CYP-dependent AA metabolites formed by liver microsomes are omega/omega-OH-AA, mainly w-OH-AA, i.e. 20HETE, and 13-28% are EETs.	omega-oh-aa	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
14626496-12	2003	In humans, 50-75% of CYP-dependent AA metabolites formed by liver microsomes are omega/omega-OH-AA, mainly w-OH-AA, i.e. 20HETE, and 13-28% are EETs.	w-oh-aa	107-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
14555336-0	2003	Identification of cytochrome P450 enzymes involved in the metabolism of 4"-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.	4'-methoxy-alpha-pyrrolidinopropiophenone	72-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
14555336-0	2003	Identification of cytochrome P450 enzymes involved in the metabolism of 4"-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.	4'-methoxy-alpha-pyrrolidinopropiophenone	115-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
14555336-2	2003	The metabolism of 4"-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a novel designer drug, to its demethylated major metabolite 4"-hydroxy-pyrrolidinopropio-phenone (HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	4'-methoxy-alpha-pyrrolidinopropiophenone	61-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-277
14555336-2	2003	The metabolism of 4"-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a novel designer drug, to its demethylated major metabolite 4"-hydroxy-pyrrolidinopropio-phenone (HO-PPP) was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.	4'-methoxy-alpha-pyrrolidinopropiophenone	61-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	279-282
12920490-9	2003	We identified hepatic CYP enzymes responsible for metabolism of some compounds (praziquantel-1A2, 2C19, 3A4; primaquine-1A2, 3A4; chloroquine-2C8, 2D6, 3A4; artesunate-2A6; pyrantel-2D6).	artesunate-2a6	157-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
12904931-2	2003	However, little is known regarding the inhibitory potential of 5-FU on the metabolism of co-administered drugs by cytochrome P(450) (CYP).	Fluorouracil	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-131
12904931-2	2003	However, little is known regarding the inhibitory potential of 5-FU on the metabolism of co-administered drugs by cytochrome P(450) (CYP).	Fluorouracil	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
12904931-3	2003	The aim of the present study was to elucidate the inhibitory effect of 5-FU on CYP isoforms using human liver microsomes.	Fluorouracil	71-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
12920490-9	2003	We identified hepatic CYP enzymes responsible for metabolism of some compounds (praziquantel-1A2, 2C19, 3A4; primaquine-1A2, 3A4; chloroquine-2C8, 2D6, 3A4; artesunate-2A6; pyrantel-2D6).	praziquantel-1a2	80-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
12920490-9	2003	We identified hepatic CYP enzymes responsible for metabolism of some compounds (praziquantel-1A2, 2C19, 3A4; primaquine-1A2, 3A4; chloroquine-2C8, 2D6, 3A4; artesunate-2A6; pyrantel-2D6).	primaquine-1a2	109-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
12920490-9	2003	We identified hepatic CYP enzymes responsible for metabolism of some compounds (praziquantel-1A2, 2C19, 3A4; primaquine-1A2, 3A4; chloroquine-2C8, 2D6, 3A4; artesunate-2A6; pyrantel-2D6).	Chloroquine	130-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-25
12971034-8	2003	In vitro experiments suggested that karenitecin is metabolized by CYP450 3A4, 2C8, and 2D6 isoenzymes and is an inhibitor of the CYP450 3A4 and 2C8 isoenzymes.	cositecan	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-135
12971034-12	2003	It was concluded that karenitecin has the potential to alter CYP450 3A4 and 2C8 drug-metabolizing activity.	cositecan	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-67
12971034-2	2003	Individual cloned cytochrome P450 (CYP450) isoenzymes were used to determine, in vitro, the metabolism of karenitecin.	cositecan	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
12971034-2	2003	Individual cloned cytochrome P450 (CYP450) isoenzymes were used to determine, in vitro, the metabolism of karenitecin.	cositecan	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-41
12971034-3	2003	Known substrates and inhibitors of each isoenzyme were employed to evaluate CYP450 drug interactions with karenitecin.	cositecan	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-82
12971034-8	2003	In vitro experiments suggested that karenitecin is metabolized by CYP450 3A4, 2C8, and 2D6 isoenzymes and is an inhibitor of the CYP450 3A4 and 2C8 isoenzymes.	cositecan	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Bupropion	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Methanol	257-265	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Methanol	257-265	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	276-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	276-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	288-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	288-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	Nitrogen	40-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
14631602-5	2003	Interindividual variability of plasma concentration of TCA"s is connected with age, concomitant diseases, genetically determined polimorphism of cytochrome P-450 enzymes (e.g. CYP2D6) and co-medications (the drug may change pharmacokinetic properties of TCA"s).	Trichloroacetic Acid	55-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
14631602-5	2003	Interindividual variability of plasma concentration of TCA"s is connected with age, concomitant diseases, genetically determined polimorphism of cytochrome P-450 enzymes (e.g. CYP2D6) and co-medications (the drug may change pharmacokinetic properties of TCA"s).	Trichloroacetic Acid	254-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	Nitrogen	40-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	desethylchloroquine	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	desethylchloroquine	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	desethylchloroquine	88-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	desethylchloroquine	88-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	N,N-dideethylchloroquine	97-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	N,N-dideethylchloroquine	97-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	N,N-dideethylchloroquine	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-146
12967198-2	2003	It is metabolized in humans through the N-dealkylation pathway, to desethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), by cytochrome P450 (CYP).	N,N-dideethylchloroquine	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
12865317-0	2003	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	Estradiol	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
12908908-4	2003	DMBA is metabolized into a DNA-attacking moiety by two phase I cytochrome P450 (CYP) enzymes CYP1A1 and CYP1B1.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
12908908-4	2003	DMBA is metabolized into a DNA-attacking moiety by two phase I cytochrome P450 (CYP) enzymes CYP1A1 and CYP1B1.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
12865317-14	2003	In conclusion, many human CYP isoforms are involved in the oxidative metabolism of 17beta-estradiol and estrone, with a varying degree of catalytic activity and distinct regioselectivity.	Estradiol	83-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
12865317-0	2003	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	Estrone	70-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-134
12865317-14	2003	In conclusion, many human CYP isoforms are involved in the oxidative metabolism of 17beta-estradiol and estrone, with a varying degree of catalytic activity and distinct regioselectivity.	Estrone	104-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
12865317-1	2003	We systematically characterized the oxidative metabolites of 17beta-estradiol and estrone formed by 15 human cytochrome P450 (CYP) isoforms.	Estradiol	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
12865317-1	2003	We systematically characterized the oxidative metabolites of 17beta-estradiol and estrone formed by 15 human cytochrome P450 (CYP) isoforms.	Estradiol	61-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
12865317-1	2003	We systematically characterized the oxidative metabolites of 17beta-estradiol and estrone formed by 15 human cytochrome P450 (CYP) isoforms.	Estrone	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
12865317-1	2003	We systematically characterized the oxidative metabolites of 17beta-estradiol and estrone formed by 15 human cytochrome P450 (CYP) isoforms.	Estrone	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
12936704-0	2003	Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.	Morphine	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
12936704-0	2003	Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.	Nitrogen	92-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
12936704-2	2003	The aim was to identify the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of morphine in vitro.	Nitrogen	78-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
12936704-2	2003	The aim was to identify the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of morphine in vitro.	Nitrogen	78-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
12936704-2	2003	The aim was to identify the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of morphine in vitro.	Morphine	97-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
12936704-2	2003	The aim was to identify the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of morphine in vitro.	Morphine	97-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
12936704-5	2003	In microsomes from a panel of 14 human livers phenotyped for 10 CYP enzymes, morphine N-demethylation correlated with testosterone 6beta-hydroxylation (r=0.91, p&lt;0.001) and paclitaxel 6-alpha hydroxylation (r=0.72, p&lt;0.001), two specific markers of CYP3A4 and CYP2C8, respectively.	morphine n	77-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
12936704-5	2003	In microsomes from a panel of 14 human livers phenotyped for 10 CYP enzymes, morphine N-demethylation correlated with testosterone 6beta-hydroxylation (r=0.91, p&lt;0.001) and paclitaxel 6-alpha hydroxylation (r=0.72, p&lt;0.001), two specific markers of CYP3A4 and CYP2C8, respectively.	Testosterone	118-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
12893130-1	2003	Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.	Tramadol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
12893130-1	2003	Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.	Nitrogen	182-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
14582238-4	2003	Genetic polymorphisms that influence human genotoxic risk are those of glutathione s-transferase and cytochrome P450 in exposure to polycyclic aromatic hydrocarbons (PAHs), those of N-acetyltransferase in both occupational and environmental exposures to aromatic amines (AAs) and similar compounds.	Polycyclic Aromatic Hydrocarbons	132-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
12818727-6	2003	epsilon-viniferin displayed a more potent inhibitory effect than resveratrol for all the CYP activities tested (Ki 0.5 to 20 microM vs. 10 to 100 microM, respectively).	epsilon-viniferin	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
12818727-6	2003	epsilon-viniferin displayed a more potent inhibitory effect than resveratrol for all the CYP activities tested (Ki 0.5 to 20 microM vs. 10 to 100 microM, respectively).	Resveratrol	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
12818727-10	2003	It displayed, like resveratrol, mixed-type inhibitions for all the CYP tested, except for CYP2E1 (non-competitive).	Resveratrol	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
12818727-11	2003	Comparison of the inhibitory effects exerted on CYP activities by epsilon-viniferin, resveratrol and non volatile components from red wine or various Cognac beverages showed that neither resveratrol, nor epsilon-viniferin is the main CYP inhibitor present in red wine solids.	epsilon-viniferin	66-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
12818727-11	2003	Comparison of the inhibitory effects exerted on CYP activities by epsilon-viniferin, resveratrol and non volatile components from red wine or various Cognac beverages showed that neither resveratrol, nor epsilon-viniferin is the main CYP inhibitor present in red wine solids.	Resveratrol	85-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
12893130-1	2003	Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.	Tramadol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
12893130-1	2003	Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.	Tramadol	149-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
12893130-1	2003	Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.	Tramadol	149-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
12818727-0	2003	Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages.	epsilon-viniferin	60-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
12818727-0	2003	Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages.	Resveratrol	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	Resveratrol	3-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	Resveratrol	3-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	Polyphenols	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	Polyphenols	19-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	simvastatin hydroxyacid	87-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	simvastatin hydroxyacid	87-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	simvastatin hydroxyacid	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	simvastatin hydroxyacid	113-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	Simvastatin	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
12848784-1	2003	AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV).	Simvastatin	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
14531067-0	2003	An adamantanone derivative that is an original modulator of redox processes in the cytochrome P-450 system can serve as an effective remedy against obliterating angiopathy of lower extremities.	adamantanone	3-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
14582238-4	2003	Genetic polymorphisms that influence human genotoxic risk are those of glutathione s-transferase and cytochrome P450 in exposure to polycyclic aromatic hydrocarbons (PAHs), those of N-acetyltransferase in both occupational and environmental exposures to aromatic amines (AAs) and similar compounds.	Polycyclic Aromatic Hydrocarbons	166-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
14582238-4	2003	Genetic polymorphisms that influence human genotoxic risk are those of glutathione s-transferase and cytochrome P450 in exposure to polycyclic aromatic hydrocarbons (PAHs), those of N-acetyltransferase in both occupational and environmental exposures to aromatic amines (AAs) and similar compounds.	aromatic amines	254-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
14582238-4	2003	Genetic polymorphisms that influence human genotoxic risk are those of glutathione s-transferase and cytochrome P450 in exposure to polycyclic aromatic hydrocarbons (PAHs), those of N-acetyltransferase in both occupational and environmental exposures to aromatic amines (AAs) and similar compounds.	aas	271-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
14581727-0	2003	Effects of cytochrome P-450 inducers on the perazine metabolism in a primary culture of human hepatocytes.	Perazine	44-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
12728288-1	2003	BACKGROUND: In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450-CYP2C9 have recently been associated with very low warfarin requirements.	Warfarin	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-112
12728288-1	2003	BACKGROUND: In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450-CYP2C9 have recently been associated with very low warfarin requirements.	Warfarin	157-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-112
12849118-2	2003	Many drugs are metabolised by the hepatic cytochrome P450 (CYP) isoenzyme system, and coadministration of AEDs and CTDs can lead to clinically relevant interactions by induction or inhibition of enzymes in shared metabolic pathways.	beta-cyclodextrin tetradecasulfate	115-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
12849118-2	2003	Many drugs are metabolised by the hepatic cytochrome P450 (CYP) isoenzyme system, and coadministration of AEDs and CTDs can lead to clinically relevant interactions by induction or inhibition of enzymes in shared metabolic pathways.	beta-cyclodextrin tetradecasulfate	115-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
12763054-1	2003	Tocopherols and tocotrienols are metabolized by side chain degradation initiated by cytochrome P450 (CYP)-catalyzed omega-hydroxylation followed by beta-oxidation.	Tocopherols	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
12763054-1	2003	Tocopherols and tocotrienols are metabolized by side chain degradation initiated by cytochrome P450 (CYP)-catalyzed omega-hydroxylation followed by beta-oxidation.	Tocopherols	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
12763054-1	2003	Tocopherols and tocotrienols are metabolized by side chain degradation initiated by cytochrome P450 (CYP)-catalyzed omega-hydroxylation followed by beta-oxidation.	Tocotrienols	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
12763054-1	2003	Tocopherols and tocotrienols are metabolized by side chain degradation initiated by cytochrome P450 (CYP)-catalyzed omega-hydroxylation followed by beta-oxidation.	Tocotrienols	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
12698250-1	2003	OBJECTIVE: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans.	Antipyrine	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Warfarin	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
12814453-7	2003	CONCLUSIONS: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme.	Nafcillin	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
12814453-7	2003	CONCLUSIONS: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme.	Nafcillin	122-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Nafcillin	6-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Nafcillin	6-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Cyclosporine	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Cyclosporine	106-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
12814453-1	2003	AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP).	Warfarin	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-178
12698250-1	2003	OBJECTIVE: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans.	Antipyrine	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
12698250-2	2003	Cytokines (e.g., interleukin-6) and nitric oxide reduce CYP 450 activity in vitro and in vivo.	Nitric Oxide	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
12698250-3	2003	Because interleukin-6 and nitric oxide production increases in children with sepsis-induced multiple organ failure, we hypothesized impaired CYP 450 mediated drug metabolism in this population.	Nitric Oxide	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-144
12870664-0	2003	Effects of cytochrome P450 inhibitors on agonist-induced Ca2+ responses and production of NO and PGI2 in vascular endothelial cells.	Epoprostenol	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
12930004-3	2003	PAHs have been well established as an enzyme inducer of cytochrome P450 (CYP) such as CYP1A1 and CYP1A2.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
12930004-3	2003	PAHs have been well established as an enzyme inducer of cytochrome P450 (CYP) such as CYP1A1 and CYP1A2.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
12870655-0	2003	Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: upregulation of CYP1B1 by all-trans-retinoic acid.	Tretinoin	103-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
12870664-2	2003	Cytochrome P450 (CYP), shown to mediate endothelium-dependent hyperpolarization via epoxyeicosatrienoic acids, is one of the candidates for EDHF.	epoxyeicosatrienoic acids	84-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12870655-2	2003	The biotransformation of this drug is catalyzed by various cytochrome P450 (CYP) enzymes, but relatively little is known about the effect of ATRA on CYP enzyme expression in leukemic cells.	Tretinoin	141-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-152
12870664-2	2003	Cytochrome P450 (CYP), shown to mediate endothelium-dependent hyperpolarization via epoxyeicosatrienoic acids, is one of the candidates for EDHF.	epoxyeicosatrienoic acids	84-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12870664-2	2003	Cytochrome P450 (CYP), shown to mediate endothelium-dependent hyperpolarization via epoxyeicosatrienoic acids, is one of the candidates for EDHF.	edhf	140-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12870664-2	2003	Cytochrome P450 (CYP), shown to mediate endothelium-dependent hyperpolarization via epoxyeicosatrienoic acids, is one of the candidates for EDHF.	edhf	140-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12870664-10	2003	These data suggest that, in addition to its regulation of EDHF production, CYP also contributes to the regulation of other endothelium-dependent vasorelaxing factors by modifying EC Ca2+ signaling.	edhf	58-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
12819521-4	2003	Cytochrome P450 activity was assessed by measuring the urine 6 beta-hydroxycortisol to cortisol ratio (6 beta-OHF/F).	beta-hydroxycortisol	63-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12819521-4	2003	Cytochrome P450 activity was assessed by measuring the urine 6 beta-hydroxycortisol to cortisol ratio (6 beta-OHF/F).	Hydrocortisone	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12819521-4	2003	Cytochrome P450 activity was assessed by measuring the urine 6 beta-hydroxycortisol to cortisol ratio (6 beta-OHF/F).	beta-ohf	105-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12819521-4	2003	Cytochrome P450 activity was assessed by measuring the urine 6 beta-hydroxycortisol to cortisol ratio (6 beta-OHF/F).	Fluorine	112-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12785830-1	2003	Intramolecular kinetic isotope effects (KIEs) were determined for cytochrome P450-catalyzed hydroxylation reactions of methyl-dideuterated trans-2-phenylcyclopropylmethane-d2 (1-d2), which gives two products from oxidation of the methyl group, trans-2-phenylcyclopropylmethanol (2) and 1-phenyl-3-buten-1ol (3).	trans-2-phenylcyclopropylmethane-d2	139-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
12785830-1	2003	Intramolecular kinetic isotope effects (KIEs) were determined for cytochrome P450-catalyzed hydroxylation reactions of methyl-dideuterated trans-2-phenylcyclopropylmethane-d2 (1-d2), which gives two products from oxidation of the methyl group, trans-2-phenylcyclopropylmethanol (2) and 1-phenyl-3-buten-1ol (3).	1-d2	176-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
12785830-1	2003	Intramolecular kinetic isotope effects (KIEs) were determined for cytochrome P450-catalyzed hydroxylation reactions of methyl-dideuterated trans-2-phenylcyclopropylmethane-d2 (1-d2), which gives two products from oxidation of the methyl group, trans-2-phenylcyclopropylmethanol (2) and 1-phenyl-3-buten-1ol (3).	trans-2-phenylcyclopropylmethanol	244-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
12785830-1	2003	Intramolecular kinetic isotope effects (KIEs) were determined for cytochrome P450-catalyzed hydroxylation reactions of methyl-dideuterated trans-2-phenylcyclopropylmethane-d2 (1-d2), which gives two products from oxidation of the methyl group, trans-2-phenylcyclopropylmethanol (2) and 1-phenyl-3-buten-1ol (3).	1-phenyl-3-buten-1ol	286-306	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
12867215-12	2003	However, as 80% of voriconazole is hepatically eliminated, primarily via the cytochrome P450 (CYP) isozymes CYP2C19, CYP3A4, and CYP2C9, voriconazole has a high potential for drug interactions, and dose reduction is recommended in patients with mild to moderate hepatic dysfunction (Child-Pugh class A or B).	Voriconazole	19-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
12787491-0	2003	Microplate assay measurement of cytochrome p450-carbon monoxide complexes.	Carbon Monoxide	48-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
12867215-12	2003	However, as 80% of voriconazole is hepatically eliminated, primarily via the cytochrome P450 (CYP) isozymes CYP2C19, CYP3A4, and CYP2C9, voriconazole has a high potential for drug interactions, and dose reduction is recommended in patients with mild to moderate hepatic dysfunction (Child-Pugh class A or B).	Voriconazole	19-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
12867215-12	2003	However, as 80% of voriconazole is hepatically eliminated, primarily via the cytochrome P450 (CYP) isozymes CYP2C19, CYP3A4, and CYP2C9, voriconazole has a high potential for drug interactions, and dose reduction is recommended in patients with mild to moderate hepatic dysfunction (Child-Pugh class A or B).	Voriconazole	137-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
12867215-12	2003	However, as 80% of voriconazole is hepatically eliminated, primarily via the cytochrome P450 (CYP) isozymes CYP2C19, CYP3A4, and CYP2C9, voriconazole has a high potential for drug interactions, and dose reduction is recommended in patients with mild to moderate hepatic dysfunction (Child-Pugh class A or B).	Voriconazole	137-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
12695341-0	2003	Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.	Voriconazole	77-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
12752938-0	2003	Cytotoxicity of bisphenol A glycidyl methacrylate on cytochrome P450-producing cells.	Bisphenol A-Glycidyl Methacrylate	16-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
12959412-1	2003	Many administered drugs are first activated by phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP), and then conjugated with ligands such as UDPGA, PAPS, and glutathione by phase II drug-metabolizing enzymes, and finally excreted by transporters.	Phosphoadenosine Phosphosulfate	161-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
12959412-1	2003	Many administered drugs are first activated by phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP), and then conjugated with ligands such as UDPGA, PAPS, and glutathione by phase II drug-metabolizing enzymes, and finally excreted by transporters.	Phosphoadenosine Phosphosulfate	161-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
12959412-1	2003	Many administered drugs are first activated by phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP), and then conjugated with ligands such as UDPGA, PAPS, and glutathione by phase II drug-metabolizing enzymes, and finally excreted by transporters.	Glutathione	171-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
12959412-1	2003	Many administered drugs are first activated by phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP), and then conjugated with ligands such as UDPGA, PAPS, and glutathione by phase II drug-metabolizing enzymes, and finally excreted by transporters.	Glutathione	171-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
12759628-3	2003	The effects of ATRA can be potentiated by inhibition of cytochrome P-450, which is known to occur with certain drugs.	Tretinoin	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
12570834-7	2003	Another important way of demethylation generated formaldehyde production is given by microsomal cytochrome P-450 dependent oxidation of xenobiotics, such as various drugs prescribed by doctors.	Formaldehyde	49-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
26984794-2	2003	OBJECTIVE: This study investigates whether low serum folate levels may contribute to depressive mood and difficulties in mental processing in patients with epilepsy treated with anti-epileptic drugs inducing the cytochrome P450.	Folic Acid	53-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-227
12725870-1	2003	Microsomal P450-mediated monooxygenase activity supported by NADPH requires an interaction between flavoprotein NADPH-cytochrome P450 reductase and cytochrome P450.	NADP	61-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
12586744-1	2003	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation.	11,12-epoxy-5,8,14-eicosatrienoic acid	52-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12721102-0	2003	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.	phenothiazine	82-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
12721102-0	2003	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.	Promazine	108-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
12721102-2	2003	The aim of the present study was to identify human cytochrome p-450 isoforms (CYPs) involved in 5-sulphoxidation and N-demethylation of the simplest phenothiazine neuroleptic promazine in human liver.	phenothiazine	149-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
12721102-2	2003	The aim of the present study was to identify human cytochrome p-450 isoforms (CYPs) involved in 5-sulphoxidation and N-demethylation of the simplest phenothiazine neuroleptic promazine in human liver.	Promazine	175-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
12586744-1	2003	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation.	11,12-epoxy-5,8,14-eicosatrienoic acid	52-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12586744-1	2003	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation.	11,12-epoxy-5,8,14-eicosatrienoic acid	84-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12586744-1	2003	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation.	11,12-epoxy-5,8,14-eicosatrienoic acid	84-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12599212-0	2003	Cyclooxygenase and cytochrome P-450 pathways induced by fetal calf serum regulate wound closure in 3T6 fibroblast cultures through the effect of prostaglandin E2 and 12 and 20 hydroxyeicosatetraenoic acids.	Dinoprostone	145-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
12599212-0	2003	Cyclooxygenase and cytochrome P-450 pathways induced by fetal calf serum regulate wound closure in 3T6 fibroblast cultures through the effect of prostaglandin E2 and 12 and 20 hydroxyeicosatetraenoic acids.	Hydroxyeicosatetraenoic Acids	176-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
12599212-6	2003	On the other hand, we show that ketoconazole, a cytochrome P-450 inhibitor, hinders the wound closure induced by FCS in wounded 3T6 fibroblast cultures.	Ketoconazole	32-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
12599212-7	2003	12 and 20 Hydroxyeicosatetraenoic acids (HETEs), which are key AA metabolites synthesized by cytochrome P-450, partially revert the effects of ketoconazole on the wound repair process.	Hydroxyeicosatetraenoic Acids	10-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
12599212-7	2003	12 and 20 Hydroxyeicosatetraenoic acids (HETEs), which are key AA metabolites synthesized by cytochrome P-450, partially revert the effects of ketoconazole on the wound repair process.	Ketoconazole	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
12599212-8	2003	Thus, the COX and cytochrome P-450 pathways of the arachidonate cascade are involved in 3T6 fibroblast wound closure.	Arachidonic Acid	51-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
12739762-4	2003	Then we tested the effects of phenobarbital and cyclophosphamide on CYP expression in both models.	Phenobarbital	30-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
12698306-1	2003	OBJECTIVE: To screen for inhibitory effects of diosmin on cytochrome P(450)-mediated metabolism of metronidazole in healthy volunteers.	Diosmin	47-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-75
12698306-1	2003	OBJECTIVE: To screen for inhibitory effects of diosmin on cytochrome P(450)-mediated metabolism of metronidazole in healthy volunteers.	Metronidazole	99-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-75
12739762-4	2003	Then we tested the effects of phenobarbital and cyclophosphamide on CYP expression in both models.	Cyclophosphamide	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
19475278-6	2003	Cytochrome P450 isoenzymes show genetic polymorphisms in neuropsychotropic drugs metabolism and the slow acetylation of N-acetyltransferase in equatorial populations (95%) increases isoniazid and hydrazine toxicity.	Isoniazid	182-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
19475278-6	2003	Cytochrome P450 isoenzymes show genetic polymorphisms in neuropsychotropic drugs metabolism and the slow acetylation of N-acetyltransferase in equatorial populations (95%) increases isoniazid and hydrazine toxicity.	hydrazine	196-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12388057-6	2003	We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not.	svec4-10	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
12734935-0	2003	[Stereoselective determination of propranolol enantiomer in transgenic cell lines expressing human cytochrome P450].	Propranolol	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-114
12734935-1	2003	OBJECTIVE: To establish a chiro chromatography for studying the stereoselective metabolism of propranolol (PL) in S(9) incubates prepared from transgenic cell lines expressing human cytochrome P450.	Propranolol	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
12734935-1	2003	OBJECTIVE: To establish a chiro chromatography for studying the stereoselective metabolism of propranolol (PL) in S(9) incubates prepared from transgenic cell lines expressing human cytochrome P450.	Propranolol	107-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
12617777-1	2003	AIM: To study the metabolism of cilnidipine and the effects of selective cytochrome P-450 (CYP450) inhibitors on the metabolism of cilnidipine in human liver microsomes in vitro.	cilnidipine	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
12617777-1	2003	AIM: To study the metabolism of cilnidipine and the effects of selective cytochrome P-450 (CYP450) inhibitors on the metabolism of cilnidipine in human liver microsomes in vitro.	cilnidipine	131-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-97
12617777-3	2003	Various selective CYP450 inhibitors were used to investigate their effects on the metabolism of cilnidipine and the principal CYP450 isoform involved in dehydrogenation of dihydropyridine ring of cilnidipine in human liver microsomes.	cilnidipine	96-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
12617777-3	2003	Various selective CYP450 inhibitors were used to investigate their effects on the metabolism of cilnidipine and the principal CYP450 isoform involved in dehydrogenation of dihydropyridine ring of cilnidipine in human liver microsomes.	1,4-dihydropyridine	172-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
12617777-3	2003	Various selective CYP450 inhibitors were used to investigate their effects on the metabolism of cilnidipine and the principal CYP450 isoform involved in dehydrogenation of dihydropyridine ring of cilnidipine in human liver microsomes.	1,4-dihydropyridine	172-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-132
12617777-3	2003	Various selective CYP450 inhibitors were used to investigate their effects on the metabolism of cilnidipine and the principal CYP450 isoform involved in dehydrogenation of dihydropyridine ring of cilnidipine in human liver microsomes.	cilnidipine	196-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-24
12617777-3	2003	Various selective CYP450 inhibitors were used to investigate their effects on the metabolism of cilnidipine and the principal CYP450 isoform involved in dehydrogenation of dihydropyridine ring of cilnidipine in human liver microsomes.	cilnidipine	196-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-132
12564927-1	2003	Human cytochrome P450 (P450) 2D6 is an important enzyme involved in the metabolism of drugs, many of which are amines or contain other basic nitrogen atoms.	Amines	111-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-32
12564927-1	2003	Human cytochrome P450 (P450) 2D6 is an important enzyme involved in the metabolism of drugs, many of which are amines or contain other basic nitrogen atoms.	Nitrogen	141-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-32
12637244-0	2003	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes.	Ethosuximide	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
12637244-2	2003	The relative roles of human hepatic cytochrome P450 (CYP) subfamilies participating in ethosuximide metabolism have been studied in vitro using humanized heterologous CYP microsomal systems expressing either CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1 or CYP3A4.	Ethosuximide	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
12637244-2	2003	The relative roles of human hepatic cytochrome P450 (CYP) subfamilies participating in ethosuximide metabolism have been studied in vitro using humanized heterologous CYP microsomal systems expressing either CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1 or CYP3A4.	Ethosuximide	87-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
12573493-3	2003	Moreover, CYP epoxygenase products as well as CYP-derived reactive oxygen species are intracellular signal transduction molecules involved in several signaling cascades affecting numerous cellular processes, including vascular cell proliferation and angiogenesis.	Reactive Oxygen Species	58-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
12388057-6	2003	We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not.	Proadifen	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
12388057-6	2003	We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not.	Ketoconazole	116-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
12388057-6	2003	We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not.	Itraconazole	146-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
12653348-5	2003	Cytochrome P450 (CYP) activity was studied before and after cold storage by means of monoethylglycinexylide (MEGX) detection in the effluent medium, after repeated lidocaine injections.	monoethylglycinexylide	85-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12505783-6	2003	In the present article, we investigated by HPLC and GC-MS whether cis-EODA is formed enzymatically from oleic acid by the cytochrome P450 (CYP) system.	9,10-epoxystearic acid	66-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
12505783-6	2003	In the present article, we investigated by HPLC and GC-MS whether cis-EODA is formed enzymatically from oleic acid by the cytochrome P450 (CYP) system.	9,10-epoxystearic acid	66-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
12505783-6	2003	In the present article, we investigated by HPLC and GC-MS whether cis-EODA is formed enzymatically from oleic acid by the cytochrome P450 (CYP) system.	Oleic Acid	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
12505783-6	2003	In the present article, we investigated by HPLC and GC-MS whether cis-EODA is formed enzymatically from oleic acid by the cytochrome P450 (CYP) system.	Oleic Acid	104-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
12505783-11	2003	The epoxidation of oleic acid was found to depend on CYP, NADPH+H(+), and O(2).	Oleic Acid	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
12505783-16	2003	Our study suggests that circulating and excretory cis-EODA may originate, at least in part, from CYP-catalyzed epoxidation of oleic acid.	Oleic Acid	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids	75-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids	75-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	14,15-epoxy-5,8,11-eicosatrienoic acid	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	14,15-epoxy-5,8,11-eicosatrienoic acid	132-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	dihydroxyeicosa-trienoic acids	159-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	dihydroxyeicosa-trienoic acids	159-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	dhets	191-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	dhets	191-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	203-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	203-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	236-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12570747-1	2003	Arachidonic acid can be metabolized by cytochrome p450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosa-trienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	236-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12570747-8	2003	CYP450 metabolites also act as second messengers for many paracrine and hormonal agents, including endothelin, nitric oxide, and angiotensin II.	Nitric Oxide	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-6
12570747-9	2003	The production of kidney CYP450 arachidonic acid metabolites is altered in diabetes, pregnancy, hepatorenal syndrome, and in various models of hypertension, and it is likely that changes in this system contribute to the abnormalities in renal function that are associated with many of these conditions.	Arachidonic Acid	32-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-31
12544321-0	2003	Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.	Simvastatin	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
12523956-1	2003	The aim of this work was to identify the form(s) of human liver cytochrome P450 (CYP) involved in the hepatic transformation of myristicin to its major metabolite, 5-allyl-1-methoxy-2,3-dihydroxybenzene.	myristicin	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
12523956-1	2003	The aim of this work was to identify the form(s) of human liver cytochrome P450 (CYP) involved in the hepatic transformation of myristicin to its major metabolite, 5-allyl-1-methoxy-2,3-dihydroxybenzene.	myristicin	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
12523956-1	2003	The aim of this work was to identify the form(s) of human liver cytochrome P450 (CYP) involved in the hepatic transformation of myristicin to its major metabolite, 5-allyl-1-methoxy-2,3-dihydroxybenzene.	5-allyl-1-methoxy-2,3-dihydroxybenzene	164-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
12523956-1	2003	The aim of this work was to identify the form(s) of human liver cytochrome P450 (CYP) involved in the hepatic transformation of myristicin to its major metabolite, 5-allyl-1-methoxy-2,3-dihydroxybenzene.	5-allyl-1-methoxy-2,3-dihydroxybenzene	164-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
12618402-6	2003	High-density oligonucleotide microarrays identified altered expression of 50 transcripts in response to TIGR/MYOC overexpression, including homologs of aquaporin-4 and cytochrome-P450, previously associated with glaucoma, and several proteins of unknown function.	Oligonucleotides	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
12875104-6	2003	However, because PIs and all statins except pravastatin are metabolized by the cytochrome P450 (CYP) system, co-administration of these agents produces a significant risk of drug interactions and statin-induced hepatotoxicity and myopathy.	Monothiopyrophosphoric acid	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
12548158-1	2003	Cytochrome P450 isoenzymes are known to contribute to estrone metabolism.	Estrone	54-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12875104-6	2003	However, because PIs and all statins except pravastatin are metabolized by the cytochrome P450 (CYP) system, co-administration of these agents produces a significant risk of drug interactions and statin-induced hepatotoxicity and myopathy.	Monothiopyrophosphoric acid	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
12875104-6	2003	However, because PIs and all statins except pravastatin are metabolized by the cytochrome P450 (CYP) system, co-administration of these agents produces a significant risk of drug interactions and statin-induced hepatotoxicity and myopathy.	Pravastatin	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
12875104-6	2003	However, because PIs and all statins except pravastatin are metabolized by the cytochrome P450 (CYP) system, co-administration of these agents produces a significant risk of drug interactions and statin-induced hepatotoxicity and myopathy.	Pravastatin	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Quetiapine Fumarate	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Clozapine	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12537513-15	2003	Overall, the results of the interaction studies suggest that modafinil has potential to affect the pharmacokinetics of drugs that are metabolised by certain CYP enzymes.	Modafinil	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Clozapine	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Olanzapine	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Olanzapine	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Clozapine	147-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Clozapine	147-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12751920-7	2003	Clinical trials have studied potential interactions of zaleplon, zolpidem and zopiclone with the following types of drugs: cytochrome P450 (CYP) inducers (rifampicin), CYP inhibitors (azoles, ritonavir and erythromycin), histamine H(2) receptor antagonists (cimetidine and ranitidine), antidepressants, antipsychotics, antagonists of benzodiazepines and drugs causing sedation.	zopiclone	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
12751920-14	2003	While triazolam and midazolam are biotransformed almost entirely via CYP3A4, the newer hypnosedatives are biotransformed by several CYP isozymes in addition to CYP3A4, resulting in CYP3A4 inhibitors and inducers having a lesser effect on their biotransformation.	Triazolam	6-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12751920-14	2003	While triazolam and midazolam are biotransformed almost entirely via CYP3A4, the newer hypnosedatives are biotransformed by several CYP isozymes in addition to CYP3A4, resulting in CYP3A4 inhibitors and inducers having a lesser effect on their biotransformation.	Midazolam	20-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Quetiapine Fumarate	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	ziprasidone	173-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	ziprasidone	173-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Olanzapine	198-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Olanzapine	198-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12846597-0	2003	Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.	ximelagatran	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Risperidone	213-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-72
12846597-4	2003	OBJECTIVE: To investigate the potential of ximelagatran, the intermediates ethyl-melagatran and hydroxy-melagatran, and melagatran to inhibit the CYP system in vitro and in vivo, and the influence of three CYP substrates on the pharmacokinetics of melagatran in vivo.	ximelagatran	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
12846597-15	2003	Together, the in vitro and in vivo studies indicate that metabolic drug-drug interactions involving the major human CYP enzymes should not be expected with ximelagatran.	ximelagatran	156-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
12665390-6	2003	Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone).	Risperidone	213-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
12846597-4	2003	OBJECTIVE: To investigate the potential of ximelagatran, the intermediates ethyl-melagatran and hydroxy-melagatran, and melagatran to inhibit the CYP system in vitro and in vivo, and the influence of three CYP substrates on the pharmacokinetics of melagatran in vivo.	melagatran	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
12841918-11	2003	The drug interaction profile of voriconazole also warrants a careful evaluation of the concomitant medication, mainly due to cytochrome P450 metabolism.	Voriconazole	32-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
12846597-5	2003	METHODS: The CYP inhibitory properties of ximelagatran, the intermediates and melagatran were tested in vitro by two different methods, using heterologously expressed enzymes or human liver microsomes.	ximelagatran	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
12846597-5	2003	METHODS: The CYP inhibitory properties of ximelagatran, the intermediates and melagatran were tested in vitro by two different methods, using heterologously expressed enzymes or human liver microsomes.	melagatran	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Omeprazole	219-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Omeprazole	219-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Lansoprazole	231-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Lansoprazole	231-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
15618733-0	2003	Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine.	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	14-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-161
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Pantoprazole	248-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
15618733-0	2003	Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine.	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	99-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-161
15618733-1	2003	In the present study, human cytochrome P450 (CYP) forms involved in producing the primary metabolites of NE-100 were identified.	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	105-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
15618733-1	2003	In the present study, human cytochrome P450 (CYP) forms involved in producing the primary metabolites of NE-100 were identified.	N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	105-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Pantoprazole	248-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
15618748-0	2003	In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.	1-aminobenzotriazole	30-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
15618748-1	2003	1-Aminobenzotriazole (ABT) is widely used as a non-specific inhibitor of animal cytochrome P450 (CYP).	1-aminobenzotriazole	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Rabeprazole	279-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
15618748-1	2003	1-Aminobenzotriazole (ABT) is widely used as a non-specific inhibitor of animal cytochrome P450 (CYP).	1-aminobenzotriazole	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
15618748-1	2003	1-Aminobenzotriazole (ABT) is widely used as a non-specific inhibitor of animal cytochrome P450 (CYP).	1-aminobenzotriazole	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Rabeprazole	279-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
15618748-1	2003	1-Aminobenzotriazole (ABT) is widely used as a non-specific inhibitor of animal cytochrome P450 (CYP).	1-aminobenzotriazole	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
15618748-2	2003	In the present study, the inhibitory effect of ABT was investigated on drug oxidations catalyzed by human CYP isoforms.	1-aminobenzotriazole	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
12569440-0	2003	Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.	Resveratrol	113-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
15618748-11	2003	ABT, SKF-525A, and ketoconazole showed different selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes.	1-aminobenzotriazole	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
15618748-11	2003	ABT, SKF-525A, and ketoconazole showed different selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes.	Proadifen	5-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
15618748-11	2003	ABT, SKF-525A, and ketoconazole showed different selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes.	Ketoconazole	19-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
15618748-12	2003	Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole.	1-aminobenzotriazole	197-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
15618748-12	2003	Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole.	Proadifen	202-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
15618748-12	2003	Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole.	Ketoconazole	216-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
12862505-5	2003	Losartan and irbesartan have a greater affinity for cytochrome p450 (CYP) isoenzymes and, thus, are more likely to be implicated in drug interactions.	Losartan	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
12862505-5	2003	Losartan and irbesartan have a greater affinity for cytochrome p450 (CYP) isoenzymes and, thus, are more likely to be implicated in drug interactions.	Losartan	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12862505-5	2003	Losartan and irbesartan have a greater affinity for cytochrome p450 (CYP) isoenzymes and, thus, are more likely to be implicated in drug interactions.	Irbesartan	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
12862505-5	2003	Losartan and irbesartan have a greater affinity for cytochrome p450 (CYP) isoenzymes and, thus, are more likely to be implicated in drug interactions.	Irbesartan	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12490585-2	2003	In the present study, we investigated the effects of arsenic trioxide (As2O3), recently used as an anticancer drug, on the expression of human cytochrome P450 (P450) 1A1, which bioactivates polycyclic aromatic hydrocarbons into mutagenic metabolites.	Arsenic Trioxide	53-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-169
12490585-2	2003	In the present study, we investigated the effects of arsenic trioxide (As2O3), recently used as an anticancer drug, on the expression of human cytochrome P450 (P450) 1A1, which bioactivates polycyclic aromatic hydrocarbons into mutagenic metabolites.	Arsenic Trioxide	71-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-169
12490585-2	2003	In the present study, we investigated the effects of arsenic trioxide (As2O3), recently used as an anticancer drug, on the expression of human cytochrome P450 (P450) 1A1, which bioactivates polycyclic aromatic hydrocarbons into mutagenic metabolites.	Polycyclic Aromatic Hydrocarbons	190-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-169
12680714-0	2003	Proliferation of intracellular structure corresponding to reduced affinity of fluconazole for cytochrome P-450 in two low-susceptibility strains of Candida albicans isolated from a Japanese AIDS patient.	Fluconazole	78-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
12680714-3	2003	We here examined characteristics related to cytochrome P-450 (CYP), especially sterol 14alpha-demethylase encoded by the ERG11 gene which is the target molecule for fluconazole.	Fluconazole	165-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
12680714-3	2003	We here examined characteristics related to cytochrome P-450 (CYP), especially sterol 14alpha-demethylase encoded by the ERG11 gene which is the target molecule for fluconazole.	Fluconazole	165-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
12680714-4	2003	In TIMM 3164 and 3165, the ergosterol synthesis by cell-free extracts was somewhat less susceptible to fluconazole, due to a decrease in fluconazole affinity for CYP.	Ergosterol	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12680714-4	2003	In TIMM 3164 and 3165, the ergosterol synthesis by cell-free extracts was somewhat less susceptible to fluconazole, due to a decrease in fluconazole affinity for CYP.	Fluconazole	137-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12680714-10	2003	In addition to the reduced intracellular accumulation, the decreased affinity of fluconazole for CYP in TIMM 3164 and 3165 is assumed to be associated with the fluconazole-resistance phenotype.	Fluconazole	81-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
12680714-10	2003	In addition to the reduced intracellular accumulation, the decreased affinity of fluconazole for CYP in TIMM 3164 and 3165 is assumed to be associated with the fluconazole-resistance phenotype.	Fluconazole	160-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
12569440-0	2003	Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.	Resveratrol	129-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
12569440-1	2003	trans-Resveratrol, a phenolic phytoalexin occurring in grapes, wine, peanuts, and cranberries, has been reported to both have anticarcinogenic, antioxidative, phytoestrogenic, and cardioprotective activities, and to be a weak inhibitor of cytochrome P450 (CYP)3A4, which might have significance for drug-drug interactions.	Resveratrol	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	239-254
12569440-2	2003	Since trans-resveratrol is rapidly converted in vivo to primarily trans-resveratrol-3-sulfate, a rapid, selective, and sensitive method using liquid chromatography/tandem mass spectrometry (LC/MS/MS) was developed to investigate human cytochrome P450 inhibition by trans-resveratrol-3-sulfate.	Resveratrol	6-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-250
12569440-3	2003	Effects of trans-resveratrol and trans-resveratrol-3-sulfate on the metabolism of selective cytochrome P450 substrates (CYP1A2/ethoxyresorufin, CYP2C9/diclofenac, CYP2C19/(S)-mephenytoin, CYP2D6/bufuralol, CYP3A4/testosterone) were monitored using cDNA-expressed human recombinant isozymes.	Resveratrol	11-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
12569440-3	2003	Effects of trans-resveratrol and trans-resveratrol-3-sulfate on the metabolism of selective cytochrome P450 substrates (CYP1A2/ethoxyresorufin, CYP2C9/diclofenac, CYP2C19/(S)-mephenytoin, CYP2D6/bufuralol, CYP3A4/testosterone) were monitored using cDNA-expressed human recombinant isozymes.	trans-resveratrol-3-sulfate	33-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
12426514-1	2002	BACKGROUND AND OBJECTIVE: Praziquantel is extensively metabolized by the hepatic cytochrome P450 (CYP) enzymes.	Praziquantel	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
12520072-2	2003	Cytochrome P450 induction was performed by incubating lymphocytes with benzanthracene.	benz(a)anthracene	71-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12469329-0	2002	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein.	Zolpidem	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
12469329-1	2002	The influence of high concentrations of zolpidem (100 microM, corresponding to approximately 200 times maximum therapeutic concentrations) on the activity of six human Cytochrome P450 (CYP) enzymes was evaluated in a model system using human liver microsomes.	Zolpidem	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-183
12469329-1	2002	The influence of high concentrations of zolpidem (100 microM, corresponding to approximately 200 times maximum therapeutic concentrations) on the activity of six human Cytochrome P450 (CYP) enzymes was evaluated in a model system using human liver microsomes.	Zolpidem	40-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-188
12437345-0	2002	Molecular mechanism of the electron transfer reaction in cytochrome P450(cam)--putidaredoxin: roles of glutamine 360 at the heme proximal site.	Glutamine	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-92
12437345-0	2002	Molecular mechanism of the electron transfer reaction in cytochrome P450(cam)--putidaredoxin: roles of glutamine 360 at the heme proximal site.	Heme	124-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-92
12543512-1	2002	An enantioselective assay for S-(-)- and R-(+)-propranolol in transgenic Chinese hamster CHL cell lines, expressing human cytochrome P450 (CYP), was developed.	s-(-)- and r-(+)-propranolol	30-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
12543512-1	2002	An enantioselective assay for S-(-)- and R-(+)-propranolol in transgenic Chinese hamster CHL cell lines, expressing human cytochrome P450 (CYP), was developed.	s-(-)- and r-(+)-propranolol	30-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
12369889-11	2002	Historically, this strategy utilized CYP 2B1 to activate oxazaphosphorines.	oxazaphosphorines	57-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
12426514-1	2002	BACKGROUND AND OBJECTIVE: Praziquantel is extensively metabolized by the hepatic cytochrome P450 (CYP) enzymes.	Praziquantel	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	inn	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	purpurin	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
12379470-6	2002	CYP1B1 was the most strongly affected CYP molecule by purpurin and alizarin among CYPs examined in this study.	purpurin	54-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	purpurin	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
12379470-6	2002	CYP1B1 was the most strongly affected CYP molecule by purpurin and alizarin among CYPs examined in this study.	alizarin	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	alizarin	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
12379470-14	2002	These results suggest that the antigenotoxic activities of purpurin and alizarin can be explained by inhibition of CYP activities responsible for activating the mutagens.	purpurin	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	alizarin	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
12379470-14	2002	These results suggest that the antigenotoxic activities of purpurin and alizarin can be explained by inhibition of CYP activities responsible for activating the mutagens.	alizarin	72-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
12487729-0	2002	Comparison of rat and human cytochrome P450 (CYP) sources of N-alkylprotoporphyrin IX.	n-alkylprotoporphyrin ix	61-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
12487729-0	2002	Comparison of rat and human cytochrome P450 (CYP) sources of N-alkylprotoporphyrin IX.	n-alkylprotoporphyrin ix	61-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	Carmine	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
12379470-3	2002	The activities of eight human recombinant cytochrome P450 (CYP) isozymes were measured in the presence of purpurin, alizarin or carminic acid.	Carmine	128-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
12487729-3	2002	The porphyrinogenicity of certain xenobiotics is due to mechanism-based inactivation of selected cytochrome P450 (CYP) enzymes, with concurrent formation of N-alkylprotoporphyrins (N-alkylPPs), which disrupt control of haem biosynthesis.	n-alkylprotoporphyrins	157-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
12487729-3	2002	The porphyrinogenicity of certain xenobiotics is due to mechanism-based inactivation of selected cytochrome P450 (CYP) enzymes, with concurrent formation of N-alkylprotoporphyrins (N-alkylPPs), which disrupt control of haem biosynthesis.	Heme	219-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
12487729-3	2002	The porphyrinogenicity of certain xenobiotics is due to mechanism-based inactivation of selected cytochrome P450 (CYP) enzymes, with concurrent formation of N-alkylprotoporphyrins (N-alkylPPs), which disrupt control of haem biosynthesis.	Heme	219-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
12487729-5	2002	The objective was to use cDNA-expressed individual rat CYP enzyme preparations in microsomes prepared from baculovirus-infected insect cells to determine which rat CYP enzymes were the source of N-alkylPPs after interaction with three porphyrinogenic xenobiotics and to compare the results with formation of N-alkylPPs in individual human CYP enzyme orthologues.	n-alkylpps	195-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-167
12487729-7	2002	A sensitive fluorometric technique was employed to quantitate N-alkylPP formation after interaction of individual CYP enzymes with a porphyrinogenic xenobiotic.	Nitrogen	62-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
12452431-1	2002	Cytochrome P450 (P450) reactions are of interest because of their relevance to the oxidative metabolism of drugs, steroids, carcinogens, and other chemicals.	Steroids	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12487729-9	2002	N-alkylPP formation was found following the interaction of three porphyrinogenic xenobiotics with CYP1A2, 2B1, 2C6, 2C11 and 3A2, in amounts ranging from 0.45 to 0.07 nmol N-alkylPP nmol(-1) CYP.	Nitrogen	0-1	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12487729-9	2002	N-alkylPP formation was found following the interaction of three porphyrinogenic xenobiotics with CYP1A2, 2B1, 2C6, 2C11 and 3A2, in amounts ranging from 0.45 to 0.07 nmol N-alkylPP nmol(-1) CYP.	alkylpp	2-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12487729-9	2002	N-alkylPP formation was found following the interaction of three porphyrinogenic xenobiotics with CYP1A2, 2B1, 2C6, 2C11 and 3A2, in amounts ranging from 0.45 to 0.07 nmol N-alkylPP nmol(-1) CYP.	n-alkylpp	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12385721-0	2002	In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos.	Carbaryl	23-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
12385721-0	2002	In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos.	Chlorpyrifos	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
12385721-2	2002	Although previous studies have demonstrated that carbaryl can be metabolized by cytochrome P450 (CYP), the identification and characterization of CYP isoforms involved in metabolism have not been described either in humans or in experimental animals.	Carbaryl	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
12385721-2	2002	Although previous studies have demonstrated that carbaryl can be metabolized by cytochrome P450 (CYP), the identification and characterization of CYP isoforms involved in metabolism have not been described either in humans or in experimental animals.	Carbaryl	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
12385721-2	2002	Although previous studies have demonstrated that carbaryl can be metabolized by cytochrome P450 (CYP), the identification and characterization of CYP isoforms involved in metabolism have not been described either in humans or in experimental animals.	Carbaryl	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-149
12385721-3	2002	The in vitro metabolic activities of human liver microsomes (HLM) and human cytochrome P450 (CYP) isoforms toward carbaryl were investigated in this study.	Carbaryl	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
12385721-3	2002	The in vitro metabolic activities of human liver microsomes (HLM) and human cytochrome P450 (CYP) isoforms toward carbaryl were investigated in this study.	Carbaryl	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
12385721-4	2002	The three major metabolites, i.e. 5-hydroxycarbaryl, 4-hydroxycarbaryl and carbaryl methylol, were identified after incubation of carbaryl with HLM or individual CYP isoforms and analysis by HPLC.	(5-hydroxynaphthalen-1-yl) N-methylcarbamate	34-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12385721-4	2002	The three major metabolites, i.e. 5-hydroxycarbaryl, 4-hydroxycarbaryl and carbaryl methylol, were identified after incubation of carbaryl with HLM or individual CYP isoforms and analysis by HPLC.	Carbaryl	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12385721-4	2002	The three major metabolites, i.e. 5-hydroxycarbaryl, 4-hydroxycarbaryl and carbaryl methylol, were identified after incubation of carbaryl with HLM or individual CYP isoforms and analysis by HPLC.	Carbaryl	62-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
12385721-5	2002	Most of the 16 human CYP isoforms studied showed some metabolic activity toward carbaryl.	Carbaryl	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
12385721-12	2002	Therefore, carbaryl metabolism in humans and its interaction with other chemicals is reflected by the concentration of CYP isoforms in HLM and their activities in the metabolic pathways for carbaryl.	Carbaryl	11-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-122
12385721-12	2002	Therefore, carbaryl metabolism in humans and its interaction with other chemicals is reflected by the concentration of CYP isoforms in HLM and their activities in the metabolic pathways for carbaryl.	Carbaryl	190-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-122
12396873-5	2002	Cotreatment of the cells with 2 microM alpha-naphthoflavone, a cytochrome P-450 inhibitor and arylhydrocarbon receptor antagonist, blocked the increase of benzo[a]pyrene hydroxylase activity induced by treatment with MEP extract alone.	alpha-naphthoflavone	39-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	benzidine	26-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12228186-0	2002	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.	Phenytoin	145-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
12374776-1	2002	Cytochrome P450 mono-oxygenases (CYP) play an essential role in steroid metabolism, and there is speculation that sex hormones might influence cardiac mass and physiology.	Steroids	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12388931-6	2002	Together these data suggest that cysteine-nitrosylation of the HNF4 DNA-binding domain is the primary molecular mechanism responsible for the drop in oxydase activities of hepatic cytochrome P450 enzymes, and the consequent impairment in drug metabolism during inflammation.	Cysteine	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	3-ohz.sbnd	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12227954-6	2002	Skin preexposure to the skin CYP450 inducer BaP largely changed label penetration depth and distribution pattern in cutaneous tissues and decreased (14)C concentration in skin and fat.	Benzo(a)pyrene	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-35
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	benzidine	64-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	N-acetylbenzidine	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	N-hydroxy-N'-acetylbenzidine	88-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12297285-1	2002	Cytochrome P450(BSbeta) is a peroxygenase that catalyzes the alpha- or beta-hydroxylation of myristic acid by utilizing H(2)O(2).	Myristic Acid	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-23
12297285-1	2002	Cytochrome P450(BSbeta) is a peroxygenase that catalyzes the alpha- or beta-hydroxylation of myristic acid by utilizing H(2)O(2).	h(2)	120-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-23
12351142-12	2002	Cytochrome P-450 oxidizes BZ to an inactive product (3-OHz.sbnd;BZ) and ABZ to N"HA and N-hydroxy-N-acetylbenzidine (NHA).	N-hydroxy-N'-acetylbenzidine	117-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12351142-13	2002	Cytochrome P-450, PHS, and horseradish peroxidase activate ABZ to bind DNA forming N"-(3"-monophospho-deoxyguanosin-8-yl)-N-acetylbenzidine (dGp-ABZ).	N-acetylbenzidine	59-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12351142-13	2002	Cytochrome P-450, PHS, and horseradish peroxidase activate ABZ to bind DNA forming N"-(3"-monophospho-deoxyguanosin-8-yl)-N-acetylbenzidine (dGp-ABZ).	N'-(3'-monophosphodeoxyguanosin-8-yl)-N-acetylbenzidine	83-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12351142-13	2002	Cytochrome P-450, PHS, and horseradish peroxidase activate ABZ to bind DNA forming N"-(3"-monophospho-deoxyguanosin-8-yl)-N-acetylbenzidine (dGp-ABZ).	dgp-abz	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
12207498-0	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by human cytochrome P450-dependent monooxygenase systems.	Polychlorinated Dibenzodioxins	14-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
12220536-0	2002	Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes.	Metals	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
12220536-0	2002	Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes.	Curcumin	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
12093814-2	2002	Cytochrome P450 (P450) 2D6 is involved in the oxidation of a large fraction ( approximately 30%) of drugs used by humans and also catalyzes the O-demethylation of the model substrates 3- and 4-methoxyphenethylamine followed by subsequent ring hydroxylation to dopamine.	3- and 4-methoxyphenethylamine	184-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
12093814-2	2002	Cytochrome P450 (P450) 2D6 is involved in the oxidation of a large fraction ( approximately 30%) of drugs used by humans and also catalyzes the O-demethylation of the model substrates 3- and 4-methoxyphenethylamine followed by subsequent ring hydroxylation to dopamine.	Dopamine	260-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
12207498-0	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by human cytochrome P450-dependent monooxygenase systems.	Polychlorinated Dibenzodioxins	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	14-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
12206675-1	2002	Cytochrome P450 (P450) 2D6 was first identified as the polymorphic human debrisoquine hydroxylase and subsequently shown to catalyze the oxidation of a variety of drugs containing a basic nitrogen.	Nitrogen	188-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	14-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-132
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	14-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-217
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-132
12207498-1	2002	Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by monooxygenase systems dependent on 12 forms of human cytochrome P450 (CYP) was examined with the recombinant yeast microsomes containing each of the human CYP.	Polychlorinated Dibenzodioxins	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-217
12207498-3	2002	Remarkable metabolism by the multiple CYP forms was observed toward dibenzo-p-dioxin (DD) and mono-, di-, and trichloroDDs.	dibenzo(1,4)dioxin	68-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
12207498-3	2002	Remarkable metabolism by the multiple CYP forms was observed toward dibenzo-p-dioxin (DD) and mono-, di-, and trichloroDDs.	dibenzo(1,4)dioxin	86-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
12207498-3	2002	Remarkable metabolism by the multiple CYP forms was observed toward dibenzo-p-dioxin (DD) and mono-, di-, and trichloroDDs.	mono-, di-, and trichlorodds	94-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
12363340-2	2002	Limitation of the dissolved oxygen supplied during cultivation of various microbial strains can decrease the activity of cytochrome P-450 monooxygenases required for the processing of pathway intermediates into their final forms, resulting in the accumulation of these intermediates as the primary products.	Oxygen	28-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
12236850-0	2002	Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.	pyranoprofen	54-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
12236850-1	2002	AIMS: To identify the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) isoforms responsible for the formation of the primary metabolite(s) of zaltoprofen, and to predict possible drug interactions by investigating the inhibition of CYP isoforms in vitro.	pyranoprofen	153-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
12236850-1	2002	AIMS: To identify the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) isoforms responsible for the formation of the primary metabolite(s) of zaltoprofen, and to predict possible drug interactions by investigating the inhibition of CYP isoforms in vitro.	pyranoprofen	153-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
12236850-1	2002	AIMS: To identify the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) isoforms responsible for the formation of the primary metabolite(s) of zaltoprofen, and to predict possible drug interactions by investigating the inhibition of CYP isoforms in vitro.	pyranoprofen	153-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	243-246
12236850-2	2002	METHODS: The metabolism of zaltoprofen was studied in vitro using recombinant CYP and UGT isoform cDNA-expression systems.	pyranoprofen	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
12236850-13	2002	CONCLUSIONS: Zaltoprofen is predominantly metabolized by CYP2C9 and UGT2B7, and is considered unlikely to cause significant drug interactions in vivo when coadministered with CYP substrates at clinically effective doses.	pyranoprofen	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
12167570-1	2002	The metabolism of methoxychlor, a proestrogenic pesticide (endocrine disruptor), was investigated with cDNA expressed human cytochrome P450s and liver microsomes (HLM).	Methoxychlor	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
12192156-0	2002	Biomimetic oxidation of 2-methylimidazole derivative with a chemical model system for cytochrome P-450.	2-methylimidazole	24-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
12167460-1	2002	Many studies have demonstrated that cyclophosphamide (CPA) can affect hepatic cytochrome p450 (CYP) isoenzyme activity in animals.	Cyclophosphamide	36-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
12167460-1	2002	Many studies have demonstrated that cyclophosphamide (CPA) can affect hepatic cytochrome p450 (CYP) isoenzyme activity in animals.	Cyclophosphamide	36-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
12167460-1	2002	Many studies have demonstrated that cyclophosphamide (CPA) can affect hepatic cytochrome p450 (CYP) isoenzyme activity in animals.	Cyclophosphamide	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
12167460-1	2002	Many studies have demonstrated that cyclophosphamide (CPA) can affect hepatic cytochrome p450 (CYP) isoenzyme activity in animals.	Cyclophosphamide	54-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
12167460-2	2002	We have investigated the effect of CPA on gene expression of various CYP enzymes as well as beta-actin in the human acute promyelocytic leukemia cell line (HL-60S) and its multidrug-resistant (MDR) phenotype HL-60R.	Cyclophosphamide	35-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12167460-4	2002	In determination of cytotoxicity and resistance factor (RF: IC(50) HL-60R/IC(50) HL-60S), concentrations of 100 and 500 micro g/ml CPA were selected to treat HL-60S and HL-60R up to 72 h. CYP gene expression in the cells prior to and after treatment with CPA was determined using semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time PCR.	Cyclophosphamide	131-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
12172927-3	2002	Although CYP and GST enzymes are involved in the activation and detoxification of N-nitrosamines and related compound, studies on the relationship between genetic polymorphisms of CYP2E1, GSTT1, and GSTM1 and the risk of gastric carcinoma (GC) are few, and the results have been conflicting.	n-nitrosamines	82-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-12
12192156-1	2002	A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone.	tetraphenylporphyrin manganese chloride	60-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
12192156-1	2002	A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone.	tppmncl	101-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
12192156-1	2002	A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone.	iodosobenzene	114-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
12171873-2	2002	IFNs affect cytochrome P450 (CYP) enzymes, which metabolize many endogenous (e.g., steroids, fatty acids) and exogenous (e.g., drugs) substrates.	Steroids	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
12192156-1	2002	A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone.	2-methylimidazole	151-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
12171873-2	2002	IFNs affect cytochrome P450 (CYP) enzymes, which metabolize many endogenous (e.g., steroids, fatty acids) and exogenous (e.g., drugs) substrates.	Steroids	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
12171873-2	2002	IFNs affect cytochrome P450 (CYP) enzymes, which metabolize many endogenous (e.g., steroids, fatty acids) and exogenous (e.g., drugs) substrates.	Fatty Acids	93-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
12192156-1	2002	A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone.	2-methylimidazolone	172-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
12171873-2	2002	IFNs affect cytochrome P450 (CYP) enzymes, which metabolize many endogenous (e.g., steroids, fatty acids) and exogenous (e.g., drugs) substrates.	Fatty Acids	93-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
12187294-2	2002	However, this could possibly influence vitamin D 25-hydroxylation because this reaction is catalyzed in part by the mitochondrial cytochrome P-450, the enzyme responsible for the 27-hydroxylation of cholesterol.	Vitamin D	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
12124303-0	2002	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4"-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.	Tamoxifen	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
12124303-0	2002	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4"-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.	4-hydroxy, 4"-hydroxy	87-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
12124303-0	2002	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4"-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.	hydroxytamoxifen	158-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
12124303-1	2002	The cytochrome P450 (P450)-mediated biotransformation of tamoxifen is important in determining both the clearance of the drug and its conversion to the active metabolite, trans-4-hydroxytamoxifen.	Tamoxifen	57-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
12124303-1	2002	The cytochrome P450 (P450)-mediated biotransformation of tamoxifen is important in determining both the clearance of the drug and its conversion to the active metabolite, trans-4-hydroxytamoxifen.	hydroxytamoxifen	171-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
12214661-0	2002	Electron supply and catalytic oxidation of nitrogen by cytochrome P450 and nitric oxide synthase.	Nitrogen	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
12214661-1	2002	Cytochrome P450 and nitric oxide synthase (NOS) oxidize nitrogen atoms, although the substrates and transformations are highly restricted for NOS.	Nitrogen	56-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12214668-7	2002	Preclinical studies in vivo have demonstrated that although AQ4N has little or no intrinsic cytotoxic activity per se it (i) enhances the antitumor effects of radiation and conventional chemotherapeutic agents, (ii) is pharmacokinetically stable, and (iii) is a substrate for cytochrome P450 (CYP).	AQ4N	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	276-291
12214668-7	2002	Preclinical studies in vivo have demonstrated that although AQ4N has little or no intrinsic cytotoxic activity per se it (i) enhances the antitumor effects of radiation and conventional chemotherapeutic agents, (ii) is pharmacokinetically stable, and (iii) is a substrate for cytochrome P450 (CYP).	AQ4N	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	293-296
12214668-8	2002	A study of AQ4N metabolism in vitro and ex vivo using purified CYP enzymes, phenotyped human livers and CYP transfected cell lines shows that CYP3A, 1A and 1B1 family members contribute to AQ4N bioreduction in the absence of oxygen.	AQ4N	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
12214668-8	2002	A study of AQ4N metabolism in vitro and ex vivo using purified CYP enzymes, phenotyped human livers and CYP transfected cell lines shows that CYP3A, 1A and 1B1 family members contribute to AQ4N bioreduction in the absence of oxygen.	AQ4N	11-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
12214668-8	2002	A study of AQ4N metabolism in vitro and ex vivo using purified CYP enzymes, phenotyped human livers and CYP transfected cell lines shows that CYP3A, 1A and 1B1 family members contribute to AQ4N bioreduction in the absence of oxygen.	AQ4N	189-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
12214668-8	2002	A study of AQ4N metabolism in vitro and ex vivo using purified CYP enzymes, phenotyped human livers and CYP transfected cell lines shows that CYP3A, 1A and 1B1 family members contribute to AQ4N bioreduction in the absence of oxygen.	Oxygen	225-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
12214668-9	2002	Importantly AQ4N is shown to be metabolized by tumors known to express CYP isoforms.	AQ4N	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74
12214673-0	2002	Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.	Nitrosamines	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
12214673-0	2002	Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.	Nitrosamines	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
12214673-0	2002	Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.	Nitrosamines	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
12201364-0	2002	Cold induces catalytic iron release of cytochrome P-450 origin: a critical step in cold storage-induced renal injury.	Iron	23-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
12201364-2	2002	Whether the cytochrome P-450 enzymes, shown to be a source for iron in several injury models, contribute to cold-induced iron release is not known.	Iron	63-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
12201364-2	2002	Whether the cytochrome P-450 enzymes, shown to be a source for iron in several injury models, contribute to cold-induced iron release is not known.	Iron	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
12201364-5	2002	As microsomes are rich in iron-containing cytochrome P-450 enzymes, microsomes were cold stored with P-450 inhibitors, cimetidine and piperonyl butoxide.	Iron	26-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
12201364-10	2002	Our data demonstrate for the first time that cold-induced catalytic iron release may be at least in part of microsomal cytochrome P-450 origin, and that it participates in cold-storage-induced renal injury.	Iron	68-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
12187294-2	2002	However, this could possibly influence vitamin D 25-hydroxylation because this reaction is catalyzed in part by the mitochondrial cytochrome P-450, the enzyme responsible for the 27-hydroxylation of cholesterol.	Cholesterol	199-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
12135382-1	2002	Cytochrome P450(BM3)-F87G reacts with aromatic aldehydes and hydrogen peroxide to generate covalent heme adducts in a reaction that may involve the formation of a stable isoporphyrin intermediate [Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J.	Aldehydes	47-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
12135382-1	2002	Cytochrome P450(BM3)-F87G reacts with aromatic aldehydes and hydrogen peroxide to generate covalent heme adducts in a reaction that may involve the formation of a stable isoporphyrin intermediate [Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J.	Hydrogen Peroxide	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
12135382-1	2002	Cytochrome P450(BM3)-F87G reacts with aromatic aldehydes and hydrogen peroxide to generate covalent heme adducts in a reaction that may involve the formation of a stable isoporphyrin intermediate [Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J.	Heme	100-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
12135382-1	2002	Cytochrome P450(BM3)-F87G reacts with aromatic aldehydes and hydrogen peroxide to generate covalent heme adducts in a reaction that may involve the formation of a stable isoporphyrin intermediate [Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J.	isoporphyrin	170-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
12126389-0	2002	Catalytic oxidations of steroid substrates by artificial cytochrome p-450 enzymes.	Steroids	24-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
12123654-1	2002	The reaction of demethylation mediated by cytochrome P450 (CYP) leads to the equimolar production of demethylated metabolite and formaldehyde.	Formaldehyde	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
12123750-0	2002	Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.	ellipticine	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
12123654-1	2002	The reaction of demethylation mediated by cytochrome P450 (CYP) leads to the equimolar production of demethylated metabolite and formaldehyde.	Formaldehyde	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
12123654-5	2002	The method first involves the limiting step of the CYP-dependent reaction, which is stopped with a mixture of zinc sulfate 5 mM and trichloroacetic acid 100 mM.	Zinc Sulfate	110-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
12123750-2	2002	Recently, we found that ellipticine also forms covalent DNA adducts and that the formation of the major adduct is dependent on the activation of ellipticine by cytochrome P450 (CYP).	ellipticine	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
12123654-5	2002	The method first involves the limiting step of the CYP-dependent reaction, which is stopped with a mixture of zinc sulfate 5 mM and trichloroacetic acid 100 mM.	Trichloroacetic Acid	132-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
12123750-2	2002	Recently, we found that ellipticine also forms covalent DNA adducts and that the formation of the major adduct is dependent on the activation of ellipticine by cytochrome P450 (CYP).	ellipticine	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
12123750-2	2002	Recently, we found that ellipticine also forms covalent DNA adducts and that the formation of the major adduct is dependent on the activation of ellipticine by cytochrome P450 (CYP).	ellipticine	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
12396131-6	2002	Homology models of both the chimeric proteins were developed using SWISS-MODEL based on the known crystal structure of cytochrome P-450 camC, BM-3, 1DT6A, and 2C17A.	camc	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
12123750-2	2002	Recently, we found that ellipticine also forms covalent DNA adducts and that the formation of the major adduct is dependent on the activation of ellipticine by cytochrome P450 (CYP).	ellipticine	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
12123750-3	2002	We examined a panel of genetically engineered V79 cell lines including the parental line V79MZ and recombinant cells expressing the human CYP enzymes CYP1A1, CYP1A2 or CYP3A4 for their ability to activate ellipticine.	ellipticine	205-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
12123750-6	2002	The nuclease P1 version of the 32P-postlabelling assay yielded a similar pattern of ellipticine-DNA adducts with two major adducts in all cells, the formation of only one of which was dependent on CYP activity.	Phosphorus-32	31-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
12123750-10	2002	The results presented here are the first report showing the formation of CYP-mediated covalent DNA adducts by ellipticine in cells in culture, and confirm the formation of covalent DNA adducts as a new mechanism of ellipticine action.	ellipticine	110-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
12123750-10	2002	The results presented here are the first report showing the formation of CYP-mediated covalent DNA adducts by ellipticine in cells in culture, and confirm the formation of covalent DNA adducts as a new mechanism of ellipticine action.	ellipticine	215-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
12107550-0	2002	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.	Thiotepa	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12084621-0	2002	Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction.	imidacloprid	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
12084621-0	2002	Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction.	Imidazolidines	94-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
12084621-0	2002	Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction.	nitroimine	125-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	NADP	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	NADP	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Alkenes	191-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Alkenes	191-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Imidazolidines	261-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Imidazolidines	261-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	nitrosoimine	290-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	nitrosoimine	290-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Guanidine	312-321	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Guanidine	312-321	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Urea	334-338	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	Urea	334-338	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	nitroimine	394-404	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
12084621-2	2002	This study with individual recombinant cytochrome P450 (CYP450) isozymes from human liver shows that the principal organoextractable NADPH-dependent metabolites are the 5-hydroxy (major) and olefin (minor) derivatives from hydroxylation and desaturation of the imidazolidine moiety and the nitrosoimine (major), guanidine (minor) and urea (trace) derivatives from reduction and cleavage of the nitroimine substituent.	nitroimine	394-404	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-62
12087352-0	2002	Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. BACKGROUND: Interferon alpha (IFN-alpha) is thought to be responsible for cytochrome P450 (CYP)-dependent drug interactions mediated by a decrease in CYP activities.	alpha-Ribavirin	21-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
12060642-1	2002	PURPOSE: This research investigated the biotransformation of thalidomide by cytochrome P-450 (CYP).	Thalidomide	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
12060642-1	2002	PURPOSE: This research investigated the biotransformation of thalidomide by cytochrome P-450 (CYP).	Thalidomide	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
12060642-2	2002	EXPERIMENTAL DESIGN: We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated metabolism of thalidomide.	Thalidomide	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
12107550-0	2002	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.	Triethylenephosphoramide	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12060642-2	2002	EXPERIMENTAL DESIGN: We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated metabolism of thalidomide.	Thalidomide	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
12107550-1	2002	PURPOSE: To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA.	Thiotepa	109-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
12107550-1	2002	PURPOSE: To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA.	Thiotepa	109-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
12107550-1	2002	PURPOSE: To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA.	Triethylenephosphoramide	163-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
12107550-1	2002	PURPOSE: To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA.	Triethylenephosphoramide	163-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
12107550-10	2002	There is a potential for CYP-mediated drug interactions with thiotepa.	Thiotepa	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
12107550-11	2002	Pharmacokinetic variability of thiotepa may be related to expression of hepatic CYP isozymes.	Thiotepa	31-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
12027667-4	2002	The reagent was exploited in a total synthesis of 13-oxotridec-9E,11E-dienoic acid, confirming the identity of this product that is generated upon autoxidation of linoleic acid and by decomposition of 13-hydroperoxy-9,11-octadecadienoate (13-HPODE), especially in the presence of redox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.	13-oxotridec-9e	50-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	316-332
12020594-0	2002	Comparative effect of colchicine and colchiceine on cytotoxicity and CYP gene expression in primary human hepatocytes.	colchiceine	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
12027667-4	2002	The reagent was exploited in a total synthesis of 13-oxotridec-9E,11E-dienoic acid, confirming the identity of this product that is generated upon autoxidation of linoleic acid and by decomposition of 13-hydroperoxy-9,11-octadecadienoate (13-HPODE), especially in the presence of redox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.	11e-dienoic acid	66-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	316-332
12027667-4	2002	The reagent was exploited in a total synthesis of 13-oxotridec-9E,11E-dienoic acid, confirming the identity of this product that is generated upon autoxidation of linoleic acid and by decomposition of 13-hydroperoxy-9,11-octadecadienoate (13-HPODE), especially in the presence of redox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.	Linoleic Acid	163-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	316-332
12027667-4	2002	The reagent was exploited in a total synthesis of 13-oxotridec-9E,11E-dienoic acid, confirming the identity of this product that is generated upon autoxidation of linoleic acid and by decomposition of 13-hydroperoxy-9,11-octadecadienoate (13-HPODE), especially in the presence of redox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.	13-hydroperoxy-9,11-octadecadienoate	201-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	316-332
12027667-4	2002	The reagent was exploited in a total synthesis of 13-oxotridec-9E,11E-dienoic acid, confirming the identity of this product that is generated upon autoxidation of linoleic acid and by decomposition of 13-hydroperoxy-9,11-octadecadienoate (13-HPODE), especially in the presence of redox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.	Metals	304-309	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	316-332
12033517-0	2002	Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.	Buprenorphine	57-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
12076522-0	2002	Kinetics of bromodichloromethane metabolism by cytochrome P450 isoenzymes in human liver microsomes.	bromodichloromethane	12-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
12076522-1	2002	The kinetic constants for the metabolism of bromodichloromethane (BDCM) by three cytochrome P450 (CYP) isoenzymes have been measured in human liver microsomes.	bromodichloromethane	44-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
12076522-1	2002	The kinetic constants for the metabolism of bromodichloromethane (BDCM) by three cytochrome P450 (CYP) isoenzymes have been measured in human liver microsomes.	bromodichloromethane	44-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12076522-1	2002	The kinetic constants for the metabolism of bromodichloromethane (BDCM) by three cytochrome P450 (CYP) isoenzymes have been measured in human liver microsomes.	bromodichloromethane	66-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
12076522-1	2002	The kinetic constants for the metabolism of bromodichloromethane (BDCM) by three cytochrome P450 (CYP) isoenzymes have been measured in human liver microsomes.	bromodichloromethane	66-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12076522-12	2002	Because of the low levels of BDCM exposure from drinking water, it appears likely that CYP2E1 will dominate hepatic CYP-mediated BDCM metabolism in humans.	Water	57-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
12076522-12	2002	Because of the low levels of BDCM exposure from drinking water, it appears likely that CYP2E1 will dominate hepatic CYP-mediated BDCM metabolism in humans.	bromodichloromethane	129-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
12033517-1	2002	The effects of buprenorphine, a powerful mixed agonist/antagonist analgesic, on several cytochrome P450 (CYP) isoform specific reactions in human liver microsomes were investigated to predict drug interaction of buprenorphine in vivo from in vitro data.	Buprenorphine	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
12033517-1	2002	The effects of buprenorphine, a powerful mixed agonist/antagonist analgesic, on several cytochrome P450 (CYP) isoform specific reactions in human liver microsomes were investigated to predict drug interaction of buprenorphine in vivo from in vitro data.	Buprenorphine	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
12033517-1	2002	The effects of buprenorphine, a powerful mixed agonist/antagonist analgesic, on several cytochrome P450 (CYP) isoform specific reactions in human liver microsomes were investigated to predict drug interaction of buprenorphine in vivo from in vitro data.	Buprenorphine	212-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
11950794-4	2002	Sulfaphenazole, flavoxamine, and antibodies raised against purified liver cytochrome P450 (P450) 2C9 that inhibit both CYP2C9- and 2C19-dependent activities, significantly inhibited microsomal oxidations of (+)- and (-)-limonene enantiomers.	flavoxamine	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-100
12067002-9	2002	RESULTS: Total recovery of propofol in the metabolites studied amounts to 38%, of which 62% was via the PG metabolite and 38% via cytochrome P-450.	Propofol	27-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
11950794-4	2002	Sulfaphenazole, flavoxamine, and antibodies raised against purified liver cytochrome P450 (P450) 2C9 that inhibit both CYP2C9- and 2C19-dependent activities, significantly inhibited microsomal oxidations of (+)- and (-)-limonene enantiomers.	(+)- and (-)-limonene	207-228	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-100
11996890-9	2002	Since these cells lack the isoenzymatic form of cytochrome P(450) mainly involved in the ethanol metabolism (namely cytochrome P(450)2E1) and also are devoid of alcohol dehydrogenase activity, we propose that the toxic actions of ethanol on liver must be linked to the activity of one or both of these systems.	Ethanol	89-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-65
11964369-2	2002	Following computer-based molecule similarity, we proposed that on cytochrome-P450 degradation, the LOS metabolite EXP3179 is generated, which shows molecule homology to indomethacin, a cyclooxygenase inhibitor with antiinflammatory and antiaggregatory properties.	Indomethacin	169-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
12422544-18	2002	Another theory involves toxic metabolites; the aromatic antiepileptic agents are metabolised by cytochrome P-450 to an arene oxide metabolite.	Benzene oxide	119-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
11996890-9	2002	Since these cells lack the isoenzymatic form of cytochrome P(450) mainly involved in the ethanol metabolism (namely cytochrome P(450)2E1) and also are devoid of alcohol dehydrogenase activity, we propose that the toxic actions of ethanol on liver must be linked to the activity of one or both of these systems.	Ethanol	230-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-65
11872324-2	2002	The current study was conducted to assess the potential for nefazodone to have metabolic drug interactions associated with cytochrome P450 (CYP) enzymes.	nefazodone	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-138
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Sparteine	72-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Hydrocortisone	103-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Caffeine	137-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Mephenytoin	187-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Antipyrine	213-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11956677-1	2002	OBJECTIVE: To determine whether the antiprotozoal drug atovaquone inhibits the cytochrome P(450) (CYP)2C9-mediated metabolism of sulphamethoxazole (SMX) to its potentially harmful hydroxylamine metabolite (SMX-HA) in vitro.	Atovaquone	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-96
11872324-2	2002	The current study was conducted to assess the potential for nefazodone to have metabolic drug interactions associated with cytochrome P450 (CYP) enzymes.	nefazodone	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-143
11956677-1	2002	OBJECTIVE: To determine whether the antiprotozoal drug atovaquone inhibits the cytochrome P(450) (CYP)2C9-mediated metabolism of sulphamethoxazole (SMX) to its potentially harmful hydroxylamine metabolite (SMX-HA) in vitro.	Sulfamethoxazole	129-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-96
11956677-1	2002	OBJECTIVE: To determine whether the antiprotozoal drug atovaquone inhibits the cytochrome P(450) (CYP)2C9-mediated metabolism of sulphamethoxazole (SMX) to its potentially harmful hydroxylamine metabolite (SMX-HA) in vitro.	Sulfamethoxazole	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-96
12028321-11	2002	Frovatriptan is principally metabolized by the CYP1A2 isoenzyme of cytochrome P-450 and is cleared by the kidney and liver, each having sufficient capacity to compensate for impairment of the other.	frovatriptan	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
11866476-2	2002	Cytochrome P450-dependent oxidation of acetaminophen results in the formation of the toxic N-acetyl-p-benzoquinone-imine (NAPQI).	Acetaminophen	39-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11891538-0	2002	The environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity in high passage PC 3 and DU 145 human prostate cancer cell lines.	Polychlorinated Dibenzodioxins	24-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
11891538-0	2002	The environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity in high passage PC 3 and DU 145 human prostate cancer cell lines.	du	118-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
11891538-6	2002	The induction of CYP1A1 and CYP1B1 by TCCD in the hormone-independent prostate cancer cell lines suggests that CYP induction should be considered in patients with advanced prostate cancer.	tccd	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
11983405-1	2002	An overview of the application of high-pressure studies on the carbon monoxide complex of cytochrome P-450 is given.	Carbon Monoxide	63-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Estradiol	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Estradiol	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-85
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	vsmcs	39-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	vsmcs	39-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-85
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Methylcholanthrene	96-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Methylcholanthrene	96-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-85
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Phenobarbital	121-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
11967242-5	2002	The inhibitory effects of estradiol on VSMCs were enhanced by cytochrome-P450 (CYP450) inducers 3-methylcholanthrene and phenobarbital.	Phenobarbital	121-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-85
11967242-6	2002	Moreover, the inhibitory effects of estradiol were blocked in the presence of the CYP450 inhibitor 1-aminobenzotriazole and the catechol-O-methyltransferase inhibitors quercetin and OR486.	Estradiol	36-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-88
11967242-6	2002	Moreover, the inhibitory effects of estradiol were blocked in the presence of the CYP450 inhibitor 1-aminobenzotriazole and the catechol-O-methyltransferase inhibitors quercetin and OR486.	1-aminobenzotriazole	99-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-88
11869873-2	2002	The environmental pollutant 3-methylsulfonyl-DDE (3-MeSO2-DDE) and the cytochrome P450 (CYP) inhibitors ketoconazole, metyrapone and aminoglutethimide were studied for their effects on the steroid formation.	Ketoconazole	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
11869873-2	2002	The environmental pollutant 3-methylsulfonyl-DDE (3-MeSO2-DDE) and the cytochrome P450 (CYP) inhibitors ketoconazole, metyrapone and aminoglutethimide were studied for their effects on the steroid formation.	Metyrapone	118-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
11869873-2	2002	The environmental pollutant 3-methylsulfonyl-DDE (3-MeSO2-DDE) and the cytochrome P450 (CYP) inhibitors ketoconazole, metyrapone and aminoglutethimide were studied for their effects on the steroid formation.	Aminoglutethimide	133-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
11869873-2	2002	The environmental pollutant 3-methylsulfonyl-DDE (3-MeSO2-DDE) and the cytochrome P450 (CYP) inhibitors ketoconazole, metyrapone and aminoglutethimide were studied for their effects on the steroid formation.	Steroids	189-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
11866476-2	2002	Cytochrome P450-dependent oxidation of acetaminophen results in the formation of the toxic N-acetyl-p-benzoquinone-imine (NAPQI).	N-acetyl-4-benzoquinoneimine	91-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11866476-2	2002	Cytochrome P450-dependent oxidation of acetaminophen results in the formation of the toxic N-acetyl-p-benzoquinone-imine (NAPQI).	N-acetyl-4-benzoquinoneimine	122-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11866476-3	2002	Inhibition of cytochrome P450 enzymes responsible for NAPQI formation might be useful--besides N-acetylcysteine treatment--in managing acetaminophen overdose.	N-acetyl-4-benzoquinoneimine	54-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
11866476-3	2002	Inhibition of cytochrome P450 enzymes responsible for NAPQI formation might be useful--besides N-acetylcysteine treatment--in managing acetaminophen overdose.	Acetylcysteine	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
11866476-3	2002	Inhibition of cytochrome P450 enzymes responsible for NAPQI formation might be useful--besides N-acetylcysteine treatment--in managing acetaminophen overdose.	Acetaminophen	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
11866476-4	2002	Investigations were carried out using human liver microsomes to test whether selective inhibition of cytochrome P450s reduces NAPQI formation.	N-acetyl-4-benzoquinoneimine	126-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
11866476-8	2002	Although cimetidin is used in the therapy of acetaminophen overdose as an inhibitor of cytochrome P450, it is not able to reduce NAPQI formation.	Cimetidine	9-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
11865972-3	2002	The objective of this study is to evaluate the effect of amiodarone on the pharmacokinetics of mexiletine through its inhibition of various cytochrome P450 (CYP) subtypes.	Amiodarone	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
11893129-3	2002	To better understand the interaction between genotype and response to warfarin therapy, we determined the frequency and functional effects of polymorphisms of the predominant cytochrome P450 subfamily responsible for warfarin metabolism (eg, CYP2C9) in an ethnically defined U.S. patient population.	Warfarin	70-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
11893129-3	2002	To better understand the interaction between genotype and response to warfarin therapy, we determined the frequency and functional effects of polymorphisms of the predominant cytochrome P450 subfamily responsible for warfarin metabolism (eg, CYP2C9) in an ethnically defined U.S. patient population.	Warfarin	217-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
11893129-11	2002	Patients with CYP polymorphisms (2C9*2, 2C9*3) had significantly lower warfarin doses compared to patients with wild-type genotypes [30.6 (+/- 2.5) mg versus 40.1 (+/- 1.7) mg, p = 0.0021] .	Warfarin	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
11893129-12	2002	Stepwise backward regression analysis suggested a moderate ability to predict warfarin dose based on CYP genotype (r2 = 0.26), p &lt; 0.01).	Warfarin	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
11893129-14	2002	As interactions between genetic factors and other variables that influence warfarin effect are more completely understood, CYP analysis may prove a useful adjunct for increasing the safety and efficacy of this agent.	Warfarin	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
11865972-3	2002	The objective of this study is to evaluate the effect of amiodarone on the pharmacokinetics of mexiletine through its inhibition of various cytochrome P450 (CYP) subtypes.	Amiodarone	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
11865972-3	2002	The objective of this study is to evaluate the effect of amiodarone on the pharmacokinetics of mexiletine through its inhibition of various cytochrome P450 (CYP) subtypes.	Mexiletine	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
11865972-3	2002	The objective of this study is to evaluate the effect of amiodarone on the pharmacokinetics of mexiletine through its inhibition of various cytochrome P450 (CYP) subtypes.	Mexiletine	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-160
11936218-0	2002	Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes.	Flavonoids	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
11936218-1	2002	A series of flavonoids isolated from Scutellariae radix were evaluated for their effects on cytochrome P-450 (CYP) activities in human liver microsomes.	Flavonoids	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
11936218-1	2002	A series of flavonoids isolated from Scutellariae radix were evaluated for their effects on cytochrome P-450 (CYP) activities in human liver microsomes.	Flavonoids	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
12071336-2	2002	Thus, we studied formation of the major maprotiline metabolite desmethylmaprotiline to identify the human cytochrome P-450 enzymes (CYP) involved.	desmethylmaprotiline	63-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfoxide	101-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11851418-2	2002	We demonstrate here that cytochrome P450 (CYP) is responsible for the conversion of the cyano group of pinacidil to the corresponding amide.	Pinacidil	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
11851418-2	2002	We demonstrate here that cytochrome P450 (CYP) is responsible for the conversion of the cyano group of pinacidil to the corresponding amide.	Pinacidil	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
11851418-2	2002	We demonstrate here that cytochrome P450 (CYP) is responsible for the conversion of the cyano group of pinacidil to the corresponding amide.	Amides	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
11851418-2	2002	We demonstrate here that cytochrome P450 (CYP) is responsible for the conversion of the cyano group of pinacidil to the corresponding amide.	Amides	134-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
11851418-4	2002	Incubations of pinacidil with recombinant CYP enzymes confirm that CYP3A4 is the principal catalyst of this reaction.	Pinacidil	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45
11816012-7	2002	Since celecoxib should be metabolized primarily by cytochrome 2C9 (CYP2C9), a poor metabolizer (PM) for this cytochrome P450 enzyme was included in the study.	Celecoxib	6-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
11839370-5	2002	We therefore hypothesize that the addition of lovastatin caused an increase in plasma quetiapine levels through competitive inhibition of the cytochrome P(450) (CYP) isoenzyme 3A4.	Lovastatin	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-159
11839370-5	2002	We therefore hypothesize that the addition of lovastatin caused an increase in plasma quetiapine levels through competitive inhibition of the cytochrome P(450) (CYP) isoenzyme 3A4.	Lovastatin	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
11839370-5	2002	We therefore hypothesize that the addition of lovastatin caused an increase in plasma quetiapine levels through competitive inhibition of the cytochrome P(450) (CYP) isoenzyme 3A4.	Quetiapine Fumarate	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-159
11839370-5	2002	We therefore hypothesize that the addition of lovastatin caused an increase in plasma quetiapine levels through competitive inhibition of the cytochrome P(450) (CYP) isoenzyme 3A4.	Quetiapine Fumarate	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
11847531-0	2002	Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.	Albendazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
11847531-0	2002	Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.	Antipyrine	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfoxide	124-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfoxide	101-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfoxide	124-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfone	133-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfone	133-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfone	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	albendazole sulfone	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	Antipyrine	202-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	Antipyrine	202-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11847531-9	2002	Since the CL(T) of antipyrine is a general measure of CYP enzymes but with a slight to moderate weight toward CYP1A2, we suggest the involvement of this enzyme in ASOX to ASON metabolism in man.	Antipyrine	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
11847531-9	2002	Since the CL(T) of antipyrine is a general measure of CYP enzymes but with a slight to moderate weight toward CYP1A2, we suggest the involvement of this enzyme in ASOX to ASON metabolism in man.	albendazole sulfone	171-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
12026186-4	2002	L-Trp also had much higher inhibitory activity on the cytochrome P-450-dependent lipid peroxidation than the previously identified antioxidants of HPE, L-phenylalanine, L-tyrosine and uracil.	Tryptophan	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
11805199-0	2002	The fallacy of using adrenochrome reaction for measurement of reactive oxygen species formed during cytochrome p450-mediated metabolism of xenobiotics.	Reactive Oxygen Species	62-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Epinephrine	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Epinephrine	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-235
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Reactive Oxygen Species	118-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Reactive Oxygen Species	118-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-235
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Cyclosporine	278-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	215-230
11805199-1	2002	The adrenochrome reaction (oxidation of epinephrine to adrenochrome) has been widely employed as a standard assay for reactive oxygen species, produced under a variety of conditions, including those produced during cytochrome P450 (CYP)-mediated oxidation of substrates such as cyclosporine.	Cyclosporine	278-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	232-235
11876575-8	2002	Sertraline is a moderate CYP2D6 inhibitor; citalopram appears to have little effect on the major CYP isoforms.	Sertraline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
11876575-9	2002	Fluoxetine deserves special attention as inhibitory effects on CYP-activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine.	Fluoxetine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
11876575-9	2002	Fluoxetine deserves special attention as inhibitory effects on CYP-activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine.	Fluoxetine	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
11876575-9	2002	Fluoxetine deserves special attention as inhibitory effects on CYP-activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine.	Fluoxetine	172-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
11876575-9	2002	Fluoxetine deserves special attention as inhibitory effects on CYP-activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine.	norfluoxetine	202-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
11805199-3	2002	Thus, in the present report, we provide evidence that measurement of adrenochrome cannot be used as an index of reactive oxygen species generated during CYP-mediated metabolism of xenobiotics because adrenochrome and its precursor, epinephrine, interact with the CYP enzyme system as substrates and inhibitors.	Epinephrine	232-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-156
11805199-3	2002	Thus, in the present report, we provide evidence that measurement of adrenochrome cannot be used as an index of reactive oxygen species generated during CYP-mediated metabolism of xenobiotics because adrenochrome and its precursor, epinephrine, interact with the CYP enzyme system as substrates and inhibitors.	Epinephrine	232-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-266
11805199-4	2002	Our results indicated that adrenochrome was moderately stable in phosphate buffer but degraded rapidly (over 50% consumed in less than 2 min) by (cloned and expressed) CYP3A4 and CYP reductase in the presence of NADPH.	NADP	212-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
12481202-2	2002	Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12481202-2	2002	Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	267-279	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12481202-2	2002	Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
12481202-2	2002	Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes.	Rosuvastatin Calcium	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	313-316
11744607-0	2002	Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.	Rifampin	92-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
12052216-1	2002	Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity.	Cyclophosphamide	66-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
12052216-1	2002	Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity.	Cyclophosphamide	66-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
12052216-1	2002	Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity.	Ifosfamide	87-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
12052216-1	2002	Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity.	Ifosfamide	87-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
12383041-1	2002	OBJECTIVE: To investigate the in vitro metabolism of the antithrombotic agent fondaparinux sodium in mammalian liver fractions and to evaluate its potential inhibitory effect on human cytochrome P450 (CYP)-mediated metabolism of other drugs.	Fondaparinux	78-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199
12383041-1	2002	OBJECTIVE: To investigate the in vitro metabolism of the antithrombotic agent fondaparinux sodium in mammalian liver fractions and to evaluate its potential inhibitory effect on human cytochrome P450 (CYP)-mediated metabolism of other drugs.	Fondaparinux	78-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-204
12383041-5	2002	Experiments were designed to determine apparent K(i) (inhibitory constant) values for fondaparinux sodium against each CYP isoform, by varying concentrations of fondaparinux sodium and the selective substrate.	Fondaparinux	86-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-122
12383041-10	2002	Apparent K(i) values for fondaparinux sodium against the CYP isoforms could not be determined because the oxidative metabolism of the isoform-selective CYP substrates was not significantly inhibited in pooled microsomal reaction mixtures.	Fondaparinux	25-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
11744605-0	2002	Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction.	Hydrogen	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
15618670-1	2002	The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated.	Selegiline	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
15618670-1	2002	The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated.	Selegiline	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
15618670-2	2002	Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline.	Selegiline	157-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
15618670-2	2002	Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline.	Selegiline	157-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
11752129-4	2002	We then examined the inhibitory effects of anti-CYP4F antibody and 17-octadecynoic acid, an inhibitor of the CYP4 family, on ebastine hydroxylation in intestinal microsomes, since CYP4F was recently found to be the predominant ebastine hydroxylase in monkey intestine; and a novel CYP4F isoform (CYP4F12), also capable of hydroxylating ebastine, was found to exist in human intestine.	ebastine	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-185
12495367-12	2002	The hepatic metabolism of rabeprazole is predominantly by nonenzymatic reactions and minimally by CYP-mediated reactions, which therefore confers an advantage over older PPIs in that genetic polymorphisms for CYP2C19 do not significantly influence rabeprazole clearance, clinical efficacy or potential for drug interactions.	Rabeprazole	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12060006-5	2002	A CYP-catalyzed arene oxide intermediate of LTG has been identified.	Benzene oxide	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	2-5
11752129-4	2002	We then examined the inhibitory effects of anti-CYP4F antibody and 17-octadecynoic acid, an inhibitor of the CYP4 family, on ebastine hydroxylation in intestinal microsomes, since CYP4F was recently found to be the predominant ebastine hydroxylase in monkey intestine; and a novel CYP4F isoform (CYP4F12), also capable of hydroxylating ebastine, was found to exist in human intestine.	ebastine	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-185
11752129-5	2002	However, the inhibitory effects were only partial (about 20%) and thus it was thought that, although human CYP4F was involved in ebastine hydroxylation, another predominant enzyme exists.	ebastine	129-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-112
11701230-0	2001	Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite.	Phenol	55-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	Arachidonic Acid	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	Arachidonic Acid	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	169-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	169-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	202-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	202-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	epoxyeicosatrienoic acids	215-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	epoxyeicosatrienoic acids	215-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	eets	242-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
11773611-1	2002	Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) and that these compounds play critical roles in the regulation of renal, pulmonary, and cardiac function and vascular tone.	eets	242-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
11773611-12	2002	Given the importance of this pathway in the control of cardiovascular function, it is likely that CYP metabolites of arachidonic acid contribute to the changes in renal function and vascular tone associated with some of these conditions and that drugs that modify the formation and/or actions of EETs and 20-HETE may have therapeutic benefits.	Arachidonic Acid	117-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
12048797-1	2002	Patients with cirrhosis of the liver were found to have a considerable suppression of the system of biotransformation of the liver before operation which correlated with the data of the direct indices of monooxigenase system of hepatocytes--cytochrome P-450 and activity of N-demethylase of amidopyrine.	Aminopyrine	291-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-287
12664659-5	2002	The CYP gene products such as CYP3A, CYP2B and PPAR are essential for metabolism of endogenous steroid hormones, fatty acids and various xenobiotics including drugs.	Steroids	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
12664659-5	2002	The CYP gene products such as CYP3A, CYP2B and PPAR are essential for metabolism of endogenous steroid hormones, fatty acids and various xenobiotics including drugs.	Fatty Acids	113-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
11701230-0	2001	Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite.	Benzene	65-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11701230-3	2001	To exert its toxic effects, benzene must be metabolized by cytochrome P450 to phenol and subsequently to catechol and hydroquinone.	Benzene	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
11701230-3	2001	To exert its toxic effects, benzene must be metabolized by cytochrome P450 to phenol and subsequently to catechol and hydroquinone.	Phenol	78-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
11701230-3	2001	To exert its toxic effects, benzene must be metabolized by cytochrome P450 to phenol and subsequently to catechol and hydroquinone.	catechol	105-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
11829200-2	2001	METHODS: Human liver microsomes or recombinant cytochrome P450 (CYP) enzymes were incubated with either (+/- )-, (+)-, or (-)-lansoprazole in the presence of reduced nicotinamide adenine dinucleotide phosphate.	(+/- )-, (+)-, or (-)-lansoprazole	104-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
11668070-1	2001	This study was conducted to test the hypothesis that the cytochrome P-450 (CYP450) metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to the afferent arteriolar response to P2 receptor activation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	94-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
11829200-2	2001	METHODS: Human liver microsomes or recombinant cytochrome P450 (CYP) enzymes were incubated with either (+/- )-, (+)-, or (-)-lansoprazole in the presence of reduced nicotinamide adenine dinucleotide phosphate.	(+/- )-, (+)-, or (-)-lansoprazole	104-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
11733614-0	2001	Cytochrome P450 metabolites of arachidonic acid: novel regulators of renal function.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11717173-0	2001	Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.	Cisapride	56-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11717173-0	2001	Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.	norcisapride	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11717173-1	2001	Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride.	Cisapride	89-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11717173-1	2001	Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride.	norcisapride	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11717173-1	2001	Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride.	norcisapride	125-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11717173-1	2001	Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride.	Cisapride	114-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11714275-1	2001	Cytochrome P450 (P450) 2D6 oxidizes a wide variety of drugs typically at a distance of 5-7 A from a basic nitrogen on the substrate.	Nitrogen	106-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
11668070-1	2001	This study was conducted to test the hypothesis that the cytochrome P-450 (CYP450) metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to the afferent arteriolar response to P2 receptor activation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	94-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-81
11668070-1	2001	This study was conducted to test the hypothesis that the cytochrome P-450 (CYP450) metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to the afferent arteriolar response to P2 receptor activation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	127-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
11668070-1	2001	This study was conducted to test the hypothesis that the cytochrome P-450 (CYP450) metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to the afferent arteriolar response to P2 receptor activation.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	127-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-81
11668070-9	2001	Taken together, these results are consistent with the hypothesis that the CYP450 metabolite 20-HETE participates in the afferent arteriolar response to activation of P2X receptors.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	92-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-80
11600130-2	2001	The relationship between the structure of N-alkylnitrosamines and CYP form(s) involved in the activation was evaluated.	n-alkylnitrosamines	42-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11725960-3	2001	These oxidations required NADPH, and were markedly inhibited by SKF-525A, indicating that cytochrome P450 (CYP) was involved.	NADP	26-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
11725960-3	2001	These oxidations required NADPH, and were markedly inhibited by SKF-525A, indicating that cytochrome P450 (CYP) was involved.	NADP	26-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
11600130-6	2001	Mutagen-producing capacity of CYP, as indicated by induced revertants/nmol promutagen/pmol CYP, for an N-alkylnitrosamine was determined for all forms of CYP.	n-alkylnitrosamine	103-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
11600130-0	2001	Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.	n-alkylnitrosamines	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
11600130-0	2001	Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.	n-alkylnitrosamines	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
11600130-0	2001	Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.	n-alkylnitrosamines	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
11600130-1	2001	The role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines was examined by Ames test using genetically engineered Salmonella typhimurium (S. typhimurium)YG7108 cells expressing each form of human CYP together with human NADPH-cytochrome P450 reductase (OR).	n-alkylnitrosamines	71-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
11600130-1	2001	The role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines was examined by Ames test using genetically engineered Salmonella typhimurium (S. typhimurium)YG7108 cells expressing each form of human CYP together with human NADPH-cytochrome P450 reductase (OR).	n-alkylnitrosamines	71-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
11600130-1	2001	The role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines was examined by Ames test using genetically engineered Salmonella typhimurium (S. typhimurium)YG7108 cells expressing each form of human CYP together with human NADPH-cytochrome P450 reductase (OR).	n-alkylnitrosamines	71-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-231
11600130-6	2001	Mutagen-producing capacity of CYP, as indicated by induced revertants/nmol promutagen/pmol CYP, for an N-alkylnitrosamine was determined for all forms of CYP.	n-alkylnitrosamine	103-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
11600130-6	2001	Mutagen-producing capacity of CYP, as indicated by induced revertants/nmol promutagen/pmol CYP, for an N-alkylnitrosamine was determined for all forms of CYP.	n-alkylnitrosamine	103-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
11525925-1	2001	Metabolic activation of 1-nitropyrene (1-NP) by human cytochrome P450 (P450) family 1 enzymes co-expressed with NADPH-cytochrome P450 reductase (NPR) in Escherichia coli membranes was investigated.	1-nitropyrene	24-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-85
11669629-7	2001	In addition, treatment of CYP4B1, CYP4F3, and CYP4A5/7 with strong base generated a new, chromatographically distinct, polar heme species with a mass of 632.3 amu rather than 616.2 amu.	Heme	125-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-40
11509577-2	2001	Cytochrome P450 (P450) 2D6 was first identified as the polymorphic human debrisoquine hydroxylase and subsequently shown to catalyze the oxidation of a variety of drugs containing a basic nitrogen.	Nitrogen	188-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
11679404-1	2001	Since the initial reports that renal cytochrome P450 (CYP) enzymes can metabolize arachidonic acid to substances which affect arterial tone, it has become increasingly clear that CYP enzymes expressed within the cardiovascular system play a crucial role in the modulation of vascular homeostasis.	Arachidonic Acid	82-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
11679404-1	2001	Since the initial reports that renal cytochrome P450 (CYP) enzymes can metabolize arachidonic acid to substances which affect arterial tone, it has become increasingly clear that CYP enzymes expressed within the cardiovascular system play a crucial role in the modulation of vascular homeostasis.	Arachidonic Acid	82-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
11679404-1	2001	Since the initial reports that renal cytochrome P450 (CYP) enzymes can metabolize arachidonic acid to substances which affect arterial tone, it has become increasingly clear that CYP enzymes expressed within the cardiovascular system play a crucial role in the modulation of vascular homeostasis.	Arachidonic Acid	82-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-182
11679404-2	2001	There is strong evidence suggesting that the activation of a CYP epoxygenase in endothelial cells is an essential step in nitric oxide and prostacyclin-independent vasodilatation of several vascular beds, particularly in the heart and kidney.	Nitric Oxide	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
11679404-2	2001	There is strong evidence suggesting that the activation of a CYP epoxygenase in endothelial cells is an essential step in nitric oxide and prostacyclin-independent vasodilatation of several vascular beds, particularly in the heart and kidney.	Epoprostenol	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
11679404-3	2001	A smooth muscle CYP omega-hydroxylase, on the other hand, generates a vasoconstrictor eicosanoid that is central to the myogenic response.	Eicosanoids	86-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
11679404-4	2001	Moreover, CYP epoxygenase and omega-hydroxylase products, as well as CYP-derived reactive oxygen species, are intracellular signal transduction molecules involved in several signaling cascades affecting numerous cellular processes, including vascular cell proliferation and angiogenesis.	Reactive Oxygen Species	81-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
11679404-5	2001	This review summarizes the vascular effects of epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, both of which are CYP-derived metabolites of arachidonic acid, endogenously generated within endothelial and vascular smooth muscle cells.	epoxyeicosatrienoic acids	47-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
11679404-5	2001	This review summarizes the vascular effects of epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, both of which are CYP-derived metabolites of arachidonic acid, endogenously generated within endothelial and vascular smooth muscle cells.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	77-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
11679404-5	2001	This review summarizes the vascular effects of epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, both of which are CYP-derived metabolites of arachidonic acid, endogenously generated within endothelial and vascular smooth muscle cells.	Arachidonic Acid	155-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
11713692-0	2001	Alternatives to the oxoferryl porphyrin cation radical as the proposed reactive intermediate of cytochrome P450: two-electron oxidized Fe(III) porphyrin derivatives.	oxoferryl porphyrin cation radical	20-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
11678785-3	2001	Owing to the difficulties associated with in vivo pharmacokinetic studies in a paediatric population, we explored the in vitro metabolism of cisapride by human cytochrome P450.	Cisapride	141-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
11673755-5	2001	In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected.	Phenytoin	55-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
11673755-5	2001	In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected.	Phenytoin	146-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
11673755-5	2001	In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected.	Phenytoin	146-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-120
11684362-1	2001	N,N-dimethylformamide (DMF), an organic solvent widely used in industry, is bioactivated by cytochrome P450 (P450) to reactive metabolites which are believed to be responsible for the hepatotoxicity observed in animals and humans.	Dimethylformamide	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
11684362-1	2001	N,N-dimethylformamide (DMF), an organic solvent widely used in industry, is bioactivated by cytochrome P450 (P450) to reactive metabolites which are believed to be responsible for the hepatotoxicity observed in animals and humans.	Dimethylformamide	23-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
11560868-1	2001	The antipsychotic agent risperidone, is metabolized by different cytochrome P-450 (CYP) enzymes, including CYP2D6, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma.	Risperidone	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
11560868-1	2001	The antipsychotic agent risperidone, is metabolized by different cytochrome P-450 (CYP) enzymes, including CYP2D6, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma.	Risperidone	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
11560868-1	2001	The antipsychotic agent risperidone, is metabolized by different cytochrome P-450 (CYP) enzymes, including CYP2D6, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma.	Paliperidone Palmitate	129-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
11560868-1	2001	The antipsychotic agent risperidone, is metabolized by different cytochrome P-450 (CYP) enzymes, including CYP2D6, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma.	Paliperidone Palmitate	129-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
11713692-0	2001	Alternatives to the oxoferryl porphyrin cation radical as the proposed reactive intermediate of cytochrome P450: two-electron oxidized Fe(III) porphyrin derivatives.	fe(iii) porphyrin	135-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
11551516-0	2001	Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples.	Cadmium	39-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
11601668-3	2001	Like nonselective NSAIDs, coxibs are hepatically metabolized: rofecoxib primarily by reduction by cytosolic enzymes and celecoxib by the cytochrome P450 (CYP) enzyme system.	rofecoxib	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-152
11601668-3	2001	Like nonselective NSAIDs, coxibs are hepatically metabolized: rofecoxib primarily by reduction by cytosolic enzymes and celecoxib by the cytochrome P450 (CYP) enzyme system.	rofecoxib	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-157
11601668-3	2001	Like nonselective NSAIDs, coxibs are hepatically metabolized: rofecoxib primarily by reduction by cytosolic enzymes and celecoxib by the cytochrome P450 (CYP) enzyme system.	Celecoxib	120-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-152
11601668-3	2001	Like nonselective NSAIDs, coxibs are hepatically metabolized: rofecoxib primarily by reduction by cytosolic enzymes and celecoxib by the cytochrome P450 (CYP) enzyme system.	Celecoxib	120-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-157
11601668-5	2001	However, potent inducers of CYP, such as rifampin, may decrease rofecoxib concentrations because of induction of general hepatic metabolic activity.	Rifampin	41-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
11601668-5	2001	However, potent inducers of CYP, such as rifampin, may decrease rofecoxib concentrations because of induction of general hepatic metabolic activity.	rofecoxib	64-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
11586481-3	2001	Modulation of xenobiotic metabolism, including cytochrome P-450 (CYP) enzyme activities, due to dietary intakes of cruciferous vegetables, has been described in animals and humans, and the induction of CYP1A enzymes is suggested mainly to be related to the content of indolyl glucosinolates in these vegetables.	indolyl glucosinolates	268-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
11516890-3	2001	Although metabolized by the cytochrome P-450 (CYP) system, venlafaxine inhibits CYP 2D6 and 3A4 to a far lesser extent than do the SSRIs.	Venlafaxine Hydrochloride	59-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
11551516-1	2001	This study was undertaken to assess associations between age, gender, cigarette smoke and non-workplace cadmium exposure, and liver pathology and inter-individual variation in cytochrome P450 (CYP) expression in human tissues.	Cadmium	104-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-196
11502591-0	2001	Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide.	Nitric Oxide	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
11556812-1	2001	Cytochrome P450 (P450) 2D6 is a polymorphic human enzyme involved in the oxidation of &gt;50 drugs, most of which contain a basic nitrogen.	Nitrogen	130-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
11470492-0	2001	Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450.	Catechin	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
11678058-5	2001	A review of recent literature suggests that clarithromycin may induce digoxin toxicity by three different mechanisms, including reduction of renal excretion of digoxin, alteration of intestinal flora, and inhibition of cytochrome P-450 in the liver.	Clarithromycin	44-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-235
11502728-0	2001	Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes.	Chlorpyrifos	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
11502728-2	2001	CPS can be activated by cytochrome P450 (CYP) through a desulfuration reaction to form chlorpyrifos-oxon (CPO), a potent anticholinesterase.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	87-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
11502728-2	2001	CPS can be activated by cytochrome P450 (CYP) through a desulfuration reaction to form chlorpyrifos-oxon (CPO), a potent anticholinesterase.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	87-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
11502728-2	2001	CPS can be activated by cytochrome P450 (CYP) through a desulfuration reaction to form chlorpyrifos-oxon (CPO), a potent anticholinesterase.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	106-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
11502728-2	2001	CPS can be activated by cytochrome P450 (CYP) through a desulfuration reaction to form chlorpyrifos-oxon (CPO), a potent anticholinesterase.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	106-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
11497333-9	2001	Cells pretreated with 50 degrees M 3-methylcholanthrene (3MC), a CYP 1A inducer, for 72 h prior to 0.15 microM AFB1, produced the activated AFB1 8,9-epoxide (AFBO).	Methylcholanthrene	35-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
11497333-9	2001	Cells pretreated with 50 degrees M 3-methylcholanthrene (3MC), a CYP 1A inducer, for 72 h prior to 0.15 microM AFB1, produced the activated AFB1 8,9-epoxide (AFBO).	Methylcholanthrene	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
11497333-9	2001	Cells pretreated with 50 degrees M 3-methylcholanthrene (3MC), a CYP 1A inducer, for 72 h prior to 0.15 microM AFB1, produced the activated AFB1 8,9-epoxide (AFBO).	afb1 8,9-epoxide	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
11497333-13	2001	Expression of CYP 1A was significantly increased in 3MC-pretreated cells, while CYP 3A4 expression increased slightly, but not to the extent of the 1A isoforms.	Methylcholanthrene	52-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
11497333-17	2001	These data support earlier findings showing modest CYP-mediated AFB1 activation in human airways, but indicate that exposure to polycyclic aromatic hydrocarbons (PAHs), such as 3MC, which induce CYP(s) that specifically activate AFB1 may increase the harmful effects of AFB1 exposures in human airways.	Polycyclic Aromatic Hydrocarbons	128-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
11497333-17	2001	These data support earlier findings showing modest CYP-mediated AFB1 activation in human airways, but indicate that exposure to polycyclic aromatic hydrocarbons (PAHs), such as 3MC, which induce CYP(s) that specifically activate AFB1 may increase the harmful effects of AFB1 exposures in human airways.	Polycyclic Aromatic Hydrocarbons	162-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
11497333-17	2001	These data support earlier findings showing modest CYP-mediated AFB1 activation in human airways, but indicate that exposure to polycyclic aromatic hydrocarbons (PAHs), such as 3MC, which induce CYP(s) that specifically activate AFB1 may increase the harmful effects of AFB1 exposures in human airways.	Methylcholanthrene	177-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-198
11502723-0	2001	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.	Loratadine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
11502723-0	2001	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.	desloratadine	67-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
11502723-0	2001	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.	3-oh-desloratadine	86-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
11502723-1	2001	The purpose of this study was to evaluate loratadine, desloratadine, and 3-OH-desloratadine as inhibitors of certain human liver cytochrome P-450 enzymes.	Loratadine	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
11502723-1	2001	The purpose of this study was to evaluate loratadine, desloratadine, and 3-OH-desloratadine as inhibitors of certain human liver cytochrome P-450 enzymes.	desloratadine	54-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
11502723-1	2001	The purpose of this study was to evaluate loratadine, desloratadine, and 3-OH-desloratadine as inhibitors of certain human liver cytochrome P-450 enzymes.	3-oh-desloratadine	73-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
11506821-6	2001	Earlier in vivo experiments with rodents indicated that indoles and isothiocyanates, two major groups of glucosinolate breakdown products, attenuate the effects of polycyclic aromatic hydrocarbons (PAHs) and nitrosamines via induction of GST and inhibition of cytochrome-P450 isoenzymes, respectively.	Indoles	56-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-275
11506821-6	2001	Earlier in vivo experiments with rodents indicated that indoles and isothiocyanates, two major groups of glucosinolate breakdown products, attenuate the effects of polycyclic aromatic hydrocarbons (PAHs) and nitrosamines via induction of GST and inhibition of cytochrome-P450 isoenzymes, respectively.	Isothiocyanates	68-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-275
11506821-6	2001	Earlier in vivo experiments with rodents indicated that indoles and isothiocyanates, two major groups of glucosinolate breakdown products, attenuate the effects of polycyclic aromatic hydrocarbons (PAHs) and nitrosamines via induction of GST and inhibition of cytochrome-P450 isoenzymes, respectively.	Polycyclic Aromatic Hydrocarbons	164-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	260-275
11470492-6	2001	The IC(50) values of catechins for the inhibition of human CYP were roughly the same as those seen in the mutagenic activation.	Catechin	21-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
11470492-7	2001	EGCG inhibited other forms of human CYP such as CYP2A6, CYP2C19 and CYP2E1, indicating the non-specific inhibitory effects of EGCG toward human CYPs.	epigallocatechin gallate	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
11470492-7	2001	EGCG inhibited other forms of human CYP such as CYP2A6, CYP2C19 and CYP2E1, indicating the non-specific inhibitory effects of EGCG toward human CYPs.	epigallocatechin gallate	126-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
11470492-8	2001	Furthermore, EGCG inhibited human NADPH-cytochrome CYP reductase (OR) with a K(i) value of 2.5 microM.	epigallocatechin gallate	13-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
11454723-1	2001	We examined the effects of several agents, including dietary flavonoids, on CYP1A1 expression utilizing a recently developed high-throughput screening system for assessing human cytochrome P450 (CYP) induction.	Flavonoids	61-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
11500893-0	2001	How Does Ethene Inactivate Cytochrome P450 En Route to Its Epoxidation?	ethylene	9-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
29711977-0	2001	How Does Ethene Inactivate Cytochrome P450 En Route to Its Epoxidation?	ethylene	9-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
29711977-2	2001	The suicidal complex 4 2, which inactivates cytochrome P450 during olefin epoxidation, was shown by density functional calculations to be formed from the same high-spin intermediate (4 1-III) that leads to stereochemical scrambling.	Alkenes	67-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
11504269-0	2001	Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations.	Clozapine	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11454729-0	2001	Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate.	phenethyl isothiocyanate	65-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	61-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	61-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	61-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-240
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
11454729-1	2001	The inhibition and mechanism-based inactivation potencies of phenethyl isothiocyanate (PEITC) for human cytochrome P450 (CYP) activities were investigated using microsomes from baculovirus-infected insect cells expressing specific human CYP isoforms.	phenethyl isothiocyanate	87-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-240
11454729-10	2001	The present study directly proved that the chemopreventive effects of PEITC for nitrosamine-induced carcinogenesis are due to the inhibition of CYP by an in vitro study.	phenethyl isothiocyanate	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
11454729-10	2001	The present study directly proved that the chemopreventive effects of PEITC for nitrosamine-induced carcinogenesis are due to the inhibition of CYP by an in vitro study.	Nitrosamines	80-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
11454729-11	2001	The possibility that PEITC would affect the pharmacokinetics of clinically used drugs that are metabolized by these CYP isoforms was also suggested.	phenethyl isothiocyanate	21-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-119
11454734-0	2001	Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.	Tramadol	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
11454734-1	2001	The metabolism of cis-tramadol has been studied in human liver microsomes and in cDNA-expressed human cytochrome P-450 (CYP) isoforms.	Tramadol	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
11454734-1	2001	The metabolism of cis-tramadol has been studied in human liver microsomes and in cDNA-expressed human cytochrome P-450 (CYP) isoforms.	Tramadol	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
11454734-4	2001	Kinetic analysis revealed that multiple CYP enzymes were involved in the metabolism of tramadol to both M1 and M2.	Tramadol	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
11454734-11	2001	By kinetic analysis and the results of the reaction phenotyping studies, tramadol metabolism in human liver is catalyzed by multiple CYP isoforms.	Tramadol	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-136
11504269-1	2001	The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM).	Nitrogen	117-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11504269-1	2001	The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM).	Nitrogen	117-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11504269-1	2001	The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM).	Clozapine	136-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11504269-1	2001	The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM).	Clozapine	136-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11452704-0	2001	Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.	Dextromethorphan	119-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	porphine	188-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Heme	283-287	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Methane	291-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Heme	329-333	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Iron	334-338	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Oxygen	347-353	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11427068-2	2001	An initial model compound was constructed from a structure obtained by 300-ps molecular dynamics simulation of compound I-formed P-450cam under physiologic conditions, and it consisted of porphine for protoporphyrin IX, S(-)-CH(3) for the side chain of Cys357 of the fifth ligand of heme, a methane molecule for the substrate, a heme iron, and an oxygen atom of the sixth ligand of heme.	Heme	329-333	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-121
11488523-1	2001	Several recent studies have demonstrated that the cytochrome p450 (CYP) family plays an important role in the metabolism of taxanes.	Taxoids	124-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11488523-1	2001	Several recent studies have demonstrated that the cytochrome p450 (CYP) family plays an important role in the metabolism of taxanes.	Taxoids	124-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11408374-0	2001	Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.	Alkenes	51-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11408374-0	2001	Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.	cj-12	59-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11408374-0	2001	Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.	Alkenes	160-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	cj-12	102-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	cj-12	102-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	diol	148-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	diol	148-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	Alcohols	182-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
11408374-2	2001	In incubations with human liver microsomes and cofactors required for cytochrome P450 (CYP) activity, CJ-12,458 was converted to two metabolites: a diol (CP-611,781) and a 1 degrees alcohol (CP-616,762).	Alcohols	182-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
11356600-10	2001	In the human forearm microvasculature, EDHF appears to be a cytochrome P-450 derivative, possibly an epoxyeicosatrienoic acid.	edhf	39-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
11343389-0	2001	Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.	Warfarin	8-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
11343389-2	2001	Warfarin is metabolized by two distinct subfamilies of the cytochrome P450 (CYP) complex.	Warfarin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
11343389-2	2001	Warfarin is metabolized by two distinct subfamilies of the cytochrome P450 (CYP) complex.	Warfarin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
11343389-3	2001	We describe two siblings with extreme sensitivity to warfarin who share an unusual CYP genotype.	Warfarin	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
11356600-10	2001	In the human forearm microvasculature, EDHF appears to be a cytochrome P-450 derivative, possibly an epoxyeicosatrienoic acid.	epoxyeicosatrienoic acid	101-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
11353747-6	2001	Furthermore, P450 MI-2 and P450 MI-3 were recognized by anti-CYP4F and anti-CYP3A antibodies, respectively, in immunoblot analysis and catalyzed leukotriene B(4) omega-hydroxylation and testosterone 6beta-hydroxylation, which are known to be mediated by CYP4F and CYP3A, respectively.	Leukotriene B4	145-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-66
11375247-1	2001	The present study examined the inhibitory effects of N-hydroxy-N"-(4-butyl-2-methylphenyl)-formamidine (HET0016) on the renal metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes.	n-hydroxy-n"-(4-butyl-2-methylphenyl)-formamidine	53-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
11375247-1	2001	The present study examined the inhibitory effects of N-hydroxy-N"-(4-butyl-2-methylphenyl)-formamidine (HET0016) on the renal metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes.	n-hydroxy-n"-(4-butyl-2-methylphenyl)-formamidine	53-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
11375247-1	2001	The present study examined the inhibitory effects of N-hydroxy-N"-(4-butyl-2-methylphenyl)-formamidine (HET0016) on the renal metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes.	Arachidonic Acid	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-175
11375247-1	2001	The present study examined the inhibitory effects of N-hydroxy-N"-(4-butyl-2-methylphenyl)-formamidine (HET0016) on the renal metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes.	Arachidonic Acid	140-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
11497349-6	2001	The use of antisense morpholino oligonucleotide strategies to target CYP enzymes may result in safer and more uniform therapeutic applications.	Morpholinos	21-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
11353758-1	2001	Ketamine is metabolized by cytochrome P450 (CYP) leading to production of pharmacologically active products and contributing to drug excretion.	Ketamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
11353758-1	2001	Ketamine is metabolized by cytochrome P450 (CYP) leading to production of pharmacologically active products and contributing to drug excretion.	Ketamine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
11353758-2	2001	We identified the CYP enzymes involved in the N-demethylation of ketamine enantiomers using pooled human liver microsomes and microsomes from human B-lymphoblastoid cells that expressed CYP enzymes.	Nitrogen	46-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
11353758-2	2001	We identified the CYP enzymes involved in the N-demethylation of ketamine enantiomers using pooled human liver microsomes and microsomes from human B-lymphoblastoid cells that expressed CYP enzymes.	Nitrogen	46-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
11498765-1	2001	The sensitivity of tumors to cyclophosphamide (CPA) and other anticancer prodrugs can be substantially enhanced by transduction of tumors with a prodrug-activating mammalian cytochrome P450 (CYP) enzyme in combination with the flavoenzyme P450 reductase.	Cyclophosphamide	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
11498765-1	2001	The sensitivity of tumors to cyclophosphamide (CPA) and other anticancer prodrugs can be substantially enhanced by transduction of tumors with a prodrug-activating mammalian cytochrome P450 (CYP) enzyme in combination with the flavoenzyme P450 reductase.	Cyclophosphamide	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-194
11498765-1	2001	The sensitivity of tumors to cyclophosphamide (CPA) and other anticancer prodrugs can be substantially enhanced by transduction of tumors with a prodrug-activating mammalian cytochrome P450 (CYP) enzyme in combination with the flavoenzyme P450 reductase.	Cyclophosphamide	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
11498765-1	2001	The sensitivity of tumors to cyclophosphamide (CPA) and other anticancer prodrugs can be substantially enhanced by transduction of tumors with a prodrug-activating mammalian cytochrome P450 (CYP) enzyme in combination with the flavoenzyme P450 reductase.	Cyclophosphamide	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-194
11353747-6	2001	Furthermore, P450 MI-2 and P450 MI-3 were recognized by anti-CYP4F and anti-CYP3A antibodies, respectively, in immunoblot analysis and catalyzed leukotriene B(4) omega-hydroxylation and testosterone 6beta-hydroxylation, which are known to be mediated by CYP4F and CYP3A, respectively.	testosterone 6beta	186-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-66
11353747-9	2001	These results indicate that P450 MI-2 belongs to the CYP4F subfamily and is mainly responsible for hydroxylation of ebastine in monkey small intestinal microsomes.	ebastine	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-58
11353749-8	2001	Cytochrome P450 (P450) reaction phenotyping studies-using P450 form selective chemical inhibitors, immunoinhibitory antibodies, recombinant P450s, and correlation analysis with microsomes prepared from a bank of human livers-revealed that the 6"-methyl hydroxylation of etoricoxib was catalyzed largely (approximately 60%) by member(s) of the CYP3A subfamily.	Etoricoxib	270-280	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11353758-2	2001	We identified the CYP enzymes involved in the N-demethylation of ketamine enantiomers using pooled human liver microsomes and microsomes from human B-lymphoblastoid cells that expressed CYP enzymes.	Ketamine	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
11353758-2	2001	We identified the CYP enzymes involved in the N-demethylation of ketamine enantiomers using pooled human liver microsomes and microsomes from human B-lymphoblastoid cells that expressed CYP enzymes.	Ketamine	65-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
11353747-6	2001	Furthermore, P450 MI-2 and P450 MI-3 were recognized by anti-CYP4F and anti-CYP3A antibodies, respectively, in immunoblot analysis and catalyzed leukotriene B(4) omega-hydroxylation and testosterone 6beta-hydroxylation, which are known to be mediated by CYP4F and CYP3A, respectively.	Leukotriene B4	145-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-259
11353758-5	2001	Among the 12 cDNA-expressed CYP enzymes examined, CYP2B6, CYP2C9, and CYP3A4 showed high activities for the N-demethylation of both enantiomers at the substrate concentration of 1 mM.	Nitrogen	15-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
11468938-0	2001	A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.	Cyclophosphamide	94-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
11468938-0	2001	A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.	Thiotepa	115-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
11468938-0	2001	A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.	Cyclophosphamide	149-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
11468938-2	2001	CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite phosphoramide mustard (PM).	4-hydroxycyclophosphamide	55-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
11468938-2	2001	CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite phosphoramide mustard (PM).	4-hydroxycyclophosphamide	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
11468938-2	2001	CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite phosphoramide mustard (PM).	phosphoramide mustard	131-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
11377097-9	2001	These results show the metabolic activation of APAP, CPA and BA by the specific CYP subtypes expressed in the transformants and demonstrate the usefulness of these transformants for in vitro metabolic and toxicological studies in human liver.	Cyclophosphamide	53-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
11377097-9	2001	These results show the metabolic activation of APAP, CPA and BA by the specific CYP subtypes expressed in the transformants and demonstrate the usefulness of these transformants for in vitro metabolic and toxicological studies in human liver.	benz(a)anthracene	61-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
11377097-9	2001	These results show the metabolic activation of APAP, CPA and BA by the specific CYP subtypes expressed in the transformants and demonstrate the usefulness of these transformants for in vitro metabolic and toxicological studies in human liver.	Acetaminophen	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
11712183-0	2001	Effect of adamantanone derivative possessing anti-HIV properties on the redox processes in the cytochrome P-450 system.	adamantanone	10-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
11336973-3	2001	Aroclor 1254-induced and uninduced rat liver microsomes were compared to human liver microsomes in the metabolism of substrates which are known to be selectively metabolized by the major human cytochrome P450 (CYP) isoforms.	Chlorodiphenyl (54% Chlorine)	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	193-208
11336973-3	2001	Aroclor 1254-induced and uninduced rat liver microsomes were compared to human liver microsomes in the metabolism of substrates which are known to be selectively metabolized by the major human cytochrome P450 (CYP) isoforms.	Chlorodiphenyl (54% Chlorine)	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	210-213
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-278
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-283
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Esomeprazole	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-278
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Esomeprazole	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-283
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-278
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-283
11476153-1	2001	The aim of the present study was to assess the interindividual variation in styrene toxicokinetics and to correlate this variation with the individual metabolic capacity for cytochrome P450 (CYP), CYP2E1, CYP1A2 and CYP2D6.	Styrene	76-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-189
11476153-1	2001	The aim of the present study was to assess the interindividual variation in styrene toxicokinetics and to correlate this variation with the individual metabolic capacity for cytochrome P450 (CYP), CYP2E1, CYP1A2 and CYP2D6.	Styrene	76-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	191-194
11259320-0	2001	Metabolism of dimethyl-4,4"-dimethoxy-5,6,5",6"-dimethylene dioxybiphenyl-2,2"-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved.	dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate	14-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
11504148-0	2001	Human cytochrome P450 isozymes in metabolism and health effects of gasoline ethers.	gasoline ethers	67-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
11504148-7	2001	Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes.	tert-Butyl Alcohol	13-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-143
11504148-7	2001	Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes.	tert-Butyl Alcohol	13-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
11504148-7	2001	Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes.	NADP	46-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
11504148-7	2001	Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes.	Carbon Monoxide	96-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-143
11504148-7	2001	Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes.	Carbon Monoxide	96-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
11504148-13	2001	Correlation analysis of the ether-metabolizing activities with individual CYP enzyme activities in the human liver microsomes showed that the highest degree of correlation was with CYP isoform 2A6 (CYP2A6)+ (r = 0.94 for MTBE, 0.95 for ETBE, and 0.90 for TAME), which is constitutively expressed in human livers and known to be polymorphic.	Ether	28-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
11504148-14	2001	CYP2A6 displayed the highest turnover number in metabolizing gasoline ethers among a battery of human CYP enzymes expressed in human B-lymphoblastoid cells.	Ethers	70-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11311457-1	2001	The bioactivation of N-nitrosamines and polycyclic aromatic hydrocarbons (PAHs) is mediated primarily by the mixed-function oxidase system, which includes dimethylnitrosamine N-demethylase I, arylhydrocarbon [benzo(a)pyerne] hydroxylase, cytochrome P450, cytochrome b(5), and ethoxycoumarin deethylase.	n-nitrosamines	21-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-269
11311457-1	2001	The bioactivation of N-nitrosamines and polycyclic aromatic hydrocarbons (PAHs) is mediated primarily by the mixed-function oxidase system, which includes dimethylnitrosamine N-demethylase I, arylhydrocarbon [benzo(a)pyerne] hydroxylase, cytochrome P450, cytochrome b(5), and ethoxycoumarin deethylase.	Polycyclic Aromatic Hydrocarbons	40-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-269
11311457-1	2001	The bioactivation of N-nitrosamines and polycyclic aromatic hydrocarbons (PAHs) is mediated primarily by the mixed-function oxidase system, which includes dimethylnitrosamine N-demethylase I, arylhydrocarbon [benzo(a)pyerne] hydroxylase, cytochrome P450, cytochrome b(5), and ethoxycoumarin deethylase.	Polycyclic Aromatic Hydrocarbons	74-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	238-269
11457014-0	2001	Multi-state epoxidation of ethene by cytochrome P450: a quantum chemical study.	ethylene	27-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
11457014-1	2001	The epoxidation of ethene by a model for Compound I of cytochrome P450, studied by the use of density functional B3LYP calculations, involves two-state reactivity (TSR) with multiple electromer species, hence "multi-state epoxidation".	ethylene	19-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
11259320-0	2001	Metabolism of dimethyl-4,4"-dimethoxy-5,6,5",6"-dimethylene dioxybiphenyl-2,2"-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved.	ddb	94-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
11259320-7	2001	Cytochrome P450 (P450) isoform(s) involved in the metabolism of DDB was identified using several in vitro approaches.	ddb	64-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11259321-1	2001	Recently we reported that resveratrol (trans-3,4",5-trihydroxystilbene) showed selective inhibition of recombinant human cytochrome P450 (P450) 1A1 in a concentration-dependent manner.	Resveratrol	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-147
11259321-1	2001	Recently we reported that resveratrol (trans-3,4",5-trihydroxystilbene) showed selective inhibition of recombinant human cytochrome P450 (P450) 1A1 in a concentration-dependent manner.	trans-3,4",5-trihydroxystilbene	39-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-147
11392178-3	2001	Phenytoin, an anti-convulsant agent, can induce the Cytochrome P450 enzyme in the liver, which metabolizes Tacrolimus.	Tacrolimus	107-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
11270913-3	2001	Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.	Fluvoxamine	8-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
11270913-3	2001	Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.	Fluvoxamine	8-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
11270913-3	2001	Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.	Melatonin	185-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
11392178-3	2001	Phenytoin, an anti-convulsant agent, can induce the Cytochrome P450 enzyme in the liver, which metabolizes Tacrolimus.	Phenytoin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
11411376-7	2001	Some recent reports about interactions (involving hepatic cytochrome P450 enzymes) between dextromethorphan and other drugs are also noteworthy.	Dextromethorphan	91-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
11742579-3	2001	The substrates for measuring the activity of individual CYP in vitro included phenacetin, tolbutamide, debrisoquine, and omeprazole.	Phenacetin	78-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
11304902-2	2001	Alosetron is extensively metabolized by multiple cytochrome P450 (CYP) enzymes, including CYP 2C9 and 3A4.	alosetron	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11304902-2	2001	Alosetron is extensively metabolized by multiple cytochrome P450 (CYP) enzymes, including CYP 2C9 and 3A4.	alosetron	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11304903-2	2001	Alosetron is extensively metabolized by multiple cytochrome P450 (CYP) enzymes, including CYP2C9 and CYP3A4.	alosetron	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11304903-2	2001	Alosetron is extensively metabolized by multiple cytochrome P450 (CYP) enzymes, including CYP2C9 and CYP3A4.	alosetron	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11274000-1	2001	BACKGROUND: Both a vascular endothelial cytochrome P450 (CYP450) product of arachidonic acid metabolism and the potassium ion (K(+)) have been identified as endothelium-derived hyperpolarizing factors (EDHFs) in animal vascular tissues.	Arachidonic Acid	76-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
11274000-1	2001	BACKGROUND: Both a vascular endothelial cytochrome P450 (CYP450) product of arachidonic acid metabolism and the potassium ion (K(+)) have been identified as endothelium-derived hyperpolarizing factors (EDHFs) in animal vascular tissues.	Arachidonic Acid	76-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
11274000-1	2001	BACKGROUND: Both a vascular endothelial cytochrome P450 (CYP450) product of arachidonic acid metabolism and the potassium ion (K(+)) have been identified as endothelium-derived hyperpolarizing factors (EDHFs) in animal vascular tissues.	edhfs	202-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
11274000-1	2001	BACKGROUND: Both a vascular endothelial cytochrome P450 (CYP450) product of arachidonic acid metabolism and the potassium ion (K(+)) have been identified as endothelium-derived hyperpolarizing factors (EDHFs) in animal vascular tissues.	edhfs	202-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-63
11274000-9	2001	EDHF-mediated vasorelaxation, however, was sensitive to the phospholipase A(2) inhibitor oleyloxyethyl phosphorylcholine and the CYP450 inhibitor ketoconazole.	edhf	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-135
11274000-9	2001	EDHF-mediated vasorelaxation, however, was sensitive to the phospholipase A(2) inhibitor oleyloxyethyl phosphorylcholine and the CYP450 inhibitor ketoconazole.	Ketoconazole	146-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-135
11274000-11	2001	A product of phospholipase A(2)/CYP450-dependent metabolism of arachidonic acid and not K(+) is the likely identity of EDHF in human subcutaneous resistance arteries.	Arachidonic Acid	63-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-38
11274000-11	2001	A product of phospholipase A(2)/CYP450-dependent metabolism of arachidonic acid and not K(+) is the likely identity of EDHF in human subcutaneous resistance arteries.	edhf	119-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-38
11237731-1	2001	CYP2A6 is known as a major cytochrome P450 (CYP) responsible for the oxidation of nicotine and coumarin in humans.	Nicotine	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
11237731-1	2001	CYP2A6 is known as a major cytochrome P450 (CYP) responsible for the oxidation of nicotine and coumarin in humans.	Nicotine	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11237731-1	2001	CYP2A6 is known as a major cytochrome P450 (CYP) responsible for the oxidation of nicotine and coumarin in humans.	coumarin	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
11237731-1	2001	CYP2A6 is known as a major cytochrome P450 (CYP) responsible for the oxidation of nicotine and coumarin in humans.	coumarin	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11383698-1	2001	Unsaturated fatty acids with triple bonds are used as inhibitors of unsaturated fatty acid metabolism or cytochrome P450 reactions because they are believed to be chemically inert.	Fatty Acids, Unsaturated	0-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
11742579-3	2001	The substrates for measuring the activity of individual CYP in vitro included phenacetin, tolbutamide, debrisoquine, and omeprazole.	Tolbutamide	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
11742579-3	2001	The substrates for measuring the activity of individual CYP in vitro included phenacetin, tolbutamide, debrisoquine, and omeprazole.	Debrisoquin	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
11742579-3	2001	The substrates for measuring the activity of individual CYP in vitro included phenacetin, tolbutamide, debrisoquine, and omeprazole.	Omeprazole	121-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
11357344-4	2001	EHF EMR was also inefficient with cells pretreated with proadifen, an inhibitor of epoxygenase (cytochrome P-450).	Proadifen	56-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
11240973-1	2001	BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
11298070-0	2001	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.	Nitrogen	62-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
11298070-0	2001	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.	Sildenafil Citrate	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
11298070-1	2001	AIMS: To characterize the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metabolism.	Sildenafil Citrate	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
11298070-1	2001	AIMS: To characterize the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metabolism.	Sildenafil Citrate	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
11298070-1	2001	AIMS: To characterize the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metabolism.	Sildenafil Citrate	193-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
11298070-1	2001	AIMS: To characterize the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metabolism.	Sildenafil Citrate	193-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-46
11298070-5	2001	RESULTS: Sildenafil conversion was found to be mediated by at least two CYP enzymes, for which the mean kinetic parameters were Km1 = 6(+/-3 microM), Km2 = 81(+/-45 microM), Vmax1 = 22(+/-9 pmol) and Vmax2 = 138(+/-77 pmol) UK-103 320 formed min(-1) mg(-1).	Sildenafil Citrate	9-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
11298076-1	2001	AIMS: To determine the cytochrome P450 (CYP) isoforms involved in the oxidation of propofol by human liver microsomes.	Propofol	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
11298076-1	2001	AIMS: To determine the cytochrome P450 (CYP) isoforms involved in the oxidation of propofol by human liver microsomes.	Propofol	83-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
11298076-2	2001	METHODS: The rate constant calculated from the disappearance of propofol in an incubation mixture with human liver microsomes and recombinant human CYP isoforms was used as a measure of the rate of metabolism of propofol.	Propofol	212-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
11298076-5	2001	The rate constants of propofol by microsomes were significantly correlated with S-mephenytoin N-demethylation, a marker of CYP2B6 (r = 0.93, P &lt; 0.0001), but not with the metabolic activities of other CYP isoform-selective substrates.	Propofol	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-126
11298076-6	2001	Of the chemical inhibitors of CYP isoforms tested, orphenadrine, a CYP2B6 inhibitor, reduced the rate constant of propofol by liver microsomes by 38% (P &lt; 0.05), while other CYP isoform-selective inhibitors had no effects.	Orphenadrine	51-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
11298076-6	2001	Of the chemical inhibitors of CYP isoforms tested, orphenadrine, a CYP2B6 inhibitor, reduced the rate constant of propofol by liver microsomes by 38% (P &lt; 0.05), while other CYP isoform-selective inhibitors had no effects.	Orphenadrine	51-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11298076-6	2001	Of the chemical inhibitors of CYP isoforms tested, orphenadrine, a CYP2B6 inhibitor, reduced the rate constant of propofol by liver microsomes by 38% (P &lt; 0.05), while other CYP isoform-selective inhibitors had no effects.	Propofol	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
11298076-6	2001	Of the chemical inhibitors of CYP isoforms tested, orphenadrine, a CYP2B6 inhibitor, reduced the rate constant of propofol by liver microsomes by 38% (P &lt; 0.05), while other CYP isoform-selective inhibitors had no effects.	Propofol	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11298076-7	2001	Of the recombinant CYP isoforms screened, CYP2B6 produced the highest rate constant for propofol metabolism (197 nmol min-1 nmol P450-1).	Propofol	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11240973-1	2001	BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
11139472-2	2001	As some CYP enzymes are reported to generate reactive oxygen species (ROS), we hypothesized that the coronary EDHF synthase may modulate vascular homeostasis by the simultaneous production of ROS and epoxyeicosatrienoic acids.	Reactive Oxygen Species	192-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
11317702-0	2001	Study on the cytochrome P-450- and glutathione-dependent biotransformation of trichloroethylene in humans.	Trichloroethylene	78-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-30
11263680-1	2001	Mammalian NADPH-ferredoxin reductase (EC 1.18.1.2) functions in the mitochondrial electron transport chain for cytochrome P-450-dependent steroid hydroxylation.	Steroids	138-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
11241591-0	2001	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor This research was sponsored in part by the Israeli Science Foundation (ISF) and the Binational German-Israeli Foundation (GIF).	Iron	63-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11241591-0	2001	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor This research was sponsored in part by the Israeli Science Foundation (ISF) and the Binational German-Israeli Foundation (GIF).	Sulfur	66-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11241591-0	2001	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor This research was sponsored in part by the Israeli Science Foundation (ISF) and the Binational German-Israeli Foundation (GIF).	thiolate	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11159809-0	2001	Stereochemical aspects of vinylcyclohexene bioactivation in rodent hepatic microsomes and purified human cytochrome P450 enzyme systems.	4-vinylcyclohexene	26-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
11139472-2	2001	As some CYP enzymes are reported to generate reactive oxygen species (ROS), we hypothesized that the coronary EDHF synthase may modulate vascular homeostasis by the simultaneous production of ROS and epoxyeicosatrienoic acids.	Reactive Oxygen Species	45-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
11139472-2	2001	As some CYP enzymes are reported to generate reactive oxygen species (ROS), we hypothesized that the coronary EDHF synthase may modulate vascular homeostasis by the simultaneous production of ROS and epoxyeicosatrienoic acids.	Reactive Oxygen Species	70-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
11235806-1	2001	2-(Allylthio)pyrazine derivatives were designed as a novel cancer chemopreventive agent that functions through selective inhibtion of cytochrome P-450 and induction of phase II enzymes involved in the detoxification of carcinogens.	2-(allylthio)pyrazine	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
11240372-9	2001	These results suggested that nNOS was more stable as to exposure to sodium cholate, mercury chloride or urea in comparison to microsomal cytochrome P-450, which may be due to the different heme environment and protein structure.	Heme	189-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-153
11213066-7	2001	CONCLUSIONS: Patients taking SJW concomitantly with CSA or other medications whose absorption and metabolism are mediated by cytochrome P-450 and/or P-glycoprotein should require close monitoring.	Cyclosporine	52-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
11139472-2	2001	As some CYP enzymes are reported to generate reactive oxygen species (ROS), we hypothesized that the coronary EDHF synthase may modulate vascular homeostasis by the simultaneous production of ROS and epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	200-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-11
11139472-3	2001	In bradykinin-stimulated coronary arteries, antisense oligonucleotides against CYP 2C almost abolished EDHF-mediated responses but potentiated nitric oxide (NO)-mediated relaxation.	Oligonucleotides	54-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
11139472-3	2001	In bradykinin-stimulated coronary arteries, antisense oligonucleotides against CYP 2C almost abolished EDHF-mediated responses but potentiated nitric oxide (NO)-mediated relaxation.	edhf	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
11475198-4	2001	RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin.	Simvastatin	133-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
11139472-3	2001	In bradykinin-stimulated coronary arteries, antisense oligonucleotides against CYP 2C almost abolished EDHF-mediated responses but potentiated nitric oxide (NO)-mediated relaxation.	Nitric Oxide	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
11475198-4	2001	RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin.	Lovastatin	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
11139472-5	2001	CYP activity and O(2-) production, determined in microsomes prepared from cells overexpressing CYP 2C9, were almost completely inhibited by sulfaphenazole.	Sulfaphenazole	140-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
11475198-4	2001	RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin.	Atorvastatin	161-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
11139472-11	2001	These results suggest that a CYP isozyme homologous to CYP 2C9 is a physiologically relevant generator of ROS in coronary endothelial cells and modulates both vascular tone and homeostasis.	Reactive Oxygen Species	106-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
11236564-3	2001	It is obvious that microsomal monooxygenase uses the energy of NADPH oxidation for the activation of the terminal agent--cytochrome P-450.	NADP	63-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
11730569-1	2001	AIM: The present study was designed to define the kinetic behavior of fluoxetine N-demethylation in human liver microsomes and to identify the isoforms of cytochrome P-450 (CYP) involved in this metabolic pathway.	fluoxetine n	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
11730569-1	2001	AIM: The present study was designed to define the kinetic behavior of fluoxetine N-demethylation in human liver microsomes and to identify the isoforms of cytochrome P-450 (CYP) involved in this metabolic pathway.	fluoxetine n	70-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-176
11730569-10	2001	CONCLUSION: Cytochrome P-450 CYP2C9 is likely to be a major CYP isoform catalyzing fluoxetine N-demethylation in human liver microsomes at a substrate concentration close to the therapeutic level, while polymorphic CYP2C19 may play a more important role in this metabolic pathway at high substrate concentration.	fluoxetine n	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
11730569-10	2001	CONCLUSION: Cytochrome P-450 CYP2C9 is likely to be a major CYP isoform catalyzing fluoxetine N-demethylation in human liver microsomes at a substrate concentration close to the therapeutic level, while polymorphic CYP2C19 may play a more important role in this metabolic pathway at high substrate concentration.	fluoxetine n	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-32
12174676-0	2001	Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers.	Steroids	50-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
12174676-2	2001	Many steroids and environmental carcinogens are subject to cytochrome P450 (P450)-mediated metabolism that generates reactive metabolites and modulates steroid potency, thereby influencing tumor initiation and promotion respectively.	Steroids	5-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
12174676-2	2001	Many steroids and environmental carcinogens are subject to cytochrome P450 (P450)-mediated metabolism that generates reactive metabolites and modulates steroid potency, thereby influencing tumor initiation and promotion respectively.	Steroids	5-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
11556126-0	2001	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes.	roxatidine acetate	102-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11556126-3	2001	In this study, the Cytochrome P450 (CYP or P450) enzymes which participate in the metabolism of ROX were identified using human liver microsomes and S9 fractions.	ROX	96-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
11327199-4	2001	Delavirdine undergoes extensive metabolism by cytochrome P450 (CYP) with little urinary excretion of unchanged drug.	Delavirdine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
11523725-3	2001	Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients.	Warfarin	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
11523725-3	2001	Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients.	Warfarin	101-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
11893055-5	2001	Recent work uses a mimic of the enzyme class cytochrome P-450 to achieve the selective hydroxylations of steroids with complete domination by the geometry of the catalyst-substrate complex.	Steroids	105-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
11327199-4	2001	Delavirdine undergoes extensive metabolism by cytochrome P450 (CYP) with little urinary excretion of unchanged drug.	Delavirdine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Rifampin	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11524025-4	2001	PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Rifampin	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11524025-4	2001	PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1.	Polycyclic Aromatic Hydrocarbons	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Rifabutin	64-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Phenytoin	75-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Carbamazepine	103-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Delavirdine	142-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11113705-1	2000	The genotoxicities of four samples of diesel exhaust particle (DEP) extracts (DEPE) and nine nitroarenes found in DEPE were investigated after activation catalyzed by human cytochrome P450 (P450) family 1 enzymes co-expressed with NADPH-cytochrome P450 reductase (NPR) in Escherichia coli membranes.	nitroarenes	93-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	173-204
11195057-0	2001	Cytochrome P450 metabolites of arachidonic acid in the control of renal function.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	Arachidonic Acid	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	141-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	174-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	epoxyeicosatrienoic acids	181-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	eets	208-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11195057-1	2001	Recent studies indicate that arachidonic acid is primarily metabolized by cytochrome P450 enzymes of the 4A and 2C families in the kidney to 20-hydroxyeicosatetraenoic acid (HETE), epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids.	dihydroxyeicosatrienoic acids	218-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
11774365-3	2001	The expression levels of CYP holo-protein in the genetically engineered S. typhimurium YG7108 cells, determined by carbon monoxide (CO) difference spectra, ranged from 62 nmol/L culture for CYP2C19 to 169 nmol/L culture for CYP3A4.	Carbon Monoxide	115-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
11774365-5	2001	Each form of CYP expressed in the S. typhimurium YG7108 cells catalyzed the oxidation of a representative substrate at an efficient rate.	yg7108	49-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
11774366-8	2001	Thus, the addition of a pyridine ring to NPYR or NPIP altered the forms of CYP primarily responsible for mutagenic activation.	pyridine	24-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
21336918-6	2001	Arachidonic acid can also be metabolized by specific cytochrome P(450) enzymes to regioisomeric epoxides and stereo specific hydro xyeicosatetraenoic (HETE) acids (6).	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-70
21336918-6	2001	Arachidonic acid can also be metabolized by specific cytochrome P(450) enzymes to regioisomeric epoxides and stereo specific hydro xyeicosatetraenoic (HETE) acids (6).	Epoxy Compounds	96-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-70
21336918-6	2001	Arachidonic acid can also be metabolized by specific cytochrome P(450) enzymes to regioisomeric epoxides and stereo specific hydro xyeicosatetraenoic (HETE) acids (6).	Hydroxyeicosatetraenoic Acids	125-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-70
11195057-11	2001	The renal production of cytochrome P450 metabolites of arachidonic acid is altered in hypertension, diabetes, toxemia of pregnancy, and hepatorenal syndrome.	Arachidonic Acid	55-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
11195057-12	2001	Given the importance of cytochrome P450 metabolites of arachidonic acid in the control of renal function, it is likely that changes in this system contribute to the abnormalities in renal function that are associated with many of these conditions.	Arachidonic Acid	55-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11192140-3	2000	Both citalopram and theophylline are metabolized by cytochrome P450 (CYP) isozymes.	Citalopram	5-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
11192140-3	2000	Both citalopram and theophylline are metabolized by cytochrome P450 (CYP) isozymes.	Citalopram	5-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11192140-3	2000	Both citalopram and theophylline are metabolized by cytochrome P450 (CYP) isozymes.	Theophylline	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
11465044-9	2000	If the latter is stable it may undergo oxidation by cytochrome P-450 to form the lactam.	Lactams	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
11192140-3	2000	Both citalopram and theophylline are metabolized by cytochrome P450 (CYP) isozymes.	Theophylline	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
11095582-0	2000	Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.	vadimezan	131-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
11095582-6	2000	The involvement of CYP1A2 in DMXAA metabolism by human livers was demonstrated by the following: 1) the potent inhibition of DMXAA metabolism by furafylline (k(inact) = 0.23 +/- 0.04 min(-1), K"(app) = 15.6 +/- 6.7 microM) and alpha-naphthoflavone (K(i) = 0.036 microM), but not by cimetidine, ketoconazole, tolbutamide, quinidine, chlorzoxazone, diethyldithiocarbamate, troleandomycin, and sulfaphenazole; 2) when incubated with human lymphoblastoid cell microsomes containing cDNA-expressed CYP isoenzymes, DMXAA was metabolized only by CYP1A2, with an apparent K(m) of 6.2 +/- 1.5 microM and V(max) of 0.014 +/- 0.001 nmol/min/mg, but not by CYP2A6, CYP2B6, CYP2C9 (Arg(144)), CYP2C19, CYP2D6 (Val(374)), CYP2E1, and CYP3A4; 3) a significant correlation (r = 0.90; P &lt;.001) between 6-methylhydroxylation of DMXAA and 7-ethoxyresorufin O-deethylation; and 4) a significant correlation (r = 0.75; P &lt;.01) between the CYP1A protein level determined by Western blots and DMXAA 6-methylhydroxylation.	furafylline	145-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11095582-1	2000	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) isoenzyme involved in the 6-methylhydroxylation of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by using a human liver library (n = 14).	vadimezan	129-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
11095582-1	2000	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) isoenzyme involved in the 6-methylhydroxylation of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by using a human liver library (n = 14).	vadimezan	129-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
11095582-1	2000	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) isoenzyme involved in the 6-methylhydroxylation of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by using a human liver library (n = 14).	vadimezan	168-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
11095582-1	2000	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) isoenzyme involved in the 6-methylhydroxylation of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by using a human liver library (n = 14).	vadimezan	168-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
11095582-3	2000	The metabolite formed in human liver microsomes and by cDNA-expressed CYP isoform was identified by liquid chromatography mass spectrometry as 6-OH-MXAA.	6-oh-mxaa	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
11095582-6	2000	The involvement of CYP1A2 in DMXAA metabolism by human livers was demonstrated by the following: 1) the potent inhibition of DMXAA metabolism by furafylline (k(inact) = 0.23 +/- 0.04 min(-1), K"(app) = 15.6 +/- 6.7 microM) and alpha-naphthoflavone (K(i) = 0.036 microM), but not by cimetidine, ketoconazole, tolbutamide, quinidine, chlorzoxazone, diethyldithiocarbamate, troleandomycin, and sulfaphenazole; 2) when incubated with human lymphoblastoid cell microsomes containing cDNA-expressed CYP isoenzymes, DMXAA was metabolized only by CYP1A2, with an apparent K(m) of 6.2 +/- 1.5 microM and V(max) of 0.014 +/- 0.001 nmol/min/mg, but not by CYP2A6, CYP2B6, CYP2C9 (Arg(144)), CYP2C19, CYP2D6 (Val(374)), CYP2E1, and CYP3A4; 3) a significant correlation (r = 0.90; P &lt;.001) between 6-methylhydroxylation of DMXAA and 7-ethoxyresorufin O-deethylation; and 4) a significant correlation (r = 0.75; P &lt;.01) between the CYP1A protein level determined by Western blots and DMXAA 6-methylhydroxylation.	vadimezan	29-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11095582-6	2000	The involvement of CYP1A2 in DMXAA metabolism by human livers was demonstrated by the following: 1) the potent inhibition of DMXAA metabolism by furafylline (k(inact) = 0.23 +/- 0.04 min(-1), K"(app) = 15.6 +/- 6.7 microM) and alpha-naphthoflavone (K(i) = 0.036 microM), but not by cimetidine, ketoconazole, tolbutamide, quinidine, chlorzoxazone, diethyldithiocarbamate, troleandomycin, and sulfaphenazole; 2) when incubated with human lymphoblastoid cell microsomes containing cDNA-expressed CYP isoenzymes, DMXAA was metabolized only by CYP1A2, with an apparent K(m) of 6.2 +/- 1.5 microM and V(max) of 0.014 +/- 0.001 nmol/min/mg, but not by CYP2A6, CYP2B6, CYP2C9 (Arg(144)), CYP2C19, CYP2D6 (Val(374)), CYP2E1, and CYP3A4; 3) a significant correlation (r = 0.90; P &lt;.001) between 6-methylhydroxylation of DMXAA and 7-ethoxyresorufin O-deethylation; and 4) a significant correlation (r = 0.75; P &lt;.01) between the CYP1A protein level determined by Western blots and DMXAA 6-methylhydroxylation.	vadimezan	125-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11102737-15	2000	The taxanes paclitaxel and docetaxel are considered excellent substrate drugs to test the concept that by inhibition of P-gp in the gut wall and CYP activity in gut wall and/or liver low oral bioavailability can be increased substantially.	Paclitaxel	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
11145063-9	2000	The method was applied to the determination of the rate and enantioselectivity of the cytochrome P-450 dependent oxidation of styrene to SO enantiomers in human liver microsomes.	Styrene	126-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
11102737-15	2000	The taxanes paclitaxel and docetaxel are considered excellent substrate drugs to test the concept that by inhibition of P-gp in the gut wall and CYP activity in gut wall and/or liver low oral bioavailability can be increased substantially.	Docetaxel	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
11061988-2	2000	We employed well-characterized inhibitors of specific cytochrome P-450 (CYP) enzymes to determine which form was likely involved in tocopherol side chain oxidation.	Tocopherols	132-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Ifosfamide	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Ifosfamide	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	chloroacetaldehyde	138-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	chloroacetaldehyde	138-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	chloroacetaldehyde	193-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	chloroacetaldehyde	193-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Ifosfamide	217-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Ifosfamide	217-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Cyclophosphamide	238-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-65
11132240-4	2000	We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity.	Cyclophosphamide	238-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
11144010-5	2000	Thyroxin is a potent activator of the cytochrome P-450- CYP 3A enzyme system, which is crucial for tacrolimus metabolism.	Tacrolimus	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
11144010-8	2000	In conclusion, it is important to consider thyroid function when prescribing medications with a narrow therapeutic range, which are metabolized by the cytochrome P-450 system such as tacrolimus, and the possible devastating effect of impaired drug metabolism during hypothyroidism.	Tacrolimus	183-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
11084219-1	2000	The present study was designed to determine the effect of venlafaxine on imipramine metabolism in an attempt to elucidate the potential for cytochrome P450 drug-drug interactions with venlafaxine.	Venlafaxine Hydrochloride	184-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-155
29711670-0	2000	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor.	Iron	63-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
29711670-0	2000	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor.	Sulfur	66-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
29711670-0	2000	The High-Valent Compound of Cytochrome P450: The Nature of the Fe-S Bond and the Role of the Thiolate Ligand as an Internal Electron Donor.	thiolate	93-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
11061988-2	2000	We employed well-characterized inhibitors of specific cytochrome P-450 (CYP) enzymes to determine which form was likely involved in tocopherol side chain oxidation.	Tocopherols	132-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
11113932-0	2000	Stereoselective determination of propafenone enantiomers in transgenic Chinese hamster CHL cells expressing human cytochrome P450.	Propafenone	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
11113932-1	2000	An enantioselective assay for S(+)- and R(-)-propafenone in transgenic Chinese hamster CHL cells expressing human cytochrome P450 was developed.	s(+)- and r(-)-propafenone	30-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
11113932-8	2000	The method allowed study of the depletion of S(+)- and R(-)-propafenone in transgenic Chinese hamster CHL cells expressing human cytochrome P450.	Sulfur	45-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
11113932-8	2000	The method allowed study of the depletion of S(+)- and R(-)-propafenone in transgenic Chinese hamster CHL cells expressing human cytochrome P450.	Propafenone	55-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
11038149-3	2000	We previously reported that the human cytochrome P450 (P450), 2A6, efficiently and specifically catalyzed NNN 5"-hydroxylation.	nnn 5"	106-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-65
11106261-2	2000	It is bioactivated to 5-FU via 5"-hydroxylation mediated by cytochrome P-450 (CYP).	Fluorouracil	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
11106261-2	2000	It is bioactivated to 5-FU via 5"-hydroxylation mediated by cytochrome P-450 (CYP).	Fluorouracil	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-81
11038157-1	2000	Human cytochrome P450 (CYP) isoforms involved in amiodarone N-deethylation were identified, and the relative contributions of these CYP isoforms were evaluated in different human liver microsomes.	Amiodarone	49-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
11038157-7	2000	However, there was a large interindividual variability in the contribution of each CYP isoform to amiodarone N-deethylase activity in human liver; the relevance of these enzymes would be dependent on the content of the respective isoforms and on the amiodarone concentration in the liver.	Amiodarone	98-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
11038157-7	2000	However, there was a large interindividual variability in the contribution of each CYP isoform to amiodarone N-deethylase activity in human liver; the relevance of these enzymes would be dependent on the content of the respective isoforms and on the amiodarone concentration in the liver.	Amiodarone	250-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
11038157-1	2000	Human cytochrome P450 (CYP) isoforms involved in amiodarone N-deethylation were identified, and the relative contributions of these CYP isoforms were evaluated in different human liver microsomes.	Amiodarone	49-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
11038154-3	2000	The objective of the study was to establish the cytochrome P450 (CYP) enzymes catalyzing the hydroxylations of the acenocoumarol enantiomers.	Acenocoumarol	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
11038157-2	2000	The mean K(M) and V(max) values of amiodarone N-deethylation in microsomes from six human livers were 31.6 +/- 7.5 microM and 1.2 +/- 0.7 pmol/min/pmol of CYP, respectively.	Amiodarone	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
11038154-3	2000	The objective of the study was to establish the cytochrome P450 (CYP) enzymes catalyzing the hydroxylations of the acenocoumarol enantiomers.	Acenocoumarol	115-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
11038157-4	2000	Of 15 recombinant human CYP enzymes (19 preparations), CYP1A1, CYP3A4, CYP1A2, CYP2D6, CYP2C8, and CYP2C19 catalyzed amiodarone N-deethylation.	amiodarone n	117-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
10997941-8	2000	Similar losses of CYP enzymes were found when human liver slices were cultured in supplemented Williams" medium E for 72 h, except that CYP2E1 apoprotein levels were better maintained.	williams" medium e	95-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Lactones	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Lactones	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Atorvastatin	197-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Atorvastatin	197-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
11038166-5	2000	Compared with atorvastatin acid, CYP-dependent metabolism of atorvastatin lactone to its para-hydroxy metabolite was 83-fold higher [formation CL(int) (V(max)/K(m)): lactone 2949 +/- 3511 versus acid 35.5 +/- 48.1 microl.	Atorvastatin lactone	61-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
11038166-5	2000	Compared with atorvastatin acid, CYP-dependent metabolism of atorvastatin lactone to its para-hydroxy metabolite was 83-fold higher [formation CL(int) (V(max)/K(m)): lactone 2949 +/- 3511 versus acid 35.5 +/- 48.1 microl.	Lactones	74-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Cimetidine	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Cimetidine	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Clarithromycin	74-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Cisapride	123-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Cisapride	123-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	mosapride	137-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	mosapride	137-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
11128045-0	2000	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450.	Ranitidine	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
11069215-5	2000	H2 antagonists, proton pump inhibitors and prokinetic agents undergo metabolism by the cytochrome P450 (CYP) system present in the liver and gastrointestinal tract.	Hydrogen	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
11069215-5	2000	H2 antagonists, proton pump inhibitors and prokinetic agents undergo metabolism by the cytochrome P450 (CYP) system present in the liver and gastrointestinal tract.	Hydrogen	0-2	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-107
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-223
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-228
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	metimazole	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-223
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	metimazole	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-228
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	171-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-223
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	171-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-228
11315104-0	2000	Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	14-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
11315104-2	2000	The metabolism of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC) was studied in human liver microsomal preparations and in cDNA-expressed human cytochrome P450 (CYP) isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	18-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-201
11315104-2	2000	The metabolism of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC) was studied in human liver microsomal preparations and in cDNA-expressed human cytochrome P450 (CYP) isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	18-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	203-206
11315104-2	2000	The metabolism of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC) was studied in human liver microsomal preparations and in cDNA-expressed human cytochrome P450 (CYP) isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-201
11315104-2	2000	The metabolism of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC) was studied in human liver microsomal preparations and in cDNA-expressed human cytochrome P450 (CYP) isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	203-206
11315104-2	2000	The metabolism of 7-benzyloxy-4-trifluoromethylcoumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC) was studied in human liver microsomal preparations and in cDNA-expressed human cytochrome P450 (CYP) isoforms.	7-hydroxy-4-trifluoromethylcoumarin	65-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-201
11315104-10	2000	Using human beta-lymphoblastoid cell microsomes containing cDNA-expressed CYP isoforms, 20 microM BFC was metabolized by CYP1A2 and CYP3A4, with lower rates of metabolism being observed with CYP2C9 and CYP2C19.	7-benzyloxy-4-trifluoromethylcoumarin	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
11315104-18	2000	In summary, by correlation analysis, use of cDNA-expressed CYP isoforms, chemical inhibition and inhibitory antibodies, BFC appears metabolized by a number of CYP isoforms in human liver.	7-benzyloxy-4-trifluoromethylcoumarin	120-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
11315104-18	2000	In summary, by correlation analysis, use of cDNA-expressed CYP isoforms, chemical inhibition and inhibitory antibodies, BFC appears metabolized by a number of CYP isoforms in human liver.	7-benzyloxy-4-trifluoromethylcoumarin	120-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
11315104-19	2000	BFC metabolism appears to be primarily catalysed by CYP1A2 and CYP3A4, with possibly some contribution by CYP2C9, CYP2C19 and perhaps other CYP isoforms.	7-benzyloxy-4-trifluoromethylcoumarin	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
10924087-1	2000	Epoxyeicosatrienoic acids (EETs) are cytochrome P-450 metabolites of arachidonic acid involved in the regulation of vascular tone.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
11026737-0	2000	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.	Perazine	90-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
11005703-13	2000	Fluvastatin has several metabolic pathways which involve the CYP enzyme system.	Fluvastatin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
10874126-0	2000	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation.	2-octenal	72-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
10874126-0	2000	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation.	Tretinoin	78-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
10874126-1	2000	The role of specific human cytochrome P450 (CYP) isoforms in the oxidative metabolism of all-trans-retinoic acid was investigated by studies in human liver microsomes using isoform-specific chemical inhibitors and inhibitory antibodies.	Tretinoin	89-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
10874126-1	2000	The role of specific human cytochrome P450 (CYP) isoforms in the oxidative metabolism of all-trans-retinoic acid was investigated by studies in human liver microsomes using isoform-specific chemical inhibitors and inhibitory antibodies.	Tretinoin	89-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
10874126-4	2000	Using inhibition studies and correlation analysis, we also concluded that CYP2C8 was the major all-trans-retinoic acid 4-hydroxylating cytochrome P450 in human liver microsomes, though CYP3A4 and, to a lesser extent CYP2C9, also made a contribution.	Tretinoin	95-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-150
10924087-1	2000	Epoxyeicosatrienoic acids (EETs) are cytochrome P-450 metabolites of arachidonic acid involved in the regulation of vascular tone.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
10924087-1	2000	Epoxyeicosatrienoic acids (EETs) are cytochrome P-450 metabolites of arachidonic acid involved in the regulation of vascular tone.	Arachidonic Acid	69-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	hyperpolarizing factor	58-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	hyperpolarizing factor	58-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	edhf	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	edhf	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	Arachidonic Acid	152-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	Arachidonic Acid	152-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	epoxyeicosatrienoic acid	192-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-137
10948089-2	2000	In some vascular beds, this so-called endothelium-derived hyperpolarizing factor (EDHF) displays the characteristics of a cytochrome P450 (CYP)-derived arachidonic acid metabolite, such as an epoxyeicosatrienoic acid.	epoxyeicosatrienoic acid	192-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
10948089-4	2000	The CYP inducer beta-naphthoflavone and the Ca(2+) antagonist nifedipine significantly increased CYP2C mRNA but did not change the expression of CYP2J or CYP2B.	beta-Naphthoflavone	16-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-7
10948089-9	2000	These results demonstrate that in porcine coronary arteries, the elevated expression of a CYP epoxygenase, homologous to CYP2C8/9, is associated with enhanced EDHF-mediated hyperpolarization in response to bradykinin.	edhf	159-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	bufuralol	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
10923005-0	2000	Cytochrome P450 polymorphisms are associated with reduced warfarin dose.	Warfarin	58-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10923005-2	2000	Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP) complex.	Warfarin	41-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
10923005-2	2000	Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP) complex.	Warfarin	41-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
10923005-3	2000	The purpose of this study was to ascertain the frequency and influence of CYP polymorphisms on warfarin dosing in our patient population.	Warfarin	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	bufuralol	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Testosterone	97-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Testosterone	97-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Dextromethorphan	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Dextromethorphan	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Phenacetin	129-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Diclofenac	141-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Mephenytoin	156-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Mephenytoin	156-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	n-alkylprotoporphyrin ix	135-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
10933836-0	2000	Improving the cytochrome P450 enzyme system for electrode-driven biocatalysis of styrene epoxidation.	Styrene	81-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
10933836-3	2000	This paper reports several improvements that make the cytochrome P450cam enzyme system more practical for the epoxidation of styrene.	Styrene	125-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	n-alkylprotoporphyrin ix	135-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	n-alkylpp	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	n-alkylpp	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	Heme	234-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
10926165-1	2000	Several porphyrinogenic xenobiotics elicit mechanism-based inactivation of cytochrome P450 (CYP) isozymes, leading to the formation of N-alkylprotoporphyrin IX (N-alkylPP), a potent inhibitor of ferrochelatase, the terminal enzyme in heme biosynthesis.	Heme	234-238	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
10871337-5	2000	Whereas vincristine and vinblastine at a concentration of 100 nM killed more than 90% of the parental cells, more than 50 and 35%, respectively, of cells that coexpressed CYP3A4 and cytochrome P450 (P450) reductase survived these treatments.	Vinblastine	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-214
10871299-5	2000	Hyperforin and I3,II8-biapigenin were isolated from the extract, and inhibition constants for the five CYP activities were measured.	hyperforin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
10859153-0	2000	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.	Cisapride	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10871299-9	2000	Hypericin also demonstrated potent inhibition of several CYP activities.	hypericin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10871299-5	2000	Hyperforin and I3,II8-biapigenin were isolated from the extract, and inhibition constants for the five CYP activities were measured.	biapigenin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
10871299-6	2000	In addition, three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes.	hypericin	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
10871299-6	2000	In addition, three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes.	Chlorogenic Acid	65-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
10860554-0	2000	Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells.	Tretinoin	120-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-81
10860554-2	2000	AF221943) encodes a leukotriene B(4) omega-hydroxylase that metabolizes leukotriene B(4) (LTB(4)) to a less potent proinflammatory eicosanoid, 20-OH-LTB(4).	Eicosanoids	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-54
10860554-2	2000	AF221943) encodes a leukotriene B(4) omega-hydroxylase that metabolizes leukotriene B(4) (LTB(4)) to a less potent proinflammatory eicosanoid, 20-OH-LTB(4).	20-oh-ltb	143-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-54
10901126-0	2000	Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry.	Valproic Acid	23-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-76
10901126-1	2000	A sensitive negative ion chemical ionization (NCI) gas chromatographic-mass spectrometric (GC-MS) method was modified for the quantitation of valproic acid (VPA) metabolites generated from in vitro cDNA-expressed human microsomal cytochrome P450 incubations.	Valproic Acid	157-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-245
10852767-0	2000	Synthesis of arachidonic acid-derived lipoxygenase and cytochrome P450 products in the intact human lung vasculature.	Arachidonic Acid	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
10941006-0	2000	Hydrogen-Bonded Dioxygen Adduct of an Iron Porphyrin with an Alkanethiolate Ligand: An Elaborate Model of Cytochrome P450 This research was supported by the Ministry of Education, Science, and Culture, Japan (Grant-in Aids #08CE2005, 09235225, and 11228207 to Y.N.)	Hydrogen	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-121
10852767-1	2000	Lipoxygenase (LO) and cytochrome P450 monooxygenase products of arachidonic acid (AA) have been implicated in a large number of vasoregulatory processes.	Arachidonic Acid	64-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
10820139-0	2000	In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.	Modafinil	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
10820139-1	2000	The ability of modafinil to affect human hepatic cytochrome P450 (CYP) activities was examined in vitro.	Modafinil	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
10820139-3	2000	Modafinil exhibited minimal capacity to inhibit any CYP enzyme, except CYP2C19.	Modafinil	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
10820139-1	2000	The ability of modafinil to affect human hepatic cytochrome P450 (CYP) activities was examined in vitro.	Modafinil	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
10820139-6	2000	The potential for induction of CYP activity was evaluated by exposing primary cultures of human hepatocytes to modafinil (10-300 microM).	Modafinil	111-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	61-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
10895987-0	2000	Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.	Silybin	22-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
10895987-1	2000	Silibinin, the main constituent of silymarin, a flavonoid drug from silybum marianum used in liver disease, was tested for inhibition of human cytochrome P-450 enzymes.	Silybin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
12526496-0	2000	Nitric oxide binding to ferric cytochrome P450: a computational study.	Nitric Oxide	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
12526496-1	2000	The interaction between nitric oxide (NO) and the active site of ferric cytochrome P450 was studied by means of density functional theory (DFT), at the generalized gradient approximation level, and of the SAM1 semiempirical method.	Nitric Oxide	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
10815927-2	2000	The objective of this study was to determine the oxidative metabolites of CPT-11 recovered in human urine samples and to identify cytochrome P450 (CYP) involved in their formation.	Irinotecan	74-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Melatonin	47-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Melatonin	145-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10877007-2	2000	We investigated potential interactions of losartan, irbesartan, valsartan, eprosartan and candesartan with cytochrome P450 (CYP) enzymes in human liver microsomes.	Losartan	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
10877007-2	2000	We investigated potential interactions of losartan, irbesartan, valsartan, eprosartan and candesartan with cytochrome P450 (CYP) enzymes in human liver microsomes.	Valsartan	64-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
10877007-2	2000	We investigated potential interactions of losartan, irbesartan, valsartan, eprosartan and candesartan with cytochrome P450 (CYP) enzymes in human liver microsomes.	candesartan	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
10877007-2	2000	We investigated potential interactions of losartan, irbesartan, valsartan, eprosartan and candesartan with cytochrome P450 (CYP) enzymes in human liver microsomes.	candesartan	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
10773020-6	2000	The increase in HO activity due to gene transfer also was associated with a parallel decrease (approximately 25%) in cytochrome P-450 (CYP) content and in CYP-dependent arachidonic acid metabolism.	Arachidonic Acid	169-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-158
10773020-9	2000	The increase in HO activity after adenoviral-mediated human HO-1 transfer was associated with a decrease in microsomal heme-CYP and CYP activity.	Heme	119-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	152-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	152-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	186-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	186-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	194-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
10797280-2	2000	This study was designed to determine the effects of smoking and 3 major cytochrome P450 (CYP) enzymes, i.e., CYP1A1, CYP1B1 and CYP3A, which metabolize polycyclic aromatic hydrocarbons (PAH) on PAH-DNA adduct formation in the bronchoalveolar macrophages (BAM) of 31 smokers and 16 non-smokers.	Polycyclic Aromatic Hydrocarbons	194-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
10833273-9	2000	CYP 4F2 was distinguished from the closely homologous CYP 4F3 (human neutrophil LTB(4) omega-hydroxylase) by its much higher K(m) for LTB(4), inability to omega-hydroxylate lipoxin B(4), and extreme instability.	Leukotriene B4	80-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-61
10833273-9	2000	CYP 4F2 was distinguished from the closely homologous CYP 4F3 (human neutrophil LTB(4) omega-hydroxylase) by its much higher K(m) for LTB(4), inability to omega-hydroxylate lipoxin B(4), and extreme instability.	Lipoxin B	173-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-61
10833273-9	2000	CYP 4F2 was distinguished from the closely homologous CYP 4F3 (human neutrophil LTB(4) omega-hydroxylase) by its much higher K(m) for LTB(4), inability to omega-hydroxylate lipoxin B(4), and extreme instability.	Lipoxin B	173-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-104
10807595-5	2000	The lipoxygenase metabolite 12(S)-hydroxyeicosatetraenoic acid (HETE) and the cytochrome P-450 metabolite 20-HETE both inhibited PCT Na(+)-K(+)-ATPase in a protein kinase C-dependent manner, but the effect was significantly more pronounced in infant PCT.	20-Hete	106-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
10807595-5	2000	The lipoxygenase metabolite 12(S)-hydroxyeicosatetraenoic acid (HETE) and the cytochrome P-450 metabolite 20-HETE both inhibited PCT Na(+)-K(+)-ATPase in a protein kinase C-dependent manner, but the effect was significantly more pronounced in infant PCT.	Polychloroterphenyl Compounds	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	106-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	Phenobarbital	152-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
10729207-1	2000	Expression of human cytochrome P450 (P450) 2B6 in Escherichia coli was achieved following supplementation of the expression medium with chloramphenicol.	Chloramphenicol	136-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-46
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Selegiline	96-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Selegiline	96-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Selegiline	96-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-239
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	desmethylselegiline	110-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	desmethylselegiline	110-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Levmetamfetamine	134-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Levmetamfetamine	134-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Selegiline	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Selegiline	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	desmethylselegiline	183-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	desmethylselegiline	183-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Levmetamfetamine	207-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10862503-2	2000	In the current work we have studied the cytochrome P450 (CYP)-catalyzed oxidative metabolism of selegiline to desmethylselegiline and 1-methamphetamine and the effects of selegiline, desmethylselegiline and 1-methamphetamine on hepatic CYP enzymes in human liver microsomes in vitro.	Levmetamfetamine	207-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10862503-8	2000	In studies with CYP-specific model activities, both selegiline and desmethylselegiline inhibited the CYP2C19-mediated S-mephenytoin 4"-hydroxylation with average IC50 values of 21 microM and 26 microM, respectively.	Selegiline	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
10862503-8	2000	In studies with CYP-specific model activities, both selegiline and desmethylselegiline inhibited the CYP2C19-mediated S-mephenytoin 4"-hydroxylation with average IC50 values of 21 microM and 26 microM, respectively.	desmethylselegiline	67-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
10862503-11	2000	Inhibitory potencies of selegiline, desmethylselegiline and 1-methamphetamine towards other CYP-model activities were much lower.	Selegiline	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
10862503-11	2000	Inhibitory potencies of selegiline, desmethylselegiline and 1-methamphetamine towards other CYP-model activities were much lower.	desmethylselegiline	36-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
10862503-11	2000	Inhibitory potencies of selegiline, desmethylselegiline and 1-methamphetamine towards other CYP-model activities were much lower.	Levmetamfetamine	60-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
11055180-4	2000	These are: microsomal ethanol oxidation system (MEOS) connected with cytochrome P-450 and peroxisome catalase system.	Ethanol	22-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
11239797-1	2000	Studies designed to elucidate the identity of the potent vasodilator autacoid endothelium-derived hyperpolarizing factor (EDHF) in the coronary vascular bed have highlighted a role for vascular cytochrome P450 (CYP) enzymes in cardiovascular homeostasis.	hyperpolarizing factor	98-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-209
11239797-1	2000	Studies designed to elucidate the identity of the potent vasodilator autacoid endothelium-derived hyperpolarizing factor (EDHF) in the coronary vascular bed have highlighted a role for vascular cytochrome P450 (CYP) enzymes in cardiovascular homeostasis.	hyperpolarizing factor	98-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
11239797-1	2000	Studies designed to elucidate the identity of the potent vasodilator autacoid endothelium-derived hyperpolarizing factor (EDHF) in the coronary vascular bed have highlighted a role for vascular cytochrome P450 (CYP) enzymes in cardiovascular homeostasis.	edhf	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-209
11239797-1	2000	Studies designed to elucidate the identity of the potent vasodilator autacoid endothelium-derived hyperpolarizing factor (EDHF) in the coronary vascular bed have highlighted a role for vascular cytochrome P450 (CYP) enzymes in cardiovascular homeostasis.	edhf	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
11239797-2	2000	Not only is there strong evidence suggesting that the putative coronary EDHF synthase is an endothelially expressed CYP epoxygenase, but CYP products such as epoxyeicosatrienoic acids and reactive oxygen species have been implicated in the regulation of intracellular signalling cascades and vascular cell proliferation.	epoxyeicosatrienoic acids	158-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
10826653-1	2000	Our previous results indicated that cytochrome P450 destruction by benzene metabolites was caused mainly by benzoquinone (Soucek et al., Biochem.	Benzene	67-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
10826653-1	2000	Our previous results indicated that cytochrome P450 destruction by benzene metabolites was caused mainly by benzoquinone (Soucek et al., Biochem.	quinone	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
10819168-0	2000	The use of "electronic nose" sensor responses to predict the inhibition activity of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline.	Alcohols	84-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-50
10819168-0	2000	The use of "electronic nose" sensor responses to predict the inhibition activity of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline.	aniline	146-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
10819168-1	2000	A quantitative structure activity relationship (QSAR) has been formulated to describe the inhibitory action of a series of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline.	Alcohols	123-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
10819168-1	2000	A quantitative structure activity relationship (QSAR) has been formulated to describe the inhibitory action of a series of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline.	aniline	185-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
10819168-3	2000	If the various electronic nose sensor response patterns for the family of test alcohols reflect differences in the chemical properties that are involved in the cytochrome P-450 inhibition process, it ought to be possible to correlate the differences in the electronic nose signals of these analytes with the differences in the cytochrome P-450 inhibition by these species.	Alcohols	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
10819168-3	2000	If the various electronic nose sensor response patterns for the family of test alcohols reflect differences in the chemical properties that are involved in the cytochrome P-450 inhibition process, it ought to be possible to correlate the differences in the electronic nose signals of these analytes with the differences in the cytochrome P-450 inhibition by these species.	Alcohols	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	327-343
10681373-0	2000	Human cytochrome P-450 metabolism of retinals to retinoic acids.	Tretinoin	49-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
10725303-2	2000	We previously showed that liver volume normalized to body weight was inversely related to age, but that the systemic clearance of a nonspecific cytochrome P450 (CYP) substrate (antipyrine) was higher in young children compared with adults even when normalized per liver volume.	Antipyrine	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-159
10725303-2	2000	We previously showed that liver volume normalized to body weight was inversely related to age, but that the systemic clearance of a nonspecific cytochrome P450 (CYP) substrate (antipyrine) was higher in young children compared with adults even when normalized per liver volume.	Antipyrine	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	Bupivacaine	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	Bupivacaine	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	pipecolylxylidine	73-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	pipecolylxylidine	73-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	ppx	92-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
10725304-2	2000	The human cytochrome P450 (CYP) involved in bupivacaine degradation into pipecolylxylidine (PPX), its major metabolite, has, to our knowledge, never been described.	ppx	92-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
10725304-5	2000	Bupivacaine incubations were then performed with specific CYP substrates and inhibitors.	Bupivacaine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
10725309-0	2000	Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.	Miocamycin	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
10725309-0	2000	Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.	Miocamycin	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
10725309-0	2000	Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.	Miocamycin	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-166
10725309-0	2000	Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.	Miocamycin	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-166
10725309-1	2000	Some macrolide antibiotics cause clinical drug interactions, resulting in altered metabolism of concomitantly administered drugs, via the formation of a metabolic intermediate (MI) complex with cytochrome P450 (CYP), or competitive inhibition of CYP.	macrolide antibiotics	5-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-209
10725309-1	2000	Some macrolide antibiotics cause clinical drug interactions, resulting in altered metabolism of concomitantly administered drugs, via the formation of a metabolic intermediate (MI) complex with cytochrome P450 (CYP), or competitive inhibition of CYP.	macrolide antibiotics	5-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-214
10725309-1	2000	Some macrolide antibiotics cause clinical drug interactions, resulting in altered metabolism of concomitantly administered drugs, via the formation of a metabolic intermediate (MI) complex with cytochrome P450 (CYP), or competitive inhibition of CYP.	macrolide antibiotics	5-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-249
10681376-10	2000	Based on responses to selective chemical inhibitors, specific activities, and levels present in adult human hepatic tissues, CYP1A2 and CYP3A4 strongly appeared to be the major CYP enzymes catalyzing hepatic oxidative conversion of t-ROH to t-RAL in the adult human liver.	t-roh	232-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	Tolbutamide	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	Tolbutamide	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	Sulfonylurea Compounds	17-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	Sulfonylurea Compounds	17-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
10780971-3	2000	The aims of this study were to investigate the metabolism of cisapride in human liver microsomes and to determine which cytochrome P-450 (CYP) isoenzyme(s) are involved in cisapride biotransformation.	Cisapride	172-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
10780971-3	2000	The aims of this study were to investigate the metabolism of cisapride in human liver microsomes and to determine which cytochrome P-450 (CYP) isoenzyme(s) are involved in cisapride biotransformation.	Cisapride	172-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
10764440-2	2000	Particular emphasis is placed on describing the newer information on the cytochrome P450 (CYP) system and the interactions of opioids, antidepressants, and the antitussive, dextromethorphan.	Dextromethorphan	173-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	tolylsulfonyl	110-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
10681376-2	2000	The purpose of this study was to investigate the role of human cytochrome P-450 (CYP)-dependent monooxygenation in the conversion of t-ROH to t-RAL.	t-roh	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
10681382-1	2000	Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily.	tolylsulfonyl	110-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
10681376-2	2000	The purpose of this study was to investigate the role of human cytochrome P-450 (CYP)-dependent monooxygenation in the conversion of t-ROH to t-RAL.	t-roh	133-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
10640505-0	2000	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450.	Estrone	27-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
10706031-4	2000	These findings are not inconsistent with the hypothesis derived from epidemiological work and animal studies that organochlorine insecticides produce a direct toxic action on the dopaminergic tracts of the substantia nigra and may contribute to the development of PD in those rendered susceptible by virtue of cytochrome P-450 polymorphism, excessive exposure, or other factors.	Hydrocarbons, Chlorinated	114-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	310-326
10746939-4	2000	Our laboratory is using the human H295R adrenocortical carcinoma cell line to examine chemicals for their potential to interfere with the activity and/or expression of several key cytochrome P450 (CYP) enzymes involved in the biosynthesis of steroid hormones.	Steroids	242-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-195
10746939-4	2000	Our laboratory is using the human H295R adrenocortical carcinoma cell line to examine chemicals for their potential to interfere with the activity and/or expression of several key cytochrome P450 (CYP) enzymes involved in the biosynthesis of steroid hormones.	Steroids	242-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
10640505-0	2000	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450.	Estradiol	39-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
10640505-1	2000	We have already reported that the quinol formation from some para-alkylphenols, which is a novel metabolic pathway catalyzed by cytochrome P-450, occurs in a rat liver microsomal system ().	Hydroquinones	34-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
10640505-1	2000	We have already reported that the quinol formation from some para-alkylphenols, which is a novel metabolic pathway catalyzed by cytochrome P-450, occurs in a rat liver microsomal system ().	para-alkylphenols	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-144
10640505-2	2000	In the present study, we investigated whether estrone and 17beta-estadiol, each of which contains a p-alkylphenol moiety, are also oxidized into the corresponding quinols by cytochrome P-450.	Estrone	46-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-190
10640505-2	2000	In the present study, we investigated whether estrone and 17beta-estadiol, each of which contains a p-alkylphenol moiety, are also oxidized into the corresponding quinols by cytochrome P-450.	17beta-estadiol	58-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-190
10640505-2	2000	In the present study, we investigated whether estrone and 17beta-estadiol, each of which contains a p-alkylphenol moiety, are also oxidized into the corresponding quinols by cytochrome P-450.	Hydroquinones	163-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-190
11390867-2	2000	In the coronary circulation, this endothelium-derived hyperpolarizing factor appears to be a cytochrome P(450)-derived arachidonic acid epoxide, the release of which may play a crucial role in the maintenance of coronary blood flow in arteriosclerosis.	arachidonic acid epoxide	119-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-111
10805063-15	2000	The inhibition of human CYP isoforms by 1,4-dihydropyridine calcium antagonists except nicardipine might be clinically insignificant.	1,4-dihydropyridine calcium	40-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
10805064-1	2000	OBJECTIVE: Halothane undergoes both oxidative and reductive metabolism by cytochrome P450 (CYP), respectively causing rare immune-mediated hepatic necrosis and common, mild subclinical hepatic toxicity.	Halothane	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
10805064-1	2000	OBJECTIVE: Halothane undergoes both oxidative and reductive metabolism by cytochrome P450 (CYP), respectively causing rare immune-mediated hepatic necrosis and common, mild subclinical hepatic toxicity.	Halothane	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-94
10805064-15	2000	CYP2A6-mediated, like CYP2E1-mediated human halothane oxidation, can be inhibited in vivo by mechanism-based CYP inhibitors.	Halothane	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
10698112-0	2000	Cytochrome P450 catalyzed nitric oxide synthesis: a theoretical study.	Nitric Oxide	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10698112-1	2000	Similar to nitric oxide synthase (NOS) cytochrome P450 isoforms (e.g. 3A and 4E) can produce nitric oxide from arginine.	Nitric Oxide	11-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
10698112-1	2000	Similar to nitric oxide synthase (NOS) cytochrome P450 isoforms (e.g. 3A and 4E) can produce nitric oxide from arginine.	Arginine	111-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
10698112-7	2000	The lowest energy conformation of the cytochrome P450 3A4-substrate complex was compared to the high resolution X-ray structure of the iNOS-arginine complex.	Arginine	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
10681399-2	2000	The demonstration of in vivo arachidonic acid epoxidation and omega-hydroxylation established the cytochrome P450 epoxygenase and omega/omega-1 hydroxylase as formal metabolic pathways and as members of the arachidonate metabolic cascade.	Arachidonic Acid	29-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10681399-2	2000	The demonstration of in vivo arachidonic acid epoxidation and omega-hydroxylation established the cytochrome P450 epoxygenase and omega/omega-1 hydroxylase as formal metabolic pathways and as members of the arachidonate metabolic cascade.	Arachidonic Acid	207-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10681399-3	2000	The characterization of the potent biological activities associated with several of the cytochrome P450-derived eicosanoids suggested new and important functional roles for these enzymes in cellular, organ, and body physiology, including the control of vascular reactivity and systemic blood pressures.	Eicosanoids	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
10681399-4	2000	Past and current advances in cytochrome P450 biochemistry and molecular biology facilitate the characterization of cytochrome P450 isoforms responsible for tissue/organ specific arachidonic acid epoxidation and omega/omega-1 hydroxylation, and thus, the analysis of cDNA and/or gene specific functional phenotypes.	Arachidonic Acid	178-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
10681399-4	2000	Past and current advances in cytochrome P450 biochemistry and molecular biology facilitate the characterization of cytochrome P450 isoforms responsible for tissue/organ specific arachidonic acid epoxidation and omega/omega-1 hydroxylation, and thus, the analysis of cDNA and/or gene specific functional phenotypes.	Arachidonic Acid	178-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
10805063-0	2000	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.	1,4-dihydropyridine calcium	47-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
10805063-2	2000	It is now commonly agreed that the oxidation of 1,4-dihydropyridine into pyridine, which is one of the main metabolic pathways, is catalysed by the cytochrome P450 (CYP) 3A4 isoform.	1,4-dihydropyridine	48-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
10805063-2	2000	It is now commonly agreed that the oxidation of 1,4-dihydropyridine into pyridine, which is one of the main metabolic pathways, is catalysed by the cytochrome P450 (CYP) 3A4 isoform.	1,4-dihydropyridine	48-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
10805063-2	2000	It is now commonly agreed that the oxidation of 1,4-dihydropyridine into pyridine, which is one of the main metabolic pathways, is catalysed by the cytochrome P450 (CYP) 3A4 isoform.	pyridine	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
10805063-2	2000	It is now commonly agreed that the oxidation of 1,4-dihydropyridine into pyridine, which is one of the main metabolic pathways, is catalysed by the cytochrome P450 (CYP) 3A4 isoform.	pyridine	59-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-168
10805063-3	2000	In the present study, the inhibitory effects of 13 kinds of 1,4-dihydropyridine calcium antagonists clinically used in Japan on human CYP-isoform-dependent reactions were investigated to predict the drug interactions using microsomes from human B-lymphoblast cells expressing CYP.	1,4-dihydropyridine calcium	60-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
10805063-12	2000	Among the human CYP isoforms investigated, the inhibitory effects of 1,4-dihydropyridine calcium antagonists were potent on human CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP2D6 as well as CYP3A4.	1,4-dihydropyridine calcium	69-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
10653206-0	2000	Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
10653206-0	2000	Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.	Clozapine	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
10653206-0	2000	Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.	Clozapine	105-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Clozapine	190-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Clozapine	190-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
10709852-5	2000	Down-regulation of CYP 2C protein by transfection of porcine coronary arteries with anti-sense oligonucleotides decreased EDHF-mediated vascular responses while EDHF-mediated hyperpolarisation and relaxation were potentiated by the CYP-inducing compound beta-naphthoflavone.	edhf	122-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
10696794-2	2000	Oxidative metabolism of Tri by cytochrome P-450 to form chloral hydrate (CH) was only detectable in kidney microsomes from one patient out of four tested and was not detected in hPT cells.	Chloral Hydrate	56-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
10709852-0	2000	EDHF: a cytochrome P450 metabolite in coronary arteries.	edhf	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-23
10709852-3	2000	In coronary arteries EDHF has been pharmacologically characterized as a cytochrome P450 (CYP)-derived metabolite of arachidonic acid.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
10709852-5	2000	Down-regulation of CYP 2C protein by transfection of porcine coronary arteries with anti-sense oligonucleotides decreased EDHF-mediated vascular responses while EDHF-mediated hyperpolarisation and relaxation were potentiated by the CYP-inducing compound beta-naphthoflavone.	edhf	161-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
10709852-3	2000	In coronary arteries EDHF has been pharmacologically characterized as a cytochrome P450 (CYP)-derived metabolite of arachidonic acid.	Arachidonic Acid	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
10709852-5	2000	Down-regulation of CYP 2C protein by transfection of porcine coronary arteries with anti-sense oligonucleotides decreased EDHF-mediated vascular responses while EDHF-mediated hyperpolarisation and relaxation were potentiated by the CYP-inducing compound beta-naphthoflavone.	Oligonucleotides	95-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
10709852-5	2000	Down-regulation of CYP 2C protein by transfection of porcine coronary arteries with anti-sense oligonucleotides decreased EDHF-mediated vascular responses while EDHF-mediated hyperpolarisation and relaxation were potentiated by the CYP-inducing compound beta-naphthoflavone.	beta-Naphthoflavone	254-273	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
10709852-6	2000	Thus, CYP 2C appears to play a crucial role in the generation of EDHF-mediated responses in porcine coronary arteries.	edhf	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11268336-6	2000	Most recently, evidence has accumulated that cytochrome P-450 (P-450), part of the alternative pathway for arachidonic acid metabolism, plays an important role in reduction of fever and inflammation.	Arachidonic Acid	107-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
10771452-0	2000	Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.	ziprasidone	127-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
10911933-3	2000	Cytochrome P450 drug metabolizing enzymes (CYPs), can activate (e.g. codeine to morphine) or deactivate (e.g. nicotine to cotinine) drugs of abuse.	Morphine	80-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10911933-3	2000	Cytochrome P450 drug metabolizing enzymes (CYPs), can activate (e.g. codeine to morphine) or deactivate (e.g. nicotine to cotinine) drugs of abuse.	Nicotine	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10911933-3	2000	Cytochrome P450 drug metabolizing enzymes (CYPs), can activate (e.g. codeine to morphine) or deactivate (e.g. nicotine to cotinine) drugs of abuse.	Cotinine	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10771452-13	2000	CONCLUSIONS: Ziprasidone is predominantly metabolized by CYP3A4 in human liver microsomes and is not expected to mediate drug interactions with coadministered CYP substrates, at clinically effective doses.	ziprasidone	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10911933-3	2000	Cytochrome P450 drug metabolizing enzymes (CYPs), can activate (e.g. codeine to morphine) or deactivate (e.g. nicotine to cotinine) drugs of abuse.	Codeine	69-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	ziprasidone	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	ziprasidone	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	ziprasidone	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-257
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	Ziprasidone Sulfoxide	127-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-37
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	Ziprasidone Sulfoxide	127-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-42
10771452-1	2000	AIMS: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.	Ziprasidone Sulfoxide	127-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-257
10771452-7	2000	RESULTS: Three CYP-mediated metabolites - ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic acid - were identified.	Ziprasidone Sulfoxide	42-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
10771452-7	2000	RESULTS: Three CYP-mediated metabolites - ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic acid - were identified.	UNII-6BZX6ST0LP	66-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
11059564-0	2000	Inhibition of the cytochrome P-450 modulates all-trans-retinoic acid-induced differentiation and apoptosis of HL-60 cells.	2-octenal	49-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
10771452-7	2000	RESULTS: Three CYP-mediated metabolites - ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic acid - were identified.	oxindole acetic acid	91-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
11059564-0	2000	Inhibition of the cytochrome P-450 modulates all-trans-retinoic acid-induced differentiation and apoptosis of HL-60 cells.	Tretinoin	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
11059564-1	2000	We studied the effects of inhibition of cytochrome P-450 by proadifen (SKF525A) on the processes induced in myeloid leukemia HL-60 cells by all-trans-retinoic acid (ATRA).	Proadifen	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
11122720-1	2000	The cytochrome P450 (CYP) is a group of enzymes that oxidatively modify drugs to a more water-soluble form for renal excretion.	Water	88-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
10747392-8	2000	For anisol and thioanisol, analogies and differences between oxidation reactions catalyzed by the enzyme cytochrome P-450 in the condensed phase and those observed for the gas-phase model FeO+ are discussed.	methylphenylsulfide	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
11122720-1	2000	The cytochrome P450 (CYP) is a group of enzymes that oxidatively modify drugs to a more water-soluble form for renal excretion.	Water	88-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
11122720-2	2000	Nearly 50% of all clinically used medications and endogenous steroids are metabolized by the CYP enzyme 3A4, which explains why many of the important potential drug interactions involved this enzyme.	Steroids	61-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Lovastatin	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
11098412-4	2000	Based on these parameters, selecting an antidepressant medication, such as venlafaxine, that has a low potential for drug interactions at the Cytochrome P450 (CYP) enzyme system, and is easy to monitor and dose, facilitate successful treatment of patients.	Venlafaxine Hydrochloride	75-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
11098412-4	2000	Based on these parameters, selecting an antidepressant medication, such as venlafaxine, that has a low potential for drug interactions at the Cytochrome P450 (CYP) enzyme system, and is easy to monitor and dose, facilitate successful treatment of patients.	Venlafaxine Hydrochloride	75-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-162
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Simvastatin	65-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Atorvastatin	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Atorvastatin	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
11122720-4	2000	This article describes the clinical significance of CYP metabolism as the pathways relate to the use of statins, including brief discussions on statins, fibrates, cyclosporine, and calcium channel blockers.	Cyclosporine	163-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55
10611138-10	2000	These data suggest that acetone and acetonitrile stimulate NADPH-mediated tolbutamide hydroxylation via the CYP reductase and not by modifying the affinity of tolbutamide for the CYP2C9 enzyme.	Acetone	24-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
10601869-1	2000	An 1H-NMR study of ferric cytochrome P450cam in different paramagnetic states was performed.	Hydrogen	3-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
10611138-10	2000	These data suggest that acetone and acetonitrile stimulate NADPH-mediated tolbutamide hydroxylation via the CYP reductase and not by modifying the affinity of tolbutamide for the CYP2C9 enzyme.	acetonitrile	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
10611138-10	2000	These data suggest that acetone and acetonitrile stimulate NADPH-mediated tolbutamide hydroxylation via the CYP reductase and not by modifying the affinity of tolbutamide for the CYP2C9 enzyme.	NADP	59-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
10611138-10	2000	These data suggest that acetone and acetonitrile stimulate NADPH-mediated tolbutamide hydroxylation via the CYP reductase and not by modifying the affinity of tolbutamide for the CYP2C9 enzyme.	Tolbutamide	74-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
10611146-0	2000	Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4.	Metyrapone	52-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
10712743-2	2000	GSTP1 and GSTM1 are mainly involved in detoxification reactions of PAH carcinogenic intermediates produced by cytochrome P450 (CYP).	p-Aminohippuric Acid	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
10712743-2	2000	GSTP1 and GSTM1 are mainly involved in detoxification reactions of PAH carcinogenic intermediates produced by cytochrome P450 (CYP).	p-Aminohippuric Acid	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
10601869-0	2000	Assignment of heme methyl 1H-NMR resonances of high-spin and low-spin ferric complexes of cytochrome p450cam using one-dimensional and two-dimensional paramagnetic signals enhancement (PASE) magnetization transfer experiments.	Heme	14-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
10601869-0	2000	Assignment of heme methyl 1H-NMR resonances of high-spin and low-spin ferric complexes of cytochrome p450cam using one-dimensional and two-dimensional paramagnetic signals enhancement (PASE) magnetization transfer experiments.	Hydrogen	26-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
10601869-2	2000	Assignment of three heme methyl resonances of the isocyanide adduct of cytochrome P450 in the ferric low-spin state was recently performed using electron exchange in the presence of putidaredoxin [Mouro, C., Bondon, A., Jung, C., Hui Bon Hoa, G., De Certaines, J.D., Spencer, R.G.S.	Heme	20-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
10601869-0	2000	Assignment of heme methyl 1H-NMR resonances of high-spin and low-spin ferric complexes of cytochrome p450cam using one-dimensional and two-dimensional paramagnetic signals enhancement (PASE) magnetization transfer experiments.	Ferric enterobactin ion	70-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
10601869-2	2000	Assignment of three heme methyl resonances of the isocyanide adduct of cytochrome P450 in the ferric low-spin state was recently performed using electron exchange in the presence of putidaredoxin [Mouro, C., Bondon, A., Jung, C., Hui Bon Hoa, G., De Certaines, J.D., Spencer, R.G.S.	Cyanides	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
10601869-2	2000	Assignment of three heme methyl resonances of the isocyanide adduct of cytochrome P450 in the ferric low-spin state was recently performed using electron exchange in the presence of putidaredoxin [Mouro, C., Bondon, A., Jung, C., Hui Bon Hoa, G., De Certaines, J.D., Spencer, R.G.S.	Ferric enterobactin ion	94-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
10601869-5	2000	In this study, heme methyl protons of cytochrome P450 in the native high-spin and low-spin states were assigned through one-dimensional and two-dimensional magnetization transfer spectroscopy using the paramagnetic signals enhancement (PASE) method.	Heme	15-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
10690614-2	2000	BACKGROUND/AIMS: Liver function can be evaluated using 13C breath tests that explore liver Cytochrome P450 activity.	13c	55-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
10798223-1	2000	The well-documented reduction of cancer risk by high dietary cruciferous vegetable intake may in part be caused by modulation of cytochrome P-450 (CYP) expression and activity by indoles.	Indoles	179-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
10711629-0	2000	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen"s disease patients.	Thalidomide	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
10798223-1	2000	The well-documented reduction of cancer risk by high dietary cruciferous vegetable intake may in part be caused by modulation of cytochrome P-450 (CYP) expression and activity by indoles.	Indoles	179-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
10616189-0	1999	Metabolism of N-nitrosobenzylmethylamine by human cytochrome P-450 enzymes.	nitrosobenzylmethylamine	14-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Midazolam	254-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-186
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Midazolam	254-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Dextromethorphan	265-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-186
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Dextromethorphan	265-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Chlorzoxazone	286-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-186
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Chlorzoxazone	286-299	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
10628896-2	1999	The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP), carbonyl reductase and uridine diphosphoglucose glucuronosyltransferase.	Haloperidol	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
10602224-0	1999	On the "Rebound" Mechanism of Alkane Hydroxylation by Cytochrome P450: Electronic Structure of the Intermediate and the Electron Transfer Character in the Rebound Step.	Alkanes	30-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69
10602224-1	1999	Two electromeric forms, a and b (a is the ground state in a solvent) exist for the hydroxo-iron complex 1, an intermediate in the rebound mechanism of alkane hydroxylation by cytochrome P450.	hydroxo-iron	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
10602224-1	1999	Two electromeric forms, a and b (a is the ground state in a solvent) exist for the hydroxo-iron complex 1, an intermediate in the rebound mechanism of alkane hydroxylation by cytochrome P450.	Alkanes	151-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	175-190
10628896-2	1999	The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP), carbonyl reductase and uridine diphosphoglucose glucuronosyltransferase.	Haloperidol	49-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
10628896-3	1999	The greatest proportion of the intrinsic hepatic clearance of haloperidol is by glucuronidation, followed by the reduction of haloperidol to reduced haloperidol and by CYP-mediated oxidation.	Haloperidol	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-171
10628896-4	1999	In studies of CYP-mediated disposition in vitro, CYP3A4 appears to be the major isoform responsible for the metabolism of haloperidol in humans.	Haloperidol	122-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-17
10580224-8	1999	In this study cytokine-induced bone resorption was blocked with cimetidine and clotrimazole, which are selective inhibitors of the cytochrome P-450 IIIA family and 7-ethoxyresorufin, a nonspecific cytochrome P-450 inhibitor.	Cimetidine	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
10580224-8	1999	In this study cytokine-induced bone resorption was blocked with cimetidine and clotrimazole, which are selective inhibitors of the cytochrome P-450 IIIA family and 7-ethoxyresorufin, a nonspecific cytochrome P-450 inhibitor.	Cimetidine	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-213
10580224-8	1999	In this study cytokine-induced bone resorption was blocked with cimetidine and clotrimazole, which are selective inhibitors of the cytochrome P-450 IIIA family and 7-ethoxyresorufin, a nonspecific cytochrome P-450 inhibitor.	Clotrimazole	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
10580224-8	1999	In this study cytokine-induced bone resorption was blocked with cimetidine and clotrimazole, which are selective inhibitors of the cytochrome P-450 IIIA family and 7-ethoxyresorufin, a nonspecific cytochrome P-450 inhibitor.	Clotrimazole	79-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-213
10647906-13	1999	The present study suggested that the selectivity of inhibition or inactivation of human CYP isoforms by methylenedioxyphenyl compounds may vary according to the structure of the side chain.	compounds	125-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
10604819-10	1999	Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.	Clobazam	58-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
10604819-10	1999	Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.	Felbamate	66-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
10604819-10	1999	Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.	Clobazam	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
10604819-10	1999	Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.	n-clb	156-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
10647906-2	1999	A series of methylenedioxyphenyl compounds were evaluated for their inhibitory and inactivation effects on nine human cytochrome P450 (CYP) activities using microsomes from human B-lymphoblast cells expressing specific human CYP isoforms.	compounds	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
10630892-0	1999	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes.	Steroids	23-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
10647906-2	1999	A series of methylenedioxyphenyl compounds were evaluated for their inhibitory and inactivation effects on nine human cytochrome P450 (CYP) activities using microsomes from human B-lymphoblast cells expressing specific human CYP isoforms.	compounds	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
10570242-0	1999	Fatty acid metabolism, conformational change, and electron transfer in cytochrome P-450(BM-3).	Fatty Acids	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-92
10870095-0	1999	Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast.	zafirlukast	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
10870095-8	1999	Clinically important inhibition by zafirlukast of other CYP isoforms is not established.	zafirlukast	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
10534319-0	1999	Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes.	Reboxetine	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
10534312-0	1999	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes.	7-ethoxycoumarin	51-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
10534312-0	1999	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes.	Chlorzoxazone	72-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
10534309-0	1999	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate.	Ranolazine	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
10534309-0	1999	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate.	Gallopamil	86-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
10534319-1	1999	In vitro studies were conducted to identify the hepatic cytochrome P-450 (CYP) enzymes responsible for the oxidative metabolism of the individual enantiomers of reboxetine.	Reboxetine	161-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
10534309-1	1999	Isoforms of cytochrome P-450 (CYP) involved in the metabolism of gallopamil enantiomers were identified by measuring the disappearance rate of parent drug from an incubation mixture with human liver microsomes and recombinant human CYPs.	Gallopamil	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
10534312-1	1999	Different roles of individual forms of human cytochrome P-450 (CYP) in the oxidation of 7-ethoxycoumarin and chlorzoxazone were investigated in liver microsomes of different human samples, and the microsomal activities thus obtained were predicted with kinetic parameters obtained from cDNA-derived recombinant CYP enzymes in microsomes of Trichoplusia ni cells.	7-ethoxycoumarin	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
10534312-1	1999	Different roles of individual forms of human cytochrome P-450 (CYP) in the oxidation of 7-ethoxycoumarin and chlorzoxazone were investigated in liver microsomes of different human samples, and the microsomal activities thus obtained were predicted with kinetic parameters obtained from cDNA-derived recombinant CYP enzymes in microsomes of Trichoplusia ni cells.	7-ethoxycoumarin	88-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
10534309-1	1999	Isoforms of cytochrome P-450 (CYP) involved in the metabolism of gallopamil enantiomers were identified by measuring the disappearance rate of parent drug from an incubation mixture with human liver microsomes and recombinant human CYPs.	Gallopamil	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
10534319-1	1999	In vitro studies were conducted to identify the hepatic cytochrome P-450 (CYP) enzymes responsible for the oxidative metabolism of the individual enantiomers of reboxetine.	Reboxetine	161-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
10534309-6	1999	Among the 10 recombinant human CYP isoforms, CYP3A4 exhibited the highest CL(int) of gallopamil enantiomers, and CYP2C8 and CYP2D6 also exhibited appreciable activity.	Gallopamil	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
10534309-10	1999	The present study suggests that CYP3A4 is a major isoform involved in the overall metabolic clearance of gallopamil enantiomers in the human liver, and that the present approach based on disappearance rate may be applicable to identify major isoforms of CYP involved in the metabolism of a drug in human liver microsomes.	Gallopamil	105-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
10534312-1	1999	Different roles of individual forms of human cytochrome P-450 (CYP) in the oxidation of 7-ethoxycoumarin and chlorzoxazone were investigated in liver microsomes of different human samples, and the microsomal activities thus obtained were predicted with kinetic parameters obtained from cDNA-derived recombinant CYP enzymes in microsomes of Trichoplusia ni cells.	Chlorzoxazone	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
10534312-1	1999	Different roles of individual forms of human cytochrome P-450 (CYP) in the oxidation of 7-ethoxycoumarin and chlorzoxazone were investigated in liver microsomes of different human samples, and the microsomal activities thus obtained were predicted with kinetic parameters obtained from cDNA-derived recombinant CYP enzymes in microsomes of Trichoplusia ni cells.	Chlorzoxazone	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
10534312-2	1999	Of 14 forms of recombinant CYP examined, CYP1A1 had the highest activities (V(max)/K(m) ratio) in catalyzing 7-ethoxycoumarin O-deethylation followed by CYP1A2, 2E1, 2A6, and 2B6, although CYP1A1 has been shown to be an extrahepatic enzyme.	7-ethoxycoumarin	109-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
10534312-4	1999	Similarly, chlorzoxazone 6-hydroxylation activities of liver microsomes were predicted with kinetic parameters of recombinant human CYP enzymes and it was found that CYP3A4 as well as CYP1A2 and 2E1 were involved in chlorzoxazone hydroxylation, depending on the contents of these CYP forms in the livers.	Chlorzoxazone	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
10534312-4	1999	Similarly, chlorzoxazone 6-hydroxylation activities of liver microsomes were predicted with kinetic parameters of recombinant human CYP enzymes and it was found that CYP3A4 as well as CYP1A2 and 2E1 were involved in chlorzoxazone hydroxylation, depending on the contents of these CYP forms in the livers.	Chlorzoxazone	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
10534312-4	1999	Similarly, chlorzoxazone 6-hydroxylation activities of liver microsomes were predicted with kinetic parameters of recombinant human CYP enzymes and it was found that CYP3A4 as well as CYP1A2 and 2E1 were involved in chlorzoxazone hydroxylation, depending on the contents of these CYP forms in the livers.	Chlorzoxazone	216-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
10579149-1	1999	Vesnarinone is an orally administered inotropic agent that is metabolized in vitro by the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1.	vesnarinone	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
10534312-4	1999	Similarly, chlorzoxazone 6-hydroxylation activities of liver microsomes were predicted with kinetic parameters of recombinant human CYP enzymes and it was found that CYP3A4 as well as CYP1A2 and 2E1 were involved in chlorzoxazone hydroxylation, depending on the contents of these CYP forms in the livers.	Chlorzoxazone	216-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-169
10534312-5	1999	Recombinant CYP2A6 and 2B6 and CYP2D6 had considerable roles (V(max)/K(m) ratio) for 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation, respectively; however, these CYP forms had relatively minor roles in the reactions, probably due to low expression in human livers.	7-ethoxycoumarin	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
10534312-5	1999	Recombinant CYP2A6 and 2B6 and CYP2D6 had considerable roles (V(max)/K(m) ratio) for 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation, respectively; however, these CYP forms had relatively minor roles in the reactions, probably due to low expression in human livers.	Chlorzoxazone	121-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
10534317-4	1999	The role of CYP enzymes in the stereoselective metabolism of R-IFA and S-IFA was investigated by monitoring the formation of both 4-hydroxy (activated) and N-dechloroethyl (DCl) (inactive, neurotoxic) metabolites.	4-hydroxyphenylacetic acid	130-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
10534317-4	1999	The role of CYP enzymes in the stereoselective metabolism of R-IFA and S-IFA was investigated by monitoring the formation of both 4-hydroxy (activated) and N-dechloroethyl (DCl) (inactive, neurotoxic) metabolites.	n-dechloroethyl	156-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
10534317-4	1999	The role of CYP enzymes in the stereoselective metabolism of R-IFA and S-IFA was investigated by monitoring the formation of both 4-hydroxy (activated) and N-dechloroethyl (DCl) (inactive, neurotoxic) metabolites.	dcl	173-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
10584978-0	1999	Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.	Fusidic Acid	10-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
10584978-1	1999	OBJECTIVE: To investigate the effects of fusidic acid therapy on the hepatic cytochrome P450 (CYP450) enzyme system.	Fusidic Acid	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
10584978-1	1999	OBJECTIVE: To investigate the effects of fusidic acid therapy on the hepatic cytochrome P450 (CYP450) enzyme system.	Fusidic Acid	41-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-100
10584978-9	1999	However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).	Fusidic Acid	104-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
10584978-9	1999	However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).	10-oxohexadecanoic acid	304-307	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
10584978-9	1999	However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).	3-hydroxymethylantipyrine	347-350	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-48
10584978-11	1999	CONCLUSIONS: Our results suggest that fusidic acid has a time-dependent activating effect on the CYP450 enzyme system.	Fusidic Acid	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-103
10575556-7	1999	Although the dogma is that the myoglobin is the source of iron, recent studies suggest that cytochrome P450 may be an important source of iron in this model.	Iron	138-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
10575556-11	1999	Recent studies indicate that cytochrome P450 may also be an important source of the catalytic iron in cisplatin nephrotoxicity.	Iron	94-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
10575556-11	1999	Recent studies indicate that cytochrome P450 may also be an important source of the catalytic iron in cisplatin nephrotoxicity.	Cisplatin	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
10579149-1	1999	Vesnarinone is an orally administered inotropic agent that is metabolized in vitro by the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1.	vesnarinone	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
10540427-2	1999	This process is the first structural evidence for an effective method for the activation of molecular oxygen as postulated for the cytochrome P-450 system.	Oxygen	102-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
10761213-0	1999	[The effect of gamma-L-glutamyl histamine on the severity of experimental anaphylactic reaction, hormonal status and liver cytochrome p-450].	gamma-l-glutamyl histamine	15-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
10574186-3	1999	Using the developed method, metabolism of coumarin in 11 samples of human liver microsomes was evaluated and 1790+/-690 pmol/min/nmol cytochrome P450 (CYP) activity was found.	coumarin	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-149
10574186-3	1999	Using the developed method, metabolism of coumarin in 11 samples of human liver microsomes was evaluated and 1790+/-690 pmol/min/nmol cytochrome P450 (CYP) activity was found.	coumarin	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
10655974-3	1999	Our aim was to assess the effect of dietary intake on in vivo cytochrome P450 (CYP) activities in eleven patients with abnormal liver function tests potentially due to fatty liver and associated with a high-sugar diet.	Sugars	207-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
10583023-0	1999	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.	artemisinin	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
10583023-1	1999	AIMS: The study aimed to identify the specific human cytochrome P450 (CYP450) enzymes involved in the metabolism of artemisinin.	artemisinin	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
10498654-0	1999	Induction of cytochrome P450 enzymes and generation of protein-aldehyde adducts are associated with sex-dependent sensitivity to alcohol-induced liver disease in micropigs.	Alcohols	129-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
10583023-1	1999	AIMS: The study aimed to identify the specific human cytochrome P450 (CYP450) enzymes involved in the metabolism of artemisinin.	artemisinin	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-76
10583023-2	1999	METHODS: Microsomes from human B-lymphoblastoid cell lines transformed with individual CYP450 cDNAs were investigated for their capacity to metabolize artemisinin.	artemisinin	151-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-93
10583023-4	1999	The relative contribution of individual CYP450 isoenzymes to artemisinin metabolism in human liver microsomes was evaluated with a tree-based regression model of artemisinin disappearance rate and specific CYP450 activities.	artemisinin	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-46
10498654-4	1999	Ethanol feeding increased the hepatic content of all CYP forms.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
10498654-7	1999	In the noncastrated ethanol-fed micropigs a low expression of each CYP form was associated with scant evidence of aldehyde-protein adducts.	Ethanol	20-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
10498654-7	1999	In the noncastrated ethanol-fed micropigs a low expression of each CYP form was associated with scant evidence of aldehyde-protein adducts.	Aldehydes	114-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
10498654-8	1999	Significant correlations emerged between the levels of different CYP forms, protein adducts, and plasma levels of sex steroids.	Steroids	118-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
10511133-1	1999	Although endothelium-derived hyperpolarizing factor (EDHF) is thought to be a cytochrome P-450 product (arachidonic acid metabolite) in some tissues, in porcine coronary arteries (PCAs) its nature remains unclear.	endothelium-derived hyperpolarizing factor	9-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
10511133-1	1999	Although endothelium-derived hyperpolarizing factor (EDHF) is thought to be a cytochrome P-450 product (arachidonic acid metabolite) in some tissues, in porcine coronary arteries (PCAs) its nature remains unclear.	edhf	53-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
10490896-8	1999	It was concluded that lovastatin is metabolized by cytochrome P-450 3A enzymes in the small intestine.	Lovastatin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
10525052-0	1999	Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.	Nitric Oxide	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10525052-0	1999	Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.	Sodium Chloride	113-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
10525052-2	1999	To probe the basis of this effect, we characterized the effects of nitric oxide (NO), a known suppressor of cytochrome P450 (CYP) enzymes, on metabolism of arachidonic acid (AA), the expression of omega-hydroxylase, and the efflux of 20-hydroxyeicosatetraenoic acid (20-HETE) from the isolated kidney.	Nitric Oxide	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-123
10525052-2	1999	To probe the basis of this effect, we characterized the effects of nitric oxide (NO), a known suppressor of cytochrome P450 (CYP) enzymes, on metabolism of arachidonic acid (AA), the expression of omega-hydroxylase, and the efflux of 20-hydroxyeicosatetraenoic acid (20-HETE) from the isolated kidney.	Nitric Oxide	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
10490896-9	1999	Compared with lovastatin, the cytochrome P-450-dependent intestinal intrinsic clearance of pravastatin was &gt;5000-fold lower and cannot be expected to significantly affect its oral bioavailability or to be a significant site of drug interactions.	Pravastatin	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Atorvastatin	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10506751-0	1999	A quantitative comparison of dibenzo[a,l]pyrene-DNA adduct formation by recombinant human cytochrome P450 microsomes.	dibenzo(a,l)pyrene	29-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
10522495-0	1999	Effects of pretreatment with cytochrome P-450 inducers, especially phenobarbital on triphenyltin metabolism and toxicity in hamsters.	triphenyltin	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
10522495-1	1999	The effects of cytochrome P-450 (CYP) induction by phenobarbital (PB), CYP 2B, 2C, and 3A inducer in mammalians, on triphenyltin metabolism and toxicity in hamsters were studied.	Phenobarbital	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
10522495-1	1999	The effects of cytochrome P-450 (CYP) induction by phenobarbital (PB), CYP 2B, 2C, and 3A inducer in mammalians, on triphenyltin metabolism and toxicity in hamsters were studied.	Phenobarbital	51-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
10522495-1	1999	The effects of cytochrome P-450 (CYP) induction by phenobarbital (PB), CYP 2B, 2C, and 3A inducer in mammalians, on triphenyltin metabolism and toxicity in hamsters were studied.	Phenobarbital	66-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
10522495-1	1999	The effects of cytochrome P-450 (CYP) induction by phenobarbital (PB), CYP 2B, 2C, and 3A inducer in mammalians, on triphenyltin metabolism and toxicity in hamsters were studied.	Phenobarbital	66-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
10522495-3	1999	Although the triphenyltin produced marked but reversible hyperglycemia and hypertriglyceridemia in PB-untreated hamsters, the pretreatment of hamsters with PB, which increased levels of CYP, suppressed the diabetogenic effects compared with PB-untreated hamsters.	Phenobarbital	156-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
10522495-3	1999	Although the triphenyltin produced marked but reversible hyperglycemia and hypertriglyceridemia in PB-untreated hamsters, the pretreatment of hamsters with PB, which increased levels of CYP, suppressed the diabetogenic effects compared with PB-untreated hamsters.	Phenobarbital	156-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
10522495-10	1999	These findings suggest that the induction of CYP system enzymes affects the metabolism and toxicity of triphenyltin in hamsters.	triphenyltin	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
10522495-11	1999	Especially, based on effects of PB and other CYP inducers, PB induction has a key role in suppressing the diabetogenic action of triphenyltin, i.e. by decreasing triphenyltin accumulation in the hamsters.	Phenobarbital	59-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Lovastatin	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Lovastatin	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Simvastatin	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Simvastatin	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Atorvastatin	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	cerivastatin	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	cerivastatin	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Fluvastatin	77-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Fluvastatin	77-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
10575059-6	1999	Clinically important interactions with simvastatin or lovastatin and drugs that inhibit the 3A4 isoenzyme (part of the CYP450 system) may result in myopathy and rhabdomyolysis, which can be fatal.	Simvastatin	39-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
10575059-6	1999	Clinically important interactions with simvastatin or lovastatin and drugs that inhibit the 3A4 isoenzyme (part of the CYP450 system) may result in myopathy and rhabdomyolysis, which can be fatal.	Lovastatin	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-125
10484519-1	1999	The medullary thick ascending limb (MTAL) metabolizes arachidonic acid (AA) via cytochrome P-450 (CyP450)- and cyclooxygenase (COX)-dependent pathways.	Arachidonic Acid	54-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-125
10460798-1	1999	Activities of testosterone, nifedipine, and midazolam oxidation by recombinant cytochrome P-450 (P-450) 3A4 coexpressed with human NADPH-P-450 reductase (NPR) in bacterial membranes (CYP3A4/NPR membranes) were determined in comparison with those of other recombinant systems and of human liver microsomes with high contents of CYP3A4.	Nifedipine	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
10583049-11	1999	These studies also indicate that as yet unknown isoforms of cytochrome P450 may be involved in RA metabolism in keratinocytes.	Tretinoin	95-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
10460798-1	1999	Activities of testosterone, nifedipine, and midazolam oxidation by recombinant cytochrome P-450 (P-450) 3A4 coexpressed with human NADPH-P-450 reductase (NPR) in bacterial membranes (CYP3A4/NPR membranes) were determined in comparison with those of other recombinant systems and of human liver microsomes with high contents of CYP3A4.	Testosterone	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
10460808-2	1999	The aim of the present study was to identify the human cytochrome P-450 (CYP) isoforms involved in zopiclone metabolism in vitro.	zopiclone	99-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
10460798-1	1999	Activities of testosterone, nifedipine, and midazolam oxidation by recombinant cytochrome P-450 (P-450) 3A4 coexpressed with human NADPH-P-450 reductase (NPR) in bacterial membranes (CYP3A4/NPR membranes) were determined in comparison with those of other recombinant systems and of human liver microsomes with high contents of CYP3A4.	Midazolam	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
10460808-2	1999	The aim of the present study was to identify the human cytochrome P-450 (CYP) isoforms involved in zopiclone metabolism in vitro.	zopiclone	99-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
11720625-3	1999	However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.	Clarithromycin	9-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
10548450-0	1999	Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.	2-(4-(3-methyl-2-thienyl)phenyl)propionic acid	79-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
10548450-12	1999	When incubated with microsomes containing cDNA-expressed CYP isozymes, S-MTPPA was substantially oxidized to MA6 only by CYP2C9.	2-(4-(3-methyl-2-thienyl)phenyl)propionic acid	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10917607-0	1999	Sphingomyelin hydrolysis and regulation of the expression of the gene for cytochrome P450.	Sphingomyelins	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
10491726-0	1999	Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.	Rabeprazole	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
10424762-7	1999	While the N-hydroxylation of the guanidine involves the usual monooxygenase activity of cytochrome P-450 (Clement et al., Biochem Pharmacol 46: 2249-2267, 1993), the resultant N-hydroxyguanidine decoupled the monooxygenase.	Nitrogen	10-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
10424762-7	1999	While the N-hydroxylation of the guanidine involves the usual monooxygenase activity of cytochrome P-450 (Clement et al., Biochem Pharmacol 46: 2249-2267, 1993), the resultant N-hydroxyguanidine decoupled the monooxygenase.	Guanidine	33-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
10424762-7	1999	While the N-hydroxylation of the guanidine involves the usual monooxygenase activity of cytochrome P-450 (Clement et al., Biochem Pharmacol 46: 2249-2267, 1993), the resultant N-hydroxyguanidine decoupled the monooxygenase.	hydroxyguanidine	176-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
10424762-13	1999	In conclusion, similarities (formation of a urea derivative) and differences (formation of a cyanamide derivative) between the physiological oxidation of N-hydroxy-L-arginine by nitric oxide synthases and non-physiological N-hydroxyguanidines by cytochrome P-450 were observed.	hydroxyguanidine	223-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	246-262
10421623-0	1999	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine.	azelastine	97-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
10421623-2	1999	The human cytochrome P-450 (CYP) isoform responsible for azelastine N-demethylation, the major metabolic pathway for azelastine, has been examined.	azelastine	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
10421623-2	1999	The human cytochrome P-450 (CYP) isoform responsible for azelastine N-demethylation, the major metabolic pathway for azelastine, has been examined.	azelastine	57-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
10421623-2	1999	The human cytochrome P-450 (CYP) isoform responsible for azelastine N-demethylation, the major metabolic pathway for azelastine, has been examined.	azelastine	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
10421623-2	1999	The human cytochrome P-450 (CYP) isoform responsible for azelastine N-demethylation, the major metabolic pathway for azelastine, has been examined.	azelastine	117-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
10460168-0	1999	Engineering cytochrome c peroxidase into cytochrome P450: a proximal effect on heme-thiolate ligation.	heme-thiolate	79-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
10460168-1	1999	In an effort to investigate factors required to stabilize heme-thiolate ligation, key structural components necessary to convert cytochrome c peroxidase (CcP) into a thiolate-ligated cytochrome P450-like enzyme have been evaluated and the H175C/D235L CcP double mutant has been engineered.	Heme	58-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
10460168-1	1999	In an effort to investigate factors required to stabilize heme-thiolate ligation, key structural components necessary to convert cytochrome c peroxidase (CcP) into a thiolate-ligated cytochrome P450-like enzyme have been evaluated and the H175C/D235L CcP double mutant has been engineered.	thiolate	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
10460168-1	1999	In an effort to investigate factors required to stabilize heme-thiolate ligation, key structural components necessary to convert cytochrome c peroxidase (CcP) into a thiolate-ligated cytochrome P450-like enzyme have been evaluated and the H175C/D235L CcP double mutant has been engineered.	thiolate	166-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
10411602-0	1999	Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.	zosuquidar trihydrochloride	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
10553719-2	1999	The cytochrome P450 (CYP)-mediated metabolism of tauromustine has been evaluated in liver and lung microsomes from various species.	1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea	49-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
10419542-0	1999	The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.	1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	39-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
10419542-0	1999	The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.	Nitric Oxide	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
20654512-0	1999	Imipramine for Cytochrome P450 Activity Determination: a Multiple-species Metabolic Probe.	Imipramine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
20654512-6	1999	To conclude, the metabolic profile of imipramine can be used to reveal a number of cytochrome P450 enzymes active in microsomal fractions.	Imipramine	38-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-98
10553719-2	1999	The cytochrome P450 (CYP)-mediated metabolism of tauromustine has been evaluated in liver and lung microsomes from various species.	1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea	49-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
10455289-8	1999	In contrast, the selective CYT-P450 hydroxylase inhibitor, N-methylsulphonyl-12,12-dibromododec-11-enamide (DDMS) attenuated the vascular response to increasing renal perfusion pressure.	n-methylsulphonyl-12,12-dibromododec-11-enamide	59-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-35
10553719-15	1999	Among the human cDNA expressed CYP enzymes, not only was tauromustine determined to be catalysed predominantly by CYP3A4, but also to some extent by CYP2C19 and CYP2D6.	1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
10409674-2	1999	Cytochrome P450 4F3 (CYP4F3) catalyzes the inactivation of leukotriene B(4) by omega-oxidation in human neutrophils.	Leukotriene B4	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-19
10409674-2	1999	Cytochrome P450 4F3 (CYP4F3) catalyzes the inactivation of leukotriene B(4) by omega-oxidation in human neutrophils.	Leukotriene B4	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-27
10424895-0	1999	Cytochrome P450-dependent metabolism of arachidonic acid.	Arachidonic Acid	40-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10424895-1	1999	The cytochrome P450-dependent metabolism of arachidonic acid, the mechanisms of regulation of stereo- and regiospecificity by cytochrome P450 isoenzymes, and the biological relevance of metabolites of the arachidonic acid cascade is discussed in this review.	Arachidonic Acid	44-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
10424895-1	1999	The cytochrome P450-dependent metabolism of arachidonic acid, the mechanisms of regulation of stereo- and regiospecificity by cytochrome P450 isoenzymes, and the biological relevance of metabolites of the arachidonic acid cascade is discussed in this review.	Arachidonic Acid	205-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
10424895-1	1999	The cytochrome P450-dependent metabolism of arachidonic acid, the mechanisms of regulation of stereo- and regiospecificity by cytochrome P450 isoenzymes, and the biological relevance of metabolites of the arachidonic acid cascade is discussed in this review.	Arachidonic Acid	205-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
10455289-8	1999	In contrast, the selective CYT-P450 hydroxylase inhibitor, N-methylsulphonyl-12,12-dibromododec-11-enamide (DDMS) attenuated the vascular response to increasing renal perfusion pressure.	DDMS	108-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-35
10383930-6	1999	Oxidative metabolism of molinate in both rats and humans appears to be mediated by cytochrome P-450 and not flavin monooxygenases as indicated by the use of metabolic inhibitors.	molinate	24-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
10383917-0	1999	Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.	Sertraline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
10383917-2	1999	We identified the cytochrome P-450 (CYP) isoforms involved in sertraline N-demethylation using pooled human liver microsomes and cDNA-expressed CYP isoforms.	Sertraline	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
10383922-0	1999	Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.	azelastine	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
10383922-2	1999	In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP.	azelastine	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
10383922-2	1999	In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP.	azelastine	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Clozapine	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-273
10383922-2	1999	In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP.	azelastine	197-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
10383922-2	1999	In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP.	azelastine	197-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
10381752-1	1999	In humans, meloxicam is metabolized mainly by cytochrome P-450 (CYP)-dependent hydroxylation of the 5"-methyl group.	Meloxicam	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
10381752-1	1999	In humans, meloxicam is metabolized mainly by cytochrome P-450 (CYP)-dependent hydroxylation of the 5"-methyl group.	Meloxicam	11-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
10381752-6	1999	Using expressed cytochrome P-450 enzymes and selective chemical inhibitors of CYP 2C9 and CYP 3A4, it was found that quinidine markedly increased the rate of CYP 3A4-mediated meloxicam hydroxylation but was virtually without effect on CYP 2C9.	Quinidine	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Clozapine	48-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	275-278
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Risperidone	59-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-273
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Risperidone	59-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	275-278
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Olanzapine	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-273
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Olanzapine	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	275-278
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Quetiapine Fumarate	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-273
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	Quetiapine Fumarate	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	275-278
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	sertindole	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	258-273
10422890-1	1999	The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes.	sertindole	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	275-278
10330055-3	1999	The inhibition by ANG II was abolished by pretreatment with eicosatetraynoic acid (10 microM), a general inhibitor of arachidonic acid metabolism, or 17-octadecynoic acid (10 microM), a highly selective inhibitor of cytochrome P-450 pathways.	17-octadecynoic acid	150-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-232
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	oxazaphosphorine	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	oxazaphosphorine	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Cyclophosphamide	157-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Cyclophosphamide	157-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Cyclophosphamide	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Cyclophosphamide	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Ifosfamide	184-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Ifosfamide	184-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
10348794-1	1999	The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated.	Ifosfamide	196-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
10220485-2	1999	Pulegone is metabolized by human liver cytochrome P-450s to menthofuran, a proximate hepatotoxic metabolite of pulegone.	pulegone	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
10220485-2	1999	Pulegone is metabolized by human liver cytochrome P-450s to menthofuran, a proximate hepatotoxic metabolite of pulegone.	menthofuran	60-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
10220485-2	1999	Pulegone is metabolized by human liver cytochrome P-450s to menthofuran, a proximate hepatotoxic metabolite of pulegone.	pulegone	111-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
10215634-0	1999	Cytochrome P-450-dependent bioactivation of 1,1-dichloroethylene to a reactive epoxide in human lung and liver microsomes.	vinylidene chloride	44-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
10215634-0	1999	Cytochrome P-450-dependent bioactivation of 1,1-dichloroethylene to a reactive epoxide in human lung and liver microsomes.	Epoxy Compounds	79-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
10215634-1	1999	We investigated the cytochrome P-450-dependent metabolism of 1, 1-dichloroethylene (DCE) by human lung and liver microsomes and compared the results from analogous experiments in mice.	vinylidene chloride	61-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
10215634-1	1999	We investigated the cytochrome P-450-dependent metabolism of 1, 1-dichloroethylene (DCE) by human lung and liver microsomes and compared the results from analogous experiments in mice.	ethylene dichloride	84-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
10499085-1	1999	Photoexcited iron porphyrins can be used to mimic the catalytic activity of cytochrome P-450 oxygenases both in the reduction of halogenated alkanes and in the oxidation of hydrocarbons by O2 itself at room temperature and atmospheric pressure.	Oxygen	189-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
10216279-2	1999	Fourteen recombinant expressed cytochrome P450 (CYP) enzymes, human liver microsomes from different donors, and selective cytochrome P450 inhibitors were used to study the hydroxylation of taurochenodeoxycholic acid and lithocholic acid.	Taurochenodeoxycholic Acid	189-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
10215728-1	1999	BACKGROUND: The S-mephenytoin hydroxylase is a polymorphic cytochrome P450 (CYP) enzyme, identified as CYP2C19, which catalyses the metabolism of omeprazole and some other drugs.	Omeprazole	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
10215728-1	1999	BACKGROUND: The S-mephenytoin hydroxylase is a polymorphic cytochrome P450 (CYP) enzyme, identified as CYP2C19, which catalyses the metabolism of omeprazole and some other drugs.	Omeprazole	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-79
10197604-0	1999	Comparison of cytochrome P450- and peroxidase-dependent metabolic activation of the potent carcinogen dibenzo[a,l]pyrene in human cell lines: formation of stable DNA adducts and absence of a detectable increase in apurinic sites.	dibenzo(a,l)pyrene	102-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-45
10380060-5	1999	Phenytoin, phenobarbiral, primidone and carbamazepine induce CYP and UDPGT enzymes while valproic acid inhibits them.	Phenytoin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
10385214-5	1999	Formation of N-debutylhalofantrine was cytochrome P450 (CYP)-mediated.	1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol	13-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
10380060-5	1999	Phenytoin, phenobarbiral, primidone and carbamazepine induce CYP and UDPGT enzymes while valproic acid inhibits them.	phenobarbiral	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
10380060-5	1999	Phenytoin, phenobarbiral, primidone and carbamazepine induce CYP and UDPGT enzymes while valproic acid inhibits them.	Primidone	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
10380060-5	1999	Phenytoin, phenobarbiral, primidone and carbamazepine induce CYP and UDPGT enzymes while valproic acid inhibits them.	Carbamazepine	40-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
10499085-1	1999	Photoexcited iron porphyrins can be used to mimic the catalytic activity of cytochrome P-450 oxygenases both in the reduction of halogenated alkanes and in the oxidation of hydrocarbons by O2 itself at room temperature and atmospheric pressure.	iron porphyrins	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
10499085-1	1999	Photoexcited iron porphyrins can be used to mimic the catalytic activity of cytochrome P-450 oxygenases both in the reduction of halogenated alkanes and in the oxidation of hydrocarbons by O2 itself at room temperature and atmospheric pressure.	Alkanes	141-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
10499085-1	1999	Photoexcited iron porphyrins can be used to mimic the catalytic activity of cytochrome P-450 oxygenases both in the reduction of halogenated alkanes and in the oxidation of hydrocarbons by O2 itself at room temperature and atmospheric pressure.	Hydrocarbons	173-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
10385214-5	1999	Formation of N-debutylhalofantrine was cytochrome P450 (CYP)-mediated.	1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol	13-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-59
10385214-6	1999	Studies using selective inhibitors of individual CYPs revealed the role of CYP 3As in the formation of N-debutylhalofantrine.	1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol	103-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
10231734-0	1999	Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications.	Melatonin	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
10385214-8	1999	In microsomes from 12 livers from man the rate of N-debutylation of halofantrine correlated strongly with CYP 3A4 relative levels (P = 0.002) and less strongly, but significantly, with CYP 2C8 levels (P = 0.025).	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
10385214-8	1999	In microsomes from 12 livers from man the rate of N-debutylation of halofantrine correlated strongly with CYP 3A4 relative levels (P = 0.002) and less strongly, but significantly, with CYP 2C8 levels (P = 0.025).	halofantrine	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
10385214-9	1999	To characterize CYP-mediated metabolism of halofantrine further, incubations were performed with yeast microsomes expressing specific CYP 3A4, CYP 3A5, CYP 2D6, CYP 2C8 and CYP 2C19 from man.	halofantrine	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
10385214-9	1999	To characterize CYP-mediated metabolism of halofantrine further, incubations were performed with yeast microsomes expressing specific CYP 3A4, CYP 3A5, CYP 2D6, CYP 2C8 and CYP 2C19 from man.	halofantrine	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
10385214-9	1999	To characterize CYP-mediated metabolism of halofantrine further, incubations were performed with yeast microsomes expressing specific CYP 3A4, CYP 3A5, CYP 2D6, CYP 2C8 and CYP 2C19 from man.	halofantrine	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
10385214-9	1999	To characterize CYP-mediated metabolism of halofantrine further, incubations were performed with yeast microsomes expressing specific CYP 3A4, CYP 3A5, CYP 2D6, CYP 2C8 and CYP 2C19 from man.	halofantrine	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
10385214-9	1999	To characterize CYP-mediated metabolism of halofantrine further, incubations were performed with yeast microsomes expressing specific CYP 3A4, CYP 3A5, CYP 2D6, CYP 2C8 and CYP 2C19 from man.	halofantrine	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
10209701-6	1999	Concomitant administration with drugs that inhibit the hepatic cytochrome P-450 (imidazole antifungals, macrolide antibiotics) or those that prolong the QT interval by the same or other mechanism (e.g. antiarrhythmics, antipsychotics, tricyclic antidepressants) increases their effect on the cardiac repolarization.	imidazole	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
11670903-0	1999	Role of the Invariant Peptide Fragment Forming NH.S Hydrogen Bonds in the Active Site of Cytochrome P-450 and Chloroperoxidase: Synthesis and Properties of Cys-Containing Peptide Fe(III) and Ga(III) (Octaethylporphinato) Complexes as Models.	Hydrogen	52-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-126
11670903-0	1999	Role of the Invariant Peptide Fragment Forming NH.S Hydrogen Bonds in the Active Site of Cytochrome P-450 and Chloroperoxidase: Synthesis and Properties of Cys-Containing Peptide Fe(III) and Ga(III) (Octaethylporphinato) Complexes as Models.	Cysteine	156-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-126
10209701-6	1999	Concomitant administration with drugs that inhibit the hepatic cytochrome P-450 (imidazole antifungals, macrolide antibiotics) or those that prolong the QT interval by the same or other mechanism (e.g. antiarrhythmics, antipsychotics, tricyclic antidepressants) increases their effect on the cardiac repolarization.	macrolide antibiotics	104-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
10084413-7	1999	Miconazole exerts its fungistatic action by inhibiting some isoenzymes of the fungal cytochrome P450 system.	Miconazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
10064574-0	1999	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.	Fluvastatin	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
10064574-12	1999	This data indicates that several human cytochrome P-450 enzymes metabolize fluvastatin with CYP2C9 contributing 50-80%.	Fluvastatin	75-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
10980926-4	1999	This liver injury is due not to the drug itself but to the formation of the toxic metabolite N-acetyl-p-benzoquinine imine generated through the cytochrome P-450 drug-metabolizing system.	n-acetyl-p-benzoquinine imine	93-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
9929520-0	1999	Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine.	carboxylic acid ester	38-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9929518-3	1999	Irbesartan oxidation follows Michaelis-Menten kinetics, consistent with the involvement of a single CYP isoform in these hydroxylation processes.	Irbesartan	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-103
9929499-0	1999	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.	Lovastatin	133-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
9929499-0	1999	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.	Pravastatin	148-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
9929518-8	1999	Oxidation of irbesartan was markedly inhibited by sulfaphenazole (CYP2C9 inhibitor), but not by any of several other CYP inhibitors.	Irbesartan	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
9929520-0	1999	Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine.	hantzsch pyridine ester	72-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9929518-8	1999	Oxidation of irbesartan was markedly inhibited by sulfaphenazole (CYP2C9 inhibitor), but not by any of several other CYP inhibitors.	Sulfaphenazole	50-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
9929520-0	1999	Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine.	pranidipine	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9929520-1	1999	Cytochrome P-450 (CYP) isoforms responsible for the cleavage of Hantzsch pyridine ester at the 3-position of pranidipine were studied in vitro using cDNA-expressed human CYP enzymes.	hantzsch pyridine ester	64-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9929520-1	1999	Cytochrome P-450 (CYP) isoforms responsible for the cleavage of Hantzsch pyridine ester at the 3-position of pranidipine were studied in vitro using cDNA-expressed human CYP enzymes.	hantzsch pyridine ester	64-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
9929520-1	1999	Cytochrome P-450 (CYP) isoforms responsible for the cleavage of Hantzsch pyridine ester at the 3-position of pranidipine were studied in vitro using cDNA-expressed human CYP enzymes.	pranidipine	109-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9929520-1	1999	Cytochrome P-450 (CYP) isoforms responsible for the cleavage of Hantzsch pyridine ester at the 3-position of pranidipine were studied in vitro using cDNA-expressed human CYP enzymes.	pranidipine	109-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
10048600-3	1999	In the present study, in vitro metabolism of risperidone (100 microM) was investigated using the recombinant human cytochrome P450 (CYP) enzymes CYP1A1, CYP1A2, CYP2C8, CYP2C9-arg144, CYP2C9-cys144, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 supplemented with an NADPH-generating system.	Risperidone	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	Carbofuran	58-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	Carbofuran	58-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-22
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	Carbaryl	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	Carbaryl	74-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-22
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	pirimicarb	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	pirimicarb	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-22
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	iron(iii) tetraarylporphyrins	165-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
10563966-2	1999	Cytochrome P450 (CP450) catalyzed oxidative metabolism of carbofuran (1), carbaryl (2), and pirimicarb (3) has been modeled using biomimetic oxidations catalyzed by iron(III) tetraarylporphyrins.	iron(iii) tetraarylporphyrins	165-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-22
10048600-3	1999	In the present study, in vitro metabolism of risperidone (100 microM) was investigated using the recombinant human cytochrome P450 (CYP) enzymes CYP1A1, CYP1A2, CYP2C8, CYP2C9-arg144, CYP2C9-cys144, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 supplemented with an NADPH-generating system.	Risperidone	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
10048600-3	1999	In the present study, in vitro metabolism of risperidone (100 microM) was investigated using the recombinant human cytochrome P450 (CYP) enzymes CYP1A1, CYP1A2, CYP2C8, CYP2C9-arg144, CYP2C9-cys144, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 supplemented with an NADPH-generating system.	NADP	255-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
10649851-3	1999	MAIN PURPOSE: In this study possible participation of eicosanoids, cytochrome P-450 and reactive oxygen species in the changes of airways reactivity evoked by toluene exposure as the source of free radicals was followed up by an indirect method.	Toluene	159-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
9935275-9	1999	Increased macrolide use in children in recent years has resulted in a growing potential for drug interactions between them and other pharmacologically active agents via the inhibition of cytochrome P450 (CYP) microsomal enzymes.	Macrolides	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	187-202
10702887-1	1999	OBJECTIVE: In vitro results suggest that cilostazol is metabolised by cytochrome P450 (CYP) isoforms 1A2, 2D6, 3A4 and 2C19.	Cilostazol	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
10702887-1	1999	OBJECTIVE: In vitro results suggest that cilostazol is metabolised by cytochrome P450 (CYP) isoforms 1A2, 2D6, 3A4 and 2C19.	Cilostazol	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
9884321-1	1999	Biotransformation of the M1-muscarinic agonist Lu 25-109 (5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine) , in development for the treatment of Alzheimer"s disease, was investigated to obtain information on the identity of human hepatic cytochrome P-450 enzymes involved in its metabolism.	LU 25-109-T	47-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	255-271
9935275-9	1999	Increased macrolide use in children in recent years has resulted in a growing potential for drug interactions between them and other pharmacologically active agents via the inhibition of cytochrome P450 (CYP) microsomal enzymes.	Macrolides	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207
9935275-11	1999	Clarithromycin is a weak inducer of CYP and exhibits fewer drug-drug interactions than erythromycin.	Clarithromycin	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
9872399-1	1998	Light absorption photometry of HepG2 cells treated with phenobarbital for enhancing the content of cytochrome P-450 and the synthesis of erythropoietin revealed an influence on all cytochromes detectable in the wavelength range between 400 and 620 nm.	Phenobarbital	56-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
9987703-1	1999	The single-dose effects of the cytochrome P-450 inhibitors erythromycin and ketoconazole on the steady-state pharmacokinetics and electrocardiographic repolarization pharmacodynamics of intranasal levocabastine, a potent and selective H1-receptor antagonist, were evaluated in healthy young male subjects.	Erythromycin	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
9987703-1	1999	The single-dose effects of the cytochrome P-450 inhibitors erythromycin and ketoconazole on the steady-state pharmacokinetics and electrocardiographic repolarization pharmacodynamics of intranasal levocabastine, a potent and selective H1-receptor antagonist, were evaluated in healthy young male subjects.	levocabastine	197-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
9987703-10	1999	Since levocabastine undergoes only minimal hepatic metabolism and is not a substrate for or an inhibitor of cytochrome P-450, the likelihood of systemic drug interactions with drugs affecting the cytochrome P-450 system is minimal.	levocabastine	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-212
10343314-9	1999	On the other hand, it must be noted that with the exception of the cytochrome P-450 metabolites of arachidonic acid, most of the major eicosanoids that are biologically active and are known to play regulatory roles in physiology and/or pathology, have commercially available antibodies and enzyme-tracers.	Arachidonic Acid	99-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
10221637-6	1999	Methylphenidate appeared to be involved primarily in pharmacokinetic interactions suggestive of cytochrome P450 inhibition while dextroamphetamine and pemoline were more often involved in apparent pharmacodynamic interactions.	Methylphenidate	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
9836023-3	1998	The present experiments were designed to identify the CYP isoenzymes involved in the metabolism of mCPP to its main metabolite p-hydroxy-mCPP (OH-mCPP).	1-(3-chlorophenyl)piperazine	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
9866708-0	1998	Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. We have used reversed phase-high performance liquid chromatography-mass spectrometry (RP-HPLC-MS) with an ion trap mass spectrometer to study the metabolism of arachidonic and linoleic acids by human recombinant cytochrome P450 (CYP) enzymes.	arachidonic	43-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
9866708-0	1998	Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. We have used reversed phase-high performance liquid chromatography-mass spectrometry (RP-HPLC-MS) with an ion trap mass spectrometer to study the metabolism of arachidonic and linoleic acids by human recombinant cytochrome P450 (CYP) enzymes.	Linoleic Acids	59-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
9866708-0	1998	Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. We have used reversed phase-high performance liquid chromatography-mass spectrometry (RP-HPLC-MS) with an ion trap mass spectrometer to study the metabolism of arachidonic and linoleic acids by human recombinant cytochrome P450 (CYP) enzymes.	arachidonic	295-306	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
9866708-0	1998	Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. We have used reversed phase-high performance liquid chromatography-mass spectrometry (RP-HPLC-MS) with an ion trap mass spectrometer to study the metabolism of arachidonic and linoleic acids by human recombinant cytochrome P450 (CYP) enzymes.	Linoleic Acids	311-325	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
9866708-9	1998	RP-HPLC-MS with MS2 seems to be useful for rapid identification of fatty acid metabolites in complex mixtures formed by cytochrome P450.	Fatty Acids	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-135
9836023-3	1998	The present experiments were designed to identify the CYP isoenzymes involved in the metabolism of mCPP to its main metabolite p-hydroxy-mCPP (OH-mCPP).	p-hydroxy-mcpp	127-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
9836023-3	1998	The present experiments were designed to identify the CYP isoenzymes involved in the metabolism of mCPP to its main metabolite p-hydroxy-mCPP (OH-mCPP).	oh-mcpp	143-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
9836023-4	1998	METHODS: The rate of production of OH-mCPP from mCPP was correlated with isoform activities in a panel of human liver microsomes, was assessed using a panel of individual complementary DNA-expressed human CYP isoenzymes, and was investigated in the presence of a specific inhibitor of CYP2D6.	oh-mcpp	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
9836023-4	1998	METHODS: The rate of production of OH-mCPP from mCPP was correlated with isoform activities in a panel of human liver microsomes, was assessed using a panel of individual complementary DNA-expressed human CYP isoenzymes, and was investigated in the presence of a specific inhibitor of CYP2D6.	1-(3-chlorophenyl)piperazine	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-208
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	bufuralol	169-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	inn	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	inn	22-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
9918136-5	1998	Adduct formation in stimulated neutrophils was inhibited 80% by the myeloperoxidase inhibitor sodium azide (1 mM) but was not affected by proadifen (100 microM), indomethacin (100 microM), or eicosatetraynoic acid (100 microM), inhibitors of cytochrome P450, prostaglandin synthetase, and lipoxygenase, respectively.	Sodium Azide	94-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	242-301
9815106-2	1998	Liver cytochrome P-450 enzymes also catalyze the oxidative cleavage of C==N bonds of compounds containing a -C(NH2)==NOH function, producing NO in vitro.	2-amino-5-chlorobenzophenone N-hydroxyamidinohydrazone	117-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-22
9815106-6	1998	Ethoxyresorufin (10(-7) to 10(-4) M), an alternate cytochrome P-450 substrate, inhibited formamidoxime-induced cGMP accumulation as well as tracheal ring relaxation in cultured tracheal smooth muscle cells.	ethoxyresorufin	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
9815106-6	1998	Ethoxyresorufin (10(-7) to 10(-4) M), an alternate cytochrome P-450 substrate, inhibited formamidoxime-induced cGMP accumulation as well as tracheal ring relaxation in cultured tracheal smooth muscle cells.	formamidoxime	89-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
9815106-8	1998	These results suggest that NO can be synthesized from formamidoxime in tracheal smooth muscle cells, presumably by a reaction catalyzed by cytochrome P-450.	formamidoxime	54-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
9820175-0	1998	Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.	satraplatin	57-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
9820175-0	1998	Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.	Platinum	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
9820175-4	1998	In this study, the capacity of JM216 to inhibit cytochrome P450 (CYP) in human liver microsomes was investigated by measuring the inhibition potential (IC50 and Ki) on prototype reactions.	satraplatin	31-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
9820175-4	1998	In this study, the capacity of JM216 to inhibit cytochrome P450 (CYP) in human liver microsomes was investigated by measuring the inhibition potential (IC50 and Ki) on prototype reactions.	satraplatin	31-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-68
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	Testosterone	36-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	Paclitaxel	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	ethoxyresorufin	93-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	coumarin	129-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	aniline	148-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9799565-7	1998	Upon reconstitution with P450 reductase and phospholipid, CYP4F2 converted LTB4 to 20-OH LTB4 at a turnover rate of 392 pmol/min/nmol P450, whereas the other human liver P450s tested, including CYP4A11, exhibited neglible LTB4 omega-hydroxylase activity.	20-oh ltb4	83-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-244
9820175-6	1998	JM216 inhibited the catalytic activities of CYP isozymes.	satraplatin	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
9825831-2	1998	To determine which cytochrome P450 is involved in taxotere biotransformation, 11 cDNA-expressed human cytochrome P450s were examined for their activity in the metabolism of taxotere and its derivatives.	Docetaxel	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9790080-6	1998	The MFO activities associated with different cytochrome P-450 isoenzymes decreased to different extents in the presence of bile with the O-dealkylation of pentoxyresorufin being more labile than that of ethoxyresorufin.	pentoxyresorufin	155-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
9790080-6	1998	The MFO activities associated with different cytochrome P-450 isoenzymes decreased to different extents in the presence of bile with the O-dealkylation of pentoxyresorufin being more labile than that of ethoxyresorufin.	ethoxyresorufin	203-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	Carbon-14	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	Carbon-14	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	129-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	Carbon-14	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	Carbon-14	175-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	179-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9763401-1	1998	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and its N-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	179-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
9844795-0	1998	Alcohol-associated rhabdomyolysis: ethanol induction of cytochrome P450 may potentiate myotoxicity.	Alcohols	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9844795-0	1998	Alcohol-associated rhabdomyolysis: ethanol induction of cytochrome P450 may potentiate myotoxicity.	Ethanol	35-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
9844795-2	1998	Ethanol is a potent inducer of cytochrome P450.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
9844795-4	1998	Accordingly, some alcohol-associated myotoxicity could be related to skeletal muscle cytochrome P450 induction by ethanol leading to the production of toxic metabolites of other compounds that then injure muscle.	Alcohols	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
9844795-4	1998	Accordingly, some alcohol-associated myotoxicity could be related to skeletal muscle cytochrome P450 induction by ethanol leading to the production of toxic metabolites of other compounds that then injure muscle.	Ethanol	114-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
9844795-5	1998	The recent identification and localization of cytochrome P450 on skeletal muscle sarcoplasmic reticulum provides supportive evidence for this potential role of ethanol in the pathogenesis of alcohol-associated rhabdomyolysis.	Ethanol	160-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
9844795-5	1998	The recent identification and localization of cytochrome P450 on skeletal muscle sarcoplasmic reticulum provides supportive evidence for this potential role of ethanol in the pathogenesis of alcohol-associated rhabdomyolysis.	Alcohols	191-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
9840430-0	1998	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.	Clozapine	80-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-41
9920346-0	1998	The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity.	1-aminobenzotriazole	39-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9920346-0	1998	The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity.	Zymosan	80-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9825831-2	1998	To determine which cytochrome P450 is involved in taxotere biotransformation, 11 cDNA-expressed human cytochrome P450s were examined for their activity in the metabolism of taxotere and its derivatives.	Docetaxel	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
9825831-2	1998	To determine which cytochrome P450 is involved in taxotere biotransformation, 11 cDNA-expressed human cytochrome P450s were examined for their activity in the metabolism of taxotere and its derivatives.	Docetaxel	173-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9825831-2	1998	To determine which cytochrome P450 is involved in taxotere biotransformation, 11 cDNA-expressed human cytochrome P450s were examined for their activity in the metabolism of taxotere and its derivatives.	Docetaxel	173-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-117
9756035-2	1998	The present study investigated the role of human cytochrome P-450 (CYP) enzymes in sulfoxidation and thiono-oxidation of DDTC-Me, intermediary steps in the activation of disulfiram.	methyl diethyldithiocarbamate	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
9756035-2	1998	The present study investigated the role of human cytochrome P-450 (CYP) enzymes in sulfoxidation and thiono-oxidation of DDTC-Me, intermediary steps in the activation of disulfiram.	methyl diethyldithiocarbamate	121-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
9756035-2	1998	The present study investigated the role of human cytochrome P-450 (CYP) enzymes in sulfoxidation and thiono-oxidation of DDTC-Me, intermediary steps in the activation of disulfiram.	Disulfiram	170-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
9756035-2	1998	The present study investigated the role of human cytochrome P-450 (CYP) enzymes in sulfoxidation and thiono-oxidation of DDTC-Me, intermediary steps in the activation of disulfiram.	Disulfiram	170-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
9733665-0	1998	Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen.	Methoxychlor	74-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
9733665-3	1998	We have elucidated the human cytochrome P450 enzymes responsible for conversion of methoxychlor into its major metabolite, the mono-O-demethylated derivative (mono-OH-M) that is estrogenic.	Methoxychlor	83-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
9733665-3	1998	We have elucidated the human cytochrome P450 enzymes responsible for conversion of methoxychlor into its major metabolite, the mono-O-demethylated derivative (mono-OH-M) that is estrogenic.	mono-o	127-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
9733665-3	1998	We have elucidated the human cytochrome P450 enzymes responsible for conversion of methoxychlor into its major metabolite, the mono-O-demethylated derivative (mono-OH-M) that is estrogenic.	mono-oh-m	159-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
9732390-0	1998	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone.	iloperidone	160-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-120
9817620-2	1998	Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans, some of which play a key role in the oxidation and hence the elimination of numerous drugs, including the SSRIs.	Heme	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9817620-2	1998	Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans, some of which play a key role in the oxidation and hence the elimination of numerous drugs, including the SSRIs.	Heme	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	228-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
9732391-3	1998	The relationships were assessed with six different human liver microsomes between the 3"-demethylation of etoposide and metabolic activities for substrate probes of the respective CYP isoforms, showing a significant correlation (r = 0.	Etoposide	106-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
9732390-2	1998	The metabolism of iloperidone was studied in human liver microsomes to define the metabolic pathways and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of major iloperidone metabolites.	iloperidone	18-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
9732390-2	1998	The metabolism of iloperidone was studied in human liver microsomes to define the metabolic pathways and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of major iloperidone metabolites.	iloperidone	18-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
9732390-2	1998	The metabolism of iloperidone was studied in human liver microsomes to define the metabolic pathways and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of major iloperidone metabolites.	iloperidone	191-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-136
9732391-7	1998	Among the nine recombinant human CYP isoforms, CYP3A4 exhibited the highest catalytic activity with respect to etoposide 3"-demethylation, compared with the minor activities of CYP1A2 and 2E1.	etoposide 3"	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-36
9732390-2	1998	The metabolism of iloperidone was studied in human liver microsomes to define the metabolic pathways and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of major iloperidone metabolites.	iloperidone	191-202	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
9732390-13	1998	The power of liquid chromatography/mass spectrometry in greatly accelerating the process of identifying the human liver CYP isoforms involved in the metabolism of iloperidone was demonstrated in this study.	iloperidone	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
10375803-1	1998	AIM: To study the effect of cytochrome P-450 (CYP450) inhibitors on clomipramine (Clo) N-demethylation in vitro.	Clomipramine	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
9916257-0	1998	[Effect of cytochrome P450-dependent metabolites of arachidonic acid on the functional state of vessels].	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
9916257-1	1998	The present paper reviews recent studies about the role of the cytochrome P-450-dependent arachidonic acid metabolites.	Arachidonic Acid	90-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
10375803-1	1998	AIM: To study the effect of cytochrome P-450 (CYP450) inhibitors on clomipramine (Clo) N-demethylation in vitro.	Clomipramine	68-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
10375803-1	1998	AIM: To study the effect of cytochrome P-450 (CYP450) inhibitors on clomipramine (Clo) N-demethylation in vitro.	Clomipramine	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
10375803-1	1998	AIM: To study the effect of cytochrome P-450 (CYP450) inhibitors on clomipramine (Clo) N-demethylation in vitro.	Clomipramine	82-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-52
9767182-3	1998	Active oxygen species formed by cytochrome P-450 isoforms can simultaneously act as stimulators of proliferation and inhibitors of intercellular communications.	Oxygen	7-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9731223-3	1998	In this study, we investigated the formation of dopamine from trace amines, using human hepatic microsomes and human cytochrome P450 (CYP) isoforms expressed in yeast.	Dopamine	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
9731223-3	1998	In this study, we investigated the formation of dopamine from trace amines, using human hepatic microsomes and human cytochrome P450 (CYP) isoforms expressed in yeast.	Dopamine	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-137
9731223-4	1998	Among the 11 isoforms of human CYP expressed in yeast, CYP2D6 was the only isoform exhibiting strong ability to convert p-tyramine and m-tyramine to dopamine.	Tyramine	120-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
9731223-4	1998	Among the 11 isoforms of human CYP expressed in yeast, CYP2D6 was the only isoform exhibiting strong ability to convert p-tyramine and m-tyramine to dopamine.	3-tyramine	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
9731223-4	1998	Among the 11 isoforms of human CYP expressed in yeast, CYP2D6 was the only isoform exhibiting strong ability to convert p-tyramine and m-tyramine to dopamine.	Dopamine	149-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-34
9723818-9	1998	The changes in ethinyl oestradiol pharmacokinetics were consistent with an increase in clearance from enzymatic induction of glucuronidation and/or cytochrome P450 hydroxylation.	Ethinyl Estradiol	15-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
9705755-1	1998	The dietary mutagens 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) are activated to genotoxins by rat and human liver cytochrome P450 (P450) 1A1- and 1A2-mediated N-oxidation.	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	21-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-211
9705755-1	1998	The dietary mutagens 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) are activated to genotoxins by rat and human liver cytochrome P450 (P450) 1A1- and 1A2-mediated N-oxidation.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	79-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-211
9694927-2	1998	Both compounds use the same cytochrome-P450 metabolic pathway, resulting in an increase in plasma concentration of terfenadine.	Terfenadine	115-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
9694927-12	1998	These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs.	Terfenadine	292-303	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-268
9694927-12	1998	These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs.	Ketoconazole	100-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-268
9701998-0	1998	[Methods of study on cytochrome P450 in relation to the metabolism and toxicity of alcohol and drugs].	Alcohols	83-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
9714539-2	1998	Here we report on the immobilisation of a fusion protein between plant cytochrome P450-71B1 (CYP71B1) and its electron donor, plant NADPH cytochrome P450 reductase using an oil-in-water macro-emulsion, termed polyaphron, which contains a proportion of internal organic phase (phi) greater than 0.74.	Oils	173-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
9714539-2	1998	Here we report on the immobilisation of a fusion protein between plant cytochrome P450-71B1 (CYP71B1) and its electron donor, plant NADPH cytochrome P450 reductase using an oil-in-water macro-emulsion, termed polyaphron, which contains a proportion of internal organic phase (phi) greater than 0.74.	Water	180-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
9714539-2	1998	Here we report on the immobilisation of a fusion protein between plant cytochrome P450-71B1 (CYP71B1) and its electron donor, plant NADPH cytochrome P450 reductase using an oil-in-water macro-emulsion, termed polyaphron, which contains a proportion of internal organic phase (phi) greater than 0.74.	polyaphron	209-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	28-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	28-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-109
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-109
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	Arachidonic Acid	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
9651188-1	1998	We previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE) is an endogenous cytochrome P450 (cP450) 4A metabolite of arachidonic acid (AA) in human lung tissue, and is a potent cyclooxygenase-dependent vasodilator of isolated pulmonary arteries.	Arachidonic Acid	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-109
9721336-5	1998	It has been known for years that NO also binds to the heme moiety of cytochrome P-450 (CYP) with high affinity.	Heme	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
9721336-5	1998	It has been known for years that NO also binds to the heme moiety of cytochrome P-450 (CYP) with high affinity.	Heme	54-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
9721340-6	1998	The reduction of NO2- ions to NO is realized by electron-donor systems with the participation of NADH, NADPH, flavoproteins, and cytochrome oxidase in mitochondria and by NADH, NADPH, flavoproteins, and cytochrome P-450 in endoplasmic reticulum.	Nitrogen Dioxide	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	203-219
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Diphenhydramine	31-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Chlorpheniramine	48-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Clemastine	66-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Perphenazine	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Hydroxyzine	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9616188-1	1998	Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6.	Tripelennamine	109-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
9744552-0	1998	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.	Pantoprazole	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
9744552-2	1998	In this study, the cytochrome P450 (CYP) induction potential of pantoprazole (PAN) was evaluated and compared to two other proton pump inhibitors (PPIs), omeprazole (OM) and lansoprazole (LAN).	Pantoprazole	64-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9744552-2	1998	In this study, the cytochrome P450 (CYP) induction potential of pantoprazole (PAN) was evaluated and compared to two other proton pump inhibitors (PPIs), omeprazole (OM) and lansoprazole (LAN).	Pantoprazole	64-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
9705898-8	1998	Experiments using human cell line cells either expressing or not expressing human cytochrome P450 enzymes in assays of acute toxicity (MTT assays) have demonstrated a directly toxic potential of AFM1 in the absence of metabolic activation, in contrast to AFB1.	monooxyethylene trimethylolpropane tristearate	135-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
9771309-0	1998	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol.	Propofol	91-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
9771309-2	1998	On the basis of potential influence of propofol on the metabolism of co-administered agents, many investigators have evaluated the effects of propofol on cytochrome P450 (CYP) activities.	Propofol	142-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
9771309-2	1998	On the basis of potential influence of propofol on the metabolism of co-administered agents, many investigators have evaluated the effects of propofol on cytochrome P450 (CYP) activities.	Propofol	142-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
9771309-3	1998	CYP isoforms involved in propofol metabolism are not defined.	Propofol	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
9771309-4	1998	In this study, our objective was to elucidate further the CYP isoforms responsible for the hydroxylation of propofol.	Propofol	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
9771309-10	1998	This low specificity among CYP isoforms may contribute to the low interindividual variability (two-fold) and may contribute to the low level of metabolic drug interactions observed with propofol.	Propofol	186-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
9616191-3	1998	Ritonavir was similarly biotransformed by microsomes containing expressed CYP3A4 or CYP3A5 isozymes (KM = 0.05-0.07 microM, Vmax = 1-1.4 nmol/min/nmol CYP).	Ritonavir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
9616191-4	1998	In contrast, both the patterns of metabolites and the enzyme kinetic parameters for the metabolism of indinavir by expressed CYP3A5 (KM = 0.21 microM, Vmax = 0.24 nmol/min/nmol CYP) and CYP3A4 (KM = 0.04 microM, Vmax = 0.68 nmol/min/nmol CYP) were different.	Indinavir	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-128
9616191-4	1998	In contrast, both the patterns of metabolites and the enzyme kinetic parameters for the metabolism of indinavir by expressed CYP3A5 (KM = 0.21 microM, Vmax = 0.24 nmol/min/nmol CYP) and CYP3A4 (KM = 0.04 microM, Vmax = 0.68 nmol/min/nmol CYP) were different.	Indinavir	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-180
9616193-0	1998	N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450.	ebastine	36-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
9616193-2	1998	The present study was performed to characterize the cytochrome P450 (CYP) isoforms responsible for ebastine N-dealkylation and hydroxylation.	ebastine	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
9616193-2	1998	The present study was performed to characterize the cytochrome P450 (CYP) isoforms responsible for ebastine N-dealkylation and hydroxylation.	ebastine	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
9616193-5	1998	In a panel of 14 human liver microsomal preparations, the rate of dealkylation showed a highly significant correlation with CYP3A-mediated testosterone 6beta-hydroxylation but not with reactions of seven other CYP isoforms.	Testosterone	139-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-127
9616193-9	1998	Among 12 cDNA-expressed human CYP isoforms, which account for up to 70% of the total CYP enzyme content in human liver, CYP3A4 alone metabolized ebastine; the ratio of des-BP to M-OH formation was 12:1.	ebastine	145-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
9578592-1	1998	In this paper two hypotheses are tested: (i) the active oxygen species is similar in energetics for all cytochrome P450 (CYP) enzymes and (ii) linear free-energy relationships can be used to evaluate the mechanism of the reaction of these enzymes.	Oxygen	56-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
9578592-0	1998	Evaluation of cytochrome P450 mechanism and kinetics using kinetic deuterium isotope effects.	Deuterium	67-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
9578592-1	1998	In this paper two hypotheses are tested: (i) the active oxygen species is similar in energetics for all cytochrome P450 (CYP) enzymes and (ii) linear free-energy relationships can be used to evaluate the mechanism of the reaction of these enzymes.	Oxygen	56-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
9606477-7	1998	Phenytoin, phenobarbital, and carbamazepine induce CYP and UGT enzymes.	Phenytoin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
9606477-7	1998	Phenytoin, phenobarbital, and carbamazepine induce CYP and UGT enzymes.	Phenobarbital	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
9606477-7	1998	Phenytoin, phenobarbital, and carbamazepine induce CYP and UGT enzymes.	Carbamazepine	30-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-54
9635877-2	1998	They are thought to be metabolically activated by N-hydroxylation, catalysed by cytochrome P450 (CYP), followed by O-acetylation catalysed by N-acetyltransferases.	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
9635877-2	1998	They are thought to be metabolically activated by N-hydroxylation, catalysed by cytochrome P450 (CYP), followed by O-acetylation catalysed by N-acetyltransferases.	Nitrogen	50-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
9635877-7	1998	The higher adduct levels observed in cells treated with the N-OH metabolites suggests that N-hydroxylation is the rate-limiting step in HMECs and this may be due to low CYP levels.	n-oh	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
9635877-7	1998	The higher adduct levels observed in cells treated with the N-OH metabolites suggests that N-hydroxylation is the rate-limiting step in HMECs and this may be due to low CYP levels.	Nitrogen	60-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
9594936-11	1998	Itraconazole has an affinity for mammalian cytochrome P-450 enzymes as well as for fungal P-450-dependent enzyme, and thus has the potential for clinically important interactions (e.g., astemizole, terfenadine, rifampin, oral contraceptives, H2 receptor antagonists, warfarin, cyclosporine).	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
9630823-1	1998	OBJECTIVE: To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.	vesnarinone	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
9630823-1	1998	OBJECTIVE: To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.	vesnarinone	87-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
9630823-1	1998	OBJECTIVE: To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.	vesnarinone	216-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
9630823-1	1998	OBJECTIVE: To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.	vesnarinone	216-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
9654063-4	1998	A reaction pathway like that of cytochrome P-450 implies oxygen transfer to the substrate from the as yet uncharacterized iron-oxo species formed in the reaction of the heine cofactor with H2O2.	Oxygen	57-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9654063-4	1998	A reaction pathway like that of cytochrome P-450 implies oxygen transfer to the substrate from the as yet uncharacterized iron-oxo species formed in the reaction of the heine cofactor with H2O2.	iron-oxo	122-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9654063-4	1998	A reaction pathway like that of cytochrome P-450 implies oxygen transfer to the substrate from the as yet uncharacterized iron-oxo species formed in the reaction of the heine cofactor with H2O2.	Hydrogen Peroxide	189-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9654063-6	1998	The results of the present study exclude Fenton-type chemistry and prove that the minicatalyst is able to catalyze the oxygen incorporation by both peroxidase and cytochrome P-450 types of reaction pathways, while exchange occurs between the high-valency iron-oxo species and H2O.	Oxygen	119-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
9654063-6	1998	The results of the present study exclude Fenton-type chemistry and prove that the minicatalyst is able to catalyze the oxygen incorporation by both peroxidase and cytochrome P-450 types of reaction pathways, while exchange occurs between the high-valency iron-oxo species and H2O.	iron-oxo	255-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
9654063-6	1998	The results of the present study exclude Fenton-type chemistry and prove that the minicatalyst is able to catalyze the oxygen incorporation by both peroxidase and cytochrome P-450 types of reaction pathways, while exchange occurs between the high-valency iron-oxo species and H2O.	Water	276-279	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
9580580-0	1998	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.	Pimozide	87-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
9580580-1	1998	Using human liver microsomes (HLMs) and recombinant human cytochrome P450 (CYP450) isoforms, we identified the major route of pimozide metabolism, the CYP450 isoforms involved, and documented the inhibitory effect of pimozide on CYP450 isoforms.	Pimozide	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
9518732-23	1998	The present data suggest that cytochrome P450 modulates cardiac ICa and cell contraction, and the modulation may result from changes in intracellular levels of cAMP by P450- mediated metabolites of arachidonic acid.	Cyclic AMP	160-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
9518732-23	1998	The present data suggest that cytochrome P450 modulates cardiac ICa and cell contraction, and the modulation may result from changes in intracellular levels of cAMP by P450- mediated metabolites of arachidonic acid.	Arachidonic Acid	198-214	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
9580580-1	1998	Using human liver microsomes (HLMs) and recombinant human cytochrome P450 (CYP450) isoforms, we identified the major route of pimozide metabolism, the CYP450 isoforms involved, and documented the inhibitory effect of pimozide on CYP450 isoforms.	Pimozide	126-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-81
9591923-3	1998	Ethanol is consumed worldwide in tremendous amounts and is an effective inducer of hepatic drug metabolism, especially involving pathways accomplished by the CYP2E1 isoform of the cytochrome P-450 (CYP) superfamily.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
9579827-3	1998	Liarozole-fumarate is an anti-tumour drug that inhibits the cytochrome P450-dependent catabolism of ATRA.	liarozole	0-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
9579827-3	1998	Liarozole-fumarate is an anti-tumour drug that inhibits the cytochrome P450-dependent catabolism of ATRA.	Tretinoin	100-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
9531517-0	1998	Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450.	artemotil	14-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
9531517-2	1998	Studies were undertaken to determine which form(s) of human cytochrome P-450 catalyze the conversion of beta-arteether to its deethylated metabolite, dihydroqinghaosu (DQHS), itself a potent antimalarial compound.	artemotil	104-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
9531517-2	1998	Studies were undertaken to determine which form(s) of human cytochrome P-450 catalyze the conversion of beta-arteether to its deethylated metabolite, dihydroqinghaosu (DQHS), itself a potent antimalarial compound.	artenimol	150-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
9556346-0	1998	Step-scan time-resolved FTIR spectroscopy of cytochrome P-450cam carbon monoxide complex: a salt link involved in the ligand-rebinding process.	Carbon Monoxide	65-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
9556346-0	1998	Step-scan time-resolved FTIR spectroscopy of cytochrome P-450cam carbon monoxide complex: a salt link involved in the ligand-rebinding process.	Salts	92-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
9539102-1	1998	Leukotriene B4 (LTB4) omega-hydroxylase catalyzes the conversion of LTB4 into a biologically less active product, 20-hydroxy-LTB4.	5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid	114-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-39
9539102-5	1998	The cDNA of CYP4F3 contained 5050 nucleotides excluding the poly(A) tail.	Poly A	60-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-18
9533981-9	1998	Higher plasma drug concentrations may also be obtained by combining the drug with CYP blockers, such as ritonavir or ketoconazole.	Ritonavir	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
9533981-10	1998	Because of its metabolic interference with the CYP system, saquinavir cannot be coadministered with astemizole, terfenadine or cisapride.	Saquinavir	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-50
9492390-2	1998	We studied the human cytochrome P450 (CYP) isoform responsible for indomethacin O-demethylation, the major metabolic pathway for indomethacin.	Indomethacin	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
9492390-2	1998	We studied the human cytochrome P450 (CYP) isoform responsible for indomethacin O-demethylation, the major metabolic pathway for indomethacin.	Indomethacin	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
9492390-2	1998	We studied the human cytochrome P450 (CYP) isoform responsible for indomethacin O-demethylation, the major metabolic pathway for indomethacin.	Indomethacin	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
9591923-3	1998	Ethanol is consumed worldwide in tremendous amounts and is an effective inducer of hepatic drug metabolism, especially involving pathways accomplished by the CYP2E1 isoform of the cytochrome P-450 (CYP) superfamily.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161
9492390-2	1998	We studied the human cytochrome P450 (CYP) isoform responsible for indomethacin O-demethylation, the major metabolic pathway for indomethacin.	Indomethacin	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
9600717-6	1998	Ketoconazole, a relatively specific CYP 3A4 inhibitor, inhibited the reaction; the concentration resulting in 50% of maximum inhibition, IC50, was 0.15 microM and the inhibition constant, Ki, was &lt; 0.04 microM in five of six livers tested.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
9523980-5	1998	An in vitro metabolic study using recombinant human cytochrome P450 (CYP) isoforms indicated that oxidation of both bisoprolol enantiomers was catalyzed by the two isoforms, CYP2D6 and CYP3A4.	Bisoprolol	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
9523980-5	1998	An in vitro metabolic study using recombinant human cytochrome P450 (CYP) isoforms indicated that oxidation of both bisoprolol enantiomers was catalyzed by the two isoforms, CYP2D6 and CYP3A4.	Bisoprolol	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
9600717-12	1998	These results show that CYP 3A4 is the primary hepatic CYP isoform mediating the N-demethylation of adinazolam and NDMAD.	Nitrogen	81-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
9600717-12	1998	These results show that CYP 3A4 is the primary hepatic CYP isoform mediating the N-demethylation of adinazolam and NDMAD.	adinazolam	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
9600717-12	1998	These results show that CYP 3A4 is the primary hepatic CYP isoform mediating the N-demethylation of adinazolam and NDMAD.	mono-N-demethyladinazolam	115-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
9600717-13	1998	Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD.	Ketoconazole	64-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
9600717-13	1998	Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD.	Erythromycin	80-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
9600717-13	1998	Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD.	adinazolam	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
9600717-13	1998	Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD.	adinazolam	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
9442307-6	1998	At the biochemical level the tests can indicate that the organism has been exposed to certain groups of chemicals (for example cytochrome P-450 enzymes responding to PAHs or metallothioneins responding to heavy metals).	Polycyclic Aromatic Hydrocarbons	166-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-143
9481028-2	1998	Premature infants have reduced activity of cytochrome p-450, the system responsible for metabolism of cisapride, which could lead to QT prolongation.	Cisapride	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Methylcholanthrene	159-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
9458080-1	1998	Isothiocyanates exert strong anticarcinogenic effects in a number of animal models of cancer, presumably by modulation of xenobiotic-metabolizing enzymes, such as by inhibition of cytochrome P-450 and/or by induction of phase II detoxifying enzymes.	Isothiocyanates	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
9498238-0	1998	Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium.	Tamoxifen	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-29
9498238-7	1998	These data suggest that the human endometrial epithelium has the potential of producing CYP enzymes known to generate genotoxic intermediates from tamoxifen and metabolites that affect oestrogen receptors.	Tamoxifen	147-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
9493761-17	1998	Examples of human teratogens that are substrates for CYP enzymes include thalidomide, phenytoin, ethanol, and several hormonal agents.	Thalidomide	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
9493761-17	1998	Examples of human teratogens that are substrates for CYP enzymes include thalidomide, phenytoin, ethanol, and several hormonal agents.	Phenytoin	86-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
9493761-17	1998	Examples of human teratogens that are substrates for CYP enzymes include thalidomide, phenytoin, ethanol, and several hormonal agents.	Ethanol	97-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
9763205-5	1998	The inhibition studies in dog liver microsomes using CYP isoform-selective inhibitors indicated that the O-deisopropylation of both bisoprolol enantiomers was mediated via the CYP2D and CYP3A subfamily, and suggested that high-affinity oxidation was dependent on CYP2D.	Bisoprolol	132-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
9740537-7	1998	Unlike other drugs of its class, cerivastatin has a dual metabolic pathway, with the involvement of more than one CYP isozyme.	cerivastatin	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
9543613-2	1998	Therefore, drugs such as cimetidine, which inhibit the cytochrome P-450 enzyme system or reduce liver blood flow, may reduce the plasma clearance of epirubicin.	Cimetidine	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
9543613-2	1998	Therefore, drugs such as cimetidine, which inhibit the cytochrome P-450 enzyme system or reduce liver blood flow, may reduce the plasma clearance of epirubicin.	Epirubicin	149-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
9763205-6	1998	The kinds of CYP subfamilies in dogs, which contribute to the metabolism of bisoprolol enantiomers, were the same as those in humans.	Bisoprolol	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
9763205-9	1998	Therefore, the species difference in the R/S ratio of metabolic clearance for the oxidation of bisoprolol enantiomers (dog &gt; human) is mainly due to the species difference in the stereoselectivity of one of the cytochrome P450 subfamilies (CYP3A).	Bisoprolol	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	214-229
9394028-13	1997	The correlation data was confirmed by inhibition studies and cDNA expressed cytochrome P450 systems demonstrating that the biotransformation of tazofelone to its metabolites is primarily mediated by CYP3A.	tazofelone	144-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
9366245-7	1997	This data suggests that metabolism of hepoxilin A3 occurs in intact human neutrophils through omega-oxidation, is likely located in the mitochondrial compartment of the cell (inhibition by CCCP) and is carried out by an activity that is independent of the well characterized, relatively stable microsomal LTB4 omega-hydroxylase.	8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	305-327
9394024-0	1997	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes.	lisofylline	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9394024-0	1997	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes.	Pentoxifylline	63-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9394024-1	1997	We describe the kinetics of pentoxifylline formation from lisofylline in human liver microsomes using selective inhibitors of cytochrome P450 isozymes, correlation studies with specific isozyme activities, and cDNA-expressed human CYP1A2 and 2E1.	Pentoxifylline	28-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
9394024-9	1997	Baculovirus insect cell expressed human CYP1A2 formed pentoxifylline at 0.987 nmol/min/nmol cytochrome P450 at 5 microM lisofylline.	Pentoxifylline	54-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
9394024-9	1997	Baculovirus insect cell expressed human CYP1A2 formed pentoxifylline at 0.987 nmol/min/nmol cytochrome P450 at 5 microM lisofylline.	lisofylline	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
9394027-0	1997	Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.	Clozapine	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
9394027-1	1997	The metabolism of clozapine was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6, and 2E1.	Clozapine	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-91
9394027-1	1997	The metabolism of clozapine was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6, and 2E1.	Clozapine	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
9394028-0	1997	In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone.	tazofelone	103-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
9394028-8	1997	Tazofelone was incubated at 20 microM concentration with human microsomes to determine which of the cytochrome P450 isozyme(s) is involved in the oxidation of tazofelone.	tazofelone	159-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
9429083-6	1997	Quercetin inhibited activity of human cytochrome P-450 towards ethoxycoumarin and ethylresorufin at relatively low substrate concentrations (0.1 microM and above).	Quercetin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
9429083-6	1997	Quercetin inhibited activity of human cytochrome P-450 towards ethoxycoumarin and ethylresorufin at relatively low substrate concentrations (0.1 microM and above).	3-ethoxychromen-2-one	63-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
9429083-6	1997	Quercetin inhibited activity of human cytochrome P-450 towards ethoxycoumarin and ethylresorufin at relatively low substrate concentrations (0.1 microM and above).	ethylresorufin	82-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
9385444-1	1997	Human cytochrome P450 (P450) 3A is known to be involved in the formation of both aflatoxin B1-exo-8,9-epoxide (exo-epoxidation) and aflatoxin Q1 (3 alpha-hydroxylation).	aflatoxin B1-2,3-oxide	81-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-31
9385444-1	1997	Human cytochrome P450 (P450) 3A is known to be involved in the formation of both aflatoxin B1-exo-8,9-epoxide (exo-epoxidation) and aflatoxin Q1 (3 alpha-hydroxylation).	aflatoxin Q1	132-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-31
9399333-0	1997	Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.	Amitriptyline	43-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
9399333-1	1997	The metabolism of amitriptyline was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6 and 2E1.	Amitriptyline	18-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
9399333-1	1997	The metabolism of amitriptyline was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6 and 2E1.	Amitriptyline	18-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
9385296-1	1997	Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9357977-0	1997	Crystal structure of cytochrome P-450cam complexed with the (1S)-camphor enantiomer.	Camphor	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
9357977-1	1997	The crystal structure of cytochrome P-450cam complexed with the enantiomer (1S)-camphor has been solved to 1.8 angstroms resolution and compared with the structure of the (1R)-camphor P-450cam complex.	Camphor	80-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
9357977-1	1997	The crystal structure of cytochrome P-450cam complexed with the enantiomer (1S)-camphor has been solved to 1.8 angstroms resolution and compared with the structure of the (1R)-camphor P-450cam complex.	(1r)-camphor p	171-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
9353130-14	1997	These results demonstrate that rat and human hepatocytes preserve the major forms of CYP isozymes and phase II activities and respond to inducing drugs such as rifampicin.	Rifampin	160-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9350042-0	1997	A microassay for the detection of low levels of cytochrome P450 O-deethylation activities with alkoxyresorufin substrates.	alkoxyresorufin	95-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
9353130-3	1997	Basal levels of cytochrome P-450 (CYP) isozymes were characterized by measuring ethoxyresorufin O-deethylation (EROD), ethoxycoumarin O-deethylation (ECOD), and the specific oxidation of testosterone (T).	ethoxyresorufin	80-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
9353130-3	1997	Basal levels of cytochrome P-450 (CYP) isozymes were characterized by measuring ethoxyresorufin O-deethylation (EROD), ethoxycoumarin O-deethylation (ECOD), and the specific oxidation of testosterone (T).	ethoxyresorufin	80-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
9353130-3	1997	Basal levels of cytochrome P-450 (CYP) isozymes were characterized by measuring ethoxyresorufin O-deethylation (EROD), ethoxycoumarin O-deethylation (ECOD), and the specific oxidation of testosterone (T).	3-ethoxychromen-2-one	119-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
9353130-3	1997	Basal levels of cytochrome P-450 (CYP) isozymes were characterized by measuring ethoxyresorufin O-deethylation (EROD), ethoxycoumarin O-deethylation (ECOD), and the specific oxidation of testosterone (T).	Testosterone	187-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
9353130-3	1997	Basal levels of cytochrome P-450 (CYP) isozymes were characterized by measuring ethoxyresorufin O-deethylation (EROD), ethoxycoumarin O-deethylation (ECOD), and the specific oxidation of testosterone (T).	Testosterone	187-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
9391787-0	1997	Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man.	Rifampin	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
9391787-10	1997	CONCLUSION: A fourfold increase of urinary 6-beta-hydroxycortisol output after induction of cytochrome P-450 by rifampicin is associated with a significant but less than 10% increase in human liver volume.	6 beta-hydroxycortisol	43-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
9391787-10	1997	CONCLUSION: A fourfold increase of urinary 6-beta-hydroxycortisol output after induction of cytochrome P-450 by rifampicin is associated with a significant but less than 10% increase in human liver volume.	Rifampin	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
9358560-0	1997	Biomimetic metabolism of artelinic acid by chemical cytochrome P-450 model systems.	artelinic acid	25-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
9430380-0	1997	Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9430380-0	1997	Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells.	14,15-epoxy-5,8,11-eicosatrienoic acid	86-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9430380-1	1997	Arachidonic acid is converted to epoxyeicosatrienoic acids (EETs) by cytochrome P450 monooxygenases.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
9440131-0	1997	Cytochrome P450 metabolites of arachidonic acid in human placenta.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9358560-1	1997	PURPOSE: To study the reaction of artelinic acid with chemical model systems of cytochrome P-450 as a means of obtaining authentic samples of the putative metabolites necessary for identification of the mammalian metabolites of artelinic acid.	artelinic acid	34-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
9430380-1	1997	Arachidonic acid is converted to epoxyeicosatrienoic acids (EETs) by cytochrome P450 monooxygenases.	epoxyeicosatrienoic acids	33-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
9358560-1	1997	PURPOSE: To study the reaction of artelinic acid with chemical model systems of cytochrome P-450 as a means of obtaining authentic samples of the putative metabolites necessary for identification of the mammalian metabolites of artelinic acid.	artelinic acid	228-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
9430380-1	1997	Arachidonic acid is converted to epoxyeicosatrienoic acids (EETs) by cytochrome P450 monooxygenases.	eets	60-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
9358560-5	1997	CONCLUSIONS: Standards of possible metabolites of artelinic acid can be produced by the reaction of the compound with ferrous complexes that may simulate cytochrome P-450 catalyzed metabolism of xenobiotics.	artelinic acid	50-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-170
9344892-0	1997	Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isozymes: involvement of CYP2E1 and hydrolase A.	Urethane	14-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-79
9361171-1	1997	BACKGROUND: Omeprazole is eliminated almost completely by hepatic metabolism within the cytochrome P-450 system and might inhibit the oxidative metabolism of other drugs.	Omeprazole	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
9344892-2	1997	Our goal in this study was to investigate the in vitro isozyme-selective metabolism of EC in lung microsomes by cytochrome P450 and carboxylesterase enzymes.	Urethane	87-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-148
9303380-1	1997	Fluconazole, an inhibitor of certain human cytochrome P-450 isozymes, is used for the prevention and treatment of a broad range of fungal infections that predominantly affect immunocompromised individuals.	Fluconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
9526800-4	1997	The way to regulate ALAS-N in the liver is suitable to supply a constant level of heme for a family of drug metabolizing enzymes, cytochrome P-450 (CYP).	Heme	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
9526800-4	1997	The way to regulate ALAS-N in the liver is suitable to supply a constant level of heme for a family of drug metabolizing enzymes, cytochrome P-450 (CYP).	Heme	82-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151
9526800-7	1997	ALAS-N in undifferentiated erythroid cells, therefore, is suggested to produce heme for CYP, whereas heme for accumulating hemoglobin (Hb) in cells undergoing differentiation is synthesized via ALAS-E.	Heme	79-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
9270401-2	1997	TDP has been associated with terfenadine use in cases of liver disease, electrolyte abnormalities, concomitant administration of drugs that inhibit cytochrome P-450, or deliberate overdose.	Terfenadine	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
9381730-0	1997	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker.	mepirodipine	127-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9305589-0	1997	Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.	Phenytoin	17-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	Phenytoin	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	Phenytoin	85-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	Phenol	98-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	catechol	109-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	hydroxyphenytoin	131-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	hydroxyphenytoin	171-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9305589-1	1997	The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4"-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3",4"-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes.	5-(3,4-dihydroxyphenyl)-5-phenylhydantoin	181-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Paclitaxel	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Paclitaxel	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Docetaxel	169-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Docetaxel	169-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
9350229-2	1997	The induction potential of metanil yellow on hepatic microsomal cytochrome P-450 (P-450)-dependent monooxygenases and cytosolic detoxification enzymes, namely, glutathione S-transferase (GST) and quinone reductase (QR), was investigated.	metanil yellow	27-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
9242187-1	1997	Epoxyeicosatrienoic acids (EETs) are potent endothelium-derived vasodilators formed from cytochrome P-450 metabolism of arachidonic acid.	epoxyeicosatrienoic acids	0-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
9242187-1	1997	Epoxyeicosatrienoic acids (EETs) are potent endothelium-derived vasodilators formed from cytochrome P-450 metabolism of arachidonic acid.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
9242187-1	1997	Epoxyeicosatrienoic acids (EETs) are potent endothelium-derived vasodilators formed from cytochrome P-450 metabolism of arachidonic acid.	Arachidonic Acid	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
9247615-0	1997	Cytochrome P450 hydroxylation of carbon atoms of the alkyl chain of symmetrical N-nitrosodialkylamines by human liver microsomes.	Carbon	33-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9247615-0	1997	Cytochrome P450 hydroxylation of carbon atoms of the alkyl chain of symmetrical N-nitrosodialkylamines by human liver microsomes.	n-nitrosodialkylamines	80-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9223567-1	1997	The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metabolism by inhibition of cytochrome P450 (CYP).	Diltiazem	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
9248661-2	1997	Multiple forms of cytochrome P450 (CYP) catalyse the oxidation of chemicals of endogenous and exogenous origin, including drugs, carcinogens, steroids and eicosanoids.	Steroids	142-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
9248661-2	1997	Multiple forms of cytochrome P450 (CYP) catalyse the oxidation of chemicals of endogenous and exogenous origin, including drugs, carcinogens, steroids and eicosanoids.	Steroids	142-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
9248661-2	1997	Multiple forms of cytochrome P450 (CYP) catalyse the oxidation of chemicals of endogenous and exogenous origin, including drugs, carcinogens, steroids and eicosanoids.	Eicosanoids	155-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
9248661-2	1997	Multiple forms of cytochrome P450 (CYP) catalyse the oxidation of chemicals of endogenous and exogenous origin, including drugs, carcinogens, steroids and eicosanoids.	Eicosanoids	155-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
9248661-10	1997	Thus, drugs with side chains containing unsaturated carbon-carbon bonds and furan ring systems are associated with CYP inactivation.	Carbon	52-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
9248661-10	1997	Thus, drugs with side chains containing unsaturated carbon-carbon bonds and furan ring systems are associated with CYP inactivation.	Carbon	59-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
9248661-10	1997	Thus, drugs with side chains containing unsaturated carbon-carbon bonds and furan ring systems are associated with CYP inactivation.	furan	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-118
9248661-11	1997	Nitrogen-containing systems may also inactivate CYP.	Nitrogen	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
9248661-15	1997	Drugs that elicit CYP complexation include the first generation macrolide antibiotics, but newer analogues appear much safer.	macrolide antibiotics	64-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
9223567-1	1997	The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metabolism by inhibition of cytochrome P450 (CYP).	Diltiazem	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-112
9223567-1	1997	The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metabolism by inhibition of cytochrome P450 (CYP).	Diltiazem	38-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
9223567-1	1997	The antihypertensive agent diltiazem (DTZ) impairs hepatic drug metabolism by inhibition of cytochrome P450 (CYP).	Diltiazem	38-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-112
9223567-3	1997	Thus, DTZ metabolites may contribute to CYP inhibition.	Diltiazem	6-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-43
9223567-4	1997	This study assessed the role of human CYPs in microsomal DTZ oxidation and the capacity of DTZ metabolites to inhibit specific CYP activities.	Diltiazem	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
9241661-1	1997	Cyclophosphamide and ifosfamide are alkylating agent prodrugs that require activation by cytochrome P450 (CYP) to manifest their cancer chemotherapeutic activity.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
9253143-0	1997	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes.	Toluene	59-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-0	1997	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes.	Styrene	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-2	1997	Cytochrome P450 isozymes from Asian (31 Chinese subjects) and Caucasian (14 Finnish subjects) livers were examined for their roles in the metabolism of toluene (rates of benzyl alcohol, o- and p-cresol formation) and styrene (rates of styrene glycol formation).	Toluene	152-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-2	1997	Cytochrome P450 isozymes from Asian (31 Chinese subjects) and Caucasian (14 Finnish subjects) livers were examined for their roles in the metabolism of toluene (rates of benzyl alcohol, o- and p-cresol formation) and styrene (rates of styrene glycol formation).	Benzyl Alcohol	170-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-2	1997	Cytochrome P450 isozymes from Asian (31 Chinese subjects) and Caucasian (14 Finnish subjects) livers were examined for their roles in the metabolism of toluene (rates of benzyl alcohol, o- and p-cresol formation) and styrene (rates of styrene glycol formation).	o- and p-cresol	186-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-2	1997	Cytochrome P450 isozymes from Asian (31 Chinese subjects) and Caucasian (14 Finnish subjects) livers were examined for their roles in the metabolism of toluene (rates of benzyl alcohol, o- and p-cresol formation) and styrene (rates of styrene glycol formation).	Styrene	217-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9253143-2	1997	Cytochrome P450 isozymes from Asian (31 Chinese subjects) and Caucasian (14 Finnish subjects) livers were examined for their roles in the metabolism of toluene (rates of benzyl alcohol, o- and p-cresol formation) and styrene (rates of styrene glycol formation).	styrene glycol	235-249	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9255560-1	1997	Cytochrome P450 (CYP) enzymes catalyze the generation of reactive species capable of binding with cellular macromolecules, leading to acute and delayed toxicity.	reactive species	57-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9255560-1	1997	Cytochrome P450 (CYP) enzymes catalyze the generation of reactive species capable of binding with cellular macromolecules, leading to acute and delayed toxicity.	reactive species	57-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9224780-0	1997	Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.	Omeprazole	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
9224780-0	1997	Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.	Lansoprazole	29-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
9224780-1	1997	The human clearance of omeprazole and lansoprazole is conducted primarily by the hepatic cytochrome P450 (CYP) system.	Omeprazole	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
9224780-1	1997	The human clearance of omeprazole and lansoprazole is conducted primarily by the hepatic cytochrome P450 (CYP) system.	Omeprazole	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
9224780-1	1997	The human clearance of omeprazole and lansoprazole is conducted primarily by the hepatic cytochrome P450 (CYP) system.	Lansoprazole	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
9224780-1	1997	The human clearance of omeprazole and lansoprazole is conducted primarily by the hepatic cytochrome P450 (CYP) system.	Lansoprazole	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
9193876-0	1997	Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.	Nortriptyline	64-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
9190854-0	1997	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.	imipramine n	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
9190854-0	1997	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.	Mephenytoin	177-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Imipramine	72-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Mephenytoin	137-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9190854-1	1997	Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4"-hydroxylation in vitro and 11 recombinant human CYP isoforms.	Mephenytoin	137-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9187259-7	1997	Direct evidence for the in vivo epoxidation of arachidonic acid by intestinal cytochrome P450 was provided by documenting, for the first time, the presence of epoxyeicosatrienoic acids in human jejunum by gas chromatography/mass spectrometry.	Arachidonic Acid	47-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
9187259-7	1997	Direct evidence for the in vivo epoxidation of arachidonic acid by intestinal cytochrome P450 was provided by documenting, for the first time, the presence of epoxyeicosatrienoic acids in human jejunum by gas chromatography/mass spectrometry.	epoxyeicosatrienoic acids	159-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
9241661-1	1997	Cyclophosphamide and ifosfamide are alkylating agent prodrugs that require activation by cytochrome P450 (CYP) to manifest their cancer chemotherapeutic activity.	Cyclophosphamide	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
9241661-1	1997	Cyclophosphamide and ifosfamide are alkylating agent prodrugs that require activation by cytochrome P450 (CYP) to manifest their cancer chemotherapeutic activity.	Ifosfamide	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
9241661-1	1997	Cyclophosphamide and ifosfamide are alkylating agent prodrugs that require activation by cytochrome P450 (CYP) to manifest their cancer chemotherapeutic activity.	Ifosfamide	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
9157990-8	1997	These studies: (a) demonstrate an underlying metabolic basis for the clinically important oxazaphosphorine autoinduction pharmacokinetics seen with these drugs in cancer patients; and (b) identify rifampin and other CYP inducers as potentially useful for increasing the rates of cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation in human liver in a manner that could favorably impact the clinical pharmacokinetics of these anticancer prodrugs.	oxazaphosphorine	90-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-219
9212781-8	1997	Overall, our results indicate that the oxidative dehalo genation of para-halogenated phenols, resulting in the formation of benzoquinones, is not specific only for cytochrome P-450 enzymes.	Phenols	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
9212781-8	1997	Overall, our results indicate that the oxidative dehalo genation of para-halogenated phenols, resulting in the formation of benzoquinones, is not specific only for cytochrome P-450 enzymes.	Benzoquinones	124-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	oxazaphosphorine	15-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
9157990-8	1997	These studies: (a) demonstrate an underlying metabolic basis for the clinically important oxazaphosphorine autoinduction pharmacokinetics seen with these drugs in cancer patients; and (b) identify rifampin and other CYP inducers as potentially useful for increasing the rates of cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation in human liver in a manner that could favorably impact the clinical pharmacokinetics of these anticancer prodrugs.	Cyclophosphamide	279-295	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-219
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	oxazaphosphorine	15-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
9157990-8	1997	These studies: (a) demonstrate an underlying metabolic basis for the clinically important oxazaphosphorine autoinduction pharmacokinetics seen with these drugs in cancer patients; and (b) identify rifampin and other CYP inducers as potentially useful for increasing the rates of cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation in human liver in a manner that could favorably impact the clinical pharmacokinetics of these anticancer prodrugs.	Ifosfamide	316-326	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-219
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	Cyclophosphamide	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	Cyclophosphamide	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
9160172-6	1997	The most favoured explanation is that continuous tretinoin treatment acts to induce drug catabolism by cytochrome P450 (CYP) enzymes.	Tretinoin	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	Ifosfamide	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-169
9157990-1	1997	The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes.	Ifosfamide	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-174
9176244-1	1997	We investigated the effect of 20-hydroxyeicosatetraenoic acid (20-HETE), an arachidonic acid metabolite of the cytochrome P-450 (cP450) 4A pathway, on human pulmonary arterial tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	30-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
9176244-1	1997	We investigated the effect of 20-hydroxyeicosatetraenoic acid (20-HETE), an arachidonic acid metabolite of the cytochrome P-450 (cP450) 4A pathway, on human pulmonary arterial tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	30-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-134
9176244-1	1997	We investigated the effect of 20-hydroxyeicosatetraenoic acid (20-HETE), an arachidonic acid metabolite of the cytochrome P-450 (cP450) 4A pathway, on human pulmonary arterial tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
9176244-1	1997	We investigated the effect of 20-hydroxyeicosatetraenoic acid (20-HETE), an arachidonic acid metabolite of the cytochrome P-450 (cP450) 4A pathway, on human pulmonary arterial tone.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-134
9160172-6	1997	The most favoured explanation is that continuous tretinoin treatment acts to induce drug catabolism by cytochrome P450 (CYP) enzymes.	Tretinoin	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
9189656-12	1997	Argemone oil/alkaloid showed a Type II binding spectra with hepatic cytochrome P-450 (P-450) protein, thereby causing loss of P-450 content and an impairment of phase I and phase II enzymes.	argemone oil	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
9130514-1	1997	The involvement of cytochrome-P450-dependent metabolism of small-molecular-weight compounds as a prerequisite for an optimal lymphocyte response to those compounds is discussed on the basis of studies with compound such as p-phenylenediamine, sulfamethoxazole, chloramphenicol and fragrances.	4-phenylenediamine	223-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9189656-12	1997	Argemone oil/alkaloid showed a Type II binding spectra with hepatic cytochrome P-450 (P-450) protein, thereby causing loss of P-450 content and an impairment of phase I and phase II enzymes.	Alkaloids	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
9130514-1	1997	The involvement of cytochrome-P450-dependent metabolism of small-molecular-weight compounds as a prerequisite for an optimal lymphocyte response to those compounds is discussed on the basis of studies with compound such as p-phenylenediamine, sulfamethoxazole, chloramphenicol and fragrances.	Sulfamethoxazole	243-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9130514-1	1997	The involvement of cytochrome-P450-dependent metabolism of small-molecular-weight compounds as a prerequisite for an optimal lymphocyte response to those compounds is discussed on the basis of studies with compound such as p-phenylenediamine, sulfamethoxazole, chloramphenicol and fragrances.	Chloramphenicol	261-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
9152386-0	1997	Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450.	Cysteine	17-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
9152386-0	1997	Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450.	Acetaminophen	61-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
9152386-4	1997	This would indicate that some of forms of cytochrome P450 (CYP) catalyzing NABQI formation have their active site on the cytosolic surface and others on the lumenal surface.	N-acetyl-4-benzoquinoneimine	75-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
9152386-4	1997	This would indicate that some of forms of cytochrome P450 (CYP) catalyzing NABQI formation have their active site on the cytosolic surface and others on the lumenal surface.	N-acetyl-4-benzoquinoneimine	75-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
9226306-0	1997	Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9041227-7	1997	Although the dogma is that the myoglobin is the source of iron, the results of recent studies suggest that cytochrome P-450 may be an important source of iron in this model.	Iron	154-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
9070354-0	1997	Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans.	Trichloroethylene	40-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Ritonavir	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Ritonavir	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Saquinavir	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Saquinavir	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Indinavir	125-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Indinavir	125-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Nelfinavir	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	Nelfinavir	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	amprenavir	152-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
9056009-2	1997	In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478.	amprenavir	152-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9056009-3	1997	The structural features of ritonavir responsible for CYP binding and inhibition were examined.	Ritonavir	27-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
27414767-6	1997	Cytochrome P-450 enzymes can hydroxylate salicylate to produce 2,5-DHBA, and it is likely that phenylalanine hydroxylase produces most of the p-tyrosine detected in hepatic tissues.	Salicylates	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
27414767-6	1997	Cytochrome P-450 enzymes can hydroxylate salicylate to produce 2,5-DHBA, and it is likely that phenylalanine hydroxylase produces most of the p-tyrosine detected in hepatic tissues.	2,5-dihydroxybenzoic acid	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
27414767-6	1997	Cytochrome P-450 enzymes can hydroxylate salicylate to produce 2,5-DHBA, and it is likely that phenylalanine hydroxylase produces most of the p-tyrosine detected in hepatic tissues.	Tyrosine	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
9130383-2	1997	It was discovered that a long wave shift occurred in the fluorescence spectra of cytochrome P450, both in solution and within phospholipid vesicles.	Phospholipids	126-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
9130383-3	1997	The efficiency of quenching of membrane-bound cytochrome P450 with acrylamide also increased after freezing.	Acrylamide	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
9078706-0	1997	[Alcohol oxidative metabolism systems of microsomes (cytochrome P-450)].	Alcohols	1-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-71
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	Chloral Hydrate	59-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	Chloral Hydrate	59-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	trichloro-	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	trichloro-	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	Dichloroacetic Acid	149-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9070354-2	1997	Cytochrome P450 (CYP)-dependent metabolism of TRI produces chloral hydrate (CH) and is rate limiting in the ultimate production of trichloro- and/or dichloroacetic acid from TRI.	Dichloroacetic Acid	149-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9003190-1	1997	Cytochrome P450 (P450) 3A4 is the most abundant human P450 and oxidizes a diversity of substrates, including various drugs, steroids, carcinogens, and macrolide natural products.	Steroids	124-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
15374139-3	1997	Although this system is an important component of the defenses that protect living organisms against toxic chemicals, some reactions catalyzed by the cytochrome P-450 system result in the formation of products that are highly reactive as well as active oxygen species.	Oxygen	253-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
8995391-4	1997	Classical cytochrome P-450 ligands such as the mechanism-based inactivator 1-aminobenzotriazole did not inhibit iNOS.	1-aminobenzotriazole	75-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
8995391-7	1997	The binding of chlorzoxazone to iNOS and human and rat liver microsomal cytochrome P-450 induced a high spin, type I spectra, which was reversed by imidazole.	Chlorzoxazone	15-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
8995391-7	1997	The binding of chlorzoxazone to iNOS and human and rat liver microsomal cytochrome P-450 induced a high spin, type I spectra, which was reversed by imidazole.	imidazole	148-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
9010633-0	1997	Identification of rat and human cytochrome P450 forms involved in the metabolism of the thromboxane A2 receptor antagonist (+)-S-145.	S 145	123-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
9443608-13	1997	CONCLUSIONS: Halomon is metabolized by mouse and human hepatic cytochrome P-450 enzymes, the identities of which remain unknown.	6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene	13-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
9054609-1	1997	Several naturally occurring coumarins to which humans are routinely exposed have been previously found to be potent inhibitors and inactivators of cytochrome P450 (P450) 1A1-mediated monooxygenase in both murine hepatic microsomes and in a reconstituted system using purified human P450 1A1 [Cai et al.	Coumarins	28-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-173
9068933-5	1997	This suggests that the change in tolbutamide clearance may be due to a slight inhibition of the cytochrome P450 (CYP) isoenzyme CYP2C9/10 when sertraline was administered in its maximum recommended dosage.	Tolbutamide	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
9068933-5	1997	This suggests that the change in tolbutamide clearance may be due to a slight inhibition of the cytochrome P450 (CYP) isoenzyme CYP2C9/10 when sertraline was administered in its maximum recommended dosage.	Tolbutamide	33-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
9068933-5	1997	This suggests that the change in tolbutamide clearance may be due to a slight inhibition of the cytochrome P450 (CYP) isoenzyme CYP2C9/10 when sertraline was administered in its maximum recommended dosage.	Sertraline	143-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-111
9068933-5	1997	This suggests that the change in tolbutamide clearance may be due to a slight inhibition of the cytochrome P450 (CYP) isoenzyme CYP2C9/10 when sertraline was administered in its maximum recommended dosage.	Sertraline	143-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-116
9068934-8	1997	The metabolism of warfarin is principally mediated by the cytochrome P450 (CYP) isoenzyme CYP2C9/10.	Warfarin	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
9068934-8	1997	The metabolism of warfarin is principally mediated by the cytochrome P450 (CYP) isoenzyme CYP2C9/10.	Warfarin	18-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
9010633-2	1997	We investigated the oxidative metabolism of (+)-S-145 and its beta-oxidized metabolites with liver microsomes from rats and humans to identify which cytochrome P450 (P450) forms are involved in these reactions.	S 145	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
9048233-5	1997	Metanil yellow treatment for 7 days also led to a significant increase in cytochrome P-450 (P-450)-dependent aryl hydrocarbon hydroxylase (AHH) activity (99-223%) in the liver and intestine.	metanil yellow	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
9342584-0	1997	Metabolism of carteolol by cDNA-expressed human cytochrome P450.	Carteolol	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
9342584-1	1997	OBJECTIVES: To determine human cytochrome P450 isoform(s) (CYPs) involved in the metabolism of carteolol, the biotransformation of the compound was investigated in vitro using ten isoforms of human cytochrome P450 expressed in human AHH-1 TK +/- cell lines.	Carteolol	95-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
9342584-1	1997	OBJECTIVES: To determine human cytochrome P450 isoform(s) (CYPs) involved in the metabolism of carteolol, the biotransformation of the compound was investigated in vitro using ten isoforms of human cytochrome P450 expressed in human AHH-1 TK +/- cell lines.	Carteolol	95-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-213
9342584-8	1997	CONCLUSION: 8-Hydroxylation is the only cytochrome P450-catalyzed metabolic reaction of carteolol by its expressed microsomes, and CYP2D6 is the principal isoform of the enzyme involved in the catalytic reaction.	Carteolol	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
9279132-4	1997	Liver microsomal cytochrome P-450 level was found to be low in ascorbate deficient animals.	Ascorbic Acid	63-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
9046019-0	1997	NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid.	NADP	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
9046019-0	1997	NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid.	Iron	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
9046019-0	1997	NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid.	Ascorbic Acid	118-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
9046019-1	1997	In this paper we demonstrate that ascorbic acid specifically prevents NADPH-initiated cytochrome P450 (P450)-mediated microsomal lipid peroxidation in the absence of free iron.	Ascorbic Acid	34-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
9046019-1	1997	In this paper we demonstrate that ascorbic acid specifically prevents NADPH-initiated cytochrome P450 (P450)-mediated microsomal lipid peroxidation in the absence of free iron.	NADP	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-101
9364799-1	1997	Arachidonic acid (AA) can be metabolized to a variety of lipid mediators including prostaglandins (PGE), and hydroxyeicosatetraenoic acids (HETE) by cyclooxygenase, lipoxygenase and cytochrome P450-dependent monooxygenase enzymatic pathways.	Hydroxyeicosatetraenoic Acids	109-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
9200152-7	1997	In summary, our findings suggested that dietary menhaden oil can modulate ADH and CYP activities in a manner that may alter the metabolism of CP and, therefore, improve its therapeutic index by increasing its therapeutic effect and decreasing its toxicity.	Menhaden oil	48-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
9364799-1	1997	Arachidonic acid (AA) can be metabolized to a variety of lipid mediators including prostaglandins (PGE), and hydroxyeicosatetraenoic acids (HETE) by cyclooxygenase, lipoxygenase and cytochrome P450-dependent monooxygenase enzymatic pathways.	Hydroxyeicosatetraenoic Acids	140-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
9364799-1	1997	Arachidonic acid (AA) can be metabolized to a variety of lipid mediators including prostaglandins (PGE), and hydroxyeicosatetraenoic acids (HETE) by cyclooxygenase, lipoxygenase and cytochrome P450-dependent monooxygenase enzymatic pathways.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-197
8971135-2	1996	The aim of this study was to identify the cytochrome P450 (CYP) enzyme primarily responsible for the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes.	NADP	101-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
8975714-0	1996	Structure and mapping of the human lanosterol 14alpha-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes.	Cholesterol	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
8975714-0	1996	Structure and mapping of the human lanosterol 14alpha-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes.	Cholesterol	120-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-75
8975714-1	1996	Sterol 14alpha-demethylase (P45014DM) encoded by CYP51 is a member of the cytochrome P450 (CYP) gene superfamily involved in sterol biosynthesis in fungi, plants, and animals.	Sterols	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
8975714-1	1996	Sterol 14alpha-demethylase (P45014DM) encoded by CYP51 is a member of the cytochrome P450 (CYP) gene superfamily involved in sterol biosynthesis in fungi, plants, and animals.	Sterols	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
8971135-2	1996	The aim of this study was to identify the cytochrome P450 (CYP) enzyme primarily responsible for the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes.	[14c]halothane	137-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
8971135-2	1996	The aim of this study was to identify the cytochrome P450 (CYP) enzyme primarily responsible for the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes.	NADP	101-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
8971135-2	1996	The aim of this study was to identify the cytochrome P450 (CYP) enzyme primarily responsible for the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes.	[14c]halothane	137-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
9030997-4	1996	Cytochrome P-450 and other enzymes involved in aldosterone synthesis were found in the tumor portions but not in the zona glomerulosa of attached adrenals, which histopathologically showed "paradoxical hyperplasia".	Aldosterone	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8942676-0	1996	Role of the polarity of the heme environment for the CO stretch modes in cytochrome P-450cam-CO.	Heme	28-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-95
8944409-8	1996	The increased buspirone concentrations are likely to be due to inhibition of first pass liver metabolism by fluvoxamine acting on the cytochrome P-450 system.	Buspirone	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
8916898-5	1996	In the reduced, CO-bound form of cytochrome P-450cam at 290 K the (1S)-camphor complex reveals another CO stretch vibration population distribution with slightly higher frequencies [1940.2 cm-1 (major band) and 1946.3 cm-1 (minor band)] compared to the (1R)-camphor complex [1939.7 cm-1 (major band) and 1930 cm-1 (minor band)].	Camphor	258-265	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
8916898-7	1996	Assuming the carbon monoxide complex as a model for the dioxygen complex, the more loosened binding of (1S)-camphor, therefore the increased water accessibility, and the weaker contact of the iron ligand to the I-helix might explain the higher amount of uncoupling of the cytochrome P-450 reaction cycle compared to that when (1R)-camphor is used as substrate.	Carbon Monoxide	13-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	272-288
8916898-7	1996	Assuming the carbon monoxide complex as a model for the dioxygen complex, the more loosened binding of (1S)-camphor, therefore the increased water accessibility, and the weaker contact of the iron ligand to the I-helix might explain the higher amount of uncoupling of the cytochrome P-450 reaction cycle compared to that when (1R)-camphor is used as substrate.	Oxygen	56-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	272-288
8937855-2	1996	In this study, human cytochrome P450 (CYP) isoform involved in cotinine formation was identified.	Cotinine	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
8937855-2	1996	In this study, human cytochrome P450 (CYP) isoform involved in cotinine formation was identified.	Cotinine	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
8940291-1	1996	As a participant of the endogenous arachidonic acid metabolic cascade, microsomal cytochrome P450 metabolizes the fatty acid to biologically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.	Arachidonic Acid	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8940291-1	1996	As a participant of the endogenous arachidonic acid metabolic cascade, microsomal cytochrome P450 metabolizes the fatty acid to biologically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.	Fatty Acids	114-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8940291-1	1996	As a participant of the endogenous arachidonic acid metabolic cascade, microsomal cytochrome P450 metabolizes the fatty acid to biologically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.	hydroxyeicosatetraenoic	148-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8940291-1	1996	As a participant of the endogenous arachidonic acid metabolic cascade, microsomal cytochrome P450 metabolizes the fatty acid to biologically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	176-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8916898-0	1996	Structural changes in cytochrome P-450cam effected by the binding of the enantiomers (1R)-camphor and (1S)-camphor.	Camphor	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8916898-0	1996	Structural changes in cytochrome P-450cam effected by the binding of the enantiomers (1R)-camphor and (1S)-camphor.	Camphor	102-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8916898-4	1996	The half-transition temperature of the thermal unfolding of 53.8 degrees C for the (1S)-camphor-bound oxidized cytochrome P-450cam is one degree lower than the value for the (1R)-camphor-bound protein (54.8 degrees C).	Camphor	88-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
8916898-4	1996	The half-transition temperature of the thermal unfolding of 53.8 degrees C for the (1S)-camphor-bound oxidized cytochrome P-450cam is one degree lower than the value for the (1R)-camphor-bound protein (54.8 degrees C).	Camphor	179-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
8916898-5	1996	In the reduced, CO-bound form of cytochrome P-450cam at 290 K the (1S)-camphor complex reveals another CO stretch vibration population distribution with slightly higher frequencies [1940.2 cm-1 (major band) and 1946.3 cm-1 (minor band)] compared to the (1R)-camphor complex [1939.7 cm-1 (major band) and 1930 cm-1 (minor band)].	(1s)	66-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
8916898-5	1996	In the reduced, CO-bound form of cytochrome P-450cam at 290 K the (1S)-camphor complex reveals another CO stretch vibration population distribution with slightly higher frequencies [1940.2 cm-1 (major band) and 1946.3 cm-1 (minor band)] compared to the (1R)-camphor complex [1939.7 cm-1 (major band) and 1930 cm-1 (minor band)].	Camphor	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
8951176-0	1996	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes.	Flunarizine	24-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
8951176-0	1996	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes.	Cinnarizine	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-131
8970575-5	1996	EDHF may be a cytochrome P-450 metabolite of arachidonic acid.	edhf	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8970575-5	1996	EDHF may be a cytochrome P-450 metabolite of arachidonic acid.	Arachidonic Acid	45-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8944409-8	1996	The increased buspirone concentrations are likely to be due to inhibition of first pass liver metabolism by fluvoxamine acting on the cytochrome P-450 system.	Fluvoxamine	108-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
8952228-6	1996	A process known to generate the O2 is the induction of certain cytochrome P450 (CYP) isozymes by drugs or environmental pollutants.	Superoxides	32-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
8948090-0	1996	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes.	Roxithromycin	11-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
8948090-0	1996	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes.	Erythromycin	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
8948090-0	1996	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes.	Troleandomycin	43-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
8952228-6	1996	A process known to generate the O2 is the induction of certain cytochrome P450 (CYP) isozymes by drugs or environmental pollutants.	Superoxides	32-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-83
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	91-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	91-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	225-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	225-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Hydroxylamine	268-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Hydroxylamine	268-277	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	225-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-70
8952228-7	1996	RESULTS: We report: 1) a correlation between the induction of each CYP gene family and the O2 yield; 2) support to an observation reported previously that the tumor promoting ability of CYP inducers is mainly mediated by the O2; and 3) the description of a method for nitroxide mediated O2 detection in vivo.	Superoxides	225-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	186-189
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Prostaglandin Endoperoxides	93-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
8946477-0	1996	CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.	Histamine	74-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
8946477-0	1996	CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.	Promethazine	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
8946477-1	1996	To determine which cytochrome P450 form is involved in the promethazine [10-(2-dimethylaminopropyl) phenothiazine] metabolism, in vitro analysis using human liver microsomes were performed.	Promethazine	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
8946477-1	1996	To determine which cytochrome P450 form is involved in the promethazine [10-(2-dimethylaminopropyl) phenothiazine] metabolism, in vitro analysis using human liver microsomes were performed.	Promethazine	73-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
8823154-0	1996	Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis.	Retinoids	137-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
8823154-0	1996	Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis.	Tretinoin	173-186	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
8823154-5	1996	Members of the alcohol dehydrogenase and short-chain dehydrogenase/reductase enzyme families catalyze the reversible interconversion of retinol and retinal, the rate-limiting step, whereas members of the aldehyde dehydrogenase and cytochrome P450 enzyme families catalyze the irreversible oxidation of retinal to retinoic acid.	Vitamin A	136-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	231-246
8823154-5	1996	Members of the alcohol dehydrogenase and short-chain dehydrogenase/reductase enzyme families catalyze the reversible interconversion of retinol and retinal, the rate-limiting step, whereas members of the aldehyde dehydrogenase and cytochrome P450 enzyme families catalyze the irreversible oxidation of retinal to retinoic acid.	Aldehydes	204-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	231-246
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Prostaglandin Endoperoxides	93-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-55
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-237
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Prostaglandin H2	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	111-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-237
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Prostaglandin H2	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-55
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-237
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	125-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	234-237
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	286-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
8765473-1	1996	Various complementary approaches were used to elucidate the major cytochrome P450 (CYP) enzyme responsible for mifepristone (RU 486) demethylation and hydroxylation in human liver microsomes: chemical and immunoinhibition of specific CYPs; correlation analyses between initial rates of mifepristone metabolism and relative immunodetectable CYP levels and rates of CYP marker substrate metabolism; and evaluation of metabolism by cDNA-expressed CYP3A4.	Mifepristone	286-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Thromboxane A2	132-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
8964509-1	1996	Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prostaglandin endoperoxide (PGH2) into thromboxane A2 (TxA2) which plays a crucial role in hemostasis and cardiovascular diseases.	Thromboxane A2	132-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-55
8884182-1	1996	Liarozole inhibits cytochrome P-450-dependent enzymes that play a key role in all-trans-retinoic acid (ATRA) catabolism.	liarozole	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
8824525-0	1996	Cytochrome P450 species involved in the metabolism of quinoline.	quinoline	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8824525-2	1996	The specific cytochrome P450 enzymes involved in quinoline metabolism in human and rat liver microsomes were determined using cDNA-expressed cytochrome P450s, correlations with specific cytochrome P450-linked monooxygenase activities in human liver microsomes and inhibition by specific inhibitors and antibodies.	quinoline	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
8824525-2	1996	The specific cytochrome P450 enzymes involved in quinoline metabolism in human and rat liver microsomes were determined using cDNA-expressed cytochrome P450s, correlations with specific cytochrome P450-linked monooxygenase activities in human liver microsomes and inhibition by specific inhibitors and antibodies.	quinoline	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
8824525-3	1996	CYP2A6 is the principal cytochrome P450 involved in the formation of quinoline-1-oxide in human liver microsomes (correlation coefficient r = 0.95), but is formed in only minute quantities in rat liver microsomes.	Quinoline 1-oxide	69-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
8824525-4	1996	CYP2E1 is the principal cytochrome P450 involved in the formation of 3-hydroxyquinoline (r = 0.93) in human liver microsomes and is involved in the formation in rat liver microsomes.	3-Hydroxyquinoline	69-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
8824531-0	1996	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.	n-nitrosodialkylamines	47-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8824531-3	1996	As the length of the alkyl chain increased from methyl to pentyl, dealkylation of symmetrical nitrosodialkylamines became less efficiently catalyzed by cytochrome P450.	nitrosodialkylamines	94-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	Midazolam	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	Midazolam	11-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	1"-hydroxy	102-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	1"-oh	114-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	hydroxide ion	105-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8886602-1	1996	Midazolam (MDZ) is metabolized in human liver microsomes by the cytochrome P450 (CYP) 3A subfamily to 1"-hydroxy (1"-OH) and 4-hydroxy (4-OH) metabolites.	4-oh	136-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
8877251-10	1996	In other tissues low in CYP activity, prostaglandin H synthase may also be responsible for bioactivation; e.g. in the kidney paracetamol (acetaminophen) toxicity is though to result from activation via this enzyme.	Acetaminophen	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
8877251-10	1996	In other tissues low in CYP activity, prostaglandin H synthase may also be responsible for bioactivation; e.g. in the kidney paracetamol (acetaminophen) toxicity is though to result from activation via this enzyme.	Acetaminophen	138-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
8884182-1	1996	Liarozole inhibits cytochrome P-450-dependent enzymes that play a key role in all-trans-retinoic acid (ATRA) catabolism.	Tretinoin	82-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
8884182-1	1996	Liarozole inhibits cytochrome P-450-dependent enzymes that play a key role in all-trans-retinoic acid (ATRA) catabolism.	Tretinoin	103-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	benz(a)anthracene	232-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	benz(a)anthracene	248-250	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	pyrazole	253-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	pyrazole	263-266	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	phenobarbital-hydrocortisone	272-300	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
21541530-1	1996	To examine the possibility that chemical inducers of cytochrome P450 may have effects on the expression of oncogenes and a tumor suppressor gene, human colon LS174T cells were treated with different cytochrome P450 inducers such as benzanthracene (Ba), pyrazole (Pyr) and phenobarbital-hydrocortisone (Pb-Hc).	pb-hc	302-307	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
8864312-11	1996	These in vitro data provide direct evidence for cytochrome P450 inhibition as the mechanism for the well documented diazepam-omeprazole clinical interaction and indicate that omeprazole sulphone, as well as the parent drug, contribute to the inhibition effect.	diazepam-omeprazole	116-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
8765221-0	1996	Interaction of nitrogen monoxide with cytochrome P-450 monitored by surface-enhanced resonance Raman scattering.	Nitric Oxide	15-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
8765221-1	1996	The reaction of mammalian cytochrome P-450 2B4 with nitrogen monoxide and oxygen has been studied by surface-enhanced resonance Raman scattering (SERRS) to obtain sharp and definitive information in situ on the nature of the changes in the active site pocket.	Nitric Oxide	52-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
8765221-1	1996	The reaction of mammalian cytochrome P-450 2B4 with nitrogen monoxide and oxygen has been studied by surface-enhanced resonance Raman scattering (SERRS) to obtain sharp and definitive information in situ on the nature of the changes in the active site pocket.	Oxygen	74-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Omeprazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
8694760-2	1996	produced during the catalytic activity of nitric oxide synthase (NOS) and cytochrome P-450 has been implicated in the oxidative denitrification of hydroxyguanidines ( &gt; C = NOH).	hydroxyguanidine	147-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
8712747-10	1996	Itraconazole and its analogues are inhibitors of both cytochrome P450 and lipoxygenase and since itraconazole can modulate BU pharmacokinetics, oxidative catabolism is probably a determinant of BU metabolism.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-86
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Omeprazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Lansoprazole	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Lansoprazole	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Pantoprazole	29-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
8827397-4	1996	Omeprazole, lansoprazole and pantoprazole are all mainly metabolished by the polymorphically expressed cytochrome P450 (CYP) isoform S-mephenytoin hydroxylase (CYP2C19), which means that within a population a few individuals (3% of Caucasians) metabolise the compounds slowly compared with the majority of the population.	Pantoprazole	29-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
8827397-12	1996	The effect of the acid pump inhibitors on enzymes in the liver has been intensely debated, and some authors have claimed that lansoprazole and pantoprazole have less potential than omeprazole to interact with other drugs metabolised by CYP.	Lansoprazole	126-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-239
8827397-12	1996	The effect of the acid pump inhibitors on enzymes in the liver has been intensely debated, and some authors have claimed that lansoprazole and pantoprazole have less potential than omeprazole to interact with other drugs metabolised by CYP.	Pantoprazole	143-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-239
8827397-12	1996	The effect of the acid pump inhibitors on enzymes in the liver has been intensely debated, and some authors have claimed that lansoprazole and pantoprazole have less potential than omeprazole to interact with other drugs metabolised by CYP.	Omeprazole	181-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	236-239
8673608-2	1996	Cytochrome P450eryF is unusual in having alanine in place of this threonine and an ordered active site water molecule (Wat 519) which is hydrogen bonded to the substrate 5-hydroxyl group and is in position to operate as an acid catalyst required for cleaving dioxygen.	Alanine	41-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8965248-6	1996	The hydroxylation of benzopyrene in human microsomes prepared from human liver samples (biopsies) was used as a model to study the treatment effect on cytochrome-P450.	Benzopyrenes	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-166
8673608-2	1996	Cytochrome P450eryF is unusual in having alanine in place of this threonine and an ordered active site water molecule (Wat 519) which is hydrogen bonded to the substrate 5-hydroxyl group and is in position to operate as an acid catalyst required for cleaving dioxygen.	Threonine	66-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8864187-0	1996	Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis.	Aflatoxin B1	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
8673608-2	1996	Cytochrome P450eryF is unusual in having alanine in place of this threonine and an ordered active site water molecule (Wat 519) which is hydrogen bonded to the substrate 5-hydroxyl group and is in position to operate as an acid catalyst required for cleaving dioxygen.	Water	103-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8673608-2	1996	Cytochrome P450eryF is unusual in having alanine in place of this threonine and an ordered active site water molecule (Wat 519) which is hydrogen bonded to the substrate 5-hydroxyl group and is in position to operate as an acid catalyst required for cleaving dioxygen.	Hydrogen	137-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8673608-2	1996	Cytochrome P450eryF is unusual in having alanine in place of this threonine and an ordered active site water molecule (Wat 519) which is hydrogen bonded to the substrate 5-hydroxyl group and is in position to operate as an acid catalyst required for cleaving dioxygen.	Oxygen	259-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8864187-1	1996	Studies were carried out to test the hypothesis that inflammatory liver disease increases the expression of specific cytochrome P-450 isoenzymes involved in aflatoxin B1 (AFB) activation.	Aflatoxin B1	157-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
8864187-1	1996	Studies were carried out to test the hypothesis that inflammatory liver disease increases the expression of specific cytochrome P-450 isoenzymes involved in aflatoxin B1 (AFB) activation.	Aflatoxin B1	171-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
8818231-0	1996	The iron(II)/reductant (DH2)-induced activation of dioxygen for the demethylation of N-methylanilines: reaction mimic for the cytochrome P-450/reductase system.	ammonium ferrous sulfate	4-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-152
8818231-0	1996	The iron(II)/reductant (DH2)-induced activation of dioxygen for the demethylation of N-methylanilines: reaction mimic for the cytochrome P-450/reductase system.	(-)-taxifolin	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-152
8818231-0	1996	The iron(II)/reductant (DH2)-induced activation of dioxygen for the demethylation of N-methylanilines: reaction mimic for the cytochrome P-450/reductase system.	Oxygen	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-152
8818231-0	1996	The iron(II)/reductant (DH2)-induced activation of dioxygen for the demethylation of N-methylanilines: reaction mimic for the cytochrome P-450/reductase system.	methylaniline	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-152
8875768-6	1996	In both cases, cytochrome P-450 and other enzymes that were involved in aldosterone synthesis were found mainly in tumor, but little in the zona glomerulosa of the adjacent adrenals, which showed paradoxical hyperplasia.	Aldosterone	72-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
8761967-0	1996	Arachidonate metabolism in human placenta, fetal membranes, decidua and myometrium: lipoxygenase and cytochrome P450 metabolites as main products in HPLC profiles.	Arachidonic Acid	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-116
8771369-2	1996	We assessed the effect of imidazole inhibitors of cytochrome P-450 on the intracytoplasmic free Ca+2 ([Ca+2]i) response generated using the microsomal ATPase inhibitor thapsigargin (THG) to deplete the intracellular Ca+2 stores.	Thapsigargin	168-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
8737124-7	1996	The nitrogen atom is possibly the site that binds cytochrome P-450, which catalyses theophylline metabolism.	Nitrogen	4-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
8737124-7	1996	The nitrogen atom is possibly the site that binds cytochrome P-450, which catalyses theophylline metabolism.	Theophylline	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
8627557-9	1996	The results indicate that CYP2A6 isozyme is a major form of CYP responsible for the S-oxidation of SM-12502 in human liver microsomes.	3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
8723743-0	1996	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron.	dolasetron	87-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
8723743-3	1996	The compound is rapidly reduced by carbonyl reductase to form its major pharmacologically active metabolite reduced dolasetron (red-dolasetron), which us further metabolized by cytochrome P450 (CYP450).	dolasetron	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-192
8723743-3	1996	The compound is rapidly reduced by carbonyl reductase to form its major pharmacologically active metabolite reduced dolasetron (red-dolasetron), which us further metabolized by cytochrome P450 (CYP450).	dolasetron	116-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-200
8723743-4	1996	Studies were conducted, using human liver microsomes, to characterize the CYP450 enzymes responsible for the in vitro metabolism of red-dolasetron.	red-dolasetron	132-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-80
8723743-7	1996	The rate of formation of 6-hydroxy red-dolasetron was significantly correlated with that of 5-hydroxy red-dolasetron, which further suggested that these metabolites were formed by the same CYP450 enzyme(s).	6-hydroxy red-dolasetron	25-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-195
8723743-7	1996	The rate of formation of 6-hydroxy red-dolasetron was significantly correlated with that of 5-hydroxy red-dolasetron, which further suggested that these metabolites were formed by the same CYP450 enzyme(s).	5-hydroxy red-dolasetron	92-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	189-195
8771369-2	1996	We assessed the effect of imidazole inhibitors of cytochrome P-450 on the intracytoplasmic free Ca+2 ([Ca+2]i) response generated using the microsomal ATPase inhibitor thapsigargin (THG) to deplete the intracellular Ca+2 stores.	Thapsigargin	182-185	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
8622628-0	1996	Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450.	Nitric Oxide	8-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
8622628-6	1996	The addition of inhibitors of nitric oxide synthase (NOS) significantly prevented the cytokine-mediated decrease in each CYP protein, indicating a role for nitric oxide (NO) in the down-regulation.	Nitric Oxide	30-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
8622628-7	1996	Treatment of hepatocytes with the NO donor 1-hydroxy-2-oxo-3,3-bis(3-aminoethyl)-1-triazene (300 microM) caused a decrease in each CYP apoprotein, with CYP2B1/2 exhibiting the greatest decrease, to 33 +/- 8% of untreated cells.	1-hydroxy-2-oxo-3,3-bis(3-aminoethyl)-1-triazene	43-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
8658503-1	1996	The purpose of this study was to find out how liver injury caused by two well-known hepatotoxins, chloroform and thioacetamide, alters the expression of hepatic xenobiotic metabolizing cytochrome P450 (CYP) enzymes of DBA/2N mice.	Chloroform	98-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-200
8638935-1	1996	Cytochrome P450 enzymes oxidize aldehydes either to the corresponding acid or, via a decarboxylation mechanism, to an olefin one carbon shorter than the parent substrate.	Aldehydes	32-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8658503-1	1996	The purpose of this study was to find out how liver injury caused by two well-known hepatotoxins, chloroform and thioacetamide, alters the expression of hepatic xenobiotic metabolizing cytochrome P450 (CYP) enzymes of DBA/2N mice.	Chloroform	98-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
8658503-1	1996	The purpose of this study was to find out how liver injury caused by two well-known hepatotoxins, chloroform and thioacetamide, alters the expression of hepatic xenobiotic metabolizing cytochrome P450 (CYP) enzymes of DBA/2N mice.	Thioacetamide	113-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	185-200
8658503-1	1996	The purpose of this study was to find out how liver injury caused by two well-known hepatotoxins, chloroform and thioacetamide, alters the expression of hepatic xenobiotic metabolizing cytochrome P450 (CYP) enzymes of DBA/2N mice.	Thioacetamide	113-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-205
8638935-1	1996	Cytochrome P450 enzymes oxidize aldehydes either to the corresponding acid or, via a decarboxylation mechanism, to an olefin one carbon shorter than the parent substrate.	Alkenes	118-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8638935-1	1996	Cytochrome P450 enzymes oxidize aldehydes either to the corresponding acid or, via a decarboxylation mechanism, to an olefin one carbon shorter than the parent substrate.	Carbon	129-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8625495-2	1996	Our previous study demonstrated that cytochrome P450 (P450) 1A2 catalyzes the formation of 4-hydroxy-1-(3-pyridyl)-1-butanone (keto alcohol) (an alpha-hydroxylation product) from NNK in human liver microsomes.	4-hydroxy-1-(3-pyridyl)-1-butanone	91-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-63
8625495-2	1996	Our previous study demonstrated that cytochrome P450 (P450) 1A2 catalyzes the formation of 4-hydroxy-1-(3-pyridyl)-1-butanone (keto alcohol) (an alpha-hydroxylation product) from NNK in human liver microsomes.	keto alcohol	127-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-63
8801056-2	1996	The antifungal agent fluconazole was found to be a potent inhibitor of cytochrome P450 (P450) 2C9 (Ki = 7-8 microM), the principal enzyme responsible for the clearance (85%) of the more potent anticoagulant (S)-warfarin to the inactive (S)-7- and (S)-6-hydroxywarfarin metabolites in vivo.	Fluconazole	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-97
8801056-2	1996	The antifungal agent fluconazole was found to be a potent inhibitor of cytochrome P450 (P450) 2C9 (Ki = 7-8 microM), the principal enzyme responsible for the clearance (85%) of the more potent anticoagulant (S)-warfarin to the inactive (S)-7- and (S)-6-hydroxywarfarin metabolites in vivo.	Warfarin	211-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-97
8801056-2	1996	The antifungal agent fluconazole was found to be a potent inhibitor of cytochrome P450 (P450) 2C9 (Ki = 7-8 microM), the principal enzyme responsible for the clearance (85%) of the more potent anticoagulant (S)-warfarin to the inactive (S)-7- and (S)-6-hydroxywarfarin metabolites in vivo.	ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate	236-242	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-97
8801056-1	1996	I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.	Warfarin	67-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
8801056-2	1996	The antifungal agent fluconazole was found to be a potent inhibitor of cytochrome P450 (P450) 2C9 (Ki = 7-8 microM), the principal enzyme responsible for the clearance (85%) of the more potent anticoagulant (S)-warfarin to the inactive (S)-7- and (S)-6-hydroxywarfarin metabolites in vivo.	6-hydroxywarfarin	247-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-97
8801056-1	1996	I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.	Fluconazole	79-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
8801058-3	1996	The results of studies of the effect of fluconazole on cytochrome P450 (P450) 2C9 activity in vivo and in vitro are used to develop an approach to the safe management of the warfarin-fluconazole drug interaction.	Fluconazole	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-81
8801058-3	1996	The results of studies of the effect of fluconazole on cytochrome P450 (P450) 2C9 activity in vivo and in vitro are used to develop an approach to the safe management of the warfarin-fluconazole drug interaction.	Warfarin	174-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-81
8801058-3	1996	The results of studies of the effect of fluconazole on cytochrome P450 (P450) 2C9 activity in vivo and in vitro are used to develop an approach to the safe management of the warfarin-fluconazole drug interaction.	Fluconazole	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-81
8801060-6	1996	This route of dofetilide metabolism is mediated by cytochrome P450 (CYP).	dofetilide	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
8801060-6	1996	This route of dofetilide metabolism is mediated by cytochrome P450 (CYP).	dofetilide	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
8854046-2	1996	The study suggests that the "larger" inhibitors (such as the [2"(4"-aminophenyl)alkyl] pyrrolidine-2,5-dione based compounds), after an initial binding of the phenylamine nitrogen lone pair electrons with the Fe3+ haem of the cytochrome P-450, preferentially utilise the region of the AR active site which would normally bind C(17) = O of the substrate.	[2"(4"-aminophenyl)alkyl] pyrrolidine-2,5-dione	61-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8612780-1	1996	The CO-binding reaction of cytochrome P-450cam bound with (1R)-camphor and (1S)-camphor are compared in the temperature region of 210-260 K using time-resolved Fourier-transform infrared spectroscopy with the CO stretch vibration as spectroscopic probe.	Camphor	58-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
8612780-1	1996	The CO-binding reaction of cytochrome P-450cam bound with (1R)-camphor and (1S)-camphor are compared in the temperature region of 210-260 K using time-resolved Fourier-transform infrared spectroscopy with the CO stretch vibration as spectroscopic probe.	Camphor	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
8728119-0	1996	Human cytochrome P450"s are pro-oxidants in iron/ascorbate-initiated microsomal lipid peroxidation.	Iron	44-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Dextromethorphan	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Debrisoquin	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Sparteine	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Mephenytoin	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
8647341-1	1996	Cytochrome P450, the most versatile biological catalyst known, was originally named as a pigment having a carbon monoxide difference spectrum at about 450 nm and no known function.	Carbon Monoxide	106-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8728119-0	1996	Human cytochrome P450"s are pro-oxidants in iron/ascorbate-initiated microsomal lipid peroxidation.	Ascorbic Acid	49-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
8854046-2	1996	The study suggests that the "larger" inhibitors (such as the [2"(4"-aminophenyl)alkyl] pyrrolidine-2,5-dione based compounds), after an initial binding of the phenylamine nitrogen lone pair electrons with the Fe3+ haem of the cytochrome P-450, preferentially utilise the region of the AR active site which would normally bind C(17) = O of the substrate.	Aniline Compounds	159-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8728119-1	1996	We have examined the effect of human cytochrome P450"s (1A1,1A2,3A4,2A6,2B6,2D6,2E1) on ascorbate/iron-induced lipid peroxidation.	Ascorbic Acid	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
8854046-2	1996	The study suggests that the "larger" inhibitors (such as the [2"(4"-aminophenyl)alkyl] pyrrolidine-2,5-dione based compounds), after an initial binding of the phenylamine nitrogen lone pair electrons with the Fe3+ haem of the cytochrome P-450, preferentially utilise the region of the AR active site which would normally bind C(17) = O of the substrate.	Nitrogen	171-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8728119-1	1996	We have examined the effect of human cytochrome P450"s (1A1,1A2,3A4,2A6,2B6,2D6,2E1) on ascorbate/iron-induced lipid peroxidation.	Iron	98-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
8728119-4	1996	It is therefore concluded that cytochrome P450"s play a significant role in ascorbate/iron peroxidation.	Ascorbic Acid	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
8854046-2	1996	The study suggests that the "larger" inhibitors (such as the [2"(4"-aminophenyl)alkyl] pyrrolidine-2,5-dione based compounds), after an initial binding of the phenylamine nitrogen lone pair electrons with the Fe3+ haem of the cytochrome P-450, preferentially utilise the region of the AR active site which would normally bind C(17) = O of the substrate.	fe3+ haem	209-218	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8728119-4	1996	It is therefore concluded that cytochrome P450"s play a significant role in ascorbate/iron peroxidation.	Iron	86-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
20650183-1	1996	Phenoxyl radicals are inevitable intermediates in the oxidative enzymatic metabolism of a phenolic antitumour drug, etoposide (VP-16), by peroxidases, cytochrome P-450, prostaglandin synthetase and tyrosinase, as well as in its interactions with oxygen and peroxyl radicals.	Etoposide	116-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
8635732-0	1996	Cloning and characterization of the Saccharomyces cerevisiae C-22 sterol desaturase gene, encoding a second cytochrome P-450 involved in ergosterol biosynthesis.	Ergosterol	137-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-124
21781659-4	1996	The pivotal role of cytochrome P450 in the mutagenicity of ochratoxin A could be demonstrated in experiments with cell lines stably expressing the human cytochrome P450 enzymes.	ochratoxin A	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-35
21781659-4	1996	The pivotal role of cytochrome P450 in the mutagenicity of ochratoxin A could be demonstrated in experiments with cell lines stably expressing the human cytochrome P450 enzymes.	ochratoxin A	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
21781659-10	1996	The discrepancies found between microsomal and cellular metabolism leads to the conclusion that ochratoxin A mediated mutagenicity requires additional processing of cytochrome P450 derived metabolism.	ochratoxin A	96-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-180
8634277-1	1996	Two general models of the membrane topology of microsomal cytochrome P450 have been proposed: (1) deep immersion in the membrane, and (2) a P450cam-like heme domain anchored to the membrane with one or two membrane-spanning helices.	Heme	153-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
8634277-3	1996	Cytochrome P450 2B4 was reconstituted into unilamellar phospholipid proteoliposomes (molar protein to lipid ratio 1:90).	Phospholipids	55-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8907578-5	1996	In phenobarbital-treated mice, interferon beta reduced the induction of total cytochrome P-450 (22%), the activities of pentoxyresorufin O-dealkylase (38%), benzyloxyresorufin O-dealkylase (30%), erythromycin N-demethylase (30%), 7-ethoxycoumarin O-deethylase (16%) and cytochrome P-450 2B1 (33%) and 3A (45%) proteins.	Phenobarbital	3-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	270-286
20650183-1	1996	Phenoxyl radicals are inevitable intermediates in the oxidative enzymatic metabolism of a phenolic antitumour drug, etoposide (VP-16), by peroxidases, cytochrome P-450, prostaglandin synthetase and tyrosinase, as well as in its interactions with oxygen and peroxyl radicals.	phenoxy radical	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
8607732-2	1996	This results from macrolide inhibition of cytochrome P-450 metabolism of numerous xenobiotics, resulting in elevated serum drug levels and clinical intoxication.	Macrolides	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
11859386-6	1996	This enterprise has been assisted by the determination of the amino acide sequence and the X-ray crystal structure of the bacterial cytochrome P450, P450(CAM).	amino acide	62-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-147
18611706-1	1996	Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
18611706-1	1996	Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
18611706-1	1996	Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450.	Triazoles	50-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
8641823-5	1996	Cytochrome P-450 activity was determined at 4 and 24 hours by measuring the formation of 7-hydroxycoumarine (7-HC) from 7-ethoxycoumarine (7-EC).	7-hydroxycoumarin	89-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8555497-0	1996	Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein.	Retinoids	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
8555497-7	1996	After isolation of microsomes, measurements showed that levels of cytochrome P450 activities in both wild-type and RA-resistant HL-60 cells were almost comparable.	Tretinoin	115-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
8555497-11	1996	Possible mechanisms for accelerated clearance of RA include the induction of non-CYP1A1 cytochrome P450 enzymes and P-glycoprotein.	Tretinoin	49-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
8857078-1	1996	OBJECTIVES: The biotransformation of caffeine has been studied in vitro using human cytochrome P-450 isoenzymes (CYPs) expressed in human B-lymphoblastoid cell lines, namely CYP1A1, 1A2, 2A6, 2B6, 2D6-Val, 2E1 and 3A4, and microsomal epoxide hydroxylase (EH).	Caffeine	37-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
8542584-0	1996	Development of human cytochrome P450-expressing cell lines: application in mutagenicity testing of ochratoxin A.	ochratoxin A	99-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
8641823-5	1996	Cytochrome P-450 activity was determined at 4 and 24 hours by measuring the formation of 7-hydroxycoumarine (7-HC) from 7-ethoxycoumarine (7-EC).	7-hydroxycoumarin	109-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8641823-5	1996	Cytochrome P-450 activity was determined at 4 and 24 hours by measuring the formation of 7-hydroxycoumarine (7-HC) from 7-ethoxycoumarine (7-EC).	7-ethoxycoumarin	120-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8641823-5	1996	Cytochrome P-450 activity was determined at 4 and 24 hours by measuring the formation of 7-hydroxycoumarine (7-HC) from 7-ethoxycoumarine (7-EC).	7-ec	139-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8533008-0	1996	Cytochrome P450: structure, function, and generation of reactive oxygen species.	Reactive Oxygen Species	56-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8603034-6	1996	Cytochrome P450-dependent enzymes are involved in the synthesis and/or degradation of many endogenous compounds, such as steroids and retinoic acid.	Steroids	121-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8603034-6	1996	Cytochrome P450-dependent enzymes are involved in the synthesis and/or degradation of many endogenous compounds, such as steroids and retinoic acid.	Tretinoin	134-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8591087-1	1995	BACKGROUND: Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism.	liarozole	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
8896115-0	1996	Effect of imidazole derivatives on cytochrome P-450 enzyme activities in a reconstructed human epidermis.	imidazole	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
8615873-9	1995	The apparent Km,app and Vmax,app for norfentanyl formation were 82 +/- 21 microM and 4.7 +/- 0.4 nmol product formed/min/nmol cytochrome P450, respectively.	norfentanyl	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-141
8554320-1	1995	The NADH-dependent microsomal electron transfer system consists of NADH-cytochrome b5 reductase and cytochrome b5, which donates reducing equivalents to fatty acyl desaturase, cytochrome P450, and other reactions.	NAD	4-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-191
8689938-0	1995	Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.	Tacrolimus	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
8689938-5	1995	The cytochrome P450 (CYP) enzymes responsible for tacrolimus metabolism in small intestine were identified using specific CYP antibodies and inhibitors.	Tacrolimus	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
8689938-5	1995	The cytochrome P450 (CYP) enzymes responsible for tacrolimus metabolism in small intestine were identified using specific CYP antibodies and inhibitors.	Tacrolimus	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
8689938-5	1995	The cytochrome P450 (CYP) enzymes responsible for tacrolimus metabolism in small intestine were identified using specific CYP antibodies and inhibitors.	Tacrolimus	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-125
8591087-1	1995	BACKGROUND: Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism.	Steroids	96-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
8624504-0	1995	The comparative study of peroxidase activity and substrate binding properties of cytochrome P450 2B4 incorporated into phospholipid vesicles with the use of two different methods.	Phospholipids	119-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
8591087-1	1995	BACKGROUND: Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism.	Tretinoin	121-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
8591723-0	1995	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.	Ondansetron	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
8750397-3	1995	Cyclosporine and tacrolimus are metabolized by the cytochrome P-450 enzyme system.	Cyclosporine	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
8750397-3	1995	Cyclosporine and tacrolimus are metabolized by the cytochrome P-450 enzyme system.	Tacrolimus	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
8591723-5	1995	The data in this study collectively indicate that multiple cytochrome P450 forms, including CYP1A1, CYP1A2, CYP2D6, and the CYP3A subfamily, are probably involved in the clearance of ondansetron in humans, with no single form of cytochrome P450 dominating the overall metabolism of ondansetron.	Ondansetron	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
8591723-8	1995	It is therefore concluded that ondansetron is metabolized by multiple forms of cytochrome P450, and this limits the likelihood of a clinically relevant interaction with ondansetron by a modulator of a single form of cytochrome P450.	Ondansetron	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
8591723-5	1995	The data in this study collectively indicate that multiple cytochrome P450 forms, including CYP1A1, CYP1A2, CYP2D6, and the CYP3A subfamily, are probably involved in the clearance of ondansetron in humans, with no single form of cytochrome P450 dominating the overall metabolism of ondansetron.	Ondansetron	183-194	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	229-244
8591723-8	1995	It is therefore concluded that ondansetron is metabolized by multiple forms of cytochrome P450, and this limits the likelihood of a clinically relevant interaction with ondansetron by a modulator of a single form of cytochrome P450.	Ondansetron	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
8591723-8	1995	It is therefore concluded that ondansetron is metabolized by multiple forms of cytochrome P450, and this limits the likelihood of a clinically relevant interaction with ondansetron by a modulator of a single form of cytochrome P450.	Ondansetron	169-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-94
8591723-5	1995	The data in this study collectively indicate that multiple cytochrome P450 forms, including CYP1A1, CYP1A2, CYP2D6, and the CYP3A subfamily, are probably involved in the clearance of ondansetron in humans, with no single form of cytochrome P450 dominating the overall metabolism of ondansetron.	Ondansetron	282-293	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
8591723-8	1995	It is therefore concluded that ondansetron is metabolized by multiple forms of cytochrome P450, and this limits the likelihood of a clinically relevant interaction with ondansetron by a modulator of a single form of cytochrome P450.	Ondansetron	169-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
8588954-7	1995	Isolated HPTC also maintained levels of reduced glutathione (GSH) (11.9 +/- 3.2 nmol mg-1 protein) and exhibited cytochrome P450-dependent activity, levels of spectrally determined P450 being 0.22 +/- 0.07 nmol mg-1 protein.	hptc	9-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Zolpidem	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Zolpidem	116-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Alcohols	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Alcohols	132-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Carboxylic Acids	185-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
8591727-1	1995	The aim of this study was to identify the form(s) of cytochrome P450 (CYP) responsible for the biotransformation of zolpidem to its alcohol derivatives which, after rapid conversion to carboxylic acids, represents the main way of metabolism in humans.	Carboxylic Acids	185-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-73
8690232-2	1995	Dapsone is a potent anti-inflammatory and anti-parasitic compound, which is metabolised by cytochrome P-450 to hydroxylamines, which in turn cause methaemoglobinaemia and haemolysis.	Dapsone	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
8690232-2	1995	Dapsone is a potent anti-inflammatory and anti-parasitic compound, which is metabolised by cytochrome P-450 to hydroxylamines, which in turn cause methaemoglobinaemia and haemolysis.	Hydroxylamines	111-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
7559586-0	1995	The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5.	Methoxyflurane	66-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
7559586-0	1995	The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5.	Benzphetamine	85-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
8654202-0	1995	Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.	Finasteride	102-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
7559586-1	1995	The complete stoichiometry of the metabolism of the cytochrome b5 (cyt b5)-requiring substrate, methoxyflurane, by purified cytochrome P-450 2B4 was compared to that of another substrate, benzphetamine, which does not require cyt b5 for its metabolism.	Methoxyflurane	96-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	1,3-butadiene	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	1,3-butadiene	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	3,4-epoxy-1-butene	26-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	3,4-epoxy-1-butene	26-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	bmo	46-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-112
7586124-3	1995	Oxidation of butadiene to 1,2-epoxy-3-butene (BMO) and further activation to BDE is catalysed by cytochrome P450 (CYP) isozymes.	bmo	46-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
8654206-0	1995	Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.	zileuton	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
8654206-0	1995	Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	Carbon-14	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	Carbon-14	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	zileuton	129-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	zileuton	129-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
7588807-0	1995	Compressibility of the heme pocket of substrate analogue complexes of cytochrome P-450cam-CO.	Heme	23-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-92
16535142-3	1995	The enzyme responsible for this demethylation (31-O-FK-506 demethylase) was isolated and shown to be a soluble cytoplasmic protein which is constitutively expressed in the cells, which requires NADPH, ferredoxin-NADP(sup+)-reductase, and ferredoxin for activity, and which shows a cytochrome P-450 light absorption characteristic.	NADP	194-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	281-297
16535142-4	1995	Carbon monoxide saturation of the enzyme preparation and known mammalian cytochrome P-450 inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and sulfaphenazole abolish the demethylating activity extensively.	QUINIDINE HYDROCHLORIDE	109-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
16535142-4	1995	Carbon monoxide saturation of the enzyme preparation and known mammalian cytochrome P-450 inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and sulfaphenazole abolish the demethylating activity extensively.	Ketoconazole	124-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
16535142-4	1995	Carbon monoxide saturation of the enzyme preparation and known mammalian cytochrome P-450 inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and sulfaphenazole abolish the demethylating activity extensively.	Troleandomycin	138-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
16535142-4	1995	Carbon monoxide saturation of the enzyme preparation and known mammalian cytochrome P-450 inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and sulfaphenazole abolish the demethylating activity extensively.	Sulfaphenazole	158-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
16535142-6	1995	The isolated demethylase is therefore a cytochrome P-450 protein that can be used as a catalyst for the synthesis of 31-O-desmethylFK-506, an important immunosuppressant and a known metabolite of FK-506 metabolism by human liver microsomes.	31-o-	117-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
16535142-6	1995	The isolated demethylase is therefore a cytochrome P-450 protein that can be used as a catalyst for the synthesis of 31-O-desmethylFK-506, an important immunosuppressant and a known metabolite of FK-506 metabolism by human liver microsomes.	Tacrolimus	131-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
8654192-7	1995	The involvement of cytochrome P450 (CYP) in the metabolism of mofarotene was examined with human liver microsomes.	mofarotene	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
8654192-7	1995	The involvement of cytochrome P450 (CYP) in the metabolism of mofarotene was examined with human liver microsomes.	mofarotene	62-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	139-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	Carbon-14	186-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
8654206-1	1995	In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]zileuton (ABT-077) and its N-dehydroxylated metabolite, [14C]Abbott-66193, by human liver microsomes.	Carbon-14	186-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
8654206-3	1995	Results suggested that whereas the metabolism of zileuton and Abbott-66193 were mediated by the same CYP forms, the CYP forms responsible for hydroxylation (CYP1A2 and CYP2C9/10) were distinct from those involved in sulfoxidation (CYP3A &gt; CYP2C9/10).	zileuton	49-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
8654202-2	1995	In this study, we identified specific human cytochrome P450 (CYP) isozyme(s) involved in the in vitro metabolism of [14C]finasteride using CYP isozyme-selective inhibitors and microsomes containing specific recombinant human CYP isozymes (expressed in human AHH-1 TK+/-cells).	[14c]finasteride	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
8654202-2	1995	In this study, we identified specific human cytochrome P450 (CYP) isozyme(s) involved in the in vitro metabolism of [14C]finasteride using CYP isozyme-selective inhibitors and microsomes containing specific recombinant human CYP isozymes (expressed in human AHH-1 TK+/-cells).	[14c]finasteride	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
8654202-2	1995	In this study, we identified specific human cytochrome P450 (CYP) isozyme(s) involved in the in vitro metabolism of [14C]finasteride using CYP isozyme-selective inhibitors and microsomes containing specific recombinant human CYP isozymes (expressed in human AHH-1 TK+/-cells).	[14c]finasteride	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
8654202-2	1995	In this study, we identified specific human cytochrome P450 (CYP) isozyme(s) involved in the in vitro metabolism of [14C]finasteride using CYP isozyme-selective inhibitors and microsomes containing specific recombinant human CYP isozymes (expressed in human AHH-1 TK+/-cells).	[14c]finasteride	116-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-142
8654202-9	1995	Other selective CYP inhibitors for CYP1A1/2 (alpha-naphthoflavone), CYP2C8-10 (sulfaphenazole), CYP2D6 (quinidine), and CYP2E1 (diallylsulfone) showed minor or no effects on both reactions.	alpha-naphthoflavone	45-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
8654202-9	1995	Other selective CYP inhibitors for CYP1A1/2 (alpha-naphthoflavone), CYP2C8-10 (sulfaphenazole), CYP2D6 (quinidine), and CYP2E1 (diallylsulfone) showed minor or no effects on both reactions.	Sulfaphenazole	79-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
8654202-9	1995	Other selective CYP inhibitors for CYP1A1/2 (alpha-naphthoflavone), CYP2C8-10 (sulfaphenazole), CYP2D6 (quinidine), and CYP2E1 (diallylsulfone) showed minor or no effects on both reactions.	Quinidine	104-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
8654202-9	1995	Other selective CYP inhibitors for CYP1A1/2 (alpha-naphthoflavone), CYP2C8-10 (sulfaphenazole), CYP2D6 (quinidine), and CYP2E1 (diallylsulfone) showed minor or no effects on both reactions.	diallyl sulfone	128-142	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-19
7496999-11	1995	The greatest increase in N-demethylation activity was observed in the reconstitution system with the lowest concentration of cytochrome P-450 reductase, conditions which most closely resemble intact microsomes.	Nitrogen	25-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
8847710-0	1995	Some aspects of the role of cytochrome P-450 isozymes in the N-oxidative transformation of secondary and tertiary amine compounds.	Amines	114-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
8847710-1	1995	Indirect evidence of the participation of cytochrome P-450 (P-450) in the microsomal N-oxygenation of secondary and tertiary nitrogen functions is presented by studies employing diagnostic modifiers of the hemoprotein system as well as antibodies directed toward the diverse P-450 isoforms and NADPH-cytochrome P-450 reductase.	Nitrogen	85-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
8847710-1	1995	Indirect evidence of the participation of cytochrome P-450 (P-450) in the microsomal N-oxygenation of secondary and tertiary nitrogen functions is presented by studies employing diagnostic modifiers of the hemoprotein system as well as antibodies directed toward the diverse P-450 isoforms and NADPH-cytochrome P-450 reductase.	Nitrogen	125-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
7491124-5	1995	The alterations, by beta-carbolines, of some important enzymatic systems, e.g. cytochrome P-450, have been clearly demonstrated, yet many discrepancies and contradictions exist so that an interpretation of the results and the definition of some common mechanism appears premature.	Carbolines	20-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-95
7493150-1	1995	The cytochrome P450-dependent monooxygenases constitute the primary enzyme system responsible for the oxidative metabolism of a variety of xenobiotics and endogenous compounds including drugs, carcinogens, fatty acids and hormones.	Fatty Acids	206-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Lidocaine	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Lidocaine	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
7636727-3	1995	Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
7636727-3	1995	Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide.	Lidocaine	106-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
7636727-3	1995	Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide.	monoethylglycinexylidide	143-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
8536426-2	1995	The high probability of interactions can be explained by two pharmacokinetic properties of coumarins: high binding to plasma albumin (99%), being displaced by other drugs with greater affinity to this protein, and metabolism by liver microsomal enzymes (cytochrome P450), which can be induced or inhibited by other compounds (Shinn &amp; Shrewsbury 1985).	Coumarins	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-269
7623862-2	1995	BD is metabolized by cytochrome P-450-dependent monoxygenases to the primary metabolite 1,2-epoxybutene-3 (epoxybutene, EB).	3,4-epoxy-1-butene	88-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
7623862-2	1995	BD is metabolized by cytochrome P-450-dependent monoxygenases to the primary metabolite 1,2-epoxybutene-3 (epoxybutene, EB).	3,4-epoxy-1-butene	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
7623862-2	1995	BD is metabolized by cytochrome P-450-dependent monoxygenases to the primary metabolite 1,2-epoxybutene-3 (epoxybutene, EB).	ethylbenzene	120-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
7622489-0	1995	Different mechanisms of hydroxylation site selection by liver and kidney cytochrome P450 species (CYP27 and CYP24) involved in vitamin D metabolism.	Vitamin D	127-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
7622489-3	1995	Lengthening the side chain is tolerated by each cytochrome P450 isoform such that 25-hydroxylation or 24-hydroxylation continues to occur at the same rate as in the native side chain, while the site of hydroxylation remains the same for the liver enzyme in that CYP27 continues to hydroxylate at C-25 and C-27 (minor) despite the two-carbon-atom extension.	Carbon	262-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
7622489-3	1995	Lengthening the side chain is tolerated by each cytochrome P450 isoform such that 25-hydroxylation or 24-hydroxylation continues to occur at the same rate as in the native side chain, while the site of hydroxylation remains the same for the liver enzyme in that CYP27 continues to hydroxylate at C-25 and C-27 (minor) despite the two-carbon-atom extension.	Carbon	296-297	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
7622489-3	1995	Lengthening the side chain is tolerated by each cytochrome P450 isoform such that 25-hydroxylation or 24-hydroxylation continues to occur at the same rate as in the native side chain, while the site of hydroxylation remains the same for the liver enzyme in that CYP27 continues to hydroxylate at C-25 and C-27 (minor) despite the two-carbon-atom extension.	Carbon	334-340	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
7625847-1	1995	The membrane-bound endogenous fatty acid arachidonic acid can be released from membranes by phospholipases and then metabolized to biologically active compounds by cyclooxygenases, lipoxygenases, and cytochrome P450 (CYP) enzymes.	Fatty Acids	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-215
7625847-1	1995	The membrane-bound endogenous fatty acid arachidonic acid can be released from membranes by phospholipases and then metabolized to biologically active compounds by cyclooxygenases, lipoxygenases, and cytochrome P450 (CYP) enzymes.	Fatty Acids	30-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
7625847-1	1995	The membrane-bound endogenous fatty acid arachidonic acid can be released from membranes by phospholipases and then metabolized to biologically active compounds by cyclooxygenases, lipoxygenases, and cytochrome P450 (CYP) enzymes.	Arachidonic Acid	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-215
7625847-1	1995	The membrane-bound endogenous fatty acid arachidonic acid can be released from membranes by phospholipases and then metabolized to biologically active compounds by cyclooxygenases, lipoxygenases, and cytochrome P450 (CYP) enzymes.	Arachidonic Acid	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	217-220
7625847-3	1995	Liver CYP arachidonate products include epoxyeicosatrienoic acids (EETs) and monohydroxylated products (HETEs).	Arachidonic Acid	10-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
7625847-3	1995	Liver CYP arachidonate products include epoxyeicosatrienoic acids (EETs) and monohydroxylated products (HETEs).	epoxyeicosatrienoic acids	40-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
7625847-3	1995	Liver CYP arachidonate products include epoxyeicosatrienoic acids (EETs) and monohydroxylated products (HETEs).	eets	67-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
7625847-4	1995	We examined metabolism of [1-14C]arachidonic acid by a panel of 10 human CYP enzymes expressed in HepG2 cells.	Arachidonic Acid	26-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-76
7788513-13	1995	Cross-reactivity with other anticonvulsant agents capable of forming arene oxide intermediates occurs in the cytochrome P-450 system.	Benzene oxide	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
8536426-2	1995	The high probability of interactions can be explained by two pharmacokinetic properties of coumarins: high binding to plasma albumin (99%), being displaced by other drugs with greater affinity to this protein, and metabolism by liver microsomal enzymes (cytochrome P450), which can be induced or inhibited by other compounds (Shinn &amp; Shrewsbury 1985).	shinn &amp	326-336	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	254-269
8586256-0	1995	Probing the cytochrome P-450 2B1 active site with diamantoid compounds.	diamantoid	50-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
8586256-1	1995	Hydrocarbone diamantane has been shown to be a specific substrate with a high affinity for the binding site of PB-inducible cytochrome P-450 2B1 (Hodek et al.	hydrocarbone diamantane	0-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
8586256-7	1995	Of all oxygen containing derivatives diamantane 1,6-dicarboxylic acid dimethylester only exhibited a pronounced ligand interaction with cytochrome P-450.	diamantane 1,6-dicarboxylic acid dimethylester	37-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
8586256-1	1995	Hydrocarbone diamantane has been shown to be a specific substrate with a high affinity for the binding site of PB-inducible cytochrome P-450 2B1 (Hodek et al.	Lead	111-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	395-411
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	395-411
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
8586256-4	1995	Of the compounds (diamantane and its analogues, adamantane and triamantane) tested, diamantane had the lowest value of a spectral dissociation constant Ks = 0.5 mumol/l, indicating that diamantane was accommodated well to the cytochrome P-450 2B1, hence values of 0.46 nm and 0.66 nm for the width and length of the diamantane molecule, respectively, were used to describe of the dimensions the cytochrome P-450 binding site.	Adamantane	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	395-411
8586256-7	1995	Of all oxygen containing derivatives diamantane 1,6-dicarboxylic acid dimethylester only exhibited a pronounced ligand interaction with cytochrome P-450.	Oxygen	7-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
8685072-12	1995	This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450.	Fluoxetine	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
8685072-12	1995	This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450.	Fluvoxamine	41-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
7750560-1	1995	13CO NMR chemical shifts and 12CO infrared stretching frequencies have been measured for cytochrome P-450cam-CO in the presence of D-camphor and of various camphor analogues.	Camphor	131-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-111
7539291-8	1995	Not only does the heme pocket of NOS have the same coordination as cytochrome P-450 in its stable form, but the partially denatured form has the same properties as cytochrome P-420, the inactive form of cytochrome P-450.	Heme	18-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	203-219
7750560-1	1995	13CO NMR chemical shifts and 12CO infrared stretching frequencies have been measured for cytochrome P-450cam-CO in the presence of D-camphor and of various camphor analogues.	Camphor	133-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-111
7723077-9	1995	We conclude that DES is metabolized to histone-binding metabolites, presumably by nuclear cytochrome P-450.	Diethylstilbestrol	17-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
7640150-0	1995	Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.	Propranolol	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-27
7640150-2	1995	Studies using human liver microsomes and six recombinant human CYP isoforms (i.e. CYP1A2, 2A6, 2B6, 2D6, 2E1 and 3A4) were performed to identify the cytochrome P450 (CYP) isoform(s) involved in the ring 4-hydroxylation and side-chain N-desisopropylation of propranolol enantiomers in humans.	Nitrogen	234-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
7640150-2	1995	Studies using human liver microsomes and six recombinant human CYP isoforms (i.e. CYP1A2, 2A6, 2B6, 2D6, 2E1 and 3A4) were performed to identify the cytochrome P450 (CYP) isoform(s) involved in the ring 4-hydroxylation and side-chain N-desisopropylation of propranolol enantiomers in humans.	Propranolol	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-164
7627274-7	1995	Immunohistochemical analysis revealed that tumor cells were positively stained for C21 hydroxylase cytochrome P-450 (P-450C21) and P-450(11) beta which convert 17-hydroxy (OH) progesterone to cortisol as well as P-450SCC, 3 beta-hydroxysteroid dehydrogenase and P-450(17) alpha which are involved in testosterone biosynthesis.	17-hydroxy (oh) progesterone	160-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7627274-7	1995	Immunohistochemical analysis revealed that tumor cells were positively stained for C21 hydroxylase cytochrome P-450 (P-450C21) and P-450(11) beta which convert 17-hydroxy (OH) progesterone to cortisol as well as P-450SCC, 3 beta-hydroxysteroid dehydrogenase and P-450(17) alpha which are involved in testosterone biosynthesis.	Hydrocortisone	192-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7627274-7	1995	Immunohistochemical analysis revealed that tumor cells were positively stained for C21 hydroxylase cytochrome P-450 (P-450C21) and P-450(11) beta which convert 17-hydroxy (OH) progesterone to cortisol as well as P-450SCC, 3 beta-hydroxysteroid dehydrogenase and P-450(17) alpha which are involved in testosterone biosynthesis.	Testosterone	300-312	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
7796864-7	1995	Dexamethasone, already used in patients to reduce the toxicity of interleukin-2 therapy, provided full protection against the cytochrome P-450 depression.	Dexamethasone	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
7663534-0	1995	Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus.	bunitrolol	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
7620235-12	1995	This again was to be expected, considering the known inhibitory effect of cimetidine on cytochrome P450.	Cimetidine	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
7616365-1	1995	This study was conducted in eight healthy volunteers to assess the time course of induction of cytochrome P-450 by phenytoin.	Phenytoin	115-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
7628308-0	1995	N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.	Sulfamethoxazole	20-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
7534104-3	1995	Several studies indicate that cytochrome P450-dependent metabolites of sulphonamides act as the nominal allergens.	Sulfonamides	71-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
7537544-0	1995	Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.	Arachidonic Acid	52-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
7864832-20	1995	The striking contrast between DBM and cytochrome P-450, which carries out both epoxidation and allylic oxidation with non-conjugated olefinic substrates, is probably a reflection of the differences in redox potential of the activated oxygen species operative for these two enzymes.	olefinic	133-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
7864832-20	1995	The striking contrast between DBM and cytochrome P-450, which carries out both epoxidation and allylic oxidation with non-conjugated olefinic substrates, is probably a reflection of the differences in redox potential of the activated oxygen species operative for these two enzymes.	Oxygen	234-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
7891318-2	1995	Kinetic and inhibitor studies with human liver microsomes and complementary DNA-expressed enzyme were performed to identify the cytochrome P450 (CYP) isoform responsible for torsemide tolyl methylhydroxylation to predict factors that might alter clearance in patients receiving torsemide.	Torsemide	174-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-143
7891318-2	1995	Kinetic and inhibitor studies with human liver microsomes and complementary DNA-expressed enzyme were performed to identify the cytochrome P450 (CYP) isoform responsible for torsemide tolyl methylhydroxylation to predict factors that might alter clearance in patients receiving torsemide.	Torsemide	174-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
7891318-2	1995	Kinetic and inhibitor studies with human liver microsomes and complementary DNA-expressed enzyme were performed to identify the cytochrome P450 (CYP) isoform responsible for torsemide tolyl methylhydroxylation to predict factors that might alter clearance in patients receiving torsemide.	Torsemide	278-287	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-143
7891318-2	1995	Kinetic and inhibitor studies with human liver microsomes and complementary DNA-expressed enzyme were performed to identify the cytochrome P450 (CYP) isoform responsible for torsemide tolyl methylhydroxylation to predict factors that might alter clearance in patients receiving torsemide.	Torsemide	278-287	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
7850793-6	1995	Plasma concentrations of dechlorethylcyclophosphamide and carboxyphosphamide were correlated in individual patients, suggesting that the activity of both aldehyde dehydrogenase and cytochrome P450 enzyme(s) determine carboxyphosphamide production in vivo.	dechlorethylcyclophosphamide	25-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
7850793-6	1995	Plasma concentrations of dechlorethylcyclophosphamide and carboxyphosphamide were correlated in individual patients, suggesting that the activity of both aldehyde dehydrogenase and cytochrome P450 enzyme(s) determine carboxyphosphamide production in vivo.	carboxyphosphamide	58-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
7850793-6	1995	Plasma concentrations of dechlorethylcyclophosphamide and carboxyphosphamide were correlated in individual patients, suggesting that the activity of both aldehyde dehydrogenase and cytochrome P450 enzyme(s) determine carboxyphosphamide production in vivo.	carboxyphosphamide	217-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	Losartan	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-219
7540767-3	1995	In order for AFB1 to exert its effects, it must be converted to its reactive epoxide by the action of the mixed function mono-oxygenase enzyme systems (cytochrome P450-dependent) in the tissues (in particular, the liver) of the affected animal.	Aflatoxin B1	13-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
7540767-3	1995	In order for AFB1 to exert its effects, it must be converted to its reactive epoxide by the action of the mixed function mono-oxygenase enzyme systems (cytochrome P450-dependent) in the tissues (in particular, the liver) of the affected animal.	Epoxy Compounds	77-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	Losartan	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-224
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	Aldehydes	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-219
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	Aldehydes	48-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-224
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	e3179	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-219
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	e3179	70-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-224
7736913-5	1995	The oxidation of both losartan and the putative aldehyde intermediate E3179 was catalyzed by the microsomal fraction, required both NADPH and molecular oxygen, and was inhibited by SKF 525-A, implicating cytochrome P450 (CYP).	Proadifen	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-219
7840155-1	1995	Cytochrome P-450 (P-450) is a NADPH-requiring and O2-dependent monooxygenase system.	NADP	30-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
15299332-0	1995	Modeling protein-substrate interactions in the heme domain of cytochrome P450(BM-3).	Heme	47-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-82
7840218-1	1995	Leukotoxin (Lx), a cytochrome P-450-dependent metabolite of linoleate synthesized by neutrophils or synthesized by OH- and linoleate in neutrophil cell membranes, has been recovered in lung lavages of patients with the adult respiratory distress syndrome.	Linoleic Acid	60-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
7967726-8	1994	Both of these hypercatabolic states can be modulated by concurrent administration of ketoconazole, an inhibitor of cytochrome P-450 and lipoxygenase-mediated oxidations.	Ketoconazole	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-148
7703274-1	1995	The NADPH-adrenodoxin complex with adrenodoxin is responsible for the transformation of the two-electron flow from NADH to the mono-electron flow to cytochrome P-450 in the steroid-hydroxyl enzyme system of mitochondria of kidney crust.	nadph-adrenodoxin	4-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
7703274-1	1995	The NADPH-adrenodoxin complex with adrenodoxin is responsible for the transformation of the two-electron flow from NADH to the mono-electron flow to cytochrome P-450 in the steroid-hydroxyl enzyme system of mitochondria of kidney crust.	NAD	115-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
7703274-1	1995	The NADPH-adrenodoxin complex with adrenodoxin is responsible for the transformation of the two-electron flow from NADH to the mono-electron flow to cytochrome P-450 in the steroid-hydroxyl enzyme system of mitochondria of kidney crust.	Steroids	173-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Fluvoxamine	335-346	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Venlafaxine Hydrochloride	352-363	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Venlafaxine Hydrochloride	352-363	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
7756927-6	1995	This mechanism operates with all the substrates and all cytochrome P-450 forms capable of catalyzing the partially coupled monooxygenase reactions proceeding with the formation of hydrogen peroxide as a by-product.	Hydrogen Peroxide	180-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
7981206-1	1994	Camphor binding to ferric cytochrome P-450cam is a two-step process.	Camphor	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Diazepam	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Diazepam	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Nordazepam	124-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Nordazepam	124-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Temazepam	167-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Temazepam	167-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Mephenytoin	272-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
7704038-1	1994	Metabolism of diazepam was studied in vitro to identify the forms of cytochrome P450 (CYP) responsible for N-demethylation (nordazepam formation) and 3-hydroxylation (temazepam formation), using liver microsomes obtained from extensive (EM) and poor metabolizers (PM) for S-mephenytoin 4"-hydroxylation.	Mephenytoin	272-285	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-89
7895609-0	1994	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes.	Propranolol	37-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
7895609-3	1994	We characterized cytochrome P450 isozymes responsible for propranolol metabolism, especially N-desisopropylation and 5-hydroxylation, in human liver microsomes.	Propranolol	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
7895609-3	1994	We characterized cytochrome P450 isozymes responsible for propranolol metabolism, especially N-desisopropylation and 5-hydroxylation, in human liver microsomes.	Nitrogen	93-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
7959460-3	1994	A group of 19 acyclic terpenes have been evaluated for potential toxicity/carcinogenicity by molecular orbital determinations of their spatial and electronic parameters, and hence prediction of their metabolic activation or detoxication by the cytochrome P-450 (CYP) superfamily of mixed-function oxidase enzymes.	Terpenes	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	244-260
7959460-3	1994	A group of 19 acyclic terpenes have been evaluated for potential toxicity/carcinogenicity by molecular orbital determinations of their spatial and electronic parameters, and hence prediction of their metabolic activation or detoxication by the cytochrome P-450 (CYP) superfamily of mixed-function oxidase enzymes.	Terpenes	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
7532811-7	1994	As a cytochrome P-450, NOS catalyzes a heme-mediated reduction of molecular oxygen, resulting in the formation of H2O2 in the absence of L-arginine.	Heme	39-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
7532811-7	1994	As a cytochrome P-450, NOS catalyzes a heme-mediated reduction of molecular oxygen, resulting in the formation of H2O2 in the absence of L-arginine.	Oxygen	76-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
7532811-7	1994	As a cytochrome P-450, NOS catalyzes a heme-mediated reduction of molecular oxygen, resulting in the formation of H2O2 in the absence of L-arginine.	Hydrogen Peroxide	114-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
7532811-7	1994	As a cytochrome P-450, NOS catalyzes a heme-mediated reduction of molecular oxygen, resulting in the formation of H2O2 in the absence of L-arginine.	Arginine	137-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
7695156-9	1995	These results indicate that cytochrome P-450 metabolic pathways have an important role in propofol clearance and propofol anesthetic recovery in Greyhounds.	Propofol	90-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
7695156-9	1995	These results indicate that cytochrome P-450 metabolic pathways have an important role in propofol clearance and propofol anesthetic recovery in Greyhounds.	Propofol	113-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
8846617-10	1995	The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown.	Fluvoxamine	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
8846617-10	1995	The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown.	Fluvoxamine	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Venlafaxine Hydrochloride	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Venlafaxine Hydrochloride	56-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Sparteine	204-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Sparteine	204-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Dextromethorphan	221-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Dextromethorphan	221-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Paroxetine	250-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Paroxetine	250-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Fluoxetine	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Fluoxetine	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	norfluoxetine	290-303	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	norfluoxetine	290-303	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Sertraline	314-324	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Sertraline	314-324	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine &gt; fluoxetine identical to norfluoxetine &gt; or = sertraline &gt; or = fluvoxamine &gt; venlafaxine.	Fluvoxamine	335-346	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
7713363-11	1995	DL decreased the PB-induced BND activity and cytochrome P-450 and cytochrome b5 content.	Phenobarbital	17-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-79
7745225-3	1995	CCl4-induced changes in hepatic biochemical parameters by reducing cytochrome P-450, by comparing the effects of colchicine and SKF 525-A, a well-known inhibitor of cytochrome P-450.	Proadifen	128-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
7532106-3	1994	These studies involved the use of the imidazole antimycotics, econazole and miconazole, which are inhibitors of cytochrome P-450.	imidazole	38-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7532106-3	1994	These studies involved the use of the imidazole antimycotics, econazole and miconazole, which are inhibitors of cytochrome P-450.	Econazole	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
7532106-3	1994	These studies involved the use of the imidazole antimycotics, econazole and miconazole, which are inhibitors of cytochrome P-450.	Miconazole	76-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
8082935-1	1994	The catabolism of various calcium channel blockers through cytochrome P-450 is heterogeneous and may be modified by concomitant use of cyclosporin A.	Cyclosporine	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
7873467-6	1994	Both the relaxing effect on vascular smooth muscle and the effect on platelets are considered to be due to a stimulation of soluble guanylate cyclase by nitric oxide derived from the organic nitrate ester molecule through metabolization catalyzed by enzymes such as glutathione S-transferase, cytochrome P-450, and possibly esterases.	Nitric Oxide	153-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	293-309
7873467-6	1994	Both the relaxing effect on vascular smooth muscle and the effect on platelets are considered to be due to a stimulation of soluble guanylate cyclase by nitric oxide derived from the organic nitrate ester molecule through metabolization catalyzed by enzymes such as glutathione S-transferase, cytochrome P-450, and possibly esterases.	nitrate ester	191-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	293-309
7949373-1	1994	Metabolic N-dealkylation is a commonly observed biotransformation with tertiary and secondary amine drugs and related N-alkylated amides, but surprisingly little is known about the cytochrome P-450 isozymes involved in these dealkylation reactions.	Nitrogen	10-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
8052309-0	1994	An efficient mimic of cytochrome P-450 from a zeolite-encaged iron complex in a polymer membrane.	Zeolites	46-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8052309-0	1994	An efficient mimic of cytochrome P-450 from a zeolite-encaged iron complex in a polymer membrane.	Iron	62-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8052309-0	1994	An efficient mimic of cytochrome P-450 from a zeolite-encaged iron complex in a polymer membrane.	Polymers	80-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8052309-7	1994	The polymer acts as a mimic of the phospholipid membrane in which cytochrome P-450 resides, acting as an interface between two immiscible phases and avoiding the need for solvents or phase-transfer agents.	Polymers	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
8052309-7	1994	The polymer acts as a mimic of the phospholipid membrane in which cytochrome P-450 resides, acting as an interface between two immiscible phases and avoiding the need for solvents or phase-transfer agents.	Phospholipids	35-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
8068004-6	1994	Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively.	Miconazole	69-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8068004-6	1994	Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively.	Econazole	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8068004-6	1994	Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively.	Clotrimazole	92-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8068004-6	1994	Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively.	Ketoconazole	109-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8068004-6	1994	Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively.	Thapsigargin	136-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8068004-9	1994	We examined whether the inhibition of Ca2+ influx was due to an interaction of the inhibitor imidazole nitrogen with the haem iron of the putative cytochrome P-450 by comparing the activity of two compounds, identical except that one was methylated at the imidazole 2-position.	imidazole nitrogen	93-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
8068004-9	1994	We examined whether the inhibition of Ca2+ influx was due to an interaction of the inhibitor imidazole nitrogen with the haem iron of the putative cytochrome P-450 by comparing the activity of two compounds, identical except that one was methylated at the imidazole 2-position.	Iron	126-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
8068004-9	1994	We examined whether the inhibition of Ca2+ influx was due to an interaction of the inhibitor imidazole nitrogen with the haem iron of the putative cytochrome P-450 by comparing the activity of two compounds, identical except that one was methylated at the imidazole 2-position.	imidazole	93-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
7986010-7	1994	A possible explanation of drug resistance based on the observation of suicide inactivation of bacterial cytochrome P-450 by the cyclopropylamine moiety has also been proposed and is discussed in this report.	cyclopropylamine	128-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Diazepam	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Diazepam	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Diazepam	203-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Diazepam	203-211	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Temazepam	225-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Temazepam	225-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Nordazepam	239-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-145
7981013-2	1994	The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam.	Nordazepam	239-258	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
7981013-11	1994	Studies with a series of CYP isoform selective inhibitors and with an inhibitory anti-CYP2C antibody indicated that temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase.	Temazepam	116-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
7935340-1	1994	Bufuralol 1"-hydroxylation is a prototypical reaction catalyzed by cytochrome P450 (P450) 2D6, an enzyme known to show debrisoquine/sparteine-type genetic polymorphism in humans.	bufuralol	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-93
7935340-1	1994	Bufuralol 1"-hydroxylation is a prototypical reaction catalyzed by cytochrome P450 (P450) 2D6, an enzyme known to show debrisoquine/sparteine-type genetic polymorphism in humans.	Debrisoquin	119-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-93
8037457-1	1994	Human cytochrome P450 (P450) 1A1 is primarily an extrahepatic enzyme and is important because of its roles in the activation of polycyclic hydrocarbons and other xenobiotic chemicals.	Hydrocarbons, Cyclic	128-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-32
7917780-0	1994	Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.	Omeprazole	75-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
7519397-1	1994	Ketoconazole, cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate, and gossypol are reported inhibitors of the lipoxygenase (LO) and cytochrome P-450 enzyme systems and are potent blockers of swelling-activated efflux of organic osmolytes and volume-sensitive anion channels in C6 glioma cells.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
7519397-1	1994	Ketoconazole, cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate, and gossypol are reported inhibitors of the lipoxygenase (LO) and cytochrome P-450 enzyme systems and are potent blockers of swelling-activated efflux of organic osmolytes and volume-sensitive anion channels in C6 glioma cells.	CINNAMYL-3,4-DIHYDROXY-ALPHA-CYANOCINNAMATE	14-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
7519397-1	1994	Ketoconazole, cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate, and gossypol are reported inhibitors of the lipoxygenase (LO) and cytochrome P-450 enzyme systems and are potent blockers of swelling-activated efflux of organic osmolytes and volume-sensitive anion channels in C6 glioma cells.	Gossypol	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
7519397-2	1994	To directly test the hypothesis that LO- or cytochrome P-450-derived products of arachidonic acid (AA) participate in the regulation of these volume-sensitive transport pathways, we incubated C6 cells with [1-14C]AA and observed the extent and profile of its conversion under basal conditions and after acute swelling.	Arachidonic Acid	81-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-60
7948817-3	1994	Cytochrome P450 content was reduced to 17% of control values after acute carbon tetrachloride and to 35% of control values after bile duct ligation.	Carbon Tetrachloride	73-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Troleandomycin	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Troleandomycin	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Troleandomycin	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Troleandomycin	57-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	alpha-naphthoflavone	63-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	alpha-naphthoflavone	63-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Ditiocarb	95-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Ditiocarb	95-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Ditiocarb	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	190-205
8203907-1	1994	A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated.	Ditiocarb	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
7917780-2	1994	The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole.	Omeprazole	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
7917780-2	1994	The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole.	Omeprazole	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
7917780-2	1994	The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole.	Omeprazole	238-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
8081318-5	1994	The demethylation of caffeine by the hepatic cytochrome P-450 oxygenases begins within minutes and dimethylxanthines (especially paraxanthine) are generated.	Caffeine	21-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
7917780-2	1994	The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole.	Omeprazole	238-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-165
8081318-5	1994	The demethylation of caffeine by the hepatic cytochrome P-450 oxygenases begins within minutes and dimethylxanthines (especially paraxanthine) are generated.	Theophylline	99-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
8081318-5	1994	The demethylation of caffeine by the hepatic cytochrome P-450 oxygenases begins within minutes and dimethylxanthines (especially paraxanthine) are generated.	1,7-dimethylxanthine	129-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
7917780-6	1994	The formation kinetics of these two metabolites from omeprazole sulphone were biphasic suggesting the involvement of multiple CYP isoforms in each case.	omeprazole sulfone	53-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129
8043490-15	1994	Non-steroidal inhibitors of cytochrome P-450 enzymes, such as imidazole and triazole derivatives have been developed which are highly selective for aromatase.	imidazole	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
8043490-15	1994	Non-steroidal inhibitors of cytochrome P-450 enzymes, such as imidazole and triazole derivatives have been developed which are highly selective for aromatase.	Triazoles	76-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
8022422-1	1994	The antihypertensive drug dihydralazine may, on rare occasions, cause immunoallergic hepatitis characterized by anti-cytochrome P450 (P450)1A2 autoantibodies.	Dihydralazine	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-142
8054246-2	1994	The activation of proguanil to cycloguanil by human liver microsomes was studied to define the cytochrome P450 (CYP) isoforms involved in this reaction.	Proguanil	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-110
8175769-0	1994	NADPH-initiated cytochrome P450-mediated free metal ion-independent oxidative damage of microsomal proteins.	NADP	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
8175769-0	1994	NADPH-initiated cytochrome P450-mediated free metal ion-independent oxidative damage of microsomal proteins.	Metals	46-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
8175769-2	1994	In this paper we demonstrate that NADPH-initiated oxidative damage of microsomal proteins occurs in the absence of free metal ions and that this protein oxidation is mediated by cytochrome P450 (cyt P450).	NADP	34-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	178-193
8175769-2	1994	In this paper we demonstrate that NADPH-initiated oxidative damage of microsomal proteins occurs in the absence of free metal ions and that this protein oxidation is mediated by cytochrome P450 (cyt P450).	NADP	34-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-203
8175769-4	1994	Ascorbate (AH2) specifically inhibits free metal ion-independent cyt P450-mediated protein oxidation and thereby prevents subsequent proteolytic degradation.	Ascorbic Acid	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-73
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	ammonium ferrous sulfate	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-8
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	ammonium ferrous sulfate	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-42
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	ammonium ferrous sulfate	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	ammonium ferrous sulfate	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	ammonium ferrous sulfate	65-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-8
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-42
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	86-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	fe2+ o2	144-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-8
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	fe2+ o2	144-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-42
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	fe2+ o2	144-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	fe2+ o2	144-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	fe2+ o2	144-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	perferryl	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-8
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	perferryl	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-42
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	perferryl	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	perferryl	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	perferryl	186-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	149-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-8
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	149-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-42
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	149-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	149-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
8175769-9	1994	Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O2-..	Oxygen	149-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-64
7938083-0	1994	5-Aminosalicylic acid inhibits leukotriene B4 omega-hydroxylase activity in human polymorphonuclear leukocytes.	Mesalamine	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-63
7938083-2	1994	To investigate the action of 5-aminosalicylic acid (5-ASA) on LTB4 omega-hydroxylase activity, we incubated human polymorphonuclear leukocytes (PMNLs) with 3H-labeled LTB4 after pre-incubation with various concentrations of 5-ASA.	Mesalamine	52-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-84
7938083-4	1994	LTB4 omega-hydroxylase activity was inhibited by 5-ASA in a concentration-dependent fashion.	Mesalamine	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-22
8054246-2	1994	The activation of proguanil to cycloguanil by human liver microsomes was studied to define the cytochrome P450 (CYP) isoforms involved in this reaction.	Proguanil	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-115
8054246-2	1994	The activation of proguanil to cycloguanil by human liver microsomes was studied to define the cytochrome P450 (CYP) isoforms involved in this reaction.	cycloguanil	31-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-115
8207335-8	1994	Corneal epithelial hypoxia in response to contact lens wear results in the time-dependent formation of NADPH-cytochrome P450-dependent arachidonate metabolites, 12(R)-HETE and 12(R)-HETrE.	(r)-hetre	178-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
8205227-11	1994	Eugenol elicited type 1 changes in the spectrum of microsomal cytochrome P-450.	Eugenol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
8205227-13	1994	Eugenol significantly protected against the degradation of cytochrome P-450 during lipid peroxidation with all the systems tested.	Eugenol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
7926597-0	1994	Modification of testicular cytochrome P-450 after fenitrothion administration.	Fenitrothion	50-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
7926597-4	1994	Acute (165 mg/kg, 1 day) and subacute (55 mg/kg, 3 days) administration of fenitrothion caused a significant decrease on testicular cytochrome P-450 content (51 and 50% respectively) but no modification on cytochrome b5 and NADPH cytochrome c reductase.	Fenitrothion	75-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
8207335-1	1994	The corneal epithelium of several species, has the capacity to metabolize arachidonic acid (arachidonic acid) via an NADPH-dependent cytochrome P450 mechanism.	Arachidonic Acid	74-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8207335-1	1994	The corneal epithelium of several species, has the capacity to metabolize arachidonic acid (arachidonic acid) via an NADPH-dependent cytochrome P450 mechanism.	Arachidonic Acid	92-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8207335-6	1994	The formation of these metabolites is unaffected by cyclooxygenase and lipoxygenase inhibitors (indomethacin, diclofenac and BW755C) but inhibited by cytochrome P450 enzyme inhibitors such as carbon monoxide, SKF-525A and clotrimazole.	Carbon Monoxide	192-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-165
8207335-10	1994	It is evident that the cytochrome P450 arachidonate metabolites should be added to the realm of cyclooxygenase and lipoxygenase-derived eicosanoids as possible inflammatory mediators.	Arachidonic Acid	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
8207335-6	1994	The formation of these metabolites is unaffected by cyclooxygenase and lipoxygenase inhibitors (indomethacin, diclofenac and BW755C) but inhibited by cytochrome P450 enzyme inhibitors such as carbon monoxide, SKF-525A and clotrimazole.	Proadifen	209-217	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-165
8173131-3	1994	DATA SYNTHESIS: Fluconazole is a broad-spectrum triazole antifungal agent primarily eliminated by renal mechanisms, although hepatic cytochrome P-450 inhibition and hepatotoxicity have been observed.	Fluconazole	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
8207335-6	1994	The formation of these metabolites is unaffected by cyclooxygenase and lipoxygenase inhibitors (indomethacin, diclofenac and BW755C) but inhibited by cytochrome P450 enzyme inhibitors such as carbon monoxide, SKF-525A and clotrimazole.	Clotrimazole	222-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-165
8207335-7	1994	The capacity of the normal corneal epithelium to metabolize arachidonic acid via cytochrome P450 is very low although under certain conditions this enzymatic pathway may become greatly induced.	Arachidonic Acid	60-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
8207335-8	1994	Corneal epithelial hypoxia in response to contact lens wear results in the time-dependent formation of NADPH-cytochrome P450-dependent arachidonate metabolites, 12(R)-HETE and 12(R)-HETrE.	NADP	103-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
8207335-8	1994	Corneal epithelial hypoxia in response to contact lens wear results in the time-dependent formation of NADPH-cytochrome P450-dependent arachidonate metabolites, 12(R)-HETE and 12(R)-HETrE.	Arachidonic Acid	135-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
8207335-8	1994	Corneal epithelial hypoxia in response to contact lens wear results in the time-dependent formation of NADPH-cytochrome P450-dependent arachidonate metabolites, 12(R)-HETE and 12(R)-HETrE.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	161-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-124
7907372-6	1994	Thus the cytochrome P-450-mediated biotransformation of taxol to 6 alpha-hydroxytaxol can be classified as a detoxification reaction.	Paclitaxel	56-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
7907372-6	1994	Thus the cytochrome P-450-mediated biotransformation of taxol to 6 alpha-hydroxytaxol can be classified as a detoxification reaction.	alpha-hydroxytaxol	67-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
8160800-6	1994	Indomethacin, 10 microM, an inhibitor of AA-dependent cyclooxygenase, did not prevent the PTH action, but 2 microM 7-ethoxyresorufin, a cytochrome P-450 inhibitor, prevented the PTH effect.	ethoxyresorufin	115-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-152
8158054-2	1994	In an attempt to inhibit cytochrome P-450 metabolism of praziquantel, cimetidine (1600 mg/day) was coadministered.	Praziquantel	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
8171446-5	1994	The irreversible binding of both these DDT metabolites was inhibited by metyrapone, indicating the involvement of cytochrome P-450.	DDT	39-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
8171446-5	1994	The irreversible binding of both these DDT metabolites was inhibited by metyrapone, indicating the involvement of cytochrome P-450.	Metyrapone	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Debrisoquin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Antipyrine	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Rifampin	134-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
8013290-0	1994	Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues.	2-Acetylaminofluorene	48-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8304420-6	1994	Together with previous results, these observations indicate that 1) epidermis generates 12-HETE by either cytochrome P-450 or lipoxygenase-based mechanisms depending on reaction conditions, and 2) 12-lipoxygenases (originally described in hematopoietic cell types) may be expressed in at least two distinct isoforms in epithelial barriers in humans, and in the case of the skin, a microsomal (platelet-type) 12-lipoxygenase is selectively overexpressed in germinal layer keratinocytes during psoriatic inflammation.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	88-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-138
8286397-2	1994	In contrast, the electronic absorption spectra for camphor-free cytochrome P-450cam between 78 K and 295 K show no significant spectral changes.	Camphor	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
7903909-0	1994	Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.	Paclitaxel	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
8171214-5	1994	The enzyme system responsible for PAC activation is the mixed-function oxidase system and, in particular, cytochrome P-450.	pac	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
8082573-2	1994	Inherent substrate factors, such as basicity, electronic state, lipophilicity, and conformation control binding of the diverse classes of amines to cytochrome P-450.	Amines	138-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
8082573-6	1994	Certain amines appear to regulate O2 association with cytochrome P-450 and stabilize the various oxy species formed.	Amines	8-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
8082573-6	1994	Certain amines appear to regulate O2 association with cytochrome P-450 and stabilize the various oxy species formed.	Oxygen	34-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
8082573-7	1994	Considering the selective prerequisites for oxidative attack by cytochrome P-450 at vulnerable nitrogen centers, many cytotoxic amines belonging to the category of relatively rigid, planar molecules undergo N-oxidative activation by the cytochrome P-450IA subfamily, while more bulky amines with flexible conformation are N-oxygenated preferentially by phenobarbital-inducible cytochromes P-450.	Nitrogen	95-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8082573-7	1994	Considering the selective prerequisites for oxidative attack by cytochrome P-450 at vulnerable nitrogen centers, many cytotoxic amines belonging to the category of relatively rigid, planar molecules undergo N-oxidative activation by the cytochrome P-450IA subfamily, while more bulky amines with flexible conformation are N-oxygenated preferentially by phenobarbital-inducible cytochromes P-450.	Amines	128-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8082573-7	1994	Considering the selective prerequisites for oxidative attack by cytochrome P-450 at vulnerable nitrogen centers, many cytotoxic amines belonging to the category of relatively rigid, planar molecules undergo N-oxidative activation by the cytochrome P-450IA subfamily, while more bulky amines with flexible conformation are N-oxygenated preferentially by phenobarbital-inducible cytochromes P-450.	Nitrogen	207-208	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8082573-7	1994	Considering the selective prerequisites for oxidative attack by cytochrome P-450 at vulnerable nitrogen centers, many cytotoxic amines belonging to the category of relatively rigid, planar molecules undergo N-oxidative activation by the cytochrome P-450IA subfamily, while more bulky amines with flexible conformation are N-oxygenated preferentially by phenobarbital-inducible cytochromes P-450.	Amines	284-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8082573-7	1994	Considering the selective prerequisites for oxidative attack by cytochrome P-450 at vulnerable nitrogen centers, many cytotoxic amines belonging to the category of relatively rigid, planar molecules undergo N-oxidative activation by the cytochrome P-450IA subfamily, while more bulky amines with flexible conformation are N-oxygenated preferentially by phenobarbital-inducible cytochromes P-450.	Phenobarbital	353-366	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8082573-8	1994	Small differences in protein structure between the various cytochrome P-450 subforms might serve to stabilize aminium radicals to permit oxygen rebound.	aminium	110-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
8082573-8	1994	Small differences in protein structure between the various cytochrome P-450 subforms might serve to stabilize aminium radicals to permit oxygen rebound.	Oxygen	137-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
7957514-6	1994	The results indicate that fluconazole is a minor inhibitor of theophylline disposition compared with enoxacin, and they suggest that the inhibitory action of fluconazole is selective for certain cytochrome P-450 isozymes, but not for the cytochrome P-4501A involved in theophylline metabolism.	Fluconazole	158-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	195-211
8123970-5	1994	DATA SYNTHESIS: Ciprofloxacin has been reported to interact with cyclosporine during concomitant use through an interaction with the cytochrome P-450 system or by additive nephrotoxicity.	Ciprofloxacin	16-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
8123970-5	1994	DATA SYNTHESIS: Ciprofloxacin has been reported to interact with cyclosporine during concomitant use through an interaction with the cytochrome P-450 system or by additive nephrotoxicity.	Cyclosporine	65-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-149
7544830-0	1994	Induction of cytochrome P-450 by 5-methoxypsoralen in the yeast Saccharomyces cerevisiae.	5-Methoxypsoralen	33-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
7544830-1	1994	Yeast cells (D7 strain) incubated in the presence of 5-methoxypsoralen (5-MOP) increase the activity of the monooxygenase system cytochrome P-450 dependent (cytochrome P-450 level and 7-ethoxycoumarin-O-diethylase activity).	5-Methoxypsoralen	53-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
7544830-1	1994	Yeast cells (D7 strain) incubated in the presence of 5-methoxypsoralen (5-MOP) increase the activity of the monooxygenase system cytochrome P-450 dependent (cytochrome P-450 level and 7-ethoxycoumarin-O-diethylase activity).	5-Methoxypsoralen	53-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
7544830-1	1994	Yeast cells (D7 strain) incubated in the presence of 5-methoxypsoralen (5-MOP) increase the activity of the monooxygenase system cytochrome P-450 dependent (cytochrome P-450 level and 7-ethoxycoumarin-O-diethylase activity).	5-Methoxypsoralen	72-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
7544830-1	1994	Yeast cells (D7 strain) incubated in the presence of 5-methoxypsoralen (5-MOP) increase the activity of the monooxygenase system cytochrome P-450 dependent (cytochrome P-450 level and 7-ethoxycoumarin-O-diethylase activity).	5-Methoxypsoralen	72-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
7544830-4	1994	The capacity of 5-MOP to induce the cytochrome P-450 system in eukaryotic cells, in which it is known to be involved in the metabolism of the psoralen, may decrease the availability of the compound for photo-induced genotoxic reactions, which may explain the good tolerance in patients.	5-Methoxypsoralen	16-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
7808019-8	1994	Both of these hypercatabolic states can be modulated by concurrent administration of ketoconazole, an inhibitor of cytochrome P-450 and lipoxygenase-mediated oxidations.	Ketoconazole	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-148
7504205-13	1993	The nutritional effect of vitamin E on hepatic microsomal cytochrome P-450 activities modified the AFB1 genotoxicity measured in vitro.	Vitamin E	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
8242617-1	1993	The present study identifies the specific human cytochrome P-450 (CYP) enzymes involved in hydroxylation leading to activation of the anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide.	Cyclophosphamide	150-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
8242617-1	1993	The present study identifies the specific human cytochrome P-450 (CYP) enzymes involved in hydroxylation leading to activation of the anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide.	Cyclophosphamide	150-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
8242617-1	1993	The present study identifies the specific human cytochrome P-450 (CYP) enzymes involved in hydroxylation leading to activation of the anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide.	Ifosfamide	194-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
8242617-1	1993	The present study identifies the specific human cytochrome P-450 (CYP) enzymes involved in hydroxylation leading to activation of the anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide.	Ifosfamide	194-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
8242617-8	1993	Furthermore, growth of cultured CYP2A6- and CYP2B6-expressing B-lymphoblastoid cells, but not of CYP-negative control cells, was inhibited by cyclophosphamide and ifosphamide as a consequence of prodrug activation to cytotoxic metabolites.	Cyclophosphamide	142-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
8242617-8	1993	Furthermore, growth of cultured CYP2A6- and CYP2B6-expressing B-lymphoblastoid cells, but not of CYP-negative control cells, was inhibited by cyclophosphamide and ifosphamide as a consequence of prodrug activation to cytotoxic metabolites.	Ifosfamide	163-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
8307581-1	1993	Human CYP2E encodes an ethanol-inducible cytochrome P450 monooxygenase that metabolizes various carcinogens and may therefore play a role in cancer susceptibility.	Ethanol	23-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-56
8230282-3	1993	We speculated that the decline in drug levels, indicating acquired resistance, resulted partly from inducible cytochrome-P450 oxidative enzymes, which can catabolize all-trans RA.	Radium	176-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-125
8230282-4	1993	PURPOSE: We studied the clinical pharmacology of all-trans RA in cancer patients to determine possible mechanisms of acquired resistance and evaluated the potential for reversal by ketoconazole, an inhibitor of cytochrome-P450 oxidative enzymes.	Ketoconazole	181-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-226
8230282-14	1993	Ketoconazole attenuates this accelerated catabolism, suggesting that oxidation by cytochrome-P450 enzymes is an important pathway for both constitutive and induced pathways of all-trans RA metabolism.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8230282-14	1993	Ketoconazole attenuates this accelerated catabolism, suggesting that oxidation by cytochrome-P450 enzymes is an important pathway for both constitutive and induced pathways of all-trans RA metabolism.	Radium	186-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
12959268-0	1993	Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.	Omeprazole	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
12959268-1	1993	1 The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the major omeprazole metabolites.	Omeprazole	29-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-157
12959268-1	1993	1 The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the major omeprazole metabolites.	Omeprazole	211-221	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	154-157
7504205-13	1993	The nutritional effect of vitamin E on hepatic microsomal cytochrome P-450 activities modified the AFB1 genotoxicity measured in vitro.	Aflatoxin B1	99-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
8240292-0	1993	Stimulation by paraquat of microsomal and cytochrome P-450-dependent oxidation of glycerol to formaldehyde.	Glycerol	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
8240292-0	1993	Stimulation by paraquat of microsomal and cytochrome P-450-dependent oxidation of glycerol to formaldehyde.	Formaldehyde	94-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
8240292-1	1993	Glycerol can be oxidized to formaldehyde by microsomes in a reaction that is dependent on cytochrome P-450.	Glycerol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
8240292-1	1993	Glycerol can be oxidized to formaldehyde by microsomes in a reaction that is dependent on cytochrome P-450.	Formaldehyde	28-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
8240292-11	1993	However, cytochrome P-450 is required for elevated rates of formaldehyde production even in the presence of paraquat.	Formaldehyde	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
8240292-11	1993	However, cytochrome P-450 is required for elevated rates of formaldehyde production even in the presence of paraquat.	Paraquat	108-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
7905377-5	1993	Biotransformation of lovastatin occurred by three distinct routes, namely hydrolysis of the lactone ring to yield the pharmacologically active dihydroxy acid, cytochrome P-450-mediated oxidation of the fused-ring system, and beta-oxidation of the dihydroxy acid side chain.	Lovastatin	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	159-175
7905377-11	1993	From these studies, cytochrome P-450 oxidation is the primary route of phase I metabolism for lovastatin in human and dog, but beta-oxidation plays a major metabolic role in rodents.	Lovastatin	94-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
8143890-1	1993	Estrogens are synthesized from C19 steroids by a unique form of cytochrome P450, aromatase cytochrome P-450 (P-450AROM; the product of the CYP19 gene).	Steroids	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-107
8111292-6	1993	This indicates that the metabolism of aflatoxin B1 brought about by the cytochrome P-450-dependent monooxygenase system plays an important role in the action of aflatoxin B1 on human lymphocytes.	Aflatoxin B1	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
8111292-6	1993	This indicates that the metabolism of aflatoxin B1 brought about by the cytochrome P-450-dependent monooxygenase system plays an important role in the action of aflatoxin B1 on human lymphocytes.	Aflatoxin B1	161-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
8310712-2	1993	A commercially-available human cytochrome P450 isozyme (CYP2D6) preparation was used in imipramine metabolism studies.	Imipramine	88-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
8240252-1	1993	Cytochrome P-450 has been suggested as a mediator of the signal between depleted platelet calcium stores and an increase in plasma membrane permeability to calcium which follows depletion of the stores.	Calcium	90-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8240252-1	1993	Cytochrome P-450 has been suggested as a mediator of the signal between depleted platelet calcium stores and an increase in plasma membrane permeability to calcium which follows depletion of the stores.	Calcium	156-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8240252-8	1993	Inhibition of cytochrome P-450 with CO bubbled through platelet suspensions did not change calcium influx in resting cells and potentiated TG-induced calcium influx (160% of control calcium accumulation at 20 min).	Thapsigargin	139-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8240252-8	1993	Inhibition of cytochrome P-450 with CO bubbled through platelet suspensions did not change calcium influx in resting cells and potentiated TG-induced calcium influx (160% of control calcium accumulation at 20 min).	Calcium	150-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8240252-2	1993	This hypothesis is based on the observations that inhibitors of cytochrome P-450, such as the imidazole antifungal agents, also inhibit influx of a calcium surrogate (manganese) into calcium-depleted platelets.	imidazole	94-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8240252-8	1993	Inhibition of cytochrome P-450 with CO bubbled through platelet suspensions did not change calcium influx in resting cells and potentiated TG-induced calcium influx (160% of control calcium accumulation at 20 min).	Calcium	150-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8240252-2	1993	This hypothesis is based on the observations that inhibitors of cytochrome P-450, such as the imidazole antifungal agents, also inhibit influx of a calcium surrogate (manganese) into calcium-depleted platelets.	Calcium	148-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8240252-2	1993	This hypothesis is based on the observations that inhibitors of cytochrome P-450, such as the imidazole antifungal agents, also inhibit influx of a calcium surrogate (manganese) into calcium-depleted platelets.	Manganese	167-176	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8257958-4	1993	The increased risk of both H1-antihistamines was associated with exposure to supratherapeutic doses; for terfenadine the risk was also associated with concomitant exposure to the cytochrome P-450 inhibitors ketoconazole, erythromycin and cimetidine.	Terfenadine	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
8240252-2	1993	This hypothesis is based on the observations that inhibitors of cytochrome P-450, such as the imidazole antifungal agents, also inhibit influx of a calcium surrogate (manganese) into calcium-depleted platelets.	Calcium	183-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
8257958-4	1993	The increased risk of both H1-antihistamines was associated with exposure to supratherapeutic doses; for terfenadine the risk was also associated with concomitant exposure to the cytochrome P-450 inhibitors ketoconazole, erythromycin and cimetidine.	Cimetidine	238-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
8247921-1	1993	Fluconazole is a triazole antifungal agent reported to have a low affinity for human cytochrome P-450, and thus would not be expected to interact with drugs metabolized through the cytochrome P-450 system, including phenytoin, cyclosporine, and warfarin.	Fluconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
7901425-5	1993	These results demonstrate racially distinct patterns of CYP1A1 genotypes, and suggest a functional link between genotype and catalytic activity of the cytochrome P-450 protein responsible for the metabolism of many carcinogenic polycyclic aromatic hydrocarbons.	Polycyclic Aromatic Hydrocarbons	228-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
8399332-0	1993	Purification of a human cytochrome P-450 isozyme catalyzing lanosterol 14 alpha-demethylation.	Lanosterol	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
8399332-1	1993	An isozyme of cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation was purified from human liver using column chromatography, including immunoaffinity chromatography.	Lanosterol	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
7690968-0	1993	Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions.	Vitamin D	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
7690968-9	1993	This work has revealed that the cytochrome P-450 CYP27 may be important in the metabolism of vitamin D analogs used as drugs.	Vitamin D	93-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
8247921-1	1993	Fluconazole is a triazole antifungal agent reported to have a low affinity for human cytochrome P-450, and thus would not be expected to interact with drugs metabolized through the cytochrome P-450 system, including phenytoin, cyclosporine, and warfarin.	Triazoles	17-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
8408733-1	1993	Quinidine and nifedipine appear to be subject to metabolism by the same isozyme of cytochrome P-450.	Quinidine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
8415911-4	1993	Of the newly synthesized Pc, two showed significant destruction of cytochrome P-450 and monooxygenase activities, and enhancement of lipid peroxidation, when added to microsomal suspension followed by irradiation with approximately 675 nm light.	phthalocyanine	25-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-101
8344930-7	1993	The cytosolic enzyme and the enzymes solubilized from the two pellets produced 12S-hydroperoxy-5,8,10,14-eicosatetraenoic acid as the primary product in contrast to cytochrome P-450 which produces primarily hydroxy acids.	Hydroxy Acids	207-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
8408733-1	1993	Quinidine and nifedipine appear to be subject to metabolism by the same isozyme of cytochrome P-450.	Nifedipine	14-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
8388882-1	1993	Epoxyeicosatrienoic acids (EETs), cytochrome P-450 metabolites of arachidonic acid, have attracted attention because of their effects on stimulus-response coupling in endocrine, renal, and vascular cells.	eets	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
8411129-1	1993	Inhibition of the metabolism of arachidonic acid by the epoxygenase (cytochrome P-450) pathway with the inhibitor ketoconazole results in excessive cell swelling upon exposure to hyposmolality instead of the rapid and complete regulatory volume decrease (RVD) normally observed.	Arachidonic Acid	32-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
8411129-1	1993	Inhibition of the metabolism of arachidonic acid by the epoxygenase (cytochrome P-450) pathway with the inhibitor ketoconazole results in excessive cell swelling upon exposure to hyposmolality instead of the rapid and complete regulatory volume decrease (RVD) normally observed.	Ketoconazole	114-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
7684611-7	1993	These findings suggest that the Ca2+/Mn2+ entry pathway opened by agonists in human neutrophils is the same that activates on emptying the Ca2+ stores and that cytochrome P-450 activity may be involved en the activation of the channels.	Manganese(2+)	37-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
8388882-1	1993	Epoxyeicosatrienoic acids (EETs), cytochrome P-450 metabolites of arachidonic acid, have attracted attention because of their effects on stimulus-response coupling in endocrine, renal, and vascular cells.	Arachidonic Acid	66-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-50
8388882-11	1993	These findings suggest that hCG stimulates granulosa cell production of EETs via an NADPH-supported, cytochrome P-450-dependent enzymatic mechanism.	NADP	84-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
7940601-1	1993	The excretion of D-glucaric acid in the urine (uGA) correlates with the total liver content of hepatic cytochrome P-450, the metabolism of which depends on adenosine triphosphate (ATP) being produced by intrahepatic cellular mitochondria.	Glucaric Acid	17-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
8332592-4	1993	The first two trajectories were calculated for cytochrome P450cam with thiocamphor bound in both its major and minor crystallographic orientations.	thiocamphor	71-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
7940601-1	1993	The excretion of D-glucaric acid in the urine (uGA) correlates with the total liver content of hepatic cytochrome P-450, the metabolism of which depends on adenosine triphosphate (ATP) being produced by intrahepatic cellular mitochondria.	Adenosine Triphosphate	156-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
7940601-1	1993	The excretion of D-glucaric acid in the urine (uGA) correlates with the total liver content of hepatic cytochrome P-450, the metabolism of which depends on adenosine triphosphate (ATP) being produced by intrahepatic cellular mitochondria.	Adenosine Triphosphate	180-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
8490024-0	1993	Regioselectivity of cytochrome P-450 catalyzed hydroxylation of fluorobenzenes predicted by calculated frontier orbital substrate characteristics.	Fluorobenzenes	64-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
8389204-0	1993	Omega-hydroxylation of lipoxin B4 by human neutrophil microsomes: identification of omega-hydroxy metabolite of lipoxin B4 and catalysis by leukotriene B4 omega-hydroxylase (cytochrome P-450LTB omega).	lipoxin B4	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-172
8389204-0	1993	Omega-hydroxylation of lipoxin B4 by human neutrophil microsomes: identification of omega-hydroxy metabolite of lipoxin B4 and catalysis by leukotriene B4 omega-hydroxylase (cytochrome P-450LTB omega).	lipoxin B4	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-199
8389204-4	1993	The reaction is inhibited by carbon monoxide, an inhibitor of cytochrome P-450 (P-450), and by antibodies raised against NADPH-P-450 reductase.	Carbon Monoxide	29-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
8389204-6	1993	The P-450 appears to be the one responsible for leukotriene B4 (LTB4) omega-hydroxylation, P-450LTB omega, based on the following observations.	Leukotriene B4	48-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-105
8389204-7	1993	The formation of 20-OH-LXB4 is inhibited solely by substrates of P-450LTB omega such as LTB4 and leukotriene B5 among various fatty acids including prostaglandins.	20-Hydroxylipoxin B4	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-79
8389204-7	1993	The formation of 20-OH-LXB4 is inhibited solely by substrates of P-450LTB omega such as LTB4 and leukotriene B5 among various fatty acids including prostaglandins.	leukotriene B5	97-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-79
8507205-0	1993	The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen.	Benzo(a)pyrene	72-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
8490024-1	1993	In the present study, a hypothesis is presented for the prediction of the regioselectivity of cytochrome P-450 catalyzed hydroxylation of fluorobenzenes.	Fluorobenzenes	138-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
8490024-5	1993	Additional in vitro experiments using 1,2-difluorobenzene as the model substrate demonstrated that minor factors influencing the regioselectivity and possibly responsible for the 6% deviation from the calculated values in in vivo experiments might be (i) the influence of biotransformation routes occurring in vivo but not of importance in in vitro microsomal incubations and (ii) a small variation due to influences of the contribution of various cytochrome P-450 enzymes.	1,2-difluorobenzene	38-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	448-464
8463342-0	1993	Cytochrome P-450 55A1 (P-450dNIR) acts as nitric oxide reductase employing NADH as the direct electron donor.	NAD	75-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8100494-5	1993	The rates of formation of 1 and 2 were both correlated with rates of nifedipine oxidation (a marker of cytochrome P-450 (P-450) 3A4) but not with markers for other human P-450s.	Nifedipine	69-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
21573617-0	1993	Activation of thio-tepa cytotoxicity toward human breast-cancer cells by hepatic cytochrome-p450.	Thiotepa	14-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96
8291131-0	1993	[Reduction of cytochrome p-450 content and activity by porphyrins after damage to the microsomal membrane by tetrachloromethane].	Porphyrins	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8291131-0	1993	[Reduction of cytochrome p-450 content and activity by porphyrins after damage to the microsomal membrane by tetrachloromethane].	Carbon Tetrachloride	109-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
8291131-1	1993	Natural porphyrin (hemin and its synthetic analogue--tetraphenylporphyrin with iron TPP-Fe3+) has been studied for its effect on activity of monooxygenase responses and cytochrome P-450 content against a background of introduction of four-chlorine carbon in the in vitro experiments.	Porphyrins	8-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
8291131-1	1993	Natural porphyrin (hemin and its synthetic analogue--tetraphenylporphyrin with iron TPP-Fe3+) has been studied for its effect on activity of monooxygenase responses and cytochrome P-450 content against a background of introduction of four-chlorine carbon in the in vitro experiments.	Hemin	19-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
8291131-1	1993	Natural porphyrin (hemin and its synthetic analogue--tetraphenylporphyrin with iron TPP-Fe3+) has been studied for its effect on activity of monooxygenase responses and cytochrome P-450 content against a background of introduction of four-chlorine carbon in the in vitro experiments.	tetraphenylporphyrin	53-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
8291131-2	1993	The reducing effect of hemin and TPP-Fe3+ on cytochrome P-450 and dependent enzymes: N-demethylase, n-hydroxylase and benz(a)pyrene hydroxylase has been noticed; the synthetic analogue of heme was more efficient.	Hemin	23-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
8291131-2	1993	The reducing effect of hemin and TPP-Fe3+ on cytochrome P-450 and dependent enzymes: N-demethylase, n-hydroxylase and benz(a)pyrene hydroxylase has been noticed; the synthetic analogue of heme was more efficient.	tpp-fe3+	33-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
8291131-2	1993	The reducing effect of hemin and TPP-Fe3+ on cytochrome P-450 and dependent enzymes: N-demethylase, n-hydroxylase and benz(a)pyrene hydroxylase has been noticed; the synthetic analogue of heme was more efficient.	Heme	188-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-61
8486631-5	1993	The microsomes from yeast cells transfected with an expression vector pAAH5 carrying isolated cDNA catalyzed the omega-hydroxylation of LTB4 with a Km value of 0.71 microM, and its activity was significantly inhibited by carbon monoxide and by antisera against CYP4A4, consistent with the properties previously reported with LTB4 omega-hydroxylase in human polymorphonuclear leukocytes.	Carbon Monoxide	221-236	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	325-347
8502233-4	1993	Correlations were obtained between rates of imipramine demethylation and cytochrome P-450 (P-450) 1A2 (r = 0.88, p &lt; 0.001) and P-450 3A (r = 0.80, p &lt; 0.02) concentrations in human liver microsomal preparations from 13 different subjects.	Imipramine	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
8516280-3	1993	PC and PG liposomes were also treated with PLA2 in the presence of a number of proteins such as cytochrome c, cytochrome b5, cytochrome P-450, polylysine, and histone H1.	Phosphatidylglycerols	7-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-169
8387283-5	1993	The unusual substituent effects were also observed in the hydroxylation of p-substituted phenol by microsomes, a cytochrome P-450-dependent reaction.	p-substituted phenol	75-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
8463342-2	1993	The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor.	Nitric Oxide	48-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8463342-2	1993	The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor.	Nitrous Oxide	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8463342-2	1993	The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor.	Nitrous Oxide	108-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8463342-2	1993	The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor.	NAD	123-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8463342-2	1993	The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor.	NADP	136-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8470252-0	1993	Role of cytochrome P-450 in modulating cyclosporine levels in transplant patients.	Cyclosporine	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
8386241-3	1993	In contrast, flutamide was oxidatively transformed by cytochrome P-450 into reactive metabolite(s) that covalently bound to microsomal proteins.	Flutamide	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Oxygen	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Oxygen	26-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	NADP	37-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Glutathione	81-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Proadifen	132-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Piperonyl Butoxide	143-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Piperonyl Butoxide	143-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Troleandomycin	166-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
8386241-4	1993	Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily).	Troleandomycin	166-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
8386241-5	1993	Covalent binding was increased markedly by pretreatment with dexamethasone (an inducer of the cytochrome P-450 3A subfamily) and moderately by pretreatment with beta-naphthoflavone (an inducer of the 1A family).	Dexamethasone	61-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
8386241-5	1993	Covalent binding was increased markedly by pretreatment with dexamethasone (an inducer of the cytochrome P-450 3A subfamily) and moderately by pretreatment with beta-naphthoflavone (an inducer of the 1A family).	beta-Naphthoflavone	161-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
8463225-1	1993	A cDNA encoding a naturally occurring variant of cytochrome P450 (P450) 2C3 that catalyzes the 6 beta- and 16 alpha-hydroxylation of progesterone exhibits six differences of nucleotide sequence leading to five amino acid substitutions from that encoding 2C3, a progesterone 16 alpha-hydroxylase that does not catalyze 6 beta-hydroxylation.	Progesterone	133-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-75
8470644-6	1993	Isoniazid induces the cytochrome P-450 system, resulting in increased metabolism of acetaminophen, formation of toxic metabolites, depletion of glutathione stores, and subsequent hepatocellular injury.	Isoniazid	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8470644-6	1993	Isoniazid induces the cytochrome P-450 system, resulting in increased metabolism of acetaminophen, formation of toxic metabolites, depletion of glutathione stores, and subsequent hepatocellular injury.	Acetaminophen	84-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8470644-6	1993	Isoniazid induces the cytochrome P-450 system, resulting in increased metabolism of acetaminophen, formation of toxic metabolites, depletion of glutathione stores, and subsequent hepatocellular injury.	Glutathione	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
8470644-7	1993	Patients on isoniazid should use caution when taking acetaminophen since the potentially hepatotoxic effects may be amplified due to induction of the cytochrome P-450 system.	Isoniazid	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
8470644-7	1993	Patients on isoniazid should use caution when taking acetaminophen since the potentially hepatotoxic effects may be amplified due to induction of the cytochrome P-450 system.	Acetaminophen	53-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
8394802-5	1993	Much has been learned about the mechanism of dioxin"s effects, especially for the induction of cytochrome P-450 enzymes.	Dioxins	45-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
8383004-0	1993	Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms.	Hydrogen Peroxide	6-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
8383004-0	1993	Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms.	Tretinoin	74-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
8383004-1	1993	Cytochrome P-450 enzymes have been implicated in the oxidative catabolism of all-trans-retinoic acid (RA), a process that is accelerated by exposure to RA in cultured cells and rodents, and also in patients receiving RA as treatment for cancer (J.F.R.	Tretinoin	80-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8383004-1	1993	Cytochrome P-450 enzymes have been implicated in the oxidative catabolism of all-trans-retinoic acid (RA), a process that is accelerated by exposure to RA in cultured cells and rodents, and also in patients receiving RA as treatment for cancer (J.F.R.	Tretinoin	102-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8383004-1	1993	Cytochrome P-450 enzymes have been implicated in the oxidative catabolism of all-trans-retinoic acid (RA), a process that is accelerated by exposure to RA in cultured cells and rodents, and also in patients receiving RA as treatment for cancer (J.F.R.	Tretinoin	152-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8383004-1	1993	Cytochrome P-450 enzymes have been implicated in the oxidative catabolism of all-trans-retinoic acid (RA), a process that is accelerated by exposure to RA in cultured cells and rodents, and also in patients receiving RA as treatment for cancer (J.F.R.	Tretinoin	152-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
8452565-0	1993	Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse.	Phenobarbital	59-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
8444412-4	1993	Purification and subfractionation of microsomal protein yielded a fraction of cytochrome P-450, which required NADPH and NADPH-cytochrome P-450 reductase and catalyzed 7 alpha-hydroxylation of the side-chain oxygenated 3 beta-hydroxy-delta 5-C27-steroids but was inactive toward cholesterol.	NADP	111-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
8444412-4	1993	Purification and subfractionation of microsomal protein yielded a fraction of cytochrome P-450, which required NADPH and NADPH-cytochrome P-450 reductase and catalyzed 7 alpha-hydroxylation of the side-chain oxygenated 3 beta-hydroxy-delta 5-C27-steroids but was inactive toward cholesterol.	Steroids	246-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
8444412-4	1993	Purification and subfractionation of microsomal protein yielded a fraction of cytochrome P-450, which required NADPH and NADPH-cytochrome P-450 reductase and catalyzed 7 alpha-hydroxylation of the side-chain oxygenated 3 beta-hydroxy-delta 5-C27-steroids but was inactive toward cholesterol.	Cholesterol	279-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
8395243-1	1993	A high affinity binding site for 14(R),15(S)-EET, one of the major cytochrome P-450 metabolites of arachidonic acid (AA) in blood vessels, liver, kidney and urine of patients with pregnancy-induced hypertension, has been identified in a membrane preparation from guinea pig mononuclear (GPM) cells.	Arachidonic Acid	99-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-83
8334787-0	1993	[Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson"s disease].	Sparteine	1-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
8480473-2	1993	Aldosterone synthase cytochrome P-450 (human P-450aldo) was detected in the tumour portion of aldosterone-producing adenoma, but not in the normal control adrenals, at the protein level.	Aldosterone	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
8431474-2	1993	The enzymatic activity of bovine adrenocortical cytochrome P-450(11) beta was inhibited by methyltrienolone in a competitive manner without exposure to light and cytochrome P-450(11) beta was photolabeled with methyltrienolone after irradiation with UV light.	Metribolone	91-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
8431474-2	1993	The enzymatic activity of bovine adrenocortical cytochrome P-450(11) beta was inhibited by methyltrienolone in a competitive manner without exposure to light and cytochrome P-450(11) beta was photolabeled with methyltrienolone after irradiation with UV light.	Metribolone	210-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
8431474-3	1993	The addition of 11-deoxycorticosterone during photolabeling protected cytochrome P-450(11) beta from photolabeling.	Desoxycorticosterone	16-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
7922394-0	1993	Prostaglandins, thromboxanes, leukotrienes, and cytochrome P-450 metabolites of arachidonic acid.	Arachidonic Acid	80-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
8095148-2	1993	Cytochrome P450 debrisoquine (CYP2D6) activity is polymorphic and under genetic control.	Debrisoquin	16-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
7922394-1	1993	Arachidonic acid is metabolized via three major enzymatic pathways: cyclooxygenase, lipoxygenase, and cytochrome P-450.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
7922394-4	1993	The cytochrome P-450 pathway metabolites are oxygenated metabolites of arachidonic acid.	Arachidonic Acid	71-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
8422907-4	1993	The LXA4 omega-hydroxylation requires both molecular oxygen and NADPH, and is inhibited by carbon monoxide, by antibodies raised against NADPH-cytochrome P-450 reductase, or competitively by leukotriene B4 (LTB4) and LTB5, substrates of LTB4 omega-hydroxylase.	Oxygen	53-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-259
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Debrisoquin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Sparteine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Sparteine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Mephenytoin	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Mephenytoin	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
8454228-2	1993	Debrisoquine/sparteine and mephenytoin polymorphisms are now known to be derived from defects in the human liver of specific forms of microsomal CYP (P450 or previously termed cytochrome P-450), CYP2D6 and CYP2C9 (2C18), respectively.	Debrisoquin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
8475046-1	1993	Site-directed mutants were constructed in cytochrome P-450cam to re-engineer the stereochemistry and coupling of ethylbenzene hydroxylation.	ethylbenzene	113-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
8424795-1	1993	Evidence from human studies in vivo and in vitro strongly suggests that the methylhydroxylation of tolbutamide and the 4-hydroxylation of phenytoin, the major pathways in the elimination of these two drugs, are catalysed by the same cytochrome P-450 isoenzyme(s).	Tolbutamide	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	233-249
8424795-1	1993	Evidence from human studies in vivo and in vitro strongly suggests that the methylhydroxylation of tolbutamide and the 4-hydroxylation of phenytoin, the major pathways in the elimination of these two drugs, are catalysed by the same cytochrome P-450 isoenzyme(s).	Phenytoin	138-147	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	233-249
8424795-3	1993	Tolbutamide was hydroxylated to varying extents by all expressed cytochrome P-450 isoenzymes, although activity was much lower for the expressed 2C8 protein.	Tolbutamide	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
8422907-4	1993	The LXA4 omega-hydroxylation requires both molecular oxygen and NADPH, and is inhibited by carbon monoxide, by antibodies raised against NADPH-cytochrome P-450 reductase, or competitively by leukotriene B4 (LTB4) and LTB5, substrates of LTB4 omega-hydroxylase.	NADP	64-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-259
8422907-4	1993	The LXA4 omega-hydroxylation requires both molecular oxygen and NADPH, and is inhibited by carbon monoxide, by antibodies raised against NADPH-cytochrome P-450 reductase, or competitively by leukotriene B4 (LTB4) and LTB5, substrates of LTB4 omega-hydroxylase.	Carbon Monoxide	91-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	237-259
8422907-5	1993	These findings indicate that the formation of 20-hydroxy-LXA4 is catalyzed by a neutrophil cytochrome P-450, the LTB4 omega-hydroxylase.	20-hydroxy-lxa4	46-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
8422907-5	1993	These findings indicate that the formation of 20-hydroxy-LXA4 is catalyzed by a neutrophil cytochrome P-450, the LTB4 omega-hydroxylase.	20-hydroxy-lxa4	46-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-135
8445979-0	1993	Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report).	Amiodarone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
7922169-5	1993	New information has also become available about the renal biology of cytochrome P-450 metabolites of arachidonic acid as well as about nonenzymatically generated biologically potent eicosanoids, the F2-isoprostanes.	Arachidonic Acid	101-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
8070855-0	1993	Characterization of the human cytochrome P450 isozymes responsible for styrene metabolism.	Styrene	71-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
8070855-3	1993	The forms of cytochrome P450 that are responsible for transforming styrene to styrene glycol were determined by vaccinia virus-mediated cDNA expression of individual P450 forms in cultured cells.	Styrene	67-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
8070855-3	1993	The forms of cytochrome P450 that are responsible for transforming styrene to styrene glycol were determined by vaccinia virus-mediated cDNA expression of individual P450 forms in cultured cells.	styrene glycol	78-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
8447722-6	1993	A participation of those isoenzymes of the cytochrome P-450 enzyme system which can be induced by phenobarbital is assumed.	Phenobarbital	98-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
8518741-4	1993	The induction process is concomitant with that of cytochrome P-450-IVA1 and cytosolic epoxide hydrolase, which, like bilirubin UGT, are mainly involved in the metabolism of endogenous substrates.	Bilirubin	117-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-71
8449148-5	1993	These include myoglobin and hemoglobin, which carry out oxygen binding or transport; mitochondrial cytochromes aa3, b, c, and c3, which are important in transferring electrons; microsomal cytochrome P-450, which catalyzes mixed-function oxidations; catalase, which decomposes H2O2; peroxidase, which activates H2O2; and tryptophan pyrrolase, which catalyzes the oxidation of tryptophan.	Hydrogen Peroxide	276-280	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
8449148-5	1993	These include myoglobin and hemoglobin, which carry out oxygen binding or transport; mitochondrial cytochromes aa3, b, c, and c3, which are important in transferring electrons; microsomal cytochrome P-450, which catalyzes mixed-function oxidations; catalase, which decomposes H2O2; peroxidase, which activates H2O2; and tryptophan pyrrolase, which catalyzes the oxidation of tryptophan.	Hydrogen Peroxide	310-314	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
8449148-5	1993	These include myoglobin and hemoglobin, which carry out oxygen binding or transport; mitochondrial cytochromes aa3, b, c, and c3, which are important in transferring electrons; microsomal cytochrome P-450, which catalyzes mixed-function oxidations; catalase, which decomposes H2O2; peroxidase, which activates H2O2; and tryptophan pyrrolase, which catalyzes the oxidation of tryptophan.	Tryptophan	320-330	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-204
8453968-1	1993	Chlormethiazole is a strong inhibitor of cytochrome P-450-dependent monooxygenases in isolated human liver microsomes.	Chlormethiazole	0-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
8445979-1	1993	Experiments were conducted on three different human liver samples to identify the cytochrome P450 isozyme which is involved in the biotransformation of the class III antiarrhythmic agent, amiodarone, into its major metabolite, desethylamiodarone (DEA).	Amiodarone	188-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8445979-1	1993	Experiments were conducted on three different human liver samples to identify the cytochrome P450 isozyme which is involved in the biotransformation of the class III antiarrhythmic agent, amiodarone, into its major metabolite, desethylamiodarone (DEA).	desethylamiodarone	227-245	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
8445979-1	1993	Experiments were conducted on three different human liver samples to identify the cytochrome P450 isozyme which is involved in the biotransformation of the class III antiarrhythmic agent, amiodarone, into its major metabolite, desethylamiodarone (DEA).	desethylamiodarone	247-250	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-97
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Ethanol	8-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
8159952-3	1993	After acute in vivo administration indium and thallium have been shown to produce decreases in the activity of some drug-metabolizing enzymes dependent on cytochrome P-450; therefore these metals would be capable of interfering with the metabolism of organic carcinogens.	Indium	35-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
8159952-3	1993	After acute in vivo administration indium and thallium have been shown to produce decreases in the activity of some drug-metabolizing enzymes dependent on cytochrome P-450; therefore these metals would be capable of interfering with the metabolism of organic carcinogens.	Thallium	46-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
1472505-6	1992	Coexistence of a mobile population with an average rotational relaxation time phi of 138-577 microseconds and immobile (phi &gt; or = 20 ms) populations of cytochrome P-450 was observed in both phospholipid vesicles and microsomes.	Phospholipids	194-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-172
1458471-1	1992	The growth-inhibitory effects of ketoconazole, an antifungal agent which inhibits arachidonic acid lipoxygenases and cytochrome P-450 enzymes, were tested in human colon and breast cancer cell lines.	Ketoconazole	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
1458471-7	1992	Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect.	Clotrimazole	12-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
1458471-7	1992	Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect.	Proadifen	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
1458471-7	1992	Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect.	Proadifen	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	226-242
1458471-7	1992	Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cells whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect.	Azoles	19-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
1458471-8	1992	The results suggest that cytochrome P-450 enzyme(s) activity(ies) could be implicated in the antiproliferative effects of ketoconazole.	Ketoconazole	122-134	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Ethanol	83-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Ethanol	83-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Acetaminophen	217-230	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Nitrosamines	249-261	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
1461639-13	1992	Chronic ethanol consumption results also in the microsomal induction of a specific ethanol-inducible form of cytochrome P--450, the cytochrome P--450IIE1 with high affinity not only to ethanol but also to some drugs (acetaminophen), procarcinogens (nitrosamines) and industrial agents (carbon tetrachloride).	Carbon Tetrachloride	286-306	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-126
1335218-3	1992	There is a strong positive correlation between the rates of ethanol metabolism and the total cytochrome P-450 levels in the hepatoma cells.	Ethanol	60-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1335218-4	1992	The involvement of the cytochrome P-450 system was further supported by the induction of aniline p-hydroxylase activity after ethanol treatment.	Ethanol	126-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
1493081-8	1992	The results are consistent with the involvement of the same cytochrome P-450 isoenzyme(s) in the metabolism of tolbutamide and phenytoin.	Phenytoin	127-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
1493081-8	1992	The results are consistent with the involvement of the same cytochrome P-450 isoenzyme(s) in the metabolism of tolbutamide and phenytoin.	Tolbutamide	111-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
1361312-3	1992	DMED, a 4(5)substituted imidazole, has been shown to inhibit adrenal steroidogenesis and human liver microsomal alfentanil metabolism, reactions mediated by cytochrome P-450.	dmed	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
1361312-3	1992	DMED, a 4(5)substituted imidazole, has been shown to inhibit adrenal steroidogenesis and human liver microsomal alfentanil metabolism, reactions mediated by cytochrome P-450.	4(5)substituted imidazole	8-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
1361312-3	1992	DMED, a 4(5)substituted imidazole, has been shown to inhibit adrenal steroidogenesis and human liver microsomal alfentanil metabolism, reactions mediated by cytochrome P-450.	Alfentanil	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-173
1361312-5	1992	The purpose of this investigation was to determine the mechanism of DMED inhibition of human cytochrome P-450-mediated microsomal metabolism, using ketamine as a probe.	Ketamine	148-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1361312-12	1992	Spectral studies showed that DMED interacted with microsomal cytochrome P-450 to elicit a Type II binding spectrum.	dmed	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
1475793-6	1992	Under the same experimental conditions, microsomal cytochrome P-450 content was decreased by 40%, 2 h after iron treatment.	Iron	108-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
1491046-1	1992	The preparation of samples for injection into a high-performance liquid chromatograph from assay mixtures for the determination of cytochrome P-450-dependent testosterone hydroxylation has been substantially facilitated.	Testosterone	158-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
1426259-0	1992	A critical role of protein-bound water in the catalytic cycle of cytochrome P-450 camphor.	Water	33-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
1426259-0	1992	A critical role of protein-bound water in the catalytic cycle of cytochrome P-450 camphor.	Camphor	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
1491046-5	1992	The modified procedure is a straightforward, easy-to-perform method that should greatly facilitate the implementation of the testosterone hydroxylation assay for sharply discriminating between many individual cytochrome P-450 species in routine enzyme diagnostics.	Testosterone	125-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
1468127-0	1992	Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	10-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1488918-12	1992	Stabilization of cytochrome P-450 protein and/or mRNA are the main processes of induction by PCN/glucocorticoids and ethanol-type inducers.	Pregnenolone Carbonitrile	93-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
1488918-12	1992	Stabilization of cytochrome P-450 protein and/or mRNA are the main processes of induction by PCN/glucocorticoids and ethanol-type inducers.	Ethanol	117-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
1336724-1	1992	The main polycyclic aromatic hydrocarbon-inducible cytochrome P450 was studied in lung tissue from 57 lung cancer patients by immunohistochemistry, using a monoclonal antibody (1-7-1) that recognizes P450IA1 and P450IA2 isozymes.	Polycyclic Aromatic Hydrocarbons	9-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66
1400482-5	1992	Immunoblotting studies demonstrated that dietary salt induced marked increases in the concentration of a cytochrome P-450 isoform(s) recognized by polyclonal antibodies raised against human liver cytochrome P-450 2C10 or rat liver cytochrome P-450 2C11.	Salts	49-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
1400482-5	1992	Immunoblotting studies demonstrated that dietary salt induced marked increases in the concentration of a cytochrome P-450 isoform(s) recognized by polyclonal antibodies raised against human liver cytochrome P-450 2C10 or rat liver cytochrome P-450 2C11.	Salts	49-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	196-212
1425665-0	1992	Heme-pocket-hydration change during the inactivation of cytochrome P-450camphor by hydrostatic pressure.	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
1334809-0	1992	Calcium influx evoked by Ca2+ store depletion in human platelets is more susceptible to cytochrome P-450 inhibitors than receptor-mediated calcium entry.	Calcium	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1334809-7	1992	In apparent agreement with this, Mn2+ influx promoted by TG and tBuBHQ, or by preincubation of cells in Ca(2+)-free medium, was inhibited by the imidazole antimycotics, econazole and miconazole, which inhibit cytochrome P-450 activity.	Manganese(2+)	33-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
1334809-7	1992	In apparent agreement with this, Mn2+ influx promoted by TG and tBuBHQ, or by preincubation of cells in Ca(2+)-free medium, was inhibited by the imidazole antimycotics, econazole and miconazole, which inhibit cytochrome P-450 activity.	imidazole	145-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
1334809-7	1992	In apparent agreement with this, Mn2+ influx promoted by TG and tBuBHQ, or by preincubation of cells in Ca(2+)-free medium, was inhibited by the imidazole antimycotics, econazole and miconazole, which inhibit cytochrome P-450 activity.	Econazole	169-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	209-225
1468127-0	1992	Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	56-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1291449-0	1992	Comparison of cytochrome P-450- and peroxidase-mediated activations of carcinogenic azo dyes and N-nitrosamines.	n-nitrosamines	97-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-46
1385058-0	1992	Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.	Tacrolimus	69-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1328295-0	1992	Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro.	4-hydroxyretinoic acid	64-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1328295-0	1992	Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro.	Tretinoin	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1328295-1	1992	Metabolism of retinoic acid to a less active metabolite, 4-hydroxyretinoic acid, occurs via cytochrome P-450 isozyme(s).	Tretinoin	14-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
1328295-1	1992	Metabolism of retinoic acid to a less active metabolite, 4-hydroxyretinoic acid, occurs via cytochrome P-450 isozyme(s).	4-hydroxyretinoic acid	57-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
1328295-6	1992	This cytochrome P-450 mediated activity was oxygen- and NADPH-dependent and was inhibited 68% by 5 microM ketoconazole (P = 0.0035, n = 8) and 51% by carbon monoxide (P = 0.02, n = 6).	Oxygen	44-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
1328295-6	1992	This cytochrome P-450 mediated activity was oxygen- and NADPH-dependent and was inhibited 68% by 5 microM ketoconazole (P = 0.0035, n = 8) and 51% by carbon monoxide (P = 0.02, n = 6).	NADP	56-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
1328295-6	1992	This cytochrome P-450 mediated activity was oxygen- and NADPH-dependent and was inhibited 68% by 5 microM ketoconazole (P = 0.0035, n = 8) and 51% by carbon monoxide (P = 0.02, n = 6).	Ketoconazole	106-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
1328295-6	1992	This cytochrome P-450 mediated activity was oxygen- and NADPH-dependent and was inhibited 68% by 5 microM ketoconazole (P = 0.0035, n = 8) and 51% by carbon monoxide (P = 0.02, n = 6).	Carbon Monoxide	150-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	5-21
1519785-3	1992	It has been shown previously that alfentanil clearance is independent of the polymorphic debrisoquine hydroxylase (P-450 2D6), and it is therefore of interest to identify the human cytochrome P-450 enzymes involved in noralfentanil formation, the primary reaction involved in the oxidative N-dealkylation at the piperidine nitrogen.	Alfentanil	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
1519785-3	1992	It has been shown previously that alfentanil clearance is independent of the polymorphic debrisoquine hydroxylase (P-450 2D6), and it is therefore of interest to identify the human cytochrome P-450 enzymes involved in noralfentanil formation, the primary reaction involved in the oxidative N-dealkylation at the piperidine nitrogen.	noralfentanil	218-231	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
1519785-3	1992	It has been shown previously that alfentanil clearance is independent of the polymorphic debrisoquine hydroxylase (P-450 2D6), and it is therefore of interest to identify the human cytochrome P-450 enzymes involved in noralfentanil formation, the primary reaction involved in the oxidative N-dealkylation at the piperidine nitrogen.	piperidine	312-322	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
1519785-3	1992	It has been shown previously that alfentanil clearance is independent of the polymorphic debrisoquine hydroxylase (P-450 2D6), and it is therefore of interest to identify the human cytochrome P-450 enzymes involved in noralfentanil formation, the primary reaction involved in the oxidative N-dealkylation at the piperidine nitrogen.	Nitrogen	323-331	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-197
1525169-2	1992	Cytochrome P450 oxidizes T-5-O to the 5,10- rather than the 5,5-dioxide but oxidizes the 5,5-dioxide rapidly and the 5,10-dioxide slowly to the 5,5,10-trioxide.	thianthrene 5-oxide	25-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1525169-2	1992	Cytochrome P450 oxidizes T-5-O to the 5,10- rather than the 5,5-dioxide but oxidizes the 5,5-dioxide rapidly and the 5,10-dioxide slowly to the 5,5,10-trioxide.	5,5-dioxide	60-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1525169-2	1992	Cytochrome P450 oxidizes T-5-O to the 5,10- rather than the 5,5-dioxide but oxidizes the 5,5-dioxide rapidly and the 5,10-dioxide slowly to the 5,5,10-trioxide.	5,5-dioxide	89-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1525169-2	1992	Cytochrome P450 oxidizes T-5-O to the 5,10- rather than the 5,5-dioxide but oxidizes the 5,5-dioxide rapidly and the 5,10-dioxide slowly to the 5,5,10-trioxide.	5,10-dioxide	117-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1525169-2	1992	Cytochrome P450 oxidizes T-5-O to the 5,10- rather than the 5,5-dioxide but oxidizes the 5,5-dioxide rapidly and the 5,10-dioxide slowly to the 5,5,10-trioxide.	5,5,10-trioxide	144-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1525169-12	1992	A large difference in the cis:trans ratios of the 5,10-dioxides produced from T-5-O by cytochrome P450 (1.3:1) and chloroperoxidase (2.5:1) vs hemoglobin (0.1:1) suggests that the hemoglobin active site severely constrains the geometry of the electrophilic oxidation.	5,10-dioxides	50-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
1525169-12	1992	A large difference in the cis:trans ratios of the 5,10-dioxides produced from T-5-O by cytochrome P450 (1.3:1) and chloroperoxidase (2.5:1) vs hemoglobin (0.1:1) suggests that the hemoglobin active site severely constrains the geometry of the electrophilic oxidation.	thianthrene 5-oxide	78-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
1463937-2	1992	Successive treatment of microsomes with protease XXVII and 3-(3-cholamidopropyl)dimethylammoniopropanesulphonic acid gave a solubilized cyt-P450 in more than 80% yield and with a three-fold increase in specific activity.	3-(3-cholamidopropyl)dimethylammoniopropanesulphonic acid	59-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-144
1463937-4	1992	The solubilized cyt-P450 was filtered on a Sephacryl-200 column and then subjected to high performance liquid chromatography with a Mono-P column (chromatofocussing).	mono-p	132-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-24
1385058-0	1992	Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.	Sirolimus	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1385058-1	1992	The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro studies.	Macrolides	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1521541-2	1992	Cytochrome P-450 species (P-450) comprise a polymorphic multigene family of heme-containing enzymes which are essential to the phase-I metabolism of xenobiotics.	Heme	76-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1385058-1	1992	The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro studies.	Tacrolimus	95-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1385058-1	1992	The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro studies.	Sirolimus	105-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1385058-7	1992	It is concluded that in human and rat liver FK506 and rapamycin are metabolized primarily by cytochrome P-450 3A4.	Tacrolimus	44-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1385058-7	1992	It is concluded that in human and rat liver FK506 and rapamycin are metabolized primarily by cytochrome P-450 3A4.	Sirolimus	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1457335-0	1992	The renal cytochrome P-450 arachidonic acid system.	Arachidonic Acid	27-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
1505911-1	1992	The localization of the expression of several cytochrome P-450 genes in normal and diseased human liver was investigated by in situ hybridization of formalin-fixed, paraffin wax-embedded archival tissue samples with 35S-labeled antisense RNA probes.	Formaldehyde	149-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
1505911-1	1992	The localization of the expression of several cytochrome P-450 genes in normal and diseased human liver was investigated by in situ hybridization of formalin-fixed, paraffin wax-embedded archival tissue samples with 35S-labeled antisense RNA probes.	Paraffin	165-177	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
1505911-1	1992	The localization of the expression of several cytochrome P-450 genes in normal and diseased human liver was investigated by in situ hybridization of formalin-fixed, paraffin wax-embedded archival tissue samples with 35S-labeled antisense RNA probes.	Sulfur-35	216-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
1331779-1	1992	Aromatase, a cytochrome P-450, catalyzes the formation of aromatic C18 estrogenic steroids from C19 androgens.	Steroids	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
1457335-3	1992	AA is metabolized by the renal cytochrome P-450 epoxygenase and omega/omega 1 hydroxylases to epoxyeicosatrienoic acids and omega/omega-1 alcohols (20- and 19-mono-hydroxyeicosatetraenoic acids), respectively.	epoxyeicosatrienoic acids	94-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1457335-3	1992	AA is metabolized by the renal cytochrome P-450 epoxygenase and omega/omega 1 hydroxylases to epoxyeicosatrienoic acids and omega/omega-1 alcohols (20- and 19-mono-hydroxyeicosatetraenoic acids), respectively.	omega/omega-1 alcohols	124-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1457335-3	1992	AA is metabolized by the renal cytochrome P-450 epoxygenase and omega/omega 1 hydroxylases to epoxyeicosatrienoic acids and omega/omega-1 alcohols (20- and 19-mono-hydroxyeicosatetraenoic acids), respectively.	mono-hydroxyeicosatetraenoic acids	159-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1441599-0	1992	Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9).	Mephenytoin	50-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Omeprazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Diazepam	145-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Phenytoin	155-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Phenacetin	307-317	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Acetaminophen	322-335	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Polycyclic Aromatic Hydrocarbons	396-428	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	aniline	430-440	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1344831-4	1992	Omeprazole interacts with the cytochrome P-450 system in the liver: inhibition of several liver mono-oxygenases activities (inhibitory effect on diazepam, phenytoin and R-warfarin metabolism with prolonged elimination); induction of P-450 (IA1 and IA2) enzymes that may potentiate the hepatotoxic effect of phenacetin and acetaminophen or increase the tumorigenic effect of chemical carcinogens (polycyclic aromatic hydrocarbons, arylamines, aflatoxin).	Aflatoxins	442-451	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
1441599-16	1992	These findings indicate that P-450 human-2 is the major cytochrome P-450 responsible for the polymorphisms in stereoselective hydroxylations of mephenytoin and hexobarbital.	Mephenytoin	144-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
1441602-2	1992	Microsomal reduction of azo dyes related to dimethylaminoazobenzene (DAB) is catalysed by at least two types of cytochrome P-450.	Azo Compounds	24-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
1441602-2	1992	Microsomal reduction of azo dyes related to dimethylaminoazobenzene (DAB) is catalysed by at least two types of cytochrome P-450.	p-Dimethylaminoazobenzene	44-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
1441602-2	1992	Microsomal reduction of azo dyes related to dimethylaminoazobenzene (DAB) is catalysed by at least two types of cytochrome P-450.	p-Dimethylaminoazobenzene	69-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
1504011-3	1992	In addition, it has been found that malondialdehyde formation is accompanied by a corresponding decrease in placental mitochondrial cytochrome P-450 content.	Malondialdehyde	36-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
1643634-0	1992	Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes.	NSC 354646	81-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
1643634-3	1992	This metabolic potentiation is inhibited by carbon monoxide or hypoxia, indicating that it is cytochrome P-450-dependent.	Carbon Monoxide	44-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
1643634-4	1992	The potentiation is also inhibited by the cytochrome P-450 inhibitors, SKF-525A and cimetidine.	Cimetidine	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
1510705-3	1992	Ketoconazole, a known inhibitor of cytochrome P450 isozymes, caused marked inhibition of carboxyprimaquine formation with IC50 and K(i) values of 15 and 6.7 microM, respectively.	Ketoconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
1510705-3	1992	Ketoconazole, a known inhibitor of cytochrome P450 isozymes, caused marked inhibition of carboxyprimaquine formation with IC50 and K(i) values of 15 and 6.7 microM, respectively.	8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline	89-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-50
1510705-4	1992	This finding and the dependency of metabolite formation on NADPH indicates that cytochrome P450 isozyme(s) catalysed metabolite production.	NADP	59-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
1617624-8	1992	Metabolite yields under various conditions were determined, including a demonstration that carbon monoxide inhibited 81% of NMAA demethylation, indicating that cytochrome P-450 enzymes were involved.	Carbon Monoxide	91-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
1496595-0	1992	Correlation of cyclosporine-induced nephropathy with renal microsomal cytochrome P-450: the preventive effect of verapamil.	Cyclosporine	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
1379068-8	1992	The reduced carbon monoxide binding spectrum shows an absorption maximum at 447 nm indicative of a cytochrome P-450 hemoprotein.	Carbon Monoxide	12-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
1627548-9	1992	These results suggested that the stimulation of catalytic activity by phospholipids involved increased interaction between cytochrome P-450 and the reductase.	Phospholipids	70-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
1617624-8	1992	Metabolite yields under various conditions were determined, including a demonstration that carbon monoxide inhibited 81% of NMAA demethylation, indicating that cytochrome P-450 enzymes were involved.	nmaa	124-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	Arachidonic Acid	35-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1628663-0	1992	The cholesterol-side-chain-cleaving cytochrome P450 spin-state equilibrium.	Cholesterol	4-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-51
1628663-3	1992	We have confirmed and characterised structurally the enzyme conformational changes deduced from the preceding thermodynamic analysis of the adrenal mitochondrial cholesterol-side-chain-cleaving cytochrome P450 spin-state equilibrium.	Cholesterol	162-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-209
1524698-3	1992	The main mechanism of most drug interactions involving cimetidine appears to be inhibition of the hepatic microsomal enzyme cytochrome P450, an effect which may be related to the different structures of H2-antagonists.	Cimetidine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
1524698-3	1992	The main mechanism of most drug interactions involving cimetidine appears to be inhibition of the hepatic microsomal enzyme cytochrome P450, an effect which may be related to the different structures of H2-antagonists.	Hydrogen	203-205	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	53-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	Thromboxanes	188-199	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	Arachidonic Acid	224-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1327375-2	1992	The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM).	Calcimycin	268-274	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1321524-1	1992	Dioxins and peroxisome proliferators represent two diverse classes of xenobiotic compounds that induce transcription of specific genes encoding cytochrome P-450 drug-metabolizing enzymes.	Dioxins	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-160
1316878-8	1992	This indicates that inhibition of LTB4 omega-hydroxylase activity by pyocyanin might be achieved by competition for NADPH.	Pyocyanine	69-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-56
1316878-8	1992	This indicates that inhibition of LTB4 omega-hydroxylase activity by pyocyanin might be achieved by competition for NADPH.	NADP	116-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-56
1640215-2	1992	The term cytochrome P450 refers to a group of hemoproteins whose Fe(2+)-carbon monoxide complex shows an absorption spectrum with a maximum near 450 nm.	fe(2+)-carbon monoxide	65-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-24
1640215-4	1992	Cytochrome P450 enzymes are involved in the metabolism of drugs, carcinogens, steroids, pesticides, hydrocarbons and natural products.	Steroids	78-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1640215-4	1992	Cytochrome P450 enzymes are involved in the metabolism of drugs, carcinogens, steroids, pesticides, hydrocarbons and natural products.	Hydrocarbons	100-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1596283-5	1992	The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production.	Ketoconazole	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
1587824-0	1992	Reconstitution of the fatty acid hydroxylation function of cytochrome P-450BM-3 utilizing its individual recombinant hemo- and flavoprotein domains.	Fatty Acids	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-79
1587824-3	1992	Prior attempts to reconstitute the fatty acid hydroxylation function of cytochrome P-450BM-3, utilizing the two domains, obtained either by trypsinolysis or by recombinant methods, were unsuccessful.	Fatty Acids	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-92
1587824-4	1992	In this paper, we describe the reconstitution of the fatty acid hydroxylation activity of cytochrome P-450BM-3 utilizing the recombinantly produced flavoprotein domain (Oster, T., Boddupalli, S. S., and Peterson, J.	Fatty Acids	53-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-110
1587824-10	1992	The combination of the hemo- and flavoprotein domains in a ratio of 20:1 respectively, in the reaction mixture, results in the transfer of 80% of the reducing equivalents from NADPH for the hydroxylation of palmitate at 25 degrees C. The ratio of the regioisomeric products obtained for lauric, myristic, and palmitic acids was similar to that obtained with the holoenzyme form of cytochrome P-450BM-3.	NADP	176-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	381-401
1587824-11	1992	The reconstitution of the fatty acid omega-hydroxylase activity, using the soluble domains of cytochrome P-450BM-3, without added factors such as lipids, may be useful for structure/function comparisons to their eukaryotic counterparts.	Fatty Acids	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-114
1596283-5	1992	The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production.	Ketoconazole	18-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
1596283-5	1992	The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production.	NADP	141-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
1596283-5	1992	The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production.	NADP	141-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	162-177
1594575-0	1992	Substrate mobility in a deeply buried active site: analysis of norcamphor bound to cytochrome P-450cam as determined by a 201-psec molecular dynamics simulation.	norcamphor	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
1423213-2	1992	The increased steroid production demonstrated by most of the pathological tissue samples examined here was associated with either an unchanged or dramatically decreased specific microsomal content of cytochrome P-450.	Steroids	14-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
1610865-5	1992	Clearance data suggests, however, that the primary mechanism for the interaction is the inhibition cyclosporine metabolism by the cytochrome P-450 system.	Cyclosporine	99-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
1394641-0	1992	Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo.	Fluconazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
1394641-2	1992	The inhibitory effect of fluconazole (FCZ), a bis-triazole antimycotic, on mouse hepatic microsomal cytochrome P-450-mediated drug-metabolizing enzyme system was compared with those of ketoconazole (KCZ) in vivo and in vitro.	Fluconazole	25-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
1394641-2	1992	The inhibitory effect of fluconazole (FCZ), a bis-triazole antimycotic, on mouse hepatic microsomal cytochrome P-450-mediated drug-metabolizing enzyme system was compared with those of ketoconazole (KCZ) in vivo and in vitro.	Fluconazole	38-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
1394641-5	1992	In contrast, in vitro the affinity and the inhibitory potency of FCZ for cytochrome P-450 and aminopyrine N-demethylation were 4- to 6-fold smaller than those of KCZ.	Fluconazole	65-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
1578365-0	1992	Human cytochrome P450 metabolism of teniposide and etoposide.	Teniposide	36-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
1578365-0	1992	Human cytochrome P450 metabolism of teniposide and etoposide.	Etoposide	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
1354126-2	1992	Cytochrome P-450 was induced in adult hen liver by administering 15% ethanol in drinking water and compared with other inducers such as phenobarbital and beta-naphthoflavone.	Ethanol	69-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1539561-1	1992	Both cimetidine and cyclosporine (CsA) are metabolized by the cytochrome P-450 system.	Cimetidine	5-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
1312930-0	1992	Effect of KCl on the interactions between NADPH:cytochrome P-450 reductase and either cytochrome c, cytochrome b5 or cytochrome P-450 in octyl glucoside micelles.	Potassium Chloride	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
1312930-0	1992	Effect of KCl on the interactions between NADPH:cytochrome P-450 reductase and either cytochrome c, cytochrome b5 or cytochrome P-450 in octyl glucoside micelles.	octyl-beta-D-glucoside	137-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
1312930-1	1992	Significant dissociation of FMN from NADPH:cytochrome P-450 reductase resulted in loss of the activity for reduction of cytochrome b5 as well as cytochrome c and cytochrome P-450.	Flavin Mononucleotide	28-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
1312930-3	1992	The reductions of cytochrome c and detergent-solubilized cytochrome b5 by NADPH:cytochrome P-450 reductase were greatly increased in the presence of high concentrations of KCl, although the stimulatory effect of the salt on cytochrome P-450 reduction was less significant.	Potassium Chloride	172-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
1312930-3	1992	The reductions of cytochrome c and detergent-solubilized cytochrome b5 by NADPH:cytochrome P-450 reductase were greatly increased in the presence of high concentrations of KCl, although the stimulatory effect of the salt on cytochrome P-450 reduction was less significant.	Salts	216-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
1523868-11	1992	The increase in toxicity of heroin and methadone produced by ethanol is concomitant with a 40% increase in cytochrome P-450 levels of the pretreated hepatocytes.	Heroin	28-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
1523868-11	1992	The increase in toxicity of heroin and methadone produced by ethanol is concomitant with a 40% increase in cytochrome P-450 levels of the pretreated hepatocytes.	Ethanol	61-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-123
1643250-3	1992	Aflatoxin Q1 and aflatoxin B1 8,9-oxide (trapped here as the glutathione conjugate) are the major oxidative products formed from aflatoxin B1 at all substrate concentrations in human liver microsomes, and cytochrome P-450 (P-450) 3A4 appears to be the dominant enzyme involved in both oxidations, as judged by studies involving correlation of activities in different liver samples, chemical inhibition, immunoinhibition, and reconstitution with purified hepatic and yeast recombinant P-450 3A4.	aflatoxin Q1	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
1643250-3	1992	Aflatoxin Q1 and aflatoxin B1 8,9-oxide (trapped here as the glutathione conjugate) are the major oxidative products formed from aflatoxin B1 at all substrate concentrations in human liver microsomes, and cytochrome P-450 (P-450) 3A4 appears to be the dominant enzyme involved in both oxidations, as judged by studies involving correlation of activities in different liver samples, chemical inhibition, immunoinhibition, and reconstitution with purified hepatic and yeast recombinant P-450 3A4.	aflatoxin B1-2,3-oxide	17-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
1643250-3	1992	Aflatoxin Q1 and aflatoxin B1 8,9-oxide (trapped here as the glutathione conjugate) are the major oxidative products formed from aflatoxin B1 at all substrate concentrations in human liver microsomes, and cytochrome P-450 (P-450) 3A4 appears to be the dominant enzyme involved in both oxidations, as judged by studies involving correlation of activities in different liver samples, chemical inhibition, immunoinhibition, and reconstitution with purified hepatic and yeast recombinant P-450 3A4.	Glutathione	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
32357628-3	1992	Recent purification and characterization of specific steroidogenic enzymes, such as cytochrome P-450, that are involved in adrenal steroid biosynthesis have made it possible to generate specific antibodies and DNA probes against the enzymes that catalyze specific reaction(s) in the complicated biochemical cascade of steroidogenesis.	Steroids	53-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
1539561-1	1992	Both cimetidine and cyclosporine (CsA) are metabolized by the cytochrome P-450 system.	Cyclosporine	20-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
1539561-1	1992	Both cimetidine and cyclosporine (CsA) are metabolized by the cytochrome P-450 system.	Cyclosporine	34-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
1546013-2	1992	The mechanism of increased susceptibility involves induction of isoenzymes of the cytochrome P-450 system by alcohol and depletion of hepatic glutathione reserves, both of which can result from chronic alcohol ingestion and both of which affect the metabolism of acetaminophen.	Alcohols	109-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
1546013-2	1992	The mechanism of increased susceptibility involves induction of isoenzymes of the cytochrome P-450 system by alcohol and depletion of hepatic glutathione reserves, both of which can result from chronic alcohol ingestion and both of which affect the metabolism of acetaminophen.	Alcohols	202-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
1546013-2	1992	The mechanism of increased susceptibility involves induction of isoenzymes of the cytochrome P-450 system by alcohol and depletion of hepatic glutathione reserves, both of which can result from chronic alcohol ingestion and both of which affect the metabolism of acetaminophen.	Acetaminophen	263-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-98
1737335-0	1992	A new form of cytochrome P-450 responsible for mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline in human livers.	2-amino-3-methylimidazo(4,5-f)quinoline	71-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	14-30
1537463-1	1992	Arachidonic acid and many products of the arachidonate cascade serve as substrates for cytochrome P450-mediated metabolism via allylic oxidation, omega hydroxylation, and epoxygenation as well as peroxide rearrangement.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
1550407-4	1992	The synthesis of 1,25(OH)2D3 and 24,25(OH)2D3 by macrophages and fibroblast-like cells respectively was inhibited by ketoconazole, indicating that both hydroxylases are dependent on cytochrome P-450.	Calcitriol	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
1550407-4	1992	The synthesis of 1,25(OH)2D3 and 24,25(OH)2D3 by macrophages and fibroblast-like cells respectively was inhibited by ketoconazole, indicating that both hydroxylases are dependent on cytochrome P-450.	24,25(oh)2d3	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
1550407-4	1992	The synthesis of 1,25(OH)2D3 and 24,25(OH)2D3 by macrophages and fibroblast-like cells respectively was inhibited by ketoconazole, indicating that both hydroxylases are dependent on cytochrome P-450.	Ketoconazole	117-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
1311943-7	1992	These data confirm that ketoconazole is a potent inhibitor of cytochrome P-450-IIIA4, and this has clinical relevance.	Ketoconazole	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-84
1311944-2	1992	Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism.	Imidazoles	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1311944-2	1992	Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism.	Imidazoles	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
1311944-2	1992	Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism.	Triazoles	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1311944-2	1992	Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism.	Triazoles	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
1311944-4	1992	In contrast, allylamines, which have a different mode of action and a weaker ability to bind to cytochrome P-450, are not expected to inhibit clinical drug oxidation.	Allylamine	13-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
1373902-6	1992	Western blot analysis of liver microsomes with antibodies to rat P-450IA2 (P-448-H), P-450IIB1 (P-450b) and human P-450IIIA4 (P-450NF) showed that ascorbic acid-deficiency resulted in a decrease in the amount of cytochrome P-450 immunochemically related to P-450IA2, but not the amounts of the forms of cytochrome P-450 cross-reactive with antibodies to P-450IIB1 and P-450IIIA4.	Ascorbic Acid	147-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	303-319
1730667-1	1992	Aromatase, a cytochrome P-450, catalyzes the formation of aromatic C18 estrogenic steroids from C19 androgens.	Steroids	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
1539615-4	1992	Two separate studies have shown that Med I"s vasodepressor action is inhibited by four procedures: mixing with Tween 20; treatment with n-butyl boronic acid; treatment of the assay animal with SKF 525A, an inhibitor of cytochrome P-450; and removing the liver from the circulation.	Proadifen	193-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-235
1536639-0	1992	Phenobarbital induction of cytochrome P-450 gene expression.	Phenobarbital	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
1537463-1	1992	Arachidonic acid and many products of the arachidonate cascade serve as substrates for cytochrome P450-mediated metabolism via allylic oxidation, omega hydroxylation, and epoxygenation as well as peroxide rearrangement.	Arachidonic Acid	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-102
1537463-3	1992	Cytochrome P450-catalyzed reactions play prominent roles in multiplying the structural and functional diversity of the arachidonate metabolic cascade.	Arachidonic Acid	119-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1537469-3	1992	The acceleration of Mn2+ entry observed in cells with empty intracellular Ca2+ stores was prevented by cytochrome P450 inhibitors.	Manganese(2+)	20-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
1581524-0	1992	A new hypothesis for the mechanism for cytochrome P-450 dependent aerobic conversion of hexahalogenated benzenes to pentahalogenated phenols.	Benzene	104-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1581524-0	1992	A new hypothesis for the mechanism for cytochrome P-450 dependent aerobic conversion of hexahalogenated benzenes to pentahalogenated phenols.	Phenols	133-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1581537-0	1992	Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.	Warfarin	17-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
1581537-0	1992	Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.	Warfarin	111-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
1581537-3	1992	In order to identify the specific form(s) of human liver cytochrome P-450 involved in this particular toxicity, we have determined the metabolic profiles of 11 human cytochrome P-450 forms expressed in HepG2 cells toward both (R)- and (S)-warfarin.	Warfarin	239-247	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
1581524-1	1992	The mechanism for cytochrome P-450 dependent conversion of hexahalogenated benzenes was investigated.	Benzene	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-34
1581524-7	1992	On the basis of the results obtained, three of the four mechanisms proposed in the literature for the mechanism of the cytochrome P-450 dependent conversion of hexahalogenated benzenes to pentahalogenated phenols could be eliminated.	Benzene	176-184	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
1581524-7	1992	On the basis of the results obtained, three of the four mechanisms proposed in the literature for the mechanism of the cytochrome P-450 dependent conversion of hexahalogenated benzenes to pentahalogenated phenols could be eliminated.	Phenols	205-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
1581524-9	1992	On the basis of the results obtained a new hypothesis for the mechanism of cytochrome P-450 dependent conversion of hexahalogenated benzenes to pentahalogenated phenols was proposed.	Benzene	132-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
1581524-9	1992	On the basis of the results obtained a new hypothesis for the mechanism of cytochrome P-450 dependent conversion of hexahalogenated benzenes to pentahalogenated phenols was proposed.	Phenols	161-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
1571442-4	1992	Certain isozymes of the cytochrome P-450 system are selectively inhibited by some fluoroquinolones.	Fluoroquinolones	82-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
1346997-0	1992	Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans.	Nitrogen	73-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
1306804-0	1992	Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies.	Dextromethorphan	40-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1346997-7	1992	This was substantiated by the finding that CQA metabolism was completely inhibited by a polyclonal antibody directed against a pregnenolone 16 alpha-carbonitrile-inducible cytochrome P-450 of rat liver.	Amodiaquine	43-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1346997-7	1992	This was substantiated by the finding that CQA metabolism was completely inhibited by a polyclonal antibody directed against a pregnenolone 16 alpha-carbonitrile-inducible cytochrome P-450 of rat liver.	Pregnenolone	127-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1346997-7	1992	This was substantiated by the finding that CQA metabolism was completely inhibited by a polyclonal antibody directed against a pregnenolone 16 alpha-carbonitrile-inducible cytochrome P-450 of rat liver.	alpha-carbonitrile	143-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1459043-0	1992	Relationship between activities of cytochrome P-450 monooxygenases in human placental microsomes and binding of benzo(a)pyrene metabolites to calf thymus DNA.	benzo(a)	112-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
1459043-0	1992	Relationship between activities of cytochrome P-450 monooxygenases in human placental microsomes and binding of benzo(a)pyrene metabolites to calf thymus DNA.	pyrene	120-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
1721276-0	1991	Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro.	Tacrolimus	11-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
1596582-2	1992	Procarbazine is converted initially to azoprocarbazine, which is then N-oxidized through a cytochrome P-450-mediated process to a mixture of the positional isomers, benzylazoxyprocarbazine and methylazoxyprocarbazine.	Procarbazine	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1596582-2	1992	Procarbazine is converted initially to azoprocarbazine, which is then N-oxidized through a cytochrome P-450-mediated process to a mixture of the positional isomers, benzylazoxyprocarbazine and methylazoxyprocarbazine.	azoprocarbazine	39-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1596582-2	1992	Procarbazine is converted initially to azoprocarbazine, which is then N-oxidized through a cytochrome P-450-mediated process to a mixture of the positional isomers, benzylazoxyprocarbazine and methylazoxyprocarbazine.	benzylazoxyprocarbazine	165-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1596582-2	1992	Procarbazine is converted initially to azoprocarbazine, which is then N-oxidized through a cytochrome P-450-mediated process to a mixture of the positional isomers, benzylazoxyprocarbazine and methylazoxyprocarbazine.	methylazoxyprocarbazine	193-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1412450-0	1992	Roles of renal cytochrome P450-dependent arachidonic acid metabolites in hypertension.	Arachidonic Acid	41-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-30
1412450-1	1992	Cytochrome P450 represents the third metabolic pathway of arachidonic acid giving rise to several biologically active compounds, such as 19-HETE, 20-HETE and EETs and their corresponding DHETs.	Arachidonic Acid	58-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1412450-1	1992	Cytochrome P450 represents the third metabolic pathway of arachidonic acid giving rise to several biologically active compounds, such as 19-HETE, 20-HETE and EETs and their corresponding DHETs.	19-hydroxy-5,8,11,14-eicosatetraenoic acid	137-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1412450-1	1992	Cytochrome P450 represents the third metabolic pathway of arachidonic acid giving rise to several biologically active compounds, such as 19-HETE, 20-HETE and EETs and their corresponding DHETs.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	146-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1412450-1	1992	Cytochrome P450 represents the third metabolic pathway of arachidonic acid giving rise to several biologically active compounds, such as 19-HETE, 20-HETE and EETs and their corresponding DHETs.	dhets	187-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1955133-1	1991	Cimetidine binds to cytochrome P-450 and inhibits hepatic metabolism of various drugs in humans.	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	20-36
1955133-6	1991	Concordantly, the calculated binding constant for the binding of cimetidine to a purified cytochrome P-450 with high tolbutamide hydroxylase activity was 4.4 mmol/L, whereas the calculated binding concentration constant for a purified cytochrome P-450-metabolizing nifedipine was 0.7 mmol/L.	Cimetidine	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
1955133-6	1991	Concordantly, the calculated binding constant for the binding of cimetidine to a purified cytochrome P-450 with high tolbutamide hydroxylase activity was 4.4 mmol/L, whereas the calculated binding concentration constant for a purified cytochrome P-450-metabolizing nifedipine was 0.7 mmol/L.	Cimetidine	65-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	235-251
1955133-6	1991	Concordantly, the calculated binding constant for the binding of cimetidine to a purified cytochrome P-450 with high tolbutamide hydroxylase activity was 4.4 mmol/L, whereas the calculated binding concentration constant for a purified cytochrome P-450-metabolizing nifedipine was 0.7 mmol/L.	Nifedipine	265-275	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
1592216-10	1992	A significant bioactivation with a possibility of only limited detoxication via cytochrome P-450-dependent oxidation suggests that human fetus may be at greater risk from 1,2-dibromoethane toxicity than adult.	Ethylene Dibromide	171-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
1594531-0	1992	Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro.	Carbon Tetrachloride	51-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1594531-0	1992	Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro.	Halothane	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
1594531-1	1992	A significant loss of human cytochrome P-450 was observed during the anaerobic incubation of NADPH-reduced human liver microsomes obtained from surgical samples, in presence of carbon tetrachloride or halothane.	NADP	93-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
1594531-1	1992	A significant loss of human cytochrome P-450 was observed during the anaerobic incubation of NADPH-reduced human liver microsomes obtained from surgical samples, in presence of carbon tetrachloride or halothane.	Carbon Tetrachloride	177-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
1594531-1	1992	A significant loss of human cytochrome P-450 was observed during the anaerobic incubation of NADPH-reduced human liver microsomes obtained from surgical samples, in presence of carbon tetrachloride or halothane.	Halothane	201-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
1594531-5	1992	The results indicate that human liver cytochrome P-450 can be inactivated reductively in vitro by CCl4 and halothane reactive metabolites and suggest that a suicide type of mechanism, similar to that which was recently demonstrated to occur, for both substrates, with rat liver microsomes (Manno et al.	Halothane	107-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
1764041-6	1991	Cytochrome P-450 inhibitors prevented the thrombin-induced Mn2+ influx, with little effect on the Ca2+ mobilization from the intracellular stores.	Manganese(2+)	59-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1764041-10	1991	The activation of the plasma-membrane Ca2+ (Mn2+) pathway may take place by a mechanism involving microsomal cytochrome P-450, similar to that described previously in thymocytes [Alvarez, Montero &amp; Garcia-Sancho (1991) Biochem.	Manganese(2+)	44-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-125
1748033-0	1991	Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.	Omeprazole	99-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
1748033-3	1991	Omeprazole contains a benzimidazole moiety and thus has the potential to interact with the cytochrome P-450 enzyme group.	Omeprazole	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1748033-3	1991	Omeprazole contains a benzimidazole moiety and thus has the potential to interact with the cytochrome P-450 enzyme group.	benzimidazole	22-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-107
1748033-6	1991	Overall, the studies reviewed suggest that omeprazole has a differential affinity toward specific cytochrome P-450 isozymes.	Omeprazole	43-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-126
1770192-4	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving cytochrome P-450: the newly discovered ethanol-inducible cytochrome P-450 (P-450IIE1) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
1771946-1	1991	A cocktail of four model substances orally administered to humans is used for simultaneous characterization of phenobarbital and 3-methylcholanthrene inducible forms of cytochrome-P450 and two genetic polymorphisms, the debrisoquine hydroxylation and N-acetylation.	Methylcholanthrene	129-149	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-184
1812615-2	1991	Benzidine and its derivatives were shown to induce those forms of cytochrome P-450 which were involved in accelerated oxidation of the carcinogenic drugs studied as well as affected the glutathione transferase, NADPH-dependent glutathione reductase activities and the activity of antioxidant system enzymes.	benzidine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
1800391-1	1991	Urinary 6 beta-hydroxycortisol (6 beta OHF) is a specific marker of the induction of the cytochrome P-450 IIIA.	6 beta-hydroxycortisol	8-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
1800391-1	1991	Urinary 6 beta-hydroxycortisol (6 beta OHF) is a specific marker of the induction of the cytochrome P-450 IIIA.	beta ohf	34-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-105
1811554-2	1991	The hypothesis that the mechanism of action of gemfibrozil involved the cytochrome P-450 system was tested by using ketoconazole, a P-450 inhibitor, which blocks the formation of endogenous polar sterols.	Gemfibrozil	47-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
1811554-2	1991	The hypothesis that the mechanism of action of gemfibrozil involved the cytochrome P-450 system was tested by using ketoconazole, a P-450 inhibitor, which blocks the formation of endogenous polar sterols.	Ketoconazole	116-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
1914510-0	1991	Immunocytochemical study of phenobarbital- and 3-methylcholanthrene-inducible cytochrome P450 isozymes in primary cultures of porcine ciliary epithelium.	Phenobarbital	28-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
1951574-7	1991	Most of the imidazole and triazole derivatives are highly potent and selective inhibitors of the cytochrome P-450-dependent 14 alpha-demethylation of lanosterol (P-45014DM).	imidazole	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1951574-7	1991	Most of the imidazole and triazole derivatives are highly potent and selective inhibitors of the cytochrome P-450-dependent 14 alpha-demethylation of lanosterol (P-45014DM).	Triazoles	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1951574-7	1991	Most of the imidazole and triazole derivatives are highly potent and selective inhibitors of the cytochrome P-450-dependent 14 alpha-demethylation of lanosterol (P-45014DM).	Lanosterol	150-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1951574-9	1991	The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450.	Triazoles	4-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
1951574-9	1991	The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450.	terconazole	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
1951574-9	1991	The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450.	Itraconazole	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
1930182-3	1991	In cases where iminium-enamine coupling is sterically prevented, the iminium in equilibrium with enamine species can be studied independently and are found to be more potent metabolism-dependent inactivators of cytochrome P-450 than are the corresponding parent amines.	iminium-enamine	15-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
1930182-3	1991	In cases where iminium-enamine coupling is sterically prevented, the iminium in equilibrium with enamine species can be studied independently and are found to be more potent metabolism-dependent inactivators of cytochrome P-450 than are the corresponding parent amines.	iminium	15-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
1930182-3	1991	In cases where iminium-enamine coupling is sterically prevented, the iminium in equilibrium with enamine species can be studied independently and are found to be more potent metabolism-dependent inactivators of cytochrome P-450 than are the corresponding parent amines.	cyclopentyl enamine	23-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
1930182-3	1991	In cases where iminium-enamine coupling is sterically prevented, the iminium in equilibrium with enamine species can be studied independently and are found to be more potent metabolism-dependent inactivators of cytochrome P-450 than are the corresponding parent amines.	Amines	262-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-227
1686246-4	1991	The activities were NADPH dependent and inhibited by 1-aminobenzotriazole, a potent cytochrome P-450 suicide substrate inhibitor.	NADP	20-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
1686246-4	1991	The activities were NADPH dependent and inhibited by 1-aminobenzotriazole, a potent cytochrome P-450 suicide substrate inhibitor.	1-aminobenzotriazole	53-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
1876834-6	1991	The results establish a new catalytic activity for a cytochrome P-450 and illustrate the cooperation of different oxygenases in pathways of fatty acid metabolism.	Fatty Acids	140-150	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
1752284-0	1991	Cyclosporin-A-induced lipid peroxidation in human liver microsomes and its influence on cytochrome P-450.	Cyclosporine	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1752284-1	1991	The present in vitro study using human liver tissue was performed to investigate the effect of cyclosporin A on lipid peroxidation and cytochrome P-450 concentration in isolated liver microsomes.	Cyclosporine	95-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-151
1752284-9	1991	Furthermore, cyclosporin-A-induced microsomal lipid peroxidation was accompanied by a significant dose-dependent decline of the microsomal cytochrome P-450 content.	Cyclosporine	13-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
1752284-10	1991	At a cyclosporin A concentration of 300 micrograms ml-1, cytochrome P-450 content was decreased to 49% in comparison to control values.	Cyclosporine	5-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-73
1752284-11	1991	In the presence of reduced glutathione, cyclosporin A decreased the cytochrome P-450 concentration only to 79% (P less than 0.05).	Glutathione	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
1752284-11	1991	In the presence of reduced glutathione, cyclosporin A decreased the cytochrome P-450 concentration only to 79% (P less than 0.05).	Cyclosporine	40-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
1650691-3	1991	Most investigations on this topic have focused on two aspects: ethanol"s capacity to induce the cytochrome P-450-dependent microsomal biotransformation system and its interference with at least one DNA repair mechanism.	Ethanol	63-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-112
1914510-0	1991	Immunocytochemical study of phenobarbital- and 3-methylcholanthrene-inducible cytochrome P450 isozymes in primary cultures of porcine ciliary epithelium.	Methylcholanthrene	47-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
1771239-1	1991	Epoxides and fatty acid diols derived from arachidonate by the action of cytochrome P-450 appear in human urine and have biological activities.	Epoxy Compounds	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
1720447-2	1991	Multiple isoforms of cytochrome P450 (P450) have been discovered that are important biomedically to drug pharmacokinetics, chemical carcinogenesis, and metabolism of endogenous agents such as steroids, arachidonic acids, and prostaglandins.	Steroids	192-200	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
1720447-2	1991	Multiple isoforms of cytochrome P450 (P450) have been discovered that are important biomedically to drug pharmacokinetics, chemical carcinogenesis, and metabolism of endogenous agents such as steroids, arachidonic acids, and prostaglandins.	Arachidonic Acids	202-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
1720447-2	1991	Multiple isoforms of cytochrome P450 (P450) have been discovered that are important biomedically to drug pharmacokinetics, chemical carcinogenesis, and metabolism of endogenous agents such as steroids, arachidonic acids, and prostaglandins.	Prostaglandins	225-239	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
1720069-6	1991	The free radical scavenger, alpha-tocopherol, and the xanthine oxidase inhibitor, allopurinol, also prevented the loss of cytochrome P-450 mediated by the interferon inducer poly rI.rC.	alpha-Tocopherol	28-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
1720069-6	1991	The free radical scavenger, alpha-tocopherol, and the xanthine oxidase inhibitor, allopurinol, also prevented the loss of cytochrome P-450 mediated by the interferon inducer poly rI.rC.	Allopurinol	82-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
1680663-0	1991	Blood levels of propylene oxide during propylene inhalation and effect on hepatic and nasal cytochrome P-450 concentrations.	propylene oxide	16-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
1680663-0	1991	Blood levels of propylene oxide during propylene inhalation and effect on hepatic and nasal cytochrome P-450 concentrations.	propylene	16-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
1857342-1	1991	Purification and immunoinhibition studies have suggested that the hydroxylations of (S)-mephenytoin and tolbutamide are catalyzed by rather similar forms of human liver cytochrome P-450 (P-450).	Mephenytoin	84-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
1857342-1	1991	Purification and immunoinhibition studies have suggested that the hydroxylations of (S)-mephenytoin and tolbutamide are catalyzed by rather similar forms of human liver cytochrome P-450 (P-450).	Tolbutamide	104-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-185
1650250-3	1991	Thus, chloroperoxidase shares many spectroscopic properties with cytochrome P-450, the only other known thiolate-ligated heme protein.	thiolate	104-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
1650250-3	1991	Thus, chloroperoxidase shares many spectroscopic properties with cytochrome P-450, the only other known thiolate-ligated heme protein.	Heme	121-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
1906712-4	1991	The calcium-stores-regulated Mn2+ influx, including that induced by agonists, was prevented by cytochrome P-450 inhibitors.	Calcium	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
1906712-4	1991	The calcium-stores-regulated Mn2+ influx, including that induced by agonists, was prevented by cytochrome P-450 inhibitors.	Manganese(2+)	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
1906712-5	1991	We propose that agonist-induced Ca2+ (Mn2+) influx in human neutrophils is secondary to the emptying of the intracellular stores which, in turn, activates plasma-membrane Ca2+ channels by a mechanism involving microsomal cytochrome P-450, similar to that described previously in thymocytes [Alvarez, Montero &amp; Garcia-Sancho (1991) Biochem.	Manganese(2+)	38-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
1771239-1	1991	Epoxides and fatty acid diols derived from arachidonate by the action of cytochrome P-450 appear in human urine and have biological activities.	fatty acid diols	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
1771239-1	1991	Epoxides and fatty acid diols derived from arachidonate by the action of cytochrome P-450 appear in human urine and have biological activities.	Arachidonic Acid	43-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
1771239-3	1991	We investigated whether dietary eicosapentaenoic acid could also be metabolized by cytochrome P-450, by assessing the excretion of its vicinal diols.	Eicosapentaenoic Acid	32-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
1771239-3	1991	We investigated whether dietary eicosapentaenoic acid could also be metabolized by cytochrome P-450, by assessing the excretion of its vicinal diols.	vicinal diols	135-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
1949908-15	1991	Moreover, both these pathways involve the cytochrome P-450 system and can be induced with phenobarbital.	Phenobarbital	90-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58
2040591-10	1991	Thus aldosterone synthase cytochrome P-450, a distinct species from cytochrome P-450(11 beta), is responsible for the biosynthesis of aldosterone in the human, at least in patients suffering from primary aldosteronism.	Aldosterone	5-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-42
2040591-10	1991	Thus aldosterone synthase cytochrome P-450, a distinct species from cytochrome P-450(11 beta), is responsible for the biosynthesis of aldosterone in the human, at least in patients suffering from primary aldosteronism.	Aldosterone	5-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
2029514-0	1991	CO binding studies of engineered cytochrome P-450ds: effects of mutations at putative distal sites in the presence of polycyclic hydrocarbons.	Hydrocarbons, Cyclic	118-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
2004631-0	1991	Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol.	stiripentol	104-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
2061924-1	1991	A series of 21 different 4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines was considered with regard to oxidation to pyridine derivatives by human liver microsomal cytochrome P-450 (P-450).	4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines	25-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
2061924-1	1991	A series of 21 different 4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines was considered with regard to oxidation to pyridine derivatives by human liver microsomal cytochrome P-450 (P-450).	pyridine	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-198
2049228-14	1991	These in vitro studies are consistent with phenytoin 4-hydroxylation and tolbutamide methylhydroxylation being catalysed by the same cytochrome P450 isozyme(s) in human liver microsomes.	Phenytoin	43-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
2066864-3	1991	The cytochrome P-450 preparation had an apparent molecular weight of 51,500 as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	Sodium Dodecyl Sulfate	89-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2066864-3	1991	The cytochrome P-450 preparation had an apparent molecular weight of 51,500 as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	polyacrylamide	112-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2049228-14	1991	These in vitro studies are consistent with phenytoin 4-hydroxylation and tolbutamide methylhydroxylation being catalysed by the same cytochrome P450 isozyme(s) in human liver microsomes.	Tolbutamide	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
1846080-4	1991	A good fit of the absorption spectra of six different cytochrome P-450 proteins in the presence and absence of substrates was found, indicating a similar pi-electron structure of the porphyrin and a similar chemical nature of the nearest coordination sphere of the iron in all cytochrome P-450 proteins.	Iron	265-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
1846317-4	1991	H2O2 production was inhibited by diphenyleneiodonium, a flavoprotein binder (concentration producing 50% inhibition, 0.3 microM), and diethyldithiocarbamate, a divalent cation chelator (concentration producing 50% inhibition, 3 microM), but not by cyanide or azide, inhibitors of electron transport, or by agents that inhibit xanthine oxidase, polyamine oxidase, or cytochrome P450.	diphenyleneiodonium	33-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	366-381
1846317-4	1991	H2O2 production was inhibited by diphenyleneiodonium, a flavoprotein binder (concentration producing 50% inhibition, 0.3 microM), and diethyldithiocarbamate, a divalent cation chelator (concentration producing 50% inhibition, 3 microM), but not by cyanide or azide, inhibitors of electron transport, or by agents that inhibit xanthine oxidase, polyamine oxidase, or cytochrome P450.	Ditiocarb	134-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	366-381
2004043-2	1991	All the progestogens are acetylenic steroids and previous studies have indicated the potential of acetylenic steroids to cause mechanism-based or "suicide" inactivation of cytochrome P-450.	acetylenic steroids	25-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
2004043-2	1991	All the progestogens are acetylenic steroids and previous studies have indicated the potential of acetylenic steroids to cause mechanism-based or "suicide" inactivation of cytochrome P-450.	acetylenic steroids	98-117	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1846317-4	1991	H2O2 production was inhibited by diphenyleneiodonium, a flavoprotein binder (concentration producing 50% inhibition, 0.3 microM), and diethyldithiocarbamate, a divalent cation chelator (concentration producing 50% inhibition, 3 microM), but not by cyanide or azide, inhibitors of electron transport, or by agents that inhibit xanthine oxidase, polyamine oxidase, or cytochrome P450.	Hydrogen Peroxide	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	366-381
1920538-2	1991	Cytochrome P-450 catalyzes oxidations of a wide variety of compounds including steroids, drugs and toxicants.	Steroids	79-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1846080-4	1991	A good fit of the absorption spectra of six different cytochrome P-450 proteins in the presence and absence of substrates was found, indicating a similar pi-electron structure of the porphyrin and a similar chemical nature of the nearest coordination sphere of the iron in all cytochrome P-450 proteins.	Iron	265-269	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-293
1669007-5	1991	These reactions are elevated after chronic ethanol consumption, due in part, to induction of a unique isozyme of cytochrome P-450.	Ethanol	43-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-129
1819909-5	1991	The phenobarbital-induced BND activity and the cytochrome P-450 content were not changed, while the beta-naphthoflavone-induced EROD activity and cytochrome P-450 and cytochrome b5 content decreased, the ECOD activity remaining unchanged.	beta-Naphthoflavone	100-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	146-180
1819909-6	1991	Nifedipine administered for three days significantly increased the BND activity and the cytochrome P-450 content.	Nifedipine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-104
1819909-7	1991	The three-day administration of nifedipine plus phenobarbital resulted in a further increase in the BND activity and the cytochrome P-450 content.	Nifedipine	32-42	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
1819909-7	1991	The three-day administration of nifedipine plus phenobarbital resulted in a further increase in the BND activity and the cytochrome P-450 content.	Phenobarbital	48-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
1819909-9	1991	Nifedipine administered at a single dose, one hour before beta-naphthoflavone had no effect per se but potentiated the enzyme-inducing effect of beta-naphthoflavone on the EROD activity and the cytochrome P-450 content but not on the ECOD activity.	Nifedipine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
1819909-9	1991	Nifedipine administered at a single dose, one hour before beta-naphthoflavone had no effect per se but potentiated the enzyme-inducing effect of beta-naphthoflavone on the EROD activity and the cytochrome P-450 content but not on the ECOD activity.	beta-Naphthoflavone	145-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	194-210
1805731-0	1991	Influence of inducers of cytochrome P-450 on dealkylation of 7-alkoxycoumarins.	7-alkoxycoumarins	61-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
1709343-2	1991	This loss in drug metabolism is due to the loss of the cytochrome P-450 component of the mixed function oxidase (the enzyme system primarily responsible for the oxidation of drugs, carcinogens and certain classes of endogenous substances such as steroids, fatty acids and prostaglandins).	Steroids	246-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
1709343-2	1991	This loss in drug metabolism is due to the loss of the cytochrome P-450 component of the mixed function oxidase (the enzyme system primarily responsible for the oxidation of drugs, carcinogens and certain classes of endogenous substances such as steroids, fatty acids and prostaglandins).	Fatty Acids	256-267	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
1709343-2	1991	This loss in drug metabolism is due to the loss of the cytochrome P-450 component of the mixed function oxidase (the enzyme system primarily responsible for the oxidation of drugs, carcinogens and certain classes of endogenous substances such as steroids, fatty acids and prostaglandins).	Prostaglandins	272-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
2014968-7	1991	However, careful clinical monitoring is necessary with all patients, irrespective of age, taking ciprofloxacin concomitantly with drugs primarily eliminated by the cytochrome P-450 system.	Ciprofloxacin	97-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
1905908-0	1991	Cytochrome P-450 metabolism of arachidonic acid.	Arachidonic Acid	31-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2009574-4	1991	Cytochrome P-450 dependent monooxygenation at a non-fluorinated para position in (fluoro)aniline derivatives proceeds by formation of the para hydroxylated derivative as the primary metabolite.	(fluoro)aniline	81-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2009574-6	1991	Thus, for fluoroanilines with a fluorine substituent at the para position bioactivation to the reactive benzoquinoneimine can be a direct result of the cytochrome P-450 dependent conversion.	fluoroanilines	10-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
2009574-6	1991	Thus, for fluoroanilines with a fluorine substituent at the para position bioactivation to the reactive benzoquinoneimine can be a direct result of the cytochrome P-450 dependent conversion.	Fluorine	32-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
2009574-6	1991	Thus, for fluoroanilines with a fluorine substituent at the para position bioactivation to the reactive benzoquinoneimine can be a direct result of the cytochrome P-450 dependent conversion.	benzoquinoneimine	104-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
1685398-10	1991	It is concluded that treatment with a commercial PCB mixture resulted in the induction of several isoforms of pigeon hepatic cytochrome P-450 in a fashion that is likely to be similar to that reported for mammals.	Polychlorinated Biphenyls	49-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-141
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
2043050-0	1991	Effects of acetone administration on cytochrome P-450-dependent monooxygenases in hamster liver, kidney, and lung.	Acetone	11-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2043050-3	1991	Administration of acetone caused significant increases of cytochrome P-450 and cytochrome b5 contents in liver microsomes.	Acetone	18-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
2043050-9	1991	Gel electrophoresis of liver and kidney microsomes from control and acetone-treated hamsters revealed that acetone treatment enhanced the intensity of a protein band(s) in the cytochrome P-450 molecular weight region.	Acetone	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
2043050-9	1991	Gel electrophoresis of liver and kidney microsomes from control and acetone-treated hamsters revealed that acetone treatment enhanced the intensity of a protein band(s) in the cytochrome P-450 molecular weight region.	Acetone	107-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	176-192
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	28-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
2043050-10	1991	Immunoblotting of the microsomal proteins showed that the protein band induced by acetone in hamster liver, kidney and lung was cross-reactive with antibody raised against ethanol-inducible human liver cytochrome P-450.	Acetone	82-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
2043050-10	1991	Immunoblotting of the microsomal proteins showed that the protein band induced by acetone in hamster liver, kidney and lung was cross-reactive with antibody raised against ethanol-inducible human liver cytochrome P-450.	Ethanol	172-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	202-218
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-137
2043050-11	1991	These results demonstrate that acetone has the ability to uniformly induce a specific form of cytochrome P-450, designated as IIE1, and to cause differential changes of monooxygenase activities in the hamster tissues.	Acetone	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
16840049-2	1991	It was also determined that ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS) involving a specific cytochrome P-450; this newly discovered ethanol-inducible cytochrome P-450 (P-450 IIEi) contributes to ethanol metabolism, tolerance, energy wastage (with associated weight loss), and the selective hepatic perivenular toxicity of various xenobiotics.	Ethanol	68-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195
1937350-11	1991	The cytochrome P-450 isozyme responsible for debrisoquine hydroxylation is of high affinity-low capacity character, which means that it can be saturated under certain circumstances.	Debrisoquin	45-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
1864266-13	1991	The possibility that myrcene exerts its antimutagenic activity by inhibiting certain forms of the cytochrome P-450 isoenzymes required for activation of premutagens and precarcinogenes is discussed.	myrcene	21-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
1667771-0	1991	Cytochrome P-450- and peroxidase-dependent activation of procarbazine and iproniazid in mammalian cells.	Procarbazine	57-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-32
1667771-0	1991	Cytochrome P-450- and peroxidase-dependent activation of procarbazine and iproniazid in mammalian cells.	Iproniazid	74-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-32
1792338-8	1991	PB and TAO increased cytochrome P-450 and associated enzyme activities, in particular those related to cytochrome P-450p or P-450NF (including oestradiol 2-hydroxylation) in the human liver.	Estradiol	143-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
1667771-3	1991	Both peroxidases and cytochrome P-450 have been reported to catalyze biotransformation of hydrazines.	Hydrazines	90-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
1667771-5	1991	However, in HL60 cells, procarbazine was metabolized by myeloperoxidase while iproniazid was metabolized mostly by the cytochrome P-450 system.	Iproniazid	78-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	119-135
1761357-2	1991	We now report that IFN-alpha-Con1, which was constructed from the most frequently observed amino acid sequences in human alpha-interferon subtypes, causes a loss in cytochrome P-450 which could be prevented by pretreating animals with either puromycin or actinomycin D.	Puromycin	242-251	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
1761357-2	1991	We now report that IFN-alpha-Con1, which was constructed from the most frequently observed amino acid sequences in human alpha-interferon subtypes, causes a loss in cytochrome P-450 which could be prevented by pretreating animals with either puromycin or actinomycin D.	Dactinomycin	255-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	165-181
1812974-3	1991	The first hypothesis concerns the role of the oxygen binding hemoprotein cytochrome P-450.	Oxygen	46-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
1812974-10	1991	The possibility exists that changes in both the cytochrome P-450 activity and in the rate of electrons flow in the respiratory chain may alter the amount of oxygen radicals in the cells and, similarly as in the "oxygen radicals" hypothesis, govern calcium channels through the control of the redox status of these channels.	Reactive Oxygen Species	157-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
1812974-10	1991	The possibility exists that changes in both the cytochrome P-450 activity and in the rate of electrons flow in the respiratory chain may alter the amount of oxygen radicals in the cells and, similarly as in the "oxygen radicals" hypothesis, govern calcium channels through the control of the redox status of these channels.	Reactive Oxygen Species	212-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
1852787-5	1991	These considerations are illustrated by examination of the generation and fate of enzyme- and substrate-derived free radicals at various stages in the catalytic cycles of two monooxygenases important in xenobiotic biotransformation, dopamine beta-hydroxylase and cytochrome P-450.	Free Radicals	112-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-279
1965943-0	1990	The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	15-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
1808966-1	1991	Caffeine is mainly metabolized by 3-methylcholanthreneinducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by the phenobarbital inducible cytochrome P-450 family.	Caffeine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-80
1808966-1	1991	Caffeine is mainly metabolized by 3-methylcholanthreneinducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by the phenobarbital inducible cytochrome P-450 family.	Dipyrone	90-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1808966-1	1991	Caffeine is mainly metabolized by 3-methylcholanthreneinducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by the phenobarbital inducible cytochrome P-450 family.	Phenobarbital	148-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1808966-2	1991	Therefore the elimination of caffeine from serum and the elimination of the main metabolites of metamizol in urine reflect the activity of these two cytochrome P-450 families.	Caffeine	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
1808966-2	1991	Therefore the elimination of caffeine from serum and the elimination of the main metabolites of metamizol in urine reflect the activity of these two cytochrome P-450 families.	Dipyrone	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
2269307-2	1990	Cytochrome P-450 (P450) NF, a member of the P450 IIIA subfamily, is the major contributor to the oxidation of the calcium-channel blocker nifedipine in human liver microsomes.	Nifedipine	138-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-26
1965943-4	1990	EPR studies confirmed that MPTP is a type II substrate for the forms of cytochrome P-450 with which it interacts and causes a shift from the high spin state of cytochrome P-450 to the low spin state.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
1965943-4	1990	EPR studies confirmed that MPTP is a type II substrate for the forms of cytochrome P-450 with which it interacts and causes a shift from the high spin state of cytochrome P-450 to the low spin state.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	27-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
1965943-5	1990	MPTP is, thus, likely to be an effective inhibitor of cytochrome P-450.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
1768430-7	1991	The Ah-receptor binding compounds, such as coal tar constituents, or 3-methylcholanthrene induce cytochrome P-450-dependent activities such as aryl hydrocarbon hydroxylase or 7-ethoxyresorufin-O-de-ethylase and NQR, whereas butyl hydroxytoluol, which does not bind to the Ah receptor, induces only NQR.	Methylcholanthrene	69-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1768430-7	1991	The Ah-receptor binding compounds, such as coal tar constituents, or 3-methylcholanthrene induce cytochrome P-450-dependent activities such as aryl hydrocarbon hydroxylase or 7-ethoxyresorufin-O-de-ethylase and NQR, whereas butyl hydroxytoluol, which does not bind to the Ah receptor, induces only NQR.	butyl hydroxytoluol	224-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1965943-0	1990	The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	61-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
1965943-0	1990	The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450.	Heme	90-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
1965943-1	1990	In vitro studies on the nature of interaction of the neurotoxin MPTP with hepatic microsomal cytochrome P-450 were carried out.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	64-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1965943-3	1990	Scatchard analysis of MPTP-cytochrome P-450 binding suggested that MPTP binds to at least 2 species of cytochrome P-450--a high affinity binding species with an apparent spectral dissociation constant (Ks) of 372 microM and a low affinity species with Ks of 37.6 mM.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-43
1965943-3	1990	Scatchard analysis of MPTP-cytochrome P-450 binding suggested that MPTP binds to at least 2 species of cytochrome P-450--a high affinity binding species with an apparent spectral dissociation constant (Ks) of 372 microM and a low affinity species with Ks of 37.6 mM.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	22-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
2099150-0	1990	Cytochrome P-450 catalyzed redox cycling of orthophenylphenol.	2-phenylphenol	44-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2099150-4	1990	Phenyl 2,5"-p-quinone was reduced to phenylhydroquinone by cytochrome P-450 reductase.	phenyl 2,5"-p-quinone	0-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
2099150-4	1990	Phenyl 2,5"-p-quinone was reduced to phenylhydroquinone by cytochrome P-450 reductase.	phenylhydroquinone	37-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
2099150-5	1990	This study provides direct evidence of cytochrome P-450 catalyzed redox cycling of o-phenylphenol.	2-phenylphenol	83-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1965943-3	1990	Scatchard analysis of MPTP-cytochrome P-450 binding suggested that MPTP binds to at least 2 species of cytochrome P-450--a high affinity binding species with an apparent spectral dissociation constant (Ks) of 372 microM and a low affinity species with Ks of 37.6 mM.	Potassium	202-204	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
1965943-3	1990	Scatchard analysis of MPTP-cytochrome P-450 binding suggested that MPTP binds to at least 2 species of cytochrome P-450--a high affinity binding species with an apparent spectral dissociation constant (Ks) of 372 microM and a low affinity species with Ks of 37.6 mM.	Potassium	252-254	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-119
2268369-0	1990	Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse.	Phenobarbital	73-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
2262908-0	1990	Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s.	Lidocaine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2148293-0	1990	The effect of substrates and inhibitors of cytochrome P-450 on the NADPH inhibition of the ATP-dependent, hepatic, microsomal calcium pump.	NADP	67-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2148293-0	1990	The effect of substrates and inhibitors of cytochrome P-450 on the NADPH inhibition of the ATP-dependent, hepatic, microsomal calcium pump.	Adenosine Triphosphate	91-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2148293-1	1990	In hepatic microsomes one or more isozymes of cytochrome P-450 inhibits the ATP-dependent Ca2+ pump.	Adenosine Triphosphate	76-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2172779-3	1990	We have previously shown that cytochrome P-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite.	Sulfamethoxazole	72-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2256435-2	1990	Antipyrine is a useful marker drug for cytochrome P-450 dependent hepatic drug metabolism.	Antipyrine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
1981505-0	1990	Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.	Quinolones	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
1981505-0	1990	Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.	Caffeine	51-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-40
1981505-7	1990	The results indicate that the reduction of caffeine clearance by concomitant quinolone application observed in vivo is primarily due to a competitive interaction of the inhibiting quinolones with the cytochrome P-450 isoenzyme(s) mediating caffeine demethylation.	Caffeine	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
1981505-7	1990	The results indicate that the reduction of caffeine clearance by concomitant quinolone application observed in vivo is primarily due to a competitive interaction of the inhibiting quinolones with the cytochrome P-450 isoenzyme(s) mediating caffeine demethylation.	Quinolones	77-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
1981505-7	1990	The results indicate that the reduction of caffeine clearance by concomitant quinolone application observed in vivo is primarily due to a competitive interaction of the inhibiting quinolones with the cytochrome P-450 isoenzyme(s) mediating caffeine demethylation.	Quinolones	180-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
1981505-7	1990	The results indicate that the reduction of caffeine clearance by concomitant quinolone application observed in vivo is primarily due to a competitive interaction of the inhibiting quinolones with the cytochrome P-450 isoenzyme(s) mediating caffeine demethylation.	Caffeine	240-248	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	200-216
1981539-8	1990	These results suggest that cytochrome P-450, rather than alcohol dehydrogenase, was responsible for the metabolism of benzyl alcohol to benzaldehyde.	Benzyl Alcohol	118-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-78
1981539-8	1990	These results suggest that cytochrome P-450, rather than alcohol dehydrogenase, was responsible for the metabolism of benzyl alcohol to benzaldehyde.	benzaldehyde	136-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-78
2172779-3	1990	We have previously shown that cytochrome P-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite.	Hydroxylamine	96-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2122459-0	1990	Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver.	Aflatoxin B1	66-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2233694-0	1990	Stereoselective S-oxygenation of 2-aryl-1,3-dithiolanes by the flavin-containing and cytochrome P-450 monooxygenases.	2-aryl-1,3-dithiolanes	33-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2226459-0	1990	Effect of the tyrosine 96 hydrogen bond on the inactivation of cytochrome P-450cam induced by hydrostatic pressure.	Tyrosine	14-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2226459-0	1990	Effect of the tyrosine 96 hydrogen bond on the inactivation of cytochrome P-450cam induced by hydrostatic pressure.	Hydrogen	26-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2233694-0	1990	Stereoselective S-oxygenation of 2-aryl-1,3-dithiolanes by the flavin-containing and cytochrome P-450 monooxygenases.	4,6-dinitro-o-cresol	63-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2233694-5	1990	For S-oxide formation in microsomes, the data provided evidence for a minor role of cytochrome P-450 in S-oxide formation, but the flavin-containing monooxygenase was mainly responsible for production of S-oxide.	Oxides	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
2242730-2	1990	Monensin was seen to cause a slight depression in the amount of cytochrome P-450 and cytochrome b5 as well as in the activities of aniline-p-hydroxylase, p-nitrophenol-hydroxylase and p-nitroanisole-O-demethylase.	Monensin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-98
2261467-1	1990	Cytochrome P-450cam reacts with phenyldiazene (PhN = NH), or less efficiently with phenylhydrazine, to give a catalytically inactive complex with an absorption maximum at 474 nm.	phenyldiazene	32-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2261467-1	1990	Cytochrome P-450cam reacts with phenyldiazene (PhN = NH), or less efficiently with phenylhydrazine, to give a catalytically inactive complex with an absorption maximum at 474 nm.	phenylhydrazine	83-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2078633-1	1990	It has been found that 3-amino-7-dimethylamino-2-methylphenazine (neutral red, NR) is responsible for the electron transport from the cathode to adrenodoxin (Ad) and cytochrome P-450 (P-450scc) from adrenal cortex mitochondria inaccessible to direct electrochemical reduction under native conditions.	Neutral Red Base	23-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	166-182
2260347-2	1990	Its mechanism of action, like that of other azoles, involves interruption of the conversion of lanosterol to ergosterol via binding to fungal cytochrome P-450 and subsequent disruption of fungal membranes.	Azoles	44-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2260347-2	1990	Its mechanism of action, like that of other azoles, involves interruption of the conversion of lanosterol to ergosterol via binding to fungal cytochrome P-450 and subsequent disruption of fungal membranes.	Lanosterol	95-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2260347-2	1990	Its mechanism of action, like that of other azoles, involves interruption of the conversion of lanosterol to ergosterol via binding to fungal cytochrome P-450 and subsequent disruption of fungal membranes.	Ergosterol	109-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
1981700-0	1990	Expressing the specificity and the potency of cytochrome P-450 inducers toward 7-ethoxyresorufin.	ethoxyresorufin	79-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2242730-3	1990	Tiamulin induced a moderate increase in the amount of cytochrome P-450 and in the activities of aniline-p-hydroxylase, p-nitrophenol-hydroxylase and aminopyrine-N-demethylase.	tiamulin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
2242730-4	1990	The combined administration of monensin and tiamulin resulted in marked induction of the microsomal enzymes; the amount of cytochrome P-450 reduced by metyrapone or carbon monoxide increased 2.5 or 2-times, respectively, and the activities of the tested microsomal hydroxylases and demethylases showed also an expressed increase.	Metyrapone	151-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
2242730-4	1990	The combined administration of monensin and tiamulin resulted in marked induction of the microsomal enzymes; the amount of cytochrome P-450 reduced by metyrapone or carbon monoxide increased 2.5 or 2-times, respectively, and the activities of the tested microsomal hydroxylases and demethylases showed also an expressed increase.	Carbon Monoxide	165-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	123-139
2290428-2	1990	The benzene derivatives are typical substrates of cytochrome P-450 catalyzed aromatic oxidation.	Benzene	4-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2079689-5	1990	The major activation step is believed to be the oxygenation of the alpha-carbon catalysed by a Cytochrome P-450-dependent enzyme system commonly know as NDMA-demethylase.	Carbon	73-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2079689-6	1990	Studies on the enzymology of NDMA metabolism show that some Cytochrome P-450 isozymes exhibit significant NDMA-demethylase activity only at high NDMA concentrations.	Dimethylnitrosamine	29-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2079689-6	1990	Studies on the enzymology of NDMA metabolism show that some Cytochrome P-450 isozymes exhibit significant NDMA-demethylase activity only at high NDMA concentrations.	Dimethylnitrosamine	106-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2168169-1	1990	The rotation of cytochrome P-450 LM2 (CYPIIB4) incorporated into large microsomal-like lipid vesicles was investigated by saturation transfer EPR using 15N- and 2H-substituted spin labels.	15n	152-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2219115-6	1990	3-Methylcholanthrene pretreatment increased and pretreatment with cobalt chloride and piperonyl butoxide decreased the hepatic covalent binding of 3HAA, indicating the involvement of cytochrome P450 in the formation of the 3HAA reactive metabolite.	Methylcholanthrene	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
2219115-6	1990	3-Methylcholanthrene pretreatment increased and pretreatment with cobalt chloride and piperonyl butoxide decreased the hepatic covalent binding of 3HAA, indicating the involvement of cytochrome P450 in the formation of the 3HAA reactive metabolite.	cobaltous chloride	66-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
2219115-6	1990	3-Methylcholanthrene pretreatment increased and pretreatment with cobalt chloride and piperonyl butoxide decreased the hepatic covalent binding of 3HAA, indicating the involvement of cytochrome P450 in the formation of the 3HAA reactive metabolite.	Piperonyl Butoxide	86-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-198
2168169-1	1990	The rotation of cytochrome P-450 LM2 (CYPIIB4) incorporated into large microsomal-like lipid vesicles was investigated by saturation transfer EPR using 15N- and 2H-substituted spin labels.	Deuterium	161-163	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2214784-1	1990	An oral antimycotic agent, ketoconazole has been demonstrated to be an inhibitor of cytochrome P-450-dependent monooxygenases.	Ketoconazole	27-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-100
2238708-6	1990	The evidence presented in this paper supports a different mechanism involving chronic induction of the microsomal cytochrome P-450 system, mobilization of hepatocellular iron and associated oxidative stress.	Iron	170-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
2214784-6	1990	From the binding mode of ketoconazole to cytochrome P-450 and the present findings, it appears likely that the agent binds to a site which is different from that of steroids or pyridine nucleotides.	Ketoconazole	25-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-57
2277761-7	1990	Cimetidine can bind to cytochrome P-450 covering the active haem group, the cytochrome proves to be of vital importance for hydroxylation reactions, involved in human steroidogenesis.	Cimetidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-39
2223769-3	1990	Mutations to neutralize the basic charge at Arg 72 (R72Q) and to both neutralize and reverse the charge at Lys 344 (K344Q, K344E) resulted in alteration of NADH oxidation rates in the reconstituted physiological electron-transfer system, which is rate limited by putidaredoxin-cytochrome P-450cam electron transfer.	Lysine	107-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-293
2277761-8	1990	Serum hydrocortisone concentrations will decrease when cytochrome P-450 becomes blocked.	Hydrocortisone	6-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
2223769-3	1990	Mutations to neutralize the basic charge at Arg 72 (R72Q) and to both neutralize and reverse the charge at Lys 344 (K344Q, K344E) resulted in alteration of NADH oxidation rates in the reconstituted physiological electron-transfer system, which is rate limited by putidaredoxin-cytochrome P-450cam electron transfer.	NAD	156-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	277-293
2223769-7	1990	Calculation of the cytochrome P-450cam electrostatic field revealed a patch of positive potential at the modeled cytochrome b5 interaction site lying directly above the nearest proximal approach to the buried heme prosthetic group.	Heme	209-213	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2233418-1	1990	The possibility that idiopathic Parkinson"s disease may be linked to a deficiency of an important detoxifying enzyme such as the cytochrome P450 enzyme bufuralol hydroxylase is examined.	bufuralol	152-161	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-144
2200675-1	1990	Hepatocytes from adult and newborn humans were put into primary culture and exposed to phenobarbital, 3-methylcholanthrene, or rifampicin, three well-known inducers of cytochrome P-450 in animals.	Rifampin	127-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
2133086-0	1990	Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.	Gestodene	81-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
2397214-7	1990	Potassium cation shows a bigger effect on the stability of cytochrome P-450 than spermine or cysteine, as revealed by a higher value of the pressure of half-inactivation, P1/2, and a bigger inactivation volume change.	Potassium	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-75
2384159-4	1990	These results demonstrate the biosynthetic origin of the human kidney 11,12- and 14,15-epoxyeicosatrienoic acids and suggest a role for renal cytochrome P-450 in the bioactivation of endogenous pools of arachidonic acid.	Arachidonic Acid	203-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-158
2397214-0	1990	The formation of cytochrome P-450 from cytochrome P-420 is promoted by spermine.	Spermine	71-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
2397214-1	1990	This paper is concerned with camphor-bound bacterial cytochrome P-450 and processes that alter its spin-state equilibrium and influence its transition to the nonactive form, cytochrome P-420, as well as its renaturation to the native camphor-bound cytochrome P-450.	Camphor	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
2397214-1	1990	This paper is concerned with camphor-bound bacterial cytochrome P-450 and processes that alter its spin-state equilibrium and influence its transition to the nonactive form, cytochrome P-420, as well as its renaturation to the native camphor-bound cytochrome P-450.	Camphor	234-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
2375760-0	1990	Isolation of four forms of acetone-induced cytochrome P-450 in chicken liver by h.p.l.c.	Acetone	27-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
2375760-2	1990	The purpose of this study was to purify and characterize the forms of cytochrome P-450 induced in chicken liver by acetone or ethanol.	Acetone	115-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
2375760-2	1990	The purpose of this study was to purify and characterize the forms of cytochrome P-450 induced in chicken liver by acetone or ethanol.	Ethanol	126-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
2375760-3	1990	Using high performance liquid ion-exchange chromatography, we were able to isolate at least four different forms of cytochrome P-450 which were induced by acetone in chicken liver.	Acetone	155-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
2375760-8	1990	Another form of cytochrome P-450 induced by acetone is highly active in the hydroxylation of p-nitrophenol and in the conversion of acetaminophen to a reactive metabolite, similar to reactions catalysed by mammalian cytochrome P450IIE.	Acetone	44-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2375760-8	1990	Another form of cytochrome P-450 induced by acetone is highly active in the hydroxylation of p-nitrophenol and in the conversion of acetaminophen to a reactive metabolite, similar to reactions catalysed by mammalian cytochrome P450IIE.	4-nitrophenol	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2375760-8	1990	Another form of cytochrome P-450 induced by acetone is highly active in the hydroxylation of p-nitrophenol and in the conversion of acetaminophen to a reactive metabolite, similar to reactions catalysed by mammalian cytochrome P450IIE.	Acetaminophen	132-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2375760-10	1990	A fourth form of cytochrome P-450 was identified whose N-terminal amino acid sequence and enzymic activities do not correspond to any mammalian cytochromes P-450 reported to be induced by acetone or ethanol.	Acetone	188-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
2375760-10	1990	A fourth form of cytochrome P-450 was identified whose N-terminal amino acid sequence and enzymic activities do not correspond to any mammalian cytochromes P-450 reported to be induced by acetone or ethanol.	Ethanol	199-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-33
2133086-1	1990	A series of 17 alpha-acetylenic steroids was examined with regard to ability to inactivate human liver microsomal cytochrome P-450 (P-450) IIA4, an enzyme involved in the oxidation of a number of drugs, carcinogens, and steroids, including estrogens and progestogens.	alpha-acetylenic steroids	15-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
2133086-1	1990	A series of 17 alpha-acetylenic steroids was examined with regard to ability to inactivate human liver microsomal cytochrome P-450 (P-450) IIA4, an enzyme involved in the oxidation of a number of drugs, carcinogens, and steroids, including estrogens and progestogens.	Steroids	32-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-130
2160283-0	1990	Cytochrome P-450 involvement in the NADPH-dependent lipid peroxidation in human placental mitochondria.	NADP	36-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2168548-0	1990	Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P-450?	Proadifen	31-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
2357863-1	1990	Because both quinidine and propranolol bind to the cytochrome P-450 responsible for the oxidation of debrisoquin, six healthy male subjects were studied to determine whether an interaction occurred between the two drugs and the pharmacodynamic consequences of that interaction.	Quinidine	13-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2357863-1	1990	Because both quinidine and propranolol bind to the cytochrome P-450 responsible for the oxidation of debrisoquin, six healthy male subjects were studied to determine whether an interaction occurred between the two drugs and the pharmacodynamic consequences of that interaction.	Propranolol	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2357863-1	1990	Because both quinidine and propranolol bind to the cytochrome P-450 responsible for the oxidation of debrisoquin, six healthy male subjects were studied to determine whether an interaction occurred between the two drugs and the pharmacodynamic consequences of that interaction.	Debrisoquin	101-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2161656-0	1990	Unusual hyperporphyrin spectrum by bis(glutathione dimethyl ester)-hemin complex, a model of cytochrome P-450-thiolate complexes.	hyperporphyrin	8-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2161656-0	1990	Unusual hyperporphyrin spectrum by bis(glutathione dimethyl ester)-hemin complex, a model of cytochrome P-450-thiolate complexes.	bis(glutathione dimethyl ester)-hemin	35-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2161656-0	1990	Unusual hyperporphyrin spectrum by bis(glutathione dimethyl ester)-hemin complex, a model of cytochrome P-450-thiolate complexes.	thiolate	110-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2161656-2	1990	The structure of the complex was characterized by comparing their electronic absorption and electron spin resonance (ESR) spectra with those of thiolate adducts of cytochrome P-450 and their chemical model complexes.	thiolate	144-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	164-180
2353556-1	1990	The inhibitory effects of pyridoglutethimide (3-ethyl-3-(4-pyridyl)piperidine-2,6-dione), an analogue of aminoglutethimide, on aromatase and other cytochrome P-450-dependent steroid-metabolizing enzymes were studied in vitro.	rogletimide	26-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2353556-1	1990	The inhibitory effects of pyridoglutethimide (3-ethyl-3-(4-pyridyl)piperidine-2,6-dione), an analogue of aminoglutethimide, on aromatase and other cytochrome P-450-dependent steroid-metabolizing enzymes were studied in vitro.	rogletimide	46-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2398265-5	1990	(a) Activities of the methyl cholanthrene-inducible forms of cytochrome P-450 were decreased compared to normal controls, whereas the activities of the phenobarbitone-inducible isozymes were relatively unaffected.	Methylcholanthrene	22-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
2238705-8	1990	Type II binding is seen with inhibitors of mammalian cytochrome P-450 such as metyrapone, and with the imidazole antifungal agents such as clotrimazole.	Metyrapone	78-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
2238705-8	1990	Type II binding is seen with inhibitors of mammalian cytochrome P-450 such as metyrapone, and with the imidazole antifungal agents such as clotrimazole.	imidazole	103-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
2238705-12	1990	Avocado cytochrome P-450 catalysed the N-demethylation of N,N-dimethylaniline (17.1 nmol/min per nmol P-450) and p-chloro-N-methylaniline (13.1 nmol/min per nmol P-450), and the hydroxylation of lauric (dodecanoic) acid (1.1 nmol/min per nmol P-450).	N,N-dimethylaniline	58-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2238705-12	1990	Avocado cytochrome P-450 catalysed the N-demethylation of N,N-dimethylaniline (17.1 nmol/min per nmol P-450) and p-chloro-N-methylaniline (13.1 nmol/min per nmol P-450), and the hydroxylation of lauric (dodecanoic) acid (1.1 nmol/min per nmol P-450).	methylaniline	121-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2238705-12	1990	Avocado cytochrome P-450 catalysed the N-demethylation of N,N-dimethylaniline (17.1 nmol/min per nmol P-450) and p-chloro-N-methylaniline (13.1 nmol/min per nmol P-450), and the hydroxylation of lauric (dodecanoic) acid (1.1 nmol/min per nmol P-450).	lauric (dodecanoic) acid	195-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2353936-10	1990	These data suggest that mianserin is activated to a cytotoxic metabolite selectively by a constitutive form of human cytochrome P-450, whereas phenytoin, amitriptyline and imipramine are selectively activated by forms of mouse cytochrome P-450 which are induced by either phenobarbitone or beta-naphthoflavone.	Mianserin	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-133
2353936-10	1990	These data suggest that mianserin is activated to a cytotoxic metabolite selectively by a constitutive form of human cytochrome P-450, whereas phenytoin, amitriptyline and imipramine are selectively activated by forms of mouse cytochrome P-450 which are induced by either phenobarbitone or beta-naphthoflavone.	Mianserin	24-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	227-243
2372742-6	1990	The impairment on antipyrine disposition produced by piroxicam has been interpreted as a consequence of a reduction in the activity of hepatic microsomal drug-metabolizing enzymes, particularly the cytochrome P-450 system.	Piroxicam	53-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-214
2231265-6	1990	Although the patterns of the inhibitory actions and the interaction of either imidazole drugs with cytochrome P-450 as 17 alpha-hydroxylase and C17,20-lyase were similar to those of KCZ, the inhibitory potencies and affinities for the cytochrome P-450 system decreased in the order of KCZ greater than MCZ greater than OZA greater than M-2 greater than M-1 greater than CIM.	imidazole	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2231265-8	1990	These results indicate that either imidazole drugs tested could inhibit a cytochrome P-450 enzyme C17,20-lyase mainly in testicular microsomes, and suggest that MCZ, a potent inhibitor subsequent to KCZ, induces a slight alteration in the testosterone biosynthesis in its clinical use.	imidazole	35-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
2231265-8	1990	These results indicate that either imidazole drugs tested could inhibit a cytochrome P-450 enzyme C17,20-lyase mainly in testicular microsomes, and suggest that MCZ, a potent inhibitor subsequent to KCZ, induces a slight alteration in the testosterone biosynthesis in its clinical use.	Miconazole	161-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
2231265-8	1990	These results indicate that either imidazole drugs tested could inhibit a cytochrome P-450 enzyme C17,20-lyase mainly in testicular microsomes, and suggest that MCZ, a potent inhibitor subsequent to KCZ, induces a slight alteration in the testosterone biosynthesis in its clinical use.	Testosterone	239-251	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-90
2160283-1	1990	The NADPH-dependent lipid peroxidation in human placental mitochondria has been found to be inhibited strongly by amphenone B, aminoglutethimide and carbon monoxide, inhibitors of cytochrome P-450-mediated reactions, but was hardly affected by respiratory chain inhibitors.	NADP	4-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
2160283-1	1990	The NADPH-dependent lipid peroxidation in human placental mitochondria has been found to be inhibited strongly by amphenone B, aminoglutethimide and carbon monoxide, inhibitors of cytochrome P-450-mediated reactions, but was hardly affected by respiratory chain inhibitors.	amphenone B	114-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
2160283-1	1990	The NADPH-dependent lipid peroxidation in human placental mitochondria has been found to be inhibited strongly by amphenone B, aminoglutethimide and carbon monoxide, inhibitors of cytochrome P-450-mediated reactions, but was hardly affected by respiratory chain inhibitors.	Aminoglutethimide	127-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
2160283-1	1990	The NADPH-dependent lipid peroxidation in human placental mitochondria has been found to be inhibited strongly by amphenone B, aminoglutethimide and carbon monoxide, inhibitors of cytochrome P-450-mediated reactions, but was hardly affected by respiratory chain inhibitors.	Carbon Monoxide	149-164	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-196
2160283-2	1990	Cytochrome c, an exogenous electron acceptor which is known to compete with cytochrome P-450 for the reducing equivalents, showed an inhibitory effect on NADPH-dependent lipid peroxidation.	NADP	154-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92
2160283-7	1990	These data provide evidence that cytochrome P-450 is involved in NADPH-dependent mitochondrial lipid peroxidation.	NADP	65-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-49
2160283-8	1990	It is suggested that superoxide liberated from cytochrome P-450, in combination with iron, may be responsible for initiation of NADPH-dependent lipid peroxidation in human placental mitochondria.	Superoxides	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2160283-8	1990	It is suggested that superoxide liberated from cytochrome P-450, in combination with iron, may be responsible for initiation of NADPH-dependent lipid peroxidation in human placental mitochondria.	NADP	128-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2376747-3	1990	Different function of the phenytoin-metabolizing cytochrome P450 subsystem was found in 6 patients, but in none of the controls.	Phenytoin	26-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
1974199-5	1990	Only pretreatment of rabbits with rifampicin, which induces cytochrome P-450 form 3c (P-450IIIA6), significantly increased the microsomal hydroxylation of tolbutamide.	Rifampin	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
1974199-5	1990	Only pretreatment of rabbits with rifampicin, which induces cytochrome P-450 form 3c (P-450IIIA6), significantly increased the microsomal hydroxylation of tolbutamide.	Tolbutamide	155-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
1974199-11	1990	Hence, it appears that the animal model approach is not likely to be successful in the identification and characterization of the cytochrome P-450 form(s) metabolizing tolbutamide in humans.	Tolbutamide	168-179	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-146
2160607-5	1990	(2) The catecholestrogen or diethylstilbestrol (DES) are oxidized to semiquinones and quinones by the peroxidatic activity of cytochrome P-450.	Estrogens, Catechol	8-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2160607-5	1990	(2) The catecholestrogen or diethylstilbestrol (DES) are oxidized to semiquinones and quinones by the peroxidatic activity of cytochrome P-450.	Diethylstilbestrol	28-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2160607-5	1990	(2) The catecholestrogen or diethylstilbestrol (DES) are oxidized to semiquinones and quinones by the peroxidatic activity of cytochrome P-450.	Diethylstilbestrol	48-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2160607-5	1990	(2) The catecholestrogen or diethylstilbestrol (DES) are oxidized to semiquinones and quinones by the peroxidatic activity of cytochrome P-450.	semiquinones	69-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2160607-5	1990	(2) The catecholestrogen or diethylstilbestrol (DES) are oxidized to semiquinones and quinones by the peroxidatic activity of cytochrome P-450.	Quinones	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2327982-0	1990	Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol.	Estradiol	82-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2157443-0	1990	Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by beta-lapachone and related naphthoquinones.	beta-lapachone	88-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
2344166-10	1990	Nonspecific inhibition of cytochrome P-450 was ruled out since erythromycin N demethylation (cytochrome P-450 mediated) was unaffected in the presence of enoxacin.	Erythromycin	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2344166-12	1990	We conclude that some quinolones are potent and selective inhibitors of specific isozymes of human cytochrome P-450 that are responsible for theophylline metabolism.	Quinolones	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2344166-12	1990	We conclude that some quinolones are potent and selective inhibitors of specific isozymes of human cytochrome P-450 that are responsible for theophylline metabolism.	Theophylline	141-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
2157443-0	1990	Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by beta-lapachone and related naphthoquinones.	Naphthoquinones	115-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-64
2327982-0	1990	Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol.	17 alpha-ethinyloestradiol	97-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-35
2157443-4	1990	These observations support the hypothesis that, in the micromolar concentration range, o-naphthoquinones inhibit microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions, by diverting reducing equivalents from NADPH to dioxygen.	1,2-naphthoquinone	87-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2378912-0	1990	[Chemical modification of cholesterol-hydroxylating cytochrome P-450 from adrenal cortex mitochondria with diethylpyrocarbonate].	Cholesterol	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2157443-4	1990	These observations support the hypothesis that, in the micromolar concentration range, o-naphthoquinones inhibit microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions, by diverting reducing equivalents from NADPH to dioxygen.	NADP	224-229	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2157443-4	1990	These observations support the hypothesis that, in the micromolar concentration range, o-naphthoquinones inhibit microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions, by diverting reducing equivalents from NADPH to dioxygen.	Oxygen	233-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-163
2340358-2	1990	The samples analyzed consisted of the chlorophenols resulting from the cytochrome P-450 mediated oxidation of isotopic mixtures of chlorobenzenes, and were analyzed on a VG-7070 double-focusing mass spectrometer.	Chlorophenols	38-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
2340358-2	1990	The samples analyzed consisted of the chlorophenols resulting from the cytochrome P-450 mediated oxidation of isotopic mixtures of chlorobenzenes, and were analyzed on a VG-7070 double-focusing mass spectrometer.	Chlorobenzenes	131-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-87
2378912-0	1990	[Chemical modification of cholesterol-hydroxylating cytochrome P-450 from adrenal cortex mitochondria with diethylpyrocarbonate].	Diethyl Pyrocarbonate	107-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2180560-5	1990	Both rat cytochrome P-450 beta NF-B (P-450 IA1) and P-450ISF-G (P-450 IA2) inactivated 1,3-dinitropyrene, with the former being more effective.	1,3-dinitropyrene	87-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
2180560-0	1990	Inactivation of 1,3-, 1,6-, and 1,8-dinitropyrene by cytochrome P-450 enzymes in human and rat liver microsomes.	1,3-, 1,6-, and 1,8-dinitropyrene	16-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-69
2182022-6	1990	It is likely that the generation of the radical proceeds via a ferryl intermediate, as in the proposed mechanisms for cytochrome P-450 and the peroxidases.	radical	40-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-134
2180560-6	1990	Correlation studies done with liver microsomes prepared from variously treated rats and immunoinhibition studies suggest that cytochrome P-450 beta NF-B and P-450ISF-G are both involved in the detoxication of all three of the dinitropyrenes in rat liver microsomes.	dinitropyrenes	226-240	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2180560-8	1990	Correlation analysis and inhibition studies with 7,8-benzoflavone and antibodies indicate that human cytochrome P-450 enzymes in the IA family are most effective in detoxicating this compound; the contribution of cytochrome P-450PA (P-450 IA2, the phenacetin O-deethylase) is deemed more important, but a role for the small amount of cytochrome P1-450 (P-450 IA1) in the liver cannot be ruled out.	alpha-naphthoflavone	49-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-117
2180560-11	1990	Thus, distinct human cytochrome P-450 enzymes are involved in the detoxication of different dinitropyrene congeners, and the situation appears to contrast with that in rat liver.	DINITROPYRENE	92-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
2155225-1	1990	Role of aldehyde dehydrogenase and leukotriene B4 omega-hydroxylase (cytochrome P-450LTB omega) in leukotriene B4 omega-oxidation.	Leukotrienes	35-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-94
2155225-4	1990	This activity has been ascribed to LTB4 omega-hydroxylase (cytochrome P-450LTB omega), a conclusion supported by our finding of the reversal of carbon monoxide inhibition by 450 nm light and by competitive inhibition studies.	Carbon Monoxide	144-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-84
2155225-5	1990	The oxidation of 20-oxo-LTB4 to 20-carboxy-LTB4 is also catalyzed by microsomes fortified with 1 mM NAD+, and this activity is not affected by cytochrome P-450LTB omega inhibitors.	20-aldehyde leukotriene B4	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-168
2155225-5	1990	The oxidation of 20-oxo-LTB4 to 20-carboxy-LTB4 is also catalyzed by microsomes fortified with 1 mM NAD+, and this activity is not affected by cytochrome P-450LTB omega inhibitors.	20-carboxyleukotriene B4	32-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-168
2310416-6	1990	Covalent binding of TAI, as that of TA, depends on cytochrome P-450-dependent monooxygenases and is almost completely inhibited in the presence of sulfur containing nucleophiles such as glutathione, cysteine or cyteamine.	Ticrynafen	20-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2328827-1	1990	The cytochrome P-450-dependent aromatase pathway utilizes the androgens testosterone (T) and androstenedione, as substrates for estrogen formation.	Testosterone	72-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2328827-1	1990	The cytochrome P-450-dependent aromatase pathway utilizes the androgens testosterone (T) and androstenedione, as substrates for estrogen formation.	Androstenedione	93-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2310416-6	1990	Covalent binding of TAI, as that of TA, depends on cytochrome P-450-dependent monooxygenases and is almost completely inhibited in the presence of sulfur containing nucleophiles such as glutathione, cysteine or cyteamine.	Sulfur	147-153	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2310416-6	1990	Covalent binding of TAI, as that of TA, depends on cytochrome P-450-dependent monooxygenases and is almost completely inhibited in the presence of sulfur containing nucleophiles such as glutathione, cysteine or cyteamine.	Glutathione	186-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2310416-6	1990	Covalent binding of TAI, as that of TA, depends on cytochrome P-450-dependent monooxygenases and is almost completely inhibited in the presence of sulfur containing nucleophiles such as glutathione, cysteine or cyteamine.	cyteamine	211-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-67
2310416-7	1990	These results show that 5-OHTA, which has been reported as the major metabolite of TA in vivo in humans, is formed by liver microsomes by a cytochrome P-450-dependent reaction.	5-ohta	24-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
2310416-7	1990	These results show that 5-OHTA, which has been reported as the major metabolite of TA in vivo in humans, is formed by liver microsomes by a cytochrome P-450-dependent reaction.	Ticrynafen	28-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
2314392-0	1990	Mechanisms of activation of phenacetin to reactive metabolites by cytochrome P-450: a theoretical study involving radical intermediates.	Phenacetin	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
2369956-0	1990	[Immunomodulators with an 8-azasteroid structure as inducers of liver cytochrome P-450].	8-azasteroid	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-87
2369956-1	1990	Two structural analogues of D-homo-8-azasteroids, both an immunostimulant and an immunodepressant, are inductors of the liver cytochrome P-450 in animals.	d-homo-8-azasteroids	28-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-142
2312782-1	1990	Quinidine has been reported to be a potent inhibitor of a specific isozyme of cytochrome P-450 (P-450db 1) that is responsible for the metabolism of a select group of drugs.	Quinidine	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
2312782-2	1990	In order to investigate the potential for quinidine to inhibit other isozymes of cytochrome P-450 and to assess whether or not P-450db 1 plays any role in antipyrine metabolism, we studied the effects of quinidine pretreatment on the pharmacokinetics and metabolism of antipyrine in six healthy, male volunteers.	Quinidine	42-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
2314392-1	1990	The cytochrome P-450-mediated activation of phenacetin (PHEN) to reactive intermediates by two hypothetical mechanisms has been studied by use of SV 6-31G ab initio energy and spin distribution calculations.	Phenacetin	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2314392-1	1990	The cytochrome P-450-mediated activation of phenacetin (PHEN) to reactive intermediates by two hypothetical mechanisms has been studied by use of SV 6-31G ab initio energy and spin distribution calculations.	Phenacetin	56-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2314392-2	1990	In our calculations, the cytochrome P-450 enzyme system has been substituted by a singlet oxygen atom in order to reduce the computational efforts and to fulfill the requirements as to spin conservation.	Singlet Oxygen	82-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-41
2310385-1	1990	Arachidonic acid (AA) can be metabolized in endothelial cells (EC) to a series of epoxides via cytochrome P-450 epoxygenase with 14,15 epoxyeicosatrienoic acid (14,15-EET) as the major product.	Arachidonic Acid	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2310385-1	1990	Arachidonic acid (AA) can be metabolized in endothelial cells (EC) to a series of epoxides via cytochrome P-450 epoxygenase with 14,15 epoxyeicosatrienoic acid (14,15-EET) as the major product.	Epoxy Compounds	82-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2310385-1	1990	Arachidonic acid (AA) can be metabolized in endothelial cells (EC) to a series of epoxides via cytochrome P-450 epoxygenase with 14,15 epoxyeicosatrienoic acid (14,15-EET) as the major product.	14,15-epoxy-5,8,11-eicosatrienoic acid	129-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2310385-1	1990	Arachidonic acid (AA) can be metabolized in endothelial cells (EC) to a series of epoxides via cytochrome P-450 epoxygenase with 14,15 epoxyeicosatrienoic acid (14,15-EET) as the major product.	14,15-epoxy-5,8,11-eicosatrienoic acid	161-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-111
2328938-2	1990	The CYP21B gene encodes an adrenal microsomal cytochrome P-450, which is specific for steroid 21-hydroxylation (P450c21).	Steroids	86-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
2182119-0	1990	Tyrosine-96 as a natural spectroscopic probe of the cytochrome P-450cam active site.	Tyrosine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-68
2155989-4	1990	These results suggest that the dose-dependent dual effect of silibinin on corticosteroid secretion may be attributed to corresponding changes in the activities of cytochrome P-450 enzymes, and that stimulation of ACTH-induced corticosteroidogenesis by silibinin is presumably due to the antioxidant property of the drug.	Silybin	61-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
2298305-0	1990	Heme maintains catalytically active structure of cytochrome P-450.	Heme	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-65
1967940-1	1990	Metyrapone, an inhibitor of cytochrome P-450-dependent monooxygenases, enhanced the induction of tyrosine aminotransferase by dexamethasone in primary cultures of hepatocytes, while it had no effect on the basal level of the enzyme activity in the absence of the hormone.	Metyrapone	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
1967940-1	1990	Metyrapone, an inhibitor of cytochrome P-450-dependent monooxygenases, enhanced the induction of tyrosine aminotransferase by dexamethasone in primary cultures of hepatocytes, while it had no effect on the basal level of the enzyme activity in the absence of the hormone.	Dexamethasone	126-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
2154220-0	1990	A possible role of cAMP dependent phosphorylation of hepatic microsomal cytochrome P450: a mechanism to increase lipid peroxidation in response to hormone.	Cyclic AMP	19-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
2154220-2	1990	cAMP dependent phosphorylation of cytochrome P450 was found to increase the NADPH dependent production of malondialdehyde (lipid peroxidation) by about 30%.	Cyclic AMP	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
2154220-2	1990	cAMP dependent phosphorylation of cytochrome P450 was found to increase the NADPH dependent production of malondialdehyde (lipid peroxidation) by about 30%.	NADP	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
1967940-4	1990	The dexamethasone activity amplification by metyrapone could be the consequence of a modulation of the glucocorticoid biotransformations due to the cytochrome P-450 inhibitor.	Dexamethasone	4-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
2298305-1	1990	Treatment of purified cytochrome P-450 LM2 and its liposome-bound form with hydrogen peroxide led to complete destruction of the P-450 heme.	Hydrogen Peroxide	76-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
1967940-4	1990	The dexamethasone activity amplification by metyrapone could be the consequence of a modulation of the glucocorticoid biotransformations due to the cytochrome P-450 inhibitor.	Metyrapone	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
2154220-2	1990	cAMP dependent phosphorylation of cytochrome P450 was found to increase the NADPH dependent production of malondialdehyde (lipid peroxidation) by about 30%.	Malondialdehyde	106-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-49
2154220-3	1990	The cytochrome P450 inhibitor cyanide abolished this activity.	Cyanides	30-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
2298305-1	1990	Treatment of purified cytochrome P-450 LM2 and its liposome-bound form with hydrogen peroxide led to complete destruction of the P-450 heme.	Heme	135-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-38
2154220-4	1990	The presence of spermine decreased the cytochrome P450 dependent lipid peroxidation in non-phosphorylated microsomes, phosphorylation partially reversed this effect.	Spermine	16-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
2298305-2	1990	The apoenzyme thus produced could be reconstituted to catalytically active cytochrome P-450 by incubation with hemin, the reconstitution efficiency being 50% for the soluble enzyme and 80% for the liposome-bound enzyme.	Hemin	111-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
2154220-7	1990	It is hypothesized that phosphorylation of cytochrome P450 alters the interaction between the components of the cytochrome P450 system, which may enhance production of free radical species, initiating lipid peroxidation.	Free Radicals	168-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
2154220-7	1990	It is hypothesized that phosphorylation of cytochrome P450 alters the interaction between the components of the cytochrome P450 system, which may enhance production of free radical species, initiating lipid peroxidation.	Free Radicals	168-180	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
2371836-0	1990	"In vitro" cyclosporin and methylprednisolone interaction with cytochrome P-450.	Cyclosporine	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2371836-0	1990	"In vitro" cyclosporin and methylprednisolone interaction with cytochrome P-450.	Methylprednisolone	27-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
2344458-1	1990	An electrochemical system of cytochrome P-450 reduction in the presence of the water-soluble redox carrier methylviologen has been developed.	Water	79-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-45
2156510-0	1990	Antibodies against rabbit omega-hydroxylases of prostaglandins and fatty acids cross-react with leukotriene B4 omega-hydroxylase in human neutrophils (cytochrome P-450LTB omega).	Prostaglandins	48-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-176
2156510-0	1990	Antibodies against rabbit omega-hydroxylases of prostaglandins and fatty acids cross-react with leukotriene B4 omega-hydroxylase in human neutrophils (cytochrome P-450LTB omega).	Fatty Acids	67-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-176
2344452-0	1990	[The role of heme in formation of the native structure of cytochrome P-450 LM2].	Heme	13-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
24487082-4	1990	Other drugs, such as chloramphenicol, propoxyphene, verapamil, and viloxazine, inhibit cytochrome P-450.	Chloramphenicol	21-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
24487082-4	1990	Other drugs, such as chloramphenicol, propoxyphene, verapamil, and viloxazine, inhibit cytochrome P-450.	Dextropropoxyphene	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
24487082-4	1990	Other drugs, such as chloramphenicol, propoxyphene, verapamil, and viloxazine, inhibit cytochrome P-450.	Verapamil	52-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
24487082-4	1990	Other drugs, such as chloramphenicol, propoxyphene, verapamil, and viloxazine, inhibit cytochrome P-450.	Viloxazine	67-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-103
2344458-2	1990	In this system cytochrome P-450 effectuates a steady-state demethylation of dimethylaniline and hydroxylation of aniline.	N,N-dimethylaniline	76-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
2344452-1	1990	The role of heme in the formation of cytochrome P-450 native structure was investigated.	Heme	12-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
2344454-6	1990	Incubation of the immobilized cytochrome P-450 LM 2 with sonicated liposomes composed of various phospholipids did not result in oligomer dissociation and protein translocation from the matrix to the lipid phase, although the catalytic activity of the immobilized cytochrome significantly increased in the presence of liposomes.	Phospholipids	97-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
2344458-2	1990	In this system cytochrome P-450 effectuates a steady-state demethylation of dimethylaniline and hydroxylation of aniline.	aniline	84-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-31
2322954-0	1990	The role of hydrophobicity and electronic factors in regulating alcohol inhibition of cytochrome P-450-mediated aniline hydroxylation.	Alcohols	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
2131820-7	1990	These results are interpreted in terms of an electron/proton/electron transfer mechanism previously postulated for the oxidation of other dihydropyridines by cytochrome P-450 enzymes and model one-electron acceptors and argue against a mechanism involving hydrogen atom abstraction from nifedipine.	Dihydropyridines	138-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-174
2131820-7	1990	These results are interpreted in terms of an electron/proton/electron transfer mechanism previously postulated for the oxidation of other dihydropyridines by cytochrome P-450 enzymes and model one-electron acceptors and argue against a mechanism involving hydrogen atom abstraction from nifedipine.	Hydrogen	256-264	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-174
2131820-7	1990	These results are interpreted in terms of an electron/proton/electron transfer mechanism previously postulated for the oxidation of other dihydropyridines by cytochrome P-450 enzymes and model one-electron acceptors and argue against a mechanism involving hydrogen atom abstraction from nifedipine.	Nifedipine	287-297	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-174
2403855-0	1990	Metabolic deactivation of furylfuramide by cytochrome P450 in human and rat liver microsomes.	Furylfuramide	26-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
2322954-0	1990	The role of hydrophobicity and electronic factors in regulating alcohol inhibition of cytochrome P-450-mediated aniline hydroxylation.	aniline	112-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
2322954-1	1990	The role of hydrophobicity and electronic factors in regulating alcohol inhibition of cytochrome P-450-mediated aniline p-hydroxylation has been investigated by the formulation of quantitative structure-activity relationships.	Alcohols	64-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
2322954-1	1990	The role of hydrophobicity and electronic factors in regulating alcohol inhibition of cytochrome P-450-mediated aniline p-hydroxylation has been investigated by the formulation of quantitative structure-activity relationships.	aniline	112-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
2322954-6	1990	Similarities are found between alcohol inhibition and the binding of alkyl amines to cytochrome P-450, suggesting that alcohols may bind to the amine binding site.	Alcohols	31-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2322954-6	1990	Similarities are found between alcohol inhibition and the binding of alkyl amines to cytochrome P-450, suggesting that alcohols may bind to the amine binding site.	alkyl amines	69-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2322954-6	1990	Similarities are found between alcohol inhibition and the binding of alkyl amines to cytochrome P-450, suggesting that alcohols may bind to the amine binding site.	Alcohols	119-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2322954-6	1990	Similarities are found between alcohol inhibition and the binding of alkyl amines to cytochrome P-450, suggesting that alcohols may bind to the amine binding site.	Amines	75-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-101
2265588-0	1990	[The role of cytochrome P-450 in detoxifying the thioethynyl esters of monothiophosphoric acids].	thioethynyl esters	49-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2264925-8	1990	In the kidney, cis-platinum appears to be the most effective inducer of cytochrome P-450, whereby the biotransformation of the prostaglandins and fatty acids could be altered.	Cisplatin	15-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2264925-8	1990	In the kidney, cis-platinum appears to be the most effective inducer of cytochrome P-450, whereby the biotransformation of the prostaglandins and fatty acids could be altered.	Prostaglandins	127-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2264925-8	1990	In the kidney, cis-platinum appears to be the most effective inducer of cytochrome P-450, whereby the biotransformation of the prostaglandins and fatty acids could be altered.	Fatty Acids	146-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2264925-9	1990	The spectrum of the effects of cis-platinum on cytochrome P-450-dependent drug metabolism and steroid hydroxylation activity mimic those produced by hypophysectomy and are for the most part reversed by the anterior pituitary hormones.	Cisplatin	31-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
2265588-0	1990	[The role of cytochrome P-450 in detoxifying the thioethynyl esters of monothiophosphoric acids].	thiophosphoric acid	71-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-29
2250572-1	1990	The administration of doxorubicin, an anti-tumor antibiotic, to rodents resulted in an increase in heme oxygenase activity and a decrease in delta-aminolevulinate (ALA) synthase activity and in cellular heme and cytochrome P450 content in liver.	Doxorubicin	22-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	212-227
1699849-3	1990	In addition, the interaction of lindane with the liver tissue results in the induction of the microsomal cytochrome P-450 system, together with enhanced rates of superoxide radical generation and a significant increase in indicators of lipid peroxidation.	Hexachlorocyclohexane	32-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
1693736-8	1990	The only significant drug interactions with felodipine occur with inducers and inhibitors of the cytochrome P-450 system, which is responsible for the metabolism of felodipine.	Felodipine	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
1693736-8	1990	The only significant drug interactions with felodipine occur with inducers and inhibitors of the cytochrome P-450 system, which is responsible for the metabolism of felodipine.	Felodipine	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-113
2250572-2	1990	Sn-protoporphyrin, a potent inhibitor of heme degradation both in vitro and in vivo, when administered to rodents prior to doxorubicin, mitigates the drug-induced toxic actions which are reflected by the drug-induced decreases of both cellular heme and cytochrome P450 content.	tin protoporphyrin IX	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-268
2273938-7	1990	Levels of cytochrome P-450 IIIA4 vary widely among individuals and can explain the variation in rates of 17 alpha-ethynylestradiol 2-hydroxylation.	Ethinyl Estradiol	105-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
2250572-3	1990	Sn-protoporphyrin thus provides a pharmacological means of protecting against the toxic effects of doxorubicin and other drugs which enhance heme oxygenase activity and thus decrease cellular heme and cytochrome P450 content in vivo.	tin protoporphyrin IX	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
2250572-3	1990	Sn-protoporphyrin thus provides a pharmacological means of protecting against the toxic effects of doxorubicin and other drugs which enhance heme oxygenase activity and thus decrease cellular heme and cytochrome P450 content in vivo.	Doxorubicin	99-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-216
2273938-9	1990	Mechanism-based inactivation of cytochrome P-450 IIIA4 can be seen with 17 alpha-ethynylestradiol and other 17 alpha-acetylenic steroids, and the progestogen gestodene appears to be unusually active in this regard.	Ethinyl Estradiol	72-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
2151997-0	1990	Cytochrome P-450s as toxicogenic catalysts: the influence of dehydroepiandrosterone.	Dehydroepiandrosterone	61-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
2273938-9	1990	Mechanism-based inactivation of cytochrome P-450 IIIA4 can be seen with 17 alpha-ethynylestradiol and other 17 alpha-acetylenic steroids, and the progestogen gestodene appears to be unusually active in this regard.	alpha-acetylenic steroids	111-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
2273938-10	1990	Other unknown factors may also modulate levels of cytochrome P-450 IIIA4 and its ability to catalyze 17 alpha-ethynylestradiol 2-hydroxylation.	Ethinyl Estradiol	101-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
2134673-4	1990	Interestingly, the clofibrate receptor, believed to be involved in clofibrate induction of certain isozymes of cytochrome P-450, has recently been shown to be a member of the steroid receptor supergene family and it is conceivable that other P-450 inducers might act via as yet uncharacterized receptors belonging to the same gene family.	Clofibrate	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
2134683-3	1990	The cytochrome P-450 enzymes are also responsible for the metabolism of endogenous substrates including fatty acids, prostaglandins and all classes of steroids.	Fatty Acids	104-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2134683-3	1990	The cytochrome P-450 enzymes are also responsible for the metabolism of endogenous substrates including fatty acids, prostaglandins and all classes of steroids.	Prostaglandins	117-131	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
2122185-0	1990	Ocular cytochrome P-450 metabolism of arachidonate: synthesis and bioassay.	Arachidonic Acid	38-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-23
2181486-2	1990	Ethanol is also oxidized in liver microsomes by an ethanol-inducible cytochrome P-450 (P-450IIE1) which contributes to ethanol metabolism and tolerance, and activates xenobiotics to toxic radicals thereby explaining increased vulnerability of the heavy drinker to industrial solvents, anesthetic agents, commonly prescribed drugs, over-the-counter analgesics, chemical carcinogens and even nutritional factors such as vitamin A.	Ethanol	0-7	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2181486-2	1990	Ethanol is also oxidized in liver microsomes by an ethanol-inducible cytochrome P-450 (P-450IIE1) which contributes to ethanol metabolism and tolerance, and activates xenobiotics to toxic radicals thereby explaining increased vulnerability of the heavy drinker to industrial solvents, anesthetic agents, commonly prescribed drugs, over-the-counter analgesics, chemical carcinogens and even nutritional factors such as vitamin A.	Ethanol	51-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2181486-2	1990	Ethanol is also oxidized in liver microsomes by an ethanol-inducible cytochrome P-450 (P-450IIE1) which contributes to ethanol metabolism and tolerance, and activates xenobiotics to toxic radicals thereby explaining increased vulnerability of the heavy drinker to industrial solvents, anesthetic agents, commonly prescribed drugs, over-the-counter analgesics, chemical carcinogens and even nutritional factors such as vitamin A.	Ethanol	119-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2181486-2	1990	Ethanol is also oxidized in liver microsomes by an ethanol-inducible cytochrome P-450 (P-450IIE1) which contributes to ethanol metabolism and tolerance, and activates xenobiotics to toxic radicals thereby explaining increased vulnerability of the heavy drinker to industrial solvents, anesthetic agents, commonly prescribed drugs, over-the-counter analgesics, chemical carcinogens and even nutritional factors such as vitamin A.	Vitamin A	418-427	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-85
2181493-4	1990	Currently available in vivo and in vitro data suggest that nitrosamines may be metabolized by cytochrome P-450, prostaglandin endoperoxide synthetase, or monoamine oxidases.	Nitrosamines	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
2134683-3	1990	The cytochrome P-450 enzymes are also responsible for the metabolism of endogenous substrates including fatty acids, prostaglandins and all classes of steroids.	Steroids	151-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
20837414-10	1990	These results indicate that isomers of Cl-DBFs induce effectively 3-methylcholanthrene-inducible type of cytochrome P-450.	cl-dbfs	39-46	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
2162582-2	1990	To exemplify the first-group reactions, cytochrome P-450 was studied, which is capable of generating different active forms of oxygen during the catalytic cycle.	Oxygen	127-133	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-56
2162582-4	1990	In the course of the reaction, cytochrome P-450 also became inactivated under the effect of active oxygen.	Oxygen	99-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
20837414-10	1990	These results indicate that isomers of Cl-DBFs induce effectively 3-methylcholanthrene-inducible type of cytochrome P-450.	Methylcholanthrene	66-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
33809117-3	2021	A clearer understanding of CYP expression is important in the pathogenesis of breast cancer as several isoforms play critical roles in metabolising steroid hormones and xenobiotics that contribute to the genesis of breast cancer.	Steroids	148-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
2220168-1	1990	Caffeine is mainly metabolized by 3-methyl-cholanthrene-inducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by phenobarbital inducible cytochromes P-450.	Caffeine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
2220168-1	1990	Caffeine is mainly metabolized by 3-methyl-cholanthrene-inducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by phenobarbital inducible cytochromes P-450.	Methylcholanthrene	34-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-82
2220168-2	1990	Therefore the elimination of caffeine from serum and the amount of the main metabolites of metamizol excreted into urine reflect the activity of these two cytochrome P-450 families.	Caffeine	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
2220168-2	1990	Therefore the elimination of caffeine from serum and the amount of the main metabolites of metamizol excreted into urine reflect the activity of these two cytochrome P-450 families.	Dipyrone	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
33973477-5	2021	The most studied drug categories were anticonvulsants and selective serotonin reuptake inhibitors associated with human leukocyte antigen and cytochrome P450 genes (HLA-A, HLA-B, CYP2C9, CYP2D6, CYP2C19), classified as critically low quality/low quality.	Serotonin	68-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	142-157
34843882-7	2022	Further study showed inhibitory effect of HGK on CYP enzymes was weaker than that of diosmetin, which may be related to the substitution of hydroxyl and methoxy in the A and B rings of the flavone skeleton.	flavone	189-196	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
23859801-4	2013	Lacosamide has a well-characterized and favorable pharmacokinetic profile, including a fast absorption rate, minimal or no interaction with cytochrome P-450 izoenzymes, and a low potential for drug-drug interactions.	Lacosamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
34847475-0	2022	The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib.	lenvatinib	98-108	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
34410044-0	2022	Translational aspects of cytochrome P450-mediated drug-drug interactions: a case study with clopidogrel.	Clopidogrel	92-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40
34410044-10	2022	This MiniReview provides an overview of translational approaches to study CYP-mediated DDIs, going beyond regulatory DDI guidelines, and an illustrative case study of how the DDI potential of clopidogrel was unveiled by combining these different methods.	Clopidogrel	192-203	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-77
34861484-2	2022	However, cancer drug resistance greatly mitigates the cure rates of tumors, and cytochrome P450 (CYP450) plays an important role in the development of cisplatin resistance.	Cisplatin	151-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
34780725-0	2022	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.	dabrafenib	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-45
34352543-0	2022	Computational insight into biotransformation of halophenols by cytochrome P450: Mechanism and reactivity for epoxidation.	halophenols	48-59	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
34352543-2	2022	Previous experimental studies have shown that XPs can be catalytically transformed into epoxides and haloquinones by cytochrome P450 enzymes (CYPs).	Epoxy Compounds	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
34352543-2	2022	Previous experimental studies have shown that XPs can be catalytically transformed into epoxides and haloquinones by cytochrome P450 enzymes (CYPs).	haloquinone	101-113	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-132
34426286-1	2022	OBJECTIVE: Bisphenol A (BPA), a common endocrine disrupter, can be activated by cytochrome P450 (CYP) metabolizing enzymes and might influence the development of breast cancer (BC).	bisphenol A	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
34426286-1	2022	OBJECTIVE: Bisphenol A (BPA), a common endocrine disrupter, can be activated by cytochrome P450 (CYP) metabolizing enzymes and might influence the development of breast cancer (BC).	bisphenol A	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
34426286-1	2022	OBJECTIVE: Bisphenol A (BPA), a common endocrine disrupter, can be activated by cytochrome P450 (CYP) metabolizing enzymes and might influence the development of breast cancer (BC).	bisphenol A	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
34426286-1	2022	OBJECTIVE: Bisphenol A (BPA), a common endocrine disrupter, can be activated by cytochrome P450 (CYP) metabolizing enzymes and might influence the development of breast cancer (BC).	bisphenol A	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	97-100
34426286-2	2022	We hypothesized that BPA could interact with CYP genes, synergistically contributing to the BC risk.	bisphenol A	21-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
34780725-8	2022	Overall, our data confirm dabrafenib as a drug frequently and potently interacting with ABC transporters and CYP isoenzymes.	dabrafenib	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	109-112
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Cannabinoids	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
34806536-0	2022	Salinomycin induces cell cycle arrest and apoptosis and modulates hepatic cytochrome P450 mRNA expression in HepG2/C3a cells.	salinomycin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
34877801-1	2022	This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics (PK) of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; omeprazole, CYP2C19) in healthy subjects.	Bupropion	165-174	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
34877801-1	2022	This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics (PK) of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; omeprazole, CYP2C19) in healthy subjects.	Midazolam	184-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156
34363188-1	2021	BACKGROUND: Hepatic impairment can impact apixaban pharmacokinetics and pharmacodynamics by decreasing cytochrome P450-mediated metabolism and factor X production.	apixaban	42-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-118
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Dronabinol	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Cannabinoids	234-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
34493602-9	2021	Significance Statement Major cannabinoids and their metabolites found in the plasma of cannabis users inhibit several CYP enzymes, including CYP2B6, CYP2C9, and CYP2D6.	Cannabinoids	29-41	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121
34648192-9	2022	CONCLUSION: CYP1A2 is the major CYP for the conversion of 4-MAA to 4-AA and 4-FAA.	4-maa	58-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
34848204-0	2022	Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology.	Fatty Acids	24-34	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34848204-0	2022	Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology.	Epoxy Compounds	35-43	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34848204-1	2022	Cytochrome P450 (CYP) enzymes are frequently referred to as the third pathway for the metabolism of arachidonic acid.	Arachidonic Acid	100-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34848204-1	2022	Cytochrome P450 (CYP) enzymes are frequently referred to as the third pathway for the metabolism of arachidonic acid.	Arachidonic Acid	100-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
34734218-4	2021	Six major xenobiotic metabolizing CYPs were screened for their capacity to catalyze 6:2 FTOH oxidation using chemical inhibitors selective towards CYP isoforms.	ftoh	88-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	147-150
34734218-5	2021	Of the CYP isoforms investigated, CYP2A6 was the only enzyme capable of catalyzing 6:2 FTOH in human liver microsomes, with KM and Vmax values of 4076 ng mL-1 and 69 ng mL-1 min-1, respectively.	ftoh	87-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
34867397-1	2021	NADPH:cytochrome P450 oxidoreductase (POR) is the obligate electron donor for microsomal cytochrome P450 (CYP) enzymes involved in the biosynthesis of endogenous substances like bile acids and other steroids as well as in the oxidative metabolism of xenobiotics.	Bile Acids and Salts	178-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
34867397-1	2021	NADPH:cytochrome P450 oxidoreductase (POR) is the obligate electron donor for microsomal cytochrome P450 (CYP) enzymes involved in the biosynthesis of endogenous substances like bile acids and other steroids as well as in the oxidative metabolism of xenobiotics.	Bile Acids and Salts	178-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
34867397-1	2021	NADPH:cytochrome P450 oxidoreductase (POR) is the obligate electron donor for microsomal cytochrome P450 (CYP) enzymes involved in the biosynthesis of endogenous substances like bile acids and other steroids as well as in the oxidative metabolism of xenobiotics.	Steroids	199-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
34867397-1	2021	NADPH:cytochrome P450 oxidoreductase (POR) is the obligate electron donor for microsomal cytochrome P450 (CYP) enzymes involved in the biosynthesis of endogenous substances like bile acids and other steroids as well as in the oxidative metabolism of xenobiotics.	Steroids	199-207	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-109
34328253-3	2021	We aimed to evaluate cytochrome P450 (CYP)-mediated levonorgestrel metabolism and quantify the effects of dolutegravir on levonorgestrel apparent intrinsic clearance (CLint.app. )	Levonorgestrel	52-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-36
34328253-3	2021	We aimed to evaluate cytochrome P450 (CYP)-mediated levonorgestrel metabolism and quantify the effects of dolutegravir on levonorgestrel apparent intrinsic clearance (CLint.app. )	Levonorgestrel	52-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-41
34328253-6	2021	of levonorgestrel was quantified using a recombinant human CYP (rhCYP) enzyme system.	Levonorgestrel	3-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
34613323-0	2021	Water biocatalytic effect attenuates cytochrome P450-mediated carcinogenicity of diethylnitrosamine: A computational insight.	Water	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
34613323-0	2021	Water biocatalytic effect attenuates cytochrome P450-mediated carcinogenicity of diethylnitrosamine: A computational insight.	Diethylnitrosamine	81-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
34613323-1	2021	The mechanism-based mutagenicity and carcinogenicity of diethylnitrosamine (DEN) are believed to act through interactions with cytochrome P450 (P450) enzymes.	Diethylnitrosamine	56-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
34613323-1	2021	The mechanism-based mutagenicity and carcinogenicity of diethylnitrosamine (DEN) are believed to act through interactions with cytochrome P450 (P450) enzymes.	Diethylnitrosamine	76-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-142
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	noramidopyrine	24-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	noramidopyrine	24-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-177
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-maa	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-maa	49-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-177
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	n-demethylated	64-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	Ampyrone	82-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34663919-3	2021	Here we describe engineered cytochrome P450 enzymes that catalyse carbene N-H insertion to prepare biologically relevant alpha-amino lactones with high activity and enantioselectivity (up to 32,100 total turnovers, >99% yield and 98% e.e.).	carbene	66-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
34663919-3	2021	Here we describe engineered cytochrome P450 enzymes that catalyse carbene N-H insertion to prepare biologically relevant alpha-amino lactones with high activity and enantioselectivity (up to 32,100 total turnovers, >99% yield and 98% e.e.).	alpha-amino lactones	121-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
34848204-4	2022	CYP enzymes can also participate in crosstalk with other PUFA pathways and metabolize prostaglandin G2 and H2, which are the precursors of effector prostaglandins, to affect macrophage function and lymphangiogenesis.	prostaglandin G2	86-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
34848204-4	2022	CYP enzymes can also participate in crosstalk with other PUFA pathways and metabolize prostaglandin G2 and H2, which are the precursors of effector prostaglandins, to affect macrophage function and lymphangiogenesis.	Deuterium	107-109	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
34848204-4	2022	CYP enzymes can also participate in crosstalk with other PUFA pathways and metabolize prostaglandin G2 and H2, which are the precursors of effector prostaglandins, to affect macrophage function and lymphangiogenesis.	Prostaglandins	148-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
34776966-4	2021	Curcumin can inhibit many CYP enzymes in vitro, and so the inhibition of curcumin on CYP enzymes was compared by human liver microsomes, human hepatocytes, and hiHeps using UPLC-MS and the cocktail method.	Curcumin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
34776966-4	2021	Curcumin can inhibit many CYP enzymes in vitro, and so the inhibition of curcumin on CYP enzymes was compared by human liver microsomes, human hepatocytes, and hiHeps using UPLC-MS and the cocktail method.	Curcumin	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
34500236-8	2021	Human recombinant cytochrome P450 (CYP) enzyme analysis revealed that metabolism of cabozantinib was mainly catalyzed by CYP3A4, while other CYP enzymes played negligible role.	cabozantinib	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-33
34500236-8	2021	Human recombinant cytochrome P450 (CYP) enzyme analysis revealed that metabolism of cabozantinib was mainly catalyzed by CYP3A4, while other CYP enzymes played negligible role.	cabozantinib	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
34672553-5	2021	In this study, we introduce iCYP-MFE, a computational framework for virtual screening on CYP inhibitors toward 1A2, 2C9, 2C19, 2D6, and 3A4 isoforms.	icyp-mfe	28-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
34672553-12	2021	An online web server for iCYP-MFE with a user-friendly interface was also deployed to support scientific communities in identifying CYP inhibitors.	icyp-mfe	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135
34663070-0	2021	Precision Biotransformation of Emerging Pollutants by Human Cytochrome P450 Using Computational-Experimental Synergy: A Case Study of Tris(1,3-dichloro-2-propyl) Phosphate.	tris(1,3-dichloro-2-propyl)phosphate	134-171	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-75
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	Ampyrone	101-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-formylaminoantipyrine	122-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-formylaminoantipyrine	122-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-177
34648192-9	2022	CONCLUSION: CYP1A2 is the major CYP for the conversion of 4-MAA to 4-AA and 4-FAA.	Ampyrone	67-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-formylaminoantipyrine	147-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	157-172
34648192-2	2022	The primary metabolite, 4-methylaminoantipyrine (4-MAA), can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (4-FAA) by cytochrome P450 (CYP)-dependent reactions.	4-formylaminoantipyrine	147-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	174-177
34648192-9	2022	CONCLUSION: CYP1A2 is the major CYP for the conversion of 4-MAA to 4-AA and 4-FAA.	4-formylaminoantipyrine	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-35
34648192-3	2022	We aimed to identify the CYPs involved in 4-MAA metabolism and to quantify the effect of CYP inhibition on 4-MAA metabolism.	4-maa	107-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
34330718-0	2021	Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.	Cannabidiol	40-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34648192-4	2022	METHODS: We investigated the metabolism of 4-MAA in vitro using CYP expressing supersomes and the pharmacokinetics of metamizole in the presence of CYP inhibitors in male subjects.	4-maa	43-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
34648192-5	2022	RESULTS: The experiments in supersomes revealed CYP1A2 as the major CYP for 4-MAA N-demethylation and 4-FAA formation with CYP2C19 and CYP2D6 contributing to N-demethylation.	4-maa	76-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
34648192-5	2022	RESULTS: The experiments in supersomes revealed CYP1A2 as the major CYP for 4-MAA N-demethylation and 4-FAA formation with CYP2C19 and CYP2D6 contributing to N-demethylation.	Nitrogen	82-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
34648192-5	2022	RESULTS: The experiments in supersomes revealed CYP1A2 as the major CYP for 4-MAA N-demethylation and 4-FAA formation with CYP2C19 and CYP2D6 contributing to N-demethylation.	4-formylaminoantipyrine	102-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71
34690761-0	2021	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.	Dutasteride	94-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
34690761-0	2021	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.	Tamsulosin	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
34330718-0	2021	Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.	7-Hydroxycannabidiol	77-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34620272-3	2021	Cytochrome-P450 (CYP) isoenzymes CYP3A4 and CYP3A5, as well P-glycoprotein (P-gp) are involved in TAC bioavailability.	Tacrolimus	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34620272-3	2021	Cytochrome-P450 (CYP) isoenzymes CYP3A4 and CYP3A5, as well P-glycoprotein (P-gp) are involved in TAC bioavailability.	Tacrolimus	98-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
34180113-0	2021	Enzymatic Tailoring in Luzopeptin Biosynthesis Involves Cytochrome P450-Mediated Carbon-Nitrogen Bond Desaturation for Hydrazone Formation.	luzopeptin	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
34556703-8	2021	Significantly, our findings suggest a potential targeted therapeutic approach to manage HNCs by exploiting intratumoural CYP expression for metabolic activation of duocarmycin-based prodrugs such as ICT2700.	(1-(chloromethyl)-1,2-dihydropyrrolo(3,2-e)indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl)methanone	199-206	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
34563259-5	2021	Studies with ovarian theca cells taken from PCOS women have demonstrated increased androgen production due to augmented ovarian steroidogenesis attributed to mainly altered expression of critical enzymes (Cytochrome P450 enzymes: CYP17, CYP21, CYP19, CYP11A) in the steroid hormone biosynthesis pathway.	Steroids	266-273	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-220
34180113-0	2021	Enzymatic Tailoring in Luzopeptin Biosynthesis Involves Cytochrome P450-Mediated Carbon-Nitrogen Bond Desaturation for Hydrazone Formation.	Carbon	81-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
34180113-0	2021	Enzymatic Tailoring in Luzopeptin Biosynthesis Involves Cytochrome P450-Mediated Carbon-Nitrogen Bond Desaturation for Hydrazone Formation.	Nitrogen	88-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
34180113-0	2021	Enzymatic Tailoring in Luzopeptin Biosynthesis Involves Cytochrome P450-Mediated Carbon-Nitrogen Bond Desaturation for Hydrazone Formation.	Hydrazones	119-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
34180113-3	2021	Significantly, we revealed a multitasking cytochrome P450 enzyme that catalyzes four consecutive oxidations including the highly unusual carbon-nitrogen bond desaturation, forming the hydrazone-bearing 4-OH-Thp residues.	Carbon	137-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
34180113-3	2021	Significantly, we revealed a multitasking cytochrome P450 enzyme that catalyzes four consecutive oxidations including the highly unusual carbon-nitrogen bond desaturation, forming the hydrazone-bearing 4-OH-Thp residues.	Nitrogen	144-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
34180113-3	2021	Significantly, we revealed a multitasking cytochrome P450 enzyme that catalyzes four consecutive oxidations including the highly unusual carbon-nitrogen bond desaturation, forming the hydrazone-bearing 4-OH-Thp residues.	Hydrazones	184-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
34180113-3	2021	Significantly, we revealed a multitasking cytochrome P450 enzyme that catalyzes four consecutive oxidations including the highly unusual carbon-nitrogen bond desaturation, forming the hydrazone-bearing 4-OH-Thp residues.	4-oh-thp	202-210	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-57
34114066-1	2021	PURPOSE: Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes.	Cyclophosphamide	60-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
34114066-1	2021	PURPOSE: Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes.	Cyclophosphamide	60-76	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Tryptophan	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
34330191-0	2021	Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase.	DS-1971a	86-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	117-153
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Tryptophan	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Nitric Oxide	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Tryptophan	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Nitric Oxide	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	Tryptophan	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	4-nitro-l-tryptophan	135-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	4-nitro-l-tryptophan	135-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	4-no2-trp	157-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-25
34319079-1	2021	TxtE is a cytochrome P450 (CYP) homologue that mediates the nitric oxide (NO)-dependent direct nitration of l-tryptophan (Trp) to form 4-nitro-l-tryptophan (4-NO2-Trp).	4-no2-trp	157-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-30
34170130-5	2021	PCZ-treated cells activated intracellular oxidative stress via cytochrome P450 and had higher mRNA levels of interleukin-1beta, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-2, MMP-9, and transforming growth factor-beta (TGF-beta) than the control.	propiconazole	0-3	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
34273352-1	2021	Cytochrome P450 (P450) 17A1 catalyzes the 17alpha-hydroxylation of progesterone and pregnenolone as well as the subsequent lyase cleavage of both products to generate androgens.	Progesterone	67-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-27
34273352-1	2021	Cytochrome P450 (P450) 17A1 catalyzes the 17alpha-hydroxylation of progesterone and pregnenolone as well as the subsequent lyase cleavage of both products to generate androgens.	Pregnenolone	84-96	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-27
34138544-0	2021	Correction to Bifunctional Cytochrome P450 Enzymes Involved in Camptothecin Biosynthesis.	Camptothecin	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
34101429-0	2021	Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.	Peroxides	73-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34101429-0	2021	Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.	artefenomel	95-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34143391-5	2021	Lenabasum is a CYP substrate, and the model predicted lenabasum clearance of 51% by CYP2C9, 37% by CYP2C8, and 12% by CYP3A4.	lenabasum	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
34143391-5	2021	Lenabasum is a CYP substrate, and the model predicted lenabasum clearance of 51% by CYP2C9, 37% by CYP2C8, and 12% by CYP3A4.	lenabasum	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-18
34143391-8	2021	The simulations of CYP inducers predicted that the strongest interaction would occur with rifampin, with the AUC decreasing to 0.36 of the control value, whereas the simulations of CYP inhibitors predicted that the greatest effect would occur with fluconazole, with a 1.43-fold increase in AUC.	Rifampin	90-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
34143391-8	2021	The simulations of CYP inducers predicted that the strongest interaction would occur with rifampin, with the AUC decreasing to 0.36 of the control value, whereas the simulations of CYP inhibitors predicted that the greatest effect would occur with fluconazole, with a 1.43-fold increase in AUC.	Fluconazole	248-259	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-184
34327042-1	2021	Bacterial cytochrome P450 (P450) 101A1 (P450cam) has served as a prototype among the P450 enzymes and has high catalytic activity towards its cognate substrate, camphor.	Camphor	161-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-38
34120382-0	2021	Targeted analysis of eicosanoids derived from cytochrome P450 pathway by high-resolution multiple-reaction monitoring mass spectrometry.	Eicosanoids	21-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
34120382-1	2021	Cytochrome P450 (CYP450) pathway is one of the critical enzymatic via eicosanoid biosynthesis.	Eicosanoids	70-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
34113252-0	2021	Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.	Voriconazole	112-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
34113252-1	2021	Aims: To explore the interactive influence of glucocorticoids and cytochrome P450 (CYP450) polymorphisms on voriconazole (VRC) plasma trough concentrations (Cmin) and provide a reliable basis for reasonable application of VRC.	Voriconazole	108-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
34113252-1	2021	Aims: To explore the interactive influence of glucocorticoids and cytochrome P450 (CYP450) polymorphisms on voriconazole (VRC) plasma trough concentrations (Cmin) and provide a reliable basis for reasonable application of VRC.	Voriconazole	122-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
34163706-4	2021	The reaction of 2 with a triphenylcarbon radical further gives triphenylmethanol and mimics the so-called oxygen rebound step of Cpd II of cytochrome P450.	triphenylcarbon radical	25-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
34163706-4	2021	The reaction of 2 with a triphenylcarbon radical further gives triphenylmethanol and mimics the so-called oxygen rebound step of Cpd II of cytochrome P450.	TRIPHENYLMETHANOL	63-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
34163706-4	2021	The reaction of 2 with a triphenylcarbon radical further gives triphenylmethanol and mimics the so-called oxygen rebound step of Cpd II of cytochrome P450.	Oxygen	106-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-154
34334558-7	2021	In the presence of human liver cytosolic fractions, the oxidative formation rate of o-hydroxyphenylacetic acid was relatively high in cytochrome P450 (P450) 1A2-rich human liver microsomes.	2-hydroxyphenylacetic acid	84-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-149
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Fluoxetine	145-155	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
34272716-8	2021	Simultaneously docking of (S)-warfarin and ABT revealed that (S)-warfarin outcompetes ABT for the distal binding site and results in the binding of ABT to the CYP2C9 active site, supporting the observations of potent inactivation of CYP2C9 when (S)-warfarin is the probe substrate.These results highlight that probe selection is crucial when evaluating CYP inhibition potential, and it is recommended that multiple probes be utilized for CYP2C9, similar to the approach routinely employed for CYP3A4.	1-aminobenzotriazole	148-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	353-356
34272716-9	2021	Further, utilization of ABT as a pan-inhibitor of CYP activity for investigational compounds, both in vitro and in vivo, should be accompanied with the understanding that residual CYP-mediated oxidative metabolism could potentially be observed for CYP2C9 substrates and should not necessarily be attributed to non-P450-mediated metabolism.	1-aminobenzotriazole	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
34272716-9	2021	Further, utilization of ABT as a pan-inhibitor of CYP activity for investigational compounds, both in vitro and in vivo, should be accompanied with the understanding that residual CYP-mediated oxidative metabolism could potentially be observed for CYP2C9 substrates and should not necessarily be attributed to non-P450-mediated metabolism.	1-aminobenzotriazole	24-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
34272718-4	2021	Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1).	Glutathione	51-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
34272718-4	2021	Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1).	Glutathione	64-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
34272718-4	2021	Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1).	Lapatinib	211-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
35523303-3	2022	To clarify the role of cholesterol (Chol) in the CYP-related drug metabolic process, we investigated the lipid bilayer entry of CYP-substrate drugs using a model membrane system as follows.	Lipid Bilayers	105-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	128-131
35523303-6	2022	Chlorzoxazone (CZX) was used as the CYP-substrate drug.	Chlorzoxazone	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
35523303-6	2022	Chlorzoxazone (CZX) was used as the CYP-substrate drug.	Chlorzoxazone	15-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
35483145-0	2022	In Silico simulation of Cytochrome P450-Mediated metabolism of aromatic amines: A case study of N-Hydroxylation.	aromatic amines	63-78	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
35483145-0	2022	In Silico simulation of Cytochrome P450-Mediated metabolism of aromatic amines: A case study of N-Hydroxylation.	Nitrogen	96-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
34272716-3	2021	In evaluating a time-saving assay using diclofenac as the CYP2C9 probe substrate, a discrepancy was observed in which minimal inhibition was detected using diclofenac whereas using (S)-warfarin resulted in potent inhibition, supporting the presence of dual-binding sites in the relatively large CYP2C9 active site cavity.These observations provided further insights into explaining the reported ineffective inactivation of CYP2C9 for the pan-CYP inactivator 1-aminobenzotriazole (ABT).	Diclofenac	40-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	442-445
34272716-3	2021	In evaluating a time-saving assay using diclofenac as the CYP2C9 probe substrate, a discrepancy was observed in which minimal inhibition was detected using diclofenac whereas using (S)-warfarin resulted in potent inhibition, supporting the presence of dual-binding sites in the relatively large CYP2C9 active site cavity.These observations provided further insights into explaining the reported ineffective inactivation of CYP2C9 for the pan-CYP inactivator 1-aminobenzotriazole (ABT).	1-aminobenzotriazole	458-478	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	442-445
34272716-3	2021	In evaluating a time-saving assay using diclofenac as the CYP2C9 probe substrate, a discrepancy was observed in which minimal inhibition was detected using diclofenac whereas using (S)-warfarin resulted in potent inhibition, supporting the presence of dual-binding sites in the relatively large CYP2C9 active site cavity.These observations provided further insights into explaining the reported ineffective inactivation of CYP2C9 for the pan-CYP inactivator 1-aminobenzotriazole (ABT).	1-aminobenzotriazole	480-483	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	442-445
35523303-0	2022	Cholesterol"s inhibition effect on entering of chlorzoxazone into phosphatidylethanolamine bilayer: Relevance to cytochrome P450 drug metabolism at endoplasmic reticulum membranes.	Cholesterol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
35523303-0	2022	Cholesterol"s inhibition effect on entering of chlorzoxazone into phosphatidylethanolamine bilayer: Relevance to cytochrome P450 drug metabolism at endoplasmic reticulum membranes.	Chlorzoxazone	47-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
35523303-0	2022	Cholesterol"s inhibition effect on entering of chlorzoxazone into phosphatidylethanolamine bilayer: Relevance to cytochrome P450 drug metabolism at endoplasmic reticulum membranes.	phosphatidylethanolamine bilayer	66-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
35594715-0	2022	Interactions of resveratrol and its metabolites (resveratrol-3-sulfate, resveratrol-3-glucuronide, and dihydroresveratrol) with serum albumin, cytochrome P450 enzymes, and OATP transporters.	Resveratrol	16-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
35594715-4	2022	Therefore, in the current study, we examined the interactions of resveratrol-3-sulfate (R3S), resveratrol-3-glucuronide, and dihydroresveratrol (DHR; a metabolite produced by the colon microbiota) with human serum albumin (HSA), cytochrome P450 (CYP) enzymes, and organic anion transporting polypeptides (OATP) employing in vitro models.	resveratrol-3-glucuronide	94-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	229-244
35594715-4	2022	Therefore, in the current study, we examined the interactions of resveratrol-3-sulfate (R3S), resveratrol-3-glucuronide, and dihydroresveratrol (DHR; a metabolite produced by the colon microbiota) with human serum albumin (HSA), cytochrome P450 (CYP) enzymes, and organic anion transporting polypeptides (OATP) employing in vitro models.	dihydroresveratrol	125-143	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	229-244
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Fluvoxamine	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Viloxazine	173-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Phenytoin	293-302	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Carbamazepine	307-320	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
35562949-3	2022	The electrophiles resulting from the cytochrome P450-mediated metabolism of N-nitrosamines can readily react with DNA and form covalent addition products (DNA adducts) that play a central role in carcinogenesis if not repaired.	n-nitrosamines	76-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
35527244-0	2022	Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan.	nilotinib	88-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
35578608-16	2022	The metabolite data demonstrated increasing CYP metabolites in occurrence with the delayed acetaminophen peak concentration.	Acetaminophen	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-47
35289081-0	2022	Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.	anlotinib	118-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-163
35289081-3	2022	In vitro experiments demonstrated that anlotinib is a substrate of cytochrome P450 (CYP) enzymes and moderate inhibitor of several common ones; however, no clinical DDI studies have been performed to investigate inhibitory effects of anlotinib on these CYP enzymes.	anlotinib	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
35289081-3	2022	In vitro experiments demonstrated that anlotinib is a substrate of cytochrome P450 (CYP) enzymes and moderate inhibitor of several common ones; however, no clinical DDI studies have been performed to investigate inhibitory effects of anlotinib on these CYP enzymes.	anlotinib	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-87
35289081-3	2022	In vitro experiments demonstrated that anlotinib is a substrate of cytochrome P450 (CYP) enzymes and moderate inhibitor of several common ones; however, no clinical DDI studies have been performed to investigate inhibitory effects of anlotinib on these CYP enzymes.	anlotinib	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-256
35289081-3	2022	In vitro experiments demonstrated that anlotinib is a substrate of cytochrome P450 (CYP) enzymes and moderate inhibitor of several common ones; however, no clinical DDI studies have been performed to investigate inhibitory effects of anlotinib on these CYP enzymes.	anlotinib	234-243	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-256
35289081-7	2022	As a result, the marginal plasma exposure changes of typical CYP3A and CYP2C9 substrates were less than the bioequivalence threshold, indicating that anlotinib has a very low potential of causing clinically meaningful DDI through the inhibition of several major CYP enzymes.	anlotinib	150-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	262-265
35115300-0	2022	Comprehensive predictions of cytochrome P450 (CYP)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent CYP inhibition in human liver microsomes.	Cannabinoids	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	29-44
35302484-2	2022	In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver.	7R9A5P7H32	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-269
35302484-2	2022	In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver.	Ritonavir	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-269
35302484-2	2022	In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver.	7R9A5P7H32	50-62	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-269
35302484-2	2022	In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver.	Arginine	63-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-269
35302484-2	2022	In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver.	7R9A5P7H32	85-97	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-269
35348513-1	2022	Budesonide (Tarpeyo) has received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy, also known as Berger"s disease.Nurses should assess if any coprescribed drugs could induce a drug-drug interaction via the cytochrome P-450 isoenzyme system.	Budesonide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-269
35348513-1	2022	Budesonide (Tarpeyo) has received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy, also known as Berger"s disease.Nurses should assess if any coprescribed drugs could induce a drug-drug interaction via the cytochrome P-450 isoenzyme system.	tarpeyo	12-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-269
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	164-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	164-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-10	2022	Significance Statement This study, combined with our previous findings, provides for the first time a comprehensive analysis of the potential for cannabidiol, delta-9-tetrahydrocannabinol, and their metabolites to inhibit cytochrome P450 enzymes in a reversible or time-dependent manner.	Cannabidiol	146-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
35115300-10	2022	Significance Statement This study, combined with our previous findings, provides for the first time a comprehensive analysis of the potential for cannabidiol, delta-9-tetrahydrocannabinol, and their metabolites to inhibit cytochrome P450 enzymes in a reversible or time-dependent manner.	Dronabinol	159-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
35115300-0	2022	Comprehensive predictions of cytochrome P450 (CYP)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent CYP inhibition in human liver microsomes.	Cannabinoids	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-49
35115300-0	2022	Comprehensive predictions of cytochrome P450 (CYP)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent CYP inhibition in human liver microsomes.	Cannabinoids	68-79	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	137-140
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Cannabidiol	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Cannabidiol	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Cannabidiol	118-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Cannabidiol	118-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	124-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	124-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	154-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	154-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35431771-0	2022	Methylated Cytochrome P450 and the Solute Carrier Family of Genes Correlate With Perturbations in Bile Acid Metabolism in Parkinson"s Disease.	Bile Acids and Salts	98-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
35408976-0	2022	Molecular Lego of Human Cytochrome P450: The Key Role of Heme Domain Flexibility for the Activity of the Chimeric Proteins.	Heme	57-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
35408976-1	2022	The cytochrome P450 superfamily are heme-thiolate enzymes able to carry out monooxygenase reactions.	Heme	36-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
35408976-1	2022	The cytochrome P450 superfamily are heme-thiolate enzymes able to carry out monooxygenase reactions.	thiolate	41-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
35230092-0	2022	Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling.	Phenol	117-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
35230092-1	2022	Intramolecular phenol coupling reactions of alkaloids can lead to active metabolites catalyzed by the mammalian cytochrome P450 enzyme (P450); however, the mechanistic knowledge of such an "unusual" process is lacking.	Phenol	15-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
35230092-1	2022	Intramolecular phenol coupling reactions of alkaloids can lead to active metabolites catalyzed by the mammalian cytochrome P450 enzyme (P450); however, the mechanistic knowledge of such an "unusual" process is lacking.	Alkaloids	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-127
35121066-0	2022	The impact of legacy and novel perfluoroalkyl substances on human cytochrome P450: An in vitro study on the inhibitory potential and underlying mechanisms.	perfluoroalkyl substances	31-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-81
35386678-9	2022	Pathway enrichment analysis shows that "phenylpropanoid biosynthesis"/"cutin, suberin, and wax biosynthesis" is significantly enriched in these groups, while the AC vs. AC and PVP groups are mainly enriched in "cytochrome P450," indicating that AC may promote the further development of roots into seedlings by stimulating "phenylpropanoid biosynthesis" and biosynthesis of stratum cutin and suberin.	phenylpropanoid	40-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-226
35107462-6	2022	Finally, the metabolite identification opportunities were also explored using efavirenz as an example drug with complex primary and secondary metabolism involving a combination of CYP, UGT and sulfotransferase enzymes.	efavirenz	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
35386280-12	2022	GSEA revealed samples with MDN1 mutation enriched in retinol metabolism, drug metabolism cytochrome P450, glucuronidation, miscellaneous transport, and binding event pathways.	gsea	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-104
35617891-2	2022	In this study, we explored the possibility of using prokaryotic water-soluble cytochrome P450 (CYP) to produce human metabolites.	Water	64-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
35617891-2	2022	In this study, we explored the possibility of using prokaryotic water-soluble cytochrome P450 (CYP) to produce human metabolites.	Water	64-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	95-98
35121066-3	2022	Recently, the interaction with cytochrome P450 (CYP) has been proposed as a potential key molecular event leading to PFAS-induced hepatotoxicity.	pfas	117-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-46
35121066-3	2022	Recently, the interaction with cytochrome P450 (CYP) has been proposed as a potential key molecular event leading to PFAS-induced hepatotoxicity.	pfas	117-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
35121066-6	2022	Using the same assays, Michaelis-Menten saturation curves were determined to explore the type of PFAS-induced CYP inhibition.	pfas	97-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	efavirenz	188-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
35280254-2	2021	Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline.	Caffeine	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
35280254-2	2021	Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline.	1,7-dimethylxanthine	114-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
35280254-2	2021	Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline.	Theobromine	155-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
35280254-2	2021	Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline.	Theophylline	171-183	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-79
35600548-0	2022	Cytochrome P450 enzymes mediated by DNA methylation is involved in deoxynivalenol-induced hepatoxicity in piglets.	deoxynivalenol	67-81	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	Cyclophosphamide	199-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	Bupropion	217-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	Methadone	228-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
35180866-0	2022	In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.	echinacoside	51-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
35135554-0	2022	Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.	Hydroxychloroquine	80-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
35185404-7	2022	In elderly or frail individuals who are on multiple comedications (particularly if >=1 moderate or strong cytochrome P-450 inhibitor), only edoxaban consistently reduced major bleeding compared to warfarin.	edoxaban	140-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	106-122
35135554-2	2022	This study aimed to investigate the relationship of cytochrome P450 (CYP450) gene polymorphisms with blood concentrations of HCQ and its metabolites and adverse drug reactions (ADRs) in patients with SLE and RA.	Hydroxychloroquine	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
33543792-8	2022	Using FAERS data, only those DDI-ADE associations were considered that met the disproportionality threshold of Omega > 0 for a CYP substrate when paired with at least two inhibitors.	ddi-ade	29-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-130
35132941-5	2022	To investigate the activation pathway of synthesized N-formyl pyrazoline substituted steroid derivatives, a molecular docking study was performed on human cytochrome P450-(CYP17A1: PDB ID 5IRQ) with the help of the free AutoDock Vina.	n-formyl pyrazoline	53-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
35132941-5	2022	To investigate the activation pathway of synthesized N-formyl pyrazoline substituted steroid derivatives, a molecular docking study was performed on human cytochrome P450-(CYP17A1: PDB ID 5IRQ) with the help of the free AutoDock Vina.	Steroids	85-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-170
34380995-3	2022	The mechanism of methadone metabolism and disposition has been shown to involve cytochrome P450 (CYP450) and P-glycoprotein.	Methadone	17-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-95
34996326-6	2022	The other important clinical applications of piperine are due to its bio enhancing effect on drugs, by modulating, absorption in the gastrointestinal tract, altering activities of transporters like p-glycoprotein substrates, and modulating drug metabolism by altering the expression of cytochrome P450 or UDP-glucuronosyltransferase enzymes.	piperine	45-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	286-301